<SEC-DOCUMENT>0001558370-23-004979.txt : 20230330
<SEC-HEADER>0001558370-23-004979.hdr.sgml : 20230330
<ACCEPTANCE-DATETIME>20230329213559
ACCESSION NUMBER:		0001558370-23-004979
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		88
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230330
DATE AS OF CHANGE:		20230329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MUSTANG BIO, INC.
		CENTRAL INDEX KEY:			0001680048
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473828760
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38191
		FILM NUMBER:		23776954

	BUSINESS ADDRESS:	
		STREET 1:		377 PLANTATION STREET
		CITY:			WORCESTER
		STATE:			MA
		ZIP:			01605
		BUSINESS PHONE:		7816524500

	MAIL ADDRESS:	
		STREET 1:		377 PLANTATION STREET
		CITY:			WORCESTER
		STATE:			MA
		ZIP:			01605
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>tmb-20221231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.0.4 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/29/2023 11:43:23 PM -->
      <!-- iXBRL Library version: 1.0.8405.27969 -->
      <!-- iXBRL Service Job ID: 1e1e1eab-93c7-4a9e-b300-91776f202e00 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mbio="http://www.mustangbio.com/20221231" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" xs:nil="true" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_7XjSGVwEtk2CuWBMSYQjOg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" xs:nil="true" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_awZt3Z56oUmD0yofqLai0w"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" sign="-" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_MmSsXYvO_kGoOGgbOrT66w">0.75</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_2XIc_zKVEUGsQyadfYD1gw">0.76</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_2GiD55UiyEGxwjX0WVPE1g">103432603</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_7cZKxgNXyEG0KfG_SPCIQQ">87885235</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_BIGXGDitnk-RSc92qeeFPA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_L5SONMef_0GOhhJFfDk_NQ">106501663</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_3yAsLCGyT0KK9PpF59rSlw" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_dBSj86xc7EiE_66a4c2vDA">93582991</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_M2XrEHX5oEeqe8nYvunwDw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_YVWlHF6eLkOniJMd6anGKw">845385</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_ReacBf4ACUWv_pBx9hfasw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_phGJeN8v4UuHhZLTTL6YTQ">845385</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_segment_8GyIjrAsdkK2LxrNi5qQyQ" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="INF" name="us-gaap:NumberOfReportableSegments" id="Hidden_1DzwVi4TWE68-iARaVzCtQ">1</ix:nonFraction><ix:nonNumeric contextRef="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_jIA82Zn-S0-9OoqzDzR2cg" name="mbio:OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement" id="Hidden_t6gbwtw4fkmKVT_BgWRqSA">P1D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w" name="mbio:EquityFeePaymentPeriod" id="Hidden_IKJI1MNkyk-jVARLuqEz6w">P5D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w" name="mbio:CashFeePaymentPeriod" id="Hidden_ZlvSq5CKKECYsdUUYJlnYw">P90D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w" name="mbio:ChangeInControlFeeMeasurementPeriodForNetSales" id="Hidden_oihncYEzmEirIm889SKJsg">P12M</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_23K9Zas0OUqKcdKbwAuUMA">250000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_qU_s14xtUkCy1Qbwy6s6qg">250000</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:EntityCentralIndexKey" id="Tc_3tyj7A9PHEml-4WjdnG0cA_2_1">0001680048</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:DocumentFiscalPeriodFocus" id="Tc_xyQzhPEGVUC4hOH-TAT_NQ_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:AmendmentFlag" id="Tc_opG9MqYB1EakAIpDrTWezw_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:TaxCreditCarryforwardExpirationDate" id="Hidden_RuW2aDq3XEWNv2WtYazZ1w">2033-12-31</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_6_14_2022_cTRV0HCiCkWfQ2PRR9auPA" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" id="Hidden_hD18g_F6S0Sosw_qw-16ow">2200000</ix:nonFraction><ix:nonNumeric contextRef="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_yUFWycn0fk-azymq7ugG3A">P10Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tmb-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_c0ZjuYLL-0CMEHMYhr3GFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_2F1anYHQf02jp38E63vSpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6zho2C1h60K0Lzm1bSUQng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_P9_Uj5uTOkOfoQ-1eRQEMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember_9MQl4Tri8UWaL1Az0682Pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mbio:CommonStockIssuableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3jzMDFTC6Uqy-qcl2JQMLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nEUVoh_PAEuYAh0Emg965A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember_r-s7nx-j2UO579la2vbCYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mbio:CommonStockIssuableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_d-YK2vIsoEm8XC9k2H7Q5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jHd2Q0o-XUCIA4E98EgSpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember_huCEWr5zL0mQORn1jbxA9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mbio:CommonStockIssuableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_iXjE7NHXYk6rJeTAc6GwOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dcd2JnkRoUu5jv05PZ7fwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u6IrjKOtBU2wn6oRGZSpiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mbio:CommonUnspecifiedClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Ix8JVts4dk2Q4KuWLN5TqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5lfujqng8EmU7km7KzrW3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mjwCtJPi90OdodwExzzejw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mbio:CommonUnspecifiedClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Ph6XHuuiYE6eukhnqC2Btw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8o0VgKjajEeXToZHvyHFfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GA4yvT9zYUmgOsGKoFCnXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mbio:CommonUnspecifiedClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_wNo8mVO2kUeHFiMORHtB9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_4VC5ZPEVB0aXZyDJ1fjJtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_ywrnZ-GLAkqK0TW0rXu5xQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_7W5zr_ZJ8k6YRLAjbxG7LQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uj9LYQ994USIWcKdot_c7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_suZlLo8Guk2LmZMnsU9VMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bhwOXV7qmUa0T2YdE_tfkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LqmnL5gbTkS17IvEqtphGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PDcmO8zz3EqNXOXuFyL8PQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_21_2022_W87ewabwMUywhrCygGG9dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BNRH5QbCykyPiw-RTmCPqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_17_2021_midR-jy3VUGn7KvHZ7QMZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nrn5fFARI0iVnAb0sMWaVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UcqZY0RuLkm6-uv8PCh07w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_21_2022_To_6_21_2022_9w7Pc3dMn0il-0WAUszkjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-21</xbrli:startDate><xbrli:endDate>2022-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M2BLxvwBtUun2VN6YRNObQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_17_2021_To_6_17_2021_sehtwXsjPE6k3If_-5V-TA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-17</xbrli:startDate><xbrli:endDate>2021-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MqmksIdNjkaWP_ipa9CSuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2aMeSdhNi0a4ZRzBQ7A_hA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4LOmmgimP0ClUtAdOe4haA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_KeRs2NdINE-YRgyA7zQiQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_3-kS7FRDbkqpKxd-4hKdeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2-wAsbb-T0KYD16SQuYxKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_Pd10hdVFnE2rD6DyKQmoRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_3OyJzUMtO0ym9UWFHhhAZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_B0vAXreZfkCUTZAJG1tYDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_XfkRl6mfqE-N6Ds1xMxrbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_9jVcGwYOxUu69mDgzJJD-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_O3YYPIPGzE-eJsI9zpkIKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nMMb4QwZpE2wkHPBjsoMzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-LQvQ6gJ9UOk8vXKCNkxng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_f1ddUvO4v0amvOZiXCEDeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-mQVcy5AFUC0fcnvfp5yUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_uHyqiEuP_0ekgE-jQl3slQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_27_2017_us-gaap_ShortTermDebtTypeAxis_us-gaap_LetterOfCreditMember_k9atZnNjs0aax30iY_FCJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_27_2017_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_n1UsR7h740ijw5e4ONDTcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_WndiQxEyWkK5zt6u8QU19g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:St.JudeChildrensResearchHospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:StJudeXscidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_DataTransferAgreementMember_-H0TdacBZkabwWvQhfMbVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:St.JudeChildrensResearchHospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:StJudeXscidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:DataTransferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_srt_ProductOrServiceAxis_mbio_Rag1ScidMb110Member_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_JHL0mUan5USsk0GX6mP-bA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:LeidenUniversityMedicalCentreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Rag1ScidMb110Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_AHlPXFWbm0S4f23bwODBgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd20TechnologyProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_ClinicalTrialAgreementsMember_Cyw5EJBd1UirM-BcQ7nr3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd20TechnologyProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:ClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_LFLvm316o0SOUKQxhoo0Mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:PscaProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_GJMbltW_ckGM-82fZ6QN9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Il13r2ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_nzRdZgaBgkaKZuJTpHtWXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Her2ProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cs1ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_OpIS0Aptykyt0fbMp5ngcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cs1ProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_flIxGqK8EE-qTKhiUM7P5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd123ProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_A95Rt4-jPk231qSpo9U-FQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:MayoClinicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_hRHdDMHNcUuPmSQBOPtXWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_aP7yNOKuS0aTGB-ItbnSAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Vx1emwLJJ0qXsajS4OcXww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_QpA72oZJUkisoiKeboPylg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:St.JudeChildrensResearchHospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:StJudeXscidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_DataTransferAgreementMember_3BooSMscyEWc_UdmNkhn6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:St.JudeChildrensResearchHospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:StJudeXscidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:DataTransferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_srt_ProductOrServiceAxis_mbio_Rag1ScidMb110Member_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_KgtU9Mq_mkeeWrJ3yEjrEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:LeidenUniversityMedicalCentreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Rag1ScidMb110Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_g-WN3OcgMk2PMIpOmGZ7LA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd20TechnologyProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_ClinicalTrialAgreementsMember_IjKtndA3yU-D5J-KXPKfPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd20TechnologyProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:ClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_VrwnpcakNUyyqsooiwPWOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:PscaProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_7XG-WubxyUykOLnPy8K1fQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Il13r2ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Avzs-VjlYkyzUP2irGzjQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Her2ProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cs1ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_-91cVSuwk066vgPNrl9tAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cs1ProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_1tC8VQmSzUSfIFLGkJX9ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd123ProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_G3TY0ZFyQk2j7jey4doOng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:MayoClinicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_KBjGOoU-1UiBWoztZE_WAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_0NxXjiJgYkGL9rgKRUKG0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_ycCeI3y-e0qyb7nr_-5MKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_FortressBiotechIncMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_3Vh1oZCe0keLsUyEjlCcKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_2GiFSZkrMEqa7kSRo1sWhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CalimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_bEUyP985oUaHNsVrsVxqYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_eqbNchRq0EKHKjmh0pCfeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd123ProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_DB6MYEz08kyNAf6LM9F59A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:MayoClinicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_FortressBiotechIncMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_qumY3pBwC0W2YfvPR7QXUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_-IXYKwdDrEqLg2blggBbbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CalimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_5I7r1d0H1kGd9E-MDAoc_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_ovDgDz0emEyMvZmp-YeELg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_RtpzWYx2kkuP6Pk7yZGiGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_6e_cd9xdR0OP-rJ8ATzk6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_FkxuDW2Odkq2TbRXzOUOkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_T6pbjl0HIEm0W7ow_5z-_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_v472pPJ0CkuqygxI_ittBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_AS2adTFum0q5lSDBbT43Cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_j5ZGnmb0UkuRYKuYvgYNtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_pzjG98ud8EGdrioXB-jwgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_aWcNk9ygQEOJpQSfWskFEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_reL4xpHEp06WZ3lLttoTLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_cTxrSq0IxUy5wwF9bj3Hhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_iCbMYI4KcESBEVBhm0Im-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_RjfDOebswEyLEhoZaNQWKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_z9Vf3QpPF0qO9yFxyz7P_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_6Mr5lfEhb0CpRxTW-j7sxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_e_acjS35Ukyn5P8Fy-MCGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_PcX9JsuOWUyJsrrbJM84DA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_wsvscCuqjEmydGhY6i4new"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_43U4KPxs6ESx8ledMlKHrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_v_0gsNjsdE2RcPa-Xt5feA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_4_2022_To_3_4_2022_8OXg7asOjUiUzJte247ykw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-04</xbrli:startDate><xbrli:endDate>2022-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_9h_ihuTMpEGBputHFvfCaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_xeewYyKVAEu67ngPqUXP6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_14_2022_cTRV0HCiCkWfQ2PRR9auPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_27_2017_r9_PBUxiKU6CIeyMRHqr4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_sJ_f6Z0h_0mK2WrP7jFDCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_N3FmWahfpU6FVAV3nHsrgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_4_2022_To_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_eHP0c1pt2kC8bNXFkSVznw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-04</xbrli:startDate><xbrli:endDate>2022-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HKp1HVK3rUeH2BUSicO2mA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_UPMzzbZe7UyasqVciLqSTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_GOVpc9dkuEG97uEvmowlTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_oh5GT7S9BUWgIrXyvuqlaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BbA2PkmH4kSDxqPMhK8S-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_4_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Q6BCOUH2V0CcXWJkApNHug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_4_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_mwjdn5zoKEerGWdy4baTKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_4_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_2HYX_b8YJ0uKkR4UevRidg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_4_2022_To_3_4_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_IRsNQ3FWukSyey7fSJ4NbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-04</xbrli:startDate><xbrli:endDate>2022-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_4_2022_To_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_sRafw2Y-jEiKjW4bMgII8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-04</xbrli:startDate><xbrli:endDate>2022-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_4_2022_To_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_85Vphemizk-HydOGFNSOgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-04</xbrli:startDate><xbrli:endDate>2022-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_26_2016_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_zbvdgNhN6kuygnfc4J47nA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_joFxX9w_pkCt5C4GrtBlWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-26</xbrli:startDate><xbrli:endDate>2016-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_VBMwjqeRtEqCOPPRYyGFBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mbio:CommonUnspecifiedClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-26</xbrli:startDate><xbrli:endDate>2016-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_u-nK5IHLB0it8Ss2uDQLIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-26</xbrli:startDate><xbrli:endDate>2016-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_HIeb-wz9Kk2lMUL_e8y1xA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_YEp120A29kC8SaLYOW75aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_5_Je6tCozUqMRQF6TTTr9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_ReacBf4ACUWv_pBx9hfasw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_BIGXGDitnk-RSc92qeeFPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mbio:CommonUnspecifiedClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_3yAsLCGyT0KK9PpF59rSlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mbio:CommonUnspecifiedClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_M2XrEHX5oEeqe8nYvunwDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_4_2020_xrfudyC3YkytVOGquusxcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_10_2020_pVBK-Ciss0-dnXh6zSgmjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_11_2020_jFP6QSBqjkOBLq38js8Gqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_qB-ZO8R0_ESmBgqQbpsWbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_hD2Rfx-DxkuN5TyT5ipjDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_cSWJg5CHcU6I0x0JrwnJzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_Jb9gSnd2k0CKnqyK9MTFMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_rZrGkA6BLUa3b3OQehnYJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_dvSvij2w6keF_tXo9314yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_jj2nVe7aqU6w_0C3fUd4mA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredClassAMember_fKYAiDFShUe0rn_iP9LuDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ycveH83leUebYfW_8jtr1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_0k_G4cx5Y0ap-y77lBqB_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_-StlwZNLwUqM0yBk4WhqVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_3jPgbp30DEyg4u1vnCNMRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredClassAMember_VD6cIIAU5EO3zkHQr1i38g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_HTuh90RZrk-KPSURpslalg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_uNZ1QlhL30egiHID6foBSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_UgDuCoveakiyI_k2GGguBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_dXkI_XX5XU-PKFM5auvM3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_EPmjxn4_W0OhVeeDC0iTvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_36vrF-2gf0O3kUT4Pd1TLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember__24V726k9U-PKRzgLSlEoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mbio:CommonStockIssuableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember_FipD5R7ULEmGI252vfGJvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mbio:CommonStockIssuableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_ck0wt0THlEGynuJiicHJLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_24_2021_To_5_24_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_mbio_RegistrationStatementsMember_uT0i13PYeUesod3TAzOW4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:RegistrationStatementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-24</xbrli:startDate><xbrli:endDate>2021-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_4_2019_To_12_4_2019_us-gaap_SubsidiarySaleOfStockAxis_mbio_RegistrationStatementsMember_t--jUxfLC0e7u7XptCY16g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:RegistrationStatementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-04</xbrli:startDate><xbrli:endDate>2019-12-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_m9J360WMFk65TIBgOb6HfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2022_To_11_30_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_J2PMFy7590ayhjU1Z1lmBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Il13r2ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_DataTransferAgreementMember_jXidwRe_gUC02_iRlrhLpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:St.JudeChildrensResearchHospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:StJudeXscidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:DataTransferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_ClinicalTrialAgreementsMember_rf7xSABuqkO4KGuRWtqIrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd20TechnologyProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:ClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_cspaXnUxZku0Ws6QbCLXDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:PscaProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cs1ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_EPbH-hiMk0qoLFPq4Tyodw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cs1ProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_AbCiEvU7_0uU3dzq5HkUFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Her2ProductOrProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_gFhn3tpHy0eOhnDxAPc2tQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_aoFLNFn800q4su8jbp-MXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_26_2016_To_7_26_2016_e467LFs_GEmfW2lDVRZA9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-26</xbrli:startDate><xbrli:endDate>2016-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_MMf1jaQkGEia07UBzms6Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:MayoClinicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_ecAzAIw_WEizUmdbx34e8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:LeidenUniversityMedicalCentreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_4_1_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_agKp6cvBpEy4-mIqOjcSeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:MayoClinicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_DataTransferAgreementMember_eFtEz1VOwUqbB4jKDO66nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:St.JudeChildrensResearchHospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:StJudeXscidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:DataTransferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_Q8BOscMl8U2O76Uoh4fs0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_QcfoZ3MG8ECfgSVpuDaKmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_eypHnY-B1U6jSlIjModjUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:PscaProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_IvIcvProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_HiZjKumNT0SZKUFTzFtdpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:IvIcvProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_-Awulcu8EUuW8KUUEOHfpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Her2ProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_X-M3RGE5aUmOLFk49REASw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd123ProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_5UGfc7o3YkaygLrJClTgXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:PscaProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_IvIcvProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_cGzyMH7f9k618wUdJrWh1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:IvIcvProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_h2tn3x-z7UuAoS7r_ftqoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Her2ProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_S6NInTxBvUmnCq_IJxa26g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:LeidenUniversityMedicalCentreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_8_2021_To_9_8_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_srt_ProductOrServiceAxis_mbio_Rag1ScidMb110Member_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_PDhxhJes-E2hyBDbO6sjlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:LeidenUniversityMedicalCentreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Rag1ScidMb110Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-08</xbrli:startDate><xbrli:endDate>2021-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_8_2021_To_9_8_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_8Z3KAV2B-EeZv3xSHR1e1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:LeidenUniversityMedicalCentreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-08</xbrli:startDate><xbrli:endDate>2021-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_DEvYfskaDUCi1Vhldrs8yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:MayoClinicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_wJVqrbyFSU-cHpd2pZX10g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:PscaProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_z0SUrOJETEa8go8i01WkEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Her2ProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_brP4CCoYMUKzdsYDsNVEpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:PscaProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_RkSGNTQj7kufffNWRIAKsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Her2ProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cs1ProductOrProcessMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_-VT2Q3jlP0OWPKoY-Ng3pA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cs1ProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2019_To_8_23_2019_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_GZks_7XceUyp2L41ZnWzfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CalimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-23</xbrli:startDate><xbrli:endDate>2019-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_3_2017_To_7_3_2017_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_CcHvzBIXtUODWCVXYAQe_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd20TechnologyProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-03</xbrli:startDate><xbrli:endDate>2017-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_ejb848nGTkG3ypqRxMLthA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd123ProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-01</xbrli:startDate><xbrli:endDate>2017-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_27_2017_To_10_27_2017_us-gaap_ShortTermDebtTypeAxis_us-gaap_LetterOfCreditMember_Gwgp6OjA0kOhW6E5eRzqQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-27</xbrli:startDate><xbrli:endDate>2017-10-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_27_2017_To_10_27_2017_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_-idbFc98Ukq2mFPsFZldJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-27</xbrli:startDate><xbrli:endDate>2017-10-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_27_2017_To_10_27_2017_HaJc4KkwbUyd0LOp2-MkEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-27</xbrli:startDate><xbrli:endDate>2017-10-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_D02sY_Okb0CAJr_sq1tImg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_bPmhKby7TEaZLqjV9yAiFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_uAr0vqstK0m70EJhq9vZvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_-GelVT3xVkGWE0zhcvX2PQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_ot8OBmwnOUaS1sRIHVm7tQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_1_1_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_eGnJ3TUB8UOJx8iUju7dfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_Trkkxq84fU-Vd0RoRhj2NQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_22_2016_To_7_22_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_FiUSuj1xYkGpO1xt7_NOcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-22</xbrli:startDate><xbrli:endDate>2016-07-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_9uDXLFrQfESucUVU2dbSlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2yJrJPxhE-PPwrFE9SShQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mbio:CommonUnspecifiedClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Qj0QYtgKVEW8_VkZm7xUBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Il13r2ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-01</xbrli:startDate><xbrli:endDate>2017-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mbio_RegistrationStatementsMember_MnKy-ABZ70yPMHS_OgN4rA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:RegistrationStatementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_13_2018_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_Xdsmbxo8fkiq_m6mzNm0Bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_YQ4fUCukB0WFke0KueexQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_zwcEeJiJR0GMOVhFZZp5MA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_tpnhJWDO60OMRtanSOx5tQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_4_1_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_M1lvnrfyyUG8MMd-TFM3OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:MayoClinicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_3_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_te1_6uZCuEC4P4P0W1cmfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Il13r2ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_SW1jOKKvIUWxGq9g6tUp4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Il13r2ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2017_To_5_31_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_jWZU2RYRvEei-C0QMO7buA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:PscaProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2017_To_5_31_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_OhC3qwHZBUG5jIk8E5CveA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Her2ProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_IvIcvProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_kFOATtbMhEW9Vm5Z1U3trQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:IvIcvProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-01</xbrli:startDate><xbrli:endDate>2017-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_GxvcEL9tsUGqvDvu2x4erg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd123ProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-01</xbrli:startDate><xbrli:endDate>2017-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_sT3IETb4eUa_bTIM6c1joQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_1_1_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_lbdL7OiZrk-lt4FN-gg-bQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_13_2015_To_3_13_2015_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_-NQvGLrolUaisD4xkEP_SA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-13</xbrli:startDate><xbrli:endDate>2015-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_jIA82Zn-S0-9OoqzDzR2cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-26</xbrli:startDate><xbrli:endDate>2016-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SQivjg3JZ0yfjAKfVkr_KQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mbio:CommonUnspecifiedClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WOYfueKSEuJAaVfesRtjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_10_31_2022_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_9mu0h1oYPUqhtCqCC9mKMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:MayoClinicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_HChGYU6CSUCiuMb3wOIWmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd20TechnologyProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_k8cUiopjJ0W74a5rURwE8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd20TechnologyProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_nx8c3dUXCUmIniCJJw81FQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd20TechnologyProductOrProcessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_8nk8OUv3G0CRBbh3Nuc4og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_27_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_JXLkfa12nEiwk3gGcQcdqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_27_2023_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_75GhEhbAEUClw7KGwNGhqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mbio:CommonUnspecifiedClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_e-lAqZ63ukC9AQjaK0X33Q"><xbrli:measure>mbio:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_Milestone_13Bi5jCZBUqZT3I2C4rjww"><xbrli:measure>mbio:Milestone</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_EUR_rzel3jVa2UO3kiVSQxNNcA"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_8yS2Dc-QmU2gfsdczKLSrA"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_segment_8GyIjrAsdkK2LxrNi5qQyQ"><xbrli:measure>mbio:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_d2e56c51_7589_464d_8ffe_8d21a05e388f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:DocumentType" id="Narr_F_fd_x6kNEWvNMtCVQKY_A"><b style="font-size:8pt;font-weight:bold;">10</b><b style="font-weight:bold;">-</b><b style="font-size:8pt;font-weight:bold;">K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18.3pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:DocumentAnnualReport" id="Narr_kJsjsWefZE2A6oMsIAcqRg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;font-style:normal;font-weight:normal;">&#9746;</span></ix:nonNumeric></span><b style="font-size:8pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">For the Fiscal&#160;Year Ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:DocumentPeriodEndDate" id="Narr_5ItsmhV_aE2KjesI-WLhHg"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:CurrentFiscalYearEndDate" id="Narr_WyT_4bOZv0uEtKhaKsCpTw"><b style="font-size:8pt;font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:DocumentFiscalYearFocus" id="Narr_qS1qWVheBkKEo8_0oG3FNA"><b style="font-size:8pt;font-weight:bold;">2022</b></ix:nonNumeric></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">or</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18.3pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:DocumentTransitionReport" id="Narr_lku40AJoBku-2fckKjTxfA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><b style="font-size:8pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Transition Period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160;to </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Commission File No.&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:EntityFileNumber" id="Narr_BiF027XimkKmtqPGNeS8HQ"><b style="font-size:8pt;font-weight:bold;">001-38191</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:EntityRegistrantName" id="Narr_cV80-UnYdEm-o4dEk2MxUQ"><b style="font-weight:bold;">MUSTANG BIO,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact Name of Registrant as Specified in its Charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_a2a139c6_bb63_42bd_a35a_4ea6d404acd1"></a><a id="Tc_fiFIcLOftUKisOA4kvkPvw_1_0"></a><a id="Tc_yFvxzP8LVEGF7SFbBFYNMw_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:EntityIncorporationStateCountryCode" id="Tc_HIhI-L_EdkiB5_kiwK70ZQ_0_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:EntityTaxIdentificationNumber" id="Tc_9ZnyF1m_kUahd-IKAqPy0g_0_1"><b style="font-size:8pt;font-weight:bold;">47-3828760</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or Other Jurisdiction of Incorporation or Organization)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer Identification No.)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:EntityAddressAddressLine1" id="Narr_ExTUyqyovEe2HdI4D4Pd4w"><b style="font-size:8pt;font-weight:bold;">377 Plantation Street</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:EntityAddressCityOrTown" id="Narr_cE5N-vo8Lkat3fx8D6ynpg"><b style="font-size:8pt;font-weight:bold;">Worcester</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">,</b> <ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:EntityAddressStateOrProvince" id="Narr_HlYdtZs0bki-rwhQxH_bFQ"><b style="font-size:8pt;font-weight:bold;">Massachusetts</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:EntityAddressPostalZipCode" id="Narr_DHXCPetnZEiKVQ3g-TQjpQ"><b style="font-size:8pt;font-weight:bold;">01605</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Address including zip code of principal executive offices)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:CityAreaCode" id="Narr_i0j8VpzElk-yLR5s7B0rnA"><b style="font-size:8pt;font-weight:bold;">781</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">)&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:LocalPhoneNumber" id="Narr_6eJGIk5wAUWL7O3kgNs0xw"><b style="font-size:8pt;font-weight:bold;">652-4500</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_9c6697bf_2ac3_46af_b405_423e95b1866d"></a><a id="Tc_vPXH0PBcM0-EcFHanmxEoQ_0_0"></a><a id="Tc_o0nmo2-KjkumIR2PdXVeeQ_0_2"></a><a id="Tc_UTXH3znIs0mpy3lYnYxvzw_0_4"></a><a id="Tc_nBxwWxz6ZEOJdW3hJ2Iwzg_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:33.92%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:1.65%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:24.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:bottom;width:1.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:37.81%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Name of each exchange on which </p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">registered</p></td></tr><tr><td style="vertical-align:bottom;width:33.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:Security12bTitle" id="Tc_NiD7Z1W1rEGht3A_x8hHQg_1_0"><span style="font-size:8pt;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:TradingSymbol" id="Tc_OIlWVFELz0mkezH31dOrzg_1_2"><span style="font-size:8pt;">MBIO</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:37.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:SecurityExchangeName" id="Narr_PnCAt8mlHEKe6tPmELpZnw"><span style="font-size:8pt;">NASDAQ</span></ix:nonNumeric><span style="font-size:8pt;"> Capital Market</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Securities registered pursuant to section 12(g)&#160;of the Act: None.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes&#160;&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_riV5baDhGU2qfmGM6HG-tg"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. Yes&#160;&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:EntityVoluntaryFilers" id="Narr_fOp3ODn1iUWsOAUsJ6uuhw"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:EntityCurrentReportingStatus" id="Narr_xSNO90xVRUuoj0mGi2l-ig"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:EntityInteractiveDataCurrent" id="Narr_uPTTXnLll0y9WgoB5taaDA"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;&#160;No&#160;&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_6b512438_3ee0_47db_aa3e_dadda9ae3c26"></a><a id="Tc_HZ2b_PpgU0q4ScHqNMkvPQ_0_0"></a><a id="Tc_ltcgMKQRHUiomF4OBMXyeQ_0_1"></a><a id="Tc_4LMldZ6JwkqC44BHNqKbJQ_0_2"></a><a id="Tc_7Gjm1PSowUOe9VE9XNF5xA_0_3"></a><a id="Tc_WqdBVx5C6021JO2_UBWhQg_1_1"></a><a id="Tc_tMu6kemrNUuYJdukBGxLrQ_1_2"></a><a id="Tc_f1l95whpDE-2r_72G4fSSQ_2_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large&#160;accelerated&#160;filer</p></td><td style="vertical-align:top;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#9723;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accelerated&#160;filer</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#9723;</span></p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:EntityFilerCategory" id="Tc_DINCo6vQA0uxDhZjGGLmdg_1_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:EntitySmallBusiness" id="Tc_vEsF_90BAUWlhFtUUYlRmA_1_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:EntityEmergingGrowthCompany" id="Tc_FBn5PIIJW0qlDuMXNHMvRg_2_1"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. &#160;&#160;<span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:IcfrAuditorAttestationFlag" id="Narr_nhHDpCsS7ESzWsfcCwK3KA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 5pt 0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:EntityShellCompany" id="Narr_jXemJl_nwU2KArHxEaKNLg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> No&#160;&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">The aggregate market value of the common stock held by non-affiliates of the registrant as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter: $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2022_8nk8OUv3G0CRBbh3Nuc4og" decimals="-5" name="dei:EntityPublicFloat" id="Narr_-ErPSfezcEOsxqaZ7IGQbA">48.8</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_427b0057_136e_400b_a5cf_5dafee37b3fe"></a><a id="Tc_FoPcegX-2Ei3kQXMNyikmw_0_0"></a><a id="Tc_il7H8D5B8Ue3iabtsyKrvg_0_2"></a><a id="Tc_4lTmv3RXk0qcru1J2pKNXw_1_0"></a><a id="Tc_SIKBfiI21ku1vgECYwaQ5Q_2_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:48.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Class&#160;of Common Stock</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:49%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding Shares as of March&#160;27, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Class&#160;A Common Stock, $0.0001 par value</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_27_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_JXLkfa12nEiwk3gGcQcdqg" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Tc_vdr6NGjslkGFWkp4nqepwQ_1_2">845,385</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Common Stock, $0.0001 par value</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_27_2023_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_75GhEhbAEUClw7KGwNGhqA" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Tc_m0uv5SJS00WqFdqWVtMrRA_2_2">109,398,635</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">DOCUMENTS INCORPORATED BY REFERENCE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Portions of the registrant&#8217;s Proxy Statement for its 2023 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:justify;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:2pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a0a17a4d_a08e_4544_a87b_7b64a14f1a5a"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MUSTANG BIO,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT ON FORM&#160;10-K</b></p><a id="TABLEOFCONTENTS_402480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:89.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:89.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTI_17530"><b style="font-style:normal;font-weight:bold;">PART&#160;I</b></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_38045"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_38045"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_686229"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_686229"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_855719"><span style="font-style:normal;font-weight:normal;">Item&#160;1B.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_855719"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">63</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_248983"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_248983"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">63</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_243219"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_243219"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">63</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_526775"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_526775"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">64</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:89.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:89.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTII_57028"><b style="font-style:normal;font-weight:bold;">PART&#160;II</b></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">64</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">64</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Reserved_101650"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Reserved_101650"><span style="font-style:normal;font-weight:normal;">Reserved</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">65</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisoft"><span style="font-style:normal;font-weight:normal;">Item&#160;7.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisoft"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">65</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item&#160;7A.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item&#160;8.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item&#160;9.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">76</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_107796"><span style="font-style:normal;font-weight:normal;">Item&#160;9A.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_107796"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">76</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_543946"><span style="font-style:normal;font-weight:normal;">Item&#160;9B.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_543946"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9CDisclosureRegardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Item&#160;9C.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9CDisclosureRegardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdiction that Prevents Inspections</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:89.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:89.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIII_757942"><b style="font-style:normal;font-weight:bold;">PART&#160;III</b></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Item&#160;10.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_785771"><span style="font-style:normal;font-weight:normal;">Item&#160;11.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_785771"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item&#160;12.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item&#160;13.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountingFeesandServices"><span style="font-style:normal;font-weight:normal;">Item&#160;14.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountingFeesandServices"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:89.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:89.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIV_456940"><b style="font-style:normal;font-weight:bold;">PART&#160;IV</b></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsFinancialStatementSchedule"><span style="font-style:normal;font-weight:normal;">Item&#160;15.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsFinancialStatementSchedule"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary_443190"><span style="font-style:normal;font-weight:normal;">Item&#160;16.</span></a></p></td><td style="vertical-align:top;width:79.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary_443190"><span style="font-style:normal;font-weight:normal;">Form&#160;10-K Summary</span></a></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">81</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6122b636_6dc8_4e74_8156_8845993b812e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain matters discussed in this annual report on Form&#160;10-K (&#8220;Form&#160;10-K&#8221;) may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;may,&#8221; &#8220;expect&#8221; and similar expressions are generally intended to identify forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation, those discussed under the captions &#8220;Risk Factors,&#8221; and elsewhere in this Form&#160;10-K. All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by these cautionary statements. Such forward-looking statements include, but are not limited to, statements about our:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expectations for increases or decreases in expenses;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expectations for the clinical and pre-clinical development, manufacturing, regulatory approval, and commercialization of our pharmaceutical product candidates or any other products we may acquire or in-license;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use of clinical research centers and other contractors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expectations for incurring capital expenditures to expand our research and development and manufacturing capabilities;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expectations for generating revenue or becoming profitable on a sustained basis;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expectations or ability to enter into marketing and other partnership agreements;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expectations or ability to enter into product acquisition and in-licensing transactions;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expectations or ability to build our own commercial infrastructure to manufacture, market and sell our drug candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expectations for the acceptance of our products by doctors, patients or payors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ability to compete against other companies and research institutions;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ability to secure adequate protection for our intellectual property;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ability to attract and retain key personnel;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ability to obtain reimbursement for our products;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">estimates of the sufficiency of our existing cash and cash equivalents and investments to finance our operating requirements, including expectations regarding the value and liquidity of our investments;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stock price and the volatility of the equity markets;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expected losses; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expectations for future capital requirements.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The forward-looking statements contained in this Form&#160;10-K reflect our views and assumptions as of the effective date of this Form&#160;10-K. Except as required by law, we assume no responsibility for updating any forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We qualify all of our forward-looking statements by these cautionary statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0834f8bb_7372_4e4d_bc92_ecc0c86307a0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SUMMARY RISK FACTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our business is subject to risks of which you should be aware before making an investment decision. The risks described below are a summary of the principal risks associated with an investment in us and are not the only risks we face. You should carefully consider these risk factors, the risk factors described in Item 1A, and the other reports and documents that we have filed with the Securities and Exchange Commission (&#8220;SEC&#8221;). &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Risks Related to our Finances and Capital Requirements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred significant losses since our inception and anticipate that we will incur continued losses for the foreseeable future.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">There is substantial doubt regarding our ability to continue as a going concern. We will need to raise additional financing in upcoming periods, which may not be available on acceptable terms to the Company, or at all. Failure to obtain necessary capital when needed may force us to delay, limit or terminate our commercial readiness efforts, activities to support a potential commercial launch following any approval of our product candidates, or other operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have not generated any revenue from our development stage products, and we do not know when, or if, we will generate any revenue.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our short operating history makes it difficult to evaluate our business and prospects. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our success is contingent upon raising additional capital, which efforts may fail. Even if successful, our future capital raising activities may dilute our current stockholders, restrict our operations, or cause us to relinquish proprietary rights.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Risks Pertaining to our Business Strategy, Structure and Organization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our future growth and success depend on our ability to successfully develop and commercialize our product candidates, which we have yet to do. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our growth and success depend on our acquiring or in-licensing products or product candidates and integrating such products into our business, and we may have limited growth opportunities if we fail to do so.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our future success is highly dependent on the successful development of our chimeric antigen receptor (&#8220;CAR&#8221;) engineered T cell (&#8220;CAR T&#8221;) technology and gene therapy product candidates. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Risks Inherent in Drug Development and Commercialization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preclinical development is highly speculative and carries a high failure risk. &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not receive the required regulatory approvals for any of our product candidates on our projected timelines, if at all, which may result in increased costs and delay our ability to generate revenue.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not obtain the desired labeling claims or intended uses for product promotion, or favorable scheduling classifications, to successfully promote our products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If a product candidate demonstrates adverse side effects, we may need to abandon or limit the development of such product candidate. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if a product candidate is approved, it may be subject to various post-marketing requirements, including studies or clinical trials, and increased regulatory scrutiny. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our competitors may develop treatments for our products&#8217; target indications, which could limit our product candidates&#8217; commercial opportunity and profitability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If our products are not broadly accepted by the healthcare community, the revenues from any such product will likely be limited. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any successful products liability claim related to any of our current or future product candidates may cause us to incur substantial liability and limit the commercialization of such products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our gene therapy product candidates are based on a novel technology, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Risks Related to Reliance on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely, and expect to continue to rely, on third parties to conduct our preclinical studies and clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials or complying with applicable regulatory requirements.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We contract with third parties for the manufacture of our product candidates for preclinical and clinical testing and may also do so for commercialization, if and when our product candidates are approved.</span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on clinical data and results obtained by third parties, which may prove inaccurate or unreliable.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Risks Relating to Legislation and Regulation Affecting the Biopharmaceutical and Other Industries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be subject to anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are subject to numerous environmental, health and safety laws and regulations and could become subject to fines or penalties or incur costs that could harm our business</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk63601521"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Risks Pertaining to Intellectual Property and Potential Disputes with Licensors Thereof</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to obtain and maintain sufficient patent protection for our technology and products, our competitors could develop and commercialize products similar or identical to ours and our ability to successfully commercialize our technology and products could be impaired.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We depend on our licensors to maintain and enforce the intellectual property covering certain of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We or our licensors may be subject to costly and time-consuming litigation for infringement of third-party intellectual property rights or to enforce our or our licensors&#8217; patents. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any dispute with our licensors may affect our ability to develop or commercialize our product candidates.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Risks Relating to Our Control by Fortress Biotech, Inc. (&#8220;Fortress&#8221;)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Fortress controls a voting majority of our common stock and has the right to receive significant share grants annually, which will result in dilution of our other stockholders and could reduce the value of our common stock. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have entered into certain agreements with Fortress and may have received better terms from unaffiliated third parties.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Risks Related to Conflicts of Interest</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We share certain directors with Fortress, which could create conflicts of interest between us and Fortress. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">General Risks</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have received notice from the Nasdaq Stock Market of non-compliance with its minimum bid price rules; our common stock may be subject to delisting from The Nasdaq Capital Market if we are unable to regain compliance which may decrease the market liquidity and market price of our common stock. </span></td></tr></table><div style="margin-top:12pt;"><a id="_0e11a4a1_9eaa_4d5c_8923_8129e4742dbc"></a><a id="_Hlk98776594"></a><a id="PARTI_17530"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;I</b></p><a id="Item1Business_38045"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item&#160;1.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OVERVIEW</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Mustang Bio,&#160;Inc. (&#8220;Mustang,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on translating today&#8217;s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our pipeline is currently focused in three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. For each therapy we have partnered with world class research institutions. For our CAR T therapies we have partnered with the City of Hope National Medical Center (&#8220;COH&#8221;), Fred Hutchinson Cancer Center (&#8220;Fred Hutch&#8221;), Nationwide Children&#8217;s Hospital (&#8220;Nationwide&#8221;) and the Mayo Foundation for Medical Education and Research (&#8220;Mayo Clinic&#8221;). For our gene therapies, </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">we have partnered with St. Jude Children&#8217;s Research Hospital (&#8220;St. Jude&#8221;) in the development of a first-in-class <i style="font-style:italic;">ex vivo</i> lentiviral treatment of X-linked severe combined immunodeficiency (&#8220;XSCID&#8221;) and with Leiden University Medical Centre (&#8220;LUMC&#8221;) for RAG1 severe combined immunodeficiency (&#8220;RAG1-SCID&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CAR T Therapies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our pipeline of CAR T therapies is being developed under exclusive licenses from several world class research institutions. Our strategy is to license these technologies, support preclinical and clinical research activities by our partners and transfer the underlying technology to our cell processing facility located in Worcester, Massachusetts, in order to conduct our own clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are developing CAR T therapies for hematologic malignancies in partnership with COH targeting CD123 (MB-102) and CS1 (MB-104) and with Fred Hutch targeting CD20 (MB-106). Phase 1 clinical trials sponsored by COH for MB-102 and MB-104 and by Fred Hutch for MB-106 are underway. In July 2019 the FDA approved our IND application to initiate a multi-center Phase 1/2 clinical trial of MB-102,&#160;and our clinical trial began enrollment in 2020 for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm (&#8220;BPDCN&#8221;). In May 2021, the FDA approved our IND application to initiate a multi-center Phase 1/2 clinical trial of MB-106, and our clinical trial began enrollment in 2022 for treatment of patients with non-Hodgkin lymphoma (&#8220;NHL&#8221;) and chronic lymphocytic leukemia (&#8220;CLL&#8221;). We plan to file an IND for a multicenter Phase 1/2 trial for MB-104 for the treatment of patients with multiple myeloma once COH has established a safe and effective dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are also developing CAR T therapies for solid tumors in partnership with COH targeting IL13R&#945;2 (MB-101), HER2 (MB-103) and PSCA (MB-105). In addition, we have partnered with Nationwide for the C134 oncolytic virus (MB-108) in order to enhance the activity of MB-101 for the treatment of patients with glioblastoma (&#8220;GBM&#8221;). Phase 1 clinical trials sponsored by COH for MB-101, MB-103 and MB-105 are underway. A Phase 1 clinical trial sponsored by the University of Alabama at Birmingham (&#8220;UAB&#8221;) for MB-108 began during the third quarter of 2019, and we plan to file an IND for the combination of MB-101 and MB-108 &#8211; which is referred to as MB-109 &#8211; for the treatment of patients with relapsed or refractory GBM and anaplastic astrocytoma in 2023. In the third quarter of 2019, we announced that COH had started enrolling patients on a Phase 1 clinical trial of MB-101 in combination with nivolumab (trade name: Opdivo<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>) and ipilimumab (trade name: Yervoy<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>) in patients with recurrent malignant glioma (ClinicalTrials.gov Identifier: NCT04003649). In the fourth quarter of 2020 we announced that COH had initiated a Phase 1, two-arm clinical trial of MB-101&#160;in patients with leptomeningeal brain tumors (e.g., glioblastoma, ependymoma or medulloblastoma; ClinicalTrials.gov Identifier: NCT04003649). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Finally, the Company is collaborating with the Mayo Clinic to develop a novel technology that may be able to transform the administration of CAR T therapies and potentially be used as an off-the-shelf therapy. Mustang plans to file an IND application for a multicenter Phase 1 clinical trial once a lead construct has been identified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Gene Therapies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In partnership with St. Jude, our XSCID gene therapy programs (MB-107 and MB-207) are being conducted under an exclusive license to develop a potentially curative treatment for XSCID, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. This first-in-class <i style="font-style:italic;">ex vivo</i> lentiviral gene therapy has been evaluated in two Phase 1/2 clinical trials involving two different autologous cell products: an ongoing multicenter trial of the MB-107 product in newly diagnosed infants sponsored by St. Jude and a single-center trial of the MB-207 product in previously transplanted patients sponsored by the National Institutes of Health (&#8220;NIH&#8221;). In 2022, the NIH study was suspended as a result of the study stopping rules. In January 2021 we received a safe to proceed &#8220;approval&#8221; from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for our MB-107 Investigational New Drug (&#8220;IND&#8221;) application allowing us to initiate a pivotal non-randomized multicenter Phase 2 clinical trial of MB-107 in newly diagnosed infants with XSCID who are under the age of two. In January 2022, the FDA issued a clinical hold, pending additional Chemistry, Manufacturing and Controls (&#8220;CMC&#8221;) data, on our IND application to conduct a pivotal non-randomized multicenter Phase 2 clinical trial of MB-207 in previously transplanted XSCID patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, we have not received approval for the sale of our product candidates in any market and, therefore, have not generated any product sales from our product candidates. In addition, we have incurred substantial operating losses since our inception, and expect to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of December&#160;31,&#160;2022, we have an accumulated deficit of $329.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a majority-controlled subsidiary of Fortress.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CORPORATE INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Mustang Bio,&#160;Inc. was incorporated in Delaware on March&#160;13, 2015. Our executive offices are located at 377 Plantation Street, Worcester, Massachusetts 01605. Our telephone number is (781) 652-4500, and our email address is <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">info@mustangbio.com</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our website address is www.mustangbio.com. The information set forth on our website is not a part of this report. We will make available free of charge through our website our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q and current reports on Form&#160;8-K, and any amendments to these reports, as soon as reasonably practicable after we electronically file such material with, or furnish such material to, the SEC. We are not including the information on our website as a part of, nor incorporating it by reference into, this report. The SEC maintains a website that contains annual, quarterly, and current reports, proxy and information statements, and other information that issuers (including us) file electronically with the SEC. The SEC&#8217;s website address is https://www.sec.gov/.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PRODUCTS UNDER DEVELOPMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CAR T Therapies for Hematologic Malignancies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">MB-102 (CD123 CAR T Cell Program for BPDCN, AML and High-Risk MDS)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">CD123 is a subunit of the heterodimeric interleukin-3-receptor (&#8220;IL-3R&#8221;) which is widely expressed on human hematologic malignancies including blastic plasmacytoid dendritic cell neoplasm (&#8220;BPDCN&#8221;) and acute myeloid leukemia (&#8220;AML&#8221;). In addition, CD123 can be found on the surface of B cell acute lymphoblastic leukemia (&#8220;B-ALL&#8221;), hairy cell leukemia, myelodysplastic syndrome (&#8220;MDS&#8221;), chronic myeloid leukemia (&#8220;CML&#8221;) and Hodgkin lymphoma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Of these malignancies, we are currently investigating CD123 as a target for adoptive cellular immunotherapy in BPDCN, since high CD123 expression is associated with enhanced cell proliferation, increased resistance of these cells to apoptosis, and poor clinical prognosis. Depending on the early results in this patient population, we may broaden the inclusion criteria to include AML and high-risk MDS (&#8220;HR-MDS&#8221;). CD123 is overexpressed in the vast majority of cases of AML and HR-MDS and in essentially all cases of BPDCN.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">AML is a cancer of the myeloid line of blood cells characterized by rapid growth of abnormal white blood cells that accumulate in the bone marrow. AML is the most common form of acute leukemia. Although AML is a relatively rare disease, there are approximately 20,000 new cases per&#160;year in the U.S. and 10,000 deaths per&#160;year, accounting for approximately 1.8% of cancer deaths in the U.S. [Source: The Surveillance, Epidemiology, and End Results (&#8220;SEER&#8221;) Program of the National Cancer Institute]. AML standard of care involves chemotherapy to induce remission followed by additional chemotherapy or a hematopoietic stem cell transplant. Allogeneic stem cell transplantation (&#8220;allo-SCT&#8221;) is the preferred treatment for AML following a second remission. It can lead to a 5-year disease-free survival in 26% of patients. Unfortunately, however, currently only about half of relapsed patients are able to achieve a second remission with traditional chemotherapy agents. Patients who do not achieve a second remission are much less likely to benefit from transplantation and face a dismal outcome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">MDS is a heterogeneous group of malignant hematopoietic stem cell disorders characterized by dysplastic and ineffective blood cell production and a variable risk of transformation to acute leukemia. Patients with MDS have varying reductions in the production of red blood cells, platelets, and mature granulocytes that may also exhibit functional defects; these abnormalities often result in anemia, bleeding, and increased risk of infection. The precise incidence of de novo MDS is not known; conservative estimates from cancer databases suggest that there are approximately 10,000 cases diagnosed annually in the U.S. The actual incidence of MDS is likely higher than that predicted by cancer databases, since the nonspecific symptoms may evade detection in early stages of the disease and suspected cases may not undergo definitive testing (i.e., bone marrow biopsy) due to comorbidities. Investigations that have analyzed reimbursement claims have estimated the incidence in the U.S. to be 30,000 to 40,000 new cases per&#160;year. MDS occurs most commonly in older adults, with a median age at diagnosis in most series of &#8805;65&#160;years and a male predominance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">MDS and AML lie along a disease continuum, with distinction between the two largely made based upon the&#160;percentage of myeloblasts, which are immature cells with large nuclei, nucleoli, and a scant rim of dark blue cytoplasm, suggesting an underlying malignant hematologic disorder. In the current World Health Organization (&#8220;WHO&#8221;) classification system, blast forms must account for less than 20% of the total cells of the bone marrow aspirate and peripheral blood to meet the criteria for MDS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">MDS prognosis is often assessed using the revised International Prognostic Scoring System (&#8220;IPSS-R&#8221;), which takes into account cytogenetics,&#160;percentage of bone marrow blasts, and the degree of anemia, thrombocytopenia, and neutropenia. This System categorizes patients into very low, low, intermediate, high, and very high risk MDS. High risk and very high risk MDS are characterized by more </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">unfavorable cytogenetics, bone marrow blast percentages greater than 5% but under the 20% threshold for AML, and worse cytopenias (anemia, thrombocytopenia, and neutropenia) &#8211; all of which cumulatively generate an IPSS-R score of &gt;4.5 to 6 for high risk MDS and &gt;6 for very high risk MDS. Furthermore, they are generally progressive in nature and can easily progress to AML. Treatment is stratified according to medical fitness in a manner similar to that for older patients with AML. Patients who are medically fit or of intermediate fitness are generally evaluated soon after diagnosis to determine their suitability for allo-SCT. For patients who are not candidates for intensive treatment, care is focused on relieving symptoms and improving the quality of life and might involve lower intensity treatment, for example, with azacitidine, decitabine, or targeted therapy. Patients with recurrent or refractory higher risk MDS may be encouraged to participate in clinical trials. Outside of a clinical trial, the management of patients with recurrent or refractory MDS is largely dependent on the patient&#8217;s prior therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">BPDCN is categorized by the WHO under AML. Most often, BPDCN presents with features of both lymphoma and leukemia. There is little data about BPDCN and the only approved drug for this disease is tagraxofusp-erzs, which is indicated for the treatment of adult and pediatric patients with both treatment-na&#239;ve and previously-treated BPDCN. The average age at diagnosis is 60 to 70&#160;years. BPDCN is very often misdiagnosed and under-reported. The skin is the most frequently involved site of disease (80&#160;percent of cases). However, BPDCN usually progresses with bone marrow involvement and a decrease in red blood cell, white blood cell and platelet counts. The lymph nodes and spleen may also be involved. Common misdiagnoses for BPCDN include non-Hodgkin lymphoma (&#8220;NHL&#8221;), AML, leukemia cutis [a nonspecific term used for cutaneous (skin) manifestation of any type of leukemia], melanoma (a type of skin cancer), and lupus erythematosus (chronic inflammatory disease that occurs when the body&#8217;s immune system attacks its own tissues and organs). There are no data or randomized clinical trials that can define the best first treatment for patients with BPDCN. In addition to the emerging use of tagraxofusp-erzs, which was approved by the FDA in December&#160;2018, treatment sometimes includes therapies that are used for AML, ALL, or lymphoma. The time for which a patient responds to these treatments is usually short. After a relapse, second remissions with conventional chemotherapy are difficult to achieve. allo-SCT, especially if offered in first remission, may result in longer remissions. The current recommendation is for BPDCN patients to be evaluated for an allo-SCT as soon as possible and to begin searching for a donor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The use of CAR T immunotherapy in relapsed BPDCN, AML, and HR-MDS patients may offer the potential to achieve a complete or longer lasting remission. COH investigators have developed CD123-targeted CAR T cells designed to be activated, to proliferate, and to kill CD123-expressing tumor cells [Mardiros A <i style="font-style:italic;">et al</i>. <i style="font-style:italic;">Blood</i>. 2013;122(18):3138-3148]. The therapy is designed to recognize and eliminate malignant cells, leading to remission in patients with relapsed or refractory BPDCN, AML, and HR-MDS, and could serve as a bridge to potentially curative allogeneic stem cell transplant. The manufacturing process genetically modifies T cells isolated from peripheral blood mononuclear cells in order to express a CD123-specific, hinge-optimized, CD28 co-stimulatory domain-expressing CAR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In October 2020, we announced the dosing of the first patient in a multicenter Phase 1/2 clinical trial of MB-102 in patients with relapsed or refractory BPDCN (<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Clinicaltrials.gov</span> Identifier: NCT04109482). This is also the first clinical trial under a Mustang IND in which a patient was dosed with cells processed in our manufacturing facility. In December 2022, we announced that the safety review team (&#8220;SRT&#8221;), after thoroughly reviewing the safety data from Dose Level 1 (100 x 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">6</sup> CAR T cells), unanimously recommended dose escalation to Dose Level 2 (300 x 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">6</sup> CAR T cells). We anticipate initiation of Dose Level 2 cohort in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"> &#160;<span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">MB-104 (CS1 CAR T for Multiple Myeloma and Light Chain Amyloidosis)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">CS1 (also known as CD319, CRACC and SLAMF7) was identified as a natural killer (&#8220;NK&#8221;) cell receptor regulating immune functions. It is also expressed on B cells, T cells, dendritic cells, NK-T cells, and monocytes. CS1 is overexpressed in multiple myeloma (&#8220;MM&#8221;) and light chain amyloidosis (&#8220;AL&#8221;), which makes it a good target for immunotherapy. A humanized anti-CS1 antibody, elotuzumab (Empliciti&#8482;), has shown promising results in clinical studies and <span style="color:#202124;background:#ffffff;">was&#160;initially approved by the FDA in 2015&#160;in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies</span>. Despite great advances in treatment, MM remains an incurable malignancy of plasma cells. AL is a protein deposition disorder that is a result of a plasma cell dysplasia, similar to MM. Immunotherapy is an attractive approach for AL because of the low burden of disease. Our academic partners at COH have developed a novel second generation CS1-specific CAR T cell therapy. In preclinical studies, they have demonstrated efficacy of these CAR T cells, both <i style="font-style:italic;">in vitro</i> and <i style="font-style:italic;">in vivo</i>, within the context of clinically relevant models of MM and AL. COH is evaluating the safety of this CS1-specific CAR T cell therapy in a Phase 1 trial that commenced in the first half of 2019 (ClinicalTrials.gov Identifier: NCT03710421). Once COH has established a safe and effective dose for MB-104 in this trial, we expect to file an IND for a multicenter Phase 1/2 trial for the treatment of patients with MM.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">MB-106 (CD20 CAR T for B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">CD20 is a promising target for immunotherapy of B-cell malignancies. CD20 is a B-cell lineage-specific phosphoprotein that is expressed in high, homogeneous density on the surface of more than 95% of B-cell NHL and CLL. CD20 is stable on the cell surface with minimal shedding, internalization, or modulation upon antibody binding and is present at only nanomolar levels as a soluble antigen. It is well established as an effective immunotherapy target, with extensive studies demonstrating improved tumor responses and survival of B-NHL patients treated with rituximab and other anti-CD20 antibodies. Importantly, CD20 continues to be expressed on the lymphoma cells of most patients with relapsed B-NHL despite repetitive rituximab treatments, and loss of CD20 expression is not a major contributor to treatment resistance. Thus, there is strong rationale for testing CD20 CAR T cells as an immunotherapy for NHL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">More than 80,000 new cases of NHL are diagnosed each&#160;year in the United States, and over 20,000 patients die of this group of diseases annually. Most forms of NHL including follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, and small lymphocytic lymphoma (&#8220;SLL&#8221;), which account collectively for ~45% of all cases of NHL, are incurable with available therapies, except for allo-SCT. However, many NHL patients are not suitable candidates for allo-SCT, and this treatment is also limited by significant rates of morbidity and mortality due to graft-versus-host disease. Aggressive B-cell lymphomas such as diffuse large B-cell lymphoma account for an additional 30-35% of NHL. The majority of patients with aggressive B-NHL are successfully treated with combination chemotherapy, but a significant proportion relapse or have refractory disease, and the outcome of these patients is poor. Innovative new treatments are therefore urgently needed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#232323;">Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a mature B cell neoplasm characterized by a progressive accumulation of monoclonal B lymphocytes. CLL is considered to be identical (i.e., one disease with different manifestations) to the NHL SLL. The malignant cells seen in CLL and SLL have identical pathologic and immunophenotypic features. The term CLL is used when the disease manifests primarily in the blood, whereas the term SLL is used when involvement is primarily nodal. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#232323;">CLL is the most common leukemia in adults in Western countries, accounting for approximately 25 to 35 percent of all leukemias in the United States. It is estimated that 18,740 new cases of CLL will be diagnosed in the United States in 2023. CLL is considered to be mainly a disease of older adults, with a median age at diagnosis of approximately 70 years; however, it is not unusual to make this diagnosis in younger individuals (e.g., from 30 to 39 years of age). The incidence increases rapidly with increasing age. The natural history of CLL is extremely variable, with survival times from initial diagnosis that range from approximately 2 to 20 years, and a median survival of approximately 10 years.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="color:#232323;">Most patients will have a complete or partial response to initial therapy. However, conventional therapy for CLL is not curative and most patients experience relapse. In addition, many patients will require a change in therapy due to intolerance.&#160;Since patients with CLL are generally elderly with a median age older than 70 years, and due to the relatively benign course of the disease in the majority of patients, only selected patients are candidates for intensive treatments such as allo-SCT. </span>Innovative new treatments with a favorable safety profile are therefore urgently needed for patients with relapsed and refractory disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under their IND, Fred Hutch is currently conducting a Phase 1/2 clinical study to evaluate the anti-tumor activity and safety of administering CD20-directed third-generation CAR T cells incorporating both 4-1BB and CD28 co-stimulatory signaling domains &#160;(MB-106) to patients with relapsed or refractory B-cell NHL or CLL (ClinicalTrials.gov Identifier: NCT03277729). Secondary endpoints of this study include safety and toxicity, preliminary antitumor activity as measured by overall response rate and complete remission rate, progression-free survival, and overall survival. The study is also assessing CAR T cell persistence and the potential immunogenicity of the cells. Finally, the study was designed so that Mustang together with Fred Hutch could determine a recommended Phase 2 dose. Fred Hutch intends to enroll approximately 50 subjects in the study, which is being led by Principal Investigator Mazyar Shadman, M.D., M.P.H., Assistant Member of Fred Hutch&#8217;s Clinical Research Division.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Fred Hutch IND was amended in 2019 to incorporate an optimized manufacturing process that had been developed in collaboration with Mustang. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2021, we announced that the FDA had approved our IND application &#160;allowing for initiation of a multi-center Phase 1/2 clinical study &#160;of MB-106 in patients with relapsed or refractory B cell NHL or CLL (Clinicaltrials.gov Identifier: NCT05360238).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2021, Mustang was awarded a grant of approximately $2 million from NCI of the National Institutes of Health. This two-year award will partially fund the Mustang-sponsored multicenter trial to assess the safety, tolerability and efficacy of MB-106.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CAR T Therapies for Solid Tumors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">MB-103 (HER2 CAR T for GBM&#160;&amp; Metastatic Breast Cancer to Brain)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">HER2/neu (&#8220;HER2&#8221;) is a growth-promoting protein on the outside of all breast cells. Breast cancer cells with higher-than-normal levels of HER2 are called HER2-positive (&#8220;HER2+&#8221;). These cancers tend to grow and spread faster than other breast cancers. Breast cancer is the most commonly diagnosed cancer in women, with over 42,000 women in the United States expected to die from advanced metastatic disease in 2023. Approximately 20% to 25% of breast cancers overexpress HER2, which is an established therapeutic target of both monoclonal antibodies (mAbs) and receptor tyrosine kinase inhibitors. With the advent of effective mAbs directed against HER2, the median overall survival of patients with metastatic HER2+ breast cancer has improved. However, management of metastatic disease in the brain and/or CNS&#160;&#8211; observed in up to 50% of HER2+ breast cancer patients&#160;&#8211; continues to be a clinical challenge in large part due to the inability of mAbs to sufficiently cross the blood-brain barrier. Although small-molecule inhibitors of HER2 exist and have been clinically approved, their single-agent efficacy in the context of metastatic disease to the brain has been limited. While HER2-targeted therapy in combination with conventional agents has shown some promise for the treatment of patients with metastatic breast cancer, control of brain metastases remains a significant unmet clinical need, as most patients survive less than two&#160;years following CNS involvement. Recent advances in cellular immunotherapy approaches have underscored the potential for potent antitumor immune responses and clinical benefit against solid cancers, and these approaches may be effective in the treatment of HER2+ cancers&#160;&#8211; in particular breast cancer&#160;&#8211; that have metastasized to the brain. Likewise, HER2 has been suggested as a suitable target for GBM, wherein elevated HER2 protein levels have been correlated with impaired survival.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">CAR T cell immunotherapy is being actively investigated for the treatment of solid tumors, including HER2+ cancers. Our academic partners at COH have developed a second-generation HER2-specific CAR T cell therapy for the treatment of brain and/or leptomeningeal metastases from HER2+ cancers, as well as for the treatment of refractory/relapsed HER2+ GBM. COH&#8217;s preclinical data demonstrate effective targeting of breast cancer brain metastases with intraventricular delivery of CAR T cells expressing HER2-CARs that contain the 4-1BB costimulatory domain. COH is evaluating the safety of this HER2-specific CAR T cell therapy in two ongoing Phase 1 clinical trials that commenced in the fourth quarter of 2018 (ClinicalTrials.gov Identifier: NCT03389230 for HER2+ GBM; ClinicalTrials.gov Identifier: NCT03696030 for HER2+ brain metastases).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">MB-105 (PSCA CAR T for Prostate&#160;&amp; Pancreatic Cancers)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">PSCA is a glycosylphosphatidylinositol-anchored cell membrane glycoprotein. In addition to being highly expressed in the prostate it is also expressed in the bladder, placenta, colon, kidney, and stomach. This gene is upregulated in a large proportion of prostate cancers and is also detected in cancers of the bladder and pancreas. The gene includes a polymorphism that results in an upstream start codon in some individuals; this polymorphism is thought to be associated with a risk for certain gastric and bladder cancers. Prostate cancer may be amenable to T cell-based immunotherapy since several tumor antigens, including prostate stem-cell antigen (&#8220;PSCA&#8221;), are widely overexpressed in metastatic disease. Our academic partners at COH have developed a second-generation PSCA-specific CAR T cell therapy that has demonstrated robust <i style="font-style:italic;">in vitro</i> and <i style="font-style:italic;">in vivo</i> anti-tumor activity in patient-derived, clinically relevant, bone-metastatic prostate cancer xenograft models. COH is evaluating the safety of this PSCA-specific CAR T cell therapy in an ongoing Phase 1 trial treating patients with PSCA+ metastatic castration-resistant prostate cancer (ClinicalTrials.gov Identifier: NCT03873805).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In October 2020,we announced initial data from this Phase 1 clinical trial in patients with PSCA-positive castration-resistance prostate cancer (&#8220;CRPC&#8221;). In the presentation at the 2020 Annual Prostate Cancer Foundation Scientific Retreat, the COH principal investigator reported results from a highly refractory patient treated with MB-105 who experienced a 94 percent reduction in prostate-specific antigen (&#8220;PSA&#8221;), a nearly complete reduction of measurable soft tissue metastasis by computerized tomography, and improvement in bone metastases by magnetic resonance imaging.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MB-109: Combination MB-101</b><span style="font-style:italic;font-weight:bold;">(IL13R&#945;2 CAR T Cell Program for Glioblastoma)</span> <b style="font-weight:bold;">and MB-108 </b><span style="font-style:italic;font-weight:bold;">(HSV-1 oncolytic virus C134) as a Potential Treatment for </span><span style="font-style:italic;font-weight:bold;">IL13R&#945;2+ Relapsed or Refractory Glioblastoma (GBM) and Anaplastic Astrocytoma (AA).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">An attractive novel approach to control glioblastoma is adoptive cellular immunotherapy utilizing CAR T cells. CAR T cells can be engineered to recognize very specific antigenically distinct tumor populations and to migrate through the brain parenchyma to kill malignant cells. In addition, oncolytic viruses (&#8220;OVs&#8221;) have been developed to effectively infect and kill cancer cells in the tumor, as well as modify the microenvironment to increase tumor immunogenicity and immune cell trafficking within the tumor. Due to these properties, OVs have been studied in combination with other treatments to enhance the effectiveness of immunotherapies. </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Preliminary anti-tumor activity has been observed in clinical studies administering the OV (MB-108) and CAR T cell therapy (MB-101) as single agents; however, the combination has not yet been explored. To determine if the combination of both therapies will result in a synergistic effect, investigators from COH developed preclinical studies in orthotopic GBM models in nude mice. &#160;Dr. Christine Brown from City of Hope presented these preclinical studies at the American Association for Cancer Research 2022 annual meeting. &#160;It was observed that co-treatment with C134 OV and IL13R&#945;2-directed CAR-T cells gave no adverse reaction and, more notably, that pre-treatment with C134 re-shaped the tumor microenvironment by increasing immune cell infiltrates and enhanced the efficacy of sub-therapeutic doses of CAR-T cell therapy delivered either intraventricularly or intratumorally. These preclinical studies aimed to provide a deeper understanding of this combination approach to support the potential benefit of a combination study that will evaluate C134 OV (MB-108) and IL13R&#945;2-directed CAR-T cells (MB-101). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We received Pre-IND Written Responses from the FDA in May 2022, and we expect to file an IND for the combination trial of C134 oncolytic virus (MB-108) and IL13R&#945;2-directed CAR- T cells (MB-101) in 2023. &#160;In the planned Phase 1 clinical study, we intend to evaluate the combination of CAR-T cells (MB-101) and the C134 oncolytic virus (MB-108) in patients with IL13R&#945;2+ high-grade gliomas. &#160;The proposed design of this study will &#160;investigate increasing doses of intratumorally administered MB-108 followed by dual intratumoral (ICT) and intraventricular (ICV) administration of MB-101.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">MB-101 (IL13R&#945;2 CAR T Cell Program for Glioblastoma)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">GBM is the most common brain and central nervous system (&#8220;CNS&#8221;) cancer, accounting for 49.1% of malignant primary brain and CNS tumors, 54% of all gliomas, and 16% of all primary brain and CNS tumors. More than 13,000 new glioblastoma cases were predicted in the U.S. for 2022. Malignant brain tumors are the second leading cause of cancer-related deaths in adolescents and young adults aged 15-39 and the most common cancer occurring among 15-19-year-olds in the U.S. While GBM is a rare disease [2-3 cases per 100,000 persons per&#160;year in the U.S. and European Union (&#8220;EU&#8221;)], it is quite lethal, with five-year survival rates historically under 10%. Standard of care therapy consists of maximal surgical resection, radiation, and chemotherapy with temozolomide, which, while rarely curative, is shown to extend median overall survival from 4.5 to 15&#160;months. GBM remains difficult to treat due to the inherent resistance of the tumor to conventional therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Immunotherapy approaches targeting brain tumors offer promise over conventional treatments. IL13R<i style="font-style:italic;">&#945;</i>2 is an attractive target for CAR T therapy, as it has limited expression in normal tissue but is overexpressed on the surface of greater than 50% of GBM tumors.&#160;CAR-T cells are designed to express membrane-tethered IL-13 receptor ligand (&#8220;IL-13&#8221;) mutated at a single site (glutamic acid at position 13 to a tyrosine; E13Y) with high affinity for IL13R&#945;2 and reduced binding to IL13R&#945;1 in order to reduce healthy tissue targeting (Kahlon KS <i style="font-style:italic;">et al. Cancer Research.</i> 2004;64:9160-9166).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are developing an optimized CAR-T product incorporating enhancements in CAR-T design and T cell engineering to improve antitumor potency and T cell persistence. These include a second-generation hinge-optimized CAR containing mutations in the IgG4 linker to reduce off-target Fc interactions (Jonnalagadda M <i style="font-style:italic;">et al. Molecular Therapy.</i> 2015;23(4):757-768.), a 4-1BB (CD137) co-stimulatory signaling domain for improved survival and maintenance of CAR T cells, and the extracellular domain of CD19 as a selection/tracking marker. In order to further improve persistence, either central memory T-cells (T<sub style="font-size:7.5pt;vertical-align:sub;">CM</sub> ) or enriched CD62L+ na&#239;ve and memory T cells (T<sub style="font-size:7.5pt;vertical-align:sub;">N/MEM</sub>) are isolated and enriched. Our manufacturing process limits <i style="font-style:italic;">ex vivo</i> expansion, which is designed to reduce T cell exhaustion and maintain a T<sub style="font-size:7.5pt;vertical-align:sub;">CM</sub> or T<sub style="font-size:7.5pt;vertical-align:sub;">N/MEM </sub>phenotype. Based on experiments with CAR-Ts in mouse xenograft models of GBM, these CAR-modified T<sub style="font-size:7.5pt;vertical-align:sub;">CM</sub> and T<sub style="font-size:7.5pt;vertical-align:sub;">N/MEM</sub> cells have been shown to be more potent and persistent than earlier generations of CAR-T cells. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our academic partners at COH have completed a Phase 1 study to assess the feasibility and safety of using T<sub style="font-size:7.5pt;vertical-align:sub;">CM</sub> or T<sub style="font-size:7.5pt;vertical-align:sub;">N/MEM</sub> enriched IL13R&#945;2-specific CAR-engineered T cells for clinical study participants with recurrent/refractory malignant glioma (ClinicalTrials.gov Identifier: NCT02208362). As of May 2022 COH had enrolled and treated 65 patients. &#160;Preliminary data for patients enrolled in Arm 2 of the protocol (the &#8220;Intracavitary Arm&#8221;) were presented at the annual meeting of the American Association for Cancer Research in April&#160;2018. The data indicated that the CAR-T cells were well tolerated, and no dose-limiting toxicities had been observed. In 2016 COH reported that a patient had achieved a complete response to treatment based on the imaging and clinical features set forth by the Response Assessment in Neuro-Oncology Criteria (&#8220;RANO&#8221;). This result was published as a case report in the <i style="font-style:italic;">New England Journal of Medicine </i>(Brown CE et al. <i style="font-style:italic;">NEJM. </i>2016;375:2561-9). As described in the paper, this patient diagnosed with recurrent multifocal glioblastoma received multiple infusions of IL13R&#945;2-specific CAR-T cells over 220&#160;days through two intracranial delivery routes&#160;&#8211; infusions into the resected tumor cavity followed by infusions into the ventricular system. Intracranial infusions of IL13R&#945;2-targeted CAR-T cells were not associated with any toxic effects of grade 3 or higher. After CAR-T cell treatment, regression of all intracranial and spinal tumors was observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid. This clinical response was sustained for 7.5&#160;months after the initiation of CAR T-cell therapy; however, the patient&#8217;s disease eventually recurred at four new locations that were distinct and non-adjacent to the original tumors, and biopsy of one of these lesions showed decreased expression of IL13R&#945;2. With </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">enrollment in this Phase 1 study completed, COH has established the recommended Phase 2 dose, schedule and route of administration, as well as the optimal T cell selection. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Results from this COH study have laid the foundation for 3 new MB-101 studies:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">MB-101 with or without nivolumab and ipilimumab in treating patients with recurrent or refractory&#160;glioblastoma (currently enrolling patients; ClinicalTrials.gov Identifier: NCT04003649) sponsored by COH;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">MB-101 in treating patients with recurrent or refractory&#160;glioblastoma with a substantial component of leptomeningeal disease (currently enrolling patients; ClinicalTrials.gov Identifier: NCT04661384) sponsored by COH;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">MB101 in combination with the C134 oncolytic virus (MB108) in treating patients with recurrent or refractory&#160;glioblastoma or anaplastic astrocytoma (IND filing expected in 2023). This combination therapy, to be administered in a phase 1 two-center trial under Mustang IND, will be referred to as MB-109.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Technology to Convert GBM from an Immunologically Cold Tumor to an Immunologically Hot Tumor</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">MB-108 (HSV-1 oncolytic virus C134)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">MB-108 is a next-generation oncolytic herpes simplex virus (&#8220;oHSV&#8221;) that is conditionally replication competent; that is, it can replicate in tumor cells, but not in normal cells, thus killing the tumor cells directly through this process. Replication of C134 in the tumor itself not only kills the infected tumor cells but causes the tumor cell to act as a factory to produce new virus. These virus particles are released as the tumor cell dies and can then proceed to infect other tumor cells in the vicinity and continue the process of tumor kill. In addition to this direct oncolytic activity, the virus promotes an immune response against surviving tumor cells, which increases the antitumor effect of the therapy. The virus expresses a gene from another virus from the same overall virus family, human cytomegalovirus, which allows it to replicate better in the tumor cells than its first-generation predecessors. However, the virus has also been genetically engineered to minimize the production of any toxic effects for the patient receiving the therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To improve this virus over its first-generation predecessors, modifications have focused on improving viral replication and spread within the tumor bed and on enhancing bystander damage to uninfected tumor cells. These effects cumulatively should result in converting an immunologically cold tumor to an immunologically hot tumor, which Mustang anticipates will increase the efficacy of its IL13R&#945;2-directed CAR T for the treatment of GBM and anaplastic astrocytoma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">UAB is the clinical trial site for the Phase 1 trial of MB-108, and the site has initiated a Phase 1 trial that began enrolling patients in 2019 (ClinicalTrials.gov Identifier: NCT03657576). The primary objective of this study is to determine the safety and tolerability of stereotactic intracerebral injections of escalating doses of MB-108 and to determine the maximally tolerated dose (&#8220;MTD&#8221;) of the oncolytic virus. Secondary objectives are to obtain preliminary information about the potential benefit of MB-108 in the treatment of patients with recurrent malignant gliomas, including relevant data on markers of efficacy, including time to tumor progression and patient survival.&#160;This trial has been on clinical hold since September 2022 due to toxicity, and UAB expects FDA clearance in 2023 in order to resume enrolling patients at a lower dose level. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">In Vivo CAR T Platform Technology</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Mustang is collaborating with the Mayo Clinic to develop a novel technology that may be able to transform the administration of CAR T therapies and potentially be used as an off-the-shelf therapy. The technology, developed by Larry R. Pease, Ph.D., principal investigator and former director of the Center for Immunology and Immune Therapies at Mayo Clinic, is a new platform to administer CAR T therapy using a two-step approach. First, a peptide is administered to the patient to drive the proliferation of the patient&#8217;s resident T cells. This is followed by the administration of a viral CAR construct directly into the lymph nodes of the patient. In turn, the viral construct infects the activated T cells and effectively forms CAR T cells <i style="font-style:italic;">in vivo</i> in the patient. Successful implementation may lead to an off-the-shelf product with no need to isolate and expand patient T cells <i style="font-style:italic;">ex vivo</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preclinical proof-of-concept has been established, and the ongoing development of this technology will take place at Mayo Clinic. &#160;Mustang plans to file an IND application for a multicenter Phase 1 clinical trial once a lead construct has been identified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Gene Therapies for Rare Genetic Disorders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">MB-107 and MB-207 (Ex vivo Lentiviral Therapy for X-linked Severe Combined Immunodeficiency (XSCID))</span></p><a id="_Hlk98695056"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">XSCID is a rare genetic immune system condition that occurs almost exclusively in males, in which affected patients do not live beyond infancy without treatment. Mustang Bio&#8217;s first-in-class <i style="font-style:italic;">ex vivo</i> lentiviral gene therapy for XSCID has been administered as two distinct cellular products using the same lentiviral vector in two phase 1/2 clinical trials: (1) an ongoing multicenter trial of MB-107 in newly diagnosed patients being led by St. Jude and including also UCSF Benioff Children&#8217;s Hospital San Francisco (&#8220;UCSF&#8221;) and Seattle Children&#8217;s Hospital (&#8220;Seattle Children&#8217;s&#8221;) (ClinicalTrials.gov Identifier: NCT01512888) and (2) a single center trial of MB-207 at the NIH in patients who have previously undergone hematopoietic stem cell transplantation (ClinicalTrials.gov Identifier: NCT01306019).</p><a id="_Hlk98695192"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MB-207 (previously transplanted patients):</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The last peer-reviewed presentation by the NIH Principal Investigator, Dr. Harry Malech, occurred at the 61st Annual Meeting of the American Society of Hematology (&#8220;ASH&#8221;) in December&#160;2019, at which time 24 patients had been treated in total. Eleven patients under the age of two&#160;years had been treated at St. Jude and UCSF and thirteen patients 3 to 34&#160;years of age had been treated at the NIH<i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The existing data from these 24 patients were encouraging. In the initial stage of accrual to the Phase 1/2 NIH trial, eight patients (referred to as Cohort A) were followed for 3 to 7&#160;years. Among Cohort A, seven patients aged 3 to 23&#160;years increased host T cells chimerism from 0-2% to 28-93% and had normal T cell proliferation response. These seven patients also normalized their IgM levels, and four of these patients were able to discontinue immunoglobulin replacement therapy. In addition, gradual clinical benefit was observed in the clearance of chronic norovirus and associated abdominal complaints, malabsorption, and growth retardation, with six of seven affected patients being cured of their disease. Five of six patients resolved their protein-losing enteropathy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While the Cohort A results were impressive, the relatively inefficient transduction of hematopoietic stem/progenitor cells (&#8220;HSPCs&#8221;) required large quantities of vector. This resulted in relatively low vector copy number in myeloid cells in some patients, with delayed immune cell recovery and persistent clinical disease, especially in the last patient treated (patient 8). To address this, NIH developed a refined enhanced transduction (&#8220;ET&#8221;) procedure and incorporated two transduction enhancers: LentiBOOST&#8482; 1mg/mL and dimethyl prostaglandin 2 (dmPGE2; 1&#181;M) into the manufacturing process from MB-207.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to the Cohort A results, the NIH presentation at the 2019 ASH Annual Meeting included data from six ET patients (referred to as Cohort B) treated from February&#160;to June&#160;2019, including re-treatment of patient 8. Prior to undergoing gene therapy, the patients, who were aged 12 to 36&#160;years, had significant problems with donor T cell infiltration of liver, bone marrow and kidneys and had nearly absent B and NK cells. The ET procedure achieved much greater transduction efficiencies than were observed in Cohort A, with greater than 10-fold less vector, and resulted in faster immune reconstitution and more significant clinical benefit by 3&#160;months. As noted by the investigators, longer follow-up will be required to know if the increased vector marking using the ET regimen will prove to be stable and safe long term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In all NIH patients, the low-dose, nonmyeloablative busulfan pretreatment conditioning was well tolerated, and of a low enough intensity to avoid the need for transfusions of red blood cells or platelets. No evidence of malignant transformation was observed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In a press release dated February 2, 2021, we further disclosed that, of the 6 Cohort A patients who were alive at the time of the 2019 NIH data readout and who did not undergo repeat therapy, 3 patients were able to discontinue chronic intravenous immunoglobulin (IVIG) and experienced sustained restoration of humoral responses to immunization.&#160;The remaining 3 patients had reduced IVIG requirements.&#160;All chronic norovirus infections were resolved, and the quality of life of all patients had improved significantly. The original 6 patients in Cohort B also continued to do well, with the longest follow-up being 22 months.&#160;Two additional patients were successfully treated with transduction enhancers, for a total of 8 patients in Cohort B. As was the case in Cohort A, no serious adverse events related to treatment were reported other than hematologic related to low-dose busulfan conditioning, and there was no evidence of malignant transformation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">As a result of the study stopping rules, the NIH study was suspended in 2022 due to the presence of clonal expansion in the myeloid lineage in 10% of the treated patients, although to date there have been no observations of insertional mutagenesis or malignancies. All patients continue to be followed and remain clinically stable with no significant hematological anomalies. Upon review of these data, the FDA agree that the risk-benefit ration of both MB-107 and MB-207 remains favorable to support moving forward with the Mustang-sponsored multicenter clinical trials once Mustang has appropriately addressed other items flagged by the Agency. &#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The IND for MB-207 was submitted to the FDA in December 2021. &#160;In January 2022, the FDA issued a clinical hold, pending additional CMC data. In order to lift this clinical hold and receive an FDA safe-to-procced for the IND, we believe the most critical activities will be </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">to (1) perform process validation manufacturing runs using healthy donor material and (2) ensure qualification of all assays related to the product release. Following completion of these activities and the earliest release of the clinical hold by FDA, we expect to enroll the first patient in a pivotal multicenter Phase 2 clinical trial in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">MB-207 received Orphan Drug Designation from the FDA in September 2020. &#160;The FDA also granted Rare Pediatric Disease Designation for MB-207 in August 2020. If Mustang&#8217;s BLA for MB-207 is approved, the Company may be eligible to receive a priority review voucher for this product as well, which can also be redeemed to obtain priority review for any subsequent marketing application and may be sold or transferred. The European Medicines Agency (&#8220;EMA&#8221;) granted Advanced Therapy Medicinal Product (&#8220;ATMP&#8221;) classification to MB-207 in April 2020 and Orphan Drug designation in April 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">MB-107 (newly diagnosed patients):</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Interim Phase 1/2 data on treatment of newly diagnosed infants under the age of two with the same LV vector used in MB-107 were updated at an oral presentation at the American Society of Gene &amp; Cell Therapy (&#8220;ASGCT&#8221;) 25<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Annual Meeting held from May 16-19, 2022. The data included 23 infants with XSCID treated with the LV vector at a median age of 3 months (range: 2 months to 14 months) with a median follow-up of 2.4 years (range: 1.4 months to 5.4 years), making it the largest known cohort of infants treated with LV gene therapy with the longest follow-up. Transduced autologous bone marrow CD34+ cells were generated for all patients with a median vector copy number (VCN) of 0.81/cell (range: 0.16-1.81), and a median CD34+ cell dose of 9.61x10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">6</sup>/kg (range 4.40-18.95). Prior to the infusion of cells, patients received busulfan targeted to a cumulative area-under-the-curve (cAUC) of 22 mg*hr/L. Severe adverse events occurred in three patients (two patients with pancytopenia and hemolytic anemia, and one patient with delayed neutrophil engraftment), and all resolved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Seventeen of 18 patients with a follow-up of &gt; 6 months achieved robust immune reconstitution [median CD3+ 2,545/&#181;L, CD4+ 1,568/&#181;L, CD4+/CCR7+/CD45R0- 1,416/&#181;L]. &#160;In these 17 patients, T cells matured appropriately as assessed by normal T cell receptor excision circles (TRECs) and TCRv&#946; repertoire diversity and were functional as judged by phytohemagglutinin activation (&#8220;PHA&#8221;). All patients were alive with stable vector marking in all cell lineages. &#160;In addition, 15 patients &#160;had &#160;discontinued intravenous immunoglobulin, and 12 patients had &#160;been successfully immunized. &#160;No evidence of clonal expansion or malignant transformation was observed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The MB-107 timeline has been extended due to unanticipated issues related to the materials used in manufacturing. These issues were communicated to the FDA and the Company received a written response on August 26, 2022.&#160; The FDA response provided additional direction enabling us to effectively continue to work with our outside suppliers. We are working towards enrolling the first patient in a pivotal multicenter Phase 2 clinical trial under our IND in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">MB-107 received Orphan Drug Designation in August 2020 and Rare Pediatric Disease and Regenerative Medicine Advanced Therapy (&#8220;RMAT&#8221;) designations in August 2019. Finally, the FDA designated MB-107 a Rare Pediatric Disease in August 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The FDA grants Rare Pediatric Disease Designation for serious and life-threatening diseases that primarily affect children ages 18 years or younger and affect fewer than 200,000 people in the United States. If Mustang&#8217;s BLA for MB-107 is approved, the Company may be eligible to receive a priority review voucher, which can be redeemed to obtain priority review for any subsequent marketing application and may be sold or transferred. This program is intended to encourage development of new drugs and biologics for the prevention and treatment of rare pediatric diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The EMA, granted Priority Medicines (&#8220;PRIME&#8221;) designation to MB-107 in July 2021, and ATMP classification to MB-107 in April 2020 and Orphan Drug designation in November 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">MB-110 (Ex vivo Lentiviral Therapy for RAG1 Severe Combined Immunodeficiency (SCID))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under an exclusive license and in partnership with LUMC, MB-110, a first-in-class <i style="font-style:italic;">ex vivo</i> treatment for RAG1 SCID, is under development. Severe combined immunodeficiency (&#8220;SCID&#8221;) due to complete recombinase-activating gene-1 (RAG1) deficiency is a rare, genetic disorder due to null mutations in the RAG1 gene resulting in less than 1% of wild type V(D)J recombination activity. Neonatal patients present with life-threatening, severe, recurrent infections by opportunistic fungal, viral and bacterial micro-organisms, as well as skin rashes, chronic diarrhea, failure to thrive and fever. Immunologic observations include profound T and B cell lymphopenia, low or absent serum immunoglobulins, and normal natural killer cell counts. As is the case with other types of SCID, RAG1-SCID is fatal in infancy unless immune reconstitution is achieved with hematopoietic stem cell transplantation (HSCT).</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">MB-110, which includes low-dose conditioning prior to reinfusion of the patients&#8217; own gene-modified blood stem cells, is currently being evaluated in a Phase 1/2 multicenter clinical trial in Europe. The ongoing clinical trial has enrolled its first patient, and additional clinical </span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">sites are expected to be added in the near future. The RAG1-SCID program has been granted Orphan Drug Designation by the European Medicines Agency. </span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Mustang also established an ongoing partnership with Frank J. Staal, Ph.D., professor of Molecular Stem Cell Biology and molecular immunologist at LUMC, whose laboratory developed the MB-110 therapy. Dr. Staal will continue the development of additional LV gene therapies in his lab, to which Mustang Bio has rights under the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INTELLECTUAL PROPERTY AND PATENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our goal is to obtain, maintain and enforce patent protection for our products, formulations, processes, methods and other proprietary technologies, preserve our trade secrets, and operate without infringing on the proprietary rights of other parties, both in the U.S. and in other countries.&#160;Our policy is to actively seek to obtain, where appropriate, the broad intellectual property protection for our product candidates, proprietary information and proprietary technology through a combination of contractual arrangements and patents, both in the U.S. and elsewhere in the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also depend upon the skills, knowledge and experience of our scientific and technical personnel, as well as that of our advisors, consultants and other contractors (&#8220;know-how&#8221;). To help protect our proprietary know-how which is not patentable, and for inventions for which patents may be difficult to enforce, we rely on trade secret protection and confidentiality agreements to protect our interests.&#160;To this end, we require all employees, consultants, advisors and other contractors to enter into confidentiality agreements which prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions that they generate or make, and which are important to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patents and other proprietary rights are crucial to the development of our business. We will be able to protect our proprietary technologies from unauthorized use by third parties only to the extent that our proprietary rights are covered by valid and enforceable patents, supported by regulatory exclusivity or are effectively maintained as trade secrets. We have a few patents and patent applications related to our compounds and other technology, but we cannot guarantee the scope of protection of the issued patents, or that such patents will survive a validity or enforceability challenge, or that any of the pending patent applications will issue as patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Generally, patent applications in the U.S. are maintained in secrecy for a period of 18&#160;months or more. The patent positions of biotechnology and pharmaceutical companies are highly uncertain and involve complex legal and factual questions. Therefore, we cannot predict the breadth of claims allowed in biotechnology and pharmaceutical patents, or their enforceability. To date, there has been no consistent policy regarding the breadth of claims allowed in biotechnology patents. Third parties or competitors may challenge or circumvent our patents or patent applications, if issued. If our competitors prepare and file patent applications in the U.S. that claim technology also claimed by us, we may have to participate in interference or derivation proceedings declared by the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) to determine priority of invention, which could result in substantial cost, even if the eventual outcome is favorable to us. Because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that before we commercialize any of our products, any related patent may expire or remain in existence for only a short period following commercialization, thus reducing any advantage of the patent. However, the life of a patent covering a product that has been subject to regulatory approval may have the ability to be extended through the patent restoration program, although any such extension could still be minimal. Additionally, statutory caps impose further limitation on any such extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If a patent is issued to a third party containing one or more preclusive or conflicting claims, and those claims are ultimately determined to be valid and enforceable, we may be required to obtain a license, if available, under such patent or to develop or obtain alternative technology. In the event of litigation involving a third party claim, an adverse outcome in the litigation could subject us to significant liabilities to such third party, require us to seek a license for the disputed rights from such third party, and/or require us to cease use of the technology. Further, our breach of an existing license or failure to obtain a license to technology required to commercialize our products may seriously harm our business. We also may need to commence litigation to enforce any patents issued to us or to determine the scope and validity of third party proprietary rights. Litigation would not only involve substantial costs but would also involve substantial time commitments on the part of our key executives and research and development personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In March&#160;2015, we licensed intellectual property related to CAR T technology from COH. The portfolio of rights licensed from COH now includes patents and application directed to CARs targeting IL13R&#945;2, CD123, CS1, HER2, and PSCA, as well as rights related to modified CAR hinge regions and methods of preparing CAR T cells in particular subpopulations of cell and administering CAR T cells. The intellectual property licensed thereunder relating to IL13R&#945;2-targeting CARs includes granted patents in the U.S., Australia, China, Europe, </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Russia, Japan, Hong Kong, Israel, and Mexico, and this patent family further includes pending applications in the U.S., Australia, Brazil, Canada, China, Europe, South Korea, Russia, Japan, Israel, Mexico, and New Zealand. Any patents issuing from the IL13R&#945;2-targeting CAR will expire no sooner than 2035. The licensed intellectual property relating to relating to CD123-targeting CARs includes issues patents in the U.S., China, Europe, Hong Kong, Israel, Japan, South Korea, and Mexico, and this patent family further includes pending applications in the U.S., Australia, Brazil, China, Europe, Hong Kong, Israel, Japan, South Korea, Mexico, and New Zealand. Any patents issuing from the CD123-targeting CAR will expire no sooner than 2033. The licensed intellectual property relating to relating to CS1-targeting CARs includes issues patents in the U.S., Australia, Israel, and Russia, as well as pending applications in the U.S., Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, South Korea, Mexico, Japan, Russia, and New Zealand. Any patents issuing from the CS1-targeting CAR will expire no sooner than 2035, and some patents relating to particular methods involving CS1-targeting CARs will expire no sooner than 2038. The licensed intellectual property relating to relating to HER2-targeting CARs includes issues patents in Japan and Russia, as well as pending applications in the U.S., Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, Japan, South Korea, Russia, Mexico, and New Zealand. Any patents issuing from the HER2-targeting CAR will expire no sooner than 2036. The licensed intellectual property relating to relating to PSCA-targeting CARs includes issues patents in Europe and Hong Kong, as well as pending applications in the U.S., Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, Japan, South Korea, Russia, and New Zealand. The licensed intellectual property relating to relating modified CAR hinge regions includes issues patents in China, Europe, and Japan, as well as pending applications in the U.S., Australia, China, and Europe. The patents issuing from the modified CAR hinge region family will expire no sooner than 2034. The licensed intellectual property relating to relating to method of preparing or administering CAR T cells includes issues patents in China, Europe, and Japan, as well as pending applications in the U.S., Australia, Brazil, Canada, China, Europe, Hong Kong, Japan, Israel, Mexico, Russia, and New Zealand. The patents relating to these technologies will expire no sooner than 2035 or, in the case of the administration methods, 2036. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Also, in March&#160;2015, we executed a sponsored research agreement with COH, pursuant to which research is performed in the laboratory of Drs.&#160;Stephen Forman and Christine Brown. The sponsored research agreement gives us the right to first negotiation under specified maximum terms regarding any future inventions arising from the laboratory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May&#160;2017, we licensed intellectual property related to CAR T technology for targeting CD20 from Fred Hutch. The intellectual property includes an international application under the Patent Cooperation Treaty (i.e., a PCT application), which has now matured into several issued patents, including issued patents in the U.S. and Europe, as well as pending applications in the U.S., Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, Japan, South Korea, Mexico, New Zealand, and Russia. These applications contain claims relating to various CD20-targeting CAR constructs and CAR T cells, as well as methods of making and using the same. The national stage applications claiming priority to the PCT application were filed in May 2018 in order to begin substantive examination of the claims. Patents maturing from these national stage applications will expire no sooner than March&#160;2037.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In March&#160;2017, we licensed intellectual property related to antibodies and binding agents that specifically bind to PSCA from the University of California Los Angeles (&#8220;UCLA&#8221;). The intellectual property includes multiple granted patents and pending applications from around the world including the U.S., Europe, Japan, China, and Canada. The granted patents and patents maturing from the pending applications will expire no sooner than March&#160;2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August&#160;2018, we licensed from St. Jude Children&#8217;s Research Hospital XSCID Technology related to an <i style="font-style:italic;">ex vivo</i> lentiviral vector gene therapy program to provide a normal copy of the <i style="font-style:italic;">IL2RG</i> gene to patients born with XSCID.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In February&#160;2019, we licensed Material and Technical Information related to the HSV-1 oncolytic virus C134 from Nationwide in Columbus, Ohio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August&#160;2019, we licensed from CSL Behring (Calimmune) the Cytegrity<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> stable producer cell line developed and used by St. Jude. The Cytegrity<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> stable producer cell line will be used to produce the viral vector for MB-107.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In September 2020, we entered into an exclusive, worldwide licensing agreement with SIRION Biotech for the rights to SIRION&#8217;s LentiBOOST<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> technology for the development of MB-207. This license includes right to granted patents and pending applications in the U.S., Europe, Japan, and Israel. In December 2021 this licensing agreement was amended to include CD20-directed CAR Ts in addition to lentiviral stem cell gene therapy for the treatment of XSCID.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2021, we entered into an exclusive, worldwide licensing agreement with Leiden University Medical Centre for a first-in-class <i style="font-style:italic;">ex vivo</i> lentiviral gene therapy for the treatment of RAG1 severe combined immunodeficiency (&#8220;RAG1-SCID&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2021, we entered into an exclusive license agreement with Mayo Clinic for a novel technology that may be able to transform the administration of CAR T therapies and potentially allow such therapies to be used as an off-the-shelf therapy.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to the technology the Company has in-licensed, Mustang has also developed its own proprietary intellectual property, both alone and in conjunction with COH. In particular, Mustang filed a U.S. provisional application directed to optimized methods for manufacturing cell-based therapeutics, and Mustang and COH, as co-applicants, filed a U.S. provisional application directed to methods of treating hematological cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to the technology the company has in-licensed, Mustang has also developed its own proprietary intellectual property, both alone and in conjunction with COH. In particular, Mustang owns pending applications in the U.S. and Europe directed to methods for manufacturing cell-based therapeutics, and pending applications in the U.S., Taiwan, and PCT relating to anti-idiotype antibodies. Mustang and COH also own as co-applicants pending application in the U.S., Taiwan, and PCT directed to methods of treating hematological cancers with a combination therapy. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Intellectual Property Rights</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We depend upon trademarks, trade secrets, knowhow and continuing technological advances to develop and maintain our competitive position. To maintain the confidentiality of trade secrets and proprietary information, we require our employees, scientific advisors, consultants and collaborators, upon commencement of a relationship with us, to execute confidentiality agreements and, in the case of parties other than our research and development collaborators, to agree to assign their inventions to us. These agreements are designed to protect our proprietary information and to grant us ownership of technologies that are developed in connection with their relationship with us. These agreements may not, however, provide protection for our trade secrets in the event of unauthorized disclosure of such information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to patent protection, we may utilize orphan drug regulations or other provisions of the Food, Drug and Cosmetic Act of 1938, as amended (the &#8220;FDCA&#8221;), to provide market exclusivity for certain of our product candidates. Orphan drug regulations provide incentives to pharmaceutical and biotechnology companies to develop and manufacture drugs for the treatment of rare diseases, currently defined as diseases that exist in fewer than 200,000 individuals in the U.S., or diseases that affect more than 200,000 individuals in the U.S. but for which the sponsor does not realistically anticipate will generate a net profit. Under these provisions, a manufacturer of a designated orphan drug can seek tax benefits, and the holder of the first approval of a designated orphan product from the FDA will be granted a seven-year period of marketing exclusivity for such FDA approved orphan product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LICENSE, CLINICAL TRIAL AND SPONSORED RESEARCH AGREEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">St. Jude Children&#8217;s Research Hospital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">XSCID License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August&#160;2, 2018, the Company entered into an exclusive worldwide license agreement with St. Jude for the development of a first-in-class <i style="font-style:italic;">ex vivo</i> lentiviral gene therapy for the treatment of XSCID. The Company paid $1.0 million in consideration for the exclusive license in addition to an annual maintenance fee of $0.1 million (beginning in 2019). St. Jude is eligible to receive payments totaling $13.5 million upon the achievement of five development and commercialization milestones. Royalty payments in the mid-single digits are due on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">XSCID Non-interventional Services Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December 2019, the Company entered into a Non-Interventional Services Agreement with Children&#39;s CGMP, LLC (&quot;Children&#8217;s&quot;), an affiliate of St. Jude Children&#39;s Research Hospital, pursuant to which Children&#8217;s provides lentiviral vector for non-clinical XSCID research purposes, as well as related advisory services. Pursuant to the agreement, we agreed to fund approximately $0.8 million upon execution of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">XSCID Data Transfer Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company entered into a Data Transfer Agreement for the XSCID program (the &#8220;XSCID DTA&#8221;). Pursuant to the terms of the XSCID DTA, we made an upfront payment of approximately $1.1 million and will reimburse St. Jude for additional costs in connection with the on-going investigator-initiated study.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">City of Hope</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In February&#160;2017, the Company and COH amended and restated their license agreement, dated March&#160;17, 2015 (the &#8220;Original Agreement&#8221;), by entering into three separate amended and restated exclusive license agreements, one relating to the CD123-directed CAR T program, one relating to the IL13R&#945;2-directed CAR T program, and one relating to the Spacer technology (described below). The total potential consideration payable to COH by the Company, in equity or cash, did not in the aggregate change materially from the Original Agreement. As of December&#160;31,&#160;2022, COH owns 845,385 shares of Class&#160;A common stock representing approximately 0.8% of ownership, and has the right to appoint a director to the Board of Directors (the &#8220;Board&#8221;). The Company considers COH to be a related party, due to the foregoing rights and ownership, as well as the high proportion of the Company&#8217;s assets that are licensed from COH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the Company entered into a sponsored research agreement with COH under which the Company has funded continued research in the amount of $2.0 million per&#160;year, payable in four equal installments, which ended in the first quarter of 2020. The research covered under this arrangement is for the IL13R&#945;2-directed CAR T program, the CD123-directed CAR T program, and the Spacer technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CD123 License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In February&#160;2017, the Company entered into an Amended and Restated Exclusive License Agreement with COH to acquire intellectual property rights pertaining to patent rights related to the CD123-directed CAR T program (the &#8220;CD123 License&#8221;). Pursuant to the CD123 License, the Company and COH acknowledged that an upfront fee had already been paid under the Original Agreement. In addition, COH is eligible to receive an annual maintenance fee of $25,000 and milestone payments totaling up to approximately $14.5 million, upon and subject to the achievement of certain milestones. Royalty payments in the mid-single digits are due on net sales of licensed products. The Company is obligated to pay COH a&#160;percentage of certain revenues received in connection with a sublicense ranging from the mid-teens to mid-thirties, depending on the timing of the sublicense in the development of any product. In addition, equity grants made under the Original Agreement were acknowledged, and the anti-dilution provisions of the Original Agreement were carried forward.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CD123 CRA (AML and BPDCN)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In February&#160;2017, the Company entered into a Clinical Research Support Agreement for CD123-directed CAR T program (the &#8220;CD123 CRA&#8221;). Pursuant to the terms of the CD123 CRA, the Company made an upfront payment of approximately $19,000 and will contribute an additional $97,000 per patient in connection with the on-going investigator-initiated study. Further, the Company agreed to fund approximately $76,000 annually pertaining to the clinical development of the CD123-directed CAR T therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">IL13R&#945;2 License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In February&#160;2017, the Company entered into an Amended and Restated Exclusive License Agreement with COH to acquire intellectual property rights pertaining to patent rights related to the IL13R&#945;2-directed CAR T program (the &#8220;IL13R&#945;2 License&#8221;). Pursuant to the IL13R&#945;2 License, the Company and COH acknowledged that an upfront fee had already been paid under the Original Agreement. In addition, COH is eligible to receive an annual maintenance fee of $25,000 and milestone payments totaling up to approximately $14.5 million, upon and subject to the achievement of certain milestones. Royalty payments in the mid-single digits are due on net sales of licensed products. The Company is obligated to pay COH a&#160;percentage of certain revenues received in connection with a sublicense ranging from the mid-teens to mid-thirties, depending on the timing of the sublicense in the development of any product. In addition, equity grants made under the Original Agreement were acknowledged, and the anti-dilution provisions of the Original Agreement were carried forward.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">IL13R&#945;2 CRA (Glioblastoma)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In February&#160;2017, the Company entered into a Clinical Research Support Agreement for the IL13R&#945;2-directed CAR T program (the &#8220;IL13R&#945;2 GBM CRA&#8221;). Pursuant to the terms of the IL13R&#945;2 CRA, the Company made an upfront payment of approximately $9,000 and will contribute an additional $140,000 per patient in connection with the on-going investigator-initiated study. Further, the Company agreed to fund approximately $66,000 annually pertaining to the clinical development of the IL13R&#945;2-directed CAR T therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">IL13R&#945;2 CRA (Leptomeningeal Glioblastoma)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In October 2020, the Company entered into a Clinical Research Support Agreement for the IL13R&#945;2-directed CAR T program for adult patients with leptomeningeal glioblastoma, ependymoma or medulloblastoma (the &#8220;IL13R&#945;2 Leptomeningeal CRA&#8221;). Pursuant to the terms of the IL13R&#945;2 Leptomeningeal CRA, the Company made an upfront payment of approximately $29,000 and will contribute an additional </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$150,000 per patient in connection with the on-going investigator-initiated study. Further, the Company agreed to fund approximately $200,000 annually pertaining to the clinical development of the IL13R&#945;2-directed CAR T therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sponsored Research Agreement - IL13R&#945;2 and C134 Combination</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2020, the Company entered into a Sponsored Research Agreement (&#8220;SRA&#8221;) with COH to conduct combination studies of a potential IL13R&#945;2<i style="font-style:italic;"> </i>CAR and C134 oncolytic virus therapy. Pursuant to the SRA, the Company funded research in the amount of $0.3 million for the program. In November 2022, the SRA was amended to include additional funding of $0.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Spacer License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In February&#160;2017, the Company entered into an Amended and Restated Exclusive License Agreement with COH to acquire intellectual property rights pertaining to patent rights related to Spacer (the &#8220;Spacer License&#8221;). Pursuant to the Spacer License, the Company and COH acknowledged that an upfront fee had already been paid under the Original Agreement. In addition, COH will receive an annual maintenance fee of $10,000. No royalties are due if the Spacer technology is used in conjunction with a CD123 CAR or an IL13R&#945;2 CAR, and royalty payments in the low single digits are due on net sales of licensed products if the Spacer technology is used in conjunction with other intellectual property. The Company is obligated to pay COH a&#160;percentage of certain revenues received in connection with a sublicense in the mid-thirties, but no such payments are due in connection with sublicenses that are granted in conjunction with the sublicense of other CARs that are licensed from COH to the Company. In addition, equity grants made under the Original Agreement were acknowledged, and the anti-dilution provisions of the Original Agreement were carried forward.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">IV/ICV License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In February&#160;2017, the Company entered into an exclusive license agreement (the &#8220;IV/ICV License&#8221;) with COH to acquire intellectual property rights in patent applications related to the intraventricular and intracerebroventricular methods of delivering T cells that express CARs. Pursuant to the IV/ICV License, in March&#160;2017, the Company paid COH an upfront fee of $0.1 million. COH is eligible to receive a milestone payment totaling approximately $0.1 million, upon and subject to the achievement of a milestone, and an annual maintenance fee. Royalty payments in the low single digits are due on net sales of licensed products. The Company is obligated to pay COH a&#160;percentage of certain revenues received in connection with a sublicense in the mid-thirties, but no such payments are due in connection with sublicenses that are granted in conjunction with the sublicense of other CAR T programs that are licensed from COH to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">HER2 Technology License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May&#160;31, 2017, the Company entered into an exclusive license agreement (the &#8220;HER2 Agreement&#8221;) with COH for the use of HER2 CAR T technology (&#8220;HER2 Technology&#8221;), which is currently being applied in the treatment of glioblastoma multiforme and in the treatment of HER2+ cancers&#160;&#8211; in particular breast cancer&#160;&#8211; that have metastasized to the brain. Pursuant to the HER2 Agreement, the Company paid an upfront fee of $0.6 million and owes an annual maintenance fee of $50,000 (which began in 2019). In addition, COH is eligible to receive milestone payments totaling up to $14.9 million, upon and subject to the achievement of certain milestones. Royalty payments in the mid-single digits are due on net sales of licensed products. The Company is obligated to pay COH a&#160;percentage of certain revenues received in connection with a sublicense ranging from the mid-teens to mid-thirties, depending on the timing of the sublicense in the development of any product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">HER2</i> <i style="font-style:italic;">CRA (HER2+ glioblastoma and HER2+ brain metastases)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2020, the Company entered into a Clinical Research Support Agreement for the HER2-directed CAR T program (the &#8220;HER2 CRA&#8221;). Pursuant to the terms of the HER2 CRA, the Company made an upfront payment of approximately $29,000 and will contribute an additional $150,000 per patient in connection with the on-going investigator-initiated study. Further, the Company agreed to fund approximately $200,000 annually pertaining to the clinical development of the HER2-directed CAR T therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CS1 Technology License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May&#160;31, 2017, the Company entered into an exclusive license agreement (the &#8220;CS1 Agreement&#8221;) with COH for the use of CS1-specific CAR T technology (&#8220;CS1 Technology&#8221;), which is currently being applied in the treatment of multiple myeloma. Pursuant to the CS1 Agreement, the Company paid an upfront fee of $0.6 million and owes an annual maintenance fee of $50,000 (which began in 2019). In addition, COH is eligible to receive milestone payments totaling up to $14.9 million, upon and subject to the achievement of certain milestones. Royalty payments in the mid-single digits are due on net sales of licensed products. The Company is obligated to pay COH </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">a&#160;percentage of certain revenues received in connection with a sublicense ranging from the mid-teens to mid-thirties, depending on the timing of the sublicense in the development of any product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CS1</i> <i style="font-style:italic;">CRA (multiple myeloma)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company entered into a Clinical Research Support Agreement for the CS1-directed CAR T program (the &#8220;CS1 CRA&#8221;). Pursuant to the terms of the CS1 CRA, the Company made an upfront payment of approximately $32,000 and will contribute an additional $130,000 per patient in connection with the on-going investigator-initiated study. Further, the Company agreed to fund approximately $200,000 annually pertaining to the clinical development of the CS1-directed CAR T therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">PSCA Technology License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May&#160;31, 2017, the Company entered into an exclusive license agreement (the &#8220;PSCA Agreement&#8221;) with COH for the use of PSCA CAR T technology (&#8220;PSCA Technology&#8221;), which is currently being applied in the treatment of PSCA+ metastatic castration-resistant prostate cancer. Pursuant to the PSCA Agreement, the Company paid an upfront fee of $0.3 million and owes an annual maintenance fee of $50,000 (which began in 2019). In addition, COH is eligible to receive milestone payments totaling up to $14.9 million, upon and subject to the achievement of certain milestones. Royalty payments in the mid-single digits are due on net sales of licensed products. The Company is obligated to pay COH a&#160;percentage of certain revenues received in connection with a sublicense ranging from the mid-teens to mid-thirties, depending on the timing of the sublicense in the development of any product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">PSCA</i> <i style="font-style:italic;">CRA</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2020, the Company entered into a Clinical Research Support Agreement for the PSCA-directed CAR T program (the &#8220;PSCA CRA&#8221;). Pursuant to the terms of the PSCA CRA, the Company made an upfront payment of $33,000 and will contribute an additional $125,000 per patient in connection with the on-going investigator-initiated study. Further, the Company agreed to fund approximately $200,000 annually pertaining to the clinical development of the PSCA-directed CAR T therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Manufacturing License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January&#160;3, 2018, the Company entered into a non-exclusive license agreement with COH to acquire patent and licensed know-how rights related to developing, manufacturing, and commercializing licensed products. The Company paid $75,000 in consideration for the licenses to the patent rights and the licensed know-how in addition to an annual maintenance fee. Royalty payments in the low-single digits are due on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sponsored Research Agreement - Manufacturing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January&#160;3, 2018, the Company entered into an SRA with COH to optimize and develop CAR T cell processing procedures. Pursuant to the SRA, the Company funded continued research in the amount of $0.9 million for the program, with an initial term of two (2)&#160;years. The SRA expired in January 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">University of California License</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March&#160;17, 2017, the Company entered into an exclusive license agreement with the Regents of UCLA (the &#8220;UCLA License&#8221;) to acquire intellectual property rights in patent applications related to the engineered anti-prostate stem cell antigen antibodies for cancer targeting and detection. Pursuant to the UCLA License, the Company paid UCLA the upfront fee of $0.2 million and owes an annual maintenance fee of $15,000 for the first two&#160;years, $25,000 for&#160;years three and four, and $50,000 per&#160;year thereafter. In addition, UCLA is eligible to receive milestone payments totaling up to $14.3 million, upon and subject to the achievement of certain milestones. Royalty payments in the mid-single digits are due on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fred Hutchinson Cancer Center</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CD20 Technology License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Effective July&#160;3, 2017, Mustang entered into an exclusive, worldwide licensing agreement with Fred Hutch for the use of a CAR T therapy related to autologous T cells engineered to express a CD20-specific CAR (the &#8220;CD20 Technology License&#8221;). Pursuant to the CD20 Technology License, the Company paid Fred Hutch an upfront fee of $0.3 million and owes an annual maintenance fee of $50,000 on each </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">anniversary of the license until the achievement by the Company of regulatory approval of a licensed product using the CD20 Technology. Additional payments are due for the achievement of eleven development milestones totaling $39.1 million. Royalty payments in the mid-single digits are due on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CD20 CTA (NHL and CLL)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Also, on July&#160;3, 2017, in conjunction with the CD20 Technology License from Fred Hutch, Mustang entered into an investigator-initiated clinical trial agreement (the &#8220;CD20 CTA&#8221;) to provide partial funding for a Phase 1/2 clinical trial at Fred Hutch evaluating the safety and efficacy of the CD20 Technology in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (&#8220;NHLs&#8221;). In connection with the CD20 CTA, the Company agreed to fund up to $5.3 million of costs associated with the clinical trial, which commenced during the fourth quarter of 2017.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2020, the CD20 CTA was amended to include additional funding of approximately $1.8 million for the treatment of five patients with chronic lymphocytic leukemia (&#8220;CLL&#8221;) and other research costs. In January 2022, the CTA was amended to increase funding by approximately $2.2 million for the treatment of additional patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sponsored Research Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March&#160;17, 2018, the Company entered into an SRA with Fred Hutch related to developing and optimizing processes and systems associated with CD20 cell processing. Pursuant to the SRA, the Company funded continued research in the amount of $0.6 million during the term of the SRA, which expired in March&#160;2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nationwide Children&#8217;s Hospital License</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February&#160;20, 2019, the Company entered into an exclusive worldwide license agreement with Nationwide for the development of an oncolytic virus (referred to by Nationwide as C134; now referred to by the Company as MB-108) for the treatment of glioblastoma multiforme. The Company paid $0.2 million in consideration for the exclusive license. Nationwide is eligible to receive additional payments totaling $77.5 million upon the achievement of ten development and commercialization milestones. Royalty payments in the low-single digits are due on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CSL Behring (Calimmune) License</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August&#160;23, 2019, the Company entered into a non-exclusive license agreement with CSL Behring (Calimmune) for the Cytegrity<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM </sup>stable producer cell line for the production of lentiviral gene therapy for the XSCID gene therapy program. The Cytegrit<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> stable producer cell line will be used to produce the viral vector for Mustang&#8217;s MB-107 and MB-207 lentiviral gene therapies for the treatment of XSCID. The Company paid $0.2 million in consideration for the license. CSL Behring (Calimmune) is eligible to receive additional payments totaling $1.2 million upon the achievement of three development and commercialization milestones. Royalty payments in the low-single digits are due on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SIRION Biotech License</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 6, 2020, the Company announced a licensing agreement under which we acquired technology rights from SIRION Biotech GmbH (&#8220;SIRION&#8221;) for LentiBOOST&#8482; technology for the development of MB-207, Mustang&#8217;s lentiviral gene therapy for the treatment of patients with XSCID, who have been previously treated with a hematopoietic stem cell transplantation (&#8220;HSCT&#8221;) and for whom re-treatment is indicated. LentiBOOST&#8482; is SIRION&#8217;s proprietary non-cytotoxic transduction enhancer for lentiviral vectors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the agreement, the Company paid SIRION a one-time upfront fee of $0.1 million. In addition, SIRION is eligible to receive additional payments totaling up to approximately $9.1 million upon the achievement of certain development and commercialization milestones. Royalty payments in the low- to mid-single digits are due on aggregate cumulative worldwide net sales of licensed products.</p><a id="_Hlk98753836"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December 2021 this licensing agreement was amended to include CD20-directed CAR Ts. SIRION is eligible to receive additional payments totaling up to approximately $9.1 million upon the achievement of certain development and commercialization milestones for the additional product.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Minaris Regenerative Medicine Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 23, 2020, we announced an agreement with Minaris Regenerative Medicine GmbH (&#8220;Minaris&#8221;) to enable technology transfer and GMP clinical manufacturing in Europe of our MB-107 lentiviral gene therapy program for the treatment of XSCID. Under the terms of the agreement, Minaris will perform technology transfer of the manufacturing and analytical processes, as well as their adoption to the European regulatory environment, for the GMP-compliant manufacturing of the drug product at its site in Ottobrunn, Germany, with the goal of supplying clinical trials in Europe. In 2022, the Company made the decision to delay the technology transfer and clinical manufacturing processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mayo Clinic</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CAR T Technology License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 12, 2021, we announced that the Company has executed an exclusive license agreement with Mayo Clinic for a novel technology that may be able to transform the administration of CAR T therapies and potentially allow such therapies to be used as an off-the-shelf therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The technology, developed by Larry R. Pease, Ph.D., principal investigator and former director of the Center for Immunology and Immune Therapies at Mayo Clinic, is a new platform to administer CAR T therapy using a two-step approach. First, a peptide is administered to the patient to drive the proliferation of the patient&#8217;s resident T cells. This is followed by the administration of a viral CAR construct directly into the lymph nodes of the patient. In turn, the viral construct infects the activated T cells and effectively forms CAR T cells <i style="font-style:italic;">in vivo</i> in the patient. Successful implementation may lead to an off-the-shelf product with no need to isolate and expand patient T cells <i style="font-style:italic;">ex vivo.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preclinical proof-of-concept has been established, and the ongoing development of this technology will take place at Mayo Clinic. Mustang plans to file an Investigational New Drug (&#8220;IND&#8221;) application for a multicenter Phase 1 clinical trial once a lead construct has been identified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to this agreement, the Company paid an upfront fee of $0.8 million and will pay an annual maintenance fee of $25,000. Additional payments are due for each of two licensed products for the achievement of eleven development and commercial milestones totaling up to $92.6 million per product, and royalty payments in the mid-single digits as a percentage of revenue are due on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sponsored Research Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Mayo Clinic license agreement, the Company entered into an SRA under which the Company will fund research in the amount of $2.1 million over a period of two years. In October 2022, the SRA was amended to include additional funding of $0.1 million. The research performed pursuant to this agreement will support the technology the Company has licensed from Mayo Clinic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Leiden University Medical Centre</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RAG1-SCID Technology License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 10, 2021, we announced an exclusive license agreement with Leiden University Medical Centre (&#8220;LUMC&#8221;) for a first-in-class <i style="font-style:italic;">ex vivo</i> lentiviral gene therapy for the treatment of RAG1 severe combined immunodeficiency (&#8220;RAG1-SCID&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to this agreement, the Company paid an upfront fee of $0.4 million. Additional payments are due for the achievement of five development and commercial milestones totaling up to $31.0 million, and royalty payments in the low to mid-single digits as a percentage of revenue are due on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sponsored Research Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the RAG1-SCID license, the Company entered into an SRA with LUMC under which the Company will fund research in the amount of 2.3 million euros over a period of five years. The research performed pursuant to this agreement will support the technology the Company has licensed from LUMC.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMPETITION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Competition in the pharmaceutical and biotechnology industries is intense. Our competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions. In addition, companies that are active in different but related fields represent substantial competition for us. Many of our competitors have significantly greater capital resources, larger research and development staffs and facilities and greater experience in drug development, regulation, manufacturing and marketing than we do. These organizations also compete with us to recruit qualified personnel, attract partners for joint ventures or other collaborations, and license technologies that are competitive with ours. To compete successfully in this industry, we must identify novel and unique drugs or methods of treatment and then complete the development of those drugs as treatments in advance of our competitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The drugs that we are attempting to develop will have to compete with existing therapies. In addition, a large number of companies are pursuing the development of pharmaceuticals that target the same conditions that we are targeting. Other companies have products or product candidates in various stages of pre-clinical or clinical development, or with marketing approvals, to treat conditions for which we are also seeking to discover and develop product candidates. Some of these potential competing drugs are further advanced in development than our product candidates and may be commercialized earlier.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The field of CAR T therapy is extremely active. Companies and partnerships currently engaged in clinical trials with CAR T modalities include Bristol Myers Squibb, Novartis Pharmaceuticals/University of Pennsylvania, 2seventy bio, Allogene Therapeutics, Cellectis, Gilead Sciences, Bellicum Pharmaceuticals, MD Anderson/Ziopharm Oncology, Atara Biotherapeutics, Celyad, Autolus Therapeutics, Precigen Inc., Precision BioSciences, Adicet Bio, Cargo Therapeutics, and ImmPACT Bio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The gene therapy field is characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. We are aware of companies currently engaged in developing gene therapies in various indications, including Abeona Therapeutics, Adverum Biotechnologies, Astellas, AVROBIO, Axovant Sciences, Biogen, bluebird bio, BioMarin Pharmaceutical, Homology Medicines, Krystal Biotech, MeiraGTx, Novartis Pharmaceuticals, Orchard Therapeutics, Passage Bio, Prevail Therapeutics, REGENXBIO, Rocket Pharmaceuticals, Roche, Sangamo Therapeutics, Sarepta Therapeutics, Solid Biosciences, Ultragenyx Pharmaceuticals, uniQure and Voyager Therapeutics, as well as several companies addressing other methods for delivering or modifying genes and regulating gene expression.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EMPLOYEES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2022, we had 113 full and part-time employees. None of our employees are represented by a labor union or covered under a collective bargaining agreement and we consider our employee relations to be good. Employees of Fortress also make valuable financial, legal, scientific and other strategic contributions to Mustang on a regular basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SUPPLY AND MANUFACTURING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As an early stage development company, we rely on our research partners to manufacture or have manufactured all lentiviral vectors used in the clinical development programs currently in progress at COH, Fred Hutch, St. Jude, the NIH, and LUMC under the IND applications filed by these institutions. In addition we rely on the NIH to produce oncolytic virus for UAB, the clinical trial site for the Phase 1 trial of Nationwide&#8217;s C134 oncolytic virus (MB-108). We will continue to rely on our research partners to manufacture lentiviral vectors and oncolytic virus for Mustang-IND trials until such time as material is available from our contract manufacturing organizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the March&#160;2015 Licensing Agreement with COH, we have the right to make and have made the cellular products, and we have negotiated Investigator-Initiated Clinical Research Support Agreements with&#160;COH and Fred Hutch which specify the cell processing costs and numbers of patients which will be supplied under filed protocols. Our research partners have extensive experience manufacturing clinical materials for development studies, but we are currently dependent on both their capacity limitations and continued operating success to manufacture viral vector and to process cells for all CAR T clinical trials for which these partners hold the INDs, as well as to have manufactured oncolytic virus for the MB-108 investigator-IND clinical trial being conducted at UAB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have limited experience in processing cells for clinical or commercial purposes. In 2018 we opened our own cell processing facility in Worcester, Massachusetts, in order to manufacture and supply cellular product candidates for all clinical trials that will be conducted under IND applications to be filed by us. In August&#160;2019, the FDA approved our IND application to initiate a multi-center Phase 1/2 clinical trial of MB-102 (CD123 CAR T) and in January&#160;2021, the FDA approved our IND application to initiate a multi-center Phase 2 clinical trial of MB-107 (XSCID). In May&#160;2021, the FDA approved our IND application to initiate a multi-center Phase 1/2 clinical trial of MB-106 (CD-</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">20). As with any supply program, obtaining raw materials of the correct quality cannot be guaranteed, and we cannot ensure that we will be successful in this endeavor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect to rely on contract manufacturing relationships for lentiviral vectors and for the MB-108 oncolytic virus, as well as for any non-CAR T products that we may in-license or acquire in the future for co-administration with our CAR T products. However, there can be no assurance that we will be able to successfully contract with such manufacturers on terms acceptable to us, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Contract manufacturers for these current and potential future non-CAR T products would be subject to ongoing periodic and unannounced inspections by the FDA, the U.S. Drug Enforcement Administration (&#8220;DEA&#8221;) and corresponding state agencies to ensure strict compliance with the Current Good Manufacturing Practice regulations (&#8220;cGMP&#8221;) and other state and federal regulations. Our contractors, if any, in Europe would face similar challenges from the numerous EU and member state regulatory agencies and authorized bodies. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards, other than through contractual obligations. If they are deemed out of compliance with cGMPs, product recalls could result, inventory could be destroyed, production could be stopped, and supplies could be delayed or otherwise disrupted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we need to change manufacturers for these current and potential future non-CAR T products after commercialization, the FDA and corresponding foreign regulatory agencies must approve these new manufacturers in advance, which will involve testing and additional inspections to ensure compliance with FDA regulations and standards and may require significant lead times and delay. Furthermore, switching manufacturers may be difficult because the number of potential manufacturers is limited. It may be difficult or impossible for us to find a replacement manufacturer quickly or on terms acceptable to us, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GOVERNMENT AND INDUSTRY REGULATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Numerous governmental authorities, principally the FDA and corresponding state and foreign regulatory agencies, impose substantial regulations upon the clinical development, manufacture and marketing of our product candidates, as well as our ongoing research and development activities. None of our product candidates has been approved for sale in any market. Before marketing in the U.S., any drug that we develop must undergo rigorous pre-clinical testing and clinical trials and an extensive regulatory approval process implemented by the FDA under the FDCA. The FDA regulates, among other things, the pre-clinical and clinical testing, safety, efficacy, approval, manufacturing, record keeping, adverse event reporting, packaging, labeling, storage, advertising, promotion, export, and the sale and distribution of biopharmaceutical products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The regulatory review and approval process is lengthy, expensive and uncertain. We are required to submit extensive preclinical and clinical data and supporting information to the FDA for each indication or use to establish a product candidate&#8217;s safety and efficacy before we can secure FDA approval to market or sell a product in the U.S. The approval process takes many&#160;years, requires the expenditure of substantial resources and may involve ongoing requirements for post-marketing studies or surveillance. Before commencing clinical trials in humans, we must submit an IND to the FDA containing, among other things, preclinical data, chemistry, manufacturing and control information, and an investigative plan. Our submission of an IND may not result in FDA authorization to commence a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA may permit expedited development, evaluation, and marketing of new therapies intended to treat persons with serious or life-threatening conditions for which there is an unmet medical need under its fast track drug development program. A sponsor can apply for fast track designation initially at the time of submission of an IND, or at any time prior to receiving a marketing approval of the new drug application (&#8220;NDA&#8221;) or biologics license application (&#8220;BLA&#8221;). To receive fast track designation, an applicant must demonstrate:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that the therapy is intended to treat a serious or life-threatening condition;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that the therapy is intended to treat a serious aspect of the condition; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that the therapy has the potential to address unmet medical needs, and this potential is being evaluated in the planned drug development program.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA must respond to a request for fast track designation within 60 calendar&#160;days of receipt of the request. Over the course of development, a product in a fast track development program must continue to meet the criteria for fast track designation. Sponsors of products in fast track drug development programs must be in regular contact with the reviewing division of the FDA to ensure that the evidence necessary to support marketing approval will be developed and presented in a format conducive to an efficient review. Sponsors of products in fast track drug development programs ordinarily are eligible for priority review of a completed application in six&#160;months or less and also may be permitted to submit portions of an NDA or BLA to the FDA for review on a rolling basis before the complete application is submitted.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with the FDCA, sponsors of drugs for serious or life-threatening diseases that fill an unmet medical need may seek approval under the FDA&#8217;s accelerated approval regulations. Under this authority, the FDA may grant marketing approval for a new drug product on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. Approval will be subject to the requirement that the applicant study the drug further to verify and describe its clinical benefit where there is uncertainty as to the relation of the surrogate endpoint to clinical benefit or uncertainty as to the relation of the observed clinical benefit to ultimate outcome.&#160;Post-marketing studies are usually underway at the time an applicant files the NDA or BLA.&#160;When required to be conducted, such post-marketing studies must also be adequate and well-controlled.&#160;The applicant must carry out any such post-marketing studies with due diligence. Many companies who have been granted the right to utilize an accelerated approval approach have failed to obtain approval. Moreover, negative or inconclusive results from the clinical trials we hope to conduct or adverse medical events could cause us to have to repeat or terminate the clinical trials. Accordingly, we may not be able to complete the clinical trials within an acceptable time frame, if at all, and, therefore, could not submit the NDA or BLA to the FDA or foreign regulatory authorities for marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical testing must meet requirements for institutional review board oversight, informed consent and good clinical practices, and must be conducted pursuant to an IND, unless exempted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For purposes of NDA or BLA approval, clinical trials are typically conducted in the following sequential phases:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase 1</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: The drug is administered to a small group of humans, either healthy volunteers or patients, for the first time to test for safety, dosage tolerance, absorption, metabolism, excretion and clinical pharmacology.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase 2</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Studies are conducted on a larger number of patients to assess the efficacy of the product, to ascertain dose tolerance and the optimal dose range, and to gather additional data relating to safety and potential adverse events.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase 3</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Studies establish safety and efficacy in an expanded patient population.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase 4</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: The FDA may request phase 4 post-marketing studies to find out more about the drug&#8217;s long-term risks, benefits, and optimal use, or to test the drug in different patient populations.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The length of time necessary to complete clinical trials varies significantly and may be difficult to predict. Clinical results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals. Additional factors that can cause delay or termination of our clinical trials, or that may increase the costs of these trials, include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">slow patient enrollment due to the nature of the clinical trial plan, the proximity of patients to clinical sites, the eligibility criteria for participation in the study or other factors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inadequately trained or insufficient personnel at the study site to assist in overseeing and monitoring clinical trials or delays in approvals from a study site&#8217;s review board;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">longer treatment time required to demonstrate efficacy or determine the appropriate product dose;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">insufficient supply of the product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse medical events or side effects in treated patients; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ineffectiveness of the product candidates.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the FDA, equivalent foreign regulatory authority, or a data safety monitoring committee for a clinical trial may place a clinical trial on hold or terminate it if it concludes that subjects are being exposed to an unacceptable health risk, or for futility. Any drug is likely to produce some toxicity or undesirable side effects in animals and in humans when administered at sufficiently high doses and/or for a sufficiently long period of time. Unacceptable toxicity or side effects may occur at any dose level at any time in the course of studies in animals designed to identify unacceptable effects of a product candidate, known as toxicological studies, or clinical trials of product candidates. The appearance of any unacceptable toxicity or side effect could cause us or regulatory authorities to interrupt, limit, delay or abort the development of any of our product candidates and could ultimately prevent approval by the FDA or foreign regulatory authorities for any or all targeted indications.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Sponsors of drugs may apply for a special protocol assessment (&#8220;SPA&#8221;) from the FDA for studies intended to form the primary basis of an efficacy claim. The SPA process is a procedure by which the FDA provides official evaluation and written guidance on the design and size of proposed protocols that are intended to form the basis for an NDA or BLA. However, final marketing approval depends on the results of efficacy, the adverse event profile and an evaluation of the benefit/risk of treatment demonstrated in the pivotal clinical trial. Once approved, the SPA may only be changed through a written agreement between the sponsor and the FDA, or in rare cases if the FDA becomes aware of a substantial scientific issue essential to product safety or efficacy the SPA can be rescinded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Before receiving FDA approval to market a product, we must demonstrate that the product is safe and effective for its intended use by submitting to the FDA an NDA or BLA containing the preclinical and clinical data that have been accumulated, together with chemistry and manufacturing and controls specifications and information, and proposed labeling, among other things. The FDA may refuse to accept an NDA or BLA for filing if certain content criteria are not met and, even after accepting an NDA or BLA, the FDA may require additional information, including clinical data, before approval for marketing a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Although uncommon, the FDA may request a Risk Evaluation and Mitigation Strategy, or REMS, as part of an NDA or BLA approval for products with serious safety concerns to help ensure that the benefits of the product outweigh the risks. The REMS plan contains post-marketing obligations of the sponsor to train prescribing physicians, monitor off-label drug use, and perhaps the conduct of Phase 4 follow-up studies and registries to ensure the continued safe use of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of the approval process, the FDA must inspect and approve each manufacturing facility. Among the conditions of approval is the requirement that a manufacturer&#8217;s quality control and manufacturing procedures conform to cGMP. Manufacturers must expend significant time, money and effort to ensure continued compliance, and the FDA conducts periodic inspections to certify compliance. It may be difficult for our manufacturers or for us to comply with the applicable cGMP, as interpreted by the FDA, and other FDA regulatory requirements. If we, or our contract manufacturers, fail to comply, then the FDA may not allow us to market products that have been affected by the failure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the FDA grants approval, the approval will be limited to those conditions and patient populations for which the product is safe and effective, as demonstrated through clinical studies and as reflected in the approved labeling. Further, a product may be marketed only in those dosage forms and for those indications approved in the NDA or BLA. Certain changes to an approved NDA or BLA, including, with certain exceptions, any significant changes to labeling, may require prior approval of a supplemental application before the drug may be marketed as changed. Any products that we manufacture or distribute pursuant to FDA approvals are subject to continuing monitoring and regulation by the FDA, including compliance with cGMP and the reporting of adverse experiences with the drugs. The nature of marketing claims that the FDA will permit us to make in the labeling and advertising of our products will generally be limited to those specified in FDA approved labeling, and the advertising of our products will be subject to comprehensive monitoring and regulation by the FDA. Drugs whose review was accelerated may carry additional restrictions on marketing activities, including the requirement that all promotional materials are pre-submitted to the FDA. Claims exceeding those contained in the approved labeling will constitute a violation of the FDCA. Violations of the FDCA or regulatory requirements at any time during the product development process, approval process, or marketing and sale following approval may result in agency enforcement actions, including withdrawal of approval, recall, seizure of products, warning letters, injunctions, fines and/or civil or criminal penalties. Any agency enforcement action could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Failure to comply with applicable federal, state and foreign laws and regulations would likely have a material adverse effect on our business. In addition, federal, state and foreign laws and regulations regarding the manufacture and sale of new drugs are subject to future changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Healthcare Laws and Compliance Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the U.S., our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services (formerly the Health Care Financing Administration), other divisions of the United States Department of Health and Human Services (e.g., the Office of Inspector General), the United States Department of Justice and individual United States Attorney offices within the Department of Justice, and state and local governments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pharmaceutical Coverage, Pricing and Reimbursement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the U.S. and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of reimbursement from third-party payors, including government health administrative authorities, managed care providers, private health insurers and other organizations. Third-party payors are increasingly examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy, and, accordingly, significant uncertainty exists as to the reimbursement status of newly approved therapeutics. Adequate third-party reimbursement may not be available for our products to </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">enable us to realize an appropriate return on our investment in research and product development. We are unable to predict the future course of federal or state health care legislation and regulations, including regulations that will be issued to implement provisions of the health care reform legislation enacted in 2010, known as the Affordable Care Act. The Affordable Care Act and further changes in the law or regulatory framework could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">International Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition to regulations in the U.S., there are a variety of foreign regulations governing clinical trials and commercial sales and distribution of our product candidates. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_13a7d219_051a_46a4_88ce_8072955ebe79"></a><a id="Item1ARiskFactors_686229"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;1A.</b></span><b style="font-weight:bold;">Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing in our Common Stock or any other type of equity or debt securities we may offer (together, our &#8220;Securities&#8221;) involves a high degree of risk. The following information sets forth risk factors that could cause our actual results to differ materially from those contained in forward-looking statements we have made in this Form&#160;10-K and those we may make from time to time. You should carefully consider the risks described below, in addition to the other information contained in this Form&#160;10-K, before making an investment decision. Our business, financial condition or results of operations could be harmed by any of these risks. The risks and uncertainties described below are not the only ones we face. Additional risks not presently known to us, or other factors not perceived by us to present significant risks to our business at this time also may impair our business operations.</i></p><a id="_Hlk66047483"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Finances and Capital Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability. We do not have any products that are approved for commercial sale and therefore do not expect to generate any revenues from product sales in the foreseeable future, if ever.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have a limited operating history. We have focused primarily on in-licensing and developing our product candidates, with the goal of supporting regulatory approval for these product candidates. We have incurred losses since our inception in March&#160;2015 and have an accumulated deficit of $329.4 million as of December&#160;31,&#160;2022. We expect to continue to incur significant operating losses for the foreseeable future. We also do not anticipate that we will achieve profitability for a period of time after generating material revenues, if ever. If we are unable to generate revenues, we will not become profitable and may be unable to continue operations without continued funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve profitability. Our net losses may fluctuate significantly from quarter to quarter and&#160;year to&#160;year. We anticipate that our expenses will increase substantially if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one or more of our product candidates receive regulatory approval and are approved for commercial sale, due to our need to establish the necessary commercial infrastructure to launch and commercialize this product candidate without substantial delays, including hiring sales and marketing personnel and contracting with third parties for manufacturing, testing, warehousing, distribution, cash collection and related commercial activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we are required by the FDA or foreign regulatory authorities to perform studies in addition to those currently expected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there are any delays in completing our clinical trials or the development of any of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we execute other collaborative, licensing or similar arrangements that require us to make payments to collaborators or licensors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there are variations in the level of expenses related to our future development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there are any product liability or intellectual property infringement lawsuits in which we may become involved; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there are any regulatory developments affecting product candidates of our competitors.</span></td></tr></table><div style="margin-top:10pt;"></div></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue from our development stage products, and we do not know when, or if, we will generate any revenue. Our ability to generate revenue depends on a number of factors, including, but not limited to, our ability to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain regulatory approval for one or more of our product candidates, or any future product candidate that we may license or acquire;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacture or have manufactured commercial quantities of one or more of our product candidates or any future product candidate, if approved, at acceptable cost levels;&#160;and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop a commercial organization and the supporting infrastructure required to successfully market and sell one or more of our product candidates or any future product candidate, if approved.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of the Company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or even continue our operations. A decline in the value of the Company could also cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">There is substantial doubt regarding our ability to continue as a going concern. We will need to raise additional funding, which may not be available on acceptable terms to the Company, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;">We are currently advancing our programs in hematologic cancers, solid tumors and rare genetic diseases through clinical development. Developing and commercializing CAR T and gene therapy products is expensive, and we do not expect to generate meaningful product revenues in the foreseeable future until we obtain marketing approval for products in the United States and following any potential commercial launch.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;">As of December 31, 2022, our cash and cash equivalents were $75.7 million. Based on our current business plan, there is substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that our financial statements for the year ended December 31, 2022 are issued. Our fundraising efforts to raise additional funding may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our potential products following marketing approval if and when obtained. In addition, we cannot guarantee that financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute all of our stockholders. Our current and the potential for additional indebtedness would result in increased fixed payment obligations, and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;">If we are unable to obtain funding on a timely basis, we may be required to further revise our business plan and strategy, which may result in us (i) significantly curtailing, delaying or discontinuing one or more of our research or development programs or the commercialization of any product candidates, (ii) selling certain of our assets (which could include our manufacturing facility) and/or (iii) may result in our being unable to expand our operations or otherwise capitalize on our business opportunities. As a result, our business, financial condition, and results of operations could be materially affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are exposed to interest rate risk under our Term Loan with Runway, which could cause our debt service obligations to increase</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">significantly.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We are exposed to market risk from changes in interest rates. Our Term Loan with Runway bears a variable interest rate equal to the (i) 8.75% and (ii) the greater of (A) the prime rate last quoted in The Wall Street Journal (or a comparable replacement rate if The Wall Street Journal ceases to quote such rate) and (B) 0.50%. The Federal Reserve has recently raised, and may in the future further raise, interest rates to combat the effects of recent high inflation. An increase in interest rates by the Federal Reserve has and could in the future cause the prime rate to increase, which has and could in the future increase our debt service obligations. Significant increases in such obligations could have a negative impact on our financial position or operating results, including cash available for servicing our indebtedness, or result in increased borrowing costs in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our short operating history makes it difficult to evaluate our business and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have only been conducting operations since our incorporation in March&#160;2015. Our operations to date have been limited to preclinical operations and the in-licensing of our product candidates. We have not yet demonstrated an ability to successfully complete clinical trials, obtain regulatory approvals, manufacture a clinical scale or commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, any predictions about our future performance may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to expand our capabilities to support commercial activities. We may not be successful in adding such capabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and&#160;year to&#160;year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any past quarterly period as an indication of future operating performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our loan agreement requires us to meet certain funding conditions and operating conditions which place restrictions on our operating and financial flexibility.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our Term Loan with Runway, which we entered into in March 2022, contains a variety of affirmative and negative covenants, including required financial reporting, limitations on certain dispositions of assets, limitations on the incurrence of additional debt, limitations on the ability to pay cash dividends and other requirements. The Term Loan also subjects us to financial covenants in respect of minimum liquidity, pursuant to which we must maintain an unrestricted cash balance in an amount equal to or greater than the trailing five months of our operating cash flow. This covenant imposes significant operational constraints on us, and it will be difficult for us to continue to comply with the covenant absent remedial measures to reduce costs and/or raise additional capital. The Term Loan contains customary events of default, which include among others, non-payment of principal, violation of covenants, inaccuracy of representations and warranties, insolvency events, materials judgments, and certain regulatory-related events. These restrictions may adversely affect our ability to operate our business, finance our operations, engage in business activities or fully pursue our business strategies. To secure our performance of our obligations under this Term Loan, we granted a security interest in substantially all of our assets, other than certain intellectual property assets and certain other excluded collateral, to Runway. Our failure to comply with the covenants in the Term Loan, the occurrence of a material impairment in our prospect of repayment or in the perfection or priority of Runway&#8217;s lien on our assets, as determined by Runway, or the occurrence of certain other specified events could result in an event of default that, if not cured or waived, could result in the acceleration of all or a substantial portion of our debt, potential foreclosure on our assets and other adverse results. In the event of an acceleration of amounts due under the Term Loan as a result of an event of default, we may not have enough available cash or be able to raise additional funds through equity or debt financing to repay such indebtedness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additionally, we are bound by certain negative covenants setting forth actions that are not permitted to be taken during the term of the Term Loan without consent of Runway, including, without limitation, incurring certain additional indebtedness, making certain asset dispositions, entering into certain mergers, acquisitions or other business combination transactions or incurring any non-permitted lien or other encumbrance on our assets. The foregoing prohibitions and constraints on our operations could result in our inability to: (i) acquire promising intellectual property or other assets on desired timelines or terms; (ii) reduce costs by disposing of assets or business segments no longer deemed advantageous to retain; (iii) stimulate further corporate growth or development through the assumption of additional debt; or (iv) enter into other arrangements that necessitate the imposition of a lien on corporate assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will require substantial additional funding which may not be available to us on acceptable terms, or at all. If we fail to raise the necessary additional capital, we may be unable to complete the development and commercialization of our product candidates or continue our development programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our operations have consumed substantial amounts of cash since inception. We will need to significantly increase our spending to advance the preclinical and clinical development of our product candidates and launch and commercialize any product candidates for which we may receive regulatory approval, including building our own commercial organizations to address certain markets. We will require additional capital for the further development and, if approved, commercialization of our product candidates, as well as to fund our other operating expenses and capital expenditures. As of December&#160;31,&#160;2022, we had $76.7 million in cash and restricted cash. We cannot provide any assurance that we will be able to raise funds to complete the development of our product candidates. Additionally, if we are unable to secure additional funding, it is likely that we will need to delay or terminate the development of certain product candidates; any such delay or </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">termination, or the announcement of any such delay or termination, may impact our potential growth and have a material adverse effect on the value of our debt and equity securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We cannot be certain that additional funding will be available on acceptable terms, or at all. Additional funding may be more difficult to obtain, or may be more expensive, as a result of recent increases in inflation and interest rates in the U.S. economy generally. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or, if approved, commercialization of one or more of our product candidates. We may also seek collaborators for one or more of our current or future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available. Any of these events could significantly harm our business, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Our future funding requirements will depend on many factors, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, design and conduct of, and results from, preclinical studies and clinical trials for our product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential for delays in our efforts to seek regulatory approval for our product candidates, and any costs associated with such delays;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of establishing a commercial organization to sell, market and distribute our product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rate of progress and costs of our efforts to prepare for the submission of an NDA or BLA for any product candidates that we may in-license or acquire in the future, and the potential that we may need to conduct additional clinical trials to support applications for regulatory approval;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights associated with our product candidates, including any such costs we may be required to expend if our licensors are unwilling or unable to do so;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost and timing of securing sufficient supplies of our product candidates from our contract manufacturers for clinical trials and in preparation for commercialization;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effect of competing technological and market developments;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of any collaborative, licensing, co-promotion or other arrangements that we may establish;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if one or more of our product candidates are approved, the potential that we may be required to file a lawsuit to defend our patent rights or regulatory exclusivities from challenges by companies seeking to market generic versions of one or more of our product candidates; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of the commercialization of one or more of our product candidates, if approved.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Future capital requirements will also depend on the extent to which we acquire or invest in additional complementary businesses, products and technologies, although we currently have no commitments or agreements relating to any of these types of transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In order to carry out our business plan and implement our strategy, we anticipate that we will need to obtain additional financing from time to time and may choose to raise additional funds through strategic collaborations, licensing arrangements, public or private equity or debt financing, bank lines of credit, asset sales, government grants, or other arrangements. We cannot be sure that any additional funding, if needed, will be available on terms favorable to us or at all. Furthermore, any additional equity or equity-related financing may be dilutive to our stockholders, and debt or equity financing, if available, may subject us to restrictive covenants and significant interest costs. If we obtain funding through a strategic collaboration or licensing arrangement, we may be required to relinquish our rights to certain of our product candidates or marketing territories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our inability to raise capital when needed would harm our business, financial condition and results of operations, and could cause our stock value to decline or require that we wind down our operations altogether.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Under current SEC regulations, if at the time we file our Annual Report on Form 10-K our public float is less than $75 million, and for so long as our public float remains less than $75 million, the amount we can raise through primary public offerings of securities in any twelve-month period using shelf registration statements is limited to an aggregate of one-third of our public float, which is referred to as the &#8220;baby shelf rules.&#8221; SEC regulations permit us to use the highest closing sales price of our common stock (or the average of the last bid and last ask prices of our common stock) on any day within 60 days of sales under the registration statement to calculate our public float. </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of the date of this Annual Report on Form 10-K, our public float was less than $75 million. As a result, for sales following the date of this Annual Report on Form 10-K, and until we again have a public float with a value in exceeds of $75 million, if ever, we only have the capacity to sell shares up to one-third of our public float under shelf registration statements in any twelve-month period. If our public float decreases, the amount of securities we may sell under our Form S-3 shelf registration statements will also decrease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital, including through lending arrangements, may cause dilution to our existing stockholders, restrict our operations or require us to relinquish proprietary rights.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, grants and license and development agreements in connection with any collaborations. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt financing, including through lending arrangements, and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will continue to incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a public company, we incur significant legal, accounting and other expenses under the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as well as rules&#160;subsequently implemented by the SEC, and the rules&#160;of the Nasdaq Stock Exchange. These rules&#160;impose various requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and appropriate corporate governance practices. Our management and other personnel have devoted and will continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules&#160;and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, these rules&#160;and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. As a result, we are required to periodically perform an evaluation of our internal controls over financial reporting to allow management to report on the effectiveness of those controls, as required by Section&#160;404 of the Sarbanes-Oxley Act. These efforts to comply with Section&#160;404 and related regulations have required, and continue to require, the commitment of significant financial and managerial resources. While we anticipate maintaining the integrity of our internal controls over financial reporting and all other aspects of Section&#160;404, we cannot be certain that a material weakness will not be identified when we test the effectiveness of our control systems in the future. If a material weakness is identified, we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources, costly litigation or a loss of public confidence in our internal controls, which could have an adverse effect on the market price of our stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Compliance with the Sarbanes-Oxley Act will require substantial financial and management resources and may increase the time and costs of completing an acquisition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A business that we identify as a potential acquisition target may not be in compliance with the provisions of the Sarbanes-Oxley Act regarding the adequacy of internal controls. The development of the internal controls of any such entity to achieve compliance with the Sarbanes-Oxley Act may increase the time and costs necessary to complete any such acquisition. Furthermore, any failure to implement required new or improved controls, or difficulties encountered in the implementation of adequate controls over our financial processes and reporting in the future, could harm our operating results or cause us to fail to meet our reporting obligations. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our securities.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to use our pre-change NOLs and other pre-change tax attributes to offset post-change taxable income or taxes may be subject to limitation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may, from time to time, carry net operating loss carryforwards (&#8220;NOLs&#8221;) as deferred tax assets on our balance sheet. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50-percentage- point cumulative change (by value) in the equity ownership of certain stockholders over a rolling three-year period), the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes to offset its post-change taxable income or taxes may be limited. We may experience ownership changes in the future as a result of shifts in our stock ownership, some of which changes are outside our control. As a result, our ability to use our pre-change NOLs and other pre-change tax attributes to offset post-change taxable income or taxes may be subject to limitation.</p><a id="_Hlk65860245"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Business Strategy, Structure, and Organization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We currently have no products for sale. We are heavily dependent on the success of our product candidates, and we cannot give any assurances that any of our product candidates will receive regulatory approval or be successfully commercialized.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, we have invested a significant portion of our efforts and financial resources in the acquisition and development of our product candidates. We have not demonstrated our ability to perform the functions necessary for the successful acquisition, development or commercialization of the technologies we are seeking to develop. As an early stage company, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area. Our future success is substantially dependent on our ability to successfully develop, obtain regulatory approval for, and then commercialize such product candidates. Most of our product candidates are currently in early stage clinical trials. Our business depends entirely on the successful development and commercialization of our product candidates, which may never occur. We currently have no drug products for sale, currently generate no revenues from sales of any drug products, and may never be able to develop or commercialize a marketable product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The successful development, and any commercialization, of our technologies and any product candidates that may occur would require us to successfully perform a variety of functions, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing our technology platform;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying, developing, formulating, manufacturing and commercializing product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">entering into successful licensing and other arrangements with product development partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">participating in regulatory approval processes, including ultimately gaining approval to market a drug product, which may not occur;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining sufficient quantities of our product candidates from our third-party manufacturers to meet clinical trial needs and, if approved, to meet commercial demand at launch and thereafter;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing and maintaining agreements with wholesalers, distributors and group purchasing organizations on commercially reasonable terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conducting sales and marketing activities including hiring, training, deploying and supporting our sales force and creating market demand for our product candidates through our own marketing and sales activities, and any other arrangements to promote our product candidates that we may establish; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining patent protection and regulatory exclusivity for our product candidates.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our operations have been limited to organizing the Company, acquiring, developing and securing our proprietary technology and identifying and obtaining preclinical data or clinical data for various product candidates. These operations provide a limited basis for you to assess our ability to continue to develop our technology, identify product candidates, develop and commercialize any product candidates we are able to identify and enter into successful collaborative arrangements with other companies, as well as for you to assess the advisability of investing in our securities. Each of these requirements will require substantial time, effort and financial resources.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each of our product candidates will require additional clinical development, management of clinical and manufacturing activities, regulatory approval in the jurisdictions in which we plan to market the product, obtaining manufacturing supply, building a commercial organization, and significant marketing efforts before we generate any revenues from product sales, which may not occur. We are not permitted to market or promote any of our product candidates in the U.S. or any other jurisdiction before we receive regulatory approval from the FDA or comparable foreign regulatory authority, respectively, and we may never receive such regulatory approval for any of our product candidates.</p><a id="_Hlk66049456"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future growth depends in part on our ability to identify and acquire or in-license products, and if we do not successfully identify and acquire or in-license related product candidates or integrate them into our operations</span><span style="font-style:italic;font-weight:bold;">, we may have limited growth opportunities</span><span style="font-style:italic;font-weight:bold;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">An important part of our business strategy is to continue to develop a pipeline of product candidates by acquiring or in-licensing products, businesses or technologies that we believe are a strategic fit with our focus on <i style="font-style:italic;">ex vivo</i> lentiviral gene therapy for rare genetic diseases and on novel combinations of CAR T cells with immuno-oncology antibodies, other biologics, and small molecule kinase inhibitors. Future in-licenses or acquisitions, however, may entail numerous operational and financial risks, including, but not necessarily limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exposure to unknown liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruption of our business and diversion of our management&#8217;s time and attention to develop acquired products or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty or inability to secure financing to fund development activities for such acquired or in-licensed technologies in the current economic environment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">higher than expected acquisition and integration costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased amortization expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to retain key employees of any acquired businesses.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. In particular, we may compete with larger pharmaceutical companies and other competitors in our efforts to establish new collaborations and in-licensing opportunities. These competitors may have access to greater financial resources than us and may have greater expertise in identifying and evaluating new opportunities. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts.</p><a id="_Hlk66049779"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our approach to the development of our product candidates is unproven, and we do not know whether we will be able to develop any products of commercial value</span><span style="font-style:italic;font-weight:bold;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our products candidates are emerging technologies and, consequently, it is conceivable that such technologies may ultimately fail to develop into commercially viable therapies to treat human patients with cancer or other diseases. One of the reasons for the lack of commercial viability could be our inability to obtain regulatory approval for such technologies.</p><a id="_Hlk66049862"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">CAR T is a new approach to cancer treatment that presents significant challenges</span><span style="font-style:italic;font-weight:bold;">.</span></p><a id="_Hlk66050479"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have concentrated much of our research and development efforts on CAR T technology, and our future success is highly dependent on the successful development of T cell immunotherapies in general and our CAR T technology and product candidates in particular. Because CAR T is a new approach to cancer immunotherapy and cancer treatment generally, developing and commercializing our product candidates subjects us to a number of challenges, including, but not necessarily limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining regulatory approval from the FDA and other regulatory authorities that may have very limited experience with the commercial development of genetically modified T cell therapies for cancer;</span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing and deploying consistent and reliable processes for engineering a patient&#8217;s T cells ex vivo and infusing the engineered T cells back into the patient;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conditioning patients with chemotherapy in conjunction with delivering each of our products, which may increase the risk of adverse side effects of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">educating medical personnel regarding the potential side effect profile of each of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing processes for the safe administration of these products, including long-term follow-up for all patients who receive our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sourcing clinical and, if approved, commercial supplies for the materials used to manufacture and process our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing a manufacturing process and distribution network with a cost of goods that allows for an attractive return on investment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing sales and marketing capabilities after obtaining any regulatory approval to gain market acceptance, and obtaining adequate coverage, reimbursement and pricing by third-party payors and government authorities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing therapies for types of cancers beyond those addressed by our current product candidates.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay the pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately and/or effectively evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are a &quot;smaller reporting company,&quot; and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a smaller reporting company, and we will remain a smaller reporting company until the fiscal&#160;year following the determination that our voting and non-voting common shares held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100 million during the most recently completed fiscal&#160;year and our voting and non-voting common shares held by non-affiliates is more than $700 million measured on the last business day of our second fiscal quarter. Smaller reporting companies are able to provide simplified executive compensation disclosure, are exempt from the auditor attestation requirements of Section&#160;404, and have certain other reduced disclosure obligations, including, among other things, being required to provide only two&#160;years of audited financial statements and not being required to provide selected financial data, supplemental financial information or risk factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have elected to take advantage of certain of the reduced reporting obligations available to us. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile.</p><a id="_Hlk65860292"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Risks Inherent in Drug Development and Commercialization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Delays in the commencement or conduct of our clinical trials could result in increased costs and delay our ability to pursue regulatory approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The commencement or conduct of clinical trials can be delayed for a variety of reasons, including, but not necessarily limited to, delays in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining regulatory approval to commence a clinical trial;</span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying, recruiting and training suitable clinical investigators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reaching and preserving agreements on acceptable terms with prospective clinical research organizations (&#8220;CROs&#8221;) and trial sites, the terms of which can be subject to extensive negotiation, may be subject to modification from time to time and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining sufficient quantities of a product candidate for use in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining Institutional Review Board (&#8220;IRB&#8221;) or ethics committee approval to conduct a clinical trial at a prospective site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing and validating companion diagnostics on a timely basis, if required;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adding new clinical sites once a trial has begun;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">change in the principal investigator or other key staff overseeing the clinical trial at a given site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying, recruiting and enrolling patients to participate in a clinical trial; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">retaining (or replacing) patients who have initiated a clinical trial but who may withdraw due to adverse events from the therapy, insufficient efficacy, fatigue with the clinical trial process, personal issues, or other reasons.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any delays in the commencement of our clinical trials will delay our ability to pursue regulatory approval for product candidates. In addition, many of the factors that cause, or lead to, a delay in the commencement of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Suspensions or delays in the completion of clinical testing could result in increased costs and delay or prevent our ability to complete development of that product or generate product revenues.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Once a clinical trial has begun, patient recruitment and enrollment may be slower than we anticipate due to the nature of the clinical trial plan, the proximity of patients to clinical sites, the eligibility criteria for participation in the study or other factors. Clinical trials may also be delayed as a result of ambiguous or negative interim results or difficulties in obtaining sufficient quantities of product manufactured in accordance with regulatory requirements and on a timely basis. Further, a clinical trial may be modified, suspended or terminated by us, an IRB, an ethics committee or a data safety monitoring committee overseeing the clinical trial, any clinical trial site with respect to that site, or the FDA or other regulatory authorities, due to a number of factors, including, but not necessarily limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inspection of the clinical trial operations or clinical trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stopping rules&#160;contained in the protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen safety issues or any determination that the clinical trial presents unacceptable health risks; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of adequate funding to continue the clinical trial.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes in regulatory requirements and guidance also may occur, and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit clinical trial protocols to IRBs for re-examination, which may in turn impact the costs and timing of, and the likelihood of successfully completing, a clinical trial. If we experience delays in the completion of, or if we must suspend or terminate, any clinical trial of any product candidate, our ability to obtain regulatory approval for that product candidate will be delayed, and the commercial prospects, if any, for the product candidate may suffer as a result. In addition, many of these factors may also ultimately lead to the denial of regulatory approval of a product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product candidates that we advance into clinical trials may not receive regulatory approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pharmaceutical development has inherent risks. We will be required to demonstrate through well-controlled clinical trials that product candidates are effective with a favorable benefit-risk profile for use in their target indications before seeking regulatory approvals for their </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">commercial sale. Success in early clinical trials does not mean that later clinical trials will be successful, as product candidates in later-stage clinical trials may fail to demonstrate sufficient safety or efficacy despite having progressed through initial clinical testing. Also, we may need to conduct additional clinical trials that are not currently anticipated. Companies frequently suffer significant setbacks in advanced clinical trials, even after earlier clinical trials have shown promising results. As a result, product candidates that we advance into clinical trials may not receive regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, even if our product candidates were to obtain approval, regulatory authorities may approve any such product candidates or any future product candidate for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. The regulatory authority may also require the label to contain warnings, contraindications, or precautions that limit the commercialization of the product. In addition, the DEA (or foreign equivalent) may classify one or more of our product candidates in scheduling under the Controlled Substances Act (or its foreign equivalent) that could impede such product&#8217;s commercial viability. Any of these scenarios could impact the commercial prospects for one or more of our current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any product candidates we advance into clinical development are subject to extensive regulation, which can be costly and time consuming, cause unanticipated delays or prevent the receipt of the required approvals to commercialize product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The research and clinical development, testing, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of any product candidate, including our product candidates, is subject to extensive regulation by the FDA in the United States and by comparable health authorities in foreign markets. In the United States, we are not permitted to market a product candidate until such product candidate&#8217;s BLA or NDA is approved by the FDA. The process of obtaining approval is uncertain, expensive, often spanning many&#160;years, and can vary substantially based upon the type, complexity and novelty of the products involved. In addition to significant and expensive clinical testing requirements, our ability to obtain marketing approval for product candidates depends on obtaining the final results of required non-clinical testing, including characterization of the manufactured components of our product candidates and validation of our manufacturing processes. The FDA may determine that our product manufacturing processes, testing procedures or equipment and facilities are inadequate to support approval. Approval policies or regulations may change, and the FDA has substantial discretion in the pharmaceutical approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in the clinical development of product candidates, regulatory approval is never guaranteed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory agencies can delay, limit or deny approval of a product candidate for many reasons, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with the trial design or implementation of our clinical trials, including proper use of clinical trial methods and methods of data analysis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an inability to establish sufficient data and information to demonstrate to the satisfaction of the FDA that a product candidate is safe and effective for an indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA may not accept clinical data from trials conducted by individual investigators or in countries where the standard of care is potentially different from that of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of clinical trials may not meet the level of statistical significance required by the FDA for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA may disagree with the interpretation of data from preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA may determine that our manufacturing processes or facilities or those of third-party manufacturers with which we or our respective collaborators currently contract for clinical supplies and plan to contract for commercial supplies do not satisfactorily comply with CGMPs; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or interpretation of regulations of the FDA may significantly change in a manner rendering the clinical data insufficient for approval or the product characteristics or benefit-risk profile unfavorable for approval.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">With respect to foreign markets, approval procedures vary among countries and, in addition to the aforementioned risks, can involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, rapid drug and biological development during the COVID-19 pandemic has raised questions about the safety and efficacy of certain marketed pharmaceuticals and may result in increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing new pharmaceuticals based on </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us from commercializing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulatory approval for our product candidates by the FDA, or any similar regulatory authorities outside the United States, is limited to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any regulatory approval is limited to the indications for use and related treatment of those specific diseases and indications set forth in the approval for which a product is deemed to be safe and effective by the FDA, or other similar regulatory authorities outside the United States. In addition to the regulatory approval required for new drug products, new formulations or indications for an approved product also require regulatory approval. If we are not able to obtain regulatory approval for any desired future indications for our products, our ability to effectively market and sell our products may be reduced and our business may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While physicians may choose to prescribe drugs for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical studies and approved by the regulatory authorities (&#8220;off-label uses&#8221;), our ability to promote the products is limited to those indications that are specifically approved by the FDA, or similar regulatory authorities outside the United States. Such off-label uses are common across medical specialties and may constitute an appropriate treatment for&#160;some&#160;patients in certain circumstances. Regulatory authorities in the U.S. generally do not regulate practice of medicine or the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical companies on the promotion of off-label use. If our promotional activities fail to comply with these regulations or guidelines, we may be subject to compliance or enforcement actions, including Warning Letters, by these authorities. In addition, our failure to follow FDA laws, regulations&#160;and guidelines relating to promotion and advertising may cause the FDA to&#160;suspend or withdraw&#160;an approved product from the market, request a recall or institute fines or penalties, or could result in disgorgement of money, operating restrictions, corrective advertising, injunctions or criminal prosecution, any of which could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If any of our product candidates are approved and we or our contract manufacturer(s)&#160;fail to produce the product, or components of the product, in the volumes that we require on a timely basis, or fail to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the commercialization of our product candidates or be unable to meet market demand, and may lose potential revenues.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls, and the use of specialized processing equipment. We may enter into development and supply agreements with contract manufacturers for the completion of pre-commercialization manufacturing development activities and, if approved, the manufacture of commercial supplies for one or more of our product candidates. Any termination or disruption of our relationships with our contract manufacturers may materially harm our business and financial condition and frustrate any commercialization efforts for each respective product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All of our contract manufacturers must comply with strictly enforced federal, state and foreign regulations, including cGMP requirements enforced by the FDA through its establishment inspection program. We are required by law to establish adequate oversight and control over raw materials, components and finished products furnished by our third-party suppliers and contract manufacturers, but we have little control over their compliance with these regulations. Any failure to comply with applicable regulations may result in fines and civil penalties, suspension of production, restrictions on imports and exports, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval, and would limit the availability of our product and customer confidence in our product. Any manufacturing defect or error discovered after products have been produced and distributed could result in even more significant consequences, including costly recalls, re-stocking costs, damage to our reputation and potential for product liability claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the contract manufacturers upon whom we may rely to manufacture one or more of our product candidates, and any future product candidate we may in-license, fails to deliver the required commercial quantities on a timely basis at commercially reasonable prices, we would likely be unable to meet demand for our products and we would lose potential revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If serious adverse or unacceptable side effects are identified during the development of one or more of our product candidates or any future product candidate, we may need to abandon or limit the development of some of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If one or more of our product candidates or any future product candidate are associated with undesirable side effects or adverse events in clinical trials or have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses or subpopulations in which the adverse events, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. In our industry, many compounds that initially showed promise in early stage testing have later </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">been found to cause serious adverse events that prevented further development of the compound. In the event that our clinical trials reveal a high or unacceptable severity and prevalence of adverse events, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development or deny approval of one or more of our product candidates or any future product candidate for any or all targeted indications. The FDA could also issue a letter requesting additional data or information prior to making a final decision regarding whether or not to approve a product candidate. The number of requests for additional data or information issued by the FDA in recent&#160;years has increased and has resulted in substantial delays in the approval of several new drugs. Adverse events or undesirable side effects caused by one or more of our product candidates or any future product candidate could also result in the inclusion of unfavorable information in our product labeling or in denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications, which would, in turn, prevent us from commercializing and generating market acceptance and revenues from the sale of that product candidate. Adverse events or side effects could affect patient recruitment or the ability of enrolled patients to complete the trial and could result in potential product liability claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, if one or more of our product candidates or any future product candidate receives marketing approval and we or others later identify undesirable side effects caused by this product, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require the addition of unfavorable labeling statements, including specific warnings , black box warnings, adverse reactions, precautions, and/or contraindications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may suspend or withdraw their approval of the product, and/or require it to be removed from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;&#160;or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of any of our product candidates or any future product candidate or could substantially increase our commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenues, or any revenues, from its sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if one or more of our product candidates receives regulatory approval, it and any other products we may market will remain subject to substantial regulatory scrutiny.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If one or more of our product candidates that we may license or acquire is approved, the approved product candidate will be subject to ongoing requirements and review by the FDA and other regulatory authorities. These requirements include labeling, packaging, storage, advertising, promotion, record-keeping and submission of safety and other post-market information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping of the drug, and requirements regarding our presentations to and interactions with health care professionals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA, or other regulatory authorities, may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product. The FDA and other applicable regulatory authorities closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and other applicable regulatory authorities impose stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we do not market our products for only their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the FDCA relating to the promotion of prescription drugs may lead to investigations, civil claims, and/or criminal charges alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on such products, operations, manufacturers or manufacturing processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling or marketing of a product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on product distribution or use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing studies or clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters, untitled letters, import alerts, and/or inspection observations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of the products from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of profits;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing or regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension of any ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions, consent decrees, and/or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA&#8217;s policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates, or negatively affect those products for which we may have already received regulatory approval, if any. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to the various actions listed above, including losing any marketing approval that we may have obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will need to obtain FDA approval of any proposed product brand names, and any failure or delay associated with such approval may adversely impact our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A pharmaceutical product cannot be marketed in the U.S. or other countries until we have completed a rigorous and extensive regulatory review process, including approval of a brand name. Any brand names we intend to use for our product candidates will require approval from the FDA regardless of whether we have secured a formal trademark registration from the USPTO. The FDA typically conducts a review of proposed product brand names, including an evaluation of the potential for confusion with other product names. The FDA may also object to a product brand name if it believes the name inappropriately implies medical claims. If the FDA objects to any of our proposed product brand names, we may be required to adopt an alternative brand name for our product candidates. If we adopt an alternative brand name, we would lose the benefit of our existing trademark applications for such product candidate and may be required to expend significant additional resources in an effort to identify a suitable product brand name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner or at all, which would limit our ability to commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Public concern regarding the safety of drug products could delay or limit our ability to obtain regulatory approval,&#160;result in the inclusion of unfavorable information in our labeling, or require us to undertake other activities that may entail additional costs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In light of widely publicized events concerning the safety risk of certain drug products, the FDA,&#160;members of the U.S. Congress, the Government Accountability Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the withdrawal of drug products, revisions to drug labeling that further limit use of the drug products and the establishment of risk management programs. The Food and Drug Administration Amendments Act of 2007, or FDAAA, grants significant expanded authority to the FDA, much of which is aimed at improving the safety of drug products before and after approval. In particular, the new law authorizes the FDA to, among other things, require post-approval studies and clinical trials, mandate changes to drug labeling to reflect new safety information and require risk evaluation and mitigation strategies for certain drugs, including certain currently approved drugs. It also significantly expands the federal government&#8217;s clinical trial registry and results databank, which we expect will result in significantly increased government oversight of clinical trials. Under the FDAAA, companies that violate these and other provisions of the new law are subject to substantial civil monetary penalties, among other regulatory, civil and criminal penalties. The increased attention to drug safety issues may result in a more cautious approach by the FDA in its review of data from our clinical trials. Data from clinical trials may receive greater scrutiny, particularly with respect to safety, which may make the FDA or other regulatory authorities more likely to require additional preclinical studies or clinical trials. If the FDA requires us to conduct additional preclinical studies or clinical trials prior to approving any of our product candidates, our ability to obtain approval of this product candidate will be delayed. If the FDA requires us </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to provide additional clinical or preclinical data following the approval of any of our product candidates, the indications for which this product candidate is approved may be limited or there may be specific warnings or limitations on dosing, and our efforts to commercialize our product candidates may be otherwise adversely impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not be able to initiate or continue clinical trials for one or more of our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. Some of our competitors have ongoing clinical trials for product candidates that treat the same indications that we are targeting for our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Available therapies for the indications we are pursuing can also affect enrollment in our clinical trials. Patient enrollment is affected by other factors including, but not necessarily limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the severity of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the eligibility criteria for the study in question;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the perceived risks and benefits of the product candidate under study;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efforts to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient referral practices of physicians;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of clinical trials sponsored by other companies for the same patient population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to monitor patients adequately during and after treatment; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity and availability of clinical trial sites for prospective patients.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates or future product candidates, which would cause the value of the Company to decline and limit our ability to obtain additional financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our competitors develop treatments for any of our product candidates&#8217; target indications and those competitor products are approved more quickly, marketed more successfully or demonstrated to be more effective, the commercial opportunity for our product candidate will be reduced or eliminated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are subject to rapid and intense technological change. We face, and will continue to face, competition in the development and, if approved, marketing of our product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies. There can be no assurance that developments by others will not render one or more of our product candidates obsolete or noncompetitive. Furthermore, new developments, including the development of other drug technologies and methods of preventing the incidence of disease, occur in the pharmaceutical industry at a rapid pace. These developments may render one or more of our product candidates obsolete or noncompetitive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Competitors may seek to develop alternative formulations that do not directly infringe on our in-licensed patent rights. The commercial opportunity for one or more of our product candidates could be significantly harmed if competitors are able to develop alternative formulations outside the scope of our in-licensed patents. Compared to us, many of our potential competitors have substantially greater:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">capital resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">development resources, including personnel and technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trial experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory experience;</span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expertise in prosecution of intellectual property rights;&#160;and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing, distribution and sales and marketing experience.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a result of these factors, our competitors may obtain regulatory approval of their products more rapidly than we are able to or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize one or more of our product candidates. Our competitors may also develop drugs that are more effective, safe, useful and less costly than ours and may be more successful than us in manufacturing and marketing their products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. We will also face competition from these third parties in establishing clinical trial sites, in patient registration for clinical trials, and in identifying and in-licensing new product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, generic therapies are typically sold at lower prices than branded therapies and are generally preferred by hospital formularies and managed care providers of health services. We anticipate that, if approved, our product candidates will face increasing competition in the form of generic versions of branded products of competitors, including those that have lost or will lose their patent exclusivity. In the future, we may face additional competition from a generic form of our own candidates when the patents covering them begin to expire, or earlier if the patents are successfully challenged. If we are unable to demonstrate to physicians and payers that the key differentiating features of our product candidates translate to overall clinical benefit or lower cost of care, we may not be able to compete with generic alternatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If any of our product candidates are successfully developed but do not achieve broad market acceptance among physicians, patients, healthcare payors and the medical community, the revenues that any such product candidates generate from sales will be limited.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors and the medical community. Coverage and reimbursement of our product candidates by third-party payors, including government payors, generally would also be necessary for commercial success. The degree of market acceptance of any approved products would depend on a number of factors, including, but not necessarily limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and safety as demonstrated in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of market introduction of such product candidate as well as competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indications for which the product is approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance by physicians, major operators of cancer clinics and patients of the product as a safe and effective treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the safety of such product candidates seen in a broader patient group, (i.e., based on actual use);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability, cost and potential advantages of alternative treatments, including less expensive generic drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of adequate reimbursement and pricing by third-party payors and government authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in regulatory requirements by government authorities for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the relative convenience and ease of administration of the product candidate for clinical practices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product labeling or product insert required by the FDA or regulatory authority in other countries, including any contradictions, warnings, drug interactions, or other precautions;</span></td></tr></table><a id="_Hlk66036702"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the standard of care for the targeted indications for our product candidate or future product candidates, which could reduce the marketing impact of any labeling or marketing claims that we could make following FDA approval</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval, availability, market acceptance and reimbursement for a companion diagnostic, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of adverse side effects;&#160;and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of our sales and marketing efforts.</span></td></tr></table><div style="margin-top:10pt;"></div></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If any product candidate that we develop does not provide a treatment regimen that is as beneficial as, or is not perceived as being as beneficial as, the current standard of care or otherwise does not provide patient benefit, that product candidate, if approved for commercial sale by the FDA or other regulatory authorities, likely will not achieve market acceptance. Our ability to effectively promote and sell any approved products will also depend on pricing and cost-effectiveness, including our ability to produce a product at a competitive price and our ability to obtain sufficient third-party coverage or reimbursement. If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, patients and third-party payors, our ability to generate revenues from that product would be substantially reduced. In addition, our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources, may be constrained by FDA rules&#160;and policies on product promotion, and may never be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our products profitably.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There is significant uncertainty related to the third-party coverage and reimbursement of newly approved drugs. Such third-party payors include government health programs such as Medicare, managed care providers, private health insurers and other organizations. We intend to seek approval to market our product candidates in the U.S., the EU and other selected foreign jurisdictions. Market acceptance and sales of our product candidates in both domestic and international markets will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for any of our product candidates and may be affected by existing and future health care reform measures. Government and other third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for new drugs and, as a result, they may not cover or provide adequate payment for our product candidates. These payors may conclude that our product candidates are less safe, less effective or less cost-effective than existing or future introduced products, and third-party payors may not approve our product candidates for coverage and reimbursement or may cease providing coverage and reimbursement for these product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. If reimbursement of our future products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In some foreign countries, particularly in the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product candidate. To obtain reimbursement or pricing approval in some countries, we may be required to conduct additional clinical trials that compare the cost-effectiveness of our product candidates to other available therapies. If reimbursement of our product candidates is unavailable or limited in scope or amount in a particular country, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability of our products in such a country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to establish sales, marketing and distribution capabilities or to enter into agreements with third parties to market and sell our product candidates, we may be unsuccessful in commercializing our product candidates, if they are approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently do not have a marketing or sales organization for the marketing, sales and distribution of pharmaceutical products. In order to commercialize any approved product candidate, we would need to build marketing, sales, distribution, managerial and other non-technical capabilities or arrange for third parties to perform these services, and we may be unsuccessful in doing so. In the event of successful development and regulatory approval of any of our current or future product candidates, we expect to build a targeted specialist sales force to market or co-promote the product. There are risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Factors that may inhibit our efforts to commercialize our products on our own include, but are not necessarily limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products;</span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the lack of complementary or other products to be offered by sales personnel, which may put us at a competitive disadvantage from the perspective of sales efficiency relative to companies with more extensive product lines; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen costs and expenses associated with creating our own sales and marketing organization.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for one or more of our product candidates or a future product candidate we may license or acquire and may have to limit their commercialization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The use of one or more of our product candidates and any future product candidate we may license or acquire in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Product liability claims might be brought against us by consumers, health care providers or others using, administering or selling our products. If we cannot successfully defend ourselves against these claims, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or termination of clinical trial sites or entire trial programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for any product candidates or products that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of investigations by regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment of our business reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to patients or other claimants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced resources of our management to pursue our business strategy; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize our product candidate or future product candidates.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will obtain limited product liability insurance coverage for any and all of our upcoming clinical trials. However, our insurance coverage may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. When needed we intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for one or more of our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product candidates, even if successfully developed and commercialized, may be effective only in combating certain specific types of cancer, and the market for drugs designed to combat such cancer type(s)&#160;may be small and unprofitable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There are many different types of cancer, and a treatment that is effective against one type of cancer may not be effective against another. CAR T or other technologies we pursue may only be effective in combating specific types of cancer but not others. Even if one or more of our products proves to be an effective treatment against a given type of cancer, the number of patients suffering from such cancer may be small, in which case potential sales from a therapy designed to combat such cancer would be limited.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk66049909"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our gene therapy product candidates are based on a novel technology, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval</span><span style="font-style:italic;font-weight:bold;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have concentrated a portion of our therapeutic product research and development efforts on our gene therapy platform, and our future success depends, in part, on the successful development of this therapeutic approach. There can be no assurance that any development problems we experience in the future related to our gene therapy platform will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may also experience delays in developing a sustainable, reproducible and commercial-scale manufacturing process or transferring that process to commercial partners, which may prevent us from completing our clinical studies or commercializing our products on a timely or profitable basis, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the clinical study requirements of the FDA, the European Medicines Agency, or EMA, and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or more extensively studied pharmaceutical or other product candidates. Currently, a limited number of gene therapy products, including CAR T therapies, have been approved by the FDA, the EMA and the European Commission. Given the few precedents of approved gene therapy products, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in the United States, the EU or other jurisdictions. Approvals by the EMA and the European Commission may not be indicative of what the FDA may require for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Regulatory requirements governing the development of gene therapy products have changed frequently and may continue to change in the future. The FDA has established the Office of Tissues and Advanced Therapies within the Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and to advise the CBER on its review. The FDA can put an IND on clinical hold if the information in an IND is not sufficient to assess the risks in pediatric patients. Before a clinical study can begin at any institution, that institution&#8217;s IRB and its Institutional Biosafety Committee will have to review the proposed clinical study to assess the safety of the study. Moreover, serious adverse events or developments in clinical trials of gene therapy product candidates conducted by others may cause the FDA or other regulatory bodies to initiate a clinical hold on our clinical trials or otherwise change the requirements for approval of any of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These regulatory review agencies, committees and advisory groups and the new requirements and guidelines they promulgate may lengthen the regulatory review process, require us to perform additional or larger studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these treatment candidates or lead to significant post-approval studies, limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory and advisory groups and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of our product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Negative public opinion and increased regulatory scrutiny of the therapies that underpin many of our product candidates may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Public perception may be influenced by claims that one or more of the therapies underpinning our product candidates, including without limitation gene therapy, is unsafe, and such therapy may not gain the acceptance of the public or the medical community. In particular, the success of our gene therapy platforms will depend upon physicians specializing in the treatment of those diseases that our product candidates target prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available. More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Adverse events in our clinical trials, even if not ultimately attributable to our product candidates, and the resulting publicity, could lead to increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our potential product candidates, stricter labeling requirements for those product candidates that do obtain approval and/or a decrease in demand for any such product candidates. Concern about environmental spread of our products, whether real or anticipated, may also hinder the commercialization of our products.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk66047505"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Risks Related to Reliance on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_Hlk66050870"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely, and expect to continue to rely, on third parties to conduct our preclinical studies and clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials or complying with applicable regulatory requirements</span><span style="font-style:italic;font-weight:bold;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely on our licensors to conduct some of our preclinical studies and some of our clinical trials for our product candidates and for future product candidates, and we rely on third-party CROs and site management organizations to conduct most of the remainder of our preclinical studies and all the rest of our clinical trials. We expect to continue to rely on third parties, such as our licensors, CROs, site management organizations, clinical data management organizations, medical institutions and clinical investigators, to conduct some of our preclinical studies and all of our clinical trials. The agreements with these third parties might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, that could delay our product development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our preclinical studies and clinical trials are conducted in accordance with the general investigational plan and protocols for the trial and for ensuring that our preclinical studies are conducted in accordance with good laboratory practices (&#8220;GLPs&#8221;) as appropriate. Moreover, the FDA requires us to comply with standards, commonly referred to as good clinical practices (&#8220;GCPs&#8221;) for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Regulatory authorities enforce these requirements through periodic inspections of trial sponsors, clinical investigators and trial sites. If we or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The third parties with whom we have contracted to help perform our preclinical studies and/or clinical trials may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our preclinical studies or clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If any of our relationships with these third-party CROs or site management organizations terminates, we may not be able to enter into arrangements with alternative CROs or site management organizations or to do so on commercially reasonable terms. Switching or adding additional CROs or site management organizations involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO or site management organization commences work. As a result, delays could occur, which could compromise our ability to meet our desired development timelines. Though we carefully manage our relationships with our CROs or site management organizations, there can be no assurance that we will not encounter similar challenges or delays in the future. Forces beyond our control, including the impacts of COVID-19, could disrupt the ability of our third-party CROs, site management organizations, clinical data management organizations, medical institutions, and clinical investigators to conduct our preclinical studies and our clinical trials for our product candidates and for any future product candidate. As of the date of this Annual Report on Form 10-K, the Company has experienced a moderate impact on its long-term development timeline and its liquidity due to the worldwide spread of the COVID-19 virus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are currently reliant on COH, Fred Hutch, St. Jude, UAB, Mayo Clinic, and LUMC for a substantial portion of our research and development efforts and the early clinical testing of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A substantial portion of our research and development has been and will continue to be conducted by COH, Fred Hutch, St. Jude, UAB, LUMC and Mayo Clinic pursuant to a sponsored research agreement and/or clinical trial agreements with each of those parties. As a result, our future success is heavily dependent on the results of research and development efforts of Dr.&#160;Stephen Forman and his team at COH, of Drs.&#160;Brian Till and Mazyar Shadman and their team at Fred Hutch, of Drs.&#160;Stephen Gottschalk and Ewelina Mamcarz and their team at St. Jude, of Dr.&#160;James M. Markert and his team at UAB, of Dr. Frank J. Staal and his team at LUMC, and of Dr. Larry R. Pease and his team at Mayo Clinic. We have limited control over the nature or timing of their research and limited visibility into their day-to-day activities, and as a result can provide little assurance that their efforts will be successful.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk66050907"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We contract with third parties for the manufacture of our product candidates for preclinical and clinical testing and may also do so for commercialization, if and when our product candidates are approved.</span><span style="font-style:italic;font-weight:bold;"> This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or any future product candidate or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may rely on third-party manufacturers or third-party collaborators for the manufacture of commercial supply of one or more product candidates for which our collaborators or we obtain marketing approval. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including, but not necessarily limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reliance on the third party for regulatory compliance and quality assurance, while still being required by law to establish adequate oversight and control over products furnished by that third party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible breach of the manufacturing agreement by the third party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing delays if our third-party manufacturers are unable to obtain raw materials due to supply chain disruptions, give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreement between us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely on our third-party manufacturers to produce or purchase from third-party suppliers the materials and equipment necessary to produce our product candidates for our preclinical and clinical trials. Forces beyond our control, including the effects of the COVID-19 pandemic, could disrupt the global supply chain and impact our or our third-party manufacturers&#8217; ability to obtain raw materials or other products necessary to manufacture our product candidates. There are a limited number of suppliers for raw materials and equipment that we use (or that are used on our behalf) to manufacture our drugs, and there may be a need to assess alternate suppliers to prevent a possible disruption of the manufacture of the materials and equipment necessary to produce our product candidates for our preclinical and clinical trials, and if approved, ultimately for commercial sale. We do not have any control over the process or timing of the acquisition of these raw materials or equipment by our third-party manufacturers. Any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing preclinical or clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our preclinical or clinical trials, product testing and potential regulatory approval of our product candidates. If our manufacturers or we are unable to purchase these raw materials or equipment after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The facilities used by contract manufacturers to potentially manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit an NDA or BLA to the FDA. We are required by law to establish adequate oversight and control over raw materials, components and finished products furnished by our contract manufacturers, but we do not control the day-to-day manufacturing operations of, and are dependent on, the contract manufacturers for compliance with cGMP regulations for manufacture of our product candidates. Third-party manufacturers may not be able to comply with the cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, restrictions on imports and exports, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">One or more of the product candidates that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply. If our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. We may incur added costs and delays in identifying and qualifying any replacement manufacturers. The DEA restricts the importation of a controlled substance finished drug product when the same substance is commercially available in the United States, which could reduce the number of potential alternative manufacturers for one or more of our product candidates.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that may receive marketing approval on a timely and competitive basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also expect to rely on other third parties to distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, if approved, producing additional losses and depriving us of potential product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on third parties to conduct all aspects of our lentiviral vector production and these third parties may not perform satisfactorily.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not independently conduct our lentiviral vector production and we currently rely, and expect to continue to rely, on third parties with respect to the manufacture of these items.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our reliance on these third parties for manufacturing lentiviral vector reduces our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations and study protocols. For products that we develop and commercialize, we will remain responsible for ensuring that each of our IND-enabling studies and clinical studies is conducted in accordance with the study plan and protocols, and that our lentiviral vectors are manufactured in accordance with GMP as applied in the relevant jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If these third parties do not successfully carry out their contractual duties, meet expected deadlines, conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, or manufacture our lentiviral vectors in accordance with GMP, we will not be able to complete, or may be delayed in completing, the preclinical and clinical studies and manufacturing process validation activities required to support future IND, market authorization application and BLA submissions and approval of our product candidates, or to support commercialization of our products, if approved. Many of our agreements with these third parties contain termination provisions that allow these third parties to terminate their relationships with us at any time. If we need to enter into alternative arrangements, our product development and commercialization activities could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be forced to enter into an agreement with a different manufacturer, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills required to manufacture lentiviral vector for our drug product candidates may be unique or proprietary to the original manufacturer, and we may have difficulty or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. Any of these events could lead to clinical study delays or failure to obtain marketing approval or impact our ability to successfully commercialize our product or any future products. Some of these events could be the basis for FDA action, including injunction, recall, seizure or total or partial suspension of production.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on clinical data and results obtained by third parties that could ultimately prove to be inaccurate or unreliable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of our strategy to mitigate development risk, we seek to develop product candidates with well-studied mechanisms of action, and we utilize biomarkers to assess potential clinical efficacy early in the development process. This strategy necessarily relies upon clinical data and other results obtained by third parties that may ultimately prove to be inaccurate or unreliable. Further, such clinical data and results may be based on products or product candidates that are significantly different from our product candidates or any future product candidate. If the third-party data and results we rely upon prove to be inaccurate, unreliable or not applicable to our product candidates or future product candidate, we could make inaccurate assumptions and conclusions about our product candidates and our research and development efforts could be compromised.</p><a id="_Hlk66050934"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms</span><span style="font-style:italic;font-weight:bold;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A third party may hold intellectual property, including patent rights that are important or necessary to the development and commercialization of our products. It may be necessary for us to use the patented or proprietary technology of third parties, who may or may not be interested in granting such a license, to commercialize our products, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Collaborative relationships with third parties could cause us to expend significant resources and incur substantial business risk with no assurance of financial return.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Establishing strategic collaborations is difficult and time-consuming. Our discussions with potential collaborators may not lead to the establishment of collaborations on favorable terms, if at all. Potential collaborators may reject collaborations based upon their assessment of our financial, regulatory or intellectual property position. In addition, there has been a significant number of recent business combinations </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Even if we successfully establish new collaborations, these relationships may never result in the successful development or commercialization of product candidates or the generation of sales revenue. To the extent that we enter into collaborative arrangements, the related product revenues are likely to be lower than if we directly marketed and sold products. Such collaborators may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for any future product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Risks Relating to Legislation and Regulation Affecting the Biopharmaceutical and Other Industries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to new legislation, regulatory proposals and managed care initiatives that may increase our costs of compliance and adversely affect our ability to market our products, obtain collaborators and raise capital.</span></p><a id="_Hlk66028609"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Legislative and regulatory changes to the healthcare systems of the United States and certain foreign countries could impact our ability to sell our products profitably. Several federal agencies including FDA, CMS and HHS, in addition to state and local governments regulate drug product development and marketing. In particular, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (&#8220;MMA&#8221;) changed the way Medicare covers and pays for pharmaceutical products by revising the payment methodology for many products reimbursed by Medicare, resulting in lower rates of reimbursement for many types of drugs, and added a prescription drug benefit to the Medicare program that involves commercial plans negotiating drug prices for their members. In addition, this law provided authority for limiting the number of drugs that will be covered in any therapeutic class. Cost reduction initiatives and other provisions of this law and future laws could decrease the coverage and price that we will receive for any approved products. While the MMA only applies to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Therefore, any limitations in reimbursement that results from the MMA may result in reductions in payments from private payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since 2003, there have been several other legislative and regulatory changes to the coverage and reimbursement landscape for pharmaceuticals. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the &#8220;Affordable Care Act&#8221; or &#8220;ACA,&#8221; was enacted in 2010 and made significant changes to the United States&#8217; healthcare system. The ACA and any revisions or replacements of that Act, any substitute legislation, and other changes in the law or regulatory framework could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Among the provisions of the ACA of importance to our potential product candidates are:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an annual, nondeductible fee on any entity that manufactures, or imports specified branded prescription drugs and biological products, apportioned among these entities according to their market share in certain government healthcare programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of healthcare fraud and abuse laws, including the federal False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for non-compliance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 138% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of the entities eligible to enroll in the 340B Drug Pricing Program to include certain critical access hospitals, freestanding cancer hospitals, rural referral centers, and sole community hospitals, but exempting certain drugs from the ceiling price requirements for these covered entities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the new requirements under the federal Open Payments program and its implementing regulations;</span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new regulatory pathway for the approval of biosimilar biological products, all of which will impact existing government healthcare programs and will result in the development of new programs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Supreme Court upheld the ACA in the main challenge to the constitutionality of the law in 2012. Specifically, the Supreme Court held that the individual mandate and corresponding penalty was constitutional because it would be considered a tax by the federal government. The Supreme Court also upheld federal subsidies for purchasers of insurance through federally facilitated exchanges in a decision released in June&#160;2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At the end of 2017, Congress passed the Tax Cuts and Jobs Act, which repealed the penalty for individuals who fail to maintain minimum essential health coverage as required by the ACA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Bipartisan Budget Act of 2018, the &#8220;BBA,&#8221; which set government spending levels for Fiscal Years 2018 and 2019, revised certain provisions of the ACA. Specifically, beginning in 2019, the BBA increased manufacturer point-of-sale discounts off negotiated prices of applicable brand drugs in the Medicare Part&#160;D coverage gap from 50% to 70%, ultimately increasing the liability for brand drug manufacturers. Further, this mandatory manufacturer discount applied to biosimilars beginning in 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the United States there is significant interest in containing healthcare costs and increasing scrutiny of pharmaceutical pricing practices. Congress has continually explored legislation intended to address the cost of prescription drugs. Notably, the major committees of jurisdiction in the Senate (Finance Committee, Health, Education, Labor and Pensions Committee, and Judiciary Committee), regularly evaluate and hold hearings on legislation intended to address various elements of the prescription drug supply chain and prescription drug pricing. Proposals include a significant overhaul of the Medicare Part&#160;D benefit design, efforts to cap the increase in drug prices, create drug price transparency, and efforts to allow the Secretary of the Department of Health and Human Services to negotiate drug prices with prescription drug manufacturers. While we cannot predict what proposals may ultimately become law, the elements under consideration could significantly change the landscape in which the pharmaceutical market operates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The former Trump administration took several regulatory steps and proposed numerous prescription drug cost control measures. Similarly, the Biden administration has identified promoting competition and lowering drug prices as a priority. State legislatures are similarly active in proposing and passing legislation and regulations aimed at controlling pharmaceutical and biological prices and drug cost transparency. There likely will continue to be legislative and regulatory proposals at the federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare products and services, including prescription drugs. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and prescription drugs may adversely affect:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the demand for any products for which we may obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to set a price that we believe is fair for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to generate revenues and achieve or maintain profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of taxes that we are required to pay; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of capital.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug. Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business or the business of our partners.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, ability to accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent&#160;years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business or the business of our partners. For example, over the last several&#160;years, including for 35&#160;days beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough nonessential FDA employees and stop routine activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. If the timing of FDA&#8217;s review and approval of new products is delayed, the timing of our or our partners&#8217; development process may be delayed, which could result in delayed milestone revenues and materially harm our operations or business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic has caused considerable disruptions at the FDA, namely with respect to diverting the FDA&#8217;s attention and resources to facilitate vaccine development and ensure rapid review and emergency use authorization of vaccines intended to prevent COVID-19. Continued focus on COVID-19 countermeasures, and the reorganization and rededication for critical resources, both at the FDA and within similar governmental authorities across the world, may impact the ability of new products and services from being developed or commercialized in a timely manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our current and future relationships with customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Healthcare providers, physicians and third-party payors in the U.S. and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, which may constrain the business or financial arrangements and relationships through which we sell, market and distribute any product candidates for which we obtain marketing approval. In addition, we may be subject to transparency laws and patient privacy regulation by the federal and state governments and by governments in foreign jurisdictions in which we conduct our business. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to operate include, but are not necessarily limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs, such as Medicare and Medicaid;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act, which impose criminal and civil penalties, including civil whistleblower or&#160;qui&#160;tam&#160;actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), and their respective implementing regulations, which impose obligations on covered healthcare providers, health plans, and healthcare </span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clearinghouses, as well as their business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Open Payments program, which requires manufacturers of certain approved drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the CMS, information related to &#8220;payments or other transfers of value&#8221; made to physicians, which is defined to include doctors, dentists, optometrists, podiatrists and chiropractors, and teaching hospitals and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by the physicians and their immediate family members. Data collection began on August&#160;1, 2013, with requirements for manufacturers to submit reports to CMS by June 30, 2014, and 90&#160;days after the end each subsequent calendar&#160;year. Disclosure of such information was made by CMS on a publicly available website beginning in September&#160;2014 and is annually updated; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, which could have a material adverse effect on our business. If any of the physicians or other healthcare providers or entities with whom we expect to do business, including our collaborators, is found not to be in compliance with applicable laws, it may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also materially affect our business.</p><a id="_Hlk66051039"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business</span><span style="font-style:italic;font-weight:bold;">.</span></p><a id="_Hlk66051058"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. Although we believe that the safety procedures for handling and disposing of these materials comply with the standards prescribed by these laws and regulations, we cannot eliminate the risk of accidental contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk66047523"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Risks Related to Intellectual Property and Potential Disputes Thereof</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk66051166"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain and maintain sufficient patent protection for our technology and products, our competitors could develop and commercialize technology and products similar or identical to ours, </span><span style="font-style:italic;font-weight:bold;">and our ability to successfully commercialize our technology and products may be impaired</span><span style="font-style:italic;font-weight:bold;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our success depends, in large part, on our ability to obtain patent protection for product candidates and their formulations and uses. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or our partners will be successful in obtaining patents or what the scope of an issued patent may ultimately be. These risks and uncertainties include, but are not necessarily limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent applications may not result in any patents being issued, or the scope of issued patents may not extend to competitive product candidates and their formulations and uses developed or produced by others;</span></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:16.65pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>our competitors, many of which have substantially greater resources than us or our partners, and many of which have made significant investments in competing technologies, may seek, or may already have obtained, patents that may limit or interfere with our abilities to make, use, and sell potential product candidates, file new patent applications, or may affect any pending patent applications that we may have;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:16.65pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>there may be significant pressure on the U.S. government and other international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful as a matter of public policy regarding worldwide health concerns; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:16.65pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable, or otherwise may not provide any competitive advantage. Moreover, we may be subject to a third-party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, reexamination, <i style="font-style:italic;">inter partes</i> review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The costs of these proceedings could be substantial, and it is possible that our efforts to establish priority of invention would be unsuccessful, resulting in a material adverse effect on our U.S. patent positions. An adverse determination in any such submission, patent office trial, proceeding or litigation could reduce the scope of, render unenforceable, or invalidate, our patent rights, allow third parties to commercialize our technologies or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Third parties are often responsible for maintaining patent protection for our product candidates, at our and their expense. If that party fails to appropriately prosecute and maintain patent protection for a product candidate, our abilities to develop and commercialize products may be adversely affected, and we may not be able to prevent competitors from making, using and selling competing products. Such a failure to properly protect intellectual property rights relating to any of our product candidates could have a material adverse effect on our financial condition and results of operations. In addition, U.S. patent laws may change, which could prevent or limit us from filing patent applications or patent claims to protect products and/or technologies or limit the exclusivity periods that are available to patent holders, as well as affect the validity, enforceability, or scope of issued patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We and our licensors also rely on trade secrets and proprietary know-how to protect product candidates. Although we have taken steps to protect our and their trade secrets and unpatented know-how, including entering into confidentiality and non-use agreements with third parties, and proprietary information and invention assignment agreements with employees, consultants and advisers, third parties may still come upon this same or similar information independently. Despite these efforts, any of these parties may also breach the agreements and may unintentionally or willfully disclose our or our licensors&#8217; proprietary information, including our trade secrets, and we may not be able to identify such breaches or obtain adequate remedies. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, if any of our or our licensors&#8217; trade secrets were to be lawfully obtained or independently developed by a competitor, we and our licensors would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our or our licensors&#8217; trade secrets were to be disclosed to or independently developed by a competitor, our competitive positions would be harmed.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify any patentable aspects of our research and development output and methodology, and, even if we do, an opportunity to obtain patent protection may have passed. Given the uncertain and time-consuming process of filing patent applications and prosecuting them, it is possible that our product(s)&#160;or process(es) originally covered by the scope of the patent application may have changed or been modified, leaving our product(s)&#160;or process(es) without patent protection. If our licensors or we fail to obtain or maintain patent protection or trade secret protection for&#160;one or more product candidates or any future product candidate we may license or acquire, third parties may be able to leverage our proprietary information and products without risk of infringement, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and achieve profitability. Moreover, should we enter into other collaborations we may be required to consult with or cede control to collaborators regarding the prosecution, maintenance and enforcement of licensed patents. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent&#160;years been the subject of much litigation. In addition, no consistent policy regarding the breadth of claims allowed in pharmaceutical or biotechnology patents has emerged to date in the U.S. The patent situation outside the U.S. is even more uncertain. The laws of foreign countries may not protect our rights to the same extent as the laws of the U.S., and we may fail to seek or obtain patent protection in all major markets. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18&#160;months after a first filing, or in some cases not at all. Therefore, we cannot know with certainty whether we or our licensors were the first to make the inventions claimed in patents or pending patent applications that we own or licensed, or that we or our licensors were the first to file for patent protection of such inventions. In the event that a third party has also filed a U.S.&#160;patent application relating to our product candidates or a similar invention, depending upon the priority dates claimed by the competing parties, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention in the U.S. We might also become involved in derivation proceedings in an event that a third party misappropriates one or more of our inventions and files their own patent application directed to such one or more inventions. The costs of these proceedings could be substantial, and it is possible that our efforts to establish priority of invention (or that a third party derived an invention from us) would be unsuccessful, resulting in a material adverse effect on our U.S.&#160;patent position. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the U.S. and other countries may diminish the value of our patents or narrow the scope of our patent protection. For example, the federal courts of the U.S. have taken an increasingly dim view of the patent eligibility of certain subject matter, such as naturally occurring nucleic acid sequences, amino acid sequences and certain methods of utilizing the same, which include their detection in a biological sample and diagnostic conclusions arising from their detection. Such subject matter, which had long been a staple of the biotechnology and biopharmaceutical industry to protect their discoveries, is now considered, with few exceptions, ineligible in the first instance for protection under the patent laws of the U.S. Accordingly, we cannot predict the breadth of claims that may be allowed and remain enforceable in our patents or in those licensed from a third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also may rely on the regulatory period of market exclusivity for any of our biologic product candidates that are successfully developed and approved for commercialization. Although this period in the United States is generally 12&#160;years from the date of marketing approval (depending on the nature of the specific product), there is a risk that the U.S. Congress could amend laws to significantly shorten this exclusivity period. Once any regulatory period of exclusivity expires, depending on the status of our patent coverage and the nature of the product, we may not be able to prevent others from marketing products that are biosimilar to or interchangeable with our products, which would materially adversely affect our business.</p><a id="_Hlk66051203"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We depend on our licensors to maintain and enforce the intellectual property covering certain of our product candidates</span><span style="font-style:italic;font-weight:bold;">. We have limited, if any, control over the resources that our licensors can or will devote to securing, maintaining, and enforcing patents protecting our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We depend on our licensors to protect the proprietary rights covering&#160;our product candidates and we have limited, if any, control over the amount or timing of resources that they devote on our behalf, or the priority they place on, maintaining patent rights and prosecuting patent applications to our advantage. Moreover, we have limited, if any, control over the strategies and arguments employed in the maintenance of </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">patent rights and the prosecution of patent applications to our advantage. Our licensors might become involved in disputes with one of their other licensees, and we or a portion of our licensed patent rights might become embroiled in such disputes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our licensors, depending on the patent or application, are responsible for maintaining issued patents and prosecuting patent applications. We cannot be sure that they will perform as required. Should they decide they no longer want to maintain any of the patents licensed to us, they are required to afford us the opportunity to do so at our expense. If our licensors do not perform, and if we do not assume the maintenance of the licensed patents in sufficient time to make required payments or filings with the appropriate governmental agencies, we risk losing the benefit of all or some of those patent rights. Moreover, and possibly unbeknownst to us, our licensors may experience serious difficulties related to their overall business or financial stability, and they may be unwilling or unable to continue to expend the financial resources required to maintain and prosecute these patents and patent applications. While we intend to take actions reasonably necessary to enforce our patent rights, we depend, in part, on our licensors to protect a substantial portion of our proprietary rights and to inform us of the status of those protections and efforts thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our licensors may also be notified of alleged infringement and be sued for infringement of third-party patents or other proprietary rights. We may have limited, if any, control or involvement over the defense of these claims, and our licensors could be subject to injunctions and temporary or permanent exclusionary orders in the U.S. or other countries. Our licensors are not obligated to defend or assist in our defense against third-party claims of infringement. We have limited, if any, control over the amount or timing of resources, if any, that our licensors devote on our behalf or the priority they place on defense of such third-party claims of infringement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because of the uncertainty inherent in any patent or other litigation involving proprietary rights, we or our licensors may not be successful in defending claims of intellectual property infringement alleged by third parties, which could have a material adverse effect on our results of operations. Regardless of the outcome of any litigation, defending the litigation may be expensive, time-consuming and distracting to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Protecting our proprietary rights is difficult and costly, and we may be unable to ensure their protection.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The degree of future protection for our proprietary rights is uncertain, because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage, in addition to being costly and time consuming to undertake. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our licensors might not have been the first to make the inventions covered by each of our pending patent applications and issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our licensors might not have been the first to file patent applications for these inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate our product candidates or any future product candidate technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that none of the pending patent applications licensed to us will result in issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of our issued patents may not extend to competitive products developed or produced by others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issued patents covering our product candidates or any future product candidate may not provide a basis for market exclusivity for active products, may not provide us with any competitive advantages, or may be challenged by third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies that are patentable;&#160;or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual property rights of others may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful, and an unfavorable outcome in any litigation would harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Competitors may infringe our issued patents or other intellectual property. To counter infringement or unauthorized use, we may be required to file one or more actions for patent infringement, which can be expensive and time consuming. Any claims we assert against accused infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents; or provoke those parties to petition the USPTO to institute <i style="font-style:italic;">inter partes</i> review against the asserted patents, which may lead to a finding that all or some of the claims of the patent are invalid. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question or as a matter of public policy. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, rendered unenforceable, or interpreted narrowly. Furthermore, adverse results on U.S. patents may affect related patents in our global portfolio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we or our licensors are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our success also depends on our ability, and the abilities of any of our respective current or future collaborators, to develop, manufacture, market and sell product candidates without infringing the proprietary rights of third parties. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing products, some of which may be directed at claims that overlap with the subject matter of our or our licensors&#8217; intellectual property. Because patent applications can take many&#160;years to issue, there may be currently pending applications, unknown to us, which may later result in issued patents that our product candidates or proprietary technologies may infringe. Similarly, there may be issued patents relevant to our product candidates of which we or our licensors are not aware. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18&#160;months after a first filing, or in some cases not at all. Therefore, we cannot know with certainty whether we or such licensors were the first to make the inventions claimed in patents or pending patent applications that we own or licensed, or that we and our licensors were the first to file for patent protection of such inventions. In the event that a third party has also filed a U.S. patent application relating to our product candidates or a similar invention, depending upon the priority dates claimed by the competing parties, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention in the U.S. The costs of these proceedings could be substantial, and it is possible that our efforts to establish priority of invention would be unsuccessful, resulting in a material adverse effect on our U.S. patent position. As a result, the issuance, scope, validity, enforceability and commercial value of our or any of our licensors&#8217; patent rights are highly uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. If a third party claims that we or any of our licensors, suppliers or collaborators infringe the third party&#8217;s intellectual property rights, we may have to, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain additional licenses, which may not be available on commercially reasonable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">abandon an infringing product candidate or redesign products or processes to avoid infringement, which may demand substantial funds, time and resources and which may result in inferior or less desirable processes and/or products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pay substantial damages, including the possibility of treble damages and attorneys&#8217; fees, if a court decides that the product or proprietary technology at issue infringes on or violates the third party&#8217;s rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pay substantial royalties, fees and/or grant cross-licenses to our product candidates; and/or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">defend litigation or administrative proceedings which may be costly regardless of outcome, and which could result in a substantial diversion of financial and management resources.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with our obligations under our intellectual property licenses and third party funding arrangements, we could lose rights that are important to our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are currently a party to license agreements with St. Jude, COH, Fred Hutch, University of California at Los Angeles (&#8220;UCLA&#8221;), Nationwide and other institutions. In the future, we may become party to licenses that are important for product development and commercialization. If we fail to comply with our obligations under current or future license and funding agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market any product or utilize any technology that is covered by these agreements or may face other penalties under the agreements. Such an occurrence could materially and adversely affect the value of a product candidate being developed under any such agreement or could restrict our drug discovery activities. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims that our employees and/or consultants have wrongfully used or disclosed to us alleged trade secrets of their former employers or other clients.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As is common in the biopharmaceutical industry, we rely on employees and consultants to assist in the development of product candidates, many of whom were previously employed at, or may have previously been or are currently providing consulting services to, other biopharmaceutical companies, including our competitors or potential competitors. We may become subject to claims related to whether these individuals have inadvertently or otherwise used, disclosed or misappropriated trade secrets or other proprietary information of their former employers or their former or current clients. Litigation may be necessary to defend against these claims. Even if we are successful in defending these claims, litigation could result in substantial costs and be a distraction to management and/or the employees or consultants that are implicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to seeking patent protection for our product candidates or any future product candidate, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position, particularly where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We limit disclosure of such trade secrets where possible but we also seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who do have access to them, such as our employees, our licensors, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and may unintentionally or willfully disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We in-license intellectual property pertaining to certain product candidates from third parties. As such, any dispute with the licensors or the non-performance of such license agreements may adversely affect our ability to develop and commercialize the applicable product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The types of disputes which may arise between us and the third parties from whom we license intellectual property include, but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under such license agreements and other interpretation-related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to such license agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope and interpretation of the representations and warranties made to us by our licensors, including those pertaining to the licensors&#8217; right title and interest in the licensed technology and the licensors&#8217; right to grant the licenses contemplated by such agreements;</span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sublicensing of patent and other rights under our license agreements and/or collaborative development relationships, and the rights and obligations associated with such sublicensing, including whether or not a given transaction constitutes a sublicense under such license agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the diligence and development obligations under license agreements (which may include specific diligence milestones) and what activities or achievements satisfy those diligence obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether or not the milestones associated with certain milestone payment obligations have been achieved or satisfied;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the applicability or scope of indemnification claims or obligations under such license agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the permissibility and advisability of, and strategy regarding, the pursuit of potential third-party infringers of the intellectual property that is the subject of such license agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the calculation of royalty, sublicense revenue and other payment obligations under such license agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which license rights, if any, are retained by licensors under such license agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether or not a material breach has occurred under such license agreements and the extent to which such breach, if deemed to have occurred, is or can be cured within applicable cure periods, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes regarding patent filing and prosecution decisions, as well as payment obligations regarding past and ongoing patent expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual property rights resulting from the joint creation or use of intellectual property (including improvements made to licensed intellectual property) by our and our partners&#8217; licensors and us and our partners; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the priority of invention of patented technology.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations or may conflict in such a way that puts us in breach of one or more agreements, which would make us susceptible to lengthy and expensive disputes with one or more of such third-party licensing partners. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreements, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</p><a id="_Hlk66047534"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Risks Relating to Our Control by Fortress</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fortress controls a voting majority of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Class&#160;A Preferred Stock held by Fortress, Fortress is entitled to cast, for each share of Class&#160;A Preferred held by Fortress, the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A)&#160;the shares of outstanding common stock and (B)&#160;the whole shares of common stock into which the shares of outstanding Class&#160;A common shares and the Class&#160;A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class&#160;A Preferred Stock. Accordingly, Fortress is able to control or significantly influence all matters requiring approval by our stockholders, including the election of directors and the approval of mergers or other business combination transactions. The interests of Fortress may not always coincide with the interests of other stockholders, and Fortress may take actions that advance its own interests and are contrary to the desires of our other stockholders. Moreover, this concentration of voting power may delay, prevent or deter a change in control of us even when such a change may be in the best interests of all stockholders, could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of Mustang or our assets, and might affect the prevailing market price of our common stock.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fortress has the right to receive a significant grant of shares of our common stock annually which will result in the dilution of your holdings of common stock upon each grant, which could reduce their value.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the terms of the Second Amended and Restated Founders Agreement (the &#8220;Founders Agreement&#8221;), which became effective July&#160;22, 2016, Fortress will receive a grant of shares of our common stock equal to two and one-half&#160;percent (2.5%) of the gross amount of any equity or debt financing. Additionally, the Class&#160;A Preferred Stock, as a class, will receive an annual dividend on January&#160;1st, payable in shares of common stock in an amount equal to two and one-half&#160;percent (2.5%) of our fully-diluted outstanding capital stock as of the business day immediately prior to January&#160;1st of such&#160;year. Fortress currently owns all outstanding shares of Class&#160;A Preferred Stock. These share issuances to Fortress and any other holder of Class&#160;A Preferred Stock will dilute your holdings in our common stock and, if the value of Mustang has not grown proportionately over the prior&#160;year, would result in a reduction in the value of your shares. The Founders Agreement has a term of 15&#160;years and renews automatically for subsequent one-year periods unless terminated by Fortress or upon a Change in Control (as defined in the Founders Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We might have received better terms from unaffiliated third parties than the terms we receive in our agreements with Fortress.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The agreements we have entered into with Fortress include a Management Services Agreement and the Founders Agreement. While we believe the terms of these agreements are reasonable, they might not reflect terms that would have resulted from arm&#8217;s-length negotiations between unaffiliated third parties. The terms of the agreements relate to, among other things, payment of a royalty on product sales and the provision of employment and transition services. We might have received better terms from third parties because, among other things, third parties might have competed with each other to win our business.</p><a id="_Hlk66051280"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The dual roles of our directors who also serve in similar roles with Fortress could create a conflict of interest and will require careful monitoring by our independent directors</span><span style="font-style:italic;font-weight:bold;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We share some directors with Fortress which could create conflicts of interest between the two companies in the future. While we believe that the Founders Agreement and the Management Services Agreement were negotiated by independent parties on both sides on arm&#8217;s length terms, and the fiduciary duties of both parties were thereby satisfied, in the future situations may arise under the operation of both agreements that may create a conflict of interest.&#160;We will have to be diligent to ensure that any such situation is resolved by independent parties. In particular, under the Management Services Agreement, Fortress and its affiliates are free to pursue opportunities which could potentially be of interest to Mustang, and they are not required to notify Mustang prior to pursuing such opportunities. Any such conflict of interest or pursuit by Fortress of a corporate opportunity independent of Mustang could expose us to claims by our investors and creditors and could harm our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">General Risks</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or third parties&#8217; cybersecurity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We are increasingly dependent upon information technology systems, infrastructure, and data to operate our business. In the ordinary course of business, we collect, store, and transmit confidential information, including, but not limited to, information related to our intellectual property and proprietary business information, personal information, and other confidential information. It is critical that we maintain such confidential information in a manner that preserves its confidentiality and integrity. Furthermore, we have outsourced elements of our operations to third party vendors, who each have access to our confidential information, which increases our disclosure risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We are in the process of implementing our internal security and business continuity measures and developing our information technology infrastructure. Our internal computer systems and those of current and future third parties on which we rely may fail and are vulnerable to damage from computer viruses and unauthorized access. Our information technology and other internal infrastructure systems, including corporate firewalls, servers, data center facilities, lab equipment, and connection to the internet, face the risk of breakdown or other damage or interruption from service interruptions, system malfunctions, natural disasters, terrorism, war, and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), each of which could compromise our system infrastructure or lead to the loss, destruction, alteration, disclosure, or dissemination of, or damage or unauthorized access to, our data or data that is processed or maintained on our behalf, or other assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, and could result in financial, legal, business, and reputational harm to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In addition, the loss or corruption of, or other damage to, clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our drug candidates or any future drug candidates and to conduct clinical trials, and similar events relating to their systems and operations could also have a material adverse effect on our business and lead to regulatory agency actions. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity, and sophistication of attempted attacks and intrusions from around the world have increased. Sophisticated cyber attackers (including foreign adversaries engaged in industrial espionage) are skilled at adapting to existing security technology and developing new methods of gaining access to organizations&#8217; sensitive business data, which could result in the loss of proprietary information, including trade secrets. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations, or hostile foreign governments or agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Any security breach or other event leading to the loss or damage to, or unauthorized access, use, alteration, disclosure, or dissemination of, personal information, including personal information regarding clinical trial subjects, contractors, directors, or employees, our intellectual property, proprietary business information, or other confidential or proprietary information, could directly harm our reputation, enable competitors to compete with us more effectively, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, or otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information. Each of the foregoing could result in significant legal and financial exposure and reputational damage that could adversely affect our business. Notifications and follow-up actions related to a security incident could impact our reputation or cause us to incur substantial costs, including legal and remediation costs, in connection with these measures and otherwise in connection with any actual or suspected security breach. We expect to incur significant costs in an effort to detect and prevent security incidents and otherwise implement our internal security and business continuity measures, and actual, potential, or anticipated attacks may cause us to incur increasing costs, including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts and consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The costs related to significant security breaches or disruptions could be material, and our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption in, or failure or security breach of, our systems or third-party systems where information important to our business operations or commercial development is stored or processed. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention. Furthermore, if the information technology systems of our third-party vendors and other contractors and consultants become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Major public health issues, and specifically the pandemic caused by the spread of&#160;COVID-19, could have an adverse impact on our financial condition and results of operations and other aspects of our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In December 2019, a novel strain of coronavirus,&#160;<span style="color:#212529;">COVID-19</span>, was first detected in Wuhan, China, and has since spread around the world. On March 11, 2020, the World Health Organization declared that the rapidly spreading&#160;<span style="color:#212529;">COVID-19 </span>outbreak had evolved into a pandemic. In response to the pandemic, many governments around the world are implementing a variety of measures to reduce the spread of&#160;<span style="color:#212529;">COVID-19</span>, including travel restrictions and bans, instructions to residents to practice social distancing, quarantine advisories, shelter-in-place orders and required closures of non-essential businesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The COVID-19&#160;pandemic has negatively impacted the global economy, disrupted global supply chains, and created significant volatility and disruption of financial markets. <span style="color:#212529;">Although COVID-19 has not had a material adverse effect on our business to date, no assurance can be given that it will not in the future if the situation persists or worsens. </span>The extent to which the coronavirus impacts our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning the coronavirus and the actions to contain the coronavirus or treat its impact, among others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Should the coronavirus continue to spread, our business operations could be delayed or interrupted. For instance, our preclinical research and clinical trials have been affected in the past by the pandemic, and they may be affected again in the future should the pandemic return </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">to previous levels of severity. Similarly, the FDA has identified COVID-19 as an important contributor to delays in response to sponsors and in scheduling of requested meetings, and it is not clear at the present time that such delays have subsided. Site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis may be paused or delayed due to changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic efforts, or other reasons related to the pandemic. If the coronavirus continues to spread, some participants and clinical investigators may not be able to comply with clinical trial protocols. For example, quarantines or other travel limitations (whether voluntary or required) may impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, and we may be unable to conduct our clinical trials. Infections and deaths related to the pandemic may disrupt the United States&#8217; and other countries&#8217; healthcare and healthcare regulatory systems. Such disruptions could divert healthcare resources away from, or materially delay FDA or other regulatory review and/or approval with respect to, our clinical trials. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of our clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We currently rely on third parties, such as contract laboratories, CROs, medical institutions and clinical investigators to conduct these studies and clinical trials. If these third parties themselves are adversely impacted by restrictions resulting from the coronavirus outbreak, we will likely experience delays and/or realize additional costs. We also rely on third parties for the manufacture of our product candidates for preclinical and clinical testing. Disruptions to the global supply chain have impacted our and our third-party manufacturers&#8217; ability to obtain raw materials or other products necessary to manufacture and distribute our product candidates. As a result, our efforts to develop our products have been delayed, and recurrence of such disruptions could delay or disrupt our ability to obtain regulatory approvals for, and to commercialize, our product candidates. Finally, we have incurred considerable expense to warehouse sufficient supplies in anticipation of future unexpected supply chain disruptions, and we may need to increase these expenses as we increase our cell processing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The potential economic impact brought by and the duration of the pandemic may be difficult to assess or predict, however it has already caused, and is likely to result in further, significant disruption of global financial markets, which may reduce our ability to access capital either at all or on favorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of the coronavirus could materially and adversely affect our business and the value of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The ultimate impact of the current pandemic, or any other health epidemic, is highly uncertain and will depend on future developments that cannot be predicted with confidence, such as the duration of the outbreak, the severity of&#160;COVID-19, and the effectiveness of actions to contain and treat for&#160;COVID-19. Although, as of the date of this Annual Report on Form 10-K, we do not expect any material impact on our long-term activity, we do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole, which could have a material adverse effect on our business, financial condition and results of operations and cash flows. <span style="background:#ffffff;">The Company has experienced some delays in clinical trial accrual and in the availability and delivery of certain consumables and raw materials used in its laboratory and manufacturing operations due to the impact of COVID-19 on the global supply chain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The ability of the Company&#8217;s employees and consultants to work may be significantly impacted by the coronavirus.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s employees and consultants are being affected by the COVID-19 pandemic. The Company may need to enact further precautionary measures to help minimize the risk of our employees being exposed to the coronavirus. COVID-19 may also compromise the ability of independent contractors who perform consulting services for us to deliver services or deliverables in a satisfactory or timely manner. &#160;Further, our management team is focused on mitigating the adverse effects of the COVID-19 pandemic, which continues to require an investment of time and resources, thereby diverting their attention from other priorities that existed prior to the outbreak of the pandemic. If these conditions worsen, or last for an extended period of time, the Company&#8217;s ability to manage its business may be impaired, and operational risks, cybersecurity risks and other risks facing the Company even prior to the pandemic may be elevated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our growth is subject to economic and political conditions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our business is affected by global and local economic and political conditions as well as the state of the financial markets, inflation, recession, financial liquidity, currency volatility, growth, and policy initiatives. There can be no assurance that global economic conditions and financial markets will not worsen and that we will not experience any adverse effects that may be material to our consolidated cash flows, results of operations, financial position or our ability to access capital, such as the adverse effects resulting from a prolonged shutdown in government operations both in the United States and internationally. Political changes, including war or other conflicts, some of which may be disruptive, could interfere with our supply chain, our customers and all of our activities in a particular location.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to manage our business effectively if we are unable to attract and retain key personnel.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not be able to attract or retain qualified management and commercial, scientific and clinical personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. If we are not able to attract and retain necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees, consultants, or third-party partners may engage in misconduct or other improper activities, including but not necessarily limited to noncompliance with regulatory standards and requirements or internal procedures, policies or agreements to which such employees, consultants and partners are subject, any of which could have a material adverse effect on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees, consultants, or third-party partners could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with cGMPs, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately, comply with internal procedures, policies or agreements to which such employees, consultants or partners are subject, or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee, consultant, or third-party misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation, as well as civil and criminal liability. The precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other civil and/or criminal sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We receive a large amount of proprietary information from potential or existing licensors of intellectual property and potential acquisition target companies, all pursuant to confidentiality agreements. The confidentiality and proprietary invention assignment agreements that we have in place with each of our employees and consultants prohibit the unauthorized disclosure of such information, but such employees or consultants may nonetheless disclose such information through negligence or willful misconduct. Any such unauthorized disclosures could subject us to monetary damages and/or injunctive or equitable relief. The notes, analyses and memoranda that we have generated based on such information are also valuable to our businesses, and the unauthorized disclosure or misappropriation of such materials by our employees and consultants could significantly harm our strategic initiatives&#160;&#8211; especially if such disclosures are made to our competitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on information technology, and any internet or internal computer system failures, inadequacies, interruptions or compromises of our systems or the security of confidential information could damage our reputation and harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although a significant portion of our business is conducted using traditional methods of contact and communications such as face-to-face meetings, our business is increasingly dependent on critical, complex and interdependent information technology systems, including internet-based systems, to support business processes as well as internal and external communications. We could experience system failures and degradations in the future. We cannot assure you that we will be able to prevent an extended and/or material system failure if any of the following or similar events occurs:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">human error;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subsystem, component, or software failure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a power or telecommunications failure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hacker attacks, cyber-attacks, software viruses, security breaches, unauthorized access or intentional acts of vandalism; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">terrorist acts or war.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If any of the foregoing events were to occur, our business operations could be disrupted in ways that would require the incurrence of substantial expenditures to remedy. Any system failure, accident or security breach that causes interruptions in our operations could result in a material disruption of our drug development programs. For example, the loss of clinical trial data from completed clinical trials for&#160;one or more of our product conducts could result in delays in our regulatory approval efforts and significantly increase our costs to recover or </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data and applications, or inappropriate/unauthorized disclosure of confidential or proprietary information (including trade secrets), we could incur liability and our business and financial condition could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The occurrence of a catastrophic disaster could damage our facilities beyond insurance limits, or we could lose key data which could cause us to curtail or cease operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are vulnerable to damage and/or loss of vital data from natural disasters, such as earthquakes, tornadoes, power loss, fire, health epidemics and pandemics, floods and similar events, as well as from accidental loss or destruction. If any disaster were to occur, our ability to operate our businesses could be seriously impaired. We have property, liability and business interruption insurance that may not be adequate to cover losses resulting from disasters or other similar significant business interruptions, and we do not plan to purchase additional insurance to cover such losses due to the cost of obtaining such coverage. Any significant losses that are not recoverable under our insurance policies could seriously impair our business, financial condition and prospects. Any of the aforementioned circumstances, including without limitation the resurgence of COVID-19 virus, may also impede our employees&#8217; and consultants&#8217; abilities to provide services in-person and/or in a timely manner; hinder our ability to raise funds to finance our operations on favorable terms or at all; and trigger effectiveness of &#8220;force majeure&#8221; clauses under agreements with respect to which we receive goods and services, or under which we are obligated to achieve developmental milestones on certain timeframes. Disputes with third parties over the applicability of such &#8220;force majeure&#8221; clauses, or the enforceability of developmental milestones and related extension mechanisms in light of such business interruptions, may arise and may become expensive and time-consuming.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our stock may be subject to substantial price and volume fluctuations due to a number of factors, many of which are beyond our control and may prevent our stockholders from reselling our common stock at a profit.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The market prices for securities of biotechnology and pharmaceutical companies have historically been highly volatile, and the market has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The market price of our common stock is likely to be highly volatile and may fluctuate substantially due to many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements concerning the progress of our efforts to obtain regulatory approval for and commercialize our product candidates or any future product candidate, including any requests we receive from the FDA for additional studies or data that result in delays in obtaining regulatory approval or launching these product candidates, if approved;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the pharmaceutical and biotechnology sectors or the economy as a whole;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">price and volume fluctuations in the overall stock market;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the failure of one or more of our product candidates or any future product candidate, if approved, to achieve commercial success;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of the introduction of new products by us or our competitors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments concerning product development results or intellectual property rights of others;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">litigation or public concern about the safety of our potential products;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual fluctuations in our quarterly operating results, and concerns by investors that such fluctuations may occur in the future;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">deviations in our operating results from the estimates of securities analysts or other analyst comments;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key personnel;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">health care reform legislation, including measures directed at controlling the pricing of pharmaceutical products, and third-party coverage and reimbursement policies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments concerning current or future strategic collaborations;&#160;and</span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discussion of us or our stock price by the financial and scientific press and in online investor communities.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have received notice from the Nasdaq Stock Market of non-compliance with its minimum bid price rules.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">On May 24, 2022, we received written notification (the &#8220;Notice Letter&#8221;) from the Nasdaq Stock Market (&#8220;Nasdaq&#8221;) indicating that we were not in compliance with Nasdaq Listing Rule 5450(a)(1), as the closing bid price for our Common Stock was below the $1.00 per share requirement for the previous 30 consecutive business days. The Notice Letter stated that we had 180 calendar days, or until November 21, 2022 (the &#8220;Initial Compliance Period&#8221;), to regain compliance with the minimum bid price requirement. On November 22, 2022, we were granted an additional 180 calendar days, or until May 24, 2023 (&#8220;Extended Compliance Period&#8221;), to regain compliance with the minimum bid price requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we can regain compliance if the closing bid price of our Common Stock is at least $1.00 for a minimum of 10 consecutive business days. Although we have taken steps toward effecting a reverse stock split in order to regain compliance with the minimum bid price requirement, and we expect to complete the reverse stock split and regain compliance within the extended compliance period, there can be no assurance that such transaction will be completed, or if completed, will be successful in regaining compliance with the minimum bid price requirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In the event that we do not regain compliance with Listing Rule 5450(a)(1) prior to the expiration of the Extended Compliance Period, we will receive written notification that our securities are subject to delisting. At that time, we may appeal the delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. A delisting of our Common Stock would have an adverse effect on the market liquidity of our Common Stock and, as a result, the market price for our Common Stock could become more volatile. Further, a delisting could also make it more difficult for us to raise additional capital. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may become involved in securities class action litigation that could divert management&#8217;s attention and harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The stock markets have from time to time experienced significant price and volume fluctuations that have affected the market prices for the common stock of biotechnology and pharmaceutical companies. These broad market fluctuations may cause the market price of our stock to decline. In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies have experienced significant stock price volatility in recent&#160;years. We may become involved in this type of litigation in the future. Litigation often is expensive and diverts management&#8217;s attention and resources, which could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b58efce9_0565_4161_9660_9806b523c839"></a><a id="Item1BUnresolvedStaffComments_855719"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;1B.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Unresolved Staff Comments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_435b0f46_fb32_4b4a_b4c2_657399e7239e"></a><a id="Item2Properties_248983"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item&#160;2.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Properties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our corporate and executive office is located at 377 Plantation Street, Worcester, MA 01605.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October&#160;27, 2017, we entered into a lease agreement with WCS&#160;- 377 Plantation Street,&#160;Inc., a Massachusetts nonprofit corporation (&#8220;Landlord&#8221;). Pursuant to the terms of the lease agreement, we agreed to lease 27,043 sf from the Landlord, located at 377 Plantation Street in Worcester, MA (the &#8220;Plantation Street Facility&#8221;), through November&#160;2026, subject to additional extensions at our option. Base rent, net of abatements of $0.6 million over the lease term, totals approximately $3.6 million, on a triple-net basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Plantation Street Facility became operational for the production of personalized CAR T and gene therapies in 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On June 14, 2022, the Company entered into a sublease agreement with The Paul Revere Life Insurance Company. Pursuant to the terms of the sublease lease agreement, the Company agreed to lease&#160;26,503&#160;square feet, located at 1 Mercantile Street, Worcester, MA (the &#8220;Mercantile Street Facility&#8221;), through January 2030. Base rent, net of abatements of $1.2 million, totals approximately $3.4 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_31add79a_7c85_4003_81c0_0e8430b4d997"></a><a id="Item3LegalProceedings_243219"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;3.</b>&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We are not involved in any legal proceedings that we believe could have a material adverse effect on our financial position or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of our executive officers, threatened against or affecting our company or our officers or directors in their capacities as such.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a80c316b_d63f_420a_8203_995e893c86ee"></a><a id="Item4MineSafetyDisclosures_526775"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;4.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Mine Safety Disclosures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not applicable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ef45e421_a4f3_4bf1_b50f_c0477bd637cf"></a><a id="PARTII_57028"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;II</b></p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:43.2pt;text-indent:-43.2pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;5.</b>&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Market information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 22, 2022, our common stock listing transferred to the NASDAQ Capital Market tier and continues to be traded under the symbol &#8220;MBIO.&#8221; Our common stock had been quoted on the NASDAQ Global Market since August&#160;22, 2017, under the symbol &#8220;MBIO.&#8221; Prior to this there was no public market for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Securities Authorized for Issuance Under Equity Compensation Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November&#160;30, 2017, July 30, 2021, and July 15, 2022, we filed a registration statement on Form&#160;S-8 under the Securities Act registering the common stock issued, issuable or reserved for issuance under our 2016 Plan. That registration statement became effective immediately upon filing, and shares covered by the registration statement are eligible for sale in the public markets, subject to grant of the underlying awards, vesting provisions and Rule&#160;144 limitations applicable to our affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our Board of Directors approved, and our stockholders subsequently approved, a reverse stock split of our Common Stock. On March 15, 2023, the Board of Directors set the reverse stock split ratio at 15-for-1. We have filed a Definitive Information Statement on Schedule 14C in connection with the reverse stock split, and once the applicable waiting periods under SEC and Nasdaq rules have expired, we plan to file a Certificate of Amendment to our Amended and Restated Certificate of Incorporation, as amended, in order to give effect to the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information required by Item 5 of Form 10-K addressing equity compensation plans is incorporated herein by reference to &#8220;Item 12, Security Ownership of Certain Beneficial Owners of Management and Related Stockholder Matters.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Holders of Record</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2022, there were approximately 75 holders of record of our common stock and one holder of record for our Class&#160;A common stock. The actual number of stockholders of our common shares is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Dividends</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have never paid or declared any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common stock in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion of our business. Any future determination to pay dividends will be at the discretion of our board of directors and will depend upon a number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors our board of directors deems relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Term Loan provides that, so long as any obligation thereunder remains unpaid, or any lender thereunder has any obligation to make any loan thereunder, the Company shall not pay any dividends or make any distribution or payment in respect of its equity interests, subject to limited exceptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Sales of Unregistered Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Issuer Purchases of Equity Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">None.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c96c3aec_3104_471d_8105_bf178bf48f14"></a><a id="Item6SelectedFinancialData_954364"></a><a id="Item6Reserved_101650"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;6.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Reserved</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6b701295_6998_433c_af47_f674b5983573"></a><a id="_Hlk96085695"></a><a id="Item7ManagementsDiscussionandAnalysisoft"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;7.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Management&#8217;s Discussion and Analysis of the Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Statements in the following discussion and throughout this report that are not historical in nature are &#8220;forward-looking statements.&#8221; You can identify forward-looking statements by the use of words such as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; and similar expressions. Although we believe the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risk and we can give no assurances that our expectations will prove to be correct. Actual results could differ from those described in this report because of numerous factors, many of which are beyond our control. These factors include, without limitation, those described under Item&#160;1A &#8220;Risk Factors.&#8221; We undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this report or to reflect actual outcomes. Please see &#8220;Forward-Looking Statements&#8221; at the beginning of this Form&#160;10-K.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes thereto and other financial information appearing elsewhere in this Form&#160;10-K. We undertake no obligation to update any forward-looking statements in the discussion of our financial condition and results of operations to reflect events or circumstances after the date of this report or to reflect actual outcomes.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Mustang is a clinical-stage biopharmaceutical company focused on translating today&#8217;s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our pipeline is currently focused in three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. For each therapy we have partnered with world class research institutions. For our CAR T therapies we have partnered with COH, Fred Hutch, Nationwide and Mayo Clinic. For our gene therapies, we have partnered with St. Jude in the development of a first-in-class <i style="font-style:italic;">ex vivo</i> lentiviral treatment of XSCID and with LUMC in the development of a first-in-class <i style="font-style:italic;">ex </i>vivo lentiviral treatment of RAG1-SCID.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">The Company expects to incur substantial expenses for the foreseeable future relating to research, development and commercialization of its potential products. However, there can be no assurance that the Company will be successful in securing additional resources when needed, on terms acceptable to the Company, if at all. Therefore, there exists substantial doubt about the Company&#8217;s ability to continue as a going concern. The consolidated financial statements do not include any adjustments related to the recoverability of assets that might be necessary despite this uncertainty.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CAR T Therapies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our pipeline of CAR T therapies is being developed under exclusive licenses from several world class research institutions. Our strategy is to license these technologies, support preclinical and clinical research activities by our academic partners and transfer the underlying technology to our cell processing facility located in Worcester, Massachusetts, in order to conduct our own clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are developing CAR T therapies for hematologic malignancies in partnership with COH targeting CD123 (MB-102) and CS1 (MB-104) and with Fred Hutch targeting CD20 (MB-106). Phase 1 clinical trials sponsored by COH for MB-102 and MB-104 and by Fred Hutch for MB-106 are underway. In the third quarter of 2019 the FDA approved our IND application to initiate a multi-center Phase 1/2 clinical trial of MB-102,&#160;and our clinical trial began enrollment in 2020 for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm (&#8220;BPDCN&#8221;). In December 2022, we announced that the safety review team (SRT), after thoroughly reviewing the safety data from Dose Level 1 (100 x 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">6 </sup>CAR T cells), unanimously recommended dose escalation to Dose Level 2 (300 x 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">6</sup> CAR T cells). We anticipate initiation of the Does Level 2 cohort in 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2021, we announced that the FDA had approved our IND application allowing for initiation of a multi-center Phase 1/2 clinical study of MB-106 in patients with relapsed or refractory B cell NHL or CLL (Clinicaltrials.gov Identifier: NCT05360238).</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to file an IND for a multicenter Phase 1/2 trial for MB-104 for the treatment of patients with multiple myeloma once COH has established a safe and effective dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are also developing CAR T therapies for solid tumors in partnership with COH targeting IL13R&#945;2 (MB-101), HER2 (MB-103) and PSCA (MB-105). In addition, we have partnered with Nationwide for the C134 oncolytic virus (MB-108) in order to enhance the activity of MB-101 for the treatment of patients with glioblastoma (&#8220;GBM&#8221;). Phase 1 clinical trials sponsored by COH for MB-101, MB-103 and MB-105 are underway. A Phase 1 clinical trial sponsored by UAB for MB-108 began during the third quarter of 2019. In the first half of 2023, we plan to file an IND for the combination of MB-101 and MB-108 &#8211; which is referred to as MB-109 &#8211; for the treatment of patients with relapsed or refractory GBM and anaplastic astrocytoma. We also plan to file INDs and initiate our own clinical trials for MB-103 for the treatment of patients with metastatic breast cancer to brain and for MB-105 for the treatment of patients with prostate and pancreatic cancer, once COH has established a safe and effective dose for each therapy. The Company is also collaborating with the Mayo Clinic to develop a novel technology that may be able to transform the administration of CAR T therapies and potentially be used as an off-the-shelf therapy. Mustang plans to file an IND application for a multicenter Phase 1 clinical trial once a lead construct has been identified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Gene Therapies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In partnership with St. Jude, our XSCID gene therapy programs (MB-107 and MB-207) are being conducted under an exclusive license to develop a potentially curative treatment for XSCID, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. This first-in-class <i style="font-style:italic;">ex vivo</i> lentiviral gene therapy has been evaluated in two Phase 1/2 clinical trials involving two different autologous cell products: an ongoing multicenter trial of the MB-107 product in newly diagnosed infants sponsored by St. Jude and a single-center trial of the MB-207 product in previously transplanted patients sponsored by the NIH. In January 2021 we received approval to proceed with our IND application with the FDA to initiate a pivotal non-randomized multicenter Phase 2 clinical trial of MB-107 in newly diagnosed infants with XSCID who are under the age of two. We expect to enroll the first patient in a pivotal multicenter Phase 2 clinical trial in 2023. Our IND for MB-207 was submitted to the FDA in December 2021. In January 2022, the FDA issued a clinical hold, pending CMC data. &#160;In order to lift this clinical hold and receive a safe-to-proceed from the FDA for the IND, we believe the most critical activities will be to (1) perform process validation manufacturing runs using healthy donor material and (2) ensure qualification of all assays related to the product release. Following completion of these activities and the earliest release of the clinical hold, we expect to enroll the first patient in a pivotal multicenter Phase 2 clinical trial 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">MB-102 (CD123 CAR T Cell Program for BPDCN, AML and High-Risk MDS)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">In December 2022, we announced that the safety review team (SRT), after thoroughly reviewing the safety data from Dose Level 1 (100 x 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">6</sup> CAR T cells), unanimously recommended dose escalation to Dose Level 2 (300 x 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">6</sup> CAR T cells). The Company anticipates initiation of the Dose Level 2 cohort in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">MB-106&#160;(CD20-targeted CAR T for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In May 2021, we announced that the FDA had approved our IND application allowing for initiation of a multi-center Phase 1/2 clinical study of MB-106 in patients with relapsed or refractory B cell NHL or CLL (Clinicaltrials.gov Identifier: NCT05360238). The phase 1 portion of the trial will enroll patients in 3 separate arms, with dose escalation planned to establish a recommended phase 2 dose for each arm:</p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin-bottom:1.5pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Arm 1: Aggressive non-Hodgkin lymphoma, with a starting dose of 1 x 106 CAR T cells/kg</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin-bottom:1.5pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Arm 2: Indolent non-Hodgkin lymphoma, with a starting dose of 3.3 x 106 CAR T cells/kg</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Arm 3: Chronic lymphocytic leukemia/small cell lymphoma, with a starting dose of 1 x 106 CAR T cells/kg</span></td></tr></table><div style="margin-top:1.5pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The FDA deferred approval of the phase 2 portion of this trial pending review of the results of each of the 3 phase 1 arms. Initially we are considering conducting non-randomized phase 2 registration trials in each of the following indications:</span></p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Diffuse large B cell lymphoma relapsed from CD19-directed CAR T therapy</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Relapsed/refractory Waldenstrom macroglobulinemia</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Relapsed/refractory chronic lymphocytic leukemia/small cell lymphoma</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In April 2022, we announced that interim Phase 1/2 data on MB-106 were presented at the 2022 Tandem Meetings | Transplantation &amp; Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research. Data demonstrated high efficacy and a very favorable safety profile in all patients (n=25). Five dose levels were used </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">during the study, and complete responses were observed at all dose levels. Durable responses were observed in a wide range of hematologic malignancies including follicular lymphoma (&#8220;FL&#8221;), CLL, diffuse large B-cell lymphoma (&#8220;DLBCL&#8221;) and Waldenstrom macroglobulinemia (&#8220;WM&#8221;). An ORR of 96% and a complete response (&#8220;CR&#8221;) rate of 72% were observed in all patients across all dose levels. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Also in April 2022, MB-106 data focused on CLL were presented at the 4th International Workshop on CAR-T and Immunotherapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2022, we announced that MB-106 data were presented in an oral session at the European Hematology Association 2022 Hybrid Congress. Dr. Mazyar Shadman of Fred Hutch presented updated interim data from the ongoing Phase 1/2 clinical trial for B-NHL and CLL. Data presented include a 94% ORR and 78% CR rate in patients with FL. Overall, for the 26 patients treated on the trial, there was a 96% ORR and 73% CR, including complete responses in both DLBCL patients, both WM patients, and both patients previously treated with CD19-targeted CAR-T therapy (1 DLBCL patient and 1 FL patient).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Also in June 2022, we announced that the FDA granted Orphan Drug Designation to MB-106 for the treatment of CD20+ Waldenstrom macroglobulinemia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In October 2022, we announced that the first patient was treated in Mustang&#8217;s multicenter, open-label, non-randomized Phase 1/2 clinical trial evaluating the safety and efficacy of MB-106. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Also in October 2022, the Company provided an update on the ongoing Phase 1/2 investigator-sponsored clinical trial at Fred Hutch. &#160;Interim Data from 28 patients treated at Fred Hutch, all with the optimized manufacturing process, continue to support MB-106 as a viable CAR-T cell therapy for B-NHLs and CLL. As of September 2022, the interim data show: </p><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin-bottom:1.5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">An overall response rate of 96% and complete response (&#8220;CR&#8221;) rate of 75% in a wide range of hematologic malignancies including follicular lymphoma (&#8220;FL&#8221;), CLL, diffuse large B-cell lymphoma, and Waldenstrom macroglobulinemia.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin-bottom:1.5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Twelve patients have experienced CR for more than 12 months (10 ongoing); four patients have experienced CR for more than two years, and the longest patient with CR is at 33 months.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin-bottom:1.5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Six patients with partial response (&#8220;PR&#8221;) at their initial 28-day assessments improved to CR, and all remain in ongoing CR. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin-bottom:1.5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All three patients previously treated with CD19 CAR-T cell therapy have responded to treatment with MB-106. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin-bottom:1.5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A favorable safety profile for MB-106 as an outpatient therapy remains with no cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) &#8805; Grade 3.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">None of the FL patients experienced ICANS of any Grade.</span></td></tr></table><div style="margin-top:1.5pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 1.5pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">In December 2022, we announced that six patients had been enrolled in Mustang&#8217;s multicenter Phase 1/2 clinical trial, with five patients infused at the starting dose levels of their respective protocol arms. We have since treated the first WM in the indolent lymphoma arm of the trial, and we expect to provide first safety and efficacy data from that arm in the second quarter of 2023, with a more substantial data set from all 3 arms in the fourth quarter of 2023. Finally, we anticipate that the indication for the first pivotal Phase 2 trial will be relapsed/refractory WM, with the first patient treated on that trial in the first quarter of 2024.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">In Vivo CAR T Platform Technology</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">In December 2022 we announced that published proof-of-concept data from murine tumor model studies are anticipated in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">MB-107 and MB-207 (Ex vivo Lentiviral Therapy for X-linked Severe Combined Immunodeficiency (XSCID))</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Interim Phase 1/2 data on treatment of newly diagnosed infants under the age of two with the same LV vector used in MB-107 were updated at an oral presentation at the American Society of Gene &amp; Cell Therapy (&#8220;ASGCT&#8221;) 25<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Annual Meeting held from May 16-19, 2022. The data included 23 infants with XSCID treated with the LV vector at a median age of 3 months (range: 2 months to 14 months) with a median follow-up of 2.4 years (range: 1.4 months to 5.4 years), making it the largest known cohort of infants treated with LV gene therapy with the longest follow-up. Transduced autologous bone marrow CD34+ cells were generated for all patients with a median vector copy number (VCN) of 0.81/cell (range: 0.16-1.81), and a median CD34+ cell dose of 9.61x10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">6</sup>/kg (range 4.40-18.95). Prior to the infusion of cells, patients received busulfan targeted to a cumulative area-under-the-curve (cAUC) of 22 mg*hr/L. Severe adverse events occurred in three patients (two patients with pancytopenia and hemolytic anemia, and one patient with delayed neutrophil engraftment, and all resolved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Seventeen of 18 patients with a follow-up of &gt; 6 months achieved robust immune reconstitution [median CD3+ 2,545/&#181;L, CD4+ 1,568/&#181;L, CD4+/CCR7+/CD45R0- 1,416/&#181;L]. &#160;In these 17 patients, T cells matured appropriately as assessed by normal T cell receptor excision circles (TRECs) and TCRv&#946; repertoire diversity and were functional as judged by phytohemagglutinin activation (&#8220;PHA&#8221;). &#160; All were alive with </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">stable vector marking in all cell lineages. &#160;In addition, 15 patients had &#160;discontinued intravenous immunoglobulin, and 12 patients had &#160;been successfully immunized. &#160;No evidence of clonal expansion or malignant transformation was observed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The MB-107 timeline has been extended due to unanticipated issues related to the materials used in manufacturing. These issues were communicated to the FDA and the Company received a written response on August 26, 2022.&#160; The FDA response provided additional direction enabling us to continue to work effectively with our outside suppliers. We are working towards enrolling the first patient in a pivotal multicenter Phase 2 clinical trial under our IND in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">As a result of the study stopping rules, the NIH single-center trial of the MB-207 product in previously transplanted patients was suspended in 2022 due to the presence of clonal expansion in the myeloid lineage in 10% of the treated patients, although to date there have been no observations of insertional mutagenesis or malignancies. &#160;All patients continue to be followed and remain clinically stable with no significant hematological anomalies. Upon review of these data, the FDA agreed that the risk-benefit ratio of both MB-107 and MB-207 remains favorable to support moving forward with Mustang-sponsored multicenter clinical trials once Mustang has appropriately addressed other items flagged by the Agency. &#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The IND for MB-207 was submitted to the FDA in December 2021. &#160;In January 2022, the FDA issued a clinical hold, pending additional CMC data. In order to lift this clinical hold and receive an FDA safe-to-procced for the IND, we believe the most critical activities will be to (1) perform process validation manufacturing runs using healthy donor material and (2) ensure qualification of all assays related to the product release. Following completion of these activities and the earliest release of the clinical hold by FDA, we expect to enroll the first patient in a pivotal multicenter Phase 2 clinical trial in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">LUMC License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">On July 27, 2022, the Company announced that the first patient successfully received LV-RAG1 <i style="font-style:italic;">ex vivo</i> lentiviral gene therapy to treat RAG1-SCID, in an ongoing Phase 1/2 multicenter clinical trial taking place in Europe at LUMC. The patient was administered LV-RAG1 without any complications. LV-RAG1 allowed the patient&#8217;s body to create a functioning immune system, and he responded well to the standard vaccinations for newborns. The same lentiviral vector drug substance produced by LUMC will be used to transduce patients&#8217; cells to create the MB-110 drug product produced at Mustang Bio&#8217;s Worcester, MA, cell processing facility for further clinical development and to facilitate eventual commercial launch of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Registration Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 23, 2020, the Company filed a shelf registration statement No. 333-249657 on Form S-3 (the &#8220;2020 S-3&#8221;), which was declared effective on December 4, 2020. Under the 2020 S-3, the Company may sell up to a total of $100.0 million of its securities. As of December&#160;31,&#160;2022, approximately $8.0&#160;million of the 2020 S-3 remained available for sales of securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On April 23, 2021, the Company filed a shelf registration statement No. 333-255476 on Form S-3 (the &#8220;2021 S-3&#8221;), which was declared effective on May 24, 2021. Under the 2021 S-3, the Company may sell up to a total of $200.0 million of its securities. As of December&#160;31,&#160;2022, there have been no sales of securities under the 2021 S-3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The amount of securities we are able to sell pursuant to the registration statements on Form S-3 is limited. See &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8211; Liquidity and Capital Resources.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Term Loan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On March&#160;4, 2022&#160;(the &#8220;Closing Date&#8221;), the Company entered into a $75.0 million long-term debt facility with Runway Growth Finance Corp. (the &#8220;Term Loan&#8221;). Under the Term Loan, $30.0 million of the $75.0 million loan was funded on the Closing Date, with the remaining $45.0 million fundable if the Company achieves certain predetermined milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Term Loan matures on April 15, 2027 (the &#8220;Maturity Date&#8221;).&#160;As of March 15, 2022, the Company began making monthly payments of interest only until April 1, 2024 (the &#8220;Amortization Date&#8221;). The Amortization Date may be extended to April 1, 2025, if the Company achieves certain predetermined milestones based on equity raises and the initiation of certain clinical trials. After that, the Company will make monthly payments of interest and principal. If the Amortization Date is extended to April 1, 2025, the monthly payments will be recalculated in equal amounts according to the remaining number of payment dates through the Maturity Date. All unpaid outstanding principal and accrued and unpaid interest will be due and payable in full on the Maturity Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Term Loan accrues interest at a variable annual rate equal to&#160;8.75% plus the greater of (i)&#160;0.50% and (ii) the three month LIBOR Rate for U.S. dollar deposits or the rate otherwise reasonably determined by the Lender to be the rate at which U.S. dollar deposits with a term of three months would be offered by banks in London, England to major banks in the London or other offshore interbank market &#160;(the &#8220;Applicable Rate&#8221;); provided that the Applicable Rate will not be less than&#160;9.25%. On December 7, 2022, the Company entered into the First Amendment (the &#8220;First Amendment&#8221;) to the Loan Agreement by and between the Company and Runway. The First Amendment amended certain definitions and other provisions of the Loan Agreement to replace LIBOR-based benchmark rates applicable to loans outstanding under the Loan Agreement with SOFR-based rates, subject to adjustments as specified in the First Amendment. The Applicable Rate at December 31, 2022, was&#160;13.40%. For the year ended December 31, 2022, the Company made interest payments of $2.7&#160;million recorded in interest expense in the Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Pursuant to the terms of the Term Loan on the Closing Date the Company paid the Lender upfront fees out of proceeds of $0.4&#160;million consisting of a&#160;1% commitment fee and a deposit of $75,000. &#160;In addition, the Company paid other cash fees directly to third parties comprising of an advisory fee and legal fees totaling $2.3&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Also, in connection with the Term Loan, on March 4, 2022, the Company issued a warrant to the Lender to purchase&#160;748,036&#160;shares of the Company&#8217;s common stock with an exercise price of $0.8021&#160;(the &#8220;Warrant&#8221;) via a warrant agreement (the &#8220;Warrant Agreement&#8221;). The Warrant is exercisable for&#160;ten years&#160;from the date of issuance. The Lender may exercise the Warrant with cash or through a net issuance conversion. The shares of the Company&#8217;s common stock will be registered at the Company&#8217;s first opportunity after the date of the exercise of the Warrant. In addition, the provisions of the Warrant Agreement provide for additional warrants to be issued upon funding of the term loan tranches. The fair value of the warrant at the grant date was determined utilizing a Black Scholes Model with the following assumptions: risk free rate of return&#160;1.74%, volatility of&#160;57.3%,&#160;10-year&#160;life yielding a value of approximately $0.4&#160;million as of March 4, 2022. &#160;The fair value of the warrant was also recorded in debt discount and will be amortized over the life of the Term Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">At-the-Market Offering</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">In July 2018, the Company entered into an At-the-Market Issuance Sales Agreement (the &#8220;Mustang ATM&#8221;) with B. Riley Securities, Inc. (formerly B. Riley FBR, Inc.), Cantor Fitzgerald &amp; Co., National Securities Corporation (now B. Riley FBR, Inc.), and Oppenheimer &amp; Co. Inc. (each an &#8220;Agent&#8221; and collectively, the &#8220;Agents&#8221;), relating to the sale of shares of common stock pursuant to the 2020 S-3. Under the Mustang ATM, the Company pays the Agents a commission rate of up to&#160;3.0% of the gross proceeds from the sale of any shares of common stock. On December 31, 2020, the Mustang ATM was amended to add H.C. Wainwright &amp; Co., LLC as an Agent.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31,&#160;2022, the Company issued approximately 7.9 million shares of common stock at an average price of $0.84 per share for gross proceeds of $6.6 million under the ATM Agreement. In connection with these sales, we paid aggregate fees of approximately $0.1 million for net proceeds of approximately $6.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31,&#160;2021, the Company issued approximately 19.4 million shares of common stock at an average price of $3.70 per share for gross proceeds of $71.9 million under the ATM Agreement. In connection with these sales, we paid aggregate fees of approximately $1.3 million for net proceeds of approximately $70.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the Founders Agreement, the Company issued&#160;196,952&#160;shares of common stock to Fortress at a weighted average price of $0.84&#160;per share for the year ended December 31, 2022, and recorded&#160;zero&#160;shares issuable to Fortress in connection with the shares issued under the Mustang ATM. Pursuant to the Founders Agreement, Mustang issued&#160;576,157&#160;shares of common stock to Fortress at a weighted average price of $3.70&#160;per share for the year ended December 31, 2021, in connection with the shares issued under the Mustang ATM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The amount of securities we are able to sell pursuant to the registration statements on Form S-3 is limited. See &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8211; Liquidity and Capital Resources.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Authorized Shares</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On June 21, 2022, the stockholders of the Company voted at the 2022 Annual Meeting to approve an amendment to Mustang&#8217;s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance by 50 million shares, bringing the total number of authorized shares of common stock to 200 million shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a majority-controlled subsidiary of Fortress. As a &#8220;Controlled Company&#8221; we rely on the exemption provided by Nasdaq Listing Rule&#160;5615(c)(2), which permits us to maintain less than a majority of independent directors on our board.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial statements include certain amounts that are based on management&#8217;s best estimates and judgments. The Company&#8217;s significant estimates include, but are not limited to, useful lives assigned to long-lived assets and amortizable intangible assets, fair value of stock options and warrants, stock-based compensation, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are described in the notes to our financial statements included elsewhere in this Report, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Research and Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company&#8217;s behalf will be expensed as services are rendered or when the milestone is achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, and costs associated with regulatory filings, laboratory costs and other supplies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with ASC 730 10 25 1, <i style="font-style:italic;">Research and Development</i>, costs incurred in obtaining technology licenses are charged to research and development expense if the technology licensed has not reached commercial feasibility and has no alternative future use. In each case, we evaluate if the license agreement results in the acquisition of an asset or a business. Such licenses purchased by the Company require substantial completion of research and development, regulatory and marketing approval efforts in order to reach commercial feasibility and has no alternative future use. Accordingly, the total purchase price for the licenses acquired during the period was reflected as research and development - licenses acquired on the Statements of Operations for the years ended December 31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Accrued Research and Development Expense</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We record accruals for estimated costs of research, preclinical, clinical and manufacturing development within accrued expenses which are significant components of research and development expenses. A substantial portion of our ongoing research and development activities is conducted by third-party service providers. We accrue the costs incurred under agreements with these third parties based on estimates of actual work completed in accordance with the respective agreements. We determine the estimated costs through discussions with internal personnel and external service providers as to the progress, or stage of completion or actual timeline (start-date and end-date) of the services and the agreed-upon fees to be paid for such services. Payments made to third parties under these arrangements in advance of the performance of the related services are recorded as prepaid expenses until the services are rendered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust accrued expenses or prepaid expenses accordingly, which impact research and development expenses. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-style:normal;font-weight:bold;">Fair Value Measurement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a </p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:43.2pt;text-align:justify;text-indent:-43.2pt;margin:0pt 0pt 0pt 35.99pt;"><i style="font-style:italic;">Level 1</i>:&#160;&#160;&#160;&#160;Quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:43.2pt;text-align:justify;text-indent:-43.2pt;margin:0pt 0pt 0pt 35.99pt;"><i style="font-style:italic;">Level 2</i>:&#160;&#160;&#160;&#160;Observable inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:43.2pt;text-align:justify;text-indent:-43.2pt;margin:0pt 0pt 10pt 35.99pt;"><i style="font-size:10pt;font-style:italic;">Level</i><i style="font-style:italic;"> </i><i style="font-size:10pt;font-style:italic;">3</i><span style="font-size:10pt;">:&#160;&#160;&#160;&#160;Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-Based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeitures, which are recorded upon occurrence. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will continue to use judgment in evaluating the expected volatility, expected terms and interest rates utilized for our stock-based compensation expense calculations on a prospective basis. &#160;The assumptions underlying these valuations represent our management&#8217;s best estimate, which involve inherent uncertainties and the application of management judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation expense could be materially different. We expect to continue to grant options and other stock-based awards in the future, and to the extent that we do, our stock-based compensation expense recognized in future periods will likely increase.</p><a id="_Hlk98754686"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under ASC 740, <i style="font-style:italic;">Income Taxes</i> (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. &#160;Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. Our unrecognized tax benefits, if recognized, would not have an impact on our effective tax rate assuming we continue to maintain a full valuation allowance position. We do not expect our unrecognized tax benefits to change significantly over the next 12 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim period, disclosure and transition. Based on the Company&#8217;s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company&#8217;s financial statements. As of December&#160;31,&#160;2022, the earliest federal tax year open for the assessment of income taxes under the applicable statutes of limitations is its 2019 tax year. The Company believes that its income tax positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in a material change to its financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s policy for recording interest and penalties associated with audits is to record such expense as a component of income tax expense. There were no amounts accrued for penalties or interest as of or during the years ended December 31, 2022 and 2021. Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its position.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 2 to the Financial Statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Smaller Reporting Company Status</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a &#8220;smaller reporting company,&#8221; meaning that the market value of our shares held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million. As a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K , have reduced disclosure obligations regarding executive compensation, and smaller reporting companies are permitted to delay adoption of certain recent accounting pronouncements discussed in Note 2 to our consolidated financial statements located in &#8220;Part IV, Item 15., Exhibits and Financial Statement Schedules&#8221; in this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the&#160;Years Ended December 31, 2022 and 2021</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 62,475</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 49,864</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,611</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development &#8211; licenses acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,474</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,842</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,368)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (75)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,210</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,017</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,193</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 76,159</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 66,723</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,436</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (76,159)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (66,723)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9,436)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,304</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,304</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 689</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 368</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 321</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 87</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,359)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (15)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,344)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,293</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total other income (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,366)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 353</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,719)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (487)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (77,525)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (66,370)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (11,155)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 17</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license, sponsored research and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, costs associated with regulatory filings, laboratory costs and other supplies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses increased by approximately $12.6 million from $49.9 million for the year ended December&#160;31,&#160;2021, to $62.5 million for the year ended December&#160;31,&#160;2022. The increase in research and development expense for the year ended December&#160;31,&#160;2022 was primarily attributable to the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$4.3 million for increased research and development employee compensation costs, including stock compensation, as we continue to increase research and development headcount to support development of our clinical programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.7 million for increased laboratory supply costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.7 million for increased vector manufacturing costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.6 million for increased clinical trial related costs;</span></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approximately $1.6 million for increased other costs including depreciation, software licenses, assay development and rent; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">offset by approximately $0.3 million for decreased costs for consulting and sponsored research agreements. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses&#160;- licenses acquired decreased by $4.4 million from $5.8 million for the&#160;year ended December&#160;31,&#160;2021 to $1.5 million for the year ended December&#160;31,&#160;2022. The decrease in research and development expenses&#160;- licenses acquired for the year ended December&#160;31,&#160;2022 was primarily attributable to the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Approximately $3.1 million for the annual stock dividend to Fortress;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.8 million for increased costs related to our license with Mayo Clinic;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.3 million related to our LUMC license; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.2 million related to our licenses with COH.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect our research and development activities to increase as we develop our existing product candidates and potentially acquire new product candidates, reflecting increasing costs associated with the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee-related expenses, which include salaries and benefits;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">license fees and milestone payments related to in-licensed products and technology;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred under agreements with CROs, investigative sites and consultants that conduct our clinical trials and our preclinical activities;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facility expenses, which include rent, utilities and maintenance costs;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of acquiring and manufacturing clinical trial materials; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs associated with non-clinical activities, and regulatory approvals.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of salaries and related expenses, including stock-based compensation, for executives and other administrative personnel, recruitment expenses, professional fees and other corporate expenses, including investor relations, legal activities including patent fees, and facilities-related expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expense increased by approximately $1.2 million from $11.0 million for the year ended December&#160;31,&#160;2021, to $12.2 million for the year ended December&#160;31,&#160;2022. The increase in general and administrative expense for the year ended December&#160;31,&#160;2022, was primarily attributable to the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.4 million for increased general and administrative employee compensation costs due primarily to additional headcount to support the Company&#8217;s continued growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.3 million for increased corporate and patent related legal costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.4 million for increased third-party consulting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.6 million for increased other costs, including outside services; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">offset by approximately $1.3 million for decreased stock-based costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.2 million decrease in state taxes.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We anticipate general and administrative expenses will increase in future periods, reflecting continued and increasing costs associated with:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">support of our expanded research and development activities, including additional product candidates entering the clinic;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stock compensation granted to key employees and non-employees;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">support of business development activities; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased professional fees and other costs associated with the regulatory requirements and increased compliance associated with being a publicly traded company.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Income (Expense)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other income (expense) consists primarily of funds received from the NIH grant, interest income earned on cash balances and short-term investments and interest expense on the Company&#8217;s notes payable. For the&#160;year ended December&#160;31,&#160;2022, and 2021, total other income (expense) was approximately $1.4 million of expense and $0.4 million of income, respectively. The $1.7 million decrease in other income (expense) for the year ended December&#160;31,&#160;2022 was primarily attributable to increased interest expense of $3.3 million partially offset by $1.3 million of grant income and increased interest income of $0.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect interest expense to remain higher so long as the Term Loan is outstanding. The amount of our interest expense may increase if interest rates continue to increase because the Term Loan has a variable rate of interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has incurred substantial operating losses and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of December&#160;31,&#160;2022, the Company had an accumulated deficit of $329.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">The Company has funded its operations to date primarily through the sale of equity and its Term Loan. The Company expects to continue to use the proceeds from previous financing transactions primarily for general corporate purposes, including financing the Company&#8217;s growth, developing new or existing product candidates, and funding capital expenditures, acquisitions and investments</span>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company will be required to expend significant funds in order to advance the development of its product candidates. The continuation of our business as a going concern is dependent upon raising additional capital and eventually attaining and maintaining profitable operations. As of December 31, 2022, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for the next 12 months from the date of issuance of these financial statements. The financial statements included in this Annual Report on Form 10-K do not include any adjustments that might be necessary should operations discontinue. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">As of the date of this Annual Report on Form 10-K, our public float was less than $75 million. As a result, we will be limited by the baby shelf rules until such time as our public float exceeds $75 million, which means we only have the capacity to sell shares up to one-third of our public float under shelf registration statements in any twelve-month period. If our public float decreases, the amount of securities we may sell under our Form S-3 shelf registration statements will also decrease. We will remain constrained by the baby shelf rules under our Form S-3 registration statements until such time as our public float exceeds $75 million, at which time the amount of securities we may sell under a Form S-3 registration statement will no longer be limited by the baby shelf rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Contractual Obligations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We enter into contracts in the normal course of business with licensors, CROs, contract manufacturing organizations (CMOs) and other third parties for the procurement of various products and services, including without limitation biopharmaceutical development, biologic assay development, commercialization, clinical and preclinical development, clinical trials management, pharmacovigilance and manufacturing and supply. These contracts typically do not contain minimum purchase commitments (although they may) and are generally terminable by us upon written notice. Payments due upon termination or cancelation/delay consist of payments for services provided or expenses incurred, including non-cancelable obligations of our service providers, up to the date of cancellation; in certain cases, our contractual arrangements with CROs and CMOs include cancelation and/or delay fees and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows for the&#160;Years Ended December&#160;31,&#160;2022 and 2021</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Statement of cash flows data:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash (used in) provided by:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (65,066)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (53,667)</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,952)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,366)</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 34,056</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 70,847</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net change in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (33,962)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,814</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities was $65.1 million for the&#160;year ended December 31, 2022, compared to $53.7 million for the&#160;year ended December 31, 2021. Net cash used in operating activities for the&#160;year ended December 31, 2022, was primarily due to approximately $77.5 million in net loss, partially offset by $4.0 million change in operating assets and liabilities, $2.7 million of depreciation expense, $2.3 million of non-cash stock compensation expenses, $1.1 million of common shares issuable for the Founders Agreement, $0.7 million equity fee to Fortress related to the Term Loan, $0.5 million of amortization of debt discount, $0.4 million of research and development-licenses acquired, $0.2 million loss on disposal of property and equipment, $0.3 million of amortization of operating lease right-of-use assets, and $0.2 million of equity fee on issuance of common shares to Fortress.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Net cash used in operating activities was $53.7 million for the&#160;year ended December 31, 2021, compared to $37.3 million for the&#160;year ended December 31, 2020. Net cash used in operating activities for the&#160;year ended December 31, 2021, was primarily due to approximately $66.4 million in net loss, partially offset by $4.2 million of common shares issuable for Founders shares, $3.3 million of non-cash stock compensation expenses, $2.2 million of depreciation expense, $1.9 million of equity fee on issuance of common shares to Fortress and $1.6 million of research and development-licenses acquired</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities was $3.0 million for the&#160;year ended December&#160;31,&#160;2022, representing $2.7 million in purchases of fixed assets and $0.4 million in purchases of research and development licenses, offset by $0.1 million of proceeds from the sale of fixed assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities was $5.4 million for the&#160;year ended December&#160;31,&#160;2021, representing $4.0 million in purchases of fixed assets and $1.4 million in purchases of research and development licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $34.1 million during the&#160;year ended December 31, 2022, <span style="background:#ffffff;">driven by (i) proceeds from the issuance of the Term Loan of $30.0 million, net of financing costs of $2.7 million; (ii) gross proceeds of $6.6 million, net of offering costs of $0.1 million, from the Mustang ATM; and (iii) $0.2 million raised from the issuance of the Company&#8217;s common shares in connection with the Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Net cash provided by financing activities was $70.8 million during the&#160;year ended December 31, 2021, representing gross proceeds of $71.9 million, net of offering costs of $1.4 million, from the Mustang ATM and $0.3 million raised from the issuance of the Company&#8217;s common shares in connection with the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_27db9e41_c374_4d9d_b7f6_c26eb588bc86"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;7A.</b>&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Quantitative and Qualitative Disclosures About Market Risks</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We are exposed to fluctuations in interest rates, subject to a designated floor and cap, on our Term Loan. A change in interest rates could have a material impact on our cash flow. For example, at December 31, 2022, a 100 basis point change in assumed interest rates for our Term Loan would have an annual impact of approximately $0.3 million on interest expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_36ff7854_de0c_4329_8cbb_54d27297634a"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;8.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Financial Statements and Supplementary Data.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information required by this Item&#160;is set forth in the financial statements and notes thereto beginning at page&#160;F-1 of this Annual Report on Form&#160;10-K.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d71a34c4_e352_4448_891a_416514419044"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;9.</b>&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_60bb2702_4aab_420f_b987_7cfc678b090c"></a><a id="Item9AControlsandProcedures_107796"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;9A.</b>&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Controls and Procedures.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) are designed only to provide reasonable assurance that they will meet their objectives. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness, as of December&#160;31,&#160;2022, of the design and operation of our disclosure controls and procedures, as such term is defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e). Based on this evaluation, our principal executive officer and principal financial officer have concluded that, as of such date, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Management&#8217;s Report on Internal Control over Financial Reporting.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f).&#160;Internal control over financial reporting refers to the process designed by, or under the supervision of, our principal executive officer and principal financial officer, and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles (&#8220;GAAP&#8221;), and that our receipts and expenditures are being made only in accordance with authorization of our management and directors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisitions, use or disposition of our assets that could have a material effect on the financial statements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Internal control over financial reporting has inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31,&#160;2022. In making the assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) in <i style="font-style:italic;">Internal Control&#160;- Integrated Framework (2013)</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on our assessment, our management has concluded that, as of December&#160;31,&#160;2022, our internal controls over financial reporting were effective based upon those criteria.</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in Internal Controls over Financial Reporting.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_2c3bfa21_91b6_47fe_8dd1_9360c1e64eb4"></a><a id="Item9BOtherInformation_543946"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;9B.</b>&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_05bc1d9a_f819_48fd_9229_f9d821487cb1"></a><a id="Item9CDisclosureRegardingForeignJurisdic"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 9C. &#160; &#160; Disclosure Regarding Foreign Jurisdiction that Prevents Inspections.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_77ab99c7_3184_432d_9711_9cf8727e6da6"></a><a id="PARTIII_757942"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;III</b></p><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;10.</b>&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Directors, Executive Officers and Corporate Governance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information required by this Item&#160;is incorporated herein by reference from our Proxy Statement for our 2023 Annual Meeting of Stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_60858864_87df_4c5e_bfb6_e4bc2b7ff656"></a><a id="Item11ExecutiveCompensation_785771"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;11.</b>&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Executive Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information required by this Item&#160;is incorporated herein by reference from our Proxy Statement for our 2023 Annual Meeting of Stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_141f1c88_41c4_4d0b_86fe_f1d4cf7d577b"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;12.</b>&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information required by this Item&#160;is incorporated herein by reference from our Proxy Statement for our 2023 Annual Meeting of Stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a562ae4d_9a2a_413e_80f9_5ec6f4a0b6cc"></a><a id="_602607"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;13.</b>&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Certain Relationships and Related Transactions, and Director Independence.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information required by this Item&#160;is incorporated herein by reference from our Proxy Statement for our 2023 Annual Meeting of Stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b9989d08_b178_42af_8b28_d6b1203a70c4"></a><a id="Item14PrincipalAccountingFeesandServices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;14.</b>&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Principal Accounting Fees and Services.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information required by this Item&#160;is incorporated herein by reference from our Proxy Statement for our 2023 Annual Meeting of Stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_15ff9415_b955_4340_bf6f_18e67edc2c04"></a><a id="PARTIV_456940"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;IV</b></p><a id="Item15ExhibitsFinancialStatementSchedule"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;15.</b>&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Exhibits, Financial Statement Schedules.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(a)&#160;Financial Statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following financial statements are filed as part of this Form&#160;10-K:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Report"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (<ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:AuditorName" id="Narr_nmNVofHJTE66_TVQ7YJt8Q">KPMG LLP</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:AuditorLocation" id="Narr_TK5VM7TbjEOcOWH13ZtVBQ">New York, NY</ix:nonNumeric>; PCAOB ID: <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="dei:AuditorFirmId" id="Narr_OgjzF29ZV0mB6ajHscVmsA">185</ix:nonNumeric>)</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial Statements:</p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BALANCESHEETS_567236"><span style="font-style:normal;font-weight:normal;">Balance Sheets as of December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#STATEMENTSOFOPERATIONS_79919"><span style="font-style:normal;font-weight:normal;">Statements of Operations for the&#160;Years Ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#STATEMENTSOFSTOCKHOLDERSEQUITY_900084"><span style="font-style:normal;font-weight:normal;">Statements of Changes in Stockholders&#8217; Equity for the&#160;Years Ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#STATEMENTSOFCASHFLOWS_1249"><span style="font-style:normal;font-weight:normal;">Statements of Cash Flows for the&#160;Years Ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-7</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestoFinancialStatements_21312"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Financial Statements</span></a></p></td><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-8 - F-28</p></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">(b)&#160;Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.07%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:88.7%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420416114788/v444946_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation of Mustang Bio,&#160;Inc. (formerly Mustang Therapeutics,&#160;Inc.), dated July&#160;26, 2016 (incorporated by reference to the Exhibit 3.1 of the Registrant&#8217;s Form 10-12G (file No. 000-55668) filed with the SEC on July 28, 2016).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420418044004/tv500038_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Mustang Bio,&#160;Inc., dated June&#160;14, 2018 (incorporated by reference to the Exhibit 3.1 of the Registrant&#8217;s Quarterly Report on Form 10-Q (file No. 001-38191) filed with the SEC on June 14, 2018). </span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.3</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420419046520/tv530251_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Mustang Bio,&#160;Inc., dated September&#160;30, 2019 (incorporated by reference to the Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K (file No. 001-38191) filed with the SEC on September 30, 2019). </span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.4</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000110465920132442/tm2037565d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Mustang Bio,&#160;Inc., dated December 4, 2020 (incorporated by reference to the Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K (file No. 001-38191) filed with the SEC on December 4, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.5</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000110465921084141/tm2120272d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Mustang Bio, Inc., dated June 17,</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000110465921084141/tm2120272d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2021 (incorporated by reference to the Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K (file No. 001-38191) filed with the SEC on June 22, 2021).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.6</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000155837022010569/tmb-20220706xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Mustang Bio, Inc., dated July 5, 2022 (incorporated by reference to the Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K (file No. 001-38191) filed with the SEC on July 5, 2022).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.7</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420416114788/v444946_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of Mustang Bio,&#160;Inc. (incorporated by reference to the Exhibit 3.2 of the Registrant&#8217;s Form 10-12G (file No. 000-55668) filed with the SEC on July 28, 2016). </span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.1</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420416114788/v444946_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen certificates evidencing shares of common stock, Class&#160;A common stock and Class&#160;A preferred stock (incorporated by reference to the Exhibit 4.1 of the Registrant&#8217;s Form 10-12G (file No. 000-55668) filed with the SEC on July 28, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.2</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420416114788/v444946_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of warrant agreement (incorporated by reference to the Exhibit 4.2 of the Registrant&#8217;s Form 10-12G (file No. 000-55668) filed with the SEC on July 28, 2016). </span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.3</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20221231xex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Securities of Mustang Bio,&#160;Inc. **</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420416114788/v444946_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Founders Agreement between Fortress Biotech,&#160;Inc. and Mustang Bio,&#160;Inc., dated July&#160;26, 2016 (incorporated by reference to the Exhibit 10.1 of the Registrant&#8217;s Form 10-12G (file No. 000-55668) filed with the SEC on July 28, 2016). </span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420416114788/v444946_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Management Services Agreement between Fortress Biotech,&#160;Inc. and Mustang Bio,&#160;Inc., dated March&#160;13, 2015 (incorporated by reference to the Exhibit 10.2 of the Registrant&#8217;s Form 10-12G (file No. 000-55668) filed with the SEC on July 28, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420416114788/v444946_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Future Advance Promissory Note&#160;to Fortress Biotech,&#160;Inc., dated May&#160;5, 2016 (incorporated by reference to the Exhibit 10.3 of the Registrant&#8217;s Form 10-12G (file No. 000-55668) filed with the SEC on July 28, 2016). </span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.4</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420416114788/v444946_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Promissory Note&#160;to NSC Biotech Venture Fund I, LLC, dated July&#160;5, 2016 (incorporated by reference to the Exhibit 10.4 of the Registrant&#8217;s Form 10-12G (file No. 000-55668) filed with the SEC on July 28, 2016). </span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.07%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:88.7%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.5</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420416114788/v444946_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Common Stock Warrant issued by Mustang Bio,&#160;Inc. to NSC Biotech Venture Fund I, LLC, dated July&#160;5, 2016 (incorporated by reference to the Exhibit 10.5 of the Registrant&#8217;s Form 10-12G (file No. 000-55668) filed with the SEC on July 28, 2016). </span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.6</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420416114788/v444946_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement by and between Mustang Bio,&#160;Inc. and City of Hope, dated March&#160;17, 2015 (incorporated by reference to the Exhibit 10.6 of the Registrant&#8217;s Form 10-12G (file No. 000-55668) filed with the SEC on July 28, 2016). #</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.7</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420416114788/v444946_ex10-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Sponsored Research Agreement by and between Mustang Bio,&#160;Inc. and City of Hope, dated March&#160;17, 2015 (incorporated by reference to the Exhibit 10.7 of the Registrant&#8217;s Form 10-12G (file No. 000-55668) filed with the SEC on July 28, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.8</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420416114788/v444946_ex10-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Mustang Bio,&#160;Inc. 2016 Incentive Plan (incorporated by reference to the Exhibit 10.8 of the Registrant&#8217;s Form 10-12G (file No. 000-55668) filed with the SEC on July 28, 2016). &#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.9</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420416114788/v444946_ex10-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Mustang Bio, Inc. Non-Employee Directors Compensation Plan (incorporated by reference to the Exhibit 10.9 of the Registrant&#8217;s Form 10-12G (file No. 000-55668) filed with the SEC on July 28, 2016). &#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.10</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420416114788/v444946_ex10-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Agreement by and between Mustang Bio, Inc. and Chord Advisors, LLC, dated April&#160;8, 2016 (incorporated by reference to the Exhibit 10.10 of the Registrant&#8217;s Form 10-12G (file No. 000-55668) filed with the SEC on July 28, 2016). </span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.11</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420417017831/v462107_ex10-11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Board Advisory Services Agreement by and between Mustang Bio, Inc. and Caribe BioAdvisors, LLC, dated January&#160;1, 2017 (incorporated by reference to the Exhibit 10.11 of the Registrant&#8217;s Annual Report on Form 10-K (file No. 000-55668) filed with the SEC on March 31, 2017).</span></a> </p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.12</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420417042638/v471618_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive License Agreement by and between Mustang Bio, Inc. and The Regents of the University of California, dated March&#160;17, 2017 (incorporated by reference to the Exhibit 10.4 of the Registrant&#8217;s Quarterly Report on Form 10-Q (file No. 000-55668) filed with the SEC on August 14, 2017). #</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.13</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420417042638/v471618_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive License Agreement&#160;(IV/ICV) by and between Mustang Bio, Inc. and City of Hope, dated February&#160;17, 2017. </span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420417042638/v471618_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Filed as Exhibit&#160;10.5 on the Company&#8217;s Form&#160;10-Q filed on August&#160;14, 2017 (incorporated by reference to the Exhibit 10.5 of the Registrant&#8217;s Quarterly Report on Form 10-Q (file No. 000-55668) filed with the SEC on August 14, 2017).</span></a> #</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.14</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420417017831/v462107_ex10-14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Exclusive License Agreement&#160;(CD123) by and between Mustang Bio, Inc. and City of Hope, dated February&#160;17, 2017 (incorporated by reference to the Exhibit 10.14 of the Registrant&#8217;s Annual Report on Form 10-K (file No. 000-55668) filed with the SEC on March 31, 2017). #</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.15</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420417017831/v462107_ex10-15.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Exclusive License Agreement&#160;(</span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:normal;">IL13R</i><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">a</span><i style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:normal;">2</i><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">) by and between Mustang Bio, Inc. and City of Hope, dated February&#160;17, 2017 (incorporated by reference to the Exhibit 10.15 of the Registrant&#8217;s Annual Report on Form 10-K (file No. 000-55668) filed with the SEC on March 31, 2017). #</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.16</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420417017831/v462107_ex10-16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Exclusive License Agreement&#160;(Spacer) by and between Mustang Bio, Inc. and City of Hope, dated February&#160;17, 2017 (incorporated by reference to the Exhibit 10.16 of the Registrant&#8217;s Annual Report on Form 10-K (file No. 000-55668) filed with the SEC on March 31, 2017). #</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.17</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420417021777/v464950_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between Manuel Litchman and Mustang Bio,&#160;Inc., effective as of April&#160;24, 2017 (incorporated by reference to the Exhibit 10.1 of the Registrant&#8217;s Current Report on Form 8-K (file No. 000-55668) filed with the SEC on April 24, 2017). &#8224;</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.18</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420417058649/tv479316_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement (CSI) by and between Mustang Bio,&#160;Inc. and City of Hope, dated May&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">31, 2017  (incorporated by reference to the Exhibit 10.1 of the Registrant&#8217;s Quarterly Report on Form 10-Q/A (file No. 001-38191) filed with the SEC on November 14, 2017). #</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.19</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420417058649/tv479316_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement (PSCA)by and between Mustang Bio,&#160;Inc. and City of Hope, dated May&#160;31, 2017 (incorporated by reference to the Exhibit 10.2 of the Registrant&#8217;s Quarterly Report on Form 10-Q/A (file No. 001-38191) filed with the SEC on November 14, 2017). #</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.07%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:88.7%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.20</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420417058649/tv479316_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement (HER2) by and between Mustang Bio,&#160;Inc. and City of Hope, dated May&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">31, 2017  (incorporated by reference to the Exhibit 10.3 of the Registrant&#8217;s Quarterly Report on Form 10-Q/A (file No. 001-38191) filed with the SEC on November 14, 2017). #</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.21</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420417058634/tv477598_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">Lease Agreement by and between Mustang Bio, Inc.  and WCS&#160;- 377 Plantation Street,&#160;Inc., dated October&#160;27, 2017 (incorporated by reference to the Exhibit 10.1 of the Registrant&#8217;s Quarterly Report on Form 10-Q (file No. 001-38191) filed with the SEC on November 14, 2017).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.22</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20221231xex10d22.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Sublease Agreement by and between Mustang Bio, Inc., and The Paul Reverse Life Insurance Company, dated June 14, 2022. **</span></a><span style="font-size:12pt;"> </span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.23</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20221231xex10d23.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Sublease Agreement by and between Mustang Bio, Inc. and The Paul Revere Life Insurance Company, dated October 25, 2022. **</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.24</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000114420419038877/tv526214_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Mustang Bio, Inc. 2019 Employee Stock Purchase Plan (incorporated by reference to the Exhibit 10.1 of the Registrant&#8217;s Quarterly Report on Form 10-Q (file No. 001-38191) filed with the SEC on August 9, 2019).&#8224;</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.25</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000110465921084141/tm2120272d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to the Mustang Bio, Inc. 2016 Equity Incentive Plan, dated June 17, 2021 (incorporated by reference to the Exhibit 10.1 of the Registrant&#8217;s Current Report on Form 8-K (file No. 001-38191) filed with the SEC on June 22, 2021). &#8224;</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.26</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000155837022010269/tmb-20220621xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Mustang Bio, Inc. 2016 Equity Incentive Plan, dated June 21,2022 (incorporated by reference to the Exhibit 10.1 of the Registrant&#8217;s Current Report on Form 8-K (file No. 001-38191) filed with the SEC on June 24, 2022). &#8224;</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.27</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000110465921084141/tm2120272d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to the Mustang Bio, Inc. 2019 Employee Stock Purchase Plan, dated June 17, 2021 (incorporated by reference to the Exhibit 10.2 of the Registrant&#8217;s Current Report on Form 8-K (file No. 001-38191) filed with the SEC on June 22, 2021). &#8224;</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.28</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000110465922031531/tm228500d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Warrant to Purchase Common Stock issued to Runway Growth Finance Corp., dated March 4, 2022 (incorporated by reference to the Exhibit 4.1 of the Registrant&#8217;s Current Report on Form 8-K (file No. 001-38191) filed with the SEC on March 8, 2022).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.29</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000110465922031531/tm228500d1_ex99-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Loan and Security Agreement by and between Mustang Bio, Inc., the Borrower, the Lenders, and Runway Growth Finance Corp. (as agent), dated March 4, 2022 (incorporated by reference to the Exhibit 99.1 of the Registrant&#8217;s Current Report on Form 8-K (file No. 001-38191) filed with the SEC on March 8, 2022).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.30</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1680048/000155837022018593/tmb-20221207xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Loan and Security Agreement by and between Mustang Bio, Inc., the Borrower, the Lenders and Runway Growth Finance Corp. (as agent), dated December 7, 2022 (incorporated by reference to the Exhibit 10.1 of the Registrant&#8217;s Current Report on Form 8-K (file No. 001-38191) filed with the SEC on December 13, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">16.1</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1680048/000110465921119372/tm2128334d1_ex16-1.htm">Letter from BDO USA, LLP to the Securities and Exchange Commission dated September 22, 2021, incorporated by</a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1680048/000110465921119372/tm2128334d1_ex16-1.htm">reference to the Form 8-K filed on September 24, 2021. *</a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.1</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20221231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Independent Registered Public Accounting Firm, KPMG, LLP,</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Hartford, Connecticut.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24.1</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNAT_855275"><span style="font-style:normal;font-weight:normal;">Power of Attorney (included on signature page).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20221231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of President and Chief Executive Officer, pursuant to Rule 13a-14(a) of the Exchange Act, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20221231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer, pursuant to Rule 13a-14(a) of the Exchange Act, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.07%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:88.7%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20221231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of President and Chief Executive Officer, pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.2</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20221231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer, pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following financial information from Mustang Bio,&#160;Inc.&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December 31, 2022, formatted in Inline Extensible Business Reporting Language (iXBRL): (i)&#160;the Balance Sheets, (ii)&#160;the Statements of Operations, (iii)&#160;the Statement of Stockholders&#8217; Equity, (iv)&#160;the Statements of Cash Flows, and (v)&#160;Notes&#160;to the Financial Statements (filed herewith).</p></td></tr><tr><td style="vertical-align:top;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in exhibit 101)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:0.3pt;"></span>#&#160;&#160;&#160;&#160;&#160;Confidential treatment has been granted with respect to omitted portions of this exhibit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:0.3pt;"></span>&#8224;&#160;&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan or arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:0.3pt;"></span>**&#160;&#160;&#160;Filed herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_79da73b7_513f_4db0_adf6_c379b2a4ddf6"></a><a id="Item16Form10KSummary_443190"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;16.</b>&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Form&#160;10-K Summary.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_17b49181_3ffb_4bec_8ae8_e9ca94d0eb6c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INDEX TO FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Report"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (KPMG LLP, New York, NY; PCAOB ID: 185)</p></td><td style="vertical-align:bottom;width:10%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BALANCESHEETS_567236"><span style="font-style:normal;font-weight:normal;">Balance Sheets as of December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#STATEMENTSOFOPERATIONS_79919"><span style="font-style:normal;font-weight:normal;">Statements of Operations for the&#160;Years Ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#STATEMENTSOFSTOCKHOLDERSEQUITY_900084"><span style="font-style:normal;font-weight:normal;">Statements of Changes in Stockholders&#8217; Equity for the&#160;Years Ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#STATEMENTSOFCASHFLOWS_1249"><span style="font-style:normal;font-weight:normal;">Statements of Cash Flows for the&#160;Years Ended December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-7</p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestoFinancialStatements_21312"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-8 &#8211; F-28</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f8f48b20_3db8_4e86_b096_e564b3871cef"></a><a id="Report"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">To the Stockholders and Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Mustang Bio, Inc.:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Opinion on the Financial Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><a id="_0"></a><a id="_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have audited the accompanying balance sheets of Mustang Bio, Inc. (the Company) as of December 31, 2022 and 2021, the related statements of operations, stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively, the financial statements).&#160;In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31,&#160;2022 and 2021, and the results of its operations and its cash flows for each of the years then ended, in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Going Concern</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</span></p><a id="_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company&#8217;s expectation to generate operating losses and negative operating cash flows in the future, projections of future inability to meet certain financial debt covenants, and the need for additional funding to support its planned operations raises substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements and supplemental information do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Basis for Opinion</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">/s/ KPMG LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Hartford, Connecticut<br />March&#160;29,&#160;2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8c03b966_7a8d_4ad4_b147_bdc5110dae75"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MUSTANG BIO,&#160;INC.</p><a id="BALANCESHEETS_567236"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(in thousands, except for share and per share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_2d4db247_ef12_40fd_ae1f_e0e638d2f852"></a><a id="Tc_SrRCaO30H0qfDch0-iN_Qw_1_2"></a><a id="Tc_2DZD4dvmAkqQ9tS1ki7Q-g_1_5"></a><a id="Tc_rgkMiG2DW0iDQgLa_HCSMQ_2_2"></a><a id="Tc_alBPeJKb4USK-YsiJx_Qwg_2_5"></a><a id="Tc_6BrN9RCcb0mMZhba1DGdSg_4_0"></a><a id="Tc_A60In8URs0Gc-7XOhSmksg_5_0"></a><a id="Tc_A7KRRutbFEqm6GHHIEhAGQ_6_0"></a><a id="Tc_jc_6QlTaGUG3X8EoBnwtvg_6_2"></a><a id="Tc_hgr9qeF3LUyvX2r8ut8piA_6_5"></a><a id="Tc_WU6lNfx9LkeywgYHQeY6eA_7_0"></a><a id="Tc_NCUx7vGRJUWigzmGC5WQbA_8_0"></a><a id="Tc_QGGQXjn63kuSla212Bex0Q_9_0"></a><a id="Tc_WeveVuQp0EaFCApOfdpSAQ_11_0"></a><a id="Tc_JeEkAtDFBUqNBOv5un44HQ_12_0"></a><a id="Tc_JeZD-X7qvUaOZLffyjqCOg_13_0"></a><a id="Tc_0mZcuxBX1ESgeekBnVbzww_14_0"></a><a id="Tc_3XcBEcSeSEKNa-a6ay6d9Q_15_0"></a><a id="Tc_iL4xj85eRk-axFdpTLDRGQ_16_0"></a><a id="Tc_Cr1WeHZwKkWEUu5APiSGXQ_16_2"></a><a id="Tc_R64My2nZAUqnEFfMvRlHsg_16_5"></a><a id="Tc_cemdzgiKVUixh5_07e1y2w_18_0"></a><a id="Tc_tRW8Ozb1nUCz6YYLl1vCrg_19_0"></a><a id="Tc_JPAA9OsIZUa438i_XOud4A_20_0"></a><a id="Tc_9X3dbXbhakWWXuBKYCsbwg_20_2"></a><a id="Tc_DHk_BdyIKkOgpyysBiKO6g_20_5"></a><a id="Tc_J3J2y8TpXE6M8D4-KetcgQ_21_0"></a><a id="Tc_iR1BB4Rpck60fGlexAgOBA_22_0"></a><a id="Tc_PD2rFRis9EOXBXxN9xzhMw_23_0"></a><a id="Tc_dQFskq_jzkKhiZYjjzHWgw_25_0"></a><a id="Tc_k6FVJhEBxEy3LAwnSkXiJw_26_0"></a><a id="Tc_oaCppPjET0-12bXoNHUPDQ_27_0"></a><a id="Tc_DksbdOwmuUGxzP96hVNYUg_28_0"></a><a id="Tc_EIbYYKP28kqqLa4isSG0kQ_30_0"></a><a id="Tc_aoExSbWUCUCK6psX-QPi-g_32_0"></a><a id="Tc_YyebeGfYwEe0WFeLjVhbQA_33_0"></a><a id="_ad61a662_a9f2_4504_9a45_a0ff0bcec44a"></a><a id="_ad61a662_a9f2_4504_9a45_a0ff0bcec44a_2"></a><a id="_ad61a662_a9f2_4504_9a45_a0ff0bcec44a_3"></a><a id="Tc_TZ_vtHvGW0GDiT7waTGsNA_34_0"></a><a id="Tc_WuO_TXjp8UGSRwkEyZRSvA_35_0"></a><a id="_10029020_2641_42a1_a67b_f60edb0a9742"></a><a id="_10029020_2641_42a1_a67b_f60edb0a9742_2"></a><a id="_10029020_2641_42a1_a67b_f60edb0a9742_3"></a><a id="Tc_w2eHeY8-0UaWFnkBbeiGXA_36_0"></a><a id="Tc_HVSdcSlc-kaTpjbBnuAvRw_37_0"></a><a id="Tc_AokJml4yUEi8ShgsK6_BYw_38_0"></a><a id="Tc_xE9oXssKJEeegr6uZawJ-A_39_0"></a><a id="Tc_D0MChf7sZEakBzJlw7yDgQ_40_0"></a><a id="Tc_C1MwevkrZEqrF79OaF9JEw_41_0"></a><a id="Tc_h8cS2yJMok2Z-XkCxXZMlA_41_2"></a><a id="Tc_XNDDBbmc_Eueh4vuqTDdig_41_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Current Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_qiMrppNFzkiIx-Ks68w_yw_6_3">75,656</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_8m-jZ_8FoUac1nlmf6rEBQ_6_6">109,618</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Other receivables - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivables" scale="3" id="Tc_OQzhIkmjp0uu3W_y3VoiZQ_7_3">36</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivables" scale="3" id="Tc_J0VHU4hV20SL9KsC7tzMFA_7_6">50</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_cYh1AWMtOkujS-kWiiztPQ_8_3">3,160</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_HvMIaEee_k2jCNggwoEG8A_8_6">2,038</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_CUPVNzb690CvdUprfwT0zQ_9_3">78,852</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_5R3l8eBvEkqogcIjdJvmfQ_9_6">111,706</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="mbio:PropertyPlantAndEquipmentExcludingAssetsUnderConstruction" scale="3" id="Tc_F01KzI6ttUWzCNfFIKUF2A_11_3">8,440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="mbio:PropertyPlantAndEquipmentExcludingAssetsUnderConstruction" scale="3" id="Tc_OE6O5qnm_0-c3CY3MwOdLg_11_6">9,025</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Fixed assets&#160;- construction in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="mbio:ConstructionInProcessNet" scale="3" id="Tc_gtNCma0c6kK8aIydTUR-0A_12_3">951</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="mbio:ConstructionInProcessNet" scale="3" id="Tc_X_1kMParOkmEmcKHhcNtaA_12_6">2,027</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_FNtiMbfL20aTPDBjPL_4ig_13_3">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_KeoVsz5Z4kmXfgkeKJqOcg_13_6">1,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_QCvtjU4qWUuoMKbVGDDB5Q_14_3">261</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_o6kYT4a17UK2xRcFYsfUcw_14_6">362</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease right-of-use asset, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_8XVgONAM_kCimBXZCNVv_w_15_3">2,918</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_850cSfEa40WteNDaliMnpg_15_6">1,050</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_fORf4rMhvEiQJ1K30UQnCg_16_3">92,422</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_fFVn8SSfpUq_5wfN3DC9OQ_16_6">125,170</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Current Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="Tc_Cc-0zLFBW0GWQ3RKGn5FZQ_20_3">13,731</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="Tc_p3jajKm1oEyjtMSrcmZbwQ_20_6">9,744</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Payables and accrued expenses&#160;- related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="Tc_YWwFFJCpjEqOlyIiMVmQjA_21_3">766</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="Tc_fYfGnsuGgEemQcp245iMEA_21_6">723</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liabilities - short-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_ZToHyfMIRUK47JbqOzU6ZQ_22_3">612</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_qv11gi57xUaLeXxr0LIGPg_22_6">348</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_iaZfWXJ-8UGg8yuT3V4Pyg_23_3">15,109</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_307NktlIl0GfUoOwssRkRg_23_6">10,815</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Deferred income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeNoncurrent" scale="3" id="Tc_nGucO7vXYkifZdTXf-JiEg_25_3">270</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeNoncurrent" scale="3" id="Tc_9PZYn639lEWuAIkcMf9VLg_25_6">270</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Note payable, long-term, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="3" id="Tc_OsODKx5KLUu0pp8rjDhqcw_26_3">27,436</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermNotesPayable" scale="3" id="Tc_QLHda2HAa0-5aHbo5NjmVQ_26_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities - long-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_73KKLZvreEKW6z20E_dc-A_27_3">3,334</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_ViAl26VbcE2u11aTBkqisw_27_6">1,685</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_NqFbUEPBs0-mVyEzB3yJDA_28_3">46,149</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_Gue22P8LtkyD91RBsSEPyw_28_6">12,770</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Commitments and Contingencies (Note 7)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_WKP7Q3v1wUSrd4t-1BFMZQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_va5mLWwmokm0YaIxmfhV4g">0.0001</ix:nonFraction></ix:nonFraction> par value), <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_6Mp0dYv7uEy8ktOtvnslgA"><ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_BRc68n6JCUamIOP5b1bRwQ">2,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_CHGLg15_yE2G093IdhRBtw"><ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_6IToXjxU2U2fQwdAiV-uZA">250,000</ix:nonFraction></ix:nonFraction> shares of Class&#160;A preferred stock issued and outstanding as of December&#160;31,&#160;2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="Tc_EaSCp0s-8k6--PTxukq-fQ_33_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="Tc_ngBpj8l58U-nvSZ_0sR89A_33_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Common stock ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_53IohRq9x0C8fuHrB4iq4A"><ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_QL4d7A1BiUaZj2cTTsHQ5A">0.0001</ix:nonFraction></ix:nonFraction> par value), <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_tg_qxhZhBEezx9KyRaHdUw">200,000,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_yZLcIb_JCk64hOgtlYroyQ">150,000,000</ix:nonFraction> shares authorized as of December&#160;31,&#160;2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Class&#160;A common shares, <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_M2XrEHX5oEeqe8nYvunwDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_F9jqhyB12UiqkovNsGNJ0w"><ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_ReacBf4ACUWv_pBx9hfasw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_HGm-eFvm40KqP0r-CLUMDA">845,385</ix:nonFraction></ix:nonFraction> shares issued and outstanding&#160;as of December&#160;31,&#160;2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_ReacBf4ACUWv_pBx9hfasw" decimals="-3" format="ixt:zerodash" name="us-gaap:CommonStockValue" scale="3" id="Tc_dVlGiN9F-UKOQVf4R8WOcA_35_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_M2XrEHX5oEeqe8nYvunwDw" decimals="-3" format="ixt:zerodash" name="us-gaap:CommonStockValue" scale="3" id="Tc_zN29-B-ixEulXZcb_iDOgg_35_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;">Common shares, </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_BIGXGDitnk-RSc92qeeFPA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_gRd9DbhL0EC3qSGTP9I1Xw">106,501,663</ix:nonFraction></span><span style="font-size:9pt;"> and </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_3yAsLCGyT0KK9PpF59rSlw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_8eySpywH5kmc6iWqAhzRCA">93,582,991</ix:nonFraction></span><span style="font-size:9pt;"> shares </span><span style="-sec-ix-hidden:Hidden_dBSj86xc7EiE_66a4c2vDA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:9pt;"> and </span><span style="-sec-ix-hidden:Hidden_L5SONMef_0GOhhJFfDk_NQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:9pt;">&#160;as of December&#160;31,&#160;2022 and 2021, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_BIGXGDitnk-RSc92qeeFPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_gXHRM8BKXU2Fk36R6uNImQ_36_3">11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_3yAsLCGyT0KK9PpF59rSlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_hWF4MEUmeUagl_j56YVGOg_36_6">9</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Common stock issuable, <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesSubscribedButUnissued" scale="0" id="Narr_XBip9-ljCUGrT9CYWsvWVQ">2,807,008</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesSubscribedButUnissued" scale="0" id="Narr_vbltne6aCEi-bYOskIwowg">2,536,607</ix:nonFraction> shares as of December&#160;31,&#160;2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesSubscriptions" scale="3" id="Tc_vqyO_a8rU0WOUs_hJOKbag_37_3">1,109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesSubscriptions" scale="3" id="Tc_SOQaQ2Ss4UW6BEFGB-5uFw_37_6">4,329</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_NKD-_lZwVUaI350HC--tNQ_38_3">374,522</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_GZsXXPYIGkOts0RrnPw01Q_38_6">359,906</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_Y4b9tDxjl0KRu1Nu023n1w_39_3">329,369</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_3yRDd4RgTEWFR6IxC3Z3ow_39_6">251,844</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_xljOFWbjakSbs4zoR0ILeg_40_3">46,273</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_RHYatvNgrUG3FNjROYFx4w_40_6">112,400</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:67.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_AxgqDBV0ZEyG_K3HdZQOLQ_41_3">92,422</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_O_MKj_vcVEKjbMKJL8El-A_41_6">125,170</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See accompanying notes to financial statements.</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c796a162_4089_4389_8c02_d8a5210f6ad5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MUSTANG BIO,&#160;INC.</p><a id="STATEMENTSOFOPERATIONS_79919"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(in thousands, except for share and per share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_62dc163e_a38c_42e2_9b54_05e347909966"></a><a id="Tc_Qlf7MFVjx06vi86c9QskgA_1_2"></a><a id="Tc_A84ZVnq_7E2ys0aCsF3ktQ_2_2"></a><a id="Tc_3H755f1QCUq51tm11mdCog_2_5"></a><a id="Tc_t4I18CYYNUqsLSRV1kAvCg_3_0"></a><a id="Tc_JzB2cDkYMkqWN_0eiEn_BQ_4_0"></a><a id="Tc_iVaUzxlCDkWV-Fh9-Xt22w_4_2"></a><a id="Tc_eztQhLqwHUKWccyg5xYwiA_4_5"></a><a id="Tc_ZB4KFgJV80G6a5npoXzFWA_5_0"></a><a id="Tc_JbAfktgxlUKWuhK6zOsXbQ_6_0"></a><a id="Tc_amil-sccM0e9Ra_8mrzRIA_7_0"></a><a id="Tc_Di98eaOo4EaxRO9k1v6Vqg_8_0"></a><a id="Tc_V9_2_A6P9kalL37lXfXiEw_10_0"></a><a id="Tc_k4tWvr1xVk2Rvy98-LE4_w_11_0"></a><a id="Tc_e1QzZRlcVEaQM1GZRV-EoA_11_6"></a><a id="Tc_FhQ4vQHYVUCXbeH2HsoS0A_12_0"></a><a id="Tc_1lb1YxCmr0GqT-Meh5iScg_13_0"></a><a id="Tc_i9z12AT0-kaN7q2QLV095g_14_0"></a><a id="Tc_pMS9zDG1PkiSQWwAsrb82g_15_0"></a><a id="Tc_zEMYzoBC1Ea6fQDO8NyzMA_15_2"></a><a id="Tc_q4TDErY5ok22Lf8rWlO5mA_15_5"></a><a id="Tc_xT5hiUQLjU6Q-6zBILPFcA_17_0"></a><a id="Tc_BJjcKzyppUGboRQj-2yucA_19_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_2ZBI4HNwvkKq_RVzim1JaA_4_3">62,475</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_Knh48dOsq0K5fXrUcQbu1A_4_6">49,864</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development&#160;&#8211; licenses acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_IvG8XtBgekaP4cgBE4ua8A_5_3">1,474</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_tLHQ5Pm_UUG0h9n9RjQcQw_5_6">5,842</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_XQrft5DoKku5cm7aZVK5qA_6_3">12,210</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_i5T04jriskG7R0ApIgnD6w_6_6">11,017</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_wA-3620CyU-RPGjsEKai3A_7_3">76,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_qzOXb7WTu0iSy__i-ni-iA_7_6">66,723</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_tFisi56v90u5BjHef_rdCw_8_3">76,159</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_Cu1q2rd6JkidlGyCvoiYzg_8_6">66,723</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="mbio:GrantIncome" scale="3" id="Tc_A2rbfgUjIEa35jUsd2FHCw_11_3">1,304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="3" id="Tc_uZvET_fZJUaxc1dSmIe2Fg_12_3">689</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="3" id="Tc_Bxnu00NNnkaAQpB6cNPWVg_12_6">368</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_-VZOkbOjtkye45URkCLtRA_13_3">3,359</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_9HB5G9wKfE-dhhH4R_HO7g_13_6">15</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other income (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_CvwqeYwtE0-8ePzhigdu1A_14_3">1,366</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_G2D2tw3hREiOKsvWOIa_7g_14_6">353</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_wxWFC-wBy0-wX3LO5veDCg_15_3">77,525</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_AcB-B66pnUSDNTLGJ-B_0w_15_6">66,370</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per common share outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_MmSsXYvO_kGoOGgbOrT66w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_UQZC8XVrSEeOpkfmkFcDxw_17_3">0.75</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_2XIc_zKVEUGsQyadfYD1gw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_me8Jh5sGkEGwveLDJoZvKA_17_6">0.76</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average number of common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_iB5wSY6qCEevBOxV6nNxYw_19_3">103,432,603</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Nnamk5vHwEurwBfYCDgJ2Q_19_6">87,885,235</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">See accompanying notes to financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_953dfa3b_04e4_4482_a732_a8704a2d9f53"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MUSTANG BIO,&#160;INC.</p><a id="STATEMENTSOFSTOCKHOLDERSEQUITY_900084"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(in thousands, except share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_f852bba8_ee98_4f29_9ec6_ecdfe7bdb106"></a><a id="Tc_Ap7wRj61a0SW-eBwKRaunQ_1_17"></a><a id="Tc_oJXQidRqdkyDJN31zNa75A_1_20"></a><a id="Tc_0FI-fD7P7UKQ0C8eTqUl2A_1_26"></a><a id="Tc_JUMeuYCBnUmefO-ABBrTfQ_2_2"></a><a id="Tc_PyeIoiijrkO8iL8jRptM9A_2_7"></a><a id="Tc_iHlofiVl6E64likfuLnZpA_2_12"></a><a id="Tc_E97xj1abo0OzAkn6mPTgoQ_2_17"></a><a id="Tc_OShuZc38EEq5kB6PhhxS8g_2_20"></a><a id="Tc_hiUkY-raT0C0hRp8vJUVUA_2_23"></a><a id="Tc_jBC5S92znkiVKcDF2vXUFg_2_26"></a><a id="Tc_WtH644HI3EGxZFY1mxAAQA_3_2"></a><a id="Tc_Q98bpcCm7kuLoJ_Nl-p_bA_3_4"></a><a id="Tc_hzfL1ngpZkG-llw6f0OPSg_3_7"></a><a id="Tc_aVkkrsyyDU2ebmQfEKPewQ_3_9"></a><a id="Tc_TVA1CTxhFUGriyH1PfmSbA_3_12"></a><a id="Tc_mdUCDKS_RU6XVDYqppU5LQ_3_14"></a><a id="Tc_2stUVwww80u781lpmmmysA_3_17"></a><a id="Tc_dw_X2EztF0O0Lx9IK7jwgw_3_20"></a><a id="Tc_WnPYvRIlK0uDIgviC6WaVg_3_23"></a><a id="Tc_S0vLA7mgD0q1cOc8LwLQ0w_3_26"></a><a id="Tc_W6PGsGUVOkCFdyWfZDnBTA_4_0"></a><a id="Tc_4qzz0m5nn0yUIS1GWKmvvA_4_4"></a><a id="Tc_Tp2fpY_n60WNvr_1W-P7lQ_4_5"></a><a id="Tc_mjaoHtljekGvXDwiJBk5uw_4_9"></a><a id="Tc_HAcrrCQsz0eQoPGDXu_Yzg_4_10"></a><a id="Tc_aPwPMzybckqCEzRID7VuNg_4_14"></a><a id="Tc_C0s88Q0UlEG7LARU94nZNw_4_17"></a><a id="Tc_PubHcLso-UCX2cGHj_YJ6Q_4_20"></a><a id="Tc_4uxHoY2Eqk6SrHc_vjvknw_4_23"></a><a id="Tc_fJ_BtaClUE2ltOz9b2nuSA_4_26"></a><a id="Tc_x90AnkuJpEe64fp-3ECflA_5_0"></a><a id="Tc_hC5jJZNBn0aMg_Uc-ExtoA_5_2"></a><a id="Tc_M-GipW_q0EKzTeQgZDOgvQ_5_5"></a><a id="Tc__GJpkJbIZkykxIFN9vtdGg_5_7"></a><a id="Tc_p7y4-fG7EkqsJydxPAtg5g_5_10"></a><a id="Tc_GP8C047_7ESnrKXm_Lj9gg_5_12"></a><a id="Tc_eipppBrgKka1THt2qRU8rA_5_15"></a><a id="Tc_RE9_scIy5ECtMTibZEZG0w_5_21"></a><a id="Tc__0QfzsXCJkeE2gpKHSQneA_5_24"></a><a id="Tc_DYFQwehM-0yp4k_4H3c7kA_6_0"></a><a id="Tc_jHYoRnDoIUOQ1nd8t0XKaA_6_2"></a><a id="Tc_9sn1_-HN_0yAWhGIIVG44Q_6_5"></a><a id="Tc_9PieXENl6UWRFVIQtcOINw_6_7"></a><a id="Tc_tv-GTnv2g0KncmB6A8FAFQ_6_10"></a><a id="Tc_srUjh0ybVUG8kBPtckxXLQ_6_15"></a><a id="Tc_Ep6Gg9vsIEO4PMD0O9rEPA_6_24"></a><a id="Tc_PQK3eraVQ0mTTHov7S9NpA_6_27"></a><a id="Tc_OuhmCBpMvE2d3H9jb-V6VA_7_0"></a><a id="Tc_LX61QCCN7EyCsNnJPGBb5Q_7_2"></a><a id="Tc_L86P8Ij9rUuB_YcG9GIH4w_7_5"></a><a id="Tc_uU6y3yZapEaFOXraYEpiRw_7_7"></a><a id="Tc_qZP_DqgoIESOFsgO6oyBIA_7_10"></a><a id="Tc_Ptb-0G9S60SF4PulrL4ojg_7_18"></a><a id="Tc__xgKQfFAEkSrMOXSFkjs_g_7_24"></a><a id="Tc_5w1pOeDYmUOBL92mqYiA_w_8_0"></a><a id="Tc_JDq3rPSTgEeaerTLHxW3nA_8_2"></a><a id="Tc_pliwUpwnDEymRRy5FxUErw_8_5"></a><a id="Tc_9MFrWX74hki0GqNy6Pu8Mg_8_7"></a><a id="Tc_-6PqoNHpMUKfRSeZLnw0hA_8_10"></a><a id="Tc_IH4shJ6LcUyWDPVyd7F4Pg_8_15"></a><a id="Tc_dArEBvDCxUCLSfU7otXtKA_8_24"></a><a id="Tc_8xJpKMeUSkiB-tFApqBpUA_9_0"></a><a id="Tc_267vkCaNOk6uleLwZVwB-Q_9_2"></a><a id="Tc_wooI5eAKoEKt7QjZbzun_g_9_5"></a><a id="Tc_EWdt4aap7UK46nzHBR-BlA_9_7"></a><a id="Tc_3kZ8sac2n0WERyEOeeDgAA_9_10"></a><a id="Tc_va9d2MavZUCmqm_4r4c_4A_9_15"></a><a id="Tc_3_PvGLEdVESvhxk03IBTvA_9_18"></a><a id="Tc_WLwApQKCLkqv2TMXTv9sHg_9_24"></a><a id="Tc_GALWtZmEG0ebbvANxNURPw_10_0"></a><a id="Tc_T2dSn7V3Qkyy1ouyYoHtwQ_10_2"></a><a id="Tc_x0SD96UHIkmJISs3LPXCWQ_10_5"></a><a id="Tc_ynhE7R1bvEypUA1Qq-Aadw_10_7"></a><a id="Tc_ox8gpir-_E-OhR5dIreyaw_10_10"></a><a id="Tc_GztOSmJIFky1-9JejnjV4g_10_15"></a><a id="Tc_kTvqPKwpAkCynUdFbfArgQ_10_18"></a><a id="Tc_m2f6v18GNku3NfhY765-NA_10_21"></a><a id="Tc_V033w9x950OJRahDDFGC4A_10_24"></a><a id="Tc_EZp88THuSEyH619wT6MIOA_10_27"></a><a id="Tc_COJrVsHUOEivJqS0aDlrEw_11_0"></a><a id="Tc__wNJ21TW-EGJ6nK1rhbiFw_11_2"></a><a id="Tc_vxkMDiijoUyZfEr6DdpXNA_11_5"></a><a id="Tc_x7ZP4hpFwEiymegUJlU2xw_11_7"></a><a id="Tc_odYNNGNcUkuEwbjXqoAArw_11_10"></a><a id="Tc_ZY1MWJVUFEKcREaZW6YyOw_11_15"></a><a id="Tc_ZMyj_Yj-W0ebcIpIOFIJBQ_11_18"></a><a id="Tc_7g5UT1BPj0-IeYeRquK3Uw_11_24"></a><a id="Tc_V8BrdnVkE0-ukqPuq9xCvQ_12_0"></a><a id="Tc_BgtTM_GLcku1Oldw30QlRQ_12_2"></a><a id="Tc_OxmtHVuVzUmcgeMP38FuRQ_12_5"></a><a id="Tc_0cARz1MNkkmw6r79e1V2aQ_12_7"></a><a id="Tc_tfjxAKQ3JE6ITzzKbRep6g_12_10"></a><a id="Tc_xD_uS8WyE0moUeEy-crRvw_12_15"></a><a id="Tc_h7x9TL1es0yGOj1p40v1sQ_12_18"></a><a id="Tc_sSO5-y4G602uW9Xiol6eWw_12_21"></a><a id="Tc_YES4Z29QmEO-pJXHTEc24A_12_24"></a><a id="Tc_GdHOwo2p50--2AdVQUwlzw_12_27"></a><a id="Tc__AUAZlQ_aU-qeQ4HtdutOQ_13_0"></a><a id="Tc_fwZrkJR4tEmgCbB_OitVgw_13_2"></a><a id="Tc__OBa1_aHJ0-A7xhPdZxB5Q_13_5"></a><a id="Tc_zcQaNbAejEi_gG1zSxN-wg_13_7"></a><a id="Tc_mLCDVQ4WDE68igF-W7Yeig_13_10"></a><a id="Tc_Ec_kSNi3hUKp59r1aa-jYw_13_12"></a><a id="Tc_TH_l3k1dy0CVXr6IfdIm3Q_13_15"></a><a id="Tc_r_d-CDRZeUmh2MFI0B3MUA_13_18"></a><a id="Tc_Sq8QRD87pEexgLbPEiK2Tg_13_21"></a><a id="Tc__KImeGUUaEiIF-RA_kzETg_14_0"></a><a id="Tc_Z0fCZWdmHEutngn0BNjBPw_14_4"></a><a id="Tc_ySs1CrWEL06usOrM-hywLg_14_5"></a><a id="Tc_bKyhoPaJh0W5V-shx3WuYg_14_9"></a><a id="Tc_IJ6TVAadkUu2zeP52_fQ3A_14_10"></a><a id="Tc_h4IpBXAM50y1QWy6KucTng_14_14"></a><a id="Tc__H2mNtBHV0GsApkN6NDeWA_14_17"></a><a id="Tc_teuLnhvVjkiVPqmU5wPjGQ_14_20"></a><a id="Tc_dEZ-debuMEeKNsD9QkbFhw_14_23"></a><a id="Tc_4lgRZjIljUKeA0lox467zw_14_26"></a><a id="Tc_uE2HHJwR4kaz9cbbDl4ArA_15_0"></a><a id="Tc_NfwEJ2DFXkSWSdPY9v5Iiw_15_2"></a><a id="Tc_YkXYVNOvEEqekIeDjXRT5A_15_5"></a><a id="Tc_ceurQ3nmmUOmRGWWrMWyTA_15_7"></a><a id="Tc_4S83bdbZgE64ibRaxr5NHg_15_10"></a><a id="Tc_e35LvSDQEUaIEZJEjJPI0Q_15_12"></a><a id="Tc_7h5gqfvUgk2XH2JqVLqVdA_15_15"></a><a id="Tc_umRhdxzb-0Gv8B2Rs1vNqw_15_21"></a><a id="Tc_Qv3SH37Ge0uoyVEdqb-Lag_15_24"></a><a id="Tc_BH5lUN0zkEeOzYLud-HbRw_16_0"></a><a id="Tc_YVWq48bGjk-ZhybZg3lnRg_16_2"></a><a id="Tc_dVcL_eNxPU68tCz7Y13nng_16_5"></a><a id="Tc_0lTvg2sKZE2kIqgOP1Rqtg_16_7"></a><a id="Tc_HCurY8laJESx-ZOl07sgCA_16_10"></a><a id="Tc_Uchqwtmsik2qjmrSswkntg_16_15"></a><a id="Tc_fnaYrx6QQ0avYqhv8VMwBg_16_24"></a><a id="Tc_ptD34EOISUGg_Z-bdv8-6A_16_27"></a><a id="Tc_TTtTIbsuf0-dU894hvbsqQ_17_0"></a><a id="Tc_Mmxdw40Di0qHrOGUvRleJQ_17_2"></a><a id="Tc_iBEXkPmNCEimbmxnWRO0bQ_17_5"></a><a id="Tc_pWGWuLqybUuGbyDc0DIIPw_17_7"></a><a id="Tc_n_XK2c3MwEC7tSjrtyByTA_17_10"></a><a id="Tc_jmydy5rORUeuVsQC-Vtmrg_17_18"></a><a id="Tc_LHwKyAOJ1E6Pd0JwtBaXwQ_17_24"></a><a id="Tc_nEGzppuxe0G4-7_xldz4uQ_18_0"></a><a id="Tc_Puw5jJGNFUiqtXetOgeeVw_18_2"></a><a id="Tc_1xs6g_zxakeS3hv-mk61Mw_18_5"></a><a id="Tc_QVKUCuqN10mPL9g89mOgXA_18_7"></a><a id="Tc_KeGo3ORu0E-C7cgMsy67qA_18_10"></a><a id="Tc_Cl-n5_-LMUeJqIRzSUcPkg_18_15"></a><a id="Tc_8rlDAFwKfU6WQ5f0hZSRWA_18_24"></a><a id="Tc__ZnYNKV_w0qyY5AMNX5R-Q_19_0"></a><a id="Tc_QPXs0kpJzUCd19uyBqEDpQ_19_2"></a><a id="Tc_ey_ifRD1r0u5KKdGjxQlIA_19_5"></a><a id="Tc_CQs3J9Jb1EKiwx2E0eFgqA_19_7"></a><a id="Tc_LLRKkMC_bkGh--sDnwZm7g_19_10"></a><a id="Tc_yRgeSdQMyUKIBWIlvXiw1Q_19_15"></a><a id="Tc_V6Ofgh1XikuUHdZzPCpVyw_19_18"></a><a id="Tc_NkiulaElnkyHUTMXEC30Tw_19_24"></a><a id="Tc_VK7LZJytO06hLAk-9AybxA_20_0"></a><a id="Tc_W1gKos7h5UGPXVUo7bFbRQ_20_2"></a><a id="Tc_wB90UbHWAk6aHiNOAQpU4A_20_5"></a><a id="Tc_6xjZwaL-vEiTrySBL9As5Q_20_7"></a><a id="Tc_-LnSDXC0O0mxWAqU7rlj6w_20_10"></a><a id="Tc__iS0mOUqDkmqk-gZCWpuFg_20_15"></a><a id="Tc_BRv3CeZCa0yT-ICfL6QFsw_20_18"></a><a id="Tc_LxpWw6klpUe4aCQnp99Zdg_20_24"></a><a id="Tc_2L4gt8TYAkaw27ll_l1gHg_21_0"></a><a id="Tc_csUA1q9j8ki1BB4_EzXRBw_21_2"></a><a id="Tc_8YW7yObQLU-Ze35z7I7LZw_21_5"></a><a id="Tc_wqQakAwovEuEI5BiOn9UrQ_21_7"></a><a id="Tc_MfMo5kf9okuSKPLUvsG8Ig_21_10"></a><a id="Tc_M-avxcbYp0-jJLQFmAuIRQ_21_12"></a><a id="Tc_wmWjSNIwrUSXSWgr2OwmUQ_21_15"></a><a id="Tc_oC___OhzSUK62mB72ferSA_21_18"></a><a id="Tc_mmICkV0Ik0OPnnO1GUuaww_21_24"></a><a id="Tc__sMsVnirn06KIWx_I2l0ZQ_22_0"></a><a id="Tc_KAl5jcsH5EeHsKFkQ016LQ_22_2"></a><a id="Tc_jQudPVRBmU22pUpU3FVXaQ_22_5"></a><a id="Tc_a1dYYLC9-EGJehDkqCmRxw_22_7"></a><a id="Tc_fJnJTK-5M0Sye1FfDXpnbA_22_10"></a><a id="Tc_Z5kanOKrfU6Z3jAOmVzlBg_22_15"></a><a id="Tc_PMnc6cJV9UKA-waal3rHeg_22_18"></a><a id="Tc_d5tdDRzq0EqGQ-2jaA6uyg_22_24"></a><a id="Tc_33c5xYBZOUOEE6OmMCFQaQ_23_0"></a><a id="Tc_2c-GPBK3aEis5cjHfrUaYg_23_2"></a><a id="Tc_Fb1x3yYmBEyjMzYWlYoPzQ_23_5"></a><a id="Tc_e315v1S7uUyxL21MWPQRdQ_23_7"></a><a id="Tc_CzmUO3ZdC0e08QiZnV0W7A_23_10"></a><a id="Tc_7YvX3S1o206slAfJ_KA5lw_23_12"></a><a id="Tc_nIzkJwndAUiXUkia-CenRA_23_15"></a><a id="Tc_UvjWaM0TUESHZaPHJeZEWA_23_18"></a><a id="Tc_L0ngV37tlkOYed1S9EdvKA_23_21"></a><a id="Tc_zUPKdLINI0eNGuQwnrGGAg_24_0"></a><a id="Tc_KgY6ZqQJ8kmbY5VmhBV0RA_24_4"></a><a id="Tc_lypNctkVD0GHlS4LraiNHA_24_5"></a><a id="Tc_c1wuZMIqBUqlGUdaS2-KYg_24_9"></a><a id="Tc_WOy8NAnhmk6rEKny8qOmeA_24_10"></a><a id="Tc_ogwqEygKQEChwxFzC3uomg_24_14"></a><a id="Tc_a2Ynt-77L0m9Bj_o-wOY0Q_24_17"></a><a id="Tc_kem7kLVtPE6g9TI1uK--QA_24_20"></a><a id="Tc_nNsjnGjKgEmFBT11Kdl1vQ_24_23"></a><a id="Tc_YuLrrKmCI0yqMMkjH0owQw_24_26"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class&#160;A&#160;Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class&#160;A&#160;Common&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances at December&#160;31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Ph6XHuuiYE6eukhnqC2Btw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_A2WDaqE1EE6A0I3390IEgQ_4_2">250,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8o0VgKjajEeXToZHvyHFfg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_ZoxzzVfhXUqxqUba21LqrA_4_7">845,385</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GA4yvT9zYUmgOsGKoFCnXg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_9gJJPUbJpkWhaTiyMhBP0g_4_12">70,920,693</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GA4yvT9zYUmgOsGKoFCnXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Rer05FTN1Euq5vg_hyotTQ_4_15">7</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember_huCEWr5zL0mQORn1jbxA9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_5ob4lH5SPke0JrJKFjaTDg_4_18">7,939</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jHd2Q0o-XUCIA4E98EgSpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_bGvEQtNlEUuqbVuwg3721w_4_21">275,963</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_d-YK2vIsoEm8XC9k2H7Q5w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Ugey093KfUGl-5_0_DUMfw_4_24">185,474</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2020_Jb9gSnd2k0CKnqyK9MTFMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_2EjiwUQk40S-gLN64WKUxw_4_27">98,435</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Common stock issuable&#160;- Founders Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember_FipD5R7ULEmGI252vfGJvg" decimals="-3" format="ixt:numdotdecimal" name="mbio:StockIssuanceCommonStockIssuableDuringPeriod" scale="3" id="Tc_X2DzWwTH90a3wlDXZlpBww_5_18">4,212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="mbio:StockIssuanceCommonStockIssuableDuringPeriod" scale="3" id="Tc_8XyAsHTrMUyZqC2S-MC3dA_5_27">4,212</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common shares&#160;- Founders Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2yJrJPxhE-PPwrFE9SShQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Tc_VkwP4Aq7Hke2fcchcpUuHw_6_12">2,001,490</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember_FipD5R7ULEmGI252vfGJvg" decimals="-3" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodValueIssuedForFoundersAgreement" sign="-" scale="3" id="Tc_45U671wVy02nVFaPvaRDDw_6_18">7,577</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_36vrF-2gf0O3kUT4Pd1TLw" decimals="-3" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodValueIssuedForFoundersAgreement" scale="3" id="Tc_UNB0yWT08ke2-FQhdJSCmA_6_21">7,577</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common shares, net of offering costs - At-the-Market Offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2yJrJPxhE-PPwrFE9SShQ" decimals="INF" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodSharesAtMarketOffering" scale="0" id="Tc_q9tzCxNLMU6LtjwC9W0cFg_7_12">19,419,944</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2yJrJPxhE-PPwrFE9SShQ" decimals="-3" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodValueAtMarketingOffering" scale="3" id="Tc__Au05-MavUuyXjwL-I7Slw_7_15">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_36vrF-2gf0O3kUT4Pd1TLw" decimals="-3" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodValueAtMarketingOffering" scale="3" id="Tc_OMtes_tiTESUcmuNetlegg_7_21">70,620</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodValueAtMarketingOffering" scale="3" id="Tc_edkCoaiWr06g6nZhCkAfkA_7_27">70,622</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common shares - Equity fee on At-the-Market Offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2yJrJPxhE-PPwrFE9SShQ" decimals="INF" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering" scale="0" id="Tc_NB1YtUuQlk6ihXupWj30dg_8_12">576,157</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember_FipD5R7ULEmGI252vfGJvg" decimals="-3" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering" sign="-" scale="3" id="Tc_RZRl48BKskmLmLPttZbNRw_8_18">245</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_36vrF-2gf0O3kUT4Pd1TLw" decimals="-3" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering" scale="3" id="Tc_1aVMdze-XEyYof3DeBfbeg_8_21">2,129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering" scale="3" id="Tc_cwtbexstIUiNk9kg1Pu6Og_8_27">1,884</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common shares under ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2yJrJPxhE-PPwrFE9SShQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_pIpYRXumDkaRdLWDrQ73DQ_9_12">114,321</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_36vrF-2gf0O3kUT4Pd1TLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_pqNYlXIAcUa2EQ-mP-HSEg_9_21">309</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_8d2GJuwjjk6N6hfTAsQ27g_9_27">309</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Correction to previously issued shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2yJrJPxhE-PPwrFE9SShQ" decimals="INF" format="ixt:numdotdecimal" name="mbio:CorrectionToPreviouslyIssuedShares" scale="0" id="Tc_WcbXSUiO3UK3ibo3_QDavQ_10_12">60,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2yJrJPxhE-PPwrFE9SShQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_l5PPM92Io0alb1j4DiCnrQ_11_12">489,249</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_36vrF-2gf0O3kUT4Pd1TLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_Ux1WuGR4d0uNHgX2a5Dxzg_11_21">3,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_bSPnhHrHa0Co_rtzXwaOnQ_11_27">3,308</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2yJrJPxhE-PPwrFE9SShQ" decimals="INF" format="ixt:numdotdecimal" name="mbio:ShareIssuedDuringPeriodSharesOnExerciseOfWarrants" scale="0" id="Tc_Xz-m1i0Zske0khjO4qSNMQ_12_12">138</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_N3FmWahfpU6FVAV3nHsrgw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_UvB5xXlaE0-Xayjecd5Hlg_13_24">66,370</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_tbCCSo-VQ0OEj-rVsGwf0Q_13_27">66,370</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances at December&#160;31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Ix8JVts4dk2Q4KuWLN5TqQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_CvQxuSQIzUC0JvHLYRaXEQ_14_2">250,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5lfujqng8EmU7km7KzrW3g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Uyll2y6HfEm8Uez7cHvlow_14_7">845,385</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mjwCtJPi90OdodwExzzejw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc__ZG4--H-ZUyajnIpECqEBw_14_12">93,582,991</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mjwCtJPi90OdodwExzzejw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_PGerqLtrtkqnGb9amX8AaA_14_15">9</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember_r-s7nx-j2UO579la2vbCYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_cHcybJmHvEuAVfLYVhTbZQ_14_18">4,329</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nEUVoh_PAEuYAh0Emg965A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_gZtXNYgvxUmlvLSRdIox7A_14_21">359,906</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3jzMDFTC6Uqy-qcl2JQMLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_vHYR6lXDLUeBy55TEfG-OQ_14_24">251,844</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_wNxzaptANUq1FeqoER_thw_14_27">112,400</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Common stock issuable&#160;- Founders Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember__24V726k9U-PKRzgLSlEoA" decimals="-3" format="ixt:numdotdecimal" name="mbio:StockIssuanceCommonStockIssuableDuringPeriod" scale="3" id="Tc_ZKSxmWT2_kK1jaDdNCyxaw_15_18">1,109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="mbio:StockIssuanceCommonStockIssuableDuringPeriod" scale="3" id="Tc_0URL02BfNESlEqosuzJXDQ_15_27">1,109</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common shares&#160;- Founders Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SQivjg3JZ0yfjAKfVkr_KQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Tc_1X2S-vLT8k2jgcINZseYIw_16_12">2,536,607</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember__24V726k9U-PKRzgLSlEoA" decimals="-3" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodValueIssuedForFoundersAgreement" sign="-" scale="3" id="Tc_zpY0PLe20UGzwPtI_KsGKQ_16_18">4,212</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WOYfueKSEuJAaVfesRtjg" decimals="-3" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodValueIssuedForFoundersAgreement" scale="3" id="Tc_B4q7F6kxykqGiqKDNIbPxg_16_21">4,212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common shares, net of offering costs - At-the-Market Offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SQivjg3JZ0yfjAKfVkr_KQ" decimals="INF" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodSharesAtMarketOffering" scale="0" id="Tc_iZqBH1t4HEeNMtslk0lbuA_17_12">7,878,095</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SQivjg3JZ0yfjAKfVkr_KQ" decimals="-3" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodValueAtMarketingOffering" scale="3" id="Tc_lnmHp2wQQEOGNKbcc7EV2A_17_15">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WOYfueKSEuJAaVfesRtjg" decimals="-3" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodValueAtMarketingOffering" scale="3" id="Tc_CWDBFewNAEKNs9H3ki_dlw_17_21">6,498</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodValueAtMarketingOffering" scale="3" id="Tc_pmUCwj6ys0e3ee0fy5DSxA_17_27">6,500</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common shares - Equity fee on At-the-Market Offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SQivjg3JZ0yfjAKfVkr_KQ" decimals="INF" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering" scale="0" id="Tc_8gzPi7yq4kuGh71A5TETig_18_12">248,247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember__24V726k9U-PKRzgLSlEoA" decimals="-3" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering" sign="-" scale="3" id="Tc_gCzIEtPMa0Kfg4qYAJhPkw_18_18">117</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WOYfueKSEuJAaVfesRtjg" decimals="-3" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering" scale="3" id="Tc_LROMbi7u_kaUUtK5OakvlA_18_21">283</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering" scale="3" id="Tc_TELLi5TlX0eDo-TcfM8ucg_18_27">166</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common shares under ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SQivjg3JZ0yfjAKfVkr_KQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_BJXG9smsHkKFd5-HtQsaUA_19_12">330,833</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WOYfueKSEuJAaVfesRtjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_DASnJdemUUat-bh7jqADkw_19_21">206</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_SN-e8bHMVEe541ZW6i9LHA_19_27">206</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common shares - Equity fee on RWG Debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SQivjg3JZ0yfjAKfVkr_KQ" decimals="INF" format="ixt:numdotdecimal" name="mbio:AdditionsToApicEquityFeesOnRwgDebtShares" scale="0" id="Tc_w3tEEDIWX0W4GZphOhhA9Q_20_12">954,927</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WOYfueKSEuJAaVfesRtjg" decimals="-3" format="ixt:numdotdecimal" name="mbio:AdditionsToApicEquityFeesOnRwgDebt" scale="3" id="Tc_PvODu4JhQUOJBWkLKqdwOg_20_21">750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="mbio:AdditionsToApicEquityFeesOnRwgDebt" scale="3" id="Tc_oefCnwEZZU-oFRZuyWtbSw_20_27">750</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of warrants for RWG Debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WOYfueKSEuJAaVfesRtjg" decimals="-3" format="ixt:numdotdecimal" name="mbio:AdditionsToApicFromIssuanceOfRwgDebtWarrants" scale="3" id="Tc_iYZFUvd8Sk6scPek79dXrA_21_21">384</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="mbio:AdditionsToApicFromIssuanceOfRwgDebtWarrants" scale="3" id="Tc_23UociLho0-PSTlKq_1mNg_21_27">384</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SQivjg3JZ0yfjAKfVkr_KQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_q3I2e392mk-qfi5xKABjUA_22_12">969,963</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WOYfueKSEuJAaVfesRtjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_KQVNfswvwUOQcOsaZw0YmQ_22_21">2,283</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_JDu946ShR0mNQa8MOzGhzA_22_27">2,283</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_sJ_f6Z0h_0mK2WrP7jFDCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_zk-CEbm1cEKr-HqNOs0X3g_23_24">77,525</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_bNo77X5nPUG-sAJk4oT7OA_23_27">77,525</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances at December&#160;31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_iXjE7NHXYk6rJeTAc6GwOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_ObUS6ZW76kyfZPpbRlkmFg_24_2">250,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dcd2JnkRoUu5jv05PZ7fwA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_DyQxE71x20ijNo5UI6ZczQ_24_7">845,385</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u6IrjKOtBU2wn6oRGZSpiw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_EYnouPc-ZUyz0eMVVHWCZg_24_12">106,501,663</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u6IrjKOtBU2wn6oRGZSpiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_X1nQj54G0keoprIh61m7PA_24_15">11</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember_9MQl4Tri8UWaL1Az0682Pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc__-yiQhzJpkGIOP8hGD-Wvg_24_18">1,109</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_P9_Uj5uTOkOfoQ-1eRQEMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_sxA3-AZUp0W9jF_Xl6acLw_24_21">374,522</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6zho2C1h60K0Lzm1bSUQng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_6tphp59s_k2CjSEMG1B65g_24_24">329,369</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_BfGInsZDsEmePe1bLnkYIw_24_27">46,273</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">See accompanying notes to financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ed0ff0c7_a29c_4245_bb90_9025fd017f53"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-weight:bold;text-align:center;margin:0pt;">MUSTANG BIO,&#160;INC.</p><a id="STATEMENTSOFCASHFLOWS_1249"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-weight:bold;text-align:center;margin:0pt;">STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_f6ec014a_540d_49e6_a7ec_68c1a11a6dc0"></a><a id="Tc_QSUBWZPsu0q_qplmmmQuvA_1_2"></a><a id="Tc_W8u-iMuhQEirkLjFxNsWmw_2_2"></a><a id="Tc_SBbo-Idmk0i7jIlYBwqWng_2_5"></a><a id="Tc_fBtB_E5mj0S4jSrGSdnOvA_3_0"></a><a id="Tc_ncQydkHkBkaFXGvKircz9A_4_0"></a><a id="Tc_-0GRMtUWBUuKWA4emt7i6Q_4_2"></a><a id="Tc_bQv7I0LWm0iUmQaz1d9lTA_4_5"></a><a id="Tc_kMQTz78EAUaCAAE7LEf52w_5_0"></a><a id="Tc_j6CcT8IzzE6cmQfZMY7V9Q_6_0"></a><a id="Tc_hZqstlO9BkCF-FtY_mV5Wg_7_0"></a><a id="Tc_ukp6iDUdwkafubfDe6oRLg_8_0"></a><a id="Tc_3mnfcDf9Jk-4-HBoc0b8kg_9_0"></a><a id="Tc_jNvMnNf4JEaqSsGs96A_wA_10_0"></a><a id="Tc_XxjqYdbE9U63ev0IE0CESA_11_0"></a><a id="Tc_z7-sfffOhkus-gBHrTdeQg_12_0"></a><a id="Tc_zTnWchILAUGjwJ4AnKXGBQ_13_0"></a><a id="Tc_styr-JklOkalre7PLdpu6A_14_0"></a><a id="Tc__okT2SPGR0isSKk1gcYwOA_15_0"></a><a id="Tc_-F9PSDNekkWfKy0KsFdTZQ_16_0"></a><a id="Tc_IQAhJXmBHU6jwiNsXt5Lkw_17_0"></a><a id="Tc_sqGus1dGDkCyppbw7jMI_w_18_0"></a><a id="Tc_OzodYm4A_0SCzHAcHRJzcw_19_0"></a><a id="Tc_OjeSdcpDTESK9k2gCu1FRw_20_0"></a><a id="Tc_acoOnD--eEekUUzV9ltf6g_21_0"></a><a id="Tc_-TUuMyC0Ak-rYIgiPR-imA_22_0"></a><a id="Tc_U13reNpxgUa6Mw7emT-wzQ_24_0"></a><a id="Tc_ac0gZXbXyUqOm3p0_CX7Hw_25_0"></a><a id="Tc_PxTmlvOmBEah5QrjgVJHUw_26_0"></a><a id="Tc_a1_pUwpeB0S-Lpxq_dGGFQ_27_0"></a><a id="Tc_yuR6joLwf0yF8wu5LMKOxQ_28_0"></a><a id="Tc_Yt5e_HHg6kqBIYcwsUaiUQ_30_0"></a><a id="Tc_1RJTSv8TMk278dgBA8Uhkw_31_0"></a><a id="Tc_nHRcQmBjXU6K2kGVX18XnA_32_0"></a><a id="Tc_w-YILIAD00q70_PfMmUZQA_33_0"></a><a id="Tc_kUdoBB8VUEmYxxVYC4x_fA_34_0"></a><a id="Tc_TL7geBSdmUaWUApQcBrB4w_35_0"></a><a id="Tc_UMBrdZg5FU6WorPjjP3dzA_36_0"></a><a id="Tc_z4NgE8kyGEyKTjIlfZQz9w_38_0"></a><a id="Tc__G3BhhCsD0eXhT4yioJP5Q_39_0"></a><a id="Tc_avmNxL1OPUy4Mo984gIpdA_40_0"></a><a id="Tc_zDaHxZPQtkOzJq_3gvaUFQ_40_2"></a><a id="Tc_xKwbCxW4cESUT0o-juhNAw_40_5"></a><a id="Tc_MmrRVAyOnk2Nle-ANGAlbg_42_0"></a><a id="Tc_OuBDBWEAfkmb7mRIvukqVA_43_0"></a><a id="Tc_OZzi989DVEKuetVe46vPGg_43_2"></a><a id="Tc_6dt8VfSf5EKMpQzp-L1qAg_43_5"></a><a id="Tc_ZeuBrdCnrkuQi6AfLtCscQ_45_0"></a><a id="Tc_uq6eOwMM80q4egoDQUM96w_46_0"></a><a id="Tc_IXL5K0MUnU67Pbb-RWOctg_46_2"></a><a id="Tc_q_0IP1FDIUm0cXAf-l71HA_46_5"></a><a id="Tc_ZT_NrZYaHE2Y4NNf4OAO1w_47_0"></a><a id="Tc_x8MCs1zSKkSTEMQ1ZiiKYA_47_2"></a><a id="Tc_anlW22BM30GRONNhBVRjxA_47_5"></a><a id="Tc_QQ84MbMKuEiGD8R1JGy4Mg_48_0"></a><a id="Tc_PyI9ee5psEKhJanBynWqTw_48_2"></a><a id="Tc_PyUUxPPuGUKzGoJdhgmb5A_48_5"></a><a id="Tc_aJoyJRO15kyjtvivFsLYJw_49_0"></a><a id="Tc_IN3IyI8EMkCN0prRnFzjCA_49_2"></a><a id="Tc__LerOFMWIkqfMS_VnAaMcA_49_5"></a><a id="Tc_ovfuScrlXUKRKHzypbUSQg_50_0"></a><a id="Tc_J55gxkGDdEKN-zGz-icfyQ_50_2"></a><a id="Tc_FYIBch_D9Ei68XQSFaLYxg_50_5"></a><a id="Tc_TCFtqqfu0kONm_XPLOqPuA_51_0"></a><a id="Tc_bdfddua8Z0u_Uw314EyjBw_51_2"></a><a id="Tc_9xp3ODJ1Ek-Gg17ygw0GoA_51_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Flows from Operating Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_gcJFJvmEjEG900aWBTAA-g_4_3">77,525</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_wa8WMfKchUuiC10bZgN67g_4_6">66,370</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common shares - Equity fee on At-the-Market Offering to Fortress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="mbio:IssuanceOfCommonSharesEquityFeeOnAtMarketOffering" scale="3" id="Tc_5StkHk9TqU6pJ6d3CzPEIA_6_3">166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="mbio:IssuanceOfCommonSharesEquityFeeOnAtMarketOffering" scale="3" id="Tc_f_QPrPiCv0KTiZXPFu9IAg_6_6">1,884</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Common shares issuable for Founders Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="mbio:AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance" scale="3" id="Tc_BTNFK6OqRkC6PeuV9zTnDg_7_3">1,109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="mbio:AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance" scale="3" id="Tc_SFsLRrq3lEiQFrX6Tsk8xQ_7_6">4,212</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Research and development - licenses acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="mbio:ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense" scale="3" id="Tc_M1Gy-zHsxEeQO8fKIiuyYg_8_3">365</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="mbio:ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense" scale="3" id="Tc_Xtzzj8RYtECIBfqrMwTDHw_8_6">1,630</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common shares - Equity fee to Fortress on note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="mbio:CommonShareIssuanceFeesRelatedPartyDebt" scale="3" id="Tc_JjYVB_b18EOJHhcbQV53Qg_9_3">750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:zerodash" name="mbio:CommonShareIssuanceFeesRelatedPartyDebt" scale="3" id="Tc_WscypbKOZEis1nYqEuq2Cw_9_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_sDce4ST-1UCfMFJwegl46g_10_3">2,283</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_2ADDno9_z0iXRLjfpqYlKw_10_6">3,308</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_qVb26YfsZUyFham9DH2ysg_11_3">2,723</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_LBV_NcqW2EmjFTUjWVkf_g_11_6">2,167</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_AnzGLM-iBEOWUF4GoqEN5g_12_3">470</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:zerodash" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_UWvpJ1B2ZUeFaK8x-waC7g_12_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_xUzFNOaNO02F79c6fjoYsw_13_3">308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_W3jjsAEQdEW-wJdGiB70Ug_13_6">139</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Loss on disposal of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="3" id="Tc_i9HI-dE0rUec2MwNrZtIaA_14_3">255</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="Tc_W0eqz-VC9kmCUiUxmrWeug_14_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_SBhfL2Z9r0ShPWhyCLWt-Q_16_3">1,021</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_3JVyPDeBr0-fIeCLq3OSMQ_16_6">401</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Other receivables - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" sign="-" scale="3" id="Tc_CU_ve4RwdkqLjD3Iw4ye6w_17_3">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="Tc_Tu_0m1DVEUuroN7riojsQQ_17_6">35</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="mbio:IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties" scale="3" id="Tc_0r7qVh8CZkK6fzG7Q_dXBQ_18_3">5,257</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="mbio:IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties" sign="-" scale="3" id="Tc_3fCIwkGNSke3WT-JKAb6pQ_18_6">408</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Payable and accrued expenses&#160;- related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="3" id="Tc_VT-Tg1tcL06B25tgmlgoZQ_19_3">43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="3" id="Tc_f4vBpWoewEa8RM4mp1_gIA_19_6">233</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Deferred income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="Tc_4jByaGPQ5EqZFo4nVYtFnQ_20_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="Tc_8dy4bdepLEy08ZDU0tnakg_20_6">270</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="mbio:IncreaseDecreaseInLeaseLiabilities" scale="3" id="Tc_oNoqXVt8wUmO1aoMDVEK3A_21_3">263</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="mbio:IncreaseDecreaseInLeaseLiabilities" scale="3" id="Tc_EyqosT-ALkKUfVI_oIMIIA_21_6">296</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_dKnmQhYInE6xItaUUhh7DQ_22_3">65,066</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_ukYfJmzt1kmTXaBpryTKHQ_22_6">53,667</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Flows from Investing Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Purchase of research and development licenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_vBoDwg3mOECVDrN1ETmZtA_25_3">365</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_FNl5yip3W0CmzGWw9DXfYg_25_6">1,380</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from the sale of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_Wq0AM_C_GEiwdoxbTvdHyw_26_3">127</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_EHxi4H8tdkuy53LQ1cSq3A_26_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Purchase of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_v8dxgpVxiky_gmhhBRbNxA_27_3">2,714</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_vxuq1cN5HkWa68htp0K0mQ_27_6">3,986</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc__Rw6XWPJ9U-Vz8x7LyeR6g_28_3">2,952</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_ZRGTSk6U30u3U5estGqN3w_28_6">5,366</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Flows from Financing Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of common shares - At-the-Market Offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="mbio:ProceedsFromIssuanceOfCommonSharesAtMarketOffering" scale="3" id="Tc_43_AdKafGEOzKFkqx7-gVQ_31_3">6,623</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="mbio:ProceedsFromIssuanceOfCommonSharesAtMarketOffering" scale="3" id="Tc_Uk0fICkOu0GSRYm6Ln4bUA_31_6">71,919</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Offering costs for the issuance of common shares - At-the-Market Offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="mbio:OfferingCostsForIssuanceOfCommonSharesAtMarketOffering" scale="3" id="Tc_9AxTnJbWFkiMJ7PpXyNBUw_32_3">123</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="mbio:OfferingCostsForIssuanceOfCommonSharesAtMarketOffering" scale="3" id="Tc_gTyccPzwckmjF7w0gVG5sA_32_6">1,381</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from debt issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" id="Tc_dBApSzGezkaPBHQTVy1ONg_33_3">30,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" id="Tc_FHMert--gkS5_PGwhRYf1A_33_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Fees paid on the issuance of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="Tc_VVrQEOuagE-AnB5eHVU6KA_34_3">2,650</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="Tc_y4EFg3iBYEOsaQbemhqfTw_34_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of common shares under ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_YSbWJMIYoU25rloSQMbGqg_35_3">206</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_YhYsLt_0v0C9num7uAhxYw_35_6">309</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_1u5p5l4ORUeZi_GXpUkCig_36_3">34,056</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_vtUDP-LXVkuFldoWwYaK4g_36_6">70,847</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net change in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="3" id="Tc_KjELpEhsBUOli-0pju-xVA_38_3">33,962</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="Tc_X3YgEdd3PUy2O95NyPiOcA_38_6">11,814</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash, beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_wO4E69btJUm62uaU3GEo2Q_39_3">110,618</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2020_Jb9gSnd2k0CKnqyK9MTFMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Wjx6VE9pMUmg1owhkI-F4w_39_6">98,804</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash, cash equivalents and restricted cash, end of the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_6sOmw6nykkqvylCgDJOcFQ_40_3">76,656</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_VQ82cucnlUqBntuVusRPow_40_6">110,618</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental disclosure of cash flow information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_kgubZO3igECgPIjxVxYykQ_43_3">2,710</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestPaidNet" scale="3" id="Tc_EG_AfSzTaEm-ivlvkNvqUQ_43_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental disclosure of noncash activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Fixed assets (acquired but not paid)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_MLmRD6-8MkCH3NWbZckdPg_46_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_5416xUfWx0G7Kys8ZBKNXA_46_6">1,270</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common shares&#160;- Founders Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssued1" scale="3" id="Tc_rTm2Q6aS80aFAdwfRkCEQA_47_3">4,212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssued1" scale="3" id="Tc_jYF6kGwvBUeGZxNVb3TxRA_47_6">7,577</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Research and development licenses included in accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:zerodash" name="mbio:ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid" scale="3" id="Tc_JQu6I-2sIUeRW9ZMO9raHA_48_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="mbio:ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid" scale="3" id="Tc_e4RW4SVPK0ORVLCDqI2v-Q_48_6">250</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Note payable final payment fee (incurred but not paid)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="Tc_mlJx93LEiEizlAPe-52PCQ_49_3">1,050</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="Tc_USihD9wOeEOHONcsaSDwVg_49_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of warrants - note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="Tc_im6EL78oHUWyWbvv_GyOzQ_50_3">384</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="Tc_oUiivimTOECDR_tnAI8gKg_50_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities arising from obtaining right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="mbio:LeaseLiabilitiesArisingFromObtainingRightOfUseAssets" scale="3" id="Tc_IGJW0zXRkk-K7Owt-oUcuw_51_3">2,176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="mbio:LeaseLiabilitiesArisingFromObtainingRightOfUseAssets" scale="3" id="Tc_Xj6oaDBPTUu2wyaWwTQlfA_51_6">101</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See accompanying notes to financial statements.</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7b3383c9_231d_4141_b577_abee0922ae89"></a><a id="NotestoFinancialStatements_21312"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Notes to Financial Statements</p><a id="_Hlk131000861"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_P-G7HBzxTEivV0xyr3l9uw" continuedAt="Tb_P-G7HBzxTEivV0xyr3l9uw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;1&#160;- Organization and Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Mustang Bio,&#160;Inc. (the &#8220;Company&#8221; or &#8220;Mustang&#8221;) was incorporated in Delaware on March&#160;13, 2015. Mustang is as a clinical-stage biopharmaceutical company focused on translating today&#8217;s medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. The Company may acquire rights to these technologies by licensing the rights or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company is a majority-controlled subsidiary of Fortress Biotech,&#160;Inc. (&#8220;Fortress&#8221; or &#8220;Parent&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has incurred substantial operating losses and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of December 31, 2022, the Company had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_MD73VC8uRkuCI9Dvdc7ysQ">329.4</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has funded its operations to date primarily through the sale of equity and via debt raises, including its loan and financing agreement with Runaway Growth Finance Corporation (the &quot;Lender&quot;), herein referred to as the &quot;Term Loan.&quot; The Company expects to continue to use the proceeds from previous financing transactions primarily for general corporate purposes, including financing the Company&#8217;s growth, developing new or existing product candidates, and funding capital expenditures, acquisitions and investments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company will be required to expend significant funds in order to advance the development of its product candidates. The Company will require additional financings through equity and debt offerings, collaborations and licensing arrangements or other sources to fully develop, prepare regulatory filings, obtain regulatory approvals and commercialize its existing and any new product candidates. The continuation of our business as a going concern is dependent upon raising additional capital and eventually attaining and maintaining profitable operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205-40, Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. In performing its evaluation, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40, the future receipt of potential funding from future equity or debt issuances, and the potential sale of priority review vouchers cannot be considered probable at this time because these plans are not entirely within the Company&#8217;s control nor have been approved by the Board of Directors as of the date of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company&#39;s expectation to generate operating losses and negative operating cash flows in the future, as well as projections of future inability to meet certain financial debt covenants, and the need for additional funding to support its planned operations raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern for a period of one year after the date that these consolidated financial statements are issued. The Company continues to monitor its spending by reducing 2023 expenses, which may include projected savings through delaying the development timelines of certain programs, or termination of such programs and the pursuit of additional cash resources through public or private equity or debt financings. The Company has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these consolidated financial statements.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_P-G7HBzxTEivV0xyr3l9uw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that may be necessary if the Company is unable to continue as a going concern. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:2pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_kctH5Oo3xkO9DjZRHYXHiQ" continuedAt="Tb_kctH5Oo3xkO9DjZRHYXHiQ_cont1" escape="true"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_2rhg2oyLlUCQkd396nfyOA" continuedAt="Tb_2rhg2oyLlUCQkd396nfyOA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;2&#160;- Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_tJLhzqJzjESJaAXVJcT6Nw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The Company has <ix:nonFraction unitRef="Unit_Standard_item_e-lAqZ63ukC9AQjaK0X33Q" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="INF" format="ixt-sec:numwordsen" name="mbio:NumberOfSubsidiaries" scale="0" id="Narr_5t2Z9sQ2MU-b35mcPUtVeQ">no</ix:nonFraction> subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">All inter-company transactions between Fortress and Mustang are classified as due from or due to related party in the financial statements. The Company believes that the assumptions underlying the financial statements are reasonable.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_Hh8d9CqPy0KRWaCQm0SoXg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Segments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="Unit_Standard_segment_8GyIjrAsdkK2LxrNi5qQyQ" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_fyTB8nw7QUOHph26ZYMHXg">one</ix:nonFraction> operating and <span style="-sec-ix-hidden:Hidden_1DzwVi4TWE68-iARaVzCtQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting</span></span> segment.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:UseOfEstimates" id="Tb_53Wkegm-sEOOeb6ODXFatw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_kb7Xf8HkPkOcyxqJX_jjeQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company considers highly liquid investments with a maturity of three&#160;months or less when purchased to be cash equivalents. Cash and cash equivalents at December&#160;31,&#160;2022 and 2021, consisted of cash and certificates of deposit in institutions in the United States. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are currently adequately protected against credit risk.&#160;At times, portions of the Company&#8217;s cash and cash equivalents may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation (FDIC) limits, though the Company customarily invests a significant portion of its cash in CDARS accounts to maximize FDIC insurance coverage across its holdings.&#160;As of December 31, 2022, the Company had not experienced losses on these accounts, and management believes the Company is not exposed to significant risk on such accounts.&#160;</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:ReceivablesPolicyTextBlock" id="Tb_iaY0CYX9Mk-952bZJr3Cww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Receivables &#8211; Related Party</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Other receivables include amounts due to the Company from Fortress and Journey Medical Corporation, both related parties, and is recorded at the invoiced amount.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_STu9Xet_rUqULPSO72oh3w" continuedAt="Tb_STu9Xet_rUqULPSO72oh3w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company records cash held in an escrow account as a security deposit for the manufacturing facility in Worcester, Massachusetts, as restricted cash. The Company had $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_W9gXwQA4y02K3RqBBXJMOA"><ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_xo5ZZsXBW0e5BcVPjLDzlA">1.0</ix:nonFraction></ix:nonFraction> million in restricted cash as of December&#160;31,&#160;2022 and 2021, respectively. The Facility initiated cell processing operations for personalized CAR T and gene therapies in 2018.</p></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_kctH5Oo3xkO9DjZRHYXHiQ_cont1" continuedAt="Tb_kctH5Oo3xkO9DjZRHYXHiQ_cont2"><ix:continuation id="Tb_2rhg2oyLlUCQkd396nfyOA_cont1" continuedAt="Tb_2rhg2oyLlUCQkd396nfyOA_cont2"><ix:continuation id="Tb_STu9Xet_rUqULPSO72oh3w_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_o2BDbl6qLUuGU8-iPsbbAw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Property, plant and equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Property and equipment, net, which consists mainly of laboratory equipment, are carried at cost less accumulated depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_5OGx7ayVU0mn5u5QHqaymQ">five years</ix:nonNumeric>, using the straight-line method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Property and equipment&#160;- Construction in Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In connection with the Company&#8217;s cell processing facility, the Company incurred costs for the design and construction of the facility and the purchase of equipment; $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_RjfDOebswEyLEhoZaNQWKg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="Narr_sYPLgKqsv0GaDydMHo2m5A">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_wsvscCuqjEmydGhY6i4new" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="Narr_vrmCz0tTPkOExF2pmzw04A">2.0</ix:nonFraction> million are recorded in fixed assets - construction in process on the balance sheet at December&#160;31,&#160;2022 and 2021, respectively. Upon completion of the facility&#8217;s construction, all costs associated with the buildout will be recorded as leasehold improvements and amortized over the shorter of the estimated useful lives or the term of the respective leases, upon the improvement being placed in service.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_cS_LNSrXY06S3DqMqTt2Mg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company&#8217;s behalf will be expensed as services are rendered or when the milestone is achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, costs associated with regulatory filings, laboratory costs and other supplies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 730-10-25-1, <i style="font-style:italic;">Research and Development, </i>costs incurred in obtaining technology licenses are charged to research and development expense if the technology licensed has not reached commercial feasibility and has no alternative future use. The licenses purchased by the Company require substantial completion of research and development, regulatory and marketing approval efforts to reach commercial feasibility and has no alternative future use. Accordingly, the total purchase price for the licenses acquired is reflected as research and development&#160;- licenses acquired in the Company&#8217;s Statements of Operations.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="mbio:AnnualStockDividendPolicyTextBlock" id="Tb_18es77844k6gt8xGpvibPA" continuedAt="Tb_18es77844k6gt8xGpvibPA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Annual Stock Dividend</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In July&#160;2016, in connection with the Amended and Restated Articles of Incorporation, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_7_22_2016_To_7_22_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_FiUSuj1xYkGpO1xt7_NOcA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsShares" scale="0" id="Narr_o3COtuwmnkaDGwgMCq7wXg">250,000</ix:nonFraction> Class&#160;A preferred shares to Fortress. The Class&#160;A preferred shares entitle the holder to a stock dividend equal to <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_7_22_2016_To_7_22_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_FiUSuj1xYkGpO1xt7_NOcA" decimals="3" format="ixt:numdotdecimal" name="mbio:DilutedOutstandingEquityPercentage" scale="-2" id="Narr_w4e5FsuMwEmYgSqkKH5VUQ">2.5</ix:nonFraction>% of the fully diluted outstanding equity of the Company (the &#8220;Annual Stock Dividend&#8221;). The Annual Stock Dividend was part of the consideration payable for formation of the Company and the identification of certain assets, including the license contributed to Mustang by Fortress (see Note&#160;4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In June&#160;2018, in connection with the Amended and Restated Articles of Incorporation, the Company amended the Annual Stock Dividend &#160;due date from March&#160;13th to January&#160;1st.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Pursuant to the Amended and Restated Articles of Incorporation, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockDividendsShares" scale="0" id="Narr_9W2OZdSpCkicbQZaryojpA">2,807,008</ix:nonFraction> shares of common stock to Fortress for the Annual Stock Dividend, representing <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w" decimals="3" format="ixt:numdotdecimal" name="mbio:DilutedOutstandingEquityPercentage" scale="-2" id="Narr_0-OfDFFnP0OMgPwo_dLWFQ">2.5</ix:nonFraction>% of the fully-diluted outstanding equity of Mustang on January 1, 2023. This was shown in the Statement of Stockholders&#8217; Equity at December 31, 2022, as Common stock issuable &#8211; Founders Agreement. The Company recorded an expense of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_hRHdDMHNcUuPmSQBOPtXWA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_Eeii2p6GBkCQ3EYohO7F5w">1.1</ix:nonFraction> million in research and development - licenses acquired related to these issuable shares during the year ended December&#160;31,&#160;2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the Amended and Restated Articles of Incorporation, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_Trkkxq84fU-Vd0RoRhj2NQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockDividendsShares" scale="0" id="Narr_NZCzEMom9kuFBjrYg5YMsg">2,536,607</ix:nonFraction> shares of common stock to Fortress for the Annual Stock Dividend, representing <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_Trkkxq84fU-Vd0RoRhj2NQ" decimals="3" format="ixt:numdotdecimal" name="mbio:DilutedOutstandingEquityPercentage" scale="-2" id="Narr_4ATMb-5qw0a_rs_P3obFPA">2.5</ix:nonFraction>% of the fully-diluted outstanding equity of Mustang on January 1, 2022. This was shown in the Statement of Stockholders&#8217; Equity at December&#160;31,&#160;2021, as Common stock issuable &#8211; </p></ix:nonNumeric></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_kctH5Oo3xkO9DjZRHYXHiQ_cont2" continuedAt="Tb_kctH5Oo3xkO9DjZRHYXHiQ_cont3"><ix:continuation id="Tb_2rhg2oyLlUCQkd396nfyOA_cont2" continuedAt="Tb_2rhg2oyLlUCQkd396nfyOA_cont3"><ix:continuation id="Tb_18es77844k6gt8xGpvibPA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Founders Agreement. The Company recorded an expense of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_KBjGOoU-1UiBWoztZE_WAg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_nrMgClkIrk2tlehgIPYyig">4.2</ix:nonFraction> million in research and development - licenses acquired related to these issuable shares during the year ended December 31, 2021.<span style="color:#201f1e;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;background:#ffffff;"> </span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_0w1zLaeki02HKNKr5VYssg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Fair Value Measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 0pt;">Level 1:&#160;&#160;&#160;&#160;Quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 10pt 0pt;">Level 2:&#160;&#160;&#160;&#160;Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;">Level 3:&#160;&#160;&#160;&#160;Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_SvX_n7vugECJyM9Qlk-GGQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the balance sheet as both a right of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#39;s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred. In calculating the right of use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_Ll_fJCABlUiePIc3rzP8xw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model or 409a valuations, as applicable. The assumptions used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_oBx4cjOMEkOk7arLaRzPTw" continuedAt="Tb_oBx4cjOMEkOk7arLaRzPTw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if management believes it is more likely than not that the deferred tax assets </p></ix:nonNumeric></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_34a38be4_4f80_405d_8c5d_5047af94954b"></a><a id="Tc_c6DqsKR99kSKsD4CWyCptw_1_2"></a><a id="Tc_3nAbRMwus06dtnglgYbIeQ_2_2"></a><a id="Tc_EPQsp_s2Fke8IQGvjz3aoA_2_4"></a><a id="Tc_X6KkAvCA8kCNNYXFSo22Yw_3_0"></a><a id="Tc_QAj6hasii0K3chofJ-SVHw_4_0"></a><a id="Tc_2Fy-Elx55U-R-D6GALoe8w_5_0"></a><a id="Tc_DsIeXjFTjE67aCLA33Mtpg_6_0"></a><a id="Tc__oydITTKYEaZV5UEnv1Zwg_7_0"></a><a id="Tc_NK77JUPTm02YCq5DJ0hvAg_8_0"></a><ix:continuation id="Tb_kctH5Oo3xkO9DjZRHYXHiQ_cont3"><ix:continuation id="Tb_2rhg2oyLlUCQkd396nfyOA_cont3"><ix:continuation id="Tb_oBx4cjOMEkOk7arLaRzPTw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_q8__QwgBK0iCqfQtt1lEFA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period less unvested restricted stock. Since dividends are declared, paid and set aside among the holders of shares of common stock and Class&#160;A common shares pro-rata on an as-if-converted basis, the two-class method of computing net loss per share is not required. Diluted net loss per share does not reflect the effect of shares of common stock to be issued upon the exercise of warrants or outstanding Class&#160;A preferred shares, as their inclusion would be anti-dilutive.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_l3Jega6nQUqBm8EDHpCXug" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_rZrGkA6BLUa3b3OQehnYJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_g1Q_OoY2Ek6I52QT4qn6KQ_3_2">1,052,920</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_0k_G4cx5Y0ap-y77lBqB_g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_1fguRp_FZUGZZjJdwj5RDw_3_4">3,308,654</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ycveH83leUebYfW_8jtr1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_uS42PbZqp0O5qPlNf_1QzA_4_2">1,141,675</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_HTuh90RZrk-KPSURpslalg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_kGAIqnAvN0iCsYfn5dea2g_4_4">1,141,675</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Class&#160;A Preferred Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredClassAMember_fKYAiDFShUe0rn_iP9LuDg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_at14GrQR406RVi5BfMfAGg_5_2">250,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredClassAMember_VD6cIIAU5EO3zkHQr1i38g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_KoVp_A-VFE6RYZba8yjX1g_5_4">250,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_jj2nVe7aqU6w_0C3fUd4mA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_k7Qtfq8cQEi9A2qXP4NhhQ_6_2">510,245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_3jPgbp30DEyg4u1vnCNMRw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_RMGvNFnD8Em6Ocvlp4sY9g_6_4">280,983</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_dvSvij2w6keF_tXo9314yw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_zbfQAFDJc02VVooVll_yTA_7_2">2,488,687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_-StlwZNLwUqM0yBk4WhqVw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_1IKGK5VHWUi8eIVB-F24eA_7_4">2,335,557</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_mDwG3XhUc0mxs1s7DiEjfw_8_2">5,443,527</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_xBMMe35WbEeDsG2dMn0J9Q_8_4">7,316,869</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_pKcQuya82Uy53IapIKdIHQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1" scale="0" id="Narr_S54Aj1k_KUOUR9RHBeyYag">no</ix:nonFraction> components of other comprehensive loss, and therefore, comprehensive loss equals net loss.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In August 2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2020-06,&#160;<i style="font-style:italic;">&#8220;Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity,&#8221;</i>&#160;which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption will be permitted. The Company is currently evaluating the impact of this standard on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">In June 2016, FASB issued ASU 2016-13,&#160;</span><i style="font-style:italic;background:#ffffff;">&#8220;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;</i><span style="background:#ffffff;">. ASU 2016-13 requires that expected credit losses relating to financial assets are measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. Recently, the FASB issued the final ASU to delay adoption for smaller reporting companies to calendar year 2023. The Company is currently assessing the impact of the adoption of this ASU on its financial statements</span>.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_896e3475_9532_4841_bd0e_cbaca3b78397"></a><a id="Tc_255aDQYEL0-SaHJiENUcyA_1_2"></a><a id="Tc_FAoCrX91VEmriCe0rOPvDA_2_0"></a><a id="Tc_3qx6AFSZkUigeggLaogafw_2_2"></a><a id="Tc_0W4OZQUsVki9gV75hfV12A_2_5"></a><a id="Tc_GjfXUvL6rUOD_531Ht-_Xw_3_0"></a><a id="Tc_yj2O9SC3h0SN4Cw5pJlnTQ_4_0"></a><a id="Tc_R7UlPQuf0UukoeUDdBCVgg_4_2"></a><a id="Tc_QUMCTtFym0iCSDB1S5wsoA_4_5"></a><a id="Tc_gxTaPrE9qkGyjI-k0a2svA_5_0"></a><a id="Tc_AEMpn_j1tUeE2gUP2YDz8g_6_0"></a><a id="Tc_QLIKxqS-ikupr2_jH4ZIJg_7_0"></a><a id="Tc_Q6LJKDMNaEGfDZSEszq74A_8_0"></a><a id="Tc_tfS9H68nwUGS_D9fA2ovlQ_9_0"></a><a id="Tc_wKH0RwZa5EmixPr5yfX4uQ_10_0"></a><a id="Tc_WxhJ1IcyIkqZ3b6BIe4kfQ_11_0"></a><a id="Tc_AW5haVStjEukClkgAAqAOw_12_0"></a><a id="Tc_wMe4q-ZjH0SlCNGxSDIuEw_12_2"></a><a id="Tc_f3GtNFtNWEuZHyzwC7di0A_12_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_n9Bp7pzF5kaiZDvV453rRg" continuedAt="Tb_n9Bp7pzF5kaiZDvV453rRg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;3&#160;- License, Clinical Trial and Sponsored Research Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Research and Development Expenses&#160;&#8211; All Licenses</b></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_bEUyP985oUaHNsVrsVxqYQ" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="Tb_O4IsLMYdx028I3ZrDqNnnA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the&#160;years ended December 31, 2022 and 2021, the Company recorded the following expense in research and development for licenses acquired:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">City of Hope National Medical Center</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">CD123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_X-M3RGE5aUmOLFk49REASw" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_sUYNrOyhlUKKwAXsy9qBiw_4_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_eqbNchRq0EKHKjmh0pCfeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_j2yux-F6Tk-1vGxHwAWyPw_4_6">250</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">IV/ICV</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_IvIcvProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_HiZjKumNT0SZKUFTzFtdpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_9sbWNen5BEuNW1RvtZNrng_5_3">125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_IvIcvProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_cGzyMH7f9k618wUdJrWh1w" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_sJvfFDBYrUG9AgN5TOd2Gw_5_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">PSCA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_eypHnY-B1U6jSlIjModjUw" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_30CYzMHIzU-JUNtknAN0gQ_6_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_5UGfc7o3YkaygLrJClTgXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_PDmZRDaaeEioeDz9HMqKsg_6_6">250</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">HER2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_-Awulcu8EUuW8KUUEOHfpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_xeJzEmKnG06oFAzi_JVmGw_7_3">200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_h2tn3x-z7UuAoS7r_ftqoQ" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_MiiaHwA0UUmpo2ZkYn4wrQ_7_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">CSL Behring (Calimmune)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_2GiFSZkrMEqa7kSRo1sWhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_zShoUBzozU2VVMdMULUoRQ_8_3">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_-IXYKwdDrEqLg2blggBbbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_QDOt7zlTKE69zMNErwAP4g_8_6">30</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Leiden University  Medical Centre</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_ecAzAIw_WEizUmdbx34e8w" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_IVAm5tBS20usCyycOIdoBQ_9_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_S6NInTxBvUmnCq_IJxa26g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_xqOvi_yQ2ECmUKFxESCbhw_9_6">350</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mayo Clinic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_MMf1jaQkGEia07UBzms6Wg" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_JPca3aipJkqA1YlRn8fYeg_10_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_DB6MYEz08kyNAf6LM9F59A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_AUz1UfCvi0Czp1ZeJ_cRSQ_10_6">750</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fortress PIK Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_FortressBiotechIncMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_3Vh1oZCe0keLsUyEjlCcKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_EYBHzr2lmEi9q8i0RNKzOQ_11_3">1,109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_FortressBiotechIncMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_qumY3pBwC0W2YfvPR7QXUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_DYsvOdo2cUO3VN0EU99OgA_11_6">4,212</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_bEUyP985oUaHNsVrsVxqYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_4yKIoqA2q0WH_smf0qpagw_12_3">1,474</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_5I7r1d0H1kGd9E-MDAoc_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_5KiVmUV7EECFLSjNNVUdgw_12_6">5,842</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">License Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">City of Hope</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">CD123 License (MB-102)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In February&#160;2017, the Company entered into an Amended and Restated Exclusive License Agreement with the City of Hope National Medical Center (&#8220;COH&#8221;) to acquire intellectual property rights pertaining to CD123 specific CAR T technology. Pursuant to this agreement, the Company and COH acknowledged that an upfront fee was previously paid. In addition, COH is eligible to receive an annual maintenance fee of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_GxvcEL9tsUGqvDvu2x4erg" decimals="0" format="ixt:numdotdecimal" name="mbio:AnnualMaintenanceFeePayable" scale="0" id="Narr_4opelZuPDU-YuAs1WMLgjw">25,000</ix:nonFraction> and milestone payments totaling $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_GxvcEL9tsUGqvDvu2x4erg" decimals="-5" format="ixt:numdotdecimal" name="mbio:MilestonesPayableUnderArrangement" scale="6" id="Narr_7Nv9g784IE6H1BFgQEccbw">14.5</ix:nonFraction> million upon the achievement of certain milestones. Royalty payments in the mid-single digits are due on net sales of licensed products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2021, the Company recorded a non-refundable milestone payment of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_eqbNchRq0EKHKjmh0pCfeQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="Narr_PIl-dcEHbkGQMixEjgcisw">0.3</ix:nonFraction> million for the 24<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> patient treated in connection with the CD123 study. <span style="background:#ffffff;">There were&#160;</span><ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_X-M3RGE5aUmOLFk49REASw" decimals="-5" format="ixt-sec:numwordsen" name="mbio:NonRefundableMilestonePayments" scale="6" id="Narr_3p4kx_83tkCquUcjTt5Maw">no</ix:nonFraction><span style="background:#ffffff;">&#160;such expenses for the year ended December 31, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">IV/ICV </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In February&#160;2017, the Company entered into an exclusive license agreement (the &#8220;IV/ICV License&#8221;) with COH to acquire intellectual property rights in patent applications related to the intraventricular and intracerebroventricular methods of delivering T cells that express CARs. Pursuant to the IV/ICV License, in March&#160;2017, the Company paid COH an upfront fee of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_IvIcvProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_kFOATtbMhEW9Vm5Z1U3trQ" decimals="-5" format="ixt:numdotdecimal" name="mbio:PaymentOfUpfrontFees" scale="6" id="Narr_IkMwcfuUCEWEyly-mm3cHQ">0.1</ix:nonFraction> million. COH is eligible to receive a milestone payment totaling approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_IvIcvProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_kFOATtbMhEW9Vm5Z1U3trQ" decimals="-5" format="ixt:numdotdecimal" name="mbio:MilestonesPayableUnderArrangement" scale="6" id="Narr_w4IXpVdmh02AgOMJ9a1cjA">0.1</ix:nonFraction> million, upon and subject to the achievement of a milestone, and an annual maintenance fee of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_IvIcvProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_kFOATtbMhEW9Vm5Z1U3trQ" decimals="0" format="ixt:numdotdecimal" name="mbio:AnnualMaintenanceFeePayable" scale="0" id="Narr_ZODCLt2V2kKPgIgkFIawpw">25,000</ix:nonFraction>. Royalty payments in the low single digits are due on net sales of licensed products. The Company is obligated to pay COH a&#160;percentage of certain revenues received in connection with a sublicense in the mid-thirties, but no such payments are due in connection with sublicenses that are granted in conjunction with the sublicense of other CAR T programs that are licensed from COH to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">For the year ended December 31, 2022, the Company expensed a non-refundable milestone payment of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_IvIcvProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_HiZjKumNT0SZKUFTzFtdpw" decimals="-5" format="ixt:numdotdecimal" name="mbio:NonRefundableMilestonePayments" scale="6" id="Narr_ioFHnIDKyUCZM4L1ivqIwg">0.1</ix:nonFraction> million in connection with the first patent within the Patent Rights issued. <span style="background:#ffffff;">There were&#160;</span><ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_IvIcvProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_cGzyMH7f9k618wUdJrWh1w" decimals="-5" format="ixt-sec:numwordsen" name="mbio:NonRefundableMilestonePayments" scale="6" id="Narr_q5X8qXKtN0-0dMKzcD3Log">no</ix:nonFraction><span style="background:#ffffff;">&#160;such expenses for the year ended December 31, 2021.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_n9Bp7pzF5kaiZDvV453rRg_cont1" continuedAt="Tb_n9Bp7pzF5kaiZDvV453rRg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">PSCA License (MB-105)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2017, the Company entered into an exclusive license agreement with COH for the use of prostate stem cell antigen (&#8220;PSCA&#8221;) CAR T technology to be used in the treatment of prostate cancer, pancreatic cancer and other solid tumors. Pursuant to this agreement, the Company paid an upfront fee of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_5_1_2017_To_5_31_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_jWZU2RYRvEei-C0QMO7buA" decimals="-5" format="ixt:numdotdecimal" name="mbio:PaymentOfUpfrontFees" scale="6" id="Narr_LEQvEyiNyUa5UN0_l0_Bmg">0.3</ix:nonFraction> million and pays an annual maintenance fee of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_5_1_2017_To_5_31_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_jWZU2RYRvEei-C0QMO7buA" decimals="0" format="ixt:numdotdecimal" name="mbio:AnnualMaintenanceFeePayable" scale="0" id="Narr_Fqe0pldnwkCVhVG_OlWU9g">50,000</ix:nonFraction>. Additional payments are due for the achievement of <ix:nonFraction unitRef="Unit_Standard_item_e-lAqZ63ukC9AQjaK0X33Q" contextRef="Duration_5_1_2017_To_5_31_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_jWZU2RYRvEei-C0QMO7buA" decimals="INF" format="ixt-sec:numwordsen" name="mbio:NumberOfMilestonesMeasured" scale="0" id="Narr__eFvjWedO0i-7TqB30saSQ">ten</ix:nonFraction> development milestones totaling $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_5_1_2017_To_5_31_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_jWZU2RYRvEei-C0QMO7buA" decimals="-5" format="ixt:numdotdecimal" name="mbio:MilestonesPayableUnderArrangement" scale="6" id="Narr_fRCFQWtKU0yRMLzKkHiCVQ">14.9</ix:nonFraction> million, and royalty payments in the mid-single digits are due on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2021, the Company expensed a non-refundable milestone payment of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_5UGfc7o3YkaygLrJClTgXQ" decimals="-5" format="ixt:numdotdecimal" name="mbio:NonRefundableMilestonePayments" scale="6" id="Narr_74KXrjrEMUe_6svNwcaQDA">0.3</ix:nonFraction> million for the twelfth patient treated in the Phase 1 clinical study of MB-105 at COH. <span style="background:#ffffff;">There were&#160;</span><ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_eypHnY-B1U6jSlIjModjUw" decimals="-5" format="ixt-sec:numwordsen" name="mbio:NonRefundableMilestonePayments" scale="6" id="Narr_7UPEVuEG9kOwD3wyY8wjQQ">no</ix:nonFraction><span style="background:#ffffff;">&#160;such expenses for the year ended December 31, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">HER2 License (MB-103)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;margin:0pt;">On May&#160;31, 2017, the Company entered into an exclusive license agreement with the COH for the use of human epidermal growth factor receptor 2 (&#8220;HER2&#8221;) CAR T technology, which will initially be applied in the treatment of glioblastoma multiforme. Pursuant to this agreement, the Company paid an upfront fee of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_5_1_2017_To_5_31_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_OhC3qwHZBUG5jIk8E5CveA" decimals="-5" format="ixt:numdotdecimal" name="mbio:PaymentOfUpfrontFees" scale="6" id="Narr_9Y68tnzBYkiQxyf-W3RuQw">0.6</ix:nonFraction> million and pays an annual maintenance fee of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_5_1_2017_To_5_31_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_OhC3qwHZBUG5jIk8E5CveA" decimals="-3" format="ixt:numdotdecimal" name="mbio:AnnualMaintenanceFeePayable" scale="0" id="Narr_sMPNF9EthkyRvpkFj1JXhw">50,000</ix:nonFraction> (which began in 2019). Additional payments are due for the achievement of <ix:nonFraction unitRef="Unit_Standard_item_e-lAqZ63ukC9AQjaK0X33Q" contextRef="Duration_5_1_2017_To_5_31_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_OhC3qwHZBUG5jIk8E5CveA" decimals="0" format="ixt-sec:numwordsen" name="mbio:NumberOfMilestonesMeasured" scale="0" id="Narr_NiE9lkXsekCh8EplNYmhPw">ten</ix:nonFraction> development milestones totaling $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_5_1_2017_To_5_31_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_OhC3qwHZBUG5jIk8E5CveA" decimals="-5" format="ixt:numdotdecimal" name="mbio:MilestonesPayableUnderArrangement" scale="6" id="Narr_OsuJO0RzOkeL6VZ0YaAvhg">14.9</ix:nonFraction> million, and royalty payments in the mid-single digits are due on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 10pt 0pt;">For the year ended, December 31, 2022, the Company expensed a non-refundable milestone payment of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_-Awulcu8EUuW8KUUEOHfpQ" decimals="-5" format="ixt:numdotdecimal" name="mbio:NonRefundableMilestonePayments" scale="6" id="Narr_JqBAT330XUa5naVvpGk69A">0.2</ix:nonFraction>&#160;million in connection with the first patent within the Patent Rights issued. There were&#160;<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_h2tn3x-z7UuAoS7r_ftqoQ" decimals="-5" format="ixt-sec:numwordsen" name="mbio:NonRefundableMilestonePayments" scale="6" id="Narr_Ggew1Vkwb023KKsxblpkuQ">no</ix:nonFraction>&#160;such expenses for the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">CSL Behring (Calimmune) License</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On August 23, 2019, the Company entered into a non-exclusive license agreement with CSL Behring (Calimmune, Inc.) (&#8220;Calimmune License&#8221;) for the rights to the Cytegrity<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> stable producer cell line for the production of viral vector for our lentiviral gene therapy program for the treatment of XSCID (MB-107 and MB-207). We previously licensed the XSCID gene therapy program from St. Jude Children&#8217;s Research Hospital, Inc. (&#8220;St. Jude&#8221;) in August 2018. Pursuant to the terms of the Calimmune License, the Company paid an upfront fee of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_8_23_2019_To_8_23_2019_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_GZks_7XceUyp2L41ZnWzfw" decimals="-5" format="ixt:numdotdecimal" name="mbio:PaymentOfUpfrontFees" scale="6" id="Narr_VipM45SDo0SO_d3rx2Z_tQ">0.2</ix:nonFraction> million. CSL Behring is eligible to receive additional payments totaling $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_8_23_2019_To_8_23_2019_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_GZks_7XceUyp2L41ZnWzfw" decimals="-5" format="ixt:numdotdecimal" name="mbio:MilestonesPayableUnderArrangement" scale="6" id="Narr_6GXfDJb7dUqAtMWszj2n8Q">1.2</ix:nonFraction> million upon the achievement of <ix:nonFraction unitRef="Unit_Standard_item_e-lAqZ63ukC9AQjaK0X33Q" contextRef="Duration_8_23_2019_To_8_23_2019_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_GZks_7XceUyp2L41ZnWzfw" decimals="0" format="ixt-sec:numwordsen" name="mbio:NumberOfMilestonesMeasured" scale="0" id="Narr_QMYAGAiOik-XaDrQaKg2IQ">three</ix:nonFraction> development and commercialization milestones. Royalty payments in the low-single digits are due on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">For the year ended December 31, 2022 and 2021, the Company expensed a non-refundable milestone payments of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_2GiFSZkrMEqa7kSRo1sWhQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="0" id="Narr_zQNGACgOmE6gP-lTu08eow">40,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_-IXYKwdDrEqLg2blggBbbg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="0" id="Narr_BgBvYWH9dkKdqwOf5HAdrw">30,000</ix:nonFraction>, respectively, in connection with the Calimmune license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">LUMC License (MB-110)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">On September 8, 2021, the Company entered into an exclusive, worldwide licensing agreement with LUMC for the use of a gene therapy under development for the treatment of severe immunodeficiency caused by RAG1 deficiency (the &#8220;LUMC License&#8221;). Pursuant to the LUMC License, the Company expensed an upfront fee of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_9_8_2021_To_9_8_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_8Z3KAV2B-EeZv3xSHR1e1g" decimals="-5" format="ixt:numdotdecimal" name="mbio:PaymentOfUpfrontFees" scale="6" id="Narr_zPyStYJxhE-i0Bbf9k3z0Q">0.4</ix:nonFraction>&#160;million. Additional payments are due for the achievement of&#160;certain&#160;development milestones totaling up to $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_9_8_2021_To_9_8_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_8Z3KAV2B-EeZv3xSHR1e1g" decimals="-6" format="ixt:numdotdecimal" name="mbio:MilestonesPayableUnderArrangement" scale="6" id="Narr_6iMImiJd_EOThuxIZzSYNw">31</ix:nonFraction>&#160;million and royalty payments in the low to mid-single digits as a percentage of revenue are due on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the year ended December 31, 2021, the Company expensed an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_S6NInTxBvUmnCq_IJxa26g" decimals="-5" format="ixt:numdotdecimal" name="mbio:NonRefundableMilestonePayments" scale="6" id="Narr_LpJRTXxKSUiKqMQmOygdDg">0.4</ix:nonFraction>&#160;million in connection with the LUMC License. <span style="background:#ffffff;">There were&#160;</span><ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_ecAzAIw_WEizUmdbx34e8w" decimals="-5" format="ixt-sec:numwordsen" name="mbio:PaymentOfUpfrontFees" scale="6" id="Narr_1U48VhlLDEO_3Z8uHmpqCw">no</ix:nonFraction><span style="background:#ffffff;">&#160;such expenses for the year ended December 31, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Mayo Clinic - CAR T Technology License</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">On April 1, 2021, the Company entered into an exclusive license agreement with Mayo Clinic for a novel technology that may be able to transform the administration of CAR T therapies and has the potential to be used as an off-the shelf therapy. Pursuant to this agreement, the Company paid an upfront fee of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_4_1_2021_To_4_1_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_agKp6cvBpEy4-mIqOjcSeg" decimals="-5" format="ixt:numdotdecimal" name="mbio:PaymentOfUpfrontFees" scale="6" id="Narr_lCkjCNwTakOlqwdKBVzOAA">0.8</ix:nonFraction>&#160;million and will pay an annual maintenance fee of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_4_1_2021_To_4_1_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_M1lvnrfyyUG8MMd-TFM3OA" decimals="0" format="ixt:numdotdecimal" name="mbio:AnnualMaintenanceFeePayable" scale="0" id="Narr_chip0dSSAkGPemKV5Y7Thw">25,000</ix:nonFraction>. Additional payments are due for each of two licensed products for the achievement of&#160;<ix:nonFraction unitRef="Unit_Standard_Milestone_13Bi5jCZBUqZT3I2C4rjww" contextRef="Duration_4_1_2021_To_4_1_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_M1lvnrfyyUG8MMd-TFM3OA" decimals="0" format="ixt-sec:numwordsen" name="mbio:NumberOfMilestonesMeasured" scale="0" id="Narr_OUXYZdaBAUCsGeX9gcoafQ">eleven</ix:nonFraction>&#160;development and </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8c39e92a_54c1_48e4_9da5_2f79f1d26265"></a><a id="Tc_vfj3DKpSbkmUI1KA_cZrQQ_1_2"></a><a id="Tc_Ighh_ROAtEKEtZcHMZRVgQ_2_0"></a><a id="Tc_Q55DQAIij02XC0tXph6mhw_2_2"></a><a id="Tc_iZgXL8hN8UiZUSdJSlSADw_2_5"></a><a id="Tc_UzQloDUQS0uGq5kYQLNudA_3_0"></a><a id="Tc_tZmjLNnrJEG3U9S2Kcj7cw_3_2"></a><a id="Tc_Um0G4D_2YU-9dte6XfBdhA_3_5"></a><a id="Tc_EwAU1X0H4kOXjgqo6CSk8w_4_0"></a><a id="Tc_6FGdUMKq8kyBqVfubLySOw_5_0"></a><a id="Tc_8wb7KYJIjUiY9tZQAD7hSA_6_0"></a><a id="Tc_EOzQ16Pu3UugLXJtLMz5Mw_7_0"></a><a id="Tc_yhdinLVLiUeb_NswwdcbZw_8_0"></a><a id="Tc_OJfPSbRVqE2KZPvoqdNzWg_9_0"></a><a id="Tc_gyrJo0noME6gUbYnSgIg_w_10_0"></a><a id="Tc_EqpT7-EGMUaZbSa_5vzmgg_11_0"></a><a id="Tc_X1FiptlHQ0mTpqnvWjdv2A_12_0"></a><a id="Tc_Uc-zwVMpAEC6M5yg8Zj2Fg_13_0"></a><a id="Tc_32Ai2VamEk2pCm1h5TZ6Lw_13_2"></a><a id="Tc_8nU2wz0SyES-NNNTurxiUg_13_5"></a><ix:continuation id="Tb_n9Bp7pzF5kaiZDvV453rRg_cont2" continuedAt="Tb_n9Bp7pzF5kaiZDvV453rRg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">commercial milestones totaling up to $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_4_1_2021_To_4_1_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_M1lvnrfyyUG8MMd-TFM3OA" decimals="-5" format="ixt:numdotdecimal" name="mbio:MilestonesPayableUnderArrangement" scale="6" id="Narr_0TEK2CTFUk2pFgekjVErxQ">92.6</ix:nonFraction>&#160;million per product, and royalty payments in the mid-single digits as a percentage of revenue are due on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">For the&#160;year ended December 31, 2021, the Company expensed an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_DB6MYEz08kyNAf6LM9F59A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="Narr_QZaCa6Mc8kuuMRQFJXra9Q">0.8</ix:nonFraction>&#160;million pursuant to the terms of the license agreement. There were&#160;<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_MMf1jaQkGEia07UBzms6Wg" decimals="-5" format="ixt-sec:numwordsen" name="mbio:PaymentOfUpfrontFees" scale="6" id="Narr_tlCcmCJ4D0Wfx8zprQfZYA">no</ix:nonFraction>&#160;such expenses for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Research and Development Expenses&#160;- Sponsored Research and Clinical Trial Agreements</b></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Vx1emwLJJ0qXsajS4OcXww" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="Tb_TVBirgOLM0qwXH45BCsu1A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the&#160;year ended December 31, 2022 and 2021, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">City of Hope National Medical Center</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_aP7yNOKuS0aTGB-ItbnSAA" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_5Aq-OuyEb0KbljliINDrSg_3_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_0NxXjiJgYkGL9rgKRUKG0w" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_ubbigLQ1f020sTsSycjJVg_3_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">CD123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_flIxGqK8EE-qTKhiUM7P5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_dMt_p4J3OU2zEveUDf9yqw_4_3">166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_1tC8VQmSzUSfIFLGkJX9ig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_A0_RIFKgDkGV76DjcZpOzQ_4_6">301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">IL13R&#945;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_GJMbltW_ckGM-82fZ6QN9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_-_3v0G-arUS5oFDf2PXpbQ_5_3">1,486</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_7XG-WubxyUykOLnPy8K1fQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_-TE2P7x_bEa3Hyx2xWIPsw_5_6">1,169</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">CS1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cs1ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_OpIS0Aptykyt0fbMp5ngcw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_8bo7Gg3U10iA38pvjgNTHw_6_3">482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cs1ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_-91cVSuwk066vgPNrl9tAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_1V-Kl7lHaUehjcPE9HU5NA_6_6">608</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">HER2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_nzRdZgaBgkaKZuJTpHtWXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_yjvF8xY-QkuHsEgsOjnBhA_7_3">784</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Avzs-VjlYkyzUP2irGzjQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_yZIttLOTCkaODVoNSud3AQ_7_6">697</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">PSCA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_LFLvm316o0SOUKQxhoo0Mw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_22tRDaOpY0u7hacxmQWVlA_8_3">103</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_VrwnpcakNUyyqsooiwPWOA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_Oh-EvSpicEy8PA4tqZCWiw_8_6">107</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fred Hutchinson Cancer Center - CD20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_AHlPXFWbm0S4f23bwODBgw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_fZ5Y2HpVo0SEWrgM60aa6g_9_3">1,987</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_g-WN3OcgMk2PMIpOmGZ7LA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_V1EAxMtr906-b3hRKM7DoA_9_6">1,979</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">St. Jude Children&#39;s Research Hospital&#160;- XSCID</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_WndiQxEyWkK5zt6u8QU19g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_yx5J19l4vUmAjAry1ZyG8Q_10_3">508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_QpA72oZJUkisoiKeboPylg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_SNr68MoqlUm047t5y2SzJA_10_6">865</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LUMC - RAG1 SCID</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_srt_ProductOrServiceAxis_mbio_Rag1ScidMb110Member_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_JHL0mUan5USsk0GX6mP-bA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_lCI6AmBq30SHjnFCy-gD2Q_11_3">505</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_srt_ProductOrServiceAxis_mbio_Rag1ScidMb110Member_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_KgtU9Mq_mkeeWrJ3yEjrEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_RaiMZZE7ykKAtdrIJ8Z7AQ_11_6">170</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mayo Clinic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_A95Rt4-jPk231qSpo9U-FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_I9Ki17mrYkKWNZPx0tBTKg_12_3">968</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_G3TY0ZFyQk2j7jey4doOng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_cBGiT2wLqUSTkC3ry_I5pw_12_6">695</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Vx1emwLJJ0qXsajS4OcXww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_utjR1-Of30KeGtljI6dwHA_13_3">6,989</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_ycCeI3y-e0qyb7nr_-5MKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_9L2VoiuedkeBI8yi48y0LQ_13_6">6,591</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">City of Hope</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">CD123 (MB-102) Clinical Research Support Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In February&#160;2017, the Company entered into a Clinical Research Support Agreement for CD123 (the &#8220;CD123 CRA&#8221;). Pursuant to the terms of the CD123 CRA the Company made an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_ejb848nGTkG3ypqRxMLthA" decimals="0" format="ixt:numdotdecimal" name="mbio:PaymentOfUpfrontFees" scale="0" id="Narr_kq182VjQP06SfyrvqNGD2w">19,450</ix:nonFraction> and will contribute an additional $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_ejb848nGTkG3ypqRxMLthA" decimals="-5" format="ixt:numdotdecimal" name="mbio:ResearchArrangementContributionPerPatient" scale="6" id="Narr_ENrzItgV9UugR8QcTIeT1Q">0.1</ix:nonFraction> million per patient in connection with the on-going investigator-initiated study. Further, the Company agreed to fund approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_ejb848nGTkG3ypqRxMLthA" decimals="-5" format="ixt:numdotdecimal" name="mbio:MilestonesPayableUnderArrangement" scale="6" id="Narr_A_dFVk2Ty0C6FubbCmjJxw">0.2</ix:nonFraction> million over <ix:nonNumeric contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_ejb848nGTkG3ypqRxMLthA" format="ixt-sec:durwordsen" name="mbio:ResearchArrangementTerm" id="Narr_0N1tH1xB30CRKUWekEj6rg">three years</ix:nonNumeric> pertaining to the clinical development of CD123. For the&#160;years ended December 31, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_flIxGqK8EE-qTKhiUM7P5g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_EvcWPCvrHU--hFZQpH0LUg">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_1tC8VQmSzUSfIFLGkJX9ig" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_ofHgwTU-fk6dXtvOJ50CmQ">0.3</ix:nonFraction> million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">IL13R&#945;2 (MB-101) Clinical Research Support Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In February&#160;2017, the Company entered into a Clinical Research Support Agreement for IL13R&#945;2 (the &#8220;IL13R&#945;2 CRA&#8221;). Pursuant to the terms of the IL13R&#945;2 CRA the Company made an upfront payment of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Qj0QYtgKVEW8_VkZm7xUBg" decimals="0" format="ixt:numdotdecimal" name="mbio:PaymentOfUpfrontFees" scale="0" id="Narr__Tkh3YYJQEGbR38eiob2_w">9,300</ix:nonFraction> and will contribute an additional $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Qj0QYtgKVEW8_VkZm7xUBg" decimals="-5" format="ixt:numdotdecimal" name="mbio:ContributionTowardPatientCosts" scale="6" id="Narr_9lB3vOc82U2uNTE9FpXxiQ">0.1</ix:nonFraction> million related to patient costs in connection with the on-going investigator-initiated study. Further, the Company agreed to fund approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Qj0QYtgKVEW8_VkZm7xUBg" decimals="-5" format="ixt:numdotdecimal" name="mbio:MilestonesPayableUnderArrangement" scale="6" id="Narr_m0V5ZBnhZ0-8pyFzCvgGBA">0.2</ix:nonFraction> million over <ix:nonNumeric contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Qj0QYtgKVEW8_VkZm7xUBg" format="ixt-sec:durwordsen" name="mbio:ResearchArrangementTerm" id="Narr_OqOuJunmA06tDrCW4bI9Xw">three years</ix:nonNumeric> pertaining to the clinical development of IL13R&#945;2. For the&#160;years ended December 31, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_GJMbltW_ckGM-82fZ6QN9A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_dNQaUrMrDUywJn54FqZPAQ">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_7XG-WubxyUykOLnPy8K1fQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_mP8lzz392kCx4sXC3UireA">1.2</ix:nonFraction> million, respectively, in research and development expenses under the IL13R&#945;2 CRA in the Statements of Operations pursuant to the terms of this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2020, the Company entered into a Clinical Research Support Agreement for the IL13R&#945;2-directed CAR T program for adult patients with leptomeningeal glioblastoma, ependymoma or medulloblastoma (the &#8220;IL13R&#945;2 Leptomeningeal CRA&#8221;). Pursuant to the terms of the IL13R&#945;2 Leptomeningeal CRA, the Company made an upfront payment of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_SW1jOKKvIUWxGq9g6tUp4A" decimals="0" format="ixt:numdotdecimal" name="mbio:PaymentOfUpfrontFees" scale="0" id="Narr_TNeIDBQ9FEKFF8HdStItWw">29,000</ix:nonFraction> and will contribute an additional $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_SW1jOKKvIUWxGq9g6tUp4A" decimals="-5" format="ixt:numdotdecimal" name="mbio:ResearchArrangementContributionPerPatient" scale="6" id="Narr_WrT7EoewAUCNKZXSxVjU1Q">0.1</ix:nonFraction> million per patient in connection with the on-going investigator-initiated study. Further, the Company agreed to fund approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_SW1jOKKvIUWxGq9g6tUp4A" decimals="-5" format="ixt:numdotdecimal" name="mbio:AnnualMaintenanceFeePayable" scale="6" id="Narr_qCJhxHboU0WvZR8bXiLYcg">0.2</ix:nonFraction> million annually pertaining to the clinical development of the IL13R&#945;2-directed CAR T therapy.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_n9Bp7pzF5kaiZDvV453rRg_cont3" continuedAt="Tb_n9Bp7pzF5kaiZDvV453rRg_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2020, the Company entered into a Sponsored Research Agreement (&#8220;SRA&#8221;) with COH to conduct combination studies of a potential IL13R&#945;2<i style="font-style:italic;"> </i>CAR and C134 oncolytic virus therapy. Pursuant to the SRA, the Company funded research in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_SW1jOKKvIUWxGq9g6tUp4A" decimals="-5" format="ixt:numdotdecimal" name="mbio:ResearchFundingAmount" scale="6" id="Narr_wL_MIjBGQEucOjZ6RanYjw">0.3</ix:nonFraction> million for the program. In November 2022, the SRA was amended to include additional funding of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_11_1_2022_To_11_30_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_J2PMFy7590ayhjU1Z1lmBg" decimals="-5" format="ixt:numdotdecimal" name="mbio:ResearchFundingAmount" scale="6" id="Narr_T73XanUp70SvAduygUJ4Wg">0.6</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In March 2021, the Company entered into a clinical research support agreement for an Institutional Review Board-approved, investigator-initiated protocol entitled: &#8220;Single Patient Treatment with Intraventricular Infusions of IL13R&#945;2-targeting and HER2-targeting CAR T cells for a Single Patient (UPN 181) with Recurrent Multifocal Malignant Glioma.&#8221; Pursuant to the terms of this agreement, the Company will contribute up to $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_3_1_2021_To_3_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_te1_6uZCuEC4P4P0W1cmfQ" decimals="-5" format="ixt:numdotdecimal" name="mbio:AnnualMaintenanceFeePayable" scale="6" id="Narr_Nsx65vwdAk6IKuYLAMWYOQ">0.2</ix:nonFraction>&#160;million in connection with the ongoing investigator-initiated study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">CS1 (MB-104) Clinical Research Support Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In June 2020, the Company entered into a clinical research support agreement with COH in connection with an Investigator-sponsored study conducted under an Institutional Review Board-approved, investigator-initiated protocol entitled: &#8220;Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CS1-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients with CS1+ Multiple Myeloma.&#8221; The CAR T being studied under this protocol has been designated as MB-104. Under the terms of the agreement the Company will reimburse COH for costs associated with this trial not to exceed $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_6_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cs1ProductOrProcessMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_-VT2Q3jlP0OWPKoY-Ng3pA" decimals="-5" format="ixt:numdotdecimal" name="mbio:MilestonesPayableUnderArrangement" scale="6" id="Narr_lOmjgEMsiU6pQxgw7__Zgg">2.4</ix:nonFraction>&#160;million. The agreement will expire upon the delivery of a final study report or earlier. For the&#160;years ended December 31, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cs1ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_OpIS0Aptykyt0fbMp5ngcw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_IXwbGGHwpk2qZ66RWeDY0g">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cs1ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_-91cVSuwk066vgPNrl9tAA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_KD2exAK-f0u9TJv-ZHgM3Q">0.6</ix:nonFraction> million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. Since inception, the Company has reimbursed COH $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cs1ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_EPbH-hiMk0qoLFPq4Tyodw" decimals="-5" format="ixt:numdotdecimal" name="mbio:ReimbursementOfFeesTotalPayments" scale="6" id="Narr_LwA2aGB3iUi-9VCT8RiH5Q">1.8</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">HER2 (MB-103) Clinical Research Support Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In September 2020, the Company entered into a clinical research support agreement with COH in connection with an Investigator-sponsored study conducted under an Institutional Review Board-approved, investigator-initiated protocol entitled: &#8220;Phase I Study of Cellular Immunotherapy using Memory-Enriched T Cells Lentivirally Transduced to Express a HER2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients with Recurrent/Refractory Malignant Glioma.&#8221; The CAR T being studied under this protocol has been designated as MB-103. Under the terms of the agreement the Company will pay COH $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_RkSGNTQj7kufffNWRIAKsA" decimals="0" format="ixt:numdotdecimal" name="mbio:MilestonesPayableUnderArrangement" scale="0" id="Narr_aa_x92N2k0u-Iz10G5UAyw">29,375</ix:nonFraction> upon execution and will reimburse COH for costs associated with this trial not to exceed $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_z0SUrOJETEa8go8i01WkEg" decimals="-5" format="ixt:numdotdecimal" name="mbio:MilestonesPayableUnderArrangement" scale="6" id="Narr_8YfpcBNs0USrXTQBMWW8_w">3.0</ix:nonFraction>&#160;million. The agreement will expire upon the delivery of a final study report or earlier. For the&#160;year ended December 31, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_nzRdZgaBgkaKZuJTpHtWXg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_NoWHt4GmDk6IL5-GmiXDhg">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Avzs-VjlYkyzUP2irGzjQg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr__VLGOkvFp0GLZ37aIMcdpA">0.7</ix:nonFraction> million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. Since inception, the Company has reimbursed $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_AbCiEvU7_0uU3dzq5HkUFg" decimals="-5" format="ixt:numdotdecimal" name="mbio:ReimbursementOfFeesTotalPayments" scale="6" id="Narr_j9rxBQMp9023MPDWtAZ8Jw">3.0</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">PSCA (MB-105)</i><i style="font-style:italic;"> Clinical Research Support Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In October 2020, the Company entered into a clinical research support agreement with COH in connection with an Investigator-sponsored study conducted under an Institutional Review Board-approved, investigator-initiated protocol entitled: &#8220;A Phase 1b study to evaluate PSCA-specific chimeric antigen receptor (CAR)-T cells for patients with metastatic castration resistant prostate cancer.&#8221; The CAR T being studied under this protocol has been designated as MB-105. Under the terms of the agreement the Company will pay COH $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_brP4CCoYMUKzdsYDsNVEpw" decimals="0" format="ixt:numdotdecimal" name="mbio:MilestonesPayableUnderArrangement" scale="0" id="Narr_-wF4AKhxg021ykSVHLWYtQ">33,000</ix:nonFraction> upon execution and will reimburse COH for costs associated with this trial not to exceed $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_wJVqrbyFSU-cHpd2pZX10g" decimals="-5" format="ixt:numdotdecimal" name="mbio:MilestonesPayableUnderArrangement" scale="6" id="Narr_K0-anN9jWkCukBfJuGa2iA">2.3</ix:nonFraction>&#160;million. &#160;The agreement will expire upon the delivery of a final study report or earlier. For the&#160;years ended December 31, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_LFLvm316o0SOUKQxhoo0Mw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_N0fyRbKaEkW6fqQuyWphmQ">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_VrwnpcakNUyyqsooiwPWOA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_W7kCUqh6eU-87Grt7Ny-pg">0.1</ix:nonFraction> million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. Since inception, the Company has reimbursed $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_cspaXnUxZku0Ws6QbCLXDg" decimals="-5" format="ixt:numdotdecimal" name="mbio:ReimbursementOfFeesTotalPayments" scale="6" id="Narr_BXaC4xQid0qBFzFU5hiceQ">0.4</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fred Hutch</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-weight:normal;">CD20 Clinical Trial Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On July&#160;3, 2017, in conjunction with the CD20 Technology License from Fred Hutch, we entered into an investigator-initiated clinical trial agreement (&#8220;CD20 CTA&#8221;) to provide partial funding for a Phase 1/2 clinical trial at Fred Hutch </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk98776328"></a><a id="Narr_77a3cIVNb0KnayeNUIh92Q"></a><ix:continuation id="Tb_n9Bp7pzF5kaiZDvV453rRg_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">evaluating the safety and efficacy of the CD20 Technology in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. In connection with the CD20 CTA, the Company agreed to fund up to $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_7_3_2017_To_7_3_2017_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_CcHvzBIXtUODWCVXYAQe_w" decimals="-5" format="ixt:numdotdecimal" name="mbio:MilestonesPayableUnderArrangement" scale="6" id="Narr_5tFlNo4e5UeXgm5aP3J4lg">5.3</ix:nonFraction> million of costs associated with the clinical trial, which commenced during the fourth quarter of 2017. In November 2020, the CD20 CTA was amended to include additional funding of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_nx8c3dUXCUmIniCJJw81FQ" decimals="-5" format="ixt:numdotdecimal" name="mbio:AdditionalMilestonesPayableUnderArrangement" scale="6" id="Narr_vhowvR6_tEia5DsUG2fpMw">1.8</ix:nonFraction> million for the treatment of five patients with chronic lymphocytic leukemia and other research costs. In January 2022, the CD20 CTA was amended to include additional funding of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_k8cUiopjJ0W74a5rURwE8g" decimals="-5" format="ixt:numdotdecimal" name="mbio:AdditionalMilestonesPayableUnderArrangement" scale="6" id="Narr_aSuHqZGUuUefwZRcK47ifQ">2.2</ix:nonFraction> million increasing the total payment obligation of the Company in connection with the CD20 CTA not to exceed $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_HChGYU6CSUCiuMb3wOIWmA" decimals="-5" format="ixt:numdotdecimal" name="mbio:AdditionalMilestonesPayableUnderArrangement" scale="6" id="Narr_ukPZLfbiNke3mT_VWRtCxw">9.3</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">For the&#160;years ended December 31, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_ClinicalTrialAgreementsMember_Cyw5EJBd1UirM-BcQ7nr3Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_Qs0c0buN8UauCdLgYSdG8w">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_ClinicalTrialAgreementsMember_IjKtndA3yU-D5J-KXPKfPw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_UBHll0SqGEyiva2zY9L5JA">2.0</ix:nonFraction> million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. Since inception, the Company has reimbursed Fred Hutch $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_ClinicalTrialAgreementsMember_rf7xSABuqkO4KGuRWtqIrw" decimals="-5" format="ixt:numdotdecimal" name="mbio:ReimbursementOfFeesTotalPayments" scale="6" id="Narr_aO0XKM1lBU-HJglNxRZ37w">7.2</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">XSCID (MB-107) Data Transfer Agreement with St. Jude </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In June 2020, the Company entered into a Data Transfer Agreement with St. Jude under which we will reimburse St. Jude for costs associated with St. Jude&#8217;s clinical trial for the treatment of infants with XSCID. &#160;Pursuant to the terms of this agreement the Company paid an upfront fee of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_6_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_DataTransferAgreementMember_eFtEz1VOwUqbB4jKDO66nw" decimals="-5" format="ixt:numdotdecimal" name="mbio:PaymentOfUpfrontFees" scale="6" id="Narr_Y8iG3OEuwUCp1wGpqyBVsw">1.1</ix:nonFraction>&#160;million in July 2020, and will continue to reimburse St. Jude for costs incurred in connection with this clinical trial. For the&#160;years ended December 31, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_DataTransferAgreementMember_-H0TdacBZkabwWvQhfMbVw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_mqBkjomtsEGhHLP8VTyeDw">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_DataTransferAgreementMember_3BooSMscyEWc_UdmNkhn6w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_LYiOwDTFPkqhC1xHvy7cKA">0.9</ix:nonFraction> million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. Since inception, the Company has reimbursed St. Jude $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_DataTransferAgreementMember_jXidwRe_gUC02_iRlrhLpA" decimals="-5" format="ixt:numdotdecimal" name="mbio:ReimbursementOfFeesTotalPayments" scale="6" id="Narr_B2pVfWpBi0G57k3XflZfHw">3.0</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">RAG1-SCID (MB-110) Sponsored Research Support Agreement with LUMC</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;margin:0pt;">On September 8, 2021, in connection with the LUMC License, the Company entered into an SRA with LUMC under which the Company will fund research in the amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_9_8_2021_To_9_8_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_srt_ProductOrServiceAxis_mbio_Rag1ScidMb110Member_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_PDhxhJes-E2hyBDbO6sjlQ" decimals="-5" format="ixt:numdotdecimal" name="mbio:MilestonesPayableUnderArrangement" scale="6" id="Narr_RKL5d1Gpsky48FT1pehNbQ">0.5</ix:nonFraction>&#160;million annually over a period of&#160;<ix:nonNumeric contextRef="Duration_9_8_2021_To_9_8_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_srt_ProductOrServiceAxis_mbio_Rag1ScidMb110Member_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_PDhxhJes-E2hyBDbO6sjlQ" format="ixt-sec:durwordsen" name="mbio:ResearchArrangementTerm" id="Narr_UAhVmREqdUCJzRQwy0Rn2g">5 years</ix:nonNumeric>. The research performed pursuant to this agreement will support technology the Company has licensed from LUMC for the use of a gene therapy under development for the treatment of severe immunodeficiency caused by RAG1. For the&#160;year ended December 31, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_srt_ProductOrServiceAxis_mbio_Rag1ScidMb110Member_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_JHL0mUan5USsk0GX6mP-bA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_mSwCSvwV-UaV3S66A_Zy4A">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_srt_ProductOrServiceAxis_mbio_Rag1ScidMb110Member_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_KgtU9Mq_mkeeWrJ3yEjrEQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_cLrbX4rurkewJVo0ZAVLUA">0.2</ix:nonFraction> million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sponsored Research Support Agreement&#160;with Mayo Clinic&#160;&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In June 2021, the Company entered into an SRA with Mayo Clinic under which the Company will fund research in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_6_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_DEvYfskaDUCi1Vhldrs8yw" decimals="-5" format="ixt:numdotdecimal" name="mbio:MilestonesPayableUnderArrangement" scale="6" id="Narr_kxr_a_0L3EmRgWdHoituFg">2.1</ix:nonFraction>&#160;million over a period of&#160;<ix:nonNumeric contextRef="Duration_6_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_DEvYfskaDUCi1Vhldrs8yw" format="ixt-sec:durwordsen" name="mbio:ResearchArrangementTerm" id="Narr_vpDEgahwoEyR-2zHsl2Lug">two years</ix:nonNumeric>. The research performed pursuant to this agreement will support technology the Company has licensed from Mayo Clinic for a novel technology that may be able to transform the administration of CAR T therapies and has the potential to be used as an off-the-shelf therapy. In October 2022, the SRA was amended to include additional funding of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_10_1_2022_To_10_31_2022_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_9mu0h1oYPUqhtCqCC9mKMA" decimals="-5" format="ixt:numdotdecimal" name="mbio:AdditionalMilestonesPayableUnderArrangement" scale="6" id="Narr_p4FafwEG3UWQN_ATrx23ig">0.1</ix:nonFraction> million. For the&#160;year ended December 31, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_A95Rt4-jPk231qSpo9U-FQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_jGVhl3CxYU2mrQC8CDYNew">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_G3TY0ZFyQk2j7jey4doOng" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="Narr_tzJl_cDIQU27voYtkf-vyQ">0.7</ix:nonFraction> million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_vQHjGF4OGkqxFlS-ZwMxAQ" continuedAt="Tb_vQHjGF4OGkqxFlS-ZwMxAQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;4&#160;- Related Party Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Founders Agreement and Management Services Agreement with Fortress</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Effective March&#160;13, 2015, the Company entered a Founders Agreement with Fortress, which was amended and restated on May&#160;17, 2016, and again on July&#160;26, 2016 (the &#8220;Mustang Founders Agreement&#8221;). The Mustang Founders Agreement provides that, in exchange for the time and capital expended in the formation of Mustang and the identification of specific assets the acquisition of which result in the formation of a viable emerging growth life science company, Fortress loaned $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_jIA82Zn-S0-9OoqzDzR2cg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="6" id="Narr_fzFi0uOYdUWtAoZNmlFNyQ">2.0</ix:nonFraction> million, representing the up-front fee required to acquire the Company&#8217;s license agreement with COH. The Mustang Founders Agreement has a term of <ix:nonNumeric contextRef="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_jIA82Zn-S0-9OoqzDzR2cg" format="ixt-sec:durwordsen" name="mbio:FoundersAgreementTerm" id="Narr_zkjj5d65tUGXZK5dwz1oLQ">15 years</ix:nonNumeric>, which upon expiration automatically renews for successive <ix:nonNumeric contextRef="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_jIA82Zn-S0-9OoqzDzR2cg" format="ixt-sec:durwordsen" name="mbio:AgreementRenewalTerm" id="Narr_BHjkynBrZESytH3CEcK48Q">one-year</ix:nonNumeric> periods unless terminated by Fortress and the Company or a Change in Control (as defined in the Mustang Founders Agreement) occurs. Concurrently with the second amendment on July&#160;26, 2016, to the Mustang Founders Agreement, Fortress entered into an Exchange Agreement whereby Fortress exchanged its <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_u-nK5IHLB0it8Ss2uDQLIw" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="6" id="Narr_DrsgJe4WfESnpng06Ga4Ow">7.25</ix:nonFraction> million Class&#160;B Common shares for <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_VBMwjqeRtEqCOPPRYyGFBg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="6" id="Narr_ht8ozKuFt0C_4N_ioYO5Aw">7.0</ix:nonFraction> million common shares and <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_joFxX9w_pkCt5C4GrtBlWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_0WTUJ0uIeUCC4xs_GVTeSQ">250,000</ix:nonFraction> Class&#160;A Preferred shares. Class&#160;A Preferred Stock is identical to common stock other than as to voting </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk98854033"></a><ix:continuation id="Tb_vQHjGF4OGkqxFlS-ZwMxAQ_cont1" continuedAt="Tb_vQHjGF4OGkqxFlS-ZwMxAQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">rights, conversion rights and the PIK Dividend right (as described below). Each share of Class&#160;A Preferred Stock is entitled to vote the number of votes that is equal to one and one-tenth (<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_7_26_2016_To_7_26_2016_e467LFs_GEmfW2lDVRZA9Q" decimals="1" format="ixt:numdotdecimal" name="mbio:PreferredStockVotingRightsMultiplier" scale="0" id="Narr_C0GsRMwLbU-nqHUrf9ppGA">1.1</ix:nonFraction>) times a fraction, the numerator of which is the sum of (A)&#160;the shares of outstanding Mustang common stock and (B)&#160;the whole shares of Mustang common stock into which the shares of outstanding Class&#160;A Common Stock and Class&#160;A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class&#160;A Preferred Stock. Thus, the Class&#160;A Preferred Stock will at all times constitute a voting majority. Each share of Class&#160;A Preferred Stock is convertible, at Fortress&#8217; option, into <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_7_26_2016_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_zbvdgNhN6kuygnfc4J47nA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_C5ojn2Pd60KRhRuBddo6xw">one</ix:nonFraction> fully paid and nonassessable share of Mustang common stock, subject to certain adjustments. As holders of Class&#160;A Preferred Stock, Fortress will receive on each January&#160;1 (each a &#8220;PIK Dividend Payment Date&#8221;) until the date all outstanding Class&#160;A Preferred Stock is converted into common stock, pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (&#8220;PIK Dividends&#8221;) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half&#160;percent (<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_jIA82Zn-S0-9OoqzDzR2cg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_sJrVSCLj2UadLzIerDgmiw">2.5</ix:nonFraction>%) of Mustang&#8217;s fully-diluted outstanding capitalization on the date that is <span style="-sec-ix-hidden:Hidden_t6gbwtw4fkmKVT_BgWRqSA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> (1)&#160;business day prior to any PIK Dividend Payment Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As additional consideration under the Mustang Founders Agreement, Mustang will also: (i)&#160;pay an equity fee in shares of common stock, payable within <span style="-sec-ix-hidden:Hidden_IKJI1MNkyk-jVARLuqEz6w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> (5)&#160;business&#160;days of the closing of any equity or debt financing for Mustang that occurs after the effective date of the Mustang Founders Agreement and ending on the date when Fortress no longer has majority voting control in the Company&#8217;s voting equity, equal to two and one-half (<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w" decimals="3" format="ixt:numdotdecimal" name="mbio:EquityFeePercentageOfFinancing" sign="-" scale="-2" id="Narr_VCYkbmeDMECum7TyxSMneQ">2.5</ix:nonFraction>%) of the gross amount of any such equity or debt financing; and (ii)&#160;pay a cash fee equal to four and one-half&#160;percent (<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w" decimals="3" format="ixt:numdotdecimal" name="mbio:CashFeeAsPercentageOfAnnualNetSales" sign="-" scale="-2" id="Narr_SeBHs8okGUac-0lV9u-73g">4.5</ix:nonFraction>%) of the Company&#8217;s annual net sales, payable on an annual basis, within <span style="-sec-ix-hidden:Hidden_ZlvSq5CKKECYsdUUYJlnYw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ninety</span></span> (90)&#160;days of the end of each calendar&#160;year. In the event of a Change in Control, the Company will pay a one-time change in control fee equal to <ix:nonFraction unitRef="Unit_Standard_item_e-lAqZ63ukC9AQjaK0X33Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w" decimals="0" format="ixt-sec:numwordsen" name="mbio:ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate" scale="0" id="Narr_cGMROYjBC0WqtLiNOMT_XQ">five</ix:nonFraction> (5x) times the product of (A)&#160;net sales for the <span style="-sec-ix-hidden:Hidden_oihncYEzmEirIm889SKJsg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twelve</span></span> (12)&#160;months immediately preceding the change in control and (B)&#160;four and one-half&#160;percent (<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w" decimals="3" format="ixt:numdotdecimal" name="mbio:ChangeInControlFeeSpecifiedRateComponent" scale="-2" id="Narr_gLkcFcX7R0irdMSUAbcVVQ">4.5</ix:nonFraction>%) (see Note&#160;9).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Effective as of March&#160;13, 2015, the Company entered into a Management Services Agreement (the &#8220;MSA&#8221;) with Fortress, pursuant to which Fortress renders advisory and consulting services to the Company. The MSA has an initial term of <ix:nonNumeric contextRef="Duration_3_13_2015_To_3_13_2015_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_-NQvGLrolUaisD4xkEP_SA" format="ixt-sec:durwordsen" name="mbio:AgreementTerm" id="Narr_NgD8a4YnLEiu0WutNfnwbQ">five years</ix:nonNumeric> and is automatically renewed for successive <ix:nonNumeric contextRef="Duration_3_13_2015_To_3_13_2015_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_-NQvGLrolUaisD4xkEP_SA" format="ixt-sec:durwordsen" name="mbio:MsaAgreementRenewalTerm" id="Narr_xFyidaicfEibt6wtR6xOtA">five-year</ix:nonNumeric> terms unless terminated in accordance with its provisions. Services provided under the MSA may include, without limitation, (i)&#160;advice and assistance concerning any and all aspects of the Company&#8217;s operations, clinical trials, financial planning and strategic transactions and financings and (ii)&#160;conducting relations on behalf of the Company with accountants, attorneys, financial advisors and other professionals (collectively, the &#8220;Services&#8221;). The Company is obligated to utilize clinical research services, medical education, communication and marketing services and investor relations/public relation services of companies or individuals designated by Fortress, provided those services are offered at market prices. However, the Company is not obligated to take or act upon any advice rendered from Fortress and Fortress shall not be liable for any of its actions or inactions based upon their advice. Pursuant to the MSA and the Company&#8217;s Certificate of Incorporation, Fortress and its affiliates, including all members of the Company&#8217;s Board of Directors, will have no fiduciary or other duty to communicate or present any corporate opportunities to the Company or to refrain from engaging in business that is similar to that of the Company. In consideration for the Services, the Company will pay Fortress an annual consulting fee of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w" decimals="-5" format="ixt:numdotdecimal" name="mbio:AnnualConsultingFees" scale="6" id="Narr_gn2QnjcBpE6Cc_6WaM5Aqw">0.5</ix:nonFraction> million (the &#8220;Annual Consulting Fee&#8221;), payable in advance in equal quarterly installments on the first business day of each calendar quarter in each&#160;year, provided, however, that such Annual Consulting Fee shall be increased to $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w" decimals="-5" format="ixt:numdotdecimal" name="mbio:IncreaseInAnnualConsultingFees" scale="6" id="Narr_8Lu9DRLTPEWnYjzteL7ZnQ">1.0</ix:nonFraction> million for each calendar&#160;year in which the Company has net assets in excess of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_D02sY_Okb0CAJr_sq1tImg" decimals="-6" format="ixt:numdotdecimal" name="mbio:ExcessInNetAssetsValue" scale="6" id="Narr_uT1Rl_0WdEWLJDDYmdfdsQ">100</ix:nonFraction> million at the beginning of the calendar&#160;year. The Company records <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w" decimals="2" format="ixt-sec:numwordsen" name="mbio:PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses" scale="-2" id="Narr_Nm7U4Lrh4EelVGF7w5rMAw">fifty</ix:nonFraction> percent of the Annual Consulting Fee in research and development expense and <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w" decimals="2" format="ixt-sec:numwordsen" name="mbio:PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses" scale="-2" id="Narr_EAvAcp8L6EG_CYDoTNjQ7A">fifty</ix:nonFraction> percent in general and administrative expense in the Statement of Operations. For the&#160;years ended December 31, 2022 and 2021, the Company recorded expense of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="Narr_580LWLy4lUGHkCeXMtFIFA">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_Trkkxq84fU-Vd0RoRhj2NQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="Narr_xmulCtxlR0WW6-Vro0_BNA">0.5</ix:nonFraction> million, respectively, related to this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the year ended December 31, 2022, the Company issued&#160;<ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Narr_WVQ6rta6n0mXuHos1b0afQ">196,952</ix:nonFraction>&#160;shares of common stock and recorded zero shares issuable to Fortress, which equaled&#160;<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w" decimals="3" format="ixt:numdotdecimal" name="mbio:DilutedOutstandingEquityPercentage" scale="-2" id="Narr_OCh5c6fTVkGtx5dtHwJY4w">2.5</ix:nonFraction>% of the gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_ouMBcYK_C0i8-W5bP9xBrQ">6.6</ix:nonFraction>&#160;million from the sale of shares of common stock under Mustang&#8217;s At-the-Market Offering. The Company recorded an expense of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_ovDgDz0emEyMvZmp-YeELg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="Narr_892wpV7WqE-dYoDksm9KoQ">0.2</ix:nonFraction>&#160;million in general and administrative expenses related to these shares for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the year ended December 31, 2021, the Company issued&#160;<ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_Trkkxq84fU-Vd0RoRhj2NQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Narr_X32740X19EykHFYXjtmWvA">576,157</ix:nonFraction>&#160;shares of common stock and recorded&#160;<ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_m9J360WMFk65TIBgOb6HfA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesSubscribedButUnissued" scale="0" id="Narr_8uEyfBhLbE2OgUT4-6GJSQ">51,295</ix:nonFraction>&#160;shares issuable to Fortress, which equaled&#160;<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_Trkkxq84fU-Vd0RoRhj2NQ" decimals="3" format="ixt:numdotdecimal" name="mbio:DilutedOutstandingEquityPercentage" scale="-2" id="Narr_1IZZgL-9U0uqSbpsYZlA1w">2.5</ix:nonFraction>% of the gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_Trkkxq84fU-Vd0RoRhj2NQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_rbGXrs8tNUOg8CqybWG13w">71.9</ix:nonFraction>&#160;million from the sale of shares of common stock under Mustang&#8217;s At-the-Market Offering. The Company recorded an expense of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_RtpzWYx2kkuP6Pk7yZGiGQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="Narr_SS4o9FCgHkirrwcX0hfgTw">1.9</ix:nonFraction>&#160;million in general and administrative expenses related to these shares for the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_vQHjGF4OGkqxFlS-ZwMxAQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Payables and Accrued Expenses Related Party</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In the normal course of business Fortress pays for certain expenses on behalf of the Company. Such expenses are recorded as Payables and accrued expenses&#160;- related party and are reimbursed to Fortress in the normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Director Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Dr.&#160;Rosenwald</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Pursuant to the terms of the Director Compensation Plan, Dr.&#160;Rosenwald will receive a cash fee of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_sT3IETb4eUa_bTIM6c1joQ" decimals="0" format="ixt:numdotdecimal" name="mbio:AnnualConsultingFees" scale="0" id="Narr_vdeOnupHnEuNe5XbdKnZbg">50,000</ix:nonFraction> per&#160;year paid quarterly and an annual stock award of the greater of (i)&#160;a number of shares of common stock having a fair market value on the grant date of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_ot8OBmwnOUaS1sRIHVm7tQ" decimals="0" format="ixt:numdotdecimal" name="mbio:DirectorCompensationValueOfSharesGranted" scale="0" id="Narr_1dmdR5yCUka1j4sWnUqZBA">50,000</ix:nonFraction> or (ii)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_ot8OBmwnOUaS1sRIHVm7tQ" decimals="0" format="ixt:numdotdecimal" name="mbio:DirectorCompensationNumberOfSharesGranted" scale="0" id="Narr_80DBDP_y9ESC41iuPwBkVg">10,000</ix:nonFraction> shares of common stock, which shares shall vest and become non-forfeitable on the third anniversary of the grant date, subject to continued service on the Board on such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">For the&#160;year ended December 31, 2022, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_sT3IETb4eUa_bTIM6c1joQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Narr_jOjvzyocMkeI3a07fExoRA">100,000</ix:nonFraction> in expense in its Statements of Operations related to the director compensation, including approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_sT3IETb4eUa_bTIM6c1joQ" decimals="0" format="ixt:numdotdecimal" name="mbio:DirectorCompensationValueOfSharesGranted" scale="0" id="Narr_hTTbdFzyxUigRnEaoGQ9Gw">50,000</ix:nonFraction> in expense related to equity incentive grants. For the&#160;year ended December 31, 2021, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_uAr0vqstK0m70EJhq9vZvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Narr_fceop7YDWUiB10MOeGqxSw">106,000</ix:nonFraction> in expense in its Statements of Operations related to the director compensation, including approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_uAr0vqstK0m70EJhq9vZvg" decimals="0" format="ixt:numdotdecimal" name="mbio:DirectorCompensationValueOfSharesGranted" scale="0" id="Narr_s4iyhT9ItEu7csFKTBznmg">56,000</ix:nonFraction> in expense related to equity incentive grants. The Company issued Dr. Rosenwald <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_3OyJzUMtO0ym9UWFHhhAZg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_BjlyE0ylNEGmTBiw1_Q38Q">71,664</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_XfkRl6mfqE-N6Ds1xMxrbQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_LMPkUXWgLUKpYJ41g_BhXQ">13,774</ix:nonFraction> restricted stock awards for the&#160;years ended December 31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Mr.&#160;Weiss&#160;- Advisory Agreement with Caribe BioAdvisors, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Board of the Company by unanimous written consent approved and authorized the execution of an advisory agreement dated January&#160;1, 2017 (the &#8220;Advisory Agreement&#8221;), with Caribe BioAdvisors, LLC (the &#8220;Advisor&#8221;), owned by Michael S. Weiss, the Chairman of the Board, to provide the board advisory services of Mr.&#160;Weiss as Chairman of the Board. Pursuant to the Advisory Agreement, the Advisor will be paid an annual cash fee of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2017_To_1_1_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_lbdL7OiZrk-lt4FN-gg-bQ" decimals="0" format="ixt:numdotdecimal" name="mbio:AnnualConsultingFees" scale="0" id="Narr_YtefBXVEY0uSFXhdmircMw">60,000</ix:nonFraction>, paid quarterly and an annual stock award of the greater of (i)&#160;a number of shares of common stock having a fair market value on the grant date of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2017_To_1_1_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_eGnJ3TUB8UOJx8iUju7dfA" decimals="0" format="ixt:numdotdecimal" name="mbio:DirectorCompensationValueOfSharesGranted" scale="0" id="Narr_kjX5fuUeNk2is8WH6cl4Yw">50,000</ix:nonFraction> or (ii)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2017_To_1_1_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_eGnJ3TUB8UOJx8iUju7dfA" decimals="0" format="ixt:numdotdecimal" name="mbio:DirectorCompensationNumberOfSharesGranted" scale="0" id="Narr_aFcmj-bRIUOZxN5yivQs3A">10,000</ix:nonFraction> shares of common stock, which shares shall vest and become non-forfeitable on the third anniversary of the grant date, subject to continued service on the Board on such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">For&#160;the year ended December 31, 2022, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_bPmhKby7TEaZLqjV9yAiFA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Narr_H654FX_sik-5mgiGvFJqdw">110,000</ix:nonFraction> in expense in its Statements of Operations related to the advisory agreement, including approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_bPmhKby7TEaZLqjV9yAiFA" decimals="0" format="ixt:numdotdecimal" name="mbio:DirectorCompensationValueOfSharesGranted" scale="0" id="Narr_hL_NKpjGyE-CWv1EVX1RcA">50,000</ix:nonFraction> in expense related to equity incentive grants. For&#160;the year ended December 31, 2021, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_-GelVT3xVkGWE0zhcvX2PQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Narr_NPgMlvwvmkiJlHQUjXlKLQ">116,000</ix:nonFraction> in expense in its Statements of Operations related to the advisory agreement, including approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_-GelVT3xVkGWE0zhcvX2PQ" decimals="0" format="ixt:numdotdecimal" name="mbio:DirectorCompensationValueOfSharesGranted" scale="0" id="Narr_IuJLlfWtyEWNXs-G_xDzLA">56,000</ix:nonFraction> in expense related to equity incentive grants. The Company issued Mr. Weiss <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_B0vAXreZfkCUTZAJG1tYDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_pwGkvOz2rUOUTZStuUomZg">71,664</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_9jVcGwYOxUu69mDgzJJD-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_Ft1rjhzB0kaVYCMQU38HxA">13,774</ix:nonFraction> restricted stock awards for the&#160;years ended December 31, 2022 and 2021, respectively.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_33b00412_f3ca_4d3e_9dd4_5106b9a32079"></a><a id="Tc_UQtNsA8VKkeKdqiPLAKgwg_1_2"></a><a id="Tc_itHXlB0b00i8MzLeI2sYbg_1_4"></a><a id="Tc_qXCAbcx1r0-2NHnZ8XCfKA_1_7"></a><a id="Tc_JAYeYpSn206AdZdeDMrqDQ_2_0"></a><a id="Tc_dXgsr2t0NkicP-1-6bWg1A_2_2"></a><a id="Tc_tKfwBo-uiEqjlIIw_O1M2A_2_4"></a><a id="Tc_TEJpACT9Nki6zpNFQkNcyw_2_7"></a><a id="Tc_4km9Bk9jrEmRkJMxzyLdxA_3_0"></a><a id="Tc_nzZNo5PgXUGJYWE73iNZSg_3_4"></a><a id="Tc_vYEm1WMZz0KAnoq1LLytWA_3_7"></a><a id="Tc_dTZyk1jWpUmUGGqoEPNGuA_4_0"></a><a id="Tc_4k9jE6_Bqk-dhJPVUBrdmA_5_0"></a><a id="Tc_jDdnQBatwUKCsBwihBYmuQ_6_0"></a><a id="Tc_ohw6AeNe1EqRZpVzByiaTQ_7_0"></a><a id="Tc_f_NKm8E9v0ia49Xd82ROOg_7_2"></a><a id="Tc_vgiV3gEbzEqRC1lFM85XGA_8_0"></a><a id="Tc_PIVf_qsfwkyxukhN3SaHFw_9_0"></a><a id="Tc_p8WIDLPNaUypxY6x6YJOyA_10_0"></a><a id="Tc_dAeguCvovkGcnXbJH5hn9A_10_4"></a><a id="Tc_jtFzZXZeOUODiRZ1Wc5ouQ_10_7"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_ky6Thh5qyk2_4B5okeTOnQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;5&#160;- Property and Equipment</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_JPSJEaSxS0CoCCFlExLYdA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Mustang&#8217;s property and equipment consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated Useful</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_aWcNk9ygQEOJpQSfWskFEA" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_QMwiICCfJEOxeosoO_Qi8g_3_2"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_v472pPJ0CkuqygxI_ittBQ" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_QMwiICCfJEOxeosoO_Qi8g_3_2_2">3</ix:nonNumeric></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_z9Vf3QpPF0qO9yFxyz7P_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_FU3ihgWzXEi60LMXEVaivA_3_5">145</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_43U4KPxs6ESx8ledMlKHrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_pltx37lWuUCY0Ui84AXuxQ_3_8">145</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_pzjG98ud8EGdrioXB-jwgw" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_wl775OpRvk-y5QhH_yymYA_4_2"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_T6pbjl0HIEm0W7ow_5z-_g" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_wl775OpRvk-y5QhH_yymYA_4_2_2">5</ix:nonNumeric></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_iCbMYI4KcESBEVBhm0Im-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Ewc0__jXvE2fkJWWZ8Z7iw_4_5">370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_PcX9JsuOWUyJsrrbJM84DA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_pgCRy2lba0Wpe81FXq5UDQ_4_8">370</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Machinery&#160;and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_AS2adTFum0q5lSDBbT43Cg" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_4RGHIZaZI0uIYDC5mTOtOg_5_2"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_6e_cd9xdR0OP-rJ8ATzk6A" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_4RGHIZaZI0uIYDC5mTOtOg_5_2_2">5</ix:nonNumeric></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_reL4xpHEp06WZ3lLttoTLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_u_uE5nTLW0GxItOJd0TXPA_5_5">8,632</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_6Mr5lfEhb0CpRxTW-j7sxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_1B-tGnj3BkSt1E9-CYHDNw_5_8">6,550</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_j5ZGnmb0UkuRYKuYvgYNtQ" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_WRs3-AOtaEODDddBr8dRvQ_6_2"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_FkxuDW2Odkq2TbRXzOUOkQ" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_WRs3-AOtaEODDddBr8dRvQ_6_2_2">9</ix:nonNumeric></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_cTxrSq0IxUy5wwF9bj3Hhw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_n_EEj_O5qU-LeAAIesStOw_6_5">7,694</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_e_acjS35Ukyn5P8Fy-MCGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_ADc-vh5GbEiCjHO8eRBcNA_6_8">7,694</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_RjfDOebswEyLEhoZaNQWKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_ncybA_YK0U6e2KQoMIhaAQ_7_5">951</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_wsvscCuqjEmydGhY6i4new" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_79hN3H1zY0iAc55v4Rgj9g_7_8">2,027</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_NVCSado0506otTAqCCrWrg_8_5">17,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_l5UdClC4aUaMkHNyBUgDdw_8_8">16,786</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_jFcBhpoxk0-ncjm37MBFjw_9_5">8,401</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_4WBf3asyZ0a-9aBRS59I2g_9_8">5,734</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_d2CIpl9N5Uy6YfiDgQo26g_10_5">9,391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_HvyunOnhuUSC7LX3TGXipg_10_8">11,052</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Mustang&#8217;s depreciation expense for the&#160;years ended December&#160;2022 and 2021 was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr__PE7TJKjpUqzEmHzr00Frg">2.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_9-TjZ_ZOUkeTkUdDEf5Grg">2.2</ix:nonFraction> million, respectively, and was recorded in research and development expense in the Statements of Operations.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;background:#ffff00;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_902c4a6f_6d81_4a41_8b0f_f8500d50aabd"></a><a id="Tc_pTlMuVBDxUK8muGBGTAoMA_1_2"></a><a id="Tc_KBHzsO2EQEeUgzpPR5l-gA_1_5"></a><a id="Tc_wPvw5W2T6k2bGj5IJziFAw_2_0"></a><a id="Tc_8SMX8_hqy0GTa0_l6OIeIw_2_2"></a><a id="Tc_PCMI-XUwKEiXpBX3OEo0DQ_2_5"></a><a id="Tc_AGc1DEMnKEKHbv9Lu9b91g_3_0"></a><a id="Tc_ypbytXkL40CjEatJxsVHhw_3_2"></a><a id="Tc_KFkarMCVIkyKdueUvZku8w_3_5"></a><a id="Tc_7xBi9ML-BUyqgj13oGpClA_4_0"></a><a id="Tc_7-fIzt7a0EinB739xaMEuQ_5_0"></a><a id="Tc_MLjwtG-Q0Uqto-uBSix6ig_6_0"></a><a id="Tc_qIEvNFNQm0m1xPnA0lHC_A_7_0"></a><a id="Tc_sOhhLLR6Q0GYSLdMabFgCA_7_2"></a><a id="Tc_FOmJJkz3vUS97Ynm9r_xKQ_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_NvwCv4B0s0aWa2G94NfxwA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;6&#160;- Accounts Payable and Accrued Expenses</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="Tb_kSVbKHx1_0meb3At_1uV9A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">At December 31, 2022 and 2021, accounts payable and accrued expenses consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_VG5RwSUYFkqYksTF8VTHMw_3_3">6,833</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_9y_I_2HZKEaf02enCQtPhg_3_6">3,512</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="mbio:ResearchAndDevelopmentCurrent" scale="3" id="Tc_IpJgx18mfEaWhC3-dBoe_w_4_3">2,782</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="mbio:ResearchAndDevelopmentCurrent" scale="3" id="Tc_YL1-fEaUuEidOi4IdSIOUw_4_6">3,083</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="mbio:AccruedCompensationCurrent" scale="3" id="Tc_Zg7yVwlkmEGkVYNBTN6RJg_5_3">3,468</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="mbio:AccruedCompensationCurrent" scale="3" id="Tc_jWyo83rcIEGg371lYoZ84g_5_6">2,595</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_KUnNJ5jQ6EqKI7aJ5Xboow_6_3">648</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_zXhtzgHRgEyItKv8TL7tSQ_6_6">554</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="Tc_T0QDSB8PyUivhd4JlItC7Q_7_3">13,731</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="Tc_B5_KiCVRzEKFgw00FWAz0w_7_6">9,744</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_A2J9XsQZjUiQ2eTWBaABAA" continuedAt="Tb_A2J9XsQZjUiQ2eTWBaABAA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;7&#160;- Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">On June 14, 2022, the Company entered into a sublease agreement with The Paul Revere Life Insurance Company. Pursuant to the terms of the sublease lease agreement, the Company agreed to lease&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_sqft_8yS2Dc-QmU2gfsdczKLSrA" contextRef="As_Of_6_14_2022_cTRV0HCiCkWfQ2PRR9auPA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:NetRentableArea" scale="0" id="Narr_TIWBXRywuUmoGwCerpYSPQ">26,503</ix:nonFraction></span><span style="background:#ffffff;">&#160;square feet, located at 1 Mercantile Street, Worcester, MA (the &#8220;Mercantile Street Facility&#8221;), through January 2030. The Company recorded a right of use&#160;</span><span style="-sec-ix-hidden:Hidden_hD18g_F6S0Sosw_qw-16ow;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">asset</span></span><span style="background:#ffffff;">&#160;and related operating lease liability of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_6_14_2022_cTRV0HCiCkWfQ2PRR9auPA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_LngLcrOMNEuKzN4dUXGg_w">2.2</ix:nonFraction></span><span style="background:#ffffff;">&#160;million on the Balance Sheet at the lease inception.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On October&#160;27, 2017, the Company entered into a lease agreement with WCS&#160;- 377 Plantation Street,&#160;Inc., a Massachusetts nonprofit corporation. Pursuant to the terms of the lease agreement, the Company agreed to lease <ix:nonFraction unitRef="Unit_Standard_sqft_8yS2Dc-QmU2gfsdczKLSrA" contextRef="As_Of_10_27_2017_r9_PBUxiKU6CIeyMRHqr4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetRentableArea" scale="0" id="Narr_YeBLRF314EaYsjYfQJ8EkA">27,043</ix:nonFraction> square feet from the landlord, located at 377 Plantation Street in Worcester, MA (the &#8220;Plantation Street Facility&#8221;), through November 2026, subject to additional extensions at the Company&#8217;s option. Base rent, net of abatements of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_10_27_2017_To_10_27_2017_HaJc4KkwbUyd0LOp2-MkEw" decimals="-5" format="ixt:numdotdecimal" name="mbio:LesseeOperatingLeaseTotalAbatementsOverLeaseTerm" scale="6" id="Narr_OyHi9Weovkm5IUazd5uGAA">0.6</ix:nonFraction> million over the lease term, totals approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_10_27_2017_To_10_27_2017_HaJc4KkwbUyd0LOp2-MkEw" decimals="-5" format="ixt:numdotdecimal" name="mbio:LesseeOperatingLeaseTotalBaseRentNetOfAbatements" scale="6" id="Narr_TIRxwCkI2UGnBxLPfL4yAg">3.6</ix:nonFraction> million, on a triple-net basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The terms of the lease also require that the Company post an initial security deposit of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_10_27_2017_r9_PBUxiKU6CIeyMRHqr4g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="6" id="Narr_7gkMAQG6UE2r5c_PEt8E9w">0.8</ix:nonFraction> million, in the form of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_10_27_2017_us-gaap_ShortTermDebtTypeAxis_us-gaap_LetterOfCreditMember_k9atZnNjs0aax30iY_FCJg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="6" id="Narr_W2BkEKCXTkOprjtyukBXGA">0.5</ix:nonFraction> million letter of credit and $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_10_27_2017_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_n1UsR7h740ijw5e4ONDTcg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="6" id="Narr_NMpYfR5H_kauQPgotdYgcA">0.3</ix:nonFraction> million in cash, which increased to $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_10_27_2017_To_10_27_2017_HaJc4KkwbUyd0LOp2-MkEw" decimals="-5" format="ixt:numdotdecimal" name="mbio:LesseeSecurityDepositUponFullOccupancy" scale="6" id="Narr_qg8dtj4fK0ODdO8aQO-jWg">1.3</ix:nonFraction> million ($<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_10_27_2017_To_10_27_2017_us-gaap_ShortTermDebtTypeAxis_us-gaap_LetterOfCreditMember_Gwgp6OjA0kOhW6E5eRzqQg" decimals="-5" format="ixt:numdotdecimal" name="mbio:LesseeSecurityDepositUponFullOccupancy" scale="6" id="Narr_-XEmtkL9wkm3lfGeL-sAGg">1.0</ix:nonFraction> million letter of credit, $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_10_27_2017_To_10_27_2017_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_-idbFc98Ukq2mFPsFZldJQ" decimals="-5" format="ixt:numdotdecimal" name="mbio:LesseeSecurityDepositUponFullOccupancy" scale="6" id="Narr_KjXU9Ccd6UmhnYZoQAiNbQ">0.3</ix:nonFraction> million in cash) on November 1, 2019. After the fifth lease year, the letter of credit obligation is subject to reduction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Plantation Street Facility began operations for the production of personalized CAR T and gene therapies in 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company leases office space and copiers under agreements classified as operating leases that expire on various dates through 2030. The Company&#8217;s lease liabilities result from the lease of its facilities in Massachusetts, which expire in 2030 and 2026, for the Mercantile Street Facility and Plantation Street Facility, respectively, and its copiers, which expire in 2024. Such leases do not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. Certain of the Company&#8217;s leases include renewal options and escalation clauses; renewal options have not been included in the calculation of the lease liabilities and right of use assets as the Company is not reasonably certain to exercise the options. The Company does not act as a lessor or have any leases classified as financing leases. At December 31, 2022, the Company had operating lease liabilities of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_XqUHoOH9f0G28GnQTYCHog">3.9</ix:nonFraction> million and right of use assets of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_AAAAPIi34kaCkL9Lw8SRQA">2.9</ix:nonFraction> million, which were included in the Balance Sheet. At December 31, 2021, the Company had operating lease liabilities of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_Ue_0thVlV0uRcoPWLSy--A">2.0</ix:nonFraction> million and right of use assets of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_J1nmOWfptUG1KSrHd3Vkog">1.1</ix:nonFraction> million, which were included in the Balance Sheet.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:LeaseCostTableTextBlock" id="Tb_3Eu8lWABGk-vxU-Lph64uQ" continuedAt="Tb_3Eu8lWABGk-vxU-Lph64uQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f63a4bc0_b8a6_4b7e_8405_971b14799d00"></a><a id="Tc_oBgs3ZMw6E65KqV4Bc-90A_1_2"></a><a id="Tc_-jZv6SGCrEqmsIx60SyHXA_2_3"></a><a id="Tc_15s_ViVJZ06nspv9N4BgJg_2_6"></a><a id="Tc_IavYN9FVv0WJE5M0DLaqpg_3_0"></a><a id="Tc_RSvZjMNHCEGpnOKkaR36xw_3_2"></a><a id="Tc_5q7V1z4-n0eYnASc7N_Fiw_3_5"></a><a id="Tc_EE05Q0R7NEeynkpZwkrarw_4_0"></a><a id="Tc_WtHjg4pTD0Gfz4xS6Nna1Q_5_0"></a><a id="Tc_jESuxMOW9Uaj3VoMRt4xyw_5_2"></a><a id="Tc_x6zrKkIC7kKaeG_SHMldow_5_5"></a><a id="Tc_OmlymBSBC0SWm1u-FSFxwQ_6_0"></a><a id="Tc_YlaIrEiLYkSj86SejJbIiQ_7_0"></a><a id="Tc_qlLi1b7_sUqsUP6bglbnZQ_7_2"></a><a id="Tc_SRs3TudIBEmJVDh2tYsLUw_7_5"></a><a id="_9d26daad_791a_4bae_9ac3_b1318c5eb3f7"></a><a id="Tc_d07KaBKp1UGV3Ud6DHJjRw_1_2"></a><a id="Tc_77oM9zB10U62osUR-Jb2ig_2_3"></a><a id="Tc_NqCi-1JSekG6y92c836Llg_2_7"></a><a id="Tc_X7nxgdw2Wk62LBqnaJNV9Q_3_0"></a><a id="Tc_8PofIklVjk2KF_fYXaSHIQ_3_2"></a><a id="Tc_YAydWECrb0an9iZ_6-kdWQ_3_6"></a><a id="Tc_YzXolrpx8kyMFl3sggepYg_4_0"></a><a id="Tc_59UdyvriBk2SmyO5zsvcsQ_4_2"></a><a id="Tc_09LSQ9tGkU6L18pW4tyOZA_4_6"></a><a id="Tc_54xs9dMXuECTgTTdxk3uTA_5_0"></a><a id="Tc_pVgUSM7AaUeS87LldJBf1A_6_0"></a><a id="Tc_GlxjdHvQQkKcgt1IWV54mQ_6_4"></a><a id="Tc_PtJ5HPhwWUWXrkU8FEC6CA_6_8"></a><a id="_8f30affe_7870_46ac_9c83_afaeb5c01c35"></a><a id="Tc_aLsEOe2X_0KzLmII3MbDYw_1_0"></a><a id="Tc_YXfeR3Zfyk6f0hAIESmtFA_2_0"></a><a id="Tc_MLa3dYDI1kSTgQIB54jq1g_2_2"></a><a id="Tc_7d5VEmoucU-EvboNXZ339g_3_0"></a><a id="Tc_wrVBVmMCCU2VYo01UrAybw_4_0"></a><a id="Tc_ccKnDyWfmEitBK7Jia649Q_5_0"></a><a id="Tc_4hMfuT27Kki523bZ-IwsHg_6_0"></a><a id="Tc_Ws328T40l0qSexA_Ru42MQ_7_0"></a><a id="Tc_K7H8lLiZTEGvUBQyTS35bg_8_0"></a><a id="Tc_h6uRmCEXPEuS9xrqhNusOA_9_0"></a><a id="Tc_lucMmH6y2Ui5msu6BU6jEg_10_0"></a><a id="Tc_p_h1Ze6eOkWdKrKmY5_tZA_10_2"></a><ix:continuation id="Tb_A2J9XsQZjUiQ2eTWBaABAA_cont1"><ix:continuation id="Tb_3Eu8lWABGk-vxU-Lph64uQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following summarizes quantitative information about the Company&#8217;s operating leases:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_zaa2zJCjaUm5jdnvcCYeIQ_5_3">565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_Kb5Y5lEEnEKhRHIzfk3IAw_5_6">315</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_fDxnTk4ueUa7U47Ewpqm7w_6_3">488</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_l26LL7Uox0KzGuxwsgcLMA_6_6">599</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_CoxsaDVYxUC_2WSmkmSbCA_7_3">1,053</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_lUvG5BKzuEmPNbv7dKMVPA_7_6">914</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:86.33%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:29.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_YQKRkpN8W06S3ic2eaD_Cw_4_3">485</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_YNDQ19cYb0WdUw1mtq8eyQ_4_7">484</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term &#8211; operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_02kb-9pjzkmcCObmmGetzA_5_3"> 5.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_2VATIISK7UOxk0YRT2o5CA_5_7"> 4.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate &#8211; operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_HhPEPfKcgUmPQH1gKBLxRA_6_3">9.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_luxqipDlsEKH35aLujj3jA_6_7">9.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_U40UV-85okSM8TamJDLMEQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Maturities of our operating leases, excluding short-term leases, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_bMBe-hy4kkeYnl8tKiUNGA_2_3">529</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_yYUiGKnVuECgqIREyj7mAQ_3_3">614</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_OqKdMmt4OUygqHkiTUp1Nw_4_3">1,139</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_ztEn3G6A2EubvUQePjYFAg_5_3">1,076</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_5KW6sixI8UKuqAlYQUj00g_6_3">650</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_Srr2tBZwQkuujT5zftR8qQ_7_3">1,381</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_R8PMSY_-jkyEG6ByKYMnag_8_3">5,389</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_NIDMvKacSkmRG0zs2KHlww_9_3">1,443</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_zE8WUJQMl0uDXSrGY_uLjA_10_3">3,946</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:DebtDisclosureTextBlock" id="Tb_uDT4uK2pI0SWOskKowa1fg" continuedAt="Tb_uDT4uK2pI0SWOskKowa1fg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Note 8 &#8211; Notes Payable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">On March 4, 2022 (the &#8220;Closing Date&#8221;), the Company entered into a $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_V-Z46JxI2EyuPIWBlmIl6A">75.0</ix:nonFraction>&#160;million long-term debt facility with Runway Growth Finance Corp. (the &#8220;Term Loan&#8221;). Under the Term Loan, $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_3_4_2022_To_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_eHP0c1pt2kC8bNXFkSVznw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="6" id="Narr_5Unt_yz06Ey3CqAt2WtN7w">30.0</ix:nonFraction>&#160;million of the $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_gMqJNwt4OUS-FrtlaPW6TA">75.0</ix:nonFraction>&#160;million loan was funded on the Closing Date, with the remaining $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="Narr_iy-Aqcvm1UiX0ByL3onPnQ">45.0</ix:nonFraction>&#160;million fundable if the Company achieves certain predetermined milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Term Loan matures on April 15, 2027 (the &#8220;Maturity Date&#8221;). &#160;As of March 15, 2022, the Company began making monthly payments of interest only until April 1, 2024 (the &#8220;Amortization Date&#8221;). The Amortization Date may be extended to April 1, 2025, if the Company achieves certain predetermined milestones based on equity raises and the initiation of certain clinical trials. After that, the Company will make monthly payments of interest and principal. If the Amortization Date is extended to April 1, 2025, the monthly payments will be recalculated in equal amounts according to the remaining number of payment dates through the Maturity Date. All unpaid outstanding principal and accrued and unpaid interest will be due and payable in full on the Maturity Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Term Loan accrues interest at a variable annual rate equal to&#160;<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_3_4_2022_To_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_85Vphemizk-HydOGFNSOgA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_afAhVpmWh0CoKu8pLAvFZg">8.75</ix:nonFraction>% plus the greater of (i)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_3_4_2022_To_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_sRafw2Y-jEiKjW4bMgII8Q" decimals="6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="Narr_Q7ctsl8xg02l3REQ7Tz7Ew">0.50</ix:nonFraction>% and (ii) the three month LIBOR Rate for U.S. dollar deposits or the rate otherwise reasonably determined by the Lender to be the rate at which U.S. dollar deposits with a term of three months would be offered by banks in London, England to major banks in the London or other offshore interbank market &#160;(the &#8220;Applicable Rate&#8221;); provided that the Applicable Rate will not be less than&#160;<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_3_4_2022_To_3_4_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_IRsNQ3FWukSyey7fSJ4NbQ" decimals="6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="Narr_Hzb04u6YaUWI0nYzuzH9BQ">9.25</ix:nonFraction>%. The Applicable Rate at December 31, 2022 was&#160;<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_uNZ1QlhL30egiHID6foBSQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="Narr_-YqA_t3Ndk202G9QePOe6A">13.40</ix:nonFraction>%. On December 7, 2022, the Company entered into the First Amendment (the &#8220;First Amendment&#8221;) to the Loan Agreement by and between the Company and Runway. The First Amendment amended certain definitions and other provisions of the Loan Agreement to replace LIBOR-based benchmark rates applicable to loans outstanding under the Loan Agreement with SOFR-based rates, subject to adjustments as specified in the First Amendment. For the year ended December 31, 2022, the Company made interest payments of </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_QYGrTbbSTkumOrH7cMHrUA_1_2"></a><a id="Tc_w37bhnm48EWZ_zxD6EZKRg_1_5"></a><a id="Tc_Y0a9hhwrZke5SXNfhbFS2A_2_0"></a><a id="Tc_PzlLkM-8K0297NEtG6ezbA_2_2"></a><a id="Tc_lpr38Q38V06PRhysAsVjqA_2_5"></a><a id="Tc_ByO9Pv8kWE2JmoAUzr5IVw_2_8"></a><a id="Tc_JsS-GwdckUylevll9fEG0w_2_10"></a><a id="Tc_2qsuaRyfAE2rfD3fM-Krtg_3_0"></a><a id="Tc_S7IwmVfxJUCbi5p_71UhYw_3_2"></a><a id="Tc_6-aKEdKIIUqB03vF1_RSoA_3_5"></a><a id="Tc_hp44j57eEk-ND42JsZmZuQ_3_6"></a><a id="Tc_IlOboK7ljkKQ-RU0eeAcJQ_3_9"></a><a id="Tc_JhvExhuZgkeAgvq3jLiTUw_3_10"></a><a id="Tc_iEiWkkBeCkW6m3fZIojc3w_4_0"></a><a id="Tc_7QMi7xVhQUuHUI9mdeqfPw_4_6"></a><a id="Tc_lDIbBsobd0GcKcbfsk_qXA_5_0"></a><a id="Tc_U6xqTlQIe02uKfIVuZUsqQ_5_2"></a><a id="Tc_ctDv6vtXnUiNcyzpbFZKKw_5_5"></a><a id="Tc_SmWk1nmnW0GI-1gwtItflQ_5_6"></a><ix:continuation id="Tb_uDT4uK2pI0SWOskKowa1fg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_uNZ1QlhL30egiHID6foBSQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_5rlZ2zjsbEacX3M9ncwAhQ">2.7</ix:nonFraction>&#160;million, recorded in interest expense in the Statements of Operations. The Company had&#160;<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_UgDuCoveakiyI_k2GGguBw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_mms04LYSs0imd7B_ca2x1A">no</ix:nonFraction>&#160;interest expense related to debt in 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Pursuant to the terms of the Term Loan on the Closing Date the Company paid the Lender upfront fees out of proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_3_4_2022_To_3_4_2022_8OXg7asOjUiUzJte247ykw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="Narr_hzb9d1cq8k-trU5mj-90cA">0.4</ix:nonFraction>&#160;million consisting of a&#160;<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_3_4_2022_To_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_eHP0c1pt2kC8bNXFkSVznw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="Narr__l6kJZmelUSMqWulAcP3eA">1</ix:nonFraction>% commitment fee and a deposit of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Narr_xUTurl7o5keiLN8QgY7Ncw">75,000</ix:nonFraction>. &#160;In addition, the Company paid other cash fees directly to third parties comprising of an advisory fee and legal fees totaling $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_3_4_2022_To_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_eHP0c1pt2kC8bNXFkSVznw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LegalFees" scale="6" id="Narr_2AlEv93RBU-i409gdl20aw">2.3</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Also, in connection with the Term Loan, on March 4, 2022, the Company issued a warrant to the Lender to purchase&#160;<ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_hh7UZBEdVEW0svSfq7M-kA">748,036</ix:nonFraction>&#160;shares of the Company&#8217;s common stock with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Qup6QNJZq0Cym55VfGjTkA">0.8021</ix:nonFraction>&#160;(the &#8220;Warrant&#8221;) via a warrant agreement (the &#8220;Warrant Agreement&#8221;). The Warrant is exercisable for&#160;<ix:nonNumeric contextRef="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_0sL6Szi3u0auy4BKy9Szxg">ten years</ix:nonNumeric>&#160;from the date of issuance. The Lender may exercise the Warrant with cash or through a net issuance conversion. The shares of the Company&#8217;s common stock will be registered at the Company&#8217;s first opportunity after the date of the exercise of the Warrant. In addition, the provisions of the Warrant Agreement provide for additional warrants to be issued upon funding of the term loan tranches. The fair value of the warrant at the grant date was determined utilizing a Black Scholes Model with the following assumptions: risk free rate of return&#160;<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="As_Of_3_4_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Q6BCOUH2V0CcXWJkApNHug" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_sdT8X8PcO0mJct6TqzBbMg">1.74</ix:nonFraction>%, volatility of&#160;<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="As_Of_3_4_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_mwjdn5zoKEerGWdy4baTKg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_J8hkdcHPAkGSVHSnAsSpxg">57.3</ix:nonFraction>%,&#160;<span style="-sec-ix-hidden:Hidden_yUFWycn0fk-azymq7ugG3A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10-year</span></span>&#160;life yielding a value of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_3_4_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_2HYX_b8YJ0uKkR4UevRidg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="Narr_bju8D20zHUW7BouZLPOVrA">0.4</ix:nonFraction>&#160;million as of March 4, 2022. &#160;The fair value of the warrant was also recorded in debt discount and will be amortized over the life of the Term Loan.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:ScheduleOfDebtTableTextBlock" id="Tb_qblU9_uS-0KXaSugs5pavA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Applicable&#160;Rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_9uDXLFrQfESucUVU2dbSlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_hjYMJk8vvU-_XSP1ER2UoA_3_3">31,050</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_uNZ1QlhL30egiHID6foBSQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="Tc_b0CpArloYE6Wck4snxwXhg_3_8">13.40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">April - 2027</p></td></tr><tr><td style="vertical-align:bottom;width:51.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Discount on note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_9uDXLFrQfESucUVU2dbSlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="Tc_I4rgbASYhESgkp_T0V0_8w_4_3">3,614</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Long-term note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_9uDXLFrQfESucUVU2dbSlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="3" id="Tc_bHAMd_JDo0GIS1EXxXVHOw_5_3">27,436</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Amortization of the debt discount associated with the Term Loan was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_uNZ1QlhL30egiHID6foBSQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="Narr_ObBdaXAay0ungK9MdGBAWQ">0.5</ix:nonFraction>&#160;million for the year ended December 31, 2022, respectively, and was recorded in interest expense in the Statements of Operations. The Company had&#160;<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_UgDuCoveakiyI_k2GGguBw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="Narr_2qnYs_eaWEeg9Sxem7VmVw">no</ix:nonFraction>&#160;expense related to debt discount amortization in 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has the option to prepay all of the outstanding Term Loan but not less. Prepayment would include outstanding principal, accrued interest, prepayment fee and final payment which is equal to the original principal amount of the Term Loan times&#160;<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_9uDXLFrQfESucUVU2dbSlQ" decimals="3" format="ixt:numdotdecimal" name="mbio:DebtInstrumentBalloonPaymentAsPercentageOfPrincipal" scale="-2" id="Narr_K_ei636xykemxyAIo5YyhQ">3.5</ix:nonFraction>% or $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_9uDXLFrQfESucUVU2dbSlQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="6" id="Narr_kpAJsKByREemp5wPxQPA2w">1.1</ix:nonFraction>&#160;million and is accreted over the life of the Term Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, the Term Loan is secured by a lien on substantially all of our assets other than certain intellectual property assets and certain other excluded collateral, and it contains a minimum liquidity covenant and other covenants that include among other items: (i) limits on indebtedness, repurchase of stock from employees, officers and directors. The Company was in compliance with all applicable covenants as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The Term Loan contains customary events of default, in certain circumstances subject to customary cure periods. Following an event of default and any cure period, if applicable, Runway will have the right upon notice to accelerate all amounts outstanding under the Term Loan, in addition to other remedies available to the lenders as secured creditors of the Company.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_JliPouztaUWNkUIH7JiPCA" continuedAt="Tb_JliPouztaUWNkUIH7JiPCA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;9&#160;- Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company, in accordance with its certificate of incorporation, as amended in November 2020 and June 2021, which was retroactively applied, and July 2022, is authorized to issue (i) <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_lqM7j6_6kUu5wdW13no2rA">200,000,000</ix:nonFraction> common shares with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_NTmbXfOTKEmGXJNe1GwMmg">0.0001</ix:nonFraction> per share, of which <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_M2XrEHX5oEeqe8nYvunwDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_howhr-Du-U6c36K1hIgDbw">1,000,000</ix:nonFraction> shares are designated as Class&#160;A Common Stock and the remainder are undesignated Common Stock, and (ii) <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_sQrh-r-IvEizbU7dIG6Ibg">2,000,000</ix:nonFraction> shares of Preferred Stock, <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_v_0gsNjsdE2RcPa-Xt5feA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_BhoxySdGt0qtxjihS0meTA">250,000</ix:nonFraction> of which are designated as Class A Preferred Stock and the remainder are undesignated Preferred Stock (see below Stock Issuances to Fortress and Note&#160;4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In connection with the Company&#8217;s formation, Fortress subscribed for <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_5_Je6tCozUqMRQF6TTTr9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesSubscribedButUnissued" scale="0" id="Narr_j3Z9wWrJAEic9fZjLU2pzg">7,000,000</ix:nonFraction> shares of the Class&#160;B Common Stock and <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_YEp120A29kC8SaLYOW75aA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesSubscribedButUnissued" scale="0" id="Narr_v-So4sHMrEmxWg1wT_U79g">2,000,000</ix:nonFraction> shares of the Company&#8217;s Common Stock, pursuant to the Founders Agreement. Fortress paid the par value of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_HIeb-wz9Kk2lMUL_e8y1xA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesSubscriptions" scale="0" id="Narr_OKtGwDLGfU62sswpa3OQ3g">900</ix:nonFraction> in 2016. The fair value of the Company&#8217;s common shares approximated par value as no licenses had been transferred at that time. Dividends, if and when declared, are to be distributed pro-rata to the Class&#160;A, B and Common Stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The holders of Common Stock are entitled to <ix:nonFraction unitRef="Unit_Standard_item_e-lAqZ63ukC9AQjaK0X33Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_dXkI_XX5XU-PKFM5auvM3w" decimals="INF" format="ixt-sec:numwordsen" name="mbio:VotingRightsNumberOfVotesPerShare" scale="0" id="Narr_vUiwYj5nBkS22Wq-KVfZuw">one</ix:nonFraction> vote per share of Common Stock held. The holders of Class&#160;A Common Stock are entitled to the number of votes equal to the number of whole shares of Common Stock into which the shares of Class&#160;A Common Stock held by such holder are convertible and for a period of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_ck0wt0THlEGynuJiicHJLQ" format="ixt-sec:durwordsen" name="mbio:StockholderAppointmentOfDirectorPeriodAfterIssuance" id="Narr_rXVhqgYZEE-WqbIEclcRag">ten years</ix:nonNumeric> from its issuance, the holders of the Class&#160;A Common Stock have the right to appoint one member of the board of directors of Mustang; to date, the holders of Class&#160;A Common Stock have not yet appointed such director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Class&#160;B Common Stockholders are entitled, for each share of Class&#160;B Common Stock held, to a number of votes equal to <ix:nonFraction unitRef="Unit_Standard_item_e-lAqZ63ukC9AQjaK0X33Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_EPmjxn4_W0OhVeeDC0iTvA" decimals="1" format="ixt:numdotdecimal" name="mbio:VotingRightsNumberOfVotesPerShare" scale="0" id="Narr_n1SkSPXC70y_eioKgv2aUg">1.1</ix:nonFraction> times a fraction, the numerator of which is the sum of (A)&#160;the shares of outstanding Common Stock and (B)&#160;the whole shares of Common Stock into which the shares of outstanding Class&#160;A Common Stock and the Class&#160;B Common Stock are convertible and the denominator of which is the number of shares of outstanding Class&#160;B common shares. There was no Class B Common Stock outstanding as of December&#160;31,&#160;2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On November 11, 2020, the Company&#8217;s Board adopted resolutions of the Board to ratify, approve and recommend stockholder approval of an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended, to revise Article IV, Section A thereof in order to effect an increase in the authorized number of shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_11_11_2020_jFP6QSBqjkOBLq38js8Gqw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_8gwij05RbEOp6sP-Ky3wtA">0.0001</ix:nonFraction>, from <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_11_10_2020_pVBK-Ciss0-dnXh6zSgmjw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_3uwv-vCwC0aAhtbKo-9xeQ">85,000,000</ix:nonFraction> to <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_11_11_2020_jFP6QSBqjkOBLq38js8Gqw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr__se33GlMK0GPonwVA25G1w">125,000,000</ix:nonFraction> (the &#8220;Amendment&#8221;). On November 11, 2020, the Company received approval of the Amendment by written consent in lieu of a meeting from the holders of a majority of issued and outstanding shares of the Company&#8217;s common and preferred stock. The increase in authorized shares to <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_4_2020_xrfudyC3YkytVOGquusxcw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_ya1QphWjNkKZzFjRjlDWGA">125,000,000</ix:nonFraction> became effective on December 4, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On June 17, 2021, the stockholders of the Company voted at the 2021 Annual Meeting to approve an amendment to Mustang&#8217;s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance by <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_6_17_2021_To_6_17_2021_sehtwXsjPE6k3If_-5V-TA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_Q-aDfdetIE2aBfHfFKdrkw">25,000,000</ix:nonFraction> shares, bringing the total number of authorized shares of common stock to <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_6_17_2021_midR-jy3VUGn7KvHZ7QMZw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_695KhS1-FUKf1TASd8xupA">150,000,000</ix:nonFraction> shares. The increase in authorized shares to <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_6_17_2021_midR-jy3VUGn7KvHZ7QMZw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_w87zZd3z4Ui57coGmayOyw">150,000,000</ix:nonFraction> became effective on June 17, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On June 21, 2022, the stockholders of the Company voted at the 2022 Annual Meeting to approve an amendment to Mustang&#8217;s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance by <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_6_21_2022_To_6_21_2022_9w7Pc3dMn0il-0WAUszkjg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_Js3PG_Wyn0yAcgS8JcL_QQ">50,000,000</ix:nonFraction> shares, bringing the total number of authorized shares of common stock to <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_6_21_2022_W87ewabwMUywhrCygGG9dg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_xc7G6opKI0-4LGhN79Z87w">200,000,000</ix:nonFraction> shares.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Narr_N9XeD8ga406ZNV-cPEC43w"></a><ix:continuation id="Tb_JliPouztaUWNkUIH7JiPCA_cont1" continuedAt="Tb_JliPouztaUWNkUIH7JiPCA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">At-the-Market Offering of Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In July 2018, the Company entered into an At-the-Market Issuance Sales Agreement (the &#8220;Mustang ATM&#8221;) with B. Riley Securities, Inc. (formerly B. Riley FBR,&#160;Inc.), Cantor Fitzgerald&#160;&amp; Co., National Securities Corporation,<span style="background:#ffffff;"> (now B. Riley FBR, Inc.),</span> and Oppenheimer&#160;&amp; Co.&#160;Inc. (each an &#8220;Agent&#8221; and collectively, the &#8220;Agents&#8221;), relating to the sale of shares of common stock pursuant to the 2020 S-3. Under the Mustang ATM, the Company pays the Agents a commission rate of up to <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="As_Of_7_13_2018_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_Xdsmbxo8fkiq_m6mzNm0Bw" decimals="3" format="ixt:numdotdecimal" name="mbio:CommissionRatePercentage" scale="-2" id="Narr_wXZLfwFC9US9S2UkNiSc-Q">3.0</ix:nonFraction>% of the gross proceeds from the sale of any shares of common stock. On December 31, 2020, the Mustang ATM was amended to add H.C. Wainwright &amp; Co., LLC as an Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">During the year ended December 31, 2022, the Company issued approximately <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_gFhn3tpHy0eOhnDxAPc2tQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="Narr_yswo6c-A3ke3fc_KlcxRlQ">7.9</ix:nonFraction> million shares of common stock at an average price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_wNo8mVO2kUeHFiMORHtB9Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_-P6n4FigrUKeFCG1vV1mlg">0.84</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_gFhn3tpHy0eOhnDxAPc2tQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_1FOirxE9jkKZ5rmhzRaEiA">6.6</ix:nonFraction> million under the ATM Agreement. In connection with these sales, the Company paid aggregate fees of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_gFhn3tpHy0eOhnDxAPc2tQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_d9v4ZEHefUaY0ZZDzKu1Tg">0.1</ix:nonFraction> million for net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_gFhn3tpHy0eOhnDxAPc2tQ" decimals="-5" format="ixt:numdotdecimal" name="mbio:ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" scale="6" id="Narr_g2cqAg1NUkiduv1IWHAvpw">6.5</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">During the year ended December 31, 2021, the Company issued approximately <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_aoFLNFn800q4su8jbp-MXw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="Narr_v_1wdg-eAUCB4bEPQvaR6g">19.4</ix:nonFraction> million shares of common stock at an average price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_ywrnZ-GLAkqK0TW0rXu5xQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_pBkdR6sdMEW9yDPd1LuL3Q">3.70</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_aoFLNFn800q4su8jbp-MXw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_Z3tNKBMjGEKvoiITBeJFng">71.9</ix:nonFraction> million under the ATM Agreement. In connection with these sales, the Company paid aggregate fees of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_aoFLNFn800q4su8jbp-MXw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_J0j-07XZgESz5mo-lRBrlg">1.3</ix:nonFraction> million for net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_aoFLNFn800q4su8jbp-MXw" decimals="-5" format="ixt:numdotdecimal" name="mbio:ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" scale="6" id="Narr_3Yl8Ua88-UeAZ1Cp1CKquw">70.6</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;margin:0pt;">Pursuant to the Founders Agreement, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_c0ZjuYLL-0CMEHMYhr3GFA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_9-O7QzOOMUW9sJ7wShWOlQ">196,952</ix:nonFraction> shares of common stock to Fortress at a weighted average price of $0.84 per share for the year ended December 31, 2022, and recorded zero shares issuable to Fortress in connection with the shares issued under the Mustang ATM. Pursuant to the Founders Agreement, Mustang issued <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_2F1anYHQf02jp38E63vSpg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_lEs9NPUC8EGU9RoPleS0jA">576,157</ix:nonFraction> shares of common stock to Fortress at a weighted average price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_4VC5ZPEVB0aXZyDJ1fjJtg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_JSRsX-B4bEWQjPQqZd1ROQ">3.70</ix:nonFraction> per share for the year ended December 31, 2021, in connection with the shares issued under the Mustang ATM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Registration Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">On October 23, 2020, the Company filed a shelf registration statement No. 333-249657 on Form S-3 (the &#8220;2020 S-3&#8221;), which was declared effective on December 4, 2020. Under the 2020 S-3, the Company may sell up to a total of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_12_4_2019_To_12_4_2019_us-gaap_SubsidiarySaleOfStockAxis_mbio_RegistrationStatementsMember_t--jUxfLC0e7u7XptCY16g" decimals="-6" format="ixt:numdotdecimal" name="mbio:ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold" scale="6" id="Narr_hV4SjXQLHky8Zg_lnZct7g">100.0</ix:nonFraction> million of its securities. As of December 31, 2022, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mbio_RegistrationStatementsMember_MnKy-ABZ70yPMHS_OgN4rA" decimals="-5" format="ixt:numdotdecimal" name="mbio:CommonStockSharesAvailableForFutureIssuanceValue" scale="6" id="Narr_pA-2MLPmuUykpqPIU1jeng">8.0</ix:nonFraction>&#160;million of the 2020 S-3 remains available for sales of securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">On April 23, 2021, the Company filed a shelf registration statement No. 333-255476 on Form S-3 (the &#8220;2021 S-3&#8221;), which was declared effective on May 24, 2021. Under the 2021 S-3, the Company may sell up to a total of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_5_24_2021_To_5_24_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_mbio_RegistrationStatementsMember_uT0i13PYeUesod3TAzOW4w" decimals="-5" format="ixt:numdotdecimal" name="mbio:ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold" scale="6" id="Narr_ubdu1g3Ya0inzU-7Hqsoww">200.0</ix:nonFraction> million of its securities. As of December 31, 2022, there have been no sales of securities under the 2021 S-3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Stock Issuances to Fortress</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under the terms of the Second Amended and Restated Founders Agreement, which became effective July 22, 2016, Fortress will receive a grant of shares of our common stock equal to two and one-half percent (<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w" decimals="3" format="ixt:numdotdecimal" name="mbio:DilutedOutstandingEquityPercentage" scale="-2" id="Narr_dK-ZdAzIsUOxLtH9UO1B8w">2.5</ix:nonFraction>%) of the gross amount of any equity or debt financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the year ended December 31, 2022, the Company issued&#160;<ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Narr_ygY1HtNtyUi7rF8_goBDQg">196,952</ix:nonFraction>&#160;shares of common stock, which equaled&#160;<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w" decimals="3" format="ixt:numdotdecimal" name="mbio:DilutedOutstandingEquityPercentage" scale="-2" id="Narr_Vs4Wc8_SYkSZ73u13ROrPA">2.5</ix:nonFraction>% of the gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_D02sY_Okb0CAJr_sq1tImg" decimals="-5" format="ixt:numdotdecimal" name="mbio:SaleOfStockAggregateOfferingPricePermittedByAgreement" scale="6" id="Narr_mwbwwetNzUCHCCjzvWlqAg">6.6</ix:nonFraction>&#160;million from the sale of shares of common stock under Mustang&#8217;s At-the-Market Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">For the year ended December 31, 2021, the Company issued&#160;<ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_Trkkxq84fU-Vd0RoRhj2NQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Narr_LJseb4BvlkyiZksCTPdJVw">576,157</ix:nonFraction>&#160;shares of common stock and recorded&#160;<ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_Trkkxq84fU-Vd0RoRhj2NQ" decimals="INF" format="ixt:numdotdecimal" name="mbio:StockIssuedDuringPeriodSharesIssuableForServices" scale="0" id="Narr_GteOTlzL1UimofLo4n-eyQ">51,295</ix:nonFraction>&#160;shares issuable to Fortress, which equaled&#160;<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_Trkkxq84fU-Vd0RoRhj2NQ" decimals="3" format="ixt:numdotdecimal" name="mbio:DilutedOutstandingEquityPercentage" scale="-2" id="Narr_ImQGrBJ1GEmab-DxZ-XzPA">2.5</ix:nonFraction>% of the gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_m9J360WMFk65TIBgOb6HfA" decimals="-5" format="ixt:numdotdecimal" name="mbio:SaleOfStockAggregateOfferingPricePermittedByAgreement" scale="6" id="Narr_gO54U0DHXE-nk9lKZ9Tjcw">71.9</ix:nonFraction>&#160;million from the sale of shares of common stock under Mustang&#8217;s At-the-Market Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Equity Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has in effect the 2016 Incentive Plan (the &#8220;Incentive Plan&#8221;). The Incentive Plan was adopted in 2016 by our stockholders and the compensation committee of the Company&#8217;s board of directors and is authorized to grant stock-based awards to directors, officers, employees and consultants. The plan initially authorized grants to issue up to <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UcqZY0RuLkm6-uv8PCh07w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_uZct2zZarU6_8dKJXfRHcg">2,000,000</ix:nonFraction> shares of authorized but unissued common stock and expires <ix:nonNumeric contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4LOmmgimP0ClUtAdOe4haA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_Jyh26kwG6EiyL0WotBLImg">10 years</ix:nonNumeric> from adoption and limits the term of each option to no more than <ix:nonNumeric contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4LOmmgimP0ClUtAdOe4haA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_x-SN9ybL5EavkW1ncABYQg">10 years</ix:nonNumeric> from the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_52ba19e8_5ef3_47d6_ae1b_3d9863efc061"></a><a id="Tc_FCJOVX5MqEq17dLIO4-YTw_1_7"></a><a id="Tc_qvVfocSSw0GEFesyrDKw2A_2_7"></a><a id="Tc_ufbGASBRzk2PasJAkBKFww_3_4"></a><a id="Tc_F8XBiU0HJ0WhA46vYjh6JQ_3_7"></a><a id="Tc_NCaxImkpUU2x7p8BvuAc4A_4_2"></a><a id="Tc_dU29Cbg8e0mkeW78Zk86gQ_4_4"></a><a id="Tc_QmgWd0MDtU-0oxhS4pWg8A_4_7"></a><a id="Tc_pn2JOj--xUOZWe5I0q22yQ_5_0"></a><a id="Tc_0CCLB1K7rEeB9A9MSH8szw_5_4"></a><a id="Tc_ybevCin6ykGnjTjC4G_gsA_6_0"></a><a id="Tc_YQ77hs1KwEK2TraDAKYd0A_6_4"></a><a id="Tc_8yBQlD6n40C6zzLM_6pdQQ_7_0"></a><a id="Tc_omCqca6XDUiI4fcSe4fdqQ_8_0"></a><a id="Tc_er9ywY6g1kW4IKsoNxMQ2Q_8_4"></a><a id="_73dd104d_a2b8_4e0e_a818_6aa9426dce4e"></a><a id="Tc_oNzLx1VQlUiOTJkgBdzgHw_1_4"></a><a id="Tc_3QdZXkemFEGNRRyr-IhkvQ_2_4"></a><a id="Tc_BKn2kaj9pUGzIcwOZYzIHg_3_2"></a><a id="Tc_v9iui-His02bP8OGjTXgFA_3_4"></a><a id="Tc_DoYmPKZitEi9tNDeqcmo4Q_4_0"></a><a id="Tc_CqPjNHyHU0KahAwAsZnaMg_4_4"></a><a id="Tc_eew8kcBR1UWsEM4gj29zyQ_5_0"></a><a id="Tc_fcYcFsGwIECt5CK6OIINRA_6_0"></a><a id="Tc_3O42W_SQ5kKPBzVG4_MwAA_7_0"></a><a id="Tc_FxlMYIbSOkGz_8qJ4rN3gA_7_4"></a><a id="Tc_nzWmtD1NwUaIBECzSaAxaw_8_0"></a><a id="Tc_5OtSSsmpUkS4vJR5O8c6WA_9_0"></a><a id="Tc_IVmc8epQ5EOJsblSFnnk0Q_10_0"></a><a id="Tc_CgNZdxiKsUKmRz7gcNjaCw_10_4"></a><ix:continuation id="Tb_JliPouztaUWNkUIH7JiPCA_cont2" continuedAt="Tb_JliPouztaUWNkUIH7JiPCA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In June&#160;2018, the Company&#8217;s stockholders approved an amendment to the Incentive Plan to increase the number of authorized shares issuable by <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2aMeSdhNi0a4ZRzBQ7A_hA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_6DUeQsFAQ0i2uDJD9UAoTw">3,000,000</ix:nonFraction> shares, for a total of <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nrn5fFARI0iVnAb0sMWaVw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_V03S_2PMmUesEAO5v51aAw">5,000,000</ix:nonFraction> shares. In June&#160;2021, the Company&#8217;s stockholders approved an amendment to the Incentive Plan to increase the number of authorized shares issuable by <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MqmksIdNjkaWP_ipa9CSuQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_PPI6C0FGm0y9OkakC7AobA">3,000,000</ix:nonFraction> shares, for a total of <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BNRH5QbCykyPiw-RTmCPqg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_zX4GbWxJukKxH6efj_13zg">8,000,000</ix:nonFraction> shares. In June&#160;2022, the Company&#8217;s stockholders approved an amendment to the Incentive Plan to increase the number of authorized shares issuable by <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_6_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M2BLxvwBtUun2VN6YRNObQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_Me1-TGzJGEyJnyKhl9YfWg">3,000,000</ix:nonFraction> shares, for a total of <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PDcmO8zz3EqNXOXuFyL8PQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_hjZs7dQo9UWUNQeWScU6Lg">11,000,000</ix:nonFraction> shares As of December 31, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BbA2PkmH4kSDxqPMhK8S-A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_yEwigPP1Mk2OFh9Vx8LCEw">4,462,870</ix:nonFraction> shares are available for issuance of stock-based awards under the Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Stock Options</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_YMLGfv2QJU2bjX3oydezaw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes stock option activities for the&#160;year ended December 31, 2022 and 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Life&#160;(in</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock&#160;Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bhwOXV7qmUa0T2YdE_tfkw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_g7Ohqkd0EEKYcwkzfAZb-Q_5_2">1,141,675</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bhwOXV7qmUa0T2YdE_tfkw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_Uy0R-AtX6kGUpfOFS7ibGA_5_5">5.73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uj9LYQ994USIWcKdot_c7w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_H6QbB8PTGkGHZMArt1U-jw_5_7"> 6.31</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_suZlLo8Guk2LmZMnsU9VMw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_yG9zFFCwkUqbE1lnl-wmJA_6_2">1,141,675</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_suZlLo8Guk2LmZMnsU9VMw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_Zl7nrMPrq0uY8S-nEn2cBQ_6_5">5.73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_7W5zr_ZJ8k6YRLAjbxG7LQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_YWKmXIKWHkOSxIl5um1W9w_6_7"> 5.31</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BbA2PkmH4kSDxqPMhK8S-A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_JzZiIuB-BEa0XqiCoJ9AYg_7_2">1,141,675</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BbA2PkmH4kSDxqPMhK8S-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_xkFP7-a05kW6sNkKblzn5g_7_5">5.73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LqmnL5gbTkS17IvEqtphGA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_wHaNnDBmfEep5b4TcpimUw_7_7"> 4.31</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BbA2PkmH4kSDxqPMhK8S-A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_84f7loI9OEGabq52bDAV3w_8_2">713,547</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BbA2PkmH4kSDxqPMhK8S-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_lvWp0md2LEqUfhrBRT_9Lw_8_5">5.73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LqmnL5gbTkS17IvEqtphGA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_ohQIrjCXRUKpBmAkqtM3ow_8_7"> 4.31</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As of December 31, 2022, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BbA2PkmH4kSDxqPMhK8S-A" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="Narr_1zE42-eBiEK4uRS_BiYmxg">no</ix:nonFraction> unrecognized stock-based compensation expense related to options. The Company accounts for forfeited awards as they occur as permitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Restricted Stock Awards</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_UPMzzbZe7UyasqVciLqSTA" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="Tb_sr1hyj1250CNn7GM21ceKQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Certain employees and directors have been awarded restricted stock. The restricted stock vesting consists of milestone and time-based vesting. The following table summarizes restricted stock award activities for the&#160;year ended December 31, 2022 and 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant&#160;Date&#160;Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_Pd10hdVFnE2rD6DyKQmoRg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_kDU3B-picUacXKPsZSVmDQ_4_2">302,114</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_Pd10hdVFnE2rD6DyKQmoRg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_hAVvML3pqkmm2oacSxsO1Q_4_5">4.93</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_O3YYPIPGzE-eJsI9zpkIKw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_rqcdyeft1kGGnbSvkKhv4A_5_2">68,870</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_O3YYPIPGzE-eJsI9zpkIKw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_MSojKK4IRkOVzm9QKA8JMg_5_5">3.63</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_O3YYPIPGzE-eJsI9zpkIKw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_9rBEQ7qWOkq-CFSMyXULmg_6_2">90,001</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_O3YYPIPGzE-eJsI9zpkIKw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_Avo9_p7oM0KFAXxpzNaQng_6_5">6.69</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_3-kS7FRDbkqpKxd-4hKdeg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_sTCTQBSCR0GLt5Y8AlCVrw_7_2">280,983</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_3-kS7FRDbkqpKxd-4hKdeg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_eL8VygfqYEGF62w118xADA_7_5">4.05</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_UPMzzbZe7UyasqVciLqSTA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_DnyTrWTt_EyPX0If29NnxQ_8_2">358,320</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_UPMzzbZe7UyasqVciLqSTA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc__K7HRB9dMkeG184L4ifX9w_8_5">0.70</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_UPMzzbZe7UyasqVciLqSTA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_u8nDgkYKSESjUaLQqCnMUw_9_2">129,058</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_UPMzzbZe7UyasqVciLqSTA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_kvWh9nYbeEK9DU2QrOCmsg_9_5">4.89</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_oh5GT7S9BUWgIrXyvuqlaw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_SohJ_7oi5UCSTAWnTHiJ-A_10_2">510,245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_oh5GT7S9BUWgIrXyvuqlaw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_ThQXyyy1GUWsV1hTEO-WlQ_10_5">1.48</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As of December 31, 2022, the Company had unrecognized stock-based compensation expense related to restricted stock of $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_oh5GT7S9BUWgIrXyvuqlaw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_5cdmrJ0hXUuzRKEXirOX3g">0.4</ix:nonFraction> million, which is expected to be recognized over a weighted average period of approximately <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_UPMzzbZe7UyasqVciLqSTA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_oqU5-x9kaESZnSZB875ZQw">2.3</ix:nonNumeric>&#160;years.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d3fc59eb_c779_48e0_9df6_1824b159357e"></a><a id="Tc_tBAv1QnmXUCzEFkz3aClCQ_1_4"></a><a id="Tc_6a5q93Hdh02OuGc5ZscIPA_2_4"></a><a id="Tc_u4pKzyoZ30ygrUcUcv5ziw_3_2"></a><a id="Tc_a3SN-4eH6k2_RFMTIbs8QQ_3_4"></a><a id="Tc_StMi0o93N0S_WXuFvb0WGg_4_0"></a><a id="Tc_dLkvPd7adEax6AMx4lttHg_4_4"></a><a id="Tc_HcOp46ZKl0aJbuVRfpPePg_5_0"></a><a id="Tc_BtH6e7rBPE61zVoS22l-CQ_6_0"></a><a id="Tc_1Ehc2KBH_EiDV2oH6qsDmA_7_0"></a><a id="Tc_1U3t0-fS_U-3RctL-f2X3w_8_0"></a><a id="Tc_s_ZU-1t-s0CN4CsevV0VLg_8_4"></a><a id="Tc_HOd4CHZvM02h35BiMDbMUQ_9_0"></a><a id="Tc_vjCf2fE0GUeZHeaQ9yffJA_10_0"></a><a id="Tc_AnFkQatsP026JUWpNwAtwg_11_0"></a><a id="Tc_84j4CeG1lUuQJDSMm7WDIQ_12_0"></a><a id="Tc_ToXq3tgdJU6FCl-Hc7heRw_12_4"></a><a id="_0dc7dadf_7baa_4d5d_b1c8_ae8c1dc7ed2f"></a><a id="Tc_y9VcPf7pWEaphZXYosxibA_1_2"></a><a id="Tc_hlBKWiwowUGt2dVcYEP7OQ_2_2"></a><a id="Tc_yUqj1FAPvEmGBiGlYkxd6w_2_5"></a><a id="Tc_0WvXUBMZ1E--bL9eTrzD1Q_3_0"></a><a id="Tc_7sAcmXWNuUm0FU7rB6L97w_3_2"></a><a id="Tc_bE-Yen9Gskig5PcsSdycYQ_3_5"></a><a id="Tc_uCCF7blV6EiZS02wpJP33g_4_0"></a><a id="Tc_1i7I_5WrjEOUgWbl8c4GTg_5_0"></a><a id="Tc_NurGaaig106NMwqui8INRw_5_2"></a><a id="Tc_TBc2UutqwUi7AkXSxDvvPg_5_5"></a><a id="_c280468d_f588_42b8_b259_c068c82be531"></a><a id="Tc_Zih0IXwwk0ej5pT3KW_P9g_1_7"></a><a id="Tc_-0teCBVBzUaRdPkF6SJ6Jw_2_7"></a><a id="Tc_PGAS2eGKGE-_ycW__I3V1w_3_4"></a><a id="Tc_k-uysiYCeEOzn2om4lqQCA_3_7"></a><a id="Tc_K-Lio7UFqk6H0ftOKJaYAA_4_2"></a><a id="Tc_XjXLxquRJUeyDKFTo7af8Q_4_4"></a><a id="Tc_3V7FXolCkE6eKVcOQD2xsA_4_7"></a><a id="Tc_qPu4zYYcoUWVQFApGQwZNA_5_0"></a><a id="Tc_j8mKy690JUKiLMiig90Y6w_5_4"></a><a id="Tc_yZ_jwqPmlE2_0FqAg8i-OA_6_0"></a><a id="Tc_TV61CG2iR0SsJhIvv2fL-Q_6_7"></a><a id="Tc_Iu4rMlSM-Eq7JtkquGEvqw_7_0"></a><a id="Tc_NJyb27V8L0O8TF1tQoe42w_7_5"></a><a id="Tc_OQNx6IJ9_kei7kgenwfz5Q_7_7"></a><a id="Tc_KT_RlZNRUEa7x7MKFZaLlw_8_0"></a><a id="Tc_qVHwT9yY70S2x-iJLn2yKg_8_4"></a><a id="Tc_VX9iYBZ8c0K5esHOlL_L-w_9_0"></a><a id="Tc_AmUMsmo60kS1rhb5vHLBUA_9_7"></a><a id="Tc_eZwgJ1HIsU27AuBWumjKNQ_10_0"></a><a id="Tc_zUOKjq5RIE-vKEiKBzf5Tw_11_0"></a><a id="Tc_Nb6PeUQ1nECx7aRiBcGJ4w_11_4"></a><ix:continuation id="Tb_JliPouztaUWNkUIH7JiPCA_cont3" continuedAt="Tb_JliPouztaUWNkUIH7JiPCA_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Restricted Stock Units</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HKp1HVK3rUeH2BUSicO2mA" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="Tb_k7UeaN5c-EmyPUMXAvrH-g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes restricted stock units&#8217; activities for the&#160;year ended December 31, 2022 and 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant&#160;Date&#160;Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2-wAsbb-T0KYD16SQuYxKg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_hxP84nPBpEO019DCfIkXdw_4_2">1,468,559</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2-wAsbb-T0KYD16SQuYxKg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_VGVNzOFetkWXor1t2Ke0ww_4_5">3.87</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nMMb4QwZpE2wkHPBjsoMzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_ExvVswWSxk2G23tvKt2rsw_5_2">1,660,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nMMb4QwZpE2wkHPBjsoMzQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_lDM30_Sjp0yOqbwRBxGhnQ_5_5">3.07</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nMMb4QwZpE2wkHPBjsoMzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_v3uf6zgI0kWKf_Vh6qXcpg_6_2">372,873</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nMMb4QwZpE2wkHPBjsoMzQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_78r8eldoZUeik-vJ4o6Pzg_6_5">3.60</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nMMb4QwZpE2wkHPBjsoMzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_RmtxOJBFukiNt0iLFMEptQ_7_2">420,379</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nMMb4QwZpE2wkHPBjsoMzQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_QKnd6SzPPkuwKJ2c32BF4g_7_5">4.27</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_KeRs2NdINE-YRgyA7zQiQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_trQsGa8HbUWYWTU6JQXg5A_8_2">2,335,557</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_KeRs2NdINE-YRgyA7zQiQg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_rW7pV0VWuUSrVwXDE6GwDw_8_5">3.27</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HKp1HVK3rUeH2BUSicO2mA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_chw0dZmxSECSUdEYBjuk_w_9_2">1,484,647</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HKp1HVK3rUeH2BUSicO2mA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_o_J7dgVPVUyrZ_HMorJc0Q_9_5">0.76</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HKp1HVK3rUeH2BUSicO2mA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_pJLpGLp1g0G86bx-WtcqKw_10_2">514,999</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HKp1HVK3rUeH2BUSicO2mA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_7nTl9G08rkeaTwXYQhbuMA_10_5">2.53</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HKp1HVK3rUeH2BUSicO2mA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_hRZ2AInKtEixR-F7AcGNEQ_11_2">816,518</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HKp1HVK3rUeH2BUSicO2mA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_PTti2J6m5EKr0meGM2Lykg_11_5">2.98</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_GOVpc9dkuEG97uEvmowlTQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_Twgprolg7kiPvWf7bke3YQ_12_2">2,488,687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_GOVpc9dkuEG97uEvmowlTQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_H8A3pFofLECE-2JghWKiGQ_12_5">1.84</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As of December 31, 2022, the Company had unrecognized stock-based compensation expense related to restricted stock units of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_GOVpc9dkuEG97uEvmowlTQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_XKEiNfwcxkOtwRi6qunlqw">2.0</ix:nonFraction> million, which is expected to be recognized over a weighted average period of approximately <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HKp1HVK3rUeH2BUSicO2mA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_Afz-lxRpt06PLCyz12IZgQ">2.7</ix:nonNumeric>&#160;years. </p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="Tb_yCznQWkIYEOCYAwshVxSBg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes stock-based compensation expense for the&#160;years ended December 31, 2022 and 2021 (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_f1ddUvO4v0amvOZiXCEDeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_B1zo195zF02sA5Llo1v_Iw_3_3">700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_uHyqiEuP_0ekgE-jQl3slQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_otp05g01akO--Hn4Q9t2qA_3_6">1,030</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-LQvQ6gJ9UOk8vXKCNkxng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc__4CaRc0gdkeTYk8Pq0PUUw_4_3">1,583</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-mQVcy5AFUC0fcnvfp5yUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_H6GoD46Ba0KPpYPNmiGJ8A_4_6">2,278</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_acajajrYOUqOcAa_aXEgeQ_5_3">2,283</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_lrqDXGLNMUmYhgXMGvEmJg_5_6">3,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In connection with the Company&#8217;s offering of shares of common stock in a private placement, each investor received a warrant equal to <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_tpnhJWDO60OMRtanSOx5tQ" decimals="2" format="ixt:numdotdecimal" name="mbio:ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased" scale="-2" id="Narr_XHfMzDl9YkWSwmuZqghfMw">25</ix:nonFraction>% of the common shares purchased in connection with the offering. Further, National Securities Corporation received Placement Agent Warrants. In connection with the Term Loan on March 4, 2022, the Company issued a warrant to the Lender to purchase <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_Om4hsBj3ME2K5w9l2S6G_w">748,036</ix:nonFraction> shares of the Company&#39;s common stock with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_yek2Ll_OykqtmkAVNC94Rg">0.8021</ix:nonFraction>, see Note 8.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="mbio:SummaryOfWarrantActivitiesTableTextBlock" id="Tb_wELrxzNDkkuTmkUTIoOpMQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of warrant activities for&#160;years ended December 31, 2022 and 2021, is presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Life&#160;(in</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_cSWJg5CHcU6I0x0JrwnJzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_gwoZ2UppwE-SZi7xfS4AaA_5_2">5,402,670</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_cSWJg5CHcU6I0x0JrwnJzQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_fo_QlKzJt0qE-2i6-WL52g_5_5">8.21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_YQ4fUCukB0WFke0KueexQA" format="ixt-sec:duryear" name="mbio:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" id="Tc_pD_UWvtVUESZYSLo2dcBJg_5_7"> 1.39</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_zwcEeJiJR0GMOVhFZZp5MA" decimals="INF" format="ixt:numdotdecimal" name="mbio:ClassOfWarrantOrRightWarrantsExpiredDuringPeriod" scale="0" id="Tc__joJaAxBxEGOvsHCwtQY4A_6_2">2,093,878</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_zwcEeJiJR0GMOVhFZZp5MA" decimals="2" format="ixt:numdotdecimal" name="mbio:WarrantExercisePriceExpiredDuringPeriod" scale="0" id="Tc_ykp5Mi2nxEOdbt_slTwkcA_6_5">8.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cashless exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_zwcEeJiJR0GMOVhFZZp5MA" decimals="INF" format="ixt:numdotdecimal" name="mbio:ClassOfWarrantOrRightWarrantsExercisedDuringPeriod" scale="0" id="Tc_C05EqSeC4EWIrF8zUOjiJw_7_2">138</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_hD2Rfx-DxkuN5TyT5ipjDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_dNgRdzyrSEiKhRDjhv0-iw_8_2">3,308,654</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_hD2Rfx-DxkuN5TyT5ipjDw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_EvyV8_h8oEGt1jfFGLqQaQ_8_5">8.02</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_zwcEeJiJR0GMOVhFZZp5MA" format="ixt-sec:duryear" name="mbio:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" id="Tc_Is2uuQecI0SeyFyc6hV7eA_8_7"> 0.73</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_tpnhJWDO60OMRtanSOx5tQ" decimals="INF" format="ixt:numdotdecimal" name="mbio:ClassOfWarrantOrRightWarrantsExpiredDuringPeriod" scale="0" id="Tc_qxW2B7X5aUqCLtHQd1wxew_9_2">3,003,770</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_tpnhJWDO60OMRtanSOx5tQ" decimals="2" format="ixt:numdotdecimal" name="mbio:WarrantExercisePriceExpiredDuringPeriod" scale="0" id="Tc_6QfFp9Qfi06qlKRpeXZYTA_9_5">8.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_tpnhJWDO60OMRtanSOx5tQ" decimals="INF" format="ixt:numdotdecimal" name="mbio:ClassOfWarrantOrRightWarrantsGrantedDuringPeriod" sign="-" scale="0" id="Tc_K06l4DRYG0G54bVVzXsZMw_10_2">748,036</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_tpnhJWDO60OMRtanSOx5tQ" decimals="2" format="ixt:numdotdecimal" name="mbio:ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod" scale="0" id="Tc_rt-mj5CiYUenp_4ZhvjMwA_10_5">0.80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_tpnhJWDO60OMRtanSOx5tQ" format="ixt-sec:duryear" name="mbio:ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod" id="Tc_kLfRDy4E4U2TRj7rUyhJew_10_7"> 9.18</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_qB-ZO8R0_ESmBgqQbpsWbg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_Isk8tBRC50ya9ysk9CqAsQ_11_2">1,052,920</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_qB-ZO8R0_ESmBgqQbpsWbg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_9Q2mlF-bcE-ILFwdQLGDsQ_11_5">1.52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_tpnhJWDO60OMRtanSOx5tQ" format="ixt-sec:duryear" name="mbio:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" id="Tc_RmRJnaBMiEmnm8Ge9L5bCQ_11_7"> 8.29</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Upon the exercise of warrants, the Company will issue new shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_JliPouztaUWNkUIH7JiPCA_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Employee Stock Purchase Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In connection with our Employee Stock Purchase Plan (&#8220;ESPP&#8221;), eligible employees of Mustang and Fortress can purchase the Company&#8217;s Common Stock at the end of a predetermined offering period at <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="INF" format="ixt:numdotdecimal" name="mbio:EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage" scale="-2" id="Narr_dbvh17AwEUOOpqQqlY5r6A">85</ix:nonFraction>% of the lower of the fair market value at the beginning or end of the offering period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of December 31, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Narr_aGOjojx3Hkap7sNNj04V9g">586,010</ix:nonFraction> shares have been purchased and <ix:nonFraction unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_BLy2ipZ4AUWpYqc-GdXIDw">413,990</ix:nonFraction> shares are available for future sale under the Company&#8217;s ESPP.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_22facca7_48e6_4b68_8fcb_2fc50f7cc38d"></a><a id="Tc_5Z8GOy1dZ0yRuo-PGF0b1Q_1_2"></a><a id="Tc_CkErwlFlSU6ojsMxQxfGEg_2_2"></a><a id="Tc_kEBfftCpeU2HgLJy58PSdQ_2_4"></a><a id="Tc_Lzfdq0Akjk-siHqd4fy3WA_3_0"></a><a id="Tc_2xcCQr7y2kWTorLS44FqxA_3_3"></a><a id="Tc_qp0-Ro_UNEqpOORUtt4q5g_3_5"></a><a id="Tc_MmNxp55vj0Kmxw4wCW_phw_4_0"></a><a id="Tc_n0wq7ymtYUizYoneq8UMrw_4_3"></a><a id="Tc__2tVCuIJRkiK5CnrTZTosQ_4_5"></a><a id="Tc_AnAkVwHLS06sWxACwiQzfA_5_0"></a><a id="Tc_VWXqxf9zBkym5K1h8CE4MA_5_3"></a><a id="Tc_uVaJnITvHEyURc-RuIwPNg_5_5"></a><a id="Tc_A0d5FRdi70eVwXhw9l9yPQ_6_0"></a><a id="Tc_w8GrVtgEMkidOxN_y-gCTw_6_3"></a><a id="Tc_rvJjU8z5akGRGLVbMnsKTQ_6_5"></a><a id="Tc_059BERtGTECKYw-QwV-CMQ_7_0"></a><a id="Tc_8tS3ZKxWj0-XDasgEMJWUQ_7_3"></a><a id="Tc_kwQZfUpCc0KW0LZDEXhkKg_7_5"></a><a id="Tc_zZ-Kdvk38EGXJsyQKLQnQg_8_0"></a><a id="Tc_0kF5M8Hs3keg5pu9fYsQgQ_8_3"></a><a id="Tc_xeXLJuR2Pk23f15eJIjt2g_8_5"></a><a id="Tc_ljwixvhCH0SwdYkxN4oEGg_9_0"></a><a id="Tc_DuoTKeB_AU6obd0mAonhRA_9_3"></a><a id="Tc_IPAtaDpYLUa114H2QGvrKQ_9_5"></a><a id="Tc_O-aaP7fFlUe1dCxN1ipxug_10_0"></a><a id="Tc_Zlambhe05Uab1N3Hi5yujQ_10_3"></a><a id="Tc_XEjy76Z2ekOM441WWzHLIA_10_5"></a><a id="Tc_hWTx0efe9UKlCp70-84bVA_11_0"></a><a id="_014e197e_9876_4031_95b3_48d9ef505b6d"></a><a id="Tc_RdWe_cxTIkeGoKUyPLdwyw_1_2"></a><a id="Tc_oAJcHlJdpEawBjn9eCy23A_2_2"></a><a id="Tc_m52Xt8VYRUutGspxi8SzHA_2_5"></a><a id="Tc_F0FyOMvAsEiCr2DgFZwXCA_3_0"></a><a id="Tc_utIR0KTir0CC8fsnzHxNuQ_4_0"></a><a id="Tc_OhSg2AqpSEyfWYoKYwfeFg_4_2"></a><a id="Tc_TtrC_QiE4EWG_wdLuDPBtQ_4_5"></a><a id="Tc_o2EiRHIs4EKIqVO1f80LBA_5_0"></a><a id="Tc_nxhB4TSVV0qB3m3YmHqYDA_6_0"></a><a id="Tc_tkWoEXcJdU-28d0DyZgbZw_7_0"></a><a id="Tc_qrnbsZDOpkyQzCWbdR1BjQ_8_0"></a><a id="Tc_Xqhtlx98EUmAhuoxcGcuAA_9_0"></a><a id="Tc_umQ8MIab_EmLJCMivmk7MA_10_0"></a><a id="Tc_pbQ-YajT9Uy6x858CFe9rQ_11_0"></a><a id="Tc_eolIZEc9M0uOIfykFdWCyg_12_0"></a><a id="Tc_jQiww2QYx0a3a3R0MIA8Cg_13_0"></a><a id="Tc_6T1VKWvPDEGGUwmpMrbjKQ_14_0"></a><a id="Tc_5HaoSYi9Xkaz-DEeW9ctFQ_15_0"></a><a id="Tc_8LGGVF3qV0mnC9Vd6ApxEQ_15_2"></a><a id="Tc_2RZpgjv5T0eggoP_Nlhm6A_15_5"></a><a id="Tc_XzAuqMEsaE-utZKWlIqzlQ_17_0"></a><a id="Tc_gY9d35ONRUGI7xD_mKUErw_18_0"></a><a id="Tc_hw39_-xNAkuruoHTqvO2Pg_19_0"></a><a id="Tc_DtpL7pWpbk2gvdFTcHOBXw_19_2"></a><a id="Tc_pkassJ3AKEqCff4tjJ_qOw_19_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_bUnrLJZiskKNJKj0RcyIbQ" continuedAt="Tb_bUnrLJZiskKNJKj0RcyIbQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;10&#160;- Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">The Company has accumulated net losses since inception and has not recorded an income tax provision or benefit during the&#160;years ended December 31, 2022 and 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_vyCqT3P2KEiZqRcqsKagBQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A reconciliation of the statutory U.S. federal rate to the Company&#8217;s effective tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;year&#160;ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statutory federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc__l97wVr5IkOSMZfvDTlsjA_3_2">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_P0LACsd2DEyGqN0anz_zMw_3_4">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes, net of federal tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_fYKT-c-Wc0KgHhPXWjaWLg_4_2">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_uAY-6VoFFku2YW9pTlmCpw_4_4">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-deductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" sign="-" scale="-2" id="Tc_P2Qjc_Nuhk6Cm3g2QJq0wA_5_2">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" sign="-" scale="-2" id="Tc_ObQbWKoQ8EGPTF3hR01nXA_5_4">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="Tc_ytbq9hLGCUqne7bDZoThog_6_2">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="Tc_qR3w6YENK0CtrcGvLILdjw_6_4">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal tax rate change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="2" format="ixt:zerodash" name="mbio:EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent" scale="-2" id="Tc_0ehmjPfpXkq_H32_3UmLzg_7_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="2" format="ixt:zerodash" name="mbio:EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent" scale="-2" id="Tc_2Xg6rBzN70KbUiR8A3M_IA_7_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State tax rate change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="2" format="ixt:zerodash" name="mbio:EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent" scale="-2" id="Tc_YGvPWX1Dp0SrEDrUwG1Bhw_8_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="2" format="ixt:zerodash" name="mbio:EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent" scale="-2" id="Tc_9UGIkp20QkmjV4MC1wGZGw_8_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="Tc_7k41BHbzSkamZSVkGdUumw_9_2">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="2" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="Tc_Bsnuspt3Rkyq0XLGQU0mew_9_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_oLNTpPXmW0e09pVKXCuXCQ_10_2">42</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_QffnamnDxECyhoXWQz6xjg_10_4">41</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income taxes provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="2" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_3cdjnFikvkmscnLRf24lgQ_11_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="2" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_kMB1P3eaCUaD_-3jgLO9tQ_11_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_M6ssxwNrIk-JDSrQpNqWUg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The components of the net deferred tax asset as of December 31, 2022 and 2021 are the following ($ in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;year&#160;ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryovers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_C6Hb_fLUZE-IPUukxasj-A_4_3">75,011</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_u_UELFtyvkGcNKQCV26kKA_4_6">66,879</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock compensation and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" id="Tc_0uP6hGtd10i50NNBvVxR2g_5_3">2,399</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" id="Tc_XxEhEHMFOEWi6lVRbF7qRg_5_6">2,702</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" scale="3" id="Tc_ncClkKWAs0-bfjYLIvJGqw_6_3">59</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" scale="3" id="Tc_Bg7YcJIlZkGdbsB5AtIkFw_6_6">59</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of license</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="Tc_6rTJLPTiLEKEAC9wsra5Gw_7_3">13,375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="Tc_D-xwBitQJUanCUdj90vhyw_7_6">13,977</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="mbio:DeferredTaxAssetOperatingLeaseLiabilities" scale="3" id="Tc_MgEzVfq2u06mHdvGDrktPg_8_3">1,466</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="mbio:DeferredTaxAssetOperatingLeaseLiabilities" scale="3" id="Tc_Gwlo7DRGK0uXi38VHFhqNA_8_6">755</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accruals and reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" scale="3" id="Tc_PjsgXoALv02tUHq68gooKQ_9_3">1,434</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" scale="3" id="Tc_nBauJ9npMUq9F5Pi1xKqIQ_9_6">1,035</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Startup costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="mbio:DeferredTaxAssetsStartUpCosts" scale="3" id="Tc_1Ykv3Tx-T0ifo6ZrYlF4aw_10_3">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="mbio:DeferredTaxAssetsStartUpCosts" scale="3" id="Tc_3MM-hMKNcEyv2PFGr38jhg_10_6">6</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="Tc_hBq86TE4W0ip7GpNcq-3mA_11_3">15,649</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="Tc_xcNkXgSMak2E2qn16ONeTg_11_6">9,728</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">174 Capitalization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="mbio:DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses" scale="3" id="Tc_WSQdchYwMEmRgEk7z6RK2A_12_3">19,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:zerodash" name="mbio:DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses" scale="3" id="Tc_8nsrEna-C0GSPobAHbgzcQ_12_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_lCqBWAGpv0eBWODKbEeaXg_13_3">129,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_pH9-ur-ynUe6BmjzexUOMw_13_6">95,141</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_90mmJ1z9akW4zgJxe5bEjw_14_3">128,101</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_GOuzEKUyhEK7DmNw20vTZQ_14_6">94,751</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_bpwunYdy90qNBxDHv6uRWw_15_3">1,085</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_tFqvSAdKRUaGm76zh0Cj8A_15_6">390</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Right of use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="Tc_aMgg5PgXkkGtYTA7jMmTXA_18_3">1,085</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="Tc_DZDth2bBXEiN_6xol9SF9Q_18_6">390</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="Tc_3iyipHWvRk-N5bBu6-0LHA_19_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="Tc_hMn1OyvZ5UKENbWZwmtkFg_19_6">&#8212;</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has determined, based upon available evidence, that it is more likely than not that the net deferred tax asset will not be realized and, accordingly, has provided a full valuation allowance against its net deferred tax assets as of December 31, 2022 and 2021. A valuation allowance of approximately $<ix:nonFraction unitRef="Unit_Standard_EUR_rzel3jVa2UO3kiVSQxNNcA" contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="Narr_XWZgGt08yUaFnE_4YroP2Q">128.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="Narr_Arhji0NIlEig-n_Q3qk_Mg">94.8</ix:nonFraction> million, respectively, was recorded for the&#160;years ended December&#160;31,&#160;2022 and 2021.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="AdditionallyASC740pro_582271"></a><ix:continuation id="Tb_bUnrLJZiskKNJKj0RcyIbQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As of December 31, 2022, the Company had federal and state net operating loss carryforwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_xeewYyKVAEu67ngPqUXP6A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_5TNnt1z_CUCFPtS0f05e-g">214.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_9h_ihuTMpEGBputHFvfCaw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_N2oQkWGqWUycBdbkn6cQxg">463.1</ix:nonFraction> million, respectively. Approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_QcfoZ3MG8ECfgSVpuDaKmA" decimals="-5" format="ixt:numdotdecimal" name="mbio:OperatingLossCarryforwardsWithoutExpiration" scale="6" id="Narr_e2SgY_POJESeipEg1TCZow">190.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_EUR_rzel3jVa2UO3kiVSQxNNcA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_Q8BOscMl8U2O76Uoh4fs0g" decimals="-5" format="ixt:numdotdecimal" name="mbio:OperatingLossCarryforwardsWithoutExpiration" scale="6" id="Narr_AhLxRstc8UGp48__QC_faQ">0.2</ix:nonFraction> million of the federal and state net operating loss carryforwards, respectively, can be carried forward indefinitely. As of December 31, 2022, the Company had federal and state income tax credits of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_QcfoZ3MG8ECfgSVpuDaKmA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxCreditsAndAdjustments" scale="6" id="Narr_fHJejMFpdEezjm2lBgpQSQ">12.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_Q8BOscMl8U2O76Uoh4fs0g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxCreditsAndAdjustments" scale="6" id="Narr_q-YE_VAUlU-Q2-rRDW6Qeg">4.0</ix:nonFraction> million, respectively, which will begin to expire in <span style="-sec-ix-hidden:Hidden_RuW2aDq3XEWNv2WtYazZ1w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2033</span></span>. Under the provisions of Section 382 of the Internal Revenue Code, a corporation that undergoes an &#8220;ownership change&#8221;, as defined therein, is subject to limitations on its use of pre-change NOLs and income tax credits carryforwards to offset future tax liabilities. Certain tax attributes may be subject to an annual limitation as a result of the Company&#8217;s January 2017 capital raise, as it appears to constitute an ownership change under Section 382. Additionally, under Section 382, annual use of the Company&#8217;s net operating loss carryforwards to offset taxable income may be limited based on cumulative changes in ownership. The Company has not completed an analysis to determine whether any such limitations have been triggered as of December 31, 2022. The Company has no income tax effect due to the recognition of a full valuation allowance on all of its deferred tax assets as it believes that it is more likely than not that the deferred tax assets will not be realized regardless of whether an &#8220;ownership change&#8221; has occurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">There are no significant items determined to be unrecognized tax benefits taken or expected to be taken in a tax return, in accordance with ASC 740 &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;), which clarifies the accounting for uncertainty in income taxes recognized in the financial statements, that have been recorded on the Company&#8217;s financial statements for the periods ended December 31, 2022 and 2021. The Company does not anticipate a material change to unrecognized tax benefits in the next twelve&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Additionally, ASC 740 provides guidance on the recognition of interest and penalties related to income taxes. There were <ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="6" id="Narr_SGYkWb6lfky_eugOu6KhWA"><ix:nonFraction unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw" contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="6" id="Narr_cnTbOo6ONEGz850mCg9oGA">no</ix:nonFraction></ix:nonFraction> interest or penalties related to income taxes that have been accrued or recognized as of and for the periods ended December 31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company is subject to U.S. federal and various state taxes. As of December 31, 2022, the earliest federal tax year open for the assessment of income taxes under the applicable statutes of limitations is its 2019 tax year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri Light';font-size:10.5pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Beginning with the 2022 tax year, the Company is required to capitalize research and development expenses for tax purposes as defined under Internal Revenue Code Section 174. For expenses that are incurred for research and development in the U.S., the amounts will be amortized over 5 years, and for expenses that are incurred for research and development outside the U.S., the amounts will be amortized over 15 years.&#160; As a result of Section 174 capitalization, the Company recognized a deferred tax asset of $19.8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (&quot;CARES Act&quot;) was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#39;s social security payments, net operating loss utilization and carryback periods and modifications to the net interest deduction limitations. The CARES Act did not have a material impact on the Company&#8217;s income tax provision for 2022 and 2021. The Company will continue to evaluate the impact of the CARES Act on its financial position, results of operations and cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">On December 27, 2020, the President of the United States signed the Consolidated Appropriations Act, 2021 (&#8220;Consolidated Appropriations Act&#8221;) into law. The Consolidated Appropriations Act is intended to enhance and expand certain provisions of the CARES Act, allows for the deductions of expenses related to the Payroll Protection Program funds received by companies, and provides an update to meals and entertainment expensing for 2021. The Consolidated Appropriations Act did not have a material impact to the Company&#8217;s income tax provision for 2022 and 2021.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw" name="us-gaap:SubsequentEventsTextBlock" id="Tb_bjmAfBtXl0ass73Ypv4z5g" continuedAt="Tb_bjmAfBtXl0ass73Ypv4z5g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;11&#160;&#8211; Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Board of Directors approved, and our stockholders subsequently approved, a reverse stock split of our Common Stock. On March 15, 2023, the Board of Directors set the reverse stock split ratio at 15-for-1. We have filed a Definitive Information Statement on Schedule 14C in connection with the reverse stock split, and once the applicable waiting periods under SEC and Nasdaq rules have expired we plan to file a Certificate of Amendment to our Amended and Restated Certificate of Incorporation, as amended, in order to give effect to the reverse stock split. The ex-dividend date is expected to be determined in April 2023.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_bjmAfBtXl0ass73Ypv4z5g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ef6c7be3_1744_4e07_81ee_42b1a0d5f06d"></a><a id="SIGNAT_855275"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of Section&#160;12 of the Securities Exchange Act of 1934, the registrant has duly caused this Form&#160;10-K to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Mustang Bio,&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Manuel Litchman</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Manuel Litchman</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Duly Authorized Signatory and Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 29, 2023</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Form&#160;10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:23.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:24%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:23.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:24%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Michael S. Weiss</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael S. Weiss</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Executive Chairman of the Board</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 29, 2023</p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:24%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Manuel Litchman</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manuel Litchman, M.D.</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 29, 2023</p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:24%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Lindsay A. Rosenwald</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lindsay A. Rosenwald, M.D.</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 29, 2023</p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:24%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Neil Herskowitz</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Neil Herskowitz</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 29, 2023</p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:24%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Adam Chill</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adam Chill</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 29, 2023</p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:24%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Michael Zelefsky</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Zelefsky, M.D.</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 29, 2023</p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:24%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eliot Lurier</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eliot Lurier</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Interim Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Principal Financial and Accounting Officer)</p></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 29, 2023</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>tmb-20221231xex4d3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/29/2023 11:43:20 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 4.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-align:center;text-transform:uppercase;margin:0pt 0pt 12pt 0pt;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES<br>REGISTERED PURSUANT TO SECTION 12 OF THE <br>SECURITIES EXCHANGE ACT OF 1934</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-align:center;margin:0pt;">DESCRIPTION OF CAPITAL STOCK </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">When used herein, the terms &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; refer to Mustang Bio, Inc. </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;">Capital Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is authorized to issue 200,000,000 shares of common stock with a par value of $0.0001 per share, of which 1,000,000 shares are designated as Class A common stock and 2,000,000 of preferred stock at $0.0001 par value of which 250,000 are designated as Class A preferred stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The holders of common stock are entitled to one vote per share of common stock held.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The undesignated preferred stock may be issued from time to time in one or more series. The Board of Directors is authorized to determine or alter the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions, if any), the redemption price or prices, the liquidation preferences and other designations, powers, preferences and relative, participating, optional or other special rights, if any, and the qualifications, limitations and restrictions granted to or imposed upon any wholly unissued series of preferred stock, and to fix the number of shares of any series of preferred stock (but not below the number of shares of any such series then outstanding).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Class A Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The holders of Class A common stock are entitled to the number of votes equal to the number of whole shares of common stock into which the shares of Class A common shares held by such holder are convertible. For a period of ten years from issuance, the holders of the Class A common stock have the right to appoint one member of the board of directors of Mustang. To date, the holders of Class A common stock have not yet appointed such director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Class A Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Class A Preferred Stock is identical to undesignated common stock other than as to voting rights, conversion rights, and the PIK dividend right.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The holders of the outstanding shares of Class A Preferred Stock receive on each January 1 (each a &#8220;PIK Dividend Payment Date&#8221;) after the original issuance date of the Class A Preferred Stock until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and non-assessable shares of common stock such that the aggregate number of shares of common stock issued pursuant to such PIK dividend is equal to 2.5% of the Corporation&#8217;s fully-diluted outstanding capitalization on the date that is one business day prior to any PIK Dividend Payment Date (&#8220;PIK Record Date&#8221;). In the event the Class A Preferred Stock converts into common stock, the holders shall receive all PIK dividends accrued through the date of such conversion. No dividend or other distribution shall be paid, or declared and set apart for payment (other than dividends payable solely in capital stock on the capital stock) on the shares of common stock until all PIK dividends on the Class A Preferred Stock shall have been paid or declared and set apart for payment. All dividends are non-cumulative. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;">On any matter presented to the stockholders for their action or consideration at any meeting of stockholders (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Class A Preferred Stock shall be entitled to cast for each share of Class A Preferred Stock held by such holder as of the record date for determining stockholders entitled to vote on such matter, the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the number of shares of outstanding common stock and (B) the whole shares of common stock in to which the shares of outstanding Class A Common Stock and the Class A Preferred Stock are convertible, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">1</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and the denominator of which is number of shares of outstanding Class A Preferred Stock. Thus, the Class A Preferred Stock will at all times constitute a voting majority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each share of Class A Preferred Stock is convertible, at the option of the holder, into one fully paid and nonassessable share of common stock, subject to certain adjustments. If the Company, at any time effects a subdivision or combination of the outstanding common stock (by any stock split, stock dividend, recapitalization, reverse stock split or otherwise), the applicable conversion ratio in effect immediately before that subdivision is proportionately decreased or increased, as applicable, so that the number of shares of common stock issuable on conversion of each share of Class A Preferred Stock shall be increased or decreased, as applicable, in proportion to such increase or decrease in the aggregate number of shares of common stock outstanding. Additionally, if any reorganization, recapitalization, reclassification, consolidation or merger involving the Company occurs in which the common stock (but not the Class A Preferred Stock) is converted into or exchanged for securities, cash or other property, then each share of Class A Preferred Stock becomes convertible into the kind and amount of securities, cash or other property which a holder of the number of shares of common stock of the Company issuable upon conversion of one share of the Class A Preferred Stock immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additional Features</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other features of our capital stock include:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;">Dividend Rights</i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. The holders of outstanding shares of our common stock, including Class A common stock, are entitled to receive dividends out of funds legally available at the times and in the amounts that our board of directors may determine. All dividends are non-cumulative.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;">Voting Rights</i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. The holders of our common stock are entitled to one vote for each share of common stock held on all matters submitted to a vote of the stockholders, including the election of directors. Our certificate of incorporation and bylaws do not provide for cumulative voting rights.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;">No Preemptive or Similar Rights</i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. The holders of our common stock have no preemptive, conversion, or subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;">Right to Receive Liquidation Distributions</i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. Upon our liquidation, dissolution, or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our common stock, including Class A common stock, outstanding at that time after payment of other claims of creditors, if any.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;">Fully Paid and Non-Assessable</i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. All of the outstanding shares of our common stock, including Class A common stock, and the Class A Preferred Stock are duly issued, fully paid and non-assessable.</font></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>3
<FILENAME>tmb-20221231xex10d22.htm
<DESCRIPTION>EX-10.22
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/29/2023 11:43:27 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.22</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">SUBLEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">This sublease (this &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublease</u><font style="font-size:12pt;">&#8221;) is made as of June 14, 2022 (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u><font style="font-size:12pt;">&#8221;), by and between THE PAUL REVERE LIFE INSURANCE COMPANY, a Massachusetts corporation (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublessor</u><font style="font-size:12pt;">&#8221;), having a notice address of c/o Unum Group, 1 Fountain Square, Suite 120, Chattanooga, Tennessee 37402, Attn: Corporate Real Estate Department, and MUSTANG BIO, INC., a Delaware corporation (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublessee</u><font style="font-size:12pt;">&#8221;), having a notice address of 377 Plantation Street, Worcester, Massachusetts 01605.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.5pt 0pt;"><font style="font-size:12pt;">RECITALS:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">WHEREAS, Sublessor is the Tenant under that certain Lease dated June 17, 2010, by and between CitySquare II Development Co. LLC (&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CitySquare II</u><font style="font-size:12pt;">&#8221;) and Sublessor, as affected by that certain Assignment and Assumption of Lease dated October 4, 2010 by and between CitySquare II and One Mercantile Place LLC (&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">One Mercantile</u><font style="font-size:12pt;">&#8221;), as amended by that certain Letter Agreement by and between One Mercantile and Sublessor dated November 11, 2011, as further amended by that certain Second Amendment to Lease dated as of July 5, 2012, by and between One Mercantile and Sublessor, as further amended by that certain Third Amendment to Lease dated as of December 19, 2012, by and between One Mercantile and Sublessor, as further affected by that certain Assignment and Assumption of Lease and Guaranty dated December 21, 2012, by and between One Mercantile and ONEMERC, LLC (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Master Lessor</u><font style="font-size:12pt;">&#8221;), as further amended by that certain Letter Agreement dated May 2, 2013, by and between Master Lessor and Sublessor, and as further amended by that certain Fourth Amendment to Lease dated as of September 16, 2015, by and between Master Lessor and Sublessor (as amended, the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Master Lease</u><font style="font-size:12pt;">&#8221;), a redacted copy of which is attached hereto as </font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">WHEREAS, pursuant to the Master Lease, Sublessor currently leases approximately 198,560 rentable square feet of space in the building known as One Mercantile Place located at One Mercantile Street in Worcester, Massachusetts together with approximately 851 parking spaces in the adjoining garage known as the Foster Street Garage (collectively, the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Master Premises</u><font style="font-size:12pt;">&#8221;); and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">WHEREAS, Sublessee desires to sublease a portion of the Master Premises from Sublessor, and Sublessor desires to sublease a portion of the Master Premises to Sublessee on the terms and conditions set forth herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">NOW, THEREFORE, in consideration of the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.</font></font><font style="font-size:12pt;">DEFINED TERMS. All capitalized terms not otherwise defined herein shall have the same meanings as set forth in the Master Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.1.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Building</u><font style="font-size:12pt;">: An eight (8) story office building containing approximately one hundred ninety-eight thousand five hundred sixty (198,560) square feet of rentable area and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">located on approximately 2.312 acres of land (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Real Property</u><font style="font-size:12pt;">&#8221; as described in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u><font style="font-size:12pt;"> to the Master Lease) at 1 Mercantile Street, Worcester, Massachusetts.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 6pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.2.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublease Premises</u><font style="font-size:12pt;">: Approximately 26,503 square feet of rentable area located on the fourth (4</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;">) floor of the Building as outlined on </font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</b><font style="font-size:12pt;"> attached hereto.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">1.3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commencement Date</u><font style="font-size:12pt;">: July 1, 2022.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.4.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rent Commencement Date</u><font style="font-size:12pt;">: The earlier of (i) the date that Tenant occupies the Sublease Premises, or (ii) the date on which Sublessee&#8217;s Work is Substantially Complete (as such term is defined in Exhibit C hereunder), but in no event later than November 1, 2022.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">1.5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination Date</u><font style="font-size:12pt;">: January 31, 2030.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.55pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.6.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublease Term</u><font style="font-size:12pt;">: Approximately seven (7) years and seven (7) months, commencing on the Commencement Date and expiring on the Termination Date unless earlier terminated pursuant to the terms of this Sublease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">1.7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Extension Terms</u><font style="font-size:12pt;">: None.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.1.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublease Year</u><font style="font-size:12pt;">: A twelve-month period from January 1 through December 31 during the Sublease Term. However, the first Sublease Year shall run from the Commencement Date through the 31st day of December immediately following; and the last Sublease Year shall run from the last January 1 through the date of the expiration or earlier termination of the Term of this Sublease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">1.8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Year for Operating Charges</u><font style="font-size:12pt;">: Calendar Year 2022 (i.e. January 1, 2022-</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">December 31, 2022).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;"><font style="font-size:12pt;">1.9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proportionate Share</u><font style="font-size:12pt;">: 13.35%.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.10.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permitted Use</u><font style="font-size:12pt;">: Class A administrative office functions and ancillary uses specifically related thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">1.11.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Building Hours</u><font style="font-size:12pt;">: Monday through Friday, 7 a.m. to 6 p.m. and Saturday 8 a.m. to</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">1 p.m.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">1.12.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Building Holidays</u><font style="font-size:12pt;">: New Year&#8217;s Day, Memorial Day, Independence Day, Labor</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">Day, Thanksgiving Day, the day after Thanksgiving Day, Christmas Eve and Christmas Day.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">1.13.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Security Deposit</u><font style="font-size:12pt;">: $48,588.83</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;"><font style="font-size:12pt;">1.14.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublessor Address for Notices</u><font style="font-size:12pt;">:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 77pt;"><font style="font-size:12pt;">The Paul Revere Life Insurance Company </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">c/o Unum Group</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 77pt;"><font style="font-size:12pt;">1 Fountain Square</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 77pt;"><font style="font-size:12pt;">Chattanooga, TN 37402 </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Attention: Corporate Real Estate</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72.55pt;"><font style="font-size:12pt;">With a copy to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72.55pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 77pt;"><font style="font-size:12pt;">Unum Law Department </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">2211 Congress Street&#8211; B268 </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Portland, ME 04122</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 77pt;"><font style="font-size:12pt;">Attn: Marybeth Fougere, Esq.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><font style="font-size:12pt;">1.15.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublessee Address For Notices</u><font style="font-size:12pt;">: </font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 77.05pt;"><font style="font-size:12pt;">Mustang Bio, Inc.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 77pt;"><font style="font-size:12pt;">377 Plantation Street</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 77pt;"><font style="font-size:12pt;">Worcester, MA 01605 </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Atten: Knut Niss</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 77pt;"><font style="font-size:12pt;">With copy to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 77pt;"><font style="font-size:12pt;">Mustang Bio, Inc. </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">377 Plantation Street</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 77pt;"><font style="font-size:12pt;">Worcester, MA 01605 </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Attention: General Counsel </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">mwein@mustangbio.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 77pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.16.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Day</u><font style="font-size:12pt;">: Means all days except Saturdays, Sundays, Building Holidays and other days when federal or state banks in the Commonwealth of Massachusetts are not open for business.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;"><font style="font-size:12pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;"><font style="font-size:12pt;">SUBLEASE PREMISES.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">2.1.</font></font><font style="font-size:12pt;">Sublessor hereby subleases to Sublessee, and Sublessee hereby subleases from Sublessor, the Sublease Premises. Sublessee has been given the opportunity to inspect the Sublease Premises and accepts the Sublease Premises in their &#8220;AS IS&#8221; and &#8220;WHERE IS,&#8221; broom clean condition on the Commencement Date. Sublessee acknowledges that Sublessor has made no representations or warranties concerning the Sublease Premises or its fitness for Sublessee&#8217;s intended use.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">2.2.</font></font><font style="font-size:12pt;">Sublessor reserves all air rights over the Sublease Premises, the use of the exterior walls, the plenum, and the right to install, maintain, use, repair and replace pipes, ducts, conduits and wires leading through the Sublease Premises in locations behind, above and beneath walls, dropped ceilings and flooring, respectively, which will not interfere with Sublessee&#8217;s use thereof to serve other parts of the Building.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">2.3.</font></font><font style="font-size:12pt;">Sublessor reserves the right at any time to make alterations or additions to the Building, provided that such alterations or additions do not have a material adverse effect upon Sublessee&#8217;s access to or use of the Sublease Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">TERM.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 0pt 0pt 40.95pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">3.1.</font></font><font style="font-size:12pt;">The term of this Sublease (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublease Term</u><font style="font-size:12pt;">&#8221;) shall commence on the Commencement Date and terminate on the Termination Date unless earlier terminated pursuant to the terms of this Sublease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">MASTER LEASE</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.55pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">4.1.</font></font><font style="font-size:12pt;">Sublessee hereby acknowledges and agrees that the interest and estate of the Sublessor in the Sublease Premises is that of a lessee of a leasehold and that this Sublease is subject and subordinate to the Master Lease. Except as otherwise provided herein or to the extent inconsistent with other specific provisions of this Sublease, Sublessee agrees to comply with all provisions of the Master Lease as if it were the named Tenant thereunder and the Sublease Premises were the premises leased thereunder, and not to do anything or fail to do anything to cause a breach or default under the Master Lease or the termination thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.05pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">4.2.</font></font><font style="font-size:12pt;">The terms, covenants and conditions of the Master Lease insofar as they relate to the Sublease Premises are incorporated herein by reference so that, except to the extent that they are modified by the provisions of this Sublease, each and every term, covenant and condition of the Master Lease applicable to the Sublease Premises binding or inuring to the benefit of the Master Lessor thereunder shall, in respect of this Sublease, bind or inure to the benefit of Sublessor, and each and every term, covenant and condition of the Master Lease applicable to the Sublease Premises binding or inuring to the benefit of the Sublessor as Tenant thereunder shall, in respect of this Sublease, bind or inure to the benefit of Sublessee, with the same force and effect as if such terms, covenants and conditions were completely set forth in this Sublease. As applied to this Sublease, the terms &#8220;Landlord,&#8221; &#8220;Tenant,&#8221; &#8220;Lease,&#8221; and &#8220;Premises&#8221; shall be deemed to refer to the Sublessor, Sublessee, Sublease and Sublease Premises, respectively. As between the Sublessor and the Sublessee only, to the extent that the terms of the Sublease conflict with the terms of the Master Lease, the Sublease shall control. Except as otherwise provided herein, the Master Lease is incorporated herein by this reference, but by so doing, (i) the Sublessee shall not have derived any rights as Tenant thereunder but rather shall derive its rights only from Sublessor as Sublessee hereunder and (ii) Sublessor shall not be deemed to have agreed to perform any obligations of Master Lessor but rather only to use reasonable efforts to cause Master Lessor to comply with its obligations under the Master Lease. Notwithstanding anything to the contrary contained herein the following portions of the Master Lease are not incorporated in this Sublease: Articles 1 through 7, Section 8.1(a), the fourth (4th) and fifth (5</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;">) paragraphs of Section 8.1(b), Section 8.1(c), Section 9.5, Section 10.1 through 10.9, Section 10.10(a), (c) and (d), Section 10.11 , Section 10.12, Section 11.1(a)(v), Section 11.2, Sections</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 5pt;"><font style="font-size:12pt;">11.4 through 11.8, Section 11.10, Sections 12.1 , 12.2, 12.4 through 12.7, Section 13.1(a), (b), (d), (e), (f) and (g), Section 13.3 through 13.8, Section 14.2, Section 14.3, Section 15.1(e), Article 24, Section 26.2, Section 26.3, Section 26.5, Section 26.13, Section 26.19, Section 26.20,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">Section 26.21, Articles 27 through 30, Articles 32 through 34 and all Exhibits (except to the extent referenced in this Sublease or required for interpretation of a provision of this Sublease or those provisions of the Master Lease incorporated herein), Letter Agreement by and between One Mercantile and Sublessor dated November 11 , 2011, and Second Amendment to Lease dated as of July 5, 2012, by and between One Mercantile and Sublessor. All Tenant indemnification obligations set forth in the Master Lease shall, for the purposes of this Sublease, be deemed to be for the benefit of Master Lessor and Sublessor. Sublessee shall be deemed a Transferee for purposes of Section 13.1(c) of the Master Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">4.3.</font></font><font style="font-size:12pt;">If the Master Lease shall terminate during the Sublease Term for any reason whatsoever, this Sublease shall terminate upon such termination with the same force and effect as if such termination date had been named herein as the date of expiration hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">SECURITY DEPOSIT</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">Sublessee shall deliver the Security Deposit to Sublessor upon execution of this Sublease. Sublessor shall not be required to pay interest on the Security Deposit or to maintain the Security Deposit in a separate account. Within three (3) days after notice of Sublessor&#8217;s application of all or a portion of the Security Deposit in satisfaction of Sublessee&#8217;s obligations under this Sublease, Sublessee shall restore the Security Deposit to the full amount. Within approximately ninety</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">(90) days after the expiration or earlier termination of the Sublease Term, Sublessor shall return the Security Deposit less such portion thereof as Sublessor may have used to satisfy Sublessee&#8217;s obligations. If Sublessor transfers the Security Deposit to a transferee of Sublessor&#8217;s interest in the Master Lease, then such transferee (and not Sublessor) shall be liable for its return.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">FIXED RENT</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.4pt 41pt;"><font style="font-size:12pt;">Sublessee shall pay &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fixed Rent</u><font style="font-size:12pt;">&#8221; as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:20.15pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:74.64%;"><tr style="height:1pt;"><td style="vertical-align:top;width:39.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:39.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:20.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:19pt;"><td style="vertical-align:top;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 38.45pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Period</u></p></td><td style="vertical-align:top;width:39.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Yearly</u></p></td><td style="vertical-align:top;width:20.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Monthly</u></p></td></tr><tr style="height:19.8pt;"><td style="vertical-align:top;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2.5pt;"><font style="font-size:12pt;">1</font><sup style="font-size:9pt;vertical-align:top;">st </sup><font style="font-size:12pt;">Sublease Year</font></p></td><td style="vertical-align:top;width:39.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">$583,066.00</font></p></td><td style="vertical-align:top;width:20.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">$48,588.83</font></p></td></tr><tr style="height:13.8pt;"><td style="vertical-align:top;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2.5pt;"><font style="font-size:12pt;">2</font><sup style="font-size:9pt;vertical-align:top;">nd </sup><font style="font-size:12pt;">Sublease Year</font></p></td><td style="vertical-align:top;width:39.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">$596,317.50</font></p></td><td style="vertical-align:top;width:20.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">$49,693.13</font></p></td></tr><tr style="height:13.75pt;"><td style="vertical-align:top;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2.5pt;"><font style="font-size:12pt;">3</font><sup style="font-size:9pt;vertical-align:top;">rd </sup><font style="font-size:12pt;">Sublease Year</font></p></td><td style="vertical-align:top;width:39.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">$609,569.00</font></p></td><td style="vertical-align:top;width:20.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">$50,797.42</font></p></td></tr><tr style="height:13.8pt;"><td style="vertical-align:top;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2.5pt;"><font style="font-size:12pt;">4</font><sup style="font-size:9pt;vertical-align:top;">th </sup><font style="font-size:12pt;">Sublease Year</font></p></td><td style="vertical-align:top;width:39.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">$622,820.50</font></p></td><td style="vertical-align:top;width:20.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">$51,901.71</font></p></td></tr><tr style="height:13.8pt;"><td style="vertical-align:top;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2.5pt;"><font style="font-size:12pt;">5</font><sup style="font-size:9pt;vertical-align:top;">th </sup><font style="font-size:12pt;">Sublease Year</font></p></td><td style="vertical-align:top;width:39.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">$636,072.00</font></p></td><td style="vertical-align:top;width:20.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">$53,006.00</font></p></td></tr><tr style="height:13.8pt;"><td style="vertical-align:top;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2.5pt;"><font style="font-size:12pt;">6</font><sup style="font-size:9pt;vertical-align:top;">th </sup><font style="font-size:12pt;">Sublease Year</font></p></td><td style="vertical-align:top;width:39.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">$649,323.50</font></p></td><td style="vertical-align:top;width:20.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">$54,110.29</font></p></td></tr><tr style="height:13.8pt;"><td style="vertical-align:top;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2.5pt;"><font style="font-size:12pt;">7</font><sup style="font-size:9pt;vertical-align:top;">th </sup><font style="font-size:12pt;">Sublease Year</font></p></td><td style="vertical-align:top;width:39.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">$662,575.00</font></p></td><td style="vertical-align:top;width:20.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">$55,214.58</font></p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:top;width:39.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2.5pt;"><font style="font-size:12pt;">8</font><sup style="font-size:9pt;vertical-align:top;">th </sup><font style="font-size:12pt;">Sublease Year</font></p></td><td style="vertical-align:top;width:39.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">$675,826.50</font></p></td><td style="vertical-align:top;width:20.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">$56,318.88</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">Notwithstanding the foregoing, and provided that Sublessee is not then in default under this Sublease commencing on the Commencement Date and continuing through 11:59 P.M. EST on the last day of the twenty fourth (24</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;">) month following the Rent Commencement Date (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rent Abatement Period</u><font style="font-size:12pt;">&#8221;), Fixed Rent shall abate with respect to the entire Sublease Premises (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rent Abatement</u><font style="font-size:12pt;">&#8221;),. During the Rent Abatement Period, however, Sublessee shall pay all Additional Rent (as hereinafter defined), including, without limitation, electricity charges for the entire Sublease Premises and any charges for additional parking permits. Sublessee shall make payment of Fixed Rent and Additional Rent for any fraction of a month at the Rent Commencement Date or expiration of the Sublease Term.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.8pt 0pt;"><font style="font-size:13pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">ADDITIONAL RENT</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">7.1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">OPERATING CHARGES</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:71.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">a)</font></font><font style="font-size:12pt;">If in any Sublease Year Operating Charges (as hereinafter defined) paid or incurred shall exceed Operating Charges paid or incurred in the Base Year for Operating</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:71.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">Charges, Sublessee shall pay, as Additional Rent for such Sublease Year, Sublessee&#8217;s Proportionate Share of such excess (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operating Charge Excess</u><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:71.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">b)</font></font><font style="font-size:12pt;">Operating Charges mean the following expenses incurred by Sublessor in its tenancy of the Building and the Real Property: (1) electricity, water, sewer and other utility charges for service provided to the common or public areas of the Building (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Common Areas</u><font style="font-size:12pt;">&#8221;), or which is not separately metered; (2) insurance premiums; (3) management fees; (4) costs of service and maintenance contracts; (5) maintenance, repair and replacement expenses;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 5pt;"><font style="font-size:12pt;">(6) amortization (on a straight-line basis over the useful life (not to exceed ten (10) years) of capital expenditures made by Sublessor to improve, repair or replace the Common Areas; (7) reasonable reserves for replacements, repairs and contingencies; (8) Sublessor&#8217;s administrative costs and overhead; and (9) any other expense incurred by Sublessor in maintaining, repairing or operating the Building and the Real Property. Operating Charges do not include: (i) costs of initial improvements to, or alterations of the Sublease Premises; (ii) costs to correct defects in the original design or construction of the Building; (iii) overhead or profit, or costs in excess of competitive third-party rates, paid to affiliates of Sublessor for services rendered to the Building;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.55pt 5pt;"><font style="font-size:12pt;">(iv) any expenses for which Sublessor is compensated through proceeds of insurance or for which Sublessor would have been so compensated had Sublessor maintained insurance in an amount and type required in this Sublease; (v) costs of repairs, alterations or replacements caused by the exercise of the rights of eminent domain; (vi) the cost of any special services rendered or costs reimbursed to another subtenant which are not generally reimbursed or rendered to other subtenants in the Building; (vii) allowances to other subtenants for construction of tenant improvements, space planner fees, real estate brokers&#8217; commissions; (viii) legal fees and other costs incurred in the negotiation of other subleases in the Building (including this Sublease) or the enforcement of subleases in the Building; (ix) salaries and employment expenses of personnel above the level of the on-site Building manager; (x) debt service payments, ground lease payments, depreciation, amortization or other similar noncash accounting charges; (xi) any cost or expense for which Sublessor is paid or reimbursed by or is legally entitled to payment or reimbursement from any subtenant of the Building (other than from subtenants paying their share of Operating Charges) or any other party; (xii) any expenses for repairs or maintenance which are covered by warranties; (xiii) costs incurred due to the violation by the Master Lessor or Sublessor of any law, code, regulation, ordinance or the like, which cost would not have been incurred but for such violation; (xiv) the cost of acquiring or leasing paintings or other objects of art for the Building; and (xv) real estate taxes, which are deemed included in Fixed Rent.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:71.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">c)</font></font><font style="font-size:12pt;">At the commencement of the Sublease Term and each Sublease Year thereafter, Sublessor shall submit a written statement indicating the amount of Operating Charges and Operating Charge Excess that Sublessor reasonably expects to be incurred during such Sublease Year. Sublessee shall pay to Sublessor on the first day of each month after receipt of such statement, until Sublessee&#8217;s receipt of a succeeding statement, an amount equal to one- twelfth (1/12</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;">) of such Operating Charge Excess. Sublessor reserves the right to submit a revised statement if Sublessor expects Operating Charges to differ from the prior estimation. If a statement is submitted after the beginning of a Sublease Year, then the first payment thereafter shall be adjusted to account for any underpayment or overpayment based on the prior statement and subsequent payments shall be based on the latest statement. If during all or any portion of any calendar year during the Sublease Term, the Building is not one hundred percent (100%) occupied by tenants, Sublessor may elect to make an appropriate adjustment of Operating</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:71.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 5pt;"><font style="font-size:12pt;">Charges for such calendar year, to determine the Operating Charges that would have been paid or incurred by Sublessor had the Building been one hundred percent (100%) occupied by tenants for the entire year and the amount so determined shall be deemed to be the Operating Charges for such year.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:71.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">d)</font></font><font style="font-size:12pt;">Within approximately one hundred twenty (120) days after each Sublease Year, Sublessor shall submit a statement indicating (1) Sublessee&#8217;s Operating Charge Excess</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">incurred during such Sublease Year, and (2) the sum of Sublessee&#8217;s estimated payments for such Sublease Year. If such statement indicates that such sum exceeds Sublessee&#8217;s actual obligation, then Sublessee shall deduct the overpayment from its next payment(s) pursuant to this Section. If such statement indicates that Sublessee&#8217;s actual obligation exceeds such sum, then Sublessee shall pay the excess. If Sublessee does not notify Sublessor in writing of any objection to such statement within thirty (30) days after receipt, then Sublessee shall be deemed to have waived such objection.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:71.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">e)</font></font><font style="font-size:12pt;">If the Sublease Term commences or expires on a day other than January 1 or December 31, respectively, then Sublessee&#8217;s liability for Operating Charges incurred during the applicable Sublease Year shall be proportionately reduced based on the number of days in the Sublease Term falling within such Sublease Year.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:71.95pt;margin:0pt 0pt 0.05pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">f)</font></font><font style="font-size:12pt;">Within sixty (60) days after Sublessor furnishes to Sublessee the statement of Operating Charges referenced in subsection (d) above (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Audit Election Period</u><font style="font-size:12pt;">&#8221;), Sublessee shall have the right, at its sole cost and expense, during Sublessor&#8217;s normal business hours, to audit Sublessor&#8217;s Operating Charges for the previous calendar year and the Base Year only, subject to the following conditions: (1) there is no uncured Event of Default under this Sublease; (2) the audit shall be prepared by an independent certified public accounting firm of recognized national standing; (3) in no event shall any audit be performed by a firm retained on a &#8220;contingency fee&#8221; basis; (4) the audit shall commence within thirty (30) days after Sublessor makes Sublessor&#8217;s books and records available to Sublessee&#8217;s auditor and shall conclude within sixty (60) days after commencement; (5) the audit shall be conducted where Sublessor maintains its books and records and shall not unreasonably interfere with the conduct of Sublessor&#8217;s business; and (6) Sublessee and its accounting firm shall treat any audit in a confidential manner and shall each execute Sublessor&#8217;s confidentiality agreement for Sublessor&#8217;s benefit before commencing the audit. Sublessee shall deliver a copy of such audit to Sublessor within five (5) Business Days of receipt by Sublessee. This subsection shall not be construed to limit, suspend, or abate Sublessee&#8217;s obligation to pay Rent when due, including the estimated Operating Charge Excess. After verification, Sublessor shall credit any overpayment determined by the audit report against the next Rent due and owing by Sublessee or, if no further Rent is due, refund such overpayment directly to Sublessee within thirty (30) days of determination. Sublessee shall pay Sublessor any underpayment determined by the audit report within thirty (30) days of determination. The foregoing obligations shall survive the expiration or earlier termination of the Sublease. If Sublessee does not give written notice of its election to audit during the Audit</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">Election Period, Sublessor&#8217;s statement of Operating Charges for the applicable calendar year shall be deemed approved for all purposes, and Sublessee shall have no further right to review or contest the same.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">7.2.</font></font><font style="font-size:12pt;">All sums other than Fixed Rent, including, without limitation, the amounts due under Sections 7 and 8 of this Sublease, late charges, damages and interest and other costs</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">relating to Sublessee&#8217;s failure to perform any of its obligations under the Sublease shall be</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">deemed &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Rent</u><font style="font-size:12pt;">&#8221;. Fixed Rent and Additional Rent are collectively referred to herein as &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rent</u><font style="font-size:12pt;">&#8221;.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">UTILITIES AND SECURITY</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.05pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">8.1.</font></font><font style="font-size:12pt;">Sublessor shall supply water, sewer, electricity, heating and air conditioning service to the Sublease Premises. Electricity to the Sublease Premises (lights and plugs) will be submetered and Sublessee will pay to Sublessor, as Additional Rent, its share of electricity charges as shown on the submeter within fifteen (15) days of receipt of Sublessor&#8217;s invoice therefor; provided, Sublessee&#8217;s share of charges for electricity supplied to the Sublease Premises during normal business hours shall not exceed $1.75 per rentable square foot of the Sublease Premises. If Sublessee desires heating or air-conditioning service at a time other than during the Building&#8217;s normal business hours, which are 7:00 a.m. to 6:00 p.m. on Business Days and 8:00</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">a.m. to 1:00 p.m. on Saturdays, then Sublessee shall pay to Sublessor the cost of such services on a floor-by-floor basis as Additional Rent within fifteen (15) days after receipt of Sublessor&#8217;s</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">invoice therefor. The rate for heating and air conditioning if used outside of the Building&#8217;s normal business hours is currently $100.00 per hour, subject to reasonable increases by Sublessor from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">8.2.</font></font><font style="font-size:12pt;">Sublessee shall at all times comply with the rules and regulations of the utility company supplying electricity to the Building. Sublessee shall not install any electrical equipment which would exceed the capacity of the Building&#8217;s electrical equipment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.55pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">8.3.</font></font><font style="font-size:12pt;">Sublessee shall cooperate fully in Sublessor&#8217;s efforts to maintain access control to the Building and shall follow all regulations promulgated by Sublessor with respect thereto. Sublessor shall permit Sublessee to utilize the Building security systems to control access to the Sublease Premises to provide access to the Sublease Premises from the Building and the exterior solely for Sublessee&#8217;s permitted employees, agents, officers, directors, contractors and escorted guests and Invitees (hereinafter defined); provided, however, that Sublessee shall pay the cost of all key cards issued to Sublessee at the then-current rate charged by Sublessor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">USE OF SUBLEASE PREMISES</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">9.1.</font></font><font style="font-size:12pt;">Sublessee shall have the right to use and occupy the Sublease Premises for the Permitted Use and for no other purpose or purposes.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.05pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">9.2.</font></font><font style="font-size:12pt;">Sublessee shall not permit any use of the Sublease Premises which shall make voidable any insurance upon the Sublease Premises or upon the property of which the Sublease Premises are a part. The Sublessee shall on demand reimburse the Sublessor for all extra</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">insurance premiums incurred by Sublessor solely and directly caused by Sublessee&#8217;s specialized use of the Sublease Premises. The Sublessee shall secure all necessary permits and licenses for the lawful operation of said business and shall provide copies of such licenses and permits to Sublessor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">9.3.</font></font><font style="font-size:12pt;">Sublessee shall at all times protect and save harmless the Master Lessor and the Sublessor from the imposition of any liens, taxes or other charges that may be imposed upon the Sublease Premises or upon other property of which the Sublease Premises are a part, by reason of the occupancy and use by Sublessee of the Sublease Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">9.4.</font></font><font style="font-size:12pt;">Subject to applicable Requirements (as defined below), Sublessee shall have access to and the right to the use of the Sublease Premises on a 24 hour per day, 7 day per week, 365 day per year basis.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">9.5.</font></font><font style="font-size:12pt;">Sublessee shall not use the Sublease Premises in a manner that would (a) violate the terms of any occupancy or use permit, (b) impair or interfere with any Building system or facility, or (c) adversely affect the Building&#8217;s appearance, character or reputation. Sublessee shall not use the Sublease Premises in any manner that will cause the Building, the Real Property or any part thereof not to comply with Sublessor&#8217;s sustainability practices and its Silver</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">certification from the United States Green Building Council&#8217;s Leadership in Energy and Environmental Design (&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LEED</u><font style="font-size:12pt;">&#8221;) rating system.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">9.6.</font></font><font style="font-size:12pt;">Subject to Section 12 of this Sublease, Sublessee shall be responsible for the cost of any alterations, additions, or changes to the Building or the Garage required pursuant to the Americans With Disabilities Act of 1990, and any amendments thereto (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ADA</u><font style="font-size:12pt;">&#8221;) as a result of the Permitted Use, Sublessee&#8217;s Work or any Alterations made by Sublessee to the Sublease Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">9.7.</font></font><font style="font-size:12pt;">Sublessee shall require any truck or other vehicle serving Sublessee to use the service area designated by Sublessor. Sublessee shall cause any such vehicle promptly to be loaded or unloaded and removed from such area. Immediately after using such service area, Sublessee shall remove any debris and clean such area to its prior condition. Sublessee&#8217;s use of such area shall comply with all rules and regulations governing such use as may be provided to Sublessee. Sublessee&#8217;s use of such area shall not unreasonably impede the use thereof by others including Sublessor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.55pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">9.8.</font></font><font style="font-size:12pt;">Sublessor shall provide Sublessee with non-exclusive access to the fitness center located in the Building for Sublessee&#8217;s employees at no additional cost; provided, however, that such access shall be contingent upon such employees signing the standard waiver and any other documents requested by Sublessor for use of the fitness center. In the event that the fitness center is renovated during the Sublease Term, Sublessee shall, upon completion of such renovation, commence paying to Sublessor each month in advance as Additional Rent Sublessor&#8217;s then-current per-person charge applied to all tenants of the Building for use of the fitness center.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.55pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">9.9.</font></font><font style="font-size:12pt;">Sublessee shall pay timely any business, rent or other tax or governmental fee that is now or hereafter assessed or imposed upon Sublessee&#8217;s use or occupancy of the Sublease Premises, the conduct of Sublessee&#8217;s business in the Sublease Premises or Sublessee&#8217;s fixtures, furnishings, inventory or personal property. If any such tax or fee is imposed upon Sublessor or Sublessor is responsible for collection or payment thereof, then Sublessee shall pay to Sublessor the amount of such tax or fee on demand.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">9.10.</font></font><font style="font-size:12pt;">Sublessee&#8217;s use of the Sublease Premises and the Common Areas shall comply in all respects with the rules and regulations set forth in </font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit D</b><font style="font-size:12pt;"> attached hereto, as such rules and regulations may be modified or restated by Sublessor from time to time (collectively, the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Requirements</u><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">9.11.</font></font><font style="font-size:12pt;">Sublessee shall, at its expense, comply and cause the Sublease Premises to comply with all applicable Requirements, subject to the provisions of Section 9.6 of this Sublease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">10.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">SUBLESSEE&#8217;S INSURANCE</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">Throughout the Sublease Term, Sublessee shall maintain with respect to the Sublease Premises commercial general liability insurance, workers&#8217; compensation insurance and &#8220;all-risk&#8221; property insurance in the amounts and on the terms stated in the following sections of the Master Lease: Article 11, subsection 11.1(a), subsections (i), (ii), (iii), (iv) (substituting the Sublease Premises for the Real Property), and (vi). Such insurance shall name Master Lessor and Sublessor as additional insureds. In addition, Sublessee agrees to comply with the remaining provisions of Article 11 of the Master Lease in the same manner as if it was the Tenant thereunder and shall provide both the Master Lessor and the Sublessor with evidence of such compliance in the form and manner set forth therein. Sublessee shall provide the waiver of subrogation set forth in Section 11.3 of the Master Lease to both Sublessor and Master Lessor.&quot;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">11.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">MAINTENANCE AND REPAIRS</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">11.1.</font></font><font style="font-size:12pt;">Sublessor shall make repairs which Sublessor deems necessary to the structure and exterior (including access doors and windows but excluding interior doors and glass) of the Sublease Premises; provided Sublessor has actual knowledge of the necessity for such repair in accordance with its obligations under the Master Lease. In addition, Sublessor shall provide cleaning service and trash removal for the Sublease Premises Monday through Friday, excluding Building Holidays.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.05pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">11.2.</font></font><font style="font-size:12pt;">Except as otherwise provided in Section 11.1, Sublessee shall maintain the Sublease Premises and all fixtures and equipment located therein or exclusively serving the Sublease Premises in clean, safe and sanitary condition, take good care thereof, make all repairs and replacements thereto and suffer no waste or injury thereto, and Sublessee shall promptly make all repairs, perform all maintenance, and make all replacements in and to the Sublease Premises that are necessary or desirable to keep the Sublease Premises in first class condition and repair, in a safe and tenantable condition, and otherwise in accordance with the requirements of this Sublease. Without limitation of the generality of the foregoing, Sublessee shall promptly make all repairs and replacements to (a) any pipes, lines, ducts, wires or conduits exclusively serving the Sublease Premises, (b) Sublessee&#8217;s signs, (c) any non-building system heating, air conditioning, ventilating, electrical or plumbing equipment installed in or exclusively serving the Sublease Premises, (d) all interior glass and doors, and (e) any other mechanical system exclusively serving the Sublease Premises. Sublessee shall give to Sublessor prompt written notice of any damage to the Sublease Premises, the Building or any part thereof. Sublessee shall maintain a maintenance contract on the heating, ventilation and air conditioning equipment and systems exclusively serving the Sublease Premises with a contractor approved by Sublessor, and shall provide a copy of such contract to Sublessor upon request. Sublessor reserves the right to establish a regular inspection and maintenance program for all heating, ventilation and air conditioning equipment maintained by Sublessee and to provide all necessary or appropriate</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">maintenance and repairs at Sublessee&#8217;s expense. Sublessee shall install and maintain fire extinguishers and other fire protection devices (other than sprinklers) as may be required or recommended by Master Lessor or any governmental authority or insurance underwriter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">Sublessee shall operate its heating and air conditioning systems servicing the Sublease Premises so as to adequately heat or cool the Sublease Premises. All damage to the Sublease Premises or to any other part of the Building or the Real Property caused by any act or omission of any invitee, agent, employee, subtenant, assignee, contractor, client, family member, licensee, concessionaire, customer or guest of Sublessee (collectively &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Invitees</u><font style="font-size:12pt;">&#8221;) or Sublessee shall be repaired by Sublessee, except that Sublessor shall have the right to make any such repair at Sublessee&#8217;s expense.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.55pt 5pt;"><font style="font-size:12pt;">Notwithstanding anything to the contrary contained in this Article 11, Sublessor may, at Sublessor&#8217;s election, perform any of Sublessee&#8217;s maintenance, repair and/or replacement obligations set forth in this Section 11 with respect to any fixtures or equipment located outside of the Sublease Premises on Sublessee&#8217;s behalf, and Sublessee shall reimburse Sublessor for the cost of any such maintenance, repair or replacement within thirty (30) days of Sublessor&#8217;s written demand therefor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">11.3.</font></font><font style="font-size:12pt;">Sublessee shall cause its operation and maintenance of the Sublease Premises to comply with the standards, requirements, guidelines and energy conservation measures set forth in </font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit E</b><font style="font-size:12pt;"> attached hereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">12.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">ALTERATIONS AND ADDITIONS</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.55pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">12.1.</font></font><font style="font-size:12pt;">The original improvement of the Sublease Premises shall be accomplished in accordance with the Work Letter attached hereto as </font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</b><font style="font-size:12pt;">. Sublessor will deliver the Sublease Premises to Sublessee in As-Is, Where-Is condition, with all base building systems in working condition. Sublessor is under no obligation to make any alterations, decorations, additions, improvements or other changes (collectively &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Alterations</u><font style="font-size:12pt;">&#8221;) in or to the Sublease Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">12.2.</font></font><font style="font-size:12pt;">Sublessee shall not make or permit anyone to make any Alteration in or to the Sublease Premises or the Building without Sublessor&#8217;s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed. Any Alteration made by Sublessee shall be made: (a) in a good, workmanlike, first-class and prompt manner; (b) using new materials only; (c) by a contractor, on days and at times and under the supervision of an architect approved in writing by Sublessor; (d) in accordance with plans and specifications prepared by an engineer or architect approved by Sublessor and reviewed (at Sublessor&#8217;s standard charge) by Sublessor;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">(e) in accordance with the Requirements, the requirements of any firm insuring the Building and the Building standards; (f) after obtaining a worker&#8217;s compensation insurance policy approved in writing by Sublessor and any bonds required by Sublessor; (g) after delivering to Sublessor</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 5pt;"><font style="font-size:12pt;">written, unconditional waivers of mechanics&#8217; and materialmen&#8217;s liens against the Sublease Premises and the Building from all proposed contractors, subcontractors, laborers and material suppliers; and (h) with respect to electrical and mechanical work, by a contractor designated by Sublessor. Subsections (c), (d), (f), and (g) of the immediately foregoing sentence shall only be applicable in the event that an Alteration requires a building permit. If a lien (or a petition to establish a lien) is filed in connection with any Alteration, then such lien (or petition) shall be discharged by Sublessee at Sublessee&#8217;s expense within ten (10) days thereafter by the payment</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">thereof or filing of a bond acceptable to Sublessor. Sublessor&#8217;s consent to an Alteration shall be deemed not to constitute Sublessor&#8217;s consent to subjecting its interest in the Sublease Premises or the Building to liens which may be filed in connection therewith. Promptly after the completion</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">of an Alteration, Sublessee at its expense shall deliver to Sublessor three (3) sets of accurate as- built drawings showing such Alteration.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">12.3.</font></font><font style="font-size:12pt;">If an Alteration is made without Sublessor&#8217;s prior written consent, then Sublessor shall have the right at Sublessee&#8217;s expense to remove such Alteration and restore the Sublease Premises and the Building to their condition immediately prior thereto or to require Sublessee to do the same. All Alterations to the Sublease Premises or the Building made by either party shall immediately become Sublessor&#8217;s property and shall be surrendered with the Sublease Premises at the expiration or earlier termination of the Sublease Term, except that (a) Sublessee shall have the right to remove, prior to the expiration or earlier termination of the Sublease Term, movable furniture, movable furnishings and movable trade fixtures installed in the Sublease Premises by Sublessee solely at Sublessee&#8217;s expense, and (b) Sublessee shall be required to remove all Alterations to the Sublease Premises or the Building which Sublessor designates in writing for removal. Movable furniture, furnishings and trade fixtures shall be deemed to exclude without limitation any item the removal of which might cause damage to the Sublease Premises or the Building or which would normally be removed from the Sublease Premises with the assistance of any tool or machinery other than a dolly. Sublessor shall have the right to repair at Sublessee&#8217;s expense any damage to the Sublease Premises or the Building caused by such removal or to require Sublessee to do the same. If any such item is not removed prior to the expiration or earlier termination of the Sublease Term, then such item shall become Sublessor&#8217;s property and shall be surrendered with the Sublease Premises as a part thereof; provided, however, that Sublessor shall have the right to remove such item from the Sublease Premises at Sublessee&#8217;s expense.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">12.4.</font></font><font style="font-size:12pt;">Sublessee shall not employ, or permit the employment of, any contractor, mechanic or laborer, or permit any materials to be delivered to or used in the Sublease Premises or the Building if, in Sublessee&#8217;s reasonable judgment, such employment, delivery or use will interfere with or obstruct or cause any conflict with other contractors, mechanics or laborers engaged in the construction, maintenance or operation of the Real Property by Sublessor, Master Lessor or others. If such interference or conflict occurs, then upon Sublessor&#8217;s request, Sublessee shall immediately cause all contractors, mechanics or laborers causing such interference or conflict to leave the Real Property.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">12.5.</font></font><font style="font-size:12pt;">The approval of plans, or consent by Sublessor to the making of any Alterations, shall not constitute Sublessor&#8217;s representation that such plans or Alterations comply with any Requirements. Sublessor shall not be liable to Sublessee or any other party in connection with Sublessor&#8217;s approval of any plans, or Sublessor&#8217;s consent to Sublessee performing any Alterations. If any Alterations made by or on behalf of Sublessee require Sublessor to make any alterations or improvements to any part of the Real Property in order to comply with any Requirements, Sublessee shall pay, within thirty (30) days following completion of such alterations or improvements and delivery of an itemized statement or invoice from Sublessor, as Additional Rent, all reasonable, out-of-pocket costs and expenses incurred by Sublessor in connection with such alterations or improvements.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">12.6.</font></font><font style="font-size:12pt;">In the case of any Alteration requiring Master Lessor approval under the Master Lease, in addition to Sublessor&#8217;s prior written consent, Sublessee may not commence such Alteration until Master Lessor has approved the same in writing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">13.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">SIGNS</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">13.1.</font></font><font style="font-size:12pt;">Notwithstanding anything to the contrary contained the Master Lease, as incorporated herein, Sublessee shall not have the right to erect any signs on the Sublease Premises, the property of which the Sublease Premises are a part, or in the windows of the Sublease Premises without Sublessor&#8217;s prior written consent, which shall not be unreasonably withheld, delayed or conditioned (provided that it shall not be unreasonable for Sublessor to withhold consent to the installation of any sign the removal of which will, in Sublessor&#8217;s sole judgment, unduly damage the Sublease Premises or the Building). All signs shall be in compliance with all applicable Requirements. Sublessee shall install a professionally lettered name sign on each service door. Sublessee shall insure, maintain in first class order, good condition and repair each sign and lettering used by Sublessee. Upon the expiration or earlier termination of the Sublease Term, Sublessee shall remove any sign and repair any damage attributable to such sign or its removal. Notwithstanding the foregoing, Sublessor may elect, in Sublessor&#8217;s sole discretion, to install and/or remove any of Sublessee&#8217;s approved signage at Sublessee&#8217;s sole cost and expense.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">13.2.</font></font><font style="font-size:12pt;">Sublessor shall provide, at Sublessor&#8217;s sole cost and expense, Sublessee with Building standard signage (a) in the main lobby Building directory, and (b) at the entry way of the Sublease Premises, as well as Building standard directional signage on the floor on which the Sublease Premises are located. Any logo or detail approved by Sublessor for the entry way signage shall be at Sublessee&#8217;s sole cost and expense.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">14.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">ASSIGNMENT AND SUBLEASING</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">14.1.</font></font><font style="font-size:12pt;">Sublessee shall not assign or sub-sublease the whole or any part of the Sublease Premises without (a) Sublessor&#8217;s prior written consent, which shall not be unreasonably withheld, conditioned or delayed, and (b) Master Lessor&#8217;s consent which shall be governed by the Master Lease. Notwithstanding such consent, Sublessee shall remain liable to Sublessor for the payment of all Rent and for the full performance of the covenants and conditions of this Sublease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">14.2.</font></font><font style="font-size:12pt;">In addition to Sublessor&#8217;s right to approve of any sub-sublessee or assignee, Sublessor shall have the option, in its sole discretion, in the event of a proposed sub-subleasing or assignment, to terminate this Sublease, or in the case of a proposed sub-subleasing of less than the entire Sublease Premises, to recapture the portion of the Sublease Premises to be sub-sublet, as of the date the sub-sublease or assignment is to be effective. The option shall be exercised, if at all, by Sublessor giving Sublessee written notice within thirty (30) days following Sublessor&#8217;s receipt of Sublessee&#8217;s written request for consent pursuant to Section 14.1. If this Sublease shall be terminated with respect to the entire Sublease Premises pursuant to this Section, the Sublease Term shall end on the date stated in Sublessee&#8217;s notice as the effective date of the sub-sublease or assignment as if that date had been originally fixed in this Sublease for the expiration of the Sublease Term. If Sublessor recaptures under this Section only a portion of the Sublease Premises, the Rent to be paid from time to time during the unexpired Sublease Term shall abate proportionately based on the proportion by which the approximate square footage of the remaining portion of the Sublease Premises shall be less than that of the Sublease Premises as of the date immediately prior to such recapture. Sublessee shall, at Sublessee&#8217;s own cost and expense, discharge in full any outstanding commission obligation which may be due and owing</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">as a result of any proposed assignment or sub-subletting, whether or not the Sublease Premises are recaptured pursuant to this Section 14.2 and rented by Sublessor to the proposed sub- sublessee or any other sublessee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">14.3.</font></font><font style="font-size:12pt;">In the event that Sublessee sells, sublets, assigns or transfers this Sublease, Sublessee shall pay to Sublessor as Additional Rent an amount equal to fifty percent (50%) of any Increased Rent (as hereinafter defined), less the Costs Component (as hereinafter defined), when and as such Increased Rent is received by Sublessee. As used in this Section, &#8220;Increased Rent&#8221; shall mean the excess of (i) all rent and other consideration which Sublessee is entitled to receive by reason of any sale, sub-sublease, assignment or other transfer of this Sublease, over</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">(ii) the rent otherwise payable by Sublessee under this Sublease at such time. For purposes of the foregoing, any consideration received by Sublessee in form other than cash shall be valued at its fair market value as determined by Sublessor in good faith. The &#8220;Costs Component&#8221; is the reasonable costs incurred by Sublessee in entering into the transaction, including without limitation, costs for leasing commissions, attorneys&#8217; fees, marketing and advertising expenses, tenant improvements, free rent and other tenant concessions in connection with such sub- sublease, assignment or other transfer, all of which may be deducted prior to paying any Increased Rent hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">15.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">SUBORDINATION</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">This Sublease shall be subject and subordinate to any and all mortgages, deeds of trust and other instruments in the nature of a mortgage, now or at any time hereafter, which are or shall be a lien or liens on the Sublease Premises or on the property of which the Sublease Premises are a part, whether granted by Sublessor or Master Lessor as mortgagor, and the Sublessee shall, when requested, promptly execute and deliver such written instruments as shall be necessary to show the subordination of this Sublease to said mortgage, deeds of trust or other such instruments in the nature of a mortgage.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">16.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">SUBLESSOR&#8217;S ACCESS</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">The Sublessor or agents of the Sublessor may, at reasonable times and upon not less than twenty-four (24) hours prior notice, enter to view the Sublease Premises and make repairs and alterations that Sublessor is obligated to perform under this Sublease or the Master Lease and may show the Sublease Premises to others in the presence of Sublessee or its agent. Sublessor shall use commercially reasonable efforts to minimize disruption to Sublessee&#8217;s business caused by such access.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">17.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">MASTER LESSOR&#8217;S ACCESS</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">The Sublessee shall provide Master Lessor with access to the Sublease Premises as provided in Article 14 of the Master Lease, as incorporated herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">18.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">INDEMNIFICATION OF MASTER LESSOR AND SUBLESSOR</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">18.1.</font></font><font style="font-size:12pt;">The provisions of Section 25.1, 25.2 and 25.3 of the Master Lease are incorporated herein; provided, however, that the references to &#8220;Landlord&#8221; in the definition of Indemnitees shall be deemed to include both Master Lessor and Sublessor, and references to the Premises shall be deemed to refer to the Sublease Premises, further provided, however, that the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">indemnities set forth in Section 25.1 shall not include any claims arising from the gross negligence or willful misconduct of Sublessor and the indemnities set forth in Section 25.2 shall not include any claims arising from the gross negligence or willful misconduct of Sublessee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">The provisions of this Section 18.1 shall survive the expiration or earlier termination of this Sublease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">18.2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">Intentionally Omitted.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">18.3.</font></font><font style="font-size:12pt;">Sublessor, its officers, directors, employees and agents shall not be liable to Sublessee or any other person or entity for any damage (including indirect and consequential damage), injury, loss or claim (including claims for the interruption of or loss to business) based on or arising out of any cause whatsoever, including without limitation: repair to any portion of the Sublease Premises or the Building; interruption in the use of the Sublease Premises or any equipment therein; accident or damage resulting from any use or operation (by Sublessor, Sublessee or any other person or entity) of elevators or heating, cooling, electrical, sewerage or plumbing equipment; termination of this Sublease by reason of damage to or condemnation of the Sublease Premises or the Building; fire, robbery, theft, vandalism, mysterious disappearance or any other casualty; actions of any other tenant of the Building or other person or entity; failure or inability to furnish or interruption in any utility or service specified in this Sublease; and leakage in any part of the Sublease Premises or the Building. If a condition exists which may be the basis of a claim of constructive eviction, then Sublessee shall give Sublessor written notice thereof and a reasonable opportunity to correct such condition, and in the interim Sublessee shall not claim that it has been constructively evicted or is entitled to any abatement of Rent. Any property placed by Sublessee in or about the Sublessee Premises or the Building shall be at the sole risk of Sublessee, and Sublessor shall not in any manner be responsible therefor. For purposes of this Section, the term &#8220;Building&#8221; shall be deemed to include the Real Property. Notwithstanding the foregoing, nothing in this Section 18 shall limit the Sublessor&#8217;s obligations under Sections 8.1 and 11 hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">18.4.</font></font><font style="font-size:12pt;">The provisions of this Section 18 shall survive the expiration or earlier termination of this Sublease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">19.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">FIRE, CASUALTY AND EMINENT DOMAIN</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">19.1.</font></font><font style="font-size:12pt;">If the Sublease Premises are rendered totally or partially inaccessible or unusable by fire or other casualty, then Sublessor shall diligently restore the Sublease Premises and the Building to substantially the same condition they were in prior to such casualty in accordance with Section 11.4 of the Master Lease; provided, however that if in Sublessor&#8217;s judgment such restoration cannot be completed within ninety (90) days after the occurrence of such casualty (taking into account the time needed for effecting a settlement with any insurance company, removal of debris, preparation of plans and issuance of all required governmental permits), then Sublessor shall have the right to terminate the Sublease Term as of the sixtieth (60th) day after such casualty by giving written notice to Sublessee. If this Sublease is not terminated pursuant to this Section, then until such restoration of the Sublease Premises are substantially complete Sublessee shall be required to pay the Rent for only the portion of the Sublease Premises that in Sublessee&#8217;s judgment is usable while such restoration is being made, except that if such casualty was caused by the act or omission of Sublessee or an employee, guest, agent or Invitee of Sublessee, then Sublessee shall not be entitled to any Rent reduction. After receipt of the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">insurance proceeds (including proceeds of any insurance maintained by Sublessee), Sublessor shall restore the Sublease Premises and the Building, except that (a) if such casualty was caused by the act or omission of Sublessee or an employee, guest, agent or Invitee of Sublessee, then Sublessee shall pay the amount by which such expenses exceed any property insurance proceeds actually received by Sublessor on account of such casualty, and (b) Sublessor shall not be required to repair or restore any Alteration made by Sublessee or any of Sublessee&#8217;s trade fixtures, furnishings, equipment or personal property. Anything herein to the contrary notwithstanding, Sublessor shall have the right to terminate this Sublease if (1) insurance proceeds are insufficient to pay the full cost of such restoration, (2) any mortgage holder does not make such proceeds available for such restoration, (3) zoning or other laws do not permit such restoration, or (4) restoration costs exceed twenty-five percent (25%) of the Building&#8217;s replacement value.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">19.2.</font></font><font style="font-size:12pt;">If one-third or more of the Sublease Premises or occupancy thereof is condemned or sold under threat of condemnation (collectively &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">condemned</u><font style="font-size:12pt;">&#8221;), then this Sublease shall</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">terminate on the day prior to the date title vests in the condemnor (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting Date</u><font style="font-size:12pt;">&#8221;). If less than such one-third is condemned, then this Sublease shall continue in full force and effect as to the part of the Sublease Premises not condemned, except that Rent shall be reduced proportionately as of the Vesting Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.55pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">19.3.</font></font><font style="font-size:12pt;">All awards, damages and compensation paid on account of such condemnation shall belong to Master Lessor in accordance with Section 12.3 of the Master Lease. Sublessee assigns to Sublessor and Master Lessor all rights thereto. Sublessee shall not make any claim against Master Lessor or Sublessor or the condemnor for any portion thereof attributable to damage to the Sublease Premises, value of the unexpired portion of the Sublease Term, loss of profits or goodwill, leasehold improvements or severance damages. The foregoing shall not prevent Sublessee from pursuing a separate claim against the condemnor for the value of movable furnishings and movable trade fixtures installed in the Sublease Premises solely at Sublessee&#8217;s expense and relocation expenses, provided that such claim in no way diminishes any award, damages or compensation payable to Sublessor or Master Lessor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">20.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">DEFAULT</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.55pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">20.1.</font></font><font style="font-size:12pt;">Any Event of Default by Sublessee pursuant to Article 15 of the Master Lease, as incorporated herein, shall be an Event of Default by Sublessee hereunder except that all references to &#8220;Tenant Obligations Guarantor&#8221; shall have no force and effect. Further, in incorporating Article 15 of the Master Lease as aforesaid, the provisions of Section 15.1(a) of the Master Lease are hereby modified such that the phrase &#8220;Fixed Rent, the TIF Payments or Tenant&#8217;s Tax Payments&#8221; shall be deleted and the word &#8220;Rent&#8221; substituted therefor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">20.2.</font></font><font style="font-size:12pt;">Sublessor shall in no event be in default under this Sublease unless Sublessor shall neglect or fail to perform any of its obligations hereunder and shall fail to remedy the same within thirty (30) days after notice to Sublessor specifying such neglect or failure, or if such failure is of such a nature that Sublessor cannot reasonably remedy the same within such thirty</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">(30) day period, Sublessor shall fail to commence promptly (and in any event within such thirty</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">(30) day period) to remedy the same and to prosecute such remedy to completion with diligence and continuity. In the event of a default by Sublessor hereunder which continues uncured</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">beyond the period described in the preceding sentence, Sublessee shall be entitled to pursue any available legal remedy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">21.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">SUBLESSOR&#8217;S REMEDIES</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">In the event of any Event of Default of this Sublease by Sublessee, Sublessor may exercise any of the rights and remedies set forth in Article 15 of the Master Lease, as incorporated herein, in accordance with the terms thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.05pt 5pt;"><font style="font-size:12pt;">In addition to Sublessor&#8217;s remedies set forth above, Sublessor&#8217;s obligation to pay the Allowance and Sublessee&#8217;s right to the Rent Abatement shall be deemed conditioned upon Sublessee&#8217;s full and faithful performance of all of the terms, covenants and conditions of this Sublease to be performed by Sublessee during the Sublease Term. Upon the occurrence of an Event of Default, Sublessor&#8217;s obligation to pay the Allowance and Sublessee&#8217;s right to the Rent Abatement shall automatically be deemed void and of no further force or effect, and the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">unamortized portion of (a) the Rent Abatement, and (b) the Allowance paid by Sublessor shall be immediately due and payable by Sublessee to Sublessor, and recoverable by Sublessor as</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">Additional Rent due under this Sublease. The &#8220;unamortized portion&#8221; shall be calculated to equal the amount of principal which would remain unpaid as of the date of the Event of Default with respect to a loan in an original principal amount equal to the Rent Abatement and the Allowance and which is repaid in equal monthly installments of principal and interest on a direct reduction over the Sublease Term with interest at the rate described in Section 22.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">22.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">SUBLESSOR&#8217;S RIGHT TO REMEDY SUBLESSEE&#8217;S DEFAULT</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.05pt 5pt;"><font style="font-size:12pt;">If Sublessee fails to observe or perform any of the Sublessee&#8217;s covenants, agreements, or obligations required of Sublessee under this Sublease, and such failure shall not be cured within the applicable grace period as provided in Section 20 hereof, the Sublessor, without being under any obligation to do so and without thereby waiving such default, may remedy such default for the account and at the expense of the Sublessee. If the Sublessor makes any expenditures or incurs any obligations for the payment of money in connection therewith, including but not</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">limited to, reasonable attorneys&#8217; fees in instituting, prosecuting or defending any action or proceeding, such sums paid or the cost of such obligations performed, with interest at the rate of five percent (5%) per annum over the base rate in effect from time to time at Bank of America shall be paid to the Sublessor by the Sublessee as Additional Rent.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">23.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">SURRENDER; HOLDOVER</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">The Sublessee shall at the expiration or earlier termination of this Sublease surrender the Sublease Premises broom clean and in a condition equal to or better than their condition on the Commencement Date, except for ordinary wear and tear. Sublessee shall remove all Sublessee&#8217;s goods and effects from the Sublease Premises (including, without hereby limiting the generality of the foregoing, all signs and lettering affixed or painted by the Sublessee, either inside or outside the Sublease Premises). Sublessee shall deliver to the Sublessor the Sublease Premises and all keys, locks thereto, and all fixtures connected therewith and, to the extent restoration is not required by Sublessor as provided herein, all alterations and additions made to or upon the Sublease Premises, in good condition, damage by fire or other casualty only excepted. In the event of the Sublessee&#8217;s failure to remove any of Sublessee&#8217;s property from the Sublease</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">17</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">Premises, Sublessor is hereby authorized, without liability to Sublessee for loss or damage thereto, and at the sole risk of Sublessee, to remove and store any of the property at Sublessee&#8217;s expense, or to retain same under Sublessor&#8217;s control or to sell at public or private sale, without notice, any or all of the property not so removed and to apply the net proceeds of such sale to the payment of any sum due hereunder, or to destroy such property.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">Any holding over by Sublessee after the expiration of the Sublease Term shall be treated as a tenancy at sufferance in accordance with the terms of Section 18.2 of the Master Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">Sublessee shall also pay to Sublessor (i) all damages, direct and indirect, sustained by reason of any such holding over, including, without limitation, loss of a sublessee, and (ii) all charges payable by Sublessor to Master Lessor as a result of such holding over.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">24.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">LATE CHARGE AND INTEREST</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">If any sums due by Sublessee to Sublessor hereunder are not paid within ten (10) Business Days after the due date, Sublessee shall pay to Sublessor, in addition to any charges in Section 22, a late charge equal to five percent (5%) of the overdue amount for each such late payment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">25.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">FORCE MAJEURE</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">In the event that the Sublessor or Sublessee is prevented from performing any covenant hereunder by reason of any cause reasonably beyond the control of such party, the party prevented from performing shall not be liable to the other party therefor nor shall the other party be entitled to any abatement or reduction of any payment due or owing by reason thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;"><font style="font-size:12pt;">26.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;"><font style="font-size:12pt;">RELATION TO MASTER LEASE</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">All obligations of Sublessor hereunder are predicated upon Sublessor&#8217;s rights under the Master Lease. Should the Master Lease be terminated for any reason or Sublessor&#8217;s rights</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">thereunder be abrogated, delayed or restricted in a manner which adversely affects Sublessee&#8217;s rights hereunder, Sublessor shall have no liability to Sublessee therefor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">27.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">LIABILITY OF PARTIES</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.55pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">27.1.</font></font><font style="font-size:12pt;">The obligations of the Sublessor shall be binding upon the Sublessor&#8217;s interest in the Master Lease, but not upon other assets of the Sublessor, and no individual officer, director, employee or agent of the Sublessor shall be personally liable for performance of the Sublessor&#8217;s obligations hereunder. Sublessor shall bear no liability for any loss of personal property or injury to the person or property of Sublessee, its employees, invitees, agents or any other person coming on to the Sublease Premises or the property of which the Sublease Premises are a part due in whole or in part to the presence of Sublessee therein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">27.2.</font></font><font style="font-size:12pt;">No individual, officer, member, director, employee or agent of the Sublessee shall be personally liable for the performance of the Sublessee&#8217;s obligations hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">28.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">NOTICE</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 0pt 0pt 40.95pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">18</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">All notices or other communications hereunder shall be in writing and delivered in the manner provided in Article 22 of the Master Lease, except that the addresses for the Sublessor and the Sublessee shall be as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">If to Sublessor, to</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 113pt;"><font style="font-size:12pt;">The Paul Revere Life Insurance Company </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">c/o Unum Group</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 113pt;"><font style="font-size:12pt;">1 Fountain Square</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 113pt;"><font style="font-size:12pt;">Chattanooga, TN 37402 </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Attention: Corporate Real Estate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 113pt;"><font style="font-size:12pt;">With a copy to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 113pt;"><font style="font-size:12pt;">Unum Law Department </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">2211 Congress Street&#8211; B268 </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Portland, ME 04122</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 113pt;"><font style="font-size:12pt;">Attn: Marybeth Fougere, Esq.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">If to Sublessee, to</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 113pt;"><font style="font-size:12pt;">Mustang Bio, Inc. </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">377 Plantation Street</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2.95pt 113pt;"><font style="font-size:12pt;">Worcester, MA 01605 </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Atten: Knut Niss</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2.95pt 113pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 113pt;"><font style="font-size:12pt;">With copy to (as of the Commencement Date): </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 113pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 113pt;"><font style="font-size:12pt;">Mustang Bio, Inc.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 113pt;"><font style="font-size:12pt;">Atten: General Counsel</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 113pt;"><font style="font-size:12pt;">1 Mercantile Street, Suite 400</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 113pt;"><font style="font-size:12pt;">Worcester, MA 01608</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">29.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">HAZARDOUS MATERIALS</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.55pt 5pt;"><font style="font-size:12pt;">Sublessee shall comply with the provisions of Section 8.1(b) of the Master Lease in the same manner as if it were Tenant thereunder and further agrees to indemnify, defend upon demand with counsel reasonably acceptable to Master Lessor and Sublessor, and hold Master Lessor and Sublessor harmless from and against, any liabilities, losses, claims, damages, interest, penalties, fines, attorneys&#8217; fees, experts&#8217; fees, court costs, remediation costs, and other expenses which result from the use, storage, handling, treatment, transportation, release, threat of release or disposal of Hazardous Materials (as defined in the Master Lease) in, on under or about the Sublease Premises, the Sublessor&#8217;s premises or the property as a whole, by Sublessee or Sublessee&#8217;s agents, employees or contractors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">30.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">PARKING</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">30.1.</font></font><font style="font-size:12pt;">Sublessee and its employees shall have the right to eighty (80) unreserved monthly parking permits for the parking of standard-sized automobiles in the Garage at no</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">19</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">additional charge. Subject to availability, Sublessee shall have the right to use additional unreserved monthly parking permits for the parking of standard-sized automobiles in the Garage by providing at least thirty (30) days prior written notice to Sublessor of its desire to use such additional permits. The charge for such additional permits shall be the prevailing rate charged from time to time by Sublessor or the Garage operator (currently $165.00 per permit, per month).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">30.2.</font></font><font style="font-size:12pt;">Throughout the Sublease Term and, Sublessor shall provide access to the Garage through the Building for Sublessee&#8217;s employees.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">30.3.</font></font><font style="font-size:12pt;">Sublessor may establish rules and regulations regarding Sublessee&#8217;s use of the Garage.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">31.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">BROKERAGE</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">Sublessee and Sublessor represent and warrant to each other that only Kelleher &amp; Sadowsky Associates, Inc. (&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Broker</u><font style="font-size:12pt;">&#8221;) had any part, or was instrumental in any way, in bringing about this Sublease. Sublessor agrees to pay any brokerage fee due to Broker pursuant to a separate agreement with Broker. Each party agrees to indemnify, defend and hold the other party harmless from and against any claims made by any other broker or other person alleging</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">that such broker, or person is owed a brokerage commission, finder&#8217;s fee or similar compensation, by reason of or in connection with this Sublease and relating to communications with such indemnifying party, and any loss, liability, damage, cost and expense (including, without limitation, reasonable attorneys&#8217; fees) in connection with such claims. All fees owed to Broker shall be satisfied by Sublessor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;"><font style="font-size:12pt;">32.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;"><font style="font-size:12pt;">APPLICABLE LAW, HEADINGS, INTEGRATION AND SIGNATURES</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">This Sublease shall be construed and enforced in accordance with the laws of The Commonwealth of Massachusetts. Section and section headings are not a part hereof and shall not be used to interpret the meaning of this Sublease. This Sublease forms the complete and entire understanding with respect hereto between the parties, and merges all prior and contemporaneous negotiations and understandings. This Sublease may not be modified or amended except by a written instrument. The parties hereto rely on no representations other than those set forth herein. If any provision of this Sublease or portion of such provision or the application thereof to any person or circumstances is held invalid, the remainder of the Sublease or of such provision and application thereof to other persons and circumstances shall not be affected thereby</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.05pt 5pt;"><font style="font-size:12pt;">This Sublease may be executed in counterparts, each of which shall be deemed an original, but all of which, taken together, shall constitute one and the same instrument.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">Signatures to this Sublease transmitted by telecopy or email shall be valid and effective to bind the party so signing. Each party agrees to promptly deliver an execution original to this Sublease with its actual signature to the other party, but a failure to do so shall not affect the enforceability of this Sublease, it being expressly agreed that each party to this Sublease shall be bound by its own telecopied or emailed signature and shall accept the telecopied or emailed signature of the other party to this Sublease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">20</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[SIGNATURES ON FOLLOWING PAGE]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">21</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.05pt 5pt;"><font style="font-size:12pt;">IN WITNESS WHEREOF, the said parties hereunto set their hands and seals this 14</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> day of June, 2022.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.05pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">SUBLESSOR:</font></p></td><td style="vertical-align:top;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:48.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">SUBLESSEE:</font></p></td></tr><tr><td style="vertical-align:top;width:48.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">THE PAUL REVERE LIFE INSURANCE COMPANY</font></p></td><td style="vertical-align:top;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">MUSTANG BIO, INC.</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 21.6pt;"><img src="tmb-20221231xex10d22001.jpg" alt="Graphic" style="display:inline-block;height:20.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:115.5pt;"></p></td><td style="vertical-align:top;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 21.6pt;"><img src="tmb-20221231xex10d22002.jpg" alt="Graphic" style="display:inline-block;height:12pt;width:115.5pt;"></p></td></tr><tr><td style="vertical-align:top;width:48.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 3.7pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">By:  </font><font style="color:#1372e5;">Devin Bloss (Jun 15, 2022 09:32 EDT)</font></p></td><td style="vertical-align:top;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-size:12pt;white-space:pre-wrap;">By:  </font><font style="color:#1372e5;">Manuel B Litchman (Jun 14, 2022 11:48 EDT)</font></p></td></tr><tr><td style="vertical-align:top;width:48.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name: Devin Bloss</font></p></td><td style="vertical-align:top;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name: Manuel Litchman</font></p></td></tr><tr><td style="vertical-align:top;width:48.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Its: AVP, Strategic Sourcing</font></p></td><td style="vertical-align:top;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Its: President and Chief Executive Officer</font></p></td></tr><tr><td style="vertical-align:top;width:48.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">22</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.5pt 0pt;"><font style="font-size:12pt;">EXHIBIT A</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">FLOOR PLAN(S) SHOWING SUBLEASE PREMISES ATTACHED TO AND MADE PART OF</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">THE SUBLEASE BETWEEN THE PAUL REVERE LIFE INSURANCE COMPANY AND MUSTANG BIO, INC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[</font><b style="font-size:12pt;font-weight:bold;">See attached</b><font style="font-size:12pt;">.]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">A-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20221231xex10d22003.jpg" alt="Graphic" style="display:inline-block;height:572.25pt;width:433.51pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">EXHIBIT B</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.75pt 0pt;"><font style="font-size:13pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">REDACTED COPY OF MASTER LEASE ATTACHED TO AND MADE PART OF</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">THE SUBLEASE BETWEEN THE PAUL REVERE LIFE INSURANCE COMPANY AND MUSTANG BIO, INC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">[Note: To be attached.]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">B-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">EXHIBIT C</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">WORK LETTER </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">ATTACHED TO AND MADE PART OF</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">THE SUBLEASE BETWEEN THE PAUL REVERE LIFE INSURANCE COMPANY </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">AND MUSTANG BIO, INC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublease: Defined Terms</u><font style="font-size:12pt;">. The Sublease is hereby incorporated by reference to the extent that the provisions of this Work Letter apply thereto. Terms not otherwise defined in this Work Letter shall have the meanings given to them in the Sublease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">2.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublessee&#8217;s Work</u><font style="font-size:12pt;">. Sublessee shall, at Sublessee&#8217;s sole cost and expense (subject to application of the Allowance as provided below) provide all labor, materials, and equipment necessary for Sublessee&#8217;s initial tenant improvements (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublessee&#8217;s Work</u><font style="font-size:12pt;">&#8221;). The Sublessee&#8217;s Work constitutes an Alteration under the Master Lease and, in addition, Sublessee&#8217;s Work shall be treated as constituting a portion of the Tenant&#8217;s Work and shall comply with the requirements of Section 1.9 of Exhibit FF to the Master Lease and Article 5 of the Master Lease. Sublessee&#8217;s Work shall comply with Sublessor&#8217;s sustainability practices and must be in conformance with the United States Green Building Council Leadership in Energy and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">Environmental Design (&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LEED</u><font style="font-size:12pt;">&#8221;) 2009 criteria for Certified Silver status.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:4.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plans and Specifications</u><font style="font-size:12pt;">.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">Promptly following the execution of the Sublease, Sublessee, shall cause to be prepared architectural drawings and specifications for Sublessee&#8217;s Work (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Preliminary Plans</u><font style="font-size:12pt;">&#8221;). MEP/PP plans and specifications shall be performed on a design/build basis by qualified subcontractors and submitted for approval with the Final Plans. The Preliminary Plans shall provide for improvements that (i) satisfy all Requirements (including the Americans with Disabilities Act); (ii) are consistent in quality to the improvements made by Sublessor in the Building; (iii) do not adversely affect the Building or any Building system; and (iv) comply with the Tenant LEED Requirements as set forth in </font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit E</b><font style="font-size:12pt;">. The Preliminary Plans shall be submitted to Sublessor as soon as available, but not later than thirty (30) days following the Commencement Date (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan Submission Date</u><font style="font-size:12pt;">&#8221;) and shall be subject to Sublessor&#8217;s and Master Lessor&#8217;s written approval. The Preliminary Plans must reflect all of the work to be performed as part of Sublessee&#8217;s Work. Sublessor shall use commercially reasonable efforts to provide Sublessee with any comments or objections to the Preliminary Plans promptly. Sublessor shall either approve such plans and specifications or provide Sublessee with the reasons that Sublessor or Master Lessor is withholding such approval. If Sublessor or Master Lessor does not approve the Preliminary Plans when submitted, Sublessee shall promptly cause its architect to revise the Preliminary Plans in a manner reasonably acceptable to Sublessor and Master Lessor and consistent with such comments, and then resubmit to Sublessor and Master Lessor for approval.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">Once Sublessor and Master Lessor have approved the Preliminary Plans, Sublessee shall promptly cause its architect to prepare (and deliver to Sublessor and Master Lessor) complete, detailed working plans and specifications (consistent with the Sublessor and Master Lessor approved Preliminary Plans) sufficient to obtain the necessary building permits</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">C-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.95pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">and to then build-out the Sublessee&#8217;s Work (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Final Plans</u><font style="font-size:12pt;">&#8221;). Such Final Plans must be submitted to Sublessor and Master Lessor for approval by no later than fourteen (14) days after Sublessor&#8217;s and Master Lessor&#8217;s approval of the Preliminary Plans. The Final Plans, once approved by Sublessor, will be the plans which Sublessee shall use to complete the Sublessee&#8217;s Work.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:4.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Construction</u><font style="font-size:12pt;">.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.05pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">Upon approval of the Final Plans, Sublessee shall select a general contractor to construct Sublessee&#8217;s Work. Such selection shall be submitted for approval to Sublessor and Master Lessor in writing (along with information regarding such general contractor&#8217;s experience and financial capability and the fees which such general contractor has agreed to charge for the Sublessee&#8217;s Work) by no later than ten (10) days following Sublessor&#8217;s approval of the Final Plans. Once submitted to Sublessor and Master Lessor, Sublessor shall approve or disapprove such selection (such approval not to unreasonably be withheld) and use commercially reasonable efforts to obtain Master Lessor&#8217;s approval. If disapproved, Sublessor shall provide the reasons for disapproval in writing to Sublessee whereupon Sublessee shall promptly submit an</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">alternative general contractor for approval, and such process will continue until the Sublessee&#8217;s contractor has been approved by Master Lessor and Sublessor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">Sublessee&#8217;s contractor will not be permitted to start construction until: (i) Sublessee has obtained all permits and approvals from applicable governmental authorities and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.1pt 5pt;"><font style="font-size:12pt;">(ii) Sublessee&#8217;s contractor has submitted evidence of insurance to Sublessor and Master Lessor in accordance with the requirements of </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1</u><font style="font-size:12pt;"> attached hereto. The Sublessee&#8217;s Work shall be completed by the selected contractor in a first class and workmanlike manner in accordance with the Final Plans and in compliance with all applicable Requirements. During the performance of the Sublessee&#8217;s Work, Sublessee will have weekly progress meetings with Sublessor and Master Lessor and their construction representatives to review and inspect the progress of Sublessee&#8217;s Work. Sublessee shall use commercially reasonable efforts to prosecute the Sublessee&#8217;s Work such that same is Substantially Completed (as defined below) on or before the Anticipated Commencement Date. The Premises shall be deemed substantially completed (&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Substantially Completed</u><font style="font-size:12pt;">&#8221; or &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Substantially Complete</u><font style="font-size:12pt;">&#8221;) when Sublessee is in receipt of a Certificate of Occupancy or Temporary Certificate of Occupancy (punchlist items excepted) for the Sublease Premises. Sublessee further agrees to indemnify, defend, and save and hold Sublessor harmless for claims for injuries to persons or damage to the property of others arising from Sublessee&#39;s Work except to the extent caused by the gross negligence or willful misconduct of Sublessor, its agents, employees or contractors. Sublessor, in Sublessor&#39;s reasonable discretion, may from time to time establish such reasonable rules and regulations for protection of property and the general safety of occupants and invitees of the Building during the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">construction of the Sublessee&#8217;s Work. Such rules and regulations shall apply to Sublessee and Sublessee&#39;s contractor as though established upon the execution of the Sublease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">Changes in the Sublessee&#8217;s Work may be accomplished only by a Change Order (defined below) approved by Master Lessor after Sublessor&#8217;s written request. As used in this Work Letter, a &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change Order</u><font style="font-size:12pt;">&#8221; shall mean a written instrument prepared by Sublessee and signed by Master Lessor, Sublessor and Sublessee stating their agreement upon all of the following: (i) the change in the Sublessee&#8217;s Work; (ii) the extent of the adjustment in the cost of</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">C-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.95pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">such Sublessee&#8217;s Work; and (iii) the extent of the adjustment in the Anticipated Commencement Date, if any.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:40.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">(d)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">Approximately three (3) Business Days prior to the date when Sublessee</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 5pt;"><font style="font-size:12pt;">anticipates the Sublessee&#8217;s Work will be Substantially Completed, Sublessor and Sublessee shall inspect the Sublease Premises. Upon completion of the inspection, unless Sublessor shall notify Sublessee in writing regarding any observed deficiencies in the Sublessee&#8217;s Work that go beyond punch list items, which notice shall be delivered to Sublessee, if at all, within three (3) Business Days next following Sublessor&#8217;s inspection, it shall be presumed that the Sublessee&#8217;s Work is Substantially Completed, except for punch list items. Within three (3) Business Days after the Sublessee&#8217;s Work is Substantially Completed, Sublessor and Sublessee shall inspect the Sublease Premises, and Sublessor and Sublessee shall agree on a punch list of minor finishing and adjustment which Sublessee has not completed materially in accordance with the Final Plans or which needs to be repaired. Sublessee agrees to complete the items set forth on the punch list within sixty (60) days of receipt of such list. Failure to include an item on the punch list will not diminish the responsibility of Sublessee to complete such Sublessee&#8217;s Work in accordance with</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">the Final Plans. Sublessee shall provide to Sublessor, or cause Sublessee&#8217;s contractor to provide to Sublessor, copies of all as built and shop plans, specifications, warranties, operating and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">maintenance manuals, shop drawings and other documents provided by the Sublessee&#8217;s contractor concerning the Sublessee&#8217;s Work within sixty (60) days after the punch-list for the Sublessee&#8217;s Work is submitted to Sublessor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:4.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Allowance and Supervision Fee</u><font style="font-size:12pt;">.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.55pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">Sublessor shall pay to Sublessee an amount not to exceed Two Hundred Sixty- Five Thousand Thirty and 00/100 Dollars ($265,030.00) (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Allowance</u><font style="font-size:12pt;">&#8221;) toward the cost of Sublessee&#8217;s Work to the extent permitted by the terms of this Section and provided that as of the date on which Sublessor is required to make such payment: (i) this Sublease is in full force and effect, and (ii) no Event of Default then exists. Sublessee shall pay all costs of Sublessee&#8217;s Work in excess of the Allowance. Sublessor shall pay the Allowance solely on account of plans, designs and specifications commissioned by Sublessee with respect to the completion of the Sublessee Work and hard construction costs and labor directly related to the Sublessee&#8217;s Work and materials, furniture and equipment approved by Sublessor and delivered to the Sublease Premises in connection with the Sublessee&#8217;s Work. Any amount of the Allowance which has not been requisitioned by sixty (60) days following the Commencement Date, shall be retained by Sublessor and Sublessee shall have no further right to claim thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.05pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">Sublessor shall make progress payments on account of the Allowance to Sublessee on a monthly basis, for the Sublessee&#8217;s Work performed during the previous month, less a retainage (&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Retainage</u><font style="font-size:12pt;">&#8221;) equal to five percent (5%) of the total contract price. Sublessor&#8217;s</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">progress payments shall be equal to 100% of the amounts owed by Sublessee under the contract less Retainage. Such progress payments shall be made payable directly to Sublessee or contractor (at Sublessor&#8217;s election) within thirty (30) days following the delivery to Sublessor of requisitions therefor. Each such requisition shall be executed by a duly authorized officer of Sublessee, and shall be accompanied by (i) with the exception of the first requisition, copies of partial waivers of lien from all contractors, subcontractors, and material suppliers covering all work and materials which were the subject of previous progress payments by Sublessor, (ii) a</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">C-3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.95pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">certification from Sublessee&#8217;s architect and contractor on completed AIA Forms G702 and G703, (iii) a requisition certificate substantially in the form of the Requisition Certification attached hereto as </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 2</u><font style="font-size:12pt;"> and incorporated herein by this reference and (iv) such additional information as may be reasonably required by Sublessor in accordance with commercially reasonable construction lending requirements. Sublessor shall hold such Retainage and disburse the Retainage, or portions thereof as requisitioned by Sublessee from time to time on account of subcontractors who have completed their respective portions of the job, upon submission by Sublessee to Sublessor of Sublessee&#8217;s requisition therefor accompanied by all documentation required under the foregoing provisions of this Section, together with (A) proof of the satisfactory completion of all required inspections and issuance of any required approvals, permits and sign offs for the work of such subcontractor, or with respect to the work of the Sublessee&#8217;s general contractor, the Sublessee&#8217;s Work, by governmental authorities having jurisdiction thereover (including issuance of the Certificate of Occupancy), and (B) issuance of final lien waivers by all contractors, subcontractors and material suppliers covering all of the Sublessee&#8217;s Work or the portion thereof as applicable (which final lien waivers may be conditioned upon, or delivered concurrent with, payment of such Retainage). In addition, concurrent with the final requisition for the Retainage, Sublessee shall submit &#8220;as-built&#8221; plans and specifications for the Sublessee&#8217;s Work. The right to receive the Allowance is for the exclusive benefit of Sublessee, and in no event shall such right be assigned to or be enforceable by or for the benefit of any third party, including any contractor, subcontractor, materialman, laborer, architect, engineer, attorney or other person or entity (excepting only a permitted assignee of Sublease).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">Sublessee shall pay on demand to Sublessor a construction supervision fee in the amount of four percent (4%) of the total cost of constructing Sublessee&#8217;s Work.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">6.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublessee Work Standards</u><font style="font-size:12pt;">. Sublessee shall cause the Sublessee Work to be done in a good and workmanlike manner in conformity with all applicable Requirements and insurance underwriters. Sublessee shall secure and pay for all permits and fees, licenses, and inspections necessary for the proper execution and completion of the Sublessee Work. Sublessee shall comply with and give all notices required by all applicable federal, state and local laws, ordinances and building codes, and requirements of public authorities and insurance underwriters. Sublessee shall be responsible for initiating, maintaining, and supervising all safety precautions and programs in connection with performance of the Sublessee Work. Sublessee shall procure insurance of the types and coverage amounts required pursuant to the Sublease or as otherwise may be appropriate given the nature and extent of Sublessee Work. Sublessee shall be responsible for the removal of all debris within and adjacent to the Sublease Premises created by Sublessee Work. All Sublessee Work shall be performed in a manner and by contractors who shall not interfere with the use of the Building by other tenants or disturb harmonious labor relations with Sublessor&#8217;s employees, agents, contractors or subcontractors. In the event that Sublessee, its employees, agents, contractors or subcontractors conflict with or interfere with labor employed by Sublessor, its contractors or subcontractors, or in the event that any work stoppages, jurisdictional labor dispute or other interference with Sublessor, or Sublessor&#8217;s employees, agents, contractors or subcontractors occurs, of which Sublessor shall be the sole and absolute judge, Sublessor shall have the right to require Sublessee, upon written demand, to remove or cause the removal forthwith of all Sublessee&#8217;s contractors and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">C-4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.95pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">subcontractors from the Premises, and Sublessee agrees to comply with such demand immediately.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">C-5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.95pt 0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.5pt 0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contractor Insurance Requirements</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">The following must be named as additional insureds:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">THE PAUL REVERE LIFE INSURANCE COMPANY ONEMERC LLC</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">Each contractor and subcontractor must provide coverage in an amount equal to or greater than those provided below:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 5pt;"><b style="font-size:12pt;font-weight:bold;">Comprehensive General Liability</b><font style="font-size:12pt;">:</font><font style="display:inline-block;width:41.34pt;"></font><font style="font-size:12pt;">$1,000,000 Each Occurrence</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.55pt 221.05pt;"><font style="font-size:12pt;">$2,000,000 General Aggregate</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><b style="font-size:12pt;font-weight:bold;">Automobile Liability Policy</b><font style="display:inline-block;width:74.67pt;"></font><font style="font-size:12pt;">$1,000,000 Owned, Non-owned &amp; Hired Vehicles:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 221.05pt;"><font style="font-size:12pt;">Bodily Injury and Property Damage </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Combined Single Limit</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><b style="font-size:12pt;font-weight:bold;">Umbrella Liability</b><font style="display:inline-block;width:120.33pt;"></font><font style="font-size:12pt;">$5,000,000</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><b style="font-size:12pt;font-weight:bold;">Worker&#8217;s Compensation:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 5pt;"><font style="font-size:12pt;">Coverage A (Worker&#8217;s Compensation)</font><font style="display:inline-block;width:29.72pt;"></font><font style="font-size:12pt;">$500,000.00 Coverage B (Employer&#8217;s Liability)</font><font style="display:inline-block;width:15.71pt;"></font><font style="font-size:12pt;">$500,000.00</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">In addition to the above, Sublessor requires notification, in writing, TEN (10) days prior to policy cancellation for any reason.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">C-6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.95pt 0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.5pt 0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 2</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.5pt 0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Form of Requisition Certification</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">In connection with that certain Sublease dated </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:73.84pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:18.25pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:12pt;">, 2022 (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublease</u><font style="font-size:12pt;">&#8221;), by and between The Paul Revere Life Insurance Company (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublessor</u><font style="font-size:12pt;">&#8221;), and Mustang Bio, Inc. (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublessee</u><font style="font-size:12pt;">&#8221;) with respect to the improvement of the Sublease Premises located within the Building at One Mercantile Place in Worcester, Massachusetts (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Project</u><font style="font-size:12pt;">&#8221;) (capitalized terms appearing but not defined herein shall have the meanings ascribed to such terms in the Sublease), Sublessee hereby certifies as follows with respect to Draw Request #</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:286.39pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="font-size:12pt;">:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 6.05pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:41.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">a.</font></font><font style="font-size:12pt;">To the knowledge of the undersigned, at the date hereof no suit or proceeding at law or in equity, and no notice has been received that any investigation or proceeding of any governmental body has been instituted or is threatened against Sublessee for matters directly relating to the Sublease Premises except for the following: none.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.95pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:41.1pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">b.</font></font><font style="font-size:12pt;">The labor, materials, equipment, work, services and supplies described herein have been performed upon or furnished to the Sublease Premises in full accordance with the Final Plans for Sublessee&#8217;s Work.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:41.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">c.</font></font><font style="font-size:12pt;">All bills for labor, materials, equipment, work, services and supplies furnished in connection with the Project, which could give rise to a mechanic&#8217;s lien if unpaid, have been paid, will be paid out of the requested advance or are not yet due and payable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 6.05pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:41.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">d.</font></font><font style="font-size:12pt;">All claims for mechanic&#8217;s liens to the extent of sums billed and paid for labor, materials, equipment, work, services or supplies furnished in connection with the Project through the last day of the period covered by the requested advance have been effectively waived in writing, or will be effectively waived in writing when payment is made, and such written waivers from the contractor shall be delivered prior to the next advance or final advance for the Project.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:41.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">e.</font></font><font style="font-size:12pt;">All funds advanced under the Allowance to date have been utilized as specified in the Draw Requests pursuant to which the same were advanced, exclusively to pay costs incurred for or in connection with the Sublessee&#8217;s Work at the Project, and no portion of the Allowance that has been paid to Sublessee has been paid for labor, materials, equipment, work, services or supplies incorporated into or employed in connection with any project other than the Project. The undersigned further represents that all funds covered by this Draw Request are for payment for labor, materials, equipment, work, services or supplies furnished solely in connection with the Project.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">The advances and disbursements on the attached sheets are hereby approved and authorized.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Date: </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:7.01pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:12pt;">MUSTANG BIO, INC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:12pt;">By: Its:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">C-7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.5pt 0pt;"><font style="font-size:12pt;">EXHIBIT D</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">RULES AND REGULATIONS </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">ATTACHED TO AND MADE PART OF</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">THE SUBLEASE BETWEEN THE PAUL REVERE LIFE INSURANCE COMPANY </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">AND MUSTANG BIO, INC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant shall not make any room-to-room canvas to solicit business from other tenants in the Building and shall not exhibit, sell or offer to sell, use, rent or exchange any item or services in or from the Leased Premises unless ordinarily included within Tenant&#8217;s use of the Leased Premises.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant shall not make any use of the Leased Premises which may be dangerous to person or property or which shall increase the cost of insurance or require additional insurance coverage.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant shall not paint, display, inscribe or affix any sign, picture, advertisement, notice, lettering or direction or install any lights on any part of the outside or inside of the Building, other than the Leased Premises, and then not on any part of the inside of the Leased Premises which can be seen from outside the Leased Premises, except as approved by Landlord in writing.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant shall not use the name of the Building in advertising or other publicity, except as the address of its business, and shall not use pictures of the Building in advertising or publicity.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant shall not obstruct or place objects on or in sidewalks, entrances, passages, courts, corridors, vestibules, halls, elevators and stairways in and about the Building. Tenant shall not place objects against glass partitions or doors or windows or adjacent to any open common space which would be unsightly from the Building corridors or from the exterior of the Building.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:22.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Bicycles shall not be permitted in the Building.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant shall not allow any animals, other than Seeing Eye dogs and service animals, in the Leased Premises or the Building.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant shall not disturb other tenants or make excessive noises, cause disturbances, create excessive vibrations, odors or noxious fumes or use or operate any devices that play loud or offensive music or emit excessive sound waves or are dangerous to other tenants of the Building or that would interfere with the operation of any device or equipment or radio or television broadcasting or reception from or within the Building or elsewhere, and shall not place or install any projections, antennae, aerials or similar devices outside of the Building or the Leased Premises.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant shall not waste electricity or water and shall cooperate fully with Landlord to assure the most effective operation of the Building&#8217;s heating and air conditioning systems, and shall refrain from attempting to adjust any controls except for the thermostats within the Leased Premises. Tenant shall keep all doors to the Leased Premises closed when not in use.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">10.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Landlord shall furnish an access card for the main entrance and Common Areas to the Building for each of Tenant&#8217;s employees at the then-current rate charged by Landlord. Tenant and Tenant&#8217;s employees shall not give their building access cards to any other individual. Tenant and Tenant&#8217;s employees shall not piggyback or allow other individuals to piggyback through access-controlled building entrances. When a Tenant&#8217;s employee</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 23pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">D-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.95pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">ceases to work at the Leased Premises, Tenant shall require such employee to return the access card, and Tenant shall notify Landlord of such in order to allow Landlord to deactivate such access card. When the Lease is terminated, Tenant shall deliver all access cards to Landlord, will deactivate the access key or other security system for the doors to the Leased Premises, and will provide to Landlord the means of opening any safes, cabinets or vaults left in the Leased Premises.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">11.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant shall not install any signal, communication, alarm or other utility or service system or equipment without the prior written consent of Landlord.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">12.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant shall not use any draperies or other window coverings instead of or in addition to the Building standard window coverings designated and approved by Landlord for exclusive use throughout each Building.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">13.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Landlord may require that all persons who enter or leave the Building identify themselves to building management/Landlord personnel by registration or otherwise. Landlord, however, shall have no responsibility or liability for any theft, robbery or other crime in the Building. Tenant shall assume full responsibility for protecting the Leased Premises, including keeping all doors to the Leased Premises locked after the close of business. Tenant shall comply with any and all written security procedures promulgated by Landlord from time to time.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">14.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant shall not overload floors; and Tenant shall obtain Landlord&#8217;s prior written approval, which approval shall not be unreasonably withheld, conditioned or delayed (provided that Tenant shall be responsible for the cost of any changes to the Building or Leased Premises required because of the installation of any such objects), as to size, maximum weight, routing and location of business machines, safes, and heavy objects. Tenant shall not install or operate machinery or any mechanical devices of a nature not directly related to Tenant&#8217;s ordinary use of the Leased Premises.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">15.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">In no event shall Tenant bring into the Building flammables such as gasoline, kerosene, naphtha and benzene, or explosives or firearms or any other articles of an intrinsically dangerous nature.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">16.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Furniture, equipment and other large articles may be brought into the Building only at the time and in the manner designated by Landlord. At no time, furniture equipment and other large articles shall not be brought through the revolving doors at the building entrances. Tenant shall furnish Landlord with a list of furniture, equipment and other large articles which are to be removed from the Building. Movements of Tenant&#8217;s property into or out of the Building and within the Building are entirely at the risk and responsibility of Tenant. Tenant shall be responsible for damage to the Building arising from such movement activity.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">17.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">No person or contractor, unless approved in advance by Landlord, shall be employed to do janitorial work, interior window washing, cleaning, decorating or similar services in the Leased Premises.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">18.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant shall not use the Leased Premises for lodging, cooking (except for microwave reheating and coffee makers) or manufacturing or selling any alcoholic beverages or for any illegal purposes.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">19.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant shall cooperate and participate in all security health, safety and well-being programs affecting the Building.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">20.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant shall not loiter, eat, drink, sit or lie in the lobby or other public areas in the Building. Tenant shall not go onto the roof of the Building or any other non-public areas</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 23pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">D-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.95pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">of the Building (except the Leased Premises), and Landlord reserves all rights to control the public and non-public areas of the Building. In no event shall Tenant have access to any electrical, telephone, plumbing or other mechanical closets without Landlord&#8217;s prior written consent.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">21.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant shall not use the freight or passenger elevators, loading docks or receiving areas of the Building except in accordance with regulations for their use established by Landlord.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">22.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant shall not dispose of any foreign substances in the toilets, urinals, sinks or other washroom facilities, nor shall Tenant permit such items to be used other than for their intended purposes; and Tenant shall be liable for all damage as a result of a violation of this rule.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:22.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">23.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant acknowledges that the Real Property is a non-smoking campus.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">24.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant and Tenant&#8217;s employees may park in the spaces identified as Tenant parking. Tenant&#8217;s guests and invitees may park in the spaces identified as &#8220;Visitor Parking&#8221;. Landlord shall have no liability for theft or damage of/from/to any Vehicles parked on the Real Property. Tenant&#8217;s employees shall not park in spaces identified as &#8220;Visitor Parking&#8221;.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">25.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Consumption of alcohol is strictly forbidden in all Common Areas and the parking garage.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">26.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant and Tenant&#8217;s employees shall not wear any clothing that contains offensive language or is considered inappropriate at all times while in Common Areas. Examples of inappropriate clothing includes, but not limited to, clothing that is too tight, short or revealing, clothing that is frayed or torn, clothing that is not cleaned, t-shirts or clothing that contains logos or slogans that would be deemed offensive to other building occupants or tenants.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">27.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.05pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant and Tenant&#8217;s employees shall follow all posted speed limits in parking lots, access roads and parking garages. Tenant and Tenant&#8217;s employees shall obey all directional signage posted in parking lots, access roads and parking garages.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:23pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">28.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Tenant and Tenant&#8217;s employees shall not bring any illegal or illicit drugs, or drug paraphernalia onto the Landlord&#8217;s property.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 23pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">D-3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">EXHIBIT E</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">OPERATION AND MAINTENANCE GUIDELINES </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">ATTACHED TO AND MADE PART OF</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">THE SUBLEASE BETWEEN THE PAUL REVERE LIFE INSURANCE COMPANY </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">AND MUSTANG BIO, INC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">OPERATION AND MAINTENANCE GUIDELINES</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.</font></font><font style="font-size:12pt;">Sublessee shall comply with all applicable provisions of (i) the LEED CS Matrix for Base Building attached as Exhibit P-1 to the Master Lease and (ii) the LEED CI Matrix for Tenant&#8217;s Work attached as Exhibit P-2 to the Master Lease (copies of which are attached hereto), as the same may be amended from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">2.</font></font><font style="font-size:12pt;">Sublessee shall comply with the following &#8220;Tenant LEED Requirements&#8221;, as the same may be amended from time to time:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><b style="font-size:12pt;font-weight:bold;">Minimum Program Requirement:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">Tenants shall share any energy and water usage data which it may have for a period of at least five years.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><b style="font-size:12pt;font-weight:bold;">EAp3: Fundamental Refrigerant Management</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 41pt;"><font style="font-size:12pt;">All Tenant installed mechanical cooling equipment will comply with the requirements of EAp3. There will be zero use of CFC-based refrigerants in all tenant-installed new mechanical cooling equipment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><b style="font-size:12pt;font-weight:bold;">IEQp1: Minimum IAQ Performance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">All HVAC systems designed and installed by the Tenant shall meet the minimum requirements of sections 4 through 7 of ASHRAE Standard 62.1-2007. In the event any base building system provided by the Landlord that needs modification to meet the minimum requirements of sections 4 through 7 of ASHRAE 62.1-2007 shall be the responsibility of the Tenant. Tenant shall provide ventilation calculations for all base building systems serving Tenant areas as well as Tenant systems serving Tenant areas. Tenant shall utilize the &#8220;62MZCalc&#8221; spreadsheet for calculations provided to the Landlord for review and acceptance.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><b style="font-size:12pt;font-weight:bold;">IEQc1: Outdoor Air Delivery Monitoring</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">Tenant shall provide CO2 monitoring control within all densely occupied spaces. Densely occupied space would apply to space with a density equal to or greater than 25 people per 1000 square feet. Tenant shall install CO2 monitors between 3 and 6 feet above finished floor. In the event a Tenant installs additional air handling systems such system shall be provided with a direct outdoor air monitoring device measuring the minimum outdoor air intake flow with an accuracy of +/- 15 percent of the design outdoor air rate minimum as defined by ASHRAE 62.1-2007 (with errata but without addenda) for each mechanical ventilation system where 20 percent or more of the design supply airflow serves non densely occupied spaces. All tenant installed CO2 control</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">systems shall be of permanent type to ensure that all minimum ventilation requirements are maintained. Monitoring equipment shall alarm to a building operator through the building automation control system in the event airflow values or CO2 levels vary by 10 percent or more from the designed value.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><b style="font-size:12pt;font-weight:bold;">IEQc5: Indoor Chemical &amp; Pollutant Source Control</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">Employ permanent entryway systems at least 10 feet long in the primary direction of travel to capture dirt and particulates entering the building at regularly used exterior entrances. Acceptable entryway systems include permanently installed grates, grills and slotted systems that allow for cleaning underneath. Roll-out mats are acceptable only when maintained on a weekly basis by a contracted service organization.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><b style="font-size:12pt;font-weight:bold;">IDc1.1: Innovation in Design: Fundamental &amp; enhanced commissioning required for all tenant spaces</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">Implement fundamental and enhanced commissioning process activities in accordance with the requirements listed under EA Prerequisite 1 and EA Credit 3 in the LEED Reference Guide for Green Building Design and Construction, 2009 Edition.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><b style="font-size:12pt;font-weight:bold;">IDc1.4: Innovation in Design: Green Housekeeping</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">Tenants will implement a Green Cleaning Policy that complies with LEED 2009 for Existing Buildings: Operations and Maintenance, IEQ pre-requisite 3.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><b style="font-size:12pt;font-weight:bold;">IDc1.5: Innovation in Design: IAQ Plan for 100% of Tenants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">Develop and implement a construction indoor air quality management plan for the construction and preoccupancy phase of the tenant space as follows and as per IEQ Credit 3:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#183;</font></font><font style="font-size:12pt;">During construction, meet or exceed the recommended control measures of the Sheet Metal and Air Conditioning National Contractors Associations (SMACNA) IAQ Guidelines for Occupied Buildings under Construction, 2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> Edition 2007, ANSI/SMACNA 008-2008 (Chapter 3).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 41pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#183;</font></font><font style="font-size:12pt;">Protect stored on-site and installed absorptive materials from moisture damage. If permanently installed air handlers are used during construction, filtration media with a minimum efficiency reporting value (MERV) of 8 must be used at each return air grille, as determined by ASHRAE Standard 52.2-1999 (with errata but without addenda). Replace all filtration media immediately prior to occupancy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 5pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">3.</font></font><font style="font-size:12pt;">Sublessee shall comply with the following &#8220;Green Cleaning Requirements&#8221;, as the same may be amended from time to time:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Green Cleaning Program Overview</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">To demonstrate its commitment to sustainable greening of the Building, Sublessor has made efforts to implement a green cleaning program. Sublessee shall perform green cleaning of the Sublease Premises. The program listed in the remainder of this section is a fully comprehensive green cleaning program that is consistent with USGBC&#8217;s LEED rating system.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">E-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.75pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Purpose of Green Cleaning</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">Many janitorial cleaning products have been shown to degrade indoor air quality, pollute the water and negatively impact the health of sensitive occupants. In an effort to maintain a clean Building, janitors often use harsh solutions that, while disinfecting the Building, contaminate the indoor air. It is Sublessor&#8217;s desire to maintain both a clean Building and a healthy environment for its occupants and Sublessor is therefore committed to the Green Cleaning Practices in this policy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 41pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Sublessee Participation</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">The following elements will be incorporated into the cleaning process: green product specification, staff training, solution storage, dilution and safe handling and equipment specifications. Sublessee agrees to comply with the cleaning program.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.75pt 0pt;"><font style="font-size:13pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Low Environmental Impact Cleaning Policy:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Hand Hygiene</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">Sublessee shall promote healthy hand hygiene by providing soap and soap dispensers in restrooms, break rooms and other areas in the Sublease Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.8pt 0pt;"><font style="font-size:13pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Chemical Storage Guidelines</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">Sublessee must comply with Sublessor&#8217;s program to reduce the exposure of the Building occupants to potentially dangerous chemical, biological and particle contaminants which adversely impact air quality, health and the environment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Any chemical stored in Sublease Premises must be in a locked container which encloses the liquid cleaning products and delivers out proper specified measurement for dilution.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">The solutions used by Sublessee must be stored in a janitor&#8217;s closet(s), and the janitorial staff must follow these guidelines:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:113pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.09pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">a.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.09pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Material Safety Data Sheets (MSDS) for all chemicals and cleaning products must be available to all employees and stored on site with the chemicals (Sublessee Personnel are trained on MSDS and chemical handling annually);</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:112.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">b.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">All containers must be properly labeled to be easily identifiable;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:113pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;"><font style="font-size:12pt;">c.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;"><font style="font-size:12pt;">All cleaning products must be properly and safely stored, and no liquids will be placed on shelves above eye level;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 2.04pt 113pt;"><font style="font-size:12pt;">d.</font><font style="display:inline-block;width:9pt;"></font><font style="font-size:12pt;">Sublessee</font><font style="display:inline-block;width:10.72pt;"></font><font style="font-size:12pt;">Personnel</font><font style="display:inline-block;width:10.82pt;"></font><font style="font-size:12pt;">must</font><font style="display:inline-block;width:10.86pt;"></font><font style="font-size:12pt;">use</font><font style="display:inline-block;width:10.75pt;"></font><font style="font-size:12pt;">appropriate</font><font style="display:inline-block;width:10.71pt;"></font><font style="font-size:12pt;">personal</font><font style="display:inline-block;width:10.9pt;"></font><font style="font-size:12pt;">protective equipment when required (e.g. gloves, proper footwear, etc.);</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:112.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">e.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">Chemical dilution systems must be adhered to; and</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18.05pt;text-indent:-18.05pt;margin:0pt 0pt 0pt 112.95pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">E-3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.95pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:113pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">f.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Unnecessary amounts of chemicals should not be stored in the janitor&#8217;s closet(s).</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 113pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 113pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 113pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 41pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Special Treatment of Carpets</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">Carpet can be a source of biopollutants, dust and volatile organic compounds (VOCs). Pesticides and cleaning products (such as stain removers) that remain on the carpet after initial application can volatilize (rise up into the air) over time and contaminate the indoor air. The following carpet treatment guidelines will mitigate the need for carpet cleaning solutions through both preventive and prescriptive treatment:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:76.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Prevent stains.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:113pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">a.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Clean up spills promptly using cold water and one or more blotting cloths</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:112.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">b.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Make a spill kit available to occupants</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Promptly clean and thoroughly dry carpets if they should become saturated with water; quick action following a leak or other water damage may prevent carpet loss and the growth of mold and/or mildew. (Do not attempt to clean a moldy carpet without proper protective equipment, clothing, respirators and air filters. Special training may be required to adequately deal with a water- soaked carpet.)</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Reducing Microbial Growth through Proper Cleaning</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">The following are basic guidelines to minimize the need for antimicrobial products at the Building:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:76.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Clean first and then apply disinfectant</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:113pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">a.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Most disinfectants are not cleaners and are usually only effective on a clean surface</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:113pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.09pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">b.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.09pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Wait the recommended time before rinsing the antimicrobial solution from the surface (usually at least 10 minutes)</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Use disinfectants only when and where required; ordinary detergents should remove more microbes than disinfectants</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:76.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Change mop heads and sponges daily and properly dispose</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Change cleaning water frequently (water used in mop buckets, etc.); do not waste water by overfilling mop buckets, etc.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Intentionally clean areas where water collects and condenses; areas such as refrigerator and air conditioner pans as well as air cleaner/humidifier machines</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 77pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">E-4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.95pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:76.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Use a drain maintainer (containing enzymes) if drains clog or have an odor</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.5pt 41pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Janitorial Training Requirements</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">Sublessee will provide training of Sublessee Personnel in the hazards, use, maintenance and disposal of cleaning chemicals, dispensing equipment and packaging. Documentation of the training sessions, attendees and topics covered shall be submitted to Sublessor upon request by Sublessor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.75pt 0pt;"><font style="font-size:13pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:76.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Basic Janitorial Training</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:113pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.09pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">a.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.09pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Janitorial workers should receive basic training, including the Green Cleaning specifications delineated in Sublessor&#8217;s Green Cleaning Policy</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:112.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">b.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">An average of 8 hours of training per custodian per year is required</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:76.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;text-align:justify;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Training Specifications</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:112.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;"><font style="font-size:12pt;">a.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;"><font style="font-size:12pt;">Material safety data sheets (MSDS)</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:112.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;"><font style="font-size:12pt;">b.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;"><font style="font-size:12pt;">Compliance with the Green Seal standard of GS &#8211; 37</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:112.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;"><font style="font-size:12pt;">c.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2.04pt;margin-top:0pt;"><font style="font-size:12pt;">Use and wear of Personal Protective Equipment</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:113pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.95pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">d.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:1.95pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Custodians should be informed of Sublessor&#8217;s product reporting requirements; all cleaning products which are not on the GS-37 list must be approved by Sublessor Personnel</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.3pt;margin-top:0pt;text-align:justify;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.3pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Provide Sublessor with monthly training logs indicating the attendees and the training topic</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:13.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Green Cleaning Materials Policy</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.55pt 41pt;"><font style="font-size:12pt;">Sublessee will implement a sustainable program for the purchase of cleaning materials and products that reduce the environmental impact of its janitorial activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">To the extent practical, no cleaning or disinfecting products should contain ingredients that are carcinogens, mutagens or teratogens. These include chemicals listed by the U.S. EPA or the National Institute for Occupational Safety and Health on the Toxics Release Inventory (40 CFR, Section 372, Subpart D). If such products containing these toxic chemicals must be used (cleaning solutions for specific equipment, etc.), only the minimum amounts should be used, and the product must be disposed of properly. A complete list of toxic chemicals is maintained by the U.S. EPA and can be found at the Toxic Release Inventory at www.epa.gov/tri/chemical. It is recommended that the cleaning products used by Sublessee at the Building must meet the Green Seal standard of GS-37. The Green Seal Organization offers extensive information regarding the GS- 37 standard on their website www.greenseal.org/certification/environmental.cfm. A complete listing of Green Seal certified products is maintained by the Green Seal organization and can be found at www.greenseal.org/findaproduct/index.cfm.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.79pt 0pt;"><font style="font-size:13pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Low Environmental Impact Cleaning Equipment Policy</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">E-5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.95pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">Sublessee must implement an equipment program to reduce building contaminants with minimum environmental impact. Sublessee should purchase cleaning equipment that meets the following requirements:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Vacuum cleaners meet the requirements of the Carpet &amp; Rug Institute &#8220;Green Label&#8221; Testing Program &#8211; Vacuum Cleaner Criteria and are capable of capturing 96% of particulates 0.3 microns in size and operates with a sound level less than 70dBA.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Hot water extraction equipment for deep cleaning carpets is capable of removing sufficient moisture such that the carpets can dry in less than twenty- four (24) hours (not applicable &#8211; restorative carpet care is provided by Sublessee).</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Powered maintenance equipment including floor buffers, floor burnishers and automatic scrubbers are equipped with vacuums, guards and/or other devices for capturing fine particulates and shall operate with a sound level less than 70dBA. Provide cut sheets on the vacuum equipment used on the Building to confirm compliance with this requirement.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:76.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Propane-powered floor equipment has high-efficiency, low-emission engines.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Automated scrubbing machines are equipped with variable-speed feed pumps to optimize the use of cleaning fluids.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Battery-powered equipment is equipped with environmentally preferable gel batteries.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Where appropriate, active micro fiber technology is used to reduce cleaning chemical consumption and prolong life of disposable scrubbing pads.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Powered equipment is ergonomically designed to minimize vibration, noise and user fatigue.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Equipment has rubber bumpers to reduce potential damage to building surfaces.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">A log will be kept on-site for </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">all</u><font style="font-size:12pt;"> powered housekeeping equipment to document the date of equipment purchase and all repair and maintenance activities and include subcontractor cut sheets for each type of equipment in use in the logbook. All equipment shall be in new condition and meet the green cleaning requirements.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:77pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.25pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">No equipment may be brought on site unless it has been approved by Sublessor</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Reporting</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 41pt;"><font style="font-size:12pt;">Sublessee must provide documentation of its comprehensive green cleaning program and must also provide written updates, including a monthly record of supply purchases (indicating compliance with the GS-37 Standard), equipment purchases and training on at least a quarterly basis.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">Sublessee should keep an ongoing log book that documents Sublessee&#8217;s compliance with all green cleaning requirements (supplies purchased, current equipment, MSDS sheets, equipment repairs, equipment taken out of service, new equipment brought on site during</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">E-6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3.95pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">the term of the Sublease, training topics/dates/sign-off sheets, entryway cleaning log and any other green cleaning requirements stated in this Sublease).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Applying Green Cleaning to the Specifications</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">The Low Environmental Impact Cleaning requirements, the Green Cleaning Materials requirements and the Low Environmental Impact Cleaning Equipment requirements are to be applied by Sublessee in addition to any Standard (Base) Cleaning Specification required by Sublessor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 41pt;"><font style="font-size:12pt;">For example, the task &#8220;clean door glass and other adjacent glass areas&#8221; must be performed using a chemical that meets the Green Seal GS-37 Standard and microfiber technology in lieu of paper products when possible. The task &#8220;fully vacuum all carpeted areas from wall to wall including walk-off mats and edges&#8221; must be performed with a vacuum cleaner that captures 96% of particulates 0.3 microns in size and operates with a sound level less than 70dBA.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Quality Control Measures</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">Sublessor is committed to maintaining the Building in an environmentally preferable way that will benefit the health of the occupants, visitors, maintenance personnel and the natural environment. To this end, Sublessor routinely evaluates the successes and shortcomings of all employed practices and makes immediate alterations accordingly. Building and site walk-throughs are completed routinely by Sublessor Personnel to ensure adoption and proper application. A cleaning audit is conducted routinely to assess the quality of the custodial services. Occupants are highly encouraged to report any outstanding custodial issues to the Sublessee. New technologies for environmentally sensitive cleaning will be continuously monitored and assessed as they become available and adopted when they are applicable. Similarly, this policy will be updated as needed to ensure that current and successful procedures are being carried out. As such, this policy is applicable as of the Effective Date of the Sublease until an updated version is drafted when deemed necessary.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">E-7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20221231xex10d22004.jpg" alt="Graphic" style="display:inline-block;height:564.29pt;width:442.51pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">E-8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20221231xex10d22005.jpg" alt="Graphic" style="display:inline-block;height:598.38pt;width:458.68pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">E-9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20221231xex10d22006.jpg" alt="Graphic" style="display:inline-block;height:598.38pt;width:457.27pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20221231xex10d22007.jpg" alt="Graphic" style="display:inline-block;height:558.9pt;width:443.14pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">E-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20221231xex10d22008.jpg" alt="Graphic" style="display:inline-block;height:581.51pt;width:439.1pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">E-3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20221231xex10d22009.jpg" alt="Graphic" style="display:inline-block;height:580.5pt;width:439.25pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">E-4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20221231xex10d22010.jpg" alt="Graphic" style="display:inline-block;height:599.06pt;width:458.75pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">E-5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20221231xex10d22011.jpg" alt="Graphic" style="display:inline-block;height:597.37pt;width:458pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">E-6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="tmb-20221231xex10d22012.jpg" alt="Graphic" style="display:inline-block;height:556.2pt;width:442.98pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">E-7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 5pt;">5534031.1</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 5pt;">5534031.2</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 5pt;">5534031.4</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>4
<FILENAME>tmb-20221231xex10d23.htm
<DESCRIPTION>EX-10.23
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/29/2023 11:43:20 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.23</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.3pt 0pt;"><b style="font-size:12pt;font-weight:bold;">FIRST AMENDMENT TO SUBLEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;">THIS FIRST AMENDMENT TO SUBLEASE (this &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</u><font style="font-size:12pt;">&#8221;) is entered into as of the</font><u style="font-family:'Lucida Console';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="font-family:'Lucida Console';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">25th</u><font style="font-size:12pt;">day of</font><font style="font-family:'Lucida Console';"> </font><u style="font-family:'Lucida Console';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">October</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  </u><font style="font-size:12pt;">, 2022 (the &#8220;Effective Date&#8221;), by and between THE PAUL REVERE LIFE INSURANCE COMPANY, a Massachusetts corporation (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublessor</u><font style="font-size:12pt;">&#8221;), having a notice address of c/o Unum Group, 1 Fountain Square, Suite 120, Chattanooga, Tennessee 37402, Attn: Corporate Real Estate Department, and MUSTANG BIO, Inc., a Delaware corporation (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublessee</u><font style="font-size:12pt;">&#8221;), having a notice address of 377 Plantation Street, Worcester, Massachusetts 01605.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.44pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recitals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="font-size:7.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">A.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">Sublessor is the tenant under that certain Lease dated June 17, 2010, by and between CitySquare II Development Co. LLC (&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CitySquare II</u><font style="font-size:12pt;">&#8221;), as landlord, and Sublessor, as</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.55pt 41pt;"><font style="font-size:12pt;">tenant, as affected by that certain (i) Assignment and Assumption of Lease dated October 4, 2010, by and between CitySquare II and One Mercantile Place LLC (&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">One Mercantile</u><font style="font-size:12pt;">&#8221;), (ii) Letter Agreement dated November 11, 2011, by and between One Mercantile and Sublessor, (iii) Second Amendment to Lease dated as of July 5, 2012, by and between One Mercantile and Sublessor, (iv) Third Amendment to Lease dated as of December 19, 2012, by and between One Mercantile and Sublessor, (v) Assignment and Assumption of Lease and Guaranty dated December 21, 2012, by and between One Mercantile and ONEMERC, LLC (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Master Lessor</u><font style="font-size:12pt;">&#8221;), (vi) Letter Agreement dated May 2, 2013, by and between Master Lessor and Sublessor, and (vii) Fourth Amendment to Lease dated as of September 16, 2015, by and between Master Lessor and Sublessor (collectively, the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Master Lease</u><font style="font-size:12pt;">&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">B.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">Pursuant to the Master Lease, Sublessor leases approximately 198,560 rentable square feet of space in the building known as One Mercantile Place located at One Mercantile Street in Worcester, Massachusetts (the &quot;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Building</u><font style="font-size:12pt;">&quot;) together with approximately 851 parking spaces in the adjoining garage known as the Foster Street Garage (collectively, the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Master Premises</u><font style="font-size:12pt;">&#8221;);</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">C.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">Pursuant to the Sublease dated as of June 14, 2022, with a Commencement Date of July 1, 2022, by and between Sublessor, as sublessor, and Sublessee, as sublessee (the &quot;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublease</u><font style="font-size:12pt;">&quot;), Sublessor has subleased to Sublessee approximately 26,503 rentable square feet of space of the Master Premises located on the fourth (4</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;">) floor of the Building as more particularly described in the Sublease (the &quot;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublease Premises</u><font style="font-size:12pt;">&quot;);</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;"><font style="font-size:12pt;">D.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;"><font style="font-size:12pt;">Sublessor is the current holder of the tenant&#39;s interest under the Master Lease and the sublessor&#39;s interest under the Sublease, and Sublessee is the current holder of the sublessee&#39;s interest under the Sublease; and</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">E.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">Sublessor and Sublessee desire to amend the Sublease in order to extend the time to use the Allowance toward the cost of Sublessee&#8217;s Work as described in Section 5 (a) of Exhibit C, the Work Letter.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;">NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which is hereby mutually acknowledged, Sublessor and Sublessee hereby agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0pt 5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.3pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capitalized Terms</u><font style="font-size:12pt;">. Each capitalized term appearing but not defined herein shall have the meaning, if any, ascribed to such term in the Sublease.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recitals</u><font style="font-size:12pt;">. The recitals above set forth are true and complete and are incorporated herein by reference.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;"><font style="font-size:12pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Extension of Time to Use Allowance</u><font style="font-size:12pt;">. The last sentence of Section 5 (a) of Exhibit C to the Sublease is hereby amended by replacing &#8220;Any amount of Allowance which has not been requisitioned by sixty (60) days following the Commencement Date, shall be retained by Sublessor and Sublessee shall have no further right to claim thereto&#8221; with &#8220;Any amount of Allowance which has not been requisitioned by July 31, 2023, shall be retained by Sublessor and Sublessee shall have no further right to claim thereto.&#8221;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u><font style="font-size:12pt;">. The parties agree that this First Amendment shall be effective from and after the Effective Date and not during any period of time prior thereto. To the extent this First Amendment contains language which purports to amend the Sublease with respect to periods of time prior to the Effective Date, such language is for clarification purposes only and shall not be deemed to change the obligations of the parties with respect thereto. In no event shall this First Amendment be construed to impose any liability on Sublessor for any period of time preceding its leasing of the Master Premises from Master Lessor.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ratification of Sublease Provisions</u><font style="font-size:12pt;">. Except as otherwise expressly amended, modified and provided for in this Amendment, Sublessee hereby ratifies all of the provisions, covenants and conditions of the Sublease, and such provisions, covenants and conditions shall be deemed to be incorporated herein and made a part hereof and shall continue in full force and effect.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brokerage</u><font style="font-size:12pt;">. Sublessor and Sublessee each represents to the other party that it has not authorized, retained or employed, or acted by implication to authorize, retain or employ, any real estate broker or salesmen to act for it or on its behalf in connection with this Amendment so as to cause the other party to be responsible for the payment of a brokerage commission. Sublessor and Sublessee each agrees to indemnify, defend and hold the other (and such other party&#8217;s employees and representatives) harmless from and against any claims, damages, costs, expenses, attorneys&#8217; fees or liability for compensation or charges which may be claimed by any such unnamed broker, finder or similar party whom the indemnified party authorized, retained or employed, or acted by implication to authorize, retain or employ, to act for the indemnifying party in connection with this Amendment.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Amendment</u><font style="font-size:12pt;">. This Amendment contains all of the agreements of the parties with respect to the subject matter hereof and supersedes all prior dealings between the parties with respect to such subject matter.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 41pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">First Amendment to Sublease</p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authority</u><font style="font-size:12pt;">. Sublessor and Sublessee each warrant to the other that the person or persons executing this Amendment on its behalf has or have authority to do so and that such execution has fully obligated and bound such party to all of the terms and provisions of this Amendment.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Amendment</u><font style="font-size:12pt;">. This Amendment shall be binding upon, and shall inure to the benefit of the parties hereto, and their respective successors and assigns.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">10.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u><font style="font-size:12pt;">. This Amendment shall be governed by the laws of The Commonwealth of Massachusetts.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;"><font style="font-size:12pt;">11.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.55pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u><font style="font-size:12pt;">. If any clause or provision of this Amendment is or should ever be held to be illegal, invalid or unenforceable under any present or future law applicable to the terms hereof, then and in that event, it is the intention of the parties hereto that the remainder of this Amendment shall not be affected thereby, and that in lieu of each such clause or provision of this Amendment that is illegal, invalid or unenforceable, such clause or provision shall be judicially construed and interpreted to be as similar in substance and content to such illegal, invalid or unenforceable clause or provision, as the context thereof would reasonably suggest, so as to thereafter be legal, valid and enforceable.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">12.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Reservation</u><font style="font-size:12pt;">. Submission of this Amendment for examination or signature is without prejudice and does not constitute a reservation, option or offer, and this Amendment shall not be effective until execution and delivery by all parties.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:41pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><font style="font-size:12pt;">13.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0.5pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u><font style="font-size:12pt;">. This Amendment may be executed simultaneously in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Additionally, telecopied of pdf signatures may be used in place of original signatures on this Amendment. Sublessor and Sublessee intend to be bound by the signatures on the telecopied or pdf document, are aware that the other party will rely on the telecopied or pdf signatures, and hereby waive any defenses to the enforcement of the terms of this Amendment based on the form of signature.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 151.2pt;"><font style="font-size:12pt;">[SIGNATURES ON FOLLOWING PAGE]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 151.2pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">First Amendment to Sublease</p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;min-height:35.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:35.95pt;margin:0pt 0pt 0.5pt 5pt;"><font style="font-size:12pt;">IN WITNESS WHEREOF, the said parties hereunto set their hands and seals as of the Effective Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">SUBLESSOR:</font></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">SUBLESSEE:</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">THE PAUL REVERE LIFE INSURANCE COMPANY</font></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">MUSTANG BIO, INC.</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3pt 0pt 0pt 21.6pt;"><img src="tmb-20221231xex10d23001.jpg" alt="Graphic" style="display:inline-block;height:20.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:115.5pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:12pt;margin:0pt;"><font style="font-size:12pt;white-space:pre-wrap;">By:  </font><font style="color:#1372e5;">Devin Bloss (Oct 25, 2022 08:25 EDT)</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3pt 0pt 0pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">By:  </font><div style="display:inline-block;height:35.95pt;width:153.3pt;"><div style="height:35.95pt;left:0pt;padding-bottom:0pt;position:relative;width:153.3pt;"><div style="height:0pt;position:relative;width:100%;"><div style="left:3.04pt;position:absolute;width:150.25pt;"><img src="tmb-20221231xex10d23002.jpg" alt="Graphic" style="width:150.25pt;"></div></div><div style="height:0pt;position:relative;width:100%;"><div style="height:35.94pt;left:0pt;position:absolute;width:70.85pt;"><img src="tmb-20221231xex10d23003.jpg" alt="Graphic" style="height:35.94pt;width:70.85pt;"></div></div></div></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name: </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10.5pt;">Devin Bloss</font></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 25.2pt;"><font style="font-size:12pt;">Name: </font><font style="font-family:'Lucida Console';">Knut Niss</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Its: </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11.5pt;">AVP, Strategic Sourcing</font></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 25.2pt;"><font style="font-size:12pt;white-space:pre-wrap;">Its:       </font><font style="font-family:'Lucida Console';">CTO</font></p></td></tr><tr><td style="vertical-align:top;width:48.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">First Amendment to Sublease</p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>tmb-20221231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/29/2023 11:43:19 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We consent to the incorporation by reference in the registration statements (<font style="font-size:12pt;"><a name="_0"></a></font>Nos. 333-255476 and 333-249657) on Form <font style="font-size:12pt;"><a name="_1"></a></font>S-3 and in the registration statements (Nos. 333-266176, 333-258310, 333-258311, 333-225007, and 333-221819) on Form S-8 of our report dated <font style="font-size:12pt;"><a name="_2"></a></font>March&#160;29,&#160;2023, with respect to the financial statements of Mustang Bio, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ KPMG LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hartford, Connecticut<font style="font-size:12pt;"><a name="_3"></a></font><br>March&#160;29,&#160;2023</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>tmb-20221231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/29/2023 11:43:40 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">I, Manuel Litchman, M.D., President and Chief Executive Officer (Principal Executive Officer), certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:33pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this Annual Report on Form 10-K for the year ended December&#160;31, 2022 of Mustang Bio, Inc. (the registrant);</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and&#160;internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disclosed in the report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:31.9pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">222</p></div></div></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated:&#160;March 29, 2023</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Manuel Litchman</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manuel Litchman, M.D.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>tmb-20221231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/29/2023 11:43:42 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">I, Eliot Lurier, Interim Chief Financial Officer (Principal Financial Officer), certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:33pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this Annual Report on Form 10-K for the year ended December&#160;31, 2022 of Mustang Bio, Inc. (the registrant);</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disclosed in the report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:34.1pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22</p></div></div></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated:&#160;March 29, 2023</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eliot Lurier</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eliot Lurier</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interim Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer) &#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>tmb-20221231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/29/2023 11:43:42 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with the Annual Report on Form 10-K of Mustang Bio, Inc. (the &#8220;Company&#8221;) for the period ended December&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Manuel Litchman, M.D., President and Chief Executive Officer, hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:31.9pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:31.9pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:29.7pt;margin:0pt;">&#160;</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated:&#160;March 29, 2023</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Manuel Litchman</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manuel Litchman, M.D.,</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>tmb-20221231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/29/2023 11:43:54 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with the Annual Report on Form 10-K of Mustang Bio, Inc. (the &#8220;Company&#8221;) for the period ended December&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Eliot Lurier, Interim Chief Financial Officer, hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:31.9pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:31.9pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company, as of, and for, the periods presented in the Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:34.1pt;margin:0pt;">&#160;</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated:&#160;March 29, 2023</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eliot Lurier</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eliot Lurier</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interim Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tmb-20221231xex10d22001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231xex10d22001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ; )H# 2(  A$! Q$!_\0
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M+SP9<_$_2/A]I27]EYS7#IE]3N3EL,$D7;&P& 8RW)Z8WC[]H#XWZSHGQ_\
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MOCEX;\%> '\6+\0]=N-<T'Q3#?V\=EITMW$J3"]#N'3R2-R[5;>.!C-?6/\
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KFNJAMXK:&.**-8XHU"(BC 4#@ #TK*HJ.GLFWZI+\FS2,JGVTODW_DC_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tmb-20221231xex10d22002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231xex10d22002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  0 )H# 2(  A$! Q$!_\0
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MV9)[FWV_Z3<R )R2L:[2 @#,3R,?PF\8:-IOCF&RU.PU+7=:L;JT_P"$QO\
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MON8?7L+_ ,_8_>CTJBO-?^&@?"W_ #Z^)/\ PFM0_P#C-'_#0/A;_GU\2?\
MA-:A_P#&:/[-QO\ SYE]S#Z]A?\ G['[T>E45YK_ ,- ^%O^?7Q)_P"$UJ'_
M ,9H_P"&@?"W_/KXD_\ ":U#_P",T?V;C?\ GS+[F'U["_\ /V/WH]*HKS[3
M/CCX;U;4K2Q@M=?6>YE6%#-X?OHD#,<#<[0A5'N2 .]>@URUL/6P[2K0<;]U
-8WI5J=9-TY)^CN?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tmb-20221231xex10d22003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231xex10d22003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +[ D(# 2(  A$! Q$!_\0
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M\+W,"R#X9:FH.>&URT4\''1L']*E_P"'T/A?_HFFH_\ @^L_\:_1ZB@#\0/
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M1_K&MMIH'T\T_6O"WTC_ (*-?:8MNNZ%Y6&W8@TC&>,9&W/Y&I?[(_X*+?\
M0=T'_P !]*_^)H ]9U[]K_XG_":33$^(OPSALH]2O4TZUEQ<0/<W+*S)%$EH
MNH1L[!'(4S+PIYXKJ_#7[?'@35=073M6TC6]%U(?>M8D@U&8>_V>TEEN0/\
M>A4^U?(^H_#S]MGX[7]O;ZKXGT*74/A_XOMKGRI+6QB%K?QV:3QS*47$H$5\
MOR'@ECG[M3+HO[<GQH\/2O/<>$_$^@?:[RR"ZOI&CR([V]Q);R?NY$/!>)\<
M= /6@#]#/"OQ\^'7C34!IVD^,M)EU8XSI5Q<"WOESTW6TNV4?BM=]7XY^*?V
M'OVN_$>D7&GO8:)!ITL;1'2M/O+2TL0&X.VVC<0J<=&"9'8BO</[(_X*+?\
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M02,\]3QC[,H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OSD_9&
M@C3_ (*;_':58T$K1ZVK.%&X@7>E$ GTR3^9]:_1NOSH_9(_Y28_'3_<UO\
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M "BBB@#\[/\ @BC"B? GQVRC#-XC //_ $Z0'^IK]$Z_._\ X(I_\D&\<_\
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M$.M%)%?)9OMFEY!&.. I_$CM7Z/U^='[)'_*3'XZ?[FM_P#I5I- 'Z+T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5S%_\+O!FJWLUY>^$="O+N=B\MQ<:;"\DC'J68KDGW-=/
M10!%;6T-G;Q6]O$D$$2"..*-0JHH&  !P !QBI:** "BBB@ HHHH **** "J
MFK:38Z]I=YIFIV=OJ.FWL+VUU9W<2RPSQ.I5XW1@0RLI(*D$$$@U;HH \WTC
M]FKX0^']5L]4TOX5^"=-U.RF2XMKVS\.V<4T$JG*NCK&"K @$$$$$5Z1110
M4444 %%%% !1110!Q7Q3^#7A#XTZ3I^G>,-+DU.UT^Z^VVIAO9[22&;RWCW+
M) Z.,I(ZD9P0W(KXI^.'A/P?\$]<^)7@K0;MM*M=1A^']_9Z5J&LSW4L\_\
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ME^$(DU'[5Y8L39Z[=3\Q[#YF_=M^\NWK\W2@#]+:*** "BBB@ HHHH ****
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M;@=DBAF =<$;C@\U^A0Z"@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
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MO/C7X=^&3_&N?3M=U=/-W:EX7BMA A$A5F5[<$[O*;&.N#Z5]"?\,[?MH_\
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M)#\78_#EY=>*+J]D\R;5V,#K'>P28&ZT;!6-% $/,956!S#\4_\ E&?\0O\
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MRII4R5R YQBOS8_X+;2*OQ0^&>3C_B2WGZR "OUU'04 +1110 4444 %%%%
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MA!_V)^C_ /I%#7J- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0I >,MR4.0<#.<#'ZT#H* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHQ+!'-<W$EQ,4#0L0&EED;&3C=QQ4O\ PH>Z_P"BI?$#_P &=O\ _(]>%?\
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M .#?B3XW?#O1=&\,&P^W6FMPWLO]HW#0IY/DS1.0RHY+#S@P7 SM(R* ./\
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M[)G[8>A:#:W.H_$C5_&5F+R-'T_2?%=Y=R)D-B5XGL1N13UP&/(^4]1^KU%
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M !;IWB?X57=KHMU->^']$UB[TS2)[B*2.3[ &66UC*R ,/*BFCA^8 XB&>:
M/<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX$_;:\%:%K?Q$^
M(OB._P!*M;O7M T?P$=*U"6,&:R,WB.[28QMU7>@"G'45]]U^6/_  42^)7B
M/0?VT?"W@'3+V.W\/>-M.\,0ZO"T*,TOV;6;F6#:Y!*;78GY>O0YH _4ZBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\BO^"VG_)4
M/AG_ -@2]_\ 1@K]=!T%?D3_ ,%MHU;XH?#/(S_Q);S]) 17Z[#H* %HHHH
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MF(X(.0>E>RT4 %<[HGPZ\+>&O$NK^(=)\.:7IFNZN%&H:C:6D<4]WM)(\UU
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MEX)5(/"'AV(/FY11B.74@PQ)+&F(R02) N3M#2+(SX: +_P4P^,    \%Z4
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MHZC9>'?#^AZE-IM@^IWJ_P#"/R0^1;JZ(9"9-148W2*O7.2, UK?%W_@HO\
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M#8&T'GKB@#](**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYH _0.BOD27Q5^VX NSP5\(C\PSF^O>G?_EI3_\ A*OVV?\ H2OA'_X'7O\
M\<H ^N**^1%\5?MMFX(;P7\(Q#M[7MZ3NS_UU]/:IO\ A*/VU?\ H3/A+_X&
M7G_QV@"/]@[_ )'W]IS_ +*;J7_H5?7-?GW\'/AK^V%\&]:^(.HZ7X6^&5U)
MXQ\07'B"[6]U"Y(BFE.66/8PPGH&R?>O3/\ A*OVV?\ H2OA'_X'7O\ \<H
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M==LM,6V=8([LRW5M.T21(50/';6^0 !N0MU<UN_\/%OV<?\ HJ>F?^ US_\
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MQQ5N/\(? DBE7\%>'64]0=*@(/\ XY750PQVT,<44:Q11J$1$&%4#@  =!0
M^BBB@ HHHH IZKHVGZ[:BVU*QMM0MPP?R;J%94W#H<,",\FOR)_X*):#INB_
M\%%O@Y::=I]KI]J]MH;-#:0K$A)U2X!.% YP ,^PK]@J_(O_ (*3<?\ !2'X
M,]_]$T+_ -.MQ0!^NE%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#=*^'WA/2_#FBP&WTS3H!!"K,7=L<EW8\L[$EF8\LS$GDFOSC^(7['G[17Q
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MF^$'[1>D_"46FMZ3-9V/Q*T]-6TK6YK8B.'[)=9>0!WB>(AU!=6903M)# @
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MC<54[0Q R0"1D\9'6LK6-/\ VQ/#_AV_OY_%_P )[@65M).VW2K[>X12W'S
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M7/2@#]&**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M22<9)-+^RO\ \FP_"#_L3]'_ /2*&O4: "BBB@ HHHH **** "BBB@ HHHH
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M-T"$VRRHK<,%;L:^GOVV/#FE?"?X?_LI:#<2*^B^&?'OAZQ>1XBX,%O"R$E
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M"_BM?W7BE?!_C70E\*^+9(7N+-8+G[5I^JQ)CS'M)RJ%F3(+1.B.H(.&7YZ
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MC=^VIH>J>#KF_P!1T_3O 6IVUS<76D7EDJ2/?V+*O^D11[B0I/RYZ5S'P/\
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M0C')P!CDC(K]%QT% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVFGZ<8HDBNYHD52]LS'"QKR230!]M45\J?\ # &B?]#YKW_@NTS_ .1:/^&
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MJOE!2_\ ;&F_?)Q_Q\+0!]>T444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5^1?_  4E_P"4D7P9_P"O70O_ $ZW%?KI7Y%_\%)O^4D/P9Q_
MSZ:%_P"G6XH _72BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K\Z/V2/^4F/QT_W-;_\ 2K2:_1>OS@_9#AN%_P""GGQXD>X#P-#K
M2I"(P-K"\TLEMV><@J,?[.>] 'Z/T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!\D:Q_P I3M#_ .R5-_Z<IJ^MZ^1M9CS_ ,%4M"?<W'PI
M8;<\?\A*?M7US0 4444 >$_MT_\ )H'Q8_[ 4_\ 2NQ_9P_Y-X^%W_8K:7_Z
M215QO[=B;_V/_BP,D?\ $BFY!P>U=A^S:GE_LZ_"Q<EMOA72AECDG_1(NM '
MH]%%% !7R/\  O\ Y2'_ +3/_8/\/?\ I#'7UQ7R)\"HMO\ P43_ &FWW,=V
MG>'OE)X'^@Q]!0!]=T444 %?(O\ P5,_Y-&U7_L,:;_Z4K7UU7R%_P %4HO.
M_9#U5=S)_P 3C3>4.#_Q\+0!]>T444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5^4/\ P4:\)ZUJ'[>GP\\4VFDWEWX>\.6/AV75]1@B+Q62
MRZO<I%YC#[N]@57U(K]7J^%_VR]0M;?Q1\6[66YABN;G1_A[Y$+R /+M\2WA
M;:IY; Y..E 'W11110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5^='[)'_*3'XZ?[FM_P#I5I-?HO7YP?LAM<G_ (*>?'@2)$MOY.M;
M&5B6+?;-+SD8Z8V?B30!^C]%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 ?%GQ'\>>&OA[_P4[T'4O%/B+2O#6G-\+_)6[UB]BM(BYU&<A0\
MC 9(!XSG@^E?09_:F^"Z@D_%[P& .I/B:R_^.U=^(?[/7PS^+6MVVL>,O VA
M^)=5M[<6L5[J5DDLJ0AF81AB,[0SN0.Q9O4UQ^J_L-_ /6=-N;&X^%/AM(+B
M,QNUM:>1( >NV2,JZ'W4@CUH ]ML[RWU&T@N[2>.ZM9XUEBGA<.DB,,JRL."
M"""".M35\O+_ ,$R_P!FY%"K\/9U4#  \1ZK@?\ DU2_\.S?V;_^B?7'_A1Z
MK_\ )5 '4_MULJ?L?_%@L0H_L*89)^E97P _:4^$6D? CX;V-]\5/!5E>VOA
MK38)[:X\16<<D4BVL89'4R JP(((/((K(3_@F7^SE'?VUR/ ,S+#DFVFU[49
M89#E2"ZO<'=C;T^Z0QR#QCN5_8K^!"*%'PF\*  8'_$MC_PH ]!\%?%7P5\2
MGO%\(^,- \5-9A#<KHFIP7A@#YV;_+9MN[:V,]=I]*ZFOFS6_P#@G%^SGK^K
M3:C<?#6WMKF8*KKINIWUE%A1@8B@G1!T[+R>3R:I?\.S?V;_ /HGUQ_X4>J_
M_)5 'U!7R+\"W4_\%$?VFE# L-.\/97//_'C'6P__!,O]G!D8#P!<*2,;AXC
MU7(]^;JH/^'8?[.0M;2(>!KD20N'DN!KNH"6X^4 B1A/R#@' Q@YVXR<@'U3
M17R__P .S?V;_P#HGUQ_X4>J_P#R51_P[-_9O_Z)]<?^%'JO_P E4 >R^)_C
MU\,O!.MW&C>(OB+X3T'6+?:9M/U/7+6VN(MRAEW1NX895@1D<@@]Z^1_^"DO
MQW^&GC;]EW4=*\._$3PIK^J2:MI[I9:7K=M<SLJSJ6(1'+$  DG' KVSPO\
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M:I)<67F^)+Q)?)D(+1[U 5MI&X<'(H ^]:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "ORT^%?CVX^&?[=?[1.OV=I'?7\0U2UM()
MV*Q&XN-1T6WB,C $K&'E4N1T4,:_4NOR$\=6_P 9?@[^V#\:=:TOX#Z[X_\
M#GB.34+!A)H-W>65W:W3VLA97APK<6R]&R"S @,. #]&+#7O'WP\\?\ @[1_
M%OB#2?%NF^++B>P22QTHZ?-87<=K-= J/.D#P,EO*OS?,K&/+-N./8Z_)KP9
M^T3^T'X)U^/6H/V:?&^L:I;P-:V=SK]AKFHM90MC='#Y\K;-VU0S#YF"@,Q
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M_:A;ZS<R0?.R%TV.Q;Y"N>AR.*_5.OR+_P""DO\ RDB^#/\ UZZ%_P"G6XH
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M$F/BK+\6)_']S+I::7_8GAWPGX>55G\WSA9V]Y!YI^4;=^S.WG&<9/6OT/H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *_(O_@I,,_\ !2'X,YY_T30O_3K<5^NE?G-^W%\&
M+#QI^TM<?$2?4;FVU'P%8>"GL[2)5,5R;SQ!=0/YA(R-H7(QWZT ?HS1110
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MW_\ #[XO_%'1? .GZ'XIT?7-82=[,ZO90)"_E1/*P+1SN1\D;D9&#C&:^F:
M"BBB@ HHHH **** "BBB@ KXI_:N_P"1R^*__8-^''_J47=?1/QM^+FJ_"\>
M%++P_P"$)O&WB'Q+J;Z;9:9%J$5B,I:SW4CM++\HQ';OQW/Z_,7QJM/'^NZ!
M\2O&GC;P&? 4&H2^ ])LK5M8M]1:=K;Q&TDK[H?N@"[C&"![$\X /NJBBB@
MHKX>^T:K_P!#3XK_ /"EU#_X]1]HU7_H:?%?_A2ZA_\ 'J /N&BOA[[1JO\
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MM0?MYPZM?1Z5X<\<WFEI<2+:7-Y\-1;S2PACL=XUMW",5P2H=@"<;FQDU/\
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>_P#'J /N&BOA[[1JO_0T^*__  I=0_\ CU% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tmb-20221231xex10d22004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231xex10d22004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1I W8# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44UN5.*^;?C/\??'
M_A?X^Z9\-O!>AZ#J#W?AB7Q"UWK5^;9<QS&)HQ@'_8.3ZGTH ^D\CUHR*^5O
M$?Q@^./A;X*ZQXXO?#GAF]U/0]5\^\T71KTW8ETE8@9BD@/^O4EGV_W13O O
M[2^O_''XHZA>_#TV4WPH\/Z(;K4-4G0F6\U"6%I([:,_P^6-I<\^G<4 ?4^:
M,U\1V?[;-W>_L*77Q$D\0^'[7XF?V1/=QZ<9$XF69E4"$MN.5'2NFO\ ]H3Q
MS#\5;KP]%<V LF^%?_"70!H/G%]AAR<_<RN=M 'UMFC(]:_./1?VO/B_:?#W
MX>^-9O&?@7Q+/KTVG1R^#+"%EU60W# ,JJ&.&4'=TKW*?XC?$_QS\?/C;\.?
M#/B#3='ET/2=%O=#N;RR\U+62<EIA* <OE5(]LB@#ZJR/6C(%?%/PB\1_M"_
M$3XN^,_#]S\0_#<-GX%UNTL=4AAT5@;V)XEF/EL6.TE21SWKM?VX?BGXS^&>
MG_#"'PCX@@\,R>(?%D&C7E_<6ZS+'#+&_P VUN, @$^PH ^H<CUHS7Q9\$?C
MMXXL/VE[;X;ZU\0="^*FC7VC7&J3:MHT"Q'2VC8!5DVDKAN>"?2O?OCGX_\
M%WAGPK"WP_T"/Q/KEY.UJ)'N!';:>OELQN)VYPJX''4D@=Z /5<@TM>(?L6^
M.-7^)/[,_@?Q+KVK/KNK:A;S27-_(@0RN+B5/N@   * ..U>WT %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBAG568G1?,#9Z_, 3G*FO;OC7^R7_P +%^(:^/\ PIXTU7X>>,6L!IMW>Z6
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M?!I91YH9!.F&C5>54(&!Z<X%?=.K:5::YIEUI]];17EE<QM#-;SJ&25&&"K
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M6DVBKIC"UW3S.N[S3QM17R3V(K]5(=/M[=@T5O%&P&,H@%3I$J*%50H'8<4
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M*** "BBB@ HHHH **** "BBB@ I*6B@ I*6B@ HHHH 2EHHH **** $I:**
M"BBB@ HHHH *2EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3 -
M(8U)SCFG4F*  #'2EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH XOXA?%SPO\+6TI?$NK1Z:^JSM;62.I9II%7<54 =<<UR7C/\
M:L^&?@'Q;_PC6M>*+>WU9"HGC2-Y%MMV"!*R@A.#GYB.*Q/CI$[_ +0/[/IP
M/*_MK5 X(!!_XEDN/U%>4:%X:U^76/B5K7PEUKPMXB\+:QK=XWB#0?$\)CGA
MO4417$8E'.PA!C=P W'!H ^R=/U&WU.QM[RUFCN+6XC66*:)MRNA&0P/<$<U
M9+ =Z^!U\=W7Q7U+P#I'A[2_$6G^"X?!$&KV.A^'-12SE$YNY+9PTC\O'$L?
M ']X'TINF>._'/Q)T/X6>&M;O[^?S(->N;O^R=5CM;O4I;*>.*VB,P^4L4=B
MRKU*^E 'WUG(XYKA/%_QF\,^"/'GA/P?JU_]GUOQ/)+'IT(4D.4&6W'^'T&>
MIXK@OV1M>UK4_!7B.PUB\>\_LCQ!=V%F+B[6YN8;==K)%-(O#2)N*D^PKYV\
M?6_C7XY^)_C+XK\*^%)M:6TFC\/^%]86[2,6DFFRF261 3D[KI6!(Z@8H ^U
M]3^(^A:1XLB\-W5^L6KRZ?+JBP$<_9HV57<^F"P%6/"7CW1?&?A#3?$VG7L;
M:-J$0FM[B4[ RGH>>G2OD%;GPM\>_C1\./&<D;!/&'PXU%)D2Y=&6>*6$/$%
M!'S(\DBD#J1STKA_#6FZ#J'PS_9_\)VUB=90:/>W\MCJ.M-9Z6Q66..229]V
MYY4).V('@%N.* /T/FU&V@M?M,EQ%';8SYSN F/7/2N0\5_%C2?"GB3P9I,[
M>:/%%S<V]M>1NIAB\FW>=F=LXQMC;GUKX;\"ZE;>)_!'@OPOXMU/[1\/K7XJ
M:OI%\1=R?9A;QVLTME TI(8P^<5 W'!PHKI[SX=> /%?C7X;^%_#\]_K/@>U
M^(VI03V\]PYMT8Z-/(UO;N#EK<.N",XR67I0!]SP:W8W.GF^BO;>2R4%C<)*
MIC '4[LXI+77=/O[)[NVOK:XM4&6GAF5D7URP.!7Y_?%'PP_@W1/C%X4\/H+
M#P;9^.?#]Q?V,DLHM;739HHS= A?F6 E1N"]BU8%Y;36NA?&'3]#OM/ET5M!
MTN;5].\"+,]FBB_43LC'A9#:;PR)U49H ^XK3XZ:/J/QGM/ %@4U![G0Y-:7
M4;699(0$F\IHC@GYNA_&J/B7XT:IX6^.7A7P->>&W72/$8E2SUTW"[6FCA:5
MX_+Z\!>M?.?PYU+X3Z!^V9I^I?#9+"UT+_A ;N?49=*0_90$G1T/IOV9W8YZ
M9YKTSXN>(]/\8_%O]EKQ)H\_VK2]2UJ]FMI\$>9#+I,[JV#Z@"@#Z;!R*6D7
M[HI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&"0% S[58T'P#X=\+Z9INGZ3HEAI]EIK%[."W@5%MV((+(!T)#$$]>37044
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 8) 9"@(
MW#DC/-/J);=%F:4* [ *6[X'3^9J6@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDH 6
MBBDSB@!:*3-+2N 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %-8$]*=10!Y9X0C;PK\5_$NFSNQCU4C4+=WZ-DG*CZ'->I YKG?%W
MA&/Q'%;SQ2FSU2S?S;2[7K&W<>ZMT(JEI_C&>P"6_B"T;3KL<&9%+V\GNK@<
M?0UBO='N=?FD8@=365:>)M.OB!;7<=QGM&<FM-<R<L,>@JT[[")****L HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** $-& >.WI2TE #4A2/[BA<
M]=H IV*6BD 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BD;IQUJ%&E$S(4_=XR'SU/IB@">BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "D-+10!!-"91MR5&X'*GG@YJ>BB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BH)79"I"LV2 0/?O4] !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 F*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBDS0 M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% $<TRP(SNP1%&2S'  ]:KP7C79#0I^Z_OMQN]Q[5
MSGBZ\:[U_1- 0D)>M)<7..\,8!V_\"8@?0&NL1 @  P!T'I4[@. I:**: **
M**8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+2'J* .'\1A;#XE^%
MKV12$N(;FQ\SL'(5U'XX:NX!S61XD\/Q^(M->V=VAD5A+#,GWHI%Y5A^-4M*
M\12682TUI1:WB_()L?NIO1@>V?0UG>P'2T5%'.D@#*RE3SD'-2 Y&:I,!:**
M*H HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCY6 .&4XH ].HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
'!1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tmb-20221231xex10d22005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231xex10d22005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 2M Y8# 2(  A$! Q$!_\0
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M 4444 %%%% !1110 4444 %%%% !24M% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %)2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 E+110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y;?\%R?^01\'?^
MN^K?^@VE%'_!<G_D$?!W_KOJW_H-I10!^I-%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 ?EM_P7)_Y!'P=_Z[ZM_P"@
MVE%'_!<G_D$?!W_KOJW_ *#:44 ?J31110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'Y;?\%R?^01\'?^N^K?^@VE%'_!
M<G_D$?!W_KOJW_H-I10!^I-%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 ?EM_P7)_Y!'P=_Z[ZM_P"@VE%'_!<G_D$?
M!W_KOJW_ *#:44 ?J31110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'Y;?\%R?^01\'?^N^K?^@VE%'_!<G_D$?!W_KOJ
MW_H-I10!^I-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 ?EM_P7)_Y!'P=_Z[ZM_P"@VE%'_!<G_D$?!W_KOJW_ *#:
M44 ?J31110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %("#T.:1EW*14%K:K;[P
MA;!8M\S%N2<GK_*@"S1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBB;:\BJ>N":8+V LJ^:FYC@#<.37P[^T-;_#&_\ VW[2V^+>JV&G^%5\ ^=
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MF\Q;LKN\P)G 7=V],]Z /M@S* 26 'K5.WU[3KNY:WAO[::=,[HHY59A@X/
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MX+D_\@CX._\ 7?5O_0;2BC_@N3_R"/@[_P!=]6_]!M** /U)HHHH \\\5?\
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MR;34I;.XLX+GX-:98WD]QXAN1+)J5A;I:PWD$<=J/-+X=(T$A=6 ^;:4Z8H
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MY%!' K[^084=^*P?!$=N?".C/;Z4NBQ-9Q%-."*GV12@/E8 P-O3 ]*WR<4
M<)\2/BK;_#K7O!&F3V$UX_BC6!H\4D3*! QB>3>V>HPA&!SS6%\=OC;??!Y?
M"4=AX:E\47OB+5O[)@MHKN.VV.8GD#%GXQB,UD_M+>!O%GBJ]^'&L>$-*M-:
MO/#/B--6GL;R]%H)(A!)&=KE6P07':O-OC3X&^+_ ,:="\'7EY\//#,5]X<\
M4#4&T&Z\0>=!J%G]EDCR9A"-A\R0C;M/ S0!VFL?M0ZYX:\)6^K:S\.;ZRO+
MSQ':>';&QCU2TF^TM.I*S"17V*H((()!I?$G[3NO>$O!TFM:M\-]0LIVUO3M
M$M++^TK65KI[N3RPRO&[*NUBH.[&<UY5XK_9\\8>(OA#8Z!8?"3PUX9&F>,]
M-\0R>'[3Q&;F#4X8MS7 ,KQKY9/RJ%QC'ITJ]K/P5\;ZE\/=1T_P[\)?#O@:
M_L_$6C:[9VD7B+SDU,VMQYLBRN(\1$!0H.&SN/I0![9\-_C\WC'X@:QX%USP
MQJ/@[Q9I]FNI+8ZB\<JW5JS[!-%)&Q5@&X(ZBLWXA_M&ZEX;\:ZIX8\+> ]6
M\<W^BV$6HZNVGS0PI:12!C&H,C#?(P1B$'85PVE?!?XD?%KXF:[XV\<B+X:W
M/_".'PYI$?A?5A>W,(>X$TMP96B503M"A2IQDFG:C\,OBW\'O%NNZG\/;?3_
M !^/$NE6EM>7WB/4Q97=M?6\31+<OMC*RHRE254+@J?6@#4UK]L=9;SPEI_A
M?P;?ZSJOB'06\0Q6>I7,6F-%;K(8_+/F\M-N!&Q0>QZ$&O7?"GQ*7Q3\,K3Q
MB='U/2UFL'OGTF^M]EY$4#%HF3^_E2 ._'K7SG\5O@W\5-6TWP8FL>&/"OQN
MAL]%^RZG%JLXTJYCU$N6:ZMYU0E4*G9M&/N@UZS\!_ _C?X6_LYZ/X>U:YAU
MGQI86-PT:W%TTL0D:21X(&F(RRH&1-Y&2%S0!Q%A^W!96FA:]?>*?!6M^%+J
MPT&U\16MA=&.26\M;BX%O"ORG]W*9612CXQNSR :MW/[9:Z%X8\2R^(O ^K:
M)XNT74M-TK_A&6GADFN9[\XM/+E5MFUB'R3C&QJ\ET3]F_XR>-?AE\2-'\>:
M5H,?B_Q'';Z@WB8:RUS)=7EM=I/;6OE"-5@ME564*I;!8GDFM37OV>_BU\2;
M?QGXXUC3M"T3QU>Z[X=U?2]!AU,W%MY>DN[K%).(P%,C32\[3CC/2@#T"?\
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MA4C(+QQ,ZC'?D"NBK"\<C3F\':XNL3/;:0UA<"\G1BICA\IO,8$<C"[CGVH
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MPE^T+\./#4&N6[W>@V6K:OI6@3N]S>PR3L#)(S]([=03L4CEB<9"UVOQ%L/
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M:4.#MVACR<\5+<_%SP;::19:I-XIT>/3;Z<6UK=M>Q^5/*3C8C9PS>PYH [
MJ,&HUB(.<XKB?BY\7]"^"_A2/Q%XB-RNFM>V]B6MH3*RO*^Q20/X0>I["HXO
MC-X>F^+<_P .8Y9VU^#21K$C>2?LZPE]H!DZ;_XMO7:0: ._Q1MK@/A/\9="
M^,5IJUUH2W<<>G7C6CB]@,+2KU2:,'[T3@$JXX8 XKOQ0 8% &*6B@!,48I:
M* "DQ2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X-^U#!?0
M2?#_ %:#7-1TZSL_%NEPRV%F52.\:6X5!YK?>**"?E'7/->3Z?K>L>'_ -H-
M[6SU5?$&MS^-KU+M8-59WBTDVK2QVILV($>PA$5\;2<-N^; ^R+NP@OE"W$*
M3JK*ZK(H8!@<AAGN#WJE'X7TJ+7)]9CTRT35YXE@EOUA43R1CD(SXR0,\"@#
MY9^.WQ!\5^./%&FZ/X7\,:\=8\)Z4/%=Y86UW!%)!>-(R6EM<'S-K*\<5RQ1
M2<C:>U5H/VM=5UC7[^ULKO3TCN_%.A6^A6I4?:+K3+RTCEEPI/)\SS8]V,*5
M/<5];)H]K%>W%Y':Q1W=P$6:=4 >0)G:&/4XR<>F3ZU2A\&Z+;SQ30Z/8Q31
M)Y<<B6Z!T3.=H;&0,DGCUH ^6_AG^T?XLU[XA:?:+?6WC6/4_#UUK%QX8TFV
MBM[W2YX[J*'R#))( ^T.VX'#97.,8JE)K_V[XD7K+XCNM/\ B!=^,;S38[)K
MMC)9Z:=.=E)M@Q79'E7WXQD9SSBOH#P%^SWX3^''B:[U[2HKR;4KB.2%9;^[
M:?[/$[B1XXMWW59P">I.!S7:CPGHZZV=:&E60UGR_*_M 0)]H*?W?,QG'MF@
M#Y>_9!\2W^K>-[RRM98KC1;7PMITFH2V^M'4HY=49W#2JQY0NBDE3@_=RH-?
M7-9FE>'-,T)[EM.TZTL#<R&:?[+ L?FN>K-M R?<UIT %%%% !1110 4444
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M&\[Y0?D?<P^=<[AS71:[^S9XAMI;S69_!]GXODB\2VUUJ&FW,\;2Z]IZ:9%
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M946TM9'LDEGNK1VC*3B8)&/G"M&P>N?L/ 6HQV^G:)X>N=3\.7OB32M=CO\
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MFZ]H!U@1ZG;M<V&C/9Z?I=SJ$]S)>R12L7=90%6-)U9OW;,&78 ,9S6)X?\
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MDL;TI, /+RJB)HB CLP8+G('% '=7WQQ^+4'@*YA?QM+#XT@40V2PZ2L\.J
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M6G7<4$.CV>E1W;7 >WCD>$E?^6T15M[%@A,I /R@55UKXZ>.]+>6PL_B7/\
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MX$8QFZEI6KW7Q.U72YH9EA$<\RZ7?VJB1K:$(L]W=JLNQXI(_,123E/F(Z4
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MPV!%Z?\ +->XH ^1-$B_L?X-Z<^GW/AZ2U&BS>$]!UC7[A[?5/(EW&6R^0E
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M//:W+)O*R2F$F7!.QWP&K[XOOV2OA?J"W7F^%E\ZYD$KSI=S)(&50JE6#Y&
MHQCZU47]D#X:?9S;W&CWFH6PMQ:QP7NI3S)$@ "E-S':PP,,.10!\)>,=*/B
M#7?%;:-XCT./3_$ L[:W99YHHEBBC2Y V21E4=G\T *$X3('S8HU=/$ES+?^
M'K_Q#IXM)M>-I:W M04:0S&2.>6XP)(K?RE$954R=I) !S7W)<?L4?"6_P#.
M:^\-SWTLL20/-<:C.7*(,*,AQVXSUJY;_L?_  JM8[=8O"@C:"V-E%(+N;>L
M1)/7?R1GACD@=Z5@/@[Q))/J\AU70M1_LK2Q?ZI#J&LW?V8B_N&2-B+4KL+P
MPJ)>9<<.4QP36O<_9=0^(UY;:98E[5;BST?5+>-FC,,[(9HH[-7+PKOC5?G9
MBHWC'3-?;VH_LC_"_5;:2UO/#/GVKX)A-U+L#;67>!N^\0S GOD^M1R?L>_"
M6X#"?P=#<!F+MYMU.^YC$(LG+\D1@*#V &*+ ?#>B74^LZ+I<-SXB^R'5=32
M]\@V<MLFKV_FF-4N5V!!*70H0""^>#\XJQ9Z'=>!9_#9@T>YTC7=?N[N]N_#
M<D\<D=R@B/D/$JC$1CD4'Y2&56&[K7W!;_LB_"BVUU=9'A".345\G$LMW/)S
M$R-&=IDV_*8T(X_AJX/V5?AB9[VX;PE;O/>3R7-Q*\\I=Y';<S9W<$D]L=AV
MI@?!TEE?:?IGA6*XM9->\/7'@_1[1[:TU QW5YJ$$DBRQ.(SOC$,LI4QJN1M
M'(K%UZVL]3T_4M)M-!N]-O9]+OH["6"\FGLM46"Y'EL2/WGF)<,,@G)"\C&*
M_0JT_95^%=BUR;?P;:1O<.9)'$DNYF,@E8[MV1EP&.,9/7-,;]DSX4&>RE3P
M38V[V=T][;?9WDB$,[[=\B!6 5FV+D]\4 ?#7B;P/I&N>'Y-:0>(KJW?Q&9K
MN50EN+.2TABCFN"\9)V2AY JE!RQWD<5;O)5DU;Q#J8U26QBM-;:YLOL.JR)
M(+6X(BBMIE*84+AF^4X#,.IK[AU/]EKX7:S%!%>>"[!XX6E<+&73>TC*TC/M
M8;RS*I);/(J#3/V3/A-HDMW+9>!].A:\!$_+MN!(8X#,0.54\>E*P'QJ7FOH
M;7PM;P&_M]=FFT"UN-;O7D,=M _GI*\D+/O5Y5*D.IYZG%<Y+<^'OB/:7NG(
M-2LX6MXHKJ33;@VNUKK;/!BS9_FC\OS(MV\(1MZ9-?H!J'[.'PYU'49]0E\(
M6"WT]U'>O<P Q.9D.58%2,<]<8SWK!NOV-_@W<QE7\ :=SCD-(#@=!D-T'8=
MNU,#X;L]3F\.ZUHVI:IJUU>3ZKJD,ZZ5)$!)93(L#3*Y>;C;')"YV#9C&.]7
M/&6HW'BGQ[X?CLKBST[5_$T^HW%U;:'K,8$=RRP03LQ"^;&YCC<QXR"&XP37
MZ#7'P0\%7QU/[5X9L;HZD"MT\R;S*"D:'DG(RL48.,<(*QK/]EGX3:=>2W=I
M\/- MKN7=NN(;-4D^;&2&'(/ Y% 'Y\V>H:_>VOC>#QAJTFE6<_AKR='L$U>
M:'[)Y5X @;S/FE^61':3MNZ8I+GPSH7B^VDN-/N-)U;45@T^\M%NM7GELM+M
MFBGB,?[M21@LDBJP()'HU?HS?? 3P#J5]:W=YX1TR]GMF9XI+B'S&4L%#9)/
MS A$X/'R@UEI^RW\*HH! G@+1Q )'E\KR3LW.NUF*YP?EX^G2@#X<N-6\-:;
MXJM?B#X79Y3/;069C2+S(;+6I7_X^9L8W1KY4K,=YPK*Q&%Q2IHMUX@L=/2.
MSM?$5HCR2V^C6D[6WVJXM5NG CG7&U 0A/RD,[ #BON#2?V7/A3X?@\G3? >
MD6$.2Y2"$J,E64]#_=9A^-7&_9P^&\D]G-_PA]@L]I!';P2J&5HXT!"*"#VR
M?KWI,#X9L+ZVN=!^&.A>%KK1E>[2W6SU@SPS-!>0J/M:218#(LC+SYC%78IT
MS6=>:O9RZ':W&OQ0ZIK=G;7W]G#6YYW6*Z,J2@HJ#N\H\M?F,9/(P!7WBO[+
MOPI348[]?A[H O8Y/-2X%FH=6SG.?KS5N3]G7X;R:BE\W@K26NH[HWJ/Y'"3
M$@M(HS@,2!DXYQ18#\^/L@UWR=0UBYUR.ZTRQCC>2/6+B[>^U*V>2V;9"JB:
M1@"[LN0,H.F<UHZQHFD:CI/@)]!O1X3U74IK5WNK"XGCNX-(9VBDL3&&8H'F
MVEER&!?!.1FONBW_ &6_A5:WR7</@32([N.5YTF6(@K(Q)9U(/!.3G'6M4_
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M+D_\@CX._P#7?5O_ $&THH_X+D_\@CX._P#7?5O_ $&THH _4FBBB@ HHHH
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MV<9_&O7*8"4M%% !1110 E+110 F,TM%% !28I:* "DQ[TM% !1110 4444
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MXGERA+>*=48B/HI,VYA]06(KUZF 4444 %%%% !1110 4444 %%%% !1110
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M:7ITD[VAN;BZ47#[V1II6E=0?[H9S@=AQ71T44 %%%% !1110 4444 %%%%
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M/;Q2V%GI%K<0Z<4>[M(KJ6:1;OKN>19-K.O/&1C)KZ["*.@Q2[1Z4 ?(5O\
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M( YP<'I7F\/AGXY9N+"9_$4;3ZW96NKWPO49;BWDU*1Y9[(C/E1K:,BG &,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW:O"?V3PG]B>.=DXNE_X2B4B900'!L[0@\\_7/?->[4P"BBB@ HHHH ****
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M* -#3OV2M4\*Z1XPU'5;;3?%4MQIEY%I>B:5!M:UGEDBE3R9)L $21!MQQR
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M11D4 +129'K1D>M "T4F:,B@!:*3-&1ZT +129HH 6BDS1D4 +129Q1N'K0
MM%)D"C(H 6BDS1D>M "T4F0>]&: %HI,BC</6@!:*3<,]:-P]: %HI-P]:3>
MN<9&: '44W>I.-PSTI/-0?Q#\Z 'T4SS4R!O7)[9I%GC<$K(IQUP: )**C,\
M8(!=<GIS0;B)>LB#ZM0!)13#-&H;+J-O)R>E--S$.LJ#_@0H EHJ(W,2D@RH
M".N6'%+]HBSCS%SZ9H DHI@FC/1U/&[KV]::;F$$YE08&?O#I0!+141NH1_R
MU3_OH4IN(EZR*.<<GO0!)134D21=RL&7ID'-+N'K0 M%)N&>HHW#UH 6BF^8
MI_B'7'6EW#UH 6BF[U]12[AZT +12;AZTA=0,D@"@!U%)N'//2DWJ.XH =12
M;@>]-65&&0P(]0: 'T4FX>M&X9QGF@!:*3(HW#UH 6BD+ =31N'K0 M%-\Q3
M_$/SI=P]: %HI-P]:-P]: %HI-P]:-P]: %HI,BC(/>@!:*** "BBB@ HHHH
M **** "BBB@ HHHH **** /RV_X+D_\ ((^#O_7?5O\ T&THH_X+D_\ ((^#
MO_7?5O\ T&THH _4FBBB@ HHHH **** "BBB@ HHHH **** "O./BKXCUC2-
M5\#Z=I-['8?VQK7V&XE>'S3Y?V::3Y1G .8UY->CUYG\6<CQ7\,/G*K_ ,))
MR /O'['<_P#UZ -.?PIXIE^S>1XP:!%4B4-IT;;SC@CYAC!YI4\*^)Q9PPMX
MP=KE=OF3+IT8#<\X7=QFN?\ C-X_\4>#?['3PQ;:7?W-Y*(4L+R9EN+IMZ K
M$!P J%W9SPH7WK ^$_Q]/Q*^-7C_ ,/6UUI<_AW2;:UDTN6"X5KFX;?+'<NR
MYR$62/ R.V>A% &IX0D\6^)]5\;V$OBMK=M'U?[!;R)81G,9MX902"W)S(P^
M@%=/9^#_ !5!&5F\;S7#[0-XTZ)><<G&[N>:S?A<^/%OQ1(' \1K\WJ?L-KD
M?A_6L;1/B3XAN_CQ?>%UFTO5M$AAE:Y73R3+I1"1/"+ECQYDN]\(.BJ&[T 4
M_$K>--+^*/AGPS!XOF%OKFG7\YN6T^)O(DM_(VX&X?>$K9^G:NQN? _BMX%
M\=W4;@G+C3H2#^&:P/&B[OVD/AB6?&-&US"@]3FT[?3-=-\;/$FH>$?AQJFK
M:;JFE:+/;;&?4-9W&W@B+@2,0O+,%)VKW; [T 4YO 7BN5[AXO'U[")%&V/^
MSX2L>""2/J 1^-?)WC/]I/XHZ#\1O&^AVFO:3]EL-1GT+2DN[<(QG9$*7$[
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MGTUM/\-_$/Q/I_B5Y;>32S/:W%Q92O"[$YVVX$<:",*,@\GWH?\ "IK+4;U
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M2>"/!UW9ZAJ>DR:C!:Z9I-Y-.J+!*(U:4)$3AT:3&>,KO)/)S2L!Z-I'Q/\
M$^KZQXAC\1_$KQ#;W,EB+K2+3398TEM(1&4<SQ;22T;G SC><=,YK#L?BO\
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M** "BBB@ HHHH _+;_@N3_R"/@[_ -=]6_\ 0;2BC_@N3_R"/@[_ -=]6_\
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MZW>-*BD@LH;S.A(&?7 IEU^S+X)O]1:^G36GN?-,RD:]>A4<]2 )>^!QTXH
M[GPIX;T+P)X?@T+0[6'3-,M PBM8W)6/+%CU)/4DU^;/QA\/W%_\6?C&]_:V
M5SX9N]<GNKAKZ8F)?LUO:L?E!!#['9D(ZX[ 5]Y7/[,O@"[N+R>?3]1DGO"6
MG<ZY? R$G/.)OY5AR_L7?"">6667P@LL\K.TLTFHW3/+N 5MY,OS9  .>W%
M'PQ E]IGQ!\3>)O"\-QX<UF6ZG2WC2>*2"TTKR8H[9[J$#RS;N)-PQSQSDU9
MOM=\?0ZSH6MRZOI6GZ^]@?"I%C;)+;%5N4=$6T4%1'(&+*QZ,4)(S7W.O['G
MPB6;SAX+M?-\C[,7^TSY,."/+/S\I@XVGBKFE_LI?"K0H+V#3_!EE;)>X^TL
MLDN^7!4@%R^[&40XS_"/2@#\\[;XI>)_"T=SJ3R,_BK6]9D>YGO$AFN$T\Q?
M9YYH6"!A-&JA'C!XRA[',?A3Q3K?A'3=,\'VNIQZII5AI]Q:&/5;*!M0^S><
MT]K:AFS\XVB5"<@8..17Z'2?LG_"N?48;^3P?:&^AM7LTN#-,76)@%8 [_O,
M  6^\1U-4;3]C7X-6EV+F+X?Z6LWD_9V9O,(>/;MPP+8/'<\T ?$>B_$/^U/
M$.H7>HZ@;"_MM2SJMM'-;;=\]N$F!=\%))H54%ER%&[O7$K\8/$/@.U?3]-U
MA;I[V6RL]/MK'_3+NW@M9 L:1*R;5" D+.3\P!VFOT4NOV-O@W>:++I$W@'3
M'TZ:YCNY8"9,/+&I5&)W9)"L1UJ0_L@?"+847P18Q*/LX'DR2QD"#/E*"K@A
M5R>.ASS0!^='B3QSXTTW6/&^@V?B2T30K>VU*=H]*N(]\:R2PS7GEL1OB#M=
M$ YYVXYVUE:MXG\>:#XYU6;0/$%[:7^M:;8?VE/J*PW$5FPM0T7E,>3*MOMC
M+@ G<,GT_2P?L?\ P>2[-XG@#2A=D@M-A]SX"@!OF^8?(ORG(XJ.Y_8W^#%X
M[R3?#S2))')9BRN<YZC[W3VZ4 ?E]\,_'5QX/U274/#NOZ]977BDPQ75W*8I
MHT6W%VI26.1F 9F>$HIQGYL#BO0O&'CR/Q.GQ(O-)OIM1N]:@TC4!<R7GDJE
MQ:".2W1P0&61I%*[4 P6P.M?H;=?LG_"*^>0S_#O0&$DJSL!9A075/+5L# R
M%X'U)ZFH9_V1/@]<R!Y/A]HTCA!$&>$DA!T .>,=L=* /SWU/XC:_P"+KY[#
M^W0+;Q9JS6VMQ7)@CMP)$@MVAMF*\32-*SR;2"=G/-4M;\67_B'Q-X;T?6/&
M)FT?P_+%N^W!;=8$$"I)+-*F!-,H*;>N5W=C7Z-']D[X2>4D0\ :,D2.LBQI
M"0JNN,, #P>!SUJS#^S!\*X8]+C'@/0VCTR3S;-9+8.(7W;MPSG)SW.: /S3
MG\775WX/N+*+6=/UJ_\ L]EI;BPF22YB>8'"3.% \I)@I*]54  FG7[6.N>(
M+O4=,U32]*OQ>NR?:+\[8XU5(W\V$MLVK*CR!QR5D'<5^D0_9/\ A D9C3X<
M>'$0D$A+%5Y!)'3T))K:?X!?#J7A_ OAYE!)P=.BZD $_=]%'Y4 ?E?XMNQ=
MCQ7!'XVM)?!FOFPCM=.CE62.&U:]N3(J*<':DD9*/D%48#H:G\5O!J%MIVD:
MCJ%EX=2:"%[IUF1KB]M#;G>4"9V"/(4A3G+%<?,:_4Y_@9X":"> ^#M#DMYT
M,<L,EC&R,I!!7!!P,$\"JL?[//PUB>-T\!^'D:,.J8TZ/"AB"P QC!*J?PH
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M B4K*&,>YAR V.M<9X&T:S:RMKHZE;V]UI0A2UFL=/E,CO;+O3+/'E2S!4+
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MK6M!>6W\F1 D,T\<,CR 2$XPAB93WR.,UZK:_!7P5:VTL0\-:?(9X(K>>62
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MZ%I)GME#W"C,JN$9.O4,P4CU.*R--^-?AG4?$T^@?V@MIJL+3YM[D;"RQ3I
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M 9X[CQ+\6IH;I;R"7Q:[QS(P9=OV2V&T$>F"/PKH[GX/>![J.(MX+T,OO5F
ML(>,'=_=_O<UQW[.$-I9^,OC58V=O':P6OC%@L,$82-=UC:MP ,=^??- '8_
M%;X=7?C>?P]?Z9?P6&JZ)>/=6[7EOY\#[XFB8,F1DX;(/8BO-?$W[*5SXGO[
M"_F\3LES#=V]Q<""V\I)Q':)!C"L I#*SKCA=Y'O7I7Q;\?W_@I-"M=-BLS>
MZO>-:1SZC*8K>+;"\F78#OLP/K7"S?M5Z;ILMG9W6E375_++:6A.G.)87FEM
MA<2>6_&Y40CG^+/% '.+^Q]+-;7<%QKMJ@;4;>\C,%D<S1PR"11.2V7<D<M[
M"O2=/^%>KQ?'"\\<7>KVEWIK6CVMEIGV78]IO5/,8.#AF<H,DC.  ,5Q^H?M
M/7#7;?V?H 9#+$L4=S<*AEA9T5YF()V;0^=IY.*ZVV^+=W%\>V\#7$-H^GW.
MFRW=I<6\A:5)8BF^.88PF5?</4"@#U=.!7B7QC^&GBW7?BCX+\9^%&TN2?0=
M-U6R>UU.1D1VNDB"-E0<A3'R.X->VKROUKPSXZ_&/7/A[\1/!'AW2+6&>WUN
MSU.ZGE,#SRH;:)&4(BD9!+\GM0!YUX8_8WU;2O&'AC[5J=K>^&-.T6VT^Z'F
MR+,SI:2V\L:*./*=IC)C(^Z!CBL6Y_8I\9W_ (&T*&]\06-_XG75;N[U>:9W
MCAN8GMTM+<J5!(>&""(#C[Q8YYKN-%_;'MSX4L-0F\/W%ZYT/2=3NKBSD7R1
M-?DQPPKN.?\ 6*RDG[N.:O2?MF:/8K$U_I$EL@U&72YV\]&$,UM<F&^?(ZQ0
MKY<A<<;9!0!RGB[]CK7?$=UXD)U;2S'JTNI>5]K220VGVE+,)<Q^DZ?99 #_
M +8YZUA:=^R]XL\8ZIX_EN)+?0U;5-:BL+NX1OM6H)<Z8MHC2,/^6.\F3'JH
MQ7IFD_M:QZQXNTG1)/"]S:Q:A<6=D+IKA"$FN[6>XME*@YPRP<GMO6O-O#/[
M9/B?3/#FFZSXJTVUGU'5M-MI;/1;$>6HGGU:2RBW3,<8PH).,#F@#73]C#48
M;O63:ZM8:3;:C<7/[RPC99H[>;118L@.,9\\"7'3\:I/^Q1J<W@:YTV2XT--
M7GT&_P!/#*DC06M[-/#+'<0Y&4"^2.@&#TK2B_:WUS4/$=_'::/"8-1T[3&T
MBQNY! \-Q/!>2RM-(3C:IM<#'4FM'7_CQXJB^"?P-\0VLP.J>,I+--0DL[$W
M+GS;-YF,4603\RCOTH V_#?[-VKZ?X'^,_A&\U+3Y=+\=7-_>V]U#$RW$4EY
M&1,)NS!6/RD=LYKD=?\ V0?%GBZPFFU?Q3I<^M"'2K&W2.U=;5;6SCF5@XZL
M[M.S>@P,5%X)_;4U(Z/\/H-3\/\ ]KW^O6L=[=WEFXB"6TM^;2&01')\PG#/
M%U3GTK-U[]N#6-'\6:[=1^'[:70;71Y);*R:X GENTUE]/W2L,^6IV9QCN*
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M.U2:I^R1:ZSK5OJ%YK+/YGB&36M3@2V41W\#F&0V;<Y">?;PR@_[&.]?15%
M'S;XA_9@O;2Q\07UA?+KEU?PZZ9=)GC2&.\:_D$T:>8?]7Y<JJ0WM7J7P-^'
MEU\,?ACH>AZC<)?ZXD7VC5M01<?;+^0[[F<^I:1F.:] HH **** "BBB@!AB
M0N'**6'1L<BGT44 %%%% !1110 4444 %%%% !1110 5R/Q*\!6/Q(\-3:)?
MW5_96TI!:73K@PRXY!4D9RI!(((Y!KKJ\T_:)U#Q'H_P@\1:AX3NVL]>M8XY
MX)$M_/8A94+HJ=RR;E]LYH Z&?P#H,_@RW\*W&F0W'A^&WAM5L91NC,46W8A
M'<#8OUQ6=\*?A)X<^$^E&RT&U$;.NV6X( >4!W9=V./EWD#CH!Z5>^(\^MVG
M@K5IO#=N]WKL<>;."/;^\DW#:IW$#:>_MFO*OV.]5\::IX#,GB^WN8@=[6;2
MOYBA?M$P9-[?.S*5Q\PQMV8ZT ?05%%% !1110 4444 %%%% !1110 4444
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MN;0:AB*53J]V\V\9(<BS-NISZCT- 'U3;^!/#,6IZ+J,.C6*7NBV[V>G3I"
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M2!F@#T?PU\4O"7C"_EL-#\1:?JEY"I=X;6=795#;2<#L&X^M;/\ ;UE_:?\
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M*B0CD8/4FK&@?LY^,;36_#%S-=QBWM?#CZ3J'GZG)+(RLUP1"C #:R^;'B4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH _+;_@N3_R"/@[_P!=]6_]!M**/^"Y/_((^#O_ %WU;_T&THH
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MR5]*DHH C\L8P!B@Q ]:DHH C\L'.!U]:/*7N,U)10!&(5';\J78!G Q3Z*
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MX>&-?L\IY@1 "').YR>^<\_2@#S7X=/O^/7Q?BVJ,?V+(& Y;-FX_P#9:]*
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M-9N6'=9#UR:I:C^S'\0S=>&1%J-A<QV<,4E_.URZO/-(MT;R,@YW1N]PFT<
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MC_@N3_R"/@[_ -=]6_\ 0;2B@#]2:*** "BBB@ HHHH **** "BBB@ HHHH
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M)T>&V@B%O9W$C"/+.TK%I''F<DDCL05'M0 MK-=17EW )K:9D5&E.TAP2>I
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M-/\ V/O#,/CC_A*6UK6;G4([V*\A\R92J".\CNQ'G&64R1#J>A-6=?\ V2=
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M (W+(07\_1R2.A_T$5ZI9R7,MU<_:(?)BC<I RON\Q, [B.QSD8KR[X6$?\
M#0'QL&<DW&CG/_;BO'Z4 >ST4E+0 4444 %%%(3B@!:*0$&B@!:**;O% #J*
M*0G H 6BF[QZTZ@ HHHH **3-!8#O0 M%)UHSS0 M%)2T %%(2!1F@!:*:7
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M"N?VK=!NKZSM-+T[4+TW*2 SB'Y+=_/EMX_,'7:TD#\]A@GK5+5/VBIKBR\
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M ,'X2>-Q\2?AOX<\3^4L+ZI91W#Q+T1R,,H^C BNPJAI=E9Z3IT%I9016EG
MFV*&%0D:*.@ ' %+IVKVNJ&?[-<1S^1*T$NQ@=DBXW*?0C/(H O4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7@+G!XY90/<BO0]7^,'PZU&"31=?\2: ZWF87L9KN.19HST!'0@CM7FWQ<\
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M=:6==8N=)MI;P7,?ER><8QOW+V.<\5W5 !1110 4444 %%%% !1110 4444
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MBM.N*^#W@4_"_P"&/A3P@;E;LZ)IL-AYZ+M5_+4+D#L..E=K0 4444 %%%%
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M5W6O?LW>$= TF]U6YU[QE]FLXGN)4BUR=B54$D!1R3Z =ZXSXL_&O1/&VO\
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MHO+YGO"[$(8=@; '3R(Q^!]:S_ 7[-NG>!?BG:^*;:Z,VGZ7X?70=(M)\O+
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MQ2VLWEY>ZG<^*]7EDFO0=Q073I&%S_ $5=N.,5[*!GFD6,(.!3ATH 6BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JAKMA_:ND7EEYDD(N87A,D+['4,I&5/8C/!J_5+6-1BTK3;F\GSY%O&T
MTFT%B%523@#KP#Q0!P/P5\.:[X<^!?AC0M=1WUZRTE;.Y^T3^8SR*I7+2=RV
M 2?>O /V4/V;_B3\*OBSXPUOQ;K\FL6%U=CRV>Y?$N;.%?,1?XPA'DY?!Q$#
MWKZC^&_CK3_B9X#T'Q5I*RKINL6B7EN)TV/L<9&Y>Q]JZ;:/04 -B!"#/6GT
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y;?\%R?^01\'?\
MKOJW_H-I11_P7)_Y!'P=_P"N^K?^@VE% 'ZDT444 %%%% !1110 4444 %%%
M% !1110 5XQ^U_8)J7[._C&"240H([:4R$X V74+_P#LM>SUXI^V/;?;/V</
M&L1#%&BMPX5=V5^U0YR/3&<^V: .TU7QQX7OA-9S>)-&^S?O(KR"2[CRR,I!
M4_-QUKS+]G>R\/\ PFTKQG87&NZ!;V6H^*]2U?34M+V,HMI/(K1+C/RD#@BN
MVNO@;\/)/[3OO^$$T.XN+@R>?BQC+3GD8)QU/3\:\S^ MKX6^)FD^(%U?X9^
M']#O="\07>BFRAM8I5B2%4*!FVXSA@#CC(H W=*\<:!'^TUXFU"37=.2P;PA
MIBI,;I A(O+S.#GW_6O38_B9X,@55'B;2L#@9O$.?UKRFT^&WA.?]I+5]+E\
M,:.UA_PAEA*MH;*,QAOM]WDA<8]*[R7X9^";#S/)\!Z'<'#/&(=,BP<8&"2O
M!)- 'F_[0?CGP[J5Q\,C;:[IMPR^/])?$%PK$(!*.<'WKV)/BKX0EF,'_"2Z
M6TH!8H+I.@./6O%_VA/A]X=T!/AA+::%I5H\GQ!T9,V]C%'\C/(I7A>A'45Z
MX/AGX34LW_".Z(DK@ E=/AQ(<Y/&WOT_&@"Y)\3O"421K)XETM"XRH^U)S].
M:\T^%E[::M^T]\4+^RGAGAGT+0AOBD#\J;L8..AKO!\-O#-W/(D_A?14CC!B
MCVZ=$3M*@@@[>,98?E7 _"O2[/1_VH/BA:V-K!:6Z:!H.%@C5 3FZR2% !/
MH ]#^+_P_?XD^$'TJ"[6RO8KJWOK6>5/,C6>"59$WI_$I*X(KR+Q?^S!X@\:
M:-(+OQC'!K$EI%%Y]G:F&%9!>O<2812/D965#W.S)KUOXS^/9OAOX&N=9MH(
MI[@7%O:Q_:&*0QM-*L8DD;LB[LD^@KR#7_VL/^%=Z )M?TVWUFY@MY&N+K0;
M@26IG^V?9XXE)YRQR3G@8QWH I^(OV0;_7[C68CXLV6-U";>-FMRTYC=,.DK
M$_.NX*5';G->L+\,;I]6\&WUSJ$<Y\-Z1+:P1>5\AO'CCC%R!VPBNN/]LUY+
MXU_;#FTR._NM+T "TM8 \7VV8++=3;%<QA!R@ 8_,>#CBMOQ%^T7JNG?%GX3
M>&H=-MH]-\4V,5WJ4[N2UNTRD0I'C[QWCD^AH ZWX8_"GQ)X2\<^(O$WB+7[
M7Q!<:I%';P^3:&!K6)7+")1G&S)8^I)R:TOC;\)Q\6['PI9RRQ)9Z5XAM-8N
M8Y2P\Y(=QV KR#DBO2H #$*\S^.'C^_^'UOX*FL7@2+5?%6GZ1=&<<""9F#X
M]#P* /$9/V,+\ZUI$J:K92:1;:]J5[)9R&4/%:SZBMY'Y;#GSE"JA)Z@GFJ,
M_P"Q'K]YJ'BZ^NO$VG75SK-W8ZBA>U/EFZM;^6X621.F?+E\O(]*[3Q/^TK>
M^%_CCXD\(PV8UJ%8M)33H8W2)%EGBNY9&:4G&-MMQ[US7A?]L#4+[XCA;O2R
M_A?6;7PH+&+<HELKC5H[K"N<_.-\"#CIS0!O_'3]ES5OC)XJUC5GU33K>&YL
M-,MH$EA<O%);2W$CMD=B9AC.?NX-<UXC_8S\3:YI%_9/XMLKIKO1]%TR<W5J
M=MR;*&[C=G Z9-RKC'>/WIOBS]I7QBW[+_@GQM UMI>OZYXKM]$N39P?:O+A
M>^F@;RX\_,^V,<>M.L_VL_%?PX\$VY\=>&9)M<@T[5==E>8K9/+IMM.D<3^4
MQ_U\@?(B&3Q[T ;GA?\ 8^N=$U'3KNZURVFNK9=+5[E(#YS?9M-GLIB&/(W^
M<&'/\'-7/V>_V5M3^#^F>,+35-8TS4!J^AV.A0M86GD[8[:"2%9)!_$["0%O
M4YKE-<_:[UGP5J\^I:G%%?>'H;K5U:WB0)+Y,4^GQV^23P5%XY;Z>U'Q3_:[
MUFWO]8M_#<5I9:?::3XBD6_F82,USIMRD2L@SAE89;'N* +?AS]CS7K/X3Q>
M"-3U/0#;V[:3)#/;VLC.SV4B$L^\D99$QQCK1JO[#,>H^,_#^LKK\=M:Z7XJ
MU/Q UI% 4!ANKU+I8DQ]UE,80MW!]JOZS^VI#X<O/$+77A[S=/T^WUN6U:.[
M4W$QTT#S/,CZQB0_<)Z\>M6O%'[2.NWWP*^,&M6>GQ^'_%?@U%A4%A/'OEM;
M>YA8=,_)<*".Q!H P+3]BG6+;P#XN\'IXFTIM.U"5)]-E_LL>>D@U$WOF7#]
M9"-S1CT4GUKT[_A6/BKXH_#==!^),VG->P>(X[U18*RQ36<%PK1(0#D,R*<\
M\9%>$>&/VP?%G@C3/'-WXK1M933M5TC1K&"\M18W$%Q<V[2223*"<09V!'[G
M-:OB;]M'5[R?PK+8:9%HJB32[S4+6>8//<1W%M=2/#$@Y*@P+^\'K0!UW_#&
M[V$&FV>G>((ETVUFEMR+FV\R9+%KU+P*CDY$X9"GF=U([@5-HG[)-_::[/J&
MJ>(+&[2"ZM6LDAL!&3#%J:7Q,Q_CE^78&[ GUK,O/VT9;W0=.NM#T;3;B[O;
MRTLU:\U)8;9&ETU[YP\N,*0$V 'J36'XA_:B\2Z7\1=8@EFCDTK1_%D=G'I^
MG*))[JS.ARWIC.>N9 ,,/2@#[.08SS3J^/V_;9UB'PK->CPUIUY?JCS+]CU'
M?;,@TUK\#S,??"J4([''K7U/X-UZ+Q5X4T?6H 1#J-G#>("<D+(BN/\ T*@#
M:HHHH **** "BBB@ HI,TM !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5%*@D.#TJ6J6J0SRVDZVLBQ7+H5B=QE5?!VDCN <<4
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MNFB81,">A#$<T 8.K?L[^ _'7AB(>')1H\3R0,-3TAUE:9(!(L:%WW;E7S9
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MT;USC- #J2C</6DWC.,T .I*-P]:3</6@!U%-W#UI=P]: %HII=0,DTNX>M
M"T4W>/6C>/6@!U%-WCUHWCUH =13=PQG/%&\>M #J*;O'K2[ACK0 M%-WKG&
M:4L!C)ZT +12;AZTA=0,Y&* '44TN ,YI/-3&=XQ]: 'T4SS4X^8<].>M(]Q
M%']Z15^IQ0!)13/.3.-XSZ9I!/&<X=3CWH DHIGG1\?.O/O1YR<?.O/O0 ^B
MF+*C#A@1[&D,\8ZR*.<<F@"2BH_M$1 (D4@G .>II?-3.-PSZ9H ?13!*A.
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M.M 'HW_#0/QGT71=2OO^%E7EW=:0L'F6\LX!F?SS%*0,<[2%C8=MX:J'B/\
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MVF(HS3H<?(7?+$ <D>E0Z&-:U7P_=*+J+2-,T^":YNM/N[HJ;Y<"[" 8SG+
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MD8Z$>U>;Z;X[U"P\,^"?#=UJ=Q;Q:4NO6>H:C:[W-T9Q"Z$G;G!"N@;^+D4
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M(QT33=T?W#]CC^7Z?+Q6[10!BMX0T4G_ )!-A@>MK'_A2)X.T*/ 71].' 4
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MMW\DR>7N 8<_,,5UU\\<=Y:$Q/)(&V@IR(PP/S-[<=:\O50/VP+<COX#E_\
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M+JOB31H8=,N;.V?2H[R2QM;"4S2F6./;*7(VJJNY79][(YXKT%?&/CR;P_\
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M?0]6U'36T>\O;2.>2P<Y,!(^[D\_GS0!U%%%% !1110 4444 %%%% !1110
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M!]JPJ$C51VXJ2HX"3&,C!J2@ HHHH **** "D)P.E5K][A+>0VR+).%)17.
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MKJ3:9;"S*RJMT(WD97*_<.U&Y/I7S7X*_8QUGPC:>'!;SZ997%G8>&K2[FM
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MNS^ XI-5^/?A;2(/&TMQ-<^7X0U"VTW5-L))2:=(7C"^HVW$>3VY]*\J\/\
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M\Y-^S<-V,XSS44EJC2F4J"X& V.0/2J?]G.VKQWN]0BP-$4V_,22"#GTZ\4
M:3.J*6)P ,\TSS%FA#H=RD9!'<4/'O7&,CH1[4Z.)8D54 55& !T H \,/PH
M\1S_ +3L7C6XL=%'A6"RDC@EM]T=_P">\2HSRGI("HVA>BC)ZUS/P8_9]\=?
M#WQKH=[?:[$VC:=82VGV6&XD="I#A4V-P<NRRENH(V]*^F]H-13,8^0,^PH
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M_P"@VE%'_!<G_D$?!W_KOJW_ *#:44 ?J31110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _+;_ (+D_P#((^#O
M_7?5O_0;2BC_ (+D_P#((^#O_7?5O_0;2B@#]2:*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _+;_@N3_R"/@[_ -=]
M6_\ 0;2BC_@N3_R"/@[_ -=]6_\ 0;2B@#]2:*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _+;_ (+D_P#((^#O_7?5
MO_0;2BC_ (+D_P#((^#O_7?5O_0;2B@#]2:*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH _+;_@N3_R"/@[_ -=]6_\
M0;2BC_@N3_R"/@[_ -=]6_\ 0;2B@#]2:*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH _+;_ (+D_P#((^#O_7?5O_0;
M2BC_ (+D_P#((^#O_7?5O_0;2B@#]2:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH _+;_@N3_R"/@[_ -=]6_\ 0;2B
MC_@N3_R"/@[_ -=]6_\ 0;2B@#]2:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _+;_ (+D_P#((^#O_7?5O_0;2BC_
M (+D_P#((^#O_7?5O_0;2B@#]2:*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH _+;_@N3_R"/@[_ -=]6_\ 0;2BC_@N
M3_R"/@[_ -=]6_\ 0;2B@#]2:*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@!JDGK3J** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** (KF1HK>1T4NZJ2%'5CCI^--M
M)9)K>-Y$,;L@+(?X21R*GHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD)Q0
M M%,60,<#J.HI] !1110 4444 ?EM_P7)_Y!'P=_Z[ZM_P"@VE%'_!<G_D$?
M!W_KOJW_ *#:44 ?J31110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%(1FEHH C2!(W=U&&?&X^N*DHHH **** "BBB@#\MO\ @N3_ ,@CX._]=]6_
M]!M**/\ @N3_ ,@CX._]=]6_]!M** /U)HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#\MO^"Y/_((^#O\ UWU;_P!!
MM**/^"Y/_((^#O\ UWU;_P!!M** /U)HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#\MO\ @N3_ ,@CX._]=]6_]!M*
M*/\ @N3_ ,@CX._]=]6_]!M** /U)HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#\MO^"Y/_((^#O\ UWU;_P!!M**/
M^"Y/_((^#O\ UWU;_P!!M** /U)HHHH **1C@5DVFK_VG=RQVB[X86*/<'[K
M,.H7UQZTK@:]%,1"IY)/N:?3 **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI&X!J&*;S)I$"L#
M'C)(P#GTH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#\MO\ @N3_ ,@CX._]=]6_]!M*
M*/\ @N3_ ,@CX._]=]6_]!M** /U)HHHH YSX@:R_A[P?JU_&_ERQ0$1MZ.?
ME4_F15KPMI:Z/H-A:JV_RH5!<]68C))]R236;\4='EUWP)K-I""93#YB =RA
M# ?CBM3POJL6M:!IU]"?DG@1Q[' R/P-2]P-8=*6BBJ **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /RV_X+D_\@CX
M._\ 7?5O_0;2BC_@N3_R"/@[_P!=]6_]!M** /U)HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BD-(T@5@,C)[4 *WW3CK6=I5E>6OVC[7>&\+S
M,\9*!?+0GA..N/6M$'(I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH _+;_@N3_P @CX._]=]6_P#0;2BC
M_@N3_P @CX._]=]6_P#0;2B@#]2:*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!",BFF,%@2!D=Z?10 @X%+110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y;?\%R?^01\'?^
:N^K?^@VE%'_!<G_D$?!W_KOJW_H-I10!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tmb-20221231xex10d22006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231xex10d22006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 2M Y,# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*82^.
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M7 DHJ/>W]VC>W]VBX$E%(*6FG< HHHI@?G'^UC_R7_Q1]+3_ -)(:*/VL?\
MDO\ XH^EI_Z20T4 ?HY1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )BC%+10
M 4444 %%%% !1110 4444 %%%% !1110 4444 %)2T4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'YQ_M8_\E_\4?2T_P#22&BC]K'_ )+_ .*/
MI:?^DD-% 'Z.4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!^<?[6/\ R7_Q1]+3_P!)(:*/VL?^2_\ BCZ6G_I)#10!
M^CE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 ?G'^UC_P E_P#%'TM/_22&BC]K'_DO_BCZ6G_I)#10!^CE%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?G'^U
MC_R7_P 4?2T_])(:*/VL?^2_^*/I:?\ I)#10!^CE%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?G'^UC_R7_Q1]+3_
M -)(:*/VL?\ DO\ XH^EI_Z20T4 ?HY1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'YQ_M8_P#)?_%'TM/_ $DAHH_:
MQ_Y+_P"*/I:?^DD-% 'Z.4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!^<?[6/_ "7_ ,4?2T_])(:*/VL?^2_^*/I:
M?^DD-% 'Z.4444 5;>^BN+B:%&+/$VU^",'&<>_X5:I@0*V13Z "BBB@ HHH
MH **** "BBB@ HI,TM !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?G'^UC_P E_P#%
M'TM/_22&BC]K'_DO_BCZ6G_I)#10!^CE%%% !1110 4444 %%%% !1110 4U
MFQCFE8[5)K/N-5M8V,<EQ#&P[-(H/;U/N/SH Y32_C)X2UO6+RQM-=MS-:/Y
M,WFYC59@')ARV 9 L;N4'S!<,1@@UUFAZW8^(M,MM2TR]@U#3[J-98+JVD$D
M<J'HRL."#7G>L_!SX=^(=;;4K_3[2XOX]5;7&D%S@K=FV^S&0@-_SR^7\,UU
M'@#POH'PZ\)Z1X9\.HEMH^GP?9[.V$WF%4!S@$DDXS^&: .CO[V/3[.>YEWF
M.%&=A&A=L 9.%4$D^P&363X*\:Z5X_\ #MIKNB7+7>EW88PS/"\+-M8J<HX#
M#!!'(%6KO7M.MSLGOK:W8C@23JAZ>YS69X<;P[X6T:RTG2[JRM=/LXEA@@2X
M4A%'0=>?K0!T[':I/H*XBS^,O@Z]O]0LH_$EC]JTZ=[:[1WV>1*DGELC[@,'
M=QCOVR.:Z)O$VDN63^T[,,HR0;A.!ZXS7GOB'X9?"SQ)/=3ZK8:-//>2127$
MGVA8WG,<S31[R&&[$CL>?7'3B@#U=3D9I:R;;Q/I5S,(8=1LYI2<!([A&8GT
MP#[5/_;=EE!]J@RXW*/-7YAG&1SS0!?HK,C\06$R.\5Y;2H@)9DF4A0!DDG/
M''-,'BC2GP%U&S))V@?:$Z_G0!K4E8I\::&B*SZO8(&S@F[C&<'!_B[&JQ^(
M7AL(C_V]I6U^%/VZ+!YQQ\W/- '245@MXZ\/Q3>2^MZ:DN,[#>19Q]-U-O/'
M6@Z<I:[UC3;1!&LI::\B0;&("MRW0D@ ]\B@#?S2USDGQ"\-PW1MI->TI+@,
M5,37T08$=>-V>U1P?$OPM<.BQ^(=(=G#%0FH0DG;][&&YQW]* .GI,US1^)7
MA5=F[Q%I2E\;0;^'G/3'S<]1^=5$^+W@N0J%\5:&=TI@7&I0\N#C:/FY.<\#
MTH [&BN)F^-7@.UM)+F?QCH4$"!6:234(E !.%/+=SP/?BH(/CM\/KJ#4)XO
M&6A26^GPBXNY1?Q[;>(L4#N<\+N4KGU&* .]HKSN[_:#^&^GK"USXX\/VZ3(
MDD3RZA&JR*_W"K9P=W;!Y[5-#\=? %Q:_:8O&&B20X<F1;Y"H"#+$G/ '<F@
M#OJ*X>/XU>!I[JQMHO%FB37%^Z1VD4=_&S7+,I=1&,_-E03QVK$_X:@^%(TO
M^TF^('AV/3C+Y"WLE^BP-)N*[1(?E)RK# /:@#U.BO+W_:<^%46[S/B!X=15
MB,Y?^T(]HC R6+9QC'O4<O[4'PLB\L_\)SHLJ/.;820W'F() %.UF4$*<,O7
M^\* /5**\@L_VN/@[J,L"6WQ&\/3&9)9%9;U2@6+B1BW0!<C)/J*DO/VK?A/
M8:M+I<_CG2$U2.2.(V0E)F+2$",! ,G=N&W'7(Q0!ZW29KR+5?VM?A)HFKSZ
M7?\ CK2K34K=T2:UE=A)%N("%QCY0V1@GCFHY/VN?A+#IM]J%QXTL+.TL4B>
MYDNUDA\E9<>46#*"-V01GJ#GI0![#17C=I^U_P#"*^U#[%;^-+*:Z"&1HXXI
M6** &W,=N%&UE;)QP<]*EN/VMOA';6TEPWCK26A6WCNMT<A<M#(&*2* "64[
M&Y'3'.* /8*3->0WO[6'POL;JWMG\2K+/<6LE["MM:3S>;;I]^5"L9W(O=AD
M"HT_:U^%\E[JMJ/$+++I7E?;2UA<*D'F+NCW,4"_,.1SS0!['17CJ_M:_#&2
MYTZ"/7;B2746"V@72[HB;)(&TB/!!*D9Z<4FF?M9_#36)+);?5[W;>PM/;/+
MI%Y$LBJQ5L,\0 8%3E3@^W(H ]CHKQNS_:X^&-_<FWAUNZ,XB6?RGTJ[1C$P
M;;( T0RIVMR..*GD_:B\"Q06UP\FKI:W'G;+@Z-=&/\ =(KR981X7"NIP<$Y
MXS0!Z[17C]M^U1\/[S3;N^@O;V6&"9H%5--G+SN(C-B)0F7)C!( Y/ ZG%9$
M7[9GP^N;B2WMHM?N;B.&>>2"/1+CS42#:9B8RH?Y=ZY&,^F<4 >[T5XQ-^UE
MX#MM.&H3OJMO8R2PP03S:7,GVF21-ZK$I4,YVX) '&X9ZU0UO]M3X6^&].BN
MM2U/4+61Y9(&M&TNX\Z*2, NCJ%PI7(R2<#(R10![M17C$/[6'@QTUT36FN6
MUQI 9GM9--=I;D 1D& +GS0WFQ[=O7<,46?[5GA"Y:U%Q8Z[I9NKUM/A_M+3
M6M]\RQAW'S'@*" 2>A- 'LU+7B?_  U;X82.66?1?$-K;(R1BXN+%4BED=V5
M(XW+XD=MC$*I)(&<8(RE[^UCX6L?[<<Z)XE>TT6-7OKL:85BC+*K1Q@LPW.^
M] % )RP!Q0![;17A6I?M=^'=(T?5[VZ\*>,(IM+G2*XT]M* NO+:-Y//5#)\
MT0$;@N#P5(KF6_X*&_">(6HG?6K>:4H)K>336\VT#(7#3*"2B[ 6+'@ <T ?
M3=%>#ZY^V#X4TC5(M.@T'Q-K%W+HHUY8M+L%N&-L6*@#$GW^/N=<<UG:A^VK
MX3T:RM;B_P!)U.TDO1*UE9N]NUS=+$@>39&)2=RAERGWCG@&@#Z)HKYWT_\
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M<*HY)XQ5&_\ VM]-TV>+S_!WB/RE6X:\BACBEN=/\E"[">!7+(2H! Y/(XH
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MOIUK;/%>2Q6_D)'>2,=K,[".9D0'R]P+ D5>UW7H8M!L+75K:T/B#3+&*_\
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MOC 7 *-N!5?E!!)R16AJ-]?^(;N_T/6_#ESXU>*WGN;NTMM5D@ATU'E#QH[
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M045;<*'5 BE@<9S0![@*6D P*6@ HHHH **** "BBB@ HHHH **** "BBB@
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M.G7';>,?VM]$T/4[JVT(:-J48U"STR/5KC5$M[%KB2&2>9'F"G:8XXP>G)D
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M;_DGOAGC'_$KM./3]RE=+0 4444 %%%% !1110 4444 %%%% !1110 4444
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M1!M0+VVGUH V?ACX,_X0/PO#I<EX^I7SR2W=[?2*%:YN97,DLF!P 68X Z
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M]8?AK@_#SPQCI_9=ICG/_+%*Z:N9^&G_ "3OPOT_Y!=IT.?^6*5TU !1110
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M/AS;?$/X4ZU:KH5MK>L11!K!98%>2-_,7)C8\J<9Z5YKXG\!>./#_C7Q3?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'A^PD:,G)4F!.]>BUY9^RQJC:W^S9\+[]X1 UQX;T^0Q+T7,"<5ZG0 4444
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M\:Z?^UUXVU6_T'6Y=&T71_#6IZ%)J-E8R:EYDEQ*U_'9Q-/+Y>(8E\P.Q7.
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M7PYTG5-:>)]3F>=9S NU,I/(@ 'L% H [FBBB@ HHHH **** "BBB@ HHHH
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M2WEGVR2?QK&M/A7X4L9[2:WT#3X9K2WBM+>1+=0T44;!XT4]@K*I'IBNLHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F
M/)L(XS3Z9(!@<9.: /G^T_:[L+]/!TD?A+6!!XGN$CMF9HBT44EP8(9Y$5B5
M1W'4]!^54/AO^UU'K^H>"]"UGPW>PZ]K=K;RW4E@IEM;-YWN! K-UPRV[,3V
MR.]=6WPF^#TL&E7#V.CF+P]Y-G:R?;V"VVR8S11MB0 D2EF4-D@GBM/1_AE\
M,+7Q%87^FZ?I1UC1I9+> Q7)9H)&>25D*[\$@R2, P)4,=N!0!Q7Q:_:AN?"
M]KXVM?#GAN>_U+1UNK&TN[F1$MI=2BM%NC"RYW!1&ZG=T)!'O6=\2OC9XZ\
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M";SD/5F=+B)BRY]3TH ]Y649QC'TI3*HZD5XGXF\?>&+?6I+J/XA:L'O+_\
MLY=/TZ6*2*&YC@F<QC=&2NX02<EL%EQFH)-8\/:QHUQ%+\6M9T:Y^P1ZA-NO
M+6.XLXFVX=LQ%1RZ@@Y'(]: .@^(7Q>OO#/CZR\-:7I%G?3OIQU*>:]U!+3$
M?F>4%0,/G;/)&1@>]>,^%_VE_&N@^$?#MOJ?AY/%FOZE:I<2W"7:6T8GDL'U
M#RD4+_JTC41@\DMCZU[?>:G\/+WPII/C36KO1-7T_3HP+3Q+J4<,A0[@A99"
MORL77D+CYNU16^N?"W27*1W/AZV;3[./4-P*#R8!#Y<<H/91$0O^Z<8Q0!X7
MXO\ VAO&TWB2[O=&DT>Y\(RPVLUO;79"F6*6>VM9=S@9P))I1D=U([5[G\"?
MAR/A)X1E\/7,VG_VA/>W.I26VG%A;QK)(,"&-SE$ "C'3=D]363/X\^$.I2-
MIT[:%-9'2EN?.>%#;/;-=M&(U;&"?M$3?(.=PSC-:=Y\4/A_'XKT^]@N;/4]
M8:Y70&O;+$CVGF+),$E.?E0F!N>>5([&@#E?CG\:]6\&?$GP%X8TLK8VFI:M
M:VVI7]S:/()%N#)%%! <;3)O7>Y)&U4']ZO1?@CXPU#QO\-]-U+5A'_:RR7%
MI>-$,(TT,SQ,R^S%,CZU:\/>)O"?Q3TYKW2+^P\06=I=#$L!$JP7"#AE./E<
M9R".>>*UO!7A'3/ OABPT+1X3!IUFK+$C,6;EBS$D\DDDDGU- &Y1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ?G'^UC_P E_P#%'TM/_22&BC]K
M'_DO_BCZ6G_I)#10!^CE%%% !1110 4444 %%%% !1110 C?=/:O@/\ X*!V
M=K?^,[ZWG=K$GP6;E;W!.PPZ@'554$;I#DA23A-Q:OON0$H0.#7P/^WEI/V_
MXH?9KEGDM=1\)6]G#&LNS_2/[8B9.JL,-D*>/NYSQ0!\>ZSHWA[P];^'9[>3
M4+V&]@$EOI^HHDM_I=U)/&S"Z>%@I@D10RL2&(# YYKUKX/W>C>'/&O@E-/C
MM;S48=2-L)K;Q1]LMHTDMS]HG%JRKMC7RV Y)#A2"<5Y/XDM=(TNWN9[[Q3?
MWNM:RL5AJD-WH30V]N\4,\R! K'S45X_)4@;MH9@.0*Z#X!7:7.L^'X;;4=+
MN;VSO8M/MM,DT7RIIXGN,2B5F5B\*PK,%"X9-R''6@#]/?V2!C]F?X9_-N']
M@VN&/\0V<'\>M>NUXY^R!*LG[,WPWVAE1=&A105Q\JY48]L 8]L5['0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %1S+N"^S _K4E-?H/J* /D'X-?LLZW'X8\(
M76O6VD:;):75I=76D/:N3*(;NYG,DN3AISYR@,<@ 'V T])_9#U_0=#U,:=X
MFTJQ\0K'#%IFH1:<X7*7%Q(\]TI<F29H[J2/(/0#Z"+X>^/_ (HZ=J6DVD\:
MOI5AJ^GZ3>6,^G2F65+@3--<K.[$X5MA QP,Y/(J+QA?_$RS^+7C*XTG5-42
M#3;N\N["!['S;3[-_95J\<87^/=<+, 1R"6&.E &CKW[(VH3P+;:1JVA);)<
M;4BOM,9OL]LMQ:S(82K#;-FW8,W(;>N1\M:_PT_977P/XE\>ZA<ZR)D\3:?<
M:8K6PE6<)+/-*9'+,5+KYVT;1T7KVJQ\)OB1X\\3?%Z[TW7XU@TE8+F:2Q;3
MI4-J \/V5EF*A3O1W+*6)R.,8->::#>_$#P5)XENI-4\1++?7DL=UJ$ME)>>
M0RW6H^08(""-DFVU1L  *0>,YH V)_V,-:O?!5QI%WKV@2W*WL)MHX-+EMK-
MK:/3VL<31I*&,IC<ON#8W #&*Z;Q-^R-9Z[97UNMWII%S'J21O-IX9HQ<Z?'
M:1\DDDQM$'!/3.!TS7)^+OB9\9],O;N2R>=-7_L]I!HIT1I+2.$62R/=)*.7
ME6<[1%N^8?+C(S6Y\9+KQ[HDW@VXDN]4MWTC4+F.WUC38/MLFJ[].E"/<6T:
M!8@9]B[3D=.03F@ _P"&0KZ]\5:AJNI>(M-U"WN,((7TS#,GVBVF(D^;:QS
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MZP2$#CYH]IR.M>AT %%-D8JA(!8@=!WH0EE!(*D]CVH =1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(^\V<\8V** $I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _./]K'_DO_BCZ6G_ *20T4?M8_\
M)?\ Q1]+3_TDAHH _1RBBB@ HHHH **** "BBB@ HHHH *^+?^"@AOT\0^%7
MLIQ:)_PB_B%9[D+N>)3+IJHR#ID.4^\",9^M?:5?&G[>-U/8^/\ X>S6GVG[
M;_PC_B$6JV98SO-OTX@(@(WG&X[3QQ0!\!ZK,3>7VFZVUTC:S?QG59;"%I9F
M2*"6&6XMLH 65NFQMFUG)SU&_P"!M'DAOI'TC1M2U*VL_)AL],NK';"S2W-L
M0"5Y!(B:02#*L$V]6K4\2>._$6DW=I&VIW3G0DFCOD_MNX$<A4*PV@$AHR'
M<J?E9@#6]\+/$^OZY?0:6SZK!.#),VLZMJ%Q$%CAD1O)6%)5:5&'E\#&T9;M
MR ?H;^R([O\ !*R:0HTK:OJY<QG*DG4;CH:]IKY]_8;00?L_:? $$8@U;5(]
M@8MM_P!-E.,MR>O4U]!4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YQ_M8_P#)?_%'TM/_
M $DAHH_:Q_Y+_P"*/I:?^DD-% 'Z.4444 %%%% !1110 4444 %%%% !7Q!_
MP4/%RGC3P%<V;K#=6GA;Q5<QW#3-$82BZ?E@5Y)P2,=\^M?;]?%7_!0>^O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(F/(SQ4OAR+X:^/-/\/>*M.^PZA!;HUEIE])(=RK;2[BJ[CD[)(-W.3\F>E
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M'J* 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YQ_M8_\ )?\
MQ1]+3_TDAHH_:Q_Y+_XH^EI_Z20T4 ?HY1110 4444 %%%% !1110 4444 %
M?&?_  4(N[S3-3\&7T<,$EI;:#XDDW3J"HN%@M7A!SV(23VX'I7V97R!_P %
M";H6&G^$+OR(;EH;;6G5+G/D[A99!<#JN0,CI0!^='BV6[L)]3TO17GTRSMK
M-I9+Z*T@>Y\J]"%K5<(%1I)1D,",* !@&J?@;09=;ETO2M%LI'U&^6<3&XC
MD"+AI@L8!$?F%3\H.Y\,1Q73ZCX7%SJ7A_1M-TR'_A([07GB&[TZ>=O.O+9'
M5X8T0L4EDR9 L9!8I&IR,8-K2/ EAX6\5ZGI7B#4%\.-;O'%<7:2/-/8.\<4
MZ.T88AR),0RQC+1HV01S0!^G'[&J10?"W6(8$>.WB\4:Q'&DJ;'51=O@,O8^
MU>\U\^?L63W$WPZ\4I>3P7%U%XQUE)7M498=WVDD[-W)7G()YYKZ#H ****
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MR><T >P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+6(&-9),DNK,JCT/U%J$&D?%#P.T:74L^CZM:K(ES93O [QM\RLCH0R_@0:
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MP^J_'_XCZMH]IKNFW][::='<Z5 UM!X;DDGNI'L5DN8EW*=N9V*@D  @@,*
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M K"QBW;C&F[);.T=3W^OO2?84 QL3&[=]P=?7Z^]6J* &(I48I]%% !37(4
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M_:Q_Y+_XH^EI_P"DD-%'[6/_ "7_ ,4?2T_])(:* /T<HHHH **** "BBB@
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M'2K&WT[RKJ5?LUW$UKNE51\J#$$@&,DY /&:L?LQ_#WQ+HWC_P 1OJ?AZ_\
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MQ=6^HPVXA55>$PC8P5GY5E8@A%+8SFOTZL/A=X$U:1)9/!OA6[B5A+:R1Z9
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M<=ZR;?X?_$"+]J/2O%E_8V,GAJ--1L89K:\(6VLY$C9-T6T9F>8,2<GCC/%
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M8 ZCH#^&:^&;W]F'Q/X '@?1=/\ #HUZ]ATC0K.;5(8GDAM+VVU&.:\N$E+
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M[.2?Q%:6_P!G@N)+B1HXQM*EQ%NV!]I*[\9P<4 =FG2O'OVA/C7=_!B'P?\
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M5U;RK/!,JR1RH<JZD9# ]P1S5J@ HHHH **** "BBB@ HHHH **** "BBB@
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M('CW3YM2T76= T>=((+O2U96AG+R;[=\L2Y6,1$OA1N8@ XS5?\ :H\?^+/
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MAY//8J%B=\A47)R0<XH Z'5_V,]*UC^T\Z\Z+>_V^"QL(RT8U.&"(X)//E"
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M-4GE\1:C=QW\D[RPM%&JXEU3^T2N1SP^8_\ =.>M9NO_ +$=CXI^'4?@R_\
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M^FO;27TXTZ2UDM8KB8.@-O8O9H& 4;@8I&W>I/45XKJ/QB\>^.-8\'Z@HO\
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M=6'YU\@>-_$_Q2-UJ&JFQGOKC3/$NHP:/;1V$@2VCBTF1HYCM(,RO.Y4;N.
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M)]S0!.2!3$GCE9U1U9D.U@#G:?0TYUW#CK4-I \40$I1I3R[(NT,: +%%%%
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MOR],*.*46<(*D1@;<X&T<$]35BB@"%+:-%"J,*.@["C[.A<-CYAP&QR*FHH
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M6277+QC!)M*[ES)P<,1GT-)+^RIX"G<L\>NON.6!\0WV#\NW'^MZ8XQ7L5%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _./]K'_DO_BCZ6G_ *20T4?M8_\
M)?\ Q1]+3_TDAHH _1RBBB@ HHHH **** "BBB@ HHHH 0C(H"@4M9VOZ_8>
M&-+FU+5+J*RL8 #)/,V%7)"C)]R0* .9^*GQ(A^%WAS^W+G3;W4K-;F*VE6R
M4,\9D81QMM."09&13CINST!KE_"?[3?@KQ?XGTCP_IM[/+JFHWNH:<$,#!([
MJR1'N(F8@<@/QZX.*UK[XR^!;J"1+G44FC">>8Y+61@54YW;2G8C/X5DZ?\
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M^@_MX?%/4-9M-(GTSPJ)[VVN9H;I3)Y:F*%)BT@W9"E1-TSR%'>J=U_P4?\
M'27EBMOH6@M'J-]?P6<%QYT<[0PQ@PR'G"^8YQ@G*@@T ?HYY@Q2[Q7YM6O[
M?7QKNUTCS_"OA714O#<6\DMX9W5;B*$S"-54Y)<#8..O/2J%A_P4)^+]]'OD
MM_!"A9VACBMH+RY:^(8*3#MP"%&68Y_A/% 'Z9^8*-X]<5^:ES^WK\8-.TA[
MN_B\-6S3,(D4Z3<#[(2A/F3L9=J*&"\=2&!%3C]O+XMZEK>E6^BR>";JSO\
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MOXO\/V%[JNEQV=_XDT[3Y(Y--"RQQ7$@7RG.[Y6V'>'QCG'6F!^F]%-3O3J
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MM!<1>9&K[B0QX/(/;D"M>X\=?$&:WV#X63RB5&#H^M6FT>Q^?H:YWPQ)XN\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^2_^*/I:?^DD-%'[6/\ R7_Q1]+3_P!)(:* /T<HHHH **** "BBB@ HHHH
M**** "FO&) 0PR",$$9S3J* (DMHT(VHJX] !3A$J\*-HZX'%/HH ;L]S^=+
MCW-+10 W;[G\Z F.Y_.G44 -V#U/YT*FW')/UIU% !24M% "8HQ2T4 )BC'-
M+10 F*\7_:;L_$E_H7A&'PQ?WNG:@GB*VN6ELHR^Y(4DE\N0#_EFY01G_?KV
MFN-^)_Q-T#X4Z'9:OXBN)+6QN=1MM-69(F?$T\@CCW8Z+N(R3P.] 'Q_KWQ*
M^)OA_3_&GBW05U\:CXIN;/5-/T^ZTQYAIMO]AD:.V=,-Y9)C7=@9W/C@G-=5
M>>/OBEIOB[4$T2"YM[6&&+6[JS;3))UO)I+BTBEA$C-F,!&E;:HR-N?6O?K?
MX[^"1XA\4:-<:];V%UX<NH;/49;UQ!$LTL7FJBNV QV') /%7%^,'A.#4)[.
M]UJRTJX2Z:TBCOKA(3<,%C(:++?.I\U ".YQ0!\R>$/B#\5/#.H:)HD]YK.I
M^5J]U'?_ &S2'D$T1UFXC<"95.=EMY9'W0!@Y-=)\*=:^*6G^)O HOUU%/#U
MUJ#Z7=Z1)IA2.VMS8O<+<-(27!\Y0F3Q\Q7K7M^C?'/P-KMG'-9^);!C-=3V
M4,,LXB>::*5H755;!/[Q2H/0FCPC\:?"GC"]TO3K?5+>UUR_MOM4>BW,RB[5
M,$_,@)[?-].: /F?Q)87OB3QO\7H=-F\;>';1;&ZM6<65W=27\K30&:>!<A!
M'$B%8DC8,V]SVP67W@?QCXD\%>&]5TM-:T&=[B]T;3]/B@N8&DM'+NM]*KNQ
M@+1!P5D#$G8%VDU]#7W[0FAV7BK6?#G]DZ_)JNG6DMY';QZ;)F]CBDCB<V_]
M\!Y8QG@')(. <<['^V!X">WTV9VU&*.^-TK%K1CY#6\OE2!\9S\_ VYSUZ4
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M#LQG)-10?MD>#;SPDMY;V]W+XA6PM=0N/#S1^7<0K*8=Z%F 1FB$Z%P#D9H
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M(XHV<!3ZMMP,XH \CB^"?CCPQKNN0V5C>36&H_V-<RWF@&'37DLH=XN+,(A
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M^S.SP3(LA5)HV8 E'4!E) X-=]0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'
MFC;2T4 %%%% !1110 4444 ?G'^UC_R7_P 4?2T_])(:*/VL?^2_^*/I:?\
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M&.T\NQRD0 .\A[MOO?W30!MZM^RMJU[K\-U;^*;2'3DU674OLAT_)4MJ37P
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MF<H./X1W- '5^)_V2= \2S_$>5]9U"T/C2YL[MA;[5.FRPL&9X">AD8$L?\
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MH *AN9%AB9V95102S,<!0!DDU-5/5K*#4K&:TNHEFMKA&BEC;HZ,""I^H)%
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MZ?X="MIVA1)B%)A;O;B1GSEL1R,.1GWH Y#6/VE?$GAKQA=:?J\.DQZ5X?\
M$5Y'XEN@61K'1=J"SN>3]YFF0L>F%;TJHG[5^NZ9X3_L;5-(CB\=MI37D<\2
M[[(3F(W*0.H8LI\@J.>K9[8->[:S\&?!FO7_ (HO-0T*WO+CQ/IR:5JSRY/V
MFV0,%C;T #'D<U4N/@'X N_$<FO3>';:35'C\MIB[X8"(0Y*YV[O+4)NQG
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MCWS[5[10 4444 %%%% !1110 4444 %%%% !4<Z;TQ4E1S$@#'KSGTH \_\
M@S\,5^%&A:OI,7V9+.YUJ^U*VAM4*I#%-)O"8]1DY^M>B5YW\&_B/>_$S1=:
MN]1T<Z'=Z=K5YI+6C2B1L0N%5R1Q\P(./>O1* "BBB@ HHHH **** "BBB@
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MN%R4.!G.,9JWXE\"^'O W[3/P670?#FEZ!Y\?B"!SIUHD)E06D+ DJ!W7H:
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M%9XG(^[)M8,%/)&?2OG[7OV+9=?\/Z1I4FL645G:I!#-:);NL4BC3ELYVPK
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#\X_P!K'_DO_BCZ6G_I)#11^UC_ ,E_\4?2T_\
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M9%VA5! R<@D@UTGP<^&/B?3_ (P>+]:\1Z7J6^[T)].GU"]N_/AO)3>S2*(
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M@IU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y
MQ_M8_P#)?_%'TM/_ $DAHH_:Q_Y+_P"*/I:?^DD-% 'Z.4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^<?[6/_ "7_
M ,4?2T_])(:*/VL?^2_^*/I:?^DD-% 'Z.4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!^<?[6/_)?_ !1]+3_TDAHH
M_:Q_Y+_XH^EI_P"DD-% 'Z.4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!^<?[6/_)?_%'TM/\ TDAHH_:Q_P"2_P#B
MCZ6G_I)#10!^CE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 ?G'^UC_ ,E_\4?2T_\ 22&BC]K'_DO_ (H^EI_Z20T4
M ?HY1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'YQ_M8_\ )?\ Q1]+3_TDAHH_:Q_Y+_XH^EI_Z20T4 ?HY1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YQ_
MM8_\E_\ %'TM/_22&BC]K'_DO_BCZ6G_ *20T4 ?HY1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%(3B@!:*0'-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YQ_M8_P#)
M?_%'TM/_ $DAHH_:Q_Y+_P"*/I:?^DD-% 'Z.4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M2$9I:* &HH3.,\G/-.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\X_VL?^
M2_\ BCZ6G_I)#11^UC_R7_Q1]+3_ -)(:* /T<HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\X_P!K'_DO_BCZ6G_I
M)#11^UC_ ,E_\4?2T_\ 22&B@#]'**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _./]K'_DO_BCZ6G_ *20T4?M8_\
M)?\ Q1]+3_TDAHH _1RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **8\H1@IZFG Y H 6BBB@ HHHH ***1ONF@!:*A@,QD
MF\P((]P\O:>2,#K^.:FH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *3.:1UWJ10J[5 ]* '4444 %%%% !1110 4
M444 %%%% !1110 4T.I. 032GI5!-)"ZLU^9Y2QA$/D[_P!T &)W;?[W.,^F
M!0!H4444 %%%% !1110 4444 %%%% !2 YILG(( R<54TE[J6T1[R%;><YW1
MH^X#DXY]QB@"]1110 4444 %)N'J*&;:*R8;4W6JW%V6N8BH^SB)V'E, 0WF
M >ISC/H* ->BD%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% 'YQ_M8_\ )?\ Q1]+3_TDAHH_:Q_Y+_XH^EI_Z20T4 ?H
MY1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0
M364,]S!.ZDR0[MA#$8R,'COQ4P&*6B@ HHHH **** "DZTM% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 (0#UH"@4M% !1110 4444 (0#UI @7H,4ZB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\X_VL?^2_\
MBCZ6G_I)#11^UC_R7_Q1]+3_ -)(:* /T<HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\X_P!K'_DO_BCZ6G_I)#11
M^UC_ ,E_\4?2T_\ 22&B@#]'**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH _./]K'_DO_BCZ6G_ *20T4?M8_\ )?\
MQ1]+3_TDAHH _1RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MI*6DI,#B[_7I-9\9+X=L;CRUMHO/OY$^\ ?N(#V)Z_2NNMK9+>((@VCT%>9^
M #O^*GCAG4+(94&.^  !^F*]2K*.KU&Q:***V$%%%% !1110!^<?[6/_ "7_
M ,4?2T_])(:*/VL?^2_^*/I:?^DD-% 'Z.4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4E+10!YKJ=G_PA_Q(;7GWKINIPK!.ZKE8Y1T)],@#FO189DF0
M,A#*PR".],NK.*[@:*:-98WX9' ((K*MO#TVFDK8WLL4/402_O%'L#U K.S3
MT W:*@CAD55WR%CCG QS4PS5)@+1115 %%%% 'YQ_M8_\E_\4?2T_P#22&BC
M]K'_ )+_ .*/I:?^DD-% 'Z.4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!^<?[6/\ R7_Q1]+3_P!)(:*/VL?^2_\
MBCZ6G_I)#10!^CE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 ?G'^UC_P E_P#%'TM/_22&BC]K'_DO_BCZ6G_I)#10
M!^CE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?G'^UC_R7_P 4?2T_])(:*/VL?^2_^*/I:?\ I)#10!^CE%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?G'^
MUC_R7_Q1]+3_ -)(:*/VL?\ DO\ XH^EI_Z20T4 ?HY1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YQ_M8_P#)?_%'
9TM/_ $DAHH_:Q_Y+_P"*/I:?^DD-% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tmb-20221231xex10d22007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231xex10d22007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1> W<# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 QE)_QIP&*6B@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,4M% !2
M4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !136<*I)X YJDNMVCOM23S3G&8P6
M&?J* +]%,20/[4^@ HHHH **** "BBB@ IKL%&2<4ZJU_#Y]K)'O,>Y2N]>J
MY&,CW&: )1,N<9Z]*>&#=#FOG'4]%^/VAZ:]MH>J:+JS_P!BWW^DZFH\YM16
M3%IM (7RVB4;L]&9CGM7T#I'V@V%L;M56Z,2&4(<@/M&[![C.: +I8+U-(KA
MLX.:YSX@Z?JNJ^#]:M=#NI+/6);61;.>)E5DFV_(<D$#GU!JWX/L+_2_#&E6
MFJ7K:CJ4%I%'<W;@ S2A0'<@<<MD\4 ;).*;YJTK_=/I7@&DV?QUTR6[DN)]
M$U&*348GAAED"E+-II3(A(Q\ZH8L'TSQF@#Z 5MPR*6HH/EC_&I,^QH 6BDS
M[49]J %HHHH **3-&?8T +129I: "BDS1F@!:*3/M2T %%)GV-&?:@!:*3-%
M "T4F?:C/M0 M%)2T %%)1F@!:*0-FD+ 4 .HIN\4NX&@!:*;N%&Z@!U%-W"
MC>* '44W>*-XH =13=PH#@T .HIN\4GF"@!]%-\P4GF"@!]%,\P4>8#0 ^BF
M[Q^-&_KQ0 ZBFEP*0R =J 'T4W>".AI/,% #Z*;O&*-_'3GTH =13=XSBD,@
M H ?13!*#]?2EWB@!U%,\P8)]*/,&,T /HIF_P!J0R@#)[4 245%YN2!C!]#
M2B89ZCTH DHJ(SJ,^U'GJ3M'WL9QF@"3-&:A\\#KBFF[0'!*@_6@"S14'VI%
MSEAQ[TT7D;'Y2&.,X!YQ0!9HJJ-0A.?WB<=?F'%(NH0M_P M4'MN% %NBJQO
MH<X\Q ?=A2&_B /[Q#@9/S#B@"S1FJIU"(+D21XQG.X8Q35U2W9MOG1%CD ;
MQDXZ_P Q0!=I*JG4H",B5,9P26'%)'J4$OW)8F_W7!H MYI:HG5;=0"TL2YZ
M98#_ #V_.I%U" C(D0\XX<4 6<TM5#J$0)&^/(Z_,*!J$+$ 2QY/;<* +6:6
MJJ7T,C%5DC8CJ P)]Z6WO8KDN(V5RAP=I!P<9H LT444 %%%% !1110 4444
M %%%% !1110 444UNI^E '#ZYJ$_B;Q>/#5K,]O:VD:W&H2QG!8-]V('MGJ?
M:NPL;""QMUAMXEAB3A408 KBOA[F7Q;XXGE7$XU(0Y/4H(U*_H:[^LTK[@(%
M I:**T **** "BBB@ HHHH 1ONFO(_#WBGXB^,X-1O=.@\.6UA'J-W9VZ74L
MYD*0S-&&?:A )VYX]:]<->7_  !,H^']VLI!?^V]6 ^GVZ;% #YS\4$(CC?P
M@9-I)1YK@'IP?N9QFLSQ3XS^(?@^XT+[5:>'+FWU35HM+7R[F=&0R [&YC.>
M5Y'O7 IH/BYOVP)=5N-%U7^P1,JP7P4M:&T-AM8^8&PO[_CRB,Y^8&O2OCNR
MK;^ LG:!XPTS!]][4 3W=]\5WN@UOI7A.*V#KD3:G<%F3^(Y$'!]!C\:;:ZC
M\5XKS?<Z9X1:QW,Q\G4KG?Y?;&8,$_I6[\4;N*U\#:I<2Z;J6JI&F3:Z2C/<
MMSC*(I!8C.=HZXJA\%9K_P#X5!X8_M?3KO2]073D2:TOCF=" 0#)Z,0 Q';.
M* .5\'>/?B;\1O"NG^(M'T?PO9Z?J*1SVZ7FHSF14W$/NVPXSQQC\:VY;KXJ
MF\A5;#P@D.]MX-_<%V3;P5_<]=W7V-1?LRR$? 7P=\I4&S; (Q@>:^/TQ61K
M^B7EE^U#X0UJ*'4[JSO/#^HV5RX=S:6CH\#QG:!M5W_>#)R3T% #O%GQ ^)/
MP_T.'6M<T7PRVGQ7-K;W8LM3G+A9KB.'<@:$#CS <$\XKAIOVG?&=V=<ALM!
M\/6[:/>"&:[O=6D$$\+,X26(K"2RE5S['([5Z'^U%&]S\%M8CC\L2?;--(+D
M!1B_M^>>*^3M9\,G5?$T-E':7EK:W5Z9;;0KJ(VHTV#S) 8OW98W"EF)&
MP)- 'L.G_M@:YJ&NO9C1=&CM(9I9;J[74C(EI9^888I'(7EVE&"HSM')[BIO
M"O[7LNN^(X].DU'PL1=QVQLHX+FY:28W#2+$5_=8<'8.AZY'!&*\%T/4'LM
ML$NY+%$N-!\7PZC;S1I&OVB&83P%BO('F9V@=0,@\UK^%[.QN?%&F7]A9Z3J
M-RD'A&]:WEGS;6MA(&:\EM@6'W;A5;GD9/'- 'J$?[8GBK_A ;_Q,/#^DR6]
MI>75H ]W)$TQ15\HJA3<,R%D;/"$<FNG?]IO79-8UK2X[+28#I]K%=?VG=7#
M+92;E$CQK(,Y9$#9(X+8 -?/'AK46EU&[U*RO+"[L%N?%4&JZY-?H+K2)UN'
M-E:P(6"[9#Y;$$$/O.2,5MZI9KH]K90:I#9Z)HUS<>'OL5Q;W0:YU:YNID34
MUFA0G;"(I'4@X"[<YH ]"T?]L#QAJ'B.TT=M!TB2;4;+49K*XAEN# )[=RJQ
MR/Y> IV.2XR!A1SD5=U+]K/Q4-#EO=+T"VO9C;PS6<,L5Q"UZDAQY\:LN_R@
MWR'Y=V2ORX.:\^\$>(=.TGQC!&+B'2H1%JUEHVEZ?J'^CI$MK+Y9\USNB9RN
MX.>-V<=C6)=RZAH7B;5]:N]TEI8>!]9NM,MKKQ)_:YN]1BBBDY*@%"I.P@$;
ML\4 >I3_ +6?CBXUQ-(L-"T:XU%HM/?[-'<22.OVJ/?D@#'[O:VX ]UJO#^U
MUXPEOK**&/PW>6UUI4^H1W5O]HV2-!(5G4 J&PH4_-C!. ,Y%>4:#=^"[1_&
M+ZCJ=MIFFR:=H7B#4=-TN;:X=+!5GL(H\[D?S41\ YPQ%6/!_B;3?#_A+P/J
M%ZNG7FN^&_ &KS0V-S)Y<0OEND:*-F)##>(P0@Z@'KUH ]4/[6WC)[#2=4LK
M3PSJNDZA>P".ZCNI(XC;2R>6#O(X=2K@J1U*CO4&A_M._%O5;CQ1ITGAC1SK
MEK%+_9]C:>=(%F"JZ1SN^T#*')(^[QGK7C!N;)/AW81Q3Z;;Z7<Z)9RQ16V#
MK2^(I+WSKBV\HG<L*QM)QC 49SD5OW7CG23XULM=6'1]-\.MXQ\2Z0+G9MMM
M0M4TA&MI)&SF0F5,!LY)&!0!W/B;]K3XBQSR:OID?AW3_"T5Q91O)JJ3"81W
M,JQK*0F?D#Y3<,Y)!Z<T_4?VKOB+IMEXLU6YG\(?V9X?B!1;>29FU.>+=)/;
MQ9 *N(@OWAP6KR+6];@U+PYIAO[#3HWOK+PC>RSV]IY=QJ-]%J(EO[38O/[N
MWA7]WC@<]\UO>+_&'A+PU>:O?:??:>UI%;>([P23&%K&VN)8%;3XYEBRID8\
MKO(<J2"* /1?&'[4WC;1+76[RVU3P[]GL= @U:,&)G&7=565VW >2^X $9((
M8$<9/*V'[7OQ5ODBMHX=/N-8MH_/N;"'2Y0UW'N9BT#%N%$6UR6&!^E<EXJ6
MXN-&\9V5_'H\6M^(/ GAQKJTUJ%8;=;JW.^^B# @!T1@_EKTW @9KH?$GB;P
MSJ?B#P[J=GK>B75_9+XBM?M%@Z.RVTNF[;9,)]T%AQ&26&<$YS0!V6@_M6>+
M->\72Z'H6HV_B>X$GVSR8M+,,BVIVHT>/,;)C9E)E.%8G:.A-7/#?[07Q5U;
MPTEWJ9TC1KPW!M)H;RV-M);RPNZS!DE<??1[>2/!Y#$5\^>$C8*/%?@W4]0L
MO#6LWMGH-W=7^KH;".ZL[93;7%BSA\QLC;7P&R[ FM#QAHUE<B/1-0\8Z3KD
MK>&?#=I8>*KNZ MKZ6UUEC=/$^2?,\IX4P>6"8Y H ]=O_VD?BEI=D;2]U7P
M[%JJZ8IFFL[22Z@AO&OA$N0ART?E"4G'(9#V%9U[^U+\3M-UL1M=KJ)BO%TZ
MXTV#P]);RK.[*T*1M))B1IHB60#'('-<IJ=UX>NO!WQ"@B\0:1#9>(1XA2")
MY4MA%*#OT]HRWSR F.1E=2JKN;K4&G^/?#P^*.G>.;O4PL5[XI\/-;W4T9:1
MH+;27AOF /.R.210[X^4\]J .INOVM/B!<^';N\M]9LM,DU&4VVB7-_I8\C[
M2JAVMI#YHW/C*@J<%@R]12C]I_XFV5]K6CWWB'3WU6TNY8(/L>DAC]G2(2BX
ME5I5\LD'[A.0&#5YWHEC9ZC\*;!;YXKG43K=UX:B2SM5.FW,5O>M>3:A &(#
M.\1$>Y><Y [U%K'CO6=5L]"NX4TC3)/$'B'4++69KN.*[%J[!$$:MC<T**JY
M ) W!=QQ0!Z7IG[4/Q0\16FHW<?B30=#6V BN[75-+DC;2&\N*8R7+ABN-K,
MH5<GY@>F:3Q+^U+X]T+5[70Y_'7AN"9%DDU#5?L?[A%$ E40 MF9_F5608*[
ME)'->8>/M-N_ ]WK\6H^*-(O-<U2"RAA:6V>Y?5X[=V5;@Q$>6I$!,8D!Z1X
MQG)K)U.#PW9:QXAN+WQ3:2:Y9S3W<=[/ \D,R7,5J@&,?((HO,3?'G.5SDB@
M#Z'\-?'[QWXDBMK@>*K.VMK?0WU+4V^PQ/-$XCQ\D/F[BJO\Q/.5VXY-<]J/
M[5'C8ZUJNG6OB V]W;V\)634M+6TB@W0QL?,5VR9,F1E521A<'!KR3S3<>%M
M?_M54CU#0K:VU(6[:;-%&]F8I;9[625@K,_D.DP4'YW"<9%97B[PGJ4<^E>)
M;DZD=0\0AM*34Q:,R+IIM V;B%U8X51&V8VRQ/L: .YT?]I;XUW_ (UN++6/
M$<VBV,-[;6*HNEV[-([[50Y,N 78\J<;0W)K6L_VG?C ?",=]#XHTS4=1AGE
MGU6%;!!]GMT##_1E#_Z1NE5D!4]J\QBO]6\,WEO)9R'Q%HYB74;9KC2_WL@+
MI#B=0 @1IH!N;);:215BU,/@_3_'EK-.=/\ "MM?Q6^AZQI]C+)>Z5-\TD=Z
M[!<1QHK LIX(?..: .Z3]K/XD101SCQ_I=U_:[PV]G9/I/D7@6X<_9IHHRQ&
M0$<,KD<D5T^A?M"?$_5;7QA$/%UJEKH$\,$^I7%E",W2R2)/:*1)C<Q:!E[[
M,]SQXG?3ZG:0:+J8T2UO-<T!WL-.E:3[1&@6TSYI)V><TS2'8[$@#H>*MSZ+
M#9FTL[22VO=(26UUN'5+6$0V:H[B&&XF1"6=$FCN(V*J03ASD+0!["OQ]^)&
MK>'=9UP?$.TTS^R;2%Y;0Z6C%)2@1O-7=E%,I+@YX0<@5H6WQW^(/BCQW)%#
MXHFT;3C=2:6NF2V"B2TG*,$N)9B"CP&4 (5(+ D=1FO!]7C9].NH+JYL?$=W
M?R/%;K:6<CP7SW*CS!']UI%6)%<O)C[C;1UJ;Q1XBAU+X>^*;GQ#:S7FH:>U
MCI5W=6^R5[?[-:LL=['%D,%=V=-_*@L#G(H ]Q\+_%;XOVH^P:KXEMM;UB:^
MAM["ZMECAL]DMO)M%QM#$,'4G<IVYVYP#6)H7Q5\?^(I/*A^+-Q'<7$$VJ:?
M%:PP7#W4)9ECCC3RP7"HC2$\$D$8 %<-H>D:?X#BFEM_L5YI^D)!K]M]CL@E
MI%;21D10M-(,R2><L9#*"75G5:=?WT?]D6>DV6J2ZIXJUS1=+U;3KFPTUO/T
MZYMU(F 15 5',GELA()3&1DYH V4^-'Q733]%NX_B/)K-C>*[VVHZ>MND=UY
MMT\-NACD56#JD89E'W?,&>E=>WQ.^)GAKPK:2>*/'4UN=)NQ%JU_:RVK+,1?
M3Q&,':-K$"W&,$A68GFO.O'4=]:SVNBRM>:S8W%G?WEE NGQ"(!XQ'++]XNK
M12L6\M1E/*]2:RM,\1S^.M \/>'[:0'1_$4L,%MXBU/3E9;J6R\U;W$:IYBA
MMRLKN 24)/2@#T/4?BYXZT2?QN;OQW?:K-X9T"UU,/9W5NL-Y<3, B(51OE!
M+Y..2H%);_&#QOI]G;V9^)E]>ZG>:\VFW.ES6:)=V\8@>1)8VQA4+PR9=_E*
M\"N(U;4[/Q/IK>,M,TYH=!CBO]%DTRX5+?;!88D%YN48F4KO.W+?,^>U</X-
M\6Z=X[T:UUZ&[N]0#W#7U[;:==I;:CJ-BEM(B6D:G!,L;GSOEZH6H ]NUCXW
M:YHOB64:CX_U>_-@NGK>0:7)"EM=F[@.Z:U9N2(FQE&/).1P*T]*\?:QJ?C6
MX@M?&/BC4-"TVR_MJYU"*]B*2QQ6Y%U!M*C#*Y! SU1AGG->6Z-IVKI-H]U>
MZ.NN:?=6*7]YX>LV\VXNXWT[$UL8#RLZH$D5AG/S;1Q2Z+J-U=^$=?LY-%6=
M==TFXL+DVJI;W6GQ(JRS+,Q^[.;8D$$98GN30!Z9/\2/%.HKJU_!X_\ $=C>
MW,6GV=OI:&WGBLY[I0RQNRJ3NVN&W]BA&*P-3^)/CJ#0]0U&;XA:LVLZ7?M8
M7VCV=Q$^X0V2M(\'R R"*256D/ .W@X!K2U/7/$N@-:F>+3=)OM7U2.\$T4U
MM]EB5($39)*67*LFQ Q (+<5G:E;:G;^(GO(_#]K9:?IM[=:?!#";=(H+6:V
MCF$&<E2''W92Q+J.@H ;K?QEUI-4T#P7'XI\82WT$5O>WVKB3R3J%LPC"R@[
M-D<,DCY\U20%*@CFNBC\6^);+Q)!%=^-]674HK/4+J"R>\9K)XX98P[RS(I#
M,H8X13GA>/F-9.GZY%J[&WN]7@N[>^T.VDTF;4@D%Q)"UL\K06YCP(X6=H(@
MY(RT7 XY=;6-U+:0Z%#I,-U9Q2W-L)=+U)/M-G"MI"9)RK';<*TK,Y4$N  <
M9Q0!GV'Q-\2V'CN#PU-X_P#&MLM_:RSW&H:O'$J:=;2.!%*@16.[&X8E"[1A
MFP*Z2W\>^(;J[MM"'Q"U"W\5P%I=&@>[VP:M"$*D3N5*A]Y&<%=O7%<W?Z_9
MZ3JNL1>+O*OSK]C>Z1J^I0S8N+B\EM5CA\M%_P!2A6,95B3R&X!KDM8\366C
M> =$MM-L[J_NKMK&XF74U$<MO8M&"L4,C88.TJ-N9L@*"2<"@#L]0^(?C2'P
M8;N[\?7UG]AMT2ZU:TNS*%O[6-$N[)4Q^\!E;:) #\R-V-=+HGBWQW8^(;(:
MSK>I3W\D#ZK+93:O%9O#;W(9;22:%ONL78IY2D_,J@=37AG@7Q]>WYTRWO-0
M_LJ]T*.XTP&X)>QOY9+=A/B7;LBF#&0AR<9Q7IL&HR:9K^A6_B;1X=2DM]!@
MT6Q^R3P[K?4X&94NS-(_EC? RR1*['Y]W&: +NJ>*_%6M6\-EIWCN^L)DN=-
M,FKZCJ4EF!+*\J26QCD7:S,T$R*$SAD(YXJGKGQ2\4QWT_V#Q+J<OVUSI5F=
M0U&6V33-0AG\E_M!52"LCLBJIP258\#FN<\-2ZW9>*+'X>SZ;K.IWE[>Q7,>
MJW#P^8EI8RSAI9#,S*TZSW3%EC&,+N&<UT6CS)H5AI\.K:K:Z5%+-::"VIWF
MIK=PS2V]XUZUU(#M(E$8ER0N#E.: -OQ)\1+J]:V3PUXG\0GQ+(;VUO=(FU.
M5TCN(K8SX1M@Y18)7VJ"'4\-TK1/Q;\:VMC_ ,)IIM]<:AX9?2I)ITO));6V
ML(4?"R@DM(T[H[L%9<'9ZC%>9>#_ !A::J=1UFWN[:07LB/ [ZG$98H(K&_L
MI[LL[8\UFN$8+QQC^Z<9^K>)+0_\([IFJ0ZE?2Z!8S:1</J\PBBO0;<AHP4;
MRV\OR\I,V,F0 9H ZOQ%\1OB-9^%M):R\<ZZTEII:IJ&F/(D=V+OY?(E\SRF
MW^8A.4'&\ $C)HOOC?K/A.'5=<N?'=YJ^A"9TM(3JK&Z2T)"?;/W<13 9LE7
M8;<;>M<_%XI\.^,XM*=QIGA#5-2L[75$U>"]+6ZQRNDLEH5C/R3>4?-+.,*2
M1TJ'P'\5M(TW7(=9ENM)O[6.V.D3016J)!<WMQ$K1,RXP1E"5?&UB#C)H Z\
M_&/XB:Q-H.DZ)XGDU2.>PCTJ?45O$BG2,3QL=0\DGY-ZO(@>0CB,'':MZ]O?
M%L/BO4[?2?$GBBZTBQ7^S$UO5]4CCANK^0"2V=-@( 56V-NPK#;W->4:E\1/
M#EQIOB"_FU'3M6G\3S8;3M.FB9[=X=B1[2 "84C$H.%Y<$BF^"8O"-CX5.DS
M>/5T/1=3EM[[29(9]LQ4!(5E>,@L7"HX" ?>7)&#0!V?B;XH^(=3T&:::]\5
M:+J-WK-G9/IFI:\EJMN!&S/N95)57^5P,C<K#!X-:WC=_'VG:QX:\(S:SXEA
MO+*P@AGU"QU99H=1ED,LY522K,Q2VV9('#GVSYP/BKK?Q"L9M%U&;3_$%G)H
M\\%Y<2PQQ0S7UO/FV>%S\\CR1A$P2.=RU3U_XNQ^(/$-UJB:OIM[_9]TL5YI
MPEDMY-0A?!9[<D B$2$J-IW#!S@4 =IX:\3ZG\3]:LM3L_&?C+1WMI;G3XXK
M:^>6U\01P0-O>V+(-DIDVXWX!VX&>^=)\0?%=CH/A"P'BOQ#;1Z_J;>)9VOK
M]6O[. IY*QW((4QPQS*^[:,'V%8</Q4T9].N-!6.$64ZK%J%EF:.YTF.%W:Z
MFC95PIE<J(^6.!N/:HY]2^U:IXJM9M,O(_%5KY"W-U;,"R6XF<QQNQ;:RR E
M@X(W%EW"@#8U;7_$FH/\4;-_''B2V@L=3M;."^FU)I/-W2N1#:; !DNDBAG(
MR%P,]:6[^-.I6NK^&=3CUZX77@SP^(;6SU*YN!8:?"7 ).S;YN<EB,\8X[UF
M:Y=:%J \96$OB_5[R(Z3!=-/J.COF:V2X>XV851F:/SW48ZGY1D UQ!\>7.I
M7K_;+Z[\)V,V@PVVHZ3<QJZS2K9K]DG2)%RHVR!7SR?F)&%H ]ATS_A+8?A[
M.(/B#<:IJD<EI-!K]WJ\J22J94F;RUVA41+>0Q_O <NX)QMJZ_CBZ\1^#M;T
MZ$ZOI<$5@WB_[5->RS7,2&:():R-N&'9!D; 5*MV->3:QXQMO#/AL^%M'GL?
M$VM-;"RU/6](TYTT^.Q2!"RLSJQ\Q7B0[E^4AN:Z^Z^)OA5[74M16'4M4M]'
MOK67[#=&X4:@[HL2PPA 5=(2Q<H> !NR<"@"S8>*T^)%DMWH^I^*'CU.:)YK
M6SU!KCR8+F6=GD=A(&&R.( @*-H4XS5#2%\6^(/B+:?9/%[^'(K'0'U+3+ZT
MU-Q:ZM;HKPK&2S9 DD,>7/W22.M4X;GR=8OKRVU>RTNTF*OIL=JCZ>"6$D3S
M!@@!\G<Y6-\9+AN0*Q?#.J:2NA>+[62\F\.VES:WFFSH;.2[\B'<#OM) @#,
M\P\WY>-S8/ % 'IWB34]'T+P\/%%_P#VKX#:+3-,FNGOOM-^W]H7<SI)9O:!
MP7PD# OD8+9Q6/+%IOAS5O'-V_B&+3K/P\O_  D2VL\5]=V]YI]\D26<L5P)
M@=@D; & 5&X'.,U?OOB)!XOL+*ZU_0-3\9:I=Z;8P7"0:'=)I]_<PS--'?+.
M OEO&)'5L=7+=JY#XCZUK?C[0/%+S:%'9G7_  W;V6LVRV,J;H[6[")%;MM^
M1R$!5&X[YYH ]$\0>$K?PWXI7PUJ%[J,E]XH33[6VU&5[V"TLFD@,K/'=%BD
MDBG 5, D':37/:]/9Z9>:5%=W&O)>VPT^#6;1I);>:XGG%S;KF!Y=S;C'YV5
M;:%YR<8HU#X@17&K7.KC3;GQ1+9Z7+-#"_AV_MY[G[-8B&WBDC?]WA_,969<
M?-'["J]QXD@G\5>"MWAR_L[.WTE=,MII["\,$#_:5EC<22*V7MY))-QDX9"0
MN,T ,\';9O!&D>)Y;IX?#]W(W]G03:Q)-=:A,MG<P^3%&CD%4D$;-NQN)Z<4
MFOZU>Z#!9'3M-UV_OTM8M<;3%*K(5GB*DL0Y\H;HP6!X'W3C.:U+3^P[[PMI
M6CZCI?B6ZL=,>9[>32-'F@,=_'D>>V8_W,<VYF1 "./I6+=7^OZ'X6OK2S\*
M>+=(T%;:[OK:.:R,MSJ$<KH59_EWQJKG'ECK\W&#0!E/XFT77M:T:TDD\51>
M&M6N?M^K27#/I[:.P@03;F+D+&2.G.0QVDUI0WNBPI%JFA^-+'2M)@OUM[:+
M1/M.HWFHI),7CDFC+XB'RM&-F[..<4OB"V\::?J5[K-MI?B&?Q%K=Q)IT$$6
MC&>P\NT"JTDD97 =P6=,8PV,]ZNZEX9'@W7+O65TN_UO,=E!I]W=Z3>?V@SQ
MR*6N!%$@2,F(F3!&-V<T :GBA+K3X= NK/3;FUU);][^]TS7+PNOVBX:!=N!
M(%BCVQEL%_E.>.*SI5UB7Q%-96T2:"]O?33)92W4\@EC6 S(J%6(DQ+'&?,4
M[2)=OK5^7Q+J6J:;]EM])N#"M[+>QV5CHMW]HE:1X)&,2>7\P'[\%GR=QX K
M<LM>OM3UG4-?OO#&N7^DZ1>W$*7K:!=03Q&? @C@1 "J1);IN;!!\P="30!R
MT-S=:;K&EZEJ<#O::O):I,=0U&YA2431 _:!)&66,"9%"KMVC=@GYA6WIMS'
M'K0N- T^$:GX3N4COM0DNKJ>RM[<H_F33!G :9V151 "5!W8[5E>'_&FH:GJ
MFN:G)H'B#3--M[*[?29]3L;YFM[H_,'-NB["L>U20>@ (!J?P;KNNZ-I^M7-
MEX<NK:#3$!U.67[5<6U^;C+":W81&1P7Y9B,QA<#K0!V7A77]<MM?N[[1=1M
M]+CNO#T>I17%];R)-+=K(GF(%?D>?O?("Y4A<<5ZO^PS9O8Z?X^5)I'L9]4M
MKBT2:=IG1'M(R=S,=V[<'R" 001@5\]Z!KVI^'=$BAOO 7C34M5M$DUN"YM;
M:9,7$"AO*+3(68,S,PW<$8&*]_\ V$K/Q+%9_$R_\26NJ6TNH^(OM</]JVC6
M[;&MT^1,@;D7@!L<\T ?5E%(*6@ HHHH **** "BBB@ HHHH **** "D(S2T
ME '%VEE)H'Q O;H+_H&LHC,XZ)<(-N#_ +RX_$5V@.14<UND\;1NBLC=0138
MK=H6^5LIC !YQ4)- 3T4@I:L HHHH **** "BBB@!#TKQN+X.>*[&YU'^R_B
M;J&FV=SJ$]\EJNFP.(?-D+E 3R1ECR:]D/2OCN\_:!^(\?BK7@^JZ!I>A03W
M\-G-=VC/^\COUM88FVON.[=N+XP ">U 'LS?"CQZ6R/BUJ Q_P!0BWS_ #K*
M\0? WQMK\5BMQ\5+J=[&]BU"#SM&@($L9RF<,.,GFO&==_:+^)NG74WE:KIK
M&VLKK4I['^QG$B6L>=MQN\S#1%AMW#H2*W?!?[0_CK6CX3UE]2TK4M U;7+/
M2I(_[+FM9&6<')1V8@E3C/TH ]E?X??$&YT]XY/B5Y$^>)[;18Q@8]&<\]:@
MTWX<_$5)IA>?$T75JP*+&-%C5@,8!)W\GOZ5ZZOW?TI0,=A0!XCX9^#7CCP5
MX<L- T7XBQPZ;8VGV>W$VBH[@CD,3OYYSD>]:<OP[^(]S> O\3E@LPRML@T2
M,.V!R"2Y&"?:O7** /"?'OP%\5?$7P_>:%K/Q+NAI=T8]T5KI,2,=DJ2(V2Q
MYW(,]JP+#]DC4M/UW4=6C^*.N&XO;N.Z95L;=5C52"84 'RQM@94=:^E::S!
M%R>E 'RA#^P=I]FUX]OXRNH9;P7B32)I=ORD\_G;0#D#8Q(0@< XZ5)??L):
M5J5SJLA\;:S#!>SK-':Q6MNB6^T@JBX7H" :^C(OB#X;F\0RZ$FM63:S%N#V
M(G7S5*J&;*YSP&4GT!%;!OH%ZNH.=N,CKZ4 ?+.I?L):?J4[W \:ZC#=%HG2
M0:9:,L+(1DHNS W 8;KG\*W4_8VTE([A4\27D3364^GB:.Q@$H@FW&:,L0=R
MG=QG.W'!KZ)^W0,0 ZG(R.0<CUJOIWB'3-8OK^SLKZ"ZNK"017<44@9H'*[@
MK@="1S@T ?-%_P#L*:+J,*6\_B_5OLI2WAGC2TMQYL$(*QQ'Y>%"Y' SS6KH
M7[&6B^'+NQDTWQ3K5K#81^7:HR0L\8,)C8,^W+*<EMK=#CTKZ0=E09/0<FN
ML/C]X U.R\/W5IXFL;B#7KN>PTQHY,_:IX=WFQIZE=C9^E 'C5K^P=H5OXAM
M]9'C/7GNX5_Y:1VY5Y,$"5AL^:0!C\QYJW-^Q%8W)4S?$/Q3.ZW'VI#-]G<)
M+@KN ,?!P2*]_P!-\;:/J_AVVURTNUETVYM!>Q2XQNA*;PV.OW>:?H_C#2==
MTBSU.RO(Y;*[@6YAD)V[HV&0V#SC!S0!\]:Q^P[I>N:C9ZA>>./$$^H6D)AB
MNFCM_, W[LYV?>!)P>H!QTJ?6?V(O#WB+3[;3=0\5>(IM-M[)[*.U@>&%2&=
M',C83F3,:_/P<#&:^B_[7LB?^/B(G@??'<9'Z GZ#-,BUVPGD6*.[ADD8D!4
MD4G@9/ /I0!X'JG[&/A_5]+U*UO/%GB>XN=0N4NY+Y[I/.$J!%4J=G&538?[
MP8@YS5C4OV)_ >LMJAO;S77BU6)(M0M(;T0VUVJJ N^%5"G 'IFNY\3_ +07
M@7P?IWB'4=6UN.VM= U&'2]0<HQ\FYE"E$P!SPX/'O1X_P#V@O!GPUU#[#J]
M_,;A;/\ M&=;2W>?[/:Y(\Z38#L3@\GT- 'GNI?L,^!=5-P9];\6.TL+P*SZ
ML6,0; 8QDKE"0 ,CL .U,E_84\!2V-G:MK7BPPVPD50NL%2ROC>&8+D@XR?Q
M]:]/\=_&KPWX M]!DO)+J]?7&==/BTVW>Y>X"Q^8S*$!XV<YZ8-;'A7XD>'/
M&/A[3-:TO5K>XL-2LUO[9S(%+PD9W;3R ,'/I@^E 'BG_#!_@)XK\SZSXJN;
MN^FAN+F]GU,//))$P,3!BAP1@#C&1UIY_85\!W#I]LUCQ1?QQO"Z13ZG\H\J
M3S5& @'W^3W[=*]5E^-/A!/']OX075HIM9GTQM6VQ?/'';*VWS'<?*H)X&3S
MBNF;Q5H\7D[]3M%$P9HB9E&\+]XCGG'?TH \&U/]A7X?:Q<VSWFI^*;FVMF=
MX[*75V: %LY^3;TPQ '3D^M5HOV _AO%(TK:AXIEE-HUB)7UAMZPMC>H('&[
M:,^N*]^;QGH2M.IU>RW6\1GE'GK\D8."YYX&2!FF3>./#]O%:22:S8HEW@V[
M-<*!+E@HV\\Y) X[F@#R"Y_8V\%WEU---J_BB02Q2Q/"=7?RQYA#,RC'R,2,
MY7%9MO\ L(_#33M#AT?3Y?$.F:9%>MJ(M[35G13<,<F0\9!^F!7MLWQ!\-V[
M:DLNN6$;:8 ;U7N%!ML]-_/RY]ZV-/U&VU6RAN[.=+FVF021RQ,&5U(R"".H
MH \)F_8O\"W,5Q%+J7BB2.8Y*OK,AV<$$+QP""1CW-5+C]@_X47EX;RXL-6N
M+W8L:W#ZK,715P%"\X4# X [5]%44 >'V/['_P .].BU!((M:!U PM=.^M7+
M-*T3!HV)+GD$=JF_X9'^',FD2:;-9ZI<V4DJ3&*?5[EP&0$+C+_+@'MBO:J*
M /"4_8G^$,=C9V<?AN:.VM$"0QIJ5P H#%A_'V8DCZU!J/[#GP@U&&Y@E\/7
M:VUR[O-!%JUTD3E\;\H),$-@9X[5[[10!X)/^PU\&KNXLYKCPH]R]F(1#YVH
M7#A!%CRQ@OC"XX';)K07]CCX41W$,T?AMXI(8Y(8C'?SKY<;NSLB@/PNYF(4
M<#<<=:]KHH \CU#]E7X::MIMG87F@-<6]G%## 'NYMR)$I2-0V[=@!F[]S4N
ME?LO?#G0M*>PTW0FL8I"YDDANI1+)OV[P\F[<P.U>"2.*]7HH \H3]EGX7I(
M)#X3MI) T4@>221B&C+&-N6ZKN./3/%/3]F#X:HMHO\ PC4;?8V9[4FXES;L
M<9*$-E2<#IZ5ZI10!Y-+^RI\*IXI(Y?!UE(LA8L"\G)9F=C][^)G9CZECFKU
MO^S;\,;,PFW\%Z5;^3.]S$(HMHBD==KL@!PNX$@XZYKTNB@#S&/]FCX8PV\=
MM%X.T^*TB+E+:,,L*[U*OA =H# D$8YR:DTW]FOX6Z.Z/8^ ]#LY$>*17@M%
M1E:,,(R".05#N!_O&O2J* //-+_9]^'>BZE%J%CX3L+6^BE,RW$88/O,9C+$
MYR3L)7GH#3)/V=/AG,\KOX*TEFE.9"8.7.S9D^IV\<]J]&HH \WF_9Q^&-S'
M)'-X'T:=)+5+)Q+;!]T**%5#GL JC\!4_P#PS_\ #G-Z?^$.TK_394FN?W'^
MM=%"JS>I   ]!7H-% 'GZ? #X;H(@/!.B8B\L(#9H=HC^X.G1>PZ"KUW\'/
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M4 1^2N2>>?>@PJ<YS^=244 1^2N .>#GK2B, D^M/HH **** "BBB@ HHHH
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M=,B&GZ;#HDDFH:7+%+')Y\D=M+K"V,L-PI \N5E!8#G@^U?8*=#]: '4444
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M+O--O+6.>PNXWAG@8?+(K## _4&IM,TFTT>QMK.SA6WMK:)88HT'"(H 51[
M "KE% $0MD48 P!^E.6)5;(')Z^]/HH 88U-.Q2T4 %%%07U[!IMG-=7,J06
M\*&225SA44<DD^E $]%<]IWC[P]K$EO'8ZU87<EP<1+#<*Q?@M@8/)PI/X&M
MTS+B@"2BN6T7XG>%?$.J#3=,\0:=?Z@1(?LMO.K2?(</\H.>#UKI%F5E!Y%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[=HX IUY\#M*T+Q39ZCHWBYM.\30VE]'I$-PT84RW#R2%W48,J*TO"GT&,4
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M W?V-,P_#!/\J]=@?S$5O[R@_G0!+1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1129&<=Z %HHHH **** "BBB@ H
MHHH *JZA%--!(D$ODS-&P23&0K8X..^#S^%6J3&: ,[0+:^M-(M(=3NDO;^.
M,+-<1IL61N[!>WTK2I,4M !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ\]_:06-O@#\2O,&Y/\ A&M0)'TMW-=QX?;S-%T]@" ;:,X/4?(* -&BBB@
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MF[USC(S1YB_WA0 ZBDW#U%)O4_Q"@!U%-WKZBEW#U% "T4@8'H0:6@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#4;F!K8,]L5.AQZC 7!&69<NO'\6* /3M:_9*M]=A\0P77BR_D@U5YIS'Y*
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M6"%1@=N*\EN_@=XB\:? ;X0>'KQHH=4T&TMKF].H?.\=U'8LD; ]V29D;/\
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MPW&%$\V5[[@>PK7T?]EBYC\(:+8W&J16]TK03W[>0&+;=)DL3$#W4-)OY]*
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MH Z\4M(.*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH 1N5-?.6C_##PSX^^.OQ9D\0::M^\%UIB0EI
M74 &RR>%('K7T:WW37C7PWD*_'7XO@G/^F:3D;>@-D1F@!W_  RO\/HI/,CT
M%-[%%;S+J8@(.P&_K[UPG[07[.'@/P_\$?B#J5AHZVEXFCW,@FDNI65,(2<
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MM^OHM 'I\?[0W@"74KBR7Q%!YD%LUX[LK",QK$DS$.1@D1R(Q'7#"F0_M%>
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEN(5^9B<!0#@CD@X- &],_P<^*WBOQ!>W<>DWVKV,D_AR]FNV">:4C_?1C)
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MSE\-7TEN\)SO7[,^3GIUKMWLKEKF54=(K>4[F91\^<CCGC! (KD?C+ID&G_
MKQ[:VENL<(\/Z@J0Q# &8),@?G0!8^#KR_\ "N?"0(;RO["T\ITQG[.F:[=7
MW*RG/'<]ZXSX4@O\)/!2"3RI6T2RVD8Z_9D_.NEBCO$FBDDE$D?E;'C"C)?/
MWL^F.U 'E/PO2"Y^+OQMLGMV,;:QI[.)!\LA:PBY'M\H_*O7#82I)&5G*Q*>
M8\ [A@\9_']*\>^&$C?\+V^-&UI7":GIFZ/ *X.G)@CTZ'->U;_.B5N1GGTH
M JW9_P! NAO#D)(..WRGBO-OV3Y%E_9N^&SJ,*=!M>,8_@KT6[1S;7.U4A!+
M$D<[UVG/TS7G7[)Z>7^S=\-ESDC0[;OG^'UH ]:HHHH **** "BBB@ HHHH
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M[2!PPW*&YSSS0!Y?XB_;#AM]-O7TGPY=270DQ8F\F5([M(]4&GW#C'*['.X
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MD[QG>V7AF&XGTC28=-(MKF#29I8TN<>2?MQ.<^:WE$%?]KK0!ZQ\-OAUX?\
M"WQW\1:I_P ),FJ^)+VPN3#IB8Q9V;WGG2 @<9\UT'.#746_[/O@JSTN'3ET
M@O9Q727BQ22,P\Q$E1<^P6:08Z<UQ/P=^!GB+P)\;=:\3:@=*ETN>RO[>*[M
M]_VRZ>XU 72M-GCY%^08]!7T+0!QOPZ^%NB_#."[BTA+C%TRF1[J=I6VJ,(@
M+=%4< 5V(&*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 0]*\1\'>7_PUI\2%R=Y\-Z*3SQCS+K]:]N/2
MO%/"<1/[5WQ%+&,HWAO1OE'W_P#6W77VH ]C,12564@( <\<YKFOB?!+>?#?
MQ;;P@RR3:3=HB X.3 X SV^M=/),D4D<3'#2$A1CK@5SWC;3YI?!WB9$N662
M;3[E8I !F/,3 ?7!R: ,_P""3K+\'? LD9W(V@6!!'<?9HZ[&YE\E02"0>.!
MFN(^ .?^%'?#S/7_ (1W3\_^ Z5W;XQS0!XQ\)RQ^/?QNSG'V_2< _\ 7@M>
MU5XW\+EV_'GXT#UNM)/_ )(__6KV+)#<]/6@".Y_U$O^Z?Y5Y'^Q_C_AF/X:
M#TT2#^5>N7'S0R#U4_RKR+]D! G[-'PY4'=MTB-,CV+"@#V*EHHH *3%+10
M4444 )1BEHH *3%+10 4F*6B@ HHHH **** "BBB@ HHHH *3%+10 E%+10
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M_#%A>QQZ-=2V]K>WEY+!$\B72P&V^2/& I_?N#Z;?6K?A_X]>./#</BZ\O\
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M+\5Y[[P#9WMO>:C':6FF7QO9]1WPV.I1)=_:9)E)R[,\MNRD<#8?2IK3P_\
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MT_BG6]8=I7;5XY[M9%O;W[,\ GF&.'6.;A1@#Y>.*T/$7[*/AKQ)"\4NIZM
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MHE>._LU>'_%'AWP'<1>+&OH[V;4)I[:TU&X2>6V@(7$9=1@C=O(]F%>Q YH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI"7<#?WVUZE\//C9K/BKXA/X+U'1+:SUS3(I;C6#;3L\4,#!#:31DCYEFW2
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** $/0UXE%*&_:VU>.69Q"/
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M?G1YRG//2@"2BH_.7.,\GI33<HKJI(R<\9YXZ\4 3456&H0&9H1*AF4!FC#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9T1&29=]WM 3S/E(^;_OH>E>GWOP]^*=[9RPR_$'2)'D386;P^C+USRI?!H
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M'X..L6UC+9R6ZQK.7 16D8%L*A.\ #;RP&<G&<4 >QT444 %%%% !12$XI:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#T
MKQ'Q'KFC^&_VF;:^U;4;#30O@N<1R7DZPD@7J%^6(&. :]N/0UX)XYT'1_%/
M[2^G:5K&C6NL1OX,N94%S"D@0_;H4)&X''#Y_"@"']H:3P-\7?A/J^D+XB\)
MW.L26\ATR2_U.!HX+DJ0&!W<$#=SVKT*+XI>#+^TF_XK3P[+%.OE+Y>IP$!L
M$,,[^>3^M0K\"/AP\A!\": 6P"'.FQ8]/[M1'X'_  TC1&3P3X=C&\A<Z=$!
MNZ?W>O% 'G?[,?Q3\%^$?@#X#TW5O&6@:?<VVE1P^1<:G"K*J.Z@\MG&!U]J
M]/;X_P#PT W?\+!\,@=C_:T&/_0J\?\ V:OA;X(\1_ _P+=7/@GP_JLMS;R^
M=<O9Q91%FF"N 5R1D  >]3_#'P3X8\5^.?'&D>(/AOX9T*3P_<P-;V=M912;
MK>:-_+>5]N&9BC,% &T$9S0 GAKXP^!(_P!I7Q[?OXRT*+39="T9X[TZM"(9
M9 ]XK1CYN2H()'N*]4;]H#X;1S<_$+PLL:J2X_M:#(/&/XJ\AT?X5^$M2_:=
M^(&AWWA?2)_#\'A71)K.S^P1E8G>XO5D91MZG"9/L*]9?X"> $U.&Z;PCHH5
M%VI$NG1;01SD_+UX&* +!^/WPSD=4'Q \,ERZC:-6@Z[L?WO6O/_ -A2X2Z_
M9VTV:*198Y=:UUU=#E64ZM=$$'N""#7J$?PG\'H(6B\+Z1'Y3Y0K91@KE@3C
MCN:\U_8BA6'X!V<:!52/7=>4 #  &K70H ZSXO?#;7/%^O>'=:\.ZCI]CJ.E
M1W5LZ:I9_:89(KA4#$+D8=3&I!Z<D'K7G]_^RQJ=YXGL-2C\97%G$M[?W=['
M;Q;3/YR1K%M(/RF/8P';:V,"NZ^-7Q0UCP/K'AO1]#CT9+[5TNYC=:]<M!;1
MI;HKE<@CYFW<>@!/.*Y"X_;%\+:7J]AIU_87BRW=[/8K<VI6:!C!%$\TBL.2
MBF5 .Y'.,4 5O"W[+VI:#K'A?4Y-<T\RZ+J0O!;6VG^7"Z[60D#<=LA4C+>N
M?6O6/!?@-_#GBCQ?KES<I=WFNWJ3*X3:8+>.)4CA]PI\QL^KFO(/#_[6,WB'
MQ[X=T2/1K98-9U3["(C=HTUM#Y"R+.Y4E268JH0<\\]#6S\,OVA=1\??$#XD
M^'#IMA"?#]S);Z1MN"K7Q1WCQ)G.TET(Z9QDX(YH ]['"\>E>=_$/P'>^*_%
M_P /=4M)H(;;0-6DO[M)!\TB&WEB4+[[G!J_\'?&M_\ $'X9Z!X@U2SAT[4K
MZWWW-I;N7CBD#%656/WAE3@]Z\D^,'QD\8>&_B'XQTC0;W1[&T\.^$4\2 :I
M;EDN'\R56C:0,-@(C !'<T <"/V)_$3>%K>RBUG3+6_.F,MU/'&VR[NQJSWT
M?F*/O1;'*$'GFK.K?L/7.J^#+_3)-2TTZB_A"UT"SO)(7<VDZWTMS.Z$G(1A
M(J =0%]*["?]L2"T-PB^%Y[V1="36X8K6Y5G<+';R7$3#'RO&MP.,D_(<XXK
M/\0?M2ZG_;ZW.F6L$?AI[.^FMILK*UZL.H6EI'<QMD 1OY\F!_LY[T 9<_['
M&NZ9K>MZCX<\1Z?H<]YJ&NW4$D=CGR(;Z&U2*$KT(1K>0D?]- 1@BNH^!O[,
M6H_"OQ1X9U34M=M]372?#^K:&8H86CWB[U&.[5@23@*L93WR*Y+Q?^V7JDL6
MI6.AZ%#9:AYSRZ5<3W*R"X@@U:#3YUF3&8G9I>.O'-=?\/\ ]HW6?'GQQT#P
MJ^EV6F6%SHNLSWD)N!+-'>65_%:[4<8W(0Y.,="3VH IP_LM>(S\.M4^'USX
M^9_ [:9?Z?86D-@JSQB=LQ>;+DF019( &W=DYK U[]BS4_$5NLEWXAT][R<:
M^]RD5AY5JDE_IHLXC#%DA1&55SZDFKWPP_:=OO$_[3/B+P=K6LZ7::!/-=VO
MAFT\M5GOY+=@LN&!W*R;905<#=\I7(S5[5OCKXKTKXNWGPP,EJWB&Y\302Z?
M*T2J?[ > SS2A?XC'Y;PEC_$X- $.C?L?75MK-M+/K\(T^*6-C%;P;7YT5-.
MG93_  N[IYF1_.L_P;^Q;J.C7/A:ZU;Q)9:BVBZIILQMX=/$4$UG8P3PQ*R9
M(,S"8,TA_N@8JC\./VU=6\76/A:T@\+IJFK:KI-M<DBX\DRW<]K-<1HJA<>7
M^ZV%^Q;I5RT_;NMM=\.ZYJ6B^&A<?V=ICZFIGN]B/$L,6YNG1;IY+<_[41H
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MYS7)?LTVWBWP3X3T/P;XJ\+R65Q-_:%Q]IBNC<Q6T*RH(HY79C^\D$C'"G:
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MC7=S.DJA90\K>2=KR,A6,DA"%=4)'W@BYH ]=HI ,4M !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !2'BEI#WH \]\<:P^K^)]+\(V\[0?;$-Q>/&?F\D
M'&P$=,_R^M=Q8Z?!86L=O;QK%#& J(HP *\SMF _:#NUD&&_LU#'CIC'_P"N
MO5A6,=6QM6 *!2'Y>G>G4USA36MA#J*0< 4#I3 6BBB@ HHHH *X'QA\'M.\
M7>--*\4'5-7TO5-/M7LE;3;QH5EA:179' ^\,J*[ZHWE4#&>: /(]7_9UCUB
M=Y)/'WC>%2TC".WUR2-5##&!@= .GI46F_LSV-A:R0OXV\;W8:02J]QX@G9D
M(7: #GIWQZTGQ;^#&N>,]3U/6_"GC"[\,:[+I#V=JRYDMX+O</*NC'G!94\Q
M/HV>H%=-\._"GB;PUJGB2Z\0^)VUZWU"6UEL[=HM@L@EK'',J^H>5'D]M^*
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M'>@SHO4\T 'D+GOZT>2OO2B53WI/.3GGI0 JQ*O04AA4G-!F0=6%+YJY(S0
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M@"2BF"0'ID_A4:7D,F[;(K[3@[2#C\J )Z*A2ZBE+A&#E#AMIS@^AI1=1,7
M<$H<,!U4^_I0!+158:E;-,T0GC,BXR@89&>F14B7,4HRCAQTRIR* ):*B-S$
M&*[UW 9VYY_*HO[4M"6'VB(E6"D;QP3T'7KQTH M456&I6I) GC)!P0''%0#
MQ!IIDC07]L6DR(P)E^?'7'/./:@#0HJ@NNZ>RAEO;=E()!$RD$#KWIYUBQ4*
M3>0 ,,KF5>?IS0!<HK.B\0Z9-.(8]0M7F)(\M9T+9'MG--;Q+I22Q1-J5HLD
MO$:-<("_T&>?PH TZ*H_VYIWEO)]NMMB?>;SEP.<<G/KQ]:8/$6ELF\:C:%
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M)KKXF^);.QN[235'N)-0N;B.TXE"VLH&=^%3ENJGKS7.WGQL\?V>G3S-X_\
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M.:#&F<<CM7SO\6_VL(_@KX].B:[HZRZ;<6$.JVM_:R,R_9 )1>3/P1MB<6X
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MT_!M]D5PR((V'WE"@8)YKUOUH 9Y*^E+Y2X(YYI]% !THHHH **** "BBB@
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ME8K'%A22&8@@ ^AKYX^(?[)7B?Q!<2IHFH>']/TV'5)]1TZV-J\36;27=K<
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M1!I>D:6+._CMX)6GO76)T109&8*JLY8.#OQ\IR* /HH'(S2TR-2B 'J/2GT
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M./F!Z"O9!TH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD#O0 M%%% !129I: "BBB@ HHHH **** "BBB@ HHI,C- "T4F1FEH ****
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M&X9VMBL34/ WP=^&?@[PS8RZ1I]OHDFOV<^C)'YETTFI;@+>2-LLS.-O!R0
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M8+KZUQ,?[(&C3>'+G0[W7M2NK2YMM-MI=D<:9%GIYLEP.>&!\PCU '2F:?\
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ML"V!DX S1>_LJ:#=^)+35EUW783%KC:^]JDR&*2X^U&Y48*DJHD/\."0 ":
M+4/[5?@S5X-(FT4:AJL&I:Q9:0DBV4D.T70?R;G$@4F$F-QO'=37:_"[XK:%
M\7O#C:YX>:ZDTX3-"LMU;- 9,<AE#<E2""#W!KB8_P!F'0+>STFW@U;6[?\
MLJUTVVM)HKA0Z?8I))(I,[3ECYSJW;!XQ73_  B^#&B_!RPU.VT>YU&Z.HW"
MW,\NHSB1B501JHVJJ@!5 Z9/4DF@#T#K2T44 %%%% !1110 4444 %4-9OVT
MO3;N\6VFO&MX7F%O;KNEEVJ3M0=V., >IJ_3'7(XZT <Q\,?'5O\3/ 6@>*[
M6TGL+?6+2.[2UNL>;$&&=CX)&X=#[BNJK'\)>%M-\%>'+#0](M19Z;8Q^5!
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M!UG@']D/6]*U[PUJ>OW/AAUTC7(+YM/TBUFCM)H(;![:.7RG^47+NQD8]!@
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M!<F_8FU?4_#VH0ZA?^&$U"YBNIK06>GR"#2+J:_M[@"TW$M'$B0$ #!WR,>
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MVA9-VX#*#/K0!]6@YI:8F<<_K3Z "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH 0UY!\9[<S?$SX+.9&1(_$EPVT?Q'^S;H
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M]*-HI:* &E0>U 0#M3J* $  H(!I:3-  % Z4M)FEH **3-+0 4444 %%%%
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M($V'&&^3J>H]17/?LU^(K?Q9\8OCGJUM9:CI\=SJFE'[/JEH]K.I&G1#YHW
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8UNI55))@@#NJYV@GJ0,G ]ZN44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 57O;L65M+,8WE$:E]D:[F; S@#N?:K%-90<$]1TH YSX=>.K7
MXC^$+#Q!9VMU8PW?F#[+>IY<\+)(T;)(O\+!E(([5TM8OA3PO8^#]&ATO3(C
M#91/+(J,Q8[I)&D<DGDDL['\:VJ "BBB@ HI"P'4@49H 6BD) [T @]Z %HH
MI,T +12 @]*-P]10 M%)N![BC(]: %HI-P]11D>HH 6BDHR/6@!:*3</44M
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MPH Z]"?PKR/X,0?9OCU\=HP695U'1P&<Y8XTJ$9/Y5[5<VT,QC>5%9HFWHS
M94X(R/0X)'XT >+_ !?8/\:/@5-%* O]L:G&"O(.=,G_ /B:]BBO%5XHF9I'
M8$;@,C*CG)' KR#XR0HGQ7^!HA B7^W;]%,8 V[M*NN0*]5T^P&G6*1PDJP&
M7>7JQ)RS$=,GF@":^NKF%L06YG!C9L[U7# <#GUZ9[5XS\/Y83^UQ\44V(MV
M?#FA._.7QNNP,_CFO8L3RSQ3@I);G('7.T@8/IZUX=X! '[;7Q4/&?\ A$M
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MSUXJ/3_V/+^&??>^+_[2>ZT?[%>7=S;.;AKI;2:UBF0B0*%59R=K DE>O)H
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M8Q7D7QO=/^%F_ QI-G_(U7"IOZ;SI-[C\>M>MV:S--OF+(P! 3C;CC'\OUH
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M>HMH?QD.[;XH\($;>"VC7 .<_P#7?TK#^&]_96W[1?QCG>\MPD\6AR*S2 #
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5SGCKP#H?Q)T"31/$>FQ:II<DL<S6\I(&^-@Z-D$'(8
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M+#^^M?8\?_!*W24EE9_']_<&2V%H9YM/C\U8PRGY/FVKD)M(Q@J3GK6MJO\
MP36CUFTNUOOB;J=Y>7$KJUU<:="Q\AH_+"8SPRC 5AC &.: /AA=+$VKZ;IT
MVHWVH6VE".0"#!D"NKG=$K[OG#A%+C@C'2LZZM=:UCPS<:4-'N;2[^R1_9+I
M[+,4DBOYC++G[SL &#_Q,>O)K[MO_P#@E[I<R6$5I\1M6TZVL[=X$2"PAW.'
M!#[V)R00<8& .H -;GA/_@G>?!&H3:CI/Q0UA[][5+ /J&G0W,8M4146'8QP
M%VJ 2 &QGD4 ?#7BO3H_B/KNH,]O?:U/<:Q) EO?$VTQ@""6Y6*WQLM_WBG[
MI^8D^M<S;:[J$.G:OKEKI\FM:89+F:&."WQ!]ECB19I6A4@,/-:.$R$ J,@&
MONC3?^"57AS3Y?,;X@:Y(P#E"MNB%&;><@[NQD/7/"J.V:DT7_@EQI>AZ,=+
MM?B5K45LUG]@D>/3[<3&#S1*4#G.%+@$]S@9H ^!='74;+0O$L6K0W^K!6_L
M^TBMD$K"6YC,CRG>3A@ %!Z<#IUJSJVGZAJNIF[B\/0V6N^&K&(Q0W%LXL(K
M-3\LFS=\[^:R?,2=SE2!VK[Z3_@EYHUK8-9V_P 3/$EO;O</<RB.VM@TLCQ&
M(LS;<EMA(SVR<8/-:-O_ ,$U],%K#:77Q-\37EI;QK##')%!PN265CCY@=QX
M/3C'(S2N!\ :OJ.J^'/"VCW=]X=_L<:3!<V]U8W6+NY%PB$K<*2-T>Z=_F'<
M-6W?6VG^"?B07LM/NM4FT[5Y_MULDS+:R2HD;@ *&P!YSQLA)'4@#%?<X_X)
MM:4EUIMVGQ&\117EE&(EN%M[=GD&\.2Q<-DEE4Y.>E1Z#_P33TK0+.UCM_B;
MXH2>ROCJ5I+%#;((YVW%V9=G[PDN3\Q(]J8'YR6&D6ME=7<&GZ=IK6$FFPS*
MDUL7:..21[@3 %OD;]Y'&"I&/ER*S]QT30=)L;CPWY/V)I6NS?SL/M5Q"X14
MN((R ZB:3(9OFY8YQ7Z-:_\ \$KO"?BC2HK/4?'7B F(ADDM(8+?)Q@LP10&
M)[D^@]*OZ'_P2W\!:%)#<Q>)M=FOX8UCCN[A89)% ?<3\RG);HQ.<KQQ0!^<
M5UXAT_P_\/;[PZP?4$NXX[BXDN(2DLN^-MD5I<%]X@5FPR8.54DGGAVJ:I_P
MD6J>&KN[M6DT+1K#3H#'!(L0BLH]XE\R!6#;G<IN;.2HYR*_1Y?^"7_@G^U)
M]1;Q=XA%Y+>F^#1^0BPR$$,(U"81&#$%1QC%5[;_ ()7> +(Q^3XGUY_+N%N
M5-PEO*0PW8!)3+#YVR&SGCTH _/M[">#4M;\2ZLPU6VL1>6;^'P0L"C[1L",
M@(/[N!PX*EF!VGM2W^I7NF236HN6_LVRCG\0W[QS!MDEPIBWM*J[@& 7"L<@
MM7Z&:9_P2W^'6EVYA3Q/XF=0C+$SSPLT;-]]@2G5N]7[O_@FMX*U2;5Y[WQA
MXHEGU80+>B)[>**98I!(BM&L04@,,B@#\XM9T35? =WI=W<Z>PFDTI]\^GR"
MY*R+NDMHQ,#EC'"J [!Z@G(IX\,?\)/HVE^')I+F/4(K:/5-/N-,L&@+S30(
MAN"S,&E9C$J/DCJ2!S7Z*6__  3(\"6?A_\ L:W\4^)8;(0&W1DDA$L2[]W[
MN39N0<G(4C()K3O/^"<O@;5M3TN[U/Q-XFOET^<7$%LUQ&L4;A%160!,H0JC
MD'DC- 'YL^+;K2_%EWXOM]>U2+3]=@M[6"1A;EY-.-L@A?:(]J1I)QM*C(+C
M-2ZN]CK<VJZCIMN=0$&FP)!*\B &VV!A,B' *CRLNIZ%B2.:_0S3O^"6WPJT
MPH\6K^*//%XUVURU[&99-ZD2([>7\RL3N(/?/K3F_P""7GPQE65;C6O$US'.
MCQSQR746V16!!P!$-F 3C'0T ?#.AWKZ]%XMM]+UXZEXUN3-&IGMXG@OEW*S
M/!,%X16\O"J,DH>0*U="F@7Q#JNE:I<7FJZ]*[3)=Z?J!)-Q*4ANY8XE0C:"
MJM@Y&#QQ7VP/^":'P_AF'V;Q3XLMH4L6T^&..\BW0PL58A6\O(.Y%.1@\>]2
MQ?\ !-#X;P7#W$>O>*DN2I1+@7Z>:BE"C+NV<K@\ ],#!XJ;@?GIJSS67@\:
M%?7=WJ]Y!'='6+&.SA2*.Y=_,N627&3+E$ Q\N%.,"K]IX=BU:"W3Q'Y>GV=
MMJ=QK%[K,*O+$\"6Z26UK'M8J5$ICB)09#,<\U^AFB?\$Y_AOX>TK4[#3]9\
M56D6I1K%=&/4E)=0BHV-T9*E@O)!S[U=@_X)\_#FT\.VVAPZKXGAT^VMI;2$
M)J2B2..6<SR[7\O(+.>3Z #C%%P/@'5_#&IV=U:Z=KL0TR]TRVM62PLG>-X-
M2N9/,2V+Y#*1YR?.6_C8GK7/PZ!XF\1:]<W%G91Z!X<WRZ<EBTH:&RE#QQ7<
M5NO#R.)$###<9X/)K]+HOV$OAS'J,MRTVMW4=U>)>:A:W]]]ICOV1E9!+O4M
M@%$^ZP.%QG%9L_\ P3R^&-S86-F]YXE^SZ9>2WVF+_::DV$DCEW\HF/(!)Y#
M$\ >E4!^=6J:O/<W>M^+XK/[;J/G3W-Z'6&2"V=HV^R6P%QD@A1+(Z)TR,Y[
M9Y@U&S\(Z'?C4;N'4#?#2Y[32=*B/]EW*JDD;;&!:2.2$R'NORJ<<5^BI_X)
MM?"W]SB_\2;8HGMUC>^B9?+<N9!@Q=6WME_O#. 0*DD_X)R?#>32(+#^V_%Z
MF*\%VMZNL8NQB'R1&)=F=@7H/;TH _.CQAJFOVPT/5;2*Z6T$]G?64,3Q2RR
M7$"DK=21! %201J-K=>W%:'@RV#^/TNH-'N9]1M/L]Z^GR7D9MK.^EFF9HH@
MV,*@D0&,9"_-GI7Z&:M_P3I^&>M:VVJW6I^*)+AX[6!U_M-51X8$*1QD+&/E
MVG'ZUC/_ ,$O?A%-I]K:3W?B6:*"260!M17K(#DC]W\IYSQWYH \!^"H\!Z/
MJOCATUF6==9L+RWL]0LHDV+!<!UN9E@SB$^>/*!'RX7.1NKSWX5?$+0O"7P\
MT;P[IEMJ6J:KH?B;^UUTRRU-=+CFLX--^6YF;D/&3'\ZG 9B1WY^S=%_X)K?
M"WPW#IQTK4_%.G7M@6C@O;?5 )! <$P$>7M,>?FQCEB3WITG_!,SX*2W+W#V
M6L-*\"6SDZB<-$HQL(VX(/4^X% 'RC\/_$'P^UZR\,6U[I>B0^9/::A+9:?;
MM;WD<CV=]->P74O!*2M)''$%Y.< 'FHI/&/PYN[/X@/H>DZ#HD<T5[8Z:]A;
MR,UQ8+#;3QX;G?(TZS0[\9."O05]<WW_  3A^%M_9W<$EYXE_P!)NK2[:7^U
M 9%>W0I%M?R\K@-_ABK-A_P3P^&>DW.D3V&H>)[2726G>R,.IJ/):8$.P_=]
M>3CL,\4 ?GC\:CHWC7Q'%!\-O[$N=(UR)OLEQ:6ZVWV-XE9UM2[87:\6QI 5
M&=@')Z^.7_B*^\<VE_JMMI4%O<Z)&VIR*5,=T[&5SO8L,/&,LI1< #:,'%?K
MCIG_  3H^$6G0Z9;/!K5Y86!9A976H[HI\@#]Z H+=/4=35^\_X)\_!B]U2]
MU!M"O([JZGEG=H]1E"@N22H7.-H).%((&: /RD\4^,&/C:XNM$TV6UEO?#EG
M9?9)9E*V_G6Z++"WR@@1L"8SC*Y&20!6CXOM+:?7-!?PW UA9PV0FN+&]U(_
M:G=S<1M$9E"J2K!W .3E@ <5^G$/_!-KX'VR_N-#U&&7S9)3<)JDHE.]%1D+
MYR5PH^4Y[UHZM_P3U^"NK2%F\/WMLAD29HK?5)T0R*"%?&X_,-S<^YH _-3X
M#R:8?BOX<TO5[6>WBMK"XN)H=?B@N%*MI%RZRI%@ L'1&*GECMS[];H7AWP+
M\0+<:F_G1RQ2:3X:DN;80V5M?37%I<R2RR6F"BM@1Q#! 5GW<$8K[ ^-O[&G
MPT^%OPX\2>+-"L-076;3R+J&YNKV2Y%LPECC,X5L_-'&S]<C&<@UXC\7/@U\
M+_#S>*]*\*V4.L^#7N+.>X9+EI(?M4]O>.Z*P_C+6\#C:?E!(_BH Y+PO\"_
M!MSX8\+3:OI-YHDT5_>RR:,UR)[^>Z_LM66R6?&\C)9@HZ9/'I@^!O@!X%T_
MQGX>L_L%UXA\.P^*&BU34KV^BMHK9H[T6HM)8\Y+A"C HV&[#%=KXX\%^%_#
M=KX?\)7/P^MKGR=3>6:>+Q!=6UI#--;V[@P%GR)W6<+\V[A2!UXZR;]DSX5Z
M#\$O&WC>]\#)<OH6NWEI:6-OJ]V$_<WAMOM%PV[)(QYC%>@'% 'R_P#"/0-3
M\*^"_'6OQZ6OB33+*\;3+'P^=/CNIY-57S%CCD9@72WMX]KD @,V!DUZ/XL_
M9_\ #=IH%YK-W:ZC:W4=HMS-K,-W';VNB^3IUG/Y;VF/G:1II0?7.>M=D_PT
M^'G@ZW\67NG^&=)U2[TQ;6RO+_1M9U!H;NYO)IHUD+NP"QHL>'?)(8\'O6#X
ML\'^"+BPT*_U/PRUM;W"6]Q>Z8?$-Q<W5^UU:W"RO Y)!@4VT*ECD\=1CD S
M=/\ V?/!<7BC6+.'2]7L(=T5I8,NN1;K^RDE)?64)7*I$KINC'!\T\X4U?\
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MYBD-]K,L5M-";2>7F8L1CS$4^^,4 ?#_ (TMXH]9MD_LNQL;37K2#Q2;F^U
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M'@I&AZ<$4 2^(_VH8M%^%?Q<\8IH#2_\(%K%SI+6CSA/M9A\CY]V/D!\_O\
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M"NCW&E>&6OH]/D;?]GN[IIEC;+$E<]"Q8ECW->B*, 4 +1110 4444 %%%%
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M-6&\B2.)%!P6>-"26&?[O%?<'A?XH>&_$^C:#?VVHPVJ:W"L]C;73B*:56)
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MA5"@GKQ3Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ IK@E>*=10!S>C>"=-T;Q5KWB"VBD34=:%NMVQ?*L(4*1X';@\^M='2
MT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !2%@HR3BEKRG]JK7-0\,_LZ?$+5=*O)=/U*TT:>2WNH#
MAXFV_>4^HH ZGXF> =-^*'@K5O#.JA_L.HQ&)WBX=#D$,I[$$9S7FMA^RMX=
ML?%AUZ'5M66;_A*5\5QVXG_=QRK 81 H[0[3]WV%<AXM^ 'A7P1X*N?%&O?$
MOX@66FVUO'+-(NML3EMJ@*H3)+,P  [FJUO\)/!NIWVCZ)_PL+XBP:M?VR7:
MP/JSK-"DBGRQ,-G[LG:V <<J: /JP,H&,US7C;P1IGCB/1TU)"Z:;J4&IQ*
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MQ#!XH@\.QZ;KZ^)!=*D.D"XGCNRTJAE &[H5PV>G6@#]^#XGTH,%;5+,,6*
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M<Q')([=1S[5+;^-;(7,+W=K926^]B\_E-ND=5(5MO8<#COWH _HQ;XC>%E8
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M-AR&4&/D>W4?A7VI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPEH(1!DLVFP8 '_ :Y+PU-\'?&(N/['L?">H"%D5_*LK? +YV=5YW%6QZXH
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MDD+PN709/=A3O#7Q>\#:]=W%AI]_:136=J;QXY(UB$<*O)&S#( PIC?/I^-
M'X]>/?VE/%7CN71%7X;74%]!9;-0MK[3VN[.:=+%;1)(X2HV$*N>O!-7;7]H
MGQ)<^+/#GB";X6^(7U)-.&F:Y)')/Y<]N=/2Q_T:/;MA?RTW;L9W>U?L=?\
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ME20>QYKYME_8YO-1\->'M#U#Q<LEEH&HZ?/8K;:>L!-M:(Z(DK*07<[R=Q.
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M4W>;)+_<R.96&01Q@5[9;1^6N.>W6IJ* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIH=6. >?2G4
M%%%% !1110 454EU&&WN((9'VR3L5C&/O$#)JT#D4 +1110 4444 %%%->18
MQEC@#DD]!0 ZBD!!&12T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !112-]TT +158>;YK$L/**\#N#DYIEA:M;*X,TDVYRX\PY
MVY/0>P[4 7**** "BBB@!DD@CVY(&3CFE0[E!-#H'QD X.1FE P* %HI,YI:
M "BBF2DA3CK0 ^BJMD)]C&=55MQQM.?E[5:H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *SK[5Q875E"T,TO
MVJ;R0T2;A&=K-N;T'RXSZD>M:--9,G- !NP,U!;733R3J8GC$;[ 6&-_'4>U
M6&7<,4BIM)- #J*** "BBB@ HHHH **** (/("RLZCYFQD^N.E3T44 %%%%
M!1110 PQ*Q!(R1T/I3@,#%+10 4A;%+36&: (+2\^UB0A'38[)AQ@G!ZCVJS
M357:*=0 5E>)I+6'1+U[Z.26T6%C*D0)=EQR !SFM6FLNZ@#-%Y-%)IZ06QE
M@E.UVW8\I-A(.#UZ ?C6G2! #FG4 %%%% #,'?GM3Z** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** $Q1C%+10 4444 %%%% !39'V*3@
MGCH.].II&30!3TJ^;4+6*9H9+<NN[RI1AE]C[U>IJJ%IU !2$9HW"@'(H 6B
MBB@ HHHH **** (W9@AV %NP-/!R*,4M !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%(WW34-N[NS;UVX8@<]
M1ZT 3T4@Z4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4AZ&EHH HRPW#WD4B3;8%#;XMOWR>G/;%7%Z4N
M*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BD+ #-0_:XS*T:MND4 E1U%*X$]%(.E+3 **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IH0
MTZB@!!Q2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH **** "DVCTI:* &E 3G S0$ [4ZB@!-H]*0QJPZ4ZB@!GE@]>:<5![4M%
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#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tmb-20221231xex10d22008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231xex10d22008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 2, V\# 2(  A$! Q$!_\0
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MH/<!L@'VJ_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !12*-HQR?K2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 (1D<TFP>E.HH ;L7T%&Q?0>M.
MHH 3:/04FQ?04ZB@! H'04;1Z4M% "!0.U 4#M2T4 )C-&T8QBEHH 3&*6BB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#D%R%("^N!6WXQ_;.\,>&=*\#2:9X=\4>+=;\::=_:ND>'M$T[S;UK8*&9Y
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M%_PC7C?5?#GB7S8L11QKIT#0W$87&&W&W5C[OWKT7P=\3-"_9/\ VSOCG/\
M%*[NO#>B^.9K._T+Q!>V\C65RL:-NA$BJ0&7>0 ?[OTR >UZ+^W)X1U_X6?$
M/Q9;Z3K-GJ_@.!IM=\*:G"MMJ-L1_#@DJ0<'# XXKDIO^"@TVAZ5X;\0>*/@
MWXW\,>#-;GMX8O$=Q]FFMXQ/_JG98W+8;(]#Z9Z5\[ZY(WQ>?]KSXVZ):7<7
MP]U7P:^BZ5>7,+0KJDD:(7G16 )1?+QN(_C^M,\3>!KOX:_#[]G[Q[XSUW7O
M'WP6FMM-&M:'<W,C1Z5<% UO=JJ ;XT;C8<],=Z /M"]_:[\-:#X[^+6A^(;
M6;0=(^'5K:7.H:Y<2JT,YN(PZ)&@^;=R !_$>*ZK]G_XMZ]\:?"7_"3ZEX)N
MO!FD7N)=)34;I7NKJW.<3/$H'E!A@@$DD'/U^+?$W[/K?M+?M3?M&:;'X@N-
M+L_L.E7^GPQJ1#=W9L8_LL[Y&'C1LG'JW-?4G[&GQPO?BW\-GTOQ+9R:5X_\
M*2_V+X@L)8RF+B+Y/.3L4?;D$9&0?:@#Z HHHH **** "BBB@ HJM]E"W1G&
M2Y79G<?NYST^M6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***9(P49/0=:38&/K'BFUTJ[BLES=:C,,Q6D."Y']X_W5
M]S4EF=3N%5[B:*V/.8HDW >GS'J:X7X1.?$>I>(O$TRK(;J\:"W<CE8DX"CT
M[5Z?_%6*;EJ R,NH^8[_ 'QBI <TM%:( HHHJP"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KF_B/X'L_B7X!\1>$]0FEM['6[";3YY8,>8B2H4)7((R >,UTE% 'S+\
M-OV*#\-=<\+WEK\7OB)J&G: T/D:)>ZJ&L9(XP0D;Q!0-N#T%<[:_P#!-[PG
M9RZ@MO\ $+X@6%C>7]QJ#6&G:R;6%'F?>X"HH[XYZ\5]>44 ?,7Q+_8(\(?$
MOQG:>*)O%GC'1M7@T6'0WN=)U4PRW$$0^4RN!N=CU.>":O7'[#7@N^^%VK>
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M4_BKI?Q&N+!F\6:;I\FEV]Z)F 6W<DLI3.#U/)'>N<U_]E?X:>)=7\<:E?\
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M?RJ$K 2T4@(/2EIH HHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!
M,4TQ*6#8&1WQ3Z* $ Q2T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%-<D*2!D^E*I) R,'TH 6BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!",
MC% XI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !2,,BEHH \T\'6[^'_B7XNL)^/M[IJ%N[' 9",$ =]K9!_"O
M216/X@\.Q:T8)5E:TO[8EK:Z09:,GKQW![@U#9ZGJEHZP7^GM*<D"XM"'1@.
MA*GE<^G/UK*W*V/H=!15:VN6N$W>3)$?208-6!5H0M%%%4 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 )BC:*6B@! ,4M%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113
M$E63.T[L$@X]10 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "FA IXXYSQ3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@!"<4B$LH)&#Z4ZB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBDS0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 9FMZ]:Z%:K+<L?G<11QJ,M(YZ*H[DU-9_:9T5YP(6!/[M#G [9/K7":_
M<-JWQDT'3&3-O86<E\2>\C$JI'T"G\Z]&5<5DFVQB;"/XB?K3Z**T2$%%%%,
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH ***0G )H 6BO//%G[0'P\\"Z[<:-K_ (NTK2M3MU1YK6YN
M KQJXRI8=@1R,UTOB3QOHGA#PS=>(=8U.WT_1;:,2R7LTF(PIQ@Y[YR,8ZYH
M WJ*Y[P?X[T3Q]H:ZOX?U&#5;!G:+SK=\@.IPRD'D,.X-6=(\6Z1KVI:II^G
MZC;W=]I<B17L$,@9K=W7<JN!T)7G'I0!L4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1129YH \W\3(NC_%KP_J;NPA
MO;9[-O[H<'*_GFO2%.:PO%GAB/Q1IXMWD-O-%(LT$Z#YHY%Y!%,T_5-0L(4C
MU>V9I@,&XM5+QO[^HK'6+&=#15>WO$NDW1AR/=2/YU.*UN(6BBBF 4444 %%
M%% !1110 4444 %%%% !112,0H))P!0 M%5UO[=VE03QEH<&0;AE,C(SZ<>M
M5I/$6EQ:?'?OJ%LEC)C9<M*HC;)P,-G!YXH T:*S4\1Z7+=7ELFHVK7%FNZY
MB$REH1ZN,_+^-0VOB_0[W3;G4+?5[*>PM5+3W,=PK1Q #<2S X''/- &Q16*
M/&6A/K4.D+K%DVJS0_:(K$7"F9X\ [PF<E<$<U;UC7M.\/:9<:CJ=[!I]A;K
MOEN;F01QH/4L>!0!?HJCHVMV'B+38-0TN\@U"QG7=%<VT@>-QZAAP:O4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %(>E+10!\M>*OA%X@^)?QB^+^EV>J)X;\/ZUI.D65_<
M/HZW#W8,4ZR^5*YVY\MD7.&VD#T%:OQ)M_%/PT\'ZPMYX;TGQEX!T"QLX_#V
MCVT-Q<ZI/=PF)8&F !4JK L2 >%!KZ/P*,"@#YR^!MEXHDT2&]T*_M_-OM=N
M+[Q7-KNC7%G+=7#B/=]CC.-D:JH16;.=F3DYKIOA%\/;'X>_&#XE0:-H,>C:
M+?0:9=I)!"52YN"+CSG+G[[Y*YR2>17L^!1@4  Z4M%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** $I:3O0* %HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tmb-20221231xex10d22009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231xex10d22009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 2) V\# 2(  A$! Q$!_\0
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MZT[8OI1L'I1J WS!Z?K1Y@]/UIVP>E&P>E&H#=X]/UHWCT_6G;%]*-B^E'O
M-WCT_6CS!Z?K3MB^E&Q?2C4!OF#T_6E$@^E+L7THV+Z468!YB^M'F+ZT;%]*
M-B^E*S 3?S2[Q1Y:^E'EKZ468!YB^M'F+ZT;%]*-B^E%F ;P>]+N%)L7THVB
MFK@.HHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DZ4M-=-Z,,
MD9[B@!0P/0TM5=/M'L[6.*2X>Z=1@RR8W-]< 5:H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** $H7/.?6EHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ I*6JT\DR2Q"- R$G>2V-HQQ@=^:
M+-%5UOH#="U\Y#<^7YOE;ANVYQNQUQGC-3CD4 +1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-;.1
MB@"O-J,$%PD#R*)W!*QY^9@.N!4Z,S+DK@^E<)X(N!X@\6>*]4D8N;2].F0!
MO^6:1@;L?5B:[T5* 0$YIU%%4 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 444T."V* '4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ .VHKC'^,W@1!(6\7Z*HCQO)OHOESZ_-1#\9O MPP6+Q?HLA/3;?Q'/_CU
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M-*N_B]XQMY],LY8#IFG@H]NA4@F;/&/8?E7>MX2T1A&&TBP81L&C!M8\(0,
MCCC K"T7P[?VWQ-\1ZU(J#3KVQLX(&#?,7C,F_([?>%=D2 : *)T#33UT^U/
M_;!/\*4Z'IY'-C;'ZPK_ (5<W"E)QUH Y[Q'HE@FA:BRV5LK"UEP1 G'R'VK
MD/V>-*LKCX%> 9)+2!W.BVI+-"N2?+'M7H6L1F[TVZAC&6DA= "<<E2!_.N8
M^"GAK4/!GPF\)Z%JR)'J.G:=%;3K&X90ZK@X(ZT =5_8]CC'V.WQZ>4O^%']
MD6/_ #YP?]^E_P *M@@T4 5AI=F.EK#_ -^U_P *Y3XKV<-M\,_%<L%E#+*F
MEW+*GEK\Q$;8'2NSWBN:^)3;_A[XGQS_ ,2NY'_D-J )?">FVC>&-&S;0-FR
MA/\ JE_YYK[5IW&F6@@DQ:P_=/\ RS7T^E5?!W_(JZ+_ ->,'_HM:U9ON'OP
M?Y4 >4?LNVT-S^S[X!DDAC=SI462R#.>?:O4CIUJ.?LT61SGRQ_A7F7[++&3
M]GWP*QZC35'Y,PKU5NA^E 'C?[-]M%-HWCG?&C[/'&O*N5' ^VOQ7KZVD*?=
MB08Z84<5Y+^S7D:-X\!4K_Q7.O=>_P#IKG->OGI0!Y7\(<2>,?BQ"\RRI'XG
M7;!C_5 Z?:'T[]:].-E 228DR>^P9_E7E7P9;/Q&^,P[CQ-#_P"FVTKUF0XZ
M4 ,^R0XQY:@>P%<;XNCN&^('@5DD46WVB\$L9&69C:MM(/M@_G73:'JO]KV*
MW'V6YLSO=/*NH]CC:Q7./0XR#Z8K"\4''C/P7S_R]W/'_;K)0!UBQ@#O^=+M
M'J?SI12T 1N,#OUQUKS7X$&9]*\7>?/YY'BK5@F&SL7[0<+_ #_.O2WXQ7EG
M[/DTTVG>.!,^\)XPU98\@C"^=D#]30!ZH% '4_G1M'O^=.HH S]3@N;B-%MK
MMK1A*C%P@;*@Y9>?4<9[5-?J/L-SR?\ 5-W]C5JJVHKNL;@9QF-A^AH XGX#
M$R_!SP@S,68Z=%SGV-=YY8QW_.O.OV<Q<K\$?!HNW62X&G('9.A.3TKTB@!O
MECU/YTAC##&3CV-/HH ;Y8XY/'O1L'J?SIU% "8HV_7\Z6B@!I0'N?SHV#W_
M #J*Y68[3 4#9&=^>G?I4P&!0 @0#U_.F2#"DX+8Z &I:* ,R[-]]IM#;&(0
MEB;A9<[BN#@+CC.<=:T @(')Z=:?10 SR5SGG/KF@QJ3FGT4 ,,2'M1Y2\<=
M*?10 WRQ1Y:XQBG44 -\M?2C8#3J* &^6/I2>4OI3Z* &>2F<XYI1&H[4ZB@
M!AB4C&.*7RU]*=10 SRU]*!$HI]% #?+4G..:;Y";MV.?6I** /'OVN8@/V;
M/B&5X;^R9!^JUZOIG_(/MO\ KDG_ *"*\K_:XY_9L^(7_8*D_FM>J:80=.ML
M?\\D_P#010!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O"/VX
M(/M'[,WBM,X_?:>W/M?VYKW>O#OVUEW?LU>+0!GY[$_^3L% 'M_\->.>)]1U
M_P 3^+?$>EZ+H\L<5CI#);:M=L&L[FY=TS!M!Y 5#N],UZY?Q37&GW,=O((;
MAXV6.0C(1B" ?P.#7E/ASX-7PLB^N:D+74YO+^U2Z S6ZW)4-N:3=G<SELDX
M!X S@4 ,^&.MR3?!5DM91?:CI]C-&\MJC)')<JC,PC!_A#C:!]!5OX<SS^++
M\ZQ=RV]QIL^G64]I:R+F>VFD5FGW'T+%1MZ#;7/V/ABZ^&7C#0M+GOP-,\0I
M)HEG9V*E88#'!-*DA1CA3L0@E,;BQ)KJA\/-6CO=1N+&]_LN2[MV@+PR;]IC
M"BW95(PHQN++CG/XT 8>F+J$GBF\BL-1CBTW58+^)H+N,)*)HCY:E%'51DEG
M.2>,XK8\+P6_C%M4L+N2*[TR&WMH+5H'92!Y0$I5@?N[TX(QR"*O>"_A>/#T
M\E]J=XVIZB\3PJ<LL4*.VZ15&>=QZLWS=LU4TGX<7W@Z_<>'XK);=-/\B*YN
MI9&G9U+&-).QC4L??&!0!D>$/$%WJ'Q!\[1M)A;1[F]N[6^O[2[62!A$B[9'
M7@K.7&PKC[JY)Z5WWQ&CBE\%ZQ'/J"Z3'+;/&;UQD09P WX'%8?@OX8R^'?%
M%SKMYJ3W5S-:16Z64$8BM;<@9E=%'+,[<EG)(  KK/%&EG6="O;(1Q2&XA:(
M+,-R9(Q\P[CO^% 'GGAH0^"7^(FL-%Y4,NHI)O.2LL@MXTW;>V6(]JL7=WXO
MAN-#O'UG3&LHHS#>)'$4%U=2/MC7!)*H RGCG(JWH/P^UG0-#\0VD.M>?<7S
MB2S:9"5@(C5<,<Y(9EW'&,;B!5;1O"?C+2/AKIFGSSZ+J/BA95EOYY;=EM9C
MN+$J!\VX#8 QR?EZT 6_'7C75/"?A&#59;41S1!9+D10O<)@D+M!7D$E@<XZ
M T[Q)J7CJPU.V31['3;NS5[;SWFD8.R%\3[% X(!!&>V?2HO"7P[U32?#?A:
MVN=:NHKW3%(NAYIN4N SAG0L_)'4!CR :Q_!UA\2-3U.WM?$D,-K865PTDFI
M1786:\PY**L2C C(V@[CG@^M 'KD;EC4E-1=JXIU !1137&Y<4 >2?M%_'J7
MX%Z)H4UAX;O/%VN:YJ(T[3]&L&"RSN(GE8@GCA(V-8?Q'_:@A\+?LY6/Q8\/
MZ3_PDMM>)9/#80S!2_GNL>W<>,JS;3[@UC?%?]GGQC\6?VAM&\4R^*IO#/A?
MPWI,D>D'2G5KK[=,P$TCJZE0/+&P'KUZ9.?-[K]COQ[I_P"SQX_^$-AJVGZG
MHD^N0ZCX:N]0D*R+ UPMQ-%.%7 PX?&.#N[4 >I_#C]K1->7XFQ^,_#LG@NX
M\ 1QW&JL;I+N$1/$905>/@L%'*]0>*S?"?[3WQ%\8:YH%]:?!?68/ 6L36PC
MUJ>ZB$\<$P^6=X =P094GT!YJAI?[)^H:=KGQE\-1O9VWPQ^(=@LIMH)&-Q8
MZ@\(CG90>J-@-UZBCX>_#C]HOPW9>&_"&H>)/"B^&=&EAAE\06D<IU"]LH@H
M$7E,-J.0N"^3]* .Y^$7[0T_Q \8?%;1=5TVVT1?!NN_V1;2/<C-X/+WAL'&
M#@KP,]:XS1_VR+N^^$'PW\;S>& @\8>+XO#*VJ7()@1[F2 39QS_ *LG;4'P
MY_8VL+?XA?%KQ!X[T70_$:^(O$9UG1&D5G>V3R]H#9Q@YQP,US?A_P#9-\=Z
M)\"/A3X02\TJ/5/"/CJ+Q'<E)F\F2T2ZEEV(<?>Q(!CIQ0!WWQ,_:+^(GP^\
M7Z7H9^&EO.FN:Y)I&BWTNMPQQWF(7E4D=4++&W#=ZI?$/]I/XA^#O$'@WPM!
MX)TB3Q5JV@SZSJ$-[K*6]M:&)U5HUF(PQ&X&NR^//PAUKXF>*_A-J^DRVL,?
MA/Q5%K5Y'=,098!#)&P3'5AOR :Y3X^_ #Q+\0?C!X:\7:1I_AO6]/L-!OM(
MNM,\2;S')YS*00%4]E(SQUH U?&/[2>L>%-#^'&EVWAF+Q#\1/&UNS6>D:9>
MJUI&T<8>61KD_+Y2[A\PSGM3=!^)WQTN/!_B-=5^%>GVGB^U$3Z7##K*/8W@
M=RK!I<91D R01SN7'>L/Q3^S-XIU_P )_#+6M*U+1O"WQ/\  D,D=@=/MG_L
M<QR#8]N8L[O+"!0"#D$5WWPC\)_%2Q\0ZOJWQ%\2Z1?PS016]CI&BVS1P6Y4
MDO*S-RSM^@H \U^%'[2/Q<^)7Q UG0O^%<Z3;6'AW6H]$UV[CUD.]L_EB1Y$
M3:-Z[77&.<YKL_!?[1&H>*_"OQGUDZ/! / NKZEIEK$)B3=BUAW[G./EW'CC
M-:/P*^#>J_#/QC\6=9U.ZM9X_%WB4ZQ:1VV<Q1>0D8#9_B^3)Q7F'C/]F;XH
MV6L?%"P\!>+M'TWPI\1+EKJ^74;=WNM-EEC$=P\&WY6WJ.,]#0!7U7]L[Q3_
M &)\)[G2/"NDW-YXU\,3^(9([W55M8X#$J,85=AAB=_Z5?UK]MRXN?V=_!/Q
M,\/^%/,F\2ZY!H::7J=VMN(I)96B#&7E=NX [NF#FG^)?V*=.U_7OAQI,\=G
M=^ ?#?A#4/#-S;7*;KAFG2-(Y8\@@$;2P/!4XQ6!=?LI_$K4/V=/!?@#5-8T
M/7-4\)>*+/4;"YOE8PSZ?;2%HHIEV\L5PI&.10![;\ _BEXG^(NDZ[<>*=(T
M?2;FQOEMH1HVJIJ$<J>4K%BR?=8$D;3ST]:BN_VE?"UG\9#X N=1L+:==--^
M;Y[V+RQ(MQY#6S#.1)N(X^OI69^S]HFK^$M?\9:#J^A^&-"G\Z#4$M_"UMY-
MNZRJP,CY )<LA^@ Q5F\_91\ ZA\;8_B7/H.FR:FMD]L]J]C$T4D[3>;]K;(
MR9L\;NN* -C]I+XJZE\&?@QK_C32K&WU*]TSR"EI<R%(Y/,GCBP6&<?ZS.?:
MN&\(?M&>--+^*7A7P#\3/ T/A[4O% NGTG4M+U!;JUE\A%=T;@,K88'&.AKN
M?VC_ (5:A\:/@IXE\%:9>6]A>ZHD*QW-TK&-"DT<F2%Y_P"6?;UKAO#'[/WC
M#Q-\8-!\?_$W7=-OI/"D<L/AS1]"A9+> RH%EFF:3+,Y"H !C&V@#S[P9^UM
M\1?''Q%O]'M]+\$:?HUEXOD\.2MJ&N>5?LD<JJ72 CYF*M\H!Y-;=K^U[XG\
M4?%_Q)X2\+>'M#N8] UM=(GT_5-7%IJ5Q%_'=Q1. &C!/ SDX]Q6?X0_9.\=
M>!/%-[>0OX UG3[_ ,7S>)9[K5M%:;4(D>5'"Q2<!74)\I'0FL'Q+^RUXJ_:
M/O=#\0ZAKFBCP])K47B&PUF33\:]9VRN72Q\P?*R!NA/04 >KV_[3\NA^-_C
MU;>)+".S\._#:UM;R.XAYEN8WMC,V0>,Y&U0/45SGA_]H+XV^*/^$8\11?#/
M1-+\'ZRT-PD&H:ZB:E]C<C]YY9 4,%97QD\<=:ZE/V9YM;\=_'"[\37T.I>&
M/B)96ME'91*5FMDCMS$^3TSD[A]*\KU?]A_Q_P"*M/\ !OASQ#X]T35O#?A.
MXMCIVH/I,@U@6\#JR0F7?LY"A6..0!0!VTG[8R^&OVLO$'PI\4:5'I?A^,64
M6F>(D+&-KJXB#I;SG&U&?Y]O/.WWJS\'?C;XA^.7P*^*FK:U86=A=Z3J>LZ'
M!#:,Q#);K@%B>YW=N*T[[]EZ/Q7X\^--UXFGAO/"WCZ+3!#:P96YM)K:$QF4
M/_"P(1E(Y&*P/V=/V=]9_9E_9S\=>%-7U:#63/<ZEJ4%Y$6,CI+$ /,+=7^0
M9^M 'T7X,);PEHA/4V$'_HM:UI1N7;DC/'%97@PY\(:(?^G&#_T6M:TG:@#R
MS]EG_DW_ ,$#!&+';@^SL*]5;H?I7E7[+1S\ O!@)!9;-E)'3(E<'^5>JL<*
M?I0!Y#^S?C^R_'H#$@>.-<SD]#]K8UZ\>AKR#]FY2FF_$!3DG_A.-;/(QUN2
M1C\Z]?/2@#R#X+.6^)?QI'IXF@_]-EI7KS)NQZ>E>0?!9@?BA\;!Z>);?_TV
M6E>PT ,"!>1UKC/&".?&_@5D(&+RZR">H^R2UVU</XTO(;7QMX#6:14,M_<Q
MIN/WF-G+@"@#MUY44M,CYI] #)!D8KR;]G:1W@^(JO(T@3QIJBKN[#<G%>MG
MI7E/[/\ CR_B& &!_P"$RU(G<,=3&?ZT >KT444 %07HS:R ]U(_0U/4-T T
M#@]"IS^5 'G7[-US]L^!W@V;"C=8+PAR/O-WKTNO)OV5"#^S_P"#=IR!:N!^
M$TE>LT %%%% !1110 4444 %%%% !112$X^M "T53-_%_: M"6\\Q^:!M.-N
M<=>F?:KE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D7
M[6YQ^S9\0S_U"9/YBO3]#S_8UCN^]Y$>?KM%>7?M<#/[-7Q$]M'F;\L'^E>G
M>')C<:!ILI(8R6T3$@8SE : -&BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *\._;5(_X9L\6_-M.ZR_]+8*]QKQ']M .W[-OC$)*(&,=L/-(!*?
MZ5#R,]Z /:PW%+NQUKR>^\.>9XJ71F^*6N6^LW,#7D>FQO:"0PCY2ZH8<[0>
M]9OBF+1O UQ:6GB'XR:IHEQ)$&CBOKNSB>1<XW@-%SSQD4 :_P 6GQ\1/A#S
MC/B"X_'_ (EUU7J8/ YKYLUB#X>ZTGAG7M0^-5^T=M<3WNE7KZG:1HTBHT$C
M#]WAPH=A[9K9>]\)QZ%%K,OQNU%=(DN&LUOFU*S6%YE&6C#^5@L!S@4 >]%A
MF@.,UX?X:^&[^*-/?4-$^-/BC5+"9B(Y[2XLI8UYZ B$YQ5#QGX7@^',%K<>
M(?CIXCT2"YF6* W\MD/-D)'RC,()^@]: /?MX%!8'_ZU>93_  Y\47$PD3XF
M:Q%&,X6.RM?FSTR2G/\ ]>FCX8^+#-O_ .%HZV8RI&P6-IW[Y\OM0!Z>'%*7
M%>4ZIX-UCP_HT]QJ/Q4U:SAACS)>W-O9HB 'DL3& /\ Z]9?A?3;OQW]HO/#
M?QHNM9LX=T4GV&&RF6-R!C+*O4=0* /:=X]<4BE 3CJ.M>6P?"SQ9';2PO\
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M_H7=+_"T3_"F#X;>%021X<TP?]NJ'^E &Q_;-B>EW!_W]7_&F_VY8'I>6_\
MW]7_ !K,7X=^&$''AW2Q_P!NB?X5&?AKX4(/_%-Z7R<\6B?X4 >?_M6ZS9G]
MG'XB%;J$LNBSL,.#V'.,\_2O3_"%R;SPIHTY<2&6R@<NJ[0V8U.0.WTKQO\
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M$JHJON)ZGIBOH[4_%_A[Q3XGT?Q#J?PV\73:UX>\YM+NYM"G#Q&5=LFSC'S
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M[3=6 ;RRR@\$ND+1@CISFO6-*^,2V]LMG;_#[QC;6]M&L<2'1I%4*HP%7Z
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MVRV*_LX>+CY8DR+10#TR;N$ _AUKVRO%OVR(FF_9O\9*@RPBMWZ]EN8B?Y4
M<EXD^)OBFV^(_P"T+ID&J^3:>%?!^F:AI,91=L-Q-#>M)(2>O,"<'CBO$_%?
M[4OQ \._#[Q;<76IFV3_ (1KPW<:;K0A!,&I7$*R2Q.N,8E57VL>-W'4BOIO
MXC_LR>#_ (K^(K[7=2;5;*ZU2QBTW41IE^]M'?VR%F2.91]X#>X]<,16AJ?[
M.G@G6--\7:;=Z8[:;XHL[.POK82D(([5-L'EC^ KP01W H \8\>?&+Q7HWP]
M_:CU6WULV]QX2AC_ +$<1+FU<Z?%+C'\69'/7UK'\9?M,^,_#^M_$?2K827M
MT?"=C#X95(>9]?>#,EN@_CD_?Q2%>RJ37MGBW]E+P#XVUR;5-5M;^5[L6RZA
M;17\D=MJ7V< 0_:(E.UR-HY/7&#6I+^SOX.?7+;6&LIFU&#Q)_PE,<YF)(O?
M),(^B",[0OH!0!K_  *\9_\ "R/@YX+\2/,9Y]2TFWFN'/!\[8!*".Q#A@1Z
MBN\$84\$_G7*?#7X=Z+\*O"UOX=\/PRVVDP2S2Q0S2F0H9)&D< GMN8X':NJ
M\Y,XS0 XIGN1^--$0'.3GZT[>",YI=P]: $" =S^=*5!_P#UT;AZT;AZT )L
M'J?SHV<8R?SI2P%-\U?6@ $87N?SH\L9ZG\Z/-7 YZT"53WH #'GN?SH,0/4
MD_C2B13WI=PH 8(0.Y/XTIB# C)Y]Z=N![T;AZT ((P/7\Z0Q*<9YQZT[<,=
M:3>/6@ V#%)Y2YS2^8OK1YB^M "&($8[4OEKZ4AE4=3BE,B@#GK0 TPJ:/)0
M8XZ>U.,BCO2>:GK0 GD(.U+Y*^@H,R#^*CSD'>@!/(3&,4&)0#Q2^:I[T&51
MWH \KTJ )^TSXA8\J?"EAM]O]+N<UZH8E],5Y?887]I76OF^_P"%+(X^EY<"
MO4/,4#DT (85QP,4"%1VIWF+ZTGF+ZT ->)>#CN/YUY-^RE&@^ /A7&""MR3
MC_KZEKUII%('/<5Y!^R4X/[/WA7G/_'W_P"E4M 'L B4=J&C5J4.I[T;U]:
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M"9$/Q5^(P!Y\W3VZ]C:\?R->AF55ZGVH 4H,5YA\75'_  E7PO;O_P )(/\
MTEGKTXR*1UKS/XM[9?$GPS8$?)XD4^G_ "[34 >F*@*@X[4I0$8(XIB3(4&&
M&,4"YB;.''% "R(-C>PKA/A<G_$Z^(F0PSXD<_-_UYVO3VKNWF3:?F'2N&^&
MUS'_ &Y\0 2%QXA/_I':T =UY8SGO3MON:C%Q&1]\?G3O.3^^/SH =MIKC&,
M>HI//C_OC\Z1Y8R!\PZCO0!YU^SM;PVOPGTZ&W3RX([R_5%!S@?;9Z])P#VK
MS7]GN,67PKL(7?)6]U#!/4C[;,17H_G1_P!\?G0 _:*-HIAGC'\8_.D6ZA;.
M)%..#@T 2;:38*B:]@09,J >NX4W^T;8,5,\88<8+"@"<( *4J"*@.H6PSF>
M/C_;%!U"U'6XB!]-XH G Q2;14/]H6V0/M$6?]\4?VA;8S]HBQ_OB@";:#U&
M:A2RA28RB-?-88+XY([#/I1_:-J/^7F+_OL4G]HVO_/S%_WV* +&*-HJO_:-
MH!S<PC_@8H_M*T_Y^H?^_@H L;11BJ_]HVG_ #\Q?]]BD_M2SSC[5#GT\P9H
M LXHQ5-M:T]!EKZW49VY,JCGTZTU]>TV-V1K^V5EZAIE&/UH O8![4;1Z50&
MOZ83@:C:D^TR_P"- \0:8PR-0M2/43+C^= %_:/2C:*H'7], R=0M0/^NR_X
MTXZYIP&?M]M_W^7_ !H NA0*-H]*I?V[IHS_ *?;<?\ 39?\:4:UI[=+ZW/_
M &U7_&@"V5!HV U4.MZ>,_Z=;<<?ZU?\:3^W-.QG[?;8]?.7_&@"[M'I2;15
M)M=TU5W'4+4#KDS+_C2_VYIW_/\ VV?3SE_QH ND T;15,:S8$X%[;D^@E7_
M !H.MZ>,9OK<9_Z:K_C0!;V"E(S5(ZYIP)S?6_'7]ZO'ZT'6]/!P;ZW!QG'F
MK_C0!YS^U.I/[./Q(VG!70;MN?:,G^E=A\-;S^T/AWX7NMH0S:7:R;1VS"AQ
M^M</^T]J5G=_LZ?$J.*[@=V\/7V%60$G]RWO77?"!MWPG\%G!!.B61Y_ZX)0
M!UU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XM^V/'YG[./C$;
MRF8K=0P[$W,0S^&:]IKRS]I[1&\1? SQ58+/';;H(Y3+*<*JI-&Y)_!30!G>
M,M.N/AY8W>O^(/B;K5KI!N(K=(TMK?;$TL@CC4?NR22S 5>UCPU<>'_#]U?W
M?Q%U]K6PCEN9'06S.RQ*S.,"+G !X]JP?C9:ZI\2H[3PE;Z:T.GC7],NY[^2
M9/)GLHI4GE*G.5;*;0.O3M7D&B?#SQ=+<66CWVGWHCTN\\6%]0DG7RKI;V*0
M6I3YCD$/CGH10![=X6\-CQ?X7T[Q%I_Q'\3'3;ZSCO(GE>W0B.10ZE@8OE."
M.#65\0K:/X=KI\NI>/?&TJZC<JD0L+6.YQCG#;(3M4^IKR&S^&%]<3^$_!DU
M[=V6F^+O#>E1>([6*Y -@=-,9ER0?D\]2(21UQ7T/\8KK5I_AIJ.D>$+R*VU
MS4E33;>[CF4?8$E(C>Y&3_RR0EP/510!QGPTT/\ X6WX._X2'PW\6O%=[I%V
M)+>"Z,4"?/'(0SJ#%SR"OIQ6+\2O$%C\%;W2[7Q+\7_%4<\D<ER&^P0S(L.\
M*TDQ6+"H"0,DC%>C^'M6\._"*3P%\.=%M2^G26,MM!<0R*4MX[= 2TISU<GK
MW8GUKG_VBAJ/C>ST?PAIMH;GP_K$A7Q%?6[1LZZ>O+VRY.=TI^7(Z#)H Q_$
MGQ(TCP?XQMO#6J?%^\BU.YCMV6%=/A=8A,VV%G=5PF\_=W8S4G_"PM,7XC#P
M'_PMO4#XD:=K5818P[!,L9E,._9MWA 6VYSBN)\7?#35]2A^)^FV>EX@\=W^
MBWNGW0= -/AMX;:.2.4YR/*^SE@!D?O..]"?"G79O%SZ%!I\46G+\37\9MK1
MN$:-[*2%F9 <[A(6)C*^A]* .\\#>-K+XD:S)I6@?%?4+J]6-[B-3I\*K/"C
M^6\D1*@.H?@LN:]";X?^)VQM^(6HKCKFR@.?TKR[X8?!9_"_Q=TR]CN[G_A%
M_"&DW6DZ*+PQAW^U2K)+@KRT:K&J@MC)_$U]$MJME&%+7<"ANA,BC/ZT <.?
MA]XG*X_X6%J(]Q90?X54L/A/XAMX56Z^)?B&\?))8PVJ;ANR!@1^G%>A#5[$
M[<7D!W<#]ZO/ZTO]JV/'^EP<]/WB_P"- 'F4_P (/%<DQ=/BMX@B0RE_+%K:
MD;#_  ?ZOZ\^]:$'PKUD2,]Q\0_$4S%@1M6W0  GC C[YY^E=XNL6#8Q>6YS
MTQ*O^-']L6'_ #^V_K_K5_QH XJU^&FM0AMWQ!U^4[B1E+;@<\?ZKW_2IU^'
MFL@#/CO76Q_>CMO_ (U77KJMDX!6[@(/I(/\:3^U['_G\@_[^K_C0!R2?#W6
M5'/CS76YSS';?_&J<?A_K!3'_"<ZWGU\NV_^-UUO]JV7/^EP'_MH/\:&U2S4
M\W4(^L@H Y!/A[K"%O\ BNM<.3G!CMN/I^ZJK/\ "W5IDE4?$#Q'&9"267[-
ME<CM^ZX%=N-7L3TO+?\ [^K_ (TU]=TV/;NO[9=QP,S*,_K0!Q,'PJU:"2)_
M^%A>))"DA?#_ &8ALC&"/*Z5+<_#+5KF.=#X^\0QB7',8ME*8]/W5=>OB#3&
M4L-0M2HZD3+_ (TT^)-)!YU*T'_;=?\ &@#B!\(M36W$7_"P_$^0K*)-]ONY
M[_ZKJ.U3P_"F^C*%_'7B2;#;B&EA&[C&.(_QKLCXATM5W'4;4+C.?/7_ !I!
MXBTIB -2M"3Q@3I_C0!R%[\*+B[>-D\:>)+<+C*QW$6&Y[YCI3\*)28C_P )
MAXC&Q"C?Z3'\^3G<?DZ_2NN/B/2E.#J5H#Z&=?\ &D_X272?^@G9_P#?]?\
M&@#DI_A1--.7'C+Q)&OF^8$6YCP.,;?]7T[U.?A:K/*S>)_$!WJ%P+M0%XZC
MY>M=*?$^C@X.J60.<8^T)U_.FIXJT:0';JMFV.N)T_QH YF+X5>7'$A\5>(G
MV+C+7:9;W/R=:CA^$\D2,I\8>)')?<&:ZCR!_=^YTKK?^$ETG /]IV>"<#]^
MO/ZTA\3:0IP=3LP?0SI_C0!XAIOP^=?V@]7T^3Q/K\J?\(O:S"5KE XS>3\9
M"=./UKT6Y^%'GQ;4\6>(X3N#;DNTSQVY3I6-9WM@/C_JFH&_MA WABU@#>:N
M,B[G)YS[C\Z] 'BO10K$ZM9 *,M_I"<#WYH YL?"I/-D<^*/$1#'(7[8N!]/
MDJ6'X7P1@[O$.OR_[][_ (+6^?%FB@J#JUEEE+#_ $A.1Z]:KW'CSPY:%1-K
MNGQ%_NA[E!G]: ,=/AC%#/'*OB+7FVL#L:]!4\]_EKRK]F3P&NN_ OPI=2:]
MK5LV+E2EM<A%.+J4=-OM7MEMX[\.ZC(L=MKFGSN2"%CN4)/ZUY]\"-:T7PI\
M(] M+S4K*PV>>1'+<*OWKB0CJ>^1^= '4+\*X5))\1^(6SV-\/\ XFD7X46Z
MQE/^$C\1'W-_S_Z#6K_PLGPIC/\ PD>EX_Z^T_QJ5/'_ (:E&4U[3F&-V1=)
MT]>M &1)\++61-IUW7P..1?D'^59'BSX96MIX4UV1=9UR1OL%QCS-08C_5-V
MQ752?$;PM$V'\0Z:I]#=)_C6+XA^)'A+5] U>TMO$FES3/;30;$NT)W&-ACK
MUYH XSX+_#*SU?X3> ;^76-=BF&A6OR1ZDX3+0KG(Z'';/2NTC^$=A!(9!K.
MONS2I(=VIN1E>V/0]QWK!^%OQ!\)^$?ASX5T34O$VDVNH66EVT$T#W<896$0
MXQFND;XT^ OG'_"7Z-E&4-_IB<$].] 'F_P1^&5AKWPXL6GO-?LS;W^IQ(BZ
MI(F1]KF7<<=<]1GI7HEG\)=/TZ!HXM7UY@54?O-3D<\# Y-<)\ /B1X6TKX?
M16MYXKTEYVU'4)8U%XA/E/>3-'W_ +I%>DQ?%;P=<?ZKQ/I;D@D;;I.W7O0!
MY?X,^"^CZ_?>-K:[U3Q %M_$5P$:'6)HF.^VMF.2I&>3QGH.*Z]OV?\ PZUE
M!:G4?$7EPAMA_MRYW9;J2V[)/UKG/AY\5O"6DZ_X^EO_ !1HUO:7GB(R63F\
M0>:ALK56[]=ZN/PKLE^/GPX9Y%'C?0BT;;6'VZ/*GT/- 'FGA[X'^']6^)GQ
M"LIM4\0YCDTUF:+6KA'_ ./8XR58>E=K%^SGX<BMA;C5O$YC\P2_-KUR3D9[
M[LXYZ5A>'/B'X2T+XF^.O$%YXJT>#2-4335MYWNT =XXI%?G/NGZUZ'%\6_!
M=RH:'Q3I4BE=V5NT(QZ]: .7/[-_A?()O_$AQM_YC]USC_@=<K\1_A+H&C:I
M\/K6)M2E6X\2)EKC4YW=<V\WW27R*].C^,/@B6)I$\5Z2T:G#-]K3 _6N"^)
MWQ.\':AKO@,P^)M*E:VUZ*9PMTA*J8I5SUZ9/6@#J-,^ OA?31E'UB;+^9^_
MUFZ?MT^_T]JEB^!?A6'R-JZG^Z##G5KD[\MN^;]YSS^G%,/[07PWBE>!O&VC
M>=$/F07:DCCZTLG[0GPXBAAF?QIHRQ3$!'-TN&STH /^%&^&(]-N[(?VJ8[E
MV=W.KW)D!/96WY4>PKE/ASX"\-ZCXB^)>G-:71-KKR(S&\G7.ZQMB,,'SG!Z
MUVM]\;? 5EIPO)_%VD16K' E:Z7;^>:X+P;\8?!&@:]X\O[[QII L]0U9+B#
M$R@(@M85R3WR5- 'H%E\&_"UC;&&*TN]A)8E]1N6;)Z\F2IF^$GAEF!-K=<
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MIG_#5_@/?=()M6<VR>9-MTJ<[%R!G[OJ10!W)^$G@HRM+_PB>C>8W4_88_\
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M]]UZU2$X!H ^=(O@EX&/QVO_  \?"]@=(/AB&[\CYQ^]-Y*I/WNX _*NS?\
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M(XH ^I;?X!_#C3FE%AX.T*T=XPL-PUFL@&3\P^8G)^7\ :Y7XJ_!_P $Z?\
M#GQQ?V7@G2+*^70+^9;^&Q2-XIDB)!7OGG(/M7HOC?1X9]0LXE^T1,8;F7,:
M%H050 [@.A(( QSUK-^,M[<7/P,\>N+(V;1^'[\2)*/O9M6/RGN,XYH YG]G
MGX7^#/%WP'^'>KZKX5T74M0N-"LY9;NXL(FDD;R0-Q8C)/UKEOVBH-'^%6N?
M#BP\/^%O#.F6?B/5YK*_NY/#JWCJ([:29%2-,$L3&1GD 5Z%^Q[(TO[+/PJ=
MW5V/ANR)93P3Y0K7U35?A]X]\:M!<ZA8WWB'P#<?VG)%Y^'TV1X73S&&>\;.
M.>.: /G_ ,-_%30/#O\ 8-CXG^$>B:?KJ6]E-XA>VLX(6LDO+LV]JRQ,-[EN
M'9%R4SSS5?P[\=/"&E:+HK:QX#T[5I9);B2^U2.PMH5M8/[9ETY6V=6PR@\=
M1SU->]ZGX>^%?Q%\<Z9KMS'I&K>)M$MK;4;:Z,OSPP.Q:WD;!PRY!*EL\\BL
M^U^&OPDNM7U'PNFF:>UWIME')<V3,<103W;W:,3G&&G#R?7- 'B.F?&/0K+4
M-'LO$OPL\-N=0\6:CHJ74$5L(+-8;W[-$&++DRL!NQQD#BOI^+X*?#\R/,?
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MXI?&NY=5FTS4O%6E7%E?Q61N);>:?1HC#/'P1'A7=B[#&W([T <M!X[M-/\
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MB$%M%LP@E$;*6VOEURH!88-<QJ.CWNL^'-+U72YD3P_?F&#1+O4;A7::W""
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M (1G4L#_ +=I*M_ 9B_P/^'C'J?#NG$_^ T= '=T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7D/[71Q^S'\4B1D#PW?<#J?W1KUZO(/VNR5_9C
M^*1#;2/#=\0V,XQ$>: /0/ <BGP1X?/*@Z=;'!ZC]TM;N]?6O%-$^#FH^(O#
M>D7O_"PO%%B)["U;R;22%(TQ"HPH,9(SUK3L_@/<V]M+#)\0?%L^_H\EU'N7
MZ$)0 GQL5G\9_!XID@>+MS8]/[.O>M>L!@%'/:O'-<_9LM=?N;*>Y\9^*O.L
M72:TD6]7,$P1T,@^3[Q61@<\<UH)\#+L0VL;?$#Q6XMRI#&ZCR^!CYCLY]Z
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M&3WFJPZW=MIT8EOX)/,2=@2"RM@;AQC..<4 >@:NC/IET%.&,+@?]\FOE_\
M8"00?LE^ WFB\R?SK^-L] 1>W!R/0Y.,^]?5$I^4=.HS]*_/;]E[]GO2/B+\
M%[76M1U_Q;I_VK7-7#)I&LR6UI!"EY*=Q4<+].YH ^V;73&TVQATRWM)GLQ
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MRG^-<?\ \,]_#H[/^*/TO]VQ=,1$;6/!(YX-5O\ AFCX7E@W_""Z*6'<VX-
M'<MXJT=20=5LACK_ *0G^-*?$^D[E4:E9EFY4?:$Y_6N//[/WPY>:29_!6BF
M64$.WV1><\'^0K5M/A)X+LHHHX?"FCHD2E4'V*,E0>3@D4 :=SK>BRS1^;J=
MH'B;S% N .??FG/XRT*. RG5[$1CC<;A<?SJK_PKCPKD?\4WI.0, _8H_P#"
MFGX9^$RFT^&='*_W38QX_+% &E%XHTB9"Z:G9NHX)$ZG'ZTC>*=(159M4LPK
M'@F=>?UK)@^%7@ZVDG>+POHZ&=M\F+*/YCZGBGGX8>$2H4^%]&('0&QBX_\
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MZU]+4 %%%% !1110 4444 %%%% !112$X'- "T4FX9QGFEZT %%%% !1110
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M L7E1P^/]>1/<?: <_F3^5?3= !1110 4444 %%%% !1110 4C?=I:0\X]*
M.=@?7AXRN$D2R/AO[&GE2*S?:1<[CN!&,;-NW!SG.:Z(<"N+^+_Q$M/A!\.=
M=\7W=A<ZA;:1;_:)+:S ,L@W*N%SW^;/X5R]I^T9X5:_U6*YNY+2WL_L/E7$
MB[A=_:8&F7RU7).U4;=QQM- 'KM%>17'[3'@NTUW6]/DU%EM]*T>SUN74-N8
M)(;IY$A6-A]]B8SP/7%;&F_'?P3K.O:'HMEXAMKC4]:M4O+*WCR6DA8,5?V!
M\M^O=30!Z+17E5I\=M/N_@_<_$%;&\%BCSQVUGA?.O'6=H8DC&<$S.%">NX4
MZ/\ :&\)1^%_"^KW]Y+IK^(8]]M93Q%IXV!VNLBKG;L;Y6)X!H ]3HKQVR_:
M1\.7NK7]L)'M+33=2U/3;^]O2(DADLD1I6 /WD_> 9'I5IOVE? ,6B1ZM)KN
MRUDN)+55:!Q()$C\U@4QN'[O#Y(QM.: /6**X70?C!X7\3>,KKPQIFK+>:O;
M6L5[+#&A*K%(BNC;L8Y5U(^M=RIR >M "T444 %%%% !1110 4444 %%%% '
M+?%4;OACXN7UT>\_]$/61^SZ^_X$_#QL@Y\/V'3_ *]TK:^)REOAOXK &2=)
MNP,_]<7K%_9\</\  GX>L%V#^P+'Y?3]PE 'H%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5X]^V%C_ (99^+&>A\,:A_Z(:O8:\E_:SC$O[,WQ
M20J&#>&=0&#T/[AJ .V^&QS\/?#!_P"H7:_^B4KI*Y3X3-O^%O@YCD$Z-9GY
MNO\ J$ZUU= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 >?7+?\7TT_+8;_ (1ZXPGJ/M,?/\J] QE:
M\KU$X_:;T)<]?"=\<?\ ;W;5ZIC"XH ^<?VJK>73?$/P^UA-:U.V!U*2RBTV
MU:".WEF,,CK+))-\J% K8]3@5Z1^SWIT6D_!_P ,64$+V\,%LR+')=QW;8\Q
MCDRQ_*Q/7C@9QVKA?VH&NTAT.#SUOHM4NX[2TTB2S@DC>=$EE=VDF(5,QC&?
M]GCK78?LUZQ;Z]\%O"M]:,7MYK=R";9+<@B5U*[$^48((^7@XSWH ].<=/J*
M^5?^"?/G6_P*NH8X&C$OBO6VW8RL8%XW!^HR!7U6_0?45\J_L#7(3X*7WFRF
M,IXSUJ%1CB0FZ? _SZ4 ?3MY902R17$D2F6(Y1SU6O@;QOX8>X\<^-]"O/&^
MD^!FDG\12M9>(K!U\^RU*5 \\,@;#KB,8/8L0:^_I-\C[3M\K:<YZYKSK3O@
MAX1T;7?$.K2:3%J^I:]<27%W<ZHOVIER<^4F\$)&O91@4 :WA-9=/\.6%A%*
ME_;*5M(KB-"@2$1*J$@_>^[U'K5_6D@MO#>I6:1^3'#8RG:BX3'EMD?KG%;$
M 6W@"MB*.+$2YX! P!^=9WBBV,VDZDV9$C6RFRH(VOF-A@_2@#XF\)ZK>:-^
MP9\%4M1:P0W-X([B]GTT7XM80MTX9(L')9D2//82&N]_8GUQYO&/C>SCA66R
MN-,TG5WOO[+^PLMU,LHGML8&5C*+@=MQK$^%7A+4_%G["'PMTO0[:)]2<1M!
MJ,E\;1=*833?Z5N'+%/[@SNS@\5[G\#=;M[K5]<TG_A8T?CV_P!,@MH;H16R
M1K:N P)++PQ8@DCMB@#AO$&F2-^SK\>[6U>XBN)=5UYU-O&SN69MQ 5<L0>A
MQS@G%<5^S!\,]73XD:'XL@D\'6VBXU:=AH&HO///'=,C0PE6 PD.T@ ]/2O7
MK&>&S^&/Q>N)]8NO#=O#K.L2S:M;1[Y;1% 9Y47N0,D>]>9_LOOX)N/B?):>
M"?AT^EPV&D1W=SXKU28"]O5NBS1N(\DGS"K,Q(&,]* /8_"DC1?$GXRM)*T*
M)/8,'$>[:/[/3G'\6#DX[XQ7R_\ LMWUAJ7QMT[5-*U>STZPN4N$6VO]"%KJ
M>JN,[I JY$$?!.#AFXXQ7U?\/T=OB]\4Q(P9#<::T8QR!]B4?S!KTJ.S@C.Y
M84#>NT T ?.O@J\;_AO;XBVZ9$;^!=&DD Z%ENKH*?P#G\Z]&_:*\F[^#WBW
M2&U"UTR\UC2;S3K*>\D\N(7$EO)LW-V'!)/8"O-O"L$D/_!0'QPYP8Y? &E[
M=O\ #MO)Q@_7)Q]#7<_M/ZQ9Z?\ ";4]/N;";4IM>*Z!:0V^P2">[#0(RL^
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MZ#HH \CO?V=-(U#X9^#/ D]]=-H/AR>TG,:ML:]^SY*+(1R!YFV3CNHKG_\
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M0T >4ZI@?M.>'O?PIJ _\F[:O5OX:\LU<A?VDO#&0,MX9U$9^ES:UZFO*C-
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M'%1?\--?"]KX6J^-M(,A1GW"<%0!URW0'VKIX?ACX1MX4BB\*Z+%&F=J+81
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M4.P\C"\5C_LGO,_[-OPX,\JS2_V); NG0_+Q^F!^% 'K-%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5YK^THI?]G[XCJ!G/AZ__ /1#5Z57G'[1
MRA_@'\15(W ^'[[CU_<-0!L?!]&B^$W@M'P771+(' QSY"=JZ^N'^!KA_@MX
M!;.<Z!8'/_;NE=OD4 >;?&D*5\$$GC_A*].QGUW/7I(Z"O.OC)*L4?@TD9SX
MHTY1QW+M7HH88ZT +12;AZT;AZT +12;AZT9% "T4FX>M&X>M "T4F11N H
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MATUPW3;<J<_K0!T]%<X/B+X98,1KNGD#K_I"\?K34^)'AA_NZ]IY_P"WA?\
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MB#*;-Q\N'Y\9W?P\9R/IBEL?A'XB@9C<?$OQ#<*5V@;(5P<YS]W\* ,3X-_
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M\>R/08T7GC[1-WZ_QT =J-6LCC_3(.1D?O%Z?G2_VG:9Q]JASUQY@_QKB?\
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M_/ZY_O4 =G_PE.C8S_:MECU^T)_C2'Q3HRYSJMD,?]/"?XURX^!?@/R8XO\
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MV'I^= '3'Q+I(ZZG9_\ ?]/\:3_A)M(_Z"EG_P"!"?XUSG_"EO!&<GPU8_\
M?!_QI?\ A2_@C_H6K'_O@_XT :FM^)=)?2+W;J=FV8)!@3J?X#[UY3^PN,?L
MC_"W/'_$EB_]":NUO_@IX'BLKDCPW8QCRV);:1CY3SUKE/V+4B@_9<^'44#!
MH(M-\N-AT*K(X4CVP!0![;1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %<%\>O\ DB?CW_L WW_HAZ[VN%^.@!^#'CL'OH5[_P"B6H J_LZX/P"^
M&YX_Y%W3^G_7NE>B5YO^S?\ )^S[\-5/4>&]/'_DNE>C;QZT >=_&B-)=/\
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MGF"FMJ]HAPUS"I]Y /ZT 7:*I?VS8@#-Y;\]/WJ\_K2?VW8YQ]LM\G_IJO\
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MY"OQ0OB\YRDK:?$6A]-O-2V?PP\:6TZR/\3+^=?+"&-["+!/][KUKEU_:O\
M#EO+H^E7+;M<U#3+2]/V,^=:QRW,,DL$?F#J'\J3!]JK?#[]KC0/$&G>'(-<
M!L-8OM MM;OO)0M;VGG0RS(A;U*02D?[ON* .^F\!>+W6 )X^N4,:D,?L,9\
MPGH3SVJG_P *U\:D./\ A9-Z,G(/V"/(X^M8%]^TC)GP4UCX6U00^)-9_LL/
M>)Y7D(;26Y2<CNK+'Q^/I3?"_P"T_HFH6?AR+4?,COM2MK%IIX(R;6*>[5C;
M1;C_ !2;" /<>M &_IWPI\76VTW?Q-U>[8(RD"UB0,2>#CVJT/AGXF5WQ\0M
M5VF,* 8(N&R26_$<5'\+_CEI'Q3OY+33[._M)!IMKJT)O8O+\^WGW!77Z,I!
MKTQ3D#/6@#S9_AGXH:977XB:JJ",J4^S1<MG[V:(_AAXG4/N^(VK.3TS;Q?+
M7I5% 'G/_"M?$OGEO^%A:KL_N?9XJ@N_A;XHN$*Q_$G6("1PRV\7'->FT4 >
M:-\,O%)V[?B-JJ@=1]FBYJO+\*?%KRRNOQ-U= Z; HM(L*<_>'O7J=% 'D=K
M\'?%T4\TLOQ4UR4R*%"&WA"IP.0,=?\ &FR?!;Q4^J+>CXJ:^I'2 0Q>7TQT
MQ7KU% 'C+? OQ5Y<83XM^)5D!.]S'"=V?;'&*MP_ W6!9SQ3_$KQ//,YRDWF
M1J8^,< +SZUZW10!Y!_PHG6/*13\3/%.Y7!W>;'RO=?N]_6G2_ O5&DC9/B1
MXJC X<>?&=PQT^[Q7KM% 'DP^!VIJJ ?$;Q22#RQGC^8>GW:%^!=\L:K_P +
M"\5$@YR;I/\ XFO6:* /+I?@M?2XQX^\3H H&%N$[=_NTB_!2]4Y/CWQ.W &
M#<IV/^[7J5% 'F)^#%V8I4/CGQ+^\.=WVE,K[#Y:D3X/7:1%?^$V\1DY)W&X
M7/\ Z#7I5(: /EOQ=X$ET7]I[X2V,GB/5KQKO1]>19[B8&1"%MSE2![_ *5[
M*?A3(4Q_PE6O#DG(N1_A7G?Q6;'[7_P(Z?-IGB,#Z^3;&OH,=* .%E^&;,58
M^)]<&U=N!< 9]^E5X?A%Y:Q@^*?$#E"3EKL<Y.>>*U_B1?ZQ8>%[F30[RQLM
M1,D21SZAS$@+@,<=VQG:.YP*R?@;X^O?B-\.-,UG48D@U1I)[:\@5=OERQ2O
M&P(['Y02.V: %C^$OEX_XJC7VY)YNA_A7SO^S+X'DU7Q)\>(K;6]3B>T^(%T
MH:&X"&4B./.\X^M?9#=OK7S#^R)#Y/CC]HA45E5OB%=,-PX),4><4 >B:;\,
M%O[=YI/%/B)&=FR!><* Q''RU;B^$2R7 ;_A*/$/E%3@B^!!]#TKNTE$LP5?
M*DB<,6.>0O0<?7->5_M$>+O%W@KPY;W7@^YL()[>VGN9;6:'S[BX6-052%,C
MCG+-V% &E_PJ11=M"OB/7ID";\-?D-R<<<=JT#\)+6W4,NO:_(<8"&^Y/IVJ
M;3?%6JZ]X<\+ZEIHMW;5+.*[?@E"KQ*S%6[8+9&>M= NHRQ?9HF>)GB81SS2
M9&7 7( [Y!SF@#R#X.?#.RU'P_K/E:_K2/#XCU6.3R[K;EQ=OG/')Z<UW\WP
MA@G50WB'7AM_NWN,_I6+^SG()-#\8@?P>,-9!SZ_:F_QKUDG% '@?@[X46FI
M?$'XBVT^L:TL<5W:H/+OV!93:+][CKR?RKM7^!^G-%"@U[Q"JQ#  U%LD8QR
M<<TOP^9A\4OB8C.'Q=V+  8(!M5X/Y5Z,W )]J /!K3X1Z8?CCJD0U;7 7T"
MTG8C46R6^T3IT],"NRN/@;IEQ-+(=<\0KYA4[5U)@%QZ<5:LHL?'+4)/+_YE
MNU7?G_IZN.*[^@#XX\:?"+2[']L7X9Z4;K5GMM2\+Z\)+MKYS,Q$MLVT/U4#
M.?QKVU/V:_#,<,L0U+Q%Y<NT.O\ :\IS@Y'?BN-^(%W<I^V_\(+<1A;=O#/B
M!C*?XCOM?E'TP#^-?1E 'DLW[-/A6:WM86O->,=L"L8&KS X)R<G//-<)^T/
M\%= \._ ?Q?=6J:I<R6>EN$BDU"5_, 8,=PSR?>OI6O,/VG'N(_@!X\:T:5+
M@:3-M:$9?IVH >_P"\+SS7TI?5"UVYD?_B92X!QCY>>*D/P&\,-'"A&I$13_
M &@'^T)<EN>#SR.>E>BQ]/\ "GT <')\&?#DFTM'>?*=P_TV7K^=?-_CWP[H
MOAO]K2]TZ"-[?[9\.3()7NG4F5=4B6,%B<XRP&!USBOLMN5-?#O[1>L'3?VO
M=4U V2WT^B_#(:A90 $M+.NL6S*N/XCD<#UH XV[UR]?6/$L?EZE+;R:7;ZJ
M+&VEN!<622RQA[4G/RNK,?F]& KJ?%'AJ]U"?Q-<:7J&L6;VIM[K3#/=NEB+
M=C&2C/NR9"CL/0D''2N?G@\5WNM^*M)O;[RYK6U$NGZG)(8_M%S;2Q3;=N?W
MD91P[@]?*(K4;7M=U'PCXLTF*Z@TR?\ <06>G74">39V_P!IAAB+NQ(+!)7=
M2>/F]J ->QGM;B[@+R74EAI#L+F47\PN;S%CYFSRR>"&=2QZ* ":MZ4K:+K$
M\'B#3]4MH+62UM;9;6[DN);JY(8>=PW,09<L2,$'TK%;7;9OA\]II]L9+Q(=
M3MM/U"6'S)#<)*T%UO"G#QLA0K(#@J/:N:T*<:CXTU#5-6U.>/3I+8:A:(T#
M1-)):6Z)<JISD0RHZCVVT >P_L_?#O1M2^-W[0]K>1R2^5XATL[HIW4$MI-N
MQ((/0EF(]L5[V/@UX9!7_1[HXZ?Z9+_\57C?[*SAOC1\?4SD_P!J:$S'W.B6
MN1^>17T[0!P;_!7PNY4FVNLJVX?Z9+U_[ZJ-_@=X5D:)C;7;&)_,3-[+PWK]
MZO0** //E^!_A<!?]&N_E.1_ITO_ ,50WP.\+,1FWO#@8Q]NE_\ BJ]!HH \
MQ7]G;P4D;QBPN]DDGF.#?S<G&/[U20?L]>![?5$U!=)D:Y7!&^\F*Y P.-V.
ME>E44 >;V/[/G@;3KQ;J'1CYZ[L,]U,P^8Y/!:K=M\#_  9;Q+&-$2106.99
MY'/))/);U-=[10!Q;_!SP;(J*V@VY5/NC>_'_CU1_P#"EO!1(/\ PC]OD'(.
M]^O_ 'U7<44 <)_PH_P1YBR?\(];[U& Q=SC_P >I1\$O!&\M_PCMKN/!)9^
MG_?5=U10!PP^"?@A>GAVV'T9_P#XJE7X*^"E8E?#UL"1@G<__P 57<44 <2?
M@QX+;.?#]L2>OS/S_P"/4]/@_P"#HU55T&W  P!O?_XJNSHH XS_ (4_X.&,
M:!;\<_>?_&@?!WP:&+#0+8,><Y;_ !KLZ* .+/P<\&DC.@6QP<_>?K_WU3U^
M$7A!6RN@VX/KN;_&NQHH X]?A)X13[NA6XYSU;K^=,?X/>#I89(6T"U:)\AD
M)8AL]<\UV=% '!)\"_ <4"6Z>%[%8$Y6,*VT?AFIHO@OX*@!\OP[:)DDX&X<
MGKWKMZ* .+?X.^#G !T"V..1EG_^*IH^"_@K&/\ A'K7KGJ_7\Z[:B@#AA\$
M_!*G(\/VX/L[_P#Q52)\&_!T:;5T.$+G.!))U_[ZKM:* .(3X+>"TQC0(.!@
M?.__ ,52_P#"E_!6<_\ "/V^?]]__BJ[:B@#A+SX0^%(;61X-$A66.-C&1))
MP=IQ_%7%?L5H\?[+GP]CE 62.P:-@!@ K-(,?I7M=R"T+ =<'K]#7CW[(,<D
M7[._A".5@TBK=!BO3/VJ:@#V:BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *X[XPR1Q?"KQB\HS&NBWI;Z>0]=C7(_%R);CX7^+XF&5;1KP$9QQY
M+T 8/[-.V/\ 9Y^&:!BP'AO3P">_^CI7I+D,,9Y-?-/P/\-?$?5_@E\-+O1O
M'5EIFGR^&=-(MIM(64JWV=<_-NZ'*_E78GP%\8O,++\3=,*XQAM!7\_OT 9?
MQR\%V7A;P[_:&D(4OM9\=^']0N#(VY3-]OM8\@=OE1>*<_['G@22[UR64ZI/
M!J%A?Z;%:2WK/%80WJD7(MP>4W@^IQVKDOC+X/\ B+I/A/3+C7/B)#?PGQ/H
M2K'!I"1A,ZC -WWNH8J1]#ZUW4GPR^+<DS,GQ8A1 Q(0:)'TSP/O4 -UO]DW
MP'X@;4GO+6\#7]S:WDWEW17;-!;BW$B\?*6B4(V.H%=%X_\ @?H'Q%B\/K<S
MZAI4NB;ELI]*NC RQM&$>)@.&1E &".PKGH_A=\5TF#O\6PR@@[/[%BP>>A^
M;I3[GX9?%:6[EEA^*R0Q.Q*PC18R$'8#YJ )-._94\"Z5K&B:A9V=Q:G2=-@
MTJ&".?\ =/%"DB0LX(RS(LL@!S_%2Z/^RWX&T'6=-U&VL[A6L-(BT00-<$Q3
MV\<4D4?FK_$RI+(H/^U5-_AA\8"^4^+4 3WT.//_ *%2-\+_ (NC'_%W(\YS
M_P @2/\ ^*H N67[,/A+3O#UEI4=QJ[+9:G!JT%U)J#O/'+$C1HBL>B>6[)M
MQT8U/9?LS>"-.U+2;VWLK@'3(+6&"W-P3"3;*RV\C+W>,.VUNW![51?X:_%R
M3/\ Q=:V4$8^70T]O]K_ #FIX?AW\6D:$-\4+5XUDW/_ ,21 S+_ '?O4 =5
MX'^$F@> KFQN=+CF26RT:#0HFEE+?Z+$S,@/OECS7=*P"C->2GX=?$5]/VGX
MH2+?;RP=-(B\LCL,;O2M:Q\%>-(HI5N?'SS%G8HZZ;&I5<# Z_6@#T7>/6C>
M/6O/QX0\9QFW5?'6^-&/F[M+CW.I' !W<8-+_P (5XN*J/\ A/9LARQQIL7(
M_N]: ._+@=Z-XS7 CP5XN#EO^$[E*Y^Z=-CX_6J-S\/O&TT;B/XDW,);HW]E
MQ$K_ ./4 >E^8N<$X-'FKZUYNW@'QJ7R/B+,%,>PJ=+B/./O [NM4#\,/'G]
MF06@^*EX)8_O7)TF$R/SGGYL4 >KF1>QS0)%(ZUY.GPN\=I)"_\ PM6^8HJJ
M0=*AP^"22>>ISC\*:_PK\=2WE[<#XJZ@BSC;'#'I<(2#C^'G\>: /6RZKU-)
MYBX)STKQN#X/>/HH9D?XP:M*[X\MSID'R>O&>:GT_P"#WC*W-TUQ\6-;NC+$
M$B_T*%!$W][ ZGV- 'KOFJ>]+YB^M>4+\)?%?]GI"?BAK9N0H5KD6T/)SR=O
M3VJ^?AAXA\O'_"P]9#_WO*B_EB@#T?S%YYI?,7UKRUOA-XFD0 ?$S7 P.=RP
MQ<_I3W^$WB1NGQ)UY3@#B*+_  H ]/$BGN*-Z^HKRH_"#Q-Y;K_PL_7PS'(8
M11?*/3I4 ^#'BC+?\76\18(  \J'C]* /7-Z^HI#(N,Y%>2?\*7\4X/_ !=7
MQ']?*A_PIC?!3Q4>?^%L>) /010_X4 <K\60TG[8'P#:)PH2P\1,X(SE?(@X
M'YC\J^ATD&W!()KY"\>^ M5T;]J/X(V%[XXUC49[NP\0K#>RK&LL3>1!PN!C
MGW]*]G;X.^(7N$<?$[Q&L:@ H%B^;'OM[T =SXT\&Z/\0/#]SHNN6:7VF7./
M-@9BN2""I!!!!! ((Z$4_P '^%-)\"Z!:Z-H]M'9Z?; A(E))R3EF9CRS$DD
MD\DFN-F^$FM27%P__"Q?$B1N5*1HT0V8Z\[><U?_ .%8:D(E \<^(-P<,6,D
M9) [?=[T =Z\B@=:^6OV9YY#XT_:!M8F"._Q!N [DG(0P(25]\9Q[U[:OPWO
M]Q8^,]>.0!CS4P/_ !VOGS]F#P?<ZIX^^/EL/$&K6DEIXZE N870&0FW3)SC
MK@X/TH ^G9+9Q<V\9?%G!&I-T'&]W5N%/J#SGW-9/C+P#X<^(ZV<&O:=!J"6
MI,L67*O#N7:<%2#A@<$=".M,D^&5U("K>+=;\LC!3S$VGW^[U]Z=%\,YX(MD
M7BG64^54#ATW!0, 9V\T ;-O;Q6>F6MI:V@BM(HDCAMX6VA%3A5&. , 5)>6
MD=_):RONAN(I'\IA@\D%<D?0U@W'PRNKA%7_ (2[7HE7H(ID4?\ H-2)\.KB
M.9I#XJUQW8*N6F3Y<>GR]^] '*_LX.!H_C@_]3GK7_I2:];,@88[U\__  )\
M'W>K:5XS1?$NL6GV?Q=JT ,,B OBXSN/R\DYZUZ+??"RYO,E_&?B-!D'$5RB
M_P#LM $?@A0GQ3^(K$8#R:>1QU_T;']*]!+#!/M7A'A'X=R7?Q/^(MM_PE'B
M"-HWTXM,MTH+YMC_ +/%=RWPGFPH'C'Q& HQ_P ?2\_^.T 4[6WF/[15U=B;
M_15\*0QF+G[YO)2&_(&O2B_I7A%MX' ^.EWI3>)M=\V7PM#*)#<C?A+R4'G;
M_M#\Z[Z'X5>3)(P\4^(3O8MAKL$#/I\M 'F'Q+D2']M7X*L7.Z70/$483Z"U
M;-?0[3*!GG\J^7/'/A*+2_VL_@[8'6M5N[J\T/Q$AGGF#20H%M""IQP2<BO8
M1\%K=;9H!XI\3;&D\PG^T/FSD'&=O3B@#T0." <UYM^TC<R6_P !_'CPRM#,
MNCW)5U&2#LJU<?"&.XF64^*/$:,I) 2] '/MMK@/B_\ !"SL?AGXXOSXF\3W
M,C:1<R&&74LQDK&QX7;QF@#WB&51QR#Z&I3(H[UY.?V?]+U2R4OXH\6!)6$W
MR:L5QE0,#Y>GM31^S3H@9"/$WB[Y2"1_;+X;'8\=* /67D7:?2OBG]H&W^W_
M +6/B*!@\"2_">6(7,:DO$'U:W5I!CD;5+'(Z5[Y_P ,U:*LKR+XG\7J6##:
M-9; ![=.W:O$-?\ @_HDO[<6@:#<76JW-G>_#:]6=YK]S+($OX% +#MAFR.^
M: /$)+#4=0L]<0?8VCAM8&M([YVV7:E?+B4,"3'M(W.>ZLP/6KSZEJ&K75I:
M:+<RSV"6T<6HS3(LJQQA3RC 8D4E"GEG."!@U]E0?LH?#^ 1F.RO$,?*8NW^
M7@@X^N:?I_[*G@+2F!L[6]ML1>3B.\<#;N+#CV).#[F@#Y!=H['3[77+"^DU
MJYN+%[6STRSLY([22SN9VLHFV_PHBG<RC^+!S1#H^J1>)+S2H;AKC7[%_MUM
M/+*##%A3&?+D/_+-A%,&3&,8[U]CO^S-X,>*.,IJ(2.,1(JWSJ$0$$*,=!D
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M_.O+3^S7X0:Z:X+ZN96!4G^U9NF,=-U4IOV5?!%Q+O=M:))4X&KS@<'(_BH
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MX _L_P#@@R!_[+F# ;>+Z?I_WW4\7P,\&PMN73)<X*\WDQX/_ J .X^UP_\
M/5/^^A2FZA'_ "U3_OH5P8^!'@L!0-+E&WI_IDW_ ,73Y/@=X/E#!M.F(88/
M^F3?_%4 =P+N$_\ +5/^^A2_:X?^>J?]]"N*_P"%*>$/LJV_]F2>6HP/]+FS
M^>ZIHO@YX2B3:NE'&,<W,I_]FH Z_P"U0XR)$/\ P(4GVR'_ )Z)_P!]"N0A
M^#OA.!55--<!>0#=2G_V:FR_!CPE+(SG37#-G)%U*.O_  *@#L5NHR?OK^8I
M3<1#_EHOYUPL'P-\)6VS99W/R1>2,WLQ^7.?[WK4K?!7PHZ@-93D#_I\E_\
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MDSTV^3(5_K7I8Z4 >6)=JG[3:VQ3YW\(>8'^EZ01^HKU2O*7C/\ PU# ^/\
MF3Y!G_M]%>K4 ?/7Q:4_\-?_   9<#_B7^* Q[D>19X'YU]"U\]?%WC]K_\
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M5MZG^V3\.M(\/Z=J\EU?S6UZ-0VI!9L[QBQ(%T7 ^Z$R,F@"35?!?QR?[/\
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M8MD>^?>O6:* /()OV7O!L\DCF76U+DDA=6F 'T&:=/\ LQ>#[CR]T^N+Y:A
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q?&48F\)ZU&>C6,X_\
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MXM&*$1ZAX8W^7^\#038WY[>U4[?1_C+M\N?7?"ZYC9?/CLY2P?G#;2<8Z#%
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MID5S;31^)O%:- H5%_M9BIQGEACD\U"_[..DNP9O$_BT'G[NL.!R?I0!ZT)
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MS%\5RB_MX? MI"5+>'O$*QX&=S;8"1^7- 'TXGW1GK3J0'BC- "TAZ49H)H
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M7S<>6=Z9BP.<<<Y]ZF?X::NZD#QSKR<]0Z?X5Z%10!P(^&VJ@'/C;73\N/\
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M6S*V6;R(FW#TY'% 'IFX>HHW ]Q7!R?#O7'Y'CC54.,<(G^%-_X5QK9CV_\
M"=:N#Q\P1/\ "@#OMP]11N'J*\\/PQU[)_XN!K7_ 'Q'_A39/A?KSXQ\0-:7
MG/"1]/3I0!Z+N'J*-P]17G?_  J[7-V?^%@:Y],1_P"%*_POUMP<>/\ 6UR,
M<!/\* /0]P]11N'J*\V@^%&NPQHI^(>O2$  L_EDD^O2DE^$^NR_\U$UY/\
M=\L?TH ]*W#U%)O7^\/SKS:/X3Z\@(/Q%UYAC'(C_P *C3X1:\KLS?$?Q X*
MA=I\L >_3_.* /3MP]11N'J*\PM/A!KML6+?$?Q%/G_GJT9QS]*LQ_"O6T"@
M_$#76"CJ2F3^E 'HVX>M&X8ZBO+6^#>MFXN91\2?$JF8*-HD3:F/[HQQFDNO
M@MK%S(TG_"R/$T3LAC/E2H%P3P0,<$>M 'J6\>HI=P]:\E/P,U?<I7XF^*P
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M<^/OV=^__%PX?_3=>U]"QG"C)[4 252UA=VE7@[^2_\ Z":N;AZU5U,;K"Y
M/6)Q_P".F@#D?@:P?X-^"BO(_L>UQ_W[%=S7G_P!E9_@GX'+J4?^R+;*GL=@
M%=_N'K0 M?-W[0,<C?M2_LTOOVP#4=<#+W9OL V_R:OH\N.>>U?.?[0>/^&E
M_P!FMN_]KZP/P_L]O\* /HU?NBEIBL HY_&E+@=Z %H;I2;QZ]:0R*>,T >"
MZ>2/VYM;7! /P]M#GU_XF$U>^UX!:OM_;KU'=@!OAW;E>>N-1DS_ #KWW>/6
M@!U%-+@4;QZT .HI-PI X- #J*;N%+N'K0 M%)N%)O% #J*;O'K1O% #J*89
M #2EP.XH =13#(!2[QZT .HIGF"CS%SC.: 'T4SS!ZTN\>M #J3%)N'X4AE4
M4 .Q1BD+@=Q1N'K0 N*6F[ACJ*-PH =28I"X ZTGFKZT .I:;O%&\&@!:6F>
M8*7<* !N!^(KPW]D6&2'X?\ B1G.8Y/%^NO%@YPOVZ0?S#5[B7!P*\9_9/\
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M30!)8W/QD):6ZM/"9 +X@B>?)X^4;B?6EBO?C 68-IWA9 J*PQ-,=[8.Y?8
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M[5[R%U"V,%U<-;PL0>6RZDD#H!FK'BGX^V/AWXO:;X!-E_I5Q!;7$M_=2^3
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MCL/AI\2U<-=_%&211C BTJ)<\\Y_"N8=F7]O] $RK?#)B6STQJ@_QKZ(4Y%
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MT_"O0(_&GQ>%HID^'VD^>4!*IJ_RANX^[TZ50'C3XW)%;9^'NA/*2WG;=8(
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MQI0JR:!X48 #<IO)<CKWH ]@9PM&\>OX5XN^K_'&9(6CT'PC%SF6)[N5CTZ
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M (.CUK^QSXDT[^U#$91:"8&0J(O-W #J/+^;Z5@Q_M#>$KKX6:-\0K.ZEO\
MPWJMU!:VTT,9W,\L_D*<'H-_Z5Q>G_LDQ:9XRL=9AU>(6]CJ5E=00_9AYBV\
M&FM9>27ZD-NW_I1:?LN:M9_LVZ+\+T\51"ZT.[MIM/U862@+';W EA1X^C'
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M-<^2IZQ8&U=R]JZ_7?V'SX@;77NO%31MJK7S.\5JN8S<:JFH KGIMV;/?.:
M/<]!^,?@_P 2>,+OPMIVNVUUKUIYHELDSO'E-LEQQ@[6R#COQ7._%CX]6_PO
M\1V&BG1)]7N;C3;G56>*XCA6*&%T1^7ZG+C %>$>$/@=\5M'^+_B?7M-M;'2
M(=+M]8M] FNRDJ2->WXN0QP-S  N?FSC.*]R^*'[-^B_%_Q'!J'B.3[79KH%
MSHCVFW )FDC<S*W56!C&* -;PU\>?!_B(Z/%%JR6MYJEE#?06MRI1UCDC,B!
M\\*Q16;;U(!-5O#'[1?@WQ;XAO=,T_5%=+=8/+NF!6.X:2.:4*F1SB."1L],
M"N'M?V29/^$DL[^_\2_VA:26EM#J<$EF@:YFM[26UBE1A_JSY<O..Z@UFV7[
M'>J:= AA\=S"\M/[/BL+C[!%^X@MK>YMMC+C#%HKIAN/< T >KS?'GP3;S11
MR>(;:/S+5;T2$'8(FC,JL6Q@916;!["F:M\=_#.G^!=1\5V]T^HZ5IU]%I]V
MUNAWPRO+'%@J>>#*A(]#7GEW^R!]M\+R^&7\9Z@F@7VGV]GJ4$5O$LMRT-N8
M PDQE PP2HX^7'0FNC_X9ZN)?A-K/A.774BU/4M134Y-6MK-$_>QSQ2H3'T)
M_<H#Z\T =;;_ !G\(W-F]TFN6[11O#$V000\DS0HI!YR9$9<>JFL;Q=\>]/\
M(_$R/PA/I\SLMG%>W.H&14A@21I B\_>8^4QP*X'2_V;]2L?BQX,O+B<7VB:
M7%?:GK%[(P3^T]1GN3/$OD@85(I'D=?3<!7>?$+X"0?$;Q.NH7VN7L6DR"V-
MUH\:)Y5PT#,R-OQO7[W(!YP* .77]K73E\-MJMSX:U2TD?[%/;6<A3S)[6Z,
MHAG!Z 'R7^4\Y '>O2_ /Q)M/']YK<=C&RV^FWGV19G8?Z1A06=5ZA0Q*Y/4
M@UP/A[]FNXT;2/$EO<^)Y]2OK[38=&TV]GMTW:=9PF1H5 QAG5I7.\\]/2M7
MX8_L^6_PQ^(.L^(;35I[FTO+.&RMK"11BV1%C#$MU<L8@W/0L_K0!Z]@48Q2
MT4 ?,/[:C"'5?@1(2P"_$;31Q[K(/ZU]-C&"?0FOF;]MM_*N/@?-CY4^)&DJ
M<C(&YF4?J17TPO5OQH \=^*'[2>F?"_Q:='NM(O[ZUM;6UO=5U*WV^3IL5S<
M&" N#RQ9P>!T JSXO_:!L/"OQET3X>FR-Q>:A!%/->/,(X[<2R/'$O(^9F,;
M8 ]*I_%#]FJQ^*'C)M9NM:O;"QO+2UL-7TNW"^5J4-O<&X@#DC*E79N1U#$4
MS6_V<IO%7C'1M=UOQ7>WD=G/;W-S8I#&D=U+;7#S6K%L;E";]I /S;1GO0![
M0F67D5\K^"B__#QSXE@N^/\ A!M+*I_#C[0W7WSG'U-?50& ?<U\F^$&"_\
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MOTIU,1P5!]J=N% "TF,T9HS0!\T^("!_P4-\'#U^'>I?^G""OI>OF3Q*V/\
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M<?\ XJO*O%(V_P#!13P$3T;X?:H!]?ML)KZ= Q0!YRVB_$H\KXET4#WTYO\
MXJGKI'Q'##/B#1B,<C^SV_\ BJ]#I: /.1H_Q)#,3XET?;U &G'C_P >JAJ'
MASXK3(WV;QCHUMQP?[*W8Y]V]*]5HH \9D\)_&=GN"OC_1%5@1&/[$'R'L>O
M.*J'P5\;S%:@_$K1DD0_OF705Q*/Q/%>XT4 >%1^"?CDKP^;\3-$:-9,R%=
M4,R9Z#G@X[TT^!_CN&S_ ,+,T(IO)'_$@7.W/ Z]<5[L0#VI: /$QX)^,PC
M_P"%EZ9YFYCSH4>,8X'7L:LGP;\8025^(>E$$# ;1$X/<]:]A*@TN* /)$\*
M_%C[1(S^/=,\HQA51=&7A^Y)STI[^$?BJ8&QX^TY)-C88:.F W8]>@KU<J#V
MI<4 >:0^&?B&OG^;XVM"K0*(MFEH-LH'S,?52<<4R#PS\1^/-\<69//W=)08
M&W''_ N?I7IQ /49HVCTH \QE\+?$@S6.SQQ9"-57[4&TI"9/4KZ9I;WPO\
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M^1EC!)T[_P 5<!^Q]]I$WQO%Z8C=CXDZD)6A!"%OLMGR : /HBBBB@ HHHH
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M"&'&?,;G(7W[U0T?XG>%==_M(VFM6CII]S'9W$LCB-%E>))44,V 24D0\>M
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MECA8L@Q9VF,$\XKW]P"IKP7]FAW_ .$V^/"F,*@\=38([DV5KG^E 'OE%%%
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M<_!?Q,A0<![NV^;G''S>^?PI]K\:O&]Q>PP-\&O$422$AIY+RV")CH3AL\T
M>Q6,/D6\<9=I"B*N]NK8&,FOEWQN^W_@I'\.!_>\ ZF#_P"!*FO48?BMXT=9
M]WPIUB+RR O^GP?/D=17SSXQ\9^()/V^/AIJ<O@Z[M]0?P-JL::6]S&96Q+N
MX8< Y 'XT ?<%%>7WOQ+\96T$DD?PTU*X*XVQQZA#N;/U':JVK_%;QKI:1&#
MX5:OJ!>381;W\'R#^\<XXH ]9HKS,_$7Q@(F*_#B_)[*=0B!/Z4UOB-XU5<C
MX;7C<@8&IQ9_]!H S;9!'^UAJ+@8\SP5;9'KB_F _G^M>OBOFFU\9^)W_:4N
M+I_!4\=X/!L:BQ-_'N*_V@_S;L8X]*],_P"%@^,F<!?AU=A<\DZE$/\ V6@"
M/X@W!@^,/PK386$LVIH2.B_Z&S9/Y5Z:A!&0<U\_>,_%?BN]^)/PQN)O"3Z<
MR7>HJ+>348RTV;*3"@[?;/X5V\OC[QM CLOP[GE*LJA5U2/Y@>I^[VH S/VC
MCML/ )'_ $.>D?\ HUJ]=4YS]:^;/CQXI\4:CIG@C[9X.;3@GC+22ADU!'WD
M3' X7C->FKXS\<^=.O\ P@:B,']VW]JKEOK\G% '$?MO*%^!$\Q=E$.N:/)Q
MWQJ$'!_.O?$).<^M?)O[9WB7Q5J7[.OB./4?"8TN)+_3&6X74$DQ_IT'.-HQ
MS@?C7N;>+_&:W3+%X)62WVY$AU-<D_3;0!Z%39/N&O.W\8^/-A*^!8BP/"G5
M%Y'_ 'Q2)XR\>.2'\"1*-V/^0JIX]?N4 -^!=W'<^'_$B1DDP^*]<C?(Z'^T
M)CC\B*])KYQ^"WB/Q78Z-XO72O"45[,_C'67N ^HA!&[73,5^[SC(KO5\8?$
MG[1.C>!+/R%91$XU;E@1\Q(V<8- 'J-?._[;F!\/_!+D9,?C[PTR^Q_M&*NW
MF\8_$I;V$1^!+)[9D;S&.K896[8&SI7@_P"UYXQ\8+\'O#%_XD\*VND/;>,O
M#US((=0$RADU"-MN=HX.!S0!]D#I2UXD_COXU"\G5?AMHK6JEO*?^W#N8<XR
M/+X[4M_X]^,T;1?9?AII,JE%+[]<VD-_$!^[[4 >V45XDOCOXS?VO-&?AKI(
MTX!MDPUP[SCI\OE\9JQ;>-OB_P"9>^?\.]+"#_CUV:T26Y_C^3C\* .3^/.I
M?V7^UO\ LVN02MPWB&TX]7M("/\ T$U]( 8 ^E?"?QM\2_%*^_:*_9\O=6\$
MZ5I^I6^IZPMA;1ZJ94GW6:;M[;!MP%]Z]ZC\<_'(\-\.- ''7^W&_P#C= 'N
M=%>#R>/OCO&^%^&.@NH[_P!OMS_Y#IDWQ$^.XSY/PLT-CCC?X@(Y_P"_= 'O
M=%>$6?CWX[3 &X^&>@0YSD+KS-_[3K1@\;?&5AF3X>:,A]!K1/\ [)0![-17
MD0\6_%V2"1O^$%T:.8#Y5;5V(;\=E1MXP^,(QCP%HIX4_P#(9;OU'W.U 'L-
M%>5:3XI^*UTO^F^"]&M&Y^[JK..O'\%7'UWXF;B%\,:*1L)R=1?KV'W: /2:
M*\WM]7^)S0!I?#VA)+_<%_(1^>VHTUOXI?Q^&M"ZC[NHOTS_ +M 'IE%><G6
M_B6%S_PC>BDYZ?V@_3_OFF2ZU\3CD)X<T/V+:@__ ,30!Z317F;:W\4A*P_X
M1K03&!P?[1?)/_?-/&L?% _\R[H(_P"XA)_\30!Z317FAUGXI*__ "+F@,".
MVH2<'_OFE36/BAO4/X<T$(1DE=0DR#_WS0!Z517E\>M?%9[J5'\-: D"G"/_
M &C)EA]-M,EU?XN>8GE^'?#>TXW;]0ER.?\ =H ]3HKRF+6?B\85\SPUX;$X
M< [=1EV[>Y'R]:FEU?XKM;OY7AWP\DX^[OOY"I&?]WTH ]0HKRO5=5^+QML:
M?H'AH3[AS<7TI7;WX ZYI8-8^+?V> 3>'?#IF! F*W\FTC'.WCCF@#U.BO-%
MU?XH_:W#>'M!^S^6-I%_)NW=_P"'I1+K/Q3$8:/PYX?9CU5M0D'_ ++0!Z71
M7F#ZW\5LMM\,^'S\H(SJ,G7T^[4=SKGQ73[*8_"^A2,\H6;_ (F<@$:XY8?+
MSZ8H ]3HKS)]=^* L+IU\+Z(;F,MY41U%\2 =.=O&:RH?&'Q@DLVDD\!:-'.
M"!Y0UACD=SG90![%17C:>,?C$5RW@'10=P! UENG<CY*67QI\8D8[?A]HTB\
MXQK)!_\ 0* /87X4UX1^SI";3XC?'F#<74^,Q,/;?86I(K3G\<_&!(<K\.=*
MD<XX_MO 'K_!7.?LK2ZI+XR^.#ZW8Q:;JC^+EEFM89O.5 UA;%<-@9R.?:@#
MZ)HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FMU%.IK=10!\]?L
M<J&T?XIYY_XN1XB_]*Z]WUC5;#P_ITU_J%S#964*[I;B=PB(/4D].M>$_L<?
M\@;XI_\ 92?$7_I77HGQ^\#_ /"Q?A#XGT);"/4[FYLG-K;2G"M<*-T1/T8
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M<&/V5];()&W4],/'_7Y%7T[&, _4U\R_\%'%W?LI>(B/X;_33_Y.15]-ITH
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MD)Q0 M%)N'K1F@!:*3.:,T +1129H 6BBDS0 M%%% !1110 4444 %)BEHH
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M3[>,RS7$K!8XTZ[F/88H \NC_:?T*:-)(_"GC)XV&58:&^"/SI3^TYHN2/\
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M !==V0?"JS4 D*S:^HSZ'_5]Z]I*@]J-H':@#R"X\>_%6$((OAI8REG16/\
M;H 4$$EO]7T!X_&H_P#A8GQ727#?"ZS9>1N37EX],_NJ]CP!VHP#VH \C;Q]
M\4UMXW_X5K9&1E3<G]NCY2<Y&?+[<58N_&/Q/@MXWC\!:=<2%L-&NLXVCUSY
M?->J;1Z4;1Z4 >9_\)5\2A'N/@G3<C^$:N<GC_KG2P>*OB1)Y);P3I\6]<N#
MJV2A]/N<UZ7M'I1@4 >9R>*?B4K,$\%::RXX/]K$9_\ (=+-XJ^),<3LO@G3
M97"Y"#5\9/I_JZ]+P*,#TH \HE\:?%"(VY7X?6$HD?;(%UK'ECU_U?-1W'CG
MXJ11W!3X<Z?*R %%&N ;_4?ZOBO6P .U&T>E 'B@^)WQ;'!^$T!(]->3GZ?N
MZ<GQ(^+;H<_"FU1SC;G7UP/7/[NO:=H]*-H]* /$T^)_Q; );X2P?)UQKR?-
M_N_NZLZ?\3OB=-<0I>?"@V\+1DR/#K<;E6[ #9S7L>T>E&T>E 'D4/Q,^)#W
MQ63X5NEF?NR#6HR_3NNS'6K:?$GQSL0O\,KP,>JIJD+;?_':]2"@=J-H]* /
M,'^(_C3+C_A6M\5&,'^TH?F_2O-OV;;^[U7]HO\ :(N;[3GTB[?4=#+V<DHD
M*?\ $K3!W#@Y'-?2[*,=*^??@BF/VI/VCVSP;_00!Z8TI* /H,4M%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4R09V_6GTR0\8H \#_9'N6O$^+\
MKKM;_A9&LIC;CA?*4''_  &O>YDWJ!C..:^6_A+\9_!WPT\6_&+3=<U)K&7_
M (3F\F1([*>8$/;6S$YC1ADL37I?_#5WPR'77KD?72;S_P"-4 >'R_!SQ'H'
MQ&\0WEIH36?AZ#QY-K:W0D'-HWAZXA><Y.6'GN%QV],5R5GX%\1V>GG4)OA]
M<_$_3/%OP^TG2=,D26()97$5O(L@DWD>6KEU?>O]WUQ7T5XE_:B^&5YX?U2#
M^W;@F6TF4?\ $IO.<QL/^>7O7/\ P?\ VE?AMH/PE\&6%QK5PLMOH]K&RKI5
MVV,1 =1%0!XPW[-WCQ?%^CZ=>Z=JFJP-J'A.?4O$::D%#"SM6AO'0;@P.[&<
M#D-Q6KX<\!?'Q/B'\/);HWRZ3:Z5:PWEY)>JWD>0]P)H94W?.\Z&#Y\'[HY!
MS7T G[5OPPP"-;N__!/>?_&JDC_:E^&4S;5UVX!'][2;P?\ M*@#RG3/@;XS
MO?V.[SPW>R7]UXXU98K[4+;5]0:7S9$N$=[?S,D(KQIMP.!N^M<$-(^*FL_$
M_6?%ND_"W4O ,%E::0B:':WL &L16^I^;+\Z':LGDG9M;JI//%?0J?M=_"Z1
MH8UUF_4RNZ*6T2] !7U/D\#T)ZU!)^V1\*T<*=6U-V=VC 30;X],<_ZGH>Q[
MT >#IX"^.<WC#X2W[:9J=O#9ZPEUJUQ_:JNT-O)JLCS02KD!E%J5Y4$G@=JY
M[Q+^S[\5M=^'7B"UO;#6-1U/6= FGO+2XU0,KW\&M)/;1IEL*QM%8 CC! -?
M32?MB_#%[=9EO=9,+2>6)/\ A'K[&X]O]35B/]K?X;7  CO-8D?S&A,:Z!>[
M@R]01Y5 'SSXA^ 'CS7=6\7:Z_AN7^UIK#Q:ND[KI&\F2\,1LQC. Y^<;NV.
M:K>._@5\8_$WCGXBS1:>5T;6O#FM:8D0U'='=RR6<2665/W2'5\] I)QUKZ/
M/[6?PZ6=X/-USS47<R?\(]>Y ]?]53+7]KOX;WNXP7&MR[#@X\/7W!(SCF+T
MH ^<K?X ?%K5+>#4+.QN="FAL=:M--M+[4!--IPEL;"$)Y@SQ--;SN"/N[QZ
MUWE]\&/B!J7[%7B'P;+#<7'BR\O3=6FGW-TN^WA%_',D/F<CY40XZ]17J2?M
M<_#B0,Z7&N,%.TG_ (1Z^X/_ 'ZJPO[5?@!EC*/KC>8"1CP_>_\ QJ@#Q]OA
M1XZ\3:!X9TFXTO6[*QB\17EQJJWVHPK+/;OI=PL7S0!046X:$ 'G//05EV/P
M7^,)LO"273R7%G/X56;7K:6]W3#6+:QG@AC!SADE:9"Q_O1@U[D_[5?@"/[S
M:ZN/7P_>_P#QJED_:J\!1@X&ONW'"^'[W)S_ -LJ /GBT_9T^(46@:_K-]I=
MQJFJR7?A\?V4-5,7VS3H+: 7MNI!VHS2(WL=H]:@OOV<OBKJ?AZP%VMS+J%C
MX=F6P3^U6/V2Z.KB>")FR-[1VI9=Y';%?1D_[5/@:(@"+Q#(2P4JGA^\XR<9
M_P!7T'>F77[6'@*WBW"+Q%,<@;(O#UYD^_,8H \"\3?LR?$6[U_Q'JL(>ZNY
M'O;BQ>34W3?/_;@G@<@' Q994=AC!JMJO[-'Q3U+4OBHS27 GU0RQVMV-4*1
MZBDFJQW*_*!F-H[=7CSG_9'%>^']KWP2;4S)I7BR4A]GEKX=NM_3KRO2JX_;
M#\(E5)\-^-AN."?^$<GX]^E 'A.K_LS_ !'L]?L+_2])M-0CT[4/%]EI\-YJ
M#*+>PU!(19/GJ0NR8;>HWBK?P6_9K^)'A'Q)\-+C6+.WBM/#OC/5=6E_T[S_
M "[&YTXQ(%) Y$G&T=,YKV\_M>^#PSC^P?&118]^_P#X1RXPWL..M+;?M<^&
M+J[CM4\*>.!.P!PWAV8 #KDGTQ0!P^G?LM:GK_Q3\>>)?$%_<6EH?$XU[0;&
MW=/)DE6S6.*>0@;P5DR=N<?**X/X7_LL>.;3P]X,T?Q7:F2VL?$5I<:Q%_:9
M>.XBAL)(I+A, $^;,R$JWUKW:3]K7PHI'E^'?&ESG:#Y7AZ?Y=QP,Y ]*E_X
M:GT(/A?!?CIQ_>'A]\'\VH ^=-$_90^)%OX&\*Z7!INGZ9?VFG+;07,6HO'_
M &)<#59;AIU51B9I(&CR>#E<=*ZV7]EWQ=JGB.6_OQ&RW_Q UG6[XF]<^9I4
MEO/'9Q$>SNC;1PN*]?7]J;0CN"^#/'65X/\ Q('[_P# J=+^U%I$4F/^$'\=
M-QG*Z$Q!'_?5 'S\G[*'Q-TOP9?Z+;S65\]_I7AZ.\::^?=+>6T-W'>3*2"
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M3M)@P?VA:@JN,YSN]>*$^,WCUHXF/P;UU6?[RG4;7Y/UH ]FHKQ>7XT^/(Y
MJ_!K7W4D M_:-J,?^/4J?&;QZT2M_P *;UX/SE#J5KQ@X'?OUH ]FHW#UKR&
M#XM>.9[IHG^$NLQ($#"5M1MMI.>G7K6A<_$CQC#;L\?PTU"9EZ(-1A!;Z4 >
MG YHSS7E.G?%#QS=VD<LOPLO[-GY\F75(-R_7 Q^M27'Q+\;Q$^7\,+Z4!2V
M5U2$9/ITH ]2) I:\?TOXM^/=0@$DWPBU.R)!^2XU6WW#!]@1S5[_A97C8%
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M6E@GBEB0D,\;AE!'7)'I7.WOQ'\.:?XJT3PY+JT#:SKD<L^GVL1+M/'&,R2
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M.V:KCX9^&1).X\/:8&GA:VE/V5/WD3*%9#QRI"J"/:N"_P"&R?@GW^)GAO\
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M;.!EFC  YZDUN?#S]H_PKH?PW\)6LMIXAFECT:R!^RZ%=3(?W"#(=4PP]P:
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M6? GQSX2^+/ASQ#J3V)M(-&@L]5G%X\SS2I:^7A49?E(D_B!PRXR,\UV5O\
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M>6UE=6*?V!X?4_;+=H7F.;P^9M8 XY"?5#Z4 ?15%%% !1110 4444 %%%%
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M 'D?CJ6.W^/OPLCY7S[/6D"K]TXBMVY]?N\5ZL4B!Y1?RKQ?XJ$C]I'X)#)
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M4$].;62MGX(7:W_P=\#W*KL670[)@N0<?N$[B@#M=@I&08Y%/IK_ ': /._
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M*7^Z*?10 SRU_NBD\E,YVC-244 ,\M>ZB@1*.BBGT4 ,,2DY(&:/+'8"GT4
M-* ]J3RE]*?10 SRE]*/*7TI]% ##&H'W17A'@RZ>3]LGXH6Y4*D?A/0-ASU
M'GWYS^9/Y5[RW2O!?"$[#]L_XEQ,FT?\(=H#H0>J_:=0'/OG(_"@#WNBBB@
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M[G!/\(R.GO0!ZA7RU^V)>_V=\7_V9KCY@/\ A.UA)5<_ZRUE3]<UZJ+KXNE
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M6^EOH%DULEY97,CJOD 88B49^;G.!Q0!]/YIKKN7K7DC6GQN,IVZMX)$7E8
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M3<^A_P!=VJ6ST+XH0DBX\7:'<<\8T1EX_":@#TK<*6O-G\/?$TER/&6CC)R
M-%. /^_M*N@_$U8D'_"7Z*S ?,3HK<GUXFH ](I,UYH_A_XHEY"/&.B!60*H
M&AM\K=V_UW/TJ.'PS\4PH\SQQI#$'DC0\ _^1: /3\T9%>8W7AKXI,ZM!XVT
M>-=V2K:'NR/3_6U.?#WQ++QG_A,-'"C.X#13EO\ R+0!Z/FC(KS63P[\3C.&
M3QGI*Q9!*'1,\=^?-[TK^'?B<4E">,M'#,#L)T0G;_Y%YH ])S1FO*CX8^++
M;?\ BNM#7&<XT \\8_Y[>O-3GPY\4_LRJ/&FB^;CEVT,_P O.H ].S1N%>7/
MX9^*SV\")XYT5)D.9)/["R'&>F/-XHD\-?%1GF"^-]&167Y/^)%DH?\ O[S^
M- 'J.:,UY1#X2^*R37;O\0=,D1X$6%#H* 1R _,_$F3D=CTH_P"$6^+1@@4>
M/=%\Q0=[G0/O^G'F\4 >K[A1FO+Y?#/Q59) GCC1D9@0C?V%G:?^_O-(?#'Q
M6*H/^$YT8$*H.-"ZD#D_ZWO0!ZCFC->6_P#"/?%N*="/&?A^:'>-PDT)PP7O
M@B?K3#X:^+3;R/'&@KE\@?V W ]/]=0!ZM29KR^S\/?%:"3,_C/0KA,GY3H3
M+U''2;L:+OPY\5I 3#XTT*$X Q_83-@]^LU 'J&:,UY/=^'_ (P102&U\9^'
M99L *+C0G"@]S\L^:?<:-\7TEB:W\5^%W7CS8YM$EP..=I%QG\Z /5&^Z:\$
M\,?\GM_$'G_F1M"X_P"WW4:Z*;3_ (U1:E;B/7?!<NG%AYS-H]RLH7_9Q<8S
M]:\_^%"^)(?VQ?B$GBB?3;K4_P#A"]%*RZ7 \,7E?;=0VC:[L=W7/..E 'TW
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(>E+2'I0!X;\(DC7]
MHOX\&-W8F\T8N'_A;^SP,#VQ@_4FN^\1_%SPSX3\3V.@:E>2Q:E>>3Y:K [H
MOFR&.(,X&U2[@J 3R:\\^#N5_:-^/R&?SW%[HS@_\\U.G@"/\""W_ J?\;_A
M3XK^)/B?PR--O=(M/#]C>V>HRRW$+_;;6YMYQ()8&4X;=&6CVN,#=D<T =QK
M'QG\+Z+\0M/\&7D]S'K%X8U1OLDAMU>0,8D:7&T,XC?:,_PGI7R'XD\$^/\
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M$]CI'V)%N=1MY_,,<\ +X*8AD)W$%<8(Y%<W%^V%9M?W>H/ITC>$XI&,4]O
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M 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[3Q':B\TZ.%Y#%! QDRD0\Z3Y1V?GH*NW'PU>[MXK,_ 7Q;%8FXBNGB37K,
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M >+-\0/C$#S\+]);_=\1=?\ R#2-X_\ C(8V*?"_20XZ!_$77\H:]JVBC:*
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MFAT[X?:3>V:[?+GEUTQLWR@G*^2<?-D?A6</'/QK+*/^%9Z %/4_\)&V1_Y
MKVK%&* /%Y_&WQICE81?#;0)4[,?$3*?_1%>"?M:>)?B7J-C\*CK_@G1]*$?
MQ&T![,V^LM/YLWVD;$;,2[5)X+#./2ON/%?,W[<P8:/\'610S+\3O#I ]3]J
M% '7?\)M\;M\G_%N/#FT,0O_ !43_,.Q_P!1Q3!XX^. P3\-/#N,\@>(W_\
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MT/6/M.A^%UT_[!<-).FH3[U_=-_"4Q^M>?\ [)%_\0T_9I^%<>CZ5X?FTO\
MX1NU*SW=W,LH.T8!55(Y&3G-?1GC:-9?!NNHXW(UA<*RD9!!B;BO)_V'CO\
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M#PZ"/]H0;1++X ()P2L%V,#V^>GS1?']6D6*X\!E ?D9K>ZR1[C?7MU% 'C
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MO+OV;6;_ (5M,'P&77-7&!_V$)Z\W/[9FJ%SM^!?Q,*JZA3_ &9&-RGJ?O\
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MXRW8D^ ?CE5Q]X-;GGZ;J /I2BOFA_VLO%ZN@7X!>/&0YW-_HXVCMQNYI/\
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M;-M,=QY:R>7SC+;'5L#/!KFOB1\=_!'PGO\ 3['Q1K2:==WR/-#$MO),1$A
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MV\]Z=10 F*0H":=10 SRQ2[!G-.I,X.* #%)L&<TZDW#- ",H8<TN.,49HW
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M?<GPE(/_ &>OJ/[,GI2B!!_#0!\L+_P4(\*C[_PR^*B=<?\ %*2'/_CU*_\
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M=@Y^F/QI;#]H_P"/,MZEE<?LVZA!<X7?+_PD-J8%SWWYYQ^=?4^P  4PP*:
M/E?_ (:/^/CO,Z?LW7ODV[,LN[Q#;!I,=/*&?FYY^E7?^&BOCDD+NW[-^I2;
M9#&1'XBLR3CJ>3R/>OIL6Z*21GFE$(]30!\MW?[3'QNA@@<?LTZV?..$"Z_9
ML1Z[@&^7\:Q/A%X[\6?$[]L6PU;Q5X#O?AV]EX$O8+:PU*ZCGFNA)J-L6D&S
MA0I11@\G<#7V!Y2XKP75;@0_MR>&K?8")?AYJ;!^XVZE9\?^/4 >^"EHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YV^'D8B_;@^+_.3+X5
M\//^4EZ*^B:^6F\=Z%\-/VROB=J6OZBMC:2^#]#?<8G? %Q=KGY5/&6'YBO5
M!^TK\/GD@C36I6>>(S1JNGW)+H.X'ET >H-TKR;X 01PVOCKRA][QCJK-\FW
MGS%S]?K5I_VD? :"+.IWG[T94C2KHC\?W?%>8_![XY^$?!EGXVEUO4+ZSAOO
M%^H7-JTVFW1WQ2NGED?N^ 3F@#Z='2EKS ?M(>!F5F6_OF"NT9*Z5='YEZC_
M %=2-^T3X&3_ %FHWD?&?FTNZ'_M.@#TNBO%]1_:]^&NFW302ZCJKLN/FBT*
M]=3GT(BJ)?VQ/AD[,HU#5\KUSH%]_P#&J /;:*\4_P"&P?AIC(U#5CSC_D W
MW_QJK.G?M6^ -72=K*;6KCR(C/(JZ#>!E0=3@QC/T'- 'L5%>/?\-4^!OL=C
M=8U[RKU"\!_X1^]RR@9)(\O*_CBK-K^TQX/O;Z:TAAU]IH6"N#H%V!G&>"8\
M'CTH ]8HKRL_M'>%?FQ:^(6"YSC0+OM_P"E3]HWPO(K,MCXC(4;C_P 4_=__
M !% 'J=%>9V_[0?A>Y!(@UR,#_GIH=TO_LE07G[1?ABTMYI5L?$5T8UW>7;Z
M%<L[\]%!09- 'J=%>3G]I+PRK$-IGB9><+_Q3]T=QP#@83WQ]0:9=?M+>&[7
MR,:-XKG\Q0Q\KP]<GRP?[WR_RS0!ZW17BR?M3:/*V(O!7CR;M\GAV4?S-3?\
M-+V7_1/_ (@_^$\__P 50!['17CA_:8L%(W> ?B JGJQ\//@?7YJ:?VG=+ !
M/@?QZ 3C)\.R_P"- 'LM%>0WG[2FD:?S<^$O&T0R /\ BGYFW9&>-N:GL/VB
M=+U/!MO"?C*1"Q4,V@RH,@ G[V/6@#U>BO-/^%YVGVIX/^$2\7EE1GS_ &,^
MT@'!P<]?05CK^TWI3XV>"_'4F6V@KX>E )].30!['17F,OQTACB23_A"O&)W
M%1M&D\C)P/XZJV_[0D%U=2P)X"\<*T;;2\FC;5/.,@E^10!ZQ17G"?&F-@2?
M!GBY,>NF#_XNJ]W\=[>RMI+B3P7XR,<8R0FCEF/T ;)H [_Q H?0]04C@V\H
M/_?!KYY_X)P.TG[%_P ."PP5COD./]F_N1_2N\NOCI;:CIFT>#/&42W44BJ\
MNCE0OR$_/\WRCZUX)^PC\8;;P;^R+X#LY_"WBF_6*/49#/IVEF>,@7]P2,AN
MO.,>H- 'VK17F%I\>+>]M8KB+P7XR\N50RAM(*M^(+\5,GQK61'9?!/B_"YX
M.F $X]/GH ])KY._X*<;5_93U61CS'K6D.H]2+R/BO8H_CH)8BX\">,@  2#
MI:@],]/,KYA_;\^+UKX^_9?\167_  BGBS0VAU'2Y%GU?2_L\3N+R/"[B_?'
M\J /NB!LJ"1M+<[3VJ6O'[S]HB'2I%CE^'_CN4[GC)MM%\U05P#T?H<\'O3K
M/]HV"]AN9%^'WCV,0)O83:)L+<XPH+\GV% 'KU%>7S?'5(+>*8^!?&;B0J J
M:4"PW' R-_&._I56]_:$6R21V^'GCF5$7=F'2%<GYMN /,SGO].: *W[12;I
M/ADV.(_'.EMGZ^:O]:]A7[M?+7QC^-:>*+?P+)%X*\7V"6OC326)U'3! 9#N
MD.$!?)/;ZUZ7+^T(L%PT ^'GCJ1EE,.Y-(7;D+G.?,Y'OZ\4 6OVHHVD_9S^
M)H"AO^*<OS\W3B!C_2O0O#YSH>GG.1]GBY_X *^=/VBOCD=2^"?Q&TG_ (0#
MQI 9_#M_']JFTU%@3-N_S,_F< =Z["'X^3^']"T]9/AMXWO MM#\UEI\4H/R
MJ.,2T >L>)0K^'=45BFTVLH/F?=^X>OM7)?L_E3\$? H4H5&BVH!B^X0(P/E
M]O3VQ7+>(/CN;O[9H[?#CQX?.@9#<IID?E+O0C[WF]L\^E8OP4^*D^A?"WP3
MHT'@+Q?=);Z';A+A;6#8510@4L91\V!G% 'T"ZAD(/0\5\Z_L!?+^S7I<(Y$
M.L:Q&"1C@:C<?XUZ1!\6+ZYE6,^ /%,1;!W20VX4?4^=7@W[$/Q#O])_9[M(
MU\(ZWJB#7-8"R62PL #?S-AMTBG.6(Z=J /KVBO-V^+VH"<Q_P#"O/%A'9Q#
M;8_]'5)#\6;^5B#\/_%2  '+PV__ ,>H P9]O_#6MKP Y\%2\]_^/Y:]A'3F
MOG:Z\?7J_M'V6H#P;KY<^#YA]E"P><<7J=O-Q^M>AI\7-1DC=Q\._%8VC.&B
MM@3]/W] 'H]9VOC=HU\/6WE'_CAKA7^,6HK(%'PY\6MD9R(;;'_HZJUU\6M2
MO[>[A_X5UXJAC:)U\Z9+95'RGD_OLXH XC_@GV<_LC_#T8&!!<#\KF6OHNOD
M#]B;XBW_ (>_98\"P0>"-?U90ER!+IZVY3_CZE&/FE!X^E>Z)\8-39$8_#CQ
M8I/5?*MN.?\ KM0!Z717FA^+^K$Y7X:^*V0=3MM0?R,])_PMK7OM,L?_  K+
MQ/Y:KNCDWVGSGTQYW'XT <)_P4&3S/V-OBDN0O\ Q+%.6.!Q/$:]D^'+E_ '
MAEB<DZ7:G_R"E?-G[9OC[4O$_P"RI\4+*X\#Z_HZG1V)N+];<Q B6/@[92>W
MI7I_@OXJZEI'@KPU;?\ "O?%%V%TNU'G6T=LR']RO3,P/YB@#V>BO,S\8]1
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M^#LA'TKXPTGQSJ=A\-[C]HJ[\.W3>*O#>OZ=X:@C.][DP1:7+:3@-CA#)+O
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ML.K8]0,URWAW]N_X;>*?A1I_C_3/[8N=*O\ 7X_#-M:"S'VN6]?&U1'OQC#
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MZI^WG\7;S3QC24\)Z)'J"LA5Q>%I'C#=MPC+9[C(H ^J@H(Z#%&T>@I1TI:
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M(_\ )NUH ^D:6D%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'R[XX^(/A;X8_MI3ZWXL\16.@6!^'<4*O?2;%9CJLASGVX'XUV!_:H^!CV\<
M,7CSPO/#/*P$44P<.XY/"J<MQ^-9EQ';7G[<UQ:7"K.&^'$<H@DC5D.-5D&[
MGO\ -C\37MS:+I5LH(L;.)5.1^Y48.>#T]: /'A^V+\#X949/'^C>?(/+&Q)
M#(0.=I 3(QZ&KK_M3_!BS"7!\=Z$/MC;#)$S-N8<8<JIQC/\73->K?V9ID;;
MC9VJ/G(8Q*#D_A7Q%XD^)NH?"+Q%\1=8LIX(M'/C?4-)DLY+02HUY/ID9L>@
M)4&X51Q_?YH ]Y3]L/X("R:,>-;!;.(;#_H5P(0,^OE;<>G:GVO[6/P0=6^S
M^,=+42+M.+29?,']T?NOF//09KP31_VD/%'A'2M>&LSZ?K.I^"[.P\+:O87T
M8M+;4/$$MRVZ1) A./)52. IW9XJ-/VY=3+7WB&+P[HT^A3^%=&U32]&\Y%F
M%[>7+02;Y<<1HRLI(Z8'/- 'T.G[6?P<:!,>,;$QQX*_Z+/A?0C]U_*EO?VM
M?@_'#&TWBV*="3M$-A<S$''4A8CC\:X_X8?M#^(/B7X^\%>'XO!.E:9!J.@2
MZ[K4EQJ"RO9QI=S6BI $4K+NDB#;B0,-ZUR6I_'#5K74/%^C3^)H=/UJT^*%
MAH6FVABB\\Z?+]G=HO+/)0H\AWXZ#.>* /5A^US\&4@?;XJAQ@.T2Z;=%CZ?
M*(<Y]NU6IOVL_A')"?,\6PS(.=@L+EVR,?PB+/<5X)_PW9J,G@OQ;?1>%]#7
M7]+UFTTRWB2\\Z"..X$[1R3R#"KD6[*-K<LXSBNT^,GQ@UK6_A%\&_$GAJ74
M/#NH>,M7L87TVQ-LMY.D]O(YA1Y@8P0R@Y/4#WH [O4_VQOA'8$I+X@O)_ND
M"WT*_FR2>  L!R?:JC_MJ_")8HYFU?6?G#%5'A?4RZ\XP1]GX)]#7@/@O]LG
MQGX=TCP7I>I:;!XBO]5U.Z2XDU!E2]@@&HI:+9/L"H;V,2%W &  ,#!S4FI_
MMA>)[KXI?;K.\T9]*TS1_%=T_A6UG+7(:PE"0&^7&8W;8S #LWMF@#W^/]L;
MX5/";A;[7VC55+2?\(GJAX;D?\N]/3]L7X6F6*)+KQ%N8@*P\(ZKCD9'/V;'
M2O.=3_;+FDU]K32I?!]OH\-_<1/K6JZJ4M)88+>SEDACD7(:<O=.H R!Y70]
MN6OOVE/%WASX@Z__ &EJEOJSZ+JWB9H-%L&$2&TM[*RDM1.,;B )S)N&."QY
M[ 'MUK^V-\)]0D:.+4-<D=3DH?"VI\8.,X-OV-3C]L#X8-,Z_:]?=TY)7PKJ
MF.F<@_9^G%>6G]K/Q9>Z3;V6D:=X5U'7G\276@_VK#>2/I-VL6EOJ!EMW7+-
M@(8F'0-WKV+X<_&&R^*?P#T_QHE[9^'KN_T :I<$R"4:<7B8^8ZDY**5+#.,
MA>* *<7[6_PVN(8I4;Q(R28V$>$M4&?_ "7J9OVM/AX0 9O$8R>!_P (IJ?!
M[?\ +O7R[:_'+4;SP!I]V?B[>V_A:Z&J7UAXB>YMQ=RR6]K&\$%PP7$?FR>8
MZP$!V3 KI_$WQ9\<^$=4UN;7O%%Q;66MZ;9>(?L\$B++HU@7A#E=R@0EG9H1
MO8@DEN,4 >J^!_CQ\'O MKJ=GX=T_P 36-O=W\^IW$47A+52AN)FWRNH-O@;
MFYP.,DUTJ_M7> .T'BL?]RAJG_R/7 ?&KXC:[XN;X17?A!-?%IXBL;_5GTC2
M=12PN[I$M$EC0NP(R"P^7/)/I7FOAG]K;QAX<E^'>A37=KXC\_3M-:YFN HN
MM7FN;R:&6*)BRDR6PB"/A22^<@ B@#Z&?]J_X?+\S1>*P!_U*&J?_(]<SX5^
M.OP=\(:WXAU+1[#Q/:ZGX@NQ?:E<#PCJQ>XF"! 23;] H  Z"O+O#'[6VM7'
MC"36];\4>'(M(0V%I?:;;NZQ:+%-?7$4AN\L=MPHBB&3@<D8Y!J]:_M;>)O$
M=SI$<>O^%=!%YI-K<0VUS:W$UQJLET;@(]H(\G:GE1Y."!N)8J,4 >T0_M>^
M /LOG3Q>*K0;BJI/X3U+<P_O + >#31^V!X FNTM;:+Q7=3/%YJ+%X2U+YAS
MW,  /'>OGWP[^U'K_A7PE/J4NOZ5>WD@\Z[O]<N7:UN9H-,AE:VME4_NY)6<
MX49Y#8!/%>R?"/X]>(O'WQ%@LM1MM*M-!U.?4K.RLX1(NH6LMF8RXN"3MW8D
M(*@<$>] '11?M6^%#L>XT7QM80. %FN/"=_MSC./EB)SCVQ3%_:\\"/;/,+7
MQ<=IXB_X1'4M[<XX_<8KPO7=6\=_%+4M-.D:CKEWJE^?$DT.GZ7KO]F0V#6U
M\EK;;SCYP@7++CDL3C%:/B']I#XB^#-1\0Z=J&J>&;2T\/:OI/A:YU.]MG*K
M=3Z=%=2W<K>8JA-[% O ^8'/:@#V73/VL/"FJ6<MXFA^-8[: LLKR^$[Y=AX
MP"/+SDYXQGWQ50_M>^%A!YJ^&?'LC;BIB7PG>;@!U/*8QGCKG\*^:_B#\4/&
M/BF;Q-XM@U34K>?3/!N@:D)=!UEXK#29;F>Z66[,(!^T18A5V&"=JD#/6NWU
M_P#:_P#%VB>(?&EA80:-K"Z397,MI"H(GB2'[(!?2@-EX)%N))!A5&V/@GG
M![3=?M4:)80)/=>#?B!!&XX)\*W3=L]%!-4H_P!L3P;/!/(FB^-]\14&$^$K
MX.<^G[O'&,]:\UUWXQZ]\2?@!?7-EXNTZ*5_'5CX7D\2^'E>.*:S>]MHY)(R
M&)1BLK*64X'..M9EO^UGXWU>>33M&_X1W[==ZK8Z=!'+;SRMHIGOWM1#>_,-
MTVQ?,'*]"2,$&@#W#3OVI/!^M7,=M#8^*XYY,%(Y_"FH+N!Z')AQ@GWKP/\
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MLXZ5^@WP^^./@3PEX.^'_AG6O$^F:=XBN="TLQZ;--^^8RP*(Q@#^(@@>N*
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MV$#W-U=7#A4AB0;F9CZ #-6+75[.^TZ&_MYXYK.6)9DG1LJR,H8,#Z%3GZ4
M>:?\+KU^:]\FW^$WC9XD(\Z606$848SE0;KY_P #4B_&G7HIYUN/A-XT2.-R
MD<D7V"7S .^!=#%=9J'Q,\*Z=X)/C"XUW3XO"_V878U<W"BW>(_=97S@@]L=
M>U4)OC)X+MO&LWA*7Q+IT7B2&#[3)ITDX62--N_+=E.SY]I.=O.,4 8;_&?Q
M!. UI\)?&<JC[WG-I\)!ST -US2VGQC\1W4Y ^$OC%+=2%,LDNGJQ_X";K.*
M8?VH?A:OAN'76\::7_9<MT;..<LV6D"[R-NW=C80^[&W:0V<'->HVD\5W!'/
M!(DL,JAT=#E64C((/<$4 >=GXMZVF"WPM\8X[E3IY_\ ;NI/^%JZX2!_PJ_Q
M?CN2^G<?^3=>C8^E&* /,Y/B[K<0^?X6^,LEMJ[/[/;/U_TOC\:#\8=7R/\
MBUWC38>C;+#K]/M=>FTF!Z4 >8R?&74T_P":7^-V[G;#8_\ R73E^+NMR[##
M\+?&+!^GF?V>F.><YN^/ZUZ85!HP* /,)OC)JT,C+_PJ[QLZJ2"RQ6)S]/\
M2Z</C'K+%0GPL\:-NZ;EL%_/_2^*]-VBDVCTH \Y?XJZZG/_  J_Q<4QDD/I
MV?IC[73?^%N:L)5C/PR\9@LN[A+ @>V?M?7VKTG:/2C:* /+8OC;J,N__BUW
MCD;6VG-M9#\1_I7(]Z>OQHU)MW_%K_' QV-O8C/_ )-UZ?BC;]* /)[OX[7]
MK;R3'X6^/65."L=E9LQ^@%US2P_'/49YVA3X6^/-P0/N:SLU7'IDW77VKU;8
M/2EV@=!B@#Q:?]I.YMYI8F^$OQ(9H_O%-)MF4_0BYP?PJ!?VGYI!Q\(_B:O/
M\6BVX_\ ;FO;]@SR ?PHV+Z"@#QI_P!HZX5[C;\*OB*ZPCDC2;?Y_P#=S<C-
M5)/VGYDQGX2?$U<X&1HD#8_*Y->X;%]!08U]!^5 'A,W[5@@D16^$WQ08'=\
MR^'D8#!QVF[]J\YT;Q\WQ)_;<^'VJ#PWX@\,+%X*UF/R/$=D+2:4FZM?N*&;
M..">G!KZ\\M?[HKYV\;*T?[<WPN(B#*?!^NC=G&P^?:'/]/QH ^BATI:0=*6
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /GC_ )R ./\ JF*_
M^G9JV/VK_"<_B+X>:3):1:K=WNG^(=+NX+;3)&4.1=Q!FF5?O1JA=B#P" :X
MCQEX]\.?#S]NO^TO$VN6.@6,GPU6%+C4)UB1G_M9C@$GDX[5Z8?VJ?@\V<_$
MSPQ_X,H_\: .$_:%@U+QY=> +[1+?Q)!)X=^(VEP7=G%"T<%Q")U$MPZC_60
MJA)#YP.>*YG2O&/@GP=XF^,">.+7^T+*3Q]')86@L&NY'N8[""XWI&H)S&$:
M3=V"DUZVW[5_P:R5_P"%F>&"WI_:*?XU\H^)OBII&NZA\4(/#WQ"\$V&G:OX
MS66Y;5]5:'[?8_V="CQQ2QY9%=UV,R\E=P!&<T ?0]Y\1?@7XCU3Q!HE]8Z5
MJ%O?JFM:E=W&E>987SQVZSJSS%-DDJP;'VGY@,5RS?$_]G@>$8;R7PK#%IXM
MYM$;3Y?##^=;6BJMRZR0[-T<&V5)<G"_.#]/*Y?$7@'Q%>:MHEY\7?AWI7A2
M]E;4/LVFW9\^UOI+!;3R$R0I@4C<.Y& ?6JFMWV@^+=!U.YU+XR?#JV\4:K<
M/;WTEA?RI%;V)L4L3Y1#AG8JGF%7RI+ <8S0!]A?# ^ =1O]0'A#2;&PN= C
M30V6WM5@,%N56YB1 !_J7$RR+C@[B>N:W9_A-X/N_&D7BZ;PSI4OBF)2D>LM
M:(;I01M_UF-W3CKTXKYT^$WQ9^&?P^^(OCO5;GX@^&['P_\ V?H^BZ=OU",O
M<I8V["2X;!XR9A&!U_='VKTU?VU_@7W^*GAG_P #1_A0!W ^#'@5=+U;3O\
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MNS>Z79WGVN$6UQY]NK^=%G.Q\CYER3P>*\SF_:Y^$T"RL?&-N_EJ6*):SLQ
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M""1[9)]^:]E7O]:^4_C-\;_#&L^$4M+:Y\1BZEU_1IX?/T.Z\NV"WMNW!,8
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MO 5/E /&*U+[P-)H.D3^'KW3=8F\/S"VTF]::UNVN9R@=T7<@)AF9]HS]PJ
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M*X1_C9";J")?!7C-O,#'?_8[!$Q_>.[J>U/3XW1%(\>"?&:[QGYM'(Q]?FH
M],HKS:+XUH\A5O!7C%!V9M(.#^34C_&Q$8_\45XR8#TT@_\ Q5 'I5%>=#XT
M0G&?!WB\9]=';_XJE_X7/ !SX0\7]<8_L=O\: /1*3->=-\:H%_YD[Q@?IH[
M?_%55NOCJMO&SKX%\:S@(6Q'HYR<=N6')H ]0HKS&W^.,4\DJGP5XTB$>WYG
MT9L-D9X^;M4P^-D./^1-\8].O]CM_P#%4 >D45YNOQIC;.?!OC!0.YT<\_\
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M)9H=8DBGF4>61'<&U59!N4YSP.@H ^\?^$6T('_D%6.3_P!.R?X4#P_H7/\
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MOHFOG?XHXC_;-^!N1]_1_$2@^G[NW- 'T..E+2#H*6@ HHHH **** "BBB@
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M&[1+T?\ D!Z\_P#V(T67]DGX2G!_Y%RTZG_8H TD_:?^'DT*3K=ZRT;XP?\
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MNZ^B&3[?-0!S7A/X ?#_ ,!^.=8\9:!X8M-,\3:OYAOM1@+[[@NP=]P+8Y8
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M9?ICF@"IJOP,\ :Y?O>W_A#2+N[?4!JSS36B,6NP@03'(Y?: ,]\#-+'\#O
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M\^(W[8WP3U7XC?#/6+;XE>'KJQTB^OIKMX[G<8E:S=5;:!GJ0/K7I5M^W-\
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M5\Z)_P %!?@*4E?_ (3R$)$=LC-97 "'T/[O@TLO_!0/X#12QPR>.XHYI?\
M5QM8W(9_]T>7S^% 'T3FEKYT/_!0/X"*F]_']O%&3M5Y;.X0,W]T$Q\M[#FF
M#_@H;^S^9!&?B':*Q7<-UK.,CU^YTH ^CJ3-?/$'_!0#X#7$>^'Q[!,N<?N[
M*X;'Y1TY_P!OCX&H1_Q6O7I_Q+;K_P"-T ?0U)FOG>X_X*!_ 6S53<>/[> L
M"<2V=PI&.O!3K[4UO^"@GP#VEO\ A8%MT+$?9+C( X)_U?0=S0!]%T5\[?\
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M[W=XW(_ G'X4 >H'X(?#OK_P@?AG/K_8]O\ _$5&OP6^'B<+X$\-+]-(M_\
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MN2=O%>M_ 6U^P^'O$D!)DV>*M9^=EP3NO9&Y_P"^NOM0!U\?@KP]&=J:%IB
M'D+9Q#W_ +M?/O[+6A:7<_%/]HBUEL+.6.#QJ-D;6Z%4!M(B !CCO^9KF?V0
M=(\2V'QE\62:CI>NV!-A<#Q'<:MYJQ7>J'4YFMG@#DJP%H0-T>% * \].J_9
M-&WXX_M-C_J<X?\ TBCH ^A)/!6@S*5?1-.=",;6M(R/_0::O@;P\N=NA:8N
M5VG%G%T]/N]*W:6@#POXI>%=(T_XI?"&.VTC388)]9NTE1+.(;_]!E(_A[8_
ME7JI\">'750V@Z8V!@9LXCC_ ,=K@?C"2OQ/^#A'7^W[D?A]@GKUM/NB@# 3
MP#X;C?<OA_2U;L5LH@??^&IH/!NA6I4PZ-I\)' ,=I&,#T^[6W2'M0!^6?B?
M4_$V@:QX_M_"=_J&EZ3:?$;7[O7HM)N;:TQIT2VY=P74MNC!W*$QU8=Z\V\.
M?%'QKH'C;6;ZXUC4]/TRYD%WK>DW%K;SS2:(S(XNXHI&(5S&P9O+.2"X&.,=
MI\3M/TC7]?\ 'NBZU_:UM9W?Q6UB%M0T>""1H8FM4\UI'F5A&B@*3QALXX(!
MKQK6O!5CI_QC\-^&?#]II_C&YL]0-IX@>:9;:6Z:-@B".52S1!DXVQC )(&1
M0!U]GX]\5O(D&GZAJFL:G;ZCINE7%W ));9X7N0Y1"(]J[(CY<A8DX?@X7-:
M.H?M.GP;XIUG4]0U$/K$]U]DA6WL$/[HSSJBW$A15"+'M, "D84'YL9JAI>E
MZMIUCX!73KC4)K?S)=NELOG?9]<:^4_9KJ:)HA$R6D9_>L&&(R-O)JC\4-,Q
MX@UN"S\/:9=>&;^WMKN=[ *$-H;N46=V"Q,0WR$X2+H'(<GC !Z7X$\=:UHW
MB"RCG\27=QI.IZ1+ML]7T] NKLD,\=PTDY545XY&4!$7/0Y-?9/[">@:;?\
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M]X7S_P!AJV_^.5S0_9!^"88,/A5X2R.A_LF+_"K*_LI?!L;?^+6^$,*I4?\
M$F@Z$Y_N^O>@#='QR^'(_P"9^\+_ /@ZMO\ XY7&?&WXP^ =4^#'CZVM_''A
MJ:6?P_J$2)'J]NS,S6T@  #\DDX%;2_LL_!Y-NWX7>#QM.1G1+<]L?W?>F0?
MLJ_!ZVE>2/X7^$5=U"L?['@(P.G!7CZB@#S3]ESXE> (_P!GWX13ZEXVT.QU
M"P\,V<3V=QK-NA1S;HK!T+CY@!C!'&:];G^,7PVN)5E/CKPI+(A4J6UFV)!&
M>?\ 6>Y_.J\/[,7PC@9V3X8^$07SN)T6W.<]>JU;L_V>?A?IPD%I\.?"EL)
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M >/^^JX/X1_M _"S3+#Q+'+\1/#,7G>)-3F02:M$NX/.6R,L..>W%>J)\&?
M41!3P1X<0@Y!&E0<'_OFED^#G@656#>#/#Q#9R#I<!SD$'^'T- &%)^TG\)E
M0M_PLKPKGH!_;$!_(;J^>_V>OCA\._"?QI_:)O-4\=^'+*TO_$MK>6L\FHQ!
M)XOL,8+(<X8 \''<$5],+\"OAVE[%>+X$\,K=Q((XYQI%OO1 ,!0VS(&.U75
M^$?@I(W0>$- V.0S+_9D.&(Z$_+SB@#ET_:I^$$CVB+\2_"Q:Z(6'_B:1?,2
M,COQP#UJ])^T?\+(XVD;XC>%@BY!)U>#_P"*K?D^%W@^8,)/"FAN&^]NTV$Y
M_P#':#\+?!S-N/A/0B<8R=-ASC_OF@#P?XH_M&?"W5?B'\*I[3XA^&9TLM=F
MDN&34XR(T:RF0$\]-S*/QKT2#]K+X.SLZ1_$[PLS1JSL/[3C& IP3R?6NU7X
M8>$5''A;1!C_ *AL/_Q-+_PK'PB0H/A71"%Z Z=#Q_X[0!R<?[4GPCEMX)E^
M)7A;RYPS1DZI$,A1D\9ST]:RK;]LCX)7K6XA^*?A5S-+Y4>-13YFZX]NGTKT
M _##P@<D^%=#)/4G38>?_':<GPS\)1YV^%]&7(VG&GP]/^^: /S'\:?$_P .
MRP_&6+2/&/A.YMY?%VKZLT-]JHCMM0BDM(S%$T>#YT<DF8SM(^91\P%8NFVW
MAF'4/"<)U_X>Z39:393F_P!(36O,M]1M)GC8)"JC<&C\POYDCAP\1 &*_5<_
M#_PV=O\ Q3VDX Q_QXQ?_$U$WPU\*.,-X9T8Y.3G3H>3Z_=H _(>U\.:+IL%
MYHNJ^*]$\0:K=VMC=KJFD>*[2Q@N'@D*Y:)P4=0BG/W7;?\ ,6R2+'C6P\-K
M::3H.G^/?#CV3B\OKC2;;48#IEA.S1,(RK$'[*3YI"1$D.2P%?KA_P *T\)A
M'3_A&-%V/]Y?[/AP?J-M/_X5WX8X'_".:05'8Z?#QZ?PT ?F1\#])\+?#WQ5
M:ZC?^-_!&E^%CILFH"&+78+J9=0N(956!9&R[?9U4(&"KN28#)*FOI7]B#X_
M_#7PE^RI\.M)UCQYX=TW4;73S'-:W.H1QR1GS7X96((XKZA_X5QX5WLW_"-:
M,&;[Q&GPY/U.VD;X;>%'8EO#&BMD<YTZ$G_T&@#DC^U#\(Q$\G_"R_"VQ 68
M_P!JP\#_ +ZK,B_;#^"TUY;6J?%'PJ9[E/-B7^TD&Y?7/3\Z[X_#+PCD8\*Z
M(".A_LZ'_P")IY^&_A4HRGPSHY5CDK]@AY_\=H X _M@?!<:JNG'XH>%OM;+
MN$?]HIR/7/3]:M#]JWX/_:(H/^%F^%?-D7<H_M2+D?7-=L?AUX6(PWAO1V'H
M=/AZ_P#?--/PV\*-G/AC1B#U!T^'G_QV@#@X/VO/@Q=3)'%\4?"K.\;RJIU.
M,?*OWCR?8U+)^UE\'8;1+I_B?X4$#KYBM_:<7*XW=,YZ5VC?"_P@X8'PKH9#
M8S_Q+8><=/X:B3X2^"HY%=?"&@*R\@KID (_\=H \]A_;6^!L]C/>)\5?"K6
MT#*LC_V@HP6Z<=3^ H'[:_P+?[.%^*_A;,YQ&/MZY8YQT[<^M>D)\-/"L,C/
M%X9T:-W7:S+I\(+ ]0?EIX^'/A969_\ A&M'WMU/]GQ<_P#CM 'F;?MM? J.
M)I&^*OAD('V%C>C&?3I4<?[</P'E#;/BMX9?:NX[;W.!Z]*]=/A72&38VEV)
M3&-OV6/&/RID'@_1;21G@T?3H'8;2T=I&I(],@=* /)8_P!N+X#2, OQ7\+N
M3V6^!_I3S^VY\"A@?\+3\- D[1_IG4_E7J]OX.T2U),.CZ="2V_]W:1KEO7I
MUJQ_PCNF@@_8+3(.<_9T_P * /(#^VY\"1'YA^*GAH)OV;C><;O3..OM49_;
MF^ @Z_%CPN/K? ?TKUX>%-(5-@TJQ50_F "UCQO_ +V,=?>HI/!.@S,&DT33
M9#C;EK.,G'_?- 'DG_#='P"_Z*SX5_\ !@/\*/\ ANCX!_\ 16?"O_@>/\*]
M6/P^\,-P?#FD'_MPB_\ B:#\/_#+##>'-(('3-A%_P#$T >6?\-Q_ 7 /_"V
M/"Q'M?#_  H_X;B^ Q#%?BOX8(7DXO0<?7BO58_ 7AR&19(] TJ.13N5ULH@
M5/J#MXJ2'P9HEL7\G1].A#GY]EG&-W.>>.>>: /*X?VU_@7<7!AC^*GACS0"
MQ5KX*< 9/4>E0C]N7X"'I\6/"Y_[?A_A7K=UX0T:]=&GTFPF*9P9+6-B,_5?
M8?E44?@/P[$Y>/0=+C<]66RB!/\ X[0!Y6O[</P&8*1\6/"Y#' _TX=?RJ2+
M]MGX%32%%^*OA</Z-?JO\Z]/_P"$"\.!74:!I>V0 ./L47S8Y&?EYYHOO 'A
MK561[[P]I5ZZ A3<6,3E0>N,K0!YP/VRO@@TT<0^*GA7S)/NK_:2<TZ7]L;X
M)P7*V[_%/PJ)BN_;_:2=*[P_"WP=N5AX3T(,O0C38<C_ ,=H_P"%6^#2#N\)
M:&Q/))TV'G_QV@#F;;]IWX2W;NL7Q*\*N4VY']JPC&1D=6]*<?VF?A.,_P#%
MRO"O'_46A_\ BJWF^$/@9RQ;P;X?8D8.=+@Y_P#':5?A'X(1 B^#O#ZJ.@&E
MP ?^@T 8*_M,?"=L8^)/A7GIG5X1_P"S4[_AI3X49(_X63X5S_V&(/\ XJMU
MOA)X(9RY\'>'R^,;CI<&?_0:BD^#?@.2-HSX*\.[&!!7^RH,$'@_PT 8B_M,
M_"9R OQ)\*DGTU:'_P"*IR_M+?"@[<?$CPL=V2/^)M#SCK_%6Z/A%X(\O8?!
MV@%,;=O]EP8QC&/N>E'_  J/P.$"CP;X?VC&%_LN#''3^&@#&_X:-^%C%0/B
M/X5W,0 /[8@Y_P#'J\D^*7Q'\*>+OVD/@!#H7BC1=:GBU353)#IU_%<NH-@P
M!(1B0,\9([U[8_P2^'[S+,? WAHRJ"H<Z3!D ]1G92:)\$_ /AG7(]9T?P5X
M>TO5XRQ2_LM+@AG4D8.'501D<4 =L.@I:0=*6@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME,DZ2%\MB3.UN>1TQ7H<?P#\%#X7R?#Q]+DE\)R+L>QDO)F)7<&"^86WX!
M&<  #I7HF*6@"&SM8[&TAMX@1%$BQH"<G &!R?85-110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1129!H 6BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** $/2H8(GC9BTC/N8GGM[5/10 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $4UP(1RK-R!
M\HS4M,?M]:?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tmb-20221231xex10d22010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231xex10d22010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 2O Y8# 2(  A$! Q$!_\0
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MBBF 4444K %%%%%@"BBBF 4444K )2T44P"BBB@!,4M%% !28I:* "BBBE8
MHHHI@%%%%*P!11118 HHHHL 44446 ****+ %%%%%@"BBBBP!11118 HHHI@
M%%%%*P!11118 HHHHL 44446 ****+ %)BEHI@%%%% "8I:**5@"D/(I:*8#
M%C5<X &?2GT44 %%%% !1112L F*,4M%, HHHH *3%+10 F*6BB@!,48I:*
M"DQ2T4 )BC I:* &[%_NBC8O]T4ZB@!NQ?[HHV+_ '13J* &[%_NBC8O]T4Z
MB@!NQ?[HHV+_ '13J* $P/2C%+10 F*,4M% !1110 4444 ?G=_P6M_Y-Z\%
M_P#8U)_Z27%%'_!:W_DWKP7_ -C4G_I)<44 ?HC1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YW?\ !:W_ )-Z\%_]
MC4G_ *27%%'_  6M_P"3>O!?_8U)_P"DEQ10!^B-%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?G=_P6M_Y-Z\%_P#8
MU)_Z27%%'_!:W_DWKP7_ -C4G_I)<44 ?HC1110 456DGE2XB18MR-G<V0-N
M!Q]<^U6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MJM>3R00NT<1F=5)5 <%CZ587E10 M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!^=W_!:W_DWKP7_P!C4G_I)<44?\%K?^3>
MO!?_ &-2?^DEQ10!^B-%%% ";1G.!FEHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** $*ANH!^M &*6B@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /SN_P""UO\ R;UX+_[&I/\
MTDN**/\ @M;_ ,F]>"_^QJ3_ -)+BB@#]$:*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH _.[_@M;_R;UX+_ .QJ3_TD
MN**/^"UO_)O7@O\ [&I/_22XHH _1&BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /SN_P""UO\ R;UX+_[&I/\ TDN*
M*/\ @M;_ ,F]>"_^QJ3_ -)+BB@#]$:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH _.[_@M;_R;UX+_ .QJ3_TDN**/
M^"UO_)O7@O\ [&I/_22XHH _1&BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ***C>98UW.0BCNQP* )**CCN(YAE'5QZJP-/!S2N M%%%, HHHH
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M9.#@T"92?PSS0!)141N(P<%AGKC(IG]H6P;!GB!Z<N/\: +%%43KFG@X-];
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MULI\;Z;,UQ(L42VQ>8LQ;:!A%..>*;-^U-\,8-3FT]_$V+R*0Q-$+&Y.7&>
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MV/XC?%F61S_PJ*TBB(/E^;XK@$A/&-P$) [YP3T[UP_Q!_:ZN_#&L>/#X?\
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MP55C:*2 >O6O1<\T9'K0!YTO[.7PN557_A /#Q"]-VGQG^8I%_9Q^%RR!_\
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M9-7?B5K?PK^'.I?$6UU?PEK,L7@S1+77+N=-9N MU%,[H$C!GSN4KSNP.>*
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ML_\ "Q_$ 'IY-K_\:IZ_#C75'/Q$\0-]8[7_ .-5Z#FEH \MN_@_KEW)</\
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MFU&[D\QOL3,!DRDC[N?P% 'T3DT9^OY5YO\ \,]>!I$^;2KK)'/_ !-KWO\
M]MJ$_9Y\#1@@:1.1TYU2\/'XS4 >D;OK^5&[V/Y5YM/^SMX"N4=9=",H<8=7
MO[HAO8CS:='^SU\/XY(G7PIIX:.1)5;Y\[U^ZQ.[YB,]3F@#/O8_^,I-+D$,
MW_(GW*^81^[/^FP\?7O]*]7+$=J\#O?@;X!LOC3H%K'X2TDVD_A^_C>U:W#0
MMBXMV#%#P6^8\G)YKLK;]F[X8VD;)'X#T$!I#*=UFK'<3G@G.!D=!Q0!Z3O]
MJ:TRKG) "]23T^M<&_P"^',BE7\"^'BNW:1_9T?3\J?;_ 7X=6BA8? OAZ,=
M/ETV+I^5 '77&N6-I<16\][;0SRDK''),JLY R0 3DD>@JM/XOT6UDDCGUC3
MX9(_OK)=QJ5],@GBN7F^ 7PVN;B.>;X?^&9IXFWQRR:5 SHQ&"02N1Q4D7P(
M^'5O+<RQ^ ?#*27*JDS#2(,RA?NACLYQVS0!N?\ "P?#(Z^(M(4^AOXO_BJ8
M?B/X57D^)=' ]]0A_P#BJK#X2^"1R/!WA_/K_9<&?_0*FC^&?A2--B^%]$1#
MU5=.A _]!H /^%F^$=^P>*=$W]=O]I0Y_P#0J5_B9X212S>*-% '4G480!_X
M]1_PK;PJ""/#.B@],C3H>G_?-*/ASX648'AK1\'@C^SX<?\ H- &;JWQM\ :
M%-!%J/C?P[923@F))]3A4R8X.WYN:@@^/7PYN9&CB\=>'9954N8X]2B9@H;:
M3@-G&>/K70Q^!] C "Z'IB;3N7;91#!]?NU8@\+Z5;S&6/3+)),%=Z6R!L>F
M0* .9/QT^'X8K_PF6B[AC(^V+WZ=ZC;X^_#I)FB/C70_-3&Z,7J%ESTR,Y%=
MH-+M!TM8 ?7RE_PIJ:19K*T@M(!(W5A$N3^.* .,/Q]^'0(!\::*"3@ W:\F
MD;]H#X<*K,?&VB!5ZG[6O%=N=-MB1_H\)Q_TS7_"G?8+?&/)B ]/+'^% '#C
MX_?#H[<>,]&.XX&+I3DU$W[0OPXQ*/\ A-='!B(#_P"DCY<]*[Y;.%>D2#Z(
M*<+= 20B GOM% 'FT7[1WP\N+J6WMO$:7DT>[<+6UGE'RG#894P<?6K:_'KP
M6Y 74KEB1D8TVYQ_Z+KT#;CI_.C:??\ .@#S\?'OP85#?VC= $[1G3+G.?\
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MWS:/2C% 'SW=_MS?#>!%:WM?%M^6) 6V\*WQ.!W^:,<'M5<_MS^"RZA/"OQ
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MB2%09.ZPMP>O8>=S5JP_:.\6:LCM:? OQZ-K!?\ 2Q9VV?<;YQQ7NN*, ]J
M/!5_:2\7O>+;+\!_'OF%6;<WV-4X_P!HS8R>PJ1?VA/'5S%.UK\!?&LDL1P4
MGN]/AW'&>"T_/7J.]>[8'I1M'H* /GT?M!_%0E0?V<?%@SU/]N:5Q_Y'IT_Q
M^^*P1#;_ +.OB61B[*1+KVF)M Q@\2GKD_3%?0&U?0?E2;%]!^5 'A$GQT^*
MJ*Y7]GW7GP/E U_3LD^A_><#W&:?%\:_BU-(R+\ M2C995CW3>);$*P(Y=2"
M?E'0D@'T!KW7:/04;1Z"@#PY_BW\8[BS=K7X'K%<D'8M[XLMD7(./F*QL0/H
M*D'Q8^,"O$K?! '=E6*^*[;"D#.?N?=/0<9^E>V[1G.!FC:/04 >)S?%3XQ>
M1(T7P2A$N/D67Q9;@$^A(B./RI+CXF_&I9W$/P9TYX3%F-F\7Q ^9GHW[C@8
M[C)]J]M*@]0*,4 >%W'Q#^/8B#0?"#PV[A48I)XSVY)^\HQ:GE?7H:;!\1?C
M[*V'^#WAN$>6S;CXSW L.B\6O>O=L#THQ0!X(WQ-^/Q *_!?P_C=R&\:KG'_
M ("]:ED^)WQU5?E^"VD,PZX\8QX_ _9Z]VQ1B@#PN#XB?'B6"*5_A'X;B\P'
M=$_C$AX^OWL6N.W8GK63^Q=+)<>&OB3<7<!L]1E^(6O/>V@<2+;SF<;XU< ;
MU!Z-@9]*^B)!E#C&:\'_ &6[>.PU7XT6D('D+\0M2F'S9^:6."63_P >8T >
M]T444 %%%% !1110 4444 %%%% !1110 4444 ?G=_P6M_Y-Z\%_]C4G_I)<
M44?\%K?^3>O!?_8U)_Z27%% 'Z(T444 %%%% !1110 4444 >">'-+73?VV_
M&=P&9GU#P5ILV#T4)=W$>!Z]*][KP30%>/\ ;9\8;IGE63P5IK*C@XAQ=W (
M4GJ#U..]>]4 !KR#]FR%H=&\;*QSCQCJY'T,^?ZUZ^>E>2_L]6S6EEXXC9W?
M_BK]48;SG ,BG'TYH ];HI,\XI: "BBDR* %HI,BC.: %HHI,@]Z %HI,T9'
MK0 M%-W#UI<CUH 6BDR/6@L!WH 6BDR* 0: %HI,T;@.] "T4F11D4 +132X
M'4XI<CUH 6BDW =Z-P]10 M%)D49'K0!YC^T^K/^SI\2PBAF_P"$=O\ "GH3
MY#5W_A\A]"TYA_%;1'/_   5R7QZT\ZO\$_'EDNTM/H5Z@#-M'^H;O73^%7\
MSPWI3\8:TA/!R/N+0!K452U75+/1[&6\O[N"QLX5W2W%Q*(XXU]68D #W)KP
M;]G[X@>-/%'C#6++Q+J5O=6D9N)866^TZ42YD39Y"VLSOY2KN&9 #R,\YH ^
MA:^:O&D.[]O3P VX R^!-8C' .,75N<X/7KTKZ4&<U\[_$2&9/VV?A#.S*+<
M^%?$2)MP&#B2Q+%O48*X]P: /?K-H+G]]$T<G5"Z$'&#R,CWKQ/]IG1_!EU<
M^#K_ ,4>,;CP;J5G?2C2KJ"WCNA([Q$2!H9(I%*A 2790$ZEA7L]M*B P).C
MS1_,ZC:K<\\@=/ZUY]\9CIFB:1:^,M6\.OKLOAFX^VVR0W,5O+;AE,4TH>61
M$*B)VW(Q^8#')P* ,/\ 94ATBQ^&4^FZ/,EY9V&MZG;B\2[6Y%PZW;[I=R(D
M:ESEMD8VKG"DXS7LD$,D1E#2^8K-N4$8V#^[FO(_V<!\/_\ A6EM=_#.RN;/
MPUJ5Q/J4%C<P2VS*TLI,C*D@!5"V<8XQT.*]2TR^EO--CN3$073?Y<;A^?[H
M88!^HH \$^%)>+]MCX[J(_W<N@^&9"_4 A+P >W?CVKW/Q7>:1;Z:;;6K^"Q
MM=186"^?,(O.>4%1&I)Y9LG '/I7A'PLO!%^VW\;[<QO_I/AWPW<EST3:+M=
MOMG=G'L:=^T[\+O&OQH\1Z9H6C6EE;:!IFCWNI1:IJ/SQKK)*)8E$4[@\($D
MFXC;\XH ]#UGX;^!KWP#8^ KTJ-'TD645M!]N:.YMG1O]%=9 P=9-R?*<Y)'
M&>:Q;KX$?#'PK=:!<WEFMI+;QVNC:?)>7TF9'6\%Y"F2<O(;A ^3RQR#7AMW
M\"/'7B_QG>^+M0\+7=K>:GJWA'Q%<6TFKH,36,C)>PJH?"X#>8H^ZP'!!J[X
M-^"'Q6LM>E?5[:X-D?%FBZSMFU@7<:+%)<_;)(MQW*I5X2%.">PXH ][U+]G
MCP#JPLFO/#_VAK/[8(7:YF1E%U)YL_S!@3N?YO8CC%=!X?LO"OP=\.>'?"U@
M;?1=-\P:=I=K+*2992&<1J6R68X9N3D\U\M67[/'Q5L? DUG,U[J=S?PZ3<:
MI83:X6:ZGBGN!=HLC/A2\;P-G(4[,=16QI7[/_Q M?BWX'U34[ ZW::5<:9=
M/KUUK)=[6."P:VFMS 0!*[2DR>: ,[O44 =_^TP=GCWX#2C;QXV0?,<#FSN!
M76#QK\-/B'X[T.WBUS2=6\3Z1+<W.FQ17!+QR*K03[.S,H+*R\D=2*Y;]IF/
M=XP^!K,K$+XXMR0..?LT^/UKS73OV5?'2VMK<Q:S+9WJ3>)5AM[B[#1:3)?-
M-]FOK3:G#A7VLC$\2$C!7D ]Y/[/?PX:YTNX/@^P\W3;J2[M6*-B&1Y1*Q S
MC;Y@#[""H;G%3O\  [P&VH6-ZWABR>\L=3FUBVG97+QW<KB220'/5G56VGC(
M!P,"OF35OV3OB')\+=#TFPM+:/4K;59+MM-GU^8V=KNM4@,J[4RZEE:4QY#!
MGR&SFM*^^ ?COQC\3?'MUI4Q\/AM0O8;?Q$UW<I,B2Z.MNL4<+#:T7GN)=P/
M!C[F@#Z6\(_#7P7X#U+5M;\.Z!IFBW.ID/>W=G&$$N&)R2.  Q)XP,DD\US]
MG\+OA5\,8M3U&P\-Z+I+QE=9N3;0[I,P;Y%F"#+$IO<KM'&XXKPG1OV0/$MW
M;:!::MIND6'A^+7!>WOANVU"6>U6%=*EM"ZDJ-SRSLDK*1@8SDM5SPY^ROX\
MT'Q]X9UX/HSF+P9%H&L7D]Q)/=2S1V30!8=R_NP7*DN&Y"\KF@#U#2=!^"/B
MFUB:RT70+\^&XQ=Q6YLB9K(2*+X,L; /DB;S0 "07/0Y%><?'[QOIWCOXE_
MBY\)WL6H7]IXCG91)$P\M[C1+B:#>C@?>4HV#R,XX-8?A_\ 8P\86NM>'KN]
MG\/[K31M&L[K4HC-]O66STZ2UFAC;&#%,S+EF.<#ID"N:\;_  KU7X/^)_@;
M;ZWJ5A;/<^(+"S-Q"S>5&]OX=FM968L1A25ZYSCGK0!Z?X/UK4=!TR2XGT"Y
M1);2\O\ 5T^Q?9-.>YD2*&&..'<=T<DJNV"0P))Y#9'BWC;PM?V_PL$_B5+3
M2-(U*/28X9=+E^WDZNFH2;+'[+,\:FS=CM>-Y$09R3@5WWAF**.[U W>AVVH
MS32M;7MU'?6]M%<VL7']H1RO(3*Q1A&(OE 4L>,UG:K'!=_#"X\-Z5J.C:OJ
MELMHEUJ6J:E87+ZIIL]VTUY %DD^SK.BLI7=QE0 <8- &3\,+3_A&-(\=W%E
M!;6?CC1(8]56VN-+M-)L=/#VTL,5Q;_9IYX7EY)<.X+ (".AKN-&O%\)>(?$
M&K6,]RVN6[7J6^AWB1VPU>2")&FFA(?,:.QD<J4^?<=N!T\VT#PQ+;P>)O#]
MY-X2G\,V<=K<>'KKPQJ]CHG]H7@G96NYX_,RDJ($R#N4[?E'S<>C:EXBT0>+
M)/$4>MZ!;6FI1'4M5%WKD']IVTMLBF2U3#O^[E(5&1>=JD#@T :NH"S/[8/P
M.:V-M]J/AK7)+M+>)8D\QX[9BX5> 3N'X=S7UH#_ "KX_GU[P[<?M5_ [^R-
M9L[^"UTOQ(DDJ7L,Q1&6WD0,RL< !M@SC[A &!7U8_BK18AE]6L$QC[US&/Z
MT :M%<T?B9X1#[/^$HT7?DKM_M&'.1U'WJB'Q6\%L&(\7:$0I 8C4X.,],_/
M0!U5%<L/BAX/?;M\5Z&=PW+C4H.1ZCYZF/Q%\*^7O'B71]@_B_M"''Y[J .C
MHKD[CXK^"K2&26;QAH,4<:&1V;4X1M7U/S=*SE^/'PX>S-XOCSPZUJ,9E&IP
MD#/3^*@#O:*\^D^/WPWA@$[^.M!$!D\H2F_CVE\9VYSC..<4ZU^/7PZOIVAM
MO&VB7,RKO:.&]1V5?4@'@?6@#OZ*X>'XU^!;@$Q>*],E [I.#_*B;XV^!;>0
MQR^*M+C<'&TS\_E0!W%%<+9_&[P-?"0P>);-Q&YC8Y8?,.HY'/UJA%^T'X E
MT^:]7Q+";>(R*_[B;?E/O839N/X#GMF@#TFBO*HOVF_AQ*SJ-?G#(&WAM+O!
MC'7K#U]J(?VFOAW-Y?E:U=S^8$*^3H]\X.\D+TA[D&@#U6BN B^.'A2>)9(Y
MM4=&Z,NB7N#_ .0:<OQK\,/NVG5WVYR%T*^)_P#1- '>T5PQ^,/A\1F3R-=*
M#&2/#U^>O_;&HC\:_#H95^R^(\MTQX:U'G_R!0!WU%<%<_&30H+5IS9>)"BX
M!V>&M0+'/H/)K'N?V@=+M;AXE\+>.KD*K,)8/"5\48#J0?+_ )]: /5:*\M3
MX\V4UNDX\(>.PC\*K>%KM6[#E2N1U[@5<3XPQOROA#QEC.,'0Y%_F: /1J*\
M\_X6\/\ H3?&)_[@Y_\ BJ9-\8TA"[O!WC/YC_!HCMCZX)H ]&HKSN+XOQS3
MM"/"'C%2%#EGT20)SV!SR?:GI\6BX<#P=XO&W^]I)&?I\U 'H-%>>O\ %B5!
MN7P3XO<<CY=-7/ ]#(#44/Q?EF8#_A!_&4>5#9?2E'X?ZSK0!Z/17G)^+[%E
M'_"%>,@3(J?\@C@9/WB=_0=ZDE^++1@X\&>,&()'RZ5G/O\ ?Z4 >@.,J:\-
M_9LMDM/%/QNC3[I\=7,F/0M:VS']2:Z<?&2>X*!/ 'C8;I5B!;2XU&3_ !',
MHPH[D\"N4_9JO?M_BKXTSFUGLI#XUEWV]RH5UQ9VP!(!(Y R,$\&@#WBBBB@
M HHHH **** "BBB@ HHHH **** "BBB@#\[O^"UO_)O7@O\ [&I/_22XHH_X
M+6_\F]>"_P#L:D_])+BB@#]$:*** "BBB@ HHHH **** /GK4]6O;']L_4H]
M/T[^TKH_#ZU81-<B%0!J<X)R01W'Y5ZI%XB\5,RB3PBB@YW%=5C./3^&O.+:
M.;_AN746!_T;_A75L&';?_:<^/TS7N^!0!R0\0>*/+8_\(FH<?=!U2+!^IVU
MP7@'1_'_ (%L/$('AK3KZXU76;O5D7^V-JQ"9E(C),>3C';BO:L"C % 'G5[
MX@^(R"%K7P?H\Q95\P/K97#?Q ?NN<5H'Q!XS5\?\(C:;,?>&KKU_P"^*[7
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M]#-C'/2O4::_;ZT >!? [X)>$-3^&6D7.HZ6VI7I-Q&]U<W4SNX6>0#)W\\
M#\*[J'X > H4*)X<A"YSS<3']=]+\!5V_#+3A_T]WO7_ *^IJ]#) ZX'UH \
MYF_9X^'=Q&5F\,6THSG$DLK<_B]?/_[5'P+\'VGB7X(0VWAK33I$OC58+^TG
M0ND\<EG,NUP2<KD#/IUK[%W C@U\Z?M=6ZS^(?@E_H;W<@\;P[0O*X-I<;@P
M[[AD#W- '@=Y^RYX,U1;G4](^&_PO'AK[1%=V^LW0N(;*XLUFD2:W!!P)\*V
M7Z8*D#Y:7PC^SY\-5\+F3Q+\&/"MK>?:\F\T[2FO8GLVNU2.9-F[Y3$Y8$?>
M #<X..GTWQ'9_P#".7^G7'AF^.@6NH3W::;+!"%DB@4HD+6[NZC=([NBDIO5
M6R>*I^$M8U#4;BZ9 +#PV+.&.U@M'W6C-YLTSK:B<ADEB4* PW(BF15!S0!P
M6GZ1\)9-3TD7OPH\"0:7J4UWI5JT>@Q22SWL5RZ",)Y8E4K $D)VDL6X->D>
M"OAG\)=9TJQO=:^$'@:)(;F\L]0U!-)MH[.>2'<!-")$#R*P0_*"-A4Y%1:#
MX@NM.\+Z7;M#JNI:Q!,;VPBU74+.XG7<^-UL1&3O6)BI&0Z@Y(KT+1/#][\-
M/#T45I?Z'X>TN.2+43I4=X[V5P\H;]ROF!G4%?F<Y.]AGC)% 'F4/@7X4V_[
M4OP3?PAX(\/:#INHVWB&RO(K"U@\F[DCB@P"8\K(!N."?<5]=GX*^ 6PQ\$^
M'V/!YTV$].G\-?+M_<00?M!_LU75KI6GZ/'-=>(8C:Z?-#+%F:(2AP8U4 L%
M5N@/S<^M?:Z'*@]L4 <39_!+P!83I<6W@?PW!<(2RS)I-N'4G@D'9UQ4T7P?
M\#01RQQ^"_#L<<K!I$32H '8="1LY(R:['%% &#9^ _#NGV\4-KH&EVT,2[(
MXXK*)0B^@ 7@59'A/1@,?V388]/LL?\ A6M10!E?\(QI(;(TRRZ8&+:/I^5/
M_P"$;TLC']G6G_@.G^%:5% %%M(M2@3[-!Y8.X+Y2X!QC.,=?>GP:=;V[EHX
M(HF(P61 I(^HJU2T 1K"$7"_*.P Q08@><G/KWJ2B@!@3'<G\:/+]S^9I]%
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M^,[6QP<=^:^1?@?87<GQ&\.W$C-J%Q;:OKO]I:SHG@R6ULKZ[>5HY'DNR^U
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M@LV4<2/J!L8)[>%97;61ITI.TGYR[B7D'*G'6H=:)B_X*3^$AL6!Y/AG<[E
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MPO3&#C\*^,-2\100?M-?VK8>*M-ETGQ#JNG3VL4/CE[#SAL\HAM.$#>>V4.
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MMK5MJZ>'X#J,%O%;1S.[G"QQ>3&Q!;!<1DH'^]M.,T >;V7[8=OJ7A5M8MO
M7B.23%A.MIFWW?9;N!IHKAW#E8T 1E;<001SQ7OND:FFKZ9:7L8 CN(DF4!@
MW#*#U'!Z]1Q7$7'P'\#W6CG2I/#-H=.:WM;4PAG4>5;(4@3(.<(K,![$YS7=
MV%E#IUE!:V\2PP0(L4<:#"JJC  ]@ * +-%%% !1110 4444 %%%% !1110
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MQGT^4USOPB;=\+O"9W;O^)9;\^O[L5T][C[++D9&QN/P-<O\(F#_  N\*,H
M4Z9;D ?[@H Z+6$NY--N4L'ACO6C80/.I:-7Q\I8#DC.,XKY!^$\-A'^T''>
MW*Z#YD^J7\$&I:?H]]9V]W? .;N.&5IO)EE\Q9"QV'.Q@#D&OKGQ'J$FDZ'J
M%]%%YTMM;2SK'_>*H6 _'&*^1_V:/&G@[Q?\13JGB&+1X/&FH):ZEI7V!KA;
M5WO+7S)UA@=VC6XC*2))(F"PP3@L10!]CH<J*^?_ -H2%&^.?[.,I3,B^*[]
M ^>@.D7A(_' _*OH"+&P5X#^T@QA^+7[.\J8WCQK,F/9M)O0?TH ]SFMHT\V
M21F=6 8JQRHQZ"O/?B;X"TCXD:1H_A?5]?U2WLYI_-N+73[KR'U2-$+/!<,O
M)B93\RC&X<=#7IBC<N&'!&.:@:UB:X+E$+J/E.T97C!P>M ',>&O#WAKPY)<
M:=X?M;#0WM?(^U0Z?;1P958P(PX &1L  ] ,=JZ*RN8[A6\N5'(^8!'#84CC
MIVIMU8AXW$86VD=0&G1%+<=N1SQGKZU%'IJQB[,!^S22JJ^9%&JLH P,<<_C
MQ0!\P>(G2R_X*5>"H\D>;\-KQ%!^8DB^9OY9JK):^,OAYXJ\9:VWCVR^$O@.
M\UL-;:;XI1-5EO9S.%DFM@TBF".<L L:[\'YL#)K0\66:C_@I%\/YI/GW_#O
M44&[L1=C)_)Z\H\4:?X7OOVH=5U7P5J<_BCQMX?\117^H:'KOAU[MH9'C\DB
MWO1B2.%5<L$4,H903B@#ZY^(6/\ A87PK8'*_P!KW0S[_8+BOGG]H$?#G4?B
MAX@N_$&B:Q\9/%.F"TTVR\(V\(BLM%^V%(XA++\JCSG*GS&+;>@ [_0'Q0DD
MB\?_  GVIYBG7IT8\\ Z?<G=Q]#[<U\[_MA>7J_B^YTW5/ GA/7;86D;6.LZ
M?++=>);.7 VR+:6[).RH^&#*^%P#CB@#W/XHVKVO@WX=0RV4>ERQ>)-%1[."
M7S$@(D \L-_$%Z9[XS7L0@R'!8X)Z9KQ+QY!);_#'X8I//<3RQZ[H*O-=!Q*
M["5 2X?+!B>H;G->YCO0!\V?M[RMI'[.=S<VN(I+76](>( <*1>Q <?C7T8X
MR>V<U\Z?\%!XR_[,NL$#.W5=);Z?Z=#S7T>@!R<YYH ^1/AQXIO?BE^T!K=W
MX;UW6_"6FWNS5$TV_P!+M+JVU6WLYS932P/N,D&74*58#LP%?7$:[SZ'K7EJ
M?LJ?"B+7H=:C\$V$6J0W!NH[J-Y59)#)YI(P_0R?-CIGG%>K*H7H,$T ><_!
M1'BM/&$;R>88_%&I<XQP9 <?K53]I2(M\(M8D35YM&G@DMYX)H())S+*DZ,D
M)CC(9Q(P"%5()#=:M?!5MP\=#KCQ7J _5*X7]K'X@:AX/TK1M-?P[;^(?#VM
MI?6M[9W=J\R7DX@/V2R!4?NC-*5'F-P-IZ$@T 7OV6+J35M*\7:Q=ZQ%J6I:
MOK"ZE<VUK:S6\%D9;6!EC19B6Y7#-S@.S# KG_V[IX[3X<^"KN9/-AM_'>@R
M/&'VLX%SC"GUYJ_^QY;R:!X?\4^%(M'T?3M,\-ZDFG17&AV<EM;RW(@1KN,"
M1F9_*F9X]^X[L>U5_P!O(1)\$["62.-VB\3Z+)&9!G:WVV,9!['D\F@#D-:\
M0:_KWC.6UM_M6NVVDZE.CW.M64<?D,$E1X[>.1O-+/&#@X 9H_E/)KS/PA:W
MDG@*XTNY?4M5\&W]@S#2)(8+6QMX6D22-T!;S%N(9(VD9'7)48YQ6R_BZ_L=
M:\8Z1IEGJ"17,NJ:6%;$\%A=-<23643;?WB>9BX;S"?+53@D=*SY[:\\&SZ5
M>:39Z01J.@0PVMG)<VZ1QE@"'OGMRKS(JK*"X)&,\#G(!M>*_$'A+4-%NXI?
M%.KRVMTVG2SZF]W)B6VC5RTT  V1B91O W ]3@8Y=)>ZYKVCQZC<ZA<M+K=G
MJEA)J=M<JR#S#Y,4TES%A2L:Y=490R'.W.:X_P /Z)K.@> 1=6'AS5-5@M8K
M:#4?#]TP62ZL+599;>=+HM_I4(7Y5;/W41#Q7::!\/K@^&DUK1[J3[%K4]S>
M36UY9+IUG<PO$4G+("27<N6RYRJAG!X% %7Q9J.G:EXK^ >MB[TS6+B3X@0P
MOJ>E&1A<1&PD6V:17^:-]CJ2F ,Y( %?=2C %?!WQBDT*+4O@JFDR7\,UMX^
MT.&6&2Y>4Q(8F$.&<# :/:,?>V;<]17WB* %HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&&1P
M<5X?\-8$M_VH?C)L55\[3]!GD('+/Y4Z9_)%'X5[C7B'PZ?/[4OQ?7TTG03_
M ..75 'M]%%% !1110 4444 %%%% !1110 4444 %%%% 'YW?\%K?^3>O!?_
M &-2?^DEQ11_P6M_Y-Z\%_\ 8U)_Z27%% 'Z(T444 %%%% !1110 4444 >!
M^/;^6V_;(^$UO&<17'AO7_, ')VO9D?J:]OMM7L[V2:.WN89Y82!(D<BLR$]
M 0#Q7RW^U%;:[J'QX\)V/A<$>)[GP%XLCTN5&VNER5M/+VGH"3@ GIQ7$Z#9
M:9X=^'^AV7PE\+^)OAYXKN[K0M+\0:S)HSB[,<DKK.CR3AUEF4AF>3! # [B
M"!0!]R>:NW=G ZYK*O/%^BV%X;2XU2S@NA)#%Y$DZJ^^4L(EP3G+[6VCO@XK
MY;O]>^-&E_%GQ#X?T_5KV=; 2G1;;4[$R0:I8)IORRF=(@GV@WAY+.O3;LQS
M7F_@CP_X_P!=^)4GB%M$\1:C-<ZSX';4KOQ!I:QRMY,=ZE\X5D"J(6E1@R ;
M200>: /OY+I)%#)\RDXRI!'7%*;A%(R0,C-?"GP\T'XA_#70/A9IMLWQ#U)]
M/\7WEKKNBR(WEW,<EP?+G-R00MM&A#[3\LFYP2"!7H7[7?B'XIZ)XD\,O\.[
M/Q"?LD0NVFTB)KF"\874*RVTL 4J3Y)D8,Y ZXY% 'U49U /MU]JIP:]87-[
M=V<-U#+=VFPW$"2!GA# LI<=1D D9ZBOC_5=5^.\MEX@U+P_?>(KG4KS6/%%
MA::?=V<*V]K;1,QTZ6,&,$-M4!"[$.3SGK7<?LR>']1B\>_%/6KN#Q0\&LQZ
M.([_ ,56OV>YN9$L=DH"[%'R-P<#;N+ <#- 'T+IOB33-9CDDT^_M;^.-MKO
M:SI*JGT)4G!Z]?2K_G+S^=?G;\-_AO\ $7PAX(34_A]X'U3PEXFTKPMJ&G:E
M--:):OJMY)J2O"8XV)$DD4(G=9&'_+51D]*]2U2Z^**>'?#FKV]_XOUBV3Q6
M%M_#T%I+;7<]B840I>7+(K*J2"282%=K9V$<@@ ^OS<*%R>/K5*#Q%IMUJMU
MID-[!)J%K&DL]JL@,D2/G8S+U ;!P>^*^3M5N?BI)I'Q$5;GQ_;^-!JB06GV
M6WC;3(]-?58 K69*[&D6T,F3]X*7)Y IGQDM_%7@'XAND&H>(+?PWJ>L^%]*
MAO+-U-W=1M)="Y@2? D).8\Y/'\)% 'UW<ZI;6:N9YDB"1M*V]@,(O+-]!ZU
M%I&O6&O:7::GIUU#?:=>1)/;W=NX>.6-@"KJPX((((-?(GASP#X];Q5X5U7Q
M+IOB?4)+SPKK&A+=M=AI;(-<O)9B\"L 9# 55I,'Y@N>:;X$\&_%?3[#P/;W
M$?B2UO1H7AV*U-M<I'I^GO#;!=3CNHE91YCMN ^4\X*E=IH ^R!."<8^M2U\
MV?L]^&/B7X6\=Z=%XEGUBYT*Z\&6TVH/JUW]IV:T+N42*I).T^2R\+\N .]?
M261ZT +129HR/6@!:*3(]:,CUH 6BDW#U%&X>HH 6BDW#U%&X>HH 6BDW#U%
M&X>HH 6BF[U]1^=+D>M "T4F:,T -E ( (!!.,&N-^#$ZS_"GPFZJJ*=.APJ
M]!\O2NRD(X^HKR_]F(Y^ _@SYG?%F1E^O$C4 >HN@<$'H1BJ\=DD0C540)'P
M@"\)_N^GX59S1F@!%&!7S[^U%-]B^(/[/USQN'CV.($]A)87:']#7T$6QV)K
MYY_:R98O%'P$G9I%"_$.S4!/5K:Y7\N: /?UV2@HK<(<$ ]Q5:^ODL1*_D2R
M2A1A(EW.XR!E1GG&1FH+286U[-;;)?,D=GW_ &?:A. 3AAU],GFIGAG,+&XE
M/F%"N^"'[ISPPSD^G7CB@"3[<$MII)5>%8B0SR #<!_$,=C2$7 M,Y!G"<E0
M2"?89J+3W9XGB=+@B,[2\T87S.O0#Z4D6I--!<L+>XA:%BO[^(Y8CHR@?>''
M:@#YL\9$K_P44^&;$']]X#U5"",$8N4-7O'G[)OBKX@?$"\\1ZI\1+/5;)-0
MBNM*T;5O#L=Q;Z9$ARR)MD0LYY_>-DCL*I^.K6<?\%!OA+.7\I#X+UA2VS(E
M(FB+*/3[P-?47FJB_,0.<9)Q0!Y1\8;?;XV^#N'";/%+9(8J#_Q+;P8XZY]#
MZ5K^)/V?OAUXTUR[US6/!VD7FN7D'V:YU/R-EU-%M"F-Y5P[+@8VDXK"^-DB
M7'B_X.O%(KM'XP!/EN#@?V=>YR >G\J]335[((/],MP.G^N7_&@#S+XSZ9!H
M?A#P=9V5LL-G;>)M%ABAB&%BC6Z0  >@XKUL=Z\Z^+FM6B>&[ 1R6]TW]M:9
MN'VA!L7[9%E^3V'-=E_PDFDH"6U.S SC)N4_QH \3_;O,*_LM>,&FC9PLE@5
M*_P-]N@VM] >:]ZM>85.X/D [AT;W_&O _VT]8TO4/V7O'\,5_:7#-:Q$)'.
MC$D7$1Z ^U>N:9XNT2UTBU#ZQIT8B@C#[[N,;?E'7+<4 =-3).E82^/_  VP
M=AX@TDJAVL1?1?*?0_-Q5:[^)7A.!MDGBC1(FV[]LFI0J<>O+=/>@#F/@E<F
M2Y^(,9(+1>+KY<#J 4B89_/->FNA8<$J?:OGSX/?%7P5I?B;XJS77BW0+2*X
M\5.\4DVIPJ)5%I;@E<MR 01D>E>EK\=/ATQ('CWPR<=?^)O!_P#%4 =K#;K"
M7*JJAFW':,9/<UX!^W<2G[/-\WEED&L:3NE'_+ ?;X/WF.^.F/>O0Y?V@OAG
M""7^(?AA<>NK0?\ Q5>$?MH_&KX>^*OV=O$-AIGC;P]J5Z]WIK1P6VI1R.=M
M_;ECM4DD!02?S[4 <_XY\3IJWB2T@L%ECDUO5[OPQ>7.FWAV0207:SQ%SY**
M\<0+#9NSFX9,MS65X9LM/LVL8H]5T_PTNFZG=3ZS:6\\BWCQQ>8D4<Z>9M,2
MSF)G1%5<NB]&-8OBSXS^%;U?&\$/C_P9:ZWJ=S,L=_>^(8<Q&&],MNR6J-L!
M:%FC\SB7.-Q(Q6)-X\\!V>IM;>(?%_@[Q'X>3^TTNS<>(X;F^O(;M%BW&1F7
M'W$? Y^4]\4 >A^"_!_B/QEI_B-=)M4NKR>W:TLWU+4I1 EFH_T<NB@-!*2"
MC11A0<L&^7KLZG8-'KWB'3HKN/5+O7K6XT>]OM4\RWT]I!&Q6WC3I')AMJ%#
MM*J1VKAQ\5O 5_X -IXD^+'AK4M:>:U@@A3Q&+)66"1<3>;$=Z,5.&8EMP &
M!R:N^)OC;\,=7_X1G1;3XF:'9^'8)9KG%MXICS#'Y>1#,T@;?F48&!C8Y&,Y
M- #OC% NGQ_"J!-;CULV'Q;TRR-W$,R*R1A)!+G[TF<J6'7 ]*^[QUK\XO'G
MQ>\%ZGX+^%T#^/\ 0)KVP\>Z)=MH^GZA;7$>GVR7#Y.^-59SL*,[D=3Q7UI)
M^V?\#(9'C?XK^$U=6*L#JD?!S0![517C:?MA?!>5E$?Q-\.,6!*E;T$,!W!Q
MS39OVQ/@O"S@_$OP\S1XWQI=[G&>AV@$T >S45X=<_MJ?!BWMGG_ .$]LI41
MMA$%O/(Q/LJQDD>XJL?VYO@FK!3XV4$C=SIMWT_[]4 >]45\_C]NWX*,T:IX
MQDE9R0JQZ1>N3CKP(:=;_MT_!F\<I;>*;NYD SY<.A7[L1Z@"')% 'OU%>#C
M]MOX2L,C6-889QD>&=2_^1ZG@_;.^%ERS+'JFLLRC)!\-:D/YP4 >XT5\\7W
M[<?P]M+EHXK#QC?* "9;;PK>E/\ QY ?TI(_VXO <R?NM$\;N^0!&/"MWN_]
M H ^B**^>6_;;\&*VT>&?'S/_=7PI=9_]!I\G[:7A:.%)CX.^(7ENS*I'A6X
MY(ZT ?0=%> V/[86D:G:_:+3X=?$VYAR5+)X3GX(^IJ9?VM;"5W6'X9_$ZX$
M<AC9H_"LN 1C/5O>@#WBBO!I?VJF6XECC^$WQ0EC1$*S#PT0'+'E0"X.0,GG
MCC%,C_:TCE6X ^$GQ6#PIOP_A5EWGT7]YR: /?**^>Y_VM;PV[/:_!;XJ3RJ
MRCRFT!8\@C)(+2XX_6F7_P"UEJUI=E(/@?\ %&\@RN)DT>)<@@$G:9<\9Q^%
M 'T/17SVW[5NM(7S\#/B>1N^7&EP9*]C_K>/H:=-^U+XA5(F3X%?$IUDS_RX
MVX*D''(,M 'T%17A<7[1GBAY(8S\$/'RF9VCC)CL\ C'+'S_ )!SU-6KGXZ^
M,[=HR/@EXR=7E$7RW%@2,@G<0)SA1C&?4B@#VJBO'$^,WCI[E(Q\%O$RQ'K*
M^HZ>,<9Z>=6=K/[0?C31KD1'X%^-[Q3@"6SFL95S^$W\Z /=**^?U_:7\8R3
MQ1+\ _'X,AV[G%FJKSCD^=Q6E<?'+Q_")=OP+\62E6 &S4=.^;)QD?OZ /;J
M*\+O/C;\4E>06?P%UR95"[6N->T^+<2>1P[8P,_4U1B^._Q>DGD5OV>=:C10
M<,?$=@=QQE<?-T)&#Z9[T ?05%> Q_'3XN%Y/-_9[UI8_*)C,?B/3V9I/[I&
MX8'^US]*@_X7Q\8UV!OV=M6.Y2V5\36!P>P//!H ^A:\)^',RG]K+XPQX;<-
M%\/L3CC!%W^O%9O_  O[XPS.5B_9QUU0%!+7'B/3D!;N!M=LCWK+^ 6MZMXA
M_:=^+E_KNB3>%M6?0]!1]%FN8[@H@-WME\Q.#NR1CMMH ^G**** "BBB@ HH
MHH **** "BBB@ HHHH **** /SN_X+6_\F]>"_\ L:D_])+BBC_@M;_R;UX+
M_P"QJ3_TDN** /T1HHHH **** "BBB@ HHHH ^6_V@9?%%K^U-\(I/!EEI-_
MXB;1->2.+6[B6"U$6;4NQ:-6;=T &#WZ5U%QJ?[2<B*(O#GPRC;=\S/K%^RX
MQSP(!WQ1\0K=6_;"^#L@9@4T+Q!\H'!!^R=:][Q0!\\OJ'[4),870OA6JJ"'
MW:EJ)W'U'[OC/OFN<L?&7[4&M>+M=T*SA^$"7.DFW><2RZF^Q9D+IT()X4C.
M!GTXKZH91@YKQ[X=*@_:2^+V N]K'0F;"X;_ %5R!D]^E ')-'^UEG(D^#)!
M]8]6X_\ 'J;_ ,99(N /@R?H-6&?_'J^D0!CI1M% 'SD4_:O)8&?X-A#C#>3
MJQP>XQNYIS1?M7"0'S_@XRX&1Y.K#![X^:OHO:/2C % 'SE-;?M5C#17'P>)
M&,J\.JD'V^]]#^%)]E_:O>17:]^#B#;AHQ::JP/X[Q7T=@>E&* /F][#]K)V
MRNL_!^,=@-.U0X_\B5%/X5_:<UGRDU34_A!,EO(MQ 3H^HRF.9.4<!I1M(/\
M0Y':OI:B@#PC_A%OVAMBX\=> %?^+_BFKDX]<?Z33&\#?M"3Q7"GXH>#+9V4
MB*6+PA*Y0^N&N\&O>:6@#YW7X9?M&K(&_P"%U^%=@7!3_A!NI]<_:Z5_A?\
MM%R1*G_"[O#$++_RVC\"AF?V(-W@ >U?0U+0!\[O\)_VB@KE/CWX?=L?*'\
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MB1?ZPMJL V?[WS\5M'POH[IM;2K%ESG!MDQ_*FGP?H3(5.BZ<5/53:1X/Z4
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MBV_;)\1:QX=TCPW8>%=/3XW77B*7P[>>$I;I_)L?)):6\=@ YM_*VR*PX;<
M#2^"?@1\0_%'[2.A?$_QCX9\*>"I=*CE:^;0=6N;Z36IFA\J-F5@J1+&N<9!
M;D\UZ#:_!34+']LB]^*,5I8?V%=^$(M&><,/M/VI+@MG&.ACVC=GH,4 =]\8
M/B7%\(/A-XA\87T*73Z39&86Z,5$\QPL<:GJ-\C*H[\BO-_AK^T?K/C7X$^-
M?%.I>&[?0_''A);R'5/#DD[.L%S#%YJ*S 9VNA5@?0UI?M)_"7Q#\:X?!WAB
MRO5TSPJ-934?$%Q%/LNA%;KO@CA!#!B9MA.1@!:X:+]FSQKX4^(7Q7GT+Q"^
ML^&O'OA:6&X;7[@27,6L*KQQ,-J*/*,3X)[8 YP* *'PT_;=N/B;X?\ @[>V
M^A6UAJ7BOQ"V@ZYI\TC[]-;[))<HT>1SO5492>"&/I5"+]J[XN3^ /&OQ"M/
M!'AC4/"'A/5M1L[ZVAU&9-0DMK.4K-)&"-FX("P&><57\/\ [%.OZ3XT^ WB
MVWUF"PO?"UE8V_BO3//=H+Z6UM6ABFCP,-(OF.F3C*D5%IW[-WQTTCP?X]^'
M6FZOX'LO!GB[6=4NKC5IDNI=1@M;V0F01H,1^8$)"DY )![4 ?5C>/\ 1XOA
MX?&GV@?V"=,_M<W!.!]G\KS0?^^:\(_9E_:)\=?&OP_XLL?$.B:7X3\;PV5O
MK&B6<BN8)-.NXM]I-*-Q8G(*N!C!XP#Q79_&CX*:GXM_9]'PM\%WEKH6G2P6
MNCW$ER&)33$VI,D>T<.T:[0>G)KF/#W[*ES\-/C9X7\:^"O$5])80V$NC:]:
M>)M0GU"2XL,!K>.V9B?*,;KD#H03F@#G/!'Q2^/%]XL^(-GKM]X#FT_P*WEZ
MFEA8722W9:P^TH82SX7YF4$-V!]:\T\/_MN_%O6/V:+G7SX<T-/B?/JUI!I^
MEJC_ &>:QN+,WB7!7>3_ *I)6SG^$U]+Z#\&]9TWQ'\;M1N;ZRDA\=21M81Q
MJX:!5L%ML3=L[AG*YX->/>'/V(?$5AJ7@W5+[Q/9"YT#P*WATVMLLPMY=32V
MGM(+W'=4MYW3!&>30!M:/\?/B1\8=<\*>&?A_+X9TZ^/A.P\4:_K6KVTLT"F
MZ'[FW@B1ARQ5F+$\ >M8?BC]KKQ_X:^%VJ-J^A:3HGB[P]XOM_"_B'5#'-<Z
M9802J'741&IWF+8Z\$\$\GBNCTK]F'XA_#BR\%:Y\/\ Q9H%CXRTKPM:^%M8
MMM8L)IM*U*&#F*0*C"2-T.<'G()!%:>E_LU^.-(\%ZQ<6WQ(8?$G6=;37]3U
M1]-4:7>R)#Y(LI+7.?LAC 4@-NR-V<\4 <K-^T?\0M(_9]^*GBK^V/!'BJ[\
M-^0VC>(O#\WFV5XDC(&6> .6B9-V#EL$<CI63I/[2_Q#T_Q%XO\ "\?B;PC\
M1[RW\'W_ (@LM8\,VI1-.N80=L-R@=E8.>%Y!.SWK6L_V+_$6J^"OBPFK:SX
M8T?Q1XZLK2R%OX8TA[72;/R'W*YB9MTCL?O,V#CCI7T3KGPJTR]^'?B'P]IE
MII^B76LZ?-:375C9I$IDDC*-(RH%W<G/)H ^<-/_ &OIO$,7[-MAH?B;2-2U
MOQE=6J>)K6"-'=$:R,T@"?\ ++]X1T^E<'X=_:;\?^,KKQ(;WXQ>'/!,NF^+
M+[1DL+OPC)=;H8IU2$+,#M+,#@GL2*]Z?]ERX;0?@+:1:Y:1WGPTN;6:ZNQ9
M!3J8BM# P&"-I8G/)-8?A3]G#XL_#BP\5:9X1^*6A:;I>K:[>:Y!%>^%_M;Q
MO<3&5XV8S@$>F%XQ0!Y]\3_VCO'>@?$WXL6+?%+PMX*TSP?)91:?8:MH8N)=
M5EFM#)Y:L) Q+2+@!03\WL*U/&'[2'CE?$WPML=3U^'X8P^(_!LFM:E')H#Z
MI)!?!XU$84995&\YSTX!YKTNZ_92M?$FM_%R;Q+JD6J6'CV#3RL,%GY4VG75
MM"4^TQRYSNW['7&-I0<\U#-^SO\ $&YU;P?XF'Q3CM?&VA>'KC0IM6&A)<+?
M>9*CB9XWD&&_=IGU.3QF@#N/@UXRN-0^#5MXCUKQ.OC)TCN+B35[?2'TP3)$
M6R!;-\RX"D<]>O<5\V7O[17Q!M_ 'P)UC4_%J>'1X_CU'4;Z]AT);\VL#1&>
MT2.!020D949Y)Y)KZP\(>#M?MO!5UHWC7Q1_PF-_=B:.;44T]+!?+D4KL$:$
M@!03SDGFOG_X8_LY^--2^%OP@@O?$5SX!\8_#;[;IEO(MA%>QW-O\UO&^UVP
M0T*QD'ZT 7-2^.NL>$_V5M?\96OC*;QEKM[=G3] O]1T'^R&:ZF=(84%NP&5
M5B7R1R ?2K'P]^)7C[QI^S7X^TZ?78(OC!X*EOM*OM1MX4,4MY;CSHI F,;)
M8BGYGH>*Z75?V9M1\??\(C%\3/&\OC^V\/:O)JZVT^E0VL5TWD^7$DBQG!"$
MLX/4L1Z53\4_L_-\,KGXH^,_AI9N-3\2^'OL)\)VD4<5K<7R!UCN@Q^[)MD(
M;U R<F@#UCX)^/5^*?PG\(^+PBQ-K6E6][)$AR(W= 77\&W"NWKA/@7X 'PK
M^$/@_P ([E=]&TJVLY'4 ;I%0;VX]6+'\:[N@ HHI,T +1110 5\S?\ !0:5
MK?X"VDZ@%HO%.A.JGH?]/B'/YU],9%?,_P#P4'59/@!$K2")?^$FT/,A&0O^
MGP\D4 ?2T8Z]N33Z9&>6'O3Z "BBB@#QGXSQ%OBM\%7QPOB&ZY],Z=.*]E7I
M7D7QCC)^(7P?FWH GB25<%L$[K"XZ#O7KB,-H.10!YU\;58Z3X797"%?$^E'
M+?\ 7RHQ^M>BJ<CIBO-OCPT2>'/#S2,P9?%&B^6%3=N8W\0 // Y/->DJ1C_
M .O0!YM^TA!Y_P $O%@YXME?AL'Y94/7\*])3H?J:\^_:#('P7\7DA6"V#L0
MQXX(->@1G@\YY- 'D7[8*E_V6?BP ,D^&;_@?]<6KK_@Y_R27P6,%<:)9###
M!'[A.M<S^U@8_P#AF;XI>:I>/_A&[_<H[CR&K>^!<GF_!?P(^2Q.A6)))SG]
MPE '<TUQD4M(QQ^- 'G?@%'C^)WQ+W$8:^LF7Z?8T_PKT:O,/ <JGXR_$^(1
MD%'TMS(3PQ-J1C'L!^M>G9H 6O%?VS[9[C]E3XK!)/+9?#MW(&QG[J;C_*O:
M<UX_^V#_ ,FL_%CK_P BQJ'_ *(:@#O?AR_F> /#+_WM,M3S_P!<4KI*YCX9
MY_X5UX6R/^85:?\ HE*Z:@!:*** /F7_ (*(V;W?[,NJLI91;ZOI4[;>X%[%
MD?K7TN@X/UKY]_;X7/[*GC1N RR:>RL>@/VZWYKZ"C((X.1Z^M #Z**:7 QR
M!GU- #J*IRZK:0.4DNX(W'56E4$?AFF'6[ #/VZVQ[S+_C0!?HK/.O:<.M_:
MC_MNG^--_P"$BTL_\Q*S_P# A/\ &@#2HK-/B/2Q_P Q*S_\"$_QJ&3Q?HD*
MNTFL:?&J?>+7<8V_7F@#8HK!F\=>';9D$VOZ7$9!N0/>Q#</49;FHW^(7AB,
M1E_$FD()#A-U_$-WT^;F@#HJ*YN7XC>%K<9E\2Z.@[%[^(?^S5')\3?"<2J6
M\3Z, Q"K_I\7S'T'- '445RL?Q0\(S?<\4:0V!GB]CZ?G2-\5?!P!_XJK1QC
M_I\C_P : .KI*Y(?%GP:5+#Q5HY4';G[8F,^G6JK_&GP*DD:'QAHP=]Q5?MB
M?-M^]CGM0!W%%>=O^T#\.H8EDD\:Z*$;;AOM0P<]/SJ-OVB_AJDJQMXYT0.R
M[@#=#)'K0!Z117FD7[1_PRN"@B\=:([.^Q0MT"6;T K1N/C9X)M8C++XEL8X
MQG+LS8&/?% '=45Y^GQW\"2QSR1^)[&9('$4GDEW*.1D @+Z&FW'QY\#VR[F
MUY2O7Y+:9OY)0!Z%17G4OQ]\$11"0ZTQ4\82QN&/IT"9JE8_M*_#_4)(DBUJ
MX5I2=OFZ9=(.!DC)C% 'J5%>>M\>O ZKG^W0P]1:3G_V2LF\_:>^'=C'YDNL
M7>PKN!72+QN-VWH(O6@#UBBO.+/X]^%=0MH+FV_MFXMYHQ)')'H5X0RDD9_U
M7J#4Y^-WAP,RF+7 5ZYT&\_^-4 >@45P1^-'A_:Q\G6R%VY/]A7G&2 /^6?J
M:KW'QT\-6O,R:W$A*A6;0;P*2W3!\KO0!Z(>U>'A\?MI2+V/P_4_7&I-7:I\
M8M!=&80ZV^UBA T.[SD>WEUYMH7B>W\2?MB)+:_:X(?^$";=%>V4ELS'^T>H
M$@!./IB@#Z%HHHH **** "BBB@ HHHH **** "BBB@ HHHH _.[_ (+6_P#)
MO7@O_L:D_P#22XHH_P""UO\ R;UX+_[&I/\ TDN** /T1HHHH **** "BBB@
M HHHH ^=?VD]4CT?XR_ *Z;3[G4Y%\17ZQV]F 92QTV8 @%E'YFNRG^-FKPS
M*D?PH\=S*5SYBV]F .<8YN:Y']HEHH?C=^SU-*VQ(O$M^Y=N%4?V9<9)/88K
MTCPK\:/!GC+48+#1?$-G?74]K]N@C7>OG0# ,B%E 91D9()ZT <U/\;_ !#Y
ML8A^#OCF<,FXEDL4"G/0YN?UKG6_:BUIO%%SX9M?@YXSG\2VUDNI-IS3:>A^
MS-(8TDWFXV\L&XSD;37N)U:S\N!WN[81S_ZMC*N'/^R<\_AFO#O&WC+P]\,/
MVB=8\4>([U=,TJU\$VB7%T8GD(WZHT<8VH"Q)>15& >6H F@^/\ \2GG"R?L
M[^,XHC_RT.K:2WZ?:<UM-\:/%_G6Z_\ "E?&91M_F/\ :=-_=X'R\?:><^W2
MNV\*_$C0/&6C?VKIMZ4LP\B$WUO)9O\ NVVN2DZHVT'C=C'/6MP:Q9M=M:BY
MMS=*I=X/,7S% ZDKG('O[T >4V/QK\:S1@W'P0\8VP(&%^V:8YSWSBYX_K4&
ML?&_Q]9I&;'X$>+]1RI+ :EID94CH/FN.<UZ!I_Q/\+:KJ&K6-MK=B\NER0Q
M7>9E5(VEC\R-0Y(5B5YP"?>M:[\2:98RF*[U*RM9@-Q2>X1&"XSG!(.,>U '
MC\/QW^([J&D_9]\81*0,C^UM*+ GKP+GM3$^._Q.9W"_L]>+1M&27UK20&YZ
M#_2.37LZ:WI[R1Q"[M#++%Y\<8G4L\?]\#.2ON.*R-;^(WAKP]86][J.N:;:
M6L][%IT4TERNQ[B1ML<(()^=B1@4 >7CXZ?%)D+#]GKQ,%W;0K:]I>[ZX\[I
M^-/7XW_%.1BB_L_>(P^2 9=?TM4^N1*3C\*]#\1?%;PMX5@LY]0UFV$5WJEO
MHR-;GS\7<[^7%&VS.W+ C+8 /6L'X@_M$>#/AEX@N]'UJ74OMMEIW]K7?V'2
M;BZ2UM-Q7SI7C0A%!!R3TP: ,6S^+'Q9OMX7X'3V94#G4/%-G&&)]"@?-6HO
MB)\7I(QGX/:?$V>5D\80Y^O%N:[?4?B-H.F:)?:HVHP7$-G#)-)%;2*\I"0^
M<5$><E_+PVWK@@\5S*?M%^"ET?Q#JE[JHTFST*6.&[?4H_L^YY+6.[18PQ_>
M$Q2*0%ZG([4 4C\0/B^ "/A)I;GJ1_PE\8Y_\!J:WQ!^,1!Q\(](_'QDG_R+
M6AH?[1?@G6+&_O[C58]#L+/[-ON=<*V2.+BU2YBV%V^;]W(I/'&#Z9KII/BC
MX3AUZVT.;Q-H\6LW*QO!8->QB>99.8RB9R=P!QZCF@#AI/'WQE,A"?"+1BF1
M\S>,EZ=_^76LM_'_ ,?/MV(_@]X6^RF3&]_')W[,CG:++&[&>,X]ZZ#6_P!H
MSPWHGQ2_X01K+6KW5(GMDO;JQTUYK2P-PK-"9Y ?D5@C?/M*C')%='J7QF\$
M:/I!U6^\6Z)9Z:+1;\W<U]&L?V=G\M9MV<;"_P H/0GB@#@I/'OQX%Z%3X1>
M%_LOG%?-?QNP<1YX;:++&[&>,_C0?&WQ^\QE_P"%5^#6CP65_P#A-9AGG&"/
ML/ISUKJ;K]H/P#;:Y>:3+XHT^*YM-)AUN:623$"V<KA(I?,^Z0S$8 Y.1ZU:
ME^._P_@2Q>7QKH$27T*W%JS:A'B:)B55TYY4E2 >Y!% ')6GBSX\W#LK_#7P
M9:*-QWOXPG?<0?E "V7&1^56SX@^.3*C+X&\$(YV[P?$]RV.><?Z&.@_.NCM
MOCGX"O9M$BM_%VBW$NN '3%ANU?[6"[(#&1U&]&7/JI'45S_ ,1?VC;+P%XF
MO-"LO#&O^,;_ $RRCU+5X_#UNDS:;;2,5B>16=2[-M<B--S%48XZ4 .FU+XZ
M;G,/A_P  &PN_6KWE??%MP:@FN?CU*B^7I'PYB9B"WF:G?N%&>1Q ,Y_2NHC
M^-G@Q_$#:"WB33X-<2 SOI\TACE11$)F# CAEC(=E^\%Y(K-T;]I+X;^(;Z.
MSTSQII-[<R>84C@D9B0D)G8],?ZI6<>H!(SB@#%M1\?G> 7%M\-8T#-YICN-
M1D)'\.T%!@COG.?:J\<7[12ZHF__ (5>VFB0951J0FV>QR0#^&*U;7]J/X=:
MS:2G0_%.GZU?FSEO;;3[:0K+<JD#3[4WA0"T:EADC(YZ UIZ5^T!X,U"SN99
MM<M+&:RL!J&H0S/D64?DI,_F2#*95)$)PQZYYH H);?&XYS=^ (OF.%%K?/A
M<\<^:.<>U6!9?&(V[9U+P,)_X3_9UZ5'/?\ ?YZ5%=?M%>$[6?3)SJ5JV@WF
MGWNHG6'F$444=LT:R91OG;F3JH(XQW%27/[2WP\L]+AU"7Q$JP2RSVX06EP9
MEEAB$LJ-%Y>]66-E<A@/E.>E %4V'QQ%SD:O\/O(V_=_LN_W$_7[3C'X4G]G
M?')L_P#$X^'L8(.?^)3?MSVY^U#BHG_:;\(V.N:I;:AJ-K!IL$%A<66H6\C7
M)O5N;>:X7;%&A90(X'8$_> )[5N:3\?? ^MZ]8Z19:_%<W=\ML;8QP2F&4SQ
M--"HEV[ SQHS!2<X7I0!DII/QN,\/G>(O 'DEQO":%?9"]\9O.3CUQ7B/P@U
MO]HGXS>$9/$FC?$;P?8QQZOJ.G26>H>%'8*(+AHT962XR<[><]..M?8KDG:>
MV:^<OV#7(^#&M0E&22#Q;KD3AAT87LF?KUH ;+\/?VGW9 OQ9\"QJ?OD>$)"
M1],W'/XTVS^&'[3DMPQO/C9X2AAZ!;?P6&/U^:<?UKLOC5\?'^$VMZ?IXM=)
M:.XTN]U.6\UG5#8P1+;F-=FX1ODL9 ,G &*-(_:C\'W%QH]AK$\F@:U>V4%S
M<:?=KDV,LEM]I^SRL.D@B#-P,8'.,@$ X^V^%7[2]Q=$7?QT\,65N%&'L_!"
MR.S ]U>X &>^#7D/[7'P]^*_AWX*+J'CCXK67B_2(=>TG[1IEAX6BT\N3?Q+
M&ZRB9S\K,K%2,';C-?6GPR^,_AWXL#41H4MV9+$0--%>V4ELX29/,A<!P,JZ
M?,".U>5_\% 4>3]F76&"AD35]%9ACM_:=N/ZB@#JKCX=?%:XU.9K?XOQVUIN
M+*G_  B=JQ&3P YDY(]Q6O)X \>3V;QI\3;NWN QVSG1+%AMR,?+M[<XY^N:
M]*0$$_7-5V%Q%#*$D660ABC2#Y5/8$#DCZ4 <!_PA?BV2X:3_A9NJQVJ)M*C
M2; !B>0P;RNW3%))X*\4LSQ_\++UM9L;E'V#3U+#'./W/3MFN0^$OQ8\8>.]
M:3PW=>%H=#ET""2R\3S32.R0:@0##':G $L;H1*7/ 5E7[V:]MLX&6W1KB03
MSA0'E"X#'C.!V!(SC- '@WQ-\!Z_!XF^&3W7CK5;^1O$P\J66QLE,#&SN.F(
MAV&.]=4_P2\4SHP/QF\:Q[BQS%%IRXST _T4]*O_ !6LXH=1^&<A,C&#Q1 $
M+-D_-;7*G/KUKTY?NT ?.?Q;^%NJ:!X:T>XN?B)XOUA1KFB0>7<SVH"N=1A!
MF^2W'S8;ITXSUKT[_A5MX7=AXZ\6X8!=OVV# QW'[CK4_P 9+B.T\$//*H98
M]2TU@#_>%]!C]:[=!P?J: /#?CE\.;BU^$?BRX?QAXIE6'3I6,?VV/#@#/(\
MH>E=JWPKEEDD<>,_%B;G+874E 'L!Y?2H/VC'CB^ _C^252\<>BW3LH."0(R
M3_*N[TJX%WIUM.HP)8D< ^A4'^M 'AW[0'PWET[X"?$20^*_$MV$T"^8QW-\
MCJW[EN"#'TI_P7^&G_"2?!7P!>/XI\3V@F\/61\FRU0PQJ#;IP J<=.*[7]H
ME#)\!?B(HZGP_?=L_P#+!Z@_9GOH]2_9Y^&MU"28I?#E@ZDC!QY"4 -;X'0R
M.K-XQ\9X (P->D _04DWP(LYYA(WB[QI@#&U?$,RK]<#O7IU% 'SYX-^%VG3
M_%SXCV;:EX@4P1Z.1=+K,XE?$#\,P;)SCG/7VKU2/X9:2KEO/U<Y['6+K _#
MS*Y[P9;M;_'#XDNR ">UTIU;/) BD7^E>GCI0!RC?#/1G3:TFJMSG/\ ;%V#
M^DM>/?M9?##1;+]FWXIW</\ :+3)X:OF!EU>[D&1$6&5:4J1D#J*^C:\K_:H
MM!??LV_$^!F*K)X;OU) Y_U#4 ?,E]?:A:WFFZ+IUOKTEM:VFD:C:V]EJ,J0
MZE UGONA)*\N(E 3*N=H#C:,YXZOQ=:64]U87T&GZND-\@A47VNO<27I8F,6
MD2BY3.-HG#@L>,8P<'SF/Q,EU<Z7#KOB632=+O\ P9I-O80V4#/);WPC1D28
MI@-"%D=]K'C<VXA0 9-7^)FH:;XINX=8TJ\M+V?2XM(LS8:7YM]B4O%#=0R
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M9'MY;>UN[>,1$ AH76Y0NK8Y3//%5- _8DU70O#<&FI)X?FEBM?"MR%FCE:
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M^43".&[RO/.PEN>,=:\A_90TWQC:^$_&,&CW6A6T">.M>6Y6YM)R0_VU]YC
M?[OH#0![MXJ^&6B>+]?@U/5(6N9(]-NM*\AB/*D@N"GF!AZ_(O-<3I7[,GAC
M3=:@U*2ZU+4)OLJ6MRMY*DGVTK;FV625BNXN(2$)! 8*"02*WKO1/BG<VR"#
MQ7X9M9_**LPT.:13)N/S#,XXQ@8]:@N/"_Q9E.8?'7AV%3&HVGPX[8?NW_'Q
MW]* *OPO^!Q^&/C#Q!J%MK5_>6&H16$4,=U<&68+;0/%MD8J 4PR[0,<@D]:
MY']OK(_9;\2D=8[_ $AS[ :G:\UUW_"'_&+&!\1/#?X^%V_^2:\6_;2\-_$6
MT_9>\;2:YXPT?5+*.73I/L]GH9MW.+^V( 8S-SD ]/:@#ZJ@OUU2ZD2QO!)]
MFG43[$W+P#NCSG@\@_E6@RL[#>3M!!7!P<^]>=VGA;QW-&TL7CFTMEE7>J#0
M4.T$#&27R2.]-3P_XZ:1(E^(5K+*WWI(M C*Y YR=^ ?8T =1IOA"ST'7M;U
M6R::*?6IX[B]#?.&D2-(U*Y^Z-B 8%;T@8R H0H (VD=?2O+UT#QO!'?7,_Q
M,2*(R%(TGT.UB\DYV  ENA8;@6Z[A55/A_XXO5LTO?B5?WD"L1+%<>'K/9.&
M&Y=^.@7U% &E\68?)?X<B-_+$'BJS&U6."#'.I'Y-7J$<B[!R!7RQ\4?#'B^
M+3?!NK7WQ!UN9;SQ7IL<5E<:19P-:L9I%# !3TR>">1BO7(/AAXL6UB6;XIZ
M[-.K O*MG9J' /3;Y>!0!K?&,+-X#N1D8%Y8$\^EY":[97'//<UX1\:/ 6LV
M/PXU6>7Q[K]S&LMH3$T=M_S]0G_GF*[*3X9:]([D_$CQ&F6) 2.V  ]/]50
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M)^?GF]J[!OAK;NRM_;OB ;3G U209H [#/UKSG]HQ1+\!/B*O3/AZ^'(./\
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M@ +GKFO?_#WB/X2O=Z/H5];ZO+JD<%GI]U?11W_V*"Z:SCG2"29#Y<;F)E<
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M "BBB@ HHHH _.[_ (+6_P#)O7@O_L:D_P#22XHH_P""UO\ R;UX+_[&I/\
MTDN** /T1HHHH **** "BBB@ HHHH \1_:+TZ*7Q+\'+]B!+:>-K94![B2"=
M#7M<:@<UX[^T;D2_"TKMR/'6F_>]-LV:Z'P7^T!\/_B!K7]D>'_%%EJ6HD.R
M0('0R!"5?864!\$'(4GI0!Z"Z C)[5XQ,N/VPK4<X;P'+QVXU&/_ !KU\ZA
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M* -0* .E)Y8S63!XOT2Y_P!3K.G2Y+A=EU&V2B[GZ-V4Y/H.:Y7XA_&KP_\
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MM;ZW:7MS<G5+6[MK703HBB.&==)BN8IE;;O8^=Y@VN0#D)QBL"?Q?XVT^_\
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M7*&'E_V5K:').22+8C^5 'L5%%% !1110 4444 %%%% !1110 4444 %%%%
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M_$\\WBJZTDZ1:WNN6GB:"6;[3*&F:\O%GT\R>OE '/\ =/3-?9(0$4OEJ>U
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MADL7CL9[.,Q2!QE"DY9@X8DC/7FL*/\ 8E@'A/2-'CUBTLY++P99>%Y9+:Q
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M%[X75J9)[ MI]T88T>>(2'ABJRH"".Y'8UZC:V<5M;PQ01I##&@1(T7"HH&
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MG),43HLA+#A2#*@P2"<UJ77B#3K)"\]]:0@3+;LTMPB@2GHF21\QX^7KSTH
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M8WQBO96^$UP\\2F\6;3_ #D##Y<W<6>>GO7JZ]#]: /&?BA\/O$,?PV\4?\
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M,<6D8XZ_W:V:* ,G_A%-&SG^R+#.,?\ 'K'_ (4]/#>EQR+(FF6:2*<JRVZ
M@^QQ6G10!76RA0_+#& !@804GV"W &((N.G[L?X59HH K?V?;GK;PG_MF/\
M"GQVL4(PD2(,YPJ@<U-10 @%%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "
M5Y!\2;A8/V@O@_N("RQZU$"3U;[/&0/_ !TUZ_7B?QA 7X__  ,.1S>:MP1U
M_P!#H ]MHI!TI: "BBB@ HHHH **** "BBB@ HHHH **** /SN_X+6_\F]>"
M_P#L:D_])+BBC_@M;_R;UX+_ .QJ3_TDN** /T1HHHH **** "BBB@ HHHH
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M46X52>J<(?F'?M[T 8GP[_9=MOAEXA\*:SHEY;VU_I[7\>KR"V)&I07,CR@
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M*N<UPUC^S+X8TK4]&O=.N-4T\Z87B2**=666U-PUPEHQ921#'*[% I4@?+G
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MZC8IY,GV2/1+:##&YC).1D\YKU67PEXE<2[?&MQ&6DWJ1IML=J_W?N\_4\T
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M!S_PC5F.GI&*3QE^SCX/T?PCXHO=(MM3L]2DT:>W6;^WM08%5@944J9RI
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M6L*P^$/@C2X/)M/"&A6T6[=LCTV$#/K]VIU^&'A%69AX7T4%A@G^SXN?_':
M-+_A+=#QG^V-/Q_U]1_XTA\7Z$!DZSIX'J;N/_&J2_#7PDB[1X7T4#.?^0=#
M_P#$T\_#SPN5V_\ ".:0%(Q@6$73_OF@"PWC/0$7<VN::%/<W<>/_0J8?'/A
MP==?TL?]OL7_ ,54$GPY\*RJJOX:T=U4Y"MI\) /K]VI8? 7ANV_U.@:5$>^
MRQB'\EH BD^)'A*%HUD\3Z,AD)"!M0A&X@9('S<X -4I/C%X"A, ?QMX=4W
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M?TI1I5JN +:  >D2_P"% '!V'[17PTU%"]OXWT:1/-\@'[2!E\$XY^AJE/\
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M$LLGQ]N/#&IZC>ZEXHM-9TSP7%)8V5E;0)'<7\EW*A>50K;[A;<1%E!VABQ
MK3L-/^-&C76NSP:GXRUL>5XEL[:SNW@7Y4CB?37B<Q@"3>SA9&SNS@Y K[(,
M8/M0L87_ /50!\26]E^T%>^!";R;Q3#K&EV?B*:Q6*6%'O9DEB;2A/C);*>8
M-I(!Y#'BNLO;'XQR1_$R:Q'BJ/Q8T%^VD2RW,!T5HF,;6JP1GYEG5"ZYP,,&
M+$\5]7F//>CRQ_D4 >%?L]^(_%^CV6G>&/'B:A/J^H2ZA>Z;-=@/)!IT,D*0
MI</DDRL),_,2W!R37D?_  B_CFW^#GQ2^&>G?#_Q##JFHZIJ^HV&J2&W-C,L
MM\)8T5B^1N0]P.AK[/,"EMV!N V@XY ],TXQB@#X*\2W/BSQ-XR\:>"$O-6U
M_4M3TKQ+:RZ8NI+-8OMLH%LX%MB0("K,0"0 Q+'+9KJH?@W\2DU'P];W=OJU
MYI&A>()8]*WZEYDMO97&@O 7D+-\Z1W;'Y6R0.F1Q7V&FF6T=T]RL$2W#C:T
MPC&\CT+=35D(!CI^5 'QSX=^$?Q9T+^R[Z75-0L[C2K2QLQ+/J#?9TA_L>6&
MY<0*Q3Y;GRG.%W$K\M,_9/G\1^-K;XGQW%_J^JZ'-H>EV-JFIZG->HU\;)UN
MVC>3E=[LA91@ ]0IXK[(>/=WQ38X$A'R*%&<X48Y[F@#XZTW]ECQ)X7^%VA7
M%M+>ZKXD:QT+3M8T.TN8M)4Z;:(3-91RP!=S,[$EV;<P&W<JU++^S[\3]2TG
MPY9)K.H:98ZC#.FJPG69&N-*C@NFNM,B67)$I4%;:5^K)W. :^P^/2C*^U '
MR/H'P8^*L_C/P=JVOW<C?:&.I:N+#4]L>E7CSN]Q#$'R9(98C%$H'*^7G(S7
MH7P'^%'C/X>:-X7BN=7BM;417$NOZ=>B34+J\NW=O+E2[>4^6 NW*!2.PQ7N
MV5'I2X'6@!K?=/TZUX!\#\+^T9^T%&LA_P"0CI3F$CA2;%?F!]\?I7O[$$=:
M^?/@J[)^U-^T#'M^7S=%<-VR;0C^E 'T(>![XKR_XS?&.Y^#UA'JLWAZXU/1
M8H9+B_U!;F."*T56C14RWWY)&DPB<9P>17J!/!KSCXK_  :A^*T5LDOB+6-#
M1()[.XCTV2/R[NWEV[XY(Y$92?D!5P R'.TC- 'H-E/]J@CEP0'4,%;J,C.#
M7%_'A0WP2^(*\'_BG[_K_P!>[UU^E:?%I.GV]G"2(+>)(8PQR0JJ%&3WX _6
MN3^-XW_!KQZHYSH-\ ,XY^SO0!PW[)W]H#]FSX7&-Q)%)X4T\HTAXC<0H,8'
M+!@2<]MOO7J.FZJUS(P9FD /E[6CV2*P)#%N>G0\=B*\H_9=U1%_9U^%%W()
MV:]\+V:'[+ ?(C"6^XLX'W>A ]<@8KTG29(]0TU'L=1O9?M:"Z2>6+8=LF=O
M!4=..#S\HS0!PFJ_%_Q!HGQLT'P7-HEJFE:L[QVM\;S?>3A(#+)<>0HPD 8B
M+<Q!W=L&O7A,OEQ-*P4M@#/&3Z8_I7GEK\$[2Q^)=WXVM_$GB"/4[U8([RT:
MYC>TG2.,HJ%&C+(A)WE49<MS7;3Z?::O$BWL!D6TN!*AG&/WB?=D&/K0!P7[
M34IA^!7BN3&=L4+?7$\==CX]UW4/#/@W7-6TO33K&HV5G-<V^GB41?:'120F
M\\#..O\ ]:N/_:0A,_P,\8*TL: VPD#X.,"6,@'W.,5Z!J%C'J=K>:?<1N;:
MYA:-V!P&#@J0#U!Q^6: //+_ ,6S>._V<YM:N+=;>YUOPQ-</#"2Z1,]H[$;
MO0'C/>NT^&S;_A[X8;INTNU./^V*5@^(?"UAX*^!^K>']+$D>G:9H%Q:6Z2.
M9'$:6[JH+'DG'<UI?"6X%Q\+_!TO=]&LV(_[8)0!U4R!T"D95OE(/<'K7GW[
M.D26_P #O!<$>SRX-.C@79T 3*@=_2O0Y& P,XY'\Z\__9^E5_@]X9(X'D.,
M?25Q0!Z$YV@'W%?-W[ 5I'8? [4;6)WD2#Q5KB;I/O?\?TG6OH]I 1^-?/'[
M$4LG_"!>.HI?E$/CS7XT4C&T"[/'YDT ?1=%-WCUHWKZB@#S/Q/-+#\?? R*
MY$<NDZHKKZX: BO3J\R\6,G_  O7P"VX;O[.U0 >O$/^%>E&15ZF@!](>WUI
M/,! (YS2%NG!_*@#Y_\ V'EV?!!T[#Q#K(Q_V_S5]!U\Z?L/3L_PFUR)LB.V
M\7:W$F5Q\HO'/\R:^B=X]_RH =28IOF>Q_*@R 'D'\J ,CQD2OA/7"NW<+&?
M&[I_JVZ^U>0?L)RF;]D7X4LQ4DZ'%]WIPS#BO8_$J_:/#NJI\PWVDJ\<'E#7
MC/["DF[]DGX8\,=FE>6,_P"S+(O]* /?**:']B/PHW>QH =129/I1GV/Y4 +
M132V.U)Y@X['WH ?24WS![?G2&95&695'N: )**K'4;8'!GB!QG'F#I^=+]O
MMO*:7SX_+7JV\8'XT 6**IMJ]FC%6NH%;T,J_P"-,EUW3X+<SR7UK'".LCSJ
M%]^<XH OT5CR>+M$B0/)K&GHA 8,UW&!@]#UJ$^//#8('_"0:4"3@?Z=%R>N
M/O4 ;U)6'_PG/AW)']O:7D=1]MB_^*I1XW\/'.-=TPXZ_P"FQ<?^/4 ;E%8)
M\>^&@<'Q!I0([?;HO_BJ0^/_  R "?$6DA2=H)OHNOI]Z@#?HK!_X3SPWNQ_
MPD&E9]/MT6?_ $*JEY\4O!]@J-/XIT:,.VQ=U_%RWI]Z@#J:*X:X^./P_M;B
M>"3QGH:30#,R&_CS&/\ :P>.M,;X[?#Y8I)#XRT7RTQN<7B%1GIS0!WE%<//
M\;? MKM\WQ1IJ!L$$S<'/3'%.3XT^"'5F7Q-I[*IPQ$IX^O% ';45YT?VAOA
MNOE;O&NBCS@#'_I0^<$X&/7D8JU_PO+P)MW?\)1IY&[;D2'KZ=* .[HKA&^.
M7@-'56\4:>K,=H!D/)].E1?\+[^'^9L>*M./DMLDQ(QVG&<'B@#T"BO,V_:1
M^'"WTMH?%-MY\:%V'E3;< 9.&V8/!Z YK0MOCIX$O%#0^)K%P5W#!8<>OW:
M.[->/_&F*1OB/\&Y!L\E/$LN\L/FYL;C;C\:Z0?';P(611XELV+G V[SS_WS
M7F7Q,^*/AKQ;\2_@_8:/J<-[>#Q.[E/)E V+:7"L0Q4+G)'?GM0!]$CH*6D'
M04M !1110 4444 %%%% !1110 4444 %%%% 'YW?\%K?^3>O!?\ V-2?^DEQ
M11_P6M_Y-Z\%_P#8U)_Z27%% 'Z(T444 %%%% !1110 4444 >"?MOSM;?LZ
M:[*L/VADU'2F$.S?OQJ-OQM[_2M#5OVG]"T:]U*WD\*>/)'LY&0M!X3O)$E(
M8K^[8+AAQG/I67^W.#_PS3XD8<[+W3'R#C&-0MS7N_W<D'N>E 'C*?M1:3<1
M6TL7@7XBRB9=RJ/"-V#WZY QT_45YS\3OBI;^+?BK\.3!X>\<Z%>16NN1VS-
MH+Q7)=[-5WPASAF09;'MGH#7U'IVJVFJ+.;2YBNO(F:WE,$@?9(OWD;'1@3R
M#TKYW_:#\0W&I^./A+J?@^X@U+4B_B%=->WD$D4MTNDW 101D$^8F/J"* /+
MD^$]A:_"M?!4@^,=UI0FN+JYD?P[ UQ>6\\16ZMI2%^<RY)W_P"L4GY6 XK>
M^)5U;^./[2VZ!\2]%CET0:9IELO@N2=;(H5>6=@)/WKNB)%AB#M! ZDUQUO\
M;-1\'Z)_PD?@CQGK/BO4=*\$:CJ/BS3=>:6>VT^_A@1XGE5E!AF,Q=/)0C<H
M/''/07GQZ\<ZCK'AN2X\36I\/'5->TE[S3+"2V@U@IIQFME5F^:)TDWQCGYG
M3(SB@#U+X>?'.+PCX&\-:'!\._BM?I86:627%_X8=9Y?)0+YDNYQM+8R-V,U
MTO\ PT=+YA!^%GQ)&/XCH"X_]'5X'I'Q]^*+Z7X6BTR\L['39='T=2=0TR:]
MN!+<Z.]V96E+ N5DC"MN&<,2>:R;C]H[Q]9:7J?B2SOQI.J^(]/\,7.F6=[I
MUQ>V,=Q<Z<9;I6P,V\,9P[/C)(VX+$4 ?2/_  TA*1G_ (57\2EZ]?#Z]O\
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MH \STSPS\4&M(?[0\<:$;H9\S[)X>81GTP&N"?UJ8^#?B"SON\=Z=L)W!?\
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M7K?[.'Q'USXBZ#J\^O7%O>75G>BW%Q96_EV[?N8W81N"1(%9B-V%(.58 @T
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M5'\.,;?D\J2_^][Y7IC-4_$H^-D_AW44:'X?R*UG,LL:O>[F^1N%)&.1Z\4
M5OV&F0_LE_"X1MOC71HT1_[RAF /Y 5[KD&OE3]CVX^("_LR_#^/3(O#4%K_
M &4!#]M-QO5A(X*MMX)R#T[8KT^1?C<&^2Y^'Y4RGAK>]^5.W\?)H ]<R/6C
M(]:\NAM_C"VF2&;4_ \6H!OW21:?>/#M_P!IC,#GZ"I;%?B?=P:C#-J_ABWO
M(FVPRII-RT39&1UG&<9P: -KXS0M<_"?QA"AP\FE7*@CU,9%;7A%6@\+:1&Y
M+.MG &)/4^6M>6?$W3/B#;?#'QF^H^(?#L]JNC7)(AT:97QY+;B?WY]\5J>#
M=*\?W'@[P^]OXHT1(&T^V*[]&D9B/*3J?/ZT >A^(BKZ#J0QG-K*,?\  &KR
M;X;^)K?3?A#X9M([F1C;:':O)*0VQ<A0(TD49,A)  &<8&16OJGA7XFM:WS-
MXZT<1.G^J7P\?E4 [@"9NK#C/;M7 _!;P-\1-7^%?@34+;Q[I=F(]*A,(?PU
M')+&K+R YDSS@9Z9Q0!O:1X.MM BMH/*TL>!UNWU61=3NY#=17<DSS-*SCY0
M$=F&TG Y].=?]D\D?!#3-Q7=_:6KD[#\I_XF=UT]O2D?X4>/-1N;)M5^(6GW
ML%O*DA1?"]N&R&#?*S,VT\#G%>=? GP'\2-1^&L)TCXI6^EV\6L:O&T7_"-V
M\VYEU*Y#-DL,9.3@<#.!0!]1N1MZ]Q7RW^PUJ+S:E^T#;,Q,5O\ %#5_+&<@
M!EB8X_&O2;3X<?%".3-W\7$N(L<JGABU0YSZDGC'M7AO[(OAG7M6\0?'^#3?
M%]YH4D'Q'O5FDATZU:2=O(AR[!D(&XG/&* /LX.I[BEW#U'YUYV/AYXP$<2_
M\+-U4E 06.F666]S^Z[4^+X?>+5W>9\2M5DSC&-.LUQZ](N] #_&;(/B=X .
M5SOU!>3S_P >V?Z5W@D4<$@$=17A'C'PKX@TWXG_  VCD\=ZM</<SZA!E[6U
M"K_HCONQY?)&W'XUV%[\+/$=[()!\3O$ELXQ\L$-FJ'\#": /1O-3GY@<>]!
M<-@Y_6O,9/@SKEQN\[XJ^, &DWX@>TCP,YVC$'3MZ^]7KGX1SS;<>//&,3#H
MR:C&/3J/*QVH ^*;75V\/?#KQQ=A+J>UM?BEXC2XT>U<QI>2;&>W$[@\0)(H
M9@Q )P>H%<5*?#>LOX9NH;C2O"FJRZ>;/5;S2;C-QOBL_,G@6>3(W,\I(\L,
MS$*W;-=GH2OING?$;1X9]9U"+6_BCK&AWLHG51'$UNLRW$H,9RJ2*N3P/F'M
M75:7XLDOKZ&\T876KZ-+##J\^J6MVD<UH7C^SM#EX2(Y1QM .2F3VH \NLO'
M,_B&;1+;58;76X[J<7D%[?:5Y]IHSPL?,0.6R3)!&9'Y*[H@?O'%=)X5U"+5
M+Z^\2V>C:GK$OBRPEG\4:>T4FFPW]UYL*(R32?)Y+ELH01D$ \5'I6LG6?">
MF8U6XTW0KRT-_>6M_J5P(-0BN,1P1&2.-E#>8Y+<_*>&VYK?\.:=X=\0Z-X=
MGMI->T^WU*)F>UU;Q*\K3B,$2P)*A*1A-JLJOR0!CDBIN!UGP]FNXOB+IB27
MFHW6FWFKW&F\:C)<B.)HS/:9C^]!\@4]T(53D"NH_88^'GAOQ/\ LP_#G5-;
MT#3-6U;3KC4VM+V\M4DFMV&J71!1R,J<\\=QFN*\/^']+@U[3X]3\3>(;,MJ
M5I!#8CQ3-;/ILPA1)1CI*FT/MVDG:O/'-:_[%/P6TWQ7^SGX9U!_%7B^TD%S
MJMLT6FZ_<6T V:G=#(C0A<G .>^: /IZQ^&/A32YM>>R\,Z5:GQ =VK-#:HO
MVXX(_>D#Y^">OJ?4UIV/A#1M+U:?5+/1[*VU*>)+>2\AMU25XDQL0L!DJ,#
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MWPYMB^SPU$V_.[S+J>3.3D_>D/>@#O?[)M,R_P"AP?O&+/\ NA\Y("DGCDD
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M@!(R!R_>JM]\8_ >F7/V:\\;>';2YV[O)FU6!7VXSG:7SC'>IC\*_!Y61/\
MA%-#V28#K_9D&&QP,_+SQ4]K\./"UD#]G\.:1;[NOE:?"N?R6@#+C^-WP^FC
M62/QQX>EC;!5TU.%E.>F"&IUQ\;?A]:*K3^./#T ;=M,FIPKG:,MC+=AUKHK
M?PSI=K"L46G6<4:#"HELBA1[ "FS^%M*N65I=-LI&7."]K&Q&>O4=Z .2?\
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M*^*M5OM*T;Q)I6JZE8-MN[.SO4EE@(.#O4,2.:VKW4K33O*-S<Q6_FL53S9
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M'K>Q#_V:FGQYX;4D-K^EK@X.;Z+KZ?>H WJ*YY_B%X8C!+^(M)0#G+7\(_\
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M>I Y(]* .-D^/,*G8/ GCS(D\K"^')3AL9_O=,=^GO267QV6^7=%\/O'JJ&
M)FT Q_,1UPS@_C7IVF:S9:UIUM?Z?<Q7UC=1K-!=6SB2*5&&596'!!!!!'K5
M&\\;:%IWB73O#UUJ=O;Z[J,,MQ::=)(!//'&5$CJG4A2RY/O0!P<GQQ8331_
M\*[\>LR1B7(T0;6YQM!\S!;OCTI\?QJ>1I4/P\\=($X!?1U ;C/'[WFO4%N%
M<$@''K2^<H!)!&.N10!Y4_QNN!:B9/AMX^D8CB(:5$K_ *S 5#-\<]02T:5/
MA3X_>81^8(!IUL&8]-N?M& ?<UZR;J)02S!5 )))P!ZTPW408J<!@-VWOCUQ
MZ4 >.GX_ZP(K63_A3?Q#:21"TD8LK3,)[ G[1@D^HHLOCGXKOHIGC^"/CB'R
M@/EN)-.C+\$_+FYY_P#KU[)#=Q2ABC*P5MK%2#@CJ#CH?:N.OOC5X+TZ/Q$]
MQKD,:^'KZWTS5,1R-]EN9_+\F-L+R6\Z+!&1\W)&#0!SDWQ9\716TDJ_!WQ2
M^,8B6\T[>W?@?:,8Y]:LI\4/&+*#_P *F\1+QT;4-/S_ .CZU+/XX>"=4/A9
M;/6X[L^)KJXM-*$43DW$EN',XQM^0)Y;Y+8&0!W%9)_:8^&S_#F[\=0^)([K
MPQ;7S:8]W;VLTCO=B01>0D03S'<N< *ISU''- #O^%F^-'(Q\)=>Y[MJ6GC_
M -K4?\+&\:X.WX3ZRLF<#.JV&.??S:Z3X:?$SP_\6/#@UOPY<3SV8GDMI$NK
M66VFAF0X>-XY%5E8'L176XXH \<N/BO\354"W^"NI32''^L\1:>B#Y03D[R>
MIQTYQ4/_  M+XNE _P#PI%NN-A\668?ZXVX_6O:0,>E% 'C<7Q*^+SE<_!NU
M0$$G/B^W.WV.(>OTR/>@?$CXP%01\&[,'T;Q? #^D!KV0#%+0!XP?B/\92R8
M^#VE!3]X-XSCW#_R6YKQ;PYXR\=P_MF>-)(? ]F_B&;P9ISR:1)XA581&MPX
MW^<(2"<D#&WO7V<P'>OF/0F>/_@HKXG7:3')\.K5O;(O<4 >CGQS\63;EE^&
M&C^;NP%/BM=NWUS]FJ<^,?BKY8Q\.=%+[NG_  E' '_@-7IXKDOB'\0;3P!8
M64UQIVJ:K/?7:6=M9Z3:^?+)(P)SU"JH"DEF( QUH Y:;QA\7OLCM#\.O#K7
M&XA5?Q4P0CL<BTS^E5].\4_&R[OHXKSP#X/T^T*Y>?\ X2J>9@V.@468_/->
M@>!?&6F_$#PII?B#2'DETW48%N('EC,;;3D8*GD'(/\ 3-;K#/YT ?)'['=U
MX_;]FCP4GAFR\,26T5S?+,^IWMRLA'VJ?<H6.(@$.<9SRHZ9->N_:?C"EVP3
M3? PC+QM(6U"_)&0/,*Y@P?]D#\:\\_X)[&6X_9CTS8WEA=3U5%#C=\WVV7Y
MOISTKZ4E/EQ#>V&^4%E[G(H \]MW^*UPUTEW#X,A <_9S#+>2;ESE=^57!]<
M$U##_P +',S7%S=^#4$;")"D=X^&( 93\XQST'/X5=\4_$RT\-^.?"'A.XM=
M3EO_ !,UQ#!=VD/^BP^6A<M)(> Q PJC)/)Q@9KL;=##=3(L9,3$.[84 ,5'
M/J23W]: /,/%X\>_\(AX@LKF\\)A#I=T9EAM;L!4\ML\[\ X/UZTSX<CXDO\
M/?"ALK[PBEH=(M"@EM+MGQY*XZ2CM7HWB=U.@ZV#;84V,K%SMVR?(XP?P'?U
M%87PT+V_PY\-71:1X%T6V MD4,01'G*XZDC P..!B@#,N-/^+UQJ=FT?B+P9
M:V*N#/$-&NI))%SSM8W(QV[5P7P"T;XEP_!?P;;Z;KWAO3HK>!A+!>:+<3R$
MB9]REA<J!]0*]2^$/Q!M_BYX)T[Q9!I=WHXN9+B'['J"A;F'RIWC*NH)VDF/
M.WJ,UB?LMPW-O\"?"D5X6-TD4RR;CDY^T2=: 'WGAWXN7"2>5XY\+VC-<-(I
M_P"$7FD"PXXCYO!DC^]^E<-\+?#OQ0NM/\1K9^/-"M1%XAU2.7/AEGW2><<,
M/])&!DY(Y^M?1;G"_P"->=?!=E:V\9*KAMGBG4@?8F4''ZT ,_X17XDBVA5_
MB#IGV@ >8R^&QM?UP//X_,_C7BOP&T/Q;<?%[]H2UM?&%M:7D7BVS:>?^R$D
M\T'2K7&$,@"\8'4_=)[U]9/]TU\X?LY!1^T+^TP<Y8^)=-!'H/[*@P?YT >G
M?\(A\0 0?^%A6^/0>'X__CM#>$/'Q4_\7"A!)XQH$7 _&2O0@<@=J6@#YL^*
MWAKQ;9^-_A#_ &CXRDU*9_$[)%)!H\$0A)L+K+,,MD8R/QKO-8^&OQ!U7R/L
M_P 6]1TM4)+"TT.RR^>F=ZMT]J/C3<RP>*OA1'' )$F\5H'E[Q@65T?U/%>J
MK]T?2@#R&W^$?CR/;YWQF\1S_*P(&EZ<N<C@\0]138/@]XTB@2.;XS>*IY%F
M$AE^PZ>I*_W,"#&#Z]:]BIK<<T ?FC%8:K8>)/CM%)/K.L6 \>M!(T+Z>"FZ
MRA\V687";=IC8Y*<_(O!R:E76FU*[U=H;;Q%<VM[K]GI%[-9V^F0/<74UM*]
MM,J^1M5 42(ON&?PJW/J]K8^./VD].N;&7Q!%J?C5(4T42,(;H?V>I<2*J,S
M*/DX4@DX&<9J*2U\)1Z'JQBM8_%NF6^IZ3(72ZFA,DBF:+[0&@5P"%=&1 0S
M>3Q@YJ&!<EL;.YU37XA=:MJ/AV*U>QL]4^R6LJ/=,7F6U1HK8AP%57>3YD)V
MJ0<G&QK=EK&F75BUS;>(Q>Q7!T/3;6ZGT^TDU"$(5DGC3RPD9$S@MGI$<KGI
M6.GA:?PZGBI?AYI^H1W-]KOV+4DMAYMKIL]O#)/<2P6+R1N#L2($%R)-Y& <
MU)X6N"/"EE>RW<.KZ/?:S%<:=-K2+<2:C;7&GAY98=WS1#S=K&*X("LNS<<"
M@#HK#1-0TCQ1X9DM_$%W'9V9M;+4M9T^ZM+>S^UF1%,5O%Y(D;$GF,QP  HP
M370?L@?#M_'GPOUSR/&'BWPP+#QEK]J;?1;^*&-S]M8Y.8FR?F'?KG%0>'XM
M/T5O"EIHC6[:9/:K>1_VUI+W,T]RA =+)7V[W+RL9&XV*!MRN#69\%_B'X@^
M%WP+\::WX:TZPOHD^*^JVU^-0E:/[/;RZDD;&-5&7?YQ@9 ^M,#Z.D^ ,\J(
MLGQ1^(8$8VAEUB)2>>,XAY/-36GP%^SV]Q$_Q$\>W32C DFUL;HSZKB,#/UR
M*\\U[XJ_%"V^)/BO1X+6WM[6X6]@\(VRV$5Q]LDMXH&DD>47 PPWRE8F5-VW
M!8'KI?!SX]:KXE\8VNA^*98+"^EM5L%LK2R=D;48Q(\[-,I:.,%$*K'N.3%+
M@G;S0'?K\$[1E0/XN\82L@'S-K<@+8[G '6I9/@O9R/N_P"$H\6+[#7)17)_
MM >.?&7@M[/4?"NI:/''8Q"\OM(O(1)<7$'VB&.24L77R[>*-Y'=U#-D* #F
MN#;XS_$;6]7O-.T">VN+K7(]9;1;-+%!)IXL+V.(&0NX$C21,S ,5&[:,T >
MT'X+6+#!\2^*S_W'9O\ &H)O@/H]Q<6\TWB'Q:[P$E/^*BNE'/J%8 _C7%?!
MGX[WGB[Q1%HWB&Y07EW:I#:+96V;6>:%";F99P2"KN'" <8C)!.17*?#_P"*
MWC+4;CQ#XHUN[\1W>BZ+J7B"+[-:VEC%IDD=I/(D,9D+&?=MCP&"\D'/'4 ]
M/?\ 9D\)/+*\FH^*I))&W[F\47PVG.<@"7 J2X_9N\&W5JML\_B((L[7 9?$
M=\&R0,\^;]WV[5YSH_[5&NQ-?Q:_X<T*P>SM);EI+/6_-AE/V*"[@1&9%Y*R
MLK#'5 1D,*Q_#G[4?B*VO-9EN+/3;[3+'6IDN_MVH>7>I;G4!:I%:PI'^]9,
M[OFQG*KG)H ][B^"7A!(U0VE\^W'S/JUV6/'<^;S0?@CX.8MNL;QMR["#JMV
M>/\ O[7A>B_M5^+[F_L7U'PAHMGI\YA9H8M5D>Y1);Z>S4#]WM+^9"&],/@$
MD<S^'OVH/''BI=#@M/"6CZ;<:S(!:R:CJ.$*?89[IEV1[GW*T*Q_-MSN)QQ0
M!Z_/^SM\/9KA)I-"=Y58L';4+HD'U_UM6O\ A0W@3_H#-US_ ,?]QU_[^5Y#
MH/Q:\8>+? /Q@UB+4;>*XA\/6NL^'K2SVO<:?YVE^<%8D8?]\&PV,'\*Y*U\
M>>/(?#GA:^M?%6H1#5M1LC/+JE_9:AYL7]GRSLD2VZ@Q!I$&]7R<8VF@#Z';
M]G_P#*Q)T5R?;4+G_P".5%/^SI\.KF*2*;P\)D=2C+)>W# CN#F2O / OQX\
M4Z3;VUC=>*=%N9;H0W<VO>*9W%J"=/L[@V\2J$9#(UQ(5!R0%Z-T$NC?M.^*
MM*U71]-6RLY[":X?S;O5;G]Y=>9J-Y!^X<E25A2W4[0C$B15^4#=0![A-^R_
M\+)UL5?P98;;(;8 ID4)\V[LW//KFK5G^SC\,]/O!<P>#].68/(XWAG"E_OX
M5F(&<= *\,M/VF_'$BZ38:DWA;1)M7M[74(]>ECN'T^QAFM[B589AO!+,UL5
M5]P!W'C( /:?#KX_>(/$?CN70]7CT*VLM(MI=6U?58FFBM_[/FC1M/FB,N/]
M8QF#;NGDF@#MW_9@^%4MV+I_ VDF82^<"8CMW^NW./TK8;X'?#YB2?!VBDD8
M)^QIT_*O(_VI?B!XQ37?#GASX>)J5WK%E;R^*=0ATHP[I+>W.8+>4R,O[J>0
M%#MRQ Z5QNM?M7^+U_X335="ET&^TZQCU"6QL)[2;SK2&WLH[F.YN71B"C^8
M5VX4Y*@'.< 'TC_PI/P"%(_X1'1P.F/LBXH/P3\ $C/@_1"0,<V2$_RKY]N/
MVC?'DFGZM<Z2NBZX-)BU2<76GV<SQ:H+>UMI46)2V4V-<,CD%B?*X&2152^_
M:6\;6T%K/;:SX9N('AU&2SE73+IAKCV[6)580#E,B[>,GG+1C'>@#Z0'P9\!
M[E<>$M&W*,!OL:<?I36^"O@!]^[P;H3[_O[[",[O3.1S7S7JOQO\7Z4UEXJU
M2Y%O+?P:W9V\$&GS2PZ4T&HVEN@D0'$K,KDEY-H7!(XS6;IO[0'CJ[_LGQ3-
M>.HFT>2TN;*.U?[-#Y>M);RWRC&UF6!XVQG&TDCY0: /JM/@[X$1=J^#M!QU
M_P"0=%_\336^#7@)F9F\&: 2QW$G3HN3C&?NUY!XA^(0UO\ 9MLM<\;Z2;_4
MKV]6TM+2SDGCBGNOM#1VLDCP89(B0KNP^4+D\\5R&A^/->^&$6B>&?#.I_\
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M*]N:\3T'PW>>$9-,9?#MYX(\-ZA\0M%71+/4;+[--:3/I\]NT?E D.J2[,3
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MOC'$;P6J[CZ F?']* .@^$]AXSL?#DS>/+[2KW7[B\FG*Z+&RVUO$Q_=PJ7
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M?^%6^$E3Y433;=0HZ ! !_*N<O8OC#-;SI(W@80-&P; O"<%:Y?X33_%2_\
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M^!=$U/Q#--X[^*LTFGI=,K)J<JVU\\)19H[4X".RF11VQG(/!- 'TAH_PO\
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MNA5L84G@CB@#Q27]MC6M.M/%>I7OA*TGTO3X-9;3QI>HR7$\SZ?>0VSF0;
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MD'PI\(!VR"W]BP9/_CM7C^SE\*OLRVO_  KCPOY"RB<1#28<"0# ;[O7'&:
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M .*^&WQE^'_@KX?>'=#UCXI^$-3U+3K&&UGO+>_M[>.5D4 LL8;"CCI71_\
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M=CWQCFLBQ_:ZTN^T58$TJZE\4-X:/B)HH8&-C'&8WDC5I"0_*IU"$ \$YP*
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M '?:A\+]5U"-D'Q'\66P9@VZV:T5ACL"8#P>]5IOA!J$HD3_ (67XWC#MO\
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MC>ZU96$B)/<*DK\)&.7;Z*.:5P+]%0)<QEB,,N.[*14JR*X!!R#1<!U%%%,
MHHHH _.[_@M;_P F]>"_^QJ3_P!)+BBC_@M;_P F]>"_^QJ3_P!)+BB@#]$:
M*** "BBB@ HHHH **** .9^)J%_AQXJ4#<6TF[ 'K^Y>OG']D_X ?#SQ_P#L
MQ?"K5];\-17U_)X<LQ),]S."2$P>C@=17TOX[&?!'B# R?[.N./^V35Y1^PZ
M2W[)?PL.-H_L* ;?0@MF@#=_X97^%?EJA\'VK*HP T\Q_P#9Z\F_:I^!W@;X
M=? _6=>\.^%+*UU.WU#1R) 78[/[5M-XY8X^4M^%?5Y.!7S_ /M3>*=$\7_
M?QO8Z1X@T^YO--NK!;R.UND=X'6_MV\N0 DJ6VE<'KG% ';_ /#/7PS%U+='
MP+H7VB0N'F^Q+N.Y@6R?<@5-'^SW\-ELOLJ^!M!6+8R?+9(&VMG<-V,\Y/?O
M7S!HOQ1U/P[\3OB4U]XMNM7US2=6\02Z5H>HZW<J'6&U\ZVA6Q5!')%]_!+
MC8,9-2>*_P!IWXK>%="EMIVT66\%]IC2Z_'IKPVMG:7=BUP \3R'YO-3RMS,
M!A^@.!0!]06G[/\ \-+*V@MX? 7AU88$$<:G38CM4=!RM3?\*,^'6,?\(+X=
MP?\ J%P__$U\[W'[1'Q2OX]2OX;72]+L8-,\-[X7TV:X>TN-21&N+AB&!>.#
M)P@&22,D8K-T_P#::^).H>%?!XM9-*O-8\9W=[H>B3QZ>R1?;+;4GC>>12_R
MQFS1I-IZ-'UY H ^EV^"'P[$H;_A!/#I;U_LR'C_ ,=J-?@-\-7.X^ /#)8'
M<&;28#@^HRO!]Z\B^/GCL_#KXF2RZSJVIZ=H^L>!-0L+*XMDF:$ZDDR,O$8.
MR4JXVGJ>0#Q7$>"?C)\7?#OCWPYX)N;9-<MX?#*;HCIT[7?VQ-+\X/<SN0-K
MS*$W+G+,%(!YH ^F$^ WPVC&!X \, $$8&CV^,'DC[E6-,^%'@G187AT[P=H
M&GP,Y=DMM*@12Q&"Q 3KBO#?V9_V@?%&NV\5A\3+VT35=:U-+'0Q!826SO-]
MC:YGMW!0+^[". _?!!)(R?'_ (Q:5XZO/&OQVTF#4_$EOI_BN_CL8+O28Y'.
MF16>GK>AHAN&TS;6BRN,LP[T ?<$/PZ\+0MOB\.:1$_S?,FGP@X)R?X>YY/K
M5N'P5H$"JL>B:;&B@*%2SB  '0?=KY&N_BI\:-/\1>/+;38+LZ=I?AF>;2;
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M!M;<G]2:]4?[AKQWX%S2/XZ^,J,V53Q9\H]/]"MJ /82@V]*\;^'#.?VBOC
MA)P+;1"!V_X]Y,G]*]E8_*37E_A"*TA^/'Q#>%PUS+IVDM<(.H($X7CZ 4 >
MH%1C.*^5HG:/_@I?.IX$GPQ3CZ:@:^JF^[TS7S)JEN(/^"BFA3J5S-\-KE&
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MD4_3/V:]#TC55O+;5+^**+4K?4H+>-(E6(Q2F8Q[@@9E=R20Q)YP*]CQ1@4
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MM 'UD.0*6N:'Q(\*@<^)=&_\&$/_ ,51_P +(\*;68^)]& 49)_M&' 'O\U
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M_4K*VWKI%Q+%=:/;S76MZW?26$T:R*D;00VRYVROOD<!L$!^@ Q7I?P<\/\
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M#Z***H HHHH _.[_ (+6_P#)O7@O_L:D_P#22XHH_P""UO\ R;UX+_[&I/\
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M?.WB'X3_ !.?XC?$K5(/&EC?66I:!>6^ES-X@AB:YGDL((8H6&[]WLF21]P
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MAUKI'J;FS _]&TC?$'Q3C*_#?66YQS?68_\ :M %>+]GGX>6=O%''X9MMD0
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MQJ3_ -)+BB@#]#V&5(J*WMVB>9C*\@=MP#?P>P]JGHH **** "BBB@ HHHH
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M7U% #J*;O7UH\Q/[P].M #J*9YJ?WA^= E0]&% #Z*:)%(SN&/6@NH&=PQ0
MZBF"5#T8?G2^8O\ >% #J*;YB_WA2>:G]X?G0 ^BF[AZT;U]10 ZBFEP.]&X
M$=: '44W>N<9Y]*#(H&<\>M #J*;YBYQGFD,J@@$X)H ?13?,7&<T;UQG- #
MJPO'2AO!?B 'H=/N ?\ OTU;7F*3C/-8WC4AO"&NKR?] G& /^F;4 <=^S*Y
MD_9X^&C$@D^'+#D=_P!PE>FUY)^R9>+J'[-'PNN$78)/#=B0HSQ^Y7UKUN@
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M'[$GP+U#PEHLDWPVTEI)+2&4R%IMY)12<OYF2.>F<5M1?L1? F%8POPST/"
M@;D<\'URW/XT >J7'Q"\,6D;23^(M(AC4X+R7\2@?B6JC)\7/!,,\L$OB_0(
MI8P"R-JD 8 ],C=7GS?L5? B1=C_  M\-2 _PO9[L_F:0?L4_ 8Y_P"+4>%7
MSP2=.4D_C0!WS_&?P"@R?&WAT?758/\ XJFM\;/A\O7QQX<Z9_Y"L'3_ +ZK
MB+?]C+X$6Q'E_"?PB#@C#:7&W7ZBK!_8^^!N.?A-X-'&/^0+ ./^^: .F;X_
M?#5" WC_ ,,@GCG5H/\ XJF-^T'\,E.#\0?# /\ V%X/_BJP1^R1\#R&_P"+
M4>"^?O?\22W_ /B:<G[)/P1C=67X4>#%93D$:);\'_OF@#7/[1OPL5=Q^(OA
M<#U_M>#_ .*JK=?M/_"2RMOM$WQ*\*I 6";SJT.,DX'\7K3?^&7?@Z)3)_PK
M#PAO/5O[%M__ (FK _9O^$PEW_\ "M_"6_&,_P!C6_3_ +XH HW'[5_P<MKU
M[23XG^$UN4C\UHSJ\.0N,YZ^E9S?MG_ Y;B& _%3PKYDR!T_XF28(/3)Z#Z&
MM_\ X9O^$P&/^%;^$P.?^8-;_P#Q-31_L\_"R%2J_#OPJH(P0-'M^G_?- ''
M_P##<OP#!(_X6QX8R./^/T8_E2']N7X" '_BZ_ACKC_C]'^%=M'\!?AC$Z[/
M 'A=6'W<:1!Q_P".U,OP1^'$:S!? GAE5E(,@&DP?,0<C/R^M '!-^W/\!$C
M,C?%3PWL!QD7>?Z5%_PW?\ C_P U3T#KS^^88^OR\5ZI#\.?!T&Y8?#.B19(
M9ECT^$9/0$_+[4__ (0#PD2__%.:,2P(;_0(>0>3GY>] 'EJ?MS? :28QK\4
M- +8)'[YN<=<';S4 _;Q^ K2L@^)6DDJ&8G9-C"]>=GY>O:O7E\#^&1@C0=*
MXZ'[%%Q_X[3D\*^&R2$TC2R5/(6UBX/Y4 >+O^W[\!([2WN3\0[+RIPQ0BUN
M"?E&3D"/*_CUI?\ AOWX"Y@ ^(=FQF3S%VV=R>,9Y_=?*?8\U[/-H7ARW,22
MZ?I<1E<1QJ\$2[VQG: 1R<9.!4Q\.Z&.NF6 R>]O'UZ>E 'A4?\ P4&^!=S)
MLL_%]QJ#^EGHU[+]>D/:FG_@H%\%\_+KFKR*0"&3P[?D'/I^YKZ"M--L;$DV
MUK!;D_\ /*-4S^0JTJA5 484#  Z"@#YR/\ P4$^#*]=7UO_ ,)O4.?_ "#5
M&X_X**?"&WNH(2WBEUD)!F7PS>[(_0MF/.#VP#7TYBDVC/4_F: /F]?^"@GP
M@=]BWGB%G[*/#5]EOI^ZJK-_P4+^& 65K73?&FHI&X1FM?"UVPP1G=RH^7WK
MZ;Q]?SHQ]?SH ^69O^"BGP^BF9$\(_$:=5./-B\)7!0^X->,_M+?M?\ A3XI
M6GPX&E>&O&MG)HOC72]8E_M3P[-;B6&&0LZQ;C\\F,;8QRW:OT,Q7S+^WC+)
M9^#/AG=PR-'-!\1-!92IP1FX(H I-_P41\" L(_!7Q+N""0!'X2G^;GJ,FF1
M_P#!1#P>[2!OAY\3H]JY7=X5E^8^G!XKZH7J?\:H:_K^F>&-)NM4U;4+?3-/
MMEWS7=W*(XHU]68\ 4 ?-T_[?_AJWMUG?X9_%%(ID\RV=_"LH$Z]R/FXP?6K
MD7[;T%Q$DL/P8^+<L+@,KKX7;!!]/GKW"'XA^&;CQ1'X:B\1:8_B&2U%ZNEK
M=H;EX.THCSNVG/7%=&.1G)H _/;P3^TP]A^U_P#%/Q6OPL^(5TUSX<TBU_LB
M#10;Z (TA\R2/?\ *K9^7UP>E>[']M*Z6,/_ ,*+^+6",@#P\,_^AU0\$AH?
M^"B/Q)55&R7P-I;EAU)6X<?R-?3TJ--&R*[H3QO4\CZ4 ?-%_P#MHZZL&[3?
MV??BG?S!PC12:5'!C(R3EGYJ@W[:'CXA3%^S)\27R2#N%LN/3^(U[S\2_BCX
M8^$6A+K?B[6!HFDF3R3</#)*NX@]=BL1T/.,5M>%O$VE^+_#&FZ_H]X-1T?4
MK:.[M+N/=MFA=0R.,X.""#0!\VC]LWQY@>;^S+\24#=-HM3_ .SUR_@?]J?Q
MS:>(O&4]M^SMX^N;V_U:%Y;3S;51;?Z+$HWL6 !. <=,'K7V:9 SE5(/&3\W
M(_"O.?APKCXB_%%))6E7^UK5E5AP@-C#P/4=3^- 'FUG^T[\5]0@,L7[,_BY
M4W,@$VL6$;9!QR&<$#/?FN+\._'7XD67Q:\?ZG#\ _$=SJ<FGZ;]HTQ=8L0T
M*H)@I#;\/NR<8].:^C="^,G@SQ-\0=7\$:9KL%UXJTB/S;W3EC<-&N0"0Y4*
MV"5R%)QD9Q67X?T=+#X_>,[P,P-WH6EEH^,#9+<KD?\ UZ //X?VCOC%<7$T
M*?LT^($,05B\WB&Q5&!&<*<\D=QVKE)OC-\96^+=GJ4WP&U!95T&XACTM/$-
MH68&YB+2>81CLHVU[O/\<O!%K\3(/A]-K\(\83@;=.\B4@$H9 ADV[ Y12VP
MMNP,XI-1=O\ A>OAP#[C^'M0) ]1<6O^- 'GI^/'QJ8+M_9TOP<<[O%-F,'\
MJ\8^*WQ1^+6I_&_X0W^I?!E='UFPN]4;0]/?Q) ZZF[6>'C>0)B$JH+9PP/2
MOJOQ+\;?!_A'QQIOA'5]8^RZ]J*PFWMS:S,K>:[1Q R*A1"S(P 9@3BO,_VA
M93!^T1^S6^T$OX@U2'D= =,E/_LM &)-\:_VGMR"']GC1\$9);QBF/\ T51%
M\9_VHF//[/FAC Y)\8*,GV_=5]5*@V@$#I2[1Z4 ?'WCKXB_M-WW@7Q+;ZG\
M&O"%O8RZ3<K.T?BUBZHT+A@H\K!95R<=_6JWP[^)W[3<?@KPM!H_P=\*W&C?
MV79K;WMWXF:-WB\E LCJ$.W(P2.<5]4?$*)9/ WB-2C-NTVY4A!\Q'DOT]ZP
MO@*1+\#_ (>L5//A[3_O_>_X]TZ^] 'C/_"P_P!K":*Y*?";P%')"P1%?Q/*
M?.!ZLI$8X'O@U:_X2W]J]I(P/ /PTV,.6_MZZ^7C_<YKZ:\M<=!1L ' Q]*
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MDG9[JUN_MCRM(I+2136\:Y/"[AG.X5]??\+X^&/!_P"%B>%/FYS_ &W;9/\
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MN+7R6S\P#'.<[A7T#)^VC\!K?(/Q>\'GJ<KJ\3']":5/VS?@+(%5/B[X.7/
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M:MC^SM\7M#M6TZQ^&'@1+(6:PLJ>*KSR[IEG697E5HB7E#JI$AY  &:V=%^
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MK?\ DWKP7_V-2?\ I)<44?\ !:W_ )-Z\%_]C4G_ *27%% 'Z(T444 %%%%
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M.,'.: /H_P"#UP)OA9X2E4$J^EV[ X/38*['=['\J^$OB+/X#^%?CK3O!9^
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MC[HKSGXC,8OB)\,]JY5M2NE/XVDE #7^)7BQ%9A\,M;; X O;3G_ ,B5X?\
MM3^.]>OK#X7S:AX"U/2TM?B#HKH]S>6Q#L6<!1M<]2=N3P*^N BXZ5\Y_MMV
MTEQX4^&L4$B0S/\ $/0 CN-RJ?M!Y([T =_/\2O&R1.R?"W5I& )"G4[,9.>
MF=])=?$;QRJGR/A9J4S\<'5K-!R<'DMV&37IP1>N.:-B^E 'CR_$CXKS7*A?
MA!$EOOQYDOBFW5MN>"5$9Y]J\P_9B\<_$ZU^"'A&VT[X96E[8)#*@NY_$T,1
M.+B0$[!$3P<C\*^KW48''<?SKRW]F6V>T^#6B6\L;1O#->QE68,1B\F Y%
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MQ0!YU=^%?B+="WV>.M-M6CEWR>7X?#"1,?<^:8XYYR.:KP^"_B2FWS?B-9.
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MAF!U:Q\)Q7$,NN3;0B->>8 NW&#M7@$<=2:]X/Q#\'DX_P"$FT;/3']HP_\
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M^P(>GI]^GCPCXWVG=\06SURNBVX_J: /0*0L!7G[>#_&Y4 ?$&0'U_L6W/\
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M"UO_ ";UX+_[&I/_ $DN**/^"UO_ ";UX+_[&I/_ $DN** /T1HHHH ****
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MI@_%_P"(Y.!S_:=J,?E;5GWW[+/]I20-=?%KXJ2>5PHA\4&V'7J?*C7=^.:
M,']G?X4>#?'GP5\)7/B;PKHNOW>FWNHFQFU2PCGDMC]OG)V%E)7D \>QKUS5
MO@SX&UQ]6;4O!NA:BVKRQ3Z@;O3(93=R1C$;R;E.YE' )R0*^=?@+^SQ'X_^
M$^G75U\2_B98O%?ZC!LT[Q5+:JX6]E4$A%'. .>YR>]=]_PQSI__ $5?XO?A
MXZNZ /6&^&7A-UU /X9TAEU"*""\5[&,I/' ,0HZXP5C'"@C"]L5P7CS]EGP
M9X_U;1+B\CN[+2],1$.@Z>Z0Z?<A)O/3?$$^7$N6/EE"W1LBL>']CS3HI5<_
M%/XMR@'.R3QS>%3]1FK5A^R3I5G)&\OQ%^*-Z$##;<^-[U@V<=<,.F.* /7=
M-\*Z/I&I:AJ%CI%C9:AJ+B2\N[>U2.6Y<# ,CJ 7([;B:2'P?HEKJ$M_#HVG
MQ7TTHFEN8[.-99) ,!RX7)8#C.<UXQ/^Q5X&NWEDN-=\=3222>:[OXQU#);U
M_P!92#]B?P#+Q-JWCBX7J/.\8:B1_P"C: /;+KPWIFHZE9ZC=Z99W-]9DFUN
MIK='EMR>IC8C*Y]B*5_#NFO+=RMIMH9;Q=ER_P!G7,Z],.<?./8Y%>)']AOX
M7GEQXIDYS\_BW4O_ (_4\7[$7PLC<.;3Q%(W/W_%>IG/'_7>@#VJ31K*9462
MRMY%63S@'@4@2?W^G7WZTKZ7:2-<;[6)C< "8F%3YH P W'S<<<UXJG[$OPE
MC@\F;1M7NU(.]KGQ+J;%R2#DG[0,]!4C?L2_!V6\N+MO#5\);A=KX\0:D%'&
M/E47&%/N* /9VTVUV(IMH=D;^8H\I?E;'W@,<'WZTW=8Q/%(S6ZM,^^-OE!=
ML8RI[G'<<UXW;?L1?!RU<,GA>Y<B'R#YNN:B^Y.^X&XY/N>:=#^Q/\%;8 ?\
M(-:R88N@EO+J3RR?[FZ4[?\ @.* /8;N>PA<S3R6T?F+Y9DE91N&?NY/49/2
MF/J6E,$#7EF2G*YE3Y>,9'/%>4?\,<_!B789? >GSJHPJSRSR*,]\-(1GWZT
M+^Q7\$5)/_"NM))/7<93_-Z /5%UW18?^8C8)\Q(/VB,9)ZGKUKG?'>B^"/B
MAX;ET/Q(VE:UH\DL<LEI/=CRG*,&7<%<9&0.#P>X(KC&_8J^!Y(_XMIH;!>F
MZ-SC\VH'[&7P/+C'PQ\/J1T MB!^6<&@#U2V\0:+;QK$FI6$:J,+&MS& H X
M  /0"@^,-"27RCK6GK)MW;#>1YQZ_>KS6W_8]^"]H[M%\-?#JLRE"3:Y.#U'
M)JW9_LH_!S3WAD@^&?A9)(22DATR(N,C!^8C)'L: .T;XC>$TM&NF\3Z,MLI
MPTS:A%L!SC!.['6H;GXI^"[26*.?Q9HD4DIQ&K:E""QQGCYO2N;7]FKX2K"\
M(^&7A,0L<M'_ &-;[6]R-M/B_9N^$ZYV?#3PD">I_L6WS_Z!["@#9G^,G@&S
M($WC7P_$602#?JD(ROK][I54_'SX:+C/C_PR,_\ 46@_^*JJG[.?PL3&WX:^
M$AC@?\26W_\ B*F?X!?#%4P?AUX5QZ#1;?\ ^(H E;X]?#95)/C[PU@9&?[5
M@_\ BJA'[0WPP:0H/B%X99QV&JPG_P!FI\?P$^&Z1^6G@#PND&[S/*&C6^TM
M_>QLZUJV/PM\(:7$D5EX5T.TA3[L<&FP(J_0!: ,=OVA?A@GWOB%X83IG=JT
M QGI_%5.?]IGX36\@1_B1X7W%@H U2%N2< <-74R_#CPO-)([^&M':20 .[:
M?"2P'0$[><9/YTZW^'?AFTC,<'A[2(8_[D>GPJ/R"T <0?VL/@[Y,,I^)GAG
MRYB%C8:C'@DG [\<^M>5?M/_ +27PM\9?LP?%*RT3Q_H.I7M[X:U.VMH(+U3
M)-)Y##:J]2?3US7TBG@?P_&FU="TQ5]!91 ?^@UY;^U;X5TBT_9C^*TEOI=C
M;RQ^%]1*/%;1J4/V=\$$+P: ,+X4?M.?"?PK\&O!=MJ7CWP]IL]EHFGV\]HM
MZK&"3[-'\FT<\5O?\-J? X!?^+CZ-SZ%S_):U_V>/#.CW7P&^&]P^F6$DC^&
M].8R?9HR2?LT?.2,UZ(?#>DITTRR'_;NG^% 'D,G[:?P.9@O_"Q=)SUSME_^
M(J&V_;-^!.G1I;V_C[1X$Y*I##(JC)R< )CJ:]@&CZ29O+^P67F%=^WR(]V,
MXSC&?QJ?^P-.7I86O'_3!/\ "@#XY^+'[0?P\\6_M)?L_P"N:/XEM[[3=-NM
M;>YN$AE 5?L##Y<IEN>,+DU[P/VKOA6J2$^*D_=!2X^Q7&1G&./+SWK@_P!H
M.(6?[3W[,GE(D<9UK5X\*N  =,F/0?2O>[K75M[^:'9>.UNJ,5BB9O,#G:-N
M.#@YSZ=: /.?^&O/A68/-'B.XEC)Q^[TB\8_D(LT6_[7'PPN$D,.LZ@1&<,O
M]A7P.?IY->F^:(5GNPWF2#Y%3S&3)XPK G&[/&<4VQURWO(VDAN$G4R/&%BE
M$A$B$AX_EXR"",9H X'3_P!J#X?:O=M:VFHZE<3*,[5T.]YYQ@$Q8)]A7/2?
M%;PO>?'#2+VW75O/_P"$<OHF!T:[5V475HP^4QY(!+<X[]:]4AN8M1OG@:_+
MA)V<HY7<I"C,8P.@#\\Y!(]:Y/5&MK/X\^$88SMED\,ZHD6,G*+<6)P>>@SG
MF@ N_CYH]K%=.-!\73B!!(!#X;NR907"83Y/F/.?IS7F?C7XVZ5J/Q;^&%__
M &%XJMC:_P!KL;:X\/W"3R VG\"E?F/'05]-*O Y;GWKRWXES"#XP?"$-(56
M74=1C"\\G^SY2/\ T$T 1P_M#Z?-*(D\&^.]W/+>&YP./<UPOQ/^/-M?GPBD
M?A/QE:LGB6P+F[\/2J&&6^53GJ?6OI+;D=3^=>:_'.XEL](\,2P1-,X\3:6I
M53R%:<*3^ )/X4 9Y_:'M@9/^*"\?D*>"/#LAW<XX^:O&/VOOC)'XP_9M\4V
MX\&>,-(0S:=(;C5](-M& NIVW!)?.3C@8YR*^P=ON?SKY[_;_B#?LB?$4[!(
M5MK9P&) R+N$@Y]B,T =Y+\998M7^P+X#\:3$GBXCTI# 1C.=_FXJY)\4[E,
M_P#%#>+6PN?ELH?_ (]UKJO#/[WPYI;-@EK2$G!R/N"M$1J.@ H \\_X6KJC
M,H3X=^+"#_$T5LN/_(U><?!/Q_J6E:/XO$/@GQ'J$DGBW5W=(D@S%F?.TDR]
M>>U?1110I[5Y?\"XK&+_ (3Y+))E0>,-2,GGK@^:2A<C_9W$X/IB@""]^,/B
MB*UD>U^$GBNZE# "(S6<98'J<F;'%4W^,GCHPVSQ_!;Q,[R F1&U&P7ROKF7
MG\*]D" =J-B^E 'PI^W1\0?%GBC]G2_AU?X9ZSX6M(]9TF7[9>ZC:.,B]CX
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MV "\]/\ 45T?Q<^(FN^ ;CP<-(TBVU.UU?Q!:Z3?W%S<>7]C@ER/,51R[%L
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M^7!QSQ22_M,^!+:>^2ZO[NR@LI%AGN[K3YXH$E;D1EV3[V.<=A0!ZJ:^;_\
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M"&!!K%N/VU])FA\#:K9>$]7F\->(-/U74+C4)-BO9K91[F38&(=FZC!Q@@T
M;J_ ?XK@#'Q_U= !@!/#EB !V[4ZY^!WQ6<[C\?]8B' _=>'K(?B<BJOAG]M
M#PSXBTB\U)_#'BK28+<:5*BZEIPB>:WU"5HK:X10Q_=EEY)P1GI5/QU^UR;#
MP'X@\2>%O VO:W!INIVVFVUY<PB"QU#S+X6DDD$NX[@CD@9 R2#TR0 ;VE?
MCQ]:2,;OXY>*+E'7YDCTS3X<OW;(B)I]_P# 7QG?RL__  N_QI  P,:P06*
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M^"?$,2[0SZ;<J"W R8GZ^U 'F'[$LIN/V3?A0[.23X?MOSVXKV_;[G\Z\/\
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MUK6*Y'6N;^&UT]]\/_#5Q(K))-I=K(RN,$$PH2".U=+0 T( ,4AB!'/(I]%
M#/+%'E# &.!Q3Z* &A !TI/*%/HH 9L]Z4H".@IU% #/+ Q[4I0'M3J* &A
M!TS2&(&GT4 -"@#H*"HIU% " 8_^O33&#VI]% #/+% B I]% "8HP/2EHH 3
M ]*"H/:EHH 3 ]*,#TI:* $P/2BEJ.4,P(7@XX)H >"#1@>E16J21Q(LT@DD
M ^9E7:"?I4U "4$#TI:0]* /G[POA/VXO'*X(\SP-I+$_P"[=W8_K7T"HP.N
M:\#T?RXOVW]?"I*KS?#^R=V<?*VV_G V_3/->^+TH 6BBB@ HHHH **** "B
MBB@ HHHH **** /SN_X+6_\ )O7@O_L:D_\ 22XHH_X+6_\ )O7@O_L:D_\
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M?(.>#WP:M:S\:]%T:""4Z=XEO1,2H6R\/7LK)@9RP$?%>@>7R3D_G1L]S^=
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M^E>J[0.P'THV#.<4 >0S?%+XF(EN8O@U>R.Z9E5O$%FHC;)X!S\W'.?>G?\
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M$L57DEE[5]%KT%>!-&R_MTVK[OD;X;S+CW&JQ\_K7OHZ4 +112$XH 6BBB@
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M.$/\JD?.*]6\5_LY>!_&WBKQ!XBU?3&N=4UWP^_AB]D$A"O9,22H7H&Y^]Z
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M^QJ3_P!)+BBC_@M;_P F]>"_^QJ3_P!)+BB@#]$:*** "BBB@ HHHH ****
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M4!+#=C)->@W?Q-\3^,OV=(-4U6?4M"ENO$D&F:AJAM_L;16)O$1YXF&,Q,A
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MH:JS_L\^-;UM]S\>O'>\ J/LT.GPKR<Y(6WYQTH ]U#J>C#\Z"P"DYKP6/\
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MLRZ]5$$_'_D/WKP.Z_;7\9V7AQYGTC1+G6$O)$GBLY'>&U1;=YXXVE,HC=I
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M=L'X/_$!21D V5OT^OG8KPKPAXX\<^#?AY!X,T277SJ>FZ*M[;-+H[3%;?\
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M(E 'SYW-U]3ZUX7^PKXR\/Z-^RYX1M+O7].CGCN-35A/>Q(Q_P")E=?-M+#
M/!'L17O;_$CPI&,MXET=5]6U"$?^S4 6[/PEHVEZI<:E9:79VFHW$,5O-=PV
MZI+)%&,1HS@9*KDX!.!5"W^&WA:SF:6W\.Z5;RM>+J#/%91J3<KDK,2!]\9.
M&Z\GUI?^%E^%"[J/$^B[EY*_VC#D#W^:HIOBIX-MTWR>+M!C7IN;4X /_0Z
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M$DV1'_HTYW8Z\^7@=#UH ]$;3K=TV-!$T> -A08X.1Q[&GFU1FW'&[&-W?\
M/\*\L?\ :F^&*I*W_"4*?*D6)@MC=$AFQ@8\OGJ.:BNOVL/A=96$]Y)XF<V\
M$JP2/%I=Y)AR"0H"PDG@$\"@#UCR0K9'!/IQ^%*(.AW98#&[O7D>G_M8_#75
MIQ#9:QJ5U(6VA8] U Y/U\CV-:J_M#^#G (;72"< _\ ".:A@G_OQ0!Z*UON
M1D9BRL"".GZU4T/P]I_AK2[73=*M(=/T^V79#;6Z!(XUZX 'N2:\XF_:A^'T
M$]U#)?ZLLEJ569?^$>U#Y"W3)\BM/_A?GA/S#&#K;."%P/#]_P!3T_Y8T >@
M_9U/_P"LTODC).3D]>37EEY^TEX6@@2:VTSQ7J,3EE#6?AB^?D'!ZQ#O4EY^
MT7X:LY$3^R_%<S,NXB+PQ?-MXSS^Z]Z /3EB"YRS')R>3S2B''\3>W?%>3G]
MI/1#<O$GA?QLX501*/"]V$;)Q@$J.>:JI^T[I+X_XHOX@ $9R?"MU_A0![$(
MB!C<:! %/!/YUX_IW[3FDZC<0Q+X-\?P+(VSS9_"MTBKUY)QP..N*V;3X[:7
M>"?'AWQ=%Y3 9E\/7*^9QG*_+R* /1A -PP<8Y&,THA SWSUSWKRI?VB=->_
MGM4\(>.&$?2?_A&[@1R<9^4D#/Y54/[2MD2VSP'\09"IP<>&)A_,B@#V0#%+
M7CVH_M(V.GRF,>!O'UTPV_\ 'OX:F8$GMDD#CO6A+\<6BG$1\ >.2V"<KHP(
M( SU\SWH ]1HKQZ?]H<0SW4(^'?Q!E: LI*>'SM; S\I,F#5N3XYS1RB,?#S
MQW(?)68E=(3 !7.W)E^]V(]: ,OXL;5_:!^"+L?^6^L(,=R;,8'Z5[1']T5\
MW^-_&+^)_CI\#9)O#NM:$GV_4F5M8@2'<38G"C:['=UX./NFOH^(YC!SF@!]
M%%% !1110 4444 %%%% !1110 4444 ?G=_P6M_Y-Z\%_P#8U)_Z27%%'_!:
MW_DWKP7_ -C4G_I)<44 ?HC1110 4444 %%%% !1110 5\Y_M;ZM<Z!XF^"6
MHVFF7FLW$'C% EAIY03S;K2=<*795[\Y(XKZ,KP#]J!MGC7X$MT_XKF ?G;3
MT 7K;X_^+;AI4'P)\?Q^6I;=+)IBA\'&!_I?)J,?'GQZX)7]G[QP5'3?J&D
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M_:)@'W$\>,1DY/S6-NQ_G7TE0!Y&O[*7PL4$#PE%@]<WER?_ &I7%^)_@/X
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ME:.0S,@*C<,91=KJV 1WKZE/@[1F,Q;2K(F9M\G[A3O;9Y>3QS\GR_3BH!X
M\.K?37JZ%IJWDLZ74EPMJ@=ID.4D)QRP/(/:@#Y:TC]JCQ1JNK?;=-M-,%M?
M:.NK?8=2N&VVXMK:62Y2$( 69VC.&9L <D=177>%OVG-=\2_%_1O#?\ 9FCV
M^E:E?W-H+4SROJ4,45G'<+<N,;/+?S  <>G)[?0$/A32;;!BTRR0A2@*VZ A
M2,%1@<#!(QZ$^M<KIOP-\,Z7\2[GQU#%<_VY/&8]K7#&WCRBQLR1=%8HBJ<<
M<=!0!\W_ !)_:9\8:UX<\?Z9I-_H_AN_MY[VS@:S:675-(6WO(H1+=H?E4SH
M[-'@8&Y?O\X] ^,'Q9\4_"_XC65C9ZOI3Z9-H%L@AU<,L4-R^H)!)?SNI#&)
M8V *@CEN2!S7OI\+Z4;FZN#IED;B["BYF-NA><+]T.<9;';.:DO="L=3S]LL
MK:[W1&%O/B5]R'JAR.5) ..AQ0!\>2?M.^.8[F+6!?Z*?M^BVL5IH\44DEK+
M<#4KJWENXG+(?+9(5(WN  Z9/KN^%/C+XS\;_#_XK>)K74DTZ^'@:PUC38]W
MG6UA>/97#R&->I&]%/)/(KZC_P"$;T[RTC%A:>6D8B5?(3"H#D*!C@9YQTSS
M4D6AV=O \,-G;PQ.GELD<2J&7GY2 ,8Y/'3DT ?&L/[4GBCX<> +[1S);ZUX
MCT6RD>U&K&>6]OHUT7[<MQ,J\X,^4RO! ('.*LZE\;_BG''XJTSQ#>Z9>Z;;
MN=,$^BZ?<6-U(TVD"^2>.3S&\O8Y\O@$G.>#Q7V'_8]J)#(+> 2%/++"-<[<
M8"YQG'M4G]GPLI#1QD'KE <\8_E0!\4:7^U!XP\#:1XLN-7U"UN0+_Q"]@-6
MCE\R*2'[+)8VJ[>61HYFV\;FP3S6MXH_:6^)WA^UTF[@DT"\CU75-3CA$MK+
M;1P):30Q)9EW8F224/(X=1GY<!2,D?7SZ3:R??MX7^8/\T:GY@,9Z=<#&:D>
MPB<#*(<-NY4'GU^M 'RM\>?BUXJ^'/QTT632M76.SG\,1R+X>GM99TU&X.HQ
MQE(W7 CD$<C88@G Y&.1E:E^U-XPNKO4M%T^^TP:IIUNR:M<1Z7/+'I#_P!L
MQVGGRJQ 95M9#(4#<[2V0M?8'V92VXA=V,!L<X^M,^P1#<515+_>(4#=]?6@
M#XB\"_M >.+#4]$TZ?QO97D%SKELJ2W>D.TNMP76N-:2O$"W^C1I$1L!SU!Y
M%6=#_:/^*5Q8:S/X@UC2?#6GG5(8GU5=(ENSH:-)<*T<L("[LF*$!BQ(\S)X
M(-?5>M_"+PIXE\5Z;XFU30[6^U[3@GV:]D!#)L8NF0#@[6)89!P>:ZUK?<A5
MCN!&,'G^= 'BO[+'B36/$NA^,)-=UJ[UN]7Q!++%-=6#V)2WEAADA"PL243#
M' R2!UYS7M^T>_YTR.,HQ).<U)0 F/K^=)M'O^=.HH 0*!05!I:* &[![_G0
M$ [4ZB@#P7X^WD>F_&'X 2/%YOG>*;JT49^ZSZ;<MN_#8?SKWB,84"OG_P#:
M4 /Q6_9X;<!M\;2<$\G.EW@X_.OH!3E010 ZBBB@ HHHH **** "BBB@ HHH
MH **** /SN_X+6_\F]>"_P#L:D_])+BBC_@M;_R;UX+_ .QJ3_TDN** /T1H
MHHH **** "BBB@ HHHH *\,_:@1!J/P=E*)YB>/=/"N3\RAHYP=H]QQ]*]SK
MYY_;+O3I6C?"O4$BN)GM?B#H[[+2(RS,I,H954<DE<\4 >L?$:WUJX\&ZHGA
MRQL]1UL(KVUI?RM##*P8$KY@!*$J#M?^%MIKQ?P9\+OB)X'^!]MX/L]'T*_G
MMT-TEOJ6I2L/WMS(TUG]H50^]8G^6ZZ[R3CO777G[4&C6$MS%)X*^(3/"Q!\
MKPE>.&_W652"/QJ(_M-B7>]K\+OB1=6Z[0)AX>:+<2,_==@W?KB@#YY?]G_7
M)@?A-/<VD>LS_#DI$5G<6]OMUE95C$N/,;RP0HDQDD9K>^)'[$WBG7;?Q!9Z
M-X@LKRWN=?76[6Y\132W5Q=*]I);O;W<C*Y=8-^Z$D$CIP0#6W??&.\/[3.D
M:])\,/'<4Y\)7=G#9MIT0E?%W"[MCS>0 5'7@L*]07]HZ_(!?X1?$95_[!49
MQ^ ES0!XM)^Q%XB7XJ:3JUIK>DV>@KX;30-1O_*EFU:;9IWV1)%=P0&W?-N5
M@2.#5WPW^QMXD\-^'H+JPNO"FG>*[74-,G@@M+*9-,2*SM9+8R;!\_GRK*S,
MX_NH.=N3ZG>?M(ZY&K_8_@M\1+U@A90;&WBW-V7+S #/J>E,_P"&@_'#7<4"
M_ 3QO\R!VE-SIP1.,[2?M'7M]: /-KK]AZYU/P=!I][J^E/K-IX.L_#EK?FR
M,@CN(;][MI06Y$<F51@.2"U+XM_8XU_Q[=^%K_5K[PQ826DEW;ZCI.C6,UM8
M?99[B&<O JL&^T!K<9<XW;N?NBO48?CGXYF;#_ WQ=&"!@M?:?\ K^_XJ@_Q
MZ^)#7'EVOP#\2G.[Y[S5K")6QC&")&Y//&.U !\<_P!F#3/CQXMTR]UJX TB
MST#4='\A=XFCEN&A*3HX(Y3RCD'@YYR#7%:+^QQJ1^)^@^+?$&N:?J"VNGV<
M-W;VUK+"%N;6"2WCDMD#A$1HY/F5E(!! X-=G'\</BU+/9Q_\*)N8&NRVQ;C
MQ/9HR8_OCG'X9JU:_%GXPW4!E/P12U.6 CN?%5JKD@^@4]>U 'ENF_L,:S_P
MA>K:/JOC32[F[FL=&T^TN(]!RMO%IRR)"3F3<7*N/F4J05XK<TO]BP:!X\\.
M>-$\3R:WKFAZ;9P^7?V^U;N[L[22WMY25;" EP6&#]WKR:[<_$[XR;X]WP;T
MU%8@9?QA ",_]LNM.3XE?&CRI&;X/:6&#E4"^+X<,O9L^5QGTZT 6_B;\*O%
M/Q;^'FF:+>Z_8:7<SV)MM<LY]+6^L+MY(U$A6-B"&C<%HVSQQUK(\/?LTC1?
M'UGJUSXAEU30+*=[^'2;NT#RM=26*64K23$_/&T<>=A'WF.21BKR?$GXTL!G
MX/:6#LW$_P#"718!]/\ 5?K6//\ &OXMVFIV6DW'PR\+66LWJL]O8W'CF$2R
MJIPS*GD[F [X!Q0!;\)_LQQ^%OBUX=\<+XAEDGTVPO+6XM(K98UO9)W)#N5/
M"(NQ%0# \M#QBM*Y_9E\,:AX<^).F7D,4MSXWDU#[5JL5M&EY#%=QB-HUDQD
MA0!C/![U2'Q$^.K"4#X2^'$;.$SXP!SZ$C[/6;J?Q"^/]C'/<R?#[P/8V4:^
M9+<7?BI]MO&!EG=O* P!D]N : ([#]DYWT;6[75/&]_JE]JMM?V\]Z+**$_Z
M59QVN55>,(D2D#N>M:_B/]EW2?$5WK-T^M7]O>ZE'+&;B)$+0^9906IVY'_3
MNLG/<D=A61%\1_CMJU_>6&E>&/AU>SV.!<[/$DTA ==T1*"/='N7##=U'-3R
M>+_C_:3Z;;WVF_"_3[C4)&B@@GU>\WNRJ6(0;/WAP"<+D@#- %'Q!^QU8Z[J
M-U-/XSUH64\US<BR2"$".6YNX;JZ96"AOWDD'0\+O..U==X1_9P\/^#OB]JG
MCRTG:2_O9KNX$$EI"/*>Y\LS$2A?,8$QC"DX&?I7"R?&SXIP76H)+JGP<6TT
MZ46M_>'Q#<JMG=,=JP2*5RKD\ 'J>.M=-9^(_CKJEQ>06=O\,9);.3R+D+J%
M](89-H8(P"?*2K*V#SA@>] %#5?V/O#^K^(M4UF[U_6)+F_DNV)S$6B6XN()
MW02;=Q4&W55!. I(JYXN_9+T+Q0=9<:_K>F-K5Q=R:D]D\8^TPW$T4S0-E>%
M#Q#!7#89@3@U+IVO_'356G-F?AA=I;2-;W#6]U?OY,Z_>1L+P1D9!P1FHV'[
M24FPH_PPMFVE60QZBX)SPP/!X';F@#TF/X=:4/B.WC5M[:H=+CT@(V"BQ+,9
M0PXSNW'K[5Y]HW[)G@[0_%":W;W>M-/#<QS6T$]_YEO:JMX;PQ1IM^5&F))R
M2><9Q6/9S?M#7^K3:9_PD_PNBN+41M=1V]E>23P*_P!UC&7&-P#8!/.*U8]
M_:#,:M-XO\"1OO*D)H5T1LSP>9?O=..GO0!9A_9=\,QW-I/_ &AJK7%LI6.2
M.8(PSJ3:AG('!\URO'\(I_@O]ECP?X'UZWUFUFUBZU*#4FU59[R^+YG,$D&6
M  !^21N2,D@$DD5 F@_'IX5_XK/P3YF1N(T"X( QV_?<\U(/#?QP\I2WQ%\(
M1C^)AX8E*^V";F@"?3_V7O!EEIMM9XU&3R+62T25[H[]CV\MNQZ8SY<S_C@]
MJY.']ER_F^+6IZK/KK6'@W[!<V^G6>E7,T-Y%-<PPQ3.2<HI"P AUY)8Y%=%
M_P (_P#&P3-&?B3X1W#!_P"18EW 'ID?:>_;UJAJ_ACXY2V<C)\7?"&E&-OG
MF'A4N%'HV^YP#R* /3_A=\,]#^$GA2'P_P"'XIHM/CEEG)N)/,DDED<L[LWJ
M6)/  KKV^Z<^E?/#^"_CI!) LGQK\*AKA]L"-X.&9"%)*K_I/S' +<>E79?A
MW\?+AX)(_B_X;B1&^>,>#@1,/?-QD?A0!4^#5T1^UE^T%:>4P51H4XD/0[K1
MAC_QVOH;(/>OB+X?>$?B7<?M4_'#3=.^(>F:9XB>ST"YN=1_X1Q98I8?)E54
M6(R_*1@C.3G/M7KJ_!_XY/O9_CS$I+%E$7A.U  ].6- 'L/C'PAI?CC1&TG5
MXFGL6FAN"B.5.^*598SD<\.BG\*WE9=O!'YUX&?@]\;RQ/\ POKCL/\ A%+3
M_&KLOP<^+#W<#+\=-12W\LB51X>L=Y;'53MP!GG!!H ])^)3AOA[XFY'_(+N
M_P#T2]>7?L(W F_8^^$S$@XT&!>/;(_I53Q?\&_B-'X2UQK[XV:U>VXTV</;
MC1+!!)^Z?<"1'D C@8Y'/-<3^Q;X%\2ZS^R]\+-0M?B+K.E6+:'$JZ;;VEJT
M: %@ &>,MV]: /KG</44;AZBO+-/^%'BJ*V$=W\6/$MW/DDRBULHLC/ VK#C
MCI5B?X4:\PR/B=XJ3UVK:<_^0* /2MZ^HKDOBW(@^%OC!B0572+LD9_Z8L:X
MS_A3VMS-+:#XK>.@<B8SK): <DC8#Y''3./>LKQM\*=4L_ OBD+\1O&-[-#I
M]S,/M5U;^7)_H[@1L%A!V\9/0Y[T >N^"Y5E\(Z(XQAK&!A^,:U/XCC:?0M2
MB12[M;2J%'4DHP KR_X?_"F2_P#">C:A+XU\8 W>G6S_ &8:NHBA)B4X38@_
MF:Z.3X6BV5I!XO\ %094(!?5691QU(V\XZT /^ P>/X+^!HY%9)$T6T5D;J"
M(E!!KNSU%>)_"7X9KK7PG\*RR^+_ !3(TNF0L9X=5>/>2O+8 XSUQ78I\(K<
M;2?$_BLD'OKDW/UYH SOV?(7C^&GERQ-$XUK6LQD=/\ B:76*[K1_#VFZ)<Z
MG<V-G';3ZE<_:[QT7!GFV*F]O4[41?HHKR/X3_#&WO?#%Z#X@\31^7K>KI^[
MUF9<XOYQD\]3U_$UUUS\&=/NK::&;Q%XL=)$*G'B"Y0C/H58$&@#S/\ 9>C,
M7QA_:/4Y_P"1VB;GWTVV/]:^CJ^0O@#\*=+OOBY\?K%]4\0Q)9>+;41M!KEU
M%(0=+MSEW5P9"=YY?)X7TKV&3]FCPU-:26TFM>,'A=P[J?%=_P#,1TY\W^5
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MK^%>5:M\>-8O9[%#IWAKPW"GBB#0VLXIEFU"XFAF0747E-'M",A<*X.1\O\
M>%,\,?M0ZWXNM(H?^$.T?P_J=Y/$+>\U2X$=LL$MK/-DL 6$@\@J < DY&:
M/5IOVPO@U;L5D^(>C(P4,1O?A3T/W:O+^U'\+G2"1?&=B8YV*1,(Y<.PZ@?)
MR:\QTWXW>(]/_9\^#^M_:]#NO$?C&WMXKC7/$DODZ="[6SS%Y2FW(8KL4#&2
M16!<?MD>(9=,U#6=-M?"^IZ:HN;6VMX;^<7'G0%!]H<''^C2EB4(4$@H>=U
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M\Q^-ER]K)\/V17);Q;8(=CE."LH.2.H]N] 'ID9RHI]11'" >@]*?N'O^5
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M);;TR2:F/C/0 ,G6]. ]3=Q__%553XC>%9%++XDT@J',1;[?%@.#C;][K[4
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MC1Y/+:RN(1M65B3NDC4=!ZU]3H=PR/6@!U%%% !1110 4444 %%%% !1110
M4444 ?G=_P %K?\ DWKP7_V-2?\ I)<44?\ !:W_ )-Z\%_]C4G_ *27%% '
MZ(T444 %%%% !1110 4444 %?/7[;ETEA\+O#EY*KM%;^+M&E=8T+L0+I> H
MY)]A7T+7@?[:;K#\*=&GD94BA\4Z*[LW8?;(Q_44 :9_:K\)_P!H362:)XSE
ME25X"8_"E\5,B@DJ#Y?)P#5'_AKOPHUL)HO#/CZ>'S/*$D?A&^(W@XQ]SKFO
M<]PY_E65-XHTBWTJ]U275;2/3;(N+F\:X40P[#A][YPNWOGI0!\J>./CA8:_
M\;O"&J6?A[QQILD7AO6[2*2?PG<.ZR2&VVN(6&9-I7.,8/ SS7/^ KCPAX)\
M<^$O$5OH'Q/G;0]+FB>&X\"7 DO;N;/G7<\RKN:5CG"\JH.!CBNI_:A^($%]
M<VFO>$->2X=O 'BZ73]6TBY601S16T+AT=2?F4KQCN*\QA^,'Q)^"UGX[DN+
M[4C?PVFA26VF:]J#ZS';VL[*EQJJS,(QL4L4:(X"LNYC@T 9^BK8WDWB-_$.
MA?&"Z>75]6OM$AL?!3B/3#=WIN4GB9DW,X"Q@JY*@Y&.:VX]/T:Z?PK<7'AC
MXV75U9ZF=4O;D^$H8WU2[EN/M#2MT-N2X (3: JA2.]=-X>_:E\>^(M=^'=I
MK.KZ+X-EU_1+*>.P;1+K46UJZN7E3=;NA'E)&$C=@P_BZXYK%O/VI?BAJWA.
M?4+J]B\&:=I^L6WA/7-;30I+W^S-1AAD:^N%A4DM$TWDQIV 8\T 78?#V@Z;
MX:L;%OA3\5M7UJQN$,.MG0[2*\D@261XK9G,H0H@D*Y/) &3WJ'[-&FC:);6
M7PH^-%GJ.C6FFVEGJMI9V$5Q;_8Q<*DB[I2OSK=3*XP001@9%<YX]^-/Q'\(
M^)_&VN:!J&H 7FG^$C<ZE<Z7*L5JLEC?NTJ6K*YB\R9(U<%25# 'G!K0\=?%
M'XG>+OB3\+--U^>_T$?VOX4U%=%TK3)S%J"2AS?327(7Y$CD*J8F(P!R#F@"
M3P_X370+[P_=67P<^-0BT;R"]NTFF(M_) LRPS3XF#,ZBX?!4J.AQFJK?#$3
M:'J-D?A#\<)KG4'G-U?G4=)CGGAE@,#6Y'G! AC.,A=V>2U=7^T=;:39?&SQ
M#=_$+2_&.JZ5=Z)8P^"AX5^UY6]65_M$:-#\D=P6,+*TGR[ W/%:4GQ-^,UE
M\6]2LW@U>/3[>[U"W&DMH9DL(],BTZ22UOA?;?GG>=8U9,G)8KM'6@#&\;^!
M+KQ_=ZU_:/P*^*,":@PN+E;7Q#I4,<H%HMJT0 N>=T2@$'G(X(K>\,Z7XD\&
M>)-'UZQ^"'C.2TT>*]N[:REUC3)KDW5WY:2L<W&.(X@ ,_Q-[5YRVK?&'Q+I
MWA=O%&K^*;ZRT?7?"&ORWEGI'E2O'=0LU[!)'$F7B@DVYP"5W'=G%;WP[\1_
M'[7;&33M>NO$>EF;Q-IUK=W::6ZW%O'*]S]J\EI(0AME40?.NX*3][DT >Y6
MOQW^)DWV5&^ 'B6%Y 6D+ZUINR-0< 9\[)<\?+@#WIFL?';XI6ES;Q67P+O9
M#-QC4?%.G6S9[84,^[\*\C^%GB[Q=X*^*.@>*_B4_BU+34?!EKI,QFTR1[.*
M_&IRPJ9=BXCEE3R7[9WL>F!5S]J3PW/>?&JPOH_"NH>(;U].L;:RM+G2IKS3
MK\I>F1XX;F!@UC<IG>7D^1D ]"* /4C\9OC-Y*D? .7SCSL/BVSV_GLS^E0O
M\:?C7&I9O@"J*.=S>,K0 #OD^5Q7A\WCOXMZT_C>X\/W_C'4[9-4O+6_QIX,
M5I!%JD<:KI;HF9)?LYGW8#'"[L9"@Z;/\5Y[73K35+WXAWQNM":+29M-TN..
M.:<27'FG4TF \L^68=N[:S $J-^%H ]53XV?'*ZGDAM?@5HL\B('VGX@VX.#
M]TD"V) (Y!IT_P 9_CE9WD5O=?!;PQ;&;/E%_B)&#(1V"FR!/X9KYW\.>$/B
M3X'M$NM/NM4T'Q7X_O\ 3?#UQ;:E-B2UC?3X?-NX%*[LVI2;Y5^4!N>E>U?M
M+>&[S7/'_@O3K/P+KVMQ20!=1\4Z;"MQ)96L=Q')Y$0:10LLCHI:0?,$#8SG
M% &Q:?'/XTS3WD,_PB\(VC68_P!)+_$:)O);L'46>5SVSBK&G?%OXXWQE'_"
MIO")NHY5#V4?CT-);Q,,H[D69'S<D#@D5Y1'\!]7\3ZG=V&M^"M5TD:1%K$M
M_KENUO(NNS27XNK1HE+EIB<$XF50A./2NZ_9LT+X@>#?&TVEZUX=:QT+4-)M
M]2N[RXB#21W)CC2.W,X<^:\2+Y;+M4+LW G=0!OGQ_\ M ZM+(=,^'O@*V\D
M!9H+CQ=-</%)UVL8[4 <$'IT-#^)/VE^"O@GX<<CH?$%Y_\ (]?.^N1^*[GQ
M;I/AO2G\2'QE/?>*[R\M="OQ:I]O6[LC9W5R78"2%(G7 .<J6P#7:ZS\._B[
M<:QXU(B\6?:9X+W[;=VNL0K:ZFK2Q/9KI\;2?NG1%D# B,$94MEP0 >E?\)9
M^TI)=/;IX4^& G10QA/B"\+@'HQ'D9 /3I6M!>?M&M:EY=-^&"SE=PC6]U(@
M''0GRN?J*X?X3_#'Q[H'C&74XM+?PU?ZEHEK;'4]6F.IQPQPW<Q>W=#/N65X
MWC92&=4P1N-<-#\"OB)+X;F@U7P->WSK=B378HO&#+/XHG F"W,1WA;=%+1R
M;25)Z;?ER0#VVXO/VD/+3RM.^%P9N"[7NID)QP<>4,\\8![U+N_:*91\GPPB
M<D<EM38=.>P[_I7D%Q\#_BM#%9W!FU'4]>N5FTO4]036?+6:S;1TC3;N;:I%
MTIPP3);YC@$UBP_"+XRZ;\,I;'2O"ET@O?#&J>'(],?7XX;JS>2:)[>[E)D>
M,N?WH(C8D #'WL  ]VMW_:0,KB<?"U(P,H\1U-B?J"!C\S2W3?M$%Y?+OOA=
M:1 @@R6^I.0#Z_.HKR+7/V9_&UUXEO=8N+:ZUG;+>O!G7Y(W=/[,M5M%V;@N
M%NH9<+VR&.02*IG]FCQ_J/B#QC-J=B^H6FNS6[W45QK"^1J43:C:3M&ZKAXS
M!#'.NX%=V< $&@#V"Z?]HB!HO,U_X5V_G2"*$-8:A^\<@D*,R\G )P/2IQI_
M[1^T'^V_AB0.3_Q+-0Y'_?ZKGQ;_ &<D^(T_@0Z7XGUGPI!X5U&"[AMM-N=L
M+Q1JR[0I!_>8.T.3P">#7LT*%(0IZ@=J /B+P99?&E_VN/B3#_;/@VV\1GPQ
MH[-<R:9=267DB248B3S@P.[=G)QSP!BO=X?#?QX?_7>.O!$7[GK%X9N7_>\^
MMV/EQCWK%T-W7]NKQ0FW,4G@.Q?<6 ((O91@#T]Z^@@@ QCB@#Q>S\+_ !U=
M9?M/Q!\&1L8UV>5X4N,!_P"+.;P9'I5J;PC\:"/W7Q'\*C_>\)2GM_U^>OZ5
MT?QK^*$?P;^'VJ>*YM&U'78K%5)L],BWR'+8W,3PB+U9SPH%=KIMVNH:?;7*
MC"SQK*!G. P!Z_C0!XY)X)^,\VE1QW_Q)\,N2K"[$'A-P'0J0P4FZ.T^YS]*
M\>_82T;Q=JG[*W@=]$\5V6DQ6QOK1TGTA;DL%NI@I&)5P=QR<^N*^R)8\QD
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MC1K'3;[5)/.O;BU@5)+IP20TC 98Y8]?4U33X8>%(]1L;]?#6E+>6$\ES:7
MM4$D$LAS(Z''REB 21U/- 'R;X4_:<\3:?9>!=/U:T\.Z[>:K-!9ZKJEKB*:
MV-U?36T+*F-GR;4^0%B<'(6NKD_:#\2^ /@Q\+];O-"C\<:IXCT=8Q<D".XO
M-2"*ZIM5=JAT69R> "F .:^AT^%OA&&Y@N(_"VCK<0-OBE%E'NC;S/,RIQP=
MYW9'?FM6/PQI<5E8VB:=:I:V)!M8!$NR @%04'\. Q''8F@#Y.7]K/Q!XO\
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M>M 'N+_';X<H&8^/?#(5&"L?[6@^5CT!^?@^U/A^.'P]GW"/QUX;<J2"%U:
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M\?\ @IM:]CR* /EKPDWE?\%'/'R<?O/A_IK_ )7;C^M?4U?*V@!8?^"DWBS
MYE^&]FQ/TO\ %?4PE&,GB@!]>=?'S4Y]$^&]Q?6I59X-0TY@67(_X_8<\?3-
M>A[UQG/%>6_M,-_Q9O6&4;F2YL7 ^EY"?Z4 >I)_%]:=4:N!GG^(T\,#WH &
MZ5\W>#+N2#]O'XD6H93'<>"](G((^92EQ.HQ['>:^D"ZXZU\T>&7C3_@H+XV
M_OOX"T]L=^+QP?YB@#Z848 I:8)%(X(I=Z^M #J;(/E-!<#O4<DJLAP>W!H
M^+/!/PAM_BE\:OVC/#VH:QJ.C16WC+2]9C;3GCQ,_P#9RF,2HZLKHK8;8PP6
M5<YQ7O5G^SKHL/CS3_%5QK6M7UU:72:F]E)/&MK<:@ML;;[9)&J#,IB)! (3
M.#MR*^;[[3_%:_'_ .-NF^#]0UG3SJOBW1'U&[T-$-U';-I$I8!F5MB;XH_F
M]3CC-4+NY^..F^#+>"XU3XA:I>:KI>EZA<7D,2K-87K07@GB"QQ ^7O2U)B3
M&UB-QP2" ?2T?[,OA4ZWI6L7-[JUYJMCKDWB%[B6ZP;NZ8@IYV!\R1[4"(,
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M5R0 ?E!SGF@#Y]U?XNQ^'-<U:TUCX+Z#/<.=.L;#1K4VMQ+)=S2W"RJ\D<3
M(H@W#Y<]MH-3VGQ:L?%'C7P'IVB?#+2- TO4=3L+/6I=0M+;[1$US82W)M5A
M\L$XV(#*#C((Q7NJ_LY?#M=#72!X1L1IXM4LQ$6?/EI(9%RV[=N#LS;\ELD\
M\UIP_!'P1!K>B:Q'X9L$U/18XXM/N50A[=8T*1[>>H5F7)R<&@#SG]JSP'X;
MTS]GOQI=V6@:7:7*VT)$UO911N +B(XW!<]A7O\ "08E(Z$ BO'?VQ%/_#,_
MC_:0K+I^X$G !$B$5ZOH<C2Z-8._WVMXRV#GG:,T 7J*** "BBB@ HHHH **
M** "BBB@ HHHH _.[_@M;_R;UX+_ .QJ3_TDN**/^"UO_)O7@O\ [&I/_22X
MHH _1&BBB@ HHHH **** "BBB@ KQO\ ;'E:#]EGXJ2IC?'X<O77(R,B,D5[
M)7CO[8<*S_LM?%5&) ;PW? D?]<C0!UEL;JZ^$<0M_,:[DT-?+\A 9"YMAC:
M,C)R>!D<XY%?.?[/KVGA3X9>(] >Q\23Z!?0K;PZQ;:)=V>HWET+%VNRP8LR
M,IC"+)PI<A5+=:]G\%_'OX96?@_0[>Y^(GA2&9-/M@\<FMVP93Y2\$%ZU&_:
M)^%"R,C?$OP>)%&X@Z[:Y ]?OT ?(7PMTJTTG0_!/B)=,U3PI81_$+[;)X:U
M6RNX6TJVDTFXB:+-P,R,T:F20H"I=V ZU[_HWB3X%:_X6^%_V.UT>]TKQ-;7
M&D>%(Y+$MYD#1L;B$ KE$*H0X; R,'FN:_:'^/'PS\36?@FPTKXE>$KB>;Q&
ML.8M;MV6(/9W47F-A^%5I%R?>O&O!_A3PYX5/A.0?%?X8RGP[!8Q:;$-<M_+
MLO,MG352HW=))=A7VW#B@#WCXF_!+X,?%'POH4=SX@TS1?"GAJ62S\C1[^UA
ML]K%6>WD/(0DJ"=I#<GUKO\ Q18?"?PYX8U34==LO#:Z/I%U)JUVUQ%%*+>Y
M$2R/*5.2)2@5L8W$;3CI7Q+X;\'?#;0=41/&'Q.^$=Y!Y8E;3K?5(Y;>WE73
M'LEF5-JJ2796VXR!GDGFK%WIW@._N+RQ'QK^&]]I%YMO[@/>-/,;\Z)'II&
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M"O"GQ@^%]Y\1K^[\!Z3,WBGQ1<:W!:KXB4&WCD51AF$9R21D8H ^K:*\@O\
MQ=\99+5OL/P]\/17)^X;OQ(Q0?4+!DU3CUWX_NH8^%? 29_Y9G6KHD?B(<4
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M%E;7<=D^E9TI8VTITE=LJ%%S]H9P4)W'*_+BOH>/]E>_B92_QE^)LP7M_;*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH Q?%NB#Q#X=U+3R>;B$HN?[W4
M?J!6/\+]2:Z\)VUK.OE7M@?L<\9X*NG&/RKL2,UBW_AQ9+PWMC,=/O6(\R2)
M 1,!V=?XOKUK.2MJ.YL#/7/'I3@<UGPKJ*R%9%MC&!PZLP8GZ8_K5U%;:-Q
M;'..E--B)**2EJP"BBB@#\[O^"UO_)O7@O\ [&I/_22XHH_X+6_\F]>"_P#L
M:D_])+BB@#]$:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHI#0 M%0.9-ZX&4YW'N/3'K4] !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 ?G=_P %K?\ DWKP7_V-2?\ I)<4
M4?\ !:W_ )-Z\%_]C4G_ *27%% 'Z(T444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !156&WE2^FG:
MYD>)T55@8#8A&<D<9R<]SVJU0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!^=W_!:W_DWKP7_ -C4G_I)<44?\%K?^3>O!?\ V-2?^DEQ10!^B-%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M ?G=_P %K?\ DWKP7_V-2?\ I)<44?\ !:W_ )-Z\%_]C4G_ *27%% 'Z(T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!^=W_!:W_DWKP7_ -C4G_I)<44?\%K?^3>O!?\ V-2?^DEQ10!^B-%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?G=
I_P %K?\ DWKP7_V-2?\ I)<44?\ !:W_ )-Z\%_]C4G_ *27%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>tmb-20221231xex10d22011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231xex10d22011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 2K Y4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4OPHQ41D
MY/S8_"@3>^?PJ>8"7%&*B,H]?TH$WO\ I1S 2X%&*C\[Z4&:CF DP*,5&)J/
M.^E',!)BC%1^=]*/.^E',!)BC%1^=]*/.^E',!)BC%1^=]*/.^E',!)BC%1^
M=]*/.'J/I1S 28HQ4?G?2CSOI1S 28HQ4?G?2CSOI1S 28HQ4?G'MBD\WW_2
MES 2XHQ47G ]#2^=1<"3%&*C\[Z4>=]*?,!)BC%1^=]*/.HY@),48%1F<>H%
M'G#L0:.8"3%&*C,U)YH]?TI<P$N*,"HO-'K^E*)OQHY@),48J/SOI1YWTI\P
M$F*,"H_.H$WOG\*.8"3%&*C\[Z4>=]*.8"3%&*C\[Z4>=]*.8"3%&*C\ZD\T
M>OZ4N8"7%'%1>:/7]*43>^?PHY@),48J/SOI1YWTI\P$F*,5'YU'G8ZXHY@)
M,48J/SOI1YWTHY@),48J/SOI1YWTHY@),48J/SOI1YWTHY@),48J/SOI1YWT
MHY@),48J/SOI1YWTHY@),48J/S3VQ1YWIBCF DQ1BH_-/H*3S>>OZ4<P$O%&
M*C\[Z4>=]*.8"3%&*C\[Z4>=]*.8"3%&*C\[Z4GFC/7]*.8"7%&*B,V?_P!5
M'FCU_2ES 2XHQ47FCU_2CS1Z_I2YO("7%&*B\T>OZ4>:/7]*.;R EQ1BHO-'
MK^E'FCU_2CF\@)<48J+S1Z_I1YO/6G?R EQ1BHO-]_TH\T>OZ47\@)<48J+S
M1Z_I1YH]?TI<WD!+BCBHO-'K^E*)O?/X4U("3%'%1>;SP?TI?.]<4^8"3%'%
M1><,]?TH,OO^E',!+BC%1>:/7]*/-'K^E+F EQ1@5%YP]?TI?.'K^E',!)BC
M%1>:/7]*/-'K^E+F EQ1Q47FCU_2E\[Z57,!)BC%1^=]*/.^E',!)BC%1^:3
M2%MO4TK@2TM0;QZT_P S%-,"2BH_-H\S'6G<"2DQ3/-I/.I7 DQ2U%YU D).
M.*$[@2T4U#G-.J@"BBB@#\FO^"X__(>^#_\ U[:K_P"AVM%'_!<?_D/?!_\
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MM% "8%&!Z4M% "8'I1BEHI6 3 HP/2EHHL F*,#TI:*+ )@>E&*6BF 4444
M%%%% 'Y-?\%Q_P#D/?!__KVU7_T.UHH_X+C_ /(>^#__ %[:K_Z':T4 ?K+1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'Y-?\ !<?_ )#WP?\ ^O;5?_0[6BC_ (+C_P#(>^#_ /U[:K_Z':T4 ?K+
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !14-W=PV5
MM+//*D,,2EGDD8*J@=22> *=#,LZ!T970@$,IR"#WH DHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R:_X+C_\
M(>^#_P#U[:K_ .AVM%'_  7'_P"0]\'_ /KVU7_T.UHH _66BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** (YK>.XB>.6-9(W&&1U!!'
MH1WIR1K&NU0 .@ & *=10 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% 'Y-?\%Q_^0]\'_\ KVU7_P!#M:*/^"X_
M_(>^#_\ U[:K_P"AVM% 'ZRT444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!^37_!<?\ Y#WP?_Z]M5_]#M:*/^"X_P#R
M'O@__P!>VJ_^AVM% 'ZRT444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!^37_  7'_P"0]\'_ /KVU7_T.UHH_P""X_\
MR'O@_P#]>VJ_^AVM% 'ZRT444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%(V<''!]Z %HI ,4M !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'Y-?\ !<?_ )#WP?\ ^O;5?_0[
M6BC_ (+C_P#(>^#_ /U[:K_Z':T4 ?K+1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'Y-?\%Q_^0]\'_P#KVU7_ -#M
M:*/^"X__ "'O@_\ ]>VJ_P#H=K10!^LM%%)0 9HK UCQ,EGJ4.EVT9O-3N%+
MK"IPJ1CJ[GLO;WJ[:VEZX5[FZ7=@;HX4PH/L3R:F[ TZ*8BLJ@%MWN:?5 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?DU_P7'_Y#WP?_
M .O;5?\ T.UHH_X+C_\ (>^#_P#U[:K_ .AVM% 'ZR&FN3D ?2GTR0\KUH \
MZ^%DG_"07_B'Q)*2TMW?/:Q;EQLAB.U5'XY/XUZ.!7G/P8MO[%TO6]%D:1KC
M3]7N58R]2KN71OH585Z/41>@!1115@%%%% !1110 4444 %%%% !1110 44F
M:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BDS2T %%%% !1110 4444 %%%
M)0 M%)FC- "T4F:,T +1110 444F: %HI-PI-XH =130X/2ER* %HI-P]:3<
M* '44FX4;J %HI-PI-XSB@!U%,$JGI2[A0 ZBDW"DWCUH =13=X]:-X]: '4
M4SS%I?,7UH =13&E51DGB@2J1F@!]%1^<N>]!F48YZT 245'YZ]C33.OU H
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M>C  E4(]L4 >NR?%GQFC +\*M<<$]1=VO_QRAOBQXT$1<?"O6R1_#]KM<_\
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MN.&!\XX&,<>U)_P@WQ5_TH-\2M.&] (BOA\?NV[D_O>:];CZ-_O&GT >-_\
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M_P"S5Z/10!Y>WQJO0?E^'_B]_IIH_P#BJ>GQEO7.#X!\6I_O:</_ (JO3:*
M/-7^,-VB%O\ A!/%9((&!IW)_P#'J1?C'=E [^!/%B YX.G9/Z-7I=)B@#S=
M?C*Y4L?!OBI5')SIC9_+-1Q_'"&17/\ PB7BL;2!AM'E%>F8HQ0!YH?C;'G
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M*L5YE%\1/%RQ0,WPXU0.X_>*MY;G8?3._GZBID^(_B=E8GX>ZLI'13<09/\
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M8^(?#UM:FVA9%.FRN2OEC@_O!W(J34=!^)4FEW*7/B7098C;2I*JZ7*NXE&
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MQ^9\0_"@8C]X%T"4X/M^^YH ]S"+V I/+7\.N*\,D\*?M P+^X\<>#+EL_\
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M*B,?[3WB9@PQ-X4TUL9Y!6[NQT_&O6: $V@'/>C%+10 F*,4M% ";:,<TM%
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M11WH\U>>>E #Z*9Y@H$JGO0 ^BF[AZTGF"@!]%-#@]#WQ2[A0 M%-+ 4N10
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M<=B=;LK'^QHK:]B@BCB<K+O15VL3*@.X\%6YX K[2A'4]LT ?/G_  4!0/\
MLA_$D$X_T.!@2,X(NH2#5IO#7QPN(HY+#QCX2739 GE12Z7/N$)4=3N^]C^=
M1?M] G]DCXC!>ILX0/K]JAKW$6\<VE+%-N*F)0VW@G 'I]* /!9-$^.UO>K>
MWGQ \&QP2.$BMAI$Q!^;& V[)+<9';%<-X)_9R^*?A35=6U'3O%/@ZU\37LL
MAN-7N=*GN;R2(R,0"\C9"'G"#@#&*^K?*L]5CL99[<Y1Q/")EP4<=#]:NOE6
M4!?EP<MZ4 ?.DWPS_:*^RRQK\4/"@,F <Z!(0GS9+#Y^3CM7DOQU\,_$SPSX
MO^"#>._'FB^(()_'UHEJ+71VM3!)]GG(8MO.0?ND<9W#TK[EC*Q.<@@,<Y)X
M]/Z5\S?MS6WVR;X%J\JP68^)&FM-)C)&(YBH ]VP* /:I-+\<N01K&B\'/-A
M(?\ V>L#XBZMXU\$>$-3UQ;_ $:YDM(T81&TD4,3(B]=W^T37J@D0<$@&O/_
M (_.I^$7B0CYMD*-@=\2H<4 61H_CO?*?[?T@J6^1?L#_*,YQG?S67K-GX\T
M'0-4U!_$6DS/:I+=JK:>ZKL5"PC.'Z<=>M>F*R8SP/K6/XUV'P?K9QN'V&XX
M49)_=M0!YSI6@?$OQ!I=CJ</CK3K2*\MX[CR%T;<$#J&V@F3D#-6;_P?\1%M
M+\R>.;*6$QNPC_LC!*[#P3OKLOAE(D_PY\+21HT:/I5HP5Q@@&%, ^];>JIN
MTZZ X)B<?^.F@#Y/_8I\.^++[]F/X:W&B^)[72M,CTZ6%[*73O-+3"YFW2;]
MPP.1QCM7N&D>"O'5OITD=_X_6ZO&+;98=(2-0.WR[SG%<7^P?%Y'[*?@.,J
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M"#KWB0Y.?^0JXH'P2TI4"KK?B, #'_(5DKT.B@#SUO@MIK*0=>\1_P#@T?\
MPIA^".F[]P\0^)@?;57Q_*O1:* /.U^"UDBHH\3>)\*<C.IG]?EJ63X/6TDA
M<^)_$P).<#4<#_T&N_HH \]_X4Q:?]#-XF/)/_(2_P#L:D_X4]:!&4>)/$HS
MW_M'G_T&N^HH ^9/CW\/+?PSJ/PCNTUG6=09?'^DJ(]0O/-3GSN<;1S7TTM>
M)_M.1^8?A1GHOQ TAN?^VM>V+TH 6BBB@ HHHH **** "BBB@ HHHH ****
M/R:_X+C_ /(>^#__ %[:K_Z':T4?\%Q_^0]\'_\ KVU7_P!#M:* /UEHHHH
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MH7Q4_:#GTW6;JZ\-:7J4L^FR2QW$#IJITN=&,3Y^>W^:4D$8W >M?8EL<YH
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M</6@!:*3</6C</6@!:*3</6@,#WH 6BDR/6C</44 +13=P]12A@>AH 6BD+
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M@;=W^T""<BOGG]O>WBMOA?X$4AB3\0="8,3D*QNLDGVZU]+I;H1 ]NRJ@((
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MGXP:*+CCRQ%X;RH]<YES6E^S2Y;Q7\;8ST3QQ<D?C;P&O=,4 ?/+_"GX]F%
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M4>F1J+6'SO*#2YQAMW\ ^;':O9E^'7B%@0/'VJ@C/)@B_P * .'_ &W4BD^
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M[?KFOHN@#B/'?Q4T7X>:KX:L=56Y,^OZBNF62V\+./,/=R.%7IR?6NU&"#@
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M]"2.!0![_P#$KX 7/Q%^(FGZTVMP6VC;+);^Q>R5IY#:S/+'Y4_WD#%R&'3
M]S69X4_9LU71;?5GU'Q):ZM=IHAT+0C-8 Q6$ E,J.Z$D.X<1\_],UKR;4OC
M7\0=,-GK9UV"6/4-(LK=YH;?-K;HNJSPSZ@ >.8C ",X&0>E7[KXU?%;5M)2
MZAO[;39[;2-'N&CAL#,ES+=:J]H[Y)&%$05\#IUZ4 >R?"_X"CX7>/KO7+?6
MFGTZ?2K?3ETX(5'FIM+S,<X)9@2,#@NW6N%M?V.'M8-"L%\4B+0K6YM9+ZSC
MLQNN([2\DN;-$?.8RI?:Q'4"N7O?BI\0!;6[ZO=#4TCUTK$EK9/$52UUB.WW
M':?FWQ,25Z=^E0)\=/B/H/AN8:YJX#SPZ+?0WZ:;M,8NK2:66$@G Q)&JACZ
MXQDT >J>,_V:CXV^*FL^(+[Q 4T#56M)[G28[8"7S[:"2*)UFSD#YRV/44_X
M;_LTGPGX%\8>'=7U[^UO^$ATZWT@W<,'DO';06OV>+/)W,%.2?PKQNW^-7Q"
M32M7U^WCN[[5[NUT[4(M/EM7V622Z1')(R(/O;9?-8J>I7'4T_4_V@_B.-!N
M-4TK5DO;#2K/5]0M[K^RV']LP6]U:QQ-C/R B65..I3(XH ]$U+]DBXUE=!E
MU?Q1'J4]C&+*=I+$(DMF/LY$:HI #[K93O.?O>PK?U;]FL:QI>BVT>O&V%C!
MJ-I*5@!$L5U=Q7/X,CPH,]QFLGXU_%GQMX8^)OAS2=$A*:?>6-I<V\*VC3?V
MA<27?ESP%QQ'Y<)$F:S1XB\4_#7]FSP]?PZO?75_=:VJZOK=Y;&>:TMI;J02
MS^6.R@* .@!H U=>_9,AU2_-];^(7M[R*".&W>2#>JGS[J1RRY&X%;QU]MH-
M:/@G]G"3P+XUT&^L?$9;0-)D>ZCTI[4;WN&M/LS.9<YV[?F"XXZ=*\6N?VC/
MB2GB#Q+;Z>UU>6EEX?GN+">YTPQ_:ECM&=;Q8\9):;:H7/0&CQWJ_CC1[7XE
M6BZ_J]S?23SM:7<=L0UM&^G6VUH@. I9I /0@]Z /6[;]GJ3Q+\19[KQ/:VM
MWH&E:_J6K:=%,@E6]2_@59$<?PF-]_U!%;-Y^SQ]L^)G]O?VQ'_9#72736!M
M5\]56 1?9A,#GR"!G8<]\5Y7I_Q4^)?AGX@Z#X7L+%KC0[>9+19KN)BU^HNK
MB*5]YY# )&<=,'-7/@3XQ\:^-%^+NIPZK-<>(3HNCSV<=Y:-%%:WILI7DA$9
MX.)/E)'KSTH ZN;X&^./#GP\UK0-/\4#6[2WT";0-"TR:(0JL4N$$EP_\;1Q
M_*N,< ^M=5X@^$6L>+O@MXB\ 7FIV]DDH2TTF[C0OY-K$(C"9!_$VZ-L^Q%>
M16G[1_CCQ#9W&HK"VAZ/]A@UPW5QI[.T%A<S);)N7_GK$\-V[+_=*&K?A;X]
M>-KW6_#=GJ,P2?49[1--MDL&4:Q:M<S)-<9/^KVQ+&^/?/0B@#N9/V>=4U_Q
M-9^(_$?B:+4M;CGT]95AM=EM]DMGDD:!5)/^L:3))_NBNO\ @9\'_P#A3WAV
M^L9]2?6]0NKUYY;^5-KM$H"01>XCB54'T]Z\G_9[^(OB?X@?&R6YUJ^N#;MX
M3$T^E?96AAL+LZA(A3)^\^Q!SU ]C7U-D#N* /G63]F'6DT7P/I5OXPVZ=X9
M\V86<]IYD-S<M<&5)W7/)0,0H/&3GL*^AH4*9W')ZY]:>7&>M)O7UH \._;/
M7_BQ%[_V&-'/_E1MZ]R3H?J?YUX9^V>"_P  ]2V, PU323D]!C4(*]S7C- #
MJ0D"EI* *MEJ$-^'>!MZH[1MQC# X-6Z:(U4\ #Z4Z@ HHHH **** "BBB@
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MKUORQ[_G2>4/?\Z /()?VAI?[4-E#\/O&%PP4MYJZ:0F <=32O\ '^]1B/\
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MV $%KVW ;(S@?-VZ57D^-WQ(BMGE/P6UIBO_ "S6_MBS<]OFKW/8/2C8#VH
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M?'Y>+&G:"!CYR;N7(/\ WQ6-^S0\<OP<T9XG:2/[3?A7=0&(^VSC) KU%@*
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M !1110 4444 %%%% !1110 4444 ?DU_P7'_ .0]\'_^O;5?_0[6BC_@N/\
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M&Y5O@9X]R.3BUC(_]"H ^C**^<&_:Q\4@@+\"?'C9Z?Z/'_\52-^UAXK7@_
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M?SKUR+1;."0R16D,;D8W)$H./3('2@#Q!/VVOA&]S%;QZS=O-(0$0:=,2?\
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MS-?S&5.G\+EA^%=VOQA^/L^X?\*4M$ )!+ZT@R/;BN\_9M4?\(5KWOXMU_\
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MS.#DDS=?RI!'\2QG][X;/I_KO\* /0,BC-<"O_"RBAR?#>[MAIO\*'/Q)^S
M*OAOS\\L7FVX_P"^: .^R*,UP2_\+)).1X;QCC#S=>_:D9/B7D[3X;QCC+3?
MX4 <7^VRH_X9C\<L> ((#_Y,1U[3II!L;?'_ #S3_P!!%?.'[5D/CBZ_9T\;
MQZPNA_9!:1/,]H\N]56>,L0&&.@-?1VF8%C!CD>4G/\ P$4 6Z*** "BBB@
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M"GKN25OQ6MOX??LU:UX,U33)-1^*/B/Q/H]G;M:OHFH)%]FFB,?EA6 &< 4
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M?LE^!+>?)^SI<VZ,3]Y$N)%4_D!0!]%[1Z4;1Z4M% "%1CI7)?%M-WPN\7C
MYT>[_P#1+5UU<Y\1)$B\">(GEC::)=-N2T:#+,/*;(% #OAZ ? 7AKH?^)9;
M?^BEK=E ^7@$[A_.L#X<R"3X?>&& (#:7:G![?N5KH)!G;]10!YW^SU%Y7P=
M\-H3N*Q2KD]_WTE>A3;50DC/!K@?@%&\7PET!)""X68''_7>3%=_,,QL/8T
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M*6BB@!,48'I2T4 )BC%+10 F*,4M% "8'I1BEHH *3%+10 4444 )BC%+10
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MT32WC<*<BTB(< <?P\T 85O^T!\.+J410>+]+FD(+!$ER2!U.,4QOVB/AK&
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M\-2^!@L;!M682#(QI4W3_OF@_M3>"/WAQK!\M=S?\2F;I_WS7KYC&?2@H"*
M/'K/]JGP/>F(1#6&:7&T'29@?3^[5V/]I#PG-=M;1P:R\JIYA5=+FZ9QUQ7J
M9BR<YP:##DYR: /([S]HW1[6Y\I?#?BBXBW &>+29-GN?PI?^&C-$:6)(M!\
M331R2F+SETF3:N.K'VKULQ9ZFE$8% 'A\G[6/A?^WM1T2RT3Q'J.LZ>D<MS8
M6^EN98X9"P24@_PDJV/H:L?\--67F*O_  @_C( \;O[(? K$\##/[;OQ34D\
M>$=!_P#1UY7MWB/Q)I7A.S2[U:^AT^VDD6%)9WVJTC'"J/<GI0!Y6/VG+0EA
M_P ()XRP.A_LAN:<O[2UE_T(WC%<]?\ B4-7IN@^*M)\4V!O=(OX-0M1,]N9
M8)-P$BG:R'T((QBM194+;<C<.<;N: /%]1_:2MKBSN(E\%>,8F>)U60Z2V%)
M4C/X5Y+^Q#\2!X._99\!VSZ+KFMRS"_DDGL;8RJC"[E)5O0^U?8-P@:"4C/W
M3W]J^:/^"=,T=Q^S'IBIP8M9U>-OK]NE//X$4 >GZ?\ '$:@^Q/!_B9""!^]
ML"O;/K4\?QE:62)!X1\1@RYY-E@#'KS7HSKC&#7,7OQ&\.Z6NO-=:O;6ZZ&R
M+J/F/C[.74,F[_>##'KG% '.:E\:7TPQ^9X-\2R*X)S#9;L8]<&L;QU\5[Z^
M\!ZY]D\'>(UGGTZY6$M:X*MY+D$\\<\5[!&!-$K9/(R#6/XN5[#PQKES$'N)
M%L9F6$G[Q$38 ^M '"?#[XCW2> ]!0>%M;?R=*M3N$ P_P"Y3[O-;,/Q.N[J
M:*,>$=>3<ZC<]N !SWYK8^& ,OPW\)N5*%M(M&*GM^Y3BNDD3!7_ 'A_.@#P
MSX"^/+NU^$^@1P>&]8O8P;D><D:XR+B7(//4=*[:Y^)U_'%SX,U\[CMPL(R/
M?K6;^S88W^$&E"*W-L%N[Y61CD[A=S9/XGG\:]1=,J>>M 'A7PZ\=:CIL'BU
M[?PAK-X\GBF\W)&JY3+)DGGH.M=?>?$_68(9C'X$U^>0$A$54&_@<YSQU/Y4
MSX-3":\^(,8;(A\5WB=.F8X6_P#9J]),8&?6@#Y ^%_BW6M%_:<_:!U&#P?J
MVH3W<GA\BS1D$D2?8W7))/3Y2<5[[=_$O6XHKIH? FNS/"H*(-B^:<] 2:X'
MX3_+^UW\>H^NZQ\.OS_UPG']*^@PH% 'F5G\2O%=U/<QGX=ZI (7 626XC"R
M#N5YKE/B)XR\176N^ _.\'75LJ>(8\-)<)R3!-TKWC ]*\Z^+,>[5/A^0 2/
M$L)Y_P"N,U $O_"<>*0S!?!%V5 X/VJ/FF_\)UXMQSX%N^F?^/N/K7H$0^2G
M8H \UF^('B]/N_#^]?/<7D8Q^M?-'PC^*&M^!?C;^T-J=SX4N+B*?Q)8F6&.
MZC!ML:>.N?O%OEX'K7W _"GBO@D7=W:_'']H==.G%EJ0\5:3+!>/$'2 ?V5)
MO?!X+A Y4>H% 'N]Q^U!>V4.ZX\%W5N[[DBBEOH@SR*5WQXSPR[ESGUI^J_M
M,:EILNFQGP1=3_;+DVFZ'48"(Y!R0?FYP.3BOF'QCJ&I^*K>#4EU"74;V_EC
MUJSBT^W^SGY;>8WRJ9/^6<P$:D'D.5(Z"G>+/"EMK?A:?18[.VM&U"&^N-'N
MM2!1-&CB*-YQ?/SL'CV./O;.1WJ;@?4%Q^T?JEKJLNGMX&OEGBNYK-V>\B"B
M2.!9CWYR' 'J:T+'XY:QK-RMG:^#9YIFR)42^CW1$*&8$?[(9<CWKY3MO''A
M[2K*7Q;X<MM1G:70&OKZ.]D;8TZQ%)1"KY;[1DKM;^Z .U=G\$O$7V_7? <*
MZ;<R:^T,L5\^]A'&GV:$O/,Q^^Y93CNP(/2G<#<_8G\<>*K7]FCP\ND>#YM9
MA_M;5D,@NTC"K_:-QG&?3I^%>Y0>-?B1+IIN#\/HX[A964V[:I'DI@;6!]<]
MJ\S_ ."<%QY_[+6E#G]WK6LIDCJ/[1G/]:^H*8'F5IXT^($[W:S?#_R?*C=H
MV_M.,B5@<!1Z9'-:2>(/&QA+MX3B7]V2(QJ";MV.!Z5W>*6@#S_5?$WC>S@S
M9^#EO)!&S!?[11>0.!GWK(F\??$B.T61/AP7F/'E_P!J1<5ZO28H X*T\1>.
M9K.W>7PC;PS,F9(SJ*'8WIGO0_B#Q\(G*>$[,R!OE!U%<$5WU% ' KK_ ([V
MKGPE:[C][&I+@?2FOXA^(' 7PC9XSU.I+G%>@44 >5VOB+XKL\GVCP;HZ#>H
M4IJN<H?O9XZCM4EMXA^*7G[;CPAI/V?'WH]3^;]17J%% 'D]_P"(_BW'/<"S
M\%Z-+$"OE-+JVTG^]NX[=J@_X2/XS&2+;X+\/*A8!]VK,2!ZC KU^B@#R&#Q
M)\9=O[WP5H ;)&%U8XQG@]*+WQ!\95=_LOA#PZZ;5*^9JC ENXZ=N/SKUZB@
M#R+3-?\ C+<7#K?>$O#EK"$RKIJ;N2WIC'2KUOJ_Q7D$GG^'?#\9#D)MOW.5
MQP>G7->GT4 >3#6OC"7M5_X1KPV%>-C,YU&3]VX/  QR"*M2:I\5U4[- \/,
M1T_TZ09X^GK7I]% 'FZZM\4?).=!T 28X'VY\9_*DBU7XHLJ[]"\/JW?%[(1
M_*O2:* /.K;4_B<[*)]&T"-=Q!*WDAXQ]*?#J/Q*9I3+H^@H /W86[D.3[\5
MZ%10!P<-_P#$.2!C+I6B1RYX474A!'Y5*EUX^)^;3]%'SD?\?$ARN.#TKMZ*
M .%AO/B";F02Z;HBP@C8RW,F3ZY&*F-SXZ )^PZ,YWX %Q(/E]>G6NTHH X6
MYU'X@*W[G1]'D'8F[<?TH_M#X@#&-'T;GK_I;\?I7=44 </!?>/I4<2Z7HT+
M;N,7+D$?E5.^U+XE107+6NB:'<2JW[E&O77>/4G'%>B44 ?,?[3&J_$&7X$_
M$*+5=!TNTTP:3(6NH+XLX7"DX7'7.?RKZ-T-MVD61]8(S_XZ*\O_ &MDBD_9
ML^) F#-%_8EP6"=<8S7IGAM@?#^FD=#:Q=?]Q: -.BBB@ HHHH **** "BBB
M@ HHHH **** /R:_X+C_ /(>^#__ %[:K_Z':T4?\%Q_^0]\'_\ KVU7_P!#
MM:* /UEHHHH **** "BBB@ HHHH *\6_;$N8[3]GWQ!-+-]GC2ZTYFEZ[!]O
MM^:]IKPG]MR!;K]FGQ5"S^6CRZ>&?^Z/MUODT >4KX=\::?X]C\1Q:7,]LOC
M+7PCP"07#R;I19++DX-L_<@<8CJ&Q^(WQ6N_ $-_J-YK5C9&_9;JZM;#-Y Z
M:<S-&58?ZO[7\NX<8 '0U](W'QS^']K/+#-XNTA)8Y&C=&N0"K#L?0U6G^/?
MPTNX7B;QGHTB.I5E^T@AEZ$8_']: /(=7UC4/%>F_L\ZEJ%P;_4M3T_4GGD7
MY6FE?1IB2,="3Z=S7C7A[PI\0-)MO!%E>6?B.^B\+V]QI$*W,S'[4MYI5S.\
MDH'WC&XCA4GN:]O\;_%7X>0_$?X,KI/B#2(]+TK4K]62&4+';I_9MPB_09('
MXBO5A^T)\-=ZI_PFNCEBP0+]H!)/84 ?/NCZO\3XT\-P2#5!H9MM,TJ?3A:X
MC,$NBNTTC'[P9;A5&<\<CO7,^%[CXR0^'_A_!;ZGKFBZ87T+1[NVBM5)BMI=
M(1II5W9(9;D!23TYKZF;]HCX:(A;_A-M'"J2"3<C ]J:G[0_PSD8J/&NCDXY
M'V@9% 'SYI/QA^*]K8>$++4;#7)]5UK2-!S-#89CAG%]+'?R2GHF81&2/?BJ
M&B^)?C>9='U.ZU/77&Z&XGL3:($?=KLUN8FXR!]D"-^35]*C]H'X<&$2KXST
MDQYV[DN 1G\*:/VA?AHS*!XTTDG&1B;M^5 'C'[2:>.+;XA^(4\'Z7>7EYKG
MA>Q\/VLJ%A;QSSZC()'9NB[8 Y+=1\M<(^B>+/#OA72?#/BSPMJ]_P"%?!/B
MB2:\TS3IGN3=Z5-;3/98?(:80S%589[ GI7U)_PT%\-GDV?\)II);)&!..W)
M_*F_\-#?#;J/&>E%0=I(EZ'TZ4 ?*HAUKQA^R?\ 'G3=$\,^(-$BEOU&C>'+
ML.MU:HZV[LJDG)0OO; /"Y%:WC'X7_%7X&:5JWB#P[J#70UO6+;^T=-\-1/L
ML+..WD4- CY.]I3'O(["OH\?M(_"\R,H\::66&2<.>WX4R/]IOX62PPRKXVT
MO9,,QDR$;A^5 'SKXO\ #GQ0\?W<EOKM_KES%IWBKPS#]@M4$5I<1_9+>6[D
M'<QB<ONR< @BJIUOXZ3>#?$DUHOB2VU*2/3+>ZDGB7?'J!O62Z:S7&/(%N0<
MGCA3ZU])R?M+_"Z(+O\ &^E#.0/WAYXSZ>E4XOVK_A%+(J)X\TLL>!\S<G_O
MF@#PKQ/H_P 9(M3\0V%EK'BE["UN-<BL)04)DBAT^"2P.[')>X\T9[\BK/B/
M6?C-<>(_%IL]-UZWBE\(7:P2;U:$WXL[>2#R5Q\C>:;A>^3QZ5[>/VJ?A-]B
MDN_^$YTSR$)4MN;J#@\8]:8O[6/PB:9XAX\THRK@,NY__B: /$O$7_"U]%U4
MV!G\63^%[7Q X%QIZK)?R++8Q20 $C!B2Y,BG\ >E=O\';GXIR_'_P 5P>)A
M>Q^'H9+Y@\ZYMIHO.067D'^$B/>6]<UVD_[6GP?MY&27Q_I2.O4%GX/_ 'S2
MM^UI\'XF&[Q]I0R 1\S]/^^: /7T)/44ZO)T_:J^%$B7+IXVTUDMUWRL-^$'
M3)^7UJ9/VGOAB\B1CQ?8^9(H=$P^64]"/E[XH ]2HKRJ']J+X7W$Y@C\76;S
M@;C$%<L!ZXVTW_AJ/X9LFY/$\,HR1A(9"?\ T&@#U>BO'9?VM?AE$#_Q/7;
M##;:2G.?^ U2?]LCX8QE?^)K>-N&?ETZ8_\ LM 'M]%>*?\ #8'PW:-'CO[^
M4/G 339R>/\ @-1M^V)\.44,;K4^<97^RY\KGH"-O!H ]OHKQJ+]K#P+->M:
MI_;#SJN\J-*GZ<?[/N*B3]K?P+)<>2B:VTFUFVC2)^@Z_P /M0![517C-S^U
M=X+M5W-;Z\R]/ET>8_TI@_:S\%,"1:^(#C_J#3_X4 87@;_D]_XI_P#8HZ#_
M .CKVNI_:+\!ZI\0=,\'6.F1RE;;Q+97MU-#MW00Q[R9 &X.#MXKQ+PG\=O#
MMC^UA\1_$<EOJYLKGPOHD"1)ILIF#++=DDIC('S#GZ^E>QG]JSP;LWFS\08S
MMQ_8\V<_E0!X%J'[-GQ4T;2+?3-+N[B5;?6M7N[F\M+E89-1EN6B:VO6' 4H
MJ^65' *9P<UT^E^'/''@C]I70[F_L+_41>MKLWVQ+XO#>0LEJUO&R'Y4:/,@
M]\''6O5S^U7X/_Y\/$7_ ()IO\*C;]J3P<SK(VG^(=RCACHLV0#VZ4 >Q'(M
MWSUVG^5?+/\ P3EF,?[-\:QQNV?$6K@E>@_TQZ[[_AJ_PI+<7-O_ &/XH41J
M-DIT6;;(2.B\<UX=^P'\5;'PS^SU'!)I&N7QF\0ZQ+NLM/:14!NF(#$=#ST]
M<T ?:J3F0SAD9!&VT$C[PP#D?G^E>._$SX+P^-?C#X'U];$3Z2AG&O1^9MBN
MUC3=9^:G_+0I,<C/3Z5M_P#"YK-KGR)-$\1^7* Z.FE. @')#'/6JL_QQL#\
MQ\->*6192RB/27!7:,\\]">!0!ZTN%49K)\6W<=IX;U.1R,"UFP/4^6QQ^AK
MS[5_C]:V.GRO#X2\5W$HV!8X=*9F.X9SC/;O5?6?C5:W"ZAIY\)^)S'Y##[2
MVFL(N8F.0<]NA]Z .Z^%THG^&GA*0#&_2+1L?6%*Z5^WU%>%^ _CC#IO@7PO
M:P>%O$VIHFDVO^E6VG$QM^Z48SGKQ72S_''9<"$>#/%#Y=%#K8'!W8YZ]!GF
M@"K^S"Q/PG@R<_\ $UU,<?\ 7]-7K,I.PXKYG^!7Q6?PI\,X+=?"'B.^!U'4
M92UI:>8!NO93@\]>:]!'QYED1!_P@?BP&0$@&PZ<XYYXH O_  9N8I;_ .(D
M:%2T7BN[1P.S&&!N??# _C7I+5X!\+/&EWH^H?$::#PGJUT;CQ3<S2+!&I9&
M^RVPVL,]< ?I77_\+HU!M6>P7P!XG)1-_GFU C/3@-GKS0!Q?PNE1?VQ_CG'
M@[_[)\.O^'EW _I7T+7R?X#\97MA^U7\:=4'A?5)Y'T/0"]K$JF5<+<X!&>_
M]*]S3XD:K+!Y@\%:VO&=C(H/\Z .]/2O-/C)*L5W\/F:-Y,^*K1 (^H)249/
ML.]:<GQ!U5(B1X-UAVVEMH5.OIUKRWXH_$GQ#=Q^#)3X'U73IXO%-CLCN)(_
MWP*ON0$' /..>] 'T/$P*#M3\UY'_P +;\5_9+>0?"S76D?.^+[1"#'C !//
M.>M+'\7O%TB?/\*=<B_>NG_'U"<*!P_7OZ4 >LR=/:OST\;6:WWQE^..%96L
MO&^BW>5)_>$Z+/&$*C[PPS<?0]J^KKKXQ^+[>* Q?";7K@R1;W474 \MO[IR
M>?\ Z]?*+ZCKGBOXQ?'J*'PS<6.H76JZ [6TEQ&);68Z7*D?.<'<3^6:3 RO
M#6G+H_PG\-R/:R:L]O9&WNI-==_M-R\H(BB1<_)_JDSCJ,&MR\U7P_XK^'KR
MSZ?!IS:AXBA\4)HL8>2<^5<^8T00G@W"12KMX&.HYK'\06-GKNF:5H%]X6UG
M[(9A>+%::FBRR:C"QC\Y!G.$)90A( &.N*Q_%^A:CKEA_;=EHMY;3P>*)=7^
MUZ1J,+6\(MXFCAM9#G("C<7'1MS5(%Z\GN;/6?%<&O1S0SZ?/<ZGI4Q5"(H9
M;5KV>W*#@O&CC*_WC[5W'A8:Y#XJT.PTJ*2\BM$T>ZMOL4BP 6DD8DFCE8Y+
M.,+$HZE5(KD+[PY?ZW?:A>#P-K'D:C<W5LIM+N,7+7EU"ZNQ.XC)48XX*X4=
M*ZSX:>']8T+Q%X4UC0]!U)M%U&R$8T<7-O(KLAW&;);<S#<ZDCIBF!ZU_P $
M\Y$;]G011OF*#Q+KD:)MP8U_M&<A3ZGG/XU]-5\6_L(>+O$&D? :==-\&W&J
MQ2>)M;=GAO(T",;Z3*X;GCI7T.OQ#\:,7!^'-V ,8)U"'FJ ]+HKS0?$+QGE
M<_#F\P>I&H0\4_\ X6'XO''_  KN^(_Z_H: /1\T9KS=OB%XQ!./AU>%?7^T
M(<TRX^(?C06K/;_#F[EF'2-M1A7/XT >ET9%>8CX@>/&,X/PXE.V11&?[4A^
M=".6/H1Z5'?>/?B%#.WV?X;^?"&P&.K0@D>N* /4J,BO+7^(/Q!C^R9^&KR>
M;_K"FKP_N><<^O'/%68O&7CV:[FB'@6&)%=A',^J1E74#@X'/- 'I.<49K@Q
MXC\=<[_"5I^&I)_A27'B'QR$C^S^$K4M_$)-23 _*@#O<BEKSL>(OB$L8/\
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MT ?6-A\,O!VF6CVUKX9TB"!R2T:64>"<8]*E3X=^%(HEC7P[I(C4* OV*/
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M_"5:RN2?O'[6U?4D4ADC0XVYP>:^6?\ @GTD:?L^ZDTI7$?B_6F!;LPO7 H
M^DIS>S:@ALV2&&.0"Y\Y"3(N,C8?Q_2L37/%6DKJMXQ\2VUA%X=C:;6+9W \
MM)(B8VD)^Z /F'K6]:ZQ'=W1MXTE)5"7<K@*>/E/O@@UX]\9_@E#\1/B-X.U
M!+9VTJ>62V\2Q0R!$OK2-"\"3#^-1,!QZ$CI0![#IUVDEA%<"3[26A1S/&I
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MQ\*:5=GQ#>:?<QWVFSD1^46\N[NXQ=2/C!/DB$X./X2.M4!]*?\ "T=< R?
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MC&77Y3RH]1VH ^:/CI\)?!FA^/O@E9V/A?3(+/5/%LME>1I  )(CI=ZVT_\
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M3DG-FG<8/;TI\/P0\ 02Q21^#]&1XD\M&%FGRKZ#BNXHH Y ?"'P2!@>%-(
MW%O^/-.IZGI3H/A-X+MFE:/PMI"&4[G(LX_F/OQ76T4 <NWPN\'MC/AC23C_
M *<X_P#"F6WPI\&V<(BA\+Z3'&"6"BSCZG\*ZNB@#E_^%7>#_P#H6-)_\ X_
M\*F'PZ\*A H\-Z5M V_\>4?3\JZ*B@#!C\ ^&8G5T\/:6K*, BSCX_2I1X+\
M/A2HT+30K *1]DCP0.@Z5LT4 9#>$-"<.&T73V#@!LVL?S =,\5)'X9T>) B
M:59(HZ*MN@'\JTZ* ,]O#VENVYM-M&;U,"G^E)_PCNE?] VT_P"_"_X5HT4
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M]>A_V#HP_P"879X_Z]T_PJ**RT*ZDGABM+&:6W8)-&L2%HR5# ,,<9!!^AH
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MEZXIDM_.61M.<*?]G/\ >]O:H/V>0W_"HM!#W NG!N0\H.0S?:9<UZ0Z@ T
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MBNE?/7;;L6]NM<G;^*?BJWBWPKITAUN2S34?[/O+EH?W=Q:_:[J)I7QT81K
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M!OQ@6W^3Q_I#3B7(#Z0-AC]#@YS2?\(3\7IKZ=F^(>FQVY(,:1Z0NY?4')H
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MM$@4#ZM@?C7IL/[/.M0N&/Q6\8N <E6N4P?TKYY_9:^$-]XF\8_'^Q'C?7[
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MN[H.M>US_'MH9+=%\#>+9!,S NMBN$P,Y/S=^E 'KC*'!!Z4D4*0J%0!5 P
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M" L<X7>P XQ74&X^,C&[DBD\'&(LP@!$YV@'C<0W.!UH ]:CLH8BQ1 NXDG
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MR#P'5D^0\'%9]_\  ;XQQ?""&T_LS[5XGN]B7<J:CB56CLIH()"W1MKLAY[
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M$:UT_0/'&O:=I^O>.]+UU;NZTB.XVPWEG'926405R"!)B1IAD8#,P]*JZ?\
M";QYX/U/_A,5\%Z5XCO-<358;WPL]VJ1:8MU*DD?E.1@J1'B3 &=QQTKZ_\
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MNZW=7"QCX;^)8U.-TDBPA1QG^_\ A6?X#.W]HOXK(1A6L=%?Z_NYA7KI0 4
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MTB1H=0G.KG9:.J@LLAQ\I (X/J*\YLO#/BWP=XYUJVD^'4/BJ2\\0R>);;Q
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M<L_W_L<V?_ F;BO>[D?N9/=3_*O!?V"AC]DOX> C!%I/P?\ KZFH ^@****
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M21OE9O++%%S@D 5V7[5/QN\!>,_@S>Z3H'C#1;_4[K5]'2&&.Z7)(U*W8GZ
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M7C#XA>5 TG@6U7S)-CJ-6&8EY^8_)TX'YTDOCCQBMQ+:CP[I/VR"(7$\+ZL
MT<9+ .1MR =K<GT- 'IFT #I1M!["O'O#7QAUWQ?YBZ+IWA[5I%4,4L];$A
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M8H9XUCED>72RJF,ACR#7VMM![5\P?M/O-#^TA^S"UN S'Q)J*-G^X;!MWZ4
M?,NM_"#Q.-*T.[TCX.>)-+UMI4O;Z,W,<WFS0%Q QEW[@7^1F/;;WS5SP[\(
M/$.F>$[*"Y^'/BJZU>*ZM]<NX+BVADBO-1AV[FFD,F90P#;01\A.>U?I4D2[
M!D#I08E.>.M 'YBWWPD\8:EX^NI+[X=>,KWPAY$LJ+<B#[7+=%_,A4LC@B.-
MQMSDDC!-23_"SQI?:'JYU'X8>)QK^KVKW$S)'!(L-Y#MBLAO+_-&L*DD8'S,
M:_3;R5].:#"O/!H _.:'1&\6_&#QUI_B#PEXL+2^$O"5P+/3HHH[Y)K2YF\N
M55W[47?#G&>QKT_Q%X%T'7?%NBZWJW@CXDZWJ5@T#M>S>41.T,[RP^8/,YV&
M1P/8^U+\8];\1Z'^T_XU_P"$2N9;/6KSPYX1L?M,$'GO#!+K%Y'/($((^5&)
MR>G6L:/XN_&2VUKPM9LVL7%V+BULH(&THB'5635;FWOI+A\8B"VJ02*> <Y&
M<T 3V_PTT2TTBZL5^&_Q+EN'N;4VU[)/"TUE]G:26)86,ORH#-)]=Q%;_A>Q
MT?PUX8\1>'=/^$WCZ+2]9T&/1+N!U@YMXXI8P5/F_?(E?GUK6^/OQ1^('A/X
MXZ'I/A:#5)=+/]E/*B69DM)4FO'BN 7"GYECV$Y(VCFO%K;XD?$F3QO+J>HZ
MAXM2R;2["R\27UKI$BMILPNKGS$M4V_O 6\E25!PISGF@#V77)M-\7>'_"^B
MS_!SQG)IN@$/:P[+>-9!]F>VP^)/F_=R-U[UQA^"/AO4/"EOX=D^&7Q N;+^
MT$O7>YOHC*S)$D*J[&3(39"@ [8XKA_ WQ#^.VF:YX"TW1H-5NHAX<M9HM/U
M*TD6&Z!M)VG:=RN%E\\1KAB",CBNG^$?B/XE:I\)_CQXATB[\2WGBMM,TR33
M)]=LFAF^V1V(-S'#&P&563>HP.>,9H ]BN-*OO%6@?V-XI\&>*==LY-=;7$2
MZD@"PA9C)#;L _,: * .<XK.\4?"+PUXM?66N?AEXBMAJ,WGSQV5W';J?W2Q
M2(NU^%D5$W+T8H">E<E!\0OB7\29=8U+PR_B/3+)-0UJ[T>*[L3!]HCATZR-
MI%(KC(1IVN, ]3FO/[GXE?&ZY^#'VMXO%<>KRZI=M8O!;L)PJ:?$_E2C;DJ+
MDR*AX!VGG&* /8[_ .&/ARXT.'2+[X9>(FTF<WV89KR$"-KH1AU'S]284*XZ
M$9J'4_A;ID=EX>C/PQ\4ZY/H4[W5L+G4(E$LYD67S)3OY(= 1Q5'XI2?$SQE
MI'PZUQ=!N+34-,BN-4M;:WE+K<W7]D2O']IBP C+/A54DC<U<]IWB3XK>)-)
M\S3;[Q=_9-E!K&H6-[>6HM[R]EBL86B@G0C.W[290G][ [4 =E_PJS13:?VE
M+\&]7DO6\-2>&/L#:A$0UDS;C$QSC)/1NHJ3PWX2M/#?PV\0>"D^%&NP6?B3
MS#J$$VK0RSW1>)5D8R$Y.  OX"N-L[CXR>&S<ZA<:AXNUEK>&:#[$4CQ(SZ(
MTY8<<LEV JGL1BN-LKCXS:IX:&HFW\12ZGIUSJL=CJEU$3=I8RVMH6,8/5P?
M/V;NK#% 'IOB+PB/$UU>+=_!+6M5M[O4+V\N%?68% EN8HHI6*\X.V)"!V(S
M51?!*RV^@Q6GP+U:[M?#C2RZ?>?\)%$'GWS+*X8C.X%UW$$]5KE--N_B=I>M
MZ ^@-XL@T._UJ\N;>6]MBTU[(^H(&^VK_"AM]Q3/  '>I-,USQY\!/A@FL3R
M:Q!I&DV#ZG)IEZPP\J:U,AM4)[S03)M7OM6@#J%\,7,&LZ=K/_"A=7MK^ROY
MKZS_ .*@APMS*SR,P7&#\[NP'8L:U[&7Q?9^'O!$&I?!C7/$-]X4>22SEU#7
M;=W>5HFC,LF5PQ*R,!D<5R&M6?Q8N/%NE6ERWB34_$.GJ-0TR81JNEYDTFX)
M,I!_UB7,FP9'\*]JZ3X):O\ %>+X$_$^]U:+6;C5HM/9]"AU*,I>_;!9GSMI
M).5\[:5_''% #_%'PS2[U.RU=_@5=SWTMY_:,D=IKT<2K-YB3@2+@ @2HK!>
MFX9[U+XA\ 6K>'X]+?X.W5Q/-:P)%96WB"-+J)()9)4=&P""CS/\P_O5SNF)
M\:]*^*7A?2DOO$5SI0TNSGN)KI!,DJM8RF[#L2%687&P*"#SM[9KFO"UE\7M
M<L="764\26M[);&QGULQYO7A>_M!(PR?W68_-RH)P 2.,4 >D:A\'K;Q)=PP
MWWP6NTCLM'72X93KJE/),9C*XV_?"LP+'U/K6UJWP]CUB;Q;#<?""4MKILI;
MV[75XT::2!/+A9&"Y1T4=1US7 :##\6[3XF_#Q9[;Q/?Z/9ZG=Z9<%Y]L:VT
M6H3K'/,V?WF^ 19R#D8(YK0^-.M?%?3_ ([:D?#=CXE_LF.T>WM9(,264B-I
MTC%P,X5Q<!.HSD=<&@#L]9\&R7'P_P!$\(7/PQN[70M(F%Y;-#KB1-:RQ[B)
M&DP""=[<^YS6!K_P)M?%_A^RT_4OA?J=XEG"]NLI\2D3SP/)YABDE RZ;LL
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M/!CR'+$Y.T* /:KNC?##P'I&D:KX+L]*M197BW5[=VS)NW"[D?SVWGIO8N,
MU\OZC\#_ !-JW@^YTR?5HK=86UZXTRT?70K6[S&W-CRK#[A27V7/%;;> [>Y
MC;1+C6]&A\,Q>(80ULNNI\VFI?3S,"=V>5D'RY]J /=O#_[.7P[\*6AMK+2
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M5^&'GK#_ ,)QHID8%E470^8"@#L=7\(Z7KT^DS:A80W4VDW0O;%Y$!-O,$9
MZ^AVNP_&LW4/A7X5U:"2&\T#3[F&6^;4WCE@5E:Z8 &4@_Q''7O7-7'[4'PK
MMW=7\=Z.&2/S&Q/G"_@/TJ*[_:F^%-D%,_CK25!(48D9LDC(Z#TH ZX?#+PR
M-1U:_P#[!T_[9JT9BOYOLZ[KE",%7..01U%.L_AMX;T[P[=Z#:Z'86^C79)G
ML8[=1%*2 "67H<X'Y"N.N/VJ?A/:&$2^.]*7S5WIAV;(QGLOZ5G#]LSX+?\
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M,\3,>Y:-E;/O5Q_VHOA<%.?%MN,#O;3_ /Q%$7[3'PRV*R>)XBC#@K:SD?\
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M\)O!-K)I7B&1CI5N%*:5(P/R#T_"O0;OXQZ?9^89-&U\B-E4E-.8@D],<^]
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MZ\VMOB_J,UNLDG@3Q'"^,F-HXR0?3[U-@^,.I2PEV\!>(XFW;=K1Q9QZ_>H
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M&"JR*>A.*]AT_P#9,^'5AX1UCPZ=*N;ZQU:YM;JZ:_O))YG>V(, \QB6"IM
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M8Q1Y)_NB@#Q#6_COHWAP6Z77PST>&4Z[<:1J4CS1"&U,?V8J^[9EMZW2#.,
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M&X6Z9_/%:F12T ?+W[7>F6UIXJ_9]%O:P1%OB-9JP2)5!7[/<9' KZ130M/
MQ]AMOPA7_"OGC]L.40^+/V>W)P/^%CV0_.WN!7TJO.?K0!0;0M- YL+4_P#;
M%?\ "F6VFZ7.C&*TM&56*'9&I (X(X':M"=!)$RG(##&1UKR?]F7PM>^#/AY
M?:/=PW<*V^O:J;?[<YDE>!KR1XW+$DG(;()[8H ]..BV '%G;_\ ?I?\*^4O
M#VEQC_@I5XR6.U2.'_A7%H.4 1F^V=<=^W/M7UUVKY<LRR?\%)+Y0R['^&@)
M7')(OTQ_.@#Z/M]'MA$ADMK=I=H#,(0 3CD_G5>]LXM/665(+.)(UW!Y%"X
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M:=XA:6140Q@#:%8R_='/-?;*6$,6W9$B!1@!5 QZ_P A^5*MI&B%%C14;JH
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MO@__ ->VJ_\ H=K11_P7'_Y#WP?_ .O;5?\ T.UHH _66BBB@ HHHH ****
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M(R!G[WN*SYO@'\.YT*OX-T=AC&/LB_6D?X#_  ]D?<_@O178+MRUFAXZXZ4
M6E^-'@-I"@\:>'2ZAF*C5(,@+]X_>[=ZKK\>?ARZ;AX^\,[?7^UH/_BJ;'\
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M$Y'M6:VH7OASPM?>+-=^R.4N+B*Z2*S=C+;^<\=OA0"WW64M@<]>E &'X_\
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MXX_%06WA*R^U7\HM] ADF@U#39#)>A;&5IIBWE\2I.BK@L 0.AS0!]:-\75
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MO!&1 &=5\SH3FNY^%7Q0_P"%ER>+MEJMO%H>NSZ.DBON%PB1Q.LH]-PEZ>U
M'?T444 ?/?[8[B+0?AC(?X/B#H?3WN,?UKZ#7O\ 6OG7]M7<O@WX>SA]@A^(
M/A\L?8WB+_[-7T1&<AOJ?YT /HIDC;$)]/2N$^#OQ)N?B?X>U/4KK2I-%FL]
M7O=,-G,X:1?(E,8+8X!( ./>@#OJ^8L8_P""C\1[M\,I?_3C#7TYVKY?NY_L
M_P#P4=TQ,J/M'PVN5YZ\7\)XH ^H:*0'-+0 4444 >8>'+8Q?M!^-Y>/WNAZ
M3WYXENQT_&O3Z\XT4C_A?GBD8Y_L'33G_MM=5Z/0!X]XZL[>Z_:$\$&YC=T3
MP_JY^7./]9:@@CN"&/%:VH+Y-_=W4TT#VEO"(]/M+?*3RQLG,>TG!;.W!'09
MK%^*&I7>E?&CP9)91&ZNI-!UP16V["R2(MLZ _4\5D^-OB#JWACQ'\/8X=.B
MU2SU?43:WDOG(?L#FW9Q$1G+2%EV[NWS$]: -7Q-]@_X6U\+[95=+NSN[\(#
M&0"GV)UR#TQC 'TKV1/NUX9JEWJ5QX\^%MQ>$2"?5[KS?*"E8]^G2.J9'969
MAD]=H/>O<T.5H ^:OV[G \ ?#Y_[GQ"\/'\[L#^M?2J]_K7SW^VN8!\,/#0F
MQN/C;P[Y61GY_P"TH?RXS7T(G?ZF@!U,D.-OU%/J.7HO^\/YT >3?LH9'P$\
M,JV,J]XN/3%Y.,5Z[7F'[-S1O\(M,,3(R?;-0P8QA?\ C^GZ5Z?0 5\U_MI0
MAE^",Q./)^)>DMC.,DPW*_CUKZ4KYP_;6C4Z-\))" 6C^(^BE3Z$F5?Y$C\:
M /HY>]+34.0?J:=0 4UAD4ZDH ^4/C1XRTKX7_M=Z7XPUMW_ +*TWX::I)=!
M1NP@U*S7('K^\_2O7A\=OASI&GZ9(OB&PM[._DDBMV2-EC#(ZHX?"XC(=U!W
M8Y8>M>-_'SP:GQ$_:LT?PLU[_9QUCX<ZM;BZV!S'C4;&3(4_>^X:UO'?['47
MC)-8A7Q/-8VNJ:K>ZC/;_94= +A[9\*#T93;##>C&@#TN;XX?#2+4]<L)M<L
MQJ%H\,6HVQMY#(&=_*B#+LRVYOE7&<]N*JZU\8/A;KVAW'AZ[\06,^FZII6Y
M[:)'*O:7#FV485>-[LR!>I.>.*X*[_96UYY/%TX\=/\ :]=U>WUDW9TY!*'A
MD5HH'8<M"J#:$X]:A\-?L:KX:T:6TM?%]X;E(;)K2Y-M&?L]S:W\EXDH7&""
M9=A4\8% '8^#?CA\-;G2O#^DVUQ;V%M//)I^G6LT!V_N)FMT9CC"!FC*KNP2
M1CK6QJ'Q_P#AO8Z'%J\NO6L]E=0P7<)MXFE>:.XWB)U15R=XCD]\*V>E><Z!
M^QRNB_V9'_PF5]/9&<7&LVK6\874V6]>\BYQF+;)(0=N,BLD?L.!/">H:&/&
MUX\306MEI[R643M8VMNTQBC''S,!<-\YYR : /;O&?Q5\#^ ]&TS4]?U"WM+
M#4\/;.;=I"Z>6',A4*2%5,%F(X&,UCZE^T-\-]&U74[2^UB.VETZREOYI9+5
MQ&T*K&TFQ]N'($D60N?O"N*^/GP9\1:SX+\'6OA@S:CK.C6%SH[7UQ<+'*\$
M]H('=]RE6W,JLW&1U%4[#]CU'U674+[Q==7)N-.GLQ T$;^5YMO#$P1F!)C7
MR<A3D?,: /1;#X\?#V\N= M(-0Q<:O;M/:0O8R*R1*Y4F0%?W:AU(RV!D56'
M[2_PV;P]<ZI;:S]KM%OX=/:.WM)'EDFF5FBVQA=S!U1F# 8(4^E<':_L;6=M
M;>!X&\6ZA<0^'+BXFF7RHU:Z$LC2&+>!F./YR-B\8Q5:S_8BTVP^'VL>&%\4
M723ZE-:E-1CM8EFCM[:-XXHQ@<E5E.'^\" <T >A_''X]:+\#_#&AZU=:3<Z
MT-;O8K"TM[4*DDCNA=!M;G)Q@#'4CI5OXV:K\/K'P?9KX[MDOM'N;^$V]E%;
M-<O<7,;>:H6.,$OM*%CVX.:R?BC^S?I7Q&\/^&=/N=>U'3AH=@^F&[5E:2:W
M>-$?<S [9/W:L)!\P;D&K-U\ +=OAQX-\/:3XBO]-U+PI@Z7K:[9)U!C:-MP
M8%7W1L02?KUH GO_ -I/X<V$VKFZU8Q?V=:_:KB9[*38454<JK;<,R"12R#D
M9Z5ROB_X^_"[Q_I3Z%K%E>:KH%]I]_?W@>QE_=BRGA26&2+&\/ND0A2.1CL:
MJ7O['&GWB:I;OXMUI].NDN'BMI65S'=7 C^T7!<C<S/Y9.#P-QQ6KXD_94TC
M7;_Q'=PZ_J-A+KDVH2W'D%?E-TEJK!>.-K6<;>^YL]: +Q_:M^&6GV>DRM?W
M21W8D2 +ILI,?ESK;%& 7Y")72/'<L*P/&/[0WPU\9:!JNG:]:RWWA34X+6Q
M8I;O)-=SSM<@VA@4>8& M),CVQ5K3?V2-)TO2Y+.+Q!?2>:[/(TB1XW-J,5\
MY50 %R\0''0&F:1^R'X>T7Q5#K U[4IIO^$IC\4^5/(N#/']L*H.,[1]M;CT
M44 =&O[2/PUT9-"M8]0:*POM.2]T^XBLW^S>089)$57 P&\N"3Y>HVX-0>'O
MVG_!/BW7O"&F:+#?7I\1W<]E!,;-HA R6JW0:0, 0CQLI5NAS7#K^P[H-M::
M-86_BC5(['3+&*SMX&\MF_=I<(&W$9 *W+9 X) KKM*_9=TO1?'FA>*;;7+Z
M.^TBXM94C!&R18M/%BR,/1T"L?0B@"3QO^U=X$\#^,4\/7$LT\L$UU%J%U!;
MLT-D;>T^TR*7 PSA"HV#GYA4FK_M5>"-/BFM8#=G4UL#?P6%W:26QF4(DCHI
M9?O*CAB,5B^*_P!DK1O%WBS5M;@\2ZC96.I7=SJ,VF6Q1H/MLUNMM+/G&<E$
M48S@$5'XA_9 T?Q7\4]2\;7'B?5/,NS(T5DK(T4)DM%MGVG&=NU0P&< YH Z
M:;]JOX;VBZ]]IU2:V31$S<F2TD57 G6W(B)&),2LJ';T+"I/B!^T!HW@FW^'
MTL.F75^GB^]:"!GC, M+=('GGGEW#Y1'&C':>3SZ5SNJ_LCZ%JFDWEG_ &S=
MHL]IJ%L9&5'P+N^CO'X(P0&C50/0UT,W[/F@W?A;P7X9FU6]N+#PPEPH228-
M)=1S6DULPD/7&R=\8]AVH YWX??%3X/^&=0AB\*:9/IU_KMVEN(;;294EG)B
M-PCD$?ZLH7<-TX/<5-XB^+_P_P#'OB/Q=\/O&&E$Q:/>M&J7$#2QW9AM1=.R
M%1PRIN.T<G::M>!OV;=-\(^(_#FL3^)]7UC4="8F'[=.IW0BU>UBC90!\J([
MD'NQ)-3>(OV;O#7B/5-4U*?4[M9M4U.?5D,-P%\J66P:R<1D=BC;OJ!0!)IW
M[1'PV\/:7H]A927%G8_;XO#]M!!I\A6VN"J".W8*#L)61,#W/H:N7'[3?P^L
MKF6V>]NC=I?0Z<+=+"4RRR2O(D>Q0,E2T4@ST^4FN,\._L>6?A"?1[K1?&&K
M64]AJ<NKRM)'%(D\\D$4);85VKA(L+CD9)J[X3_9%T;PSXCM-6C\1:I<_9;V
M&]CAF*-GRYYI@K-C<^3.X+$Y(QZ4 :47[5G@B7Q!J.G!;W[#;6=O<1W8LW(N
MY)KB2%(H4QF0YA8Y'&!6H_[37PU74Y+(:T&E6U2XDG6V<Q+&T#W"*TF,!FC1
MV"]3M(ZUQ\/[(-I8M/<Q>--934($M8=)O"8]VEQ03RS(D?&""9G4[LY&/2J'
MAO\ 91@M?'7B-M4O9%\%)!IL>E:>DH_?20VDT,DLY(SN#7#D<X.>1P* /1M8
M_:(^'^DV*SSZD\D;&QCBCBM7D:0W<+S6ZHH&26CB=L?[/TI?&OQNTGPEK7A2
MT.G2W:>(%B<7#XB6W@>>*+>X89X:="5XKS^;]C:QN_#>L:;=^+]5N[O49K)V
MO)8XCY26MO);PQHFW"[4D.".0P!S7<>+OV>]&\8GPR+[4;UXM%LH]/53)DW$
M:302_O#W+&W )[AC0!J^&_CWX&\375G;:;JX:XNRHMHGMWC,RLDCHRY7E66&
M0@]\5S^I?M5^$-(\.ZQKUQ([Z7;JCV#P*TCWX-DEV<(!E-J.N2>!D'O7&Z5^
MS%KEGXFNK4^+KV#1+"UTY=!OHO+^U69ACN(7A VX*^3.1D\YYJY=_L=:7!X;
M?2]&\4ZQIDK6<=@+OY)2(!81V4B[6& 7CB4D]=PH ]9\&?&+P]XXUZ]T/3I+
M@ZM800SW<#P,%B\Q5;;YF-K,-P! /&:X/]DF,Q^'_B(QQ^\\>:XP .<?Z1CG
M\JT_AW\ K/P#\3M9\76^KWEQ]OL8;!;!E5(HUC5%#G R[8C&">0"167^R8@3
M2OB<H&,>/M9[_P"VE 'N]%%% !1110 4444 %%%% !1110 4444 ?DU_P7'_
M .0]\'_^O;5?_0[6BC_@N/\ \A[X/_\ 7MJO_H=K10!^LM%%% !1110 4444
M %%%% !5+65WZ3>J,9,+CGI]TU=JGJ:M)97$:@DO$Z@#U*G% 'B_[$:&+]EC
MX?(1M*V<JD#U%Q+7N$R%D '4&O#_ -B6)X/V7? <4F?,C@N$;)R<BZF!_45[
MG0!\A?M.? O4;'PK\3?'5SKL-QI>GZ+K.KVM@MDB3^?)ILEN8Y)1@R0A"2%/
M.0O/ K4\.?LIKXAUFS\9R:WM&H7\&NBT,(8!6T+^SS%S[N'S[8KU;]J@*W[-
M7Q64IO!\*ZGE?4?9I,BNP^':C_A ?#('"C2[7 ]/W*T ?..A?L-R:1?^&)7\
M9W#VVGKHLE_"+.,O=SZ?"8582$;D5T."H[\U=B_8IEM]&\F/QG<IJ=D-)CTJ
MZ6QA$=M'ITSR6XDCQB4GS,,S<G KZDP*,4 ?/GPL_90@^&_CC2?$TFMOJU];
M6>I)=&:V11/=WMY]IEG4#B/! 4*N!@?6KA_9HO;#XC7VLZ+XVU;1/"^I:VGB
M._\ #EH$5+B^"A6/FXWK&^U&>,'!*^]>[XHQ0!\O:K^Q%::CH\=FOBN^MI(-
M'@TZWFB@C&V6'4C?Q3L,88AR$VGC&?6GZQ^Q/::UI26\WB6>.Z70/[&,\-G$
M@WG5(]1:<(!@$O'MP.,,>]?3V!1B@#YUU?\ 8WT?5I[VY.O:C;WDFL7VM6LL
M83%I-<7<%T-JD8(1[=< \$,<T:Y^R#%XF\1>&=:U;QKK6I7FC3PW!%R(V29X
MKS[4AV[<)AL)\N/E%?15% 'B.K_LRV6I?"*W\#Q:W>6ZVVL3ZS!?-&DA\V2Z
MFN"KQL"KJ#.RX([ ]16;9_LEV=A^SOX@^$J^)M5NM/U:5Y#J=XRR7,>^1)"H
MXP1E,#/8U] 8HH \?\7?LX:+K6D:);Z%.WA#4=(U)=5@U'28(U=KCR'MW9U*
ME6W1R.O([CTKFM!_8ZT#PW>Z4]GJU_\ 9[".QC\J0AC,+>"\BRS8ZM]M=C[J
M*^A101F@#YI\+?L9Q^$M$BM+3QKJ\]W;3:*UK>7,<3M!%IK-Y,0&W!#*[ D\
M\Y[5;\ ?L9:+\/O$)U>V\0ZM?W#:C9:@_P!M97W&V\X*IXYRLQ!)YX%?1=&*
M /$_AG^S)I_PL\1:'JNEZ[J<RZ9HDFA?8YG7RIH#<R3Q[L#(,?F%5QC  ]*Y
MB?\ 8JTS6]2U2?Q#XLUG78+C3[W3K9;CRUF@BN71VW2JH:4H4787)V@"OI/&
M:* /F[5/V,[/6=,5[KQKXA/B9]3;4;CQ#')&MQ,#9FR,1 7:$\DE< >]:UQ^
MR+X=G\.7NE+JFIPO*FBFVO4D436DVF<VTR'&-V>2#P:][P*,9H ^=]4_8UT/
M6M?\*ZQJ'B'6M1O]'6%+NXO)EE?5$BNQ=QK,Q&0!* ?EQP,=*Z7XF_LW:;\2
M?%DOB >(->\.WEW8IINHKHMYY"WULDGF*DG&>"7 (P<,1GFO8\4<4 ?/>I?L
M:>&=7U[Q)?7.L:PUGJ\>IB'31.!;Z?+J$1CNYH1C[S Y&<@'..M/UG]CS0=1
M=I[;7M8TV^&I6&IQWMK*HDCDM=.&GC&1R'A!W9[G(KZ!Z44 ?/6L?L9>&=1\
M,>%M'M]<UW2QH>@GPRUS8W6R2^TYF1F@FXPRDH#Q@]:]2^''PQT_X:)KZ:;)
M*T6L:K)JLD<K9$+M%''L3_9 B7 ^M=I24 +129HS0!\Z?MOA5^&O@Z1L%$\>
M^&V.?3^T8J^B8_XOJ:^:?^"@%U)8?!+1KF(#S8/&.@2)QGD7\1%?2R?Q<YY-
M "N"5XZUS7@GP)8^!EUM;!I2-6U2XU>?S7W8FF(+[?1<C@5T])0 =J^4O$<H
MC_X*4^#U(&9/A[? ?^!2'^E?5IKY-\81O'_P4J^'SD?)+X"U%0?I.N?Z4 ?6
M0Z"EI!TI: "BBB@#S;2E9?V@?$I+<'P]I^!_V\77->D"O*-.24?M0^(6Y\@^
M$=.'7C<+R[_IBO5Z /GO]H47P^+_ ,,3ID9DOUM-9>(_:/)1,);DO(>Z 9)7
MN*X:QN;75T\+Z?96,4A%S_;5C=7"-;>=J%OO28W$8/$1A8%,9R67->H?%A<_
MM!?"5@6!%EKHP#P<PP#!]AG/X5SMI::]?Z7X,O\ 5()K*X75(["\6^D3SY%5
M&5G4H"JB4@,0<< =S0!9\0P6GA[Q;\+=MC<6B2>)S96\JON^T*NGRQK+(?1@
MB@ \_**^A(S\H^E>"?$2.7^V?A(DUFNGP0^+(XK: -\V%M[@ D>A4$X]Z][C
M^Z* /!/VTV5/A7H3-CCQCX>P2,X/]I0=*]\0YR/>O ?VW ?^%*0E3MD7Q)H;
M(W]UO[1@P:]\3J<]: )*9)T'U'\Z?37Z#ZB@#S;]G@,OPPMD:)("NHZD/*CZ
M+_IL_P#^O\:]+KSGX!@CX>C*[#_:FI<?]OLU>BT +7S+^WC*MOX&^&LK$JJ?
M$70,D#.,W!']:^FJ^7?^"@[>7\*?!,@ZIX^T!A_X%"@#Z@4]?K3J:HQGZTZ@
M I#2T4 ?)OQYUJX\-_M3Z;J=I:37]_;?#'77M+6V.)I91=VF!&>N[!)XYP#6
M1^S-XN\37GP+^(?AN>ZU:XUG0;2XDM?%$BRO%>R2Q2N&M1(-VV-E4$'/S$]L
M5O\ QPU>S\,_MG_"?7-0E2VTW3_"OB">^NG&1#"/)^9L=MQ _&O2D_:/^&UM
MHD6I-KT-G9&:6V=98FC:-X_+,F]" 5 \Z(DGLX- 'RQ=W?B/0O!,AM-0\1Z=
M+8:%#<74L)FD>1&319KF0[L[I?GN0,<@;Q7<7OQO^*[>(=?LUN(;:![Z&VMH
M;?3FDELX9=4AMXY=Q3:P:VD9SDG!YP,5[HW[0/PY_MC6=-?7K07.EI(UTI0D
M,J,B2*AQ\Y#21*0.[**S-"_:1\%ZI<-%<&:PGEURYT.VA>W9Y)Y+<H&<J!E5
M!D7KTSF@#D?@9\2_'/B+X[>.?#/B&>_O?#VEB>.TFFL5AC7RYA&FYM@)=ERW
M!(8<\5XC\+-1\>WG@;X7Z/<'Q"EMX>UFWUW[2Z29O[*[NIHK>VE8_,6B5F+
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M.1R .IKUJ3]KWP NDQZF!K#6\U]=6$ CT]F>0VR&2>0 'A$0,Q)P<#I6E?\
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M@$$#XA:M@C_=AH ]VZTM)2T %%%% !1110 4444 %%%% !1110!^37_!<?\
MY#WP?_Z]M5_]#M:*/^"X_P#R'O@__P!>VJ_^AVM% 'ZRT444 %%%% !1110
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MI(S@QYSZ#WI_BSP-X.\7:AJ5X_ASXB6]SJ.K3ZC*_P#PC\<B".:&VBF@"NQ
M!%K&0PY!)P:\WOKM-8^*_P )+_PC;WFE1ZCX+\4RVCRH[745\8,R,JY/RD!-
MBITS@<BK-AJ>MO\ #W5)=0C\467AE5OG\,FR>^N)FU;[#9^6&8J)"AF\[;O
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MB%^$_C1P#C<L=J1_Z.IX^/VKE7'_  JOQ@)5Q^Z*VNX@YYQYW3@\U\Y6.O\
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MDG0?4&N/A^+WA>8?+?W!('(.GW(_]IU7N?C)X52$L;ZZ(W!?ETVY/.<?\\Z
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M% !1110 4444 %%%% !1110 4444 ?DU_P %Q_\ D/?!_P#Z]M5_]#M:*/\
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MZ\4 ?._Q ^.?Q9T?2[+4M-U)X#J7B75K2**YTS]W!%:.%@M\+&S,)6W#<?O
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M3XY7Q-83_P!GZGJ&^2TL7N;BZ60"RM=3OP@D9F)9C;/ 0W4@Y)S7N%K^R/\
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M0S^,-!13D MJ4(Z=?XJHQ? GX>P.C1^#-$3825Q8Q_*3UQQ[4_\ X4=\/_\
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M\,_C#K7Q#_:PT^PO]5L!IL&C:^K>'[)&\RT:#4+:*%K@DG<[IN=2 /E?CUH
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M !1110 4444 %%%% !1110 4444 ?DU_P7'_ .0]\'_^O;5?_0[6BC_@N/\
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MW+GCV^]0![5D>M?/'_!0,?\ &'?Q.(Y*V$38'M<1&NA=OCQLPJ^!@WJ5NO\
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MS -PR.#TK)^+GQ)^(6C>.?%-EX5O=!@T[P]X8@\02P:G922O<$RW >/S%<!
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MQL^)/AO6IK(Z9I5OIEUI,-HAW+!.)PS2L>KEHCTX  ]Z ,P?LF^#1IR6(O\
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MN J#@>E9%O\ LT_"_P SQ$8?#-D)=8F5[^2)V#AUD,J[6#9CP[,X"XP6)[T
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M]I6 (/K7B'C7X:KIGQ!^%FG#Q)XEN'FNM3@>\FU.5I0#I\IW;NS95<&O0O\
MA3L16,?\)9XJR@C&?[8ERVTY)//5NA]J .<_:4U2;1?"WA*Z@ \P>,]!CY&1
MA[^-&_1C7L:NH.,U\[?M(_#^/3O!^BSQZYKCM)XIT*(++J<K*A;485W*">&^
M;K]*T+!TDD3S[SQ05>>XDDGM;^X6UAMTF==[R,PP=B[B.^.* .K_ &EQ*_P+
M\8BVQY_V/*%B5 (D3&3VKTJW9O*4L"#M&?KBOE;X_II.H_"'Q*+36-5OKBVT
MIM0#KJT\L84M@/D-R,H1CGD@8KVV+X1:5>PVDIU37E\L;TVZO. -PR?XN>M
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M^,_[%U#Q]9_\*_%UJOA^:Q\FVM-<O;DI'=74D2I<F('RYC&@EV+G"RINQUH
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MO-'H-NB7U]J>O)<FRM_.F9X2H4;Y0C1J'7Y2 0> *O-8?!K3=-U/6Q\)M?\
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M22>M76\5?![4[BWM=)^%NM:\UTMN++[- J_:GEM/M?EIOE7#)"-S9P >,DT
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MC57"%CDKD'!/-=2+R J2)HR!U.\8KX.TWQ-X"T>]O],U#X930VE_K,^BV^A
M,=1EN/\ 1%0O(92BC$YSANF#V-: \3_ G5-5O;.+X::I/J"S_9K&U@;*ZE<"
MX%L\:LLFU2LHVYDP" 6&10!]Q"ZB) $B$GI\PI3,OK^M?"]X_P .]%\4:E+J
MWPRD\-:)IK:?->3:E)(]RJW$5Y)(@1)" RO:J!@X(8^M;<OB3X,Z!I4HF^'/
MB-;[S7GN-+E)>YMXH[;[8)B3-M"&$%@ V<@J1GB@#[-\Y "2ZC'N*074+=)4
M/T85YE;_   ^'.M6]E?1Z!"\3;;J%EDD ;<-P)&[D<]#3Y_V:_AW<)<(WAR%
M5G<2/LED7)]L-QT[4 >FEU SG%?/?P:Q_P -=?M$'_ICX9_](IZ[&S_9D^'=
MA (ET,S*K^8IGNII"IQC@ES@>U<'\ _#%OX3_:?^/=E8VIM+ 6_AHVZ9)&T6
M<ZG!/NI'X4 ?2 Z4M%% !1110 4444 %%%% !1110 4444 ?DU_P7'_Y#WP?
M_P"O;5?_ $.UHH_X+C_\A[X/_P#7MJO_ *':T4 ?K+1110 4444 %%%% !11
M10 4UR .:=37^[0!\^_LI2*=1^.$:GYD^)&J$CTS% :V/C#^T-!\(?&_AC0[
MC2A>1:N%:6<W0C:-6N8K<"-"/G;=.I()48!YS6?^S(0/$_QSC^4-_P )_=G&
M,=;6U-;WQ5_9NT#XM>*M+UO5;R^MS:PI:7=G:RA8=0MDG6X2*4$$@"6-6RI!
MZC.#0!6^+_QROOA9XHT&R;PQ/J.CW<]I!-J7VI8B9I[I8$@@C()FE&XR,@QA
M$)S7B'P9^-&M_#+P5H'@S0/!,WC&X%KKFN33QWZ6V(8M6FC=(PX.]_G! R*]
MZUGX ?V_XY\->++[QCKSZGH0G%LB/"(CYLH=LH8R,[0(]PP=G&>3GQSX/?L[
M6WQ(^'&EZM)XEUWPQJ<']NZ*[:'.L.ZWEU29Y%)9203M R,$9H ]2LOVJO =
MW!X?9KJ_CN-<T8:W8P?8G8SQ^0;CRD(&&E\M6.P$G@UF>+_VK-%TVV6XT"(:
MS:+9W%U-=.&CC0IIOV^( @'?OC(SM^[G'6BW_8_\):#XPT7Q/I$NH1WF@+;G
M2]-DN<V<)M[1[6%-NTL$V.<@'D\]:P_A+^QW9^'/A1X9T'Q'=^7K%DVJ7%V-
M'<I;^9?(T;QIN!;9'&RHGH$'TH Z;2_VL/!]_=:=I)EN)==O8HT18+61K)KP
MV0O#;+<XV%A'R>X[\\5RGA3]N/P]XF\#>$]770]5.JZO>Z/97>EQV[@V1U /
MY,VY@-\.8G <<$@BL;2/V.-:TKXNZ1<P:Q%;_#S2KW[?!8QSR^=))_9HL<O&
M?DWD98R#&3@XSU[S3OV-O"&DZ/86%KJ6M0_8;30[2VN$NP)(1I3RO;.IV\,3
M/('[$'H* (_B;^T\OP]^//AWX>_V9:W-OJ%O%/>:A)>"(VJR2.F3D;5VJA<A
MV!8$;0:Z'XC?&>Z^&GQ&\.Z?J5C#_P (=J^E:A<_VUYA!@N[6/SQ$PZ;7A60
M@]24-8_Q@_8W\"_&SQ!?:KK\VKPF_C@6\M=.U&2W@N7@#"WE=5ZO'O;:??G-
M=E\4?@9X<^,'@&#PCXD2>YTR&6WG21)BLP>$@J=_7) (;U!([T >*Z3^VU'X
M=\(MXB^(>EKH8EL-.O(])TQ7ENHOM4<TP$F_"\10EL#G@CDXKT5OVLOA\NIZ
M;IYU.<3W]V+:'=%L&UK/[8LQSC$;1'AC_%QUJ3XD?LH>"/BC?:K>:Q'?1W&H
M?9,R65TT)@^SI)''Y97[N4FD4^H-4_%7['7PW\7WVI7-[IDP?4- M_#<PCN&
M4&T@D1XL=PX\M5W]=HQWH L_"C]J7PU\7/&E]X9TNPUJQU"TLHKZ0ZI9^0NU
MT1PN"=V=LBGD8YX-1?$[XI>.=%^);^'_  EIVBWT%CX>;7[N/5)9(Y)@)WB\
MN-EX4X4G)!YIM[^RCX?@\6^(_%N@:KJN@^*M5M9;:"_BNFD33_,*%V@C;A"=
M@XZ#MBMKQ_\ L\:1\1?$%MK-YKFOZ;>KIATBY_LC47M5O+4N7,<H7J"S-TQU
M- '))^V1X2>3P_MT_6IHM;TN#5+::V@61")8995C W;RVV"3G;CCKS4/B/\
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M]4+CM3JC5@N[CO3MX[\?6@!U%)FD+@=>!0!Y1\79C:_$OX-2KG+^([F X/\
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M [G*/_H[CY?;C'US7IHF6@"2O.OVCAN_9Z^* SC/A;5.?^W26O0O-7UKSO\
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M\-_BC9^+/A'J45MXOU&+3KJ826^J:GLBALWO"1]I\J49DC@("@^8&  ;D9H
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MFVBHS$F1YVC(EY*L <\4 ?2(_9I\$KX9\4:"MG>1Z9XDTJTT?4(!=2?-;VT
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ME)>1.S$8P\<?'?Y@30!F7&E?'Z625D\1^ K5<+L7^QKJ3O\ -DFX':IU\/\
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MO2;F&XL/$/B2PG:*:"^>SO$@_M".283%)0B  ;A@%-IP2* /%-1N_ =K\&O
M'Q M;/QP+/Q9J'V(6E_XTU&%K,>1=2M(Y\P[@!;-P!SNXK5@N_@?/9ZM--XA
M\>11:392WT\Q\0ZJ+=UB6/S4AD,H$A4S1@@?WO8U[-)^ROX<E^&_@GP3)?ZG
M)H_A+5/[3L&:53*?W=Q&L3''*!+EP._RKS5"3]CSP?<Z!%HES=ZM<Z4D6I1"
M"2=3D7HC$A)V]5\I2OH<YS0!Y58^$?@3KGPHO?B#!J_CF72--NOL<L \5:G]
MKCN_,2-;;8+CF1G=% R0=PYJIX-\*^"O'/Q8TKP9HEAXW72Y=(NKW4KS4_%>
MJ1364T,XA-KL\XC>'^\<XP01G->])^S'X8'PNU3P-+/J,MAJ-\-4FO1,L=T+
MM94ECF5D4*K(\:$87'RC@UI?#OX!Z#\-M=36+"ZU*\U,V]Q#<7-_<F9[EIY_
M/EED)'+LX'/    % 'R\FM_!N_OH5TG5/&W]FV>M7.CZC<WWB75HS$T$,KN8
ME$QW'="R@-C/XT77B_X3Z3K]EIAL/B,+*WBN+O59;G6=3%WIS+%;RH94,_,1
MBF#YR0,=,DU[1?\ [&_AF"WUJYLM0U.XU2[\V:V.I7'FPQ3&.=4W!0&<*;AS
MDL6Z<\"L'X3?LD7;Z3XBU'XH:@NL>+-<6XM)9M-NI7CBM7M8+7 =P"SE(%.2
M!@M@9QD@&#]G\#7/@_XB^*A9^*XE\+ZX^BV]K+XIO@NH3A(!#M EX5WN$7&.
MV:74Y?A[:7&B6ME)K+>(+C58])U"VN]<U/R;9HYXX9^1(<,7N%\O< ).*]7\
M4?LV:=>?#GQYX<TB_N+6;Q+<QZG%)<OO2UOHDA$4B@ $#=;QEN3DYJ0_LQ^'
M-4UC6?$&H_:8M>UZ;2KW4S9SE(/M-E(DJM$I^Z&>-2W=L"@#PX>.?A)XPMK6
M:QF\3VGAFVO+N#4-2N=;U&UF006\LX,2K+ELF%@0V.V!R*W[CQY\&(X(+R[_
M .$UME"R17B3W-^ITQ4=8V>Z'F_N@"Z?,<Y# ]*[^Q_8X\$VSWOVB;5]16Z$
MJ,+N]W8C>*:+9D $[5G<AB2P(4Y.*LW7[)GA34/"VOZ-J6H:WJ;Z[97%EJ6I
M75YNNKE)I$D9F<*/F'E(H.. ,8H YOXB6WPP^%.HZ?I&JQ>*[V:Y2-I'LM1O
M;@6T4DHA269_-^56=@ >>A/ %<1X:UCX:W>E>%M'UVT\5Z;J^NQ[8$M->OI4
M:7SIXHXQ,9@V]_LK_CP3S7HGQW_9S\1_%3X@>'-5TGQ)'HNC000VFKVP63S;
MN*.ZCN%&0VUAE-N&'\1Y[5<N/V-_!=SK.GZI'>:W9W%BT<D*PWV KQM.T;<@
MX*FXD( P.A()H \D3QY\);[3[?5(D\8P:(@O;*9)M4U"._>[AEMK;9%&)<28
M><(7W<,HQW-6Y-<^"NAR:1(9_B!.-1AMHG>35=2D6P\V\-K"+G,W[MFG5DSR
M?E/:O2M+_8P\)V-AHMG>:UXBU>VT:)8;&.[O5Q"HN(;CHB+DF2!"2<D\^M<I
M\1?V/=3UOQMX='A_68M-\&"ZBO=:M)I)3<W,L6HG4$P0=K+YI*@'&P,2,\"@
M#A)M4TC2M&\.7UEX1U^^AGU.XTG4K>3Q??&=+X7?D/;6\9<F9A@RY.%6-3@U
MTGCF_P##'@KP?X:N+/2;B;QOK-W;V=UH,GB:\/V*7R6E<3^6S/E4B*C*\DKV
MS7>Z)^REYJZ#J^K>*];T_P 76,]Y>W-YH5T(8))KJY$\X5'5L [5CSUV9&>3
M7=>/?@%X=\<1O-$)_#6N?:A>KKV@E;:_6;RVC+F7:=V4=E.X'K]* /(_A7X/
MB^*-[JU]JOA35M \*11VUYI.IP^*;R234 T:2ME5D'RC=C/\6.E<3:>-O@;J
M&D7&IVL7Q"E,&ISB6"+4M0:=62$3R2%1/Q$(FW8SQ@C%?77A[P-8>&_ ]AX3
MM1*=+L]/334\V0M(8EC\OE^I8COZG->5^$_V./!7@V&XBLI]8E6:U>TQ/>[@
MD;6GV3Y1C&1%@;NN1DYH X3PSIWPVU/XI:9X*T6U\6:A;S"^9]<NM>OC;>9"
ML+O'$[3$R,/-P1T7! /:L-?#UQ-\0];\'S>$;B_M='O+*YFN])\6ZAYUK;7%
MPRQF<M(/G\I7F*@[0H KWCPC^SEH/@WQM9^);34-7FDLHIX[33[B[W6EL9DB
M69TC"CYG\E23GJ6QC-=-H7PLT/0-1\7WL4+W,WBJ[%WJ7VIO,#D0K"(P.R!%
MX7_:;UH ^>O%VO>"?"GQ7L?!MGI^H7MJ4LFN]3E\2WB1H;N9HH1'ABK$%"3N
M9>H Y-5_"WAO0+KX/'Q-\0-"\<^!KN'43IXT>+Q/J%Q=3.TPCA\O;*&?>SC
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MM !1110 4444 %%%% !1110 4444 ?DU_P %Q_\ D/?!_P#Z]M5_]#M:*/\
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M4\[S6+[1R:I_"?\ 9(NK7X;>&[?Q+<OH^N6FK:CJ\ME8S"YA@6>":VAM5D8
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MO\* /2-P]11D>HKS@> _' &?^%CW1_[A=M_A4;> ?'3!L_$N\!/3;I=J,?\
MCM &5\=R@\6_!IF<J5\9H%V]R=/O1C\C7KZL,#FOF7XR^#O&%AXB^$INO']Q
M>[_&,,:E]-MU*,;*[Y&!UQQ^->FCX?>.CO!^)U]\RX4C2[7*GU'RT 8W[6TB
MQ_ [6G*JPCO--DW,<>7C4+?YQ[CK61K]KHVBZG+X,U.ROM<TNZT.YLT,UA+-
M/Y;M+YL;3+]X2*<!>#A>O-87Q_\  'BS2?@UXCN-4^)NJWUM!#$SAM-M1G_2
M(B&X3J,<5V:?!;QJE_)<#XP>('9HVC DLK,A0<D$#R^H)X/M0!Y?\0UET#X
M:CH5]&=4TJW\-W\%_J*.I$%RMO\ N(/*&2L6?N<[E,8##K7TWX'DW^#M"9FW
M,;"W))/7]TM>%^.?@1XHTOX:^)(C\6/$4]FFEW;/ ]I:$29B8L&/E9(//YUI
M>$_@OXOU/PIH=S%\8?%5K'+I]NXBCBM=J9B4X'[J@#V[Q"P_L/4>1_Q[2_\
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MM%7&$'B"ZQP/]^@#TEL'CO3>./E)KS"?X#VD^?\ BKO&2 MNPOB"XX_6F_\
M"@;!I3*_BOQB[E=O/B"XQC_OJ@#U,@'M348'^$X[<5XNG[*WAM)/,7Q#XQ5P
MV\$>)+OALYS]^M&']G72K::22'Q1XQC>1S(Y'B&Y.XG'JWMVH ]8+[3C!_*@
MGZUY-=_LYZ/?7-O//XD\7O);DF(_\)%=#:2<]FY_'-5W_9@\-R;BVO>+RQ);
M=_PDEYG=Z_?H ]A!!_A/Y4X&O&T_9>\-%B7UWQ=*Y^\S>)+P;CZ\/_*D;]EK
MPSM(&N^+UY!R/$MYD>W^LH ]D)P.A/X4F1G[I_*O&1^ROX88C.N>+R?[W_"2
MWF2/3[]/;]E;PJ59?[8\6 -]['B6\Y'I_K* /8P1G[I'X4I/L:\:D_99\+2N
M[G6/%H=L?,/$MYQC_MI3(OV6/#L3EAXD\9'(Q@^)+K'U^_0![06QV/Y4F_CH
M?RKQY/V8?#P<L?$'B]\_WO$=W_\ %U-;_LR^&[6421ZUXL#AMP/_  DEX><8
M_P">E 'K9DP0,&EWX'0UY/\ \,VZ ;RVNCKGBLSVRA(F_P"$BN_E&2>F_!ZG
MK4UM^S]IM@ MMXG\80*#T7Q#<G^;&@#U'?GM07&>>/K7F[?!:,@ >,?&"J#T
M&MRG^=0P? N"V$2Q^,O&2I%G:AUR8CGU)Y- 'IV[_9-!D ZC%>/M^S3I#7"3
M_P#"5^-!,G(<>(KGCG/3=BKDW[/]C-)!(GB[QC \)<JT>O3]7.3G)YH ]3,@
MV\=*\#\&SB+]M7XE0$.QE\(Z),&"G;@7%VO)]<]O2NLD^!,<DDS'QOXT_>H$
M(&MR   YR/0\=:X7X9:#'X3_ &O_ (@:>M[J.I/=>#]%NC<:C.9V7%S>1[=Q
MZ?=!Q]3WH ^C1P*6D!R,TM !1110 4444 %%%% !1110 4444 ?DU_P7'_Y#
MWP?_ .O;5?\ T.UHH_X+C_\ (>^#_P#U[:K_ .AVM% 'ZRT444 %%%% !111
M0 4444 %(WW32TC<*: /G_\ 9^8-\=_VCT]/%.GL1]='L_\ "OH#:/2OGG]G
MS)_: _:2XX_X2?3>1U_Y!%KU]J^AZ $(%>8? 3!T3Q2-C)_Q5.K\.>O^DMS]
M*]/KR[X!G.C^+1D<>*]6[_\ 3PU 'J.T'M1@"BEH **** &[!Z4!0.@IU% "
M  4FT YQS3J* $Q2T44 %)BEHH **** $Q1@4M% !28I:* "BBB@ HHHH 3%
M+110 4444 <G\6U5OA7XQ5C@'1KT$GM^X>O/_P!BEMW[)7PB/'_(L6(X_P"N
M0KTKXB%!X \2^9;B[3^S+K= >D@\IOE_'I7F?[$IS^R1\(N__%,V7_HL4 >W
M4F*6B@!"*^=OVXW\KX4>&W/1?&WAPDG_ +"<-?1.:^<OV\&_XLSHOH/&/A[_
M -.4% 'T8O?ZTO6D7@GW-.H **** /&_VA-B:W\(F*@L?'5H%R3P3:7?/Y5[
M$OW17D'[0=NT^J?":1651!XYLG8'J0;:Y7 _%J]@4Y44 >3?M20)<_ GQ=%,
M=L#6\0D(!)V>?'N QWQG'OBO5T.<\YKRO]J.W2\^ 7C:"240QR6!4REMH0;T
MR<]L=:]34<GN* .:^*.3\.?%8&23I-WP.O\ J6J3X;-O^'WAA@20=*M3S_UQ
M2H?BG:?;?AKXMM_,:'S=(NT\Q#AES"PR*=\+5\OX:>$U)R1I%H"?7]PE &WK
M8SI%Z!W@D_\ 037@/_!/<Y_9'\!K@C9'=+S[7,M?06HJ'L+A3T,;@\_[)KP'
M]@0J/V6O"2)]R.6^13QT%Y** /HBBF[P?I06Q0!Y+HF4_:@\5C;\K>%]..?I
M<7 KUNO(=(64?M1^)I#_ ,>Y\)Z>.>F[[5<_TKUPRJO>@!V,UR_Q/7?\-O%B
MD9W:1=@C_MB]=*)E-9'BV%;[PQK-N1Y@ELIHR@P<YC88_6@#R3]AB0S_ +(G
MPH=B23H, Y]LU[M7@W["\BK^R-\*UX&-$B&!CCEJ]V\Q?4#\: 'T4PRJ.XH,
MBXZC\Z /F;_@HE(D7[-EZ7!V_P!N:-C:,G/V^*OI>W_U*?[H_D*^;?\ @H2S
M-^S)K/EX8_VGI61C/'VV+I7T?:R*+>/!R-@Z?2@"Q133(H[CZYH\Q?4?G0 Z
MDQ3?,7UI#.H[C/IF@"2BH_.4]Z/.7UR?04 24F*C^T)GDXH\\$\<CUH EHI@
MD))^4T[.* %I,4WS!Z'\J4/GL?RH 7&:6F&4 \@BE#9[&@!<9HP*;Y@YX/%'
MF#T/Y4 .Q1C--,H'7CZT>:,9H ?148DSVI?,'H?RH ?28%,,H'8_E2B0'UH
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MK=^!\0_A[$/[RZ!,3^LE?4U% 'R^/!G[6#>7N^)/@%.#NV>')3CCCK+S3/\
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M@_[B:?\ Q- _89\49^;]H[XJD^VJ)_\ $U];T4 ?):_L0^+E4JO[2/Q4 /\
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MAOY](T6P7^S]'\B""73[SSU>*,N3&A4[ H/'7)Z5?3XK_M&W%S+$OP/T"V1
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M*GW/'>M^+QY^U/*[LOPL\!6Z%PB+-XFG+ >I*Q$8'YTZ/QI^U6693\-?ATH
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MVX1_F"Z;>OYB_P#?8VYH ^C(L!:^:_\ @H9A/V;;N3=Y>S7]$?S,;BF-1@Y
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M,>MZO"8;CPX+@R2K?S"64MY@P'<,VW'&: /O'(]:"0.XKYL;X7?M)MMQ\;=
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M7O@:QD"97:1TZ8P/7&: /EC3O%%[K?B^S\26EAH\GB*]NKN76-:AU9IK$#8
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M.?Q- 'I9A0_PTOE+Z4X4M #0@ I<449H -HSGO1M%&:,T ($ &!P*7%+29H
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M"@,#0 M%)N&<4;A0 M%)FC<* #%&,4F\>M+N% !11NHW<XYH ,48I X-+N%
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M]93&YN,<T >)_$'_ (6E+\//%JZB/",%J=&O SVSW;./W#Y(S@59\%Q?$Q/
MFA#3I/"<L"Z7:"V-R+O<W[E.7(;C\*[OXKL$^&'B]F 95T>\)!Z$>0]'PHN%
MO/AEX2N$4(DNCV;JJ] # A_K0!PUWIWQPNH9(SJO@*.)B0P_L^\8["#E<^:/
MIGVS7+_"[2OB\GPR\)PZ#JO@JPT^#2XH5BN-.NYFWKD$Y\X<<=*^B)EW(1Z@
MBN$^!$HG^$WAIUQ@VN./9V% '+QZ1\>1(GF>)? ?E[ANVZ)=YQ[?Z17B?[(M
MI\3;CPEXR7P]JOA6U$'CK6%U%K[3KB7[1+YJ%FCVRKL!!P!S7VBW;ZBOF?\
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MCX%\":T+^'4/%>M1BSEL3I^M^(+B[LVADB,3(T#'81L)&".*N-^TGKRH[?\
M"B/B?\JER!:Z9D^P_P!.Y/M3H/VD=>N+43CX%?$Y%(9O+EMM-5^"!]W[;U.>
M/7GTH I_#;]BSX9?"WQ3IVO:-8ZK+<Z4KQZ5;ZEJT]W;:6'!5S;12,5C)4D9
M'0'C%27'[&7PRG^'.@>#1IU_!9:!=SW^E:C;7\D5]9SRR-)(Z3KA@26.1T(
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M/,U$X/K]T4Z1/VF?)$:K\+-^03.9=1''<;-GZYH W_VN,?\ #,WQ1S%YR_\
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M'>Z1:V?AZQG@)-S+;R,[F5VR!]G& ,=: /H <BEIJ#:H![4Z@ HHHH ****
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M **** "BBB@ HHHH _)K_@N/_P A[X/_ /7MJO\ Z':T4?\ !<?_ )#WP?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /R:_P""X_\ R'O@_P#]>VJ_^AVM%'_!<?\ Y#WP?_Z]
MM5_]#M:* /UEHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#\FO^"X__ "'O@_\ ]>VJ_P#H=K11_P %Q_\ D/?!_P#Z
M]M5_]#M:* /UEHHHH **** "DS],T'I5:&S,5S++YDC^9M^5FRJ8'\([9[T
M60<TM(.E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y-?\%Q
M_P#D/?!__KVU7_T.UHH_X+C_ /(>^#__ %[:K_Z':T4 ?K+1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y-?\ !<?_
M )#WP?\ ^O;5?_0[6BC_ (+C_P#(>^#_ /U[:K_Z':T4 ?K+1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%(: %HI@D4OMW#=C.,\XI] !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 ?DU_P7'_Y#WP?_ .O;5?\ T.UHH_X+C_\ (>^#_P#U[:K_ .AVM% '
MZRT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !2'I2T4 -"#.<"G444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!^37_!<?_D/?!__ *]M5_\ 0[6BC_@N/_R'O@__ ->VJ_\
'H=K10!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>tmb-20221231xex10d22012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231xex10d22012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 19 W8# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 444AH 6BJDNI6\%U#;23Q1SS9\J)G :3 R=HZG ZXJT#D4 +
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110! ]G!)<1
MSO#&\T>=DC*"RYX.#VS4V,4M% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3@$93H3T/>@#U>BO*+_]I_X>Z8P674=2D)9T(@T.^DP5.#G$/3/?O3Y_VFO
M%N$+:AJ9WP"X&W0[YOESC!Q#PW^R><<T >J45X]!^UC\.;G'EWNLL"VT'_A'
M=0 S_P!^*MV?[37@;4+Q;:VDUR:5C@ >'K\#\S"!0!ZM17F4W[0?AJ&!YA8^
M))(U5F)C\/7C=#@X'EY_QIH_:'\,^:J&P\3 E=V3X<O<=/7R\4 >GT5Y</VB
MO##,JKI_B=V9MH"^'+W_ .-TL_[0F@09SHWBQSG&U/#5XQZX_P">= 'J%%<!
M?_&"UL;9Y5\,>*[N01F5+>#1)O,D QPN[ SST)'>L\_'&7(Q\./'9_[A4?\
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M:K\:,D+X8\$GYNIUZ[Z?^ M1W.K?&U8F\CPMX(:7'R^9X@NP,]L_Z+0!ZX6
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M\22Q^5R>';]W\V!QC@'K4,_PD\8:C!;"[^+WB6&:*,([Z;8:=;B5N[%3;O\
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M,5S:WUQ'*AZ@^8<?H0?QKT$=_K41BDM %HHHK0 HHHH **** "BBB@ HHHH
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M_P"SM:NM1M,*+S;]IB8\,RC <>AQU]<5KQRAP2,CG'S"I:* $I:** "BBB@
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MD?P9\ !9MO@?PVOVB,QS8TFW_>(>JM\G(/H:TD^'/A5(EC'AG1Q&H "#3X0
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M:P<G@G;+G^5>D[AZT 0FRA8C<BL!T! ('T]*>D*H %R . !P*=N'- 8'Z>M
M#3%G^)OSIVP>I_.EW"@L!0 GE@]V_,TGE#^\W_?5.W#UI"P'6@ " =S^9I=O
MN?SI/,7UI!(I[B@!=ON?SI=ON?SI-X]11O7U%  $QW/YTTP*V<C(/6G;U_O#
M\Z03(3C<*  1(,\=:3R$SG:*42J21D<>]'FID#<,GWH 3R4_N@4>0G]T4[>O
MJ/SH\Q?[P_.@!OD+Z?G2^6OICZ4&5!GD<>]+O'K0 @C4$\4NP4!P>E+N'O\
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M@//?HP[<4RSA^-1>$7-UX!1"Q\TPVUZ2!CC;F3D_6O1M </H>G,2"3;1G/\
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MXC^&F=_E4+J4;$GL.#5#]D!@_P"S=X#=6#H]BS*RG(93+(01[$8H ]DHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&. ?I2TU_NGZ4 ?#
M6M_%'6O#?BOQ[X8\.7/CK0]7L?&5_>S:GX?\)IK5C.DT$4JPOO9?F"D'C&#Z
MUYW-X-TJU\+V?A_PQI_Q?T"[A\,77A?6+R;P,ERVH6]U,]T\FTR 1N99G<%2
M>&"]J^Q?@%(/^$K^,4()W1^,92?3YK2W;^M>Q+&1G)/6@#\\_'^N;O#'Q$AT
M/P9\4;W5O$.CZ59Z?%+X5^RC3+RPC*QWPG\TG*C#E<<>7@9W5ZM\/?V@=*\
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MH30!\Z^!;3XBZG>^*->L?V@?#5A>7%[!::BNI>##92Q720@1P/'/,I7,9#
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MSD$VY)!QC(.>#7M%% 'BH_8R^"6\N?ACX=9R "S6N3^II!^QA\$  #\,/#A
M.>;3/]:]KHH \5;]C+X(/U^%_AL_]N0_QIR?L:_!),8^%_AK !&#9 ]:]HHH
M \DG_9-^#EQ<Q7$GPR\,-+$JJC#38Q@+TXQBKNG_ +,OPETJR2TMOAGX32W0
MY"MH\#GGW92?UKTVEH \TM_V:_A/:AA%\,_"2JQ+$-HMN1G\4JP/V=OA5MQ_
MPK3PACT_L*U_^-UZ'10!Y\O[/7PM1LK\-O"*G&W(T*U''I]RI(/@#\,;5P\/
MPY\)PNIR&CT2V4@_@E=[10!Q9^"GP].W_BA/#7RD$?\ $GM^".G\%1R? OX<
M31B.3P#X8DC#F0*VC6Q&X]3]SJ?6NXHH X=?@9\.(\[? 'A9<\<:+;=/^^*1
MO@5\-V.3\/\ PN3_ -@:V_\ B*[FB@#S^3]GOX6RL6?X;>$78G)+:':D_P#H
M%'_#/7PM 7_BVWA'Y3D?\2*UX/J/DKT"B@#@3\ ?ADT8C/P[\*&,+LV'1+;&
MW.<8V=,U+'\"_AQ#:"UC\ >%X[8.)?(31K8)O'1L;,9'K7<T4 <D?A=X.L89
M&MO">AP-MY:+38%/'3HM<+^QV"O[-W@9"=VRUE08]!/( /R%>PW8S PZYKQK
M]CBV-C^SMX5M'V"2V:]@<(" K+>S@C!Y[4 >UT444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4USA3]*=36^Z?I0!XY\!QCQU\9P-X'_  EV
M>>G_ !XVO2O9:^:?A!X_TKPA\6/CO'KNJI:0R>+H?LL;*[;?^);:[ONJ<9.3
M7JQ^/G@!02WB2W4!MA+1R  ^GW: .L\4C/AG5Q_TYS?^@&L+X.'/PH\('K_Q
M*;;_ -%BL/6_CAX#O]%U*VA\2VDDLEM*@55=CDH>P6N=^$'QF\$:%\*/"5I>
M>);9+BWTJWCD5TD# A!G*E<@T >WT5Y^GQ\\ 2$!?$ML22 /DDZGI_#3)/V@
MOAW$P5_%=BK'^$[\_P#H- 'H=%>?#X_> 2KL/$<#*C;6*PRD ^GW*>?CMX&
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M@56Y*J2"BN=QR !CU'M74:!]KB\/0+>W7VR_^;$ZQ)"9OFR"J= 0"!^%?/\
MI-I^T#X?\,V.AZ=\./A[;:?I]N+:R#^+[V5H0%*J0SVY)(!X).?>M6V\0?M'
MV\%M&/A]\-W^S 1H[>*;HL#C!Y^S=2* ,K]@5X[?P;\4K2%TE-K\1M>C:4(5
MW_Z1D$Y]1CZ5F?%3]H3Q#X=_:2B33+Z^D\#>&Y--TKQ!:0V)DLQ+?,^^>:Y
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M=J+SP!<1L=H^VV+$YQP+R$]3]*[I>!^)H XGXSSVUM\.=:EG.ABX6VD^Q?\
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MIX4$8P@TNV"CV\M:C^(OCE? 5G97TT,,EF\WESM)>) Z*1U17QYAS_ "#Z4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /)?VJR!\ _%A.>(H3P<'/GQUZRO3\:\F_:L&?@!XO\ :WC/Y31UZR*
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MVJ'POXVM[P*'M_&^NHFS^XUXSKGWPXH ]OHHHH **** "BBB@ HHHH ****
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MK>@M.;5=3L9K+S@N[9O0KG'?&:\*_:O5C\8?V;MO3_A-CDGT^QS5],(HV]*
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M7<D\4<K77V."?>W^KEYD\R,$AD4-Q6Y:K)IMAJ?AV;2;C3]2FD,$5_J&I+-
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MBO\ S1@8P'\W.WVI&_8C^%KHJO9:^V#GGQ)?G\#^]Z4 >]^>OJ"?3(S2&Y0
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M=-_:BLM:\9V?]E^!M)-C>W5AH]K?3S1K?/=7EI]H@;R0F3;9*HS@Y'S-C"T
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M\/?$_P Q VD6@(Y[CSZ9/\2]:$;%/ASXGD8(6"[K,;CG&,F>O0-H]*/+7TH
M\OD^*WB2."9E^%?BF2=1^[C\ZR <\?Q>?QU/Y5\_^,/&GBC4_P!LWX0:A=>
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M QZ?NJ@O?A#J-[',I^(WC" R@*6@NH4*^Z_NN#7IE% 'DLGP'NYRI;XF^/<
MY(3543/MQ'_*M>'X2+'-*[^+_%TP9B51M8<! 1C P!]>:]"I: .!3X21"$(/
M%?BW@8R=;ES]<TP_".)[=8#XL\7<$'S1K<H<X]2*]!HH \U_X478&8R'Q3XR
M+&<W&/\ A)+H#<5*] V,8/W>G?&:J7?[/6D7DCO)XF\; M(LA\OQ3>*,@8'
M?&/;O7JM% 'C\_[,_A^<Q;O$?CB,1H$_=^+;Y=WN<2<GGK4J_LW^'T5 =;\8
MR[)!(-_BF].<*%P?WG(P,X]>:]:Q1B@#S<? GP^A+"_\1KNV\#Q!>8X.?^>G
MY^M/_P"%%^&V;<;C7R3ZZ_>8_P#1E>C44 >=CX$^&@,>?KIYSSKUY_\ '*>/
M@=X:W,3+K;;EV\ZY>=/^_E>@T4 >=I\"/"\<BN&UK*YX.NWA'Y>;2K\#?"R
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M_AY.\2Q^,-*=I9#$@6?.]P,E1QR:MQ?&CP7/&9(O$5I+& 263<1@'!Z+Z@T
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M@#T N!2[AZUY^WPGN78D^/?%XYZ+>P@?^B:8_P )+AD"GQ]XQ&#G(OX@>O\
MURH ]"WKZBC>OJ*\JN/@//<R,Y^)OQ 0%R^V/5XE SVXAZ>@IH^ DRHZCXE?
M$!MV.3K2Y&/3]UWH ]7+@4;A7FD7P9:*WCA_X3KQNY1F8R/K.6?<N,$[.@Z@
M#'/K4C?!F-[.2$^+_&/F.BH;C^W9!(-O\0XP">_% 'I&:3?[&O/(/@W;QW<M
MP?%?B^0N%Q&^NR[%(SR /7/-,C^"MFES)*WB;Q?(SYR'\03D#Z#/% 'H^[V-
M)NXS@_E7F=S\"-+N9B[>(O%P)7:53Q#<@=<_WNM67^"6D.A!U?Q*?FWG&NW/
M7_OJ@#T,/GL:/,!SWKRF7]G^U=D\GQKXZM1'NVB'Q'-C#$G'(/ SQ39/V?K:
MXFBDN/&_CJX,<7E*&\0R(,>IV*,GW- 'K.[V-)N]C7D4O[.5@[R2)XU\>PNY
M!_=^)9_EQV&<]:</V>K%(HT'C'QRY1BVYO$D^YQM(P3Z9.>.] 'K$I#H1@XQ
MS7D7P?)3XM_&:(Q;$_MBR<,!]XFPB_\ B15F+]GS3XK(6\GBWQM<E7,GFR^(
MY]YR/NDC''M67\#M.71/BC\8=.2XNKE(]4L)!+>3M-(=UE'P6;G V\4 >VT4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AI:* /G;4]!TW
M7_VW9;74].M]2A/P[1PEW&LB*1J3#A2/UKU:Y^#7@2\+&X\&>'KC>-K>9I<#
M9'H<K7FBD_\ #>C#G'_"M ?_ "J&O?J .(C^"?P_MG62'P-X;BD3E6328 01
MW'RU\Q?V;;Z-I>J7=EX2\)W]K#\5)-)NI-6T^.1[>SFN+=&6W39C<68=2,=>
M:^TV^Z>U>'?!;PI8:_#\2+/6+&.\MXO'][>PQS#@2(8)(W'N&P1]* .=_:$M
M--^'E]X!GTGP)X.OM/U[Q;8:+JTU]IR-<*ES,(P8@$VLQYRS$8'8U!\;[GPM
M\(O$6G/:_#SPMJ>F#2+BZFL1I]O#<3S?:[2V@6.1EVHH-T2Q(.%''H?=+WX<
M>&M1M5MKG1[>>!=33651P2%O4<.DXYX8,H/X4[Q#X!\/^,+J.;6M)@U%DA,*
MFX7<-AECEQ_W\AC;ZJ* /FR7XH^#]'@O6O/@OH<$NE-.NMM;_9&6V:*\CM6:
M+,0,R_O!)DA<*"#\V!1'\6_"%E<WK7GPI\/V/AJ6:<I>L;42+9VMY]FNY[J
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M:]NC\2Z3+,D2:E:/*XRJ+.A8C&>!GGBO _%/@S1?&G[9D>GZ[I%GK6G/\/9
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M/-:5(0/'NO9CZEH[4[_][,5#?#S6)89(G\>>("'7:65;567G.5(BX/:NZHH
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MA ;SYN>PH ]-&/\ (I"1C!'X8KQ^Z\4^(+;QG-X6D^(F@0:U#I7]LO:2>&Y
MRV@D,;3$_:\;=PQCJ,>]1^%/%>O>+](TG5=,^)WAB^T_58VFLGCT!HS<HI(9
MD5KS) (/(':@#V/Y!V'Y4HD4]Z\@OM1\2S6YOD^+7A>TTV*98I9ET>(QAO\
MGF7:[(!/IUJCJEAX\O-1^PV_QIT+3[^54DAM(O#MNTNS!)(1[DDA@"<^@XH
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MR1Q-;;MH$8+S( [$!ADXQ6"WCNQM=2TNPD^%GA>&_N?%$6ASV)L8'%K:M>-
MTGFJ/F<!2>@'3Z5]$7?P0\&7]_K]W<^'K6>;7HVBU(.S&.Y5L;BR$[0QVJ2P
M .5!SQ3#\"O [VD-L?#=H4BG2Z5F9V<2I*)E?<6R6$@#Y)Y- 'C7CGQ,_ASX
MKS^%=+^'7A:YM;:[T5+0O;Q(]Q'=+=&89VD1E6MU"G!ZFLJ+]H?PMI]K'K%K
M\+M.M;*XATL2SD0_:#>WY<1Q%(X6)6/RWWR'K\NT'FOI+4_AQX?UCQ);Z]>:
M1;76L6YB,5ZP(D7RRYCY!YVF1\9Z;C6;'\%_!<.EW>G+X8T_[#>" 3P&+*N(
M<^5G_<R<$=,T >,Z9^T7H&I^+?#NF'X?);/J*VJ7A:V!FM7N9YH8=H\K#QYM
MY"S,R8!7@G-?1$/A/1HTPNCZ>@R<A;6,?TK&@^$OA&'4]*U!?#M@M[I40ALI
MQ%AX$#%L*?\ >8GGN3ZFNQ P* ,3_A"M &<:#IGW=N?L<?W>N/N]*E_X1+1>
MO]CV&>/^76/_  K7HH HC1+#O8VW' _<KT_*E71;!>EE;#Z0K_A5VB@"B=%L
M/^?&V/?_ %*_X4HT:Q4$"RMP#UQ$O^%7:* (8K2*!=L421+Z(H _2G^4A.2H
M)]<4^B@!AA4_PC\J-OMFGT4 -V9]:-OU_.G44 9'BB/=X<U1=Q&ZUF&0>1\C
M=*\D_8D/_&*GPV&XL!INW/KB5Q7L/B(9T+4 1Q]FE_\ 0#7CG[$7'[*WPZ''
M%BX^7I_KI* /<ZJ-J-O_ &B+(7$?VKRC-Y&\>9LSC?MZ[<\9Z9JTZ[A@5Y@?
M /V']H./Q?;Z2H6[\.R:=?:H'^9F6XC>&,@G.,>8>!]: /3PO'4U\X?M30O_
M ,+7_9VE4@>7XU;YG!P,V%P.O:OI =OI7SG^U3"%^)/[/UV4D(@\;#,@^X@:
MRN%^;^F.] 'M<#78MHIB8)W+,-L+%8]I?@]\G%:T</V.V"J7GV#@R-ECSW-9
MO]H+!]GFDFCBA"8902J@DC!(.,#'KZU<FFA,ZV[JS2/$Q"["05& 0>V>>E '
M/VFO>'O'UE&UK>V^M0VNHF'S;8L5BN(R>,J<;E(//0&MO:\859$'E*ZB+!Y4
M8X+9(YSV%>=_"GX>WOPXT;6]+M;&+2[*?Q1<WUI;Z?L$:6DC*02O  .&R!SD
MYYKN(-2@U:QN6COS!$9&@5UCV-"\9VN,MP?F'&0/;- '"W%UJ'_"Z/!T-WM)
M>RU;*VBL8M@:'9O+#A\''!P2.,]O6D0 =!FO,]<U6Y7XT^!K6"XE2SGT_5!-
M$<XD9##M)SZ'./K7IJ]* /,/C'>?8=:^&;"W%PLGBN"'!7)7=;7(W_A7IT:
M*.!7E/QUFEMM4^&!C<H6\8V:$CN##< C\0:]748'% 'DW[1[>3X0\/2*H++X
MLT(CCO\ VC!7K(4<\=Z\M_:)N39>"='N0BR&+Q/H;889'_(2MQ_6O4UZ'ZT
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MO^(],\/&QCO[RUM6O[E+.V6XE"&>5ND:9^\V 3@>E 'A'Q<^)S>(+KX;R_\
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M!.?GCY*\$ GL:H']G]H?!WCW0(-2@@B\3:?;64(CM=D5J8K40%MBGG)7/'8
M=JM> ?@MJ?@OQWXFUP:Y;C3=4M_*@TRSL]BQ2G:7G9F9OG)7HH53U()&: ,F
MV\=Z;_80U&3X]Z=-9071M9[]8;%8FD.2(\XP#@'GG.#6YXHOKOPK86TVM?%^
M'1(;YDBM;B[M+.,2.>0$W#YB0<\=!7!^#_V3=2T6Q>+6?%%KKDKPM \KV&WS
M%-M/!N8%B-W[X'C X( &:Z3Q9^S]?:[X2\#V5IKUM:ZSX<TIM'>]N[#[5'<0
MR6Z0S%8RPVN0@(;)QR#G)H ;XA\;Q>%[#5'U#XUVR/ITB)=K'86DDUL6=$ =
M$Y'S2("<<;AFFVWB:_O-0L[.X^,#:/J-]<S6UGIU[I=E'/<-'(T1*+DDJ61L
M'OTZ\5AZ-^SAJM[8WMKJ-Y:V-G8W=Y_8\1M \I#F(1S3R!LRY$>2O'."<[1C
M4_X9LO1J3O%XAMEL+^;?JT)TX-+*J7TUW$()2V8B&G*G.X$ $ 'F@#8\-2:M
MXPOK^QT/XWVVL7=B=MU!9Z=8RO =Q7Y@O3E6'U!':NE;P+XZ*@+\2[A3GJ=%
MM3QZ=*Q?A7\#!\.O$]IJL=[;SI#I,^FLL5KY3.9+UKD-D=AN*X/?)[UZ_0!Y
MQ+X"\<-T^)MV@R#QHUI^7W:Y+X<Z=<Z9^TG\08[O4)=3N)-!TAC/-&B'A[@'
MA0!SUKW,\@UXOX6PO[5WC@#.6\,Z8?;_ %UQ0![31110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !2&EHH ^>_B0\B?ME_!@!SY;Z%XA!3MD"
MUP:^A*\"^)=NO_#7GP6G).Y=(\0(/Q2V/]*]\W4 (_"GZ=Z\1TSP%IGC;QE\
M:= U5)9-/UBYTUKE8Y=K$?8H^A'*\QCK7MKG*D?RKS#X?+L^,WQ3;:N2VE9*
MYR?]$/)_QH L^.?@/X5^(^GZW8^(]/.LP:I#+;AKXK,]BDD(BD%JS F'<H&=
MO4C/6IO%/P3\-^,=*T'3-1MI_P"S]%BEAM88)S$-DEL]LRMMZ_NW;'H<&O0=
MWL?RHW>QH \VU#X!>%-5O-4N[BTN/M&I6\MM.RW3C"26JVKX&<9,2@9['FJV
MD_LX^"]&\1MKD.G7,UX5.V&>]E>U21K=;=YE@+>6LCQ*%9PN3R>IKU+?CL?R
MH+X[$T >(3?L??#:XTK0]-DTB]>TT:Q.FVR?VG.N^ W N<28;YR)E#9/3Z5J
M7?[,7@B\AG5K+4(99)S.EQ;:K<030$S33%8G1P8U+W,^57C#D=*];#9'0T;O
M8_E0!YOIWP%\):3?V%W:Z9);26%U:WEM'#=2".&6WMWMHBJ[N@BD=2#P<Y-5
MO%/[-W@+QIK.H:IK7A\7]Q?O'+=Q-=3+;W$T841S/$&V&5 H <C(%>I;O8_E
M2;O8_E0!YY?_  (\&:GKFNZI=:(+B;6X'@OX'N9?LTX<*'<PAM@D8*H,@&[Y
M1S6<?V9OA[]DD@&@L0]Q)=&1KR=I/.>>.=I [.6#>9%&V<Y&W'2O4RYQP/SI
M&E"KDX ]2: .2\1?"WPWXJOKZ]U31;:]NKR*"&:5RP9EA=I(<$$;2CNQ##!Y
MZXK*?X!^!9-4M-0/A:Q%W:0QV\4@W@;(V=X\@-ABK2R$,P+9=N>:[_[7&"=S
MHN.""P!I#>Q#K)'ST^<4 4_#GA^Q\+:+9Z3IEHECIMG&(;>VC^Y$@^ZH]A6I
M5<7L1S^\C./1Q0+V(_\ +2/'LXH L457^W0G.)8S_P #'^-5WUVQB4E[VU4#
M.29U &/QH T**S/^$BTX!BU_:*%^]FX3Y?KS31XHTEC@:G9$YQ@72=?SH U:
M*RO^$GTO)']I661U_P!)3C]:A/C/0T^]K.FJ?0WD>?YT ;=%<V?B/X5 <GQ+
MHP"-M<_VA%\I]#\W6FCXE>%"Q7_A)]%+@[2HU"+AO3[W6@#IJ*YK_A9/A4.R
M'Q-HP=?O+]OBR/\ QZF+\4/![KE/%>B,/;48?_BJ .HHKC+OXR>![%YUN/%^
MA1&",2R!M0BRJG.#C/?!Z5D2?M(_"^*;R7\?>'UE_NF^3/\ .@#T6XYB8=R"
M!FO OV$$B3]EOP:L,C.%>]#;R3AOMLV1S7=_\-!_#>YVK'XVT9RS!5"W0.XG
MH!7BW[$/Q,\/>'OV;/#-KK&O6D-PEU?[$9RQ5#>3%1P..O2@#ZN8$CBO'M>^
M'5[_ ,-->%/&EG92/:#0[_3M1NVN'9(SNB:!1&6VKDB3)49/>NG;XY>!D=E/
MB2R!4X(!<D?^.U$_QR\!&0 ^)K,.>V'_ /B: /0%Z"OF3]N?Y=+^#LA(2-/B
M1HI9CV^9Z]<;X[^ TR3XEL_E&3P_3_OFOFW]L7XR>$/&?AGX9MHVMQWAMO'V
MBW+LL$P"H)9%).4]CQU]J /L]#USZFGUY!)^U7\,K>29)?$4D;1'#%M,NQ_$
M1Q^ZYY':KVG_ +2?@35(?.L]1O;J' .^/2+L@YX_YY4 >HTAKSI/CYX1D#;)
M-4;:,_\ ('N__C=,/Q_\*?*"NL_.,C_B27?_ ,;H L^-('N/B)X$,90;7OB3
M(F[_ )=^U<U\>OA?>_$*_P#ASJ.F6%M<ZCX=\466I/<3D*\-JI83E">Y!7@=
M<5S?CSXP:'J7Q(^&-Q:OJZ1PZA>-+&=)ND,BFT<8P4YYP<5VTG[0/AJ*]2V.
MG^)G=BHWIX?NRGS9QEMF!TY]* ,_X_QD7/PQVJS@>-M.)YZ<3<_3FO8EZ5\[
M_%7XOZ!KO_"-1I9>)(Y+#7M/O0S:#=*K8E*[0Q3!/)X'-=FW[1F@+)Y::%XO
ME?DXC\-79QCU^2@"U^T38_VA\++Z/"DI?:?-R2,;+V!\\=QMR/>O2DZ'ZFO!
M/BO\6;#Q9\+=6:VT'Q/#$+BT7S+K1IK<9^TQ$?? ./>O2A\2 LERA\,^)/W3
M-AO[-)#X./E(;G/:@#B/VT8#<_LH_%A!SGPY>D?A&3_2NY^#>X_"+P1O&'_L
M*QR#Z_9TKRC]I[QR_B+]G'XF6$?A/Q'%)/X=OHU-U8^5'DPMU;=P*W/A;\4I
M--^%G@F%/!_BG4E_L*Q(N;.P5HW_ -'3H3(#^)&* /;**\TE^,]Y'C'PX\:O
MQGY;&'_X]4%U\:]4MER/A=XVG_=+*/*MK4Y)_AYG&&'<4 -\!V_V;XY_%!\Y
M:XBTE\9Z 0RK_2O5*\.\)>+=3'Q?\<W \$ZWNFL],;86M5/W)>I\[!(Z5WS^
M.M:56(\!ZZQ';SK/G_R/0!V=>5_M3LR_LX_$LI9B_8>'KW%LW23]RW%:]_\
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M;2<LHM@>V?I0!["B8'(I^!V%>5Z?XK^*NI;Y8_"/A<V+@-;74?B"1Q.A (8
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M2H[,1.5 (7S4,A'/&.]?25% $%FLP@3[1M,NT;]F=N[OC/.,]/:IL4M% "8
M["C&*6B@!,"C ]*6B@!,#.<<T8%+10 A&.E>!VCM_P -U:BN?D/P[@./?^T7
MKWP\ UX-;N!^V]=?NU4M\/DQ)SEL:B>/P_K0![U1110 4444 %%%% !1110
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M/%-Q;:GXJ.@^&M$L->_M1M?N6CO+6ZADG5A&6SE53^+U K.T7X@Z?I?AR_\
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M&0* 9 +V,8S^/X4 >E?\+X\ VKRQ'Q/;!HY2CAEE)#$G@_+5)/V@OA]$V?\
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MM;_[/W@#QMIGBE;_ ,566I0%-+U+3[>_U&X6:=(9+JVDMT9M[-D 2D;CGWH
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M_#;^P+Q[.]U*\O;K4=3N+*%HX)IIY68A$8DK&J;(PI)PJ8Z5ZN2&'(I&E52
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MTYK@_AM^Q9HWA;5]9N?$.L/XEM;VSBTVUL8X&M8K2UBO6O(UXD8EA*5QMVJ
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MG% 'R5I?C'P;HMOIC^)_@'X#!O/%-_HEQJ-G8V:VFFP6]W';J928F8R$R#'
M4D<L,BO2/V5OAWX3\7Z!\0H]:\.:)KK:?X\UNS@74-+@E-M$L^%B4LIPH!X
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M6;P[KNTYZ<VN: /H!/NTZD48%+0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!X1^T'\OQ1^ W_8W2_P#INN:]SCD4H,,#QZU\Z?M<:->>
M(?$/P:TW3M4OM#OKGQ:8X]3TT(9[8FRN,NH<%>G7(Z9HM_V7O'+PQ._[1/Q
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M\Q_"OPJIP1SIJ'K]10!U[?&KX?%?,'CKPSL&<O\ VQ;8&.O\?M7S/^R1\8?
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M_A;X0BC:-/"NAK&SER@TV$#<>I^[UJS:?#_PWI[(UKX?TFV= P1XK&)64'J
M0O&: /EGXP_MI?!'Q4_@9=,^)GA^\>P\4V%[<*)'^2%-^]Q\O;(YKO4_;_\
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MIC<\GFUCH X<?M.^+BB'_AG_ .(X9CC'EV/'U_TBA_VF?&2<K^S]\0W&2/\
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M F8Z7K<:S>@V0DK^F?PH ]Q&:6D!R!2T %%%% !1110 4444 %%%% !1110
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MZ$FJB>,-"D8JNM:<S#J!=QD_SH V**R8_%FBS.4CU>PD8=0MU&2/UII\8:$
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M_P#9.E6X^.G[1]Q'@B?Q#IT^X C(?3XFZ'D=>E 'HUO^R3\%[6-43X7^%MB
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M6QU:21-/LGM90(Y(V<F0%P6)?YOG4@8KWG]CFY6__97^$LH7;CPMIT>,Y^Y
MJ]?^ U\K^#X+3P[=:GI5Q;!-;E:=;JY^SQM<7]F-)D,=PZJ5^S)'O12<D_(<
M@EJ^FOV&\#]D?X3\DG_A'[?K]#5 >Y>6OI0$ IU(3B@ VBFB)0<XYIV<T4 &
MT#M1M'I1FC=0 FP4NT4;J6@! H':C:/2BC=0 !0*3:!2YHS0 P-N<KM..N:=
MM!IU)F@ VBC:/2C-+0 W8*7%&1FC- !@48&*,BC- !BC%&:,T &!1@49HS0
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M]0O_ (9>%[B[NM)M)YI6TV,EW:%"23CDYKIA^R%\% ,?\*M\*\?]0R/_  H
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M9[;1M/MYQTDBM(U8?B!7#_![2+:;3?$(FBBNFA\2ZGL>6-&*?Z02 ,CC&>*
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M5)O([$CUQ0!\S-\0OVJD(/\ PJ'P)(,_=3Q;(#^9AJ;_ (6%^U((\_\ "H/
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M_"$>-N?XO["? _6O1"JAB>I-.W+C_P"M0!Y7??'G[-(BI\/O'LX,;R%XM!;
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MDVC3RDON7.TB<8ZY_&O9'^+7@E5;=XO\/KCUU2#_ .+^GYUY=\%?B=X1T/\
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M;\18?&<:Q-V_'BK$7@"")64:UK[9Y^?5)2?SS4/_  LRVY_XD7B/C_J"S_\
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M\%^'[8M:S#='I<((RC#((6L;X4_"'P'J/PU\+3W/@SP_=RMIEOF6?2X&9L(
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MT6-GD?\ +'P; 2#_ ,"N#523X4_&YT6,?'.T0 [O,7P7:[V]0<S;<=^ #[T
M>Z;12&-2<XYKP6X^$'QQEC18_CZL#!<%T\$V)+'U.9"/RIMW\'OCG.L(C_:!
M6V*)M8Q^";$F0_WCND.#],#VH ]\,:GM08U/45\^I\%_CN&!;]HIV'I_PA&G
M#_V:K=I\'OC5%#*+C]H"XGE(_=LG@[3D"GW'.?S% 'NQ@0]1GC&:7REKQZW^
M$_Q01G,OQNU.12V5"^&],7"^A_=G/UJ2W^%7Q,5F\[XTZF_SL5\OP[IJ84]
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M4 >M[%/I1L7&,_K7D=O\"->MVW'XR>/Y_P#9EET_'Z6@J.Y^ .NW$01?C/\
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M23P]I#2Y\PR-8Q;\YZD[<YR*TQI6FRKY@L+1P> 1"A_7%?GOX<^)OQ#7Q_\
M#OQK<&]U&X7X/VVI>)M!BC:2XU.W:],3RQ+G G16$WJP5E_BKWO]A>^BU/\
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M63P]IAQUM8CQ_N+7$_M*1M-\ OB B?>.BW6/^_9KM_"QSX:TK_KTA_\ 0%H
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M*_9G^%OP[\06^N>&/ VC:'J]M&T4-[90;)(U88(!SP,<53/P#U0RJX^+'C\
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MI_KZ=_PNCQ^57'P.\3$GL=4TT?\ M>O8@J(#TQUH!3@[AB@#R!OC!\0 =O\
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M48/MQ0!QX^/7@ M*@\5:>SQ$!U5V)4D9 .!QQ3)/C]\/UC=CXHL@JJ78C><
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M/VU-;UF/P;XP\S_A7L40L/['/VO/V\'<(MW*^^>N17V?Q[5\ZPH8_P!OK4'
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M^(&M?$CX92ZQXAOK/4=135]1M#<V#*T#1Q7+K&$90 X"@#< ,XS0!>B^)'Q
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M)YYV[0J^F* /=M8^'O[..E>+/#>DWFAZ3'J'B'29K^RF,TPCDLK=%D:1Y/,
M  ?(+>_I3=5^&GP!C^'>K^+-$\$V_CS3((C9S1>&C)J%U*KLH:- 91SR"?F'
M S6!XU^&6B_$#2/"]E_PBGCW3-,T+PUJ'A=H?["0S75E=6RPL S2Y1@8D<$
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M,8*#M2VNF>#1'.__  T?X82_GTV71I776)Y=J-9S0X3+X4^889-P&X",\Y-
M'V-#\%M:CD9G^*OC>53-YFUI;;@8(V#$/3G/KQ5N'X/:G]E$1^)?C)Y!C,QN
M8 QP?:+'/L*^)[F+P5J@T5[S]I#P9YEO<74]RL&KW"I^]N[68)&/-SA8X)H\
MM_SV/%?1/P5_:#^#OPL^&UAX=O/C#X4U&33VN96N(]1RJQ27#NB_,20%#JO)
M[4 >MCX0W@;)^('B]O;[;&!_Z+J*7X+3S312'X@^-5V,6VIJ:A6]B/+Y%<E%
M^W#\#;BWFFMOB9HUTL)(9;<R2OD''"JI)^HJ2]_;8^"MA LK>/["92=N+:*:
M5A]0J$B@#6G_ &=A.TI/Q(^(*^9(92$UTJ%;VPG ]JG/[/L#W<$LGCWQY)%$
MBK]F;Q!((WP.K8 .3WP17,_\-T_!/:"?&\2@\\V-U_\ &ZLM^VM\'DB:8>+C
M/;C:#+!IMU(BD] 66+ ;_9/- '1WWP!L+VX@D7Q=XTM5C;+Q6_B"<),/[KYR
M<?0BG_\ "@M*^VK<'Q-XP8*K+Y#>(+@QG/<C/4=JYS_AM+X0[XT/BF4-(YC4
M'2KP9<<E?]5U]JFMOVPOA;>H9;/6[_4(E;87LM#OIE4^A*PG!H Z1O@5HKME
M]8\3L>^=>N>?_'JKP_L^>'X4E4ZOXHD,C%M\GB"Z++GL/GX'M6))^UY\-XSC
M[7KQ_P!WPSJ1_P#:%1-^V!\.>,3^(R"=N1X6U(@?7]Q0!TTWP%\/SSR2MJ/B
M(%XO**KKMT%Q@C@;^N#UZU0C_9G\(I;Q0_;/$K)&=P+>(KTD]."?,R>E8+_M
MD_#X2M'%!XNNF5/,/D>$=2; SC'^HZ]\>E0I^V-X4EA$\7ACX@30LVW>GA&]
MQUQT* ]: .IC_9M\&QZC+> ZX99$\LJVO7I0#U"F7&?>M*]^!?A6_AGBE34P
ML\\=PY35[I260DC!$G Y.0.#WKC+']K;P_J@<V?@WXASA',;%?"5VN&]/F45
M83]J72&^[X(^(C_-MX\*7/7TZ4 =RGP@\*H7(L)\N=S?Z?<<G_OY3O\ A4?A
M?G_09^?^G^X_^.5PMO\ M1:;=&98? 7Q&E\DD.1X5N!C\\4RZ_:AM889&C^'
M'Q*GF0 B"/PM-N;Z$D#\S0!V>H?!#P9JML]O>:5)<P.06CDOK@J<=./,JNO[
M/_@!)EE7PW;+(,?,))<\+M'\?H<5Q$O[59C)5/A%\59R.I3PR1M/IS)2K^U+
M=2;]OP;^*IPF\9T"-=P]!F;K[&@#T%?@GX'6../_ (1RS*1@!0=QQC\:>/@Q
MX)#!O^$;L2PZ$H3_ %KSR/\ :>U%TF;_ (4O\4AY:ER#H\ +8."!^_Y/H.XJ
MXW[1FJ^7"P^#OQ)VR,J#_B6VV1D9R1]HR!ZD]* .W_X4QX(SG_A&=.S[Q?\
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MAJ]AG _B \WH?S]JLGXC^.MI(^%.ID]@=8LAG_Q^@#?/P@\#E67_ (0_00K
MA@-,APP/K\M?,^O_  [\,6O[?_AG1D\.:.FBS_#N[#::MC$+>3;=C@Q[=IP#
MZ5[N?B/X\$FT?"G4R,9W?VQ9=?3[]>"?$+7?B+!^U+X,\7V?PDOKVZ3PMJ5@
MFGC6[-'E/FQ/RY;:H&1WR=WM0!3D^-_@G5KCXE2>"OAIX#N[3PC!!/9ZK?36
MMM;WD)>2.XGW(C%8XVC*  %F)  YYZ'4?B3X,\*6'PMU35?@I8Z7_P )7HT^
MKZHW]DVXET6*"U$[JZ; S$9QC (],\5RVK_#"Y\5P:JL_P"R&EBVN^3'?)#X
MFL+6.3R&,D9D$)&%WG.5Y)P3VK;U#3/B'<Z3X:AO/V9X-5M_#PFBTZWG\:02
MSQ+*ACDW,YPZNK$$.QZT =AI7Q6\$ZE\(/&7C32/AS%I^L^$H97N?#NH:7#%
M=QS&W2XB3]V&'[V.6)@5)X?!&>*XKX7_ !QU;Q9>?"Z+3_ 7@NP@\3W=W9ZC
MID44T%]I;VNYKAA&\*_<4QJ=V/GD7&0V:;X2TGXB:1X(U3P39?LM6&F^&=3#
MM?6U[XPMI!=%U"MO8%G8[54 D\!0!@ 5I^$/#_Q$^'L_A^/0/V==%L?[*BNH
M+.[?Q<DLELL[1M/EV4L3(8X\GD_(.@% &U^P!HUA=_LRZ*9K*VE(U/5!\\*G
M_E^F]J^C3X>TTX_XE]IQT_T=./TKY,_9%/Q4\ _!6WT&R\&Z+JTEEK.JQ7$D
MNOB'9)]LD+* (F! )(SGG':O;(_%OQ>DE16^'V@Q*3S(?$A8+R.WD9/>@#TA
M-!T^,<65J/I @_I3O[%L>]G;D_\ 7%?\*Y,ZG\0\#_B1:#GO_P 3*7_XU3#J
M?Q&\X#^P= \ON?[3ES_Z*H Z;4]%LO[.N0+2W4F)P"L*\?*?:N9^"ME'_P *
MG\)-A2YTR#<X0 L=@Y/%1W6H?$22$H="\/[7RK9U*7@8_P"N=<9\*;SXDP_#
M/P;'IFC^&WM%TR,2FZU&<2;L< ;8\>F<T >UBTCB **J\C@* .M>6?LVJ3X.
MUY6ZIXHUE1TX'VV3BK"WOQD*Q;])\%J=Y\P_;[HC;VV_N^OUKS7X.1_%G3M$
M\0P^'['P2T7_  DFI/,;R]O&(D:8L^-J=,DT ?3+Q[4.&(/M7EOP<65?%WQ3
M1Y-W_%2[E"L3M4VD'!]#Q5<_\+UD )_X5]%EL%/].8!<=<\<Y[5S7P]L_B3!
MXS\?&VE\)0O)K$3W68+HAB;6(97YO;OZ4 ?0'EGCYC^)KSO1[IX_CMXIM#/*
M5.@Z;.L1'R#,UTN[/J=N,>U'V?XL[S_IW@\)V_T2Z)_]#KSZSC^(?_#0>N0B
M\\,C4?\ A%].9G-K<&,QB[N^,;\YR3^E 'T+L)YW$>U)Y38P'(_.O-[RP^+D
MPA-MK/A*W(+>8'TZY?(_AQ^\&.]176E_&"6XB:W\0^$H80<NDFDW#$C'0'S1
MWSS0!<^/A$/POU!V)^2ZL3GZ7<.*]" +$\D8-?/?QNTCXGM\.]<EO?$?AIK,
M"U:."#1YBPD%U$<EFFY7CTR*Z<>'OC8]T,^-/"$=J9#O\OP_.9%7/\.;C!./
M7B@#U\)[U%, B,6(P!DENGXUP,/ACXD/'^_\<Z7'(2<^3H'R@9XQF;/2H[GP
M;\0YH9D_X6!8D2+A=WAQ&"_4>;S0!\T?'GQ5?_#7XR_&'Q+X9O8]+U=O .CO
M%?(BR*A.H21"0YRH"JQRQX Y/ K"^'O[1?Q!UCQG\*(KCQ.VI2ZBMK;OI26(
M\G7('N[R*\O1*$ )MT@MV#*0&WDX^85Z-XA^"WQ-NOC]>7WASXHV6@:A/X5M
MK267_A&H)HVBCN9,((V8@<N?P.*Z2Q^"W[0:A/M'[0-G&%)&+?P59<+GMF@#
MS'Q/^U+XZ\!>-OB;I]WJ&B&TT[Q.UG9W&J6\JV^GVRZ9]IBB;9R6G=2BL3C>
M&QDE17H/Q_\ B5XYA_9Y\'_$+P_-<>%;XW.D7NK:(+/SKF6*XFA22U#8_=8\
MTY8CHO;-76^"'Q\_>;?V@8"2WREO!=E\P[;_ %-(_P "?CV0"/VC)6)&&5_"
M%D5_ 4 ><_&WQ]\1_"WC'XDZ;)XPO['0%U+P^WV_1[#$FAZ5<3RI=21G:^7"
MHI9\'OP*V_\ @G;KNM^)]+^+.I^*+5[+Q'<^*A)>02Q>4W_'C;B.0I_"7C".
M>!RYKK9/@3\;X$:23]I"Z50I+NWA&P&!CGDGI7$_!7X)^//^$A^*8L?C=JD>
MH7&OQRWNHP:'98NY&LK?$@4@A?D" ;>.,]S0!]B[1[8H*J1V%>&2_!+XFRZ?
M%:CX[^($99-[W T2QWN,8"YV<#U]:;IWP"\?I<.VI_'CQ=>0,/ECMK&QMV4^
MN[RFR/;% 'NA13W% 4#^(8KQ2T^ GC!6F^V_&WQO< N?*$$5C%M7L#^X.X^_
M%,E_9_\ %TMG+&OQN\=QW!+>7-MLMJ^F5\CG'U% 'N.X#N/SI-Z_WA^=> S?
MLO\ B&[*RS_'CXGB7: WV>]LXD)[D(+?BJT/[*GB$*WG?'WXJ2-N)!34+1>.
MPQ]GH ^A]X]1^='F+_>'YU\]Q?LJ:]MQ)\>_BJ6R>1J5H!CM_P N]2']E?6M
M@7_A?'Q5R.XU2UR?_)>@#Z WKZC\Z3S!ZBO 5_99UI=G_%]?BHV&R<ZI:\CT
M_P"/>I1^RWJI55?XW_%)R#DG^UX%S[<04 >\>;[4HDR3@&O!Y?V6+N1W(^,O
MQ33/(VZ\G!]?]55N']F0?N//^)WQ*N3$A4E_$;KN/]X[5'/TXH ]NWCN"/PH
MW\9P:\<M_P!F>RB0^9\0/B+.Y&"S^)YP3_WSBG+^S-I:@C_A-OB"RG@JWBJZ
MP?UH ]@#Y[&D,A ^Z?P%>/Q_LRZ3$H">,_B H"X 'BN[./IEJK77[*GA[4#"
M;SQ7X_NQ%()4#^+KY &'0_(XS]#Q0![3YIQ]PY^AH\T_W3^ ->"S_L6^!KN\
MEN9=<\?&61R[$>-M449/L)L"ID_8W\$0L3%K7CJ,F)HF*^,]3^8'KG,W7GK0
M![H)LC[C _0TOF<9VG\C7@/_  Q1X% 4#7?B  !@8\<:H/\ VO3H_P!BOP%'
MM/\ :WCMR"#^\\;:J<\]_P!_0![V)?56'X&E\SU4_D:\4_X9&\"-*KM<>+&"
MQ^6(SXLU+:<G.2//Y;MGTI?^&0_ATS2&2W\03[^\OB74'*\?PYFXH ]J\P_W
M3^5&_P!CGZ5XC9?L>?#2TB@C:PUN[\D'YKKQ#?R,Y/=B9OFQ^E+_ ,,<_#'R
M&3^RM5Y)._\ MZ^W_@?.H ]M\P_W32AL]B*\,N_V,?AA>"+_ (E^M0;"#F'Q
M%?H7_P![]]S3W_8T^%K @Z/J9.5.[^W;[/!]?._/UH ]P+8[&D\ST4_E7BLO
M['OPP=2(](U.W).=T&NWR'\Q-6:O[$?PP#[F@\22C.=LOBC4&'Y&;I0![[NY
M'!_*D+X.,$_A7AC_ +%OPK<,O]D:JI,?E[UUZ^##G.[/G?>]ZBC_ &)?A2D1
M1M)U:;*E?WWB"^<C/<$S=1V/:@#WDOC'!KRC]J<;O@/XK)&%6&-R3T $R$_H
M*YX?L4_"L21,-)U<+&H41C7[X(W7DKYO)]Z\U_:>_9=^''A'X&^(]0TK0);6
M\1[0K.=2N690;B)6^](0003D8YR: /L"%MP)XP22"#D$5)5>TB6WC6).$0;5
M7T X'Z"K% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D
MO[6I9?V7OBR4(##PMJ6-PR,_9WK<^'?@W0KGP1X<N)=%TZ69M+M,RO9QEC^X
M3OMS6E\6/"C^.OAAXM\.1Q1S2ZMI5U8I'*VU6:2)D )[#)%>,>&O&/[07A[P
M[I.ECX/Z!.UE90V[S'Q:JB1DC520!"<9(/% 'OA\):*5V_V18;?3[+'C^5>=
M?&C2K#2AX(EMK*SMY'\5:?&76!%)#%U8=.X)%<\/B1^T 8]Q^#6@C@G'_"7I
M^'_+&L#Q5>?';X@VVA)<_##PYI$FFZ[9ZA^_\4&4,D19F(V0]>@_&@#Z%B\+
M:3%RFF6*G/&VUC']*>?#6EG=_P 2ZRRXPQ^S)\P]#Q7EA\6?'(I/L^'_ (1W
M*^(RWBB8!QZ\6IQ]*QYO%G[2#2A(OA_\/XU$C M-XINN4XVD 6O4<YS^% 'N
ML&FV]LNV*"*)>RQQJH_05+]G3!&U>?85X*GB#]I@CYO!GPV!)ZCQ#>_*/?\
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MP(]S0!X2/VU/AV84E^R>,-CML4_\(AJ7)Z8QY-37/[8_@.SOELYM.\8I<L5
MC_X1'43DM]WD0XY^M>XK'@=6_$FD,0R3N;_OHT >-C]J_P )':#HOC-&;HK>
M%+_)_P#(=5Y_VOO!-O9F\?2O&8M58HTH\):@<'..GE9Z^U>V>4,D[F_,T[;Q
MC)_.@#Q";]K_ ,%6]O\ :)-)\9BVW"/S?^$2U C<>@QY6?QQCWJ*3]LKP+%)
M-$VE>-//A!9XAX1U D =3GRL'\#7N7EC^\WYFE\OG[S?F: /#)/VR/ T<,<I
MTGQH4D7<A'A+4/F]O]5P?K7G'[1GQZT_XI?!#Q+HOASPGXSN-6N(H9+6.Y\-
M742,Z3HP#,R\?=/6OKH1\YRWYT>7SG)_,T 0:=+)<6<$TJ;)7C5F3^Z2 2/S
M-6J0*%S@8S2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M )C/6DV#TIU% "8'I1M'H*6B@!-M&T9SBEHH *8SKN"G&3T]Z?32@)R1S0 H
M%&/I0.E+0 FVC:/2EHH 3:/2C:!VI:* $VCTHQ]*6B@!,4$9I:* $VCTI:**
M $(!HVCTI:* $I:** $Q2T44 %)M'I2T4 )M'I2T44 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%,D8J 0,\\T /HJ"U>9U?SHA$P8A0'W9'8]!^53T %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !31NW<@;:=10 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !2'BEI",C%  #FEIJKM4"G
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !12,"1Q4,;2%I-ZA<-A=K9R/4
M\4 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)M
M!.:6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!$]O')*DK
M(ID0$*Y49&>N#4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% &5J6AI>3Q74<AM[R'(CG4 D XRI!Z@X'%*+NZM
MB5:S:?'&Z&1>??#$8^E:3_<;Z5$O^M7Z5/* R&\DF<+]EECX^\Y7'Z$U9%0I
/_#]/ZU,.E" 6BBBJ __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>tmb-20221231xex10d23001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231xex10d23001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ; )H# 2(  A$! Q$!_\0
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M+SP9<_$_2/A]I27]EYS7#IE]3N3EL,$D7;&P& 8RW)Z8WC[]H#XWZSHGQ_\
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MOCEX;\%> '\6+\0]=N-<T'Q3#?V\=EITMW$J3"]#N'3R2-R[5;>.!C-?6/\
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KFNJAMXK:&.**-8XHU"(BC 4#@ #TK*HJ.GLFWZI+\FS2,JGVTODW_DC_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>tmb-20221231xex10d23002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231xex10d23002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ! 2T# 2(  A$! Q$!_\0
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<* "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>tmb-20221231xex10d23003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20221231xex10d23003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !( (X# 2(  A$! Q$!_\0
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9<_DS"7:D6%4;MR?/O' ^[C/-%%"%:Q__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>25
<FILENAME>tmb-20221231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/29/2023 11:43:38 PM-->
<!--Modified on: 3/29/2023 11:43:38 PM-->
<xsd:schema targetNamespace="http://www.mustangbio.com/20221231" elementFormDefault="qualified" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:mbio="http://www.mustangbio.com/20221231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>00100 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/StatementStatementsOfOperations" id="StatementStatementsOfOperations">
        <link:definition>00200 - Statement - STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00400 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>40502 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails" id="DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails">
        <link:definition>40601 - Disclosure - Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails">
        <link:definition>40702 - Disclosure - Commitments and Contingencies (Schedule of Operating Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails" id="DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails">
        <link:definition>40704 - Disclosure - Commitments and Contingencies (Maturities of Operating Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails" id="DisclosureNotesPayableNarrativeDetails">
        <link:definition>40801 - Disclosure - Notes Payable (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" id="DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>41002 - Disclosure - Income Taxes (Effective Income Tax Rate Reconciliation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails">
        <link:definition>41003 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity">
        <link:definition>00300 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureOrganizationAndDescriptionOfBusiness" id="DisclosureOrganizationAndDescriptionOfBusiness">
        <link:definition>10101 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreements" id="DisclosureLicenseClinicalTrialAndSponsoredResearchAgreements">
        <link:definition>10301 - Disclosure - License, Clinical Trial and Sponsored Research Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureRelatedPartyAgreements" id="DisclosureRelatedPartyAgreements">
        <link:definition>10401 - Disclosure - Related Party Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>10501 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpenses" id="DisclosureAccountsPayableAndAccruedExpenses">
        <link:definition>10601 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureNotesPayable" id="DisclosureNotesPayable">
        <link:definition>10801 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10901 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11001 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11101 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesTables" id="DisclosureSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables" id="DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables">
        <link:definition>30303 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>30503 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables" id="DisclosureAccountsPayableAndAccruedExpensesTables">
        <link:definition>30603 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>30703 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>30903 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31003 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureOrganizationAndDescriptionOfBusinessDetails" id="DisclosureOrganizationAndDescriptionOfBusinessDetails">
        <link:definition>40101 - Disclosure - Organization and Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" id="DisclosureSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>40201 - Disclosure - Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" id="DisclosureSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails">
        <link:definition>40202 - Disclosure - Significant Accounting Policies (Schedule of Potentially Dilutive Securities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails" id="DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails">
        <link:definition>40301 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (License Agreements) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails" id="DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails">
        <link:definition>40302 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (City of Hope - Licenses) (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" id="DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails">
        <link:definition>40303 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (Sponsored Research and Clinical Trial Agreements) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" id="DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails">
        <link:definition>40304 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (City of Hope - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" id="DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails">
        <link:definition>40305 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (Other - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails" id="DisclosureRelatedPartyAgreementsNarrativeDetails">
        <link:definition>40401 - Disclosure - Related Party Agreements (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" id="DisclosurePropertyAndEquipmentNarrativeDetails">
        <link:definition>40501 - Disclosure - Property and Equipment (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" id="DisclosureCommitmentsAndContingenciesNarrativeDetails">
        <link:definition>40701 - Disclosure - Commitments and Contingencies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesCashFlowsDetails" id="DisclosureCommitmentsAndContingenciesCashFlowsDetails">
        <link:definition>40703 - Disclosure - Commitments and Contingencies (Cash Flows) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" id="DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails">
        <link:definition>40901 - Disclosure - Stockholders Equity (Common Stock and Equity Offerings) (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails" id="DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails">
        <link:definition>40902 - Disclosure - Stockholders Equity (Equity Incentive Plan) (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails" id="DisclosureStockholdersEquityStockOptionsDetails">
        <link:definition>40903 - Disclosure - Stockholders Equity (Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails" id="DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails">
        <link:definition>40904 - Disclosure - Stockholders Equity (Restricted Stock Awards and Restricted Stock Units) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" id="DisclosureStockholdersEquityStockBasedCompensationExpenseDetails">
        <link:definition>40905 - Disclosure - Stockholders Equity (Stock-based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails" id="DisclosureStockholdersEquityStockWarrantsDetails">
        <link:definition>40906 - Disclosure - Stockholders' Equity (Stock Warrants) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>41001 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10701 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mustangbio.com/role/DisclosureNotesPayableTables" id="DisclosureNotesPayableTables">
        <link:definition>30803 - Disclosure - Notes Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:element name="PropertyPlantAndEquipmentExcludingAssetsUnderConstruction" id="mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ConstructionInProcessNet" id="mbio_ConstructionInProcessNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="CommonStockIssuableMember" id="mbio_CommonStockIssuableMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement" name="StockIssuedDuringPeriodValueIssuedForFoundersAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="IncreaseDecreaseInLeaseLiabilities" id="mbio_IncreaseDecreaseInLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mbio_SponsoredResearchAndClinicalTrialAgreementsMember" name="SponsoredResearchAndClinicalTrialAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_FredHutchinsonCancerResearchCenterMember" name="FredHutchinsonCancerResearchCenterMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_PaymentOfUpfrontFees" name="PaymentOfUpfrontFees" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element name="FortressBiotechIncMember" id="mbio_FortressBiotechIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_AnnualConsultingFees" name="AnnualConsultingFees" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="mbio_IncreaseInAnnualConsultingFees" name="IncreaseInAnnualConsultingFees" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="mbio_ExcessInNetAssetsValue" name="ExcessInNetAssetsValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="mbio_StockIssuedDuringPeriodSharesAtMarketOffering" name="StockIssuedDuringPeriodSharesAtMarketOffering" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_StockIssuedDuringPeriodValueAtMarketingOffering" name="StockIssuedDuringPeriodValueAtMarketingOffering" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="mbio_StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering" name="StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering" name="StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="mbio_ProceedsFromIssuanceOfCommonSharesAtMarketOffering" name="ProceedsFromIssuanceOfCommonSharesAtMarketOffering" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="mbio_OfferingCostsForIssuanceOfCommonSharesAtMarketOffering" name="OfferingCostsForIssuanceOfCommonSharesAtMarketOffering" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="mbio_ShareIssuedDuringPeriodValueOnExerciseOfWarrants" name="ShareIssuedDuringPeriodValueOnExerciseOfWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants" name="ShareIssuedDuringPeriodSharesOnExerciseOfWarrants" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid" name="ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="mbio_NumberOfSubsidiaries" name="NumberOfSubsidiaries" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_DilutedOutstandingEquityPercentage" name="DilutedOutstandingEquityPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_MilestonesPayableUnderArrangement" name="MilestonesPayableUnderArrangement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="mbio_NumberOfMilestonesMeasured" name="NumberOfMilestonesMeasured" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_AnnualMaintenanceFeePayable" name="AnnualMaintenanceFeePayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="mbio_ResearchArrangementContributionPerPatient" name="ResearchArrangementContributionPerPatient" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="mbio_ResearchArrangementTerm" name="ResearchArrangementTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_ContributionTowardPatientCosts" name="ContributionTowardPatientCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="mbio_FoundersAgreementTerm" name="FoundersAgreementTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_AgreementRenewalTerm" name="AgreementRenewalTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_PreferredStockVotingRightsMultiplier" name="PreferredStockVotingRightsMultiplier" nillable="true" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement" name="OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_EquityFeePaymentPeriod" name="EquityFeePaymentPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_EquityFeePercentageOfFinancing" name="EquityFeePercentageOfFinancing" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_CashFeePaymentPeriod" name="CashFeePaymentPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_CashFeeAsPercentageOfAnnualNetSales" name="CashFeeAsPercentageOfAnnualNetSales" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate" name="ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_ChangeInControlFeeMeasurementPeriodForNetSales" name="ChangeInControlFeeMeasurementPeriodForNetSales" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_ChangeInControlFeeSpecifiedRateComponent" name="ChangeInControlFeeSpecifiedRateComponent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_AgreementTerm" name="AgreementTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_DirectorCompensationValueOfSharesGranted" name="DirectorCompensationValueOfSharesGranted" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="mbio_DirectorCompensationNumberOfSharesGranted" name="DirectorCompensationNumberOfSharesGranted" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_VotingRightsNumberOfVotesPerShare" name="VotingRightsNumberOfVotesPerShare" nillable="true" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_StockholderAppointmentOfDirectorPeriodAfterIssuance" name="StockholderAppointmentOfDirectorPeriodAfterIssuance" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_CommissionRatePercentage" name="CommissionRatePercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="mbio_ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased" name="ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_DeferredTaxAssetsStartUpCosts" name="DeferredTaxAssetsStartUpCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="mbio_LicenseAgreementsMember" name="LicenseAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_CityOfHopeNationalMedicalCenterCohMember" name="CityOfHopeNationalMedicalCenterCohMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_Il13r2ProductMember" name="Il13r2ProductMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_IvIcvProductOrProcessMember" name="IvIcvProductOrProcessMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_PscaProductOrProcessMember" name="PscaProductOrProcessMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_Her2ProductOrProcessMember" name="Her2ProductOrProcessMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_Cs1ProductOrProcessMember" name="Cs1ProductOrProcessMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_Cd123ProductOrProcessMember" name="Cd123ProductOrProcessMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_CommonUnspecifiedClassMember" name="CommonUnspecifiedClassMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties" name="IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="mbio_ClassOfWarrantOrRightWarrantsGrantedDuringPeriod" name="ClassOfWarrantOrRightWarrantsGrantedDuringPeriod" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod" name="ClassOfWarrantOrRightWarrantsExercisedDuringPeriod" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod" name="ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" name="ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod" name="ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance" name="AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="mbio_AtMarketOfferingMember" name="AtMarketOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_LesseeSecurityDepositUponFullOccupancy" name="LesseeSecurityDepositUponFullOccupancy" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="mbio_LesseeOperatingLeaseTotalBaseRentNetOfAbatements" name="LesseeOperatingLeaseTotalBaseRentNetOfAbatements" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="mbio_LesseeOperatingLeaseTotalAbatementsOverLeaseTerm" name="LesseeOperatingLeaseTotalAbatementsOverLeaseTerm" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="mbio_IssuanceOfCommonSharesEquityFeeOnAtMarketOffering" name="IssuanceOfCommonSharesEquityFeeOnAtMarketOffering" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="mbio_CalimmuneMember" name="CalimmuneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_StJudeXscidMember" name="StJudeXscidMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_CityOfHopeMember" name="CityOfHopeMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_StockIssuanceCommonStockIssuableDuringPeriod" name="StockIssuanceCommonStockIssuableDuringPeriod" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="mbio_ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense" name="ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="mbio_EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent" name="EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent" name="EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_AccruedCompensationCurrent" name="AccruedCompensationCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="mbio_ResearchAndDevelopmentCurrent" name="ResearchAndDevelopmentCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="mbio_DeferredTaxAssetOperatingLeaseLiabilities" name="DeferredTaxAssetOperatingLeaseLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage" name="EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_Cd20TechnologyProductOrProcessMember" name="Cd20TechnologyProductOrProcessMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" name="ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses" name="PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses" name="PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_AdditionalMilestonesPayableUnderArrangement" name="AdditionalMilestonesPayableUnderArrangement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="mbio_StockIssuedDuringPeriodSharesIssuableForServices" name="StockIssuedDuringPeriodSharesIssuableForServices" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_AnnualStockDividendPolicyTextBlock" name="AnnualStockDividendPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_St.JudeChildrensResearchHospitalMember" name="St.JudeChildrensResearchHospitalMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_RegistrationStatementsMember" name="RegistrationStatementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_SummaryOfWarrantActivitiesTableTextBlock" name="SummaryOfWarrantActivitiesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_ClinicalTrialAgreementsMember" name="ClinicalTrialAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_DataTransferAgreementMember" name="DataTransferAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_OperatingLossCarryforwardsWithoutExpiration" name="OperatingLossCarryforwardsWithoutExpiration" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement" name="SaleOfStockAggregateOfferingPricePermittedByAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="mbio_CommonStockSharesAvailableForFutureIssuanceValue" name="CommonStockSharesAvailableForFutureIssuanceValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="mbio_MayoClinicMember" name="MayoClinicMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_LeaseLiabilitiesArisingFromObtainingRightOfUseAssets" name="LeaseLiabilitiesArisingFromObtainingRightOfUseAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="mbio_LeidenUniversityMedicalCentreMember" name="LeidenUniversityMedicalCentreMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mbio_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod" name="ClassOfWarrantOrRightWarrantsExpiredDuringPeriod" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mbio_WarrantExercisePriceExpiredDuringPeriod" name="WarrantExercisePriceExpiredDuringPeriod" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="Rag1ScidMb110Member" id="mbio_Rag1ScidMb110Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CorrectionToPreviouslyIssuedShares" id="mbio_CorrectionToPreviouslyIssuedShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold" id="mbio_ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RunwayDebtFacilityMember" id="mbio_RunwayDebtFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AdditionsToApicEquityFeesOnRwgDebt" id="mbio_AdditionsToApicEquityFeesOnRwgDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AdditionsToApicEquityFeesOnRwgDebtShares" id="mbio_AdditionsToApicEquityFeesOnRwgDebtShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AdditionsToApicFromIssuanceOfRwgDebtWarrants" id="mbio_AdditionsToApicFromIssuanceOfRwgDebtWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtInstrumentBalloonPaymentAsPercentageOfPrincipal" id="mbio_DebtInstrumentBalloonPaymentAsPercentageOfPrincipal" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="CommonShareIssuanceFeesRelatedPartyDebt" id="mbio_CommonShareIssuanceFeesRelatedPartyDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ReimbursementOfFeesTotalPayments" id="mbio_ReimbursementOfFeesTotalPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NonRefundableMilestonePayments" id="mbio_NonRefundableMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="GrantIncome" id="mbio_GrantIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MsaAgreementRenewalTerm" id="mbio_MsaAgreementRenewalTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses" id="mbio_DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchFundingAmount" id="mbio_ResearchFundingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>26
<FILENAME>tmb-20221231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/29/2023 11:43:38 PM-->
<!--Modified on: 3/29/2023 11:43:38 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementBalanceSheets" roleURI="http://www.mustangbio.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementStatementsOfOperations" roleURI="http://www.mustangbio.com/role/StatementStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.mustangbio.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails" roleURI="http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails" roleURI="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails" roleURI="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureNotesPayableNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" roleURI="http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" />
  <calculationLink xlink:role="http://www.mustangbio.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638157302168536153" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638157302168536153" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638157302168536153" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638157302168536153" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638157302168536153" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables_638157302168536153" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638157302168536153" xlink:to="us-gaap_OtherReceivables_638157302168536153" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638157302168536153" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638157302168536153" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638157302168536153" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction" xlink:label="mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction_638157302168536153" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction_638157302168536153" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ConstructionInProcessNet" xlink:label="mbio_ConstructionInProcessNet_638157302168546160" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="mbio_ConstructionInProcessNet_638157302168546160" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638157302168546160" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent_638157302168546160" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638157302168546160" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638157302168546160" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638157302168546160" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638157302168546160" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638157302168546160" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638157302168546160" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638157302168546160" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638157302168546160" xlink:to="us-gaap_LiabilitiesCurrent_638157302168546160" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638157302168546160" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638157302168546160" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638157302168546160" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_638157302168546160" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638157302168546160" xlink:to="us-gaap_DueToRelatedPartiesCurrent_638157302168546160" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638157302168556143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638157302168546160" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638157302168556143" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_638157302168556143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638157302168546160" xlink:to="us-gaap_LongTermNotesPayable_638157302168556143" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638157302168556143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638157302168546160" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638157302168556143" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent_638157302168556143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638157302168546160" xlink:to="us-gaap_DeferredIncomeNoncurrent_638157302168556143" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638157302168556143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638157302168556143" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638157302168556143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638157302168556143" xlink:to="us-gaap_PreferredStockValue_638157302168556143" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638157302168556143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638157302168556143" xlink:to="us-gaap_CommonStockValue_638157302168556143" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions_638157302168556143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638157302168556143" xlink:to="us-gaap_CommonStockSharesSubscriptions_638157302168556143" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638157302168566139" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638157302168556143" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638157302168566139" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638157302168566139" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638157302168556143" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638157302168566139" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.mustangbio.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638157302168566139" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_638157302168566139" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638157302168566139" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638157302168566139" xlink:to="us-gaap_OperatingExpenses_638157302168566139" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638157302168566139" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638157302168566139" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638157302168566139" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638157302168566139" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638157302168566139" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638157302168566139" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638157302168566139" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638157302168566139" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638157302168566139" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638157302168576143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense_638157302168576143" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_GrantIncome" xlink:label="mbio_GrantIncome_638157302168576143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638157302168576143" xlink:to="mbio_GrantIncome_638157302168576143" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther_638157302168576143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638157302168576143" xlink:to="us-gaap_InterestIncomeOther_638157302168576143" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638157302168576143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638157302168576143" xlink:to="us-gaap_InterestExpenseDebt_638157302168576143" order="3" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.mustangbio.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157302168576143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157302168576143" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638157302168576143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157302168576143" xlink:to="us-gaap_NetIncomeLoss_638157302168576143" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense" xlink:label="mbio_ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense_638157302168576143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157302168576143" xlink:to="mbio_ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense_638157302168576143" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638157302168576143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157302168576143" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638157302168576143" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance" xlink:label="mbio_AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance_638157302168586145" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157302168576143" xlink:to="mbio_AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance_638157302168586145" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638157302168586145" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157302168576143" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638157302168586145" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommonShareIssuanceFeesRelatedPartyDebt" xlink:label="mbio_CommonShareIssuanceFeesRelatedPartyDebt_638157302168586145" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157302168576143" xlink:to="mbio_CommonShareIssuanceFeesRelatedPartyDebt_638157302168586145" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_IssuanceOfCommonSharesEquityFeeOnAtMarketOffering" xlink:label="mbio_IssuanceOfCommonSharesEquityFeeOnAtMarketOffering_638157302168586145" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157302168576143" xlink:to="mbio_IssuanceOfCommonSharesEquityFeeOnAtMarketOffering_638157302168586145" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638157302168586145" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157302168576143" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638157302168586145" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638157302168586145" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157302168576143" xlink:to="us-gaap_ShareBasedCompensation_638157302168586145" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638157302168586145" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157302168576143" xlink:to="us-gaap_Depreciation_638157302168586145" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638157302168586145" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157302168576143" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638157302168586145" order="11" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638157302168586145" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157302168576143" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638157302168586145" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties" xlink:label="mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties_638157302168596139" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157302168576143" xlink:to="mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties_638157302168596139" order="13" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_638157302168596139" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157302168576143" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_638157302168596139" order="14" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_638157302168596139" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157302168576143" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_638157302168596139" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_IncreaseDecreaseInLeaseLiabilities" xlink:label="mbio_IncreaseDecreaseInLeaseLiabilities_638157302168596139" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157302168576143" xlink:to="mbio_IncreaseDecreaseInLeaseLiabilities_638157302168596139" order="16" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638157302168596139" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638157302168596139" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638157302168596139" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638157302168596139" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638157302168596139" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638157302168596139" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638157302168596139" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638157302168596139" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638157302168606143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638157302168596139" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638157302168606143" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638157302168606143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638157302168606143" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_638157302168606143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638157302168606143" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_638157302168606143" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_638157302168606143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638157302168606143" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_638157302168606143" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ProceedsFromIssuanceOfCommonSharesAtMarketOffering" xlink:label="mbio_ProceedsFromIssuanceOfCommonSharesAtMarketOffering_638157302168606143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638157302168606143" xlink:to="mbio_ProceedsFromIssuanceOfCommonSharesAtMarketOffering_638157302168606143" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_OfferingCostsForIssuanceOfCommonSharesAtMarketOffering" xlink:label="mbio_OfferingCostsForIssuanceOfCommonSharesAtMarketOffering_638157302168606143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638157302168606143" xlink:to="mbio_OfferingCostsForIssuanceOfCommonSharesAtMarketOffering_638157302168606143" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638157302168606143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638157302168606143" xlink:to="us-gaap_ProceedsFromStockPlans_638157302168606143" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638157302168616139" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638157302168616139" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638157302168616139" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638157302168616139" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Expenses) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638157302168616139" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent_638157302168616139" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AccruedCompensationCurrent" xlink:label="mbio_AccruedCompensationCurrent_638157302168616139" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="mbio_AccruedCompensationCurrent_638157302168616139" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ResearchAndDevelopmentCurrent" xlink:label="mbio_ResearchAndDevelopmentCurrent_638157302168616139" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="mbio_ResearchAndDevelopmentCurrent_638157302168616139" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_638157302168616139" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_638157302168616139" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Commitments and Contingencies (Schedule of Operating Leases) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638157302168626143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_638157302168626143" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638157302168626143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost_638157302168626143" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Commitments and Contingencies (Maturities of Operating Leases) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638157302168626143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638157302168626143" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638157302168626143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638157302168626143" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638157302168626143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638157302168626143" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638157302168626143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638157302168626143" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638157302168626143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638157302168626143" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638157302168626143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638157302168626143" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Notes Payable (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638157302168636142" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermNotesPayable_2" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638157302168636142" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_638157302168636142" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermNotesPayable_2" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_638157302168636142" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Income Taxes (Effective Income Tax Rate Reconciliation) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637038917271332158" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638157302168636142" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637038917271332158" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638157302168636142" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638157302168636142" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637038917271332158" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638157302168636142" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_638157302168636142" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637038917271332158" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_638157302168636142" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638157302168636142" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637038917271332158" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638157302168636142" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent" xlink:label="mbio_EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent_638157302168636142" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637038917271332158" xlink:to="mbio_EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent_638157302168636142" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent" xlink:label="mbio_EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent_638157302168646142" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637038917271332158" xlink:to="mbio_EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent_638157302168646142" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638157302168646142" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637038917271332158" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638157302168646142" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638157302168646142" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637038917271332158" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638157302168646142" order="8" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638157302168646142" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638157302168646142" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638157302168646142" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_638157302168646142" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638157302168646142" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638157302168646142" xlink:to="us-gaap_DeferredTaxAssetsGross_638157302168646142" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638157302168646142" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638157302168646142" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638157302168646142" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_638157302168646142" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638157302168646142" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_638157302168646142" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_638157302168656141" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638157302168646142" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments_638157302168656141" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_638157302168656141" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638157302168646142" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_638157302168656141" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_638157302168656141" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638157302168646142" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_638157302168656141" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DeferredTaxAssetOperatingLeaseLiabilities" xlink:label="mbio_DeferredTaxAssetOperatingLeaseLiabilities_638157302168656141" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638157302168646142" xlink:to="mbio_DeferredTaxAssetOperatingLeaseLiabilities_638157302168656141" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DeferredTaxAssetsStartUpCosts" xlink:label="mbio_DeferredTaxAssetsStartUpCosts_638157302168656141" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638157302168646142" xlink:to="mbio_DeferredTaxAssetsStartUpCosts_638157302168656141" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses" xlink:label="mbio_DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses_638157302168656141" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638157302168646142" xlink:to="mbio_DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses_638157302168656141" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638157302168656141" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638157302168646142" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638157302168656141" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638157302168656141" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638157302168646142" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638157302168656141" order="2" use="optional" weight="-1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>27
<FILENAME>tmb-20221231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/29/2023 11:43:38 PM-->
<!--Modified on: 3/29/2023 11:43:38 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementBalanceSheets" roleURI="http://www.mustangbio.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables" roleURI="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" roleURI="http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails" roleURI="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" roleURI="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureRelatedPartyAgreementsNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureNotesPayableNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityStockOptionsDetails" roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails" roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityStockWarrantsDetails" roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureIncomeTaxesNarrativeDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.mustangbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="tmb-20221231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.mustangbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis_1" xlink:title="us-gaap_TaxPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_1" xlink:title="us-gaap_TaxPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxPeriodAxis_1" xlink:to="us-gaap_TaxPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxPeriodAxis_1 To us-gaap_TaxPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommonUnspecifiedClassMember" xlink:label="mbio_CommonUnspecifiedClassMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mbio_CommonUnspecifiedClassMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommonUnspecifiedClassMember" xlink:label="mbio_CommonUnspecifiedClassMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mbio_CommonUnspecifiedClassMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction" xlink:label="mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ConstructionInProcessNet" xlink:label="mbio_ConstructionInProcessNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="mbio_ConstructionInProcessNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermNotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockSharesSubscriptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - BALANCE SHEETS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommonUnspecifiedClassMember" xlink:label="mbio_CommonUnspecifiedClassMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mbio_CommonUnspecifiedClassMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommonUnspecifiedClassMember" xlink:label="mbio_CommonUnspecifiedClassMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mbio_CommonUnspecifiedClassMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommonStockIssuableMember" xlink:label="mbio_CommonStockIssuableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mbio_CommonStockIssuableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuanceCommonStockIssuableDuringPeriod" xlink:label="mbio_StockIssuanceCommonStockIssuableDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="mbio_StockIssuanceCommonStockIssuableDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement" xlink:label="mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuedDuringPeriodValueAtMarketingOffering" xlink:label="mbio_StockIssuedDuringPeriodValueAtMarketingOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="mbio_StockIssuedDuringPeriodValueAtMarketingOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuedDuringPeriodSharesAtMarketOffering" xlink:label="mbio_StockIssuedDuringPeriodSharesAtMarketOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="mbio_StockIssuedDuringPeriodValueAtMarketingOffering" xlink:to="mbio_StockIssuedDuringPeriodSharesAtMarketOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering" xlink:label="mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering" xlink:label="mbio_StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering" xlink:to="mbio_StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CorrectionToPreviouslyIssuedShares" xlink:label="mbio_CorrectionToPreviouslyIssuedShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="mbio_CorrectionToPreviouslyIssuedShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AdditionsToApicEquityFeesOnRwgDebt" xlink:label="mbio_AdditionsToApicEquityFeesOnRwgDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="mbio_AdditionsToApicEquityFeesOnRwgDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AdditionsToApicEquityFeesOnRwgDebtShares" xlink:label="mbio_AdditionsToApicEquityFeesOnRwgDebtShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="mbio_AdditionsToApicEquityFeesOnRwgDebt" xlink:to="mbio_AdditionsToApicEquityFeesOnRwgDebtShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AdditionsToApicFromIssuanceOfRwgDebtWarrants" xlink:label="mbio_AdditionsToApicFromIssuanceOfRwgDebtWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="mbio_AdditionsToApicFromIssuanceOfRwgDebtWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ShareIssuedDuringPeriodValueOnExerciseOfWarrants" xlink:label="mbio_ShareIssuedDuringPeriodValueOnExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="mbio_ShareIssuedDuringPeriodValueOnExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants" xlink:label="mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="mbio_ShareIssuedDuringPeriodValueOnExerciseOfWarrants" xlink:to="mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables" xlink:type="extended" xlink:title="30303 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LicenseAgreementsMember" xlink:label="mbio_LicenseAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mbio_LicenseAgreementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_SponsoredResearchAndClinicalTrialAgreementsMember" xlink:label="mbio_SponsoredResearchAndClinicalTrialAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mbio_SponsoredResearchAndClinicalTrialAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30903 - Disclosure - Stockholders' Equity (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_SummaryOfWarrantActivitiesTableTextBlock" xlink:label="mbio_SummaryOfWarrantActivitiesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mbio_SummaryOfWarrantActivitiesTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Significant Accounting Policies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_FortressBiotechIncMember" xlink:label="mbio_FortressBiotechIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mbio_FortressBiotechIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LicenseAgreementsMember" xlink:label="mbio_LicenseAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mbio_LicenseAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_NumberOfSubsidiaries" xlink:label="mbio_NumberOfSubsidiaries" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mbio_NumberOfSubsidiaries" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="us-gaap_PreferredStockDividendsShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendsShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsShares" xlink:label="us-gaap_CommonStockDividendsShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DilutedOutstandingEquityPercentage" xlink:label="mbio_DilutedOutstandingEquityPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="mbio_DilutedOutstandingEquityPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Significant Accounting Policies (Schedule of Potentially Dilutive Securities) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_PreferredClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (License Agreements) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cd123ProductOrProcessMember" xlink:label="mbio_Cd123ProductOrProcessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_Cd123ProductOrProcessMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_IvIcvProductOrProcessMember" xlink:label="mbio_IvIcvProductOrProcessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_IvIcvProductOrProcessMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PscaProductOrProcessMember" xlink:label="mbio_PscaProductOrProcessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_PscaProductOrProcessMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Her2ProductOrProcessMember" xlink:label="mbio_Her2ProductOrProcessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_Her2ProductOrProcessMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CityOfHopeNationalMedicalCenterCohMember" xlink:label="mbio_CityOfHopeNationalMedicalCenterCohMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_CityOfHopeNationalMedicalCenterCohMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CalimmuneMember" xlink:label="mbio_CalimmuneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_CalimmuneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LeidenUniversityMedicalCentreMember" xlink:label="mbio_LeidenUniversityMedicalCentreMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_LeidenUniversityMedicalCentreMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MayoClinicMember" xlink:label="mbio_MayoClinicMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_MayoClinicMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_FortressBiotechIncMember" xlink:label="mbio_FortressBiotechIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_FortressBiotechIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LicenseAgreementsMember" xlink:label="mbio_LicenseAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mbio_LicenseAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails" xlink:type="extended" xlink:title="40302 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (City of Hope - Licenses) (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LicenseAgreementsMember" xlink:label="mbio_LicenseAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mbio_LicenseAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cd123ProductOrProcessMember" xlink:label="mbio_Cd123ProductOrProcessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_Cd123ProductOrProcessMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_IvIcvProductOrProcessMember" xlink:label="mbio_IvIcvProductOrProcessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_IvIcvProductOrProcessMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PscaProductOrProcessMember" xlink:label="mbio_PscaProductOrProcessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_PscaProductOrProcessMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Her2ProductOrProcessMember" xlink:label="mbio_Her2ProductOrProcessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_Her2ProductOrProcessMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CityOfHopeNationalMedicalCenterCohMember" xlink:label="mbio_CityOfHopeNationalMedicalCenterCohMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_CityOfHopeNationalMedicalCenterCohMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CalimmuneMember" xlink:label="mbio_CalimmuneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_CalimmuneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LeidenUniversityMedicalCentreMember" xlink:label="mbio_LeidenUniversityMedicalCentreMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_LeidenUniversityMedicalCentreMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MayoClinicMember" xlink:label="mbio_MayoClinicMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_MayoClinicMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AnnualMaintenanceFeePayable" xlink:label="mbio_AnnualMaintenanceFeePayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mbio_AnnualMaintenanceFeePayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PaymentOfUpfrontFees" xlink:label="mbio_PaymentOfUpfrontFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mbio_PaymentOfUpfrontFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_NumberOfMilestonesMeasured" xlink:label="mbio_NumberOfMilestonesMeasured" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mbio_NumberOfMilestonesMeasured" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MilestonesPayableUnderArrangement" xlink:label="mbio_MilestonesPayableUnderArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mbio_MilestonesPayableUnderArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_NonRefundableMilestonePayments" xlink:label="mbio_NonRefundableMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mbio_NonRefundableMilestonePayments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" xlink:type="extended" xlink:title="40303 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (Sponsored Research and Clinical Trial Agreements) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CityOfHopeMember" xlink:label="mbio_CityOfHopeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_CityOfHopeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cd123ProductOrProcessMember" xlink:label="mbio_Cd123ProductOrProcessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="mbio_CityOfHopeMember" xlink:to="mbio_Cd123ProductOrProcessMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Il13r2ProductMember" xlink:label="mbio_Il13r2ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mbio_CityOfHopeMember" xlink:to="mbio_Il13r2ProductMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cs1ProductOrProcessMember" xlink:label="mbio_Cs1ProductOrProcessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mbio_CityOfHopeMember" xlink:to="mbio_Cs1ProductOrProcessMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Her2ProductOrProcessMember" xlink:label="mbio_Her2ProductOrProcessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mbio_CityOfHopeMember" xlink:to="mbio_Her2ProductOrProcessMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PscaProductOrProcessMember" xlink:label="mbio_PscaProductOrProcessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mbio_CityOfHopeMember" xlink:to="mbio_PscaProductOrProcessMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cd20TechnologyProductOrProcessMember" xlink:label="mbio_Cd20TechnologyProductOrProcessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_Cd20TechnologyProductOrProcessMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StJudeXscidMember" xlink:label="mbio_StJudeXscidMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_StJudeXscidMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Rag1ScidMb110Member" xlink:label="mbio_Rag1ScidMb110Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_Rag1ScidMb110Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CityOfHopeNationalMedicalCenterCohMember" xlink:label="mbio_CityOfHopeNationalMedicalCenterCohMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_CityOfHopeNationalMedicalCenterCohMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_FredHutchinsonCancerResearchCenterMember" xlink:label="mbio_FredHutchinsonCancerResearchCenterMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_FredHutchinsonCancerResearchCenterMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_St.JudeChildrensResearchHospitalMember" xlink:label="mbio_St.JudeChildrensResearchHospitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_St.JudeChildrensResearchHospitalMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MayoClinicMember" xlink:label="mbio_MayoClinicMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_MayoClinicMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LeidenUniversityMedicalCentreMember" xlink:label="mbio_LeidenUniversityMedicalCentreMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_LeidenUniversityMedicalCentreMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_SponsoredResearchAndClinicalTrialAgreementsMember" xlink:label="mbio_SponsoredResearchAndClinicalTrialAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mbio_SponsoredResearchAndClinicalTrialAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" xlink:type="extended" xlink:title="40304 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (City of Hope - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_SponsoredResearchAndClinicalTrialAgreementsMember" xlink:label="mbio_SponsoredResearchAndClinicalTrialAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mbio_SponsoredResearchAndClinicalTrialAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cd123ProductOrProcessMember" xlink:label="mbio_Cd123ProductOrProcessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_Cd123ProductOrProcessMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Il13r2ProductMember" xlink:label="mbio_Il13r2ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_Il13r2ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cs1ProductOrProcessMember" xlink:label="mbio_Cs1ProductOrProcessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_Cs1ProductOrProcessMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Her2ProductOrProcessMember" xlink:label="mbio_Her2ProductOrProcessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_Her2ProductOrProcessMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PscaProductOrProcessMember" xlink:label="mbio_PscaProductOrProcessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_PscaProductOrProcessMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cd20TechnologyProductOrProcessMember" xlink:label="mbio_Cd20TechnologyProductOrProcessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_Cd20TechnologyProductOrProcessMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StJudeXscidMember" xlink:label="mbio_StJudeXscidMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_StJudeXscidMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Rag1ScidMb110Member" xlink:label="mbio_Rag1ScidMb110Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_Rag1ScidMb110Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CityOfHopeNationalMedicalCenterCohMember" xlink:label="mbio_CityOfHopeNationalMedicalCenterCohMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_CityOfHopeNationalMedicalCenterCohMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LeidenUniversityMedicalCentreMember" xlink:label="mbio_LeidenUniversityMedicalCentreMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_LeidenUniversityMedicalCentreMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_FredHutchinsonCancerResearchCenterMember" xlink:label="mbio_FredHutchinsonCancerResearchCenterMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_FredHutchinsonCancerResearchCenterMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MayoClinicMember" xlink:label="mbio_MayoClinicMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_MayoClinicMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_St.JudeChildrensResearchHospitalMember" xlink:label="mbio_St.JudeChildrensResearchHospitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_St.JudeChildrensResearchHospitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PaymentOfUpfrontFees" xlink:label="mbio_PaymentOfUpfrontFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mbio_PaymentOfUpfrontFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ResearchFundingAmount" xlink:label="mbio_ResearchFundingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mbio_ResearchFundingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MilestonesPayableUnderArrangement" xlink:label="mbio_MilestonesPayableUnderArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mbio_MilestonesPayableUnderArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AdditionalMilestonesPayableUnderArrangement" xlink:label="mbio_AdditionalMilestonesPayableUnderArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mbio_AdditionalMilestonesPayableUnderArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ContributionTowardPatientCosts" xlink:label="mbio_ContributionTowardPatientCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mbio_ContributionTowardPatientCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ResearchArrangementContributionPerPatient" xlink:label="mbio_ResearchArrangementContributionPerPatient" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mbio_ResearchArrangementContributionPerPatient" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ResearchArrangementTerm" xlink:label="mbio_ResearchArrangementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mbio_ResearchArrangementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AnnualMaintenanceFeePayable" xlink:label="mbio_AnnualMaintenanceFeePayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mbio_AnnualMaintenanceFeePayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ReimbursementOfFeesTotalPayments" xlink:label="mbio_ReimbursementOfFeesTotalPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mbio_ReimbursementOfFeesTotalPayments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" xlink:type="extended" xlink:title="40305 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (Other - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_FredHutchinsonCancerResearchCenterMember" xlink:label="mbio_FredHutchinsonCancerResearchCenterMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_FredHutchinsonCancerResearchCenterMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_St.JudeChildrensResearchHospitalMember" xlink:label="mbio_St.JudeChildrensResearchHospitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_St.JudeChildrensResearchHospitalMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MayoClinicMember" xlink:label="mbio_MayoClinicMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_MayoClinicMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LeidenUniversityMedicalCentreMember" xlink:label="mbio_LeidenUniversityMedicalCentreMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mbio_LeidenUniversityMedicalCentreMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_SponsoredResearchAndClinicalTrialAgreementsMember" xlink:label="mbio_SponsoredResearchAndClinicalTrialAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mbio_SponsoredResearchAndClinicalTrialAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClinicalTrialAgreementsMember" xlink:label="mbio_ClinicalTrialAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="mbio_SponsoredResearchAndClinicalTrialAgreementsMember" xlink:to="mbio_ClinicalTrialAgreementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DataTransferAgreementMember" xlink:label="mbio_DataTransferAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mbio_SponsoredResearchAndClinicalTrialAgreementsMember" xlink:to="mbio_DataTransferAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cd20TechnologyProductOrProcessMember" xlink:label="mbio_Cd20TechnologyProductOrProcessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_Cd20TechnologyProductOrProcessMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StJudeXscidMember" xlink:label="mbio_StJudeXscidMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_StJudeXscidMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Rag1ScidMb110Member" xlink:label="mbio_Rag1ScidMb110Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mbio_Rag1ScidMb110Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PaymentOfUpfrontFees" xlink:label="mbio_PaymentOfUpfrontFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mbio_PaymentOfUpfrontFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MilestonesPayableUnderArrangement" xlink:label="mbio_MilestonesPayableUnderArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mbio_MilestonesPayableUnderArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AdditionalMilestonesPayableUnderArrangement" xlink:label="mbio_AdditionalMilestonesPayableUnderArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mbio_AdditionalMilestonesPayableUnderArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ReimbursementOfFeesTotalPayments" xlink:label="mbio_ReimbursementOfFeesTotalPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mbio_ReimbursementOfFeesTotalPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ResearchArrangementTerm" xlink:label="mbio_ResearchArrangementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mbio_ResearchArrangementTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Related Party Agreements (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_FortressBiotechIncMember" xlink:label="mbio_FortressBiotechIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mbio_FortressBiotechIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_DirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommonUnspecifiedClassMember" xlink:label="mbio_CommonUnspecifiedClassMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mbio_CommonUnspecifiedClassMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AtMarketOfferingMember" xlink:label="mbio_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mbio_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_RunwayDebtFacilityMember" xlink:label="mbio_RunwayDebtFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mbio_RunwayDebtFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses" xlink:label="mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses" xlink:label="mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuedDuringPeriodSharesIssuableForServices" xlink:label="mbio_StockIssuedDuringPeriodSharesIssuableForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_StockIssuedDuringPeriodSharesIssuableForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DilutedOutstandingEquityPercentage" xlink:label="mbio_DilutedOutstandingEquityPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_DilutedOutstandingEquityPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_FoundersAgreementTerm" xlink:label="mbio_FoundersAgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_FoundersAgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AgreementRenewalTerm" xlink:label="mbio_AgreementRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_AgreementRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PreferredStockVotingRightsMultiplier" xlink:label="mbio_PreferredStockVotingRightsMultiplier" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_PreferredStockVotingRightsMultiplier" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement" xlink:label="mbio_OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_EquityFeePaymentPeriod" xlink:label="mbio_EquityFeePaymentPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_EquityFeePaymentPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_EquityFeePercentageOfFinancing" xlink:label="mbio_EquityFeePercentageOfFinancing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_EquityFeePercentageOfFinancing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CashFeeAsPercentageOfAnnualNetSales" xlink:label="mbio_CashFeeAsPercentageOfAnnualNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_CashFeeAsPercentageOfAnnualNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CashFeePaymentPeriod" xlink:label="mbio_CashFeePaymentPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_CashFeePaymentPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate" xlink:label="mbio_ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ChangeInControlFeeMeasurementPeriodForNetSales" xlink:label="mbio_ChangeInControlFeeMeasurementPeriodForNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_ChangeInControlFeeMeasurementPeriodForNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ChangeInControlFeeSpecifiedRateComponent" xlink:label="mbio_ChangeInControlFeeSpecifiedRateComponent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_ChangeInControlFeeSpecifiedRateComponent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AgreementTerm" xlink:label="mbio_AgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_AgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MsaAgreementRenewalTerm" xlink:label="mbio_MsaAgreementRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_MsaAgreementRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AnnualConsultingFees" xlink:label="mbio_AnnualConsultingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_AnnualConsultingFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_IncreaseInAnnualConsultingFees" xlink:label="mbio_IncreaseInAnnualConsultingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_IncreaseInAnnualConsultingFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ExcessInNetAssetsValue" xlink:label="mbio_ExcessInNetAssetsValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_ExcessInNetAssetsValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DirectorCompensationValueOfSharesGranted" xlink:label="mbio_DirectorCompensationValueOfSharesGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_DirectorCompensationValueOfSharesGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DirectorCompensationNumberOfSharesGranted" xlink:label="mbio_DirectorCompensationNumberOfSharesGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mbio_DirectorCompensationNumberOfSharesGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Commitments and Contingencies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_NetRentableArea" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LesseeOperatingLeaseTotalBaseRentNetOfAbatements" xlink:label="mbio_LesseeOperatingLeaseTotalBaseRentNetOfAbatements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="mbio_LesseeOperatingLeaseTotalBaseRentNetOfAbatements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LesseeOperatingLeaseTotalAbatementsOverLeaseTerm" xlink:label="mbio_LesseeOperatingLeaseTotalAbatementsOverLeaseTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="mbio_LesseeOperatingLeaseTotalAbatementsOverLeaseTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LesseeSecurityDepositUponFullOccupancy" xlink:label="mbio_LesseeSecurityDepositUponFullOccupancy" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="mbio_LesseeSecurityDepositUponFullOccupancy" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Notes Payable (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_RunwayDebtFacilityMember" xlink:label="mbio_RunwayDebtFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mbio_RunwayDebtFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember" xlink:label="us-gaap_BaseRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_BaseRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LegalFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DebtInstrumentBalloonPaymentAsPercentageOfPrincipal" xlink:label="mbio_DebtInstrumentBalloonPaymentAsPercentageOfPrincipal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="mbio_DebtInstrumentBalloonPaymentAsPercentageOfPrincipal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermNotesPayable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stockholders Equity (Common Stock and Equity Offerings) (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AtMarketOfferingMember" xlink:label="mbio_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mbio_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_RegistrationStatementsMember" xlink:label="mbio_RegistrationStatementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mbio_RegistrationStatementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_FortressBiotechIncMember" xlink:label="mbio_FortressBiotechIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mbio_FortressBiotechIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement" xlink:label="mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold" xlink:label="mbio_ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mbio_ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommonStockSharesAvailableForFutureIssuanceValue" xlink:label="mbio_CommonStockSharesAvailableForFutureIssuanceValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mbio_CommonStockSharesAvailableForFutureIssuanceValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DilutedOutstandingEquityPercentage" xlink:label="mbio_DilutedOutstandingEquityPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mbio_DilutedOutstandingEquityPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuedDuringPeriodSharesIssuableForServices" xlink:label="mbio_StockIssuedDuringPeriodSharesIssuableForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mbio_StockIssuedDuringPeriodSharesIssuableForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesSubscriptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_VotingRightsNumberOfVotesPerShare" xlink:label="mbio_VotingRightsNumberOfVotesPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mbio_VotingRightsNumberOfVotesPerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockholderAppointmentOfDirectorPeriodAfterIssuance" xlink:label="mbio_StockholderAppointmentOfDirectorPeriodAfterIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mbio_StockholderAppointmentOfDirectorPeriodAfterIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommissionRatePercentage" xlink:label="mbio_CommissionRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mbio_CommissionRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" xlink:label="mbio_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mbio_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Stockholders Equity (Equity Incentive Plan) (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage" xlink:label="mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Stockholders Equity (Stock Options) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Stockholders Equity (Restricted Stock Awards and Restricted Stock Units) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Stockholders Equity (Stock-based Compensation Expense) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Stockholders' Equity (Stock Warrants) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_RunwayDebtFacilityMember" xlink:label="mbio_RunwayDebtFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mbio_RunwayDebtFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased" xlink:label="mbio_ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mbio_ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod" xlink:label="mbio_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mbio_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightWarrantsGrantedDuringPeriod" xlink:label="mbio_ClassOfWarrantOrRightWarrantsGrantedDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mbio_ClassOfWarrantOrRightWarrantsGrantedDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod" xlink:label="mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_WarrantExercisePriceExpiredDuringPeriod" xlink:label="mbio_WarrantExercisePriceExpiredDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mbio_WarrantExercisePriceExpiredDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod" xlink:label="mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" xlink:label="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod" xlink:label="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.mustangbio.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Income Taxes (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_OperatingLossCarryforwardsWithoutExpiration" xlink:label="mbio_OperatingLossCarryforwardsWithoutExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="mbio_OperatingLossCarryforwardsWithoutExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>28
<FILENAME>tmb-20221231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/29/2023 11:43:38 PM-->
<!--Modified on: 3/29/2023 11:43:38 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US">Class A Common Shares [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommonUnspecifiedClassMember" xlink:label="mbio_CommonUnspecifiedClassMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_CommonUnspecifiedClassMember" xlink:to="mbio_CommonUnspecifiedClassMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_CommonUnspecifiedClassMember_lbl" xml:lang="en-US">Classification of common stock representing ownership interest in a corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_CommonUnspecifiedClassMember_lbl" xml:lang="en-US">Common Shares [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Other receivables - related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction" xlink:label="mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction" xlink:to="mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction_lbl" xml:lang="en-US">Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale but excluding construction in process assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction_lbl" xml:lang="en-US">Property, Plant And Equipment Excluding Assets Under Construction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ConstructionInProcessNet" xlink:label="mbio_ConstructionInProcessNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ConstructionInProcessNet" xlink:to="mbio_ConstructionInProcessNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ConstructionInProcessNet_lbl" xml:lang="en-US">Amount after accumulated depreciation, depletion and amortization of assets under construction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ConstructionInProcessNet_lbl" xml:lang="en-US">Construction In Process Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mbio_ConstructionInProcessNet_lbl" xml:lang="en-US">Fixed assets - construction in process</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted Cash, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Payables and accrued expenses - related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities - short-term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeNoncurrent" xlink:to="us-gaap_DeferredIncomeNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeNoncurrent_lbl" xml:lang="en-US">Deferred Income, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeNoncurrent_lbl" xml:lang="en-US">Deferred income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Notes Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Note payable, long-term, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Long-term note payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities - long-term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 11)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock ($0.0001 par value), 2,000,000 shares authorized, 250,000 shares of Class A preferred stock issued and outstanding as of December 31, 2022 and 2021, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock ($0.0001 par value), 200,000,000 and 150,000,000 shares authorized as of December 31, 2022 and 2021, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscriptions" xlink:to="us-gaap_CommonStockSharesSubscriptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xml:lang="en-US">Common Stock, Value, Subscriptions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xml:lang="en-US">Aggregate value of shares subscribed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xml:lang="en-US">Common stock issuable, 2,807,008 and 2,536,607 shares as of December 31, 2022 and 2021, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xml:lang="en-US">Common Stock, Shares Subscribed but Unissued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xml:lang="en-US">Common stock, shares issuable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xml:lang="en-US">Research and development for licenses acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xml:lang="en-US">Research and development - licenses acquired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_GrantIncome" xlink:label="mbio_GrantIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_GrantIncome" xlink:to="mbio_GrantIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_GrantIncome_lbl" xml:lang="en-US">The amount of grant income, such as from governmental agencies in reimbursement of covered expenses, recognized during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_GrantIncome_lbl" xml:lang="en-US">Grant income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_GrantIncome_lbl" xml:lang="en-US">Grant income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest Income, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per common share outstanding, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per common share outstanding, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">STATEMENTS OF STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassAMember" xlink:to="us-gaap_PreferredClassAMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredClassAMember_lbl" xml:lang="en-US">Preferred Class A [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommonStockIssuableMember" xlink:label="mbio_CommonStockIssuableMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_CommonStockIssuableMember" xlink:to="mbio_CommonStockIssuableMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_CommonStockIssuableMember_lbl" xml:lang="en-US">Common Stock Issuable [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balances (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balances (in shares)</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuanceCommonStockIssuableDuringPeriod" xlink:label="mbio_StockIssuanceCommonStockIssuableDuringPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_StockIssuanceCommonStockIssuableDuringPeriod" xlink:to="mbio_StockIssuanceCommonStockIssuableDuringPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_StockIssuanceCommonStockIssuableDuringPeriod_lbl" xml:lang="en-US">Value of new common stock issuable during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_StockIssuanceCommonStockIssuableDuringPeriod_lbl" xml:lang="en-US">Stock Issuance Common Stock Issuable During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_StockIssuanceCommonStockIssuableDuringPeriod_lbl" xml:lang="en-US">Common stock issuable - Founders Agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement" xlink:label="mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement" xlink:to="mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement_lbl" xml:lang="en-US">The Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement_lbl" xml:lang="en-US">Stock Issued During Period Value Issued For Founders Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement_lbl" xml:lang="en-US">Issuance of common shares - Founders Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Shares issued for services (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common shares - Founders Agreement (in shares)</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuedDuringPeriodValueAtMarketingOffering" xlink:label="mbio_StockIssuedDuringPeriodValueAtMarketingOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_StockIssuedDuringPeriodValueAtMarketingOffering" xlink:to="mbio_StockIssuedDuringPeriodValueAtMarketingOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_StockIssuedDuringPeriodValueAtMarketingOffering_lbl" xml:lang="en-US">Value of stock issued at the market offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_StockIssuedDuringPeriodValueAtMarketingOffering_lbl" xml:lang="en-US">Stock Issued During Period Value, At The Marketing Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mbio_StockIssuedDuringPeriodValueAtMarketingOffering_lbl" xml:lang="en-US">Issuance of common shares, net of offering costs - At-the-Market Offering</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuedDuringPeriodSharesAtMarketOffering" xlink:label="mbio_StockIssuedDuringPeriodSharesAtMarketOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_StockIssuedDuringPeriodSharesAtMarketOffering" xlink:to="mbio_StockIssuedDuringPeriodSharesAtMarketOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_StockIssuedDuringPeriodSharesAtMarketOffering_lbl" xml:lang="en-US">Number of shares issued at the market offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_StockIssuedDuringPeriodSharesAtMarketOffering_lbl" xml:lang="en-US">Stock Issued During Period Shares , At The Market Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mbio_StockIssuedDuringPeriodSharesAtMarketOffering_lbl" xml:lang="en-US">Issuance of common shares, net of offering costs - At-the-Market Offering (in shares)</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering" xlink:label="mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering" xlink:to="mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering_lbl" xml:lang="en-US">Value of number of shares issued at equity market offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering_lbl" xml:lang="en-US">Stock Issued During Period Value Equity Fee On At Market Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering_lbl" xml:lang="en-US">Issuance of common shares - Equity fee on At-the-Market Offering</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering" xlink:label="mbio_StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering" xlink:to="mbio_StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering_lbl" xml:lang="en-US">Common Shares issued equity fee on the market offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering_lbl" xml:lang="en-US">Stock Issued During Period Shares ,Equity Fee On At The Market Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mbio_StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering_lbl" xml:lang="en-US">Issuance of common shares - Equity fee on At-the-Market Offering (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Issuance of common shares under ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Issuance of common shares under ESPP (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Number of shares purchased under ESPP</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CorrectionToPreviouslyIssuedShares" xlink:label="mbio_CorrectionToPreviouslyIssuedShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_CorrectionToPreviouslyIssuedShares" xlink:to="mbio_CorrectionToPreviouslyIssuedShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_CorrectionToPreviouslyIssuedShares_lbl" xml:lang="en-US">Correction to previously issued shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_CorrectionToPreviouslyIssuedShares_lbl" xml:lang="en-US">Correction to previously issued shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_CorrectionToPreviouslyIssuedShares_lbl" xml:lang="en-US">Correction to previously issued shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expenses (in shares)</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AdditionsToApicEquityFeesOnRwgDebt" xlink:label="mbio_AdditionsToApicEquityFeesOnRwgDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_AdditionsToApicEquityFeesOnRwgDebt" xlink:to="mbio_AdditionsToApicEquityFeesOnRwgDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_AdditionsToApicEquityFeesOnRwgDebt_lbl" xml:lang="en-US">Represents additions to APIC attributable to equity fees on RWG debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_AdditionsToApicEquityFeesOnRwgDebt_lbl" xml:lang="en-US">Additions To APIC - Equity Fees On RWG Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_AdditionsToApicEquityFeesOnRwgDebt_lbl" xml:lang="en-US">Issuance of common shares - Equity fee on RWG Debt</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AdditionsToApicEquityFeesOnRwgDebtShares" xlink:label="mbio_AdditionsToApicEquityFeesOnRwgDebtShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_AdditionsToApicEquityFeesOnRwgDebtShares" xlink:to="mbio_AdditionsToApicEquityFeesOnRwgDebtShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_AdditionsToApicEquityFeesOnRwgDebtShares_lbl" xml:lang="en-US">Number of shares issued related to RWG debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_AdditionsToApicEquityFeesOnRwgDebtShares_lbl" xml:lang="en-US">Additions to APIC - Equity Fees On RWG Debt, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_AdditionsToApicEquityFeesOnRwgDebtShares_lbl" xml:lang="en-US">Issuance of common shares - Equity fee on RWG Debt (in shares)</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AdditionsToApicFromIssuanceOfRwgDebtWarrants" xlink:label="mbio_AdditionsToApicFromIssuanceOfRwgDebtWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_AdditionsToApicFromIssuanceOfRwgDebtWarrants" xlink:to="mbio_AdditionsToApicFromIssuanceOfRwgDebtWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_AdditionsToApicFromIssuanceOfRwgDebtWarrants_lbl" xml:lang="en-US">Additions to APIC from the issuance of warrants related to RWG debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_AdditionsToApicFromIssuanceOfRwgDebtWarrants_lbl" xml:lang="en-US">Additions To APIC From Issuance Of RWG Debt Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_AdditionsToApicFromIssuanceOfRwgDebtWarrants_lbl" xml:lang="en-US">Issuance of warrants for RWG Debt</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ShareIssuedDuringPeriodValueOnExerciseOfWarrants" xlink:label="mbio_ShareIssuedDuringPeriodValueOnExerciseOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ShareIssuedDuringPeriodValueOnExerciseOfWarrants" xlink:to="mbio_ShareIssuedDuringPeriodValueOnExerciseOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ShareIssuedDuringPeriodValueOnExerciseOfWarrants_lbl" xml:lang="en-US">The value of shares issued on exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ShareIssuedDuringPeriodValueOnExerciseOfWarrants_lbl" xml:lang="en-US">Share Issued During Period, Value, On Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_ShareIssuedDuringPeriodValueOnExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants" xlink:label="mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants" xlink:to="mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants_lbl" xml:lang="en-US">The number of shares issued on exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants_lbl" xml:lang="en-US">Share Issued During Period, Shares, On Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Operating Activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_IssuanceOfCommonSharesEquityFeeOnAtMarketOffering" xlink:label="mbio_IssuanceOfCommonSharesEquityFeeOnAtMarketOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_IssuanceOfCommonSharesEquityFeeOnAtMarketOffering" xlink:to="mbio_IssuanceOfCommonSharesEquityFeeOnAtMarketOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_IssuanceOfCommonSharesEquityFeeOnAtMarketOffering_lbl" xml:lang="en-US">It Represents issuance of common stock for equity fee at market offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_IssuanceOfCommonSharesEquityFeeOnAtMarketOffering_lbl" xml:lang="en-US">Issuance Of Common Shares Equity Fee On At Market Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mbio_IssuanceOfCommonSharesEquityFeeOnAtMarketOffering_lbl" xml:lang="en-US">Issuance of common shares - Equity fee on at-the-market offering to Fortress Biotech</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance" xlink:label="mbio_AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance" xlink:to="mbio_AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance_lbl" xml:lang="en-US">Adjustment to net income (loss) for research and development expense attributable to licenses acquired via issuance of stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance_lbl" xml:lang="en-US">Adjustment To Recognize Effect Of Research And Development Expense Attributable To Asset Acquired Via Stock Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance_lbl" xml:lang="en-US">Common shares issuable for Founders Agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense" xlink:label="mbio_ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense" xlink:to="mbio_ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense_lbl" xml:lang="en-US">R&amp;D include in Accounts payable and accrued expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense_lbl" xml:lang="en-US">Research And Development License In Accounts Payable And Accrued Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mbio_ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense_lbl" xml:lang="en-US">Research and development - licenses acquired</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommonShareIssuanceFeesRelatedPartyDebt" xlink:label="mbio_CommonShareIssuanceFeesRelatedPartyDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_CommonShareIssuanceFeesRelatedPartyDebt" xlink:to="mbio_CommonShareIssuanceFeesRelatedPartyDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_CommonShareIssuanceFeesRelatedPartyDebt_lbl" xml:lang="en-US">Represents the non-cash fees related to issuance of common shares on note payable to Fortress Biotech.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_CommonShareIssuanceFeesRelatedPartyDebt_lbl" xml:lang="en-US">Common Share Issuance Fees, Related Party Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_CommonShareIssuanceFeesRelatedPartyDebt_lbl" xml:lang="en-US">Issuance of common shares - Equity fee to Fortress Biotech on note payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Operating Lease Right Of Use Assets Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposal of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Increase (Decrease) in Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Other receivables - related party</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties" xlink:label="mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties" xlink:to="mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties_lbl" xml:lang="en-US">The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid excluding those attributable to related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties_lbl" xml:lang="en-US">Increase (Decrease) In Accounts Payable And Accrued Expenses Excluding Amounts Due To Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xml:lang="en-US">Increase (Decrease) in Due to Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xml:lang="en-US">Payable and accrued expenses - related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred income</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_IncreaseDecreaseInLeaseLiabilities" xlink:label="mbio_IncreaseDecreaseInLeaseLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_IncreaseDecreaseInLeaseLiabilities" xlink:to="mbio_IncreaseDecreaseInLeaseLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_IncreaseDecreaseInLeaseLiabilities_lbl" xml:lang="en-US">Amount of Increase Decrease In Lease Liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_IncreaseDecreaseInLeaseLiabilities_lbl" xml:lang="en-US">Increase Decrease In Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mbio_IncreaseDecreaseInLeaseLiabilities_lbl" xml:lang="en-US">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Investing Activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchase of research and development licenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from the sale of fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing Activities:</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ProceedsFromIssuanceOfCommonSharesAtMarketOffering" xlink:label="mbio_ProceedsFromIssuanceOfCommonSharesAtMarketOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ProceedsFromIssuanceOfCommonSharesAtMarketOffering" xlink:to="mbio_ProceedsFromIssuanceOfCommonSharesAtMarketOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ProceedsFromIssuanceOfCommonSharesAtMarketOffering_lbl" xml:lang="en-US">Proceeds from issuance of common shares - At-the-Market Offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ProceedsFromIssuanceOfCommonSharesAtMarketOffering_lbl" xml:lang="en-US">Proceeds From Issuance of Common Shares - At-the-Market Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_ProceedsFromIssuanceOfCommonSharesAtMarketOffering_lbl" xml:lang="en-US">Proceeds from issuance of common shares - at-the-market offering</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_OfferingCostsForIssuanceOfCommonSharesAtMarketOffering" xlink:label="mbio_OfferingCostsForIssuanceOfCommonSharesAtMarketOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_OfferingCostsForIssuanceOfCommonSharesAtMarketOffering" xlink:to="mbio_OfferingCostsForIssuanceOfCommonSharesAtMarketOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_OfferingCostsForIssuanceOfCommonSharesAtMarketOffering_lbl" xml:lang="en-US">Offering costs for the issuance of common shares - At-the-Market Offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_OfferingCostsForIssuanceOfCommonSharesAtMarketOffering_lbl" xml:lang="en-US">Offering Costs For the Issuance of Common Shares - At-the-Market Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mbio_OfferingCostsForIssuanceOfCommonSharesAtMarketOffering_lbl" xml:lang="en-US">Offering costs for the issuance of common shares - at-the-market offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from Issuance of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from debt issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Fees paid on the issuance of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Upfront fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US">Proceeds from Stock Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US">Proceeds from issuance of common shares under ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosure of noncash activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Fixed assets (acquired but not paid)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Stock Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Issuance of common shares - Founders Agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid" xlink:label="mbio_ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid" xlink:to="mbio_ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid_lbl" xml:lang="en-US">Future cash outflow to pay for research and development licenses expenditures that have occurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid_lbl" xml:lang="en-US">Research And Development Licenses Expenditure Incurred But Not Yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid_lbl" xml:lang="en-US">Research and development licenses included in accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US">Note payable final payment fee (incurred but not paid)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Issuance of warrants - note payable</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LeaseLiabilitiesArisingFromObtainingRightOfUseAssets" xlink:label="mbio_LeaseLiabilitiesArisingFromObtainingRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_LeaseLiabilitiesArisingFromObtainingRightOfUseAssets" xlink:to="mbio_LeaseLiabilitiesArisingFromObtainingRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_LeaseLiabilitiesArisingFromObtainingRightOfUseAssets_lbl" xml:lang="en-US">Lease liabilities arising from obtaining right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_LeaseLiabilitiesArisingFromObtainingRightOfUseAssets_lbl" xml:lang="en-US">Lease liabilities arising from obtaining right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization and Description of Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Description of Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">License, Clinical Trial and Sponsored Research Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">License, Clinical Trial and Sponsored Research Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable and Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Notes Payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure. [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">Receivable [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">Other Receivables - Related Party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, plant and equipment, net and Property and equipment - Construction in Process</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AnnualStockDividendPolicyTextBlock" xlink:label="mbio_AnnualStockDividendPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_AnnualStockDividendPolicyTextBlock" xlink:to="mbio_AnnualStockDividendPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_AnnualStockDividendPolicyTextBlock_lbl" xml:lang="en-US">Annual Stock Dividend [Policy Text Block].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_AnnualStockDividendPolicyTextBlock_lbl" xml:lang="en-US">Annual Stock Dividend [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_AnnualStockDividendPolicyTextBlock_lbl" xml:lang="en-US">Annual Stock Dividend</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Potentially Dilutive Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LicenseAgreementsMember" xlink:label="mbio_LicenseAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_LicenseAgreementsMember" xlink:to="mbio_LicenseAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_LicenseAgreementsMember_lbl" xml:lang="en-US">Information pertaining to collaborative agreements involving pharmaceutical products or processes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_LicenseAgreementsMember_lbl" xml:lang="en-US">License Agreements [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_SponsoredResearchAndClinicalTrialAgreementsMember" xlink:label="mbio_SponsoredResearchAndClinicalTrialAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_SponsoredResearchAndClinicalTrialAgreementsMember" xlink:to="mbio_SponsoredResearchAndClinicalTrialAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_SponsoredResearchAndClinicalTrialAgreementsMember_lbl" xml:lang="en-US">Information pertaining to collaborative agreements involving sponsored research and clinical trials of pharmaceutical products or processes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_SponsoredResearchAndClinicalTrialAgreementsMember_lbl" xml:lang="en-US">Sponsored Research and Clinical Trial Agreements [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">License, Clinical Trial and Sponsored Research Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Clinical Trial and Sponsored Research Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of information about operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturities of operating leases excluding short term leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">Summary of long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock Awards [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Option Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedules of Restricted Stock and Restricted Stock Unit Activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_SummaryOfWarrantActivitiesTableTextBlock" xlink:label="mbio_SummaryOfWarrantActivitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_SummaryOfWarrantActivitiesTableTextBlock" xlink:to="mbio_SummaryOfWarrantActivitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_SummaryOfWarrantActivitiesTableTextBlock_lbl" xml:lang="en-US">Summary of warrant activities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_SummaryOfWarrantActivitiesTableTextBlock_lbl" xml:lang="en-US">Summary of warrant activities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_SummaryOfWarrantActivitiesTableTextBlock_lbl" xml:lang="en-US">Summary of Warrant Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_FortressBiotechIncMember" xlink:label="mbio_FortressBiotechIncMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_FortressBiotechIncMember" xlink:to="mbio_FortressBiotechIncMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_FortressBiotechIncMember_lbl" xml:lang="en-US">Fortress Biotech, Inc [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction in Process [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_NumberOfSubsidiaries" xlink:label="mbio_NumberOfSubsidiaries" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_NumberOfSubsidiaries" xlink:to="mbio_NumberOfSubsidiaries_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_NumberOfSubsidiaries_lbl" xml:lang="en-US">The number of subsidiaries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_NumberOfSubsidiaries_lbl" xml:lang="en-US">Number Of Subsidiaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_NumberOfSubsidiaries_lbl" xml:lang="en-US">Number of subsidiaries</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, plant and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="us-gaap_PreferredStockDividendsShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsShares" xlink:to="us-gaap_PreferredStockDividendsShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsShares_lbl" xml:lang="en-US">Preferred Stock Dividends, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockDividendsShares_lbl" xml:lang="en-US">Preferred stock dividends issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsShares" xlink:label="us-gaap_CommonStockDividendsShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockDividendsShares_lbl" xml:lang="en-US">Common Stock Dividends, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockDividendsShares_lbl" xml:lang="en-US">Common stock dividend issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DilutedOutstandingEquityPercentage" xlink:label="mbio_DilutedOutstandingEquityPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_DilutedOutstandingEquityPercentage" xlink:to="mbio_DilutedOutstandingEquityPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_DilutedOutstandingEquityPercentage_lbl" xml:lang="en-US">Represents the percentage of diluted outstanding equity paid as equity fee or used to calculate stock issuance to maintain parity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_DilutedOutstandingEquityPercentage_lbl" xml:lang="en-US">Diluted Outstanding Equity, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_DilutedOutstandingEquityPercentage_lbl" xml:lang="en-US">Percentage of fully diluted equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_lbl" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_lbl" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Options [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Potentially dilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cd123ProductOrProcessMember" xlink:label="mbio_Cd123ProductOrProcessMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_Cd123ProductOrProcessMember" xlink:to="mbio_Cd123ProductOrProcessMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_Cd123ProductOrProcessMember_lbl" xml:lang="en-US">Information pertaining to CD123, a pharmaceutical product or process.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_Cd123ProductOrProcessMember_lbl" xml:lang="en-US">CD123 (MB-102) [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_IvIcvProductOrProcessMember" xlink:label="mbio_IvIcvProductOrProcessMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_IvIcvProductOrProcessMember" xlink:to="mbio_IvIcvProductOrProcessMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_IvIcvProductOrProcessMember_lbl" xml:lang="en-US">Information pertaining to IV/ICV, a pharmaceutical product or process.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_IvIcvProductOrProcessMember_lbl" xml:lang="en-US">IV/ICV Product or Process [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PscaProductOrProcessMember" xlink:label="mbio_PscaProductOrProcessMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_PscaProductOrProcessMember" xlink:to="mbio_PscaProductOrProcessMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_PscaProductOrProcessMember_lbl" xml:lang="en-US">Information pertaining to PSCA, a pharmaceutical product or process.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_PscaProductOrProcessMember_lbl" xml:lang="en-US">PSCA (MB-105) [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Her2ProductOrProcessMember" xlink:label="mbio_Her2ProductOrProcessMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_Her2ProductOrProcessMember" xlink:to="mbio_Her2ProductOrProcessMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_Her2ProductOrProcessMember_lbl" xml:lang="en-US">Information pertaining to HER2, a pharmaceutical product or process.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_Her2ProductOrProcessMember_lbl" xml:lang="en-US">HER2 (MB 103) [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CityOfHopeNationalMedicalCenterCohMember" xlink:label="mbio_CityOfHopeNationalMedicalCenterCohMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_CityOfHopeNationalMedicalCenterCohMember" xlink:to="mbio_CityOfHopeNationalMedicalCenterCohMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_CityOfHopeNationalMedicalCenterCohMember_lbl" xml:lang="en-US">Information pertaining to City Of Hope National Medical Center ("COH"), a counterparty in agreement(s) with the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_CityOfHopeNationalMedicalCenterCohMember_lbl" xml:lang="en-US">City of Hope National Medical Center ("COH") [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CalimmuneMember" xlink:label="mbio_CalimmuneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_CalimmuneMember" xlink:to="mbio_CalimmuneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_CalimmuneMember_lbl" xml:lang="en-US">Represents the information pertaining to Calimmune.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_CalimmuneMember_lbl" xml:lang="en-US">CSL Behring (Calimmune) [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LeidenUniversityMedicalCentreMember" xlink:label="mbio_LeidenUniversityMedicalCentreMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_LeidenUniversityMedicalCentreMember" xlink:to="mbio_LeidenUniversityMedicalCentreMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_LeidenUniversityMedicalCentreMember_lbl" xml:lang="en-US">Leiden University Medical Centre [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_LeidenUniversityMedicalCentreMember_lbl" xml:lang="en-US">Leiden University Medical Centre [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MayoClinicMember" xlink:label="mbio_MayoClinicMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_MayoClinicMember" xlink:to="mbio_MayoClinicMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_MayoClinicMember_lbl" xml:lang="en-US">Mayo Clinic [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_MayoClinicMember_lbl" xml:lang="en-US">Mayo Clinic [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AnnualMaintenanceFeePayable" xlink:label="mbio_AnnualMaintenanceFeePayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_AnnualMaintenanceFeePayable" xlink:to="mbio_AnnualMaintenanceFeePayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_AnnualMaintenanceFeePayable_lbl" xml:lang="en-US">The amount of annual maintenance fee payable under the arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_AnnualMaintenanceFeePayable_lbl" xml:lang="en-US">Annual Maintenance Fee Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_AnnualMaintenanceFeePayable_lbl" xml:lang="en-US">Annual maintenance fee payable</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PaymentOfUpfrontFees" xlink:label="mbio_PaymentOfUpfrontFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_PaymentOfUpfrontFees" xlink:to="mbio_PaymentOfUpfrontFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_PaymentOfUpfrontFees_lbl" xml:lang="en-US">Payment of Upfront Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_PaymentOfUpfrontFees_lbl" xml:lang="en-US">Payment Of Upfront Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_PaymentOfUpfrontFees_lbl" xml:lang="en-US">Upfront fees paid</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_NumberOfMilestonesMeasured" xlink:label="mbio_NumberOfMilestonesMeasured" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_NumberOfMilestonesMeasured" xlink:to="mbio_NumberOfMilestonesMeasured_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_NumberOfMilestonesMeasured_lbl" xml:lang="en-US">The number of milestones measured under the arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_NumberOfMilestonesMeasured_lbl" xml:lang="en-US">Number Of Milestones Measured</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_NumberOfMilestonesMeasured_lbl" xml:lang="en-US">Number of milestones</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MilestonesPayableUnderArrangement" xlink:label="mbio_MilestonesPayableUnderArrangement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_MilestonesPayableUnderArrangement" xlink:to="mbio_MilestonesPayableUnderArrangement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_MilestonesPayableUnderArrangement_lbl" xml:lang="en-US">The amount of milestones payable under the arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_MilestonesPayableUnderArrangement_lbl" xml:lang="en-US">Milestones Payable Under The Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_MilestonesPayableUnderArrangement_lbl" xml:lang="en-US">Milestones payable</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_NonRefundableMilestonePayments" xlink:label="mbio_NonRefundableMilestonePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_NonRefundableMilestonePayments" xlink:to="mbio_NonRefundableMilestonePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_NonRefundableMilestonePayments_lbl" xml:lang="en-US">Non-refundable milestone payment expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_NonRefundableMilestonePayments_lbl" xml:lang="en-US">Non-Refundable Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_NonRefundableMilestonePayments_lbl" xml:lang="en-US">Non-refundable milestone payments</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CityOfHopeMember" xlink:label="mbio_CityOfHopeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_CityOfHopeMember" xlink:to="mbio_CityOfHopeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_CityOfHopeMember_lbl" xml:lang="en-US">Information pertaining to City of hope, a pharmaceutical product or process.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_CityOfHopeMember_lbl" xml:lang="en-US">City of Hope [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Il13r2ProductMember" xlink:label="mbio_Il13r2ProductMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_Il13r2ProductMember" xlink:to="mbio_Il13r2ProductMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_Il13r2ProductMember_lbl" xml:lang="en-US">Information pertaining to Il13r2, a pharmaceutical product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_Il13r2ProductMember_lbl" xml:lang="en-US">IL13Ra2 (MB-101) [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cs1ProductOrProcessMember" xlink:label="mbio_Cs1ProductOrProcessMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_Cs1ProductOrProcessMember" xlink:to="mbio_Cs1ProductOrProcessMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_Cs1ProductOrProcessMember_lbl" xml:lang="en-US">Information pertaining to CS1, a pharmaceutical product or process.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_Cs1ProductOrProcessMember_lbl" xml:lang="en-US">CS1 (MB-104) [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cd20TechnologyProductOrProcessMember" xlink:label="mbio_Cd20TechnologyProductOrProcessMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_Cd20TechnologyProductOrProcessMember" xlink:to="mbio_Cd20TechnologyProductOrProcessMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_Cd20TechnologyProductOrProcessMember_lbl" xml:lang="en-US">Represents information pertaining to CD20 Technology License.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_Cd20TechnologyProductOrProcessMember_lbl" xml:lang="en-US">CD20 (MB-106) [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StJudeXscidMember" xlink:label="mbio_StJudeXscidMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_StJudeXscidMember" xlink:to="mbio_StJudeXscidMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_StJudeXscidMember_lbl" xml:lang="en-US">Information pertaining to St Jude - XSCID, a pharmaceutical product or process.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_StJudeXscidMember_lbl" xml:lang="en-US">ST. Jude - XSCID [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Rag1ScidMb110Member" xlink:label="mbio_Rag1ScidMb110Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_Rag1ScidMb110Member" xlink:to="mbio_Rag1ScidMb110Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_Rag1ScidMb110Member_lbl" xml:lang="en-US">RAG1 SCID (MB-110) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_Rag1ScidMb110Member_lbl" xml:lang="en-US">RAG1 SCID (MB-110) [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_FredHutchinsonCancerResearchCenterMember" xlink:label="mbio_FredHutchinsonCancerResearchCenterMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_FredHutchinsonCancerResearchCenterMember" xlink:to="mbio_FredHutchinsonCancerResearchCenterMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_FredHutchinsonCancerResearchCenterMember_lbl" xml:lang="en-US">Information pertaining to Fred Hutchinson Cancer Research Center, a counterparty in agreement(s) with the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_FredHutchinsonCancerResearchCenterMember_lbl" xml:lang="en-US">Fred Hutchinson Cancer Center [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_St.JudeChildrensResearchHospitalMember" xlink:label="mbio_St.JudeChildrensResearchHospitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_St.JudeChildrensResearchHospitalMember" xlink:to="mbio_St.JudeChildrensResearchHospitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_St.JudeChildrensResearchHospitalMember_lbl" xml:lang="en-US">St. Jude Children's Research Hospital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_St.JudeChildrensResearchHospitalMember_lbl" xml:lang="en-US">St. Jude Children's Research Hospital [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ResearchFundingAmount" xlink:label="mbio_ResearchFundingAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ResearchFundingAmount" xlink:to="mbio_ResearchFundingAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ResearchFundingAmount_lbl" xml:lang="en-US">The amount of research funding provided by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ResearchFundingAmount_lbl" xml:lang="en-US">Research Funding, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_ResearchFundingAmount_lbl" xml:lang="en-US">Research funding</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AdditionalMilestonesPayableUnderArrangement" xlink:label="mbio_AdditionalMilestonesPayableUnderArrangement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_AdditionalMilestonesPayableUnderArrangement" xlink:to="mbio_AdditionalMilestonesPayableUnderArrangement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_AdditionalMilestonesPayableUnderArrangement_lbl" xml:lang="en-US">The amount of additional milestones payable under the arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_AdditionalMilestonesPayableUnderArrangement_lbl" xml:lang="en-US">Additional Milestones Payable Under Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_AdditionalMilestonesPayableUnderArrangement_lbl" xml:lang="en-US">Additional milestone payments</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ContributionTowardPatientCosts" xlink:label="mbio_ContributionTowardPatientCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ContributionTowardPatientCosts" xlink:to="mbio_ContributionTowardPatientCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ContributionTowardPatientCosts_lbl" xml:lang="en-US">The amount of contribution to be paid toward patient costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ContributionTowardPatientCosts_lbl" xml:lang="en-US">Contribution Toward Patient Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_ContributionTowardPatientCosts_lbl" xml:lang="en-US">Contribution toward patient costs</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ResearchArrangementContributionPerPatient" xlink:label="mbio_ResearchArrangementContributionPerPatient" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ResearchArrangementContributionPerPatient" xlink:to="mbio_ResearchArrangementContributionPerPatient_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ResearchArrangementContributionPerPatient_lbl" xml:lang="en-US">The amount of contribution to be paid per patient under the arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ResearchArrangementContributionPerPatient_lbl" xml:lang="en-US">Research Arrangement, Contribution Per Patient</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_ResearchArrangementContributionPerPatient_lbl" xml:lang="en-US">Contribution per patient</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ResearchArrangementTerm" xlink:label="mbio_ResearchArrangementTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ResearchArrangementTerm" xlink:to="mbio_ResearchArrangementTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ResearchArrangementTerm_lbl" xml:lang="en-US">The term of the research arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ResearchArrangementTerm_lbl" xml:lang="en-US">Research Arrangement Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_ResearchArrangementTerm_lbl" xml:lang="en-US">Agreement term</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ReimbursementOfFeesTotalPayments" xlink:label="mbio_ReimbursementOfFeesTotalPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ReimbursementOfFeesTotalPayments" xlink:to="mbio_ReimbursementOfFeesTotalPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ReimbursementOfFeesTotalPayments_lbl" xml:lang="en-US">Represents total payments for reimbursable expenses over the lifetime of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ReimbursementOfFeesTotalPayments_lbl" xml:lang="en-US">Reimbursement Of Fees, Total Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_ReimbursementOfFeesTotalPayments_lbl" xml:lang="en-US">Total reimbursement payments made</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClinicalTrialAgreementsMember" xlink:label="mbio_ClinicalTrialAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ClinicalTrialAgreementsMember" xlink:to="mbio_ClinicalTrialAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ClinicalTrialAgreementsMember_lbl" xml:lang="en-US">Clinical Trial Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ClinicalTrialAgreementsMember_lbl" xml:lang="en-US">Clinical Trial Agreements [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DataTransferAgreementMember" xlink:label="mbio_DataTransferAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_DataTransferAgreementMember" xlink:to="mbio_DataTransferAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_DataTransferAgreementMember_lbl" xml:lang="en-US">Data Transfer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_DataTransferAgreementMember_lbl" xml:lang="en-US">Data Transfer Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US">Class B Common Shares [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AtMarketOfferingMember" xlink:label="mbio_AtMarketOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_AtMarketOfferingMember" xlink:to="mbio_AtMarketOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_AtMarketOfferingMember_lbl" xml:lang="en-US">Information pertaining to issuances of stock offered on an At The Market basis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_AtMarketOfferingMember_lbl" xml:lang="en-US">At the Market Offering [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_RunwayDebtFacilityMember" xlink:label="mbio_RunwayDebtFacilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_RunwayDebtFacilityMember" xlink:to="mbio_RunwayDebtFacilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_RunwayDebtFacilityMember_lbl" xml:lang="en-US">Information pertaining to the long-term debt facility with Runway Growth Capital LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_RunwayDebtFacilityMember_lbl" xml:lang="en-US">Runway Debt Facility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from related party debt</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses" xlink:label="mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses" xlink:to="mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Percentage of annual fees expense related to Management Services Agreement recorded in research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Percentage of Annual Fees Expenses Related to Management Services Agreement recorded in research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Percentage of annual fees expense related to Management Services Agreement recorded in research and development expenses</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses" xlink:label="mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses" xlink:to="mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common shares</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuedDuringPeriodSharesIssuableForServices" xlink:label="mbio_StockIssuedDuringPeriodSharesIssuableForServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_StockIssuedDuringPeriodSharesIssuableForServices" xlink:to="mbio_StockIssuedDuringPeriodSharesIssuableForServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_StockIssuedDuringPeriodSharesIssuableForServices_lbl" xml:lang="en-US">Number of shares issuable for services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_StockIssuedDuringPeriodSharesIssuableForServices_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Issuable for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_StockIssuedDuringPeriodSharesIssuableForServices_lbl" xml:lang="en-US">Common shares issuable recorded - Founders Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Expenses from related party transaction</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_FoundersAgreementTerm" xlink:label="mbio_FoundersAgreementTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_FoundersAgreementTerm" xlink:to="mbio_FoundersAgreementTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_FoundersAgreementTerm_lbl" xml:lang="en-US">This element represents the agreement term with the founders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_FoundersAgreementTerm_lbl" xml:lang="en-US">Founders Agreement Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_FoundersAgreementTerm_lbl" xml:lang="en-US">Founders agreement term</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AgreementRenewalTerm" xlink:label="mbio_AgreementRenewalTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_AgreementRenewalTerm" xlink:to="mbio_AgreementRenewalTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_AgreementRenewalTerm_lbl" xml:lang="en-US">The period of time for which the agreement may be renewed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_AgreementRenewalTerm_lbl" xml:lang="en-US">Agreement Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_AgreementRenewalTerm_lbl" xml:lang="en-US">Agreement renewal term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Number of shares issued in conversion</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PreferredStockVotingRightsMultiplier" xlink:label="mbio_PreferredStockVotingRightsMultiplier" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_PreferredStockVotingRightsMultiplier" xlink:to="mbio_PreferredStockVotingRightsMultiplier_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_PreferredStockVotingRightsMultiplier_lbl" xml:lang="en-US">The multiplier applied to shares of stock to determine the voting rights per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_PreferredStockVotingRightsMultiplier_lbl" xml:lang="en-US">Preferred Stock Voting Rights Multiplier</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_PreferredStockVotingRightsMultiplier_lbl" xml:lang="en-US">Preferred stock voting rights multiplier</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Shares issuable on conversion, per share converted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Stock dividend (as a percent)</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement" xlink:label="mbio_OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement" xlink:to="mbio_OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement_lbl" xml:lang="en-US">The number of days prior to the dividend payment date that the outstanding capitalization is to be measured.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement_lbl" xml:lang="en-US">Outstanding Capitalization, Number Of Days Prior To Payment For Measurement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement_lbl" xml:lang="en-US">Paid in kind dividend, period prior to payment date for measuring ownership</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_EquityFeePaymentPeriod" xlink:label="mbio_EquityFeePaymentPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_EquityFeePaymentPeriod" xlink:to="mbio_EquityFeePaymentPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_EquityFeePaymentPeriod_lbl" xml:lang="en-US">The number of days after closing of equity or debt financing allowed for payment of the equity fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_EquityFeePaymentPeriod_lbl" xml:lang="en-US">Equity Fee Payment Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_EquityFeePaymentPeriod_lbl" xml:lang="en-US">Equity fee, period for payment after financing</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_EquityFeePercentageOfFinancing" xlink:label="mbio_EquityFeePercentageOfFinancing" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_EquityFeePercentageOfFinancing" xlink:to="mbio_EquityFeePercentageOfFinancing_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_EquityFeePercentageOfFinancing_lbl" xml:lang="en-US">The percentage of equity or debt financing payable as an equity fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_EquityFeePercentageOfFinancing_lbl" xml:lang="en-US">Equity Fee, Percentage Of Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_EquityFeePercentageOfFinancing_lbl" xml:lang="en-US">Equity fee payable in shares (as a percent)</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CashFeeAsPercentageOfAnnualNetSales" xlink:label="mbio_CashFeeAsPercentageOfAnnualNetSales" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_CashFeeAsPercentageOfAnnualNetSales" xlink:to="mbio_CashFeeAsPercentageOfAnnualNetSales_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_CashFeeAsPercentageOfAnnualNetSales_lbl" xml:lang="en-US">The cash fee payable as a percentage of annual net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_CashFeeAsPercentageOfAnnualNetSales_lbl" xml:lang="en-US">Cash Fee As A Percentage Of Annual Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_CashFeeAsPercentageOfAnnualNetSales_lbl" xml:lang="en-US">Cash fee (as a percent)</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CashFeePaymentPeriod" xlink:label="mbio_CashFeePaymentPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_CashFeePaymentPeriod" xlink:to="mbio_CashFeePaymentPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_CashFeePaymentPeriod_lbl" xml:lang="en-US">The number of days after the end of the calendar year allowed for payment of the cash fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_CashFeePaymentPeriod_lbl" xml:lang="en-US">Cash Fee Payment Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_CashFeePaymentPeriod_lbl" xml:lang="en-US">Cash fee, period for payment</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate" xlink:label="mbio_ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate" xlink:to="mbio_ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate_lbl" xml:lang="en-US">The multiple applied to the product of sales and the specified rate, to determine the change in control fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate_lbl" xml:lang="en-US">Change In Control Fee, Multiple Applied To Product Of Sales And Specified Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate_lbl" xml:lang="en-US">Change in control fee, multiplier</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ChangeInControlFeeMeasurementPeriodForNetSales" xlink:label="mbio_ChangeInControlFeeMeasurementPeriodForNetSales" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ChangeInControlFeeMeasurementPeriodForNetSales" xlink:to="mbio_ChangeInControlFeeMeasurementPeriodForNetSales_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ChangeInControlFeeMeasurementPeriodForNetSales_lbl" xml:lang="en-US">The period of time for measurement of net sales used as a component in the calculation of the change in control fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ChangeInControlFeeMeasurementPeriodForNetSales_lbl" xml:lang="en-US">Change In Control Fee, Measurement Period For Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_ChangeInControlFeeMeasurementPeriodForNetSales_lbl" xml:lang="en-US">Change in control fee, measurement period</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ChangeInControlFeeSpecifiedRateComponent" xlink:label="mbio_ChangeInControlFeeSpecifiedRateComponent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ChangeInControlFeeSpecifiedRateComponent" xlink:to="mbio_ChangeInControlFeeSpecifiedRateComponent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ChangeInControlFeeSpecifiedRateComponent_lbl" xml:lang="en-US">The specified rate component in the calculation of the change in control fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ChangeInControlFeeSpecifiedRateComponent_lbl" xml:lang="en-US">Change In Control Fee, Specified Rate Component</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_ChangeInControlFeeSpecifiedRateComponent_lbl" xml:lang="en-US">Change in control fee, specified rate component</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AgreementTerm" xlink:label="mbio_AgreementTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_AgreementTerm" xlink:to="mbio_AgreementTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_AgreementTerm_lbl" xml:lang="en-US">The term of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_AgreementTerm_lbl" xml:lang="en-US">Agreement Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_AgreementTerm_lbl" xml:lang="en-US">MSA agreement term</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MsaAgreementRenewalTerm" xlink:label="mbio_MsaAgreementRenewalTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_MsaAgreementRenewalTerm" xlink:to="mbio_MsaAgreementRenewalTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_MsaAgreementRenewalTerm_lbl" xml:lang="en-US">The term of the agreement renewal term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_MsaAgreementRenewalTerm_lbl" xml:lang="en-US">MSA Agreement Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_MsaAgreementRenewalTerm_lbl" xml:lang="en-US">MSA agreement renewal term</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AnnualConsultingFees" xlink:label="mbio_AnnualConsultingFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_AnnualConsultingFees" xlink:to="mbio_AnnualConsultingFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_AnnualConsultingFees_lbl" xml:lang="en-US">This element represents the amount of annual consulting fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_AnnualConsultingFees_lbl" xml:lang="en-US">Annual Consulting Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_AnnualConsultingFees_lbl" xml:lang="en-US">Annual consulting fee</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_IncreaseInAnnualConsultingFees" xlink:label="mbio_IncreaseInAnnualConsultingFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_IncreaseInAnnualConsultingFees" xlink:to="mbio_IncreaseInAnnualConsultingFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_IncreaseInAnnualConsultingFees_lbl" xml:lang="en-US">This element represents the increase in the amount of annual consulting fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_IncreaseInAnnualConsultingFees_lbl" xml:lang="en-US">Increase In Annual Consulting Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_IncreaseInAnnualConsultingFees_lbl" xml:lang="en-US">Consulting fee when net assets exceed threshold</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ExcessInNetAssetsValue" xlink:label="mbio_ExcessInNetAssetsValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ExcessInNetAssetsValue" xlink:to="mbio_ExcessInNetAssetsValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ExcessInNetAssetsValue_lbl" xml:lang="en-US">This element represents the amount of net assets in excess of liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ExcessInNetAssetsValue_lbl" xml:lang="en-US">Excess In Net Assets Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_ExcessInNetAssetsValue_lbl" xml:lang="en-US">Net assets threshold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrant term</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DirectorCompensationValueOfSharesGranted" xlink:label="mbio_DirectorCompensationValueOfSharesGranted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_DirectorCompensationValueOfSharesGranted" xlink:to="mbio_DirectorCompensationValueOfSharesGranted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_DirectorCompensationValueOfSharesGranted_lbl" xml:lang="en-US">The market value of shares granted, or to be granted, as a component of director compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_DirectorCompensationValueOfSharesGranted_lbl" xml:lang="en-US">Director Compensation Value Of Shares Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_DirectorCompensationValueOfSharesGranted_lbl" xml:lang="en-US">Value of shares granted as compensation</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DirectorCompensationNumberOfSharesGranted" xlink:label="mbio_DirectorCompensationNumberOfSharesGranted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_DirectorCompensationNumberOfSharesGranted" xlink:to="mbio_DirectorCompensationNumberOfSharesGranted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_DirectorCompensationNumberOfSharesGranted_lbl" xml:lang="en-US">The number of shares granted, or to be granted, as a component of director compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_DirectorCompensationNumberOfSharesGranted_lbl" xml:lang="en-US">Director Compensation Number Of Shares Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_DirectorCompensationNumberOfSharesGranted_lbl" xml:lang="en-US">Number of shares granted as compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and Equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ResearchAndDevelopmentCurrent" xlink:label="mbio_ResearchAndDevelopmentCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ResearchAndDevelopmentCurrent" xlink:to="mbio_ResearchAndDevelopmentCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ResearchAndDevelopmentCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable for research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ResearchAndDevelopmentCurrent_lbl" xml:lang="en-US">Research and Development Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_ResearchAndDevelopmentCurrent_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AccruedCompensationCurrent" xlink:label="mbio_AccruedCompensationCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_AccruedCompensationCurrent" xlink:to="mbio_AccruedCompensationCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_AccruedCompensationCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_AccruedCompensationCurrent_lbl" xml:lang="en-US">Accrued Compensation Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_AccruedCompensationCurrent_lbl" xml:lang="en-US">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Other Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashMember_lbl" xml:lang="en-US">Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LetterOfCreditMember_lbl" xml:lang="en-US">Letter of Credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetRentableArea_lbl" xml:lang="en-US">Net Rentable Area</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetRentableArea_lbl" xml:lang="en-US">Leased area (in square feet)</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LesseeOperatingLeaseTotalBaseRentNetOfAbatements" xlink:label="mbio_LesseeOperatingLeaseTotalBaseRentNetOfAbatements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_LesseeOperatingLeaseTotalBaseRentNetOfAbatements" xlink:to="mbio_LesseeOperatingLeaseTotalBaseRentNetOfAbatements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_LesseeOperatingLeaseTotalBaseRentNetOfAbatements_lbl" xml:lang="en-US">The total base rent, net of abatements, for the operating lease over the lease term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_LesseeOperatingLeaseTotalBaseRentNetOfAbatements_lbl" xml:lang="en-US">Lessee, Operating Lease, Total Base Rent Net Of Abatements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_LesseeOperatingLeaseTotalBaseRentNetOfAbatements_lbl" xml:lang="en-US">Total base rent, net of abatements</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LesseeOperatingLeaseTotalAbatementsOverLeaseTerm" xlink:label="mbio_LesseeOperatingLeaseTotalAbatementsOverLeaseTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_LesseeOperatingLeaseTotalAbatementsOverLeaseTerm" xlink:to="mbio_LesseeOperatingLeaseTotalAbatementsOverLeaseTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_LesseeOperatingLeaseTotalAbatementsOverLeaseTerm_lbl" xml:lang="en-US">The total abatements for the operating lease over the lease term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_LesseeOperatingLeaseTotalAbatementsOverLeaseTerm_lbl" xml:lang="en-US">Lessee, Operating Lease Total Abatements Over Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_LesseeOperatingLeaseTotalAbatementsOverLeaseTerm_lbl" xml:lang="en-US">Total abatements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LesseeSecurityDepositUponFullOccupancy" xlink:label="mbio_LesseeSecurityDepositUponFullOccupancy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_LesseeSecurityDepositUponFullOccupancy" xlink:to="mbio_LesseeSecurityDepositUponFullOccupancy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_LesseeSecurityDepositUponFullOccupancy_lbl" xml:lang="en-US">The amount of security deposit required when the facility is fully-occupied by the lessee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_LesseeSecurityDepositUponFullOccupancy_lbl" xml:lang="en-US">Lessee Security Deposit Upon Full Occupancy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_LesseeSecurityDepositUponFullOccupancy_lbl" xml:lang="en-US">Security deposit, fully-occupied</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease, Cost [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term - operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate - operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Year ended December 31, 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Year ended December 31, 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Year ended December 31, 2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Year ended December 31, 2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Year ended December 31, 2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less present value discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US">Variable Rate [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US">Variable Rate [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember" xlink:label="us-gaap_BaseRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BaseRateMember" xlink:to="us-gaap_BaseRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BaseRateMember_lbl" xml:lang="en-US">Base Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BaseRateMember_lbl" xml:lang="en-US">Base Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xml:lang="en-US">LIBOR Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xml:lang="en-US">Three month LIBOR</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Long-term debt facility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from Lines of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Amount funded upon closing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US">Amount available under facility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Variable interest rate floor (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl" xml:lang="en-US">Commitment fee percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Advisory and legal fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US">Derivative Liability, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US">Fair value of warrants assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Fair value</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DebtInstrumentBalloonPaymentAsPercentageOfPrincipal" xlink:label="mbio_DebtInstrumentBalloonPaymentAsPercentageOfPrincipal" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_DebtInstrumentBalloonPaymentAsPercentageOfPrincipal" xlink:to="mbio_DebtInstrumentBalloonPaymentAsPercentageOfPrincipal_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_DebtInstrumentBalloonPaymentAsPercentageOfPrincipal_lbl" xml:lang="en-US">Represents the balloon payment amount as a percentage of debt principal.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_DebtInstrumentBalloonPaymentAsPercentageOfPrincipal_lbl" xml:lang="en-US">Debt Instrument, Balloon Payment As A Percentage Of Principal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_DebtInstrumentBalloonPaymentAsPercentageOfPrincipal_lbl" xml:lang="en-US">Final payment as a percentage of original principal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xml:lang="en-US">Final Payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest rate during period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Note payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Discount on note payable</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_RegistrationStatementsMember" xlink:label="mbio_RegistrationStatementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_RegistrationStatementsMember" xlink:to="mbio_RegistrationStatementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_RegistrationStatementsMember_lbl" xml:lang="en-US">Registration Statements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_RegistrationStatementsMember_lbl" xml:lang="en-US">Registration Statements [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement" xlink:label="mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement" xlink:to="mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement_lbl" xml:lang="en-US">Sale of Stock aggregate offering price permitted by agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement_lbl" xml:lang="en-US">Sale of Stock aggregate offering price permitted by agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement_lbl" xml:lang="en-US">Sale of Stock aggregate offering price - Founders Agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold" xlink:label="mbio_ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold" xlink:to="mbio_ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold_lbl" xml:lang="en-US">Shelf Registration statement, value of securities authorized to be sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold_lbl" xml:lang="en-US">Shelf Registration statement, value of securities authorized to be sold</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommonStockSharesAvailableForFutureIssuanceValue" xlink:label="mbio_CommonStockSharesAvailableForFutureIssuanceValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_CommonStockSharesAvailableForFutureIssuanceValue" xlink:to="mbio_CommonStockSharesAvailableForFutureIssuanceValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_CommonStockSharesAvailableForFutureIssuanceValue_lbl" xml:lang="en-US">Common Stock Shares Available For Future Issuance Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_CommonStockSharesAvailableForFutureIssuanceValue_lbl" xml:lang="en-US">Common Stock Shares Available For Future Issuance Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_CommonStockSharesAvailableForFutureIssuanceValue_lbl" xml:lang="en-US">Shares available for future issuance - Founders Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Number of shares converted</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_VotingRightsNumberOfVotesPerShare" xlink:label="mbio_VotingRightsNumberOfVotesPerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_VotingRightsNumberOfVotesPerShare" xlink:to="mbio_VotingRightsNumberOfVotesPerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_VotingRightsNumberOfVotesPerShare_lbl" xml:lang="en-US">The number of votes per share of stock held.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_VotingRightsNumberOfVotesPerShare_lbl" xml:lang="en-US">Voting Rights Number Of Votes Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_VotingRightsNumberOfVotesPerShare_lbl" xml:lang="en-US">Number of votes per share</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockholderAppointmentOfDirectorPeriodAfterIssuance" xlink:label="mbio_StockholderAppointmentOfDirectorPeriodAfterIssuance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_StockholderAppointmentOfDirectorPeriodAfterIssuance" xlink:to="mbio_StockholderAppointmentOfDirectorPeriodAfterIssuance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_StockholderAppointmentOfDirectorPeriodAfterIssuance_lbl" xml:lang="en-US">The period of time after issuance of the stock that the owners of that class may appoint the specified number of directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_StockholderAppointmentOfDirectorPeriodAfterIssuance_lbl" xml:lang="en-US">Stockholder Appointment Of Director, Period After Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_StockholderAppointmentOfDirectorPeriodAfterIssuance_lbl" xml:lang="en-US">Director appointment right, period</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommissionRatePercentage" xlink:label="mbio_CommissionRatePercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_CommissionRatePercentage" xlink:to="mbio_CommissionRatePercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_CommissionRatePercentage_lbl" xml:lang="en-US">Percentage of commission rate on gross sale of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_CommissionRatePercentage_lbl" xml:lang="en-US">Commission Rate Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_CommissionRatePercentage_lbl" xml:lang="en-US">Agent commission (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common shares (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued, price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Aggregate fees of stock issuance</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" xlink:label="mbio_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" xlink:to="mbio_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock, net of offering costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock, net of offering costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts_lbl" xml:lang="en-US">Proceeds from issuance of Common Stock, net of offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares available for future sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for grant</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage" xlink:label="mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage" xlink:to="mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage_lbl" xml:lang="en-US">Employee stock purchase plan, predetermined offering period, lower fair market value percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage_lbl" xml:lang="en-US">Employee Stock Purchase Plan, Predetermined Offering Period, Lower Fair Market Value Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage_lbl" xml:lang="en-US">Predetermined offering period, lower fair market value percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Options rollforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options, Outstanding, Number, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Stock Options, Outstanding, Number, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, options vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life, Options outstanding (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life, Options vested and exercisable (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Restricted stock and RSU rollforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Nonvested, Number, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Nonvested, Number, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Nonvested, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Nonvested, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Unrecognized compensation recognition period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased" xlink:label="mbio_ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased" xlink:to="mbio_ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased_lbl" xml:lang="en-US">The percentage of common shares purchased that investors received in warrants or rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased_lbl" xml:lang="en-US">Class Of Warrant Or Right, Units Received As A Percentage Of Common Shares Purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased_lbl" xml:lang="en-US">Warrants received, as a percentage of common shares purchased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding, ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding, beginning</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod" xlink:label="mbio_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod" xlink:to="mbio_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod_lbl" xml:lang="en-US">The number of warrants or rights expired during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod_lbl" xml:lang="en-US">Class Of Warrant Or Right Warrants Expired During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mbio_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod_lbl" xml:lang="en-US">Warrants, expired</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightWarrantsGrantedDuringPeriod" xlink:label="mbio_ClassOfWarrantOrRightWarrantsGrantedDuringPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ClassOfWarrantOrRightWarrantsGrantedDuringPeriod" xlink:to="mbio_ClassOfWarrantOrRightWarrantsGrantedDuringPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ClassOfWarrantOrRightWarrantsGrantedDuringPeriod_lbl" xml:lang="en-US">The number of warrants or rights granted during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ClassOfWarrantOrRightWarrantsGrantedDuringPeriod_lbl" xml:lang="en-US">Class Of Warrant Or Right Warrants Granted During The Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_ClassOfWarrantOrRightWarrantsGrantedDuringPeriod_lbl" xml:lang="en-US">Warrants granted</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod" xlink:label="mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod" xlink:to="mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod_lbl" xml:lang="en-US">The number of warrants or rights exercised during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod_lbl" xml:lang="en-US">Class Of Warrant Or Right, Warrants Exercised During The Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod_lbl" xml:lang="en-US">Warrants exercised</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_WarrantExercisePriceExpiredDuringPeriod" xlink:label="mbio_WarrantExercisePriceExpiredDuringPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_WarrantExercisePriceExpiredDuringPeriod" xlink:to="mbio_WarrantExercisePriceExpiredDuringPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_WarrantExercisePriceExpiredDuringPeriod_lbl" xml:lang="en-US">Warrant exercise price, expired during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_WarrantExercisePriceExpiredDuringPeriod_lbl" xml:lang="en-US">Warrant exercise price, expired during the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_WarrantExercisePriceExpiredDuringPeriod_lbl" xml:lang="en-US">Warrants exercise price, expired (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod" xlink:label="mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod" xlink:to="mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod_lbl" xml:lang="en-US">Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants that were granted during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod_lbl" xml:lang="en-US">Class Of Warrant Or Right, Weighted Average Exercise Price, Grants During The Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod_lbl" xml:lang="en-US">Warrant exercise price, grants during the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" xlink:label="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" xlink:to="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US">The weighted average remaining contractual life for warrants outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US">Class Of Warrant Or Right Weighted Average Remaining Contractual Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US">Warrants outstanding, remaining contractual life</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod" xlink:label="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod" xlink:to="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod_lbl" xml:lang="en-US">The weighted average remaining contractual life for warrants granted during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod_lbl" xml:lang="en-US">Class Of Warrant Or Right Weighted Average Remaining Contractual Life, Grants In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod_lbl" xml:lang="en-US">Warrants granted, remaining contractual life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_OperatingLossCarryforwardsWithoutExpiration" xlink:label="mbio_OperatingLossCarryforwardsWithoutExpiration" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_OperatingLossCarryforwardsWithoutExpiration" xlink:to="mbio_OperatingLossCarryforwardsWithoutExpiration_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_OperatingLossCarryforwardsWithoutExpiration_lbl" xml:lang="en-US">Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_OperatingLossCarryforwardsWithoutExpiration_lbl" xml:lang="en-US">Operating loss carryforwards without expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_OperatingLossCarryforwardsWithoutExpiration_lbl" xml:lang="en-US">Operating loss carryforwards without expiration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred tax assets, valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxCreditsAndAdjustments" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments_lbl" xml:lang="en-US">Income Tax Credits and Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments_lbl" xml:lang="en-US">Income tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardExpirationDate" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" xml:lang="en-US">Tax Credit Carryforward, Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" xml:lang="en-US">Tax credits, expiration date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US">Interest or penalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory federal income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal tax benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Non-deductible items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Credits</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent" xlink:label="mbio_EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent" xlink:to="mbio_EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent_lbl" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic state income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation Change In Federal Enacted Tax Rate Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mbio_EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent_lbl" xml:lang="en-US">Federal tax rate change</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent" xlink:label="mbio_EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent" xlink:to="mbio_EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent_lbl" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation Change In State Enacted Tax Rate Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mbio_EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent_lbl" xml:lang="en-US">State tax rate change</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Income taxes provision (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryovers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Stock compensation and other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xml:lang="en-US">Deferred Tax Assets, Derivative Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Amortization of license</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DeferredTaxAssetOperatingLeaseLiabilities" xlink:label="mbio_DeferredTaxAssetOperatingLeaseLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_DeferredTaxAssetOperatingLeaseLiabilities" xlink:to="mbio_DeferredTaxAssetOperatingLeaseLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_DeferredTaxAssetOperatingLeaseLiabilities_lbl" xml:lang="en-US">The amount of deferred tax asset operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_DeferredTaxAssetOperatingLeaseLiabilities_lbl" xml:lang="en-US">Deferred Tax Asset Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_DeferredTaxAssetOperatingLeaseLiabilities_lbl" xml:lang="en-US">Lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl" xml:lang="en-US">Accruals and reserves</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DeferredTaxAssetsStartUpCosts" xlink:label="mbio_DeferredTaxAssetsStartUpCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_DeferredTaxAssetsStartUpCosts" xlink:to="mbio_DeferredTaxAssetsStartUpCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_DeferredTaxAssetsStartUpCosts_lbl" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from start up costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_DeferredTaxAssetsStartUpCosts_lbl" xml:lang="en-US">Deferred Tax Assets Start Up Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_DeferredTaxAssetsStartUpCosts_lbl" xml:lang="en-US">Startup costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Tax credits</label>
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses" xlink:label="mbio_DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mbio_DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses" xlink:to="mbio_DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mbio_DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to capitalization of research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mbio_DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Deferred Tax Assets, Capitalization of Research and Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mbio_DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">174 Capitalization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US">Right of use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Total deferred tax assets, net</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>29
<FILENAME>tmb-20221231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/29/2023 11:43:38 PM-->
<!--Modified on: 3/29/2023 11:43:38 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementBalanceSheets" roleURI="http://www.mustangbio.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementStatementsOfOperations" roleURI="http://www.mustangbio.com/role/StatementStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.mustangbio.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureOrganizationAndDescriptionOfBusiness" roleURI="http://www.mustangbio.com/role/DisclosureOrganizationAndDescriptionOfBusiness" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.mustangbio.com/role/DisclosureSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureLicenseClinicalTrialAndSponsoredResearchAgreements" roleURI="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreements" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureRelatedPartyAgreements" roleURI="http://www.mustangbio.com/role/DisclosureRelatedPartyAgreements" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosurePropertyAndEquipment" roleURI="http://www.mustangbio.com/role/DisclosurePropertyAndEquipment" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureAccountsPayableAndAccruedExpenses" roleURI="http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpenses" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureNotesPayable" roleURI="http://www.mustangbio.com/role/DisclosureNotesPayable" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquity" roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxes" roleURI="http://www.mustangbio.com/role/DisclosureIncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureSubsequentEvents" roleURI="http://www.mustangbio.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureSignificantAccountingPoliciesTables" roleURI="http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables" roleURI="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosurePropertyAndEquipmentTables" roleURI="http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureAccountsPayableAndAccruedExpensesTables" roleURI="http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureNotesPayableTables" roleURI="http://www.mustangbio.com/role/DisclosureNotesPayableTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.mustangbio.com/role/DisclosureIncomeTaxesTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureOrganizationAndDescriptionOfBusinessDetails" roleURI="http://www.mustangbio.com/role/DisclosureOrganizationAndDescriptionOfBusinessDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" roleURI="http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails" roleURI="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" roleURI="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureRelatedPartyAgreementsNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosurePropertyAndEquipmentNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails" roleURI="http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails" roleURI="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingenciesCashFlowsDetails" roleURI="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesCashFlowsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails" roleURI="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureNotesPayableNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityStockOptionsDetails" roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails" roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureStockholdersEquityStockWarrantsDetails" roleURI="http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.mustangbio.com/role/DisclosureIncomeTaxesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20221231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" roleURI="http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <presentationLink xlink:role="http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable_638157302169796150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable_638157302169796150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638157302169796150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_638157302169796150" xlink:to="us-gaap_StatementClassOfStockAxis_638157302169796150" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638157302169796150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638157302169796150" xlink:to="us-gaap_ClassOfStockDomain_638157302169796150" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_638157302169796150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638157302169796150" xlink:to="us-gaap_CommonClassAMember_638157302169796150" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommonUnspecifiedClassMember" xlink:label="mbio_CommonUnspecifiedClassMember_638157302169806154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638157302169796150" xlink:to="mbio_CommonUnspecifiedClassMember_638157302169806154" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems_638157302169806154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_638157302169796150" xlink:to="dei_DocumentInformationLineItems_638157302169806154" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638157302169806154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_DocumentType_638157302169806154" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638157302169806154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_DocumentAnnualReport_638157302169806154" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638157302169806154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_DocumentPeriodEndDate_638157302169806154" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638157302169806154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_DocumentTransitionReport_638157302169806154" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638157302169806154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_EntityFileNumber_638157302169806154" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638157302169806154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_EntityRegistrantName_638157302169806154" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638157302169806154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_EntityIncorporationStateCountryCode_638157302169806154" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638157302169806154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_EntityTaxIdentificationNumber_638157302169806154" order="8" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638157302169806154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_EntityAddressAddressLine1_638157302169806154" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638157302169806154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_EntityAddressCityOrTown_638157302169806154" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638157302169806154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_EntityAddressStateOrProvince_638157302169806154" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638157302169816155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_EntityAddressPostalZipCode_638157302169816155" order="12" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638157302169816155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_CityAreaCode_638157302169816155" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638157302169816155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_LocalPhoneNumber_638157302169816155" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638157302169816155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_Security12bTitle_638157302169816155" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638157302169816155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_TradingSymbol_638157302169816155" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638157302169816155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_SecurityExchangeName_638157302169816155" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638157302169816155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_EntityWellKnownSeasonedIssuer_638157302169816155" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638157302169816155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_EntityVoluntaryFilers_638157302169816155" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638157302169816155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_EntityCurrentReportingStatus_638157302169816155" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638157302169826151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_EntityInteractiveDataCurrent_638157302169826151" order="21" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638157302169826151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_EntityFilerCategory_638157302169826151" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638157302169826151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_EntitySmallBusiness_638157302169826151" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638157302169826151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_EntityEmergingGrowthCompany_638157302169826151" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638157302169826151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_EntityShellCompany_638157302169826151" order="25" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638157302169826151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_EntityCommonStockSharesOutstanding_638157302169826151" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638157302169826151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_EntityPublicFloat_638157302169826151" order="27" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638157302169826151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_EntityCentralIndexKey_638157302169826151" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638157302169836151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_DocumentFiscalYearFocus_638157302169836151" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638157302169836151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_DocumentFiscalPeriodFocus_638157302169836151" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638157302169836151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_CurrentFiscalYearEndDate_638157302169836151" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638157302169836151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_AmendmentFlag_638157302169836151" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638157302169836151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_IcfrAuditorAttestationFlag_638157302169836151" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638157302169836151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_AuditorName_638157302169836151" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638157302169836151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_AuditorFirmId_638157302169836151" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638157302169846152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638157302169806154" xlink:to="dei_AuditorLocation_638157302169846152" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_29" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638157302169846152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_StatementTable_638157302169846152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638157302169846152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157302169846152" xlink:to="us-gaap_StatementClassOfStockAxis_638157302169846152" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638157302169846152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638157302169846152" xlink:to="us-gaap_ClassOfStockDomain_638157302169846152" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_638157302169846152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638157302169846152" xlink:to="us-gaap_CommonClassAMember_638157302169846152" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommonUnspecifiedClassMember" xlink:label="mbio_CommonUnspecifiedClassMember_638157302169856168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638157302169846152" xlink:to="mbio_CommonUnspecifiedClassMember_638157302169856168" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638157302169856168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157302169846152" xlink:to="us-gaap_StatementLineItems_638157302169856168" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638157302169856168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169856168" xlink:to="us-gaap_AssetsAbstract_638157302169856168" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638157302169856168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638157302169856168" xlink:to="us-gaap_AssetsCurrentAbstract_638157302169856168" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638157302169856168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638157302169856168" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638157302169856168" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables_638157302169856168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638157302169856168" xlink:to="us-gaap_OtherReceivables_638157302169856168" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638157302169856168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638157302169856168" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638157302169856168" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638157302169856168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638157302169856168" xlink:to="us-gaap_AssetsCurrent_638157302169856168" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction" xlink:label="mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction_638157302169856168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638157302169856168" xlink:to="mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction_638157302169856168" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ConstructionInProcessNet" xlink:label="mbio_ConstructionInProcessNet_638157302169856168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638157302169856168" xlink:to="mbio_ConstructionInProcessNet_638157302169856168" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638157302169856168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638157302169856168" xlink:to="us-gaap_RestrictedCashNoncurrent_638157302169856168" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638157302169866178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638157302169856168" xlink:to="us-gaap_OtherAssetsNoncurrent_638157302169866178" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638157302169866178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638157302169856168" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638157302169866178" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638157302169866178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638157302169856168" xlink:to="us-gaap_Assets_638157302169866178" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638157302169866178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169856168" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638157302169866178" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638157302169866178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638157302169866178" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638157302169866178" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638157302169866178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638157302169866178" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638157302169866178" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_638157302169866178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638157302169866178" xlink:to="us-gaap_DueToRelatedPartiesCurrent_638157302169866178" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638157302169866178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638157302169866178" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638157302169866178" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638157302169866178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638157302169866178" xlink:to="us-gaap_LiabilitiesCurrent_638157302169866178" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent_638157302169876149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638157302169866178" xlink:to="us-gaap_DeferredIncomeNoncurrent_638157302169876149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_638157302169876149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638157302169866178" xlink:to="us-gaap_LongTermNotesPayable_638157302169876149" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638157302169876149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638157302169866178" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638157302169876149" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638157302169876149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638157302169866178" xlink:to="us-gaap_Liabilities_638157302169876149" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638157302169876149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638157302169866178" xlink:to="us-gaap_CommitmentsAndContingencies_638157302169876149" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638157302169876149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638157302169866178" xlink:to="us-gaap_StockholdersEquityAbstract_638157302169876149" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638157302169876149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638157302169876149" xlink:to="us-gaap_PreferredStockValue_638157302169876149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638157302169886167" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638157302169876149" xlink:to="us-gaap_CommonStockValue_638157302169886167" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions_638157302169886167" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638157302169876149" xlink:to="us-gaap_CommonStockSharesSubscriptions_638157302169886167" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638157302169886167" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638157302169876149" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638157302169886167" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638157302169886167" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638157302169876149" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638157302169886167" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638157302169886167" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638157302169876149" xlink:to="us-gaap_StockholdersEquity_638157302169886167" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638157302169886167" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638157302169876149" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638157302169886167" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - BALANCE SHEETS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_130" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638157302169896141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_130" xlink:to="us-gaap_StatementTable_638157302169896141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638157302169896141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157302169896141" xlink:to="us-gaap_StatementClassOfStockAxis_638157302169896141" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638157302169896141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638157302169896141" xlink:to="us-gaap_ClassOfStockDomain_638157302169896141" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_638157302169896141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638157302169896141" xlink:to="us-gaap_CommonClassAMember_638157302169896141" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommonUnspecifiedClassMember" xlink:label="mbio_CommonUnspecifiedClassMember_638157302169896141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638157302169896141" xlink:to="mbio_CommonUnspecifiedClassMember_638157302169896141" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638157302169896141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157302169896141" xlink:to="us-gaap_StatementLineItems_638157302169896141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638157302169896141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169896141" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638157302169896141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638157302169896141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169896141" xlink:to="us-gaap_PreferredStockSharesAuthorized_638157302169896141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638157302169896141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169896141" xlink:to="us-gaap_PreferredStockSharesIssued_638157302169896141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638157302169896141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169896141" xlink:to="us-gaap_PreferredStockSharesOutstanding_638157302169896141" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638157302169896141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169896141" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638157302169896141" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638157302169896141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169896141" xlink:to="us-gaap_CommonStockSharesAuthorized_638157302169896141" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638157302169906153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169896141" xlink:to="us-gaap_CommonStockSharesIssued_638157302169906153" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638157302169906153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169896141" xlink:to="us-gaap_CommonStockSharesOutstanding_638157302169906153" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_638157302169906153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169896141" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued_638157302169906153" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638157302169906153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638157302169906153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638157302169906153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638157302169906153" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638157302169906153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638157302169906153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638157302169906153" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638157302169906153" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638157302169906153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638157302169906153" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638157302169906153" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638157302169906153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638157302169906153" xlink:to="us-gaap_OperatingExpenses_638157302169906153" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638157302169906153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638157302169906153" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638157302169916149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638157302169916149" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_GrantIncome" xlink:label="mbio_GrantIncome_638157302169916149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638157302169916149" xlink:to="mbio_GrantIncome_638157302169916149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther_638157302169916149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638157302169916149" xlink:to="us-gaap_InterestIncomeOther_638157302169916149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638157302169916149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638157302169916149" xlink:to="us-gaap_InterestExpenseDebt_638157302169916149" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638157302169916149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638157302169916149" xlink:to="us-gaap_NonoperatingIncomeExpense_638157302169916149" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638157302169916149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638157302169916149" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638157302169916149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638157302169916149" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638157302169916149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638157302169916149" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638157302169916149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638157302169916149" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638157302169916149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638157302169916149" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_576" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638157302169926145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_576" xlink:to="us-gaap_StatementTable_638157302169926145" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638157302169926145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157302169926145" xlink:to="us-gaap_StatementClassOfStockAxis_638157302169926145" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember_638157302169926145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638157302169926145" xlink:to="us-gaap_PreferredClassAMember_638157302169926145" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_638157302169926145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638157302169926145" xlink:to="us-gaap_CommonClassAMember_638157302169926145" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommonUnspecifiedClassMember" xlink:label="mbio_CommonUnspecifiedClassMember_638157302169926145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638157302169926145" xlink:to="mbio_CommonUnspecifiedClassMember_638157302169926145" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638157302169926145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638157302169926145" xlink:to="us-gaap_ClassOfStockDomain_638157302169926145" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638157302169926145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157302169926145" xlink:to="us-gaap_StatementEquityComponentsAxis_638157302169926145" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638157302169926145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638157302169926145" xlink:to="us-gaap_PreferredStockMember_638157302169926145" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638157302169926145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638157302169926145" xlink:to="us-gaap_CommonStockMember_638157302169926145" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommonStockIssuableMember" xlink:label="mbio_CommonStockIssuableMember_638157302169926145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638157302169926145" xlink:to="mbio_CommonStockIssuableMember_638157302169926145" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638157302169926145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638157302169926145" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638157302169926145" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638157302169926145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638157302169926145" xlink:to="us-gaap_RetainedEarningsMember_638157302169926145" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638157302169936146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638157302169926145" xlink:to="us-gaap_EquityComponentDomain_638157302169936146" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638157302169936146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157302169926145" xlink:to="us-gaap_StatementLineItems_638157302169936146" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638157302169936146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169936146" xlink:to="us-gaap_StockholdersEquity_638157302169936146" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638157302169936146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169936146" xlink:to="us-gaap_SharesOutstanding_638157302169936146" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuanceCommonStockIssuableDuringPeriod" xlink:label="mbio_StockIssuanceCommonStockIssuableDuringPeriod_638157302169936146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169936146" xlink:to="mbio_StockIssuanceCommonStockIssuableDuringPeriod_638157302169936146" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement" xlink:label="mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement_638157302169936146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169936146" xlink:to="mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement_638157302169936146" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_638157302169936146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement_638157302169936146" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_638157302169936146" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuedDuringPeriodValueAtMarketingOffering" xlink:label="mbio_StockIssuedDuringPeriodValueAtMarketingOffering_638157302169936146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169936146" xlink:to="mbio_StockIssuedDuringPeriodValueAtMarketingOffering_638157302169936146" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuedDuringPeriodSharesAtMarketOffering" xlink:label="mbio_StockIssuedDuringPeriodSharesAtMarketOffering_638157302169936146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mbio_StockIssuedDuringPeriodValueAtMarketingOffering_638157302169936146" xlink:to="mbio_StockIssuedDuringPeriodSharesAtMarketOffering_638157302169936146" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering" xlink:label="mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering_638157302169936146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169936146" xlink:to="mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering_638157302169936146" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering" xlink:label="mbio_StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering_638157302169936146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering_638157302169936146" xlink:to="mbio_StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering_638157302169936146" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638157302169946144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169936146" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638157302169946144" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638157302169946144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638157302169946144" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638157302169946144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CorrectionToPreviouslyIssuedShares" xlink:label="mbio_CorrectionToPreviouslyIssuedShares_638157302169946144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169936146" xlink:to="mbio_CorrectionToPreviouslyIssuedShares_638157302169946144" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638157302169946144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169936146" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638157302169946144" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_638157302169946144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638157302169946144" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_638157302169946144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AdditionsToApicEquityFeesOnRwgDebt" xlink:label="mbio_AdditionsToApicEquityFeesOnRwgDebt_638157302169946144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169936146" xlink:to="mbio_AdditionsToApicEquityFeesOnRwgDebt_638157302169946144" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AdditionsToApicEquityFeesOnRwgDebtShares" xlink:label="mbio_AdditionsToApicEquityFeesOnRwgDebtShares_638157302169946144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mbio_AdditionsToApicEquityFeesOnRwgDebt_638157302169946144" xlink:to="mbio_AdditionsToApicEquityFeesOnRwgDebtShares_638157302169946144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AdditionsToApicFromIssuanceOfRwgDebtWarrants" xlink:label="mbio_AdditionsToApicFromIssuanceOfRwgDebtWarrants_638157302169946144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169936146" xlink:to="mbio_AdditionsToApicFromIssuanceOfRwgDebtWarrants_638157302169946144" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ShareIssuedDuringPeriodValueOnExerciseOfWarrants" xlink:label="mbio_ShareIssuedDuringPeriodValueOnExerciseOfWarrants_638157302169956139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169936146" xlink:to="mbio_ShareIssuedDuringPeriodValueOnExerciseOfWarrants_638157302169956139" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants" xlink:label="mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants_638157302169956139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mbio_ShareIssuedDuringPeriodValueOnExerciseOfWarrants_638157302169956139" xlink:to="mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants_638157302169956139" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638157302169956139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169936146" xlink:to="us-gaap_NetIncomeLoss_638157302169956139" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638157302169956139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169936146" xlink:to="us-gaap_StockholdersEquity_638157302169956139" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638157302169956139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302169936146" xlink:to="us-gaap_SharesOutstanding_638157302169956139" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638157302169966148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638157302169966148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638157302169966148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638157302169966148" xlink:to="us-gaap_NetIncomeLoss_638157302169966148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638157302169966148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638157302169966148" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638157302169966148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_IssuanceOfCommonSharesEquityFeeOnAtMarketOffering" xlink:label="mbio_IssuanceOfCommonSharesEquityFeeOnAtMarketOffering_638157302169966148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638157302169966148" xlink:to="mbio_IssuanceOfCommonSharesEquityFeeOnAtMarketOffering_638157302169966148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance" xlink:label="mbio_AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance_638157302169966148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638157302169966148" xlink:to="mbio_AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance_638157302169966148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense" xlink:label="mbio_ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense_638157302169966148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638157302169966148" xlink:to="mbio_ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense_638157302169966148" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommonShareIssuanceFeesRelatedPartyDebt" xlink:label="mbio_CommonShareIssuanceFeesRelatedPartyDebt_638157302169966148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638157302169966148" xlink:to="mbio_CommonShareIssuanceFeesRelatedPartyDebt_638157302169966148" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638157302169966148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638157302169966148" xlink:to="us-gaap_ShareBasedCompensation_638157302169966148" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638157302169966148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638157302169966148" xlink:to="us-gaap_Depreciation_638157302169966148" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638157302169966148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638157302169966148" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638157302169966148" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638157302169966148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638157302169966148" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638157302169966148" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638157302169966148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638157302169966148" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638157302169966148" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638157302169966148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638157302169966148" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638157302169966148" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638157302169976143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638157302169966148" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638157302169976143" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_638157302169976143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638157302169966148" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_638157302169976143" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties" xlink:label="mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties_638157302169976143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638157302169966148" xlink:to="mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties_638157302169976143" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_638157302169976143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638157302169966148" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_638157302169976143" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638157302169976143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638157302169966148" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638157302169976143" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_IncreaseDecreaseInLeaseLiabilities" xlink:label="mbio_IncreaseDecreaseInLeaseLiabilities_638157302169976143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638157302169966148" xlink:to="mbio_IncreaseDecreaseInLeaseLiabilities_638157302169976143" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157302169976143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638157302169966148" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638157302169976143" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638157302169976143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638157302169976143" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638157302169976143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638157302169976143" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638157302169976143" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638157302169976143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638157302169976143" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638157302169976143" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638157302169986139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638157302169976143" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638157302169986139" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638157302169986139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638157302169976143" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638157302169986139" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638157302169986139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638157302169986139" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ProceedsFromIssuanceOfCommonSharesAtMarketOffering" xlink:label="mbio_ProceedsFromIssuanceOfCommonSharesAtMarketOffering_638157302169986139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638157302169986139" xlink:to="mbio_ProceedsFromIssuanceOfCommonSharesAtMarketOffering_638157302169986139" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_OfferingCostsForIssuanceOfCommonSharesAtMarketOffering" xlink:label="mbio_OfferingCostsForIssuanceOfCommonSharesAtMarketOffering_638157302169986139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638157302169986139" xlink:to="mbio_OfferingCostsForIssuanceOfCommonSharesAtMarketOffering_638157302169986139" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_638157302169986139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638157302169986139" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_638157302169986139" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_638157302169986139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638157302169986139" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_638157302169986139" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638157302169986139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638157302169986139" xlink:to="us-gaap_ProceedsFromStockPlans_638157302169986139" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638157302169996138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638157302169986139" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638157302169996138" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638157302169996138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638157302169996138" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638157302169996138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638157302169996138" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381573021699961381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381573021699961381" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638157302169996138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638157302169996138" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638157302169996138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638157302169996138" xlink:to="us-gaap_InterestPaidNet_638157302169996138" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638157302169996138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638157302169996138" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638157302169996138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638157302169996138" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638157302169996138" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1_638157302170006139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638157302169996138" xlink:to="us-gaap_StockIssued1_638157302170006139" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid" xlink:label="mbio_ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid_638157302170006139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638157302169996138" xlink:to="mbio_ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid_638157302170006139" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_638157302170006139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638157302169996138" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_638157302170006139" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_638157302170006139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638157302169996138" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_638157302170006139" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LeaseLiabilitiesArisingFromObtainingRightOfUseAssets" xlink:label="mbio_LeaseLiabilitiesArisingFromObtainingRightOfUseAssets_638157302170006139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638157302169996138" xlink:to="mbio_LeaseLiabilitiesArisingFromObtainingRightOfUseAssets_638157302170006139" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureOrganizationAndDescriptionOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Organization and Description of Business">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638157302170016141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638157302170016141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638157302170016141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638157302170016141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreements" xlink:type="extended" xlink:title="10301 - Disclosure - License, Clinical Trial and Sponsored Research Agreements">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_638157302170016141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_638157302170016141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureRelatedPartyAgreements" xlink:type="extended" xlink:title="10401 - Disclosure - Related Party Agreements">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638157302170016141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638157302170016141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosurePropertyAndEquipment" xlink:type="extended" xlink:title="10501 - Disclosure - Property and Equipment">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638157302170016141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638157302170016141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpenses" xlink:type="extended" xlink:title="10601 - Disclosure - Accounts Payable and Accrued Expenses">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638157302170016141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638157302170016141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10701 - Disclosure - Commitments and Contingencies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638157302170026144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638157302170026144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureNotesPayable" xlink:type="extended" xlink:title="10801 - Disclosure - Notes Payable">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638157302170026144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_638157302170026144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10901 - Disclosure - Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638157302170026144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638157302170026144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11001 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638157302170026144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638157302170026144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11101 - Disclosure - Subsequent Events">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638157302170026144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638157302170026144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Significant Accounting Policies (Policies)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638157302170036147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638157302170036147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638157302170036147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638157302170036147" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638157302170036147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638157302170036147" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638157302170036147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638157302170036147" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock_638157302170036147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock_638157302170036147" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638157302170036147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638157302170036147" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638157302170036147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638157302170036147" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638157302170036147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638157302170036147" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AnnualStockDividendPolicyTextBlock" xlink:label="mbio_AnnualStockDividendPolicyTextBlock_638157302170036147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mbio_AnnualStockDividendPolicyTextBlock_638157302170036147" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638157302170036147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638157302170036147" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638157302170036147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638157302170036147" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638157302170046144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638157302170046144" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638157302170046144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638157302170046144" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638157302170046144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638157302170046144" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638157302170046144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638157302170046144" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638157302170046144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638157302170046144" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Significant Accounting Policies (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637038917268322158" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638157302170046144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637038917268322158" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638157302170046144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables" xlink:type="extended" xlink:title="30303 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170046144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170046144" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638157302170046144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170046144" xlink:to="us-gaap_TypeOfArrangementAxis_638157302170046144" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170046144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638157302170046144" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170046144" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LicenseAgreementsMember" xlink:label="mbio_LicenseAgreementsMember_638157302170056142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170046144" xlink:to="mbio_LicenseAgreementsMember_638157302170056142" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_SponsoredResearchAndClinicalTrialAgreementsMember" xlink:label="mbio_SponsoredResearchAndClinicalTrialAgreementsMember_638157302170056142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170046144" xlink:to="mbio_SponsoredResearchAndClinicalTrialAgreementsMember_638157302170056142" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170056142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170046144" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170056142" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_638157302170056142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170056142" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_638157302170056142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentTables" xlink:type="extended" xlink:title="30503 - Disclosure - Property and Equipment (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638157302170056142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638157302170056142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables" xlink:type="extended" xlink:title="30603 - Disclosure - Accounts Payable and Accrued Expenses (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_638157302170056142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_638157302170056142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="30703 - Disclosure - Commitments and Contingencies (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638157302170066166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_638157302170066166" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638157302170066166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638157302170066166" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureNotesPayableTables" xlink:type="extended" xlink:title="30803 - Disclosure - Notes Payable (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_638157302170066166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_2" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_638157302170066166" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30903 - Disclosure - Stockholders' Equity (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_109" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170066166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_109" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170066166" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638157302170066166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170066166" xlink:to="us-gaap_AwardTypeAxis_638157302170066166" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157302170066166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638157302170066166" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157302170066166" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638157302170066166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157302170066166" xlink:to="us-gaap_RestrictedStockMember_638157302170066166" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638157302170066166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157302170066166" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638157302170066166" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170066166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170066166" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170066166" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638157302170066166" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170066166" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638157302170066166" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_638157302170076156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170066166" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_638157302170076156" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_638157302170076156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170066166" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_638157302170076156" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_SummaryOfWarrantActivitiesTableTextBlock" xlink:label="mbio_SummaryOfWarrantActivitiesTableTextBlock_638157302170076156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170066166" xlink:to="mbio_SummaryOfWarrantActivitiesTableTextBlock_638157302170076156" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31003 - Disclosure - Income Taxes (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638157302170076156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638157302170076156" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638157302170076156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638157302170076156" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureOrganizationAndDescriptionOfBusinessDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization and Description of Business (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_147" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638157302170076156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_147" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638157302170076156" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Significant Accounting Policies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638157302170076156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_638157302170076156" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638157302170086154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638157302170076156" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638157302170086154" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638157302170086154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638157302170086154" xlink:to="us-gaap_RelatedPartyDomain_638157302170086154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_FortressBiotechIncMember" xlink:label="mbio_FortressBiotechIncMember_638157302170086154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638157302170086154" xlink:to="mbio_FortressBiotechIncMember_638157302170086154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638157302170086154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638157302170076156" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638157302170086154" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638157302170086154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638157302170086154" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638157302170086154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_638157302170086154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638157302170086154" xlink:to="us-gaap_ConstructionInProgressMember_638157302170086154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638157302170086154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638157302170076156" xlink:to="us-gaap_StatementClassOfStockAxis_638157302170086154" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638157302170086154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638157302170086154" xlink:to="us-gaap_ClassOfStockDomain_638157302170086154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember_638157302170086154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638157302170086154" xlink:to="us-gaap_PreferredClassAMember_638157302170086154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638157302170086154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638157302170076156" xlink:to="us-gaap_TypeOfArrangementAxis_638157302170086154" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170086154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638157302170086154" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170086154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LicenseAgreementsMember" xlink:label="mbio_LicenseAgreementsMember_638157302170086154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170086154" xlink:to="mbio_LicenseAgreementsMember_638157302170086154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638157302170086154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638157302170076156" xlink:to="us-gaap_ClassOfStockLineItems_638157302170086154" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_NumberOfSubsidiaries" xlink:label="mbio_NumberOfSubsidiaries_638157302170096153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638157302170086154" xlink:to="mbio_NumberOfSubsidiaries_638157302170096153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638157302170096153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638157302170086154" xlink:to="us-gaap_NumberOfOperatingSegments_638157302170096153" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_638157302170096153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638157302170086154" xlink:to="us-gaap_NumberOfReportableSegments_638157302170096153" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638157302170096153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638157302170086154" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638157302170096153" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638157302170096153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638157302170086154" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638157302170096153" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638157302170096153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638157302170086154" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638157302170096153" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="us-gaap_PreferredStockDividendsShares_638157302170096153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638157302170086154" xlink:to="us-gaap_PreferredStockDividendsShares_638157302170096153" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsShares" xlink:label="us-gaap_CommonStockDividendsShares_638157302170096153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638157302170086154" xlink:to="us-gaap_CommonStockDividendsShares_638157302170096153" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DilutedOutstandingEquityPercentage" xlink:label="mbio_DilutedOutstandingEquityPercentage_638157302170096153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638157302170086154" xlink:to="mbio_DilutedOutstandingEquityPercentage_638157302170096153" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638157302170096153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638157302170086154" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638157302170096153" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_638157302170106168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638157302170086154" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1_638157302170106168" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Significant Accounting Policies (Schedule of Potentially Dilutive Securities) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637038917268522158" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638157302170106168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637038917268522158" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638157302170106168" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638157302170106168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638157302170106168" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638157302170106168" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638157302170106168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638157302170106168" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638157302170106168" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638157302170106168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638157302170106168" xlink:to="us-gaap_WarrantMember_638157302170106168" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638157302170106168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638157302170106168" xlink:to="us-gaap_EmployeeStockOptionMember_638157302170106168" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember_638157302170106168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638157302170106168" xlink:to="us-gaap_PreferredClassAMember_638157302170106168" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638157302170106168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638157302170106168" xlink:to="us-gaap_RestrictedStockMember_638157302170106168" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638157302170106168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638157302170106168" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638157302170106168" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638157302170106168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638157302170106168" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638157302170106168" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638157302170116156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638157302170106168" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638157302170116156" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (License Agreements) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_637553721320871282" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170116156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract_637553721320871282" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170116156" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638157302170116156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170116156" xlink:to="srt_ProductOrServiceAxis_638157302170116156" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638157302170116156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638157302170116156" xlink:to="srt_ProductsAndServicesDomain_638157302170116156" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cd123ProductOrProcessMember" xlink:label="mbio_Cd123ProductOrProcessMember_638157302170116156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170116156" xlink:to="mbio_Cd123ProductOrProcessMember_638157302170116156" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_IvIcvProductOrProcessMember" xlink:label="mbio_IvIcvProductOrProcessMember_638157302170116156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170116156" xlink:to="mbio_IvIcvProductOrProcessMember_638157302170116156" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PscaProductOrProcessMember" xlink:label="mbio_PscaProductOrProcessMember_638157302170116156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170116156" xlink:to="mbio_PscaProductOrProcessMember_638157302170116156" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Her2ProductOrProcessMember" xlink:label="mbio_Her2ProductOrProcessMember_638157302170116156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170116156" xlink:to="mbio_Her2ProductOrProcessMember_638157302170116156" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638157302170116156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170116156" xlink:to="srt_CounterpartyNameAxis_638157302170116156" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170116156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638157302170116156" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170116156" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CityOfHopeNationalMedicalCenterCohMember" xlink:label="mbio_CityOfHopeNationalMedicalCenterCohMember_638157302170116156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170116156" xlink:to="mbio_CityOfHopeNationalMedicalCenterCohMember_638157302170116156" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CalimmuneMember" xlink:label="mbio_CalimmuneMember_638157302170116156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170116156" xlink:to="mbio_CalimmuneMember_638157302170116156" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LeidenUniversityMedicalCentreMember" xlink:label="mbio_LeidenUniversityMedicalCentreMember_638157302170126154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170116156" xlink:to="mbio_LeidenUniversityMedicalCentreMember_638157302170126154" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MayoClinicMember" xlink:label="mbio_MayoClinicMember_638157302170126154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170116156" xlink:to="mbio_MayoClinicMember_638157302170126154" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_FortressBiotechIncMember" xlink:label="mbio_FortressBiotechIncMember_638157302170126154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170116156" xlink:to="mbio_FortressBiotechIncMember_638157302170126154" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638157302170126154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170116156" xlink:to="us-gaap_TypeOfArrangementAxis_638157302170126154" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170126154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638157302170126154" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170126154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LicenseAgreementsMember" xlink:label="mbio_LicenseAgreementsMember_638157302170126154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170126154" xlink:to="mbio_LicenseAgreementsMember_638157302170126154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170126154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170116156" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170126154" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638157302170126154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170126154" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638157302170126154" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails" xlink:type="extended" xlink:title="40302 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (City of Hope - Licenses) (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170136154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170136154" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638157302170136154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170136154" xlink:to="us-gaap_TypeOfArrangementAxis_638157302170136154" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170136154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638157302170136154" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170136154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LicenseAgreementsMember" xlink:label="mbio_LicenseAgreementsMember_638157302170136154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170136154" xlink:to="mbio_LicenseAgreementsMember_638157302170136154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638157302170136154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170136154" xlink:to="srt_ProductOrServiceAxis_638157302170136154" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638157302170136154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638157302170136154" xlink:to="srt_ProductsAndServicesDomain_638157302170136154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cd123ProductOrProcessMember" xlink:label="mbio_Cd123ProductOrProcessMember_638157302170136154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170136154" xlink:to="mbio_Cd123ProductOrProcessMember_638157302170136154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_IvIcvProductOrProcessMember" xlink:label="mbio_IvIcvProductOrProcessMember_638157302170136154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170136154" xlink:to="mbio_IvIcvProductOrProcessMember_638157302170136154" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PscaProductOrProcessMember" xlink:label="mbio_PscaProductOrProcessMember_638157302170136154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170136154" xlink:to="mbio_PscaProductOrProcessMember_638157302170136154" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Her2ProductOrProcessMember" xlink:label="mbio_Her2ProductOrProcessMember_638157302170136154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170136154" xlink:to="mbio_Her2ProductOrProcessMember_638157302170136154" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638157302170136154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170136154" xlink:to="srt_CounterpartyNameAxis_638157302170136154" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170136154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638157302170136154" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170136154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CityOfHopeNationalMedicalCenterCohMember" xlink:label="mbio_CityOfHopeNationalMedicalCenterCohMember_638157302170136154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170136154" xlink:to="mbio_CityOfHopeNationalMedicalCenterCohMember_638157302170136154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CalimmuneMember" xlink:label="mbio_CalimmuneMember_638157302170136154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170136154" xlink:to="mbio_CalimmuneMember_638157302170136154" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LeidenUniversityMedicalCentreMember" xlink:label="mbio_LeidenUniversityMedicalCentreMember_638157302170146160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170136154" xlink:to="mbio_LeidenUniversityMedicalCentreMember_638157302170146160" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MayoClinicMember" xlink:label="mbio_MayoClinicMember_638157302170146160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170136154" xlink:to="mbio_MayoClinicMember_638157302170146160" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170146160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170136154" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170146160" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AnnualMaintenanceFeePayable" xlink:label="mbio_AnnualMaintenanceFeePayable_638157302170146160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170146160" xlink:to="mbio_AnnualMaintenanceFeePayable_638157302170146160" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PaymentOfUpfrontFees" xlink:label="mbio_PaymentOfUpfrontFees_638157302170146160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170146160" xlink:to="mbio_PaymentOfUpfrontFees_638157302170146160" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_NumberOfMilestonesMeasured" xlink:label="mbio_NumberOfMilestonesMeasured_638157302170146160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170146160" xlink:to="mbio_NumberOfMilestonesMeasured_638157302170146160" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MilestonesPayableUnderArrangement" xlink:label="mbio_MilestonesPayableUnderArrangement_638157302170146160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170146160" xlink:to="mbio_MilestonesPayableUnderArrangement_638157302170146160" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638157302170146160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170146160" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638157302170146160" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_NonRefundableMilestonePayments" xlink:label="mbio_NonRefundableMilestonePayments_638157302170146160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170146160" xlink:to="mbio_NonRefundableMilestonePayments_638157302170146160" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails" xlink:type="extended" xlink:title="40303 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (Sponsored Research and Clinical Trial Agreements) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_637553721853490479" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170156154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract_637553721853490479" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170156154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638157302170156154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170156154" xlink:to="srt_ProductOrServiceAxis_638157302170156154" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638157302170156154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638157302170156154" xlink:to="srt_ProductsAndServicesDomain_638157302170156154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CityOfHopeMember" xlink:label="mbio_CityOfHopeMember_638157302170156154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170156154" xlink:to="mbio_CityOfHopeMember_638157302170156154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cd123ProductOrProcessMember" xlink:label="mbio_Cd123ProductOrProcessMember_638157302170156154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mbio_CityOfHopeMember_638157302170156154" xlink:to="mbio_Cd123ProductOrProcessMember_638157302170156154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Il13r2ProductMember" xlink:label="mbio_Il13r2ProductMember_638157302170156154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mbio_CityOfHopeMember_638157302170156154" xlink:to="mbio_Il13r2ProductMember_638157302170156154" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cs1ProductOrProcessMember" xlink:label="mbio_Cs1ProductOrProcessMember_638157302170156154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mbio_CityOfHopeMember_638157302170156154" xlink:to="mbio_Cs1ProductOrProcessMember_638157302170156154" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Her2ProductOrProcessMember" xlink:label="mbio_Her2ProductOrProcessMember_638157302170156154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mbio_CityOfHopeMember_638157302170156154" xlink:to="mbio_Her2ProductOrProcessMember_638157302170156154" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PscaProductOrProcessMember" xlink:label="mbio_PscaProductOrProcessMember_638157302170156154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mbio_CityOfHopeMember_638157302170156154" xlink:to="mbio_PscaProductOrProcessMember_638157302170156154" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cd20TechnologyProductOrProcessMember" xlink:label="mbio_Cd20TechnologyProductOrProcessMember_638157302170156154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170156154" xlink:to="mbio_Cd20TechnologyProductOrProcessMember_638157302170156154" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StJudeXscidMember" xlink:label="mbio_StJudeXscidMember_638157302170156154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170156154" xlink:to="mbio_StJudeXscidMember_638157302170156154" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Rag1ScidMb110Member" xlink:label="mbio_Rag1ScidMb110Member_638157302170166156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170156154" xlink:to="mbio_Rag1ScidMb110Member_638157302170166156" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638157302170166156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170156154" xlink:to="srt_CounterpartyNameAxis_638157302170166156" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170166156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638157302170166156" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170166156" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CityOfHopeNationalMedicalCenterCohMember" xlink:label="mbio_CityOfHopeNationalMedicalCenterCohMember_638157302170166156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170166156" xlink:to="mbio_CityOfHopeNationalMedicalCenterCohMember_638157302170166156" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_FredHutchinsonCancerResearchCenterMember" xlink:label="mbio_FredHutchinsonCancerResearchCenterMember_638157302170166156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170166156" xlink:to="mbio_FredHutchinsonCancerResearchCenterMember_638157302170166156" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_St.JudeChildrensResearchHospitalMember" xlink:label="mbio_St.JudeChildrensResearchHospitalMember_638157302170166156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170166156" xlink:to="mbio_St.JudeChildrensResearchHospitalMember_638157302170166156" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MayoClinicMember" xlink:label="mbio_MayoClinicMember_638157302170166156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170166156" xlink:to="mbio_MayoClinicMember_638157302170166156" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LeidenUniversityMedicalCentreMember" xlink:label="mbio_LeidenUniversityMedicalCentreMember_638157302170166156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170166156" xlink:to="mbio_LeidenUniversityMedicalCentreMember_638157302170166156" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638157302170166156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170156154" xlink:to="us-gaap_TypeOfArrangementAxis_638157302170166156" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170166156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638157302170166156" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170166156" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_SponsoredResearchAndClinicalTrialAgreementsMember" xlink:label="mbio_SponsoredResearchAndClinicalTrialAgreementsMember_638157302170166156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170166156" xlink:to="mbio_SponsoredResearchAndClinicalTrialAgreementsMember_638157302170166156" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170176150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170156154" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170176150" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638157302170176150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170176150" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638157302170176150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" xlink:type="extended" xlink:title="40304 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (City of Hope - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_637504029967455478" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170216152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract_637504029967455478" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170216152" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638157302170216152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170216152" xlink:to="us-gaap_TypeOfArrangementAxis_638157302170216152" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170216152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638157302170216152" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170216152" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_SponsoredResearchAndClinicalTrialAgreementsMember" xlink:label="mbio_SponsoredResearchAndClinicalTrialAgreementsMember_638157302170216152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170216152" xlink:to="mbio_SponsoredResearchAndClinicalTrialAgreementsMember_638157302170216152" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638157302170216152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170216152" xlink:to="srt_ProductOrServiceAxis_638157302170216152" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638157302170216152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638157302170216152" xlink:to="srt_ProductsAndServicesDomain_638157302170216152" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cd123ProductOrProcessMember" xlink:label="mbio_Cd123ProductOrProcessMember_638157302170216152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170216152" xlink:to="mbio_Cd123ProductOrProcessMember_638157302170216152" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Il13r2ProductMember" xlink:label="mbio_Il13r2ProductMember_638157302170216152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170216152" xlink:to="mbio_Il13r2ProductMember_638157302170216152" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cs1ProductOrProcessMember" xlink:label="mbio_Cs1ProductOrProcessMember_638157302170216152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170216152" xlink:to="mbio_Cs1ProductOrProcessMember_638157302170216152" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PscaProductOrProcessMember" xlink:label="mbio_PscaProductOrProcessMember_638157302170216152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170216152" xlink:to="mbio_PscaProductOrProcessMember_638157302170216152" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Her2ProductOrProcessMember" xlink:label="mbio_Her2ProductOrProcessMember_638157302170216152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170216152" xlink:to="mbio_Her2ProductOrProcessMember_638157302170216152" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cd20TechnologyProductOrProcessMember" xlink:label="mbio_Cd20TechnologyProductOrProcessMember_638157302170226159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170216152" xlink:to="mbio_Cd20TechnologyProductOrProcessMember_638157302170226159" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StJudeXscidMember" xlink:label="mbio_StJudeXscidMember_638157302170226159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170216152" xlink:to="mbio_StJudeXscidMember_638157302170226159" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Rag1ScidMb110Member" xlink:label="mbio_Rag1ScidMb110Member_638157302170226159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170216152" xlink:to="mbio_Rag1ScidMb110Member_638157302170226159" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638157302170226159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170216152" xlink:to="srt_CounterpartyNameAxis_638157302170226159" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170226159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638157302170226159" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170226159" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CityOfHopeNationalMedicalCenterCohMember" xlink:label="mbio_CityOfHopeNationalMedicalCenterCohMember_638157302170226159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170226159" xlink:to="mbio_CityOfHopeNationalMedicalCenterCohMember_638157302170226159" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LeidenUniversityMedicalCentreMember" xlink:label="mbio_LeidenUniversityMedicalCentreMember_638157302170226159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170226159" xlink:to="mbio_LeidenUniversityMedicalCentreMember_638157302170226159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_FredHutchinsonCancerResearchCenterMember" xlink:label="mbio_FredHutchinsonCancerResearchCenterMember_638157302170226159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170226159" xlink:to="mbio_FredHutchinsonCancerResearchCenterMember_638157302170226159" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MayoClinicMember" xlink:label="mbio_MayoClinicMember_638157302170226159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170226159" xlink:to="mbio_MayoClinicMember_638157302170226159" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_St.JudeChildrensResearchHospitalMember" xlink:label="mbio_St.JudeChildrensResearchHospitalMember_638157302170226159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170226159" xlink:to="mbio_St.JudeChildrensResearchHospitalMember_638157302170226159" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638157302170226159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170216152" xlink:to="srt_RangeAxis_638157302170226159" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638157302170236163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638157302170226159" xlink:to="srt_RangeMember_638157302170236163" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638157302170236163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638157302170236163" xlink:to="srt_MaximumMember_638157302170236163" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170236163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170216152" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170236163" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PaymentOfUpfrontFees" xlink:label="mbio_PaymentOfUpfrontFees_638157302170236163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170236163" xlink:to="mbio_PaymentOfUpfrontFees_638157302170236163" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ResearchFundingAmount" xlink:label="mbio_ResearchFundingAmount_638157302170236163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170236163" xlink:to="mbio_ResearchFundingAmount_638157302170236163" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MilestonesPayableUnderArrangement" xlink:label="mbio_MilestonesPayableUnderArrangement_638157302170236163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170236163" xlink:to="mbio_MilestonesPayableUnderArrangement_638157302170236163" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AdditionalMilestonesPayableUnderArrangement" xlink:label="mbio_AdditionalMilestonesPayableUnderArrangement_638157302170236163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170236163" xlink:to="mbio_AdditionalMilestonesPayableUnderArrangement_638157302170236163" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ContributionTowardPatientCosts" xlink:label="mbio_ContributionTowardPatientCosts_638157302170236163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170236163" xlink:to="mbio_ContributionTowardPatientCosts_638157302170236163" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ResearchArrangementContributionPerPatient" xlink:label="mbio_ResearchArrangementContributionPerPatient_638157302170236163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170236163" xlink:to="mbio_ResearchArrangementContributionPerPatient_638157302170236163" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ResearchArrangementTerm" xlink:label="mbio_ResearchArrangementTerm_638157302170246155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170236163" xlink:to="mbio_ResearchArrangementTerm_638157302170246155" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638157302170246155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170236163" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638157302170246155" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AnnualMaintenanceFeePayable" xlink:label="mbio_AnnualMaintenanceFeePayable_638157302170246155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170236163" xlink:to="mbio_AnnualMaintenanceFeePayable_638157302170246155" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ReimbursementOfFeesTotalPayments" xlink:label="mbio_ReimbursementOfFeesTotalPayments_638157302170246155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170236163" xlink:to="mbio_ReimbursementOfFeesTotalPayments_638157302170246155" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails" xlink:type="extended" xlink:title="40305 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (Other - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_637504030684262216" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170246155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract_637504030684262216" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170246155" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638157302170246155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170246155" xlink:to="srt_CounterpartyNameAxis_638157302170246155" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170256157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638157302170246155" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170256157" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_FredHutchinsonCancerResearchCenterMember" xlink:label="mbio_FredHutchinsonCancerResearchCenterMember_638157302170256157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170256157" xlink:to="mbio_FredHutchinsonCancerResearchCenterMember_638157302170256157" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_St.JudeChildrensResearchHospitalMember" xlink:label="mbio_St.JudeChildrensResearchHospitalMember_638157302170256157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170256157" xlink:to="mbio_St.JudeChildrensResearchHospitalMember_638157302170256157" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MayoClinicMember" xlink:label="mbio_MayoClinicMember_638157302170256157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170256157" xlink:to="mbio_MayoClinicMember_638157302170256157" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LeidenUniversityMedicalCentreMember" xlink:label="mbio_LeidenUniversityMedicalCentreMember_638157302170256157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638157302170256157" xlink:to="mbio_LeidenUniversityMedicalCentreMember_638157302170256157" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638157302170256157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170246155" xlink:to="us-gaap_TypeOfArrangementAxis_638157302170256157" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170256157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638157302170256157" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170256157" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_SponsoredResearchAndClinicalTrialAgreementsMember" xlink:label="mbio_SponsoredResearchAndClinicalTrialAgreementsMember_638157302170256157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638157302170256157" xlink:to="mbio_SponsoredResearchAndClinicalTrialAgreementsMember_638157302170256157" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClinicalTrialAgreementsMember" xlink:label="mbio_ClinicalTrialAgreementsMember_638157302170256157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mbio_SponsoredResearchAndClinicalTrialAgreementsMember_638157302170256157" xlink:to="mbio_ClinicalTrialAgreementsMember_638157302170256157" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DataTransferAgreementMember" xlink:label="mbio_DataTransferAgreementMember_638157302170256157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mbio_SponsoredResearchAndClinicalTrialAgreementsMember_638157302170256157" xlink:to="mbio_DataTransferAgreementMember_638157302170256157" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638157302170256157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170246155" xlink:to="srt_ProductOrServiceAxis_638157302170256157" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638157302170256157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638157302170256157" xlink:to="srt_ProductsAndServicesDomain_638157302170256157" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Cd20TechnologyProductOrProcessMember" xlink:label="mbio_Cd20TechnologyProductOrProcessMember_638157302170266143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170256157" xlink:to="mbio_Cd20TechnologyProductOrProcessMember_638157302170266143" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StJudeXscidMember" xlink:label="mbio_StJudeXscidMember_638157302170266143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170256157" xlink:to="mbio_StJudeXscidMember_638157302170266143" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_Rag1ScidMb110Member" xlink:label="mbio_Rag1ScidMb110Member_638157302170266143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638157302170256157" xlink:to="mbio_Rag1ScidMb110Member_638157302170266143" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170266143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638157302170246155" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170266143" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PaymentOfUpfrontFees" xlink:label="mbio_PaymentOfUpfrontFees_638157302170266143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170266143" xlink:to="mbio_PaymentOfUpfrontFees_638157302170266143" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MilestonesPayableUnderArrangement" xlink:label="mbio_MilestonesPayableUnderArrangement_638157302170266143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170266143" xlink:to="mbio_MilestonesPayableUnderArrangement_638157302170266143" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AdditionalMilestonesPayableUnderArrangement" xlink:label="mbio_AdditionalMilestonesPayableUnderArrangement_638157302170266143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170266143" xlink:to="mbio_AdditionalMilestonesPayableUnderArrangement_638157302170266143" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638157302170266143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170266143" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638157302170266143" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ReimbursementOfFeesTotalPayments" xlink:label="mbio_ReimbursementOfFeesTotalPayments_638157302170266143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170266143" xlink:to="mbio_ReimbursementOfFeesTotalPayments_638157302170266143" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ResearchArrangementTerm" xlink:label="mbio_ResearchArrangementTerm_638157302170266143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638157302170266143" xlink:to="mbio_ResearchArrangementTerm_638157302170266143" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Related Party Agreements (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_311" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638157302170276139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_311" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638157302170276139" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638157302170276139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638157302170276139" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638157302170276139" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638157302170276139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638157302170276139" xlink:to="us-gaap_RelatedPartyDomain_638157302170276139" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_FortressBiotechIncMember" xlink:label="mbio_FortressBiotechIncMember_638157302170276139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638157302170276139" xlink:to="mbio_FortressBiotechIncMember_638157302170276139" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_638157302170276139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638157302170276139" xlink:to="srt_DirectorMember_638157302170276139" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember_638157302170276139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638157302170276139" xlink:to="srt_BoardOfDirectorsChairmanMember_638157302170276139" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638157302170276139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638157302170276139" xlink:to="srt_RangeAxis_638157302170276139" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638157302170276139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638157302170276139" xlink:to="srt_RangeMember_638157302170276139" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638157302170276139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638157302170276139" xlink:to="srt_MaximumMember_638157302170276139" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638157302170276139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638157302170276139" xlink:to="us-gaap_StatementClassOfStockAxis_638157302170276139" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638157302170286146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638157302170276139" xlink:to="us-gaap_ClassOfStockDomain_638157302170286146" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_638157302170286146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638157302170286146" xlink:to="us-gaap_CommonClassBMember_638157302170286146" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommonUnspecifiedClassMember" xlink:label="mbio_CommonUnspecifiedClassMember_638157302170286146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638157302170286146" xlink:to="mbio_CommonUnspecifiedClassMember_638157302170286146" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember_638157302170286146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638157302170286146" xlink:to="us-gaap_PreferredClassAMember_638157302170286146" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638157302170286146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638157302170276139" xlink:to="us-gaap_IncomeStatementLocationAxis_638157302170286146" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638157302170286146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638157302170286146" xlink:to="us-gaap_IncomeStatementLocationDomain_638157302170286146" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638157302170286146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638157302170286146" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638157302170286146" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638157302170286146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638157302170276139" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638157302170286146" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638157302170286146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638157302170286146" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638157302170286146" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AtMarketOfferingMember" xlink:label="mbio_AtMarketOfferingMember_638157302170286146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638157302170286146" xlink:to="mbio_AtMarketOfferingMember_638157302170286146" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638157302170286146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638157302170276139" xlink:to="us-gaap_AwardTypeAxis_638157302170286146" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157302170296138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638157302170286146" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157302170296138" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638157302170296138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157302170296138" xlink:to="us-gaap_RestrictedStockMember_638157302170296138" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638157302170296138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638157302170276139" xlink:to="us-gaap_DebtInstrumentAxis_638157302170296138" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638157302170296138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638157302170296138" xlink:to="us-gaap_DebtInstrumentNameDomain_638157302170296138" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_RunwayDebtFacilityMember" xlink:label="mbio_RunwayDebtFacilityMember_638157302170296138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638157302170296138" xlink:to="mbio_RunwayDebtFacilityMember_638157302170296138" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638157302170276139" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_638157302170296138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_638157302170296138" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses" xlink:label="mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses_638157302170296138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses_638157302170296138" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses" xlink:label="mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses_638157302170296138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses_638157302170296138" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_638157302170306137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_638157302170306137" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_638157302170306137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued_638157302170306137" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638157302170306137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638157302170306137" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuedDuringPeriodSharesIssuableForServices" xlink:label="mbio_StockIssuedDuringPeriodSharesIssuableForServices_638157302170306137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_StockIssuedDuringPeriodSharesIssuableForServices_638157302170306137" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638157302170306137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638157302170306137" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DilutedOutstandingEquityPercentage" xlink:label="mbio_DilutedOutstandingEquityPercentage_638157302170306137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_DilutedOutstandingEquityPercentage_638157302170306137" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_638157302170306137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_638157302170306137" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_FoundersAgreementTerm" xlink:label="mbio_FoundersAgreementTerm_638157302170306137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_FoundersAgreementTerm_638157302170306137" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AgreementRenewalTerm" xlink:label="mbio_AgreementRenewalTerm_638157302170316137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_AgreementRenewalTerm_638157302170316137" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_638157302170316137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="us-gaap_ConversionOfStockSharesIssued1_638157302170316137" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_PreferredStockVotingRightsMultiplier" xlink:label="mbio_PreferredStockVotingRightsMultiplier_638157302170316137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_PreferredStockVotingRightsMultiplier_638157302170316137" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_638157302170316137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_638157302170316137" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638157302170316137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638157302170316137" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement" xlink:label="mbio_OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement_638157302170316137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement_638157302170316137" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_EquityFeePaymentPeriod" xlink:label="mbio_EquityFeePaymentPeriod_638157302170326136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_EquityFeePaymentPeriod_638157302170326136" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_EquityFeePercentageOfFinancing" xlink:label="mbio_EquityFeePercentageOfFinancing_638157302170326136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_EquityFeePercentageOfFinancing_638157302170326136" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CashFeeAsPercentageOfAnnualNetSales" xlink:label="mbio_CashFeeAsPercentageOfAnnualNetSales_638157302170326136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_CashFeeAsPercentageOfAnnualNetSales_638157302170326136" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CashFeePaymentPeriod" xlink:label="mbio_CashFeePaymentPeriod_638157302170326136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_CashFeePaymentPeriod_638157302170326136" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate" xlink:label="mbio_ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate_638157302170326136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate_638157302170326136" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ChangeInControlFeeMeasurementPeriodForNetSales" xlink:label="mbio_ChangeInControlFeeMeasurementPeriodForNetSales_638157302170326136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_ChangeInControlFeeMeasurementPeriodForNetSales_638157302170326136" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ChangeInControlFeeSpecifiedRateComponent" xlink:label="mbio_ChangeInControlFeeSpecifiedRateComponent_638157302170326136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_ChangeInControlFeeSpecifiedRateComponent_638157302170326136" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AgreementTerm" xlink:label="mbio_AgreementTerm_638157302170336135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_AgreementTerm_638157302170336135" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_MsaAgreementRenewalTerm" xlink:label="mbio_MsaAgreementRenewalTerm_638157302170336135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_MsaAgreementRenewalTerm_638157302170336135" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AnnualConsultingFees" xlink:label="mbio_AnnualConsultingFees_638157302170336135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_AnnualConsultingFees_638157302170336135" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_IncreaseInAnnualConsultingFees" xlink:label="mbio_IncreaseInAnnualConsultingFees_638157302170336135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_IncreaseInAnnualConsultingFees_638157302170336135" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ExcessInNetAssetsValue" xlink:label="mbio_ExcessInNetAssetsValue_638157302170336135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_ExcessInNetAssetsValue_638157302170336135" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_638157302170346138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_638157302170346138" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DirectorCompensationValueOfSharesGranted" xlink:label="mbio_DirectorCompensationValueOfSharesGranted_638157302170346138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_DirectorCompensationValueOfSharesGranted_638157302170346138" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DirectorCompensationNumberOfSharesGranted" xlink:label="mbio_DirectorCompensationNumberOfSharesGranted_638157302170346138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="mbio_DirectorCompensationNumberOfSharesGranted_638157302170346138" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638157302170346138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638157302170346138" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_638157302170346138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638157302170296138" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_638157302170346138" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentNarrativeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Property and Equipment (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638157302170356138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation_638157302170356138" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_338963" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638157302170356138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_338963" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638157302170356138" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638157302170356138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638157302170356138" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638157302170356138" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638157302170356138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638157302170356138" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638157302170356138" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_638157302170356138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638157302170356138" xlink:to="us-gaap_ComputerEquipmentMember_638157302170356138" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638157302170356138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638157302170356138" xlink:to="us-gaap_FurnitureAndFixturesMember_638157302170356138" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_638157302170356138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638157302170356138" xlink:to="us-gaap_MachineryAndEquipmentMember_638157302170356138" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638157302170356138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638157302170356138" xlink:to="us-gaap_LeaseholdImprovementsMember_638157302170356138" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_638157302170366149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638157302170356138" xlink:to="us-gaap_ConstructionInProgressMember_638157302170366149" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638157302170366149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638157302170356138" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638157302170366149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638157302170366149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638157302170366149" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638157302170366149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638157302170366149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638157302170366149" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638157302170366149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638157302170366149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638157302170366149" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638157302170366149" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638157302170366149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638157302170366149" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638157302170366149" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Expenses) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638157302170366149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableCurrent_638157302170366149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ResearchAndDevelopmentCurrent" xlink:label="mbio_ResearchAndDevelopmentCurrent_638157302170366149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mbio_ResearchAndDevelopmentCurrent_638157302170366149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AccruedCompensationCurrent" xlink:label="mbio_AccruedCompensationCurrent_638157302170366149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mbio_AccruedCompensationCurrent_638157302170366149" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_638157302170366149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_638157302170366149" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638157302170376148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638157302170376148" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Commitments and Contingencies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638157302170376148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638157302170376148" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_638157302170376148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638157302170376148" xlink:to="us-gaap_CashAndCashEquivalentsAxis_638157302170376148" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638157302170376148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_638157302170376148" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638157302170376148" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember_638157302170376148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638157302170376148" xlink:to="us-gaap_CashMember_638157302170376148" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_638157302170376148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638157302170376148" xlink:to="us-gaap_ShortTermDebtTypeAxis_638157302170376148" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_638157302170376148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis_638157302170376148" xlink:to="us-gaap_ShortTermDebtTypeDomain_638157302170376148" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember_638157302170376148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_638157302170376148" xlink:to="us-gaap_LetterOfCreditMember_638157302170376148" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638157302170376148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638157302170376148" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638157302170376148" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea_638157302170376148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638157302170376148" xlink:to="us-gaap_NetRentableArea_638157302170376148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LesseeOperatingLeaseTotalBaseRentNetOfAbatements" xlink:label="mbio_LesseeOperatingLeaseTotalBaseRentNetOfAbatements_638157302170376148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638157302170376148" xlink:to="mbio_LesseeOperatingLeaseTotalBaseRentNetOfAbatements_638157302170376148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LesseeOperatingLeaseTotalAbatementsOverLeaseTerm" xlink:label="mbio_LesseeOperatingLeaseTotalAbatementsOverLeaseTerm_638157302170386143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638157302170376148" xlink:to="mbio_LesseeOperatingLeaseTotalAbatementsOverLeaseTerm_638157302170386143" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638157302170386143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638157302170376148" xlink:to="us-gaap_SecurityDeposit_638157302170386143" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_LesseeSecurityDepositUponFullOccupancy" xlink:label="mbio_LesseeSecurityDepositUponFullOccupancy_638157302170386143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638157302170376148" xlink:to="mbio_LesseeSecurityDepositUponFullOccupancy_638157302170386143" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638157302170386143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638157302170376148" xlink:to="us-gaap_OperatingLeaseLiability_638157302170386143" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638157302170386143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638157302170376148" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638157302170386143" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Commitments and Contingencies (Schedule of Operating Leases) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_638157302170386143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostAbstract_638157302170386143" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638157302170386143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638157302170386143" xlink:to="us-gaap_OperatingLeaseCost_638157302170386143" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638157302170386143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638157302170386143" xlink:to="us-gaap_VariableLeaseCost_638157302170386143" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638157302170386143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638157302170386143" xlink:to="us-gaap_LeaseCost_638157302170386143" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesCashFlowsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Commitments and Contingencies (Cash Flows) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638157302170396141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasePayments_638157302170396141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638157302170396141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638157302170396141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638157302170396141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638157302170396141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Commitments and Contingencies (Maturities of Operating Leases) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638157302170396141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638157302170396141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638157302170396141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638157302170396141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638157302170396141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638157302170396141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638157302170396141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638157302170396141" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638157302170396141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638157302170396141" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638157302170396141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638157302170396141" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638157302170396141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638157302170396141" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638157302170396141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638157302170396141" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638157302170396141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability_638157302170396141" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Notes Payable (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638157302170406142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_StatementTable_638157302170406142" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638157302170406142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157302170406142" xlink:to="us-gaap_DebtInstrumentAxis_638157302170406142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638157302170406142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638157302170406142" xlink:to="us-gaap_DebtInstrumentNameDomain_638157302170406142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_RunwayDebtFacilityMember" xlink:label="mbio_RunwayDebtFacilityMember_638157302170406142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638157302170406142" xlink:to="mbio_RunwayDebtFacilityMember_638157302170406142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_638157302170406142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157302170406142" xlink:to="us-gaap_VariableRateAxis_638157302170406142" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_638157302170406142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_638157302170406142" xlink:to="us-gaap_VariableRateDomain_638157302170406142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember" xlink:label="us-gaap_BaseRateMember_638157302170406142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638157302170406142" xlink:to="us-gaap_BaseRateMember_638157302170406142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_638157302170406142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638157302170406142" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember_638157302170406142" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638157302170406142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157302170406142" xlink:to="srt_RangeAxis_638157302170406142" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638157302170406142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638157302170406142" xlink:to="srt_RangeMember_638157302170406142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638157302170406142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638157302170406142" xlink:to="srt_MinimumMember_638157302170406142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638157302170416142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157302170406142" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638157302170416142" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638157302170416142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638157302170416142" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638157302170416142" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638157302170416142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638157302170416142" xlink:to="us-gaap_WarrantMember_638157302170416142" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638157302170416142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157302170406142" xlink:to="us-gaap_MeasurementInputTypeAxis_638157302170416142" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638157302170416142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638157302170416142" xlink:to="us-gaap_MeasurementInputTypeDomain_638157302170416142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638157302170416142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638157302170416142" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638157302170416142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638157302170416142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638157302170416142" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638157302170416142" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638157302170416142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157302170406142" xlink:to="us-gaap_StatementLineItems_638157302170416142" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638157302170416142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638157302170416142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit_638157302170416142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="us-gaap_ProceedsFromLinesOfCredit_638157302170416142" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_638157302170426138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_638157302170426138" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638157302170426138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638157302170426138" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_638157302170426138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_638157302170426138" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_638157302170426138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_638157302170426138" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638157302170426138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="us-gaap_SecurityDeposit_638157302170426138" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees_638157302170426138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="us-gaap_LegalFees_638157302170426138" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638157302170426138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638157302170426138" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638157302170426138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638157302170426138" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_638157302170426138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_638157302170426138" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_638157302170436139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_638157302170436139" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_638157302170436139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_638157302170436139" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638157302170436139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638157302170436139" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DebtInstrumentBalloonPaymentAsPercentageOfPrincipal" xlink:label="mbio_DebtInstrumentBalloonPaymentAsPercentageOfPrincipal_638157302170436139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="mbio_DebtInstrumentBalloonPaymentAsPercentageOfPrincipal_638157302170436139" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_638157302170436139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_638157302170436139" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_638157302170436139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_638157302170436139" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638157302170436139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="us-gaap_InterestExpenseDebt_638157302170436139" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638157302170436139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638157302170436139" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_638157302170446139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_638157302170446139" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_638157302170446139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170416142" xlink:to="us-gaap_LongTermNotesPayable_638157302170446139" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stockholders Equity (Common Stock and Equity Offerings) (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_637056991551936177" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170446139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_637056991551936177" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170446139" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638157302170446139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170446139" xlink:to="us-gaap_IncomeStatementLocationAxis_638157302170446139" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638157302170446139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638157302170446139" xlink:to="us-gaap_IncomeStatementLocationDomain_638157302170446139" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638157302170446139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638157302170446139" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638157302170446139" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638157302170456146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170446139" xlink:to="us-gaap_StatementClassOfStockAxis_638157302170456146" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638157302170456146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638157302170456146" xlink:to="us-gaap_ClassOfStockDomain_638157302170456146" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638157302170456146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638157302170456146" xlink:to="us-gaap_CommonStockMember_638157302170456146" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_638157302170456146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638157302170456146" xlink:to="us-gaap_CommonClassAMember_638157302170456146" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_638157302170456146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638157302170456146" xlink:to="us-gaap_CommonClassBMember_638157302170456146" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember_638157302170456146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638157302170456146" xlink:to="us-gaap_PreferredClassAMember_638157302170456146" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638157302170456146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170446139" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638157302170456146" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638157302170456146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638157302170456146" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638157302170456146" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_AtMarketOfferingMember" xlink:label="mbio_AtMarketOfferingMember_638157302170456146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638157302170456146" xlink:to="mbio_AtMarketOfferingMember_638157302170456146" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_RegistrationStatementsMember" xlink:label="mbio_RegistrationStatementsMember_638157302170456146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638157302170456146" xlink:to="mbio_RegistrationStatementsMember_638157302170456146" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638157302170456146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170446139" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638157302170456146" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638157302170456146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638157302170456146" xlink:to="us-gaap_RelatedPartyDomain_638157302170456146" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_FortressBiotechIncMember" xlink:label="mbio_FortressBiotechIncMember_638157302170466184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638157302170456146" xlink:to="mbio_FortressBiotechIncMember_638157302170466184" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638157302170466184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170446139" xlink:to="srt_RangeAxis_638157302170466184" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638157302170466184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638157302170466184" xlink:to="srt_RangeMember_638157302170466184" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638157302170466184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638157302170466184" xlink:to="srt_MaximumMember_638157302170466184" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170446139" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_638157302170466184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_638157302170466184" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement" xlink:label="mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement_638157302170466184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement_638157302170466184" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold" xlink:label="mbio_ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold_638157302170466184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="mbio_ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold_638157302170466184" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommonStockSharesAvailableForFutureIssuanceValue" xlink:label="mbio_CommonStockSharesAvailableForFutureIssuanceValue_638157302170466184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="mbio_CommonStockSharesAvailableForFutureIssuanceValue_638157302170466184" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DilutedOutstandingEquityPercentage" xlink:label="mbio_DilutedOutstandingEquityPercentage_638157302170476171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="mbio_DilutedOutstandingEquityPercentage_638157302170476171" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockIssuedDuringPeriodSharesIssuableForServices" xlink:label="mbio_StockIssuedDuringPeriodSharesIssuableForServices_638157302170476171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="mbio_StockIssuedDuringPeriodSharesIssuableForServices_638157302170476171" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_638157302170476171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_638157302170476171" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_638157302170476171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="us-gaap_ConversionOfStockSharesConverted1_638157302170476171" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_638157302170476171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="us-gaap_ConversionOfStockSharesIssued1_638157302170476171" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638157302170476171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="us-gaap_CommonStockSharesAuthorized_638157302170476171" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638157302170476171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638157302170476171" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638157302170476171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="us-gaap_PreferredStockSharesAuthorized_638157302170476171" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638157302170486159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="us-gaap_PreferredStockSharesIssued_638157302170486159" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions_638157302170486159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="us-gaap_CommonStockSharesSubscriptions_638157302170486159" order="14" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_VotingRightsNumberOfVotesPerShare" xlink:label="mbio_VotingRightsNumberOfVotesPerShare_638157302170486159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="mbio_VotingRightsNumberOfVotesPerShare_638157302170486159" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_StockholderAppointmentOfDirectorPeriodAfterIssuance" xlink:label="mbio_StockholderAppointmentOfDirectorPeriodAfterIssuance_638157302170486159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="mbio_StockholderAppointmentOfDirectorPeriodAfterIssuance_638157302170486159" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638157302170486159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="us-gaap_CommonStockSharesIssued_638157302170486159" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_CommissionRatePercentage" xlink:label="mbio_CommissionRatePercentage_638157302170486159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="mbio_CommissionRatePercentage_638157302170486159" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638157302170486159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638157302170486159" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638157302170496152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="us-gaap_SharesIssuedPricePerShare_638157302170496152" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_638157302170496152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued_638157302170496152" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638157302170496152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638157302170496152" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638157302170496152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638157302170496152" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" xlink:label="mbio_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts_638157302170496152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="mbio_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts_638157302170496152" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638157302170496152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638157302170496152" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638157302170496152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170466184" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638157302170496152" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Stockholders Equity (Equity Incentive Plan) (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_614" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170506153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_614" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170506153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638157302170506153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170506153" xlink:to="us-gaap_AwardTypeAxis_638157302170506153" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157302170506153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638157302170506153" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157302170506153" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638157302170506153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157302170506153" xlink:to="us-gaap_EmployeeStockOptionMember_638157302170506153" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170506153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170506153" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170506153" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638157302170506153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170506153" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638157302170506153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638157302170506153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170506153" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638157302170506153" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638157302170506153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170506153" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638157302170506153" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638157302170516153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170506153" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638157302170516153" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage" xlink:label="mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage_638157302170516153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170506153" xlink:to="mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage_638157302170516153" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638157302170516153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170506153" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638157302170516153" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638157302170516153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170506153" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638157302170516153" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Stockholders Equity (Stock Options) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_520" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170516153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_520" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170516153" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638157302170516153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170516153" xlink:to="us-gaap_AwardTypeAxis_638157302170516153" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157302170516153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638157302170516153" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157302170516153" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638157302170516153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157302170516153" xlink:to="us-gaap_EmployeeStockOptionMember_638157302170516153" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170516153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170516153" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170516153" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638157302170516153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170516153" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638157302170516153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638157302170526154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638157302170516153" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638157302170526154" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6381573021705261541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638157302170516153" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6381573021705261541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638157302170526154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638157302170516153" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638157302170526154" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638157302170526154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170516153" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638157302170526154" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638157302170526154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638157302170526154" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638157302170526154" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381573021705261541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638157302170526154" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381573021705261541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638157302170526154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638157302170526154" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638157302170526154" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638157302170526154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170516153" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638157302170526154" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638157302170526154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170516153" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638157302170526154" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638157302170526154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170516153" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638157302170526154" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Stockholders Equity (Restricted Stock Awards and Restricted Stock Units) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_540" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170536156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_540" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170536156" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638157302170536156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170536156" xlink:to="us-gaap_AwardTypeAxis_638157302170536156" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157302170536156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638157302170536156" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157302170536156" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638157302170536156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157302170536156" xlink:to="us-gaap_RestrictedStockMember_638157302170536156" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638157302170536156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638157302170536156" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638157302170536156" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170536156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638157302170536156" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170536156" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638157302170536156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170536156" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638157302170536156" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638157302170536156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638157302170536156" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638157302170536156" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638157302170536156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638157302170536156" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638157302170536156" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638157302170536156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638157302170536156" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638157302170536156" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638157302170536156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638157302170536156" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638157302170536156" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6381573021705361561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638157302170536156" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6381573021705361561" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638157302170546154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170536156" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638157302170546154" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638157302170546154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638157302170546154" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638157302170546154" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638157302170546154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638157302170546154" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638157302170546154" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638157302170546154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638157302170546154" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638157302170546154" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638157302170546154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638157302170546154" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638157302170546154" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6381573021705461541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638157302170546154" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6381573021705461541" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638157302170546154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170536156" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638157302170546154" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638157302170546154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638157302170536156" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638157302170546154" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Stockholders Equity (Stock-based Compensation Expense) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_339035" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638157302170556155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_339035" xlink:to="us-gaap_StatementTable_638157302170556155" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638157302170556155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157302170556155" xlink:to="us-gaap_IncomeStatementLocationAxis_638157302170556155" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638157302170556155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638157302170556155" xlink:to="us-gaap_IncomeStatementLocationDomain_638157302170556155" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638157302170556155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638157302170556155" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638157302170556155" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638157302170556155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638157302170556155" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638157302170556155" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638157302170556155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157302170556155" xlink:to="us-gaap_StatementLineItems_638157302170556155" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638157302170556155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170556155" xlink:to="us-gaap_ShareBasedCompensation_638157302170556155" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Stockholders' Equity (Stock Warrants) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_556" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638157302170556155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_556" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638157302170556155" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638157302170556155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638157302170556155" xlink:to="us-gaap_StatementEquityComponentsAxis_638157302170556155" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638157302170556155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638157302170556155" xlink:to="us-gaap_EquityComponentDomain_638157302170556155" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638157302170556155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638157302170556155" xlink:to="us-gaap_WarrantMember_638157302170556155" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638157302170566155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638157302170556155" xlink:to="us-gaap_DebtInstrumentAxis_638157302170566155" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638157302170566155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638157302170566155" xlink:to="us-gaap_DebtInstrumentNameDomain_638157302170566155" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_RunwayDebtFacilityMember" xlink:label="mbio_RunwayDebtFacilityMember_638157302170566155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638157302170566155" xlink:to="mbio_RunwayDebtFacilityMember_638157302170566155" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638157302170566155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638157302170556155" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638157302170566155" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased" xlink:label="mbio_ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased_638157302170566155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638157302170566155" xlink:to="mbio_ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased_638157302170566155" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638157302170566155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638157302170566155" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638157302170566155" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod" xlink:label="mbio_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod_638157302170566155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638157302170566155" xlink:to="mbio_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod_638157302170566155" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightWarrantsGrantedDuringPeriod" xlink:label="mbio_ClassOfWarrantOrRightWarrantsGrantedDuringPeriod_638157302170566155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638157302170566155" xlink:to="mbio_ClassOfWarrantOrRightWarrantsGrantedDuringPeriod_638157302170566155" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod" xlink:label="mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod_638157302170566155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638157302170566155" xlink:to="mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod_638157302170566155" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_6381573021705661551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638157302170566155" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_6381573021705661551" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638157302170566155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638157302170566155" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638157302170566155" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_WarrantExercisePriceExpiredDuringPeriod" xlink:label="mbio_WarrantExercisePriceExpiredDuringPeriod_638157302170566155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638157302170566155" xlink:to="mbio_WarrantExercisePriceExpiredDuringPeriod_638157302170566155" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod" xlink:label="mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod_638157302170576155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638157302170566155" xlink:to="mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod_638157302170576155" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" xlink:label="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife_638157302170576155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638157302170566155" xlink:to="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife_638157302170576155" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod" xlink:label="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod_638157302170576155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638157302170566155" xlink:to="mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod_638157302170576155" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638157302170576155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638157302170566155" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638157302170576155" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Income Taxes (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637038917271372158" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638157302170576155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637038917271372158" xlink:to="us-gaap_StatementTable_638157302170576155" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638157302170576155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157302170576155" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638157302170576155" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638157302170576155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638157302170576155" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638157302170576155" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638157302170586155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638157302170576155" xlink:to="us-gaap_DomesticCountryMember_638157302170586155" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638157302170586155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638157302170576155" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638157302170586155" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638157302170586155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638157302170576155" xlink:to="us-gaap_StatementLineItems_638157302170586155" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_OperatingLossCarryforwardsWithoutExpiration" xlink:label="mbio_OperatingLossCarryforwardsWithoutExpiration_638157302170586155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170586155" xlink:to="mbio_OperatingLossCarryforwardsWithoutExpiration_638157302170586155" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638157302170586155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170586155" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638157302170586155" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638157302170586155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170586155" xlink:to="us-gaap_OperatingLossCarryforwards_638157302170586155" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments_638157302170586155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170586155" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments_638157302170586155" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_638157302170586155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170586155" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate_638157302170586155" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_638157302170586155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638157302170586155" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_638157302170586155" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Income Taxes (Effective Income Tax Rate Reconciliation) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637038917271312158" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638157302170586155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637038917271312158" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638157302170586155" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638157302170586155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637038917271312158" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638157302170586155" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_638157302170596160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637038917271312158" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_638157302170596160" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638157302170596160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637038917271312158" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638157302170596160" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent" xlink:label="mbio_EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent_638157302170596160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637038917271312158" xlink:to="mbio_EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent_638157302170596160" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent" xlink:label="mbio_EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent_638157302170596160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637038917271312158" xlink:to="mbio_EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent_638157302170596160" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638157302170596160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637038917271312158" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638157302170596160" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638157302170596160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637038917271312158" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638157302170596160" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638157302170596160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637038917271312158" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638157302170596160" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637038917271342158" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_638157302170596160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637038917271342158" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_638157302170596160" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638157302170596160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638157302170596160" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638157302170596160" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_638157302170596160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638157302170596160" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_638157302170596160" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_638157302170596160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638157302170596160" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments_638157302170596160" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_638157302170606156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638157302170596160" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_638157302170606156" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DeferredTaxAssetOperatingLeaseLiabilities" xlink:label="mbio_DeferredTaxAssetOperatingLeaseLiabilities_638157302170606156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638157302170596160" xlink:to="mbio_DeferredTaxAssetOperatingLeaseLiabilities_638157302170606156" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_638157302170606156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638157302170596160" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_638157302170606156" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DeferredTaxAssetsStartUpCosts" xlink:label="mbio_DeferredTaxAssetsStartUpCosts_638157302170606156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638157302170596160" xlink:to="mbio_DeferredTaxAssetsStartUpCosts_638157302170606156" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638157302170606156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638157302170596160" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638157302170606156" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20221231.xsd#mbio_DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses" xlink:label="mbio_DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses_638157302170606156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638157302170596160" xlink:to="mbio_DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses_638157302170606156" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638157302170606156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638157302170596160" xlink:to="us-gaap_DeferredTaxAssetsGross_638157302170606156" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638157302170606156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638157302170596160" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638157302170606156" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638157302170606156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638157302170596160" xlink:to="us-gaap_DeferredTaxAssetsNet_638157302170606156" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_638157302170606156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637038917271342158" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_638157302170606156" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638157302170606156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638157302170606156" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638157302170606156" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638157302170606156" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638157302170606156" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638157302170606156" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154998975952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 27, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MUSTANG BIO,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3828760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">377 Plantation Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Worcester<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">01605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">652-4500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBIO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001680048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">New York, NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mbio_CommonUnspecifiedClassMember', window );">Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,398,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mbio_CommonUnspecifiedClassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mbio_CommonUnspecifiedClassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155001956656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 75,656<span></span>
</td>
<td class="nump">$ 109,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables - related party</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,160<span></span>
</td>
<td class="nump">2,038<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">78,852<span></span>
</td>
<td class="nump">111,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction', window );">Property, plant and equipment, net</a></td>
<td class="nump">8,440<span></span>
</td>
<td class="nump">9,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ConstructionInProcessNet', window );">Fixed assets - construction in process</a></td>
<td class="nump">951<span></span>
</td>
<td class="nump">2,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset, net</a></td>
<td class="nump">2,918<span></span>
</td>
<td class="nump">1,050<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">92,422<span></span>
</td>
<td class="nump">125,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">13,731<span></span>
</td>
<td class="nump">9,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Payables and accrued expenses - related party</a></td>
<td class="nump">766<span></span>
</td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - short-term</a></td>
<td class="nump">612<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">15,109<span></span>
</td>
<td class="nump">10,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeNoncurrent', window );">Deferred income</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable, long-term, net</a></td>
<td class="nump">27,436<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="nump">3,334<span></span>
</td>
<td class="nump">1,685<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">46,149<span></span>
</td>
<td class="nump">12,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock ($0.0001 par value), 2,000,000 shares authorized, 250,000 shares of Class A preferred stock issued and outstanding as of December 31, 2022 and 2021, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Common stock issuable, 2,807,008 and 2,536,607 shares as of December 31, 2022 and 2021, respectively</a></td>
<td class="nump">1,109<span></span>
</td>
<td class="nump">4,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">374,522<span></span>
</td>
<td class="nump">359,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(329,369)<span></span>
</td>
<td class="num">(251,844)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">46,273<span></span>
</td>
<td class="nump">112,400<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">92,422<span></span>
</td>
<td class="nump">125,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock ($0.0001 par value), 200,000,000 and 150,000,000 shares authorized as of December 31, 2022 and 2021, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mbio_CommonUnspecifiedClassMember', window );">Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock ($0.0001 par value), 200,000,000 and 150,000,000 shares authorized as of December 31, 2022 and 2021, respectively</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ConstructionInProcessNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of assets under construction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ConstructionInProcessNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale but excluding construction in process assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mbio_CommonUnspecifiedClassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mbio_CommonUnspecifiedClassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154998282224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common stock, shares issuable</a></td>
<td class="nump">2,807,008<span></span>
</td>
<td class="nump">2,536,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">845,385<span></span>
</td>
<td class="nump">845,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">845,385<span></span>
</td>
<td class="nump">845,385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mbio_CommonUnspecifiedClassMember', window );">Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">106,501,663<span></span>
</td>
<td class="nump">93,582,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">106,501,663<span></span>
</td>
<td class="nump">93,582,991<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mbio_CommonUnspecifiedClassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mbio_CommonUnspecifiedClassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155084006336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 62,475<span></span>
</td>
<td class="nump">$ 49,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development - licenses acquired</a></td>
<td class="nump">1,474<span></span>
</td>
<td class="nump">5,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,210<span></span>
</td>
<td class="nump">11,017<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">76,159<span></span>
</td>
<td class="nump">66,723<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(76,159)<span></span>
</td>
<td class="num">(66,723)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_GrantIncome', window );">Grant income</a></td>
<td class="nump">1,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">689<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="num">(3,359)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(1,366)<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (77,525)<span></span>
</td>
<td class="num">$ (66,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share outstanding, basic</a></td>
<td class="num">$ (0.75)<span></span>
</td>
<td class="num">$ (0.76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share outstanding, diluted</a></td>
<td class="num">$ (0.75)<span></span>
</td>
<td class="num">$ (0.76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding, basic</a></td>
<td class="nump">103,432,603<span></span>
</td>
<td class="nump">87,885,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding, diluted</a></td>
<td class="nump">103,432,603<span></span>
</td>
<td class="nump">87,885,235<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of grant income, such as from governmental agencies in reimbursement of covered expenses, recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155001570928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Preferred Class A [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Class A Common Shares [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Common Shares [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th"><div>Common Stock Issuable [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 7,939<span></span>
</td>
<td class="nump">$ 275,963<span></span>
</td>
<td class="num">$ (185,474)<span></span>
</td>
<td class="nump">$ 98,435<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2020</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">845,385<span></span>
</td>
<td class="nump">70,920,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_StockIssuanceCommonStockIssuableDuringPeriod', window );">Common stock issuable - Founders Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement', window );">Issuance of common shares - Founders Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,577)<span></span>
</td>
<td class="nump">7,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common shares - Founders Agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,001,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_StockIssuedDuringPeriodValueAtMarketingOffering', window );">Issuance of common shares, net of offering costs - At-the-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_StockIssuedDuringPeriodSharesAtMarketOffering', window );">Issuance of common shares, net of offering costs - At-the-Market Offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,419,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering', window );">Issuance of common shares - Equity fee on At-the-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(245)<span></span>
</td>
<td class="nump">2,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering', window );">Issuance of common shares - Equity fee on At-the-Market Offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common shares under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common shares under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_CorrectionToPreviouslyIssuedShares', window );">Correction to previously issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,370)<span></span>
</td>
<td class="num">(66,370)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">4,329<span></span>
</td>
<td class="nump">359,906<span></span>
</td>
<td class="num">(251,844)<span></span>
</td>
<td class="nump">112,400<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2021</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">845,385<span></span>
</td>
<td class="nump">93,582,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_StockIssuanceCommonStockIssuableDuringPeriod', window );">Common stock issuable - Founders Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement', window );">Issuance of common shares - Founders Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,212)<span></span>
</td>
<td class="nump">4,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common shares - Founders Agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,536,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_StockIssuedDuringPeriodValueAtMarketingOffering', window );">Issuance of common shares, net of offering costs - At-the-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_StockIssuedDuringPeriodSharesAtMarketOffering', window );">Issuance of common shares, net of offering costs - At-the-Market Offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,878,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering', window );">Issuance of common shares - Equity fee on At-the-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117)<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering', window );">Issuance of common shares - Equity fee on At-the-Market Offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common shares under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common shares under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">969,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AdditionsToApicEquityFeesOnRwgDebt', window );">Issuance of common shares - Equity fee on RWG Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AdditionsToApicEquityFeesOnRwgDebtShares', window );">Issuance of common shares - Equity fee on RWG Debt (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">954,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AdditionsToApicFromIssuanceOfRwgDebtWarrants', window );">Issuance of warrants for RWG Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,525)<span></span>
</td>
<td class="num">(77,525)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 1,109<span></span>
</td>
<td class="nump">$ 374,522<span></span>
</td>
<td class="num">$ (329,369)<span></span>
</td>
<td class="nump">$ 46,273<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2022</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">845,385<span></span>
</td>
<td class="nump">106,501,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_AdditionsToApicEquityFeesOnRwgDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents additions to APIC attributable to equity fees on RWG debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_AdditionsToApicEquityFeesOnRwgDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_AdditionsToApicEquityFeesOnRwgDebtShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued related to RWG debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_AdditionsToApicEquityFeesOnRwgDebtShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_AdditionsToApicFromIssuanceOfRwgDebtWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions to APIC from the issuance of warrants related to RWG debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_AdditionsToApicFromIssuanceOfRwgDebtWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_CorrectionToPreviouslyIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Correction to previously issued shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_CorrectionToPreviouslyIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued on exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_StockIssuanceCommonStockIssuableDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new common stock issuable during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_StockIssuanceCommonStockIssuableDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_StockIssuedDuringPeriodSharesAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued at the market offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_StockIssuedDuringPeriodSharesAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Shares issued equity fee on the market offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_StockIssuedDuringPeriodValueAtMarketingOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued at the market offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_StockIssuedDuringPeriodValueAtMarketingOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of number of shares issued at equity market offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154996475360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (77,525)<span></span>
</td>
<td class="num">$ (66,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_IssuanceOfCommonSharesEquityFeeOnAtMarketOffering', window );">Issuance of common shares - Equity fee on at-the-market offering to Fortress Biotech</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">1,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance', window );">Common shares issuable for Founders Agreement</a></td>
<td class="nump">1,109<span></span>
</td>
<td class="nump">4,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense', window );">Research and development - licenses acquired</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">1,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_CommonShareIssuanceFeesRelatedPartyDebt', window );">Issuance of common shares - Equity fee to Fortress Biotech on note payable</a></td>
<td class="nump">750<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expenses</a></td>
<td class="nump">2,283<span></span>
</td>
<td class="nump">3,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">2,723<span></span>
</td>
<td class="nump">2,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">470<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">255<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(1,021)<span></span>
</td>
<td class="num">(401)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables - related party</a></td>
<td class="nump">14<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">5,257<span></span>
</td>
<td class="num">(408)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Payable and accrued expenses - related party</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(263)<span></span>
</td>
<td class="num">(296)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(65,066)<span></span>
</td>
<td class="num">(53,667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of research and development licenses</a></td>
<td class="num">(365)<span></span>
</td>
<td class="num">(1,380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of fixed assets</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(2,714)<span></span>
</td>
<td class="num">(3,986)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,952)<span></span>
</td>
<td class="num">(5,366)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ProceedsFromIssuanceOfCommonSharesAtMarketOffering', window );">Proceeds from issuance of common shares - at-the-market offering</a></td>
<td class="nump">6,623<span></span>
</td>
<td class="nump">71,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_OfferingCostsForIssuanceOfCommonSharesAtMarketOffering', window );">Offering costs for the issuance of common shares - at-the-market offering</a></td>
<td class="num">(123)<span></span>
</td>
<td class="num">(1,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt issuance</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Fees paid on the issuance of debt</a></td>
<td class="num">(2,650)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common shares under ESPP</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">34,056<span></span>
</td>
<td class="nump">70,847<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(33,962)<span></span>
</td>
<td class="nump">11,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of the period</a></td>
<td class="nump">110,618<span></span>
</td>
<td class="nump">98,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of the period</a></td>
<td class="nump">76,656<span></span>
</td>
<td class="nump">110,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">2,710<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Fixed assets (acquired but not paid)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common shares - Founders Agreement</a></td>
<td class="nump">4,212<span></span>
</td>
<td class="nump">7,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid', window );">Research and development licenses included in accounts payable and accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Note payable final payment fee (incurred but not paid)</a></td>
<td class="nump">1,050<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Issuance of warrants - note payable</a></td>
<td class="nump">384<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_LeaseLiabilitiesArisingFromObtainingRightOfUseAssets', window );">Lease liabilities arising from obtaining right-of-use assets</a></td>
<td class="nump">$ 2,176<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to net income (loss) for research and development expense attributable to licenses acquired via issuance of stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_CommonShareIssuanceFeesRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the non-cash fees related to issuance of common shares on note payable to Fortress Biotech.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_CommonShareIssuanceFeesRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid excluding those attributable to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Increase Decrease In Lease Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_IssuanceOfCommonSharesEquityFeeOnAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It Represents issuance of common stock for equity fee at market offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_IssuanceOfCommonSharesEquityFeeOnAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_LeaseLiabilitiesArisingFromObtainingRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease liabilities arising from obtaining right-of-use assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_LeaseLiabilitiesArisingFromObtainingRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_OfferingCostsForIssuanceOfCommonSharesAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering costs for the issuance of common shares - At-the-Market Offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_OfferingCostsForIssuanceOfCommonSharesAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ProceedsFromIssuanceOfCommonSharesAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common shares - At-the-Market Offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ProceedsFromIssuanceOfCommonSharesAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>R&amp;D include in Accounts payable and accrued expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for research and development licenses expenditures that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155003416704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Description of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;1&#160;- Organization and Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Mustang Bio,&#160;Inc. (the &#8220;Company&#8221; or &#8220;Mustang&#8221;) was incorporated in Delaware on March&#160;13, 2015. Mustang is as a clinical-stage biopharmaceutical company focused on translating today&#8217;s medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. The Company may acquire rights to these technologies by licensing the rights or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company is a majority-controlled subsidiary of Fortress Biotech,&#160;Inc. (&#8220;Fortress&#8221; or &#8220;Parent&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has incurred substantial operating losses and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of December 31, 2022, the Company had an accumulated deficit of $329.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has funded its operations to date primarily through the sale of equity and via debt raises, including its loan and financing agreement with Runaway Growth Finance Corporation (the "Lender"), herein referred to as the "Term Loan." The Company expects to continue to use the proceeds from previous financing transactions primarily for general corporate purposes, including financing the Company&#8217;s growth, developing new or existing product candidates, and funding capital expenditures, acquisitions and investments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company will be required to expend significant funds in order to advance the development of its product candidates. The Company will require additional financings through equity and debt offerings, collaborations and licensing arrangements or other sources to fully develop, prepare regulatory filings, obtain regulatory approvals and commercialize its existing and any new product candidates. The continuation of our business as a going concern is dependent upon raising additional capital and eventually attaining and maintaining profitable operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205-40, Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. In performing its evaluation, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40, the future receipt of potential funding from future equity or debt issuances, and the potential sale of priority review vouchers cannot be considered probable at this time because these plans are not entirely within the Company&#8217;s control nor have been approved by the Board of Directors as of the date of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company's expectation to generate operating losses and negative operating cash flows in the future, as well as projections of future inability to meet certain financial debt covenants, and the need for additional funding to support its planned operations raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern for a period of one year after the date that these consolidated financial statements are issued. The Company continues to monitor its spending by reducing 2023 expenses, which may include projected savings through delaying the development timelines of certain programs, or termination of such programs and the pursuit of additional cash resources through public or private equity or debt financings. The Company has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that may be necessary if the Company is unable to continue as a going concern. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:2pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155000592992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;2&#160;- Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The Company has no subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">All inter-company transactions between Fortress and Mustang are classified as due from or due to related party in the financial statements. The Company believes that the assumptions underlying the financial statements are reasonable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Segments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating and <span style="-sec-ix-hidden:Hidden_1DzwVi4TWE68-iARaVzCtQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting</span></span> segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company considers highly liquid investments with a maturity of three&#160;months or less when purchased to be cash equivalents. Cash and cash equivalents at December&#160;31,&#160;2022 and 2021, consisted of cash and certificates of deposit in institutions in the United States. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are currently adequately protected against credit risk.&#160;At times, portions of the Company&#8217;s cash and cash equivalents may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation (FDIC) limits, though the Company customarily invests a significant portion of its cash in CDARS accounts to maximize FDIC insurance coverage across its holdings.&#160;As of December 31, 2022, the Company had not experienced losses on these accounts, and management believes the Company is not exposed to significant risk on such accounts.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Receivables &#8211; Related Party</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Other receivables include amounts due to the Company from Fortress and Journey Medical Corporation, both related parties, and is recorded at the invoiced amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company records cash held in an escrow account as a security deposit for the manufacturing facility in Worcester, Massachusetts, as restricted cash. The Company had $1.0 million in restricted cash as of December&#160;31,&#160;2022 and 2021, respectively. The Facility initiated cell processing operations for personalized CAR T and gene therapies in 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Property, plant and equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Property and equipment, net, which consists mainly of laboratory equipment, are carried at cost less accumulated depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally five years, using the straight-line method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Property and equipment&#160;- Construction in Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In connection with the Company&#8217;s cell processing facility, the Company incurred costs for the design and construction of the facility and the purchase of equipment; $1.0 million and $2.0 million are recorded in fixed assets - construction in process on the balance sheet at December&#160;31,&#160;2022 and 2021, respectively. Upon completion of the facility&#8217;s construction, all costs associated with the buildout will be recorded as leasehold improvements and amortized over the shorter of the estimated useful lives or the term of the respective leases, upon the improvement being placed in service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company&#8217;s behalf will be expensed as services are rendered or when the milestone is achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, costs associated with regulatory filings, laboratory costs and other supplies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 730-10-25-1, <i style="font-style:italic;">Research and Development, </i>costs incurred in obtaining technology licenses are charged to research and development expense if the technology licensed has not reached commercial feasibility and has no alternative future use. The licenses purchased by the Company require substantial completion of research and development, regulatory and marketing approval efforts to reach commercial feasibility and has no alternative future use. Accordingly, the total purchase price for the licenses acquired is reflected as research and development&#160;- licenses acquired in the Company&#8217;s Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Annual Stock Dividend</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In July&#160;2016, in connection with the Amended and Restated Articles of Incorporation, the Company issued 250,000 Class&#160;A preferred shares to Fortress. The Class&#160;A preferred shares entitle the holder to a stock dividend equal to 2.5% of the fully diluted outstanding equity of the Company (the &#8220;Annual Stock Dividend&#8221;). The Annual Stock Dividend was part of the consideration payable for formation of the Company and the identification of certain assets, including the license contributed to Mustang by Fortress (see Note&#160;4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In June&#160;2018, in connection with the Amended and Restated Articles of Incorporation, the Company amended the Annual Stock Dividend &#160;due date from March&#160;13th to January&#160;1st.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Pursuant to the Amended and Restated Articles of Incorporation, the Company issued 2,807,008 shares of common stock to Fortress for the Annual Stock Dividend, representing 2.5% of the fully-diluted outstanding equity of Mustang on January 1, 2023. This was shown in the Statement of Stockholders&#8217; Equity at December 31, 2022, as Common stock issuable &#8211; Founders Agreement. The Company recorded an expense of approximately $1.1 million in research and development - licenses acquired related to these issuable shares during the year ended December&#160;31,&#160;2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the Amended and Restated Articles of Incorporation, the Company issued 2,536,607 shares of common stock to Fortress for the Annual Stock Dividend, representing 2.5% of the fully-diluted outstanding equity of Mustang on January 1, 2022. This was shown in the Statement of Stockholders&#8217; Equity at December&#160;31,&#160;2021, as Common stock issuable &#8211; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Founders Agreement. The Company recorded an expense of approximately $4.2 million in research and development - licenses acquired related to these issuable shares during the year ended December 31, 2021.<span style="color:#201f1e;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Fair Value Measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 0pt;">Level 1:&#160;&#160;&#160;&#160;Quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 10pt 0pt;">Level 2:&#160;&#160;&#160;&#160;Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;">Level 3:&#160;&#160;&#160;&#160;Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the balance sheet as both a right of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company's incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred. In calculating the right of use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model or 409a valuations, as applicable. The assumptions used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if management believes it is more likely than not that the deferred tax assets </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period less unvested restricted stock. Since dividends are declared, paid and set aside among the holders of shares of common stock and Class&#160;A common shares pro-rata on an as-if-converted basis, the two-class method of computing net loss per share is not required. Diluted net loss per share does not reflect the effect of shares of common stock to be issued upon the exercise of warrants or outstanding Class&#160;A preferred shares, as their inclusion would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,052,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,308,654</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,141,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,141,675</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Class&#160;A Preferred Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 510,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 280,983</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,488,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,335,557</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,443,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,316,869</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has no components of other comprehensive loss, and therefore, comprehensive loss equals net loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In August 2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2020-06,&#160;<i style="font-style:italic;">&#8220;Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity,&#8221;</i>&#160;which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption will be permitted. The Company is currently evaluating the impact of this standard on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">In June 2016, FASB issued ASU 2016-13,&#160;</span><i style="font-style:italic;background:#ffffff;">&#8220;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;</i><span style="background:#ffffff;">. ASU 2016-13 requires that expected credit losses relating to financial assets are measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. Recently, the FASB issued the final ASU to delay adoption for smaller reporting companies to calendar year 2023. The Company is currently assessing the impact of the adoption of this ASU on its financial statements</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155003516768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Clinical Trial and Sponsored Research Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License, Clinical Trial and Sponsored Research Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;3&#160;- License, Clinical Trial and Sponsored Research Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Research and Development Expenses&#160;&#8211; All Licenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the&#160;years ended December 31, 2022 and 2021, the Company recorded the following expense in research and development for licenses acquired:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">City of Hope National Medical Center</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">CD123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">IV/ICV</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">PSCA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">HER2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">CSL Behring (Calimmune)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30</p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Leiden University  Medical Centre</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 350</p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mayo Clinic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 750</p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fortress PIK Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,212</p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,474</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,842</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">License Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">City of Hope</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">CD123 License (MB-102)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In February&#160;2017, the Company entered into an Amended and Restated Exclusive License Agreement with the City of Hope National Medical Center (&#8220;COH&#8221;) to acquire intellectual property rights pertaining to CD123 specific CAR T technology. Pursuant to this agreement, the Company and COH acknowledged that an upfront fee was previously paid. In addition, COH is eligible to receive an annual maintenance fee of $25,000 and milestone payments totaling $14.5 million upon the achievement of certain milestones. Royalty payments in the mid-single digits are due on net sales of licensed products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2021, the Company recorded a non-refundable milestone payment of $0.3 million for the 24<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> patient treated in connection with the CD123 study. <span style="background:#ffffff;">There were&#160;</span>no<span style="background:#ffffff;">&#160;such expenses for the year ended December 31, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">IV/ICV </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In February&#160;2017, the Company entered into an exclusive license agreement (the &#8220;IV/ICV License&#8221;) with COH to acquire intellectual property rights in patent applications related to the intraventricular and intracerebroventricular methods of delivering T cells that express CARs. Pursuant to the IV/ICV License, in March&#160;2017, the Company paid COH an upfront fee of $0.1 million. COH is eligible to receive a milestone payment totaling approximately $0.1 million, upon and subject to the achievement of a milestone, and an annual maintenance fee of $25,000. Royalty payments in the low single digits are due on net sales of licensed products. The Company is obligated to pay COH a&#160;percentage of certain revenues received in connection with a sublicense in the mid-thirties, but no such payments are due in connection with sublicenses that are granted in conjunction with the sublicense of other CAR T programs that are licensed from COH to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">For the year ended December 31, 2022, the Company expensed a non-refundable milestone payment of $0.1 million in connection with the first patent within the Patent Rights issued. <span style="background:#ffffff;">There were&#160;</span>no<span style="background:#ffffff;">&#160;such expenses for the year ended December 31, 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">PSCA License (MB-105)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2017, the Company entered into an exclusive license agreement with COH for the use of prostate stem cell antigen (&#8220;PSCA&#8221;) CAR T technology to be used in the treatment of prostate cancer, pancreatic cancer and other solid tumors. Pursuant to this agreement, the Company paid an upfront fee of $0.3 million and pays an annual maintenance fee of $50,000. Additional payments are due for the achievement of ten development milestones totaling $14.9 million, and royalty payments in the mid-single digits are due on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2021, the Company expensed a non-refundable milestone payment of $0.3 million for the twelfth patient treated in the Phase 1 clinical study of MB-105 at COH. <span style="background:#ffffff;">There were&#160;</span>no<span style="background:#ffffff;">&#160;such expenses for the year ended December 31, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">HER2 License (MB-103)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;margin:0pt;">On May&#160;31, 2017, the Company entered into an exclusive license agreement with the COH for the use of human epidermal growth factor receptor 2 (&#8220;HER2&#8221;) CAR T technology, which will initially be applied in the treatment of glioblastoma multiforme. Pursuant to this agreement, the Company paid an upfront fee of $0.6 million and pays an annual maintenance fee of $50,000 (which began in 2019). Additional payments are due for the achievement of ten development milestones totaling $14.9 million, and royalty payments in the mid-single digits are due on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 10pt 0pt;">For the year ended, December 31, 2022, the Company expensed a non-refundable milestone payment of $0.2&#160;million in connection with the first patent within the Patent Rights issued. There were&#160;no&#160;such expenses for the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">CSL Behring (Calimmune) License</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On August 23, 2019, the Company entered into a non-exclusive license agreement with CSL Behring (Calimmune, Inc.) (&#8220;Calimmune License&#8221;) for the rights to the Cytegrity<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> stable producer cell line for the production of viral vector for our lentiviral gene therapy program for the treatment of XSCID (MB-107 and MB-207). We previously licensed the XSCID gene therapy program from St. Jude Children&#8217;s Research Hospital, Inc. (&#8220;St. Jude&#8221;) in August 2018. Pursuant to the terms of the Calimmune License, the Company paid an upfront fee of $0.2 million. CSL Behring is eligible to receive additional payments totaling $1.2 million upon the achievement of three development and commercialization milestones. Royalty payments in the low-single digits are due on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">For the year ended December 31, 2022 and 2021, the Company expensed a non-refundable milestone payments of $40,000 and $30,000, respectively, in connection with the Calimmune license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">LUMC License (MB-110)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">On September 8, 2021, the Company entered into an exclusive, worldwide licensing agreement with LUMC for the use of a gene therapy under development for the treatment of severe immunodeficiency caused by RAG1 deficiency (the &#8220;LUMC License&#8221;). Pursuant to the LUMC License, the Company expensed an upfront fee of $0.4&#160;million. Additional payments are due for the achievement of&#160;certain&#160;development milestones totaling up to $31&#160;million and royalty payments in the low to mid-single digits as a percentage of revenue are due on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the year ended December 31, 2021, the Company expensed an upfront payment of $0.4&#160;million in connection with the LUMC License. <span style="background:#ffffff;">There were&#160;</span>no<span style="background:#ffffff;">&#160;such expenses for the year ended December 31, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Mayo Clinic - CAR T Technology License</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">On April 1, 2021, the Company entered into an exclusive license agreement with Mayo Clinic for a novel technology that may be able to transform the administration of CAR T therapies and has the potential to be used as an off-the shelf therapy. Pursuant to this agreement, the Company paid an upfront fee of $0.8&#160;million and will pay an annual maintenance fee of $25,000. Additional payments are due for each of two licensed products for the achievement of&#160;eleven&#160;development and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">commercial milestones totaling up to $92.6&#160;million per product, and royalty payments in the mid-single digits as a percentage of revenue are due on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">For the&#160;year ended December 31, 2021, the Company expensed an upfront payment of $0.8&#160;million pursuant to the terms of the license agreement. There were&#160;no&#160;such expenses for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">Research and Development Expenses&#160;- Sponsored Research and Clinical Trial Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the&#160;year ended December 31, 2022 and 2021, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">City of Hope National Medical Center</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">CD123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 301</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">IL13R&#945;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,486</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,169</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">CS1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 608</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">HER2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 697</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">PSCA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 107</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fred Hutchinson Cancer Center - CD20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,979</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">St. Jude Children's Research Hospital&#160;- XSCID</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 865</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LUMC - RAG1 SCID</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 505</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 170</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mayo Clinic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 695</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,591</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">City of Hope</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">CD123 (MB-102) Clinical Research Support Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In February&#160;2017, the Company entered into a Clinical Research Support Agreement for CD123 (the &#8220;CD123 CRA&#8221;). Pursuant to the terms of the CD123 CRA the Company made an upfront payment of $19,450 and will contribute an additional $0.1 million per patient in connection with the on-going investigator-initiated study. Further, the Company agreed to fund approximately $0.2 million over three years pertaining to the clinical development of CD123. For the&#160;years ended December 31, 2022 and 2021, the Company recorded $0.2 million and $0.3 million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">IL13R&#945;2 (MB-101) Clinical Research Support Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In February&#160;2017, the Company entered into a Clinical Research Support Agreement for IL13R&#945;2 (the &#8220;IL13R&#945;2 CRA&#8221;). Pursuant to the terms of the IL13R&#945;2 CRA the Company made an upfront payment of approximately $9,300 and will contribute an additional $0.1 million related to patient costs in connection with the on-going investigator-initiated study. Further, the Company agreed to fund approximately $0.2 million over three years pertaining to the clinical development of IL13R&#945;2. For the&#160;years ended December 31, 2022 and 2021, the Company recorded $1.5 million and $1.2 million, respectively, in research and development expenses under the IL13R&#945;2 CRA in the Statements of Operations pursuant to the terms of this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2020, the Company entered into a Clinical Research Support Agreement for the IL13R&#945;2-directed CAR T program for adult patients with leptomeningeal glioblastoma, ependymoma or medulloblastoma (the &#8220;IL13R&#945;2 Leptomeningeal CRA&#8221;). Pursuant to the terms of the IL13R&#945;2 Leptomeningeal CRA, the Company made an upfront payment of approximately $29,000 and will contribute an additional $0.1 million per patient in connection with the on-going investigator-initiated study. Further, the Company agreed to fund approximately $0.2 million annually pertaining to the clinical development of the IL13R&#945;2-directed CAR T therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2020, the Company entered into a Sponsored Research Agreement (&#8220;SRA&#8221;) with COH to conduct combination studies of a potential IL13R&#945;2<i style="font-style:italic;"> </i>CAR and C134 oncolytic virus therapy. Pursuant to the SRA, the Company funded research in the amount of $0.3 million for the program. In November 2022, the SRA was amended to include additional funding of $0.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In March 2021, the Company entered into a clinical research support agreement for an Institutional Review Board-approved, investigator-initiated protocol entitled: &#8220;Single Patient Treatment with Intraventricular Infusions of IL13R&#945;2-targeting and HER2-targeting CAR T cells for a Single Patient (UPN 181) with Recurrent Multifocal Malignant Glioma.&#8221; Pursuant to the terms of this agreement, the Company will contribute up to $0.2&#160;million in connection with the ongoing investigator-initiated study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">CS1 (MB-104) Clinical Research Support Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In June 2020, the Company entered into a clinical research support agreement with COH in connection with an Investigator-sponsored study conducted under an Institutional Review Board-approved, investigator-initiated protocol entitled: &#8220;Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CS1-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients with CS1+ Multiple Myeloma.&#8221; The CAR T being studied under this protocol has been designated as MB-104. Under the terms of the agreement the Company will reimburse COH for costs associated with this trial not to exceed $2.4&#160;million. The agreement will expire upon the delivery of a final study report or earlier. For the&#160;years ended December 31, 2022 and 2021, the Company recorded $0.5 million and $0.6 million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. Since inception, the Company has reimbursed COH $1.8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">HER2 (MB-103) Clinical Research Support Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In September 2020, the Company entered into a clinical research support agreement with COH in connection with an Investigator-sponsored study conducted under an Institutional Review Board-approved, investigator-initiated protocol entitled: &#8220;Phase I Study of Cellular Immunotherapy using Memory-Enriched T Cells Lentivirally Transduced to Express a HER2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients with Recurrent/Refractory Malignant Glioma.&#8221; The CAR T being studied under this protocol has been designated as MB-103. Under the terms of the agreement the Company will pay COH $29,375 upon execution and will reimburse COH for costs associated with this trial not to exceed $3.0&#160;million. The agreement will expire upon the delivery of a final study report or earlier. For the&#160;year ended December 31, 2022 and 2021, the Company recorded $0.8 million and $0.7 million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. Since inception, the Company has reimbursed $3.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">PSCA (MB-105)</i><i style="font-style:italic;"> Clinical Research Support Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In October 2020, the Company entered into a clinical research support agreement with COH in connection with an Investigator-sponsored study conducted under an Institutional Review Board-approved, investigator-initiated protocol entitled: &#8220;A Phase 1b study to evaluate PSCA-specific chimeric antigen receptor (CAR)-T cells for patients with metastatic castration resistant prostate cancer.&#8221; The CAR T being studied under this protocol has been designated as MB-105. Under the terms of the agreement the Company will pay COH $33,000 upon execution and will reimburse COH for costs associated with this trial not to exceed $2.3&#160;million. &#160;The agreement will expire upon the delivery of a final study report or earlier. For the&#160;years ended December 31, 2022 and 2021, the Company recorded $0.1 million and $0.1 million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. Since inception, the Company has reimbursed $0.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fred Hutch</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-weight:normal;">CD20 Clinical Trial Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On July&#160;3, 2017, in conjunction with the CD20 Technology License from Fred Hutch, we entered into an investigator-initiated clinical trial agreement (&#8220;CD20 CTA&#8221;) to provide partial funding for a Phase 1/2 clinical trial at Fred Hutch </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">evaluating the safety and efficacy of the CD20 Technology in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. In connection with the CD20 CTA, the Company agreed to fund up to $5.3 million of costs associated with the clinical trial, which commenced during the fourth quarter of 2017. In November 2020, the CD20 CTA was amended to include additional funding of approximately $1.8 million for the treatment of five patients with chronic lymphocytic leukemia and other research costs. In January 2022, the CD20 CTA was amended to include additional funding of $2.2 million increasing the total payment obligation of the Company in connection with the CD20 CTA not to exceed $9.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">For the&#160;years ended December 31, 2022 and 2021, the Company recorded $2.0 million and $2.0 million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. Since inception, the Company has reimbursed Fred Hutch $7.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">XSCID (MB-107) Data Transfer Agreement with St. Jude </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In June 2020, the Company entered into a Data Transfer Agreement with St. Jude under which we will reimburse St. Jude for costs associated with St. Jude&#8217;s clinical trial for the treatment of infants with XSCID. &#160;Pursuant to the terms of this agreement the Company paid an upfront fee of $1.1&#160;million in July 2020, and will continue to reimburse St. Jude for costs incurred in connection with this clinical trial. For the&#160;years ended December 31, 2022 and 2021, the Company recorded $0.5 million and $0.9 million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. Since inception, the Company has reimbursed St. Jude $3.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">RAG1-SCID (MB-110) Sponsored Research Support Agreement with LUMC</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;margin:0pt;">On September 8, 2021, in connection with the LUMC License, the Company entered into an SRA with LUMC under which the Company will fund research in the amount of approximately $0.5&#160;million annually over a period of&#160;5 years. The research performed pursuant to this agreement will support technology the Company has licensed from LUMC for the use of a gene therapy under development for the treatment of severe immunodeficiency caused by RAG1. For the&#160;year ended December 31, 2022 and 2021, the Company recorded $0.5 million and $0.2 million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sponsored Research Support Agreement&#160;with Mayo Clinic&#160;&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In June 2021, the Company entered into an SRA with Mayo Clinic under which the Company will fund research in the amount of $2.1&#160;million over a period of&#160;two years. The research performed pursuant to this agreement will support technology the Company has licensed from Mayo Clinic for a novel technology that may be able to transform the administration of CAR T therapies and has the potential to be used as an off-the-shelf therapy. In October 2022, the SRA was amended to include additional funding of approximately $0.1 million. For the&#160;year ended December 31, 2022 and 2021, the Company recorded $1.0 million and $0.7 million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155003484368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;4&#160;- Related Party Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Founders Agreement and Management Services Agreement with Fortress</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Effective March&#160;13, 2015, the Company entered a Founders Agreement with Fortress, which was amended and restated on May&#160;17, 2016, and again on July&#160;26, 2016 (the &#8220;Mustang Founders Agreement&#8221;). The Mustang Founders Agreement provides that, in exchange for the time and capital expended in the formation of Mustang and the identification of specific assets the acquisition of which result in the formation of a viable emerging growth life science company, Fortress loaned $2.0 million, representing the up-front fee required to acquire the Company&#8217;s license agreement with COH. The Mustang Founders Agreement has a term of 15 years, which upon expiration automatically renews for successive one-year periods unless terminated by Fortress and the Company or a Change in Control (as defined in the Mustang Founders Agreement) occurs. Concurrently with the second amendment on July&#160;26, 2016, to the Mustang Founders Agreement, Fortress entered into an Exchange Agreement whereby Fortress exchanged its 7.25 million Class&#160;B Common shares for 7.0 million common shares and 250,000 Class&#160;A Preferred shares. Class&#160;A Preferred Stock is identical to common stock other than as to voting </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">rights, conversion rights and the PIK Dividend right (as described below). Each share of Class&#160;A Preferred Stock is entitled to vote the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A)&#160;the shares of outstanding Mustang common stock and (B)&#160;the whole shares of Mustang common stock into which the shares of outstanding Class&#160;A Common Stock and Class&#160;A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class&#160;A Preferred Stock. Thus, the Class&#160;A Preferred Stock will at all times constitute a voting majority. Each share of Class&#160;A Preferred Stock is convertible, at Fortress&#8217; option, into one fully paid and nonassessable share of Mustang common stock, subject to certain adjustments. As holders of Class&#160;A Preferred Stock, Fortress will receive on each January&#160;1 (each a &#8220;PIK Dividend Payment Date&#8221;) until the date all outstanding Class&#160;A Preferred Stock is converted into common stock, pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (&#8220;PIK Dividends&#8221;) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half&#160;percent (2.5%) of Mustang&#8217;s fully-diluted outstanding capitalization on the date that is <span style="-sec-ix-hidden:Hidden_t6gbwtw4fkmKVT_BgWRqSA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> (1)&#160;business day prior to any PIK Dividend Payment Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As additional consideration under the Mustang Founders Agreement, Mustang will also: (i)&#160;pay an equity fee in shares of common stock, payable within <span style="-sec-ix-hidden:Hidden_IKJI1MNkyk-jVARLuqEz6w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> (5)&#160;business&#160;days of the closing of any equity or debt financing for Mustang that occurs after the effective date of the Mustang Founders Agreement and ending on the date when Fortress no longer has majority voting control in the Company&#8217;s voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii)&#160;pay a cash fee equal to four and one-half&#160;percent (4.5%) of the Company&#8217;s annual net sales, payable on an annual basis, within <span style="-sec-ix-hidden:Hidden_ZlvSq5CKKECYsdUUYJlnYw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ninety</span></span> (90)&#160;days of the end of each calendar&#160;year. In the event of a Change in Control, the Company will pay a one-time change in control fee equal to five (5x) times the product of (A)&#160;net sales for the <span style="-sec-ix-hidden:Hidden_oihncYEzmEirIm889SKJsg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twelve</span></span> (12)&#160;months immediately preceding the change in control and (B)&#160;four and one-half&#160;percent (4.5%) (see Note&#160;9).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Effective as of March&#160;13, 2015, the Company entered into a Management Services Agreement (the &#8220;MSA&#8221;) with Fortress, pursuant to which Fortress renders advisory and consulting services to the Company. The MSA has an initial term of five years and is automatically renewed for successive five-year terms unless terminated in accordance with its provisions. Services provided under the MSA may include, without limitation, (i)&#160;advice and assistance concerning any and all aspects of the Company&#8217;s operations, clinical trials, financial planning and strategic transactions and financings and (ii)&#160;conducting relations on behalf of the Company with accountants, attorneys, financial advisors and other professionals (collectively, the &#8220;Services&#8221;). The Company is obligated to utilize clinical research services, medical education, communication and marketing services and investor relations/public relation services of companies or individuals designated by Fortress, provided those services are offered at market prices. However, the Company is not obligated to take or act upon any advice rendered from Fortress and Fortress shall not be liable for any of its actions or inactions based upon their advice. Pursuant to the MSA and the Company&#8217;s Certificate of Incorporation, Fortress and its affiliates, including all members of the Company&#8217;s Board of Directors, will have no fiduciary or other duty to communicate or present any corporate opportunities to the Company or to refrain from engaging in business that is similar to that of the Company. In consideration for the Services, the Company will pay Fortress an annual consulting fee of $0.5 million (the &#8220;Annual Consulting Fee&#8221;), payable in advance in equal quarterly installments on the first business day of each calendar quarter in each&#160;year, provided, however, that such Annual Consulting Fee shall be increased to $1.0 million for each calendar&#160;year in which the Company has net assets in excess of $100 million at the beginning of the calendar&#160;year. The Company records fifty percent of the Annual Consulting Fee in research and development expense and fifty percent in general and administrative expense in the Statement of Operations. For the&#160;years ended December 31, 2022 and 2021, the Company recorded expense of $1.0 million and $0.5 million, respectively, related to this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the year ended December 31, 2022, the Company issued&#160;196,952&#160;shares of common stock and recorded zero shares issuable to Fortress, which equaled&#160;2.5% of the gross proceeds of $6.6&#160;million from the sale of shares of common stock under Mustang&#8217;s At-the-Market Offering. The Company recorded an expense of approximately $0.2&#160;million in general and administrative expenses related to these shares for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the year ended December 31, 2021, the Company issued&#160;576,157&#160;shares of common stock and recorded&#160;51,295&#160;shares issuable to Fortress, which equaled&#160;2.5% of the gross proceeds of $71.9&#160;million from the sale of shares of common stock under Mustang&#8217;s At-the-Market Offering. The Company recorded an expense of approximately $1.9&#160;million in general and administrative expenses related to these shares for the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Payables and Accrued Expenses Related Party</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In the normal course of business Fortress pays for certain expenses on behalf of the Company. Such expenses are recorded as Payables and accrued expenses&#160;- related party and are reimbursed to Fortress in the normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Director Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Dr.&#160;Rosenwald</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Pursuant to the terms of the Director Compensation Plan, Dr.&#160;Rosenwald will receive a cash fee of $50,000 per&#160;year paid quarterly and an annual stock award of the greater of (i)&#160;a number of shares of common stock having a fair market value on the grant date of $50,000 or (ii)&#160;10,000 shares of common stock, which shares shall vest and become non-forfeitable on the third anniversary of the grant date, subject to continued service on the Board on such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">For the&#160;year ended December 31, 2022, the Company recognized $100,000 in expense in its Statements of Operations related to the director compensation, including approximately $50,000 in expense related to equity incentive grants. For the&#160;year ended December 31, 2021, the Company recognized $106,000 in expense in its Statements of Operations related to the director compensation, including approximately $56,000 in expense related to equity incentive grants. The Company issued Dr. Rosenwald 71,664 and 13,774 restricted stock awards for the&#160;years ended December 31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Mr.&#160;Weiss&#160;- Advisory Agreement with Caribe BioAdvisors, LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Board of the Company by unanimous written consent approved and authorized the execution of an advisory agreement dated January&#160;1, 2017 (the &#8220;Advisory Agreement&#8221;), with Caribe BioAdvisors, LLC (the &#8220;Advisor&#8221;), owned by Michael S. Weiss, the Chairman of the Board, to provide the board advisory services of Mr.&#160;Weiss as Chairman of the Board. Pursuant to the Advisory Agreement, the Advisor will be paid an annual cash fee of $60,000, paid quarterly and an annual stock award of the greater of (i)&#160;a number of shares of common stock having a fair market value on the grant date of $50,000 or (ii)&#160;10,000 shares of common stock, which shares shall vest and become non-forfeitable on the third anniversary of the grant date, subject to continued service on the Board on such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">For&#160;the year ended December 31, 2022, the Company recognized $110,000 in expense in its Statements of Operations related to the advisory agreement, including approximately $50,000 in expense related to equity incentive grants. For&#160;the year ended December 31, 2021, the Company recognized $116,000 in expense in its Statements of Operations related to the advisory agreement, including approximately $56,000 in expense related to equity incentive grants. The Company issued Mr. Weiss 71,664 and 13,774 restricted stock awards for the&#160;years ended December 31, 2022 and 2021, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155003664720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;5&#160;- Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Mustang&#8217;s property and equipment consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated Useful</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145</p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 370</p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Machinery&#160;and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,550</p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,694</p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 951</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,027</p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,786</p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,401)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,734)</p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,052</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Mustang&#8217;s depreciation expense for the&#160;years ended December&#160;2022 and 2021 was approximately $2.7 million and $2.2 million, respectively, and was recorded in research and development expense in the Statements of Operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155003630624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;6&#160;- Accounts Payable and Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">At December 31, 2022 and 2021, accounts payable and accrued expenses consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,512</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,083</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,595</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 554</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,744</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155003664720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;7&#160;- Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">On June 14, 2022, the Company entered into a sublease agreement with The Paul Revere Life Insurance Company. Pursuant to the terms of the sublease lease agreement, the Company agreed to lease&#160;</span><span style="background:#ffffff;">26,503</span><span style="background:#ffffff;">&#160;square feet, located at 1 Mercantile Street, Worcester, MA (the &#8220;Mercantile Street Facility&#8221;), through January 2030. The Company recorded a right of use&#160;</span><span style="-sec-ix-hidden:Hidden_hD18g_F6S0Sosw_qw-16ow;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">asset</span></span><span style="background:#ffffff;">&#160;and related operating lease liability of </span><span style="background:#ffffff;">$2.2</span><span style="background:#ffffff;">&#160;million on the Balance Sheet at the lease inception.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On October&#160;27, 2017, the Company entered into a lease agreement with WCS&#160;- 377 Plantation Street,&#160;Inc., a Massachusetts nonprofit corporation. Pursuant to the terms of the lease agreement, the Company agreed to lease 27,043 square feet from the landlord, located at 377 Plantation Street in Worcester, MA (the &#8220;Plantation Street Facility&#8221;), through November 2026, subject to additional extensions at the Company&#8217;s option. Base rent, net of abatements of $0.6 million over the lease term, totals approximately $3.6 million, on a triple-net basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The terms of the lease also require that the Company post an initial security deposit of $0.8 million, in the form of $0.5 million letter of credit and $0.3 million in cash, which increased to $1.3 million ($1.0 million letter of credit, $0.3 million in cash) on November 1, 2019. After the fifth lease year, the letter of credit obligation is subject to reduction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Plantation Street Facility began operations for the production of personalized CAR T and gene therapies in 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company leases office space and copiers under agreements classified as operating leases that expire on various dates through 2030. The Company&#8217;s lease liabilities result from the lease of its facilities in Massachusetts, which expire in 2030 and 2026, for the Mercantile Street Facility and Plantation Street Facility, respectively, and its copiers, which expire in 2024. Such leases do not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. Certain of the Company&#8217;s leases include renewal options and escalation clauses; renewal options have not been included in the calculation of the lease liabilities and right of use assets as the Company is not reasonably certain to exercise the options. The Company does not act as a lessor or have any leases classified as financing leases. At December 31, 2022, the Company had operating lease liabilities of $3.9 million and right of use assets of $2.9 million, which were included in the Balance Sheet. At December 31, 2021, the Company had operating lease liabilities of $2.0 million and right of use assets of $1.1 million, which were included in the Balance Sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following summarizes quantitative information about the Company&#8217;s operating leases:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 565</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 315</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 488</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 599</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,053</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 914</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:86.33%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:29.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term &#8211; operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate &#8211; operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Maturities of our operating leases, excluding short-term leases, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 529</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 614</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,139</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,076</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 650</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,381</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,389</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,443)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,946</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154998275136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Note 8 &#8211; Notes Payable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">On March 4, 2022 (the &#8220;Closing Date&#8221;), the Company entered into a $75.0&#160;million long-term debt facility with Runway Growth Finance Corp. (the &#8220;Term Loan&#8221;). Under the Term Loan, $30.0&#160;million of the $75.0&#160;million loan was funded on the Closing Date, with the remaining $45.0&#160;million fundable if the Company achieves certain predetermined milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Term Loan matures on April 15, 2027 (the &#8220;Maturity Date&#8221;). &#160;As of March 15, 2022, the Company began making monthly payments of interest only until April 1, 2024 (the &#8220;Amortization Date&#8221;). The Amortization Date may be extended to April 1, 2025, if the Company achieves certain predetermined milestones based on equity raises and the initiation of certain clinical trials. After that, the Company will make monthly payments of interest and principal. If the Amortization Date is extended to April 1, 2025, the monthly payments will be recalculated in equal amounts according to the remaining number of payment dates through the Maturity Date. All unpaid outstanding principal and accrued and unpaid interest will be due and payable in full on the Maturity Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Term Loan accrues interest at a variable annual rate equal to&#160;8.75% plus the greater of (i)&#160;0.50% and (ii) the three month LIBOR Rate for U.S. dollar deposits or the rate otherwise reasonably determined by the Lender to be the rate at which U.S. dollar deposits with a term of three months would be offered by banks in London, England to major banks in the London or other offshore interbank market &#160;(the &#8220;Applicable Rate&#8221;); provided that the Applicable Rate will not be less than&#160;9.25%. The Applicable Rate at December 31, 2022 was&#160;13.40%. On December 7, 2022, the Company entered into the First Amendment (the &#8220;First Amendment&#8221;) to the Loan Agreement by and between the Company and Runway. The First Amendment amended certain definitions and other provisions of the Loan Agreement to replace LIBOR-based benchmark rates applicable to loans outstanding under the Loan Agreement with SOFR-based rates, subject to adjustments as specified in the First Amendment. For the year ended December 31, 2022, the Company made interest payments of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">$2.7&#160;million, recorded in interest expense in the Statements of Operations. The Company had&#160;no&#160;interest expense related to debt in 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Pursuant to the terms of the Term Loan on the Closing Date the Company paid the Lender upfront fees out of proceeds of $0.4&#160;million consisting of a&#160;1% commitment fee and a deposit of $75,000. &#160;In addition, the Company paid other cash fees directly to third parties comprising of an advisory fee and legal fees totaling $2.3&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Also, in connection with the Term Loan, on March 4, 2022, the Company issued a warrant to the Lender to purchase&#160;748,036&#160;shares of the Company&#8217;s common stock with an exercise price of $0.8021&#160;(the &#8220;Warrant&#8221;) via a warrant agreement (the &#8220;Warrant Agreement&#8221;). The Warrant is exercisable for&#160;ten years&#160;from the date of issuance. The Lender may exercise the Warrant with cash or through a net issuance conversion. The shares of the Company&#8217;s common stock will be registered at the Company&#8217;s first opportunity after the date of the exercise of the Warrant. In addition, the provisions of the Warrant Agreement provide for additional warrants to be issued upon funding of the term loan tranches. The fair value of the warrant at the grant date was determined utilizing a Black Scholes Model with the following assumptions: risk free rate of return&#160;1.74%, volatility of&#160;57.3%,&#160;<span style="-sec-ix-hidden:Hidden_yUFWycn0fk-azymq7ugG3A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10-year</span></span>&#160;life yielding a value of approximately $0.4&#160;million as of March 4, 2022. &#160;The fair value of the warrant was also recorded in debt discount and will be amortized over the life of the Term Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Applicable&#160;Rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">April - 2027</p></td></tr><tr><td style="vertical-align:bottom;width:51.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Discount on note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,614)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Long-term note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Amortization of the debt discount associated with the Term Loan was approximately $0.5&#160;million for the year ended December 31, 2022, respectively, and was recorded in interest expense in the Statements of Operations. The Company had&#160;no&#160;expense related to debt discount amortization in 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has the option to prepay all of the outstanding Term Loan but not less. Prepayment would include outstanding principal, accrued interest, prepayment fee and final payment which is equal to the original principal amount of the Term Loan times&#160;3.5% or $1.1&#160;million and is accreted over the life of the Term Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, the Term Loan is secured by a lien on substantially all of our assets other than certain intellectual property assets and certain other excluded collateral, and it contains a minimum liquidity covenant and other covenants that include among other items: (i) limits on indebtedness, repurchase of stock from employees, officers and directors. The Company was in compliance with all applicable covenants as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The Term Loan contains customary events of default, in certain circumstances subject to customary cure periods. Following an event of default and any cure period, if applicable, Runway will have the right upon notice to accelerate all amounts outstanding under the Term Loan, in addition to other remedies available to the lenders as secured creditors of the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155003451056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;9&#160;- Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company, in accordance with its certificate of incorporation, as amended in November 2020 and June 2021, which was retroactively applied, and July 2022, is authorized to issue (i) 200,000,000 common shares with a par value of $0.0001 per share, of which 1,000,000 shares are designated as Class&#160;A Common Stock and the remainder are undesignated Common Stock, and (ii) 2,000,000 shares of Preferred Stock, 250,000 of which are designated as Class A Preferred Stock and the remainder are undesignated Preferred Stock (see below Stock Issuances to Fortress and Note&#160;4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In connection with the Company&#8217;s formation, Fortress subscribed for 7,000,000 shares of the Class&#160;B Common Stock and 2,000,000 shares of the Company&#8217;s Common Stock, pursuant to the Founders Agreement. Fortress paid the par value of $900 in 2016. The fair value of the Company&#8217;s common shares approximated par value as no licenses had been transferred at that time. Dividends, if and when declared, are to be distributed pro-rata to the Class&#160;A, B and Common Stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The holders of Common Stock are entitled to one vote per share of Common Stock held. The holders of Class&#160;A Common Stock are entitled to the number of votes equal to the number of whole shares of Common Stock into which the shares of Class&#160;A Common Stock held by such holder are convertible and for a period of ten years from its issuance, the holders of the Class&#160;A Common Stock have the right to appoint one member of the board of directors of Mustang; to date, the holders of Class&#160;A Common Stock have not yet appointed such director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Class&#160;B Common Stockholders are entitled, for each share of Class&#160;B Common Stock held, to a number of votes equal to 1.1 times a fraction, the numerator of which is the sum of (A)&#160;the shares of outstanding Common Stock and (B)&#160;the whole shares of Common Stock into which the shares of outstanding Class&#160;A Common Stock and the Class&#160;B Common Stock are convertible and the denominator of which is the number of shares of outstanding Class&#160;B common shares. There was no Class B Common Stock outstanding as of December&#160;31,&#160;2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On November 11, 2020, the Company&#8217;s Board adopted resolutions of the Board to ratify, approve and recommend stockholder approval of an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended, to revise Article IV, Section A thereof in order to effect an increase in the authorized number of shares of the Company&#8217;s common stock, par value $0.0001, from 85,000,000 to 125,000,000 (the &#8220;Amendment&#8221;). On November 11, 2020, the Company received approval of the Amendment by written consent in lieu of a meeting from the holders of a majority of issued and outstanding shares of the Company&#8217;s common and preferred stock. The increase in authorized shares to 125,000,000 became effective on December 4, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On June 17, 2021, the stockholders of the Company voted at the 2021 Annual Meeting to approve an amendment to Mustang&#8217;s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance by 25,000,000 shares, bringing the total number of authorized shares of common stock to 150,000,000 shares. The increase in authorized shares to 150,000,000 became effective on June 17, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On June 21, 2022, the stockholders of the Company voted at the 2022 Annual Meeting to approve an amendment to Mustang&#8217;s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance by 50,000,000 shares, bringing the total number of authorized shares of common stock to 200,000,000 shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">At-the-Market Offering of Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In July 2018, the Company entered into an At-the-Market Issuance Sales Agreement (the &#8220;Mustang ATM&#8221;) with B. Riley Securities, Inc. (formerly B. Riley FBR,&#160;Inc.), Cantor Fitzgerald&#160;&amp; Co., National Securities Corporation,<span style="background:#ffffff;"> (now B. Riley FBR, Inc.),</span> and Oppenheimer&#160;&amp; Co.&#160;Inc. (each an &#8220;Agent&#8221; and collectively, the &#8220;Agents&#8221;), relating to the sale of shares of common stock pursuant to the 2020 S-3. Under the Mustang ATM, the Company pays the Agents a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of common stock. On December 31, 2020, the Mustang ATM was amended to add H.C. Wainwright &amp; Co., LLC as an Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">During the year ended December 31, 2022, the Company issued approximately 7.9 million shares of common stock at an average price of $0.84 per share for gross proceeds of $6.6 million under the ATM Agreement. In connection with these sales, the Company paid aggregate fees of approximately $0.1 million for net proceeds of approximately $6.5 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">During the year ended December 31, 2021, the Company issued approximately 19.4 million shares of common stock at an average price of $3.70 per share for gross proceeds of $71.9 million under the ATM Agreement. In connection with these sales, the Company paid aggregate fees of approximately $1.3 million for net proceeds of approximately $70.6 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;margin:0pt;">Pursuant to the Founders Agreement, the Company issued 196,952 shares of common stock to Fortress at a weighted average price of $0.84 per share for the year ended December 31, 2022, and recorded zero shares issuable to Fortress in connection with the shares issued under the Mustang ATM. Pursuant to the Founders Agreement, Mustang issued 576,157 shares of common stock to Fortress at a weighted average price of $3.70 per share for the year ended December 31, 2021, in connection with the shares issued under the Mustang ATM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Registration Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">On October 23, 2020, the Company filed a shelf registration statement No. 333-249657 on Form S-3 (the &#8220;2020 S-3&#8221;), which was declared effective on December 4, 2020. Under the 2020 S-3, the Company may sell up to a total of $100.0 million of its securities. As of December 31, 2022, approximately $8.0&#160;million of the 2020 S-3 remains available for sales of securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">On April 23, 2021, the Company filed a shelf registration statement No. 333-255476 on Form S-3 (the &#8220;2021 S-3&#8221;), which was declared effective on May 24, 2021. Under the 2021 S-3, the Company may sell up to a total of $200.0 million of its securities. As of December 31, 2022, there have been no sales of securities under the 2021 S-3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Stock Issuances to Fortress</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under the terms of the Second Amended and Restated Founders Agreement, which became effective July 22, 2016, Fortress will receive a grant of shares of our common stock equal to two and one-half percent (2.5%) of the gross amount of any equity or debt financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the year ended December 31, 2022, the Company issued&#160;196,952&#160;shares of common stock, which equaled&#160;2.5% of the gross proceeds of $6.6&#160;million from the sale of shares of common stock under Mustang&#8217;s At-the-Market Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">For the year ended December 31, 2021, the Company issued&#160;576,157&#160;shares of common stock and recorded&#160;51,295&#160;shares issuable to Fortress, which equaled&#160;2.5% of the gross proceeds of $71.9&#160;million from the sale of shares of common stock under Mustang&#8217;s At-the-Market Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Equity Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has in effect the 2016 Incentive Plan (the &#8220;Incentive Plan&#8221;). The Incentive Plan was adopted in 2016 by our stockholders and the compensation committee of the Company&#8217;s board of directors and is authorized to grant stock-based awards to directors, officers, employees and consultants. The plan initially authorized grants to issue up to 2,000,000 shares of authorized but unissued common stock and expires 10 years from adoption and limits the term of each option to no more than 10 years from the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In June&#160;2018, the Company&#8217;s stockholders approved an amendment to the Incentive Plan to increase the number of authorized shares issuable by 3,000,000 shares, for a total of 5,000,000 shares. In June&#160;2021, the Company&#8217;s stockholders approved an amendment to the Incentive Plan to increase the number of authorized shares issuable by 3,000,000 shares, for a total of 8,000,000 shares. In June&#160;2022, the Company&#8217;s stockholders approved an amendment to the Incentive Plan to increase the number of authorized shares issuable by 3,000,000 shares, for a total of 11,000,000 shares As of December 31, 2022, 4,462,870 shares are available for issuance of stock-based awards under the Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes stock option activities for the&#160;year ended December 31, 2022 and 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Life&#160;(in</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock&#160;Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,141,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.31</p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,141,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.31</p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,141,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.31</p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 713,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.31</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As of December 31, 2022, the Company had no unrecognized stock-based compensation expense related to options. The Company accounts for forfeited awards as they occur as permitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Restricted Stock Awards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Certain employees and directors have been awarded restricted stock. The restricted stock vesting consists of milestone and time-based vesting. The following table summarizes restricted stock award activities for the&#160;year ended December 31, 2022 and 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant&#160;Date&#160;Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 302,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.93</p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 68,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.63</p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (90,001)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.69</p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 280,983</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.05</p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 358,320</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.70</p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (129,058)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.89</p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 510,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.48</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As of December 31, 2022, the Company had unrecognized stock-based compensation expense related to restricted stock of $0.4 million, which is expected to be recognized over a weighted average period of approximately 2.3&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Restricted Stock Units</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes restricted stock units&#8217; activities for the&#160;year ended December 31, 2022 and 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant&#160;Date&#160;Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,468,559</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.87</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,660,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.07</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (372,873)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.60</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (420,379)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.27</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,335,557</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.27</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,484,647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.76</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (514,999)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.53</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (816,518)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.98</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,488,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.84</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As of December 31, 2022, the Company had unrecognized stock-based compensation expense related to restricted stock units of approximately $2.0 million, which is expected to be recognized over a weighted average period of approximately 2.7&#160;years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes stock-based compensation expense for the&#160;years ended December 31, 2022 and 2021 (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In connection with the Company&#8217;s offering of shares of common stock in a private placement, each investor received a warrant equal to 25% of the common shares purchased in connection with the offering. Further, National Securities Corporation received Placement Agent Warrants. In connection with the Term Loan on March 4, 2022, the Company issued a warrant to the Lender to purchase 748,036 shares of the Company's common stock with an exercise price of $0.8021, see Note 8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of warrant activities for&#160;years ended December 31, 2022 and 2021, is presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Life&#160;(in</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,402,670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.39</p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,093,878)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cashless exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (138)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,308,654</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.73</p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,003,770)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 748,036</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.18</p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,052,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.29</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Upon the exercise of warrants, the Company will issue new shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Employee Stock Purchase Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In connection with our Employee Stock Purchase Plan (&#8220;ESPP&#8221;), eligible employees of Mustang and Fortress can purchase the Company&#8217;s Common Stock at the end of a predetermined offering period at 85% of the lower of the fair market value at the beginning or end of the offering period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of December 31, 2022, 586,010 shares have been purchased and 413,990 shares are available for future sale under the Company&#8217;s ESPP.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155003689120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;10&#160;- Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">The Company has accumulated net losses since inception and has not recorded an income tax provision or benefit during the&#160;years ended December 31, 2022 and 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A reconciliation of the statutory U.S. federal rate to the Company&#8217;s effective tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;year&#160;ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statutory federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes, net of federal tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-deductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal tax rate change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State tax rate change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (41)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income taxes provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The components of the net deferred tax asset as of December 31, 2022 and 2021 are the following ($ in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;year&#160;ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryovers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66,879</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock compensation and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,702</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of license</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,977</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 755</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accruals and reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,434</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,035</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Startup costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,728</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">174 Capitalization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 129,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95,141</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (128,101)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (94,751)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 390</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Right of use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,085)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (390)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has determined, based upon available evidence, that it is more likely than not that the net deferred tax asset will not be realized and, accordingly, has provided a full valuation allowance against its net deferred tax assets as of December 31, 2022 and 2021. A valuation allowance of approximately $128.1 million and $94.8 million, respectively, was recorded for the&#160;years ended December&#160;31,&#160;2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As of December 31, 2022, the Company had federal and state net operating loss carryforwards of approximately $214.0 million and $463.1 million, respectively. Approximately $190.4 million and $0.2 million of the federal and state net operating loss carryforwards, respectively, can be carried forward indefinitely. As of December 31, 2022, the Company had federal and state income tax credits of approximately $12.5 million and $4.0 million, respectively, which will begin to expire in <span style="-sec-ix-hidden:Hidden_RuW2aDq3XEWNv2WtYazZ1w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2033</span></span>. Under the provisions of Section 382 of the Internal Revenue Code, a corporation that undergoes an &#8220;ownership change&#8221;, as defined therein, is subject to limitations on its use of pre-change NOLs and income tax credits carryforwards to offset future tax liabilities. Certain tax attributes may be subject to an annual limitation as a result of the Company&#8217;s January 2017 capital raise, as it appears to constitute an ownership change under Section 382. Additionally, under Section 382, annual use of the Company&#8217;s net operating loss carryforwards to offset taxable income may be limited based on cumulative changes in ownership. The Company has not completed an analysis to determine whether any such limitations have been triggered as of December 31, 2022. The Company has no income tax effect due to the recognition of a full valuation allowance on all of its deferred tax assets as it believes that it is more likely than not that the deferred tax assets will not be realized regardless of whether an &#8220;ownership change&#8221; has occurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">There are no significant items determined to be unrecognized tax benefits taken or expected to be taken in a tax return, in accordance with ASC 740 &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;), which clarifies the accounting for uncertainty in income taxes recognized in the financial statements, that have been recorded on the Company&#8217;s financial statements for the periods ended December 31, 2022 and 2021. The Company does not anticipate a material change to unrecognized tax benefits in the next twelve&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Additionally, ASC 740 provides guidance on the recognition of interest and penalties related to income taxes. There were no interest or penalties related to income taxes that have been accrued or recognized as of and for the periods ended December 31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company is subject to U.S. federal and various state taxes. As of December 31, 2022, the earliest federal tax year open for the assessment of income taxes under the applicable statutes of limitations is its 2019 tax year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri Light';font-size:10.5pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Beginning with the 2022 tax year, the Company is required to capitalize research and development expenses for tax purposes as defined under Internal Revenue Code Section 174. For expenses that are incurred for research and development in the U.S., the amounts will be amortized over 5 years, and for expenses that are incurred for research and development outside the U.S., the amounts will be amortized over 15 years.&#160; As a result of Section 174 capitalization, the Company recognized a deferred tax asset of $19.8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer's social security payments, net operating loss utilization and carryback periods and modifications to the net interest deduction limitations. The CARES Act did not have a material impact on the Company&#8217;s income tax provision for 2022 and 2021. The Company will continue to evaluate the impact of the CARES Act on its financial position, results of operations and cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">On December 27, 2020, the President of the United States signed the Consolidated Appropriations Act, 2021 (&#8220;Consolidated Appropriations Act&#8221;) into law. The Consolidated Appropriations Act is intended to enhance and expand certain provisions of the CARES Act, allows for the deductions of expenses related to the Payroll Protection Program funds received by companies, and provides an update to meals and entertainment expensing for 2021. The Consolidated Appropriations Act did not have a material impact to the Company&#8217;s income tax provision for 2022 and 2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155003449056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;11&#160;&#8211; Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Board of Directors approved, and our stockholders subsequently approved, a reverse stock split of our Common Stock. On March 15, 2023, the Board of Directors set the reverse stock split ratio at 15-for-1. We have filed a Definitive Information Statement on Schedule 14C in connection with the reverse stock split, and once the applicable waiting periods under SEC and Nasdaq rules have expired we plan to file a Certificate of Amendment to our Amended and Restated Certificate of Incorporation, as amended, in order to give effect to the reverse stock split. The ex-dividend date is expected to be determined in April 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155084021120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The Company has no subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">All inter-company transactions between Fortress and Mustang are classified as due from or due to related party in the financial statements. The Company believes that the assumptions underlying the financial statements are reasonable.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Segments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating and <span style="-sec-ix-hidden:Hidden_1DzwVi4TWE68-iARaVzCtQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting</span></span> segment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company considers highly liquid investments with a maturity of three&#160;months or less when purchased to be cash equivalents. Cash and cash equivalents at December&#160;31,&#160;2022 and 2021, consisted of cash and certificates of deposit in institutions in the United States. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are currently adequately protected against credit risk.&#160;At times, portions of the Company&#8217;s cash and cash equivalents may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation (FDIC) limits, though the Company customarily invests a significant portion of its cash in CDARS accounts to maximize FDIC insurance coverage across its holdings.&#160;As of December 31, 2022, the Company had not experienced losses on these accounts, and management believes the Company is not exposed to significant risk on such accounts.&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Other Receivables - Related Party</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Receivables &#8211; Related Party</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Other receivables include amounts due to the Company from Fortress and Journey Medical Corporation, both related parties, and is recorded at the invoiced amount.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company records cash held in an escrow account as a security deposit for the manufacturing facility in Worcester, Massachusetts, as restricted cash. The Company had $1.0 million in restricted cash as of December&#160;31,&#160;2022 and 2021, respectively. The Facility initiated cell processing operations for personalized CAR T and gene therapies in 2018.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and equipment, net and Property and equipment - Construction in Process</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Property, plant and equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Property and equipment, net, which consists mainly of laboratory equipment, are carried at cost less accumulated depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally five years, using the straight-line method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Property and equipment&#160;- Construction in Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In connection with the Company&#8217;s cell processing facility, the Company incurred costs for the design and construction of the facility and the purchase of equipment; $1.0 million and $2.0 million are recorded in fixed assets - construction in process on the balance sheet at December&#160;31,&#160;2022 and 2021, respectively. Upon completion of the facility&#8217;s construction, all costs associated with the buildout will be recorded as leasehold improvements and amortized over the shorter of the estimated useful lives or the term of the respective leases, upon the improvement being placed in service.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company&#8217;s behalf will be expensed as services are rendered or when the milestone is achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, costs associated with regulatory filings, laboratory costs and other supplies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 730-10-25-1, <i style="font-style:italic;">Research and Development, </i>costs incurred in obtaining technology licenses are charged to research and development expense if the technology licensed has not reached commercial feasibility and has no alternative future use. The licenses purchased by the Company require substantial completion of research and development, regulatory and marketing approval efforts to reach commercial feasibility and has no alternative future use. Accordingly, the total purchase price for the licenses acquired is reflected as research and development&#160;- licenses acquired in the Company&#8217;s Statements of Operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AnnualStockDividendPolicyTextBlock', window );">Annual Stock Dividend</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Annual Stock Dividend</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In July&#160;2016, in connection with the Amended and Restated Articles of Incorporation, the Company issued 250,000 Class&#160;A preferred shares to Fortress. The Class&#160;A preferred shares entitle the holder to a stock dividend equal to 2.5% of the fully diluted outstanding equity of the Company (the &#8220;Annual Stock Dividend&#8221;). The Annual Stock Dividend was part of the consideration payable for formation of the Company and the identification of certain assets, including the license contributed to Mustang by Fortress (see Note&#160;4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In June&#160;2018, in connection with the Amended and Restated Articles of Incorporation, the Company amended the Annual Stock Dividend &#160;due date from March&#160;13th to January&#160;1st.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Pursuant to the Amended and Restated Articles of Incorporation, the Company issued 2,807,008 shares of common stock to Fortress for the Annual Stock Dividend, representing 2.5% of the fully-diluted outstanding equity of Mustang on January 1, 2023. This was shown in the Statement of Stockholders&#8217; Equity at December 31, 2022, as Common stock issuable &#8211; Founders Agreement. The Company recorded an expense of approximately $1.1 million in research and development - licenses acquired related to these issuable shares during the year ended December&#160;31,&#160;2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the Amended and Restated Articles of Incorporation, the Company issued 2,536,607 shares of common stock to Fortress for the Annual Stock Dividend, representing 2.5% of the fully-diluted outstanding equity of Mustang on January 1, 2022. This was shown in the Statement of Stockholders&#8217; Equity at December&#160;31,&#160;2021, as Common stock issuable &#8211; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Founders Agreement. The Company recorded an expense of approximately $4.2 million in research and development - licenses acquired related to these issuable shares during the year ended December 31, 2021.<span style="color:#201f1e;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;background:#ffffff;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Fair Value Measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 0pt;">Level 1:&#160;&#160;&#160;&#160;Quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 10pt 0pt;">Level 2:&#160;&#160;&#160;&#160;Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;">Level 3:&#160;&#160;&#160;&#160;Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the balance sheet as both a right of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company's incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred. In calculating the right of use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model or 409a valuations, as applicable. The assumptions used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if management believes it is more likely than not that the deferred tax assets </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period less unvested restricted stock. Since dividends are declared, paid and set aside among the holders of shares of common stock and Class&#160;A common shares pro-rata on an as-if-converted basis, the two-class method of computing net loss per share is not required. Diluted net loss per share does not reflect the effect of shares of common stock to be issued upon the exercise of warrants or outstanding Class&#160;A preferred shares, as their inclusion would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,052,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,308,654</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,141,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,141,675</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Class&#160;A Preferred Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 510,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 280,983</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,488,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,335,557</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,443,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,316,869</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has no components of other comprehensive loss, and therefore, comprehensive loss equals net loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;2&#160;- Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The Company has no subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">All inter-company transactions between Fortress and Mustang are classified as due from or due to related party in the financial statements. The Company believes that the assumptions underlying the financial statements are reasonable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Segments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating and <span style="-sec-ix-hidden:Hidden_1DzwVi4TWE68-iARaVzCtQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting</span></span> segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company considers highly liquid investments with a maturity of three&#160;months or less when purchased to be cash equivalents. Cash and cash equivalents at December&#160;31,&#160;2022 and 2021, consisted of cash and certificates of deposit in institutions in the United States. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are currently adequately protected against credit risk.&#160;At times, portions of the Company&#8217;s cash and cash equivalents may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation (FDIC) limits, though the Company customarily invests a significant portion of its cash in CDARS accounts to maximize FDIC insurance coverage across its holdings.&#160;As of December 31, 2022, the Company had not experienced losses on these accounts, and management believes the Company is not exposed to significant risk on such accounts.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Receivables &#8211; Related Party</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Other receivables include amounts due to the Company from Fortress and Journey Medical Corporation, both related parties, and is recorded at the invoiced amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company records cash held in an escrow account as a security deposit for the manufacturing facility in Worcester, Massachusetts, as restricted cash. The Company had $1.0 million in restricted cash as of December&#160;31,&#160;2022 and 2021, respectively. The Facility initiated cell processing operations for personalized CAR T and gene therapies in 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Property, plant and equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Property and equipment, net, which consists mainly of laboratory equipment, are carried at cost less accumulated depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally five years, using the straight-line method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Property and equipment&#160;- Construction in Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In connection with the Company&#8217;s cell processing facility, the Company incurred costs for the design and construction of the facility and the purchase of equipment; $1.0 million and $2.0 million are recorded in fixed assets - construction in process on the balance sheet at December&#160;31,&#160;2022 and 2021, respectively. Upon completion of the facility&#8217;s construction, all costs associated with the buildout will be recorded as leasehold improvements and amortized over the shorter of the estimated useful lives or the term of the respective leases, upon the improvement being placed in service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company&#8217;s behalf will be expensed as services are rendered or when the milestone is achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, costs associated with regulatory filings, laboratory costs and other supplies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 730-10-25-1, <i style="font-style:italic;">Research and Development, </i>costs incurred in obtaining technology licenses are charged to research and development expense if the technology licensed has not reached commercial feasibility and has no alternative future use. The licenses purchased by the Company require substantial completion of research and development, regulatory and marketing approval efforts to reach commercial feasibility and has no alternative future use. Accordingly, the total purchase price for the licenses acquired is reflected as research and development&#160;- licenses acquired in the Company&#8217;s Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Annual Stock Dividend</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In July&#160;2016, in connection with the Amended and Restated Articles of Incorporation, the Company issued 250,000 Class&#160;A preferred shares to Fortress. The Class&#160;A preferred shares entitle the holder to a stock dividend equal to 2.5% of the fully diluted outstanding equity of the Company (the &#8220;Annual Stock Dividend&#8221;). The Annual Stock Dividend was part of the consideration payable for formation of the Company and the identification of certain assets, including the license contributed to Mustang by Fortress (see Note&#160;4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In June&#160;2018, in connection with the Amended and Restated Articles of Incorporation, the Company amended the Annual Stock Dividend &#160;due date from March&#160;13th to January&#160;1st.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Pursuant to the Amended and Restated Articles of Incorporation, the Company issued 2,807,008 shares of common stock to Fortress for the Annual Stock Dividend, representing 2.5% of the fully-diluted outstanding equity of Mustang on January 1, 2023. This was shown in the Statement of Stockholders&#8217; Equity at December 31, 2022, as Common stock issuable &#8211; Founders Agreement. The Company recorded an expense of approximately $1.1 million in research and development - licenses acquired related to these issuable shares during the year ended December&#160;31,&#160;2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the Amended and Restated Articles of Incorporation, the Company issued 2,536,607 shares of common stock to Fortress for the Annual Stock Dividend, representing 2.5% of the fully-diluted outstanding equity of Mustang on January 1, 2022. This was shown in the Statement of Stockholders&#8217; Equity at December&#160;31,&#160;2021, as Common stock issuable &#8211; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Founders Agreement. The Company recorded an expense of approximately $4.2 million in research and development - licenses acquired related to these issuable shares during the year ended December 31, 2021.<span style="color:#201f1e;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Fair Value Measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 0pt;">Level 1:&#160;&#160;&#160;&#160;Quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 10pt 0pt;">Level 2:&#160;&#160;&#160;&#160;Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;">Level 3:&#160;&#160;&#160;&#160;Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the balance sheet as both a right of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company's incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred. In calculating the right of use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model or 409a valuations, as applicable. The assumptions used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if management believes it is more likely than not that the deferred tax assets </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period less unvested restricted stock. Since dividends are declared, paid and set aside among the holders of shares of common stock and Class&#160;A common shares pro-rata on an as-if-converted basis, the two-class method of computing net loss per share is not required. Diluted net loss per share does not reflect the effect of shares of common stock to be issued upon the exercise of warrants or outstanding Class&#160;A preferred shares, as their inclusion would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,052,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,308,654</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,141,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,141,675</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Class&#160;A Preferred Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 510,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 280,983</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,488,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,335,557</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,443,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,316,869</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has no components of other comprehensive loss, and therefore, comprehensive loss equals net loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In August 2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2020-06,&#160;<i style="font-style:italic;">&#8220;Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity,&#8221;</i>&#160;which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption will be permitted. The Company is currently evaluating the impact of this standard on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">In June 2016, FASB issued ASU 2016-13,&#160;</span><i style="font-style:italic;background:#ffffff;">&#8220;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;</i><span style="background:#ffffff;">. ASU 2016-13 requires that expected credit losses relating to financial assets are measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. Recently, the FASB issued the final ASU to delay adoption for smaller reporting companies to calendar year 2023. The Company is currently assessing the impact of the adoption of this ASU on its financial statements</span>.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_AnnualStockDividendPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Stock Dividend [Policy Text Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_AnnualStockDividendPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155003484368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,052,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,308,654</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,141,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,141,675</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Class&#160;A Preferred Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 510,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 280,983</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,488,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,335,557</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,443,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,316,869</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155004535584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Clinical Trial and Sponsored Research Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_LicenseAgreementsMember', window );">License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Clinical Trial and Sponsored Research Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the&#160;years ended December 31, 2022 and 2021, the Company recorded the following expense in research and development for licenses acquired:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">City of Hope National Medical Center</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">CD123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">IV/ICV</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">PSCA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">HER2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">CSL Behring (Calimmune)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30</p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Leiden University  Medical Centre</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 350</p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mayo Clinic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 750</p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fortress PIK Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,212</p></td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,474</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,842</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember', window );">Sponsored Research and Clinical Trial Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Clinical Trial and Sponsored Research Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the&#160;year ended December 31, 2022 and 2021, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">City of Hope National Medical Center</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">CD123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 301</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">IL13R&#945;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,486</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,169</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">CS1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 608</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">HER2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 697</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">PSCA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 107</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fred Hutchinson Cancer Center - CD20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,987</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,979</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">St. Jude Children's Research Hospital&#160;- XSCID</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 865</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LUMC - RAG1 SCID</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 505</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 170</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mayo Clinic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 695</p></td></tr><tr><td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,591</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mbio_LicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mbio_LicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155003630624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Mustang&#8217;s property and equipment consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated Useful</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145</p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 370</p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Machinery&#160;and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,550</p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,694</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,694</p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 951</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,027</p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,786</p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,401)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,734)</p></td></tr><tr><td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,052</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155003520624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">At December 31, 2022 and 2021, accounts payable and accrued expenses consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,512</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,083</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,595</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 554</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,744</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155003466992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of information about operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following summarizes quantitative information about the Company&#8217;s operating leases:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 565</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 315</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 488</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 599</p></td></tr><tr><td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,053</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 914</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:86.33%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:29.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term &#8211; operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate &#8211; operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of operating leases excluding short term leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Maturities of our operating leases, excluding short-term leases, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 529</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 614</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,139</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,076</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ended December&#160;31,&#160;2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 650</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,381</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,389</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,443)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,946</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155003567008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of long-term debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Applicable&#160;Rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturity</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">April - 2027</p></td></tr><tr><td style="vertical-align:bottom;width:51.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Discount on note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,614)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Long-term note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155001532048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes stock option activities for the&#160;year ended December 31, 2022 and 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Life&#160;(in</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock&#160;Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,141,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.31</p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,141,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.31</p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,141,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.31</p></td></tr><tr><td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 713,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.31</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes stock-based compensation expense for the&#160;years ended December 31, 2022 and 2021 (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_SummaryOfWarrantActivitiesTableTextBlock', window );">Summary of Warrant Activities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of warrant activities for&#160;years ended December 31, 2022 and 2021, is presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Life&#160;(in</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,402,670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.39</p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,093,878)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cashless exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (138)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,308,654</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.73</p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,003,770)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 748,036</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.18</p></td></tr><tr><td style="vertical-align:bottom;width:49.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,052,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.29</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedules of Restricted Stock and Restricted Stock Unit Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Certain employees and directors have been awarded restricted stock. The restricted stock vesting consists of milestone and time-based vesting. The following table summarizes restricted stock award activities for the&#160;year ended December 31, 2022 and 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant&#160;Date&#160;Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 302,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.93</p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 68,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.63</p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (90,001)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.69</p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 280,983</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.05</p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 358,320</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.70</p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (129,058)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.89</p></td></tr><tr><td style="vertical-align:bottom;width:63.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 510,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.48</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedules of Restricted Stock and Restricted Stock Unit Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes restricted stock units&#8217; activities for the&#160;year ended December 31, 2022 and 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant&#160;Date&#160;Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,468,559</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.87</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,660,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.07</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (372,873)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.60</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (420,379)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.27</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,335,557</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.27</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,484,647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.76</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (514,999)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.53</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (816,518)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.98</p></td></tr><tr><td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,488,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.84</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_SummaryOfWarrantActivitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of warrant activities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_SummaryOfWarrantActivitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155001536576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A reconciliation of the statutory U.S. federal rate to the Company&#8217;s effective tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;year&#160;ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statutory federal income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes, net of federal tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-deductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal tax rate change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State tax rate change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (41)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income taxes provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The components of the net deferred tax asset as of December 31, 2022 and 2021 are the following ($ in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;year&#160;ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryovers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75,011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66,879</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock compensation and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,702</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of license</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,977</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 755</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accruals and reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,434</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,035</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Startup costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,728</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">174 Capitalization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 129,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95,141</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (128,101)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (94,751)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 390</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Right of use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,085)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (390)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred tax assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155003589136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Description of Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Description of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (329,369)<span></span>
</td>
<td class="num">$ (251,844)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155000418928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 22, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment </div>
<div>item </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_NumberOfSubsidiaries', window );">Number of subsidiaries | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,792,000<span></span>
</td>
<td class="nump">16,786,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,475,000<span></span>
</td>
<td class="nump">49,864,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Process [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 951,000<span></span>
</td>
<td class="nump">$ 2,027,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbio_FortressBiotechIncMember', window );">Fortress Biotech, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Common stock dividend issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,807,008<span></span>
</td>
<td class="nump">2,536,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_DilutedOutstandingEquityPercentage', window );">Percentage of fully diluted equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbio_FortressBiotechIncMember', window );">Fortress Biotech, Inc [Member] | License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbio_FortressBiotechIncMember', window );">Fortress Biotech, Inc [Member] | Preferred Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsShares', window );">Preferred stock dividends issued (in shares) | shares</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_DilutedOutstandingEquityPercentage', window );">Percentage of fully diluted equity</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_DilutedOutstandingEquityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of diluted outstanding equity paid as equity fee or used to calculate stock issuance to maintain parity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_DilutedOutstandingEquityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_NumberOfSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_NumberOfSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbio_FortressBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbio_FortressBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mbio_LicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mbio_LicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155084002512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Schedule of Potentially Dilutive Securities) (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">5,443,527<span></span>
</td>
<td class="nump">7,316,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">1,052,920<span></span>
</td>
<td class="nump">3,308,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">1,141,675<span></span>
</td>
<td class="nump">1,141,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredClassAMember', window );">Preferred Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">510,245<span></span>
</td>
<td class="nump">280,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">2,488,687<span></span>
</td>
<td class="nump">2,335,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154997550624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Clinical Trial and Sponsored Research Agreements (License Agreements) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development for licenses acquired</a></td>
<td class="nump">$ 1,474,000<span></span>
</td>
<td class="nump">$ 5,842,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_LicenseAgreementsMember', window );">License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development for licenses acquired</a></td>
<td class="nump">1,474,000<span></span>
</td>
<td class="nump">5,842,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbio_CalimmuneMember', window );">CSL Behring (Calimmune) [Member] | License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development for licenses acquired</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbio_LeidenUniversityMedicalCentreMember', window );">Leiden University Medical Centre [Member] | License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development for licenses acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbio_MayoClinicMember', window );">Mayo Clinic [Member] | License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development for licenses acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbio_FortressBiotechIncMember', window );">Fortress Biotech, Inc [Member] | License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development for licenses acquired</a></td>
<td class="nump">1,109,000<span></span>
</td>
<td class="nump">4,212,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mbio_Cd123ProductOrProcessMember', window );">CD123 (MB-102) [Member] | City of Hope National Medical Center ("COH") [Member] | License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development for licenses acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mbio_IvIcvProductOrProcessMember', window );">IV/ICV Product or Process [Member] | City of Hope National Medical Center ("COH") [Member] | License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development for licenses acquired</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mbio_PscaProductOrProcessMember', window );">PSCA (MB-105) [Member] | City of Hope National Medical Center ("COH") [Member] | License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development for licenses acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mbio_Her2ProductOrProcessMember', window );">HER2 (MB 103) [Member] | City of Hope National Medical Center ("COH") [Member] | License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development for licenses acquired</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mbio_LicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mbio_LicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_CalimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_CalimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_LeidenUniversityMedicalCentreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_LeidenUniversityMedicalCentreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_MayoClinicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_MayoClinicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_FortressBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_FortressBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_Cd123ProductOrProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_Cd123ProductOrProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_CityOfHopeNationalMedicalCenterCohMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_CityOfHopeNationalMedicalCenterCohMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_IvIcvProductOrProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_IvIcvProductOrProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_PscaProductOrProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_PscaProductOrProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_Her2ProductOrProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_Her2ProductOrProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154997129600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Clinical Trial and Sponsored Research Agreements (City of Hope - Licenses) (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 08, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 01, 2021 </div>
<div>USD ($) </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Aug. 23, 2019 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development - licenses acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,474,000<span></span>
</td>
<td class="nump">$ 5,842,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbio_MayoClinicMember', window );">Mayo Clinic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_PaymentOfUpfrontFees', window );">Upfront fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_LicenseAgreementsMember', window );">License Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development - licenses acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,474,000<span></span>
</td>
<td class="nump">5,842,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_LicenseAgreementsMember', window );">License Agreements [Member] | CSL Behring (Calimmune) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_PaymentOfUpfrontFees', window );">Upfront fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_NumberOfMilestonesMeasured', window );">Number of milestones | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MilestonesPayableUnderArrangement', window );">Milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development - licenses acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_LicenseAgreementsMember', window );">License Agreements [Member] | Leiden University Medical Centre [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_PaymentOfUpfrontFees', window );">Upfront fees paid</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MilestonesPayableUnderArrangement', window );">Milestones payable</a></td>
<td class="nump">$ 31,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development - licenses acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_LicenseAgreementsMember', window );">License Agreements [Member] | Mayo Clinic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AnnualMaintenanceFeePayable', window );">Annual maintenance fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_PaymentOfUpfrontFees', window );">Upfront fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_NumberOfMilestonesMeasured', window );">Number of milestones | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MilestonesPayableUnderArrangement', window );">Milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development - licenses acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_LicenseAgreementsMember', window );">License Agreements [Member] | CD123 (MB-102) [Member] | City of Hope National Medical Center ("COH") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AnnualMaintenanceFeePayable', window );">Annual maintenance fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MilestonesPayableUnderArrangement', window );">Milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development - licenses acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_LicenseAgreementsMember', window );">License Agreements [Member] | IV/ICV Product or Process [Member] | City of Hope National Medical Center ("COH") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AnnualMaintenanceFeePayable', window );">Annual maintenance fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_PaymentOfUpfrontFees', window );">Upfront fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MilestonesPayableUnderArrangement', window );">Milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development - licenses acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_LicenseAgreementsMember', window );">License Agreements [Member] | PSCA (MB-105) [Member] | City of Hope National Medical Center ("COH") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AnnualMaintenanceFeePayable', window );">Annual maintenance fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_PaymentOfUpfrontFees', window );">Upfront fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_NumberOfMilestonesMeasured', window );">Number of milestones | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MilestonesPayableUnderArrangement', window );">Milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development - licenses acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_LicenseAgreementsMember', window );">License Agreements [Member] | HER2 (MB 103) [Member] | City of Hope National Medical Center ("COH") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AnnualMaintenanceFeePayable', window );">Annual maintenance fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_PaymentOfUpfrontFees', window );">Upfront fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_NumberOfMilestonesMeasured', window );">Number of milestones | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MilestonesPayableUnderArrangement', window );">Milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development - licenses acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_AnnualMaintenanceFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of annual maintenance fee payable under the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_AnnualMaintenanceFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_MilestonesPayableUnderArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestones payable under the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_MilestonesPayableUnderArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_NonRefundableMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable milestone payment expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_NonRefundableMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_NumberOfMilestonesMeasured">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of milestones measured under the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_NumberOfMilestonesMeasured</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_PaymentOfUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of Upfront Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_PaymentOfUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_MayoClinicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_MayoClinicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mbio_LicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mbio_LicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_CalimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_CalimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_LeidenUniversityMedicalCentreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_LeidenUniversityMedicalCentreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_Cd123ProductOrProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_Cd123ProductOrProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_CityOfHopeNationalMedicalCenterCohMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_CityOfHopeNationalMedicalCenterCohMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_IvIcvProductOrProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_IvIcvProductOrProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_PscaProductOrProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_PscaProductOrProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_Her2ProductOrProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_Her2ProductOrProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154999127536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Clinical Trial and Sponsored Research Agreements (Sponsored Research and Clinical Trial Agreements) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">$ 62,475<span></span>
</td>
<td class="nump">$ 49,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember', window );">Sponsored Research and Clinical Trial Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">6,989<span></span>
</td>
<td class="nump">6,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbio_CityOfHopeNationalMedicalCenterCohMember', window );">City of Hope National Medical Center ("COH") [Member] | Sponsored Research and Clinical Trial Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbio_MayoClinicMember', window );">Mayo Clinic [Member] | Sponsored Research and Clinical Trial Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">968<span></span>
</td>
<td class="nump">695<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mbio_Cd123ProductOrProcessMember', window );">CD123 (MB-102) [Member] | City of Hope National Medical Center ("COH") [Member] | Sponsored Research and Clinical Trial Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mbio_Il13r2ProductMember', window );">IL13Ra2 (MB-101) [Member] | City of Hope National Medical Center ("COH") [Member] | Sponsored Research and Clinical Trial Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">1,486<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mbio_Cs1ProductOrProcessMember', window );">CS1 (MB-104) [Member] | City of Hope National Medical Center ("COH") [Member] | Sponsored Research and Clinical Trial Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mbio_Her2ProductOrProcessMember', window );">HER2 (MB 103) [Member] | City of Hope National Medical Center ("COH") [Member] | Sponsored Research and Clinical Trial Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">784<span></span>
</td>
<td class="nump">697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mbio_PscaProductOrProcessMember', window );">PSCA (MB-105) [Member] | City of Hope National Medical Center ("COH") [Member] | Sponsored Research and Clinical Trial Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mbio_Cd20TechnologyProductOrProcessMember', window );">CD20 (MB-106) [Member] | Fred Hutchinson Cancer Center [Member] | Sponsored Research and Clinical Trial Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">1,987<span></span>
</td>
<td class="nump">1,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mbio_StJudeXscidMember', window );">ST. Jude - XSCID [Member] | St. Jude Children's Research Hospital [Member] | Sponsored Research and Clinical Trial Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">508<span></span>
</td>
<td class="nump">865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mbio_Rag1ScidMb110Member', window );">RAG1 SCID (MB-110) [Member] | Leiden University Medical Centre [Member] | Sponsored Research and Clinical Trial Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">$ 505<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_CityOfHopeNationalMedicalCenterCohMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_CityOfHopeNationalMedicalCenterCohMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_MayoClinicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_MayoClinicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_Cd123ProductOrProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_Cd123ProductOrProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_Il13r2ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_Il13r2ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_Cs1ProductOrProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_Cs1ProductOrProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_Her2ProductOrProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_Her2ProductOrProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_PscaProductOrProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_PscaProductOrProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_Cd20TechnologyProductOrProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_Cd20TechnologyProductOrProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_FredHutchinsonCancerResearchCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_FredHutchinsonCancerResearchCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_StJudeXscidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_StJudeXscidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_St.JudeChildrensResearchHospitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_St.JudeChildrensResearchHospitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_Rag1ScidMb110Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_Rag1ScidMb110Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_LeidenUniversityMedicalCentreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_LeidenUniversityMedicalCentreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154991434480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Clinical Trial and Sponsored Research Agreements (City of Hope - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 08, 2021</div></th>
<th class="th"><div>Apr. 01, 2021</div></th>
<th class="th"><div>Jul. 03, 2017</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,475,000<span></span>
</td>
<td class="nump">$ 49,864,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbio_MayoClinicMember', window );">Mayo Clinic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_PaymentOfUpfrontFees', window );">Upfront fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mbio_Her2ProductOrProcessMember', window );">HER2 (MB 103) [Member] | City of Hope National Medical Center ("COH") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ReimbursementOfFeesTotalPayments', window );">Total reimbursement payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember', window );">Sponsored Research and Clinical Trial Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,989,000<span></span>
</td>
<td class="nump">6,591,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember', window );">Sponsored Research and Clinical Trial Agreements [Member] | City of Hope National Medical Center ("COH") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember', window );">Sponsored Research and Clinical Trial Agreements [Member] | Mayo Clinic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MilestonesPayableUnderArrangement', window );">Milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AdditionalMilestonesPayableUnderArrangement', window );">Additional milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ResearchArrangementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">968,000<span></span>
</td>
<td class="nump">695,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember', window );">Sponsored Research and Clinical Trial Agreements [Member] | CD123 (MB-102) [Member] | City of Hope National Medical Center ("COH") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_PaymentOfUpfrontFees', window );">Upfront fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MilestonesPayableUnderArrangement', window );">Milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ResearchArrangementContributionPerPatient', window );">Contribution per patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ResearchArrangementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,000<span></span>
</td>
<td class="nump">301,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember', window );">Sponsored Research and Clinical Trial Agreements [Member] | IL13Ra2 (MB-101) [Member] | City of Hope National Medical Center ("COH") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_PaymentOfUpfrontFees', window );">Upfront fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ResearchFundingAmount', window );">Research funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MilestonesPayableUnderArrangement', window );">Milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ContributionTowardPatientCosts', window );">Contribution toward patient costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ResearchArrangementContributionPerPatient', window );">Contribution per patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ResearchArrangementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,486,000<span></span>
</td>
<td class="nump">1,169,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AnnualMaintenanceFeePayable', window );">Annual maintenance fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember', window );">Sponsored Research and Clinical Trial Agreements [Member] | CS1 (MB-104) [Member] | City of Hope National Medical Center ("COH") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482,000<span></span>
</td>
<td class="nump">608,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ReimbursementOfFeesTotalPayments', window );">Total reimbursement payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember', window );">Sponsored Research and Clinical Trial Agreements [Member] | CS1 (MB-104) [Member] | City of Hope National Medical Center ("COH") [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MilestonesPayableUnderArrangement', window );">Milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember', window );">Sponsored Research and Clinical Trial Agreements [Member] | PSCA (MB-105) [Member] | City of Hope National Medical Center ("COH") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MilestonesPayableUnderArrangement', window );">Milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,000<span></span>
</td>
<td class="nump">107,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ReimbursementOfFeesTotalPayments', window );">Total reimbursement payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember', window );">Sponsored Research and Clinical Trial Agreements [Member] | PSCA (MB-105) [Member] | City of Hope National Medical Center ("COH") [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MilestonesPayableUnderArrangement', window );">Milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember', window );">Sponsored Research and Clinical Trial Agreements [Member] | HER2 (MB 103) [Member] | City of Hope National Medical Center ("COH") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MilestonesPayableUnderArrangement', window );">Milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">784,000<span></span>
</td>
<td class="nump">697,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember', window );">Sponsored Research and Clinical Trial Agreements [Member] | HER2 (MB 103) [Member] | City of Hope National Medical Center ("COH") [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MilestonesPayableUnderArrangement', window );">Milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember', window );">Sponsored Research and Clinical Trial Agreements [Member] | CD20 (MB-106) [Member] | Fred Hutchinson Cancer Center [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MilestonesPayableUnderArrangement', window );">Milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AdditionalMilestonesPayableUnderArrangement', window );">Additional milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,987,000<span></span>
</td>
<td class="nump">1,979,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember', window );">Sponsored Research and Clinical Trial Agreements [Member] | CD20 (MB-106) [Member] | Fred Hutchinson Cancer Center [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AdditionalMilestonesPayableUnderArrangement', window );">Additional milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember', window );">Sponsored Research and Clinical Trial Agreements [Member] | ST. Jude - XSCID [Member] | St. Jude Children's Research Hospital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508,000<span></span>
</td>
<td class="nump">865,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember', window );">Sponsored Research and Clinical Trial Agreements [Member] | RAG1 SCID (MB-110) [Member] | Leiden University Medical Centre [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MilestonesPayableUnderArrangement', window );">Milestones payable</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ResearchArrangementTerm', window );">Agreement term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 505,000<span></span>
</td>
<td class="nump">$ 170,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_AdditionalMilestonesPayableUnderArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional milestones payable under the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_AdditionalMilestonesPayableUnderArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_AnnualMaintenanceFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of annual maintenance fee payable under the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_AnnualMaintenanceFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ContributionTowardPatientCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contribution to be paid toward patient costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ContributionTowardPatientCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_MilestonesPayableUnderArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestones payable under the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_MilestonesPayableUnderArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_PaymentOfUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of Upfront Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_PaymentOfUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ReimbursementOfFeesTotalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents total payments for reimbursable expenses over the lifetime of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ReimbursementOfFeesTotalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ResearchArrangementContributionPerPatient">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contribution to be paid per patient under the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ResearchArrangementContributionPerPatient</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ResearchArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The term of the research arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ResearchArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ResearchFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of research funding provided by the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ResearchFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_MayoClinicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_MayoClinicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_Her2ProductOrProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_Her2ProductOrProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_CityOfHopeNationalMedicalCenterCohMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_CityOfHopeNationalMedicalCenterCohMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_Cd123ProductOrProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_Cd123ProductOrProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_Il13r2ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_Il13r2ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_Cs1ProductOrProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_Cs1ProductOrProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_PscaProductOrProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_PscaProductOrProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_Cd20TechnologyProductOrProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_Cd20TechnologyProductOrProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_FredHutchinsonCancerResearchCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_FredHutchinsonCancerResearchCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_StJudeXscidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_StJudeXscidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_St.JudeChildrensResearchHospitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_St.JudeChildrensResearchHospitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_Rag1ScidMb110Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_Rag1ScidMb110Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_LeidenUniversityMedicalCentreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_LeidenUniversityMedicalCentreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154996655776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Clinical Trial and Sponsored Research Agreements (Other - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 08, 2021</div></th>
<th class="th"><div>Apr. 01, 2021</div></th>
<th class="th"><div>Jul. 03, 2017</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,475<span></span>
</td>
<td class="nump">$ 49,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember', window );">Sponsored Research and Clinical Trial Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,989<span></span>
</td>
<td class="nump">6,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbio_FredHutchinsonCancerResearchCenterMember', window );">Fred Hutchinson Cancer Center [Member] | Sponsored Research and Clinical Trial Agreements [Member] | CD20 (MB-106) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MilestonesPayableUnderArrangement', window );">Milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AdditionalMilestonesPayableUnderArrangement', window );">Additional milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,987<span></span>
</td>
<td class="nump">1,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbio_FredHutchinsonCancerResearchCenterMember', window );">Fred Hutchinson Cancer Center [Member] | Clinical Trial Agreements [Member] | CD20 (MB-106) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ReimbursementOfFeesTotalPayments', window );">Total reimbursement payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbio_St.JudeChildrensResearchHospitalMember', window );">St. Jude Children's Research Hospital [Member] | Sponsored Research and Clinical Trial Agreements [Member] | ST. Jude - XSCID [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="nump">865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbio_St.JudeChildrensResearchHospitalMember', window );">St. Jude Children's Research Hospital [Member] | Data Transfer Agreement [Member] | ST. Jude - XSCID [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_PaymentOfUpfrontFees', window );">Upfront fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ReimbursementOfFeesTotalPayments', window );">Total reimbursement payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbio_MayoClinicMember', window );">Mayo Clinic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_PaymentOfUpfrontFees', window );">Upfront fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbio_MayoClinicMember', window );">Mayo Clinic [Member] | Sponsored Research and Clinical Trial Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MilestonesPayableUnderArrangement', window );">Milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AdditionalMilestonesPayableUnderArrangement', window );">Additional milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">968<span></span>
</td>
<td class="nump">695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ResearchArrangementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mbio_LeidenUniversityMedicalCentreMember', window );">Leiden University Medical Centre [Member] | Sponsored Research and Clinical Trial Agreements [Member] | RAG1 SCID (MB-110) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License, Clinical Trial and Sponsored Research Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MilestonesPayableUnderArrangement', window );">Milestones payable</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 505<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ResearchArrangementTerm', window );">Agreement term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_AdditionalMilestonesPayableUnderArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional milestones payable under the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_AdditionalMilestonesPayableUnderArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_MilestonesPayableUnderArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestones payable under the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_MilestonesPayableUnderArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_PaymentOfUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of Upfront Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_PaymentOfUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ReimbursementOfFeesTotalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents total payments for reimbursable expenses over the lifetime of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ReimbursementOfFeesTotalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ResearchArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The term of the research arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ResearchArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_FredHutchinsonCancerResearchCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_FredHutchinsonCancerResearchCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_Cd20TechnologyProductOrProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_Cd20TechnologyProductOrProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mbio_ClinicalTrialAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mbio_ClinicalTrialAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_St.JudeChildrensResearchHospitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_St.JudeChildrensResearchHospitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_StJudeXscidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_StJudeXscidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mbio_DataTransferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mbio_DataTransferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_MayoClinicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_MayoClinicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mbio_LeidenUniversityMedicalCentreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mbio_LeidenUniversityMedicalCentreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mbio_Rag1ScidMb110Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mbio_Rag1ScidMb110Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154990256784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Agreements (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 26, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Jul. 22, 2016</div></th>
<th class="th"><div>Mar. 13, 2015</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>item </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 04, 2022</div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common stock, shares issuable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,807,008<span></span>
</td>
<td class="nump">2,536,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_PreferredStockVotingRightsMultiplier', window );">Preferred stock voting rights multiplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mbio_RunwayDebtFacilityMember', window );">Runway Debt Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,320<span></span>
</td>
<td class="nump">68,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbio_AtMarketOfferingMember', window );">At the Market Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="nump">$ 71,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember', window );">Preferred Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issuable on conversion, per share converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbio_FortressBiotechIncMember', window );">Fortress Biotech, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses', window );">Percentage of annual fees expense related to Management Services Agreement recorded in research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses', window );">Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,952<span></span>
</td>
<td class="nump">576,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common stock, shares issuable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="nump">$ 71,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_StockIssuedDuringPeriodSharesIssuableForServices', window );">Common shares issuable recorded - Founders Agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_DilutedOutstandingEquityPercentage', window );">Percentage of fully diluted equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from related party transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_FoundersAgreementTerm', window );">Founders agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AgreementRenewalTerm', window );">Agreement renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Stock dividend (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement', window );">Paid in kind dividend, period prior to payment date for measuring ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_EquityFeePaymentPeriod', window );">Equity fee, period for payment after financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_EquityFeePercentageOfFinancing', window );">Equity fee payable in shares (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_CashFeeAsPercentageOfAnnualNetSales', window );">Cash fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_CashFeePaymentPeriod', window );">Cash fee, period for payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate', window );">Change in control fee, multiplier | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ChangeInControlFeeMeasurementPeriodForNetSales', window );">Change in control fee, measurement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ChangeInControlFeeSpecifiedRateComponent', window );">Change in control fee, specified rate component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AgreementTerm', window );">MSA agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_MsaAgreementRenewalTerm', window );">MSA agreement renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AnnualConsultingFees', window );">Annual consulting fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_IncreaseInAnnualConsultingFees', window );">Consulting fee when net assets exceed threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ExcessInNetAssetsValue', window );">Net assets threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbio_FortressBiotechIncMember', window );">Fortress Biotech, Inc [Member] | General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from related party transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbio_FortressBiotechIncMember', window );">Fortress Biotech, Inc [Member] | Class B Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common stock, shares issuable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbio_FortressBiotechIncMember', window );">Fortress Biotech, Inc [Member] | Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbio_FortressBiotechIncMember', window );">Fortress Biotech, Inc [Member] | Preferred Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_DilutedOutstandingEquityPercentage', window );">Percentage of fully diluted equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from related party transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">106,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AnnualConsultingFees', window );">Annual consulting fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_DirectorCompensationValueOfSharesGranted', window );">Value of shares granted as compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director [Member] | Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,664<span></span>
</td>
<td class="nump">13,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_DirectorCompensationValueOfSharesGranted', window );">Value of shares granted as compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_DirectorCompensationNumberOfSharesGranted', window );">Number of shares granted as compensation | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from related party transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="nump">$ 116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AnnualConsultingFees', window );">Annual consulting fee</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_DirectorCompensationValueOfSharesGranted', window );">Value of shares granted as compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member] | Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,664<span></span>
</td>
<td class="nump">13,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_DirectorCompensationValueOfSharesGranted', window );">Value of shares granted as compensation</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_DirectorCompensationNumberOfSharesGranted', window );">Number of shares granted as compensation | shares</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_AgreementRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time for which the agreement may be renewed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_AgreementRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_AgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The term of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_AgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_AnnualConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of annual consulting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_AnnualConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_CashFeeAsPercentageOfAnnualNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash fee payable as a percentage of annual net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_CashFeeAsPercentageOfAnnualNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_CashFeePaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of days after the end of the calendar year allowed for payment of the cash fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_CashFeePaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ChangeInControlFeeMeasurementPeriodForNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time for measurement of net sales used as a component in the calculation of the change in control fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ChangeInControlFeeMeasurementPeriodForNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The multiple applied to the product of sales and the specified rate, to determine the change in control fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ChangeInControlFeeSpecifiedRateComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The specified rate component in the calculation of the change in control fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ChangeInControlFeeSpecifiedRateComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_DilutedOutstandingEquityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of diluted outstanding equity paid as equity fee or used to calculate stock issuance to maintain parity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_DilutedOutstandingEquityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_DirectorCompensationNumberOfSharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares granted, or to be granted, as a component of director compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_DirectorCompensationNumberOfSharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_DirectorCompensationValueOfSharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The market value of shares granted, or to be granted, as a component of director compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_DirectorCompensationValueOfSharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_EquityFeePaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of days after closing of equity or debt financing allowed for payment of the equity fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_EquityFeePaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_EquityFeePercentageOfFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of equity or debt financing payable as an equity fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_EquityFeePercentageOfFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ExcessInNetAssetsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of net assets in excess of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ExcessInNetAssetsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_FoundersAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the agreement term with the founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_FoundersAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_IncreaseInAnnualConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the increase in the amount of annual consulting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_IncreaseInAnnualConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_MsaAgreementRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The term of the agreement renewal term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_MsaAgreementRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of days prior to the dividend payment date that the outstanding capitalization is to be measured.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual fees expense related to Management Services Agreement recorded in research and development expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_PreferredStockVotingRightsMultiplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The multiplier applied to shares of stock to determine the voting rights per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_PreferredStockVotingRightsMultiplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_StockIssuedDuringPeriodSharesIssuableForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issuable for services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_StockIssuedDuringPeriodSharesIssuableForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mbio_RunwayDebtFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mbio_RunwayDebtFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mbio_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mbio_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbio_FortressBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbio_FortressBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mbio_CommonUnspecifiedClassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mbio_CommonUnspecifiedClassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154997420416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2,723<span></span>
</td>
<td class="nump">$ 2,167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155000547568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Schedule of Property and Equipment) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 17,792<span></span>
</td>
<td class="nump">$ 16,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(8,401)<span></span>
</td>
<td class="num">(5,734)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 9,391<span></span>
</td>
<td class="nump">$ 11,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 370<span></span>
</td>
<td class="nump">$ 370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 8,632<span></span>
</td>
<td class="nump">$ 6,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 7,694<span></span>
</td>
<td class="nump">$ 7,694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Process [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 951<span></span>
</td>
<td class="nump">$ 2,027<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154998243408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accounts Payable and Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 6,833<span></span>
</td>
<td class="nump">$ 3,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ResearchAndDevelopmentCurrent', window );">Research and development</a></td>
<td class="nump">2,782<span></span>
</td>
<td class="nump">3,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_AccruedCompensationCurrent', window );">Accrued compensation</a></td>
<td class="nump">3,468<span></span>
</td>
<td class="nump">2,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Other</a></td>
<td class="nump">648<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued expenses</a></td>
<td class="nump">$ 13,731<span></span>
</td>
<td class="nump">$ 9,744<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_AccruedCompensationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_AccruedCompensationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154997565744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Oct. 27, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 14, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Leased area (in square feet) | ft&#178;</a></td>
<td class="nump">27,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_LesseeOperatingLeaseTotalBaseRentNetOfAbatements', window );">Total base rent, net of abatements</a></td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_LesseeOperatingLeaseTotalAbatementsOverLeaseTerm', window );">Total abatements</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_LesseeSecurityDepositUponFullOccupancy', window );">Security deposit, fully-occupied</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,946<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,918<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 1,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_LesseeSecurityDepositUponFullOccupancy', window );">Security deposit, fully-occupied</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_LesseeSecurityDepositUponFullOccupancy', window );">Security deposit, fully-occupied</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_LesseeOperatingLeaseTotalAbatementsOverLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total abatements for the operating lease over the lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_LesseeOperatingLeaseTotalAbatementsOverLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_LesseeOperatingLeaseTotalBaseRentNetOfAbatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total base rent, net of abatements, for the operating lease over the lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_LesseeOperatingLeaseTotalBaseRentNetOfAbatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_LesseeSecurityDepositUponFullOccupancy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of security deposit required when the facility is fully-occupied by the lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_LesseeSecurityDepositUponFullOccupancy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154996398048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Schedule of Operating Leases) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 565<span></span>
</td>
<td class="nump">$ 315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">488<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">$ 1,053<span></span>
</td>
<td class="nump">$ 914<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155003875168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Cash Flows) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 485<span></span>
</td>
<td class="nump">$ 484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term - operating leases</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases</a></td>
<td class="nump">9.10%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155004500448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Maturities of Operating Leases) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 14, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year ended December 31, 2023</a></td>
<td class="nump">$ 529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Year ended December 31, 2024</a></td>
<td class="nump">614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Year ended December 31, 2025</a></td>
<td class="nump">1,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Year ended December 31, 2026</a></td>
<td class="nump">1,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Year ended December 31, 2027</a></td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">5,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less present value discount</a></td>
<td class="num">(1,443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 3,946<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154998165648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 04, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 27, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Upfront fees</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 2,650,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,359,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Long-term note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,436,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mbio_RunwayDebtFacilityMember', window );">Runway Debt Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Long-term debt facility</a></td>
<td class="nump">75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Amount funded upon closing</a></td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Amount available under facility</a></td>
<td class="nump">$ 45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Advisory and legal fees</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued | shares</a></td>
<td class="nump">748,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.8021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_DebtInstrumentBalloonPaymentAsPercentageOfPrincipal', window );">Final payment as a percentage of original principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Final Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,614,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Long-term note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,436,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mbio_RunwayDebtFacilityMember', window );">Runway Debt Facility | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mbio_RunwayDebtFacilityMember', window );">Runway Debt Facility | Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of warrants assumptions</a></td>
<td class="nump">0.0174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mbio_RunwayDebtFacilityMember', window );">Runway Debt Facility | Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of warrants assumptions</a></td>
<td class="nump">0.573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mbio_RunwayDebtFacilityMember', window );">Runway Debt Facility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate floor (as a percent)</a></td>
<td class="nump">0.0925%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mbio_RunwayDebtFacilityMember', window );">Runway Debt Facility | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate floor (as a percent)</a></td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mbio_RunwayDebtFacilityMember', window );">Runway Debt Facility | Three month LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate floor (as a percent)</a></td>
<td class="nump">0.005%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_DebtInstrumentBalloonPaymentAsPercentageOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the balloon payment amount as a percentage of debt principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_DebtInstrumentBalloonPaymentAsPercentageOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mbio_RunwayDebtFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mbio_RunwayDebtFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154993062736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity (Common Stock and Equity Offerings) (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 24, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 04, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 26, 2016 </div>
<div>shares</div>
</th>
<th class="th"><div>Jul. 22, 2016</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 04, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 11, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 10, 2020 </div>
<div>shares</div>
</th>
<th class="th"><div>Jul. 13, 2018</div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Aggregate value of shares subscribed | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,109,000<span></span>
</td>
<td class="nump">$ 4,329,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common stock, shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,807,008<span></span>
</td>
<td class="nump">2,536,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbio_FortressBiotechIncMember', window );">Fortress Biotech, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common shares - Founders Agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,952<span></span>
</td>
<td class="nump">576,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement', window );">Sale of Stock aggregate offering price - Founders Agreement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="nump">$ 71,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_DilutedOutstandingEquityPercentage', window );">Percentage of fully diluted equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_StockIssuedDuringPeriodSharesIssuableForServices', window );">Common shares issuable recorded - Founders Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from related party transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Aggregate value of shares subscribed | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common stock, shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="nump">$ 71,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Stock dividend (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbio_AtMarketOfferingMember', window );">At the Market Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_CommissionRatePercentage', window );">Agent commission (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,900,000<span></span>
</td>
<td class="nump">19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.84<span></span>
</td>
<td class="nump">$ 3.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="nump">$ 71,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Aggregate fees of stock issuance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts', window );">Proceeds from issuance of Common Stock, net of offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="nump">$ 70,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbio_AtMarketOfferingMember', window );">At the Market Offering [Member] | Fortress Biotech, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,952<span></span>
</td>
<td class="nump">576,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbio_RegistrationStatementsMember', window );">Registration Statements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold', window );">Shelf Registration statement, value of securities authorized to be sold | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_CommonStockSharesAvailableForFutureIssuanceValue', window );">Shares available for future issuance - Founders Agreement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mbio_RegistrationStatementsMember', window );">Registration Statements [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold', window );">Shelf Registration statement, value of securities authorized to be sold | $</a></td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_VotingRightsNumberOfVotesPerShare', window );">Number of votes per share | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Fortress Biotech, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common stock, shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_StockholderAppointmentOfDirectorPeriodAfterIssuance', window );">Director appointment right, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845,385<span></span>
</td>
<td class="nump">845,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_VotingRightsNumberOfVotesPerShare', window );">Number of votes per share | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Shares [Member] | Fortress Biotech, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common stock, shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember', window );">Preferred Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember', window );">Preferred Class A [Member] | Fortress Biotech, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_DilutedOutstandingEquityPercentage', window );">Percentage of fully diluted equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member] | Fortress Biotech, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from related party transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_CommissionRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission rate on gross sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_CommissionRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_CommonStockSharesAvailableForFutureIssuanceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Shares Available For Future Issuance Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_CommonStockSharesAvailableForFutureIssuanceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_DilutedOutstandingEquityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of diluted outstanding equity paid as equity fee or used to calculate stock issuance to maintain parity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_DilutedOutstandingEquityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock aggregate offering price permitted by agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration statement, value of securities authorized to be sold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_StockIssuedDuringPeriodSharesIssuableForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issuable for services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_StockIssuedDuringPeriodSharesIssuableForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_StockholderAppointmentOfDirectorPeriodAfterIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time after issuance of the stock that the owners of that class may appoint the specified number of directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_StockholderAppointmentOfDirectorPeriodAfterIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_VotingRightsNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of votes per share of stock held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_VotingRightsNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbio_FortressBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbio_FortressBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mbio_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mbio_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mbio_RegistrationStatementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mbio_RegistrationStatementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154997438912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity (Equity Incentive Plan) (Narrative) (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 21, 2022</div></th>
<th class="th"><div>Jun. 17, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage', window );">Predetermined offering period, lower fair market value percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Number of shares purchased under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,462,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan, predetermined offering period, lower fair market value percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154997525072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity (Stock Options) (Details) - Options [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options rollforward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding, Number, Beginning Balance</a></td>
<td class="nump">1,141,675<span></span>
</td>
<td class="nump">1,141,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding, Number, Ending Balance</a></td>
<td class="nump">1,141,675<span></span>
</td>
<td class="nump">1,141,675<span></span>
</td>
<td class="nump">1,141,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options vested and exercisable</a></td>
<td class="nump">713,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning</a></td>
<td class="nump">$ 5.73<span></span>
</td>
<td class="nump">$ 5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending</a></td>
<td class="nump">5.73<span></span>
</td>
<td class="nump">$ 5.73<span></span>
</td>
<td class="nump">$ 5.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, options vested and exercisable</a></td>
<td class="nump">$ 5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Options outstanding (in years)</a></td>
<td class="text">4 years 3 months 21 days<span></span>
</td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
<td class="text">6 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Options vested and exercisable (in years)</a></td>
<td class="text">4 years 3 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155000548480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity (Restricted Stock Awards and Restricted Stock Units) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted stock and RSU rollforward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, Number, Beginning Balance</a></td>
<td class="nump">280,983<span></span>
</td>
<td class="nump">302,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">358,320<span></span>
</td>
<td class="nump">68,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(129,058)<span></span>
</td>
<td class="num">(90,001)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, Number, Ending Balance</a></td>
<td class="nump">510,245<span></span>
</td>
<td class="nump">280,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, Beginning Balance</a></td>
<td class="nump">$ 4.05<span></span>
</td>
<td class="nump">$ 4.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="nump">0.70<span></span>
</td>
<td class="nump">3.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested</a></td>
<td class="nump">4.89<span></span>
</td>
<td class="nump">6.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, Ending Balance</a></td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="nump">$ 4.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation recognition period</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted stock and RSU rollforward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, Number, Beginning Balance</a></td>
<td class="nump">2,335,557<span></span>
</td>
<td class="nump">1,468,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">1,484,647<span></span>
</td>
<td class="nump">1,660,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="num">(514,999)<span></span>
</td>
<td class="num">(372,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(816,518)<span></span>
</td>
<td class="num">(420,379)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, Number, Ending Balance</a></td>
<td class="nump">2,488,687<span></span>
</td>
<td class="nump">2,335,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, Beginning Balance</a></td>
<td class="nump">$ 3.27<span></span>
</td>
<td class="nump">$ 3.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="nump">0.76<span></span>
</td>
<td class="nump">3.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited</a></td>
<td class="nump">2.53<span></span>
</td>
<td class="nump">3.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested</a></td>
<td class="nump">2.98<span></span>
</td>
<td class="nump">4.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, Ending Balance</a></td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation recognition period</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154999142608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity (Stock-based Compensation Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="nump">$ 2,283<span></span>
</td>
<td class="nump">$ 3,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">1,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="nump">$ 1,583<span></span>
</td>
<td class="nump">$ 2,278<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154990206720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Stock Warrants) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 04, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mbio_RunwayDebtFacilityMember', window );">Runway Debt Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">748,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased', window );">Warrants received, as a percentage of common shares purchased</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning</a></td>
<td class="nump">3,308,654<span></span>
</td>
<td class="nump">5,402,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod', window );">Warrants, expired</a></td>
<td class="num">(3,003,770)<span></span>
</td>
<td class="num">(2,093,878)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ClassOfWarrantOrRightWarrantsGrantedDuringPeriod', window );">Warrants granted</a></td>
<td class="num">(748,036)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(138)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending</a></td>
<td class="nump">1,052,920<span></span>
</td>
<td class="nump">3,308,654<span></span>
</td>
<td class="nump">5,402,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="nump">$ 8.02<span></span>
</td>
<td class="nump">$ 8.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_WarrantExercisePriceExpiredDuringPeriod', window );">Warrants exercise price, expired (in dollars per share)</a></td>
<td class="nump">8.50<span></span>
</td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod', window );">Warrant exercise price, grants during the period (in dollars per share)</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife', window );">Warrants outstanding, remaining contractual life</a></td>
<td class="text">8 years 3 months 14 days<span></span>
</td>
<td class="text">8 months 23 days<span></span>
</td>
<td class="text">1 year 4 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod', window );">Warrants granted, remaining contractual life</a></td>
<td class="text">9 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of common shares purchased that investors received in warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights expired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ClassOfWarrantOrRightWarrantsGrantedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ClassOfWarrantOrRightWarrantsGrantedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants that were granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life for warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life for warrants granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_WarrantExercisePriceExpiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant exercise price, expired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_WarrantExercisePriceExpiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mbio_RunwayDebtFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mbio_RunwayDebtFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155004505456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details)<br> $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">$ 128,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,751<span></span>
</td>
<td class="nump">&#8364; 128.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Tax credits, expiration date</a></td>
<td class="text">Dec. 31,  2033<span></span>
</td>
<td class="text">Dec. 31,  2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Interest or penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_OperatingLossCarryforwardsWithoutExpiration', window );">Operating loss carryforwards without expiration</a></td>
<td class="nump">190,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">214,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Income tax credits</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_OperatingLossCarryforwardsWithoutExpiration', window );">Operating loss carryforwards without expiration | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">463,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Income tax credits</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_OperatingLossCarryforwardsWithoutExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_OperatingLossCarryforwardsWithoutExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxCreditsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxCreditsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the tax credit carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140155003908320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Effective Income Tax Rate Reconciliation) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal tax benefit</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible items</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent', window );">Federal tax rate change</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent', window );">State tax rate change</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Other</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(42.00%)<span></span>
</td>
<td class="num">(41.00%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income taxes provision (benefit)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic state income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140154992997152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Deferred Tax Assets) (Details)<br> $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryovers</a></td>
<td class="nump">$ 75,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock compensation and other</a></td>
<td class="nump">2,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDerivativeInstruments', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Amortization of license</a></td>
<td class="nump">13,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_DeferredTaxAssetOperatingLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">1,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves', window );">Accruals and reserves</a></td>
<td class="nump">1,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_DeferredTaxAssetsStartUpCosts', window );">Startup costs</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">15,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mbio_DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses', window );">174 Capitalization</a></td>
<td class="nump">19,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">129,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(128,101)<span></span>
</td>
<td class="num">&#8364; (128.1)<span></span>
</td>
<td class="num">(94,751)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">1,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right of use asset</a></td>
<td class="num">(1,085)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(390)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total deferred tax assets, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_DeferredTaxAssetOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax asset operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_DeferredTaxAssetOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to capitalization of research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mbio_DeferredTaxAssetsStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from start up costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mbio_DeferredTaxAssetsStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>tmb-20221231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mbio="http://www.mustangbio.com/20221231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tmb-20221231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_c0ZjuYLL-0CMEHMYhr3GFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_2F1anYHQf02jp38E63vSpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6zho2C1h60K0Lzm1bSUQng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_P9_Uj5uTOkOfoQ-1eRQEMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember_9MQl4Tri8UWaL1Az0682Pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mbio:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3jzMDFTC6Uqy-qcl2JQMLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nEUVoh_PAEuYAh0Emg965A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember_r-s7nx-j2UO579la2vbCYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mbio:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_d-YK2vIsoEm8XC9k2H7Q5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jHd2Q0o-XUCIA4E98EgSpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember_huCEWr5zL0mQORn1jbxA9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mbio:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_iXjE7NHXYk6rJeTAc6GwOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dcd2JnkRoUu5jv05PZ7fwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u6IrjKOtBU2wn6oRGZSpiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mbio:CommonUnspecifiedClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Ix8JVts4dk2Q4KuWLN5TqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5lfujqng8EmU7km7KzrW3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mjwCtJPi90OdodwExzzejw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mbio:CommonUnspecifiedClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Ph6XHuuiYE6eukhnqC2Btw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8o0VgKjajEeXToZHvyHFfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GA4yvT9zYUmgOsGKoFCnXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mbio:CommonUnspecifiedClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_wNo8mVO2kUeHFiMORHtB9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_4VC5ZPEVB0aXZyDJ1fjJtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_ywrnZ-GLAkqK0TW0rXu5xQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_7W5zr_ZJ8k6YRLAjbxG7LQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uj9LYQ994USIWcKdot_c7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_suZlLo8Guk2LmZMnsU9VMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bhwOXV7qmUa0T2YdE_tfkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LqmnL5gbTkS17IvEqtphGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PDcmO8zz3EqNXOXuFyL8PQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_21_2022_W87ewabwMUywhrCygGG9dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
        </entity>
        <period>
            <instant>2022-06-21</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BNRH5QbCykyPiw-RTmCPqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_17_2021_midR-jy3VUGn7KvHZ7QMZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
        </entity>
        <period>
            <instant>2021-06-17</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nrn5fFARI0iVnAb0sMWaVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UcqZY0RuLkm6-uv8PCh07w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="Duration_6_21_2022_To_6_21_2022_9w7Pc3dMn0il-0WAUszkjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
        </entity>
        <period>
            <startDate>2022-06-21</startDate>
            <endDate>2022-06-21</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M2BLxvwBtUun2VN6YRNObQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_17_2021_To_6_17_2021_sehtwXsjPE6k3If_-5V-TA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
        </entity>
        <period>
            <startDate>2021-06-17</startDate>
            <endDate>2021-06-17</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MqmksIdNjkaWP_ipa9CSuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2aMeSdhNi0a4ZRzBQ7A_hA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4LOmmgimP0ClUtAdOe4haA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_KeRs2NdINE-YRgyA7zQiQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_3-kS7FRDbkqpKxd-4hKdeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2-wAsbb-T0KYD16SQuYxKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_Pd10hdVFnE2rD6DyKQmoRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_3OyJzUMtO0ym9UWFHhhAZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_B0vAXreZfkCUTZAJG1tYDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_XfkRl6mfqE-N6Ds1xMxrbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_9jVcGwYOxUu69mDgzJJD-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_O3YYPIPGzE-eJsI9zpkIKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nMMb4QwZpE2wkHPBjsoMzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-LQvQ6gJ9UOk8vXKCNkxng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_f1ddUvO4v0amvOZiXCEDeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-mQVcy5AFUC0fcnvfp5yUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_uHyqiEuP_0ekgE-jQl3slQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_27_2017_us-gaap_ShortTermDebtTypeAxis_us-gaap_LetterOfCreditMember_k9atZnNjs0aax30iY_FCJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-27</instant>
        </period>
    </context>
    <context id="As_Of_10_27_2017_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_n1UsR7h740ijw5e4ONDTcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-27</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_WndiQxEyWkK5zt6u8QU19g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:St.JudeChildrensResearchHospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:StJudeXscidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_DataTransferAgreementMember_-H0TdacBZkabwWvQhfMbVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:St.JudeChildrensResearchHospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:StJudeXscidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:DataTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_srt_ProductOrServiceAxis_mbio_Rag1ScidMb110Member_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_JHL0mUan5USsk0GX6mP-bA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:LeidenUniversityMedicalCentreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Rag1ScidMb110Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_AHlPXFWbm0S4f23bwODBgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd20TechnologyProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_ClinicalTrialAgreementsMember_Cyw5EJBd1UirM-BcQ7nr3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd20TechnologyProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:ClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_LFLvm316o0SOUKQxhoo0Mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:PscaProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_GJMbltW_ckGM-82fZ6QN9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Il13r2ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_nzRdZgaBgkaKZuJTpHtWXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Her2ProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cs1ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_OpIS0Aptykyt0fbMp5ngcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cs1ProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_flIxGqK8EE-qTKhiUM7P5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd123ProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_A95Rt4-jPk231qSpo9U-FQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:MayoClinicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_hRHdDMHNcUuPmSQBOPtXWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_aP7yNOKuS0aTGB-ItbnSAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Vx1emwLJJ0qXsajS4OcXww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_QpA72oZJUkisoiKeboPylg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:St.JudeChildrensResearchHospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:StJudeXscidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_DataTransferAgreementMember_3BooSMscyEWc_UdmNkhn6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:St.JudeChildrensResearchHospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:StJudeXscidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:DataTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_srt_ProductOrServiceAxis_mbio_Rag1ScidMb110Member_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_KgtU9Mq_mkeeWrJ3yEjrEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:LeidenUniversityMedicalCentreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Rag1ScidMb110Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_g-WN3OcgMk2PMIpOmGZ7LA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd20TechnologyProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_ClinicalTrialAgreementsMember_IjKtndA3yU-D5J-KXPKfPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd20TechnologyProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:ClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_VrwnpcakNUyyqsooiwPWOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:PscaProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_7XG-WubxyUykOLnPy8K1fQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Il13r2ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Avzs-VjlYkyzUP2irGzjQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Her2ProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cs1ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_-91cVSuwk066vgPNrl9tAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cs1ProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_1tC8VQmSzUSfIFLGkJX9ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd123ProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_G3TY0ZFyQk2j7jey4doOng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:MayoClinicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_KBjGOoU-1UiBWoztZE_WAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_0NxXjiJgYkGL9rgKRUKG0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_ycCeI3y-e0qyb7nr_-5MKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_FortressBiotechIncMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_3Vh1oZCe0keLsUyEjlCcKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_2GiFSZkrMEqa7kSRo1sWhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CalimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_bEUyP985oUaHNsVrsVxqYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_eqbNchRq0EKHKjmh0pCfeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd123ProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_DB6MYEz08kyNAf6LM9F59A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:MayoClinicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_FortressBiotechIncMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_qumY3pBwC0W2YfvPR7QXUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_-IXYKwdDrEqLg2blggBbbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CalimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_5I7r1d0H1kGd9E-MDAoc_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_ovDgDz0emEyMvZmp-YeELg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_RtpzWYx2kkuP6Pk7yZGiGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_6e_cd9xdR0OP-rJ8ATzk6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_FkxuDW2Odkq2TbRXzOUOkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_T6pbjl0HIEm0W7ow_5z-_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_v472pPJ0CkuqygxI_ittBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_AS2adTFum0q5lSDBbT43Cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_j5ZGnmb0UkuRYKuYvgYNtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_pzjG98ud8EGdrioXB-jwgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_aWcNk9ygQEOJpQSfWskFEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_reL4xpHEp06WZ3lLttoTLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_cTxrSq0IxUy5wwF9bj3Hhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_iCbMYI4KcESBEVBhm0Im-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_RjfDOebswEyLEhoZaNQWKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_z9Vf3QpPF0qO9yFxyz7P_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_6Mr5lfEhb0CpRxTW-j7sxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_e_acjS35Ukyn5P8Fy-MCGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_PcX9JsuOWUyJsrrbJM84DA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_wsvscCuqjEmydGhY6i4new">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_43U4KPxs6ESx8ledMlKHrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_v_0gsNjsdE2RcPa-Xt5feA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_4_2022_To_3_4_2022_8OXg7asOjUiUzJte247ykw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
        </entity>
        <period>
            <startDate>2022-03-04</startDate>
            <endDate>2022-03-04</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_9h_ihuTMpEGBputHFvfCaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_xeewYyKVAEu67ngPqUXP6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_14_2022_cTRV0HCiCkWfQ2PRR9auPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
        </entity>
        <period>
            <instant>2022-06-14</instant>
        </period>
    </context>
    <context id="As_Of_10_27_2017_r9_PBUxiKU6CIeyMRHqr4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
        </entity>
        <period>
            <instant>2017-10-27</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_sJ_f6Z0h_0mK2WrP7jFDCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_N3FmWahfpU6FVAV3nHsrgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_4_2022_To_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_eHP0c1pt2kC8bNXFkSVznw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-04</startDate>
            <endDate>2022-03-04</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HKp1HVK3rUeH2BUSicO2mA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_UPMzzbZe7UyasqVciLqSTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_GOVpc9dkuEG97uEvmowlTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_oh5GT7S9BUWgIrXyvuqlaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BbA2PkmH4kSDxqPMhK8S-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_4_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Q6BCOUH2V0CcXWJkApNHug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-04</instant>
        </period>
    </context>
    <context id="As_Of_3_4_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_mwjdn5zoKEerGWdy4baTKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-04</instant>
        </period>
    </context>
    <context id="As_Of_3_4_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_2HYX_b8YJ0uKkR4UevRidg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-04</instant>
        </period>
    </context>
    <context id="Duration_3_4_2022_To_3_4_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_IRsNQ3FWukSyey7fSJ4NbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-04</startDate>
            <endDate>2022-03-04</endDate>
        </period>
    </context>
    <context id="Duration_3_4_2022_To_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_sRafw2Y-jEiKjW4bMgII8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-04</startDate>
            <endDate>2022-03-04</endDate>
        </period>
    </context>
    <context id="Duration_3_4_2022_To_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_85Vphemizk-HydOGFNSOgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-04</startDate>
            <endDate>2022-03-04</endDate>
        </period>
    </context>
    <context id="As_Of_7_26_2016_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_zbvdgNhN6kuygnfc4J47nA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-07-26</instant>
        </period>
    </context>
    <context id="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_joFxX9w_pkCt5C4GrtBlWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-26</startDate>
            <endDate>2016-07-26</endDate>
        </period>
    </context>
    <context id="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_VBMwjqeRtEqCOPPRYyGFBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mbio:CommonUnspecifiedClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-26</startDate>
            <endDate>2016-07-26</endDate>
        </period>
    </context>
    <context id="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_u-nK5IHLB0it8Ss2uDQLIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-26</startDate>
            <endDate>2016-07-26</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_HIeb-wz9Kk2lMUL_e8y1xA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_YEp120A29kC8SaLYOW75aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_5_Je6tCozUqMRQF6TTTr9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_ReacBf4ACUWv_pBx9hfasw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_BIGXGDitnk-RSc92qeeFPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mbio:CommonUnspecifiedClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_3yAsLCGyT0KK9PpF59rSlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mbio:CommonUnspecifiedClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_M2XrEHX5oEeqe8nYvunwDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_4_2020_xrfudyC3YkytVOGquusxcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
        </entity>
        <period>
            <instant>2020-12-04</instant>
        </period>
    </context>
    <context id="As_Of_11_10_2020_pVBK-Ciss0-dnXh6zSgmjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
        </entity>
        <period>
            <instant>2020-11-10</instant>
        </period>
    </context>
    <context id="As_Of_11_11_2020_jFP6QSBqjkOBLq38js8Gqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
        </entity>
        <period>
            <instant>2020-11-11</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_qB-ZO8R0_ESmBgqQbpsWbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-04</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_hD2Rfx-DxkuN5TyT5ipjDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_cSWJg5CHcU6I0x0JrwnJzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_Jb9gSnd2k0CKnqyK9MTFMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_rZrGkA6BLUa3b3OQehnYJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_dvSvij2w6keF_tXo9314yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_jj2nVe7aqU6w_0C3fUd4mA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredClassAMember_fKYAiDFShUe0rn_iP9LuDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ycveH83leUebYfW_8jtr1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_0k_G4cx5Y0ap-y77lBqB_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_-StlwZNLwUqM0yBk4WhqVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_3jPgbp30DEyg4u1vnCNMRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredClassAMember_VD6cIIAU5EO3zkHQr1i38g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_HTuh90RZrk-KPSURpslalg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_uNZ1QlhL30egiHID6foBSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_UgDuCoveakiyI_k2GGguBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_dXkI_XX5XU-PKFM5auvM3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_EPmjxn4_W0OhVeeDC0iTvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_36vrF-2gf0O3kUT4Pd1TLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember__24V726k9U-PKRzgLSlEoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mbio:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember_FipD5R7ULEmGI252vfGJvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mbio:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_ck0wt0THlEGynuJiicHJLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_24_2021_To_5_24_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_mbio_RegistrationStatementsMember_uT0i13PYeUesod3TAzOW4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:RegistrationStatementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-24</startDate>
            <endDate>2021-05-24</endDate>
        </period>
    </context>
    <context id="Duration_12_4_2019_To_12_4_2019_us-gaap_SubsidiarySaleOfStockAxis_mbio_RegistrationStatementsMember_t--jUxfLC0e7u7XptCY16g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:RegistrationStatementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-04</startDate>
            <endDate>2019-12-04</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_m9J360WMFk65TIBgOb6HfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_11_1_2022_To_11_30_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_J2PMFy7590ayhjU1Z1lmBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Il13r2ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_DataTransferAgreementMember_jXidwRe_gUC02_iRlrhLpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:St.JudeChildrensResearchHospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:StJudeXscidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:DataTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_ClinicalTrialAgreementsMember_rf7xSABuqkO4KGuRWtqIrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd20TechnologyProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:ClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_cspaXnUxZku0Ws6QbCLXDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:PscaProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cs1ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_EPbH-hiMk0qoLFPq4Tyodw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cs1ProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_AbCiEvU7_0uU3dzq5HkUFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Her2ProductOrProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_gFhn3tpHy0eOhnDxAPc2tQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_aoFLNFn800q4su8jbp-MXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_26_2016_To_7_26_2016_e467LFs_GEmfW2lDVRZA9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
        </entity>
        <period>
            <startDate>2016-07-26</startDate>
            <endDate>2016-07-26</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_MMf1jaQkGEia07UBzms6Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:MayoClinicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_ecAzAIw_WEizUmdbx34e8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:LeidenUniversityMedicalCentreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_4_1_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_agKp6cvBpEy4-mIqOjcSeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:MayoClinicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-01</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_DataTransferAgreementMember_eFtEz1VOwUqbB4jKDO66nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:St.JudeChildrensResearchHospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:StJudeXscidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:DataTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_Q8BOscMl8U2O76Uoh4fs0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_QcfoZ3MG8ECfgSVpuDaKmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_eypHnY-B1U6jSlIjModjUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:PscaProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_IvIcvProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_HiZjKumNT0SZKUFTzFtdpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:IvIcvProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_-Awulcu8EUuW8KUUEOHfpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Her2ProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_X-M3RGE5aUmOLFk49REASw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd123ProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_5UGfc7o3YkaygLrJClTgXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:PscaProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_IvIcvProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_cGzyMH7f9k618wUdJrWh1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:IvIcvProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_h2tn3x-z7UuAoS7r_ftqoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Her2ProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_S6NInTxBvUmnCq_IJxa26g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:LeidenUniversityMedicalCentreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_8_2021_To_9_8_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_srt_ProductOrServiceAxis_mbio_Rag1ScidMb110Member_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_PDhxhJes-E2hyBDbO6sjlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:LeidenUniversityMedicalCentreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Rag1ScidMb110Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-08</startDate>
            <endDate>2021-09-08</endDate>
        </period>
    </context>
    <context id="Duration_9_8_2021_To_9_8_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_8Z3KAV2B-EeZv3xSHR1e1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:LeidenUniversityMedicalCentreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-08</startDate>
            <endDate>2021-09-08</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_DEvYfskaDUCi1Vhldrs8yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:MayoClinicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_wJVqrbyFSU-cHpd2pZX10g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:PscaProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_z0SUrOJETEa8go8i01WkEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Her2ProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_brP4CCoYMUKzdsYDsNVEpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:PscaProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_RkSGNTQj7kufffNWRIAKsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Her2ProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cs1ProductOrProcessMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_-VT2Q3jlP0OWPKoY-Ng3pA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cs1ProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2019_To_8_23_2019_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_GZks_7XceUyp2L41ZnWzfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CalimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-23</startDate>
            <endDate>2019-08-23</endDate>
        </period>
    </context>
    <context id="Duration_7_3_2017_To_7_3_2017_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_CcHvzBIXtUODWCVXYAQe_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd20TechnologyProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-07-03</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_ejb848nGTkG3ypqRxMLthA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd123ProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="Duration_10_27_2017_To_10_27_2017_us-gaap_ShortTermDebtTypeAxis_us-gaap_LetterOfCreditMember_Gwgp6OjA0kOhW6E5eRzqQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-27</startDate>
            <endDate>2017-10-27</endDate>
        </period>
    </context>
    <context id="Duration_10_27_2017_To_10_27_2017_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_-idbFc98Ukq2mFPsFZldJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-27</startDate>
            <endDate>2017-10-27</endDate>
        </period>
    </context>
    <context id="Duration_10_27_2017_To_10_27_2017_HaJc4KkwbUyd0LOp2-MkEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
        </entity>
        <period>
            <startDate>2017-10-27</startDate>
            <endDate>2017-10-27</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_D02sY_Okb0CAJr_sq1tImg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_bPmhKby7TEaZLqjV9yAiFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_uAr0vqstK0m70EJhq9vZvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_-GelVT3xVkGWE0zhcvX2PQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_ot8OBmwnOUaS1sRIHVm7tQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_1_1_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_eGnJ3TUB8UOJx8iUju7dfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_Trkkxq84fU-Vd0RoRhj2NQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_22_2016_To_7_22_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_FiUSuj1xYkGpO1xt7_NOcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-22</startDate>
            <endDate>2016-07-22</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_9uDXLFrQfESucUVU2dbSlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mbio:RunwayDebtFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2yJrJPxhE-PPwrFE9SShQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mbio:CommonUnspecifiedClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Qj0QYtgKVEW8_VkZm7xUBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Il13r2ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mbio_RegistrationStatementsMember_MnKy-ABZ70yPMHS_OgN4rA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:RegistrationStatementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_13_2018_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_Xdsmbxo8fkiq_m6mzNm0Bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mbio:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-13</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_YQ4fUCukB0WFke0KueexQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_zwcEeJiJR0GMOVhFZZp5MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_tpnhJWDO60OMRtanSOx5tQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_4_1_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_M1lvnrfyyUG8MMd-TFM3OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:MayoClinicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-01</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_3_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_te1_6uZCuEC4P4P0W1cmfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Il13r2ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_SW1jOKKvIUWxGq9g6tUp4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Il13r2ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2017_To_5_31_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_jWZU2RYRvEei-C0QMO7buA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:PscaProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2017_To_5_31_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_OhC3qwHZBUG5jIk8E5CveA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Her2ProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_IvIcvProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_kFOATtbMhEW9Vm5Z1U3trQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:IvIcvProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_GxvcEL9tsUGqvDvu2x4erg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:CityOfHopeNationalMedicalCenterCohMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd123ProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:LicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_sT3IETb4eUa_bTIM6c1joQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_1_1_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_lbdL7OiZrk-lt4FN-gg-bQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-01</endDate>
        </period>
    </context>
    <context id="Duration_3_13_2015_To_3_13_2015_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_-NQvGLrolUaisD4xkEP_SA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-13</startDate>
            <endDate>2015-03-13</endDate>
        </period>
    </context>
    <context id="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_jIA82Zn-S0-9OoqzDzR2cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mbio:FortressBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-26</startDate>
            <endDate>2016-07-26</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SQivjg3JZ0yfjAKfVkr_KQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mbio:CommonUnspecifiedClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WOYfueKSEuJAaVfesRtjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_10_31_2022_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_9mu0h1oYPUqhtCqCC9mKMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:MayoClinicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_HChGYU6CSUCiuMb3wOIWmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd20TechnologyProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_k8cUiopjJ0W74a5rURwE8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd20TechnologyProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_nx8c3dUXCUmIniCJJw81FQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mbio:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mbio:Cd20TechnologyProductOrProcessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mbio:SponsoredResearchAndClinicalTrialAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_8nk8OUv3G0CRBbh3Nuc4og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_27_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_JXLkfa12nEiwk3gGcQcdqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-27</instant>
        </period>
    </context>
    <context id="As_Of_3_27_2023_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_75GhEhbAEUClw7KGwNGhqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mbio:CommonUnspecifiedClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-27</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680048</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_e-lAqZ63ukC9AQjaK0X33Q">
        <measure>mbio:item</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_Milestone_13Bi5jCZBUqZT3I2C4rjww">
        <measure>mbio:Milestone</measure>
    </unit>
    <unit id="Unit_Standard_EUR_rzel3jVa2UO3kiVSQxNNcA">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Standard_sqft_8yS2Dc-QmU2gfsdczKLSrA">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Standard_segment_8GyIjrAsdkK2LxrNi5qQyQ">
        <measure>mbio:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      id="Hidden_7XjSGVwEtk2CuWBMSYQjOg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      id="Hidden_awZt3Z56oUmD0yofqLai0w"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="2"
      id="Hidden_MmSsXYvO_kGoOGgbOrT66w"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">-0.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="2"
      id="Hidden_2XIc_zKVEUGsQyadfYD1gw"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">-0.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="INF"
      id="Hidden_2GiD55UiyEGxwjX0WVPE1g"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">103432603</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="INF"
      id="Hidden_7cZKxgNXyEG0KfG_SPCIQQ"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">87885235</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_BIGXGDitnk-RSc92qeeFPA"
      decimals="INF"
      id="Hidden_L5SONMef_0GOhhJFfDk_NQ"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">106501663</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_3yAsLCGyT0KK9PpF59rSlw"
      decimals="INF"
      id="Hidden_dBSj86xc7EiE_66a4c2vDA"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">93582991</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_M2XrEHX5oEeqe8nYvunwDw"
      decimals="INF"
      id="Hidden_YVWlHF6eLkOniJMd6anGKw"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">845385</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_ReacBf4ACUWv_pBx9hfasw"
      decimals="INF"
      id="Hidden_phGJeN8v4UuHhZLTTL6YTQ"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">845385</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="INF"
      id="Hidden_1DzwVi4TWE68-iARaVzCtQ"
      unitRef="Unit_Standard_segment_8GyIjrAsdkK2LxrNi5qQyQ">1</us-gaap:NumberOfReportableSegments>
    <mbio:OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement
      contextRef="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_jIA82Zn-S0-9OoqzDzR2cg"
      id="Hidden_t6gbwtw4fkmKVT_BgWRqSA">P1D</mbio:OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement>
    <mbio:EquityFeePaymentPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"
      id="Hidden_IKJI1MNkyk-jVARLuqEz6w">P5D</mbio:EquityFeePaymentPeriod>
    <mbio:CashFeePaymentPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"
      id="Hidden_ZlvSq5CKKECYsdUUYJlnYw">P90D</mbio:CashFeePaymentPeriod>
    <mbio:ChangeInControlFeeMeasurementPeriodForNetSales
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"
      id="Hidden_oihncYEzmEirIm889SKJsg">P12M</mbio:ChangeInControlFeeMeasurementPeriodForNetSales>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="INF"
      id="Hidden_23K9Zas0OUqKcdKbwAuUMA"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">250000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="INF"
      id="Hidden_qU_s14xtUkCy1Qbwy6s6qg"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">250000</us-gaap:PreferredStockSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tc_3tyj7A9PHEml-4WjdnG0cA_2_1">0001680048</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tc_xyQzhPEGVUC4hOH-TAT_NQ_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tc_opG9MqYB1EakAIpDrTWezw_6_1">false</dei:AmendmentFlag>
    <us-gaap:TaxCreditCarryforwardExpirationDate
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Hidden_RuW2aDq3XEWNv2WtYazZ1w">2033-12-31</us-gaap:TaxCreditCarryforwardExpirationDate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_14_2022_cTRV0HCiCkWfQ2PRR9auPA"
      decimals="-5"
      id="Hidden_hD18g_F6S0Sosw_qw-16ow"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g"
      id="Hidden_yUFWycn0fk-azymq7ugG3A">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_F_fd_x6kNEWvNMtCVQKY_A">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_kJsjsWefZE2A6oMsIAcqRg">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_5ItsmhV_aE2KjesI-WLhHg">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_WyT_4bOZv0uEtKhaKsCpTw">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_qS1qWVheBkKEo8_0oG3FNA">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_lku40AJoBku-2fckKjTxfA">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_BiF027XimkKmtqPGNeS8HQ">001-38191</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_cV80-UnYdEm-o4dEk2MxUQ">MUSTANG BIO,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tc_HIhI-L_EdkiB5_kiwK70ZQ_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tc_9ZnyF1m_kUahd-IKAqPy0g_0_1">47-3828760</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_ExTUyqyovEe2HdI4D4Pd4w">377 Plantation Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_cE5N-vo8Lkat3fx8D6ynpg">Worcester</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_HlYdtZs0bki-rwhQxH_bFQ">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_DHXCPetnZEiKVQ3g-TQjpQ">01605</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_i0j8VpzElk-yLR5s7B0rnA">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_6eJGIk5wAUWL7O3kgNs0xw">652-4500</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tc_NiD7Z1W1rEGht3A_x8hHQg_1_0">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tc_OIlWVFELz0mkezH31dOrzg_1_2">MBIO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_PnCAt8mlHEKe6tPmELpZnw">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_riV5baDhGU2qfmGM6HG-tg">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_fOp3ODn1iUWsOAUsJ6uuhw">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_xSNO90xVRUuoj0mGi2l-ig">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_uPTTXnLll0y9WgoB5taaDA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tc_DINCo6vQA0uxDhZjGGLmdg_1_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tc_vEsF_90BAUWlhFtUUYlRmA_1_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tc_FBn5PIIJW0qlDuMXNHMvRg_2_1">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_nhHDpCsS7ESzWsfcCwK3KA">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_jXemJl_nwU2KArHxEaKNLg">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2022_8nk8OUv3G0CRBbh3Nuc4og"
      decimals="-5"
      id="Narr_-ErPSfezcEOsxqaZ7IGQbA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">48800000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_27_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_JXLkfa12nEiwk3gGcQcdqg"
      decimals="INF"
      id="Tc_vdr6NGjslkGFWkp4nqepwQ_1_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">845385</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_27_2023_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_75GhEhbAEUClw7KGwNGhqA"
      decimals="INF"
      id="Tc_m0uv5SJS00WqFdqWVtMrRA_2_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">109398635</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_nmNVofHJTE66_TVQ7YJt8Q">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_TK5VM7TbjEOcOWH13ZtVBQ">New York, NY</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_OgjzF29ZV0mB6ajHscVmsA">185</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_qiMrppNFzkiIx-Ks68w_yw_6_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">75656000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_8m-jZ_8FoUac1nlmf6rEBQ_6_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">109618000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherReceivables
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_OQzhIkmjp0uu3W_y3VoiZQ_7_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">36000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_J0VHU4hV20SL9KsC7tzMFA_7_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">50000</us-gaap:OtherReceivables>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_cYh1AWMtOkujS-kWiiztPQ_8_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">3160000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_HvMIaEee_k2jCNggwoEG8A_8_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2038000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_CUPVNzb690CvdUprfwT0zQ_9_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">78852000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_5R3l8eBvEkqogcIjdJvmfQ_9_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">111706000</us-gaap:AssetsCurrent>
    <mbio:PropertyPlantAndEquipmentExcludingAssetsUnderConstruction
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_F01KzI6ttUWzCNfFIKUF2A_11_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">8440000</mbio:PropertyPlantAndEquipmentExcludingAssetsUnderConstruction>
    <mbio:PropertyPlantAndEquipmentExcludingAssetsUnderConstruction
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_OE6O5qnm_0-c3CY3MwOdLg_11_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">9025000</mbio:PropertyPlantAndEquipmentExcludingAssetsUnderConstruction>
    <mbio:ConstructionInProcessNet
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_gtNCma0c6kK8aIydTUR-0A_12_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">951000</mbio:ConstructionInProcessNet>
    <mbio:ConstructionInProcessNet
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_X_1kMParOkmEmcKHhcNtaA_12_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2027000</mbio:ConstructionInProcessNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_FNtiMbfL20aTPDBjPL_4ig_13_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_KeoVsz5Z4kmXfgkeKJqOcg_13_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_QCvtjU4qWUuoMKbVGDDB5Q_14_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">261000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_o6kYT4a17UK2xRcFYsfUcw_14_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">362000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_8XVgONAM_kCimBXZCNVv_w_15_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2918000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_850cSfEa40WteNDaliMnpg_15_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1050000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_fORf4rMhvEiQJ1K30UQnCg_16_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">92422000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_fFVn8SSfpUq_5wfN3DC9OQ_16_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">125170000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_Cc-0zLFBW0GWQ3RKGn5FZQ_20_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">13731000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_p3jajKm1oEyjtMSrcmZbwQ_20_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">9744000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_YWwFFJCpjEqOlyIiMVmQjA_21_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">766000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_fYfGnsuGgEemQcp245iMEA_21_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">723000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_ZToHyfMIRUK47JbqOzU6ZQ_22_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">612000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_qv11gi57xUaLeXxr0LIGPg_22_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">348000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_iaZfWXJ-8UGg8yuT3V4Pyg_23_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">15109000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_307NktlIl0GfUoOwssRkRg_23_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">10815000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_nGucO7vXYkifZdTXf-JiEg_25_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">270000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_9PZYn639lEWuAIkcMf9VLg_25_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">270000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_OsODKx5KLUu0pp8rjDhqcw_26_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">27436000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_QLHda2HAa0-5aHbo5NjmVQ_26_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:LongTermNotesPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_73KKLZvreEKW6z20E_dc-A_27_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">3334000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_ViAl26VbcE2u11aTBkqisw_27_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1685000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_NqFbUEPBs0-mVyEzB3yJDA_28_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">46149000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_Gue22P8LtkyD91RBsSEPyw_28_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">12770000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="INF"
      id="Narr_WKP7Q3v1wUSrd4t-1BFMZQ"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="INF"
      id="Narr_va5mLWwmokm0YaIxmfhV4g"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="INF"
      id="Narr_6Mp0dYv7uEy8ktOtvnslgA"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="INF"
      id="Narr_BRc68n6JCUamIOP5b1bRwQ"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="INF"
      id="Narr_CHGLg15_yE2G093IdhRBtw"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">250000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="INF"
      id="Narr_6IToXjxU2U2fQwdAiV-uZA"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">250000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_EaSCp0s-8k6--PTxukq-fQ_33_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_ngBpj8l58U-nvSZ_0sR89A_33_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="INF"
      id="Narr_53IohRq9x0C8fuHrB4iq4A"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="INF"
      id="Narr_QL4d7A1BiUaZj2cTTsHQ5A"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="INF"
      id="Narr_tg_qxhZhBEezx9KyRaHdUw"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="INF"
      id="Narr_yZLcIb_JCk64hOgtlYroyQ"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_M2XrEHX5oEeqe8nYvunwDw"
      decimals="INF"
      id="Narr_F9jqhyB12UiqkovNsGNJ0w"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">845385</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_ReacBf4ACUWv_pBx9hfasw"
      decimals="INF"
      id="Narr_HGm-eFvm40KqP0r-CLUMDA"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">845385</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_ReacBf4ACUWv_pBx9hfasw"
      decimals="-3"
      id="Tc_dVlGiN9F-UKOQVf4R8WOcA_35_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_M2XrEHX5oEeqe8nYvunwDw"
      decimals="-3"
      id="Tc_zN29-B-ixEulXZcb_iDOgg_35_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_BIGXGDitnk-RSc92qeeFPA"
      decimals="INF"
      id="Narr_gRd9DbhL0EC3qSGTP9I1Xw"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">106501663</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_3yAsLCGyT0KK9PpF59rSlw"
      decimals="INF"
      id="Narr_8eySpywH5kmc6iWqAhzRCA"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">93582991</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_BIGXGDitnk-RSc92qeeFPA"
      decimals="-3"
      id="Tc_gXHRM8BKXU2Fk36R6uNImQ_36_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">11000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_3yAsLCGyT0KK9PpF59rSlw"
      decimals="-3"
      id="Tc_hWF4MEUmeUagl_j56YVGOg_36_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">9000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="INF"
      id="Narr_XBip9-ljCUGrT9CYWsvWVQ"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">2807008</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="INF"
      id="Narr_vbltne6aCEi-bYOskIwowg"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">2536607</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_vqyO_a8rU0WOUs_hJOKbag_37_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1109000</us-gaap:CommonStockSharesSubscriptions>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_SOQaQ2Ss4UW6BEFGB-5uFw_37_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">4329000</us-gaap:CommonStockSharesSubscriptions>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_NKD-_lZwVUaI350HC--tNQ_38_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">374522000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_GZsXXPYIGkOts0RrnPw01Q_38_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">359906000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_Y4b9tDxjl0KRu1Nu023n1w_39_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-329369000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_3yRDd4RgTEWFR6IxC3Z3ow_39_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-251844000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_xljOFWbjakSbs4zoR0ILeg_40_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">46273000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_RHYatvNgrUG3FNjROYFx4w_40_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">112400000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_AxgqDBV0ZEyG_K3HdZQOLQ_41_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">92422000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_O_MKj_vcVEKjbMKJL8El-A_41_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">125170000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_2ZBI4HNwvkKq_RVzim1JaA_4_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">62475000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_Knh48dOsq0K5fXrUcQbu1A_4_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">49864000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_IvG8XtBgekaP4cgBE4ua8A_5_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1474000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_tLHQ5Pm_UUG0h9n9RjQcQw_5_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">5842000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_XQrft5DoKku5cm7aZVK5qA_6_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">12210000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_i5T04jriskG7R0ApIgnD6w_6_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">11017000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_wA-3620CyU-RPGjsEKai3A_7_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">76159000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_qzOXb7WTu0iSy__i-ni-iA_7_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">66723000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_tFisi56v90u5BjHef_rdCw_8_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-76159000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_Cu1q2rd6JkidlGyCvoiYzg_8_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-66723000</us-gaap:OperatingIncomeLoss>
    <mbio:GrantIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_A2rbfgUjIEa35jUsd2FHCw_11_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1304000</mbio:GrantIncome>
    <us-gaap:InterestIncomeOther
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_uZvET_fZJUaxc1dSmIe2Fg_12_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">689000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_Bxnu00NNnkaAQpB6cNPWVg_12_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">368000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_-VZOkbOjtkye45URkCLtRA_13_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">3359000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_9HB5G9wKfE-dhhH4R_HO7g_13_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">15000</us-gaap:InterestExpenseDebt>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_CvwqeYwtE0-8ePzhigdu1A_14_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-1366000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_G2D2tw3hREiOKsvWOIa_7g_14_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">353000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_wxWFC-wBy0-wX3LO5veDCg_15_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-77525000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_AcB-B66pnUSDNTLGJ-B_0w_15_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-66370000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="2"
      id="Tc_UQZC8XVrSEeOpkfmkFcDxw_17_3"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">-0.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="2"
      id="Tc_me8Jh5sGkEGwveLDJoZvKA_17_6"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">-0.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="INF"
      id="Tc_iB5wSY6qCEevBOxV6nNxYw_19_3"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">103432603</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="INF"
      id="Tc_Nnamk5vHwEurwBfYCDgJ2Q_19_6"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">87885235</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Ph6XHuuiYE6eukhnqC2Btw"
      decimals="INF"
      id="Tc_A2WDaqE1EE6A0I3390IEgQ_4_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">250000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8o0VgKjajEeXToZHvyHFfg"
      decimals="INF"
      id="Tc_ZoxzzVfhXUqxqUba21LqrA_4_7"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">845385</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GA4yvT9zYUmgOsGKoFCnXg"
      decimals="INF"
      id="Tc_9gJJPUbJpkWhaTiyMhBP0g_4_12"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">70920693</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GA4yvT9zYUmgOsGKoFCnXg"
      decimals="-3"
      id="Tc_Rer05FTN1Euq5vg_hyotTQ_4_15"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember_huCEWr5zL0mQORn1jbxA9Q"
      decimals="-3"
      id="Tc_5ob4lH5SPke0JrJKFjaTDg_4_18"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">7939000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jHd2Q0o-XUCIA4E98EgSpw"
      decimals="-3"
      id="Tc_bGvEQtNlEUuqbVuwg3721w_4_21"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">275963000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_d-YK2vIsoEm8XC9k2H7Q5w"
      decimals="-3"
      id="Tc_Ugey093KfUGl-5_0_DUMfw_4_24"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-185474000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_Jb9gSnd2k0CKnqyK9MTFMA"
      decimals="-3"
      id="Tc_2EjiwUQk40S-gLN64WKUxw_4_27"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">98435000</us-gaap:StockholdersEquity>
    <mbio:StockIssuanceCommonStockIssuableDuringPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember_FipD5R7ULEmGI252vfGJvg"
      decimals="-3"
      id="Tc_X2DzWwTH90a3wlDXZlpBww_5_18"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">4212000</mbio:StockIssuanceCommonStockIssuableDuringPeriod>
    <mbio:StockIssuanceCommonStockIssuableDuringPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_8XyAsHTrMUyZqC2S-MC3dA_5_27"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">4212000</mbio:StockIssuanceCommonStockIssuableDuringPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2yJrJPxhE-PPwrFE9SShQ"
      decimals="INF"
      id="Tc_VkwP4Aq7Hke2fcchcpUuHw_6_12"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">2001490</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <mbio:StockIssuedDuringPeriodValueIssuedForFoundersAgreement
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember_FipD5R7ULEmGI252vfGJvg"
      decimals="-3"
      id="Tc_45U671wVy02nVFaPvaRDDw_6_18"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-7577000</mbio:StockIssuedDuringPeriodValueIssuedForFoundersAgreement>
    <mbio:StockIssuedDuringPeriodValueIssuedForFoundersAgreement
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_36vrF-2gf0O3kUT4Pd1TLw"
      decimals="-3"
      id="Tc_UNB0yWT08ke2-FQhdJSCmA_6_21"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">7577000</mbio:StockIssuedDuringPeriodValueIssuedForFoundersAgreement>
    <mbio:StockIssuedDuringPeriodSharesAtMarketOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2yJrJPxhE-PPwrFE9SShQ"
      decimals="INF"
      id="Tc_q9tzCxNLMU6LtjwC9W0cFg_7_12"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">19419944</mbio:StockIssuedDuringPeriodSharesAtMarketOffering>
    <mbio:StockIssuedDuringPeriodValueAtMarketingOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2yJrJPxhE-PPwrFE9SShQ"
      decimals="-3"
      id="Tc__Au05-MavUuyXjwL-I7Slw_7_15"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2000</mbio:StockIssuedDuringPeriodValueAtMarketingOffering>
    <mbio:StockIssuedDuringPeriodValueAtMarketingOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_36vrF-2gf0O3kUT4Pd1TLw"
      decimals="-3"
      id="Tc_OMtes_tiTESUcmuNetlegg_7_21"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">70620000</mbio:StockIssuedDuringPeriodValueAtMarketingOffering>
    <mbio:StockIssuedDuringPeriodValueAtMarketingOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_edkCoaiWr06g6nZhCkAfkA_7_27"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">70622000</mbio:StockIssuedDuringPeriodValueAtMarketingOffering>
    <mbio:StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2yJrJPxhE-PPwrFE9SShQ"
      decimals="INF"
      id="Tc_NB1YtUuQlk6ihXupWj30dg_8_12"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">576157</mbio:StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering>
    <mbio:StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember_FipD5R7ULEmGI252vfGJvg"
      decimals="-3"
      id="Tc_RZRl48BKskmLmLPttZbNRw_8_18"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-245000</mbio:StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering>
    <mbio:StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_36vrF-2gf0O3kUT4Pd1TLw"
      decimals="-3"
      id="Tc_1aVMdze-XEyYof3DeBfbeg_8_21"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2129000</mbio:StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering>
    <mbio:StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_cwtbexstIUiNk9kg1Pu6Og_8_27"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1884000</mbio:StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2yJrJPxhE-PPwrFE9SShQ"
      decimals="INF"
      id="Tc_pIpYRXumDkaRdLWDrQ73DQ_9_12"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">114321</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_36vrF-2gf0O3kUT4Pd1TLw"
      decimals="-3"
      id="Tc_pqNYlXIAcUa2EQ-mP-HSEg_9_21"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">309000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_8d2GJuwjjk6N6hfTAsQ27g_9_27"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">309000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <mbio:CorrectionToPreviouslyIssuedShares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2yJrJPxhE-PPwrFE9SShQ"
      decimals="INF"
      id="Tc_WcbXSUiO3UK3ibo3_QDavQ_10_12"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">60999</mbio:CorrectionToPreviouslyIssuedShares>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2yJrJPxhE-PPwrFE9SShQ"
      decimals="INF"
      id="Tc_l5PPM92Io0alb1j4DiCnrQ_11_12"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">489249</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_36vrF-2gf0O3kUT4Pd1TLw"
      decimals="-3"
      id="Tc_Ux1WuGR4d0uNHgX2a5Dxzg_11_21"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">3308000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_bSPnhHrHa0Co_rtzXwaOnQ_11_27"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">3308000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <mbio:ShareIssuedDuringPeriodSharesOnExerciseOfWarrants
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e2yJrJPxhE-PPwrFE9SShQ"
      decimals="INF"
      id="Tc_Xz-m1i0Zske0khjO4qSNMQ_12_12"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">138</mbio:ShareIssuedDuringPeriodSharesOnExerciseOfWarrants>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_N3FmWahfpU6FVAV3nHsrgw"
      decimals="-3"
      id="Tc_UvB5xXlaE0-Xayjecd5Hlg_13_24"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-66370000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_tbCCSo-VQ0OEj-rVsGwf0Q_13_27"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-66370000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Ix8JVts4dk2Q4KuWLN5TqQ"
      decimals="INF"
      id="Tc_CvQxuSQIzUC0JvHLYRaXEQ_14_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">250000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5lfujqng8EmU7km7KzrW3g"
      decimals="INF"
      id="Tc_Uyll2y6HfEm8Uez7cHvlow_14_7"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">845385</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mjwCtJPi90OdodwExzzejw"
      decimals="INF"
      id="Tc__ZG4--H-ZUyajnIpECqEBw_14_12"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">93582991</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mjwCtJPi90OdodwExzzejw"
      decimals="-3"
      id="Tc_PGerqLtrtkqnGb9amX8AaA_14_15"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember_r-s7nx-j2UO579la2vbCYg"
      decimals="-3"
      id="Tc_cHcybJmHvEuAVfLYVhTbZQ_14_18"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">4329000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nEUVoh_PAEuYAh0Emg965A"
      decimals="-3"
      id="Tc_gZtXNYgvxUmlvLSRdIox7A_14_21"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">359906000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3jzMDFTC6Uqy-qcl2JQMLw"
      decimals="-3"
      id="Tc_vHYR6lXDLUeBy55TEfG-OQ_14_24"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-251844000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_wNxzaptANUq1FeqoER_thw_14_27"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">112400000</us-gaap:StockholdersEquity>
    <mbio:StockIssuanceCommonStockIssuableDuringPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember__24V726k9U-PKRzgLSlEoA"
      decimals="-3"
      id="Tc_ZKSxmWT2_kK1jaDdNCyxaw_15_18"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1109000</mbio:StockIssuanceCommonStockIssuableDuringPeriod>
    <mbio:StockIssuanceCommonStockIssuableDuringPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_0URL02BfNESlEqosuzJXDQ_15_27"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1109000</mbio:StockIssuanceCommonStockIssuableDuringPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SQivjg3JZ0yfjAKfVkr_KQ"
      decimals="INF"
      id="Tc_1X2S-vLT8k2jgcINZseYIw_16_12"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">2536607</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <mbio:StockIssuedDuringPeriodValueIssuedForFoundersAgreement
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember__24V726k9U-PKRzgLSlEoA"
      decimals="-3"
      id="Tc_zpY0PLe20UGzwPtI_KsGKQ_16_18"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-4212000</mbio:StockIssuedDuringPeriodValueIssuedForFoundersAgreement>
    <mbio:StockIssuedDuringPeriodValueIssuedForFoundersAgreement
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WOYfueKSEuJAaVfesRtjg"
      decimals="-3"
      id="Tc_B4q7F6kxykqGiqKDNIbPxg_16_21"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">4212000</mbio:StockIssuedDuringPeriodValueIssuedForFoundersAgreement>
    <mbio:StockIssuedDuringPeriodSharesAtMarketOffering
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SQivjg3JZ0yfjAKfVkr_KQ"
      decimals="INF"
      id="Tc_iZqBH1t4HEeNMtslk0lbuA_17_12"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">7878095</mbio:StockIssuedDuringPeriodSharesAtMarketOffering>
    <mbio:StockIssuedDuringPeriodValueAtMarketingOffering
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SQivjg3JZ0yfjAKfVkr_KQ"
      decimals="-3"
      id="Tc_lnmHp2wQQEOGNKbcc7EV2A_17_15"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2000</mbio:StockIssuedDuringPeriodValueAtMarketingOffering>
    <mbio:StockIssuedDuringPeriodValueAtMarketingOffering
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WOYfueKSEuJAaVfesRtjg"
      decimals="-3"
      id="Tc_CWDBFewNAEKNs9H3ki_dlw_17_21"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">6498000</mbio:StockIssuedDuringPeriodValueAtMarketingOffering>
    <mbio:StockIssuedDuringPeriodValueAtMarketingOffering
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_pmUCwj6ys0e3ee0fy5DSxA_17_27"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">6500000</mbio:StockIssuedDuringPeriodValueAtMarketingOffering>
    <mbio:StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SQivjg3JZ0yfjAKfVkr_KQ"
      decimals="INF"
      id="Tc_8gzPi7yq4kuGh71A5TETig_18_12"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">248247</mbio:StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering>
    <mbio:StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember__24V726k9U-PKRzgLSlEoA"
      decimals="-3"
      id="Tc_gCzIEtPMa0Kfg4qYAJhPkw_18_18"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-117000</mbio:StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering>
    <mbio:StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WOYfueKSEuJAaVfesRtjg"
      decimals="-3"
      id="Tc_LROMbi7u_kaUUtK5OakvlA_18_21"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">283000</mbio:StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering>
    <mbio:StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_TELLi5TlX0eDo-TcfM8ucg_18_27"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">166000</mbio:StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SQivjg3JZ0yfjAKfVkr_KQ"
      decimals="INF"
      id="Tc_BJXG9smsHkKFd5-HtQsaUA_19_12"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">330833</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WOYfueKSEuJAaVfesRtjg"
      decimals="-3"
      id="Tc_DASnJdemUUat-bh7jqADkw_19_21"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">206000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_SN-e8bHMVEe541ZW6i9LHA_19_27"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">206000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <mbio:AdditionsToApicEquityFeesOnRwgDebtShares
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SQivjg3JZ0yfjAKfVkr_KQ"
      decimals="INF"
      id="Tc_w3tEEDIWX0W4GZphOhhA9Q_20_12"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">954927</mbio:AdditionsToApicEquityFeesOnRwgDebtShares>
    <mbio:AdditionsToApicEquityFeesOnRwgDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WOYfueKSEuJAaVfesRtjg"
      decimals="-3"
      id="Tc_PvODu4JhQUOJBWkLKqdwOg_20_21"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">750000</mbio:AdditionsToApicEquityFeesOnRwgDebt>
    <mbio:AdditionsToApicEquityFeesOnRwgDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_oefCnwEZZU-oFRZuyWtbSw_20_27"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">750000</mbio:AdditionsToApicEquityFeesOnRwgDebt>
    <mbio:AdditionsToApicFromIssuanceOfRwgDebtWarrants
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WOYfueKSEuJAaVfesRtjg"
      decimals="-3"
      id="Tc_iYZFUvd8Sk6scPek79dXrA_21_21"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">384000</mbio:AdditionsToApicFromIssuanceOfRwgDebtWarrants>
    <mbio:AdditionsToApicFromIssuanceOfRwgDebtWarrants
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_23UociLho0-PSTlKq_1mNg_21_27"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">384000</mbio:AdditionsToApicFromIssuanceOfRwgDebtWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SQivjg3JZ0yfjAKfVkr_KQ"
      decimals="INF"
      id="Tc_q3I2e392mk-qfi5xKABjUA_22_12"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">969963</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WOYfueKSEuJAaVfesRtjg"
      decimals="-3"
      id="Tc_KQVNfswvwUOQcOsaZw0YmQ_22_21"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2283000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_JDu946ShR0mNQa8MOzGhzA_22_27"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2283000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_sJ_f6Z0h_0mK2WrP7jFDCA"
      decimals="-3"
      id="Tc_zk-CEbm1cEKr-HqNOs0X3g_23_24"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-77525000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_bNo77X5nPUG-sAJk4oT7OA_23_27"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-77525000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_iXjE7NHXYk6rJeTAc6GwOQ"
      decimals="INF"
      id="Tc_ObUS6ZW76kyfZPpbRlkmFg_24_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">250000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dcd2JnkRoUu5jv05PZ7fwA"
      decimals="INF"
      id="Tc_DyQxE71x20ijNo5UI6ZczQ_24_7"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">845385</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u6IrjKOtBU2wn6oRGZSpiw"
      decimals="INF"
      id="Tc_EYnouPc-ZUyz0eMVVHWCZg_24_12"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">106501663</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u6IrjKOtBU2wn6oRGZSpiw"
      decimals="-3"
      id="Tc_X1nQj54G0keoprIh61m7PA_24_15"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_mbio_CommonStockIssuableMember_9MQl4Tri8UWaL1Az0682Pw"
      decimals="-3"
      id="Tc__-yiQhzJpkGIOP8hGD-Wvg_24_18"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1109000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_P9_Uj5uTOkOfoQ-1eRQEMA"
      decimals="-3"
      id="Tc_sxA3-AZUp0W9jF_Xl6acLw_24_21"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">374522000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6zho2C1h60K0Lzm1bSUQng"
      decimals="-3"
      id="Tc_6tphp59s_k2CjSEMG1B65g_24_24"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-329369000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_BfGInsZDsEmePe1bLnkYIw_24_27"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">46273000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_gcJFJvmEjEG900aWBTAA-g_4_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-77525000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_wa8WMfKchUuiC10bZgN67g_4_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-66370000</us-gaap:NetIncomeLoss>
    <mbio:IssuanceOfCommonSharesEquityFeeOnAtMarketOffering
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_5StkHk9TqU6pJ6d3CzPEIA_6_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">166000</mbio:IssuanceOfCommonSharesEquityFeeOnAtMarketOffering>
    <mbio:IssuanceOfCommonSharesEquityFeeOnAtMarketOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_f_QPrPiCv0KTiZXPFu9IAg_6_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1884000</mbio:IssuanceOfCommonSharesEquityFeeOnAtMarketOffering>
    <mbio:AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_BTNFK6OqRkC6PeuV9zTnDg_7_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1109000</mbio:AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance>
    <mbio:AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_SFsLRrq3lEiQFrX6Tsk8xQ_7_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">4212000</mbio:AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance>
    <mbio:ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_M1Gy-zHsxEeQO8fKIiuyYg_8_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">365000</mbio:ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense>
    <mbio:ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_Xtzzj8RYtECIBfqrMwTDHw_8_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1630000</mbio:ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense>
    <mbio:CommonShareIssuanceFeesRelatedPartyDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_JjYVB_b18EOJHhcbQV53Qg_9_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">750000</mbio:CommonShareIssuanceFeesRelatedPartyDebt>
    <mbio:CommonShareIssuanceFeesRelatedPartyDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_WscypbKOZEis1nYqEuq2Cw_9_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</mbio:CommonShareIssuanceFeesRelatedPartyDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_sDce4ST-1UCfMFJwegl46g_10_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2283000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_2ADDno9_z0iXRLjfpqYlKw_10_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">3308000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_qVb26YfsZUyFham9DH2ysg_11_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2723000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_LBV_NcqW2EmjFTUjWVkf_g_11_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2167000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_AnzGLM-iBEOWUF4GoqEN5g_12_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">470000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_UWvpJ1B2ZUeFaK8x-waC7g_12_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_xUzFNOaNO02F79c6fjoYsw_13_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">308000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_W3jjsAEQdEW-wJdGiB70Ug_13_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">139000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_i9HI-dE0rUec2MwNrZtIaA_14_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-255000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_W0eqz-VC9kmCUiUxmrWeug_14_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_SBhfL2Z9r0ShPWhyCLWt-Q_16_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1021000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_3JVyPDeBr0-fIeCLq3OSMQ_16_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">401000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_CU_ve4RwdkqLjD3Iw4ye6w_17_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-14000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_Tu_0m1DVEUuroN7riojsQQ_17_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">35000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <mbio:IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_0r7qVh8CZkK6fzG7Q_dXBQ_18_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">5257000</mbio:IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties>
    <mbio:IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_3fCIwkGNSke3WT-JKAb6pQ_18_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-408000</mbio:IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_VT-Tg1tcL06B25tgmlgoZQ_19_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">43000</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_f4vBpWoewEa8RM4mp1_gIA_19_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">233000</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_4jByaGPQ5EqZFo4nVYtFnQ_20_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_8dy4bdepLEy08ZDU0tnakg_20_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">270000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <mbio:IncreaseDecreaseInLeaseLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_oNoqXVt8wUmO1aoMDVEK3A_21_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">263000</mbio:IncreaseDecreaseInLeaseLiabilities>
    <mbio:IncreaseDecreaseInLeaseLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_EyqosT-ALkKUfVI_oIMIIA_21_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">296000</mbio:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_dKnmQhYInE6xItaUUhh7DQ_22_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-65066000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_ukYfJmzt1kmTXaBpryTKHQ_22_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-53667000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_vBoDwg3mOECVDrN1ETmZtA_25_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">365000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_FNl5yip3W0CmzGWw9DXfYg_25_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1380000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_Wq0AM_C_GEiwdoxbTvdHyw_26_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">127000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_EHxi4H8tdkuy53LQ1cSq3A_26_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_v8dxgpVxiky_gmhhBRbNxA_27_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2714000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_vxuq1cN5HkWa68htp0K0mQ_27_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">3986000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc__Rw6XWPJ9U-Vz8x7LyeR6g_28_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-2952000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_ZRGTSk6U30u3U5estGqN3w_28_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-5366000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <mbio:ProceedsFromIssuanceOfCommonSharesAtMarketOffering
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_43_AdKafGEOzKFkqx7-gVQ_31_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">6623000</mbio:ProceedsFromIssuanceOfCommonSharesAtMarketOffering>
    <mbio:ProceedsFromIssuanceOfCommonSharesAtMarketOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_Uk0fICkOu0GSRYm6Ln4bUA_31_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">71919000</mbio:ProceedsFromIssuanceOfCommonSharesAtMarketOffering>
    <mbio:OfferingCostsForIssuanceOfCommonSharesAtMarketOffering
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_9AxTnJbWFkiMJ7PpXyNBUw_32_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">123000</mbio:OfferingCostsForIssuanceOfCommonSharesAtMarketOffering>
    <mbio:OfferingCostsForIssuanceOfCommonSharesAtMarketOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_gTyccPzwckmjF7w0gVG5sA_32_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1381000</mbio:OfferingCostsForIssuanceOfCommonSharesAtMarketOffering>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_dBApSzGezkaPBHQTVy1ONg_33_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">30000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_FHMert--gkS5_PGwhRYf1A_33_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_VVrQEOuagE-AnB5eHVU6KA_34_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2650000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_y4EFg3iBYEOsaQbemhqfTw_34_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_YSbWJMIYoU25rloSQMbGqg_35_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">206000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_YhYsLt_0v0C9num7uAhxYw_35_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">309000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_1u5p5l4ORUeZi_GXpUkCig_36_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">34056000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_vtUDP-LXVkuFldoWwYaK4g_36_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">70847000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_KjELpEhsBUOli-0pju-xVA_38_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-33962000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_X3YgEdd3PUy2O95NyPiOcA_38_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">11814000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_wO4E69btJUm62uaU3GEo2Q_39_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">110618000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_Jb9gSnd2k0CKnqyK9MTFMA"
      decimals="-3"
      id="Tc_Wjx6VE9pMUmg1owhkI-F4w_39_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">98804000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_6sOmw6nykkqvylCgDJOcFQ_40_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">76656000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_VQ82cucnlUqBntuVusRPow_40_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">110618000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_kgubZO3igECgPIjxVxYykQ_43_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2710000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_EG_AfSzTaEm-ivlvkNvqUQ_43_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_MLmRD6-8MkCH3NWbZckdPg_46_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_5416xUfWx0G7Kys8ZBKNXA_46_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1270000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:StockIssued1
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_rTm2Q6aS80aFAdwfRkCEQA_47_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">4212000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_jYF6kGwvBUeGZxNVb3TxRA_47_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">7577000</us-gaap:StockIssued1>
    <mbio:ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_JQu6I-2sIUeRW9ZMO9raHA_48_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</mbio:ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid>
    <mbio:ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_e4RW4SVPK0ORVLCDqI2v-Q_48_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">250000</mbio:ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_mlJx93LEiEizlAPe-52PCQ_49_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1050000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_USihD9wOeEOHONcsaSDwVg_49_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_im6EL78oHUWyWbvv_GyOzQ_50_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">384000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_oUiivimTOECDR_tnAI8gKg_50_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <mbio:LeaseLiabilitiesArisingFromObtainingRightOfUseAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_IGJW0zXRkk-K7Owt-oUcuw_51_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2176000</mbio:LeaseLiabilitiesArisingFromObtainingRightOfUseAssets>
    <mbio:LeaseLiabilitiesArisingFromObtainingRightOfUseAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_Xj6oaDBPTUu2wyaWwTQlfA_51_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">101000</mbio:LeaseLiabilitiesArisingFromObtainingRightOfUseAssets>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_P-G7HBzxTEivV0xyr3l9uw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;1&#160;- Organization and Description of Business&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Mustang Bio,&#160;Inc. (the &#x201c;Company&#x201d; or &#x201c;Mustang&#x201d;) was incorporated in Delaware on March&#160;13, 2015. Mustang is as a clinical-stage biopharmaceutical company focused on translating today&#x2019;s medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. The Company may acquire rights to these technologies by licensing the rights or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company is a majority-controlled subsidiary of Fortress Biotech,&#160;Inc. (&#x201c;Fortress&#x201d; or &#x201c;Parent&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Liquidity and Capital Resources&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company has incurred substantial operating losses and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of December 31, 2022, the Company had an accumulated deficit of $329.4 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company has funded its operations to date primarily through the sale of equity and via debt raises, including its loan and financing agreement with Runaway Growth Finance Corporation (the "Lender"), herein referred to as the "Term Loan." The Company expects to continue to use the proceeds from previous financing transactions primarily for general corporate purposes, including financing the Company&#x2019;s growth, developing new or existing product candidates, and funding capital expenditures, acquisitions and investments. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company will be required to expend significant funds in order to advance the development of its product candidates. The Company will require additional financings through equity and debt offerings, collaborations and licensing arrangements or other sources to fully develop, prepare regulatory filings, obtain regulatory approvals and commercialize its existing and any new product candidates. The continuation of our business as a going concern is dependent upon raising additional capital and eventually attaining and maintaining profitable operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 205-40, Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#x2019;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#x2019;s ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. In performing its evaluation, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40, the future receipt of potential funding from future equity or debt issuances, and the potential sale of priority review vouchers cannot be considered probable at this time because these plans are not entirely within the Company&#x2019;s control nor have been approved by the Board of Directors as of the date of these financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company's expectation to generate operating losses and negative operating cash flows in the future, as well as projections of future inability to meet certain financial debt covenants, and the need for additional funding to support its planned operations raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern for a period of one year after the date that these consolidated financial statements are issued. The Company continues to monitor its spending by reducing 2023 expenses, which may include projected savings through delaying the development timelines of certain programs, or termination of such programs and the pursuit of additional cash resources through public or private equity or debt financings. The Company has concluded that substantial doubt exists about the Company&#x2019;s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that may be necessary if the Company is unable to continue as a going concern. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:2pt;margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-5"
      id="Narr_MD73VC8uRkuCI9Dvdc7ysQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">-329400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_kctH5Oo3xkO9DjZRHYXHiQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;2&#160;- Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The Company has no subsidiaries.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;All inter-company transactions between Fortress and Mustang are classified as due from or due to related party in the financial statements. The Company believes that the assumptions underlying the financial statements are reasonable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Segments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating and &lt;span style="-sec-ix-hidden:Hidden_1DzwVi4TWE68-iARaVzCtQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;reporting&lt;/span&gt;&lt;/span&gt; segment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company considers highly liquid investments with a maturity of three&#160;months or less when purchased to be cash equivalents. Cash and cash equivalents at December&#160;31,&#160;2022 and 2021, consisted of cash and certificates of deposit in institutions in the United States. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are currently adequately protected against credit risk.&#160;At times, portions of the Company&#x2019;s cash and cash equivalents may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation (FDIC) limits, though the Company customarily invests a significant portion of its cash in CDARS accounts to maximize FDIC insurance coverage across its holdings.&#160;As of December 31, 2022, the Company had not experienced losses on these accounts, and management believes the Company is not exposed to significant risk on such accounts.&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Other Receivables &#x2013; Related Party&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Other receivables include amounts due to the Company from Fortress and Journey Medical Corporation, both related parties, and is recorded at the invoiced amount.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company records cash held in an escrow account as a security deposit for the manufacturing facility in Worcester, Massachusetts, as restricted cash. The Company had $1.0 million in restricted cash as of December&#160;31,&#160;2022 and 2021, respectively. The Facility initiated cell processing operations for personalized CAR T and gene therapies in 2018.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Property, plant and equipment, net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Property and equipment, net, which consists mainly of laboratory equipment, are carried at cost less accumulated depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally five years, using the straight-line method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Property and equipment&#160;- Construction in Process&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In connection with the Company&#x2019;s cell processing facility, the Company incurred costs for the design and construction of the facility and the purchase of equipment; $1.0 million and $2.0 million are recorded in fixed assets - construction in process on the balance sheet at December&#160;31,&#160;2022 and 2021, respectively. Upon completion of the facility&#x2019;s construction, all costs associated with the buildout will be recorded as leasehold improvements and amortized over the shorter of the estimated useful lives or the term of the respective leases, upon the improvement being placed in service.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company&#x2019;s behalf will be expensed as services are rendered or when the milestone is achieved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, costs associated with regulatory filings, laboratory costs and other supplies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 730-10-25-1, &lt;i style="font-style:italic;"&gt;Research and Development, &lt;/i&gt;costs incurred in obtaining technology licenses are charged to research and development expense if the technology licensed has not reached commercial feasibility and has no alternative future use. The licenses purchased by the Company require substantial completion of research and development, regulatory and marketing approval efforts to reach commercial feasibility and has no alternative future use. Accordingly, the total purchase price for the licenses acquired is reflected as research and development&#160;- licenses acquired in the Company&#x2019;s Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Annual Stock Dividend&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In July&#160;2016, in connection with the Amended and Restated Articles of Incorporation, the Company issued 250,000 Class&#160;A preferred shares to Fortress. The Class&#160;A preferred shares entitle the holder to a stock dividend equal to 2.5% of the fully diluted outstanding equity of the Company (the &#x201c;Annual Stock Dividend&#x201d;). The Annual Stock Dividend was part of the consideration payable for formation of the Company and the identification of certain assets, including the license contributed to Mustang by Fortress (see Note&#160;4).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In June&#160;2018, in connection with the Amended and Restated Articles of Incorporation, the Company amended the Annual Stock Dividend &#160;due date from March&#160;13th to January&#160;1st.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Pursuant to the Amended and Restated Articles of Incorporation, the Company issued 2,807,008 shares of common stock to Fortress for the Annual Stock Dividend, representing 2.5% of the fully-diluted outstanding equity of Mustang on January 1, 2023. This was shown in the Statement of Stockholders&#x2019; Equity at December 31, 2022, as Common stock issuable &#x2013; Founders Agreement. The Company recorded an expense of approximately $1.1 million in research and development - licenses acquired related to these issuable shares during the year ended December&#160;31,&#160;2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Pursuant to the Amended and Restated Articles of Incorporation, the Company issued 2,536,607 shares of common stock to Fortress for the Annual Stock Dividend, representing 2.5% of the fully-diluted outstanding equity of Mustang on January 1, 2022. This was shown in the Statement of Stockholders&#x2019; Equity at December&#160;31,&#160;2021, as Common stock issuable &#x2013; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Founders Agreement. The Company recorded an expense of approximately $4.2 million in research and development - licenses acquired related to these issuable shares during the year ended December 31, 2021.&lt;span style="color:#201f1e;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;background:#ffffff;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Fair Value Measurement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 0pt;"&gt;Level 1:&#160;&#160;&#160;&#160;Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 10pt 0pt;"&gt;Level 2:&#160;&#160;&#160;&#160;Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"&gt;Level 3:&#160;&#160;&#160;&#160;Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the balance sheet as both a right of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company's incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred. In calculating the right of use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model or 409a valuations, as applicable. The assumptions used in calculating the fair value of stock-based awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if management believes it is more likely than not that the deferred tax assets &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period less unvested restricted stock. Since dividends are declared, paid and set aside among the holders of shares of common stock and Class&#160;A common shares pro-rata on an as-if-converted basis, the two-class method of computing net loss per share is not required. Diluted net loss per share does not reflect the effect of shares of common stock to be issued upon the exercise of warrants or outstanding Class&#160;A preferred shares, as their inclusion would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,052,920&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,308,654&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,141,675&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,141,675&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Class&#160;A Preferred Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock awards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 510,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 280,983&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,488,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,335,557&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,443,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,316,869&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Comprehensive Loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company has no components of other comprehensive loss, and therefore, comprehensive loss equals net loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In August 2020, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2020-06,&#160;&lt;i style="font-style:italic;"&gt;&#x201c;Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity,&#x201d;&lt;/i&gt;&#160;which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption will be permitted. The Company is currently evaluating the impact of this standard on its financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;In June 2016, FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;&#x201c;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#x201d;&lt;/i&gt;&lt;span style="background:#ffffff;"&gt;. ASU 2016-13 requires that expected credit losses relating to financial assets are measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. Recently, the FASB issued the final ASU to delay adoption for smaller reporting companies to calendar year 2023. The Company is currently assessing the impact of the adoption of this ASU on its financial statements&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_2rhg2oyLlUCQkd396nfyOA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;2&#160;- Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The Company has no subsidiaries.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;All inter-company transactions between Fortress and Mustang are classified as due from or due to related party in the financial statements. The Company believes that the assumptions underlying the financial statements are reasonable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Segments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating and &lt;span style="-sec-ix-hidden:Hidden_1DzwVi4TWE68-iARaVzCtQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;reporting&lt;/span&gt;&lt;/span&gt; segment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company considers highly liquid investments with a maturity of three&#160;months or less when purchased to be cash equivalents. Cash and cash equivalents at December&#160;31,&#160;2022 and 2021, consisted of cash and certificates of deposit in institutions in the United States. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are currently adequately protected against credit risk.&#160;At times, portions of the Company&#x2019;s cash and cash equivalents may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation (FDIC) limits, though the Company customarily invests a significant portion of its cash in CDARS accounts to maximize FDIC insurance coverage across its holdings.&#160;As of December 31, 2022, the Company had not experienced losses on these accounts, and management believes the Company is not exposed to significant risk on such accounts.&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Other Receivables &#x2013; Related Party&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Other receivables include amounts due to the Company from Fortress and Journey Medical Corporation, both related parties, and is recorded at the invoiced amount.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company records cash held in an escrow account as a security deposit for the manufacturing facility in Worcester, Massachusetts, as restricted cash. The Company had $1.0 million in restricted cash as of December&#160;31,&#160;2022 and 2021, respectively. The Facility initiated cell processing operations for personalized CAR T and gene therapies in 2018.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Property, plant and equipment, net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Property and equipment, net, which consists mainly of laboratory equipment, are carried at cost less accumulated depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally five years, using the straight-line method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Property and equipment&#160;- Construction in Process&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In connection with the Company&#x2019;s cell processing facility, the Company incurred costs for the design and construction of the facility and the purchase of equipment; $1.0 million and $2.0 million are recorded in fixed assets - construction in process on the balance sheet at December&#160;31,&#160;2022 and 2021, respectively. Upon completion of the facility&#x2019;s construction, all costs associated with the buildout will be recorded as leasehold improvements and amortized over the shorter of the estimated useful lives or the term of the respective leases, upon the improvement being placed in service.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company&#x2019;s behalf will be expensed as services are rendered or when the milestone is achieved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, costs associated with regulatory filings, laboratory costs and other supplies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 730-10-25-1, &lt;i style="font-style:italic;"&gt;Research and Development, &lt;/i&gt;costs incurred in obtaining technology licenses are charged to research and development expense if the technology licensed has not reached commercial feasibility and has no alternative future use. The licenses purchased by the Company require substantial completion of research and development, regulatory and marketing approval efforts to reach commercial feasibility and has no alternative future use. Accordingly, the total purchase price for the licenses acquired is reflected as research and development&#160;- licenses acquired in the Company&#x2019;s Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Annual Stock Dividend&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In July&#160;2016, in connection with the Amended and Restated Articles of Incorporation, the Company issued 250,000 Class&#160;A preferred shares to Fortress. The Class&#160;A preferred shares entitle the holder to a stock dividend equal to 2.5% of the fully diluted outstanding equity of the Company (the &#x201c;Annual Stock Dividend&#x201d;). The Annual Stock Dividend was part of the consideration payable for formation of the Company and the identification of certain assets, including the license contributed to Mustang by Fortress (see Note&#160;4).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In June&#160;2018, in connection with the Amended and Restated Articles of Incorporation, the Company amended the Annual Stock Dividend &#160;due date from March&#160;13th to January&#160;1st.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Pursuant to the Amended and Restated Articles of Incorporation, the Company issued 2,807,008 shares of common stock to Fortress for the Annual Stock Dividend, representing 2.5% of the fully-diluted outstanding equity of Mustang on January 1, 2023. This was shown in the Statement of Stockholders&#x2019; Equity at December 31, 2022, as Common stock issuable &#x2013; Founders Agreement. The Company recorded an expense of approximately $1.1 million in research and development - licenses acquired related to these issuable shares during the year ended December&#160;31,&#160;2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Pursuant to the Amended and Restated Articles of Incorporation, the Company issued 2,536,607 shares of common stock to Fortress for the Annual Stock Dividend, representing 2.5% of the fully-diluted outstanding equity of Mustang on January 1, 2022. This was shown in the Statement of Stockholders&#x2019; Equity at December&#160;31,&#160;2021, as Common stock issuable &#x2013; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Founders Agreement. The Company recorded an expense of approximately $4.2 million in research and development - licenses acquired related to these issuable shares during the year ended December 31, 2021.&lt;span style="color:#201f1e;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;background:#ffffff;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Fair Value Measurement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 0pt;"&gt;Level 1:&#160;&#160;&#160;&#160;Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 10pt 0pt;"&gt;Level 2:&#160;&#160;&#160;&#160;Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"&gt;Level 3:&#160;&#160;&#160;&#160;Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the balance sheet as both a right of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company's incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred. In calculating the right of use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model or 409a valuations, as applicable. The assumptions used in calculating the fair value of stock-based awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if management believes it is more likely than not that the deferred tax assets &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period less unvested restricted stock. Since dividends are declared, paid and set aside among the holders of shares of common stock and Class&#160;A common shares pro-rata on an as-if-converted basis, the two-class method of computing net loss per share is not required. Diluted net loss per share does not reflect the effect of shares of common stock to be issued upon the exercise of warrants or outstanding Class&#160;A preferred shares, as their inclusion would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,052,920&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,308,654&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,141,675&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,141,675&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Class&#160;A Preferred Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock awards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 510,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 280,983&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,488,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,335,557&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,443,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,316,869&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Comprehensive Loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company has no components of other comprehensive loss, and therefore, comprehensive loss equals net loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In August 2020, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2020-06,&#160;&lt;i style="font-style:italic;"&gt;&#x201c;Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity,&#x201d;&lt;/i&gt;&#160;which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption will be permitted. The Company is currently evaluating the impact of this standard on its financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;In June 2016, FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;&#x201c;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#x201d;&lt;/i&gt;&lt;span style="background:#ffffff;"&gt;. ASU 2016-13 requires that expected credit losses relating to financial assets are measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. Recently, the FASB issued the final ASU to delay adoption for smaller reporting companies to calendar year 2023. The Company is currently assessing the impact of the adoption of this ASU on its financial statements&lt;/span&gt;.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_tJLhzqJzjESJaAXVJcT6Nw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The Company has no subsidiaries.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;All inter-company transactions between Fortress and Mustang are classified as due from or due to related party in the financial statements. The Company believes that the assumptions underlying the financial statements are reasonable.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <mbio:NumberOfSubsidiaries
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="INF"
      id="Narr_5t2Z9sQ2MU-b35mcPUtVeQ"
      unitRef="Unit_Standard_item_e-lAqZ63ukC9AQjaK0X33Q">0</mbio:NumberOfSubsidiaries>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_Hh8d9CqPy0KRWaCQm0SoXg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Segments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating and &lt;span style="-sec-ix-hidden:Hidden_1DzwVi4TWE68-iARaVzCtQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;reporting&lt;/span&gt;&lt;/span&gt; segment.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="INF"
      id="Narr_fyTB8nw7QUOHph26ZYMHXg"
      unitRef="Unit_Standard_segment_8GyIjrAsdkK2LxrNi5qQyQ">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_53Wkegm-sEOOeb6ODXFatw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_kb7Xf8HkPkOcyxqJX_jjeQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company considers highly liquid investments with a maturity of three&#160;months or less when purchased to be cash equivalents. Cash and cash equivalents at December&#160;31,&#160;2022 and 2021, consisted of cash and certificates of deposit in institutions in the United States. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are currently adequately protected against credit risk.&#160;At times, portions of the Company&#x2019;s cash and cash equivalents may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation (FDIC) limits, though the Company customarily invests a significant portion of its cash in CDARS accounts to maximize FDIC insurance coverage across its holdings.&#160;As of December 31, 2022, the Company had not experienced losses on these accounts, and management believes the Company is not exposed to significant risk on such accounts.&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_iaY0CYX9Mk-952bZJr3Cww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Other Receivables &#x2013; Related Party&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Other receivables include amounts due to the Company from Fortress and Journey Medical Corporation, both related parties, and is recorded at the invoiced amount.&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_STu9Xet_rUqULPSO72oh3w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company records cash held in an escrow account as a security deposit for the manufacturing facility in Worcester, Massachusetts, as restricted cash. The Company had $1.0 million in restricted cash as of December&#160;31,&#160;2022 and 2021, respectively. The Facility initiated cell processing operations for personalized CAR T and gene therapies in 2018.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-5"
      id="Narr_W9gXwQA4y02K3RqBBXJMOA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1000000.0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-5"
      id="Narr_xo5ZZsXBW0e5BcVPjLDzlA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1000000.0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_o2BDbl6qLUuGU8-iPsbbAw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Property, plant and equipment, net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Property and equipment, net, which consists mainly of laboratory equipment, are carried at cost less accumulated depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally five years, using the straight-line method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Property and equipment&#160;- Construction in Process&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In connection with the Company&#x2019;s cell processing facility, the Company incurred costs for the design and construction of the facility and the purchase of equipment; $1.0 million and $2.0 million are recorded in fixed assets - construction in process on the balance sheet at December&#160;31,&#160;2022 and 2021, respectively. Upon completion of the facility&#x2019;s construction, all costs associated with the buildout will be recorded as leasehold improvements and amortized over the shorter of the estimated useful lives or the term of the respective leases, upon the improvement being placed in service.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Narr_5OGx7ayVU0mn5u5QHqaymQ">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_RjfDOebswEyLEhoZaNQWKg"
      decimals="-5"
      id="Narr_sYPLgKqsv0GaDydMHo2m5A"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_wsvscCuqjEmydGhY6i4new"
      decimals="-5"
      id="Narr_vrmCz0tTPkOExF2pmzw04A"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_cS_LNSrXY06S3DqMqTt2Mg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company&#x2019;s behalf will be expensed as services are rendered or when the milestone is achieved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants, the cost of acquiring and manufacturing clinical trial materials, costs associated with regulatory filings, laboratory costs and other supplies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 730-10-25-1, &lt;i style="font-style:italic;"&gt;Research and Development, &lt;/i&gt;costs incurred in obtaining technology licenses are charged to research and development expense if the technology licensed has not reached commercial feasibility and has no alternative future use. The licenses purchased by the Company require substantial completion of research and development, regulatory and marketing approval efforts to reach commercial feasibility and has no alternative future use. Accordingly, the total purchase price for the licenses acquired is reflected as research and development&#160;- licenses acquired in the Company&#x2019;s Statements of Operations.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <mbio:AnnualStockDividendPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_18es77844k6gt8xGpvibPA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Annual Stock Dividend&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In July&#160;2016, in connection with the Amended and Restated Articles of Incorporation, the Company issued 250,000 Class&#160;A preferred shares to Fortress. The Class&#160;A preferred shares entitle the holder to a stock dividend equal to 2.5% of the fully diluted outstanding equity of the Company (the &#x201c;Annual Stock Dividend&#x201d;). The Annual Stock Dividend was part of the consideration payable for formation of the Company and the identification of certain assets, including the license contributed to Mustang by Fortress (see Note&#160;4).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In June&#160;2018, in connection with the Amended and Restated Articles of Incorporation, the Company amended the Annual Stock Dividend &#160;due date from March&#160;13th to January&#160;1st.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Pursuant to the Amended and Restated Articles of Incorporation, the Company issued 2,807,008 shares of common stock to Fortress for the Annual Stock Dividend, representing 2.5% of the fully-diluted outstanding equity of Mustang on January 1, 2023. This was shown in the Statement of Stockholders&#x2019; Equity at December 31, 2022, as Common stock issuable &#x2013; Founders Agreement. The Company recorded an expense of approximately $1.1 million in research and development - licenses acquired related to these issuable shares during the year ended December&#160;31,&#160;2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Pursuant to the Amended and Restated Articles of Incorporation, the Company issued 2,536,607 shares of common stock to Fortress for the Annual Stock Dividend, representing 2.5% of the fully-diluted outstanding equity of Mustang on January 1, 2022. This was shown in the Statement of Stockholders&#x2019; Equity at December&#160;31,&#160;2021, as Common stock issuable &#x2013; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Founders Agreement. The Company recorded an expense of approximately $4.2 million in research and development - licenses acquired related to these issuable shares during the year ended December 31, 2021.&lt;span style="color:#201f1e;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;background:#ffffff;"&gt; &lt;/span&gt;&lt;/p&gt;</mbio:AnnualStockDividendPolicyTextBlock>
    <us-gaap:PreferredStockDividendsShares
      contextRef="Duration_7_22_2016_To_7_22_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_FiUSuj1xYkGpO1xt7_NOcA"
      decimals="INF"
      id="Narr_o3COtuwmnkaDGwgMCq7wXg"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">250000</us-gaap:PreferredStockDividendsShares>
    <mbio:DilutedOutstandingEquityPercentage
      contextRef="Duration_7_22_2016_To_7_22_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_FiUSuj1xYkGpO1xt7_NOcA"
      decimals="3"
      id="Narr_w4e5FsuMwEmYgSqkKH5VUQ"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.025</mbio:DilutedOutstandingEquityPercentage>
    <us-gaap:CommonStockDividendsShares
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"
      decimals="INF"
      id="Narr_9W2OZdSpCkicbQZaryojpA"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">2807008</us-gaap:CommonStockDividendsShares>
    <mbio:DilutedOutstandingEquityPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"
      decimals="3"
      id="Narr_0-OfDFFnP0OMgPwo_dLWFQ"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.025</mbio:DilutedOutstandingEquityPercentage>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_hRHdDMHNcUuPmSQBOPtXWA"
      decimals="-5"
      id="Narr_Eeii2p6GBkCQ3EYohO7F5w"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:CommonStockDividendsShares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_Trkkxq84fU-Vd0RoRhj2NQ"
      decimals="INF"
      id="Narr_NZCzEMom9kuFBjrYg5YMsg"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">2536607</us-gaap:CommonStockDividendsShares>
    <mbio:DilutedOutstandingEquityPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_Trkkxq84fU-Vd0RoRhj2NQ"
      decimals="3"
      id="Narr_4ATMb-5qw0a_rs_P3obFPA"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.025</mbio:DilutedOutstandingEquityPercentage>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_KBjGOoU-1UiBWoztZE_WAg"
      decimals="-5"
      id="Narr_nrMgClkIrk2tlehgIPYyig"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">4200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_0w1zLaeki02HKNKr5VYssg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Fair Value Measurement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 0pt;"&gt;Level 1:&#160;&#160;&#160;&#160;Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 10pt 0pt;"&gt;Level 2:&#160;&#160;&#160;&#160;Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"&gt;Level 3:&#160;&#160;&#160;&#160;Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_SvX_n7vugECJyM9Qlk-GGQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the balance sheet as both a right of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company's incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred. In calculating the right of use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_Ll_fJCABlUiePIc3rzP8xw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model or 409a valuations, as applicable. The assumptions used in calculating the fair value of stock-based awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_oBx4cjOMEkOk7arLaRzPTw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if management believes it is more likely than not that the deferred tax assets &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_q8__QwgBK0iCqfQtt1lEFA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period less unvested restricted stock. Since dividends are declared, paid and set aside among the holders of shares of common stock and Class&#160;A common shares pro-rata on an as-if-converted basis, the two-class method of computing net loss per share is not required. Diluted net loss per share does not reflect the effect of shares of common stock to be issued upon the exercise of warrants or outstanding Class&#160;A preferred shares, as their inclusion would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,052,920&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,308,654&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,141,675&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,141,675&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Class&#160;A Preferred Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock awards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 510,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 280,983&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,488,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,335,557&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,443,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,316,869&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_l3Jega6nQUqBm8EDHpCXug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,052,920&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,308,654&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,141,675&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,141,675&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Class&#160;A Preferred Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock awards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 510,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 280,983&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,488,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,335,557&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,443,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,316,869&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_rZrGkA6BLUa3b3OQehnYJg"
      decimals="0"
      id="Tc_g1Q_OoY2Ek6I52QT4qn6KQ_3_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">1052920</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_0k_G4cx5Y0ap-y77lBqB_g"
      decimals="0"
      id="Tc_1fguRp_FZUGZZjJdwj5RDw_3_4"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">3308654</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ycveH83leUebYfW_8jtr1Q"
      decimals="0"
      id="Tc_uS42PbZqp0O5qPlNf_1QzA_4_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">1141675</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_HTuh90RZrk-KPSURpslalg"
      decimals="0"
      id="Tc_kGAIqnAvN0iCsYfn5dea2g_4_4"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">1141675</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredClassAMember_fKYAiDFShUe0rn_iP9LuDg"
      decimals="0"
      id="Tc_at14GrQR406RVi5BfMfAGg_5_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">250000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredClassAMember_VD6cIIAU5EO3zkHQr1i38g"
      decimals="0"
      id="Tc_KoVp_A-VFE6RYZba8yjX1g_5_4"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">250000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_jj2nVe7aqU6w_0C3fUd4mA"
      decimals="0"
      id="Tc_k7Qtfq8cQEi9A2qXP4NhhQ_6_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">510245</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_3jPgbp30DEyg4u1vnCNMRw"
      decimals="0"
      id="Tc_RMGvNFnD8Em6Ocvlp4sY9g_6_4"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">280983</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_dvSvij2w6keF_tXo9314yw"
      decimals="0"
      id="Tc_zbfQAFDJc02VVooVll_yTA_7_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">2488687</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_-StlwZNLwUqM0yBk4WhqVw"
      decimals="0"
      id="Tc_1IKGK5VHWUi8eIVB-F24eA_7_4"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">2335557</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="0"
      id="Tc_mDwG3XhUc0mxs1s7DiEjfw_8_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">5443527</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="0"
      id="Tc_xBMMe35WbEeDsG2dMn0J9Q_8_4"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">7316869</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_pKcQuya82Uy53IapIKdIHQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Comprehensive Loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company has no components of other comprehensive loss, and therefore, comprehensive loss equals net loss.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="0"
      id="Narr_S54Aj1k_KUOUR9RHBeyYag"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_n9Bp7pzF5kaiZDvV453rRg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;3&#160;- License, Clinical Trial and Sponsored Research Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;"&gt;Research and Development Expenses&#160;&#x2013; All Licenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;For the&#160;years ended December 31, 2022 and 2021, the Company recorded the following expense in research and development for licenses acquired:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;($ in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;City of Hope National Medical Center&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;CD123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;IV/ICV&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;PSCA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;HER2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;CSL Behring (Calimmune)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Leiden University  Medical Centre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 350&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Mayo Clinic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fortress PIK Dividend&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,212&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,474&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,842&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;"&gt;License Agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;City of Hope&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;CD123 License (MB-102)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In February&#160;2017, the Company entered into an Amended and Restated Exclusive License Agreement with the City of Hope National Medical Center (&#x201c;COH&#x201d;) to acquire intellectual property rights pertaining to CD123 specific CAR T technology. Pursuant to this agreement, the Company and COH acknowledged that an upfront fee was previously paid. In addition, COH is eligible to receive an annual maintenance fee of $25,000 and milestone payments totaling $14.5 million upon the achievement of certain milestones. Royalty payments in the mid-single digits are due on net sales of licensed products. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended December 31, 2021, the Company recorded a non-refundable milestone payment of $0.3 million for the 24&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;th&lt;/sup&gt; patient treated in connection with the CD123 study. &lt;span style="background:#ffffff;"&gt;There were&#160;&lt;/span&gt;no&lt;span style="background:#ffffff;"&gt;&#160;such expenses for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;IV/ICV &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In February&#160;2017, the Company entered into an exclusive license agreement (the &#x201c;IV/ICV License&#x201d;) with COH to acquire intellectual property rights in patent applications related to the intraventricular and intracerebroventricular methods of delivering T cells that express CARs. Pursuant to the IV/ICV License, in March&#160;2017, the Company paid COH an upfront fee of $0.1 million. COH is eligible to receive a milestone payment totaling approximately $0.1 million, upon and subject to the achievement of a milestone, and an annual maintenance fee of $25,000. Royalty payments in the low single digits are due on net sales of licensed products. The Company is obligated to pay COH a&#160;percentage of certain revenues received in connection with a sublicense in the mid-thirties, but no such payments are due in connection with sublicenses that are granted in conjunction with the sublicense of other CAR T programs that are licensed from COH to the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;For the year ended December 31, 2022, the Company expensed a non-refundable milestone payment of $0.1 million in connection with the first patent within the Patent Rights issued. &lt;span style="background:#ffffff;"&gt;There were&#160;&lt;/span&gt;no&lt;span style="background:#ffffff;"&gt;&#160;such expenses for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;PSCA License (MB-105)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In May 2017, the Company entered into an exclusive license agreement with COH for the use of prostate stem cell antigen (&#x201c;PSCA&#x201d;) CAR T technology to be used in the treatment of prostate cancer, pancreatic cancer and other solid tumors. Pursuant to this agreement, the Company paid an upfront fee of $0.3 million and pays an annual maintenance fee of $50,000. Additional payments are due for the achievement of ten development milestones totaling $14.9 million, and royalty payments in the mid-single digits are due on net sales of licensed products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended December 31, 2021, the Company expensed a non-refundable milestone payment of $0.3 million for the twelfth patient treated in the Phase 1 clinical study of MB-105 at COH. &lt;span style="background:#ffffff;"&gt;There were&#160;&lt;/span&gt;no&lt;span style="background:#ffffff;"&gt;&#160;such expenses for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;HER2 License (MB-103)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;margin:0pt;"&gt;On May&#160;31, 2017, the Company entered into an exclusive license agreement with the COH for the use of human epidermal growth factor receptor 2 (&#x201c;HER2&#x201d;) CAR T technology, which will initially be applied in the treatment of glioblastoma multiforme. Pursuant to this agreement, the Company paid an upfront fee of $0.6 million and pays an annual maintenance fee of $50,000 (which began in 2019). Additional payments are due for the achievement of ten development milestones totaling $14.9 million, and royalty payments in the mid-single digits are due on net sales of licensed products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 10pt 0pt;"&gt;For the year ended, December 31, 2022, the Company expensed a non-refundable milestone payment of $0.2&#160;million in connection with the first patent within the Patent Rights issued. There were&#160;no&#160;such expenses for the year ended December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;CSL Behring (Calimmune) License&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;On August 23, 2019, the Company entered into a non-exclusive license agreement with CSL Behring (Calimmune, Inc.) (&#x201c;Calimmune License&#x201d;) for the rights to the Cytegrity&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt; stable producer cell line for the production of viral vector for our lentiviral gene therapy program for the treatment of XSCID (MB-107 and MB-207). We previously licensed the XSCID gene therapy program from St. Jude Children&#x2019;s Research Hospital, Inc. (&#x201c;St. Jude&#x201d;) in August 2018. Pursuant to the terms of the Calimmune License, the Company paid an upfront fee of $0.2 million. CSL Behring is eligible to receive additional payments totaling $1.2 million upon the achievement of three development and commercialization milestones. Royalty payments in the low-single digits are due on net sales of licensed products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;For the year ended December 31, 2022 and 2021, the Company expensed a non-refundable milestone payments of $40,000 and $30,000, respectively, in connection with the Calimmune license.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;LUMC License (MB-110)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;On September 8, 2021, the Company entered into an exclusive, worldwide licensing agreement with LUMC for the use of a gene therapy under development for the treatment of severe immunodeficiency caused by RAG1 deficiency (the &#x201c;LUMC License&#x201d;). Pursuant to the LUMC License, the Company expensed an upfront fee of $0.4&#160;million. Additional payments are due for the achievement of&#160;certain&#160;development milestones totaling up to $31&#160;million and royalty payments in the low to mid-single digits as a percentage of revenue are due on net sales of licensed products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;For the year ended December 31, 2021, the Company expensed an upfront payment of $0.4&#160;million in connection with the LUMC License. &lt;span style="background:#ffffff;"&gt;There were&#160;&lt;/span&gt;no&lt;span style="background:#ffffff;"&gt;&#160;such expenses for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Mayo Clinic - CAR T Technology License&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;On April 1, 2021, the Company entered into an exclusive license agreement with Mayo Clinic for a novel technology that may be able to transform the administration of CAR T therapies and has the potential to be used as an off-the shelf therapy. Pursuant to this agreement, the Company paid an upfront fee of $0.8&#160;million and will pay an annual maintenance fee of $25,000. Additional payments are due for each of two licensed products for the achievement of&#160;eleven&#160;development and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;commercial milestones totaling up to $92.6&#160;million per product, and royalty payments in the mid-single digits as a percentage of revenue are due on net sales of licensed products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;For the&#160;year ended December 31, 2021, the Company expensed an upfront payment of $0.8&#160;million pursuant to the terms of the license agreement. There were&#160;no&#160;such expenses for the year ended December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;"&gt;Research and Development Expenses&#160;- Sponsored Research and Clinical Trial Agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;For the&#160;year ended December 31, 2022 and 2021, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;City of Hope National Medical Center&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;CD123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;IL13R&#x3b1;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,486&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;CS1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 482&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 608&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;HER2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 784&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 697&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;PSCA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 103&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 107&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fred Hutchinson Cancer Center - CD20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,987&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,979&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;St. Jude Children's Research Hospital&#160;- XSCID&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 865&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;LUMC - RAG1 SCID&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 505&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 170&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Mayo Clinic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 968&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 695&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,989&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,591&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;City of Hope&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;CD123 (MB-102) Clinical Research Support Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In February&#160;2017, the Company entered into a Clinical Research Support Agreement for CD123 (the &#x201c;CD123 CRA&#x201d;). Pursuant to the terms of the CD123 CRA the Company made an upfront payment of $19,450 and will contribute an additional $0.1 million per patient in connection with the on-going investigator-initiated study. Further, the Company agreed to fund approximately $0.2 million over three years pertaining to the clinical development of CD123. For the&#160;years ended December 31, 2022 and 2021, the Company recorded $0.2 million and $0.3 million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;IL13R&#x3b1;2 (MB-101) Clinical Research Support Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In February&#160;2017, the Company entered into a Clinical Research Support Agreement for IL13R&#x3b1;2 (the &#x201c;IL13R&#x3b1;2 CRA&#x201d;). Pursuant to the terms of the IL13R&#x3b1;2 CRA the Company made an upfront payment of approximately $9,300 and will contribute an additional $0.1 million related to patient costs in connection with the on-going investigator-initiated study. Further, the Company agreed to fund approximately $0.2 million over three years pertaining to the clinical development of IL13R&#x3b1;2. For the&#160;years ended December 31, 2022 and 2021, the Company recorded $1.5 million and $1.2 million, respectively, in research and development expenses under the IL13R&#x3b1;2 CRA in the Statements of Operations pursuant to the terms of this agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In October 2020, the Company entered into a Clinical Research Support Agreement for the IL13R&#x3b1;2-directed CAR T program for adult patients with leptomeningeal glioblastoma, ependymoma or medulloblastoma (the &#x201c;IL13R&#x3b1;2 Leptomeningeal CRA&#x201d;). Pursuant to the terms of the IL13R&#x3b1;2 Leptomeningeal CRA, the Company made an upfront payment of approximately $29,000 and will contribute an additional $0.1 million per patient in connection with the on-going investigator-initiated study. Further, the Company agreed to fund approximately $0.2 million annually pertaining to the clinical development of the IL13R&#x3b1;2-directed CAR T therapy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In October 2020, the Company entered into a Sponsored Research Agreement (&#x201c;SRA&#x201d;) with COH to conduct combination studies of a potential IL13R&#x3b1;2&lt;i style="font-style:italic;"&gt; &lt;/i&gt;CAR and C134 oncolytic virus therapy. Pursuant to the SRA, the Company funded research in the amount of $0.3 million for the program. In November 2022, the SRA was amended to include additional funding of $0.6 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In March 2021, the Company entered into a clinical research support agreement for an Institutional Review Board-approved, investigator-initiated protocol entitled: &#x201c;Single Patient Treatment with Intraventricular Infusions of IL13R&#x3b1;2-targeting and HER2-targeting CAR T cells for a Single Patient (UPN 181) with Recurrent Multifocal Malignant Glioma.&#x201d; Pursuant to the terms of this agreement, the Company will contribute up to $0.2&#160;million in connection with the ongoing investigator-initiated study.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;CS1 (MB-104) Clinical Research Support Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In June 2020, the Company entered into a clinical research support agreement with COH in connection with an Investigator-sponsored study conducted under an Institutional Review Board-approved, investigator-initiated protocol entitled: &#x201c;Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CS1-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients with CS1+ Multiple Myeloma.&#x201d; The CAR T being studied under this protocol has been designated as MB-104. Under the terms of the agreement the Company will reimburse COH for costs associated with this trial not to exceed $2.4&#160;million. The agreement will expire upon the delivery of a final study report or earlier. For the&#160;years ended December 31, 2022 and 2021, the Company recorded $0.5 million and $0.6 million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. Since inception, the Company has reimbursed COH $1.8 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;HER2 (MB-103) Clinical Research Support Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In September 2020, the Company entered into a clinical research support agreement with COH in connection with an Investigator-sponsored study conducted under an Institutional Review Board-approved, investigator-initiated protocol entitled: &#x201c;Phase I Study of Cellular Immunotherapy using Memory-Enriched T Cells Lentivirally Transduced to Express a HER2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients with Recurrent/Refractory Malignant Glioma.&#x201d; The CAR T being studied under this protocol has been designated as MB-103. Under the terms of the agreement the Company will pay COH $29,375 upon execution and will reimburse COH for costs associated with this trial not to exceed $3.0&#160;million. The agreement will expire upon the delivery of a final study report or earlier. For the&#160;year ended December 31, 2022 and 2021, the Company recorded $0.8 million and $0.7 million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. Since inception, the Company has reimbursed $3.0 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;PSCA (MB-105)&lt;/i&gt;&lt;i style="font-style:italic;"&gt; Clinical Research Support Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In October 2020, the Company entered into a clinical research support agreement with COH in connection with an Investigator-sponsored study conducted under an Institutional Review Board-approved, investigator-initiated protocol entitled: &#x201c;A Phase 1b study to evaluate PSCA-specific chimeric antigen receptor (CAR)-T cells for patients with metastatic castration resistant prostate cancer.&#x201d; The CAR T being studied under this protocol has been designated as MB-105. Under the terms of the agreement the Company will pay COH $33,000 upon execution and will reimburse COH for costs associated with this trial not to exceed $2.3&#160;million. &#160;The agreement will expire upon the delivery of a final study report or earlier. For the&#160;years ended December 31, 2022 and 2021, the Company recorded $0.1 million and $0.1 million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. Since inception, the Company has reimbursed $0.4 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fred Hutch&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-weight:normal;"&gt;CD20 Clinical Trial Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On July&#160;3, 2017, in conjunction with the CD20 Technology License from Fred Hutch, we entered into an investigator-initiated clinical trial agreement (&#x201c;CD20 CTA&#x201d;) to provide partial funding for a Phase 1/2 clinical trial at Fred Hutch &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;evaluating the safety and efficacy of the CD20 Technology in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. In connection with the CD20 CTA, the Company agreed to fund up to $5.3 million of costs associated with the clinical trial, which commenced during the fourth quarter of 2017. In November 2020, the CD20 CTA was amended to include additional funding of approximately $1.8 million for the treatment of five patients with chronic lymphocytic leukemia and other research costs. In January 2022, the CD20 CTA was amended to include additional funding of $2.2 million increasing the total payment obligation of the Company in connection with the CD20 CTA not to exceed $9.3 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;For the&#160;years ended December 31, 2022 and 2021, the Company recorded $2.0 million and $2.0 million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. Since inception, the Company has reimbursed Fred Hutch $7.2 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;XSCID (MB-107) Data Transfer Agreement with St. Jude &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In June 2020, the Company entered into a Data Transfer Agreement with St. Jude under which we will reimburse St. Jude for costs associated with St. Jude&#x2019;s clinical trial for the treatment of infants with XSCID. &#160;Pursuant to the terms of this agreement the Company paid an upfront fee of $1.1&#160;million in July 2020, and will continue to reimburse St. Jude for costs incurred in connection with this clinical trial. For the&#160;years ended December 31, 2022 and 2021, the Company recorded $0.5 million and $0.9 million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. Since inception, the Company has reimbursed St. Jude $3.0 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;RAG1-SCID (MB-110) Sponsored Research Support Agreement with LUMC&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;margin:0pt;"&gt;On September 8, 2021, in connection with the LUMC License, the Company entered into an SRA with LUMC under which the Company will fund research in the amount of approximately $0.5&#160;million annually over a period of&#160;5 years. The research performed pursuant to this agreement will support technology the Company has licensed from LUMC for the use of a gene therapy under development for the treatment of severe immunodeficiency caused by RAG1. For the&#160;year ended December 31, 2022 and 2021, the Company recorded $0.5 million and $0.2 million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Sponsored Research Support Agreement&#160;with Mayo Clinic&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In June 2021, the Company entered into an SRA with Mayo Clinic under which the Company will fund research in the amount of $2.1&#160;million over a period of&#160;two years. The research performed pursuant to this agreement will support technology the Company has licensed from Mayo Clinic for a novel technology that may be able to transform the administration of CAR T therapies and has the potential to be used as an off-the-shelf therapy. In October 2022, the SRA was amended to include additional funding of approximately $0.1 million. For the&#160;year ended December 31, 2022 and 2021, the Company recorded $1.0 million and $0.7 million, respectively, in research and development expenses in the Statements of Operations pursuant to the terms of this agreement. &lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_bEUyP985oUaHNsVrsVxqYQ"
      id="Tb_O4IsLMYdx028I3ZrDqNnnA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;For the&#160;years ended December 31, 2022 and 2021, the Company recorded the following expense in research and development for licenses acquired:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;($ in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;City of Hope National Medical Center&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;CD123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;IV/ICV&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;PSCA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;HER2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;CSL Behring (Calimmune)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Leiden University  Medical Centre&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 350&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Mayo Clinic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fortress PIK Dividend&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,212&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,474&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,842&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_X-M3RGE5aUmOLFk49REASw"
      decimals="-3"
      id="Tc_sUYNrOyhlUKKwAXsy9qBiw_4_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_eqbNchRq0EKHKjmh0pCfeQ"
      decimals="-3"
      id="Tc_j2yux-F6Tk-1vGxHwAWyPw_4_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">250000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_IvIcvProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_HiZjKumNT0SZKUFTzFtdpw"
      decimals="-3"
      id="Tc_9sbWNen5BEuNW1RvtZNrng_5_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">125000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_IvIcvProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_cGzyMH7f9k618wUdJrWh1w"
      decimals="-3"
      id="Tc_sJvfFDBYrUG9AgN5TOd2Gw_5_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_eypHnY-B1U6jSlIjModjUw"
      decimals="-3"
      id="Tc_30CYzMHIzU-JUNtknAN0gQ_6_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_5UGfc7o3YkaygLrJClTgXQ"
      decimals="-3"
      id="Tc_PDmZRDaaeEioeDz9HMqKsg_6_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">250000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_-Awulcu8EUuW8KUUEOHfpQ"
      decimals="-3"
      id="Tc_xeJzEmKnG06oFAzi_JVmGw_7_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">200000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_h2tn3x-z7UuAoS7r_ftqoQ"
      decimals="-3"
      id="Tc_MiiaHwA0UUmpo2ZkYn4wrQ_7_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_2GiFSZkrMEqa7kSRo1sWhQ"
      decimals="-3"
      id="Tc_zShoUBzozU2VVMdMULUoRQ_8_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">40000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_-IXYKwdDrEqLg2blggBbbg"
      decimals="-3"
      id="Tc_QDOt7zlTKE69zMNErwAP4g_8_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">30000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_ecAzAIw_WEizUmdbx34e8w"
      decimals="-3"
      id="Tc_IVAm5tBS20usCyycOIdoBQ_9_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_S6NInTxBvUmnCq_IJxa26g"
      decimals="-3"
      id="Tc_xqOvi_yQ2ECmUKFxESCbhw_9_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">350000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_MMf1jaQkGEia07UBzms6Wg"
      decimals="-3"
      id="Tc_JPca3aipJkqA1YlRn8fYeg_10_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_DB6MYEz08kyNAf6LM9F59A"
      decimals="-3"
      id="Tc_AUz1UfCvi0Czp1ZeJ_cRSQ_10_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">750000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_FortressBiotechIncMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_3Vh1oZCe0keLsUyEjlCcKw"
      decimals="-3"
      id="Tc_EYBHzr2lmEi9q8i0RNKzOQ_11_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1109000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_FortressBiotechIncMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_qumY3pBwC0W2YfvPR7QXUA"
      decimals="-3"
      id="Tc_DYsvOdo2cUO3VN0EU99OgA_11_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">4212000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_bEUyP985oUaHNsVrsVxqYQ"
      decimals="-3"
      id="Tc_4yKIoqA2q0WH_smf0qpagw_12_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1474000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_5I7r1d0H1kGd9E-MDAoc_Q"
      decimals="-3"
      id="Tc_5KiVmUV7EECFLSjNNVUdgw_12_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">5842000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <mbio:AnnualMaintenanceFeePayable
      contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_GxvcEL9tsUGqvDvu2x4erg"
      decimals="0"
      id="Narr_4opelZuPDU-YuAs1WMLgjw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">25000</mbio:AnnualMaintenanceFeePayable>
    <mbio:MilestonesPayableUnderArrangement
      contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_GxvcEL9tsUGqvDvu2x4erg"
      decimals="-5"
      id="Narr_7Nv9g784IE6H1BFgQEccbw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">14500000</mbio:MilestonesPayableUnderArrangement>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_eqbNchRq0EKHKjmh0pCfeQ"
      decimals="-5"
      id="Narr_PIl-dcEHbkGQMixEjgcisw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">300000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <mbio:NonRefundableMilestonePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_X-M3RGE5aUmOLFk49REASw"
      decimals="-5"
      id="Narr_3p4kx_83tkCquUcjTt5Maw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</mbio:NonRefundableMilestonePayments>
    <mbio:PaymentOfUpfrontFees
      contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_IvIcvProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_kFOATtbMhEW9Vm5Z1U3trQ"
      decimals="-5"
      id="Narr_IkMwcfuUCEWEyly-mm3cHQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">100000</mbio:PaymentOfUpfrontFees>
    <mbio:MilestonesPayableUnderArrangement
      contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_IvIcvProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_kFOATtbMhEW9Vm5Z1U3trQ"
      decimals="-5"
      id="Narr_w4IXpVdmh02AgOMJ9a1cjA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">100000</mbio:MilestonesPayableUnderArrangement>
    <mbio:AnnualMaintenanceFeePayable
      contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_IvIcvProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_kFOATtbMhEW9Vm5Z1U3trQ"
      decimals="0"
      id="Narr_ZODCLt2V2kKPgIgkFIawpw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">25000</mbio:AnnualMaintenanceFeePayable>
    <mbio:NonRefundableMilestonePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_IvIcvProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_HiZjKumNT0SZKUFTzFtdpw"
      decimals="-5"
      id="Narr_ioFHnIDKyUCZM4L1ivqIwg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">100000</mbio:NonRefundableMilestonePayments>
    <mbio:NonRefundableMilestonePayments
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_IvIcvProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_cGzyMH7f9k618wUdJrWh1w"
      decimals="-5"
      id="Narr_q5X8qXKtN0-0dMKzcD3Log"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</mbio:NonRefundableMilestonePayments>
    <mbio:PaymentOfUpfrontFees
      contextRef="Duration_5_1_2017_To_5_31_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_jWZU2RYRvEei-C0QMO7buA"
      decimals="-5"
      id="Narr_LEQvEyiNyUa5UN0_l0_Bmg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">300000</mbio:PaymentOfUpfrontFees>
    <mbio:AnnualMaintenanceFeePayable
      contextRef="Duration_5_1_2017_To_5_31_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_jWZU2RYRvEei-C0QMO7buA"
      decimals="0"
      id="Narr_Fqe0pldnwkCVhVG_OlWU9g"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">50000</mbio:AnnualMaintenanceFeePayable>
    <mbio:NumberOfMilestonesMeasured
      contextRef="Duration_5_1_2017_To_5_31_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_jWZU2RYRvEei-C0QMO7buA"
      decimals="INF"
      id="Narr__eFvjWedO0i-7TqB30saSQ"
      unitRef="Unit_Standard_item_e-lAqZ63ukC9AQjaK0X33Q">10</mbio:NumberOfMilestonesMeasured>
    <mbio:MilestonesPayableUnderArrangement
      contextRef="Duration_5_1_2017_To_5_31_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_jWZU2RYRvEei-C0QMO7buA"
      decimals="-5"
      id="Narr_fRCFQWtKU0yRMLzKkHiCVQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">14900000</mbio:MilestonesPayableUnderArrangement>
    <mbio:NonRefundableMilestonePayments
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_5UGfc7o3YkaygLrJClTgXQ"
      decimals="-5"
      id="Narr_74KXrjrEMUe_6svNwcaQDA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">300000</mbio:NonRefundableMilestonePayments>
    <mbio:NonRefundableMilestonePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_eypHnY-B1U6jSlIjModjUw"
      decimals="-5"
      id="Narr_7UPEVuEG9kOwD3wyY8wjQQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</mbio:NonRefundableMilestonePayments>
    <mbio:PaymentOfUpfrontFees
      contextRef="Duration_5_1_2017_To_5_31_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_OhC3qwHZBUG5jIk8E5CveA"
      decimals="-5"
      id="Narr_9Y68tnzBYkiQxyf-W3RuQw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">600000</mbio:PaymentOfUpfrontFees>
    <mbio:AnnualMaintenanceFeePayable
      contextRef="Duration_5_1_2017_To_5_31_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_OhC3qwHZBUG5jIk8E5CveA"
      decimals="-3"
      id="Narr_sMPNF9EthkyRvpkFj1JXhw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">50000</mbio:AnnualMaintenanceFeePayable>
    <mbio:NumberOfMilestonesMeasured
      contextRef="Duration_5_1_2017_To_5_31_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_OhC3qwHZBUG5jIk8E5CveA"
      decimals="0"
      id="Narr_NiE9lkXsekCh8EplNYmhPw"
      unitRef="Unit_Standard_item_e-lAqZ63ukC9AQjaK0X33Q">10</mbio:NumberOfMilestonesMeasured>
    <mbio:MilestonesPayableUnderArrangement
      contextRef="Duration_5_1_2017_To_5_31_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_OhC3qwHZBUG5jIk8E5CveA"
      decimals="-5"
      id="Narr_OsuJO0RzOkeL6VZ0YaAvhg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">14900000</mbio:MilestonesPayableUnderArrangement>
    <mbio:NonRefundableMilestonePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_-Awulcu8EUuW8KUUEOHfpQ"
      decimals="-5"
      id="Narr_JqBAT330XUa5naVvpGk69A"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">200000</mbio:NonRefundableMilestonePayments>
    <mbio:NonRefundableMilestonePayments
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_h2tn3x-z7UuAoS7r_ftqoQ"
      decimals="-5"
      id="Narr_Ggew1Vkwb023KKsxblpkuQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</mbio:NonRefundableMilestonePayments>
    <mbio:PaymentOfUpfrontFees
      contextRef="Duration_8_23_2019_To_8_23_2019_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_GZks_7XceUyp2L41ZnWzfw"
      decimals="-5"
      id="Narr_VipM45SDo0SO_d3rx2Z_tQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">200000</mbio:PaymentOfUpfrontFees>
    <mbio:MilestonesPayableUnderArrangement
      contextRef="Duration_8_23_2019_To_8_23_2019_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_GZks_7XceUyp2L41ZnWzfw"
      decimals="-5"
      id="Narr_6GXfDJb7dUqAtMWszj2n8Q"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1200000</mbio:MilestonesPayableUnderArrangement>
    <mbio:NumberOfMilestonesMeasured
      contextRef="Duration_8_23_2019_To_8_23_2019_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_GZks_7XceUyp2L41ZnWzfw"
      decimals="0"
      id="Narr_QMYAGAiOik-XaDrQaKg2IQ"
      unitRef="Unit_Standard_item_e-lAqZ63ukC9AQjaK0X33Q">3</mbio:NumberOfMilestonesMeasured>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_2GiFSZkrMEqa7kSRo1sWhQ"
      decimals="0"
      id="Narr_zQNGACgOmE6gP-lTu08eow"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">40000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_-IXYKwdDrEqLg2blggBbbg"
      decimals="0"
      id="Narr_BgBvYWH9dkKdqwOf5HAdrw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">30000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <mbio:PaymentOfUpfrontFees
      contextRef="Duration_9_8_2021_To_9_8_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_8Z3KAV2B-EeZv3xSHR1e1g"
      decimals="-5"
      id="Narr_zPyStYJxhE-i0Bbf9k3z0Q"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">400000</mbio:PaymentOfUpfrontFees>
    <mbio:MilestonesPayableUnderArrangement
      contextRef="Duration_9_8_2021_To_9_8_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_8Z3KAV2B-EeZv3xSHR1e1g"
      decimals="-6"
      id="Narr_6iMImiJd_EOThuxIZzSYNw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">31000000</mbio:MilestonesPayableUnderArrangement>
    <mbio:NonRefundableMilestonePayments
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_S6NInTxBvUmnCq_IJxa26g"
      decimals="-5"
      id="Narr_LpJRTXxKSUiKqMQmOygdDg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">400000</mbio:NonRefundableMilestonePayments>
    <mbio:PaymentOfUpfrontFees
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_ecAzAIw_WEizUmdbx34e8w"
      decimals="-5"
      id="Narr_1U48VhlLDEO_3Z8uHmpqCw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</mbio:PaymentOfUpfrontFees>
    <mbio:PaymentOfUpfrontFees
      contextRef="Duration_4_1_2021_To_4_1_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_agKp6cvBpEy4-mIqOjcSeg"
      decimals="-5"
      id="Narr_lCkjCNwTakOlqwdKBVzOAA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">800000</mbio:PaymentOfUpfrontFees>
    <mbio:AnnualMaintenanceFeePayable
      contextRef="Duration_4_1_2021_To_4_1_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_M1lvnrfyyUG8MMd-TFM3OA"
      decimals="0"
      id="Narr_chip0dSSAkGPemKV5Y7Thw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">25000</mbio:AnnualMaintenanceFeePayable>
    <mbio:NumberOfMilestonesMeasured
      contextRef="Duration_4_1_2021_To_4_1_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_M1lvnrfyyUG8MMd-TFM3OA"
      decimals="0"
      id="Narr_OUXYZdaBAUCsGeX9gcoafQ"
      unitRef="Unit_Standard_Milestone_13Bi5jCZBUqZT3I2C4rjww">11</mbio:NumberOfMilestonesMeasured>
    <mbio:MilestonesPayableUnderArrangement
      contextRef="Duration_4_1_2021_To_4_1_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_M1lvnrfyyUG8MMd-TFM3OA"
      decimals="-5"
      id="Narr_0TEK2CTFUk2pFgekjVErxQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">92600000</mbio:MilestonesPayableUnderArrangement>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_DB6MYEz08kyNAf6LM9F59A"
      decimals="-5"
      id="Narr_QZaCa6Mc8kuuMRQFJXra9Q"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">800000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <mbio:PaymentOfUpfrontFees
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_MMf1jaQkGEia07UBzms6Wg"
      decimals="-5"
      id="Narr_tlCcmCJ4D0Wfx8zprQfZYA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</mbio:PaymentOfUpfrontFees>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Vx1emwLJJ0qXsajS4OcXww"
      id="Tb_TVBirgOLM0qwXH45BCsu1A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;For the&#160;year ended December 31, 2022 and 2021, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;City of Hope National Medical Center&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;CD123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;IL13R&#x3b1;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,486&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;CS1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 482&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 608&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;HER2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 784&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 697&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;PSCA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 103&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 107&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fred Hutchinson Cancer Center - CD20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,987&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,979&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;St. Jude Children's Research Hospital&#160;- XSCID&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 865&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;LUMC - RAG1 SCID&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 505&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 170&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Mayo Clinic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 968&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 695&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,989&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,591&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_aP7yNOKuS0aTGB-ItbnSAA"
      decimals="-3"
      id="Tc_5Aq-OuyEb0KbljliINDrSg_3_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_0NxXjiJgYkGL9rgKRUKG0w"
      decimals="-3"
      id="Tc_ubbigLQ1f020sTsSycjJVg_3_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_flIxGqK8EE-qTKhiUM7P5g"
      decimals="-3"
      id="Tc_dMt_p4J3OU2zEveUDf9yqw_4_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">166000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_1tC8VQmSzUSfIFLGkJX9ig"
      decimals="-3"
      id="Tc_A0_RIFKgDkGV76DjcZpOzQ_4_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">301000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_GJMbltW_ckGM-82fZ6QN9A"
      decimals="-3"
      id="Tc_-_3v0G-arUS5oFDf2PXpbQ_5_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1486000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_7XG-WubxyUykOLnPy8K1fQ"
      decimals="-3"
      id="Tc_-TE2P7x_bEa3Hyx2xWIPsw_5_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1169000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cs1ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_OpIS0Aptykyt0fbMp5ngcw"
      decimals="-3"
      id="Tc_8bo7Gg3U10iA38pvjgNTHw_6_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">482000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cs1ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_-91cVSuwk066vgPNrl9tAA"
      decimals="-3"
      id="Tc_1V-Kl7lHaUehjcPE9HU5NA_6_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">608000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_nzRdZgaBgkaKZuJTpHtWXg"
      decimals="-3"
      id="Tc_yjvF8xY-QkuHsEgsOjnBhA_7_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">784000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Avzs-VjlYkyzUP2irGzjQg"
      decimals="-3"
      id="Tc_yZIttLOTCkaODVoNSud3AQ_7_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">697000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_LFLvm316o0SOUKQxhoo0Mw"
      decimals="-3"
      id="Tc_22tRDaOpY0u7hacxmQWVlA_8_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">103000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_VrwnpcakNUyyqsooiwPWOA"
      decimals="-3"
      id="Tc_Oh-EvSpicEy8PA4tqZCWiw_8_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">107000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_AHlPXFWbm0S4f23bwODBgw"
      decimals="-3"
      id="Tc_fZ5Y2HpVo0SEWrgM60aa6g_9_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1987000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_g-WN3OcgMk2PMIpOmGZ7LA"
      decimals="-3"
      id="Tc_V1EAxMtr906-b3hRKM7DoA_9_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1979000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_WndiQxEyWkK5zt6u8QU19g"
      decimals="-3"
      id="Tc_yx5J19l4vUmAjAry1ZyG8Q_10_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">508000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_QpA72oZJUkisoiKeboPylg"
      decimals="-3"
      id="Tc_SNr68MoqlUm047t5y2SzJA_10_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">865000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_srt_ProductOrServiceAxis_mbio_Rag1ScidMb110Member_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_JHL0mUan5USsk0GX6mP-bA"
      decimals="-3"
      id="Tc_lCI6AmBq30SHjnFCy-gD2Q_11_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">505000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_srt_ProductOrServiceAxis_mbio_Rag1ScidMb110Member_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_KgtU9Mq_mkeeWrJ3yEjrEQ"
      decimals="-3"
      id="Tc_RaiMZZE7ykKAtdrIJ8Z7AQ_11_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">170000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_A95Rt4-jPk231qSpo9U-FQ"
      decimals="-3"
      id="Tc_I9Ki17mrYkKWNZPx0tBTKg_12_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">968000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_G3TY0ZFyQk2j7jey4doOng"
      decimals="-3"
      id="Tc_cBGiT2wLqUSTkC3ry_I5pw_12_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">695000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Vx1emwLJJ0qXsajS4OcXww"
      decimals="-3"
      id="Tc_utjR1-Of30KeGtljI6dwHA_13_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">6989000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_ycCeI3y-e0qyb7nr_-5MKA"
      decimals="-3"
      id="Tc_9L2VoiuedkeBI8yi48y0LQ_13_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">6591000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <mbio:PaymentOfUpfrontFees
      contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_ejb848nGTkG3ypqRxMLthA"
      decimals="0"
      id="Narr_kq182VjQP06SfyrvqNGD2w"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">19450</mbio:PaymentOfUpfrontFees>
    <mbio:ResearchArrangementContributionPerPatient
      contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_ejb848nGTkG3ypqRxMLthA"
      decimals="-5"
      id="Narr_ENrzItgV9UugR8QcTIeT1Q"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">100000</mbio:ResearchArrangementContributionPerPatient>
    <mbio:MilestonesPayableUnderArrangement
      contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_ejb848nGTkG3ypqRxMLthA"
      decimals="-5"
      id="Narr_A_dFVk2Ty0C6FubbCmjJxw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">200000</mbio:MilestonesPayableUnderArrangement>
    <mbio:ResearchArrangementTerm
      contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_ejb848nGTkG3ypqRxMLthA"
      id="Narr_0N1tH1xB30CRKUWekEj6rg">P3Y</mbio:ResearchArrangementTerm>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_flIxGqK8EE-qTKhiUM7P5g"
      decimals="-5"
      id="Narr_EvcWPCvrHU--hFZQpH0LUg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cd123ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_1tC8VQmSzUSfIFLGkJX9ig"
      decimals="-5"
      id="Narr_ofHgwTU-fk6dXtvOJ50CmQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <mbio:PaymentOfUpfrontFees
      contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Qj0QYtgKVEW8_VkZm7xUBg"
      decimals="0"
      id="Narr__Tkh3YYJQEGbR38eiob2_w"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">9300</mbio:PaymentOfUpfrontFees>
    <mbio:ContributionTowardPatientCosts
      contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Qj0QYtgKVEW8_VkZm7xUBg"
      decimals="-5"
      id="Narr_9lB3vOc82U2uNTE9FpXxiQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">100000</mbio:ContributionTowardPatientCosts>
    <mbio:MilestonesPayableUnderArrangement
      contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Qj0QYtgKVEW8_VkZm7xUBg"
      decimals="-5"
      id="Narr_m0V5ZBnhZ0-8pyFzCvgGBA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">200000</mbio:MilestonesPayableUnderArrangement>
    <mbio:ResearchArrangementTerm
      contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Qj0QYtgKVEW8_VkZm7xUBg"
      id="Narr_OqOuJunmA06tDrCW4bI9Xw">P3Y</mbio:ResearchArrangementTerm>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_GJMbltW_ckGM-82fZ6QN9A"
      decimals="-5"
      id="Narr_dNQaUrMrDUywJn54FqZPAQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_7XG-WubxyUykOLnPy8K1fQ"
      decimals="-5"
      id="Narr_mP8lzz392kCx4sXC3UireA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <mbio:PaymentOfUpfrontFees
      contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_SW1jOKKvIUWxGq9g6tUp4A"
      decimals="0"
      id="Narr_TNeIDBQ9FEKFF8HdStItWw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">29000</mbio:PaymentOfUpfrontFees>
    <mbio:ResearchArrangementContributionPerPatient
      contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_SW1jOKKvIUWxGq9g6tUp4A"
      decimals="-5"
      id="Narr_WrT7EoewAUCNKZXSxVjU1Q"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">100000</mbio:ResearchArrangementContributionPerPatient>
    <mbio:AnnualMaintenanceFeePayable
      contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_SW1jOKKvIUWxGq9g6tUp4A"
      decimals="-5"
      id="Narr_qCJhxHboU0WvZR8bXiLYcg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">200000</mbio:AnnualMaintenanceFeePayable>
    <mbio:ResearchFundingAmount
      contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_SW1jOKKvIUWxGq9g6tUp4A"
      decimals="-5"
      id="Narr_wL_MIjBGQEucOjZ6RanYjw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">300000</mbio:ResearchFundingAmount>
    <mbio:ResearchFundingAmount
      contextRef="Duration_11_1_2022_To_11_30_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_J2PMFy7590ayhjU1Z1lmBg"
      decimals="-5"
      id="Narr_T73XanUp70SvAduygUJ4Wg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">600000</mbio:ResearchFundingAmount>
    <mbio:AnnualMaintenanceFeePayable
      contextRef="Duration_3_1_2021_To_3_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Il13r2ProductMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_te1_6uZCuEC4P4P0W1cmfQ"
      decimals="-5"
      id="Narr_Nsx65vwdAk6IKuYLAMWYOQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">200000</mbio:AnnualMaintenanceFeePayable>
    <mbio:MilestonesPayableUnderArrangement
      contextRef="Duration_6_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cs1ProductOrProcessMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_-VT2Q3jlP0OWPKoY-Ng3pA"
      decimals="-5"
      id="Narr_lOmjgEMsiU6pQxgw7__Zgg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2400000</mbio:MilestonesPayableUnderArrangement>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cs1ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_OpIS0Aptykyt0fbMp5ngcw"
      decimals="-5"
      id="Narr_IXwbGGHwpk2qZ66RWeDY0g"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cs1ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_-91cVSuwk066vgPNrl9tAA"
      decimals="-5"
      id="Narr_KD2exAK-f0u9TJv-ZHgM3Q"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <mbio:ReimbursementOfFeesTotalPayments
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Cs1ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_EPbH-hiMk0qoLFPq4Tyodw"
      decimals="-5"
      id="Narr_LwA2aGB3iUi-9VCT8RiH5Q"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1800000</mbio:ReimbursementOfFeesTotalPayments>
    <mbio:MilestonesPayableUnderArrangement
      contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_RkSGNTQj7kufffNWRIAKsA"
      decimals="0"
      id="Narr_aa_x92N2k0u-Iz10G5UAyw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">29375</mbio:MilestonesPayableUnderArrangement>
    <mbio:MilestonesPayableUnderArrangement
      contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_z0SUrOJETEa8go8i01WkEg"
      decimals="-5"
      id="Narr_8YfpcBNs0USrXTQBMWW8_w"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">3000000.0</mbio:MilestonesPayableUnderArrangement>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_nzRdZgaBgkaKZuJTpHtWXg"
      decimals="-5"
      id="Narr_NoWHt4GmDk6IL5-GmiXDhg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_Avzs-VjlYkyzUP2irGzjQg"
      decimals="-5"
      id="Narr__VLGOkvFp0GLZ37aIMcdpA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <mbio:ReimbursementOfFeesTotalPayments
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_AbCiEvU7_0uU3dzq5HkUFg"
      decimals="-5"
      id="Narr_j9rxBQMp9023MPDWtAZ8Jw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">3000000.0</mbio:ReimbursementOfFeesTotalPayments>
    <mbio:MilestonesPayableUnderArrangement
      contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_brP4CCoYMUKzdsYDsNVEpw"
      decimals="0"
      id="Narr_-wF4AKhxg021ykSVHLWYtQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">33000</mbio:MilestonesPayableUnderArrangement>
    <mbio:MilestonesPayableUnderArrangement
      contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_wJVqrbyFSU-cHpd2pZX10g"
      decimals="-5"
      id="Narr_K0-anN9jWkCukBfJuGa2iA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2300000</mbio:MilestonesPayableUnderArrangement>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_LFLvm316o0SOUKQxhoo0Mw"
      decimals="-5"
      id="Narr_N0fyRbKaEkW6fqQuyWphmQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_VrwnpcakNUyyqsooiwPWOA"
      decimals="-5"
      id="Narr_W7kCUqh6eU-87Grt7Ny-pg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <mbio:ReimbursementOfFeesTotalPayments
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_PscaProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_cspaXnUxZku0Ws6QbCLXDg"
      decimals="-5"
      id="Narr_BXaC4xQid0qBFzFU5hiceQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">400000</mbio:ReimbursementOfFeesTotalPayments>
    <mbio:MilestonesPayableUnderArrangement
      contextRef="Duration_7_3_2017_To_7_3_2017_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_CcHvzBIXtUODWCVXYAQe_w"
      decimals="-5"
      id="Narr_5tFlNo4e5UeXgm5aP3J4lg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">5300000</mbio:MilestonesPayableUnderArrangement>
    <mbio:AdditionalMilestonesPayableUnderArrangement
      contextRef="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_nx8c3dUXCUmIniCJJw81FQ"
      decimals="-5"
      id="Narr_vhowvR6_tEia5DsUG2fpMw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1800000</mbio:AdditionalMilestonesPayableUnderArrangement>
    <mbio:AdditionalMilestonesPayableUnderArrangement
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_k8cUiopjJ0W74a5rURwE8g"
      decimals="-5"
      id="Narr_aSuHqZGUuUefwZRcK47ifQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2200000</mbio:AdditionalMilestonesPayableUnderArrangement>
    <mbio:AdditionalMilestonesPayableUnderArrangement
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_HChGYU6CSUCiuMb3wOIWmA"
      decimals="-5"
      id="Narr_ukPZLfbiNke3mT_VWRtCxw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">9300000</mbio:AdditionalMilestonesPayableUnderArrangement>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_ClinicalTrialAgreementsMember_Cyw5EJBd1UirM-BcQ7nr3Q"
      decimals="-5"
      id="Narr_Qs0c0buN8UauCdLgYSdG8w"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_ClinicalTrialAgreementsMember_IjKtndA3yU-D5J-KXPKfPw"
      decimals="-5"
      id="Narr_UBHll0SqGEyiva2zY9L5JA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <mbio:ReimbursementOfFeesTotalPayments
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_ClinicalTrialAgreementsMember_rf7xSABuqkO4KGuRWtqIrw"
      decimals="-5"
      id="Narr_aO0XKM1lBU-HJglNxRZ37w"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">7200000</mbio:ReimbursementOfFeesTotalPayments>
    <mbio:PaymentOfUpfrontFees
      contextRef="Duration_6_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_DataTransferAgreementMember_eFtEz1VOwUqbB4jKDO66nw"
      decimals="-5"
      id="Narr_Y8iG3OEuwUCp1wGpqyBVsw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1100000</mbio:PaymentOfUpfrontFees>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_DataTransferAgreementMember_-H0TdacBZkabwWvQhfMbVw"
      decimals="-5"
      id="Narr_mqBkjomtsEGhHLP8VTyeDw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_DataTransferAgreementMember_3BooSMscyEWc_UdmNkhn6w"
      decimals="-5"
      id="Narr_LYiOwDTFPkqhC1xHvy7cKA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <mbio:ReimbursementOfFeesTotalPayments
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_St.JudeChildrensResearchHospitalMember_srt_ProductOrServiceAxis_mbio_StJudeXscidMember_us-gaap_TypeOfArrangementAxis_mbio_DataTransferAgreementMember_jXidwRe_gUC02_iRlrhLpA"
      decimals="-5"
      id="Narr_B2pVfWpBi0G57k3XflZfHw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">3000000.0</mbio:ReimbursementOfFeesTotalPayments>
    <mbio:MilestonesPayableUnderArrangement
      contextRef="Duration_9_8_2021_To_9_8_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_srt_ProductOrServiceAxis_mbio_Rag1ScidMb110Member_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_PDhxhJes-E2hyBDbO6sjlQ"
      decimals="-5"
      id="Narr_RKL5d1Gpsky48FT1pehNbQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">500000</mbio:MilestonesPayableUnderArrangement>
    <mbio:ResearchArrangementTerm
      contextRef="Duration_9_8_2021_To_9_8_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_srt_ProductOrServiceAxis_mbio_Rag1ScidMb110Member_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_PDhxhJes-E2hyBDbO6sjlQ"
      id="Narr_UAhVmREqdUCJzRQwy0Rn2g">P5Y</mbio:ResearchArrangementTerm>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_srt_ProductOrServiceAxis_mbio_Rag1ScidMb110Member_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_JHL0mUan5USsk0GX6mP-bA"
      decimals="-5"
      id="Narr_mSwCSvwV-UaV3S66A_Zy4A"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_LeidenUniversityMedicalCentreMember_srt_ProductOrServiceAxis_mbio_Rag1ScidMb110Member_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_KgtU9Mq_mkeeWrJ3yEjrEQ"
      decimals="-5"
      id="Narr_cLrbX4rurkewJVo0ZAVLUA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <mbio:MilestonesPayableUnderArrangement
      contextRef="Duration_6_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_DEvYfskaDUCi1Vhldrs8yw"
      decimals="-5"
      id="Narr_kxr_a_0L3EmRgWdHoituFg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2100000</mbio:MilestonesPayableUnderArrangement>
    <mbio:ResearchArrangementTerm
      contextRef="Duration_6_1_2021_To_6_30_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_DEvYfskaDUCi1Vhldrs8yw"
      id="Narr_vpDEgahwoEyR-2zHsl2Lug">P2Y</mbio:ResearchArrangementTerm>
    <mbio:AdditionalMilestonesPayableUnderArrangement
      contextRef="Duration_10_1_2022_To_10_31_2022_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_9mu0h1oYPUqhtCqCC9mKMA"
      decimals="-5"
      id="Narr_p4FafwEG3UWQN_ATrx23ig"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">100000</mbio:AdditionalMilestonesPayableUnderArrangement>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_A95Rt4-jPk231qSpo9U-FQ"
      decimals="-5"
      id="Narr_jGVhl3CxYU2mrQC8CDYNew"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_mbio_MayoClinicMember_us-gaap_TypeOfArrangementAxis_mbio_SponsoredResearchAndClinicalTrialAgreementsMember_G3TY0ZFyQk2j7jey4doOng"
      decimals="-5"
      id="Narr_tzJl_cDIQU27voYtkf-vyQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_vQHjGF4OGkqxFlS-ZwMxAQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;4&#160;- Related Party Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Founders Agreement and Management Services Agreement with Fortress&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Effective March&#160;13, 2015, the Company entered a Founders Agreement with Fortress, which was amended and restated on May&#160;17, 2016, and again on July&#160;26, 2016 (the &#x201c;Mustang Founders Agreement&#x201d;). The Mustang Founders Agreement provides that, in exchange for the time and capital expended in the formation of Mustang and the identification of specific assets the acquisition of which result in the formation of a viable emerging growth life science company, Fortress loaned $2.0 million, representing the up-front fee required to acquire the Company&#x2019;s license agreement with COH. The Mustang Founders Agreement has a term of 15 years, which upon expiration automatically renews for successive one-year periods unless terminated by Fortress and the Company or a Change in Control (as defined in the Mustang Founders Agreement) occurs. Concurrently with the second amendment on July&#160;26, 2016, to the Mustang Founders Agreement, Fortress entered into an Exchange Agreement whereby Fortress exchanged its 7.25 million Class&#160;B Common shares for 7.0 million common shares and 250,000 Class&#160;A Preferred shares. Class&#160;A Preferred Stock is identical to common stock other than as to voting &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;rights, conversion rights and the PIK Dividend right (as described below). Each share of Class&#160;A Preferred Stock is entitled to vote the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A)&#160;the shares of outstanding Mustang common stock and (B)&#160;the whole shares of Mustang common stock into which the shares of outstanding Class&#160;A Common Stock and Class&#160;A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class&#160;A Preferred Stock. Thus, the Class&#160;A Preferred Stock will at all times constitute a voting majority. Each share of Class&#160;A Preferred Stock is convertible, at Fortress&#x2019; option, into one fully paid and nonassessable share of Mustang common stock, subject to certain adjustments. As holders of Class&#160;A Preferred Stock, Fortress will receive on each January&#160;1 (each a &#x201c;PIK Dividend Payment Date&#x201d;) until the date all outstanding Class&#160;A Preferred Stock is converted into common stock, pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (&#x201c;PIK Dividends&#x201d;) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half&#160;percent (2.5%) of Mustang&#x2019;s fully-diluted outstanding capitalization on the date that is &lt;span style="-sec-ix-hidden:Hidden_t6gbwtw4fkmKVT_BgWRqSA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; (1)&#160;business day prior to any PIK Dividend Payment Date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;As additional consideration under the Mustang Founders Agreement, Mustang will also: (i)&#160;pay an equity fee in shares of common stock, payable within &lt;span style="-sec-ix-hidden:Hidden_IKJI1MNkyk-jVARLuqEz6w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt; (5)&#160;business&#160;days of the closing of any equity or debt financing for Mustang that occurs after the effective date of the Mustang Founders Agreement and ending on the date when Fortress no longer has majority voting control in the Company&#x2019;s voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii)&#160;pay a cash fee equal to four and one-half&#160;percent (4.5%) of the Company&#x2019;s annual net sales, payable on an annual basis, within &lt;span style="-sec-ix-hidden:Hidden_ZlvSq5CKKECYsdUUYJlnYw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;ninety&lt;/span&gt;&lt;/span&gt; (90)&#160;days of the end of each calendar&#160;year. In the event of a Change in Control, the Company will pay a one-time change in control fee equal to five (5x) times the product of (A)&#160;net sales for the &lt;span style="-sec-ix-hidden:Hidden_oihncYEzmEirIm889SKJsg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;twelve&lt;/span&gt;&lt;/span&gt; (12)&#160;months immediately preceding the change in control and (B)&#160;four and one-half&#160;percent (4.5%) (see Note&#160;9).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Effective as of March&#160;13, 2015, the Company entered into a Management Services Agreement (the &#x201c;MSA&#x201d;) with Fortress, pursuant to which Fortress renders advisory and consulting services to the Company. The MSA has an initial term of five years and is automatically renewed for successive five-year terms unless terminated in accordance with its provisions. Services provided under the MSA may include, without limitation, (i)&#160;advice and assistance concerning any and all aspects of the Company&#x2019;s operations, clinical trials, financial planning and strategic transactions and financings and (ii)&#160;conducting relations on behalf of the Company with accountants, attorneys, financial advisors and other professionals (collectively, the &#x201c;Services&#x201d;). The Company is obligated to utilize clinical research services, medical education, communication and marketing services and investor relations/public relation services of companies or individuals designated by Fortress, provided those services are offered at market prices. However, the Company is not obligated to take or act upon any advice rendered from Fortress and Fortress shall not be liable for any of its actions or inactions based upon their advice. Pursuant to the MSA and the Company&#x2019;s Certificate of Incorporation, Fortress and its affiliates, including all members of the Company&#x2019;s Board of Directors, will have no fiduciary or other duty to communicate or present any corporate opportunities to the Company or to refrain from engaging in business that is similar to that of the Company. In consideration for the Services, the Company will pay Fortress an annual consulting fee of $0.5 million (the &#x201c;Annual Consulting Fee&#x201d;), payable in advance in equal quarterly installments on the first business day of each calendar quarter in each&#160;year, provided, however, that such Annual Consulting Fee shall be increased to $1.0 million for each calendar&#160;year in which the Company has net assets in excess of $100 million at the beginning of the calendar&#160;year. The Company records fifty percent of the Annual Consulting Fee in research and development expense and fifty percent in general and administrative expense in the Statement of Operations. For the&#160;years ended December 31, 2022 and 2021, the Company recorded expense of $1.0 million and $0.5 million, respectively, related to this agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;For the year ended December 31, 2022, the Company issued&#160;196,952&#160;shares of common stock and recorded zero shares issuable to Fortress, which equaled&#160;2.5% of the gross proceeds of $6.6&#160;million from the sale of shares of common stock under Mustang&#x2019;s At-the-Market Offering. The Company recorded an expense of approximately $0.2&#160;million in general and administrative expenses related to these shares for the year ended December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;For the year ended December 31, 2021, the Company issued&#160;576,157&#160;shares of common stock and recorded&#160;51,295&#160;shares issuable to Fortress, which equaled&#160;2.5% of the gross proceeds of $71.9&#160;million from the sale of shares of common stock under Mustang&#x2019;s At-the-Market Offering. The Company recorded an expense of approximately $1.9&#160;million in general and administrative expenses related to these shares for the year ended December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Payables and Accrued Expenses Related Party&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In the normal course of business Fortress pays for certain expenses on behalf of the Company. Such expenses are recorded as Payables and accrued expenses&#160;- related party and are reimbursed to Fortress in the normal course of business.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Director Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Dr.&#160;Rosenwald&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Pursuant to the terms of the Director Compensation Plan, Dr.&#160;Rosenwald will receive a cash fee of $50,000 per&#160;year paid quarterly and an annual stock award of the greater of (i)&#160;a number of shares of common stock having a fair market value on the grant date of $50,000 or (ii)&#160;10,000 shares of common stock, which shares shall vest and become non-forfeitable on the third anniversary of the grant date, subject to continued service on the Board on such date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;For the&#160;year ended December 31, 2022, the Company recognized $100,000 in expense in its Statements of Operations related to the director compensation, including approximately $50,000 in expense related to equity incentive grants. For the&#160;year ended December 31, 2021, the Company recognized $106,000 in expense in its Statements of Operations related to the director compensation, including approximately $56,000 in expense related to equity incentive grants. The Company issued Dr. Rosenwald 71,664 and 13,774 restricted stock awards for the&#160;years ended December 31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Mr.&#160;Weiss&#160;- Advisory Agreement with Caribe BioAdvisors, LLC&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Board of the Company by unanimous written consent approved and authorized the execution of an advisory agreement dated January&#160;1, 2017 (the &#x201c;Advisory Agreement&#x201d;), with Caribe BioAdvisors, LLC (the &#x201c;Advisor&#x201d;), owned by Michael S. Weiss, the Chairman of the Board, to provide the board advisory services of Mr.&#160;Weiss as Chairman of the Board. Pursuant to the Advisory Agreement, the Advisor will be paid an annual cash fee of $60,000, paid quarterly and an annual stock award of the greater of (i)&#160;a number of shares of common stock having a fair market value on the grant date of $50,000 or (ii)&#160;10,000 shares of common stock, which shares shall vest and become non-forfeitable on the third anniversary of the grant date, subject to continued service on the Board on such date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;For&#160;the year ended December 31, 2022, the Company recognized $110,000 in expense in its Statements of Operations related to the advisory agreement, including approximately $50,000 in expense related to equity incentive grants. For&#160;the year ended December 31, 2021, the Company recognized $116,000 in expense in its Statements of Operations related to the advisory agreement, including approximately $56,000 in expense related to equity incentive grants. The Company issued Mr. Weiss 71,664 and 13,774 restricted stock awards for the&#160;years ended December 31, 2022 and 2021, respectively.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_jIA82Zn-S0-9OoqzDzR2cg"
      decimals="-5"
      id="Narr_fzFi0uOYdUWtAoZNmlFNyQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2000000.0</us-gaap:ProceedsFromRelatedPartyDebt>
    <mbio:FoundersAgreementTerm
      contextRef="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_jIA82Zn-S0-9OoqzDzR2cg"
      id="Narr_zkjj5d65tUGXZK5dwz1oLQ">P15Y</mbio:FoundersAgreementTerm>
    <mbio:AgreementRenewalTerm
      contextRef="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_jIA82Zn-S0-9OoqzDzR2cg"
      id="Narr_BHjkynBrZESytH3CEcK48Q">P1Y</mbio:AgreementRenewalTerm>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_u-nK5IHLB0it8Ss2uDQLIw"
      decimals="-4"
      id="Narr_DrsgJe4WfESnpng06Ga4Ow"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">7250000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_VBMwjqeRtEqCOPPRYyGFBg"
      decimals="-5"
      id="Narr_ht8ozKuFt0C_4N_ioYO5Aw"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">7000000.0</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_joFxX9w_pkCt5C4GrtBlWg"
      decimals="INF"
      id="Narr_0WTUJ0uIeUCC4xs_GVTeSQ"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">250000</us-gaap:ConversionOfStockSharesIssued1>
    <mbio:PreferredStockVotingRightsMultiplier
      contextRef="Duration_7_26_2016_To_7_26_2016_e467LFs_GEmfW2lDVRZA9Q"
      decimals="1"
      id="Narr_C0GsRMwLbU-nqHUrf9ppGA"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">1.1</mbio:PreferredStockVotingRightsMultiplier>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_7_26_2016_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_zbvdgNhN6kuygnfc4J47nA"
      decimals="INF"
      id="Narr_C5ojn2Pd60KRhRuBddo6xw"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">1</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_7_26_2016_To_7_26_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_jIA82Zn-S0-9OoqzDzR2cg"
      decimals="3"
      id="Narr_sJrVSCLj2UadLzIerDgmiw"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.025</us-gaap:PreferredStockDividendRatePercentage>
    <mbio:EquityFeePercentageOfFinancing
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"
      decimals="3"
      id="Narr_VCYkbmeDMECum7TyxSMneQ"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">-0.025</mbio:EquityFeePercentageOfFinancing>
    <mbio:CashFeeAsPercentageOfAnnualNetSales
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"
      decimals="3"
      id="Narr_SeBHs8okGUac-0lV9u-73g"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">-0.045</mbio:CashFeeAsPercentageOfAnnualNetSales>
    <mbio:ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"
      decimals="0"
      id="Narr_cGMROYjBC0WqtLiNOMT_XQ"
      unitRef="Unit_Standard_item_e-lAqZ63ukC9AQjaK0X33Q">5</mbio:ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate>
    <mbio:ChangeInControlFeeSpecifiedRateComponent
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"
      decimals="3"
      id="Narr_gLkcFcX7R0irdMSUAbcVVQ"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.045</mbio:ChangeInControlFeeSpecifiedRateComponent>
    <mbio:AgreementTerm
      contextRef="Duration_3_13_2015_To_3_13_2015_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_-NQvGLrolUaisD4xkEP_SA"
      id="Narr_NgD8a4YnLEiu0WutNfnwbQ">P5Y</mbio:AgreementTerm>
    <mbio:MsaAgreementRenewalTerm
      contextRef="Duration_3_13_2015_To_3_13_2015_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_-NQvGLrolUaisD4xkEP_SA"
      id="Narr_xFyidaicfEibt6wtR6xOtA">P5Y</mbio:MsaAgreementRenewalTerm>
    <mbio:AnnualConsultingFees
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"
      decimals="-5"
      id="Narr_gn2QnjcBpE6Cc_6WaM5Aqw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">500000</mbio:AnnualConsultingFees>
    <mbio:IncreaseInAnnualConsultingFees
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"
      decimals="-5"
      id="Narr_8Lu9DRLTPEWnYjzteL7ZnQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1000000.0</mbio:IncreaseInAnnualConsultingFees>
    <mbio:ExcessInNetAssetsValue
      contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_D02sY_Okb0CAJr_sq1tImg"
      decimals="-6"
      id="Narr_uT1Rl_0WdEWLJDDYmdfdsQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">100000000</mbio:ExcessInNetAssetsValue>
    <mbio:PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"
      decimals="2"
      id="Narr_Nm7U4Lrh4EelVGF7w5rMAw"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.50</mbio:PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses>
    <mbio:PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"
      decimals="2"
      id="Narr_EAvAcp8L6EG_CYDoTNjQ7A"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.50</mbio:PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"
      decimals="-5"
      id="Narr_580LWLy4lUGHkCeXMtFIFA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1000000.0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_Trkkxq84fU-Vd0RoRhj2NQ"
      decimals="-5"
      id="Narr_xmulCtxlR0WW6-Vro0_BNA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">500000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"
      decimals="INF"
      id="Narr_WVQ6rta6n0mXuHos1b0afQ"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">196952</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <mbio:DilutedOutstandingEquityPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"
      decimals="3"
      id="Narr_OCh5c6fTVkGtx5dtHwJY4w"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.025</mbio:DilutedOutstandingEquityPercentage>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"
      decimals="-5"
      id="Narr_ouMBcYK_C0i8-W5bP9xBrQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">6600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_ovDgDz0emEyMvZmp-YeELg"
      decimals="-5"
      id="Narr_892wpV7WqE-dYoDksm9KoQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">200000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_Trkkxq84fU-Vd0RoRhj2NQ"
      decimals="INF"
      id="Narr_X32740X19EykHFYXjtmWvA"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">576157</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_m9J360WMFk65TIBgOb6HfA"
      decimals="INF"
      id="Narr_8uEyfBhLbE2OgUT4-6GJSQ"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">51295</us-gaap:CommonStockSharesSubscribedButUnissued>
    <mbio:DilutedOutstandingEquityPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_Trkkxq84fU-Vd0RoRhj2NQ"
      decimals="3"
      id="Narr_1IZZgL-9U0uqSbpsYZlA1w"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.025</mbio:DilutedOutstandingEquityPercentage>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_Trkkxq84fU-Vd0RoRhj2NQ"
      decimals="-5"
      id="Narr_rbGXrs8tNUOg8CqybWG13w"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">71900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_RtpzWYx2kkuP6Pk7yZGiGQ"
      decimals="-5"
      id="Narr_SS4o9FCgHkirrwcX0hfgTw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1900000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <mbio:AnnualConsultingFees
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_sT3IETb4eUa_bTIM6c1joQ"
      decimals="0"
      id="Narr_vdeOnupHnEuNe5XbdKnZbg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">50000</mbio:AnnualConsultingFees>
    <mbio:DirectorCompensationValueOfSharesGranted
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_ot8OBmwnOUaS1sRIHVm7tQ"
      decimals="0"
      id="Narr_1dmdR5yCUka1j4sWnUqZBA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">50000</mbio:DirectorCompensationValueOfSharesGranted>
    <mbio:DirectorCompensationNumberOfSharesGranted
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_ot8OBmwnOUaS1sRIHVm7tQ"
      decimals="0"
      id="Narr_80DBDP_y9ESC41iuPwBkVg"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">10000</mbio:DirectorCompensationNumberOfSharesGranted>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_sT3IETb4eUa_bTIM6c1joQ"
      decimals="0"
      id="Narr_jOjvzyocMkeI3a07fExoRA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <mbio:DirectorCompensationValueOfSharesGranted
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_sT3IETb4eUa_bTIM6c1joQ"
      decimals="0"
      id="Narr_hTTbdFzyxUigRnEaoGQ9Gw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">50000</mbio:DirectorCompensationValueOfSharesGranted>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_uAr0vqstK0m70EJhq9vZvg"
      decimals="0"
      id="Narr_fceop7YDWUiB10MOeGqxSw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">106000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <mbio:DirectorCompensationValueOfSharesGranted
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_uAr0vqstK0m70EJhq9vZvg"
      decimals="0"
      id="Narr_s4iyhT9ItEu7csFKTBznmg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">56000</mbio:DirectorCompensationValueOfSharesGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_3OyJzUMtO0ym9UWFHhhAZg"
      decimals="INF"
      id="Narr_BjlyE0ylNEGmTBiw1_Q38Q"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">71664</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_XfkRl6mfqE-N6Ds1xMxrbQ"
      decimals="INF"
      id="Narr_LMPkUXWgLUKpYJ41g_BhXQ"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">13774</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <mbio:AnnualConsultingFees
      contextRef="Duration_1_1_2017_To_1_1_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_lbdL7OiZrk-lt4FN-gg-bQ"
      decimals="0"
      id="Narr_YtefBXVEY0uSFXhdmircMw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">60000</mbio:AnnualConsultingFees>
    <mbio:DirectorCompensationValueOfSharesGranted
      contextRef="Duration_1_1_2017_To_1_1_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_eGnJ3TUB8UOJx8iUju7dfA"
      decimals="0"
      id="Narr_kjX5fuUeNk2is8WH6cl4Yw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">50000</mbio:DirectorCompensationValueOfSharesGranted>
    <mbio:DirectorCompensationNumberOfSharesGranted
      contextRef="Duration_1_1_2017_To_1_1_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_eGnJ3TUB8UOJx8iUju7dfA"
      decimals="0"
      id="Narr_aFcmj-bRIUOZxN5yivQs3A"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">10000</mbio:DirectorCompensationNumberOfSharesGranted>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_bPmhKby7TEaZLqjV9yAiFA"
      decimals="0"
      id="Narr_H654FX_sik-5mgiGvFJqdw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">110000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <mbio:DirectorCompensationValueOfSharesGranted
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_bPmhKby7TEaZLqjV9yAiFA"
      decimals="0"
      id="Narr_hL_NKpjGyE-CWv1EVX1RcA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">50000</mbio:DirectorCompensationValueOfSharesGranted>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_-GelVT3xVkGWE0zhcvX2PQ"
      decimals="0"
      id="Narr_NPgMlvwvmkiJlHQUjXlKLQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">116000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <mbio:DirectorCompensationValueOfSharesGranted
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_-GelVT3xVkGWE0zhcvX2PQ"
      decimals="0"
      id="Narr_IuJLlfWtyEWNXs-G_xDzLA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">56000</mbio:DirectorCompensationValueOfSharesGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_B0vAXreZfkCUTZAJG1tYDw"
      decimals="INF"
      id="Narr_pwGkvOz2rUOUTZStuUomZg"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">71664</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_9jVcGwYOxUu69mDgzJJD-Q"
      decimals="INF"
      id="Narr_Ft1rjhzB0kaVYCMQU38HxA"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">13774</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_ky6Thh5qyk2_4B5okeTOnQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;5&#160;- Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Mustang&#x2019;s property and equipment consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated Useful&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life (in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 145&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 145&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 370&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Machinery&#160;and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,632&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,694&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,694&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Construction in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 951&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total property, plant and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,792&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,786&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,401)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,734)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property, plant and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,052&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Mustang&#x2019;s depreciation expense for the&#160;years ended December&#160;2022 and 2021 was approximately $2.7 million and $2.2 million, respectively, and was recorded in research and development expense in the Statements of Operations.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_JPSJEaSxS0CoCCFlExLYdA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Mustang&#x2019;s property and equipment consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated Useful&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life (in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 145&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 145&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 370&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Machinery&#160;and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,632&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,694&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,694&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Construction in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;N/A&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 951&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total property, plant and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,792&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,786&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,401)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,734)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property, plant and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,052&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_aWcNk9ygQEOJpQSfWskFEA"
      id="Tc_QMwiICCfJEOxeosoO_Qi8g_3_2">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_v472pPJ0CkuqygxI_ittBQ"
      id="Tc_QMwiICCfJEOxeosoO_Qi8g_3_2_2">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_z9Vf3QpPF0qO9yFxyz7P_Q"
      decimals="-3"
      id="Tc_FU3ihgWzXEi60LMXEVaivA_3_5"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">145000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_43U4KPxs6ESx8ledMlKHrw"
      decimals="-3"
      id="Tc_pltx37lWuUCY0Ui84AXuxQ_3_8"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">145000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_pzjG98ud8EGdrioXB-jwgw"
      id="Tc_wl775OpRvk-y5QhH_yymYA_4_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_T6pbjl0HIEm0W7ow_5z-_g"
      id="Tc_wl775OpRvk-y5QhH_yymYA_4_2_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_iCbMYI4KcESBEVBhm0Im-Q"
      decimals="-3"
      id="Tc_Ewc0__jXvE2fkJWWZ8Z7iw_4_5"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">370000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_PcX9JsuOWUyJsrrbJM84DA"
      decimals="-3"
      id="Tc_pgCRy2lba0Wpe81FXq5UDQ_4_8"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">370000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_AS2adTFum0q5lSDBbT43Cg"
      id="Tc_4RGHIZaZI0uIYDC5mTOtOg_5_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_6e_cd9xdR0OP-rJ8ATzk6A"
      id="Tc_4RGHIZaZI0uIYDC5mTOtOg_5_2_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_reL4xpHEp06WZ3lLttoTLA"
      decimals="-3"
      id="Tc_u_uE5nTLW0GxItOJd0TXPA_5_5"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">8632000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_6Mr5lfEhb0CpRxTW-j7sxg"
      decimals="-3"
      id="Tc_1B-tGnj3BkSt1E9-CYHDNw_5_8"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">6550000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_j5ZGnmb0UkuRYKuYvgYNtQ"
      id="Tc_WRs3-AOtaEODDddBr8dRvQ_6_2">P9Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_FkxuDW2Odkq2TbRXzOUOkQ"
      id="Tc_WRs3-AOtaEODDddBr8dRvQ_6_2_2">P9Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_cTxrSq0IxUy5wwF9bj3Hhw"
      decimals="-3"
      id="Tc_n_EEj_O5qU-LeAAIesStOw_6_5"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">7694000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_e_acjS35Ukyn5P8Fy-MCGA"
      decimals="-3"
      id="Tc_ADc-vh5GbEiCjHO8eRBcNA_6_8"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">7694000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_RjfDOebswEyLEhoZaNQWKg"
      decimals="-3"
      id="Tc_ncybA_YK0U6e2KQoMIhaAQ_7_5"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">951000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_wsvscCuqjEmydGhY6i4new"
      decimals="-3"
      id="Tc_79hN3H1zY0iAc55v4Rgj9g_7_8"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2027000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_NVCSado0506otTAqCCrWrg_8_5"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">17792000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_l5UdClC4aUaMkHNyBUgDdw_8_8"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">16786000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_jFcBhpoxk0-ncjm37MBFjw_9_5"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">8401000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_4WBf3asyZ0a-9aBRS59I2g_9_8"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">5734000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_d2CIpl9N5Uy6YfiDgQo26g_10_5"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">9391000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_HvyunOnhuUSC7LX3TGXipg_10_8"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">11052000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-5"
      id="Narr__PE7TJKjpUqzEmHzr00Frg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-5"
      id="Narr_9-TjZ_ZOUkeTkUdDEf5Grg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2200000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_NvwCv4B0s0aWa2G94NfxwA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;6&#160;- Accounts Payable and Accrued Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;At December 31, 2022 and 2021, accounts payable and accrued expenses consisted of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,833&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,512&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,083&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,595&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 648&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 554&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total accounts payable and accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,731&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,744&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_kSVbKHx1_0meb3At_1uV9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;At December 31, 2022 and 2021, accounts payable and accrued expenses consisted of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,833&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,512&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,083&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,595&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 648&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 554&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total accounts payable and accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,731&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,744&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_VG5RwSUYFkqYksTF8VTHMw_3_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">6833000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_9y_I_2HZKEaf02enCQtPhg_3_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">3512000</us-gaap:AccountsPayableCurrent>
    <mbio:ResearchAndDevelopmentCurrent
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_IpJgx18mfEaWhC3-dBoe_w_4_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2782000</mbio:ResearchAndDevelopmentCurrent>
    <mbio:ResearchAndDevelopmentCurrent
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_YL1-fEaUuEidOi4IdSIOUw_4_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">3083000</mbio:ResearchAndDevelopmentCurrent>
    <mbio:AccruedCompensationCurrent
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_Zg7yVwlkmEGkVYNBTN6RJg_5_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">3468000</mbio:AccruedCompensationCurrent>
    <mbio:AccruedCompensationCurrent
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_jWyo83rcIEGg371lYoZ84g_5_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2595000</mbio:AccruedCompensationCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_KUnNJ5jQ6EqKI7aJ5Xboow_6_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">648000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_zXhtzgHRgEyItKv8TL7tSQ_6_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">554000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_T0QDSB8PyUivhd4JlItC7Q_7_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">13731000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_B5_KiCVRzEKFgw00FWAz0w_7_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">9744000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_A2J9XsQZjUiQ2eTWBaABAA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;7&#160;- Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On June 14, 2022, the Company entered into a sublease agreement with The Paul Revere Life Insurance Company. Pursuant to the terms of the sublease lease agreement, the Company agreed to lease&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;26,503&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;square feet, located at 1 Mercantile Street, Worcester, MA (the &#x201c;Mercantile Street Facility&#x201d;), through January 2030. The Company recorded a right of use&#160;&lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_hD18g_F6S0Sosw_qw-16ow;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;asset&lt;/span&gt;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;and related operating lease liability of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$2.2&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million on the Balance Sheet at the lease inception.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;On October&#160;27, 2017, the Company entered into a lease agreement with WCS&#160;- 377 Plantation Street,&#160;Inc., a Massachusetts nonprofit corporation. Pursuant to the terms of the lease agreement, the Company agreed to lease 27,043 square feet from the landlord, located at 377 Plantation Street in Worcester, MA (the &#x201c;Plantation Street Facility&#x201d;), through November 2026, subject to additional extensions at the Company&#x2019;s option. Base rent, net of abatements of $0.6 million over the lease term, totals approximately $3.6 million, on a triple-net basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The terms of the lease also require that the Company post an initial security deposit of $0.8 million, in the form of $0.5 million letter of credit and $0.3 million in cash, which increased to $1.3 million ($1.0 million letter of credit, $0.3 million in cash) on November 1, 2019. After the fifth lease year, the letter of credit obligation is subject to reduction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Plantation Street Facility began operations for the production of personalized CAR T and gene therapies in 2018.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company leases office space and copiers under agreements classified as operating leases that expire on various dates through 2030. The Company&#x2019;s lease liabilities result from the lease of its facilities in Massachusetts, which expire in 2030 and 2026, for the Mercantile Street Facility and Plantation Street Facility, respectively, and its copiers, which expire in 2024. Such leases do not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. Certain of the Company&#x2019;s leases include renewal options and escalation clauses; renewal options have not been included in the calculation of the lease liabilities and right of use assets as the Company is not reasonably certain to exercise the options. The Company does not act as a lessor or have any leases classified as financing leases. At December 31, 2022, the Company had operating lease liabilities of $3.9 million and right of use assets of $2.9 million, which were included in the Balance Sheet. At December 31, 2021, the Company had operating lease liabilities of $2.0 million and right of use assets of $1.1 million, which were included in the Balance Sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following summarizes quantitative information about the Company&#x2019;s operating leases:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 565&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 315&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 488&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 599&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,053&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 914&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:86.33%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:29.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 485&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 484&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average remaining lease term &#x2013; operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average discount rate &#x2013; operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Maturities of our operating leases, excluding short-term leases, are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ended December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 529&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ended December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 614&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ended December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,139&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ended December&#160;31,&#160;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,076&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ended December&#160;31,&#160;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 650&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,381&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,389&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less present value discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,443)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,946&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:NetRentableArea
      contextRef="As_Of_6_14_2022_cTRV0HCiCkWfQ2PRR9auPA"
      decimals="INF"
      id="Narr_TIWBXRywuUmoGwCerpYSPQ"
      unitRef="Unit_Standard_sqft_8yS2Dc-QmU2gfsdczKLSrA">26503</us-gaap:NetRentableArea>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_6_14_2022_cTRV0HCiCkWfQ2PRR9auPA"
      decimals="-5"
      id="Narr_LngLcrOMNEuKzN4dUXGg_w"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:NetRentableArea
      contextRef="As_Of_10_27_2017_r9_PBUxiKU6CIeyMRHqr4g"
      decimals="0"
      id="Narr_YeBLRF314EaYsjYfQJ8EkA"
      unitRef="Unit_Standard_sqft_8yS2Dc-QmU2gfsdczKLSrA">27043</us-gaap:NetRentableArea>
    <mbio:LesseeOperatingLeaseTotalAbatementsOverLeaseTerm
      contextRef="Duration_10_27_2017_To_10_27_2017_HaJc4KkwbUyd0LOp2-MkEw"
      decimals="-5"
      id="Narr_OyHi9Weovkm5IUazd5uGAA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">600000</mbio:LesseeOperatingLeaseTotalAbatementsOverLeaseTerm>
    <mbio:LesseeOperatingLeaseTotalBaseRentNetOfAbatements
      contextRef="Duration_10_27_2017_To_10_27_2017_HaJc4KkwbUyd0LOp2-MkEw"
      decimals="-5"
      id="Narr_TIRxwCkI2UGnBxLPfL4yAg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">3600000</mbio:LesseeOperatingLeaseTotalBaseRentNetOfAbatements>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_10_27_2017_r9_PBUxiKU6CIeyMRHqr4g"
      decimals="-5"
      id="Narr_7gkMAQG6UE2r5c_PEt8E9w"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">800000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_10_27_2017_us-gaap_ShortTermDebtTypeAxis_us-gaap_LetterOfCreditMember_k9atZnNjs0aax30iY_FCJg"
      decimals="-5"
      id="Narr_W2BkEKCXTkOprjtyukBXGA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">500000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_10_27_2017_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_n1UsR7h740ijw5e4ONDTcg"
      decimals="-5"
      id="Narr_NMpYfR5H_kauQPgotdYgcA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">300000</us-gaap:SecurityDeposit>
    <mbio:LesseeSecurityDepositUponFullOccupancy
      contextRef="Duration_10_27_2017_To_10_27_2017_HaJc4KkwbUyd0LOp2-MkEw"
      decimals="-5"
      id="Narr_qg8dtj4fK0ODdO8aQO-jWg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1300000</mbio:LesseeSecurityDepositUponFullOccupancy>
    <mbio:LesseeSecurityDepositUponFullOccupancy
      contextRef="Duration_10_27_2017_To_10_27_2017_us-gaap_ShortTermDebtTypeAxis_us-gaap_LetterOfCreditMember_Gwgp6OjA0kOhW6E5eRzqQg"
      decimals="-5"
      id="Narr_-XEmtkL9wkm3lfGeL-sAGg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1000000.0</mbio:LesseeSecurityDepositUponFullOccupancy>
    <mbio:LesseeSecurityDepositUponFullOccupancy
      contextRef="Duration_10_27_2017_To_10_27_2017_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember_-idbFc98Ukq2mFPsFZldJQ"
      decimals="-5"
      id="Narr_KjXU9Ccd6UmhnYZoQAiNbQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">300000</mbio:LesseeSecurityDepositUponFullOccupancy>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-5"
      id="Narr_XqUHoOH9f0G28GnQTYCHog"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">3900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-5"
      id="Narr_AAAAPIi34kaCkL9Lw8SRQA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-5"
      id="Narr_Ue_0thVlV0uRcoPWLSy--A"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-5"
      id="Narr_J1nmOWfptUG1KSrHd3Vkog"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_3Eu8lWABGk-vxU-Lph64uQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following summarizes quantitative information about the Company&#x2019;s operating leases:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 565&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 315&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 488&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 599&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,053&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 914&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:86.33%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:29.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 485&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 484&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average remaining lease term &#x2013; operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average discount rate &#x2013; operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_zaa2zJCjaUm5jdnvcCYeIQ_5_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">565000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_Kb5Y5lEEnEKhRHIzfk3IAw_5_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">315000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_fDxnTk4ueUa7U47Ewpqm7w_6_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">488000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_l26LL7Uox0KzGuxwsgcLMA_6_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">599000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_CoxsaDVYxUC_2WSmkmSbCA_7_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1053000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_lUvG5BKzuEmPNbv7dKMVPA_7_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">914000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_YQKRkpN8W06S3ic2eaD_Cw_4_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">485000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_YNDQ19cYb0WdUw1mtq8eyQ_4_7"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">484000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      id="Tc_02kb-9pjzkmcCObmmGetzA_5_3">P5Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      id="Tc_2VATIISK7UOxk0YRT2o5CA_5_7">P4Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="4"
      id="Tc_HhPEPfKcgUmPQH1gKBLxRA_6_3"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.091</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="4"
      id="Tc_luxqipDlsEKH35aLujj3jA_6_7"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.090</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_U40UV-85okSM8TamJDLMEQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Maturities of our operating leases, excluding short-term leases, are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ended December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 529&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ended December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 614&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ended December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,139&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ended December&#160;31,&#160;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,076&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ended December&#160;31,&#160;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 650&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,381&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,389&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less present value discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,443)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,946&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_bMBe-hy4kkeYnl8tKiUNGA_2_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">529000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_yYUiGKnVuECgqIREyj7mAQ_3_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">614000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_OqKdMmt4OUygqHkiTUp1Nw_4_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1139000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_ztEn3G6A2EubvUQePjYFAg_5_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1076000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_5KW6sixI8UKuqAlYQUj00g_6_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">650000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_Srr2tBZwQkuujT5zftR8qQ_7_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1381000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_R8PMSY_-jkyEG6ByKYMnag_8_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">5389000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_NIDMvKacSkmRG0zs2KHlww_9_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1443000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_zE8WUJQMl0uDXSrGY_uLjA_10_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">3946000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_uDT4uK2pI0SWOskKowa1fg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 8 &#x2013; Notes Payable&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;On March 4, 2022 (the &#x201c;Closing Date&#x201d;), the Company entered into a $75.0&#160;million long-term debt facility with Runway Growth Finance Corp. (the &#x201c;Term Loan&#x201d;). Under the Term Loan, $30.0&#160;million of the $75.0&#160;million loan was funded on the Closing Date, with the remaining $45.0&#160;million fundable if the Company achieves certain predetermined milestones.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;The Term Loan matures on April 15, 2027 (the &#x201c;Maturity Date&#x201d;). &#160;As of March 15, 2022, the Company began making monthly payments of interest only until April 1, 2024 (the &#x201c;Amortization Date&#x201d;). The Amortization Date may be extended to April 1, 2025, if the Company achieves certain predetermined milestones based on equity raises and the initiation of certain clinical trials. After that, the Company will make monthly payments of interest and principal. If the Amortization Date is extended to April 1, 2025, the monthly payments will be recalculated in equal amounts according to the remaining number of payment dates through the Maturity Date. All unpaid outstanding principal and accrued and unpaid interest will be due and payable in full on the Maturity Date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;The Term Loan accrues interest at a variable annual rate equal to&#160;8.75% plus the greater of (i)&#160;0.50% and (ii) the three month LIBOR Rate for U.S. dollar deposits or the rate otherwise reasonably determined by the Lender to be the rate at which U.S. dollar deposits with a term of three months would be offered by banks in London, England to major banks in the London or other offshore interbank market &#160;(the &#x201c;Applicable Rate&#x201d;); provided that the Applicable Rate will not be less than&#160;9.25%. The Applicable Rate at December 31, 2022 was&#160;13.40%. On December 7, 2022, the Company entered into the First Amendment (the &#x201c;First Amendment&#x201d;) to the Loan Agreement by and between the Company and Runway. The First Amendment amended certain definitions and other provisions of the Loan Agreement to replace LIBOR-based benchmark rates applicable to loans outstanding under the Loan Agreement with SOFR-based rates, subject to adjustments as specified in the First Amendment. For the year ended December 31, 2022, the Company made interest payments of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;$2.7&#160;million, recorded in interest expense in the Statements of Operations. The Company had&#160;no&#160;interest expense related to debt in 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;Pursuant to the terms of the Term Loan on the Closing Date the Company paid the Lender upfront fees out of proceeds of $0.4&#160;million consisting of a&#160;1% commitment fee and a deposit of $75,000. &#160;In addition, the Company paid other cash fees directly to third parties comprising of an advisory fee and legal fees totaling $2.3&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;Also, in connection with the Term Loan, on March 4, 2022, the Company issued a warrant to the Lender to purchase&#160;748,036&#160;shares of the Company&#x2019;s common stock with an exercise price of $0.8021&#160;(the &#x201c;Warrant&#x201d;) via a warrant agreement (the &#x201c;Warrant Agreement&#x201d;). The Warrant is exercisable for&#160;ten years&#160;from the date of issuance. The Lender may exercise the Warrant with cash or through a net issuance conversion. The shares of the Company&#x2019;s common stock will be registered at the Company&#x2019;s first opportunity after the date of the exercise of the Warrant. In addition, the provisions of the Warrant Agreement provide for additional warrants to be issued upon funding of the term loan tranches. The fair value of the warrant at the grant date was determined utilizing a Black Scholes Model with the following assumptions: risk free rate of return&#160;1.74%, volatility of&#160;57.3%,&#160;&lt;span style="-sec-ix-hidden:Hidden_yUFWycn0fk-azymq7ugG3A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;10-year&lt;/span&gt;&lt;/span&gt;&#160;life yielding a value of approximately $0.4&#160;million as of March 4, 2022. &#160;The fair value of the warrant was also recorded in debt discount and will be amortized over the life of the Term Loan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Applicable&#160;Rate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Note payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;April - 2027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Discount on note payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,614)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Long-term note payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;Amortization of the debt discount associated with the Term Loan was approximately $0.5&#160;million for the year ended December 31, 2022, respectively, and was recorded in interest expense in the Statements of Operations. The Company had&#160;no&#160;expense related to debt discount amortization in 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company has the option to prepay all of the outstanding Term Loan but not less. Prepayment would include outstanding principal, accrued interest, prepayment fee and final payment which is equal to the original principal amount of the Term Loan times&#160;3.5% or $1.1&#160;million and is accreted over the life of the Term Loan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In addition, the Term Loan is secured by a lien on substantially all of our assets other than certain intellectual property assets and certain other excluded collateral, and it contains a minimum liquidity covenant and other covenants that include among other items: (i) limits on indebtedness, repurchase of stock from employees, officers and directors. The Company was in compliance with all applicable covenants as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;The Term Loan contains customary events of default, in certain circumstances subject to customary cure periods. Following an event of default and any cure period, if applicable, Runway will have the right upon notice to accelerate all amounts outstanding under the Term Loan, in addition to other remedies available to the lenders as secured creditors of the Company.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g"
      decimals="-5"
      id="Narr_V-Z46JxI2EyuPIWBlmIl6A"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">75000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="Duration_3_4_2022_To_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_eHP0c1pt2kC8bNXFkSVznw"
      decimals="2"
      id="Narr_5Unt_yz06Ey3CqAt2WtN7w"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">30000000.0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g"
      decimals="-5"
      id="Narr_gMqJNwt4OUS-FrtlaPW6TA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">75000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g"
      decimals="-5"
      id="Narr_iy-Aqcvm1UiX0ByL3onPnQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">45000000.0</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_3_4_2022_To_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_85Vphemizk-HydOGFNSOgA"
      decimals="4"
      id="Narr_afAhVpmWh0CoKu8pLAvFZg"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.0875</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_3_4_2022_To_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_sRafw2Y-jEiKjW4bMgII8Q"
      decimals="6"
      id="Narr_Q7ctsl8xg02l3REQ7Tz7Ew"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.000050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_3_4_2022_To_3_4_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_IRsNQ3FWukSyey7fSJ4NbQ"
      decimals="6"
      id="Narr_Hzb04u6YaUWI0nYzuzH9BQ"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.000925</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_uNZ1QlhL30egiHID6foBSQ"
      decimals="4"
      id="Narr_-YqA_t3Ndk202G9QePOe6A"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.1340</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_uNZ1QlhL30egiHID6foBSQ"
      decimals="-5"
      id="Narr_5rlZ2zjsbEacX3M9ncwAhQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2700000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_UgDuCoveakiyI_k2GGguBw"
      decimals="-5"
      id="Narr_mms04LYSs0imd7B_ca2x1A"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:InterestExpenseDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="Duration_3_4_2022_To_3_4_2022_8OXg7asOjUiUzJte247ykw"
      decimals="-5"
      id="Narr_hzb9d1cq8k-trU5mj-90cA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">400000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="Duration_3_4_2022_To_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_eHP0c1pt2kC8bNXFkSVznw"
      decimals="2"
      id="Narr__l6kJZmelUSMqWulAcP3eA"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.01</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g"
      decimals="0"
      id="Narr_xUTurl7o5keiLN8QgY7Ncw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">75000</us-gaap:SecurityDeposit>
    <us-gaap:LegalFees
      contextRef="Duration_3_4_2022_To_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_eHP0c1pt2kC8bNXFkSVznw"
      decimals="-5"
      id="Narr_2AlEv93RBU-i409gdl20aw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2300000</us-gaap:LegalFees>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g"
      decimals="INF"
      id="Narr_hh7UZBEdVEW0svSfq7M-kA"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">748036</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g"
      decimals="4"
      id="Narr_Qup6QNJZq0Cym55VfGjTkA"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">0.8021</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g"
      id="Narr_0sL6Szi3u0auy4BKy9Szxg">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_4_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Q6BCOUH2V0CcXWJkApNHug"
      decimals="4"
      id="Narr_sdT8X8PcO0mJct6TqzBbMg"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.0174</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_3_4_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_mwjdn5zoKEerGWdy4baTKg"
      decimals="4"
      id="Narr_J8hkdcHPAkGSVHSnAsSpxg"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.573</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="As_Of_3_4_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_2HYX_b8YJ0uKkR4UevRidg"
      decimals="-5"
      id="Narr_bju8D20zHUW7BouZLPOVrA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">400000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_qblU9_uS-0KXaSugs5pavA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Applicable&#160;Rate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Note payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;April - 2027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Discount on note payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,614)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Long-term note payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_9uDXLFrQfESucUVU2dbSlQ"
      decimals="-3"
      id="Tc_hjYMJk8vvU-_XSP1ER2UoA_3_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">31050000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_uNZ1QlhL30egiHID6foBSQ"
      decimals="4"
      id="Tc_b0CpArloYE6Wck4snxwXhg_3_8"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.1340</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_9uDXLFrQfESucUVU2dbSlQ"
      decimals="-3"
      id="Tc_I4rgbASYhESgkp_T0V0_8w_4_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">3614000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermNotesPayable
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_9uDXLFrQfESucUVU2dbSlQ"
      decimals="-3"
      id="Tc_bHAMd_JDo0GIS1EXxXVHOw_5_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">27436000</us-gaap:LongTermNotesPayable>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_uNZ1QlhL30egiHID6foBSQ"
      decimals="-5"
      id="Narr_ObBdaXAay0ungK9MdGBAWQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">500000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_UgDuCoveakiyI_k2GGguBw"
      decimals="-5"
      id="Narr_2qnYs_eaWEeg9Sxem7VmVw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <mbio:DebtInstrumentBalloonPaymentAsPercentageOfPrincipal
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_9uDXLFrQfESucUVU2dbSlQ"
      decimals="3"
      id="Narr_K_ei636xykemxyAIo5YyhQ"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.035</mbio:DebtInstrumentBalloonPaymentAsPercentageOfPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_9uDXLFrQfESucUVU2dbSlQ"
      decimals="-5"
      id="Narr_kpAJsKByREemp5wPxQPA2w"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1100000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_JliPouztaUWNkUIH7JiPCA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;9&#160;- Stockholders&#x2019; Equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company, in accordance with its certificate of incorporation, as amended in November 2020 and June 2021, which was retroactively applied, and July 2022, is authorized to issue (i) 200,000,000 common shares with a par value of $0.0001 per share, of which 1,000,000 shares are designated as Class&#160;A Common Stock and the remainder are undesignated Common Stock, and (ii) 2,000,000 shares of Preferred Stock, 250,000 of which are designated as Class A Preferred Stock and the remainder are undesignated Preferred Stock (see below Stock Issuances to Fortress and Note&#160;4).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In connection with the Company&#x2019;s formation, Fortress subscribed for 7,000,000 shares of the Class&#160;B Common Stock and 2,000,000 shares of the Company&#x2019;s Common Stock, pursuant to the Founders Agreement. Fortress paid the par value of $900 in 2016. The fair value of the Company&#x2019;s common shares approximated par value as no licenses had been transferred at that time. Dividends, if and when declared, are to be distributed pro-rata to the Class&#160;A, B and Common Stockholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The holders of Common Stock are entitled to one vote per share of Common Stock held. The holders of Class&#160;A Common Stock are entitled to the number of votes equal to the number of whole shares of Common Stock into which the shares of Class&#160;A Common Stock held by such holder are convertible and for a period of ten years from its issuance, the holders of the Class&#160;A Common Stock have the right to appoint one member of the board of directors of Mustang; to date, the holders of Class&#160;A Common Stock have not yet appointed such director.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Class&#160;B Common Stockholders are entitled, for each share of Class&#160;B Common Stock held, to a number of votes equal to 1.1 times a fraction, the numerator of which is the sum of (A)&#160;the shares of outstanding Common Stock and (B)&#160;the whole shares of Common Stock into which the shares of outstanding Class&#160;A Common Stock and the Class&#160;B Common Stock are convertible and the denominator of which is the number of shares of outstanding Class&#160;B common shares. There was no Class B Common Stock outstanding as of December&#160;31,&#160;2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;On November 11, 2020, the Company&#x2019;s Board adopted resolutions of the Board to ratify, approve and recommend stockholder approval of an amendment to the Company&#x2019;s Amended and Restated Certificate of Incorporation, as amended, to revise Article IV, Section A thereof in order to effect an increase in the authorized number of shares of the Company&#x2019;s common stock, par value $0.0001, from 85,000,000 to 125,000,000 (the &#x201c;Amendment&#x201d;). On November 11, 2020, the Company received approval of the Amendment by written consent in lieu of a meeting from the holders of a majority of issued and outstanding shares of the Company&#x2019;s common and preferred stock. The increase in authorized shares to 125,000,000 became effective on December 4, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;On June 17, 2021, the stockholders of the Company voted at the 2021 Annual Meeting to approve an amendment to Mustang&#x2019;s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance by 25,000,000 shares, bringing the total number of authorized shares of common stock to 150,000,000 shares. The increase in authorized shares to 150,000,000 became effective on June 17, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;On June 21, 2022, the stockholders of the Company voted at the 2022 Annual Meeting to approve an amendment to Mustang&#x2019;s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance by 50,000,000 shares, bringing the total number of authorized shares of common stock to 200,000,000 shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;At-the-Market Offering of Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In July 2018, the Company entered into an At-the-Market Issuance Sales Agreement (the &#x201c;Mustang ATM&#x201d;) with B. Riley Securities, Inc. (formerly B. Riley FBR,&#160;Inc.), Cantor Fitzgerald&#160;&amp;amp; Co., National Securities Corporation,&lt;span style="background:#ffffff;"&gt; (now B. Riley FBR, Inc.),&lt;/span&gt; and Oppenheimer&#160;&amp;amp; Co.&#160;Inc. (each an &#x201c;Agent&#x201d; and collectively, the &#x201c;Agents&#x201d;), relating to the sale of shares of common stock pursuant to the 2020 S-3. Under the Mustang ATM, the Company pays the Agents a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of common stock. On December 31, 2020, the Mustang ATM was amended to add H.C. Wainwright &amp;amp; Co., LLC as an Agent.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;During the year ended December 31, 2022, the Company issued approximately 7.9 million shares of common stock at an average price of $0.84 per share for gross proceeds of $6.6 million under the ATM Agreement. In connection with these sales, the Company paid aggregate fees of approximately $0.1 million for net proceeds of approximately $6.5 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;During the year ended December 31, 2021, the Company issued approximately 19.4 million shares of common stock at an average price of $3.70 per share for gross proceeds of $71.9 million under the ATM Agreement. In connection with these sales, the Company paid aggregate fees of approximately $1.3 million for net proceeds of approximately $70.6 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;margin:0pt;"&gt;Pursuant to the Founders Agreement, the Company issued 196,952 shares of common stock to Fortress at a weighted average price of $0.84 per share for the year ended December 31, 2022, and recorded zero shares issuable to Fortress in connection with the shares issued under the Mustang ATM. Pursuant to the Founders Agreement, Mustang issued 576,157 shares of common stock to Fortress at a weighted average price of $3.70 per share for the year ended December 31, 2021, in connection with the shares issued under the Mustang ATM.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Registration Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;On October 23, 2020, the Company filed a shelf registration statement No. 333-249657 on Form S-3 (the &#x201c;2020 S-3&#x201d;), which was declared effective on December 4, 2020. Under the 2020 S-3, the Company may sell up to a total of $100.0 million of its securities. As of December 31, 2022, approximately $8.0&#160;million of the 2020 S-3 remains available for sales of securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;On April 23, 2021, the Company filed a shelf registration statement No. 333-255476 on Form S-3 (the &#x201c;2021 S-3&#x201d;), which was declared effective on May 24, 2021. Under the 2021 S-3, the Company may sell up to a total of $200.0 million of its securities. As of December 31, 2022, there have been no sales of securities under the 2021 S-3.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Stock Issuances to Fortress&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Under the terms of the Second Amended and Restated Founders Agreement, which became effective July 22, 2016, Fortress will receive a grant of shares of our common stock equal to two and one-half percent (2.5%) of the gross amount of any equity or debt financing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;For the year ended December 31, 2022, the Company issued&#160;196,952&#160;shares of common stock, which equaled&#160;2.5% of the gross proceeds of $6.6&#160;million from the sale of shares of common stock under Mustang&#x2019;s At-the-Market Offering.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;For the year ended December 31, 2021, the Company issued&#160;576,157&#160;shares of common stock and recorded&#160;51,295&#160;shares issuable to Fortress, which equaled&#160;2.5% of the gross proceeds of $71.9&#160;million from the sale of shares of common stock under Mustang&#x2019;s At-the-Market Offering.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Equity Incentive Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company has in effect the 2016 Incentive Plan (the &#x201c;Incentive Plan&#x201d;). The Incentive Plan was adopted in 2016 by our stockholders and the compensation committee of the Company&#x2019;s board of directors and is authorized to grant stock-based awards to directors, officers, employees and consultants. The plan initially authorized grants to issue up to 2,000,000 shares of authorized but unissued common stock and expires 10 years from adoption and limits the term of each option to no more than 10 years from the date of grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In June&#160;2018, the Company&#x2019;s stockholders approved an amendment to the Incentive Plan to increase the number of authorized shares issuable by 3,000,000 shares, for a total of 5,000,000 shares. In June&#160;2021, the Company&#x2019;s stockholders approved an amendment to the Incentive Plan to increase the number of authorized shares issuable by 3,000,000 shares, for a total of 8,000,000 shares. In June&#160;2022, the Company&#x2019;s stockholders approved an amendment to the Incentive Plan to increase the number of authorized shares issuable by 3,000,000 shares, for a total of 11,000,000 shares As of December 31, 2022, 4,462,870 shares are available for issuance of stock-based awards under the Incentive Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Stock Options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes stock option activities for the&#160;year ended December 31, 2022 and 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Life&#160;(in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock&#160;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,141,675&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,141,675&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,141,675&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options vested and exercisable at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 713,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;As of December 31, 2022, the Company had no unrecognized stock-based compensation expense related to options. The Company accounts for forfeited awards as they occur as permitted.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Restricted Stock Awards&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Certain employees and directors have been awarded restricted stock. The restricted stock vesting consists of milestone and time-based vesting. The following table summarizes restricted stock award activities for the&#160;year ended December 31, 2022 and 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&#160;Date&#160;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Nonvested at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 302,114&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.93&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 68,870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.63&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (90,001)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Nonvested at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 280,983&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.05&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 358,320&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (129,058)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.89&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Nonvested at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 510,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.48&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;As of December 31, 2022, the Company had unrecognized stock-based compensation expense related to restricted stock of $0.4 million, which is expected to be recognized over a weighted average period of approximately 2.3&#160;years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Restricted Stock Units&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes restricted stock units&#x2019; activities for the&#160;year ended December 31, 2022 and 2020:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&#160;Date&#160;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Nonvested at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,468,559&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,660,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.07&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (372,873)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.60&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (420,379)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.27&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Nonvested at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,335,557&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.27&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,484,647&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.76&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (514,999)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.53&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (816,518)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.98&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Nonvested at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,488,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.84&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;As of December 31, 2022, the Company had unrecognized stock-based compensation expense related to restricted stock units of approximately $2.0 million, which is expected to be recognized over a weighted average period of approximately 2.7&#160;years. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes stock-based compensation expense for the&#160;years ended December 31, 2022 and 2021 (in thousands).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 700&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,030&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,583&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,283&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Stock Warrants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In connection with the Company&#x2019;s offering of shares of common stock in a private placement, each investor received a warrant equal to 25% of the common shares purchased in connection with the offering. Further, National Securities Corporation received Placement Agent Warrants. In connection with the Term Loan on March 4, 2022, the Company issued a warrant to the Lender to purchase 748,036 shares of the Company's common stock with an exercise price of $0.8021, see Note 8.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A summary of warrant activities for&#160;years ended December 31, 2022 and 2021, is presented below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Life&#160;(in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,402,670&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,093,878)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cashless exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (138)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,308,654&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.73&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,003,770)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 748,036&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.18&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,052,920&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.29&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Upon the exercise of warrants, the Company will issue new shares of Common Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Employee Stock Purchase Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In connection with our Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), eligible employees of Mustang and Fortress can purchase the Company&#x2019;s Common Stock at the end of a predetermined offering period at 85% of the lower of the fair market value at the beginning or end of the offering period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As of December 31, 2022, 586,010 shares have been purchased and 413,990 shares are available for future sale under the Company&#x2019;s ESPP.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="INF"
      id="Narr_lqM7j6_6kUu5wdW13no2rA"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="INF"
      id="Narr_NTmbXfOTKEmGXJNe1GwMmg"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_M2XrEHX5oEeqe8nYvunwDw"
      decimals="INF"
      id="Narr_howhr-Du-U6c36K1hIgDbw"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">1000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="INF"
      id="Narr_sQrh-r-IvEizbU7dIG6Ibg"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassAMember_v_0gsNjsdE2RcPa-Xt5feA"
      decimals="INF"
      id="Narr_BhoxySdGt0qtxjihS0meTA"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">250000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="As_Of_12_31_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_5_Je6tCozUqMRQF6TTTr9A"
      decimals="INF"
      id="Narr_j3Z9wWrJAEic9fZjLU2pzg"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">7000000</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="As_Of_12_31_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_YEp120A29kC8SaLYOW75aA"
      decimals="INF"
      id="Narr_v-So4sHMrEmxWg1wT_U79g"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">2000000</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="As_Of_12_31_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_HIeb-wz9Kk2lMUL_e8y1xA"
      decimals="0"
      id="Narr_OKtGwDLGfU62sswpa3OQ3g"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">900</us-gaap:CommonStockSharesSubscriptions>
    <mbio:VotingRightsNumberOfVotesPerShare
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_dXkI_XX5XU-PKFM5auvM3w"
      decimals="INF"
      id="Narr_vUiwYj5nBkS22Wq-KVfZuw"
      unitRef="Unit_Standard_item_e-lAqZ63ukC9AQjaK0X33Q">1</mbio:VotingRightsNumberOfVotesPerShare>
    <mbio:StockholderAppointmentOfDirectorPeriodAfterIssuance
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_ck0wt0THlEGynuJiicHJLQ"
      id="Narr_rXVhqgYZEE-WqbIEclcRag">P10Y</mbio:StockholderAppointmentOfDirectorPeriodAfterIssuance>
    <mbio:VotingRightsNumberOfVotesPerShare
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_EPmjxn4_W0OhVeeDC0iTvA"
      decimals="1"
      id="Narr_n1SkSPXC70y_eioKgv2aUg"
      unitRef="Unit_Standard_item_e-lAqZ63ukC9AQjaK0X33Q">1.1</mbio:VotingRightsNumberOfVotesPerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_11_11_2020_jFP6QSBqjkOBLq38js8Gqw"
      decimals="INF"
      id="Narr_8gwij05RbEOp6sP-Ky3wtA"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_11_10_2020_pVBK-Ciss0-dnXh6zSgmjw"
      decimals="INF"
      id="Narr_3uwv-vCwC0aAhtbKo-9xeQ"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">85000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_11_11_2020_jFP6QSBqjkOBLq38js8Gqw"
      decimals="INF"
      id="Narr__se33GlMK0GPonwVA25G1w"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_4_2020_xrfudyC3YkytVOGquusxcw"
      decimals="INF"
      id="Narr_ya1QphWjNkKZzFjRjlDWGA"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_6_17_2021_To_6_17_2021_sehtwXsjPE6k3If_-5V-TA"
      decimals="INF"
      id="Narr_Q-aDfdetIE2aBfHfFKdrkw"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">25000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_17_2021_midR-jy3VUGn7KvHZ7QMZw"
      decimals="INF"
      id="Narr_695KhS1-FUKf1TASd8xupA"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">150000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_17_2021_midR-jy3VUGn7KvHZ7QMZw"
      decimals="INF"
      id="Narr_w87zZd3z4Ui57coGmayOyw"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">150000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_6_21_2022_To_6_21_2022_9w7Pc3dMn0il-0WAUszkjg"
      decimals="INF"
      id="Narr_Js3PG_Wyn0yAcgS8JcL_QQ"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">50000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_21_2022_W87ewabwMUywhrCygGG9dg"
      decimals="INF"
      id="Narr_xc7G6opKI0-4LGhN79Z87w"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">200000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mbio:CommissionRatePercentage
      contextRef="As_Of_7_13_2018_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_Xdsmbxo8fkiq_m6mzNm0Bw"
      decimals="3"
      id="Narr_wXZLfwFC9US9S2UkNiSc-Q"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.030</mbio:CommissionRatePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_gFhn3tpHy0eOhnDxAPc2tQ"
      decimals="-5"
      id="Narr_yswo6c-A3ke3fc_KlcxRlQ"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">7900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_wNo8mVO2kUeHFiMORHtB9Q"
      decimals="2"
      id="Narr_-P6n4FigrUKeFCG1vV1mlg"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">0.84</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_gFhn3tpHy0eOhnDxAPc2tQ"
      decimals="-5"
      id="Narr_1FOirxE9jkKZ5rmhzRaEiA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">6600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_gFhn3tpHy0eOhnDxAPc2tQ"
      decimals="-5"
      id="Narr_d9v4ZEHefUaY0ZZDzKu1Tg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <mbio:ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_gFhn3tpHy0eOhnDxAPc2tQ"
      decimals="-5"
      id="Narr_g2cqAg1NUkiduv1IWHAvpw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">6500000</mbio:ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_aoFLNFn800q4su8jbp-MXw"
      decimals="-5"
      id="Narr_v_1wdg-eAUCB4bEPQvaR6g"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">19400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_ywrnZ-GLAkqK0TW0rXu5xQ"
      decimals="2"
      id="Narr_pBkdR6sdMEW9yDPd1LuL3Q"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">3.70</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_aoFLNFn800q4su8jbp-MXw"
      decimals="-5"
      id="Narr_Z3tNKBMjGEKvoiITBeJFng"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">71900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_aoFLNFn800q4su8jbp-MXw"
      decimals="-5"
      id="Narr_J0j-07XZgESz5mo-lRBrlg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <mbio:ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_aoFLNFn800q4su8jbp-MXw"
      decimals="-5"
      id="Narr_3Yl8Ua88-UeAZ1Cp1CKquw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">70600000</mbio:ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_c0ZjuYLL-0CMEHMYhr3GFA"
      decimals="INF"
      id="Narr_9-O7QzOOMUW9sJ7wShWOlQ"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">196952</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_2F1anYHQf02jp38E63vSpg"
      decimals="INF"
      id="Narr_lEs9NPUC8EGU9RoPleS0jA"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">576157</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_us-gaap_SubsidiarySaleOfStockAxis_mbio_AtMarketOfferingMember_4VC5ZPEVB0aXZyDJ1fjJtg"
      decimals="2"
      id="Narr_JSRsX-B4bEWQjPQqZd1ROQ"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">3.70</us-gaap:SharesIssuedPricePerShare>
    <mbio:ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold
      contextRef="Duration_12_4_2019_To_12_4_2019_us-gaap_SubsidiarySaleOfStockAxis_mbio_RegistrationStatementsMember_t--jUxfLC0e7u7XptCY16g"
      decimals="-6"
      id="Narr_hV4SjXQLHky8Zg_lnZct7g"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">100000000.0</mbio:ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold>
    <mbio:CommonStockSharesAvailableForFutureIssuanceValue
      contextRef="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mbio_RegistrationStatementsMember_MnKy-ABZ70yPMHS_OgN4rA"
      decimals="-5"
      id="Narr_pA-2MLPmuUykpqPIU1jeng"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">8000000.0</mbio:CommonStockSharesAvailableForFutureIssuanceValue>
    <mbio:ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold
      contextRef="Duration_5_24_2021_To_5_24_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_mbio_RegistrationStatementsMember_uT0i13PYeUesod3TAzOW4w"
      decimals="-5"
      id="Narr_ubdu1g3Ya0inzU-7Hqsoww"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">200000000.0</mbio:ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold>
    <mbio:DilutedOutstandingEquityPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"
      decimals="3"
      id="Narr_dK-ZdAzIsUOxLtH9UO1B8w"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.025</mbio:DilutedOutstandingEquityPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"
      decimals="INF"
      id="Narr_ygY1HtNtyUi7rF8_goBDQg"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">196952</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <mbio:DilutedOutstandingEquityPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_7MyIjljaRUivB_lhkFjr2w"
      decimals="3"
      id="Narr_Vs4Wc8_SYkSZ73u13ROrPA"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.025</mbio:DilutedOutstandingEquityPercentage>
    <mbio:SaleOfStockAggregateOfferingPricePermittedByAgreement
      contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_D02sY_Okb0CAJr_sq1tImg"
      decimals="-5"
      id="Narr_mwbwwetNzUCHCCjzvWlqAg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">6600000</mbio:SaleOfStockAggregateOfferingPricePermittedByAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_Trkkxq84fU-Vd0RoRhj2NQ"
      decimals="INF"
      id="Narr_LJseb4BvlkyiZksCTPdJVw"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">576157</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <mbio:StockIssuedDuringPeriodSharesIssuableForServices
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_Trkkxq84fU-Vd0RoRhj2NQ"
      decimals="INF"
      id="Narr_GteOTlzL1UimofLo4n-eyQ"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">51295</mbio:StockIssuedDuringPeriodSharesIssuableForServices>
    <mbio:DilutedOutstandingEquityPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_Trkkxq84fU-Vd0RoRhj2NQ"
      decimals="3"
      id="Narr_ImQGrBJ1GEmab-DxZ-XzPA"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.025</mbio:DilutedOutstandingEquityPercentage>
    <mbio:SaleOfStockAggregateOfferingPricePermittedByAgreement
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mbio_FortressBiotechIncMember_m9J360WMFk65TIBgOb6HfA"
      decimals="-5"
      id="Narr_gO54U0DHXE-nk9lKZ9Tjcw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">71900000</mbio:SaleOfStockAggregateOfferingPricePermittedByAgreement>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UcqZY0RuLkm6-uv8PCh07w"
      decimals="INF"
      id="Narr_uZct2zZarU6_8dKJXfRHcg"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4LOmmgimP0ClUtAdOe4haA"
      id="Narr_Jyh26kwG6EiyL0WotBLImg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4LOmmgimP0ClUtAdOe4haA"
      id="Narr_x-SN9ybL5EavkW1ncABYQg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2aMeSdhNi0a4ZRzBQ7A_hA"
      decimals="INF"
      id="Narr_6DUeQsFAQ0i2uDJD9UAoTw"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nrn5fFARI0iVnAb0sMWaVw"
      decimals="INF"
      id="Narr_V03S_2PMmUesEAO5v51aAw"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MqmksIdNjkaWP_ipa9CSuQ"
      decimals="INF"
      id="Narr_PPI6C0FGm0y9OkakC7AobA"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BNRH5QbCykyPiw-RTmCPqg"
      decimals="INF"
      id="Narr_zX4GbWxJukKxH6efj_13zg"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_6_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_M2BLxvwBtUun2VN6YRNObQ"
      decimals="INF"
      id="Narr_Me1-TGzJGEyJnyKhl9YfWg"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PDcmO8zz3EqNXOXuFyL8PQ"
      decimals="INF"
      id="Narr_hjZs7dQo9UWUNQeWScU6Lg"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">11000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BbA2PkmH4kSDxqPMhK8S-A"
      decimals="INF"
      id="Narr_yEwigPP1Mk2OFh9Vx8LCEw"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">4462870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_YMLGfv2QJU2bjX3oydezaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes stock option activities for the&#160;year ended December 31, 2022 and 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Life&#160;(in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock&#160;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,141,675&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,141,675&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,141,675&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options vested and exercisable at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 713,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bhwOXV7qmUa0T2YdE_tfkw"
      decimals="INF"
      id="Tc_g7Ohqkd0EEKYcwkzfAZb-Q_5_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">1141675</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bhwOXV7qmUa0T2YdE_tfkw"
      decimals="2"
      id="Tc_Uy0R-AtX6kGUpfOFS7ibGA_5_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">5.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_uj9LYQ994USIWcKdot_c7w"
      id="Tc_H6QbB8PTGkGHZMArt1U-jw_5_7">P6Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_suZlLo8Guk2LmZMnsU9VMw"
      decimals="INF"
      id="Tc_yG9zFFCwkUqbE1lnl-wmJA_6_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">1141675</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_suZlLo8Guk2LmZMnsU9VMw"
      decimals="2"
      id="Tc_Zl7nrMPrq0uY8S-nEn2cBQ_6_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">5.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_7W5zr_ZJ8k6YRLAjbxG7LQ"
      id="Tc_YWKmXIKWHkOSxIl5um1W9w_6_7">P5Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BbA2PkmH4kSDxqPMhK8S-A"
      decimals="INF"
      id="Tc_JzZiIuB-BEa0XqiCoJ9AYg_7_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">1141675</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BbA2PkmH4kSDxqPMhK8S-A"
      decimals="2"
      id="Tc_xkFP7-a05kW6sNkKblzn5g_7_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">5.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LqmnL5gbTkS17IvEqtphGA"
      id="Tc_wHaNnDBmfEep5b4TcpimUw_7_7">P4Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BbA2PkmH4kSDxqPMhK8S-A"
      decimals="INF"
      id="Tc_84f7loI9OEGabq52bDAV3w_8_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">713547</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BbA2PkmH4kSDxqPMhK8S-A"
      decimals="2"
      id="Tc_lvWp0md2LEqUfhrBRT_9Lw_8_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">5.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LqmnL5gbTkS17IvEqtphGA"
      id="Tc_ohQIrjCXRUKpBmAkqtM3ow_8_7">P4Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BbA2PkmH4kSDxqPMhK8S-A"
      decimals="-3"
      id="Narr_1zE42-eBiEK4uRS_BiYmxg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_UPMzzbZe7UyasqVciLqSTA"
      id="Tb_sr1hyj1250CNn7GM21ceKQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Certain employees and directors have been awarded restricted stock. The restricted stock vesting consists of milestone and time-based vesting. The following table summarizes restricted stock award activities for the&#160;year ended December 31, 2022 and 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&#160;Date&#160;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Nonvested at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 302,114&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.93&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 68,870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.63&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (90,001)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Nonvested at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 280,983&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.05&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 358,320&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (129,058)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.89&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Nonvested at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 510,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.48&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_Pd10hdVFnE2rD6DyKQmoRg"
      decimals="INF"
      id="Tc_kDU3B-picUacXKPsZSVmDQ_4_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">302114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_Pd10hdVFnE2rD6DyKQmoRg"
      decimals="2"
      id="Tc_hAVvML3pqkmm2oacSxsO1Q_4_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">4.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_O3YYPIPGzE-eJsI9zpkIKw"
      decimals="INF"
      id="Tc_rqcdyeft1kGGnbSvkKhv4A_5_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">68870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_O3YYPIPGzE-eJsI9zpkIKw"
      decimals="2"
      id="Tc_MSojKK4IRkOVzm9QKA8JMg_5_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">3.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_O3YYPIPGzE-eJsI9zpkIKw"
      decimals="INF"
      id="Tc_9rBEQ7qWOkq-CFSMyXULmg_6_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">90001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_O3YYPIPGzE-eJsI9zpkIKw"
      decimals="2"
      id="Tc_Avo9_p7oM0KFAXxpzNaQng_6_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">6.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_3-kS7FRDbkqpKxd-4hKdeg"
      decimals="INF"
      id="Tc_sTCTQBSCR0GLt5Y8AlCVrw_7_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">280983</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_3-kS7FRDbkqpKxd-4hKdeg"
      decimals="2"
      id="Tc_eL8VygfqYEGF62w118xADA_7_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">4.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_UPMzzbZe7UyasqVciLqSTA"
      decimals="INF"
      id="Tc_DnyTrWTt_EyPX0If29NnxQ_8_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">358320</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_UPMzzbZe7UyasqVciLqSTA"
      decimals="2"
      id="Tc__K7HRB9dMkeG184L4ifX9w_8_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_UPMzzbZe7UyasqVciLqSTA"
      decimals="INF"
      id="Tc_u8nDgkYKSESjUaLQqCnMUw_9_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">129058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_UPMzzbZe7UyasqVciLqSTA"
      decimals="2"
      id="Tc_kvWh9nYbeEK9DU2QrOCmsg_9_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">4.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_oh5GT7S9BUWgIrXyvuqlaw"
      decimals="INF"
      id="Tc_SohJ_7oi5UCSTAWnTHiJ-A_10_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">510245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_oh5GT7S9BUWgIrXyvuqlaw"
      decimals="2"
      id="Tc_ThQXyyy1GUWsV1hTEO-WlQ_10_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">1.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_oh5GT7S9BUWgIrXyvuqlaw"
      decimals="-5"
      id="Narr_5cdmrJ0hXUuzRKEXirOX3g"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_UPMzzbZe7UyasqVciLqSTA"
      id="Narr_oqU5-x9kaESZnSZB875ZQw">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HKp1HVK3rUeH2BUSicO2mA"
      id="Tb_k7UeaN5c-EmyPUMXAvrH-g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes restricted stock units&#x2019; activities for the&#160;year ended December 31, 2022 and 2020:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&#160;Date&#160;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Nonvested at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,468,559&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,660,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.07&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (372,873)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.60&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (420,379)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.27&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Nonvested at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,335,557&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.27&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,484,647&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.76&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (514,999)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.53&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (816,518)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.98&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Nonvested at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,488,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.84&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2-wAsbb-T0KYD16SQuYxKg"
      decimals="INF"
      id="Tc_hxP84nPBpEO019DCfIkXdw_4_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">1468559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2-wAsbb-T0KYD16SQuYxKg"
      decimals="2"
      id="Tc_VGVNzOFetkWXor1t2Ke0ww_4_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">3.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nMMb4QwZpE2wkHPBjsoMzQ"
      decimals="INF"
      id="Tc_ExvVswWSxk2G23tvKt2rsw_5_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">1660250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nMMb4QwZpE2wkHPBjsoMzQ"
      decimals="2"
      id="Tc_lDM30_Sjp0yOqbwRBxGhnQ_5_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">3.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nMMb4QwZpE2wkHPBjsoMzQ"
      decimals="INF"
      id="Tc_v3uf6zgI0kWKf_Vh6qXcpg_6_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">372873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nMMb4QwZpE2wkHPBjsoMzQ"
      decimals="2"
      id="Tc_78r8eldoZUeik-vJ4o6Pzg_6_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">3.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nMMb4QwZpE2wkHPBjsoMzQ"
      decimals="INF"
      id="Tc_RmtxOJBFukiNt0iLFMEptQ_7_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">420379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nMMb4QwZpE2wkHPBjsoMzQ"
      decimals="2"
      id="Tc_QKnd6SzPPkuwKJ2c32BF4g_7_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">4.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_KeRs2NdINE-YRgyA7zQiQg"
      decimals="INF"
      id="Tc_trQsGa8HbUWYWTU6JQXg5A_8_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">2335557</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_KeRs2NdINE-YRgyA7zQiQg"
      decimals="2"
      id="Tc_rW7pV0VWuUSrVwXDE6GwDw_8_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">3.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HKp1HVK3rUeH2BUSicO2mA"
      decimals="INF"
      id="Tc_chw0dZmxSECSUdEYBjuk_w_9_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">1484647</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HKp1HVK3rUeH2BUSicO2mA"
      decimals="2"
      id="Tc_o_J7dgVPVUyrZ_HMorJc0Q_9_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HKp1HVK3rUeH2BUSicO2mA"
      decimals="INF"
      id="Tc_pJLpGLp1g0G86bx-WtcqKw_10_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">514999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HKp1HVK3rUeH2BUSicO2mA"
      decimals="2"
      id="Tc_7nTl9G08rkeaTwXYQhbuMA_10_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">2.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HKp1HVK3rUeH2BUSicO2mA"
      decimals="INF"
      id="Tc_hRZ2AInKtEixR-F7AcGNEQ_11_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">816518</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HKp1HVK3rUeH2BUSicO2mA"
      decimals="2"
      id="Tc_PTti2J6m5EKr0meGM2Lykg_11_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">2.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_GOVpc9dkuEG97uEvmowlTQ"
      decimals="INF"
      id="Tc_Twgprolg7kiPvWf7bke3YQ_12_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">2488687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_GOVpc9dkuEG97uEvmowlTQ"
      decimals="2"
      id="Tc_H8A3pFofLECE-2JghWKiGQ_12_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">1.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_GOVpc9dkuEG97uEvmowlTQ"
      decimals="-5"
      id="Narr_XKEiNfwcxkOtwRi6qunlqw"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HKp1HVK3rUeH2BUSicO2mA"
      id="Narr_Afz-lxRpt06PLCyz12IZgQ">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_yCznQWkIYEOCYAwshVxSBg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes stock-based compensation expense for the&#160;years ended December 31, 2022 and 2021 (in thousands).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 700&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,030&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,583&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,283&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_f1ddUvO4v0amvOZiXCEDeQ"
      decimals="-3"
      id="Tc_B1zo195zF02sA5Llo1v_Iw_3_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">700000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_uHyqiEuP_0ekgE-jQl3slQ"
      decimals="-3"
      id="Tc_otp05g01akO--Hn4Q9t2qA_3_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1030000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-LQvQ6gJ9UOk8vXKCNkxng"
      decimals="-3"
      id="Tc__4CaRc0gdkeTYk8Pq0PUUw_4_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1583000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_-mQVcy5AFUC0fcnvfp5yUg"
      decimals="-3"
      id="Tc_H6GoD46Ba0KPpYPNmiGJ8A_4_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2278000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-3"
      id="Tc_acajajrYOUqOcAa_aXEgeQ_5_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2283000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-3"
      id="Tc_lrqDXGLNMUmYhgXMGvEmJg_5_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">3308000</us-gaap:ShareBasedCompensation>
    <mbio:ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_tpnhJWDO60OMRtanSOx5tQ"
      decimals="2"
      id="Narr_XHfMzDl9YkWSwmuZqghfMw"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.25</mbio:ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g"
      decimals="INF"
      id="Narr_Om4hsBj3ME2K5w9l2S6G_w"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">748036</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g"
      decimals="4"
      id="Narr_yek2Ll_OykqtmkAVNC94Rg"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">0.8021</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mbio:SummaryOfWarrantActivitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_wELrxzNDkkuTmkUTIoOpMQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A summary of warrant activities for&#160;years ended December 31, 2022 and 2021, is presented below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Life&#160;(in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,402,670&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,093,878)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cashless exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (138)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,308,654&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.73&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,003,770)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 748,036&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.18&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,052,920&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.29&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</mbio:SummaryOfWarrantActivitiesTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_cSWJg5CHcU6I0x0JrwnJzQ"
      decimals="INF"
      id="Tc_gwoZ2UppwE-SZi7xfS4AaA_5_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">5402670</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_cSWJg5CHcU6I0x0JrwnJzQ"
      decimals="2"
      id="Tc_fo_QlKzJt0qE-2i6-WL52g_5_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">8.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mbio:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_YQ4fUCukB0WFke0KueexQA"
      id="Tc_pD_UWvtVUESZYSLo2dcBJg_5_7">P1Y4M20D</mbio:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife>
    <mbio:ClassOfWarrantOrRightWarrantsExpiredDuringPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_zwcEeJiJR0GMOVhFZZp5MA"
      decimals="INF"
      id="Tc__joJaAxBxEGOvsHCwtQY4A_6_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">2093878</mbio:ClassOfWarrantOrRightWarrantsExpiredDuringPeriod>
    <mbio:WarrantExercisePriceExpiredDuringPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_zwcEeJiJR0GMOVhFZZp5MA"
      decimals="2"
      id="Tc_ykp5Mi2nxEOdbt_slTwkcA_6_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">8.50</mbio:WarrantExercisePriceExpiredDuringPeriod>
    <mbio:ClassOfWarrantOrRightWarrantsExercisedDuringPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_zwcEeJiJR0GMOVhFZZp5MA"
      decimals="INF"
      id="Tc_C05EqSeC4EWIrF8zUOjiJw_7_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">138</mbio:ClassOfWarrantOrRightWarrantsExercisedDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_hD2Rfx-DxkuN5TyT5ipjDw"
      decimals="INF"
      id="Tc_dNgRdzyrSEiKhRDjhv0-iw_8_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">3308654</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_hD2Rfx-DxkuN5TyT5ipjDw"
      decimals="2"
      id="Tc_EvyV8_h8oEGt1jfFGLqQaQ_8_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">8.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mbio:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_zwcEeJiJR0GMOVhFZZp5MA"
      id="Tc_Is2uuQecI0SeyFyc6hV7eA_8_7">P0Y8M23D</mbio:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife>
    <mbio:ClassOfWarrantOrRightWarrantsExpiredDuringPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_tpnhJWDO60OMRtanSOx5tQ"
      decimals="INF"
      id="Tc_qxW2B7X5aUqCLtHQd1wxew_9_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">3003770</mbio:ClassOfWarrantOrRightWarrantsExpiredDuringPeriod>
    <mbio:WarrantExercisePriceExpiredDuringPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_tpnhJWDO60OMRtanSOx5tQ"
      decimals="2"
      id="Tc_6QfFp9Qfi06qlKRpeXZYTA_9_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">8.50</mbio:WarrantExercisePriceExpiredDuringPeriod>
    <mbio:ClassOfWarrantOrRightWarrantsGrantedDuringPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_tpnhJWDO60OMRtanSOx5tQ"
      decimals="INF"
      id="Tc_K06l4DRYG0G54bVVzXsZMw_10_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">-748036</mbio:ClassOfWarrantOrRightWarrantsGrantedDuringPeriod>
    <mbio:ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_tpnhJWDO60OMRtanSOx5tQ"
      decimals="2"
      id="Tc_rt-mj5CiYUenp_4ZhvjMwA_10_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">0.80</mbio:ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod>
    <mbio:ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_tpnhJWDO60OMRtanSOx5tQ"
      id="Tc_kLfRDy4E4U2TRj7rUyhJew_10_7">P9Y2M4D</mbio:ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_qB-ZO8R0_ESmBgqQbpsWbg"
      decimals="INF"
      id="Tc_Isk8tBRC50ya9ysk9CqAsQ_11_2"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">1052920</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_qB-ZO8R0_ESmBgqQbpsWbg"
      decimals="2"
      id="Tc_9Q2mlF-bcE-ILFwdQLGDsQ_11_5"
      unitRef="Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ">1.52</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mbio:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_tpnhJWDO60OMRtanSOx5tQ"
      id="Tc_RmRJnaBMiEmnm8Ge9L5bCQ_11_7">P8Y3M14D</mbio:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife>
    <mbio:EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="INF"
      id="Narr_dbvh17AwEUOOpqQqlY5r6A"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.85</mbio:EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="INF"
      id="Narr_aGOjojx3Hkap7sNNj04V9g"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">586010</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="INF"
      id="Narr_BLy2ipZ4AUWpYqc-GdXIDw"
      unitRef="Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A">413990</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_bUnrLJZiskKNJKj0RcyIbQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;10&#160;- Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company has accumulated net losses since inception and has not recorded an income tax provision or benefit during the&#160;years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A reconciliation of the statutory U.S. federal rate to the Company&#x2019;s effective tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;year&#160;ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statutory federal income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State taxes, net of federal tax benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-deductible items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal tax rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State tax rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (41)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income taxes provision (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The components of the net deferred tax asset as of December 31, 2022 and 2021 are the following ($ in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;year&#160;ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carryovers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75,011&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 66,879&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock compensation and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,702&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Change in fair value of warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization of license&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,977&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,466&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 755&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accruals and reserves&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,434&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,035&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Startup costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,649&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,728&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;174 Capitalization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 129,186&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 95,141&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (128,101)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (94,751)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 390&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Right of use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,085)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (390)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax assets, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company has determined, based upon available evidence, that it is more likely than not that the net deferred tax asset will not be realized and, accordingly, has provided a full valuation allowance against its net deferred tax assets as of December 31, 2022 and 2021. A valuation allowance of approximately $128.1 million and $94.8 million, respectively, was recorded for the&#160;years ended December&#160;31,&#160;2022 and 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;As of December 31, 2022, the Company had federal and state net operating loss carryforwards of approximately $214.0 million and $463.1 million, respectively. Approximately $190.4 million and $0.2 million of the federal and state net operating loss carryforwards, respectively, can be carried forward indefinitely. As of December 31, 2022, the Company had federal and state income tax credits of approximately $12.5 million and $4.0 million, respectively, which will begin to expire in &lt;span style="-sec-ix-hidden:Hidden_RuW2aDq3XEWNv2WtYazZ1w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2033&lt;/span&gt;&lt;/span&gt;. Under the provisions of Section 382 of the Internal Revenue Code, a corporation that undergoes an &#x201c;ownership change&#x201d;, as defined therein, is subject to limitations on its use of pre-change NOLs and income tax credits carryforwards to offset future tax liabilities. Certain tax attributes may be subject to an annual limitation as a result of the Company&#x2019;s January 2017 capital raise, as it appears to constitute an ownership change under Section 382. Additionally, under Section 382, annual use of the Company&#x2019;s net operating loss carryforwards to offset taxable income may be limited based on cumulative changes in ownership. The Company has not completed an analysis to determine whether any such limitations have been triggered as of December 31, 2022. The Company has no income tax effect due to the recognition of a full valuation allowance on all of its deferred tax assets as it believes that it is more likely than not that the deferred tax assets will not be realized regardless of whether an &#x201c;ownership change&#x201d; has occurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;There are no significant items determined to be unrecognized tax benefits taken or expected to be taken in a tax return, in accordance with ASC 740 &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;), which clarifies the accounting for uncertainty in income taxes recognized in the financial statements, that have been recorded on the Company&#x2019;s financial statements for the periods ended December 31, 2022 and 2021. The Company does not anticipate a material change to unrecognized tax benefits in the next twelve&#160;months.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Additionally, ASC 740 provides guidance on the recognition of interest and penalties related to income taxes. There were no interest or penalties related to income taxes that have been accrued or recognized as of and for the periods ended December 31, 2022 and 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company is subject to U.S. federal and various state taxes. As of December 31, 2022, the earliest federal tax year open for the assessment of income taxes under the applicable statutes of limitations is its 2019 tax year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'Calibri Light';font-size:10.5pt;margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Beginning with the 2022 tax year, the Company is required to capitalize research and development expenses for tax purposes as defined under Internal Revenue Code Section 174. For expenses that are incurred for research and development in the U.S., the amounts will be amortized over 5 years, and for expenses that are incurred for research and development outside the U.S., the amounts will be amortized over 15 years.&#160; As a result of Section 174 capitalization, the Company recognized a deferred tax asset of $19.8 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer's social security payments, net operating loss utilization and carryback periods and modifications to the net interest deduction limitations. The CARES Act did not have a material impact on the Company&#x2019;s income tax provision for 2022 and 2021. The Company will continue to evaluate the impact of the CARES Act on its financial position, results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;On December 27, 2020, the President of the United States signed the Consolidated Appropriations Act, 2021 (&#x201c;Consolidated Appropriations Act&#x201d;) into law. The Consolidated Appropriations Act is intended to enhance and expand certain provisions of the CARES Act, allows for the deductions of expenses related to the Payroll Protection Program funds received by companies, and provides an update to meals and entertainment expensing for 2021. The Consolidated Appropriations Act did not have a material impact to the Company&#x2019;s income tax provision for 2022 and 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_vyCqT3P2KEiZqRcqsKagBQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A reconciliation of the statutory U.S. federal rate to the Company&#x2019;s effective tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;year&#160;ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statutory federal income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State taxes, net of federal tax benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-deductible items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal tax rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State tax rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (41)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income taxes provision (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="2"
      id="Tc__l97wVr5IkOSMZfvDTlsjA_3_2"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="2"
      id="Tc_P0LACsd2DEyGqN0anz_zMw_3_4"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="2"
      id="Tc_fYKT-c-Wc0KgHhPXWjaWLg_4_2"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.16</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="2"
      id="Tc_uAY-6VoFFku2YW9pTlmCpw_4_4"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.16</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="2"
      id="Tc_P2Qjc_Nuhk6Cm3g2QJq0wA_5_2"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="2"
      id="Tc_ObQbWKoQ8EGPTF3hR01nXA_5_4"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="2"
      id="Tc_ytbq9hLGCUqne7bDZoThog_6_2"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="2"
      id="Tc_qR3w6YENK0CtrcGvLILdjw_6_4"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <mbio:EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="2"
      id="Tc_0ehmjPfpXkq_H32_3UmLzg_7_2"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0</mbio:EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent>
    <mbio:EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="2"
      id="Tc_2Xg6rBzN70KbUiR8A3M_IA_7_4"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0</mbio:EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent>
    <mbio:EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="2"
      id="Tc_YGvPWX1Dp0SrEDrUwG1Bhw_8_2"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0</mbio:EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent>
    <mbio:EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="2"
      id="Tc_9UGIkp20QkmjV4MC1wGZGw_8_4"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0</mbio:EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="2"
      id="Tc_7k41BHbzSkamZSVkGdUumw_9_2"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="2"
      id="Tc_Bsnuspt3Rkyq0XLGQU0mew_9_4"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="2"
      id="Tc_oLNTpPXmW0e09pVKXCuXCQ_10_2"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">-0.42</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="2"
      id="Tc_QffnamnDxECyhoXWQz6xjg_10_4"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">-0.41</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="2"
      id="Tc_3cdjnFikvkmscnLRf24lgQ_11_2"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="2"
      id="Tc_kMB1P3eaCUaD_-3jgLO9tQ_11_4"
      unitRef="Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_M6ssxwNrIk-JDSrQpNqWUg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The components of the net deferred tax asset as of December 31, 2022 and 2021 are the following ($ in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;year&#160;ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carryovers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75,011&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 66,879&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock compensation and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,702&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Change in fair value of warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization of license&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,977&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,466&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 755&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accruals and reserves&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,434&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,035&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Startup costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,649&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,728&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;174 Capitalization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,787&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 129,186&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 95,141&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (128,101)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (94,751)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 390&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Right of use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,085)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (390)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred tax assets, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_C6Hb_fLUZE-IPUukxasj-A_4_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">75011000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_u_UELFtyvkGcNKQCV26kKA_4_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">66879000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_0uP6hGtd10i50NNBvVxR2g_5_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2399000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_XxEhEHMFOEWi6lVRbF7qRg_5_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">2702000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_ncClkKWAs0-bfjYLIvJGqw_6_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">59000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_Bg7YcJIlZkGdbsB5AtIkFw_6_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">59000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_6rTJLPTiLEKEAC9wsra5Gw_7_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">13375000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_D-xwBitQJUanCUdj90vhyw_7_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">13977000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <mbio:DeferredTaxAssetOperatingLeaseLiabilities
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_MgEzVfq2u06mHdvGDrktPg_8_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1466000</mbio:DeferredTaxAssetOperatingLeaseLiabilities>
    <mbio:DeferredTaxAssetOperatingLeaseLiabilities
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_Gwlo7DRGK0uXi38VHFhqNA_8_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">755000</mbio:DeferredTaxAssetOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_PjsgXoALv02tUHq68gooKQ_9_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1434000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_nBauJ9npMUq9F5Pi1xKqIQ_9_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1035000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <mbio:DeferredTaxAssetsStartUpCosts
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_1Ykv3Tx-T0ifo6ZrYlF4aw_10_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">6000</mbio:DeferredTaxAssetsStartUpCosts>
    <mbio:DeferredTaxAssetsStartUpCosts
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_3MM-hMKNcEyv2PFGr38jhg_10_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">6000</mbio:DeferredTaxAssetsStartUpCosts>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_hBq86TE4W0ip7GpNcq-3mA_11_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">15649000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_xcNkXgSMak2E2qn16ONeTg_11_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">9728000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <mbio:DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_WSQdchYwMEmRgEk7z6RK2A_12_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">19787000</mbio:DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses>
    <mbio:DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_8nsrEna-C0GSPobAHbgzcQ_12_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</mbio:DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_lCqBWAGpv0eBWODKbEeaXg_13_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">129186000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_pH9-ur-ynUe6BmjzexUOMw_13_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">95141000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_90mmJ1z9akW4zgJxe5bEjw_14_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">128101000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_GOuzEKUyhEK7DmNw20vTZQ_14_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">94751000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_bpwunYdy90qNBxDHv6uRWw_15_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1085000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_tFqvSAdKRUaGm76zh0Cj8A_15_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">390000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_aMgg5PgXkkGtYTA7jMmTXA_18_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">1085000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_DZDth2bBXEiN_6xol9SF9Q_18_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">390000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-3"
      id="Tc_3iyipHWvRk-N5bBu6-0LHA_19_3"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-3"
      id="Tc_hMn1OyvZ5UKENbWZwmtkFg_19_6"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ"
      decimals="-5"
      id="Narr_XWZgGt08yUaFnE_4YroP2Q"
      unitRef="Unit_Standard_EUR_rzel3jVa2UO3kiVSQxNNcA">128100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_KF2m_eSz00aUG_n3gBNXwA"
      decimals="-5"
      id="Narr_Arhji0NIlEig-n_Q3qk_Mg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">94800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_xeewYyKVAEu67ngPqUXP6A"
      decimals="-5"
      id="Narr_5TNnt1z_CUCFPtS0f05e-g"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">214000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_9h_ihuTMpEGBputHFvfCaw"
      decimals="-5"
      id="Narr_N2oQkWGqWUycBdbkn6cQxg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">463100000</us-gaap:OperatingLossCarryforwards>
    <mbio:OperatingLossCarryforwardsWithoutExpiration
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_QcfoZ3MG8ECfgSVpuDaKmA"
      decimals="-5"
      id="Narr_e2SgY_POJESeipEg1TCZow"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">190400000</mbio:OperatingLossCarryforwardsWithoutExpiration>
    <mbio:OperatingLossCarryforwardsWithoutExpiration
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_Q8BOscMl8U2O76Uoh4fs0g"
      decimals="-5"
      id="Narr_AhLxRstc8UGp48__QC_faQ"
      unitRef="Unit_Standard_EUR_rzel3jVa2UO3kiVSQxNNcA">200000</mbio:OperatingLossCarryforwardsWithoutExpiration>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_QcfoZ3MG8ECfgSVpuDaKmA"
      decimals="-5"
      id="Narr_fHJejMFpdEezjm2lBgpQSQ"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">12500000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_Q8BOscMl8U2O76Uoh4fs0g"
      decimals="-5"
      id="Narr_q-YE_VAUlU-Q2-rRDW6Qeg"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">4000000.0</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_A8Mvq9501kSc4Kml8mdwog"
      decimals="-5"
      id="Narr_SGYkWb6lfky_eugOu6KhWA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      decimals="-5"
      id="Narr_cnTbOo6ONEGz850mCg9oGA"
      unitRef="Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw"
      id="Tb_bjmAfBtXl0ass73Ypv4z5g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;11&#160;&#x2013; Subsequent Events&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Our Board of Directors approved, and our stockholders subsequently approved, a reverse stock split of our Common Stock. On March 15, 2023, the Board of Directors set the reverse stock split ratio at 15-for-1. We have filed a Definitive Information Statement on Schedule 14C in connection with the reverse stock split, and once the applicable waiting periods under SEC and Nasdaq rules have expired we plan to file a Certificate of Amendment to our Amended and Restated Certificate of Incorporation, as amended, in order to give effect to the reverse stock split. The ex-dividend date is expected to be determined in April 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MF0ZO#U:U!65(K )JL ,U: 9J3EA$U?@8(CG*:MO4 :7M6%4[6('U;:$9$JM
M&^Z@#1OV/H:E/<C'L?H6!FL]X)AKFQA8UI:6(;$*K=&.U@@\PLTE]SJ*"9IE
MR3UA.DJPAF7977=DG]DZ4F!I6U*&Q"JDSG:DSIJ0NB7+B O9M 2:X43;%6&=
MFZ^+N_'L([J:?CDI=FXZ\T]UZ$"=MN@,B570V5;I\JPF\*9I0)GLBKF[.$$+
M(0<S1!GR:98*]BK_AUJB!]0G'W3XX**V_$RI50'NV62["< [_(*FH1S=HH<H
M*#Q:?:\](.D-9:]U1L.!I:4'%K>F9TBM2L\IZ3E-Z(W#4*KSD^T'E-O;+ZF^
MS<&2[G"(YK$<!HJS(+^2$4@+$M1I#=*06A5D&1)LT#C_!Z2OEF0'OJ//J18B
M+/>-LH!PH6V^/ES;&MPQ$H%=1@(;-O4_@ML-?7-&GZ(TT#=!6/-FK,5F-">8
M4JMB*Y."#5O\'['-*1<R,?P9K>NO%;"B)?>MK^5F-#:84JMR*X.##?O]O%^.
M&<'UF&"!X4CKYN"JUI".D1/L,BC8L+O_3 /9EN8KFD+>]X#(H.]TO;ZEOX8:
MC0FFU*JTRJ!@PR[_+A(R(] '9#MO[]^A!0DR)EN9%AFLY-,DR2^9-'@\06O,
MT!..,X+>6*>6S!)H31CB*\RTR0O6;LWT&(G"+B.%#6<!&5'#*%VBQ6MR3V,M
MR@-A0J8(+26CV<&46O4V:QD>'-C>;YL:^O 2K'"Z)+7)ZX#0;+R8C'_7WJHU
MFA5,J55YE5G!:905OI$X[CZFTIG)SHJY'.5"-.4\TP]S!S1G5(O-:$@PI5;%
M5H8$IU%(^(/&,HQB5MP48=JIA@-*-;",!@%3:E5891!P&@4!/V-,W6LK;K#E
M0YDTMID>&JSXG>BJ?+BJ-;5CI "G3 %.HQ0P367D*68<U?U<O,6HI08KUE$S
M&@),J56IE2' :10"\NZ(?)F;EI1I?<<!G1E-NS@(B)21(F$AJ*5G- J84JO2
M*Z.  SOY#;U%@N,8765<?LWU_1/6J9MM@<M:PSI&)'#*2.# ;GX#ZT-"V%*-
M9A^E@EC)$)6L<:IO<_]S!@&N:XWM&-G *;.!TV@68;&2E@.$!<O4PS)J^DVI
M56&5IM]I-)$PS^[C*$#7,<7Z@=^DA?>-JDTV:OU<33W:\W3IC4Y'Y[TG#1FW
M-/INHUD"7UX*F4SFTS0D+^@3T3:E U(J2 Y&EN6-M(\:&+7[IM2JU$J[[\+6
M?#?A>1UQ=4/C.Y&)^EJNU([R!\3JIH?ALM;$CN'TW=+IN[ __Y'89GJ]GADL
M=_U=2\RHW3>E5B6V]W 0;,ZW/G^_B4%/(QR0ZW9MI^MJ[S#"E:VQ'</ONZ7?
M=V%W/I:M+"Q:6HR76E"P0.T5$:YKC>D8!M\M#;X+&_.I?WV+QED8"<K06 C"
M-[-JM=1@O7IJ1HV]*;4JM=+8N[ AWP*KNQEVH/S3_.8C^OQYKN5DU-.;4JMR
M*CV]"UOP+:?KB"5H.M&B@A7LD7;&"*YJ3>D8%MXM+;P+>^\M)34IHOJ>%A,L
M,2//Z#MECR=HIK\B&G7QIM2JO$H7[\(NWH\QYVB,MI,9:KZ"H[]NB)I'TC\L
M:]30&U6;F%*K/B];&G^OL,A&'S[V3)IXWZC:Q)1:E6<9";Q&,P#5B;9-$_V2
M"7EY3=6\DY:J2:/O;]0&>T%QY/5=-9X^57@=(Q!X92#P8 ??O!/#0JWQ&,T(
MIM2J$,N,X!WA#0+/Z"L$1M4FIM2J//?>(F@T6?"_.K')=.!OU/8[L6V=N6>C
M@?N??FPT2/3VWBM2=V3S][,X"M33HL4K1KNUNW? QOF;3[WRY\4+9#=8W=#E
M*"8/LM0Z'4KOSHIWLHH%0=?Y6TKW5 B:Y!]7!(>$J1_([Q\H%=L%M8'=FW&7
M_P)02P,$%     @ >ZQ]5O:VPA6&!@  *AX  !@   !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6S-6=]OVS80_E<(K]@:P(E%ZI>=)09<)T4'M%U0M]O#L =&
MIF.ADNB*5)+NK]]14B1+I!AG]<,>$DO6W?F[T_&^C]+% \^_BBUC$CVF228N
M1ULI=^>3B8BV+*7BC.]8!E<V/$^IA-/\;B)V.:/KTBE-)L1Q@DE*XVPTORB_
MN\GG%[R029RQFQR)(DUI_OT-2_C#Y0B/GK[X%-]MI?IB,K_8T3NV8O++[B:'
MLTD391VG+!,QSU#.-I>C!3Y?NKYR*"W^B-F#V#M&*I5;SK^JD]_6ER-'(6()
MBZ0*0>'CGBU9DJA(@.-;'734_*9RW#]^BOZV3!Z2N:6"+7GR9[R6V\O1=(36
M;$.+1'[B#^]8G5 ),.*)*/^CA]K6&:&H$)*GM3,@2..L^J2/=2'V'+ WX$!J
M!W*H@UL[N&6B%;(RK2LJZ?PBYP\H5]8031V4M2F](9LX4[=Q)7.X&H.?G+]9
MO%]\7%ZCU;OKZ\\K=(J^K*[0ZU<GZ!6*,_1YRPM!L[6XF$CX,>4RB>K ;ZK
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M [B^X;"[J4_4Z\+F]?#\7U!+ P04    " ![K'U6,/*%>5(#  #W#0  &
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;*V7T8Z;.!2&7\6BJZJ5NH,-@9!I
M$FDFG:J5ME74M+L752\<. EH %/;2=I]^MK D! ()-'D(MAPSL_WPX%CQCO&
M'T4((-&O)$[%Q BES&Y-4_@A)%3<L Q2=63%>$*EFO*U*3(.-,B3DMBT,';-
MA$:I,1WG^^9\.F8;&4<IS#D2FR2A_/<]Q&PW,8CQM.-+M ZEWF%.QQE=PP+D
MMVS.U<RL5((H@51$+$4<5A/CCMS.B*,3\HA_(]B)@S'25I:,/>K)QV!B8$T$
M,?A22U"UV<(,XE@K*8Z?I:A1G5,G'HZ?U-_GYI69)14P8_%_42##B>$9*( 5
MW<3R"]M]@-)0#NBS6.3_:%?$#D8&\C="LJ1,5@1)E!9;^JN\$ <)9' BP2H3
MK',3[#+!SHT69+FM=U32Z9BS'>(Z6JGI07YM\FSE)DKU;5Q(KHY&*D].[^_^
MN?L\>T"+#P\/7Q?HU9QR2&4(,O)I_!K]C?Y")A*AVBO&IE0GU&FF7XK?%^+6
M"?%WX-\@F[Q!%K:LEO39^>FDGFXJFY57J_)JY7J#$WIS52' .01(75;_$664
MHRV--X!>12D*6!Q3+E &O##\NLUP<08O/X-^1+93?(,Q5GC;0V.]834#=F7
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MH?HR ZX#U/$58_)IHM?^U;?>] ]02P,$%     @ >ZQ]5H<,P04G!   M@\
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M="1VE-S0IE=TS0*$UY71)<"'4-[939"B>.$_PJ]DUN"Z#X ;"R:0&,0>T56
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MK)5$YZ,%>%]:M,]T0PK&GW*N_@]02P,$%     @ >ZQ]5@[)J0MQ%   1SH
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MMV8E/WS>@K9,\3H\HK6P99 41H-(X4K^!136I3)$(?"G!A@+V':U6]MLC?W
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M6;LZH<Q$7>MZS1?SA^]!3<@B0Y,* 7"$:3 5C!>\.:Q/8;&21 B:V CT8K5
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M)\M:BY-^<>0\&W+ GV#K=;9N8?"9;P1XA(NN?QABY>K/L\D4J4I1< Q0/MQ
M9PR)4V+:L&-K.%TK]G+^^PXZ^!HF:(9,CE0_\YX]<=N$(;Y1Y%- VD' JY_4
M%[Z  DO"OM);RTS'E;/+"4)<VM_ %FT+$B]:2P9@2_(Y4B72X[!DX+>1CX>\
M3:[9>!;L&Q#]D$"X:I_N85NFJ\J* &0.1HN]!EC7;EH1&3 ,C+:,U(3,2/Q&
M D0Q6LOF'[K+# WN+E=@U[(M8%3N3#1V'5&]_QXE4?:2'N^-KO"TK8/C!=\T
M9;5C2B'4QL XY9,#=$ ^<0WLFZJ5=!N4O1'FP/ 184J?A[.?&+2^#Q@:)+)O
M9Z"FY -RIED=A3DW9!S$>*=@A#@DR$^(/8)CYI@CX/"R+[NT]L_S] %'U%YO
M@>#2WG.\S-'0N'^Q+0,NWOX%3ZFDV/([WKVO E\1C3/#"S.$54?"!((1Q<.>
M2@#19:(VD?R+UA8YA_+ CIQ;9Y%JR")H0QY V0W0N$LB-]@G6++?4L&KUQ3'
M50&L0W(HB[%P,R"3?"-)W]:3*[D8T''T5^A,"$\YMJ4('D820IN)UWX'%U(X
MD<9KQKOW<Y[\[,D"?OJ D[$.L@67E]\QK[9Z+YB3G*V<RX4&_G[O[P,!V]J+
M1=NT+"D'+N=*E ^94P@X8N1,3Q9(QBH9M*0M$GC$=0)0EV>+.\,B&)PU\P8^
M(:[VN)#MV"!Z(JF"0_.V#B(.ME%.$U&.#M!6T7T)PAZ:PQA&^GA>/E3UA5GK
M8AD)E_(@;A5EHSSW =8=J)1@4@9Y1RS['5XC>?4QE#?2)(/B)$I31#<=\H^1
MCP<X2X;B5NR[%S"82XG3*E"]$&_N?"SQ\ 0 F7T;+SC\)^7%8Q\91!H3(QX3
MF82M !%*BIEZS!%<PE78:,NQ7YF3O<FA^S[!,MFZ=(5;[9^\CLD!9) A1FZZ
M:J5+^UOJ3"%9\ $<XK")#5_J!B02:E%@:E>:E1EAAD<CKD0(H(M: G\D;;J4
M:%=0XD0THQ0WY-+]X*1_"N5>)AXW9-\JLR(?2DYW"0N)*':4.F*_*;*N;K?;
M@JM!'TH.GJJ<M9_/2BIC2)/*7%/@=>URR;(XA/>5IZO;ZU!X4A<GT_%L.IZ?
MC6',#UFID;HJ2TID;TE2U#LH?0Z))RA^:"&I"$W.1[XF\,A]7FU(.7(^DV)%
MQOX* I05XO0_E%D:C?9#Z[K%ZOG9=#2=3M4UU;#4%;$9&33I6[W65&V J(1P
MU\=YAU8"&]L4'%IQYD#6QU'TR9CE 3/*V0KZ93XY^TMT8RV%(+DM))QI&ZJN
ML>:19PXI=@?],_H2:#Y$P'[Y;YC&.]@:4H!P>$C]A:70F%BUZ@I:#^ (L00=
MV'3B0.DXXB/MZTY-SY;0^J#:K'EVT7I5#E7%Q;[+,9[5QB@NV)X^GXA<P I0
MR/J'R(7V>YN#9".GP 4>SH4^L53/3NAJIWZ SFJHUZQ&^G+35G6KI4SU[Q+7
MT>7T @)[&82.JU*;#66!#&4BKC$P'$2#XJNM%+6)*8^$<?RT, 9.X>*(,T=P
M)R1Q\$HD7 B*=F6HL]R&ZA=M9UA$26KO$KDB1>'I0%3(6==UBB?1@\4SY+;O
M'1>$H9FKRO ]DX%\D:D?_!.;W"U<QCW':E! Q+ZS!WG;L$,=!PFNO=&FB*-S
M29+K1Q@]KY)Z'N492J3A$;)_D."<G9R/SJ<7_V\%9_X'",[L?TUP3B?S_VO!
MF4W4>VTK];,N8*$^(9E ",Z7IN@L75&X79TVG5:M%6</V)=TPAV?L.E.$)'H
MBID'JM]^!^?SR4&4-A(9D5C0=0OJJ2'T+G.?.PV ,DKW0RB2Q@RSP384S=*Z
MGC#R:5P\\FD)5\4EL9.T@$IHE&1K[YDHK-YJ*\2GKA?5SW7$:N^K2B0!5=%K
MC,6^&&+J;SB((]?,;K4O7'.<GC"!7 87$JE<]Q _[4_QH7*Z3VK ZX!);BA[
M9&+(6E<^;G@,@22T:$F\2B:>Q)D=&1*L10.&1"1V80X)RJ+?#^QZ*)(8<LO(
M6PN61&$;-0^H8+]RE&6\8.6<GKQ4'TEUU.R%^L_6<0FQXL3(AED&CZG(IP0A
M62>?G$-$\9SXT^8OU.<%Y5BL8K;<MK2TRQ;]G?ZN$1]=6R@W-&_P8-]DHOXA
M2)-1:9YKX]VW]#I?>"2P.9L/8)V\@$JX1X!)58T.IQ!=FD4+ZLHT%&OBGM(%
M=L><6:(R#U._!5&UOH7#W2'F7VA]1KF2ZE<0D8W+#:49Q$82AU##7()YOB!&
M.1:G0 FE./FRO[9&2J8[5KJZ!\.24UI"3\I7 D#7'>PD+$I=6O[^1YNOQ"U4
MH=["5<(@.U^X/!3/0))<D4D&>8K:=4=*:Y?(EG8'"*)6+/UCGDA"6CY:V0[R
MCTP$:XA4] ) 9 O^.U;T0:==!,E6#'QE 'XT!QQ@NYWA@BJ)%C5%"!H1"MLG
MHX\QAO5Y,CCK(+WDX)*Y_!4/S,0[>MO3DBCXNY^ZAYMS3=TA\U2W-S"^CK5.
MREJH%(C4%LAM34:PA!NC@4O,VT<NM2&&@CU?><NU,28Z$?8W-DBBEM+<P+!#
MU_WN_".^2"5/:H5IP72X#%I+FP0^DBK-+$AU )N%@R^/T"/CUT7F"^2+?51,
M%B\NQ\J&6/*(14IYSM5'[Z!X<L%NMC3NT@3C),M\#.AY_Q]<&A1FP90L7%6)
M[:[8K7WL@1C*>KR#I7*QEPD3DDF9$\C;3)Y',(V&)9#V]JAKD#\F";G+QP78
M#K<)!;()9T)9-0+@4C0[3Q^N](?W\MT!,*3SSJ787H^ FK-=H#@$WL^ZLFPB
MY&'L]_=$A>U&5XVE!H+G>IP)^">E)<T&>!20BQH(_A<$KI?LDEJ7Y5B^=;,O
M_5#8W'-_L)9J]Y@%R8OZ6M\17-*;*AA1SC%F\X=# 7XXP:C2[+JX0@*[=!**
M1K \P*$30<2!G?G-U ^H7'*9)>7"0@:WALC/*<3X+<OE=5*3?("J9\JA"B;1
MT$!QW-Z8Y"*V6U3["U5<+]%]Z]RU!U8P0,U8R@E)Q"Q2IW=<:2/4X2N7QDI1
M_?&@0C?_\L#$XB!)>QR'AW)=G?2WWB($^3:^S9!2$1JRJN?ZB7&GT^^TBI-+
MXM$U%0PSF:OZ\G VRT=[#T5V #)/6H]JC.83NY^4S*&\_5$?:AD7=V1I$+[1
MMK;TA:<XPL.$%%B#1@^<'7S*A'/IC5%?]+VI!SO.5A8TO*"C9**!T:2$?N&[
M4"KL]AZ<(/)&@.4\CZFX;ZC01L/33)1C2.F,30GY.HBCJRBAEC$@PS,I(4LY
M,(K$+5@>HNM-(-E:1KH.3T9)\)%TKQ+4%F)PN;K<F6'G!P9HA9].X<N!(C/_
MD4@#,0L72=E1-S5'$VX[-AEV.3@_8:6]XRHR@M\H.>>HGN8HXAQA'OB1,(([
M,;3*]P'ON.O2Y5AE.KO'8>$_/.98B8" V6"X1D)!/?D@.IT'#I)1M,H,PX83
MI<574X%$XG#J ^H6A.H;\<0,LFW3U8K]JB2^WG;X/DT,^5;PQ$U(<<ZF?PD
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M4-[PY07+]S/"^3P>"O67+/6S(WC8RX3D43X8*(B"6/^G7W,^6 -.^FL&N/D
M5]&M%U)4OJ&2OGZ9\B5)\6F8#3^HK:K10%P0HU!N90IW Q@G7W\(/. PZY )
MW D\&I*[-("_-/;);<)CP5/FDQLF&$V]!3F;IXR!3*1X>2AA>9SDT,N7.M=+
MN6N6<EQRQ6.Y$.1M[#._.L$AT&V(=POBS]V-,[YA7H\,G YQ^ZZ[8;Z!8<9
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M^PK]@_,=OBRX$7>J_"HS6UP-9@.6B9RWI?VLGO\A.G\FA)>JTKC_[-G+)N&
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M\UE/N/C%)-X$6_)7BJ4-P19\N5$2_8X(\'QE$9;ZAC9H/UN=_0]02P,$%
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ML0'I2TO=- @<8'PC5W\#4$L#!!0    ( 'NL?58I/E1M5Q8  $US   9
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MU<GW]3'SJR;H."VAWYG 2N>"D8#R .) IM,3 H*P()V*!_=63$".-@W%;!:
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MDRTE2)6^DL;U7Z\[[[GP%^98&>!L! BP)Z]L.Z5TL!#;XN,]HJB1N'-?)I+
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M8DO_&33>@/0[395XW/@ TY]K]2]02P,$%     @ >ZQ]5OZGSD-#!   _0X
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M5;#V3U^Z/NP$3#X*\+L W_!N$QF6-U31>";XE@CMC6AZ84HUT4BN8'I3'I1
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M_2N$!A0ML$:BOBQGM@#'V= ^! MB='T8]L!(US81271).F[__4A)D2S+8>N
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M\M_/2*,AG>4$]?RA-!XT/?\=1AIT7 FE*13-%I5Q_0/:]7^ID4;C.\L-&@-
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M>XGHK):V[_FMRNX(&OBPN["])EE/FVR0\%= '\!$& OP2UA^FL4 7I&X&LY
MI$T8.+""7R?685/4X)^NX=U=$-H4MQUZ0V *FW[#IK\_0?@F63$$IK ";6E2
M;..2J"%7R]UN"4(;HJ:ZXJ>@-M6K\)76P_=N]:Y/8=NA-86F$H8D86A_-5\_
MRQ0SAM!49J3Q@UH'M5O5X[62]AVO7??K08X_V%#YTI%!O24+QA!A<'!U?@1M
MI+SL/\1'0I_]UJ5A"$WE6MI).-BC:(P:2E-H*C/24D*M-]M--,Z:'J#CM$6S
M'H3M#>X)2J\']6;OXA+BFQ#5LH$?4#;:_+<N#D-H*MO2K$)OC[(Q:CM-H:G,
M2.,)M0YN-]GXZ[+I>VNZZ8B"CM\M'"0M(=);PF *:]'T/YYH]+EO6QJFT%2F
MI:-%<'^B04:MJRDTE1EI79'6 .XDFAIR50Y]#[4TTQ'DV-X&R4@_B?1^<O+E
MIOK0 &CC#Z@9HW.3IM!4JJ471OT]:L:H<S6%IC(CG2O2SX3NI)G!FAQ<K]_6
MS'J0X[L;-"/M)-+;R>MI<%9_9P8?4#-&)SU-H:E42RN,W#UJQJAM-86F,B-M
M*])/LNZD&6_==MFXK9FNH$V:D5X2Z;UD,$9VK1E'J?VOY0!.%CR:)6(T<Q"$
M>2144HOEW41B="+4%)JZ%BAM+[;WN!IHU*::0E.9D385ZR=>=Q%)#:G4O^^Y
M+95T1KD;_H/!TCUBO7N<WAZ#GQ<Q 4?@CVEP,58$P.M[P2Q)8T;R'PHYJ!-:
MS!,N!OV]%*-/?.NZ>(]95+RR?+[/]7.S"^CO85*Q-*G8_!IZ#;FJA8'=GE_N
M"/*<#?/+6#I'_!_.\>PG""JA5-\6:"O?EDN2Q"0'=WGR1%A1FK-5+\;(^XG%
MZ.RI*3258VEW\1Y7Y+%1=VH*365&NE-L?E6^AG05L;3WFW0$0;>]#-E;V>&5
M$?98;7PK0$07.5_N;&JN-IOKSJHM9:WKY_ D6&Z1DS#+'7M7(7L4M@RDY$%
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MH6?[.;<##S^^U\7NP9</YN-DG5^NYO\UFVYNWIR-SIQI?CVYFV_>K[[(O'I
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M>"ZJ5]>E>_:Z].^K37DP5.2SQ<>[8OWMNMO].QDYB\FT.5W0_C2J^:@6H)I
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MGPE4LZ$:A6H.5&-0C4,U46KU [3#*PD-"XU/76HSJJX00WFM^VV7VM1FZWQ
MNS^@F@W5*%1SH!J#:ARJB5+;?^N;QQ>C46/6DU1U=1CJKHX[[R4J#Y349R2@
MG1Q0S8)J-E2C4,V!:@RJ<:@FH)J+TNHAJSI#C'>\C8<![1B!:A94LZ$:A6H.
M5&-0C4,U =5<E%9/8M598J@[2\X[(P%M\BBU_:/7H[]KLJ!#VE"-0C4'JC&H
MQJ&:@&HN2JL'I^K=,-2W_6B:)_X_C5>-N8.V=$ U"ZK94(U"-0>J,:C&H9J
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M&XF%)"9(3))81&(QB2D(L^)[M8WOU0N]<;HB TUB(8D)$I,D%I%83&(*PJQ
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M@6IR>#B_;[\P0S<8HYJB-#NQIE8;NFNU8XE=GXG8G"7>'(<[(XL6:Z@6HII
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M;4G3%+5SH/N54G9GN ##?,Y^ U!+ P04    " ![K'U66B+6W'<$  "7&
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M]>/DY7TA4NK#S%#U*X _@C'_\P_L6G_UB1P(K"5Y5$L>Z=#GUT*&JN @0)F
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M!1G)Z__H6R/B),#UW@APFP#W/,!](V#:!$POS3!K F:79I@W =74[7KNE;@
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MINNCH^Y4XWE'P62[?X >[(+24BB:&836IX=NG_Y*_[C @I2+,:ORH'X=E):
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M:L>Z^:9>P/<L_[99[=O_!U!+ P04    " ![K'U6-O7DR]X$  !"(@  &0
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M/TD9D)WA^31*\[]@5]H:&O W*:=QZ2P8Q&%2_,<_RT0T') ]X(!*!]1Q@-:
M@UDZF'F@!;,\K!O,\6S"Z ZPS%J@90=Y;G)O$4V89&5\Y$S<#84?GSURZK^N
M:!00EH+??VQ"_@;.'DC*6>AS$H#\/KC:81:D "<!Z-U[2D*>?@5G-X3C,!)'
M%^#I\0:<??D*O@ =I"O,2 K"I# \%Q?%\5T81:**Z43G(HB,BNZ7A.<%831
M&")P1Q.^$FR3@ 1M %U$7Z4 O:=@CI2(-\0? 1.> V0@)"%TO;\[5- QJXJ8
M.9XU@#>4_+_O2/Q"V#^RE"D1LTYPF:ZQ3Z::V.HI85NBS7[]!3K&;[)P3P36
M"MZJ@K=R=//CX-,\^/R1>WP"C$99T\I2(4N =<H$G BLE0"[2H"MK/XWFFQ%
M#DAP#KYMLGJ?@SE9ADD2)DLPQQ%.?")+0('JY*A9Z][.D&MXKCG1M\W0^F:F
M>&JA59FU2#L5:4=)^@^&$][=BP4OI[^@[9K(Z/#JFSFN.S;DM,85K;&2UG.>
M2!FK<6^Y"X@\PW8[M"1VGF$84,[+K7BYA]98]+(/"NSVJ-C00);=8=PWZSP'
M+<9>Q=A3;LOON1J*37FU)4RH.\@K#H3B$'"+0P:><;21TO9.N3%/!-9* 31J
MI33V+=M>6[*$\QJUL$9&MV!2*V^@7K AZ_#8+5EZPG%C26,T[O*26)DC9X@8
MJHFA(S=EZ=A:T1JY7I>8Q,P9.=X L5IVH5IW&^7]>#>66,VJP9'5;1\2J]83
MT&9::R14*M#L*6'$I\LD_#>3R6R^NL@FV0#X-!;C?8JS 5G*NL"U6X6WNJ0_
M0_Y@K7]0+8"MX)H!@?)Z?KPF+*3RIT@-C\ ;P6+4-4%<3)'0!0%^DPVBUVJH
M8S-1BRI4JZI\TE;.@6K$0]OMJ=#:\=?J#<>?,@M"Y51P<!).A-9.0CTJP(-G
MA?W$1S((F*9MV[T^WS>$EN/:]E!#K6<&J-1CI01YDD5=R[%Z["2&CF,@>V T
M1+6:([6:WU*V(.$ O]*W-?C9T/*\KAC)#,TQ<L<#.HEJ 4=J 1_6R=*QM:8+
M'1MVY4=F:"'#' ^4%M4BCM0B?M0$6V*V'DG+=1VW6W298>?9;?.N-1Z9GS3'
MHI.^8I\*K9V&>H! Z@'BT$FVA&O.,>8(]<HFLW*':E8/!$BMV(HV4GIV)UFG
M2TQB9HZ,(6:U0".U0*M;B--?%(WL[@NYS$R,V0/4:NU$Q[[ZEHX=7EZO=TC,
MK&;-V\1J/4-[Z]D>'<.53-EN=V"56)G#3&OY0FKY.GK*+G%;">Y2_HPW6;/6
M/E.M??]WQOX _GW&=JL9&PW.V&JH0S.A-WX(CPE;YM\'4A'B)N'%#\+5U>H;
MQ%7^RWOG^AQ>7A=?$FJ8XL/&'6:B8Z8@(@L!*;J-:"ZL^%90G'"ZSG]N?Z&<
MTS@_7!$<$)89B/L+2OG[2;9 ]<5F]A]02P,$%     @ >ZQ]5E?2!ER_ @
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M$,9 [\\Y5^N).:#]+Q#_ 5!+ P04    " ![K'U6PTT]! 4%  "1'0  &0
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MV$D=,,<+M*'RCNW^PC50I//EC(KJ%^SJMIX#\HV0K*B#50\*4N[_T4M=B*,
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M2CPO",P(8&8'GH<AL!IQ!', 'C#$\XKWX,[[R-F^IYSZ7RJ3OU!+ P04
M" ![K'U6EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M   2'P  $P   %M#;VYT96YT7U1Y<&5S72YX;6S-V<ENPC 4!=!?0=E6Q'B
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M<' N>&UL4$L! A0#%     @ >ZQ]5K[G'%WN    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ >ZQ]5IE<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " ![K'U6%E4<8>L'   E-P  &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ >ZQ]5O:VPA6&
M!@  *AX  !@              ("!+A   'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( 'NL?58P\H5Y4@,  /<-   8              "
M@>H6  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " ![K'U6
MAPS!!2<$  "V#P  &               @(%R&@  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ >ZQ]5AK?#&84"0  "E4  !@
M     ("!SQX  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M 'NL?58*^CNE90@  &PF   8              " @1DH  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " ![K'U6N:CJ2[,)  #6&0  &
M            @(&T,   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ >ZQ]5@[)J0MQ%   1SH  !@              ("!G3H  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( 'NL?5;N@#OQJQ   *I*
M   8              " @41/  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " ![K'U6J(?&>IP,  "2)P  &0              @($E8
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( 'NL?59:ZBW3
MA@,  )X(   9              " @?AL  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ >ZQ]5OV+$""Q @  % <  !D
M ("!M7   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " ![
MK'U6,4'LJV4'   H%0  &0              @(&=<P  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( 'NL?5:^VR[5_@D  #4:   9
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M970Q."YX;6Q02P$"% ,4    " ![K'U6&@I:(Q<#  #%!@  &0
M    @(&ON   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M 'NL?5;^I\Y#0P0  /T.   9              " @?V[  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ >ZQ]5D+__ \B P  K@<  !D
M             ("!=\   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " ![K'U6 _'AZ;4"  #R!@  &0              @('0PP  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( 'NL?5:"\BL9K0,
M "\+   9              " @;S&  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ >ZQ]5BEM!W2  @  4 8  !D              ("!
MH,H  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " ![K'U6
MZAZ\22(&  !'&   &0              @(%7S0  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( 'NL?58\02BS@P0  % ,   9
M      " @;#3  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ >ZQ]5B<0*2$D @  (P4  !D              ("!:M@  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " ![K'U6+>%]G&P%  #3'P
M&0              @('%V@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( 'NL?5;-36(TPP,  #83   9              " @6C@  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ >ZQ]5H5:X0GR
M!   52$  !D              ("!8N0  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " ![K'U6L+-<4 X+  "QC@  &0
M@(&+Z0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( 'NL
M?59KOH^)H 4  )8H   9              " @=#T  !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ >ZQ]5LUYQ8E[$P  <&4! !D
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M=#,W+GAM;%!+ 0(4 Q0    ( 'NL?5:AXCHHL0(  -<'   9
M  " @:,P 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
M>ZQ]5IN??OU$!   ,QL  !D              ("!BS,! 'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    " ![K'U6__0U!9<"  #F!@  &0
M            @($&. $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( 'NL?58L^,?)PP(  )\'   9              " @=0Z 0!X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ >ZQ]5A*PNZ%, P
MX0X  !D              ("!SCT! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    " ![K'U6D4^]/Y,'   4.   &0              @(%1
M00$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( 'NL?58R
MG0N<KA   )?W   9              " @1M) 0!X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ >ZQ]5C;UY,O>!   0B(  !D
M     ("! %H! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'NL?59YT*DA(P0  .\4   9              "
M@?UP 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ >ZQ]
M5@;-$7@W P  &@L  !D              ("!5W4! 'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    " ![K'U6U !LLVT$  ##$P  &0
M        @('%> $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( 'NL?5:S:-JPAP,  %\9   -              "  6E] 0!X;"]S='EL
M97,N>&UL4$L! A0#%     @ >ZQ]5I>*NQS     $P(   L
M ( !&X$! %]R96QS+RYR96QS4$L! A0#%     @ >ZQ]5JYB[UQF!   ["(
M  \              ( !!((! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M 'NL?5:*,79?SP$  #,?   :              "  9>& 0!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( 'NL?58RX8'AQP$  !(?   3
M              "  9Z( 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     \
- #P 6Q   ):* 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>250</ContextCount>
  <ElementCount>338</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/StatementBalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/StatementStatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureOrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - License, Clinical Trial and Sponsored Research Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreements</Role>
      <ShortName>License, Clinical Trial and Sponsored Research Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Related Party Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureRelatedPartyAgreements</Role>
      <ShortName>Related Party Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureNotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30303 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables</Role>
      <ShortName>License, Clinical Trial and Sponsored Research Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpenses</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureNotesPayableTables</Role>
      <ShortName>Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureNotesPayable</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Organization and Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureOrganizationAndDescriptionOfBusinessDetails</Role>
      <ShortName>Organization and Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureOrganizationAndDescriptionOfBusiness</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Significant Accounting Policies (Schedule of Potentially Dilutive Securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails</Role>
      <ShortName>Significant Accounting Policies (Schedule of Potentially Dilutive Securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40301 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (License Agreements) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails</Role>
      <ShortName>License, Clinical Trial and Sponsored Research Agreements (License Agreements) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40302 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (City of Hope - Licenses) (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails</Role>
      <ShortName>License, Clinical Trial and Sponsored Research Agreements (City of Hope - Licenses) (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40303 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (Sponsored Research and Clinical Trial Agreements) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails</Role>
      <ShortName>License, Clinical Trial and Sponsored Research Agreements (Sponsored Research and Clinical Trial Agreements) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40304 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (City of Hope - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails</Role>
      <ShortName>License, Clinical Trial and Sponsored Research Agreements (City of Hope - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40305 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (Other - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails</Role>
      <ShortName>License, Clinical Trial and Sponsored Research Agreements (Other - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Related Party Agreements (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails</Role>
      <ShortName>Related Party Agreements (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureRelatedPartyAgreements</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Property and Equipment (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Schedule of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Commitments and Contingencies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Commitments and Contingencies (Schedule of Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies (Schedule of Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Commitments and Contingencies (Cash Flows) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesCashFlowsDetails</Role>
      <ShortName>Commitments and Contingencies (Cash Flows) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Commitments and Contingencies (Maturities of Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies (Maturities of Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Notes Payable (Narrative) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails</Role>
      <ShortName>Notes Payable (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureNotesPayableTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Stockholders Equity (Common Stock and Equity Offerings) (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails</Role>
      <ShortName>Stockholders Equity (Common Stock and Equity Offerings) (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Stockholders Equity (Equity Incentive Plan) (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails</Role>
      <ShortName>Stockholders Equity (Equity Incentive Plan) (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Stockholders Equity (Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails</Role>
      <ShortName>Stockholders Equity (Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40904 - Disclosure - Stockholders Equity (Restricted Stock Awards and Restricted Stock Units) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails</Role>
      <ShortName>Stockholders Equity (Restricted Stock Awards and Restricted Stock Units) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40905 - Disclosure - Stockholders Equity (Stock-based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders Equity (Stock-based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40906 - Disclosure - Stockholders' Equity (Stock Warrants) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails</Role>
      <ShortName>Stockholders' Equity (Stock Warrants) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Income Taxes (Effective Income Tax Rate Reconciliation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes (Effective Income Tax Rate Reconciliation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="tmb-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes (Schedule of Deferred Tax Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrent in us-gaap/2021 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. tmb-20221231x10k.htm 92</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty in us-gaap/2021 used in 8 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. tmb-20221231x10k.htm 106, 107</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept LondonInterbankOfferedRateLIBORMember in us-gaap/2021 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. tmb-20221231x10k.htm 109</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 18 fact(s) appearing in ix:hidden were eligible for transformation: mbio:CashFeePaymentPeriod, mbio:ChangeInControlFeeMeasurementPeriodForNetSales, mbio:EquityFeePaymentPeriod, mbio:OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:EarningsPerShareDiluted, us-gaap:NumberOfReportableSegments, us-gaap:OperatingLeaseRightOfUseAsset, us-gaap:PreferredStockSharesOutstanding, us-gaap:TaxCreditCarryforwardExpirationDate, us-gaap:WarrantsAndRightsOutstandingTerm, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  tmb-20221231x10k.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  tmb-20221231x10k.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="tmb-20221231x10k.htm">tmb-20221231x10k.htm</File>
    <File>tmb-20221231.xsd</File>
    <File>tmb-20221231_cal.xml</File>
    <File>tmb-20221231_def.xml</File>
    <File>tmb-20221231_lab.xml</File>
    <File>tmb-20221231_pre.xml</File>
    <File>tmb-20221231xex10d22.htm</File>
    <File>tmb-20221231xex10d23.htm</File>
    <File>tmb-20221231xex23d1.htm</File>
    <File>tmb-20221231xex31d1.htm</File>
    <File>tmb-20221231xex31d2.htm</File>
    <File>tmb-20221231xex32d1.htm</File>
    <File>tmb-20221231xex32d2.htm</File>
    <File>tmb-20221231xex4d3.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="587">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>89
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tmb-20221231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2021-01-31": 587,
    "http://xbrl.sec.gov/dei/2021q4": 37
   },
   "contextCount": 250,
   "dts": {
    "calculationLink": {
     "local": [
      "tmb-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tmb-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "tmb-20221231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tmb-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tmb-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "tmb-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 488,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 16,
    "http://www.mustangbio.com/20221231": 4,
    "http://xbrl.sec.gov/dei/2021q4": 3,
    "total": 23
   },
   "keyCustom": 88,
   "keyStandard": 250,
   "memberCustom": 25,
   "memberStandard": 30,
   "nsprefix": "mbio",
   "nsuri": "http://www.mustangbio.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Related Party Agreements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreements",
     "shortName": "Related Party Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.mustangbio.com/role/DisclosurePropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Accounts Payable and Accrued Expenses",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Notes Payable",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.mustangbio.com/role/DisclosureNotesPayable",
     "shortName": "Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.mustangbio.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.mustangbio.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "18",
     "role": "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.mustangbio.com/role/StatementBalanceSheets",
     "shortName": "BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_bEUyP985oUaHNsVrsVxqYQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables",
     "shortName": "License, Clinical Trial and Sponsored Research Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_bEUyP985oUaHNsVrsVxqYQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Notes Payable (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.mustangbio.com/role/DisclosureNotesPayableTables",
     "shortName": "Notes Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.mustangbio.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Organization and Description of Business (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.mustangbio.com/role/DisclosureOrganizationAndDescriptionOfBusinessDetails",
     "shortName": "Organization and Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "mbio:NumberOfSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_e-lAqZ63ukC9AQjaK0X33Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Significant Accounting Policies (Narrative) (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Significant Accounting Policies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "mbio:NumberOfSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_e-lAqZ63ukC9AQjaK0X33Q",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Significant Accounting Policies (Schedule of Potentially Dilutive Securities) (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails",
     "shortName": "Significant Accounting Policies (Schedule of Potentially Dilutive Securities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical",
     "shortName": "BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (License Agreements) (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails",
     "shortName": "License, Clinical Trial and Sponsored Research Agreements (License Agreements) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_FortressBiotechIncMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_3Vh1oZCe0keLsUyEjlCcKw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (City of Hope - Licenses) (Narrative) (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
     "shortName": "License, Clinical Trial and Sponsored Research Agreements (City of Hope - Licenses) (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_8_23_2019_To_8_23_2019_srt_CounterpartyNameAxis_mbio_CalimmuneMember_us-gaap_TypeOfArrangementAxis_mbio_LicenseAgreementsMember_GZks_7XceUyp2L41ZnWzfw",
      "decimals": "-5",
      "lang": null,
      "name": "mbio:PaymentOfUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40303 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (Sponsored Research and Clinical Trial Agreements) (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails",
     "shortName": "License, Clinical Trial and Sponsored Research Agreements (Sponsored Research and Clinical Trial Agreements) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40304 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (City of Hope - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
     "shortName": "License, Clinical Trial and Sponsored Research Agreements (City of Hope - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_srt_CounterpartyNameAxis_mbio_CityOfHopeNationalMedicalCenterCohMember_srt_ProductOrServiceAxis_mbio_Her2ProductOrProcessMember_AbCiEvU7_0uU3dzq5HkUFg",
      "decimals": "-5",
      "lang": null,
      "name": "mbio:ReimbursementOfFeesTotalPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40305 - Disclosure - License, Clinical Trial and Sponsored Research Agreements (Other - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
     "shortName": "License, Clinical Trial and Sponsored Research Agreements (Other - Sponsored Research and Clinical Trial Agreements) (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_mbio_FredHutchinsonCancerResearchCenterMember_srt_ProductOrServiceAxis_mbio_Cd20TechnologyProductOrProcessMember_us-gaap_TypeOfArrangementAxis_mbio_ClinicalTrialAgreementsMember_Cyw5EJBd1UirM-BcQ7nr3Q",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesSubscribedButUnissued",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Related Party Agreements (Narrative) (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
     "shortName": "Related Party Agreements (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_7_26_2016_To_7_26_2016_e467LFs_GEmfW2lDVRZA9Q",
      "decimals": "1",
      "lang": null,
      "name": "mbio:PreferredStockVotingRightsMultiplier",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Property and Equipment (Narrative) (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentNarrativeDetails",
     "shortName": "Property and Equipment (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
     "shortName": "Property and Equipment (Schedule of Property and Equipment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Expenses) (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails",
     "shortName": "Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Expenses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_10_27_2017_r9_PBUxiKU6CIeyMRHqr4g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetRentableArea",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_sqft_8yS2Dc-QmU2gfsdczKLSrA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Commitments and Contingencies (Narrative) (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_10_27_2017_r9_PBUxiKU6CIeyMRHqr4g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetRentableArea",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_sqft_8yS2Dc-QmU2gfsdczKLSrA",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.mustangbio.com/role/StatementStatementsOfOperations",
     "shortName": "STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Commitments and Contingencies (Schedule of Operating Leases) (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails",
     "shortName": "Commitments and Contingencies (Schedule of Operating Leases) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - Commitments and Contingencies (Cash Flows) (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesCashFlowsDetails",
     "shortName": "Commitments and Contingencies (Cash Flows) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40704 - Disclosure - Commitments and Contingencies (Maturities of Operating Leases) (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails",
     "shortName": "Commitments and Contingencies (Maturities of Operating Leases) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_3_4_2022_To_3_4_2022_8OXg7asOjUiUzJte247ykw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfDebtIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Notes Payable (Narrative) (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
     "shortName": "Notes Payable (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_3_4_2022_To_3_4_2022_8OXg7asOjUiUzJte247ykw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfDebtIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Stockholders Equity (Common Stock and Equity Offerings) (Narrative) (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails",
     "shortName": "Stockholders Equity (Common Stock and Equity Offerings) (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_4_2020_xrfudyC3YkytVOGquusxcw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_6_21_2022_W87ewabwMUywhrCygGG9dg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - Stockholders Equity (Equity Incentive Plan) (Narrative) (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails",
     "shortName": "Stockholders Equity (Equity Incentive Plan) (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_6_21_2022_W87ewabwMUywhrCygGG9dg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_suZlLo8Guk2LmZMnsU9VMw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - Stockholders Equity (Stock Options) (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails",
     "shortName": "Stockholders Equity (Stock Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_BbA2PkmH4kSDxqPMhK8S-A",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_3-kS7FRDbkqpKxd-4hKdeg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40904 - Disclosure - Stockholders Equity (Restricted Stock Awards and Restricted Stock Units) (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails",
     "shortName": "Stockholders Equity (Restricted Stock Awards and Restricted Stock Units) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_Pd10hdVFnE2rD6DyKQmoRg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_Ip-_Z-tCLEq_NziKZEKv9A",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40905 - Disclosure - Stockholders Equity (Stock-based Compensation Expense) (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails",
     "shortName": "Stockholders Equity (Stock-based Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_f1ddUvO4v0amvOZiXCEDeQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_3_4_2022_us-gaap_DebtInstrumentAxis_mbio_RunwayDebtFacilityMember_CXcrJqej_ki5tv-0gJyS4g",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_u7UB810fdk2ehqkkn4fMSQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40906 - Disclosure - Stockholders' Equity (Stock Warrants) (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails",
     "shortName": "Stockholders' Equity (Stock Warrants) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_tpnhJWDO60OMRtanSOx5tQ",
      "decimals": "2",
      "lang": null,
      "name": "mbio:ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GA4yvT9zYUmgOsGKoFCnXg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity",
     "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_mbio_CommonUnspecifiedClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GA4yvT9zYUmgOsGKoFCnXg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Income Taxes (Narrative) (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.mustangbio.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Income Taxes (Effective Income Tax Rate Reconciliation) (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes (Effective Income Tax Rate Reconciliation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_WIOS3eUMnkGJP4mTevmXaA",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41003 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets) (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails",
     "shortName": "Income Taxes (Schedule of Deferred Tax Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_wGaaWUbUREuDP3F9xmIKeQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.mustangbio.com/role/StatementStatementsOfCashFlows",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": "-3",
      "lang": null,
      "name": "mbio:IssuanceOfCommonSharesEquityFeeOnAtMarketOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_M3CiEaAc5USac3JIz7dfGw",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Organization and Description of Business",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.mustangbio.com/role/DisclosureOrganizationAndDescriptionOfBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.mustangbio.com/role/DisclosureSignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - License, Clinical Trial and Sponsored Research Agreements",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreements",
     "shortName": "License, Clinical Trial and Sponsored Research Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_RC0n4oQ5q02p0i0TrVeqaw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 62,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mbio_AccruedCompensationCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued compensation.",
        "label": "Accrued Compensation Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedCompensationCurrent",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_AdditionalMilestonesPayableUnderArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of additional milestones payable under the arrangement.",
        "label": "Additional Milestones Payable Under Arrangement",
        "terseLabel": "Additional milestone payments"
       }
      }
     },
     "localname": "AdditionalMilestonesPayableUnderArrangement",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_AdditionsToApicEquityFeesOnRwgDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents additions to APIC attributable to equity fees on RWG debt.",
        "label": "Additions To APIC - Equity Fees On RWG Debt",
        "terseLabel": "Issuance of common shares - Equity fee on RWG Debt"
       }
      }
     },
     "localname": "AdditionsToApicEquityFeesOnRwgDebt",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_AdditionsToApicEquityFeesOnRwgDebtShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued related to RWG debt.",
        "label": "Additions to APIC - Equity Fees On RWG Debt, Shares",
        "terseLabel": "Issuance of common shares - Equity fee on RWG Debt (in shares)"
       }
      }
     },
     "localname": "AdditionsToApicEquityFeesOnRwgDebtShares",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "mbio_AdditionsToApicFromIssuanceOfRwgDebtWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions to APIC from the issuance of warrants related to RWG debt.",
        "label": "Additions To APIC From Issuance Of RWG Debt Warrants",
        "terseLabel": "Issuance of warrants for RWG Debt"
       }
      }
     },
     "localname": "AdditionsToApicFromIssuanceOfRwgDebtWarrants",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to net income (loss) for research and development expense attributable to licenses acquired via issuance of stock.",
        "label": "Adjustment To Recognize Effect Of Research And Development Expense Attributable To Asset Acquired Via Stock Issuance",
        "terseLabel": "Common shares issuable for Founders Agreement"
       }
      }
     },
     "localname": "AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_AgreementRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time for which the agreement may be renewed.",
        "label": "Agreement Renewal Term",
        "terseLabel": "Agreement renewal term"
       }
      }
     },
     "localname": "AgreementRenewalTerm",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mbio_AgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term of the agreement.",
        "label": "Agreement Term",
        "terseLabel": "MSA agreement term"
       }
      }
     },
     "localname": "AgreementTerm",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mbio_AnnualConsultingFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of annual consulting fees.",
        "label": "Annual Consulting Fees",
        "terseLabel": "Annual consulting fee"
       }
      }
     },
     "localname": "AnnualConsultingFees",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_AnnualMaintenanceFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of annual maintenance fee payable under the arrangement.",
        "label": "Annual Maintenance Fee Payable",
        "terseLabel": "Annual maintenance fee payable"
       }
      }
     },
     "localname": "AnnualMaintenanceFeePayable",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_AnnualStockDividendPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Stock Dividend [Policy Text Block].",
        "label": "Annual Stock Dividend [Policy Text Block]",
        "terseLabel": "Annual Stock Dividend"
       }
      }
     },
     "localname": "AnnualStockDividendPolicyTextBlock",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mbio_AtMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to issuances of stock offered on an At The Market basis.",
        "label": "At the Market Offering [Member]"
       }
      }
     },
     "localname": "AtMarketOfferingMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_CalimmuneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Calimmune.",
        "label": "CSL Behring (Calimmune) [Member]"
       }
      }
     },
     "localname": "CalimmuneMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_CashFeeAsPercentageOfAnnualNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash fee payable as a percentage of annual net sales.",
        "label": "Cash Fee As A Percentage Of Annual Net Sales",
        "terseLabel": "Cash fee (as a percent)"
       }
      }
     },
     "localname": "CashFeeAsPercentageOfAnnualNetSales",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mbio_CashFeePaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of days after the end of the calendar year allowed for payment of the cash fee.",
        "label": "Cash Fee Payment Period",
        "terseLabel": "Cash fee, period for payment"
       }
      }
     },
     "localname": "CashFeePaymentPeriod",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mbio_Cd123ProductOrProcessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to CD123, a pharmaceutical product or process.",
        "label": "CD123 (MB-102) [Member]"
       }
      }
     },
     "localname": "Cd123ProductOrProcessMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_Cd20TechnologyProductOrProcessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to CD20 Technology License.",
        "label": "CD20 (MB-106) [Member]"
       }
      }
     },
     "localname": "Cd20TechnologyProductOrProcessMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_ChangeInControlFeeMeasurementPeriodForNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time for measurement of net sales used as a component in the calculation of the change in control fee.",
        "label": "Change In Control Fee, Measurement Period For Net Sales",
        "terseLabel": "Change in control fee, measurement period"
       }
      }
     },
     "localname": "ChangeInControlFeeMeasurementPeriodForNetSales",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mbio_ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The multiple applied to the product of sales and the specified rate, to determine the change in control fee.",
        "label": "Change In Control Fee, Multiple Applied To Product Of Sales And Specified Rate",
        "terseLabel": "Change in control fee, multiplier"
       }
      }
     },
     "localname": "ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mbio_ChangeInControlFeeSpecifiedRateComponent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The specified rate component in the calculation of the change in control fee.",
        "label": "Change In Control Fee, Specified Rate Component",
        "terseLabel": "Change in control fee, specified rate component"
       }
      }
     },
     "localname": "ChangeInControlFeeSpecifiedRateComponent",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mbio_CityOfHopeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to City of hope, a pharmaceutical product or process.",
        "label": "City of Hope [Member]"
       }
      }
     },
     "localname": "CityOfHopeMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_CityOfHopeNationalMedicalCenterCohMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to City Of Hope National Medical Center (\"COH\"), a counterparty in agreement(s) with the entity.",
        "label": "City of Hope National Medical Center (\"COH\") [Member]"
       }
      }
     },
     "localname": "CityOfHopeNationalMedicalCenterCohMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of common shares purchased that investors received in warrants or rights.",
        "label": "Class Of Warrant Or Right, Units Received As A Percentage Of Common Shares Purchased",
        "terseLabel": "Warrants received, as a percentage of common shares purchased"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightUnitsReceivedAsPercentageOfCommonSharesPurchased",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mbio_ClassOfWarrantOrRightWarrantsExercisedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights exercised during the period.",
        "label": "Class Of Warrant Or Right, Warrants Exercised During The Period",
        "negatedLabel": "Warrants exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWarrantsExercisedDuringPeriod",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mbio_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights expired during the period.",
        "label": "Class Of Warrant Or Right Warrants Expired During Period",
        "negatedLabel": "Warrants, expired"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWarrantsExpiredDuringPeriod",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mbio_ClassOfWarrantOrRightWarrantsGrantedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights granted during the period.",
        "label": "Class Of Warrant Or Right Warrants Granted During The Period",
        "terseLabel": "Warrants granted"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWarrantsGrantedDuringPeriod",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mbio_ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants that were granted during the period.",
        "label": "Class Of Warrant Or Right, Weighted Average Exercise Price, Grants During The Period",
        "terseLabel": "Warrant exercise price, grants during the period (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceGrantsDuringPeriod",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average remaining contractual life for warrants outstanding.",
        "label": "Class Of Warrant Or Right Weighted Average Remaining Contractual Life",
        "terseLabel": "Warrants outstanding, remaining contractual life"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualLife",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mbio_ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average remaining contractual life for warrants granted during the period.",
        "label": "Class Of Warrant Or Right Weighted Average Remaining Contractual Life, Grants In Period",
        "terseLabel": "Warrants granted, remaining contractual life"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantsInPeriod",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mbio_ClinicalTrialAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Trial Agreements [Member]",
        "label": "Clinical Trial Agreements [Member]"
       }
      }
     },
     "localname": "ClinicalTrialAgreementsMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_CommissionRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission rate on gross sale of common stock.",
        "label": "Commission Rate Percentage",
        "terseLabel": "Agent commission (as a percent)"
       }
      }
     },
     "localname": "CommissionRatePercentage",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mbio_CommonShareIssuanceFeesRelatedPartyDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the non-cash fees related to issuance of common shares on note payable to Fortress Biotech.",
        "label": "Common Share Issuance Fees, Related Party Debt",
        "terseLabel": "Issuance of common shares - Equity fee to Fortress Biotech on note payable"
       }
      }
     },
     "localname": "CommonShareIssuanceFeesRelatedPartyDebt",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_CommonStockIssuableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Issuable [Member]"
       }
      }
     },
     "localname": "CommonStockIssuableMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_CommonStockSharesAvailableForFutureIssuanceValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Shares Available For Future Issuance Value",
        "label": "Common Stock Shares Available For Future Issuance Value",
        "terseLabel": "Shares available for future issuance - Founders Agreement"
       }
      }
     },
     "localname": "CommonStockSharesAvailableForFutureIssuanceValue",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_CommonUnspecifiedClassMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Shares [Member]"
       }
      }
     },
     "localname": "CommonUnspecifiedClassMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation",
      "http://www.mustangbio.com/role/StatementBalanceSheets",
      "http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical",
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_ConstructionInProcessNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of assets under construction.",
        "label": "Construction In Process Net",
        "verboseLabel": "Fixed assets - construction in process"
       }
      }
     },
     "localname": "ConstructionInProcessNet",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_ContributionTowardPatientCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of contribution to be paid toward patient costs.",
        "label": "Contribution Toward Patient Costs",
        "terseLabel": "Contribution toward patient costs"
       }
      }
     },
     "localname": "ContributionTowardPatientCosts",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_CorrectionToPreviouslyIssuedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Correction to previously issued shares.",
        "label": "Correction to previously issued shares",
        "terseLabel": "Correction to previously issued shares"
       }
      }
     },
     "localname": "CorrectionToPreviouslyIssuedShares",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "mbio_Cs1ProductOrProcessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to CS1, a pharmaceutical product or process.",
        "label": "CS1 (MB-104) [Member]"
       }
      }
     },
     "localname": "Cs1ProductOrProcessMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_DataTransferAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Data Transfer Agreement [Member]",
        "label": "Data Transfer Agreement [Member]"
       }
      }
     },
     "localname": "DataTransferAgreementMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_DebtInstrumentBalloonPaymentAsPercentageOfPrincipal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the balloon payment amount as a percentage of debt principal.",
        "label": "Debt Instrument, Balloon Payment As A Percentage Of Principal",
        "terseLabel": "Final payment as a percentage of original principal"
       }
      }
     },
     "localname": "DebtInstrumentBalloonPaymentAsPercentageOfPrincipal",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mbio_DeferredTaxAssetOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deferred tax asset operating lease liabilities.",
        "label": "Deferred Tax Asset Operating Lease Liabilities",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetOperatingLeaseLiabilities",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to capitalization of research and development expenses.",
        "label": "Deferred Tax Assets, Capitalization of Research and Development Expenses",
        "terseLabel": "174 Capitalization"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizationOfResearchAndDevelopmentExpenses",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_DeferredTaxAssetsStartUpCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from start up costs.",
        "label": "Deferred Tax Assets Start Up Costs",
        "terseLabel": "Startup costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsStartUpCosts",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_DilutedOutstandingEquityPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of diluted outstanding equity paid as equity fee or used to calculate stock issuance to maintain parity.",
        "label": "Diluted Outstanding Equity, Percentage",
        "terseLabel": "Percentage of fully diluted equity"
       }
      }
     },
     "localname": "DilutedOutstandingEquityPercentage",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mbio_DirectorCompensationNumberOfSharesGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares granted, or to be granted, as a component of director compensation.",
        "label": "Director Compensation Number Of Shares Granted",
        "terseLabel": "Number of shares granted as compensation"
       }
      }
     },
     "localname": "DirectorCompensationNumberOfSharesGranted",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mbio_DirectorCompensationValueOfSharesGranted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The market value of shares granted, or to be granted, as a component of director compensation.",
        "label": "Director Compensation Value Of Shares Granted",
        "terseLabel": "Value of shares granted as compensation"
       }
      }
     },
     "localname": "DirectorCompensationValueOfSharesGranted",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic state income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation Change In Federal Enacted Tax Rate Percent",
        "verboseLabel": "Federal tax rate change"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mbio_EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation Change In State Enacted Tax Rate Percent",
        "verboseLabel": "State tax rate change"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mbio_EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan, predetermined offering period, lower fair market value percentage.",
        "label": "Employee Stock Purchase Plan, Predetermined Offering Period, Lower Fair Market Value Percentage",
        "terseLabel": "Predetermined offering period, lower fair market value percentage"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mbio_EquityFeePaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of days after closing of equity or debt financing allowed for payment of the equity fee.",
        "label": "Equity Fee Payment Period",
        "terseLabel": "Equity fee, period for payment after financing"
       }
      }
     },
     "localname": "EquityFeePaymentPeriod",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mbio_EquityFeePercentageOfFinancing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of equity or debt financing payable as an equity fee.",
        "label": "Equity Fee, Percentage Of Financing",
        "terseLabel": "Equity fee payable in shares (as a percent)"
       }
      }
     },
     "localname": "EquityFeePercentageOfFinancing",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mbio_ExcessInNetAssetsValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of net assets in excess of liabilities.",
        "label": "Excess In Net Assets Value",
        "terseLabel": "Net assets threshold"
       }
      }
     },
     "localname": "ExcessInNetAssetsValue",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_FortressBiotechIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fortress Biotech, Inc [Member]"
       }
      }
     },
     "localname": "FortressBiotechIncMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_FoundersAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the agreement term with the founders.",
        "label": "Founders Agreement Term",
        "terseLabel": "Founders agreement term"
       }
      }
     },
     "localname": "FoundersAgreementTerm",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mbio_FredHutchinsonCancerResearchCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Fred Hutchinson Cancer Research Center, a counterparty in agreement(s) with the entity.",
        "label": "Fred Hutchinson Cancer Center [Member]"
       }
      }
     },
     "localname": "FredHutchinsonCancerResearchCenterMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_GrantIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of grant income, such as from governmental agencies in reimbursement of covered expenses, recognized during the period.",
        "label": "Grant income",
        "terseLabel": "Grant income"
       }
      }
     },
     "localname": "GrantIncome",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_Her2ProductOrProcessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to HER2, a pharmaceutical product or process.",
        "label": "HER2 (MB 103) [Member]"
       }
      }
     },
     "localname": "Her2ProductOrProcessMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_Il13r2ProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Il13r2, a pharmaceutical product.",
        "label": "IL13Ra2 (MB-101) [Member]"
       }
      }
     },
     "localname": "Il13r2ProductMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid excluding those attributable to related parties.",
        "label": "Increase (Decrease) In Accounts Payable And Accrued Expenses Excluding Amounts Due To Related Parties",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_IncreaseDecreaseInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Increase Decrease In Lease Liabilities.",
        "label": "Increase Decrease In Lease Liabilities",
        "negatedLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_IncreaseInAnnualConsultingFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the increase in the amount of annual consulting fees.",
        "label": "Increase In Annual Consulting Fees",
        "terseLabel": "Consulting fee when net assets exceed threshold"
       }
      }
     },
     "localname": "IncreaseInAnnualConsultingFees",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_IssuanceOfCommonSharesEquityFeeOnAtMarketOffering": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It Represents issuance of common stock for equity fee at market offering.",
        "label": "Issuance Of Common Shares Equity Fee On At Market Offering",
        "verboseLabel": "Issuance of common shares - Equity fee on at-the-market offering to Fortress Biotech"
       }
      }
     },
     "localname": "IssuanceOfCommonSharesEquityFeeOnAtMarketOffering",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_IvIcvProductOrProcessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to IV/ICV, a pharmaceutical product or process.",
        "label": "IV/ICV Product or Process [Member]"
       }
      }
     },
     "localname": "IvIcvProductOrProcessMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_LeaseLiabilitiesArisingFromObtainingRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease liabilities arising from obtaining right-of-use assets",
        "label": "Lease liabilities arising from obtaining right-of-use assets"
       }
      }
     },
     "localname": "LeaseLiabilitiesArisingFromObtainingRightOfUseAssets",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_LeidenUniversityMedicalCentreMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leiden University Medical Centre [Member]",
        "label": "Leiden University Medical Centre [Member]"
       }
      }
     },
     "localname": "LeidenUniversityMedicalCentreMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_LesseeOperatingLeaseTotalAbatementsOverLeaseTerm": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total abatements for the operating lease over the lease term.",
        "label": "Lessee, Operating Lease Total Abatements Over Lease Term",
        "terseLabel": "Total abatements"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTotalAbatementsOverLeaseTerm",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_LesseeOperatingLeaseTotalBaseRentNetOfAbatements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total base rent, net of abatements, for the operating lease over the lease term.",
        "label": "Lessee, Operating Lease, Total Base Rent Net Of Abatements",
        "terseLabel": "Total base rent, net of abatements"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTotalBaseRentNetOfAbatements",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_LesseeSecurityDepositUponFullOccupancy": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of security deposit required when the facility is fully-occupied by the lessee.",
        "label": "Lessee Security Deposit Upon Full Occupancy",
        "terseLabel": "Security deposit, fully-occupied"
       }
      }
     },
     "localname": "LesseeSecurityDepositUponFullOccupancy",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_LicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to collaborative agreements involving pharmaceutical products or processes.",
        "label": "License Agreements [Member]"
       }
      }
     },
     "localname": "LicenseAgreementsMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_MayoClinicMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mayo Clinic [Member]",
        "label": "Mayo Clinic [Member]"
       }
      }
     },
     "localname": "MayoClinicMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_MilestonesPayableUnderArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestones payable under the arrangement.",
        "label": "Milestones Payable Under The Arrangement",
        "terseLabel": "Milestones payable"
       }
      }
     },
     "localname": "MilestonesPayableUnderArrangement",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_MsaAgreementRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term of the agreement renewal term",
        "label": "MSA Agreement Renewal Term",
        "terseLabel": "MSA agreement renewal term"
       }
      }
     },
     "localname": "MsaAgreementRenewalTerm",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mbio_NonRefundableMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable milestone payment expenses.",
        "label": "Non-Refundable Milestone Payments",
        "terseLabel": "Non-refundable milestone payments"
       }
      }
     },
     "localname": "NonRefundableMilestonePayments",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_NumberOfMilestonesMeasured": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of milestones measured under the arrangement.",
        "label": "Number Of Milestones Measured",
        "terseLabel": "Number of milestones"
       }
      }
     },
     "localname": "NumberOfMilestonesMeasured",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mbio_NumberOfSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of subsidiaries.",
        "label": "Number Of Subsidiaries",
        "terseLabel": "Number of subsidiaries"
       }
      }
     },
     "localname": "NumberOfSubsidiaries",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mbio_OfferingCostsForIssuanceOfCommonSharesAtMarketOffering": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering costs for the issuance of common shares - At-the-Market Offering.",
        "label": "Offering Costs For the Issuance of Common Shares - At-the-Market Offering",
        "negatedLabel": "Offering costs for the issuance of common shares - at-the-market offering"
       }
      }
     },
     "localname": "OfferingCostsForIssuanceOfCommonSharesAtMarketOffering",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_OperatingLossCarryforwardsWithoutExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating loss carryforwards without expiration",
        "terseLabel": "Operating loss carryforwards without expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsWithoutExpiration",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of days prior to the dividend payment date that the outstanding capitalization is to be measured.",
        "label": "Outstanding Capitalization, Number Of Days Prior To Payment For Measurement",
        "terseLabel": "Paid in kind dividend, period prior to payment date for measuring ownership"
       }
      }
     },
     "localname": "OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mbio_PaymentOfUpfrontFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of Upfront Fees",
        "label": "Payment Of Upfront Fees",
        "terseLabel": "Upfront fees paid"
       }
      }
     },
     "localname": "PaymentOfUpfrontFees",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses",
        "label": "Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses",
        "terseLabel": "Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses"
       }
      }
     },
     "localname": "PercentageOfAnnualFeesExpenseRelatedToManagementServicesAgreementRecordedInGeneralAndAdministrativeExpenses",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mbio_PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of annual fees expense related to Management Services Agreement recorded in research and development expenses",
        "label": "Percentage of Annual Fees Expenses Related to Management Services Agreement recorded in research and development expenses",
        "terseLabel": "Percentage of annual fees expense related to Management Services Agreement recorded in research and development expenses"
       }
      }
     },
     "localname": "PercentageOfAnnualFeesExpensesRelatedToManagementServicesAgreementRecordedInResearchAndDevelopmentExpenses",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mbio_PreferredStockVotingRightsMultiplier": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The multiplier applied to shares of stock to determine the voting rights per share.",
        "label": "Preferred Stock Voting Rights Multiplier",
        "terseLabel": "Preferred stock voting rights multiplier"
       }
      }
     },
     "localname": "PreferredStockVotingRightsMultiplier",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "mbio_ProceedsFromIssuanceOfCommonSharesAtMarketOffering": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common shares - At-the-Market Offering.",
        "label": "Proceeds From Issuance of Common Shares - At-the-Market Offering",
        "terseLabel": "Proceeds from issuance of common shares - at-the-market offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonSharesAtMarketOffering",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance Of Common Stock, net of offering costs.",
        "label": "Proceeds From Issuance Of Common Stock, net of offering costs",
        "terseLabel": "Proceeds from issuance of Common Stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_PropertyPlantAndEquipmentExcludingAssetsUnderConstruction": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale but excluding construction in process assets.",
        "label": "Property, Plant And Equipment Excluding Assets Under Construction",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentExcludingAssetsUnderConstruction",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_PscaProductOrProcessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to PSCA, a pharmaceutical product or process.",
        "label": "PSCA (MB-105) [Member]"
       }
      }
     },
     "localname": "PscaProductOrProcessMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_Rag1ScidMb110Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RAG1 SCID (MB-110) [Member]",
        "label": "RAG1 SCID (MB-110) [Member]"
       }
      }
     },
     "localname": "Rag1ScidMb110Member",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_RegistrationStatementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registration Statements [Member]",
        "label": "Registration Statements [Member]"
       }
      }
     },
     "localname": "RegistrationStatementsMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_ReimbursementOfFeesTotalPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents total payments for reimbursable expenses over the lifetime of the agreement.",
        "label": "Reimbursement Of Fees, Total Payments",
        "terseLabel": "Total reimbursement payments made"
       }
      }
     },
     "localname": "ReimbursementOfFeesTotalPayments",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_ResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for research and development.",
        "label": "Research and Development Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCurrent",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "R&amp;D include in Accounts payable and accrued expense.",
        "label": "Research And Development License In Accounts Payable And Accrued Expense",
        "verboseLabel": "Research and development - licenses acquired"
       }
      }
     },
     "localname": "ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for research and development licenses expenditures that have occurred.",
        "label": "Research And Development Licenses Expenditure Incurred But Not Yet Paid",
        "terseLabel": "Research and development licenses included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_ResearchArrangementContributionPerPatient": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of contribution to be paid per patient under the arrangement.",
        "label": "Research Arrangement, Contribution Per Patient",
        "terseLabel": "Contribution per patient"
       }
      }
     },
     "localname": "ResearchArrangementContributionPerPatient",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_ResearchArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term of the research arrangement.",
        "label": "Research Arrangement Term",
        "terseLabel": "Agreement term"
       }
      }
     },
     "localname": "ResearchArrangementTerm",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mbio_ResearchFundingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of research funding provided by the company.",
        "label": "Research Funding, Amount",
        "terseLabel": "Research funding"
       }
      }
     },
     "localname": "ResearchFundingAmount",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_RunwayDebtFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the long-term debt facility with Runway Growth Capital LLC.",
        "label": "Runway Debt Facility"
       }
      }
     },
     "localname": "RunwayDebtFacilityMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_SaleOfStockAggregateOfferingPricePermittedByAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock aggregate offering price permitted by agreement.",
        "label": "Sale of Stock aggregate offering price permitted by agreement",
        "terseLabel": "Sale of Stock aggregate offering price - Founders Agreement"
       }
      }
     },
     "localname": "SaleOfStockAggregateOfferingPricePermittedByAgreement",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_ShareIssuedDuringPeriodSharesOnExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued on exercise of warrants.",
        "label": "Share Issued During Period, Shares, On Exercise Of Warrants",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "ShareIssuedDuringPeriodSharesOnExerciseOfWarrants",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "mbio_ShareIssuedDuringPeriodValueOnExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of shares issued on exercise of warrants.",
        "label": "Share Issued During Period, Value, On Exercise Of Warrants",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "ShareIssuedDuringPeriodValueOnExerciseOfWarrants",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration statement, value of securities authorized to be sold",
        "label": "Shelf Registration statement, value of securities authorized to be sold"
       }
      }
     },
     "localname": "ShelfRegistrationStatementValueOfSecuritiesAuthorizedToBeSold",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_SponsoredResearchAndClinicalTrialAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to collaborative agreements involving sponsored research and clinical trials of pharmaceutical products or processes.",
        "label": "Sponsored Research and Clinical Trial Agreements [Member]"
       }
      }
     },
     "localname": "SponsoredResearchAndClinicalTrialAgreementsMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_St.JudeChildrensResearchHospitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "St. Jude Children's Research Hospital [Member]",
        "label": "St. Jude Children's Research Hospital [Member]"
       }
      }
     },
     "localname": "St.JudeChildrensResearchHospitalMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_StJudeXscidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to St Jude - XSCID, a pharmaceutical product or process.",
        "label": "ST. Jude - XSCID [Member]"
       }
      }
     },
     "localname": "StJudeXscidMember",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mbio_StockIssuanceCommonStockIssuableDuringPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new common stock issuable during the period.",
        "label": "Stock Issuance Common Stock Issuable During Period",
        "terseLabel": "Common stock issuable - Founders Agreement"
       }
      }
     },
     "localname": "StockIssuanceCommonStockIssuableDuringPeriod",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_StockIssuedDuringPeriodSharesAtMarketOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued at the market offering",
        "label": "Stock Issued During Period Shares , At The Market Offering",
        "verboseLabel": "Issuance of common shares, net of offering costs - At-the-Market Offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAtMarketOffering",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "mbio_StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Shares issued equity fee on the market offering.",
        "label": "Stock Issued During Period Shares ,Equity Fee On At The Market Offering",
        "verboseLabel": "Issuance of common shares - Equity fee on At-the-Market Offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEquityFeeOnAtMarketOffering",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "mbio_StockIssuedDuringPeriodSharesIssuableForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issuable for services.",
        "label": "Stock Issued During Period, Shares, Issuable for Services",
        "terseLabel": "Common shares issuable recorded - Founders Agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuableForServices",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mbio_StockIssuedDuringPeriodValueAtMarketingOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued at the market offering",
        "label": "Stock Issued During Period Value, At The Marketing Offering",
        "verboseLabel": "Issuance of common shares, net of offering costs - At-the-Market Offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAtMarketingOffering",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of number of shares issued at equity market offering.",
        "label": "Stock Issued During Period Value Equity Fee On At Market Offering",
        "verboseLabel": "Issuance of common shares - Equity fee on At-the-Market Offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_StockIssuedDuringPeriodValueIssuedForFoundersAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period Value Issued For Founders Agreement",
        "terseLabel": "Issuance of common shares - Founders Agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForFoundersAgreement",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mbio_StockholderAppointmentOfDirectorPeriodAfterIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time after issuance of the stock that the owners of that class may appoint the specified number of directors.",
        "label": "Stockholder Appointment Of Director, Period After Issuance",
        "terseLabel": "Director appointment right, period"
       }
      }
     },
     "localname": "StockholderAppointmentOfDirectorPeriodAfterIssuance",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mbio_SummaryOfWarrantActivitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of warrant activities [Table Text Block]",
        "label": "Summary of warrant activities [Table Text Block]",
        "terseLabel": "Summary of Warrant Activities"
       }
      }
     },
     "localname": "SummaryOfWarrantActivitiesTableTextBlock",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mbio_VotingRightsNumberOfVotesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of votes per share of stock held.",
        "label": "Voting Rights Number Of Votes Per Share",
        "terseLabel": "Number of votes per share"
       }
      }
     },
     "localname": "VotingRightsNumberOfVotesPerShare",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "mbio_WarrantExercisePriceExpiredDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant exercise price, expired during the period.",
        "label": "Warrant exercise price, expired during the period",
        "terseLabel": "Warrants exercise price, expired (in dollars per share)"
       }
      }
     },
     "localname": "WarrantExercisePriceExpiredDuringPeriod",
     "nsuri": "http://www.mustangbio.com/20221231",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r167",
      "r168",
      "r234",
      "r261",
      "r376",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r279",
      "r344",
      "r361",
      "r372",
      "r373",
      "r388",
      "r390",
      "r394",
      "r428",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r279",
      "r344",
      "r361",
      "r372",
      "r373",
      "r388",
      "r390",
      "r394",
      "r428",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r212",
      "r345",
      "r389",
      "r393",
      "r430",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r212",
      "r345",
      "r389",
      "r393",
      "r430",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r277",
      "r279",
      "r343",
      "r344",
      "r361",
      "r372",
      "r373",
      "r388",
      "r390",
      "r394",
      "r428",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r277",
      "r279",
      "r343",
      "r344",
      "r361",
      "r372",
      "r373",
      "r388",
      "r390",
      "r394",
      "r428",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r167",
      "r168",
      "r234",
      "r261",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Total accounts payable and accrued expenses",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails",
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r25",
      "r392"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r23",
      "r75"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, before Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossBeforeTax1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r414",
      "r415",
      "r416",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r47",
      "r57",
      "r127",
      "r253"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount",
        "verboseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r135",
      "r142",
      "r165",
      "r200",
      "r208",
      "r210",
      "r214",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r306",
      "r308",
      "r315",
      "r392",
      "r426",
      "r427",
      "r445"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r40",
      "r165",
      "r214",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r306",
      "r308",
      "r315",
      "r392",
      "r426",
      "r427",
      "r445"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r98",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r61",
      "r62",
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Fixed assets (acquired but not paid)"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r20",
      "r59"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r4",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r4",
      "r60",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r54",
      "r59",
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r54",
      "r126"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "verboseLabel": "Supplemental disclosure of noncash activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r165",
      "r185",
      "r186",
      "r188",
      "r190",
      "r194",
      "r195",
      "r214",
      "r220",
      "r223",
      "r224",
      "r225",
      "r229",
      "r230",
      "r259",
      "r260",
      "r263",
      "r267",
      "r315",
      "r374",
      "r404",
      "r410",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails",
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation",
      "http://www.mustangbio.com/role/StatementBalanceSheets",
      "http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical",
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Warrants outstanding, ending",
        "periodStartLabel": "Warrants outstanding, beginning"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r94",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r303",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License, Clinical Trial and Sponsored Research Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "terseLabel": "License, Clinical Trial and Sponsored Research Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r34",
      "r79",
      "r139",
      "r146"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies.",
        "verboseLabel": "Commitments and Contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r78",
      "r80",
      "r218",
      "r219",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Class A Common Shares [Member]"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails",
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation",
      "http://www.mustangbio.com/role/StatementBalanceSheets",
      "http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical",
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Class B Common Shares [Member]"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares available for future sale"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsShares": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.",
        "label": "Common Stock Dividends, Shares",
        "terseLabel": "Common stock dividend issued (in shares)"
       }
      }
     },
     "localname": "CommonStockDividendsShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r414",
      "r415",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails",
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails",
      "http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails",
      "http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails",
      "http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r12",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscribedButUnissued": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common Stock, Shares Subscribed but Unissued",
        "terseLabel": "Common stock, shares issuable"
       }
      }
     },
     "localname": "CommonStockSharesSubscribedButUnissued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails",
      "http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscriptions": {
     "auth_ref": [
      "r12",
      "r83"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common Stock, Value, Subscriptions",
        "netLabel": "Aggregate value of shares subscribed",
        "terseLabel": "Common stock issuable, 2,807,008 and 2,536,607 shares as of December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockSharesSubscriptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails",
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r12",
      "r392"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock ($0.0001 par value), 200,000,000 and 150,000,000 shares authorized as of December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Process [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r61",
      "r62",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Number of shares converted"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r61",
      "r62",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Number of shares issued in conversion"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r10",
      "r11",
      "r86",
      "r89",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Shares issuable on conversion, per share converted"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r61",
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Issuance of warrants - note payable"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r163",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r247",
      "r254",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure. [Text Block]",
        "terseLabel": "Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r136",
      "r137",
      "r141",
      "r169",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r237",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r322",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable interest rate floor (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r9",
      "r137",
      "r141",
      "r257"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Note payable"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r32",
      "r128",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Interest rate during period"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r33",
      "r169",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r237",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r322",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "verboseLabel": "Final Payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r127",
      "r129",
      "r429"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Discount on note payable"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r61",
      "r62",
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Note payable final payment fee (incurred but not paid)"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeNoncurrent": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Income, Noncurrent",
        "verboseLabel": "Deferred income"
       }
      }
     },
     "localname": "DeferredIncomeNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDerivativeInstruments": {
     "auth_ref": [
      "r123",
      "r435"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.",
        "label": "Deferred Tax Assets, Derivative Instruments",
        "verboseLabel": "Change in fair value of warrant liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsDerivativeInstruments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "verboseLabel": "Amortization of license"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "verboseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r123",
      "r435"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carryovers"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r122",
      "r123",
      "r435"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "verboseLabel": "Tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r123",
      "r435"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "verboseLabel": "Stock compensation and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves": {
     "auth_ref": [
      "r123",
      "r435"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves",
        "verboseLabel": "Accruals and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance",
        "terseLabel": "Deferred tax assets, valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r123",
      "r435"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r57",
      "r73"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentNarrativeDetails",
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r41",
      "r125",
      "r133",
      "r150",
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure derivative liability.",
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Fair value of warrants assumptions"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r98",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r25",
      "r222",
      "r223",
      "r224",
      "r228",
      "r229",
      "r230",
      "r338",
      "r413"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Payables and accrued expenses - related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r157",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r183",
      "r185",
      "r188",
      "r189",
      "r190",
      "r192",
      "r311",
      "r312",
      "r358",
      "r360",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share outstanding, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r157",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r185",
      "r188",
      "r189",
      "r190",
      "r192",
      "r311",
      "r312",
      "r358",
      "r360",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share outstanding, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r66",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Income taxes provision (benefit)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r166",
      "r286",
      "r298"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Statutory federal income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r432",
      "r436"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "verboseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r298",
      "r432"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r432",
      "r436"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "verboseLabel": "Non-deductible items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r432",
      "r436"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State taxes, net of federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r432",
      "r436"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "verboseLabel": "Credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options",
        "terseLabel": "Unrecognized share-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r85",
      "r148",
      "r154",
      "r155",
      "r156",
      "r170",
      "r171",
      "r172",
      "r174",
      "r180",
      "r182",
      "r193",
      "r215",
      "r276",
      "r280",
      "r281",
      "r282",
      "r295",
      "r296",
      "r310",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r362",
      "r363",
      "r364",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails",
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense.",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF OPERATIONS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r216",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxCreditsAndAdjustments": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.",
        "label": "Income Tax Credits and Adjustments",
        "terseLabel": "Income tax credits"
       }
      }
     },
     "localname": "IncomeTaxCreditsAndAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r166",
      "r287",
      "r288",
      "r293",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Interest or penalties"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r153",
      "r284",
      "r285",
      "r288",
      "r289",
      "r292",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred income"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Due to Related Parties",
        "verboseLabel": "Payable and accrued expenses - related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables - related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r47",
      "r251",
      "r258",
      "r386",
      "r387"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "negatedLabel": "Interest expense",
        "verboseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
      "http://www.mustangbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r158",
      "r160",
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "verboseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r333",
      "r391"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "verboseLabel": "Lease cost"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of information about operating leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Advisory and legal fees"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of operating leases excluding short term leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "Year ended December 31, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "verboseLabel": "Year ended December 31, 2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "verboseLabel": "Year ended December 31, 2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "verboseLabel": "Year ended December 31, 2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "verboseLabel": "Year ended December 31, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less present value discount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30",
      "r165",
      "r214",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r307",
      "r308",
      "r309",
      "r315",
      "r381",
      "r426",
      "r445",
      "r446"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r17",
      "r138",
      "r144",
      "r392",
      "r412",
      "r424",
      "r441"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31",
      "r165",
      "r214",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r307",
      "r308",
      "r309",
      "r315",
      "r392",
      "r426",
      "r445",
      "r446"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Long-term debt facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Amount available under facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "LIBOR Rate [Member]",
        "terseLabel": "Three month LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Note payable, long-term, net",
        "totalLabel": "Long-term note payable"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r54",
      "r55",
      "r58"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r42",
      "r58",
      "r140",
      "r147",
      "r149",
      "r151",
      "r152",
      "r156",
      "r165",
      "r173",
      "r175",
      "r176",
      "r177",
      "r178",
      "r181",
      "r182",
      "r187",
      "r200",
      "r207",
      "r209",
      "r211",
      "r214",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r312",
      "r315",
      "r382",
      "r426"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.mustangbio.com/role/StatementStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net Loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows",
      "http://www.mustangbio.com/role/StatementStatementsOfOperations",
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net rentable area for properties owned.",
        "label": "Net Rentable Area",
        "terseLabel": "Leased area (in square feet)"
       }
      }
     },
     "localname": "NetRentableArea",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r200",
      "r207",
      "r209",
      "r211",
      "r382"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r328",
      "r391"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfOperatingLeasesDetails",
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities - short-term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities - long-term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r325",
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r408"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease Right Of Use Assets Amortization",
        "verboseLabel": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r332",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Weighted-average discount rate - operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesCashFlowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r331",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted-average remaining lease term - operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesCashFlowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r122"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureOrganizationAndDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.",
        "label": "Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivables": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from parties in nontrade transactions, classified as other.",
        "label": "Other Receivables",
        "verboseLabel": "Other receivables - related party"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Fees paid on the issuance of debt",
        "terseLabel": "Upfront fees"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "verboseLabel": "Aggregate fees of stock issuance"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Purchase of research and development licenses"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Preferred Class A [Member]"
       }
      }
     },
     "localname": "PreferredClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails",
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "terseLabel": "Stock dividend (as a percent)"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockDividendsShares": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.",
        "label": "Preferred Stock Dividends, Shares",
        "verboseLabel": "Preferred stock dividends issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockDividendsShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails",
      "http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r11",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails",
      "http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r11",
      "r392"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock ($0.0001 par value), 2,000,000 shares authorized, 250,000 shares of Class A preferred stock issued and outstanding as of December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r2",
      "r18",
      "r19"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from debt issuance"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r51",
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Amount funded upon closing"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds from Related Party Debt",
        "terseLabel": "Proceeds from related party debt"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from the sale of fixed assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common shares under ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r23",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r77",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r22",
      "r74"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r5",
      "r6",
      "r76",
      "r145",
      "r359",
      "r392"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r21",
      "r76",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, plant and equipment, net and Property and equipment - Construction in Process"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r5",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r5",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Other Receivables - Related Party"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r278",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Expenses from related party transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Agreements"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r278",
      "r337",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r335",
      "r336",
      "r338",
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Agreements"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License, Clinical Trial and Sponsored Research Agreements"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Research and development for licenses acquired",
        "verboseLabel": "Research and development - licenses acquired"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails",
      "http://www.mustangbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.mustangbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r4",
      "r59",
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r367",
      "r405",
      "r406",
      "r409"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock Awards [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r14",
      "r93",
      "r143",
      "r283",
      "r365",
      "r366",
      "r392"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureOrganizationAndDescriptionOfBusinessDetails",
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r148",
      "r170",
      "r171",
      "r172",
      "r174",
      "r180",
      "r182",
      "r215",
      "r280",
      "r281",
      "r282",
      "r295",
      "r296",
      "r310",
      "r362",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Table Text Block]",
        "terseLabel": "Schedule of Clinical Trial and Sponsored Research Agreements"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Summary of long-term debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r23",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r131",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r98",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r103",
      "r112",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activities"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedules of Restricted Stock and Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r35",
      "r82",
      "r83",
      "r84",
      "r86",
      "r87",
      "r88",
      "r90",
      "r91",
      "r92",
      "r93",
      "r194",
      "r259",
      "r260",
      "r261",
      "r263",
      "r267",
      "r273",
      "r388",
      "r404",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "verboseLabel": "Stock-based compensation expenses"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails",
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested, Number, Ending Balance",
        "periodStartLabel": "Nonvested, Number, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted stock and RSU rollforward"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested, Ending Balance",
        "periodStartLabel": "Nonvested, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, options vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r105",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options, Outstanding, Number, Ending Balance",
        "periodStartLabel": "Stock Options, Outstanding, Number, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options rollforward"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r96",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r98",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life, Options vested and exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life, Options outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "verboseLabel": "Shares issued, price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balances (in shares)",
        "periodStartLabel": "Balances (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r65",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r85",
      "r165",
      "r185",
      "r186",
      "r188",
      "r190",
      "r194",
      "r195",
      "r214",
      "r220",
      "r223",
      "r224",
      "r225",
      "r229",
      "r230",
      "r259",
      "r260",
      "r263",
      "r267",
      "r315",
      "r374",
      "r404",
      "r410",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails",
      "http://www.mustangbio.com/role/DocumentDocumentAndEntityInformation",
      "http://www.mustangbio.com/role/StatementBalanceSheets",
      "http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical",
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r37",
      "r85",
      "r148",
      "r154",
      "r155",
      "r156",
      "r170",
      "r171",
      "r172",
      "r174",
      "r180",
      "r182",
      "r193",
      "r215",
      "r276",
      "r280",
      "r281",
      "r282",
      "r295",
      "r296",
      "r310",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r362",
      "r363",
      "r364",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails",
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails",
      "http://www.mustangbio.com/role/StatementBalanceSheets",
      "http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical",
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r193",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails",
      "http://www.mustangbio.com/role/StatementBalanceSheets",
      "http://www.mustangbio.com/role/StatementBalanceSheetsParenthetical",
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r61",
      "r62",
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "verboseLabel": "Issuance of common shares - Founders Agreement"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r11",
      "r12",
      "r85",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common shares under ESPP (in shares)",
        "verboseLabel": "Number of shares purchased under ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityEquityIncentivePlanNarrativeDetails",
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Shares issued for services (in shares)",
        "verboseLabel": "Issuance of common shares - Founders Agreement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails",
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r11",
      "r12",
      "r85",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r11",
      "r12",
      "r85",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "verboseLabel": "Stock-based compensation expenses (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r11",
      "r12",
      "r85",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common shares under ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r11",
      "r12",
      "r93",
      "r97",
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "verboseLabel": "Stock-based compensation expenses"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r12",
      "r15",
      "r16",
      "r71",
      "r392",
      "r412",
      "r424",
      "r441"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balances",
        "periodStartLabel": "Balances",
        "totalLabel": "Total Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets",
      "http://www.mustangbio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r164",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r274",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityCommonStockAndEquityOfferingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardExpirationDate": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of the tax credit carryforward, in YYYY-MM-DD format.",
        "label": "Tax Credit Carryforward, Expiration Date",
        "verboseLabel": "Tax credits, expiration date"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeLicensesNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsCityOfHopeSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsLicenseAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsOtherSponsoredResearchAndClinicalTrialAgreementsNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsSponsoredResearchAndClinicalTrialAgreementsDetails",
      "http://www.mustangbio.com/role/DisclosureLicenseClinicalTrialAndSponsoredResearchAgreementsTables",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r196",
      "r197",
      "r198",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r329",
      "r391"
     ],
     "calculation": {
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "verboseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails",
      "http://www.mustangbio.com/role/DisclosureStockholdersEquityStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrant term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/DisclosureNotesPayableNarrativeDetails",
      "http://www.mustangbio.com/role/DisclosureRelatedPartyAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r184",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of common shares outstanding, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r183",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mustangbio.com/role/StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r395": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r396": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r397": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r398": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r399": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r401": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r402": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r403": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0001558370-23-004979-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-004979-xbrl.zip
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M+XE'E#A@F_I]Z\1*.,(?$5,+N%H!6TORM0+&5L3YY[-]=OLE^3 $3[Q?U&\
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MN-1<N-0L2^J1&/3S2*07'3L$M#W#7W#\Q0>1;YZ+/+1<NAZ+@EEPPL$*6'2
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M0@6VU] [<_:YG,10\SST/!^Y<O#T7;F0ED:G),TX='+V<NSIQ*JD,E= \.A
MN<8>^#6!3Z<&PDBPTM2W%2CV;)K+4S*\S]8(.M%0W"/V)Q91E$V%3U":22,]
M5WF. F9;'RBJ,'RM*:@FFWE>3SVH@TTTZ'X3KQ7J^OQF*T![V6MD-U@AU!0-
M._R6T8V:RT#.R3*<X&@-0*N<YAKUJ)(CR@4'!Z)98[3.;;!JJ#J7Z/O$NWG%
MS"8<)(QVV^-^TCS?]]<* : MFD&;\=O;R-3,[AH_8Y>J-:SH8+4*F8$F"^(
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M&3ASV<&_(G.8ES9D[D.[N6J\?3'>OAAO7S14.?WM"PCC*3]/5US'BJ7_%D)
M@I)XR4%;=?[K/VI /%[N$J86E,3D*?(]WR&^.)F%N!R$4WHM'@KZP9U6;LF<
MT=7688<##ZD&2&]AR\M#.,$V'BL*/L!B=(_6F,1L.!N")*H X9S7&B41(^!@
MVD<M7#@1O\=&_\.\&R].P%?5^((NJ1NJ:SRY@S:&TK 5".>XQH!:<P<.9:G[
MZDN$%DEPZR]DR!K5A)"^VQA-(XX.!\%?B#S[B*X2A-3/S7'+F $(6?Z%OTO_
MQ?=0Z$7"5&B&=2"D\[4 3,D+.+QR;Z>8@:6J "%_JS%2*D:ZCAN[](.$KJRY
M=X32*Y)S1.C>/':>RRN3<2T0F5;-]ETF[( ;+[GD!Y?H!068S\97KRPD#EV]
MND'"&)FZE!,Z"?#C+Q=%T06.RDDY6VD11,).&YNR/JO@5&'JNLDJX?$CLWB)
M" N,)&C)'*@O:)]&[!PM,$&/SNN91 %JM ,BTZ0Q[#48!!OQN??<S7%,E==W
M@F##9S+*RP-R$\(C6&WC03]8QX-N"9G@Q21'RF1+RV1/#)R(T2FETJL(*QWY
MR&.)2)EN)#$/+IXMM@^#TA6!K\QF0:;M=#+,E-*,]/.-N '5E?XN>X08^=JF
M"A8FN2X%"6*Y$]*GS1^@KP;D++.'L:?7%VA9 K*K&<K#ZU(9$$>DAKJ:!Z3$
M!@3I%UYY2>]]*I%0E(=P'%<'%05+$! ZM.@HR6%<'60 QTH=6FX3R>%;'53&
M/"5]GZBU@!+$G",-S:&*0Z#=?<<MA'"?MD4DCA!J9\-RL*E(&K(_73'723=*
MN&T;KFW5CBZV)*;#>DVA$B5IY]+[6+WBW>!]A:QJ[C<X/KTW^NI"1.*<M.B_
MRI*B/['C>R]QX]GV)7N!(TY>#*+WK(LW%N02Z, .LH&-,971$PE]7)JR SNV
M= I8DKV(@RY>C_7HOW=D92=\\DA\9?$A74U&>K)_,E;%1M?1!C<O-^Z+N<B5
MQ8>T=>Q$KF2C:Y'/(]<QE[BJ])#N(3N!J[CH6MZ_(O+!7-ZJTD,Z?NSDK>*B
MZV )HV7T@MG]B*Q9<@WF#Y%8/^)B$#-/=&7]B"4P%&SW:)T]*+_;;I0)E%I#
M%G4!6$<J!=UB8\%1%]82'<.SQ:]XC>Z<M-W/R&-[QPO$2+C 2X7I9%QW:#O*
M6N/V=I4QCUV XP3^:I6$2(%!N<C0]E,#49=9Z>**+F)QN%]".G^2B$*; Y,H
MI&Q4;6A#JK[DC=CKVL+Z[&QPZKB2XU M,[0U55_H55ZZEO !9E7[ODV)PTZT
M=ICY-[2Y@L9'4\>T'6/:CEYBTHXZ;<?XRN;XRB; Z 'QC:-I%*%X>\V(7TEY
M7#KAXY+@Y'EYGD14O.S6$1UV(=]5_D[-OAB%L\5"'J;4<C<08@JZUM3VI798
M(09[YT56MVX^^8_5^T,-@@T86>Q6$2-LWQ*+. "8@_Z-1A^\D>W+(/$(X_9E
MW+Z,VY=#WKX<96S68*>38VS6&)LUQF:-L5EC;-88FU5'WF-LUAB;=9@'66-L
MUAB;-<9F=1^;U?4*- 9JC8%:8 *UQMBL#F*S(#AEQS/P\0R\AV<YIF&8T*64
MCHL8A4[HHFN$YLY&<(BE+W[,I\QZ[CMW-*3/H,\67]:4Y3"F?0L?4!&7@Y 7
MJ%-LQ&QW#<KVH8K/?H"B&(>([LL==FCNB:!1E8:0(JA3@%3,=QYNONLS&ZY?
M0BJ'' M"&T=?"4+&H$Y!,Y !N$S*8Y16DS= CC!*J^$4C\-[M$A"CZG_;CQD
MRXWX"3--#1!OAG0ZU6L$<%B!==5/H5>L7CNKS\<6 ^T$GUFM4D-CSA\P47='
M&5<RYOP9XTJZCBO9G028G(A .?FPB""IT-[YB<:11.HHU0-(A$YP]G%WF*^(
MS!$5&]*_9B9:(=F=:V]T9J&[\L)#NL@,-5=._!AI(_%MF4FVGPB;HXH@^[Z.
MG(>,'+OP/IP^(G<9X@ _;VR6.Y-Z0Y_PVT2HFO#3-1H/\7\G'OI;Y/J>7/2"
M0D.?YYO+64!\UT*]=Y[/'EA_3V=GIW*Q"HL-?8!O+E@A^6/H(_"+'V/HXQCZ
M.(8^'EQ:NFN"O%^3V%WZ883#"Q;U0+8.YK1_15XIX[I#6T\-\DP9\]B)$?4M
MLS$NEG[@$3HC;#O^%4=K/V9Z(K>LS&H.;6[5!\:4PS'5'>APRB./&&XUYUWW
M$<-O.G_$F/YNS!]1A?^@\D=8Q#(H; ?[1HXAYT0-MB&,SO$BP7B1X'"2Z5V]
MKED 5/H<G!\^;X,";\+,/WV!(]D#?(U:/.;+"ZT(Z+""]O8^$XMINW;"O.^Z
M2YA7(ZQO3*P')<3OC6R,QL1ZX\9HW!B-&Z-!-T9'&4X]V&GM&$[]9L*ICR3X
M]Y#2]!UH$+!E6CX1^6/\;PN190HFQO1[AYI^[YB#@P\GO>01!0G_N=GZ:,+/
M6XT+_DL3T0J(?\NAP#\TD>48"GQH\0QC*/ 8"CR& A]^%M2CB<!K-1IXJ)R=
M1QBEW6HP\*!1VF,$\!CZWFL<L"F'@UE<S%*46,>Y;P.8Q)+$B-V;Q#FV!T5%
M.&PJ7P'8LA4=*DAR: W_[+SZJV0EE6;I^^ &:17ZK3A+E$((JQ@C6L>(UAY2
M8Q]0PN6>XTD'3+B\-66NDY#'JJZ8121T;(H+'GT>; G?8X9EH&FQ>\VP+'D#
MP//\S)E4!T6KZD>?,=M*&IV?9M)YF?A/"6OS$7]UB#>G7/&-9"3.7:RK<<PY
MJHT$T-<"ER,\3](<D8P>U:)G4/GHDU!;R&( 3!\161DBF!8=\DQV*+Q2S@_D
M@8&W<7/MTS#[S(YOKKW1-Y3.3H<PD(9\1.D>^:NGA$0HW;JR/>LCCIU ]9R#
MODZ_H/7LZC&4P6%=#^5OC/1Q,_3[%F^&<J+'*Z&'?27T*"/)!GOU88PD&R/)
MWDQ$3*N19&/>0J A9&/>PF%"Q,:\A8,%C(UY"SNUSB2GPV-ZCC$]QYB>0]W(
MF)ZCM:-(6[0 (]-,)?='C>K271MXET[L</59(++K78Z'LOC@3Y,U1T/)7]=G
M4$>9O&:P^X5C\IJWD[SF:*[K-TQG,U[7[RB-S7A=O[W$-7U=UQ^O%(Q7"L8K
M!>.5@K<3NC[$50,  <Y'&[H^Q%6$@4+7QZC,0[OH<!!1F4<0ZC?$_8<V(OW>
M6+0\D-L-IM'RW<5AWJ/ B9$W9\>]C6,GOSL]*\=.9NU/> >%T$B \8UY8>0Q
M/=\4OAB%,%JU-=#J:T*AXKC<I@&($8XUX"XNI>;LP["V]E0)O=FJ@D!.P.UU
M5H98EW&,F,2$&DWG/HZ1N[P)%>%8\K(0SK'E*K,/2I0R,-3AS26U7%W:H#23
M2[D !">-6M(BJH<2[SEVB#=;;,F)+I:.3U9.*!6WK@($IXM>_#HNQL1<UC%L
M-=??,??6F'MKS+UEL;^)Z5CBH;V!$T6SQ4.,W3\49KVB/,2(E(96O();".#E
MJ5(:[:*"0(QVK0+F\1#Q 0((O%KAD%-WK@PN%A6$8,O+-:D@?@'UG62Y8=U\
M":,U<OV%CSS>HR+X1UD>@@&O%J\!$Q"4?$X;0X1DE$V5>BXI"\&:-U-U"0,0
M<*"[:+Q"NWGSEG7%!"E?M)4U(&;E;;AL*_D%#*%R#=?4 ;*<&RBG 5*0UO9?
M4(@(SS\Q]594LE&<GDQDQZ+*:="P+@0+P$@E\] 9\@8!PH?D*?(]WR&;!X=-
M+]I-CKS\ +.E)!B@O4V.G%L0X.V)8E=.9XL<B\H)TZ0BD%E3JZ %O SXZB(T
M*_[LD#]0/%M0P\@/G^7VN*PDA&G.7)OV8502=B ,CBE+:,EN?BIFLU*9 68P
M2=Q+:S-8B4,(P#PL'8+.G8AN(/"*+8BI&92+&CG?[,MDP3B<CSTSH3</G%":
M9:;;KH#,C$(%+\R&G7 /087N$36I?)=J/Y^NE(:FI"R(&;?#D5 *7A2)  *2
ME^@IO@DI>8DFQX2HX #SM20 KK7Y6L0F/)RT$Z^\.)#)4ZYW<C0Z3N-UGX1?
MG0WK\MIQ_8 GAY%>CI.6A3"OZ91E']HI90."SDN&\JWF]IN^VG WVDQ9$M]2
MLYK;^K^(UIHS'[L(>=$UE5PAOH6JJ=2GKZH"X9BE#O!JKKJ.C9_3-9AJAO/,
M4O?P1,HL0#]SH449/8_XLQ,ZJ;&TO9"["Y:^1RX3BG<3*F]OB*\E]M@[A*,?
M&_WH74"#JIH=*QK7K[VNM=T]A*M][2I;VQ("=]V/;]INHBA!WF7"W&Q4'#[V
M^,XP2G^_QMM$)?+H)+M&(%SJJV6M6/()#NTTVH&SD1+-/. N\9^0=Y[$7ZC&
M,AZ4033ZRA#N]M5!UY0_<*CF;2FFA2P),4O[L&/'P+*4U(-P ;"I>2EAK>N%
M7SM9L*V,?&ZMV0:$]XVLEV![-L&-0:V[5>9MO?IG0OG8>S32-S4>ETXXXQQ%
MO] FXN@F3&52]S"BM>XA/)-4:^WN34*=)YST@X1R/TMB=HF8I09(2=P;LJ*I
MQ*06B%>3K&</$\[ S1<2+K<[!;9NY;U@O_OQ,E_%SCUHWBJ()YCJ#._&G'<]
M:J]QPI*_[+>-LF0,DH+](M."IT_%3.?YC/9[\Q!]=0*9K,7E^A5U6TXS,2_@
M)KX+'/+G"7"8Q0/E=\]GDGE-5ZE?Q%KP/)DRUKEW<AMOSSO_#<=T];SWGY=Q
M]#D)8G\=^.(S0K-Z_<+2@J/'@C>@ ROVZ5:IR$%>I;ZL<;C7.>5HLVRI7ZQ;
M=?O4X!8<^D72+_T7]A2,=T^E(=T6V%7M%]]674$F['4]T>9V)Q<.?X#*_Q??
M@=XEC//9XM+91'-&Q"/.=I_7+*^$PW(VR?(NMM!HO["VY3!J@?&N 4_WH.FC
MO*Q'H?M&6;)?:%IPM2BYZ4_>N?.\:Y\]C4RU1"UW<8U^0RO:\H;HN.H:APLG
M6M+>IU'U7/4.Q>P>@-#3;52M7T1:\$Z8L]83+-K)2%RN7\&WY7P0\]*YI)?,
MHWS#S,68<DD)R+8-:+IF>P>/+DG9PQ(+#CY_8CN[?<[,$B$LS1OM%\.VO!HM
M,#X X'M#(]4Z:GPH)S_+%OJ%LJU &ULN^\>MH#CLF B'$LO;O&Z_6+7E S'G
MKS=7KM:'.X#S]D,+?@@1$YV_U1 YIBYR:=%^!=V"0T#-3N=ZS T^.IXBMGZ%
MS[(W2\3E^A5V6]MT,2]=2_HF= E=6.CL92IS78U^I=_63ES'5><[\E?V2L%-
M2%?T:12A./K-"1*A=2LKV6_P>FL[< DWX'S&O_,'<'DB_?1\(^=6$RP'YM7Z
MQ:W%* (]:]T']Z2Y;/-!2EQ_Z/:&GT?P:*-*C*YEW7X!:FL_;\[?$"AM7<^U
M8))4[A>GMO;L%@R"FQ/%@<.&U_/*%?J%K\6P!!530[Z,0NE:(_:80,C#,OE5
MKOT54M%7N\=2OC_]4'XL9=OHA*X"DUVSDV^VW4[P0E(&SALJ6_I8-H<X+QVS
M9U-TU8<:J&*BSC>:Q#Q&-2&^C6(&8VD<ZUD%,NU*6*-=*[-!&-4$DAC"0F>-
M4,RS" %%MN G,2([ G5)F<6E(:29L%#(TATR,4\0X+E.")4F7=8H/]?^*_M+
MG-[9I *$Q ,U05*Q!0&GSXZ[I-89*1@R2J"4-2"D *B)E)(O"%#=,@?;$@?>
MS6I-\$N:6$L)E;(&A OT-:%2\@4!*N;^C$G"-S_\#=5G]D269H5258%PB[WV
M,J5B# ):4L8J^U93>S!7<;@<2>9LB;,DZ;8 AYP82<S8EP@MDN#67\C#EPUJ
M@K96=*X8/7L0W6ABJG\A.+(>NEDET(9,/1 SSL#A-W7=9)5PQ^$E6A/D^FE:
M>K0.$)=[Z$U7F,19V+64/PG2[34/VF)2ZD1[,@"G/5):[Y#"C:ZH MK4JC?R
M.5]#^M)9,A0_YF8ZI8L%>OGA,PI=']5]:OPOU:?&<YUPYWBA&T#OC=]2\Q<A
MOH>Y1"SI#X=!Y1Y7UAAF@^-$+,L=^P_3LA<GX-C*'>&J"G#\WP;0%+8V"J8@
MS(W[?-EB2L6_&F8AK],D$-^X7GO%6<?KL Q!#QAI:N=#K@ $CW@;BEL>J)
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M2R== ;E1+U3ZBI>F=>XAJ-#5:AW@#4H7CQFG19D12U$>PF7]+D=$7B$48H"
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MGM>#XX3V0^S+4;X.=O: W\Q(3X=:<'[VN2 M!M;&=KP$<+Z)?:8I%N)!7=?
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M+BZ#1)HJS63:("(EN5J+U,EM'<2:/Z75DJ6^"3:(!##AH7R%N^CT T7+[IQ
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MO2. )+XT2\]$7P'(GI6R]U3[>['VLG^E;!O7."?%!F_VQ\''S(B\F6]S_(#
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M,S"T=CZ:+E8_Z(DFI-M$^DBB")VG)^%843^WE[/;N@Q!N]FD,P=<D6_^) V
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M(!+LX'_Y#76E6<V33?:GB((7AN1Y6 F?^3@DYP/Q2O <9>:%\ C9&]3JH;)
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M2/*IACW-S8>%1CMQ34(&Z,U: UQ;V:D ]&&%D5G6+RX A;RNM"P,+RGG"J7
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M=)VC%S[Z*W5D(^;R\.3I227^^"NLR^TNR5XHY>=DMVS&-HSW6\;&;4XC"I6
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M[&[UQ)(87B2( 8G.FRY(,ZKPFLQ;=KPM&Y"9;4G:(1>DDS>%XR/GGM"/:=Z
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MVS__[\S?U[8$C/Q &+?D_T@+P2C)/;IG_T==$*;Y;NC7]2=[""?FA:UYU9\
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M1G1-<Z9V$.,5!2T+*/ BZLHD2?89"O[J%GL;3*2PR5ZH3A UC#9_2&7+4S_
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M)2FR;C>%5P"N2/# #O\\B2+0B72<'\@E2SM?B(?[:-EC]R+[I@\6Z!A^9[T
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M_:P[I'1<\+ 2Y1*[9^T-QHGO)Y;W"-9!B#L3X8J9"&NC?)116IPN#GN$[0'
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MC!KM4I@:>T0=3B5TW58/P1:5/NY >48#7WB/.,,NO]0KW1/MCV2=CV)5I5Y
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M^XM-;\CH48KO 7:\T@LZ*.F0@%6#"5:)T9)9,PP)3?HT6DI(P*KXA,:,!!9
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MFL1?K? /$,_F<%_I^@OR.0E?4C^0VBEYY\3$(:Q>T_$$/8F"$K!0IN!*&?T
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M7=4Z>Q.$,51E=.D&,;"7M[Y-GL1)9:N]/CT=GQ_K@Q3[A,TEGE2[D:QG:S2
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ML\-]X1272CKGL6YP(];M>/\"G,LD_N:[7'LB;.7]I5@'_0C+EJW5M/40!C8
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M$F<@ \EK5@)H]GPRE^ED4K*M*UB](<;)*0#I:N(=0OH]>J\Y3+5BI%$IE\"
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M?9T"ZJ1J&I(CVA6S <R9+.YT@OKH6*(LO8C%(2FI#!+HYM>AIT6W'IH8NF5
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MHVQ'K-AW9DH\T9%#$T6J"^+6?.;)K2;[]N[8:3,FPT_QZ*LI3Q;!XJPI>/;
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M;F_SOI+1EI7]&_,:O;#ZGN6/O:;J"H&;:TO.?VW*0UJ^C;1XED>5=31=S[I
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M9!\&!3ETW(E**V0Y<,&[  VQ[S96N%.F-CS$@X*"W44SN..:7Z_D(O&VK&^
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MZR3/T<3=:WJ.>2'9T&F"Q<>J<W+(/79I>Q]J'$0Z"5;FH#AT)QCPM.*5&]S
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M$B X>#[]+K?2[4E#9ISC18JVN8JJ09XI"HA?,E0Y7I?S>T3T2KVM[@CI76Z
M*-*EHTQ$7@AIIU>'L^*H-MJM.S8/D$F$,[>@!LEJWHG9O Z9C=AGA"*RX$Z"
MFEE.F,%:Z3:S $ZK<A1D]U.:9^4K]@:("DFDRK$IO$]-<UMEEZ#VT#;P@@!B
MK&\M('9CA.#G)T >/.A)ID'R.76[F"4O38B4G4W+*<M^&CIKB:3?T*J-4L8O
M^(/C B^<F[4JM!;[ *?@H&.R*>,;F9FG!IX#A_FJU,(O3D(QHH63L[Y&FRL%
MT ?52LXK3EAF10;&AS?@3T7J0XP>#WIP.5Y%C0?FTH/.?"(48HJ4A-"C]S/)
ME6QW@&3H,4.L\0K!?BPXB(+P5L?\N7TO?Z-P@<@B#E^IY&4W37_%4ICU):0M
M$&,(:#&;[ABFZI"#7RKZ8)]FZ=Q+OIU[F+AF=QI=*]@J6V;OQO%OQS\_L3RC
M:XCCJ\EIBN:E%X)CY8+UG4J91(ONF?^3+]KTS+5"Y(<-N1/[I4:!AF?;81<>
M._GQ(1I-+-C,DMSEO<AO; :JSQJ2P67H)'@7CAHS?+9GJ?*R3(FF??WY?H2W
M,ATGCHC-KB"72CYH'0^'8*%6SP.I)K;W]G:B8E$GZ+IT6CPM6HM9NVPR!U&"
M!D;+[9^.IB[9P<=K'RQ] 9;(UPH('FB?9J\ZIF6"DX5=8A3D7.9?)\;9&5&)
MZ"(H*XD"AJ%PQA;*X"9$[I<FT[P$"X666\5*^ RF]Y,F7U* 6-K+2N^V[T%:
M=,@!<0%=ZKD6-!V=FADSV%4-A[G-'E/:9F%LF$FAL8"FMD-Z2S';U'V47N*.
MC,O,<_,)D)!)I<]U3Z@4'3(M\ %!4J'=JK%QE>6ZR@+RJ&FI@MF30>5TQBO=
MHR"N@_F%/E6L?&5)!MP"Y3 \:!X7SHK7Q2/$ZF!ZMZ#]G.IEPT"$1D:PE9B%
MH\1#\;A?9QPW0/3.._T0I#+3 *6E9 5EB>/G08_#KMDJ7J!QTX/%Q(Z1D(Y(
M+58F6XTJ?B+@7]J$UR!@]5 HR4!T?5U=&)IOMUIE$($E+1BA#1C/K,JE3[WZ
M5>YHY7.8J:,BO;ST%M7A)9)'!G3XRL YG\;^\=]'_#_Q68 (-<YWG4;9Y_T)
MV.0=^$@9Y"V>R6HV8&W_A1PO5L#,+N]^ .K+8=C@'9C%3H(CQ(D*+TN/3H]X
M*\3<@*01Y@(@B5&/LB>9? =)%3P+UF%W7G9AI0\RWWQ9:KYP6 K8['((F8RX
MRN>R0Z6.P;7/Z&??+=W(SAI:L896K*$5=PD]DBQ(QY+IS+A-BQ-=T5V&!@ ,
M TE5,[4<L-'Z2M1ADC)M6N'RE.2:(4# 1NTH*#Q+F5ZD!L%7:)?YBAWS:#:3
MGUCQ<NA7J$\\L+/.0F'EF%B9$K)VMS!C(A:9I'Q(3';BKA\"[Q;F$&3=72!'
MJFKS*[9-%\%U[?RVZ^/QL,KL474KN&NPSFA1#KFWU0R&^,NJN20URVR] G!L
M-7&)L/Y;8=<1-J#@[EQ6DKUE_,X[4+IS8^B7RD80W=WK?9 G-I?H<RPW/AZ9
MI>.R_2].#J-?J/W##IV$-"<S%)TI8)Q4[F6N=IA3UT!ID],VOS%3\*IL!F,%
M85OU)A\)C8A8,1.2KUH0!V\TR[27D"L-B6_+WA6-!5P-Y*Y*34?U7J*F(8)4
M>&]YP#5.B@NB<,Q4PW_6)L X"FLUXWPX_-2UE'7S?SB\D@"ZP8OTU])AE]_1
MY8TO3M_Y%A0 OGCY0>\8+!'X+:59+P8>[IIAL*[AE5^[E\OOZEC>W??V:;*Q
M"I[S+6 2OZO9/H92R2=! MTJJJ+\0GN^&5&V @7A73O&:IW\9H'G1OO*ZR)R
M**29#5TS ?@=C'I?3+XL W\P7O)/Z63V7+KVV!GW2)"?CWR*;'OO/\@37<5
MC&A 5TU>MI>,/J7-2U+.8+Z,P4L\^\]V*FB<%9K* ?=O;[^+I(VT?[GP)+B:
M+N)ZKY$G(A: 7!RW&H?3QW5?VA]$9WM'PV/)!@F\R^S'Q.)EW"9D5__QQ%AS
M],<^RD:WV-[<302I8/?H;>X&=]FS[Y\@M\Z)@WRNB<Z*@W9(-B LQ1$QCG[(
M6T6O0J\100)7A_YHKC1<AVW1<" #T;4PA73T<F?WSR'#J=8DJ]L9Q2_C=U^2
M*-[X[>@-UT1N;1[T?N LEDW%UB86D3Y^(I$V=QL_ *G!HU\_V]SO?>AM?;E=
MMB^;[(?WESH>^%!;W=[!YK.])T&>3Y(\DG'@R)>4\P>8!#5P7 C1,<5R3PY?
M$8U:S[3+9YK+;09-=07NI,-?CWB"$(Z]_#_CZH>33</FMF*>#L_%T3:$DGP2
ME/&9T:K,@$JEE\VF>2JIP&QBW ;3;)*GFH&9^MJK*&4_S9HYF07CG#M4@'D>
M\LK62AIQ<K1[K7_O/]AS7DJN=1TEO8.%@Q1)CS]=SI\G^R8N7%JV*OLP8Y<G
M1O_'GZ$_)]N=O=V]'P1(<-*AS^A8]3I[^P?Q9S\<'9T]I?^^W-T[V^K2%;N]
M?;OB?^/FA5!C3X, KB&N)LS0/6P'#&OEP)?P8 RX<OUPL@^#G(_7(*^8+&3C
MXNS542TIH(NCLRL4Z^\_YWQ3-2]SYNW%P3#.#T&8-=.!1MOHL7]OAAJ3G(WI
M$"!H>XD&.DC^6!U>"/=X]]K9MZW <9 Q$UB3A(9;Z=Y<TJ;\8AK\KH.9\Y"M
MGF>DUZ^1 E*&;)\H&]Z2(=-&:]MQ%DEN(1T7PER-9L)@ZLLEK:3H0B@_B*/?
MGBA]X-CN=W7N8:&H98:$*[9(4&_(W<D <FF4:\,S6@PES+P06+'83.T,ORBH
MXYH"R8]Y$X-&MIE:DP ?^'8=0]6]=2HM3:ZUZ:ICN2F]%[VOUI<&^LU%=Y=J
M$]QA& >7PEI)%*+$DH$2'*H)BF##5,UU6;U7%D]@*9LY2GTYZX$^(73$M#\3
MKI/F!<A_U$%E_^='?\0,Q_.12EC'@CXE%M2[3RPH#M'POEP1X^&O,N/*(='L
MFBLL!"5<SX?30^^O!+&$.GIL[QFPI\SYY1,]=G4V=&FY50-K1YG6N^2C1"1F
MF\-+]7VC>PX>@/Z>.9)D8_:,&.2A0%)E_!>VF1QVB=!M#;2(!PY?#6M,JP$J
MZ?>9";>"7CS*K@U-L.UZ<);2%8-WRJ]3;D5XCOY]]5WQQ=Z7CB^&8<1O'D&4
MJ"9W]<UK;5XMS[9R@ZQ=-P]JB2$)@-HZ*G!&/:#PJC)M*^D;^MAON=IOYK:&
MK?):)-^W7.35Z6''A7'?V;[PP5]G%9\=G[Y:)C0U:*OE?+\TQ8TBT[!6"/8N
M#_+V/C;(^X8.AT\&?%]EN;VM.VMQSPY_[MVC#G>Q#/<AZ,;8"@(#F-7,DKPE
MPZDV6+QKD#;.9QJ6^O7TJ)/(7( !YI-+7_WI][-&<\(L-6*=!=+%14\&-J/Y
MPHQ:-2?=Q&]OL3B#;E5*TEMG7?,8%>W=[24;& 7.A+NI*T3NN$KDH1:5V[VG
MY)$M-MOD]^'XG:"VU)\LI(0!<&E&4%WGX,>[F67);QLOG_SBQR="4NDJ-VG]
MR=2>AP ^C?G*HK25I-1:8=2>'2S -9('73+$J$%!,;T3^=F7J/^2W<S"FYXM
M>>))/JC*;EE=IG3QI(YZ3]3O45B2UF- SPQ*22*\JL99VDE&:5XTE8+-JEQ;
M5(XPM,V03#>&@UG/4](^W!LBN>"?O5!''*0]$@#K,,@8&D] \'2/9M+RJVMK
MB,91BBDB&O0G*$,SI2GEENF"(L\#R*+X)X(VO)E);8WL3RQMU\K41[PJ^=15
MC#=37N/E@9P\B/A((]_[UO.^/C^ZN+5A[A$=L7Z5DUQXG1573+P)&4&WZ7Y:
MG\3/X/XV61DPI&)%:X_-C'#D,XO+5ED8E0V++M3<2A WY\/JVF(*4-S-7,WR
MPW/7"RHVNTJ+QLI3TR!ULQHXARLEA:J@7:V";UW%S5U<?T%C_+1Q:US5^\KN
MU]\Y(<[N&K6U1FU]YZBMQR4QP=@JU*&NO8"U#ACZ>E]4?9&V1EQ>Q))71N:L
MN0BD^0*K(C.*[5V)$]E,[K9./VH.[P-T_W(=)QZOM^8HCH$,"CN#!60K"W8W
M&$_>)[]L(A8!4\WQ1Y8C9I-F9A'7>_T<^I!S_"]R3Q Y<=][&F925NE<K?KK
M,;.C"OLFV.!]B>U<8]WD +FR=9!3\&@$A!RQM+<B X$*C//:N;2L1+2!GLOM
M,F(>:!H_;VF6B3%\HLJXG.?A7,C;<#?';RY>G9R\.KKX]? D>7?V]MVKLXO_
M3@[?O$S>'5Z\>G-Q_GUQ4OW,8=GB@4\.>G=?EC#.:A\$ZP0MX+E#/?F3 S8=
M,ZF\G6MZ GXF(O[&D<3E3)+)+^$H**@6O@P*N<NAQ+'$"9 4:,9-H1TU9)[Q
MSS).GO&]Y]P/MD:;T+GZ'G1^ +1P7%)DXR*;PT0M4P/4NGOK/D<?4GDNVBW@
M,5Q!8F')S?--\]#E,O9B*M2L2.H&,S4K:3&-<#NU3$R=9>_#R;OFZIP@QRMQ
MRWY5IIRP)"%"\]<(N2:2M3>WS"E"E4,@DF5B_&M%S->@"%@VG;XE1AHUTT%&
MLV3J;QX'N9< =TR$M4,X2R5SO72.LJ+.Y"7UF^NR*AZN)!3)+0C^88::DJ29
MZ2:HN8]'A\%!Y$Q<.E96K9;D+4$S73.=!/=EYB J)D^X3TE=E--I5K3:0Z9S
M^VDZO,JE\0"\4G)]4IM!VT0RR6@\;.$4#*<[+J^#UMHE8%LSVP6V_&XY[1?F
M_'%UMJX1+#WC4:FX4'LJ3C_^*=?K8EITFMR\$;H[*_B;SS9#PBML9D;=^1,7
M[DQM'#(2EE2IV'0ZH]9&)^X%L-%1@^KJ)K6%""V1/HW+1QD0D$UF17F39?$\
M=MSTKIA1'K\TW>"0U,JAZ3Q4Y9@,&$&.:44P@BER&-QOVR<K.- (]O-\V^"#
MNR@S#&W9B1(T-XX$F6X-[OA A>-?P#%<82]J,VF_=E;[=N- 98(W>*]+K;Q[
M0I525O-4'HAI[Z-$ 6UO'HP\6'?;<D&OPAA#'U3-(/?T22W[)GH7Y*^M+,MJ
M^E8=EE"5"!"RF:8-*8J*.8@:U+'>,.'5T%2!=/W1<3#,8*ZGO%D]>BR=8&>X
M9"34E#Q$)T*U^%"NK;)+J$>8@A8AYL+G2AR5(+]O*EBY"4,MR//!U9\I$F[N
M@'O)'6:F(E $WHB;%9+9%ZY1R+*._D;7"-I-(68NFY3='NTK,2"-Q6P?7B[8
M)I="/_?>G*)*T=$@D$&\BM+C */GJ=,)<),GG2H&8Y(,&6DE?R?DX2R,I=6#
MRUY7FIM@-)@Y??*#G0>U\Y I7S;82+=66;CL( O"@@]NM$H<BJL<"B8NZA(/
MX5": VMFFOKM+(3Z>1G8!+Q/QBG)N$'62/WC@).JN3K,8]KGS)(X(.O$S$"2
M3P R:NC_0U*@-9)H'C4C_M& )80>R0.I,AJU:!;=2FC5DP_F:@UEZ1 !86"K
MTGQ22U\E>>T[AQMO,M!<Q;N'=>K03*\J0!%-65$8F9(:='0JTVIH.)B/&)IM
M+F1W0WE2:?NSG/44%*_;SOQE7@V:R16+.H@8/1QEM6R+=,"B(H>+\^5VA.WN
M-*NS5!40$Z3?M<WX+/&;A8:B<"3@4Y%4W/ JX[&SJ('(Y49E#+B2 #WIWA'-
M+MM2R"Y5!AC4OF0THS5]3'>M?.DSC^&=CA')"(@VY-23MS!,?+N87\_?7;SU
M'>?"=C,N2\]8;]6;+KG?:J@4-VI%FP4F6U-N&DZ@8_>2)S$ -U?>*AY'5YH7
M&3=\,^G#.H*3>\P+XFAO1F648Z/-E]7:R&D8BGY?_YX&O6K4XN<V>< *E&1-
M\!BDKQ!.$Q\F]#FOH#K1\$ME8NR%"3ZM,!H! 2U X\Q@M'#/3J[ESZ?"B<@K
MR(X'%&&*GE35W,3-**Q%=$]6#CONR\>T(/*:*']'4QPKQ7#RJ-7>S-%\V/C$
M%.+V&.;Y\'N[@TNK^'>M6 QF4J A2*JY?8I(ANH0B?<YX*!O#^@.2<B2HO&^
M@&]!@!^TI73!N:TA-A>MJE@CW'@-W)R'0]\'L0/XZ[SA 0[26<U66NW9:-"]
M2--0;&*V'_)PRNHX6!%N#E(W!M'W%I-@#Y4A!L!X53^01);T9@DX'9$ FDN.
M!W+4J$(X7Z62%?4W!9TB@4*[$VZQVJ6VE1-,+<HIA?"DEG)GR9E>I7DAOY)0
M5V"/))(EL]8W. !ZBX+&,170G)>1C@HTNU(KE7896+$$AP'UJ U>PKG"B^+-
M79V"$S1*UN?OH9M+=[I@/D-6C2*7G9T+?0^_2? L[Y?H3Q&8<+/A0$/D>,P:
MB 8U9X4O;N%>-.D_L*@(;SE@>%D@"L/9^4GV=T>,=]*B@[%T(/3,JS86NG&0
MRVXO'-OB7C6%:QQ+OU#L\8Y0H!OZX)'!L.A%L);#A=:PA>\'\1<L@_>+^7":
M>O:GH:G=SHF:KK%QC,WJ[=I1M!D6G8G-Y,0_^)K7W_4A-8NKK<"D!:E<S"^T
M[$+63'B[?"Y.L(7&TLHY6.\S*(5LT&B;->&6R](*WB7X%P.?S 5#OIEP$K:O
M4XS&,1#N\=G7;;(JFA;X.]J R>\EWNQ';U^KK4QZCO1;7C)@3HZ#N[E=FC"3
MG67<0V<KQ/^Y'HGRU%HKG+#IPUZ*J"7I;>_0'^>]3O+ZU=FV2,5WYT>'49A)
M1Q.\B\O0XZ7&Z"[/E'DP[S@7H1%6=LY@$N+189,D!1_EDK"@O3(K9Q:KM:(M
M3:\;,7[K%C)IRR?=31L;W")J)67(@/.XH:2?&YXJ-[F687-'SINMG>2P04^J
M C"5(WI]^D,R;9WOEJIE;YWT7R?]O_.D_U>U1\\:\H'HH/^2TIN0N 3QYU]*
MP/&.ZRKEP#RHO\B\&)1F7>8FH[6=LS.[O0@WZJD5'G(D:EY4Z3]S>M!1.DV'
MBZ+GG*RY,8VI CRO-5P;8S@^3-3_FZ5@,B:GH65=,#F947VL%I@2X5)O#L1K
M)5GA#G6_LR=B^CY*4F5S^'=63RL%M%9*+97/K9E9LE@Z+]&<?;L%_*3A?=K:
M+9G$.Q9MY_,6[;SW24L63%-XH&P?!^;(ESPS2Z9^Z9SK>KC1?-P2M*?DKE,C
M#S!Z=D^?J5,<F$YF:7F7;\G\W_ZT@\]:;IB-'['>/(\/M+#+SI2-XM/.UN++
MWS'7^Y\UUS#,/V*N92KXE8+9>!SSO3#/GSHMMW@BMTQ-:_ 8C8[V4Z='[X@[
MA<CBE5MGY;A-T]R^D78_:R.)U(C=,Z1U5CE;WW8J[[_35A@WMVZR90)5>!*B
M=.T=$CH! ;[U:0E([EH-BU4\=_3L/U0L];"H2Q[NL@B&1%VX>MR3SOK8BT$7
M!*EX]/9U)YDU5=UHHE_R'.YR&$Q"8^AQK0'FD&;I964PC/-Y-AMGT^0GN VB
M%([&%4?G,MH$Y?545NS645URN*B1X@YVLZ0[+X#ZT^RRG.>R$AIP17L2/G;D
M9>239L+<_760=4.433"X(0J"CD@='5__3@])/W^:WKC%?/K9X2C$$;UR>;F]
MI7TX,/.OFSEZ@Z^.N3@)D6HV3N!=2,L&D2F/\-2LVU$I"#I\>8$2IYMD(]_,
M-E%]]N[H(OSQ$TNJC9G:^]I1F##DAFNBTF(A]>^;A,3?+"#)G ![4/UH(BP0
M6Z$=;"P1T8@T!6)YC%"P7:52;(W5;!DJKN>TA.P":1_-01#*4[XK7!TWH)1]
MX19<NI+%0\307#F0YL-X&\1KK,PP>:'4:"G*5'L'#(4T$N8^J<D@DWH%"99.
M C@ARV2>"TON*MU->(+KVP=\B_B/9.C.@[;PB<7YQTH S%Z?S)#,2KIUMU\*
MAHX!,R(OA6,=%Y@9ZB7AKU-'[8. #XAFRPH,5B=E3=;S958$]<F_'IT$M#WW
MD"9<PX6:_78X5EI1+3F?/+"48X0>$!J( 7]X[6CJ.0PL.#G#,L"E#UZUJY8/
MZ;Z;:?M!-Y/08+C==!#O)GY#U[%QH>_JF6EFUX!5"/PNPM19L/,^K8VN<CA%
MU'E6&B,X/!#8D.K0DE#FM5.)</L#CT^VSW[FQ\G- VXV4O33@)/P(9<H;HDE
M7;#"13H-^9\O''CX.$"1MEB)7I__UNVAC8 2S4F;E*/>SJZL^!O^U35FE?M\
M%,VD#SC.VW%>/J+-^FS)9CTZ/TE>9&,^GQN02URU^T0B,C?S[!)ZZ,OQ$UZ<
M*@NF\HU)+M@*D9D_*FAJQSHTB[HFB[AYF)$9HI7')"<)E_!<14?/LZ%\R=5O
M)UIC3FGQ4J;2')N-O9#4H",2GK>H; !18I';<GY\=OSV#>J-8/ Z^($F-NF.
M<H$39[X5X%=8AK;-O8@XUN: 0M1B0 2G$YV7<V^=&-FL+;6''XE%RIB2J*.&
M1,"7SBJ8 B>.-<;*^MG.=.EGMBGYZ6&OP4">^YKXA0;I#.@(.62^N/#]'KE@
MCF.&E=X7.!HG&:H-0C..:T71 X6NJ3(%_'XR%4BPW'<O,C-KU/=E W'UL<ZD
M?'"-=(]5\2PL\4*0LT->.7,(Z)Q/::F+N((JG1O:S#"ACO!Q6?P)%KGX^:X@
MDX6$ 3T!L02DTC!7=I$@WE@;I.S2EZ,1<^#6XZP8N2K1[Q7LL/^8Q,@:[+ &
M.SPVL,.2]L"1&/+4=PC&H:6WFMZ=N!N9U$*:U0L*%9"\Q+6C2_Q_+?9,"T!Z
MM11V4$[_KHS!+A3-%HO/AOJ'2P0IE>@>NX7U8C RA,F5LWD^X:HL"WB-N,PM
M;+L#0Z7;3PU8ELZX!$2AQ*[N'^$#!,E3!.:Z^CP.17[TH(+8&VM)(=4/N]D-
MI'?C8VHCW=HG@T>]3^@I=X=Y@_#PTN7YR)URMX5^D>;79IHC0!I&=!&TZ^9#
M<F1N.+=K(;S-]@Z42<4TMG?BLA'</H!/VI3&D!X6>SMZ"?'<OQ^*A+>,^CD.
M-^$["U:>L1?YP)[!7[.XZ-PJF= V-*8M0 GW6!N/*ZT'[RV7_>0FA,+*6X<U
M"4(KJFP,8>D7C%K37%SNYJX2"1 70_/&"4:T0!D0%#U'Y=EX9%">'=;*KZQ]
M)\/)I>KH:YX;P]D[_A(]8/13Q\B"&!>P]Y(;O:V@FS,TK4RP*[Z;NX:V&/Q*
M0'MKE#CFTGBTU#INK2P,Z[*E&DS30<%P4 K.1$ NDK.T-KG-V6#A!"XHN#9V
M&JQ5F!67VM<J#&6)R)UF@<25P2Z;U"4#Y@J(<MY)QE:496'<)4P4\<;)6R4P
M475U7%7/_DWPSH]%8RX0F;B"(M(84E<B#$^@WK5J,T')5[ZF72P)5^/_4UG2
MGF1.*%8&93UA"L+# 4]3[]G. =LG%L#9P(_4I_[IY9'+T'3"H+I0#4>EXE@5
M*\N-"_\"JI!-XZA:> .[<SX=<(Q I$VKO%;)A@.KPM<'+\@FT\&9,A4OC3$P
M&;%1$'<".D%$&+3&/>:AYI(A[+8EE-)(FM%;-&G14N)EU;J+TE)S>=I];L&5
M-9XZ8^Z1$,FPS(1X@]ZK8)9/<>5=$P()Z#K&AC29"G_&*)]O)K]:$MXX_VNI
M[4W#&:Q$,@9,ZN%&!&FU<,VD'Q)MB.QJZC+N\"AWF#LR?U<>N>*^MG.B_H(6
ME[9(9\K!H6D7O-]!#;JGP6YO3S[WW#-!B;M;CWN<_%(GQT>OWIR_ZB1')\=O
MCH\.3Y*+LV/Z+QBFSM^]?7/^]NS5R^3LU?FKP[.CU\GASV>O7IT^.._4;6_T
M$9G#!WV'6\.:DM(\$1<&P<T'H\IJ)< ZB21L0\=\=?RQ'11>B$2ZQ5J1GOA6
MT6 )^4M:3-]JEN;#Y ^]S:V$IKE0QX59%(8&([);+09<6XD(QIQQQSJV5S/T
MH:=WSMA@^,/69L\]8X,Q)U/E>4:^\<FFGR4P"2UA_I^E-\9&A)F@W_ZAM[.Y
MYV[JR*&4-=C>>H0?AS,N=FRKWAVW0<'X%!KVK+Q)"]1TVB-5C4SR81<Q_P(*
M[S(W\[#AMC!0"75:"/NQ2YU:">O#"<9[',$WY;3+(#,UAVD)S^D?^8#Y+74O
M/^0!C1-I2$^O/IK\-L=WO8W&,ISTW'E&LO/HY]-WG>3DY"C9^-,_FG+^O"U=
MY=,G4O,]&I%%R01.HV5(#K[C@C1>AO9<D.%JR=5+L!HXC=,2@D+)D64%G2M$
M=P<A00PZ,Y""^G5<2\WSL9F\"T8S#YDBV7#F?[$S,VJFVMSL@U7TTY$^B$^?
M%AQ[V-@CX)V\Q_9_B<Z9%]K1X]%L^%_ B2[Y^ELV^XJQ.ZG]7Q'?;>B9Z+M?
M! "R]F80,*^NI;M>72H @[#N9&#"XQ)1R>HLWB6]0/ SPUG.O>_R2;\!94*D
M'$/V;ZZ&7^X-D[CM"O4K//B:B^S+BD18#GAR!A*/9OC]IM.>KM-IZW3:.IWV
MB:[1D09%7Y>S["%]GV7XPJ>Q+'>I!0T<*4O'7!"%'/5;<"DZB;2T#I"NN"W*
M3R+Q_I;V.;>B=SK!AZ'ZJD9$@DK'D0QQP%DJ\8UEX[D%< &V-F[@$94 ::EL
M#%_R5$S+?A$51J_ZH37M;?_X?)8.(K[#9(-LJ$&5]P$,)//_6C'2[$ $[%RQ
MOT.:S+ @6)M^E)_ET#3BYT)L.$CK,>@^A=E%O83T\A+U+PASC[FQLK6J+&Y\
M-&9Q>;BK"@IZU-"5M=WI=1R<&0PC-").LAWL[G5V#O:2>DPN"/_N"*ZC7'O(
M_DT)45$.WJ-OK#3 T215H)W)A./>.BY$+=,[3EL%0/0KTK=H$2ZKXGM#ORC3
MBH-&+_6+.MJ&_'4,4;?=;]->\ULI@7] ;L8)26T<Q'&ODJ:5M;Z1=6(C! ,/
MB7R%Z9!#]&45FJ3Z=&=KHS_O/(C$+W#$/(;0]JTFX+VJS+14R,<^0\ !C/O,
M9:_"&]F6GH RF_WX[2!6,+-=BOAAQYT<1'8YN?2/ACEW28 4A<H)&8"(%[VY
MQ#/IVFHN04[I'(FMXL9AG*Q6\(3F0)[9FHG]U."]EPBY6SI9Z'5!J#Q23X;?
MYC'$TNZA]MJAM,- W9R9NGGEU(V^U(+O+D(C'4@V<T5YCDB*F6157+V_$ 0N
MT##=M2TBR1;-^&H?*KILA?H?.![SH0HB[U@A?H;VUFD![M(;84SDL)TO_ENF
M3"+I@:>L"*O='K7;WN.4"J>#+$"V)!+7S%1)1([?KH_.::J8:1@\V^.2:)WE
MO[YV."[21#F:>A?P(C7)F][(PL@.IMT#ITV)+VV$W)]3&E-K6]\ESFJ*US5[
M"?(J+EJG%YC3>G+JC?\QSK6#@8 /@KX'<RGX4RT6W%4GHQU3GMZXG$R\%]1Z
MT2ZS[,??MI.T_WNP1;UP9/#,,"\:(]EL)4Y7W6U LCL74E5TJW[4(O7H[##9
M.#P]X9=^\>[ET9LGWY5X50@T+8*+19X+;7DK6O21@H_FY9Z!(W=]N\GOO2-(
MSYP0<LUSR*H'D"2=AC&C/SQ[JGV)J[#9^:='D#SO922W;XV*/MW7T4*HT@>Q
M[I%B6EV1UIE=J7XB?/BC.R>AQ;6V0#[? KF'!1N=QV7SO_IH+KMZ;9:LS9*U
M6?*=F"71 6;KY&?:ROTBI7TY27^GQLEGR\6?7YQ^A,G2GN-/M5SN;;CT=K<>
MWG+9_RS+Y;;E^8X,&#Y1)]F,#A.W!\_H;1_L@,F9>CN8E[YX^QN>)DG)HM>&
M8V^0%NKQ]%P&TT."'!KB9D)_Y^X!&?V^<%_?8KC$]_S$L[IXET\]NMOW/;O?
M:Y;Y8)UE7F>9UUGFU4KC#[V]1Z"4#=7^+Z>5SUU:RVDSK\6ZL=AGEQ4D.T>^
M..Z!#>%[*^U;W].H&<Z].HQB#[07I3XD* K$7LO%P0Q[4(43=OO,)Y@Z;!$W
MK6U"(]LY"YKYO*UP-;5X2T)Q:W/')13-.%$#A%W$D*!CNV-/6<68$BAF/%I]
M4WK(OCWDT6YW3C2NXV>?%3_360RMS'AB5QN5\74/&1)3A.1] F$]5@Z;=$B2
MBL-1UN<1X29M@[>(B\EKX2)95MZ=6KR>SC_,_VG+&3X\DT!+M2+ZQ>PGGQ;]
M^K0!2]7>TLWS(.&T( KHXV:H/9N6UJ#L)J@M;;)E=_3W"Z I5K6U;!9:T3?7
M$EWZ%:T$M[@LM<S1.B;WB1&$WWXX/OKM.Q7>MS$I1>YZ]))+S9%[B7)N5G5K
M*V,\-$<S<%1P5-J:0?@HT"&<1M]'\:'_+B!1&&9%KOTFC6U=BTX!@JOY0"S)
MBD3OMH3;NS6'+-99>,3ROU7IM'EKBF,Q=^%3%PNE%KV/SED$]Y=SN%*5K,YE
M?(8T7PO?.)KV,6+X<4HYM.<(&6@?@;A[&Y"V[_08!OV%I!V_[ )VVDL[<U6T
M829?OL !OQ'>S,^<1V(+')(.AR^;[V>.2\9C)*,ZSC#>*HS.W"# &'L6KL?3
M_VPT,C)7#'_M/4_BQH$(G-5SO3*^4#OVTK21K*6+TII9(73?]BLZKHM2-9[#
M)1)TJ?3<C\J%RFLAP;_%"-8PS89,9C^[9,Y\JRN];\;Y[D0R4L?/UJGC1Y Z
M?KSRD:NR[\"5(<,D9S(ZR=Q8B#_FX^0.6E8_=%*WS1_\A5)0W.[I'HE<D:WW
M3@C9Y5\]\_.["! O6X3''1@^.N\]L!7R50T/O-[][0ZTI[.N$JOMCWC*/M/\
M<#TD)C>TF2;I$LQ[^ IKM?_P:O][S5$_6^>HUSGJ=8YZM:9<V_-?U]"XKSG?
MUHD/;;'?CSSD8XQU&!KW*0XAU?\1I2%R]:=:ZCO;][;4=[Y_2WW)"CQN0YT;
MF_VKQ OY9>]OM_/E*^WUULQ]IL&.N_W9P@D <0Q2ZVC1K;(ZY\9_.,V<N-?P
MW^+)C=_POF;]SMJL7T?SOD?MC^U^/_7_O2#-/D;=<V_T>^A[D6/W5OAV^;TU
M_A]V=NZMX[4J['O6\<NF_7$K^=.H4\/C4/&_T)@< &+G;C979E2\LZ%4"^-@
M& ;: TY\ _G213. 162:+G:.CL51=XO. B$I)O(.C2"\K4_WE/!Z!66KSV++
MSHMA<P;-61S]?8E=;\4-_,Z84N^ (T?'X#O;_E,!U 9[W-KWA)T5@I;66*M!
M5M?2@9K^.FRJ962BJ]# ]R(:VO+661L7W%'C!89ASN!F*!F6H==ELK']Q+,2
MZ;G!"TK'8#:#=(:$:>@1$GSS?8;9H%0K/0XKMK]%W\P?&9B'ORU\+1NY+HL<
M]'BK^TN;Z'XXRKRWTR6T=I_AGSE]?Y9)$VYZ8[3,CBP8_J -:ONR6+8,=G7&
MPV8<I'.U?,-.?$YC3((FXMP.@GVQQ+>:EP.IS2T63USX,DL\-/Z:O= %/VW[
M8_VTGB@?.YK"XD7G+SA['5>I3U<%GR?"-X@'@2A,-. ??#+57\K&3\9A\I;O
MQZ_R6<[?SJ-U_OZU)-)/.!>OFSG--6G8*;K%8\\?\4E_O-T+T)OWX?/0K[@+
M"C;]+TT1J?RGOBW;2IEYKXZV?GW:0:PT]E"BEO0--S KF]K!< ,I./__V7OW
MYS:.)%OX7T',[KUA1X <27Z/=R>"EA^C7=OR)\GK;[]?)AI @^Q1HQO3#U*8
MO_[+DX^JK.X&2-D:4]SM&WO'% GTHRHK*ROSY#EUP.-F(G*<U+!3MJ')83Y%
MN#;YA0EOZ%[LG::NP(1.GN.A5EV?/)JKKG/5=:ZZGJBZ5A)$XPBAB1L+/NGT
M4I2CV"$E$6;5+!'N@AA#JN0TC ;(UW+N:.S9SA<7,?LUPK6;JQZ$,'F)M'"2
M>HK1C)-6^>@+W\7P/RK(N7U7?_J*C@@__D4X_YY^__V]5G,ORK8&6_;4!G^L
M&>'('BB9_;CM'8\0CN1%0^JR Y_U,0";#J$_3 4-0H#-76^N"+/_= 6AQ\=_
M?#*Z0><WZ9P62:^4WZ@Q9-N\D][,?$NA0[8.JW'X_G),<PPF<"![F&,-8<5M
MDZUY*7YUQH<QI /_4F\N7]/WRL-N?T6SVH;B'!E&&\./9],99AN$D[EC/8M\
MXB(-G#)8^2)KVWHMHQXNFHZ.50--?Y,.AI*$Y>-8C=QURJK\^+/[Y++V?=Q6
MI[#%]E;-W"-]D<]'>:*D_+D5]2@__>LK"O4HV)3)77-G>YGWK_-=D470Y/??
M!Q/F )![>APE=8NL[+,DFZ0-ZM/OA.Z*/+S)ZC"J';A#^.2;9-[?R_N\IV[T
M5+;TWNO_PPS379.CSA5-)O;%2B1U&E*C;9M+JKT](-LS7MB\" 99U7>>2HW@
M6N<C0M+4KJ_D[#%/FO9 ?O&_+#'Q(_^2#\<CB2[3\WI/TJ;#GE^VZY,R:6^E
M8.A&XIB&834B"?F -M:\T>,^>3MW$7*-X!7YDG;:F\7@8\E^V2Y^^.KL\://
M/YQVB$<ZX:9J93[#>7>-PW/_U,?Z>">B\!A(?_;9'30*NT%(_NLE"A]DX>U>
M5O?3E]\OOLJOV!M^@#K(;M=7^8?OR8).]$@_NGTYW[&$?>2= \CST.673=$=
M_JWMT_?F-R%3IN?#V)YI9H6/Y4A/X,'I2,S2R?J>]&N<_W]8T(F_W_^9#AI8
M.&)M>2-;'J[EJWLP1 V#;Y,V%3VZY$^!-NB5>Y=W^2KR)HOCKV("R\Q6(N<>
M?(0?>*3CJ(>OL*>PJ_N,%S_]^(1^G!X#*PZ-W.%1@=<[.;_@\HY9R:_R?X_=
MK8^Z/RX'S0[P]W6 +Y^]>/;\Q\57H@;_GO@] [-]NIS LV5513$M3KK99+G"
M:QQ!O50JN!N/L-6Z+2="!@/PW6[UETBXQG\+YS^LD>^Q&+]Z_OSE*_KUQY\_
M^=)?]TA8).MX.5KJ;Z7;G)Y=>9$C5J^E'U]HIIK\NJC[EHZ1_%4[7&2+JYR.
ME_6^+G)$9K'@W$$S=%_2$4/65J J>/GT57+LQ2/1S7:TWL_B8Q58<!L4O//-
M^<30T-_C$)JH[;ZAI\!)F15L#^0DZ/2[ED<QSY]75U+_PWU'^K?WMT9/".6.
M"DMJ6!EDZL[H.#A5;W?9U:2NK=_]-;YVDN[>Y7&/^E^K:[\[#VR X:.>V(GD
M];M>LOGN''(71YTMBLV__^&O?RE??_'Y9Y]\]/E'G_Y!J@KW+E#]Y/&")<HF
M2ZK3J2XN@J; 3QKBAV(,L=K@'LFCNQ]@%?3Q7 6=JZ!S%?1]BUI_**JL(8?(
MD#X^PI G_"&G4 3G+Y=DOM<P-A8[/K) %@%IC%^KX='\]'LEL:E^U-?7\DHT
M:V- VIDF/'SW=S_\%(M'"?H<F_8W/5"-3%O6-W8*/1:A>FV 8P?0GP-)9-+\
MX4(F>UL^+^_S!FF[R:?7KZ;/+&1V&2<;LS+FV8<:L 7D"Y"0%QP[+B3OFE6^
M )]7])YU)4]F[T5#1F:[VY<%@K[T_OI0FZ:_#&7ZC&)BVG]I:7++TW/:S%9-
M7U%$]QV- 4L'ASK>92W5_K;?[\L#KIA6]MHX*QP=NL*2[YB1\\::B32E$E%F
M!QWV:3LX8@-A /^7G8!_R ZU=D6]QSA#AMB]=VVTDJ"D7[)_>SSP;TP7YPT6
M,L/YFWS==^+];DU5NKE1E$!%/K5,3!LWV64'%H[6V%C,G;T)AZ,[NH UN_+^
MZP"+A5;F D<ZA<CT/Z"\[$4E63_4U2&GES$&L-YNS^C/9^U57F[OO4'K5;+B
MEQ:YT].NR%JRAES<B_/%3Z@^+Q<_79U_?;ZD)4\GCV+/^LP1ZF$'?@KTH]"W
M82HX8N:Y>(:$H,P!OL#_S)%VM$'M_/0M<7ZAZ:.7WY/'E<FIP]P$GDS;803P
ME %+3FLAW\LAADXIYXMO 3)?@M8^)Z\N)9EXG0BXM_8_.,4&1J;IY;+8YM$6
MW"=#E@+]T!M\55&KR*8BUX$C#DQ#!G7:MC)-\>)UD&+M&FP,,H[E01+U?$ &
MZH#,>9.W@\=@;T].606_Y7+Q4D4%L&^KIS;:GCG18_A:!<(('+CD7-*N=5T[
M[2V=K+3G7!?7-?>\ZE$^/-;+?HT=8MN3O=">R.M4#X&T_BA4W6BC6+HR;'/D
M%5W59 -ZZB4/G'72 9"_V?,BU"F[V[/F;_A9S^_3"?Y$\VK[*;UHO3VC_Z/)
M6I-MLK_CS%S.Q8*"QL.Q8=>5M)^..D#)SIR#X^BHRU[G6#CK?+"NS@-Z"VD\
M]E);.I$S97M8TW(6QPA\C6C%0LAG/WX=DWRQ<T4]+5=2Y81LV*PA,@NOB2PL
M9CX::'AK7D/%MLCOC[$[3=C!4;PM=<'G"?Y;0M7L<"=IRMNQF8P0UXZU,1/^
MW=&;:6IF$LRI,+,OGC@8"#=)R]U.\_E/9/%:=L"><T"Y!AY"J>5!PI:.@ Q]
MC#0*HVX'-?ERB?\L6SH#%$]@BIZX5"(%9HW81%%OS*BU^S(E*/@- BXN88Z
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M0+B!R5X!+(I;V;J._H#Z AG!F+] J0<X'@C<\R#;D#/[6TS=Q SQ:IQX)UV
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MTV?$$&2;:R75T"GB8@5+'I +ZX32'[O%FCD VKHLR";[7:V-_\P+C$,M;>C
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MB=K=)X\@_ (7#G=&%E" -J-GO1+&V(HU?$"G$<99?&B[M)4@PLT=7;NO4TL
M0*?[6G@N.EK_^1FKC\JI_D,[FH:W#.)9 P-'#NFW&3A?X>Y&KKC#P*6+Y%E3
MB##78- 'Y\)ANIX^N>T"TY]  <,EEI(3#%*K=L6,!=VZ%KS_J>:J3Y?4[ZDG
MV,/9%YM__\-?_U*^_O23SS]]].3C3_X@;OJ?'(.H4UTE=QD@-HKV=4LK4/(I
M].QPJ%_9*>5E:%>@G_IUI(1Z[JC@_NV/JW?IZ6Z1FO6/_S\).O/+5*=,:+$Q
M*!DO0:R'JSR[+MBCH3K.1S/-#L>FK%,$F3%Q="F:K$Y.P[ *U>'X5>P<?U0A
M147CAM+M489E<]^[Y"L1N5<]DFL[Y(CRHTL)#N3]+$^9UCEBDB(H!\8#_! >
M<YJM7"<?)>>=*(?AF0;NS9*_XFHM>Y9JR3MS@!2X>Z+EL)P]V;LGX)<(#[",
MM.NIU<N(*Q8J],-"B-!]29)?R=#K;O<(:@-XW4,^>&4D;^(;)Y:$S92]\"ZV
MB2T:]F4"FM0M6!N$0P'2']Z3/F%6UKN1@WBV+S;X+! Q(GZ;EQNT/P%D 91X
MPRI&?,]540]D[FF$,I7HE"W05F31#FH\R=H=S&_RMCK*2ZL"'6'$#774*EUI
MDAV9LK8?P"9TNJ\[.J5B,+\I-Y"\<LAOR;NUG MB^?/4/<$>?X.$UM+K@N6<
M68%6J#2*C;SHINDOQZYTZ3X9@'55;=@7[2L7_*YFMY(++4,Z4I[ R0X90&.P
ML$14 YE>_J!>Z%[+8=/3X3F4!W.RM$E)'(-]_!B<!:/$,S3(S??MR-9#5<O+
MAP</Y^KV]\3H[W\U=Z._)]WH:KL&0PRV>4 ?;@=[.D'J,IO0;$)_^+,58I12
MT^R)NS@D"X!_1(J\"$^)'E+57^].>CV;WFQZ?_ASJF[LMF2'^XU*X2,$\!1"
M%:$JLBJS[<VV=]+VY$P##(M6'J?.%J%0Z6&3*(<"[X'P68$OX0N1;2E+@N;E
M0,^78\+91F<;/6FC<NH=,-S^O<<YNKLCQRUW29S!V \#FELKE*?'66V3&JOJ
MAH]'68Q-ON/S3^<5A^&K<ZZ'SN8]F_?I[3\17#'0N;G4V(_%F_W-55WF2$H
M=AOZA)A&G;Z)LOU^L>^;]5762H^6UY^N?6*HA,!UUM95%+B<374VU9.FJCH?
MD> CMB"QL48T?XP3KKBW8@E0#YLT3E?[LCZ8M:LJB)W=K6&^T?0PT&"=D"HI
M0?+.*%V..'UK#C,Y=O=\N)T\=WC2F.N:XH?E$LRN/BIH=(1!]C13Y$R@."^E
M/WLGKURG9%Z=]DF[=I:4\/1PPO)GYL2[4WHYG@ N$ZSRO/+\2KIQ&DSV:6@H
M7&NSF$\2B6,Q&0:=G, OX+*13 @8$TURK _1K=<8I0G-%EZ!@7^!N;<6MZEZ
MCG12N'=C1/"&67;UW584&$@1A):^L$"U7"].ZT^#IC(I9R2IU67$+D\5:'R3
MZJ (,ETHT.*BU5 B,)I%;3H1K4G2(PGU]T1B1!RZZ_ES'8KC 1 T-%FMC0(C
MHKD504[& Q#JXIN,8OU "S#FWYP"N0L(2TK(QRK(#Q;>^F2&M\[PUAG>>GSC
M,8]Q&E(S:EN*>X OT;H.&4 .[3/:/..K%"[6G<KN*9+A;_3I=E.LK;$W4@0S
MEVU,Z6FGB>3SXNZ5WI0%B Y08B]*(2@YIB2Z'+&6QH#=L#:K?(L>5GJ64*G'
M+I*6ZFU$E5UV(M,8T%/XC= 8ZG9O- I-B/=/HY]TS'X^?WF^4+5%V6W\*+K'
M/@64$I0N7>U;D7#D#4N8,?!UZ)-/]+L=F)1C+WUZY2%I1A9 @MV3T1_'1)1/
MON8(O?CIHX^_^/B33_]9Z,5_%D!<@3CD]6^ZJP!-@9!5UDR!;Y+8(R'(#HJ9
M*0JD8.J23<V&E< 9[G I:V:=IE.11E+AB,YW$@.E1%?F&-]Z:%*V& L0=91J
M/I7W%3N.7WV+^\;X751HSJ(7R;0H9L8>@$K&R UXUI&X-UOLBWTN?+O;J6E:
M'>*Y()E<5Q!NEXX\76AF'(#&T@@KNDU^K9&P8PK:%EW48MS6ZYZ3>?]6')^,
M/_PY?[.X+J[K?_MC\6?01&$3:&C5PX-R>CK;RV&RP<WP6SII(Z7(Q'MR-*G(
MH&D,/$D8I]N?7KQ8O%JL*9;64+O8[?JJ/JNKM1UTNF)5;WC/$<>X*D3N2E=,
MNT.'\ZXN*: F1_>:KLYM9E<4VR&=B08^7K1QH;1!IE9V<[K257TC'&F<?L%Y
MNEQ4/>TR.""%%3(BI6"@H*ME86HZ7KL&H"S*@SL-SE"C.6\3LO5O]D+B@!Z#
MZG6%#*.1@Q0SV&.VG]N@:D7;]'L/;PU;D;"$J"Z1_36&^:$=*'1%9QVWBPM#
M9MBMUMK2'!"O@\UF-M'91&\Q46UW/T@PXV'IR'_E3NH"_>;]D/TSEH$8;!UZ
M\V&52>R;ZL;8J<K$ G(*QNH=!25Y1:%+S4HAL_'.QGL:QUF)^0AQ@,^]FMA*
MD&4IVK97^LV$61I5OTQB8Q]NSJ8WF]Y)TU/.-NXG%@;F?#/J [/S?,%@C/:D
MRN]L5K-9L4=3!M1L!Z"$$<TJ<>=L/[/]W#6<,RHE)9!:1;XZKQ-5;1SGJ+:^
MA?C-);%"0NK8EV?3G$WSM&O;[;.BL1J65.?(BJZ*O5K7Z_P@I:2"*30@)-;2
M;/(_CAOF1O*WCI%B2*QKE!,S4FLVTMOW7Z_^)S2YL,M\!QACGI\RQ1.0K.ER
M_6-]2:ENWP]W4%(.BL0&(U .,_OF([:#80%$E(X"_'ZR'C*4D$U"Y6'IR_(#
M1;5MLM:(24!HYUKT0W$+Y530!+(_*4&EV"P&+?N1!B#V6<G7N!9AX!_'4!N@
MGLH/[Q4>]-G]"/A:FJ&T_ U"$2X3J@"Z@[$335%,\ FCCWR8_%7[ M,K= 57
M4T9@,R,*IG\RXV'Z8)'X6\=.Z<03&YCDJ&S'L^XOK80BJ+QS:=JX&S=,KZ@W
M,]Y">@_&B;%=!89=4,96^;80BD_AF93YF*Q2?_;9%P^M2LUU>2!$A*#];HPA
M*%OV%7>G5 $#H(5H%"= [LOV;.+"$S0%#I!G_*D&U&"NJP=;_7T>AZP=\EI0
M,("O78[<#@@WJR!9P#SJ!1@Q*Z I9.A@S*+4Y+\+&W9-<6;.-LKLOI+VB^M"
M+X=:K":>(+C2+:YZ&@O @HN(9EPC5=5$#F2KU)XOGE=!/U,Z.MI _U)F(-A*
MIS0PV0<FYGJH<7N:9V3\[I-+\/-/G[S3)?A.R8JY@%VTS$%ZDRP]'6>>B%T0
MH]I# 0=SX8%*%&"698X8\]TLD60 /WGT\7WZ,(L#V/ K9>39]1' %B2!ANQ&
M00&G4IR QPR;(,N8&P?9LQ.$5D/&&'H*02 H]B"NHL*$TLIPM^%S&/'^!*PK
M1A#GBZ]R8;^]W5K\,^@Q>VA&@85PA!P?4@@<\?1*,->:> .0#BMXA*TSQ!G5
M,)]Q?E.+[:T(Q1@B3[/P1\8?]A\T9H<IZJ_  YYTTB;K6S%)O%?NZHV(%>BB
MC\M]R_376&PGTDT/$$W_T8RFG]'T#P9-/V\C\S:2\'!)5&B-OCA2%6UG^5?(
M4AH'GDH@P(U3!%-4N7#A9';\"; G YPJKE73+-N^M1J&?3WL$NT"[DE.7MRU
M(%><RQ*S&=_:YLXN3IMS_2G\*M^%.%^TC?^FY(3R@0V9]K68<#YN]TGZ4A*I
M$V"213E$!(*8[5ID,88,)W/)=S;@6T#*9";*FI"S7)PKZ*;Z/S&;ZPP.AK8M
M5%5[PHAG^YOM[ZYQ0+K#BW[E%NV-.SIO<H-+9)M.^JHB@TA94\ .@AJZ!(0*
MS_J]@//H'!B]\U4=.MZF$RBSU<Y6>])JN<C%T:IKIAWP?[ELA>(2HF&;^B$R
M=-96&JC&HM:GDBW,!CH;Z&\X7@WZK<VR5&E6:,'@6:N\NZF;UQ*<9H+^0FZM
MKC=6EH5/;;4;V#2!I5F9+EXA#R\\&#/^?K;1VT-/SV8W11*VSO:A6V[!24!'
M(B!=_>,,-  165$%5E&6UXXBW.X"47A15+'1)E_L5CV=J0+\"[J"^#!+RSID
M"EF-$>FQ1+M\(::V9[38;/]OX:/3&D5WV M43(H5(+4XU,P4"CE->N@&83++
MDGB0TUO1?+VGF+)?I89D0F-:PIW$H^UI6?<YYPJM:CL>,($FX1@<FC ,FT&^
MB)_A'ZQN?XR P;[J2ELK>CY0>_!!6=8]I-\!9N+T#M._2L78<%EE\3HOBRO:
M=Q7 A/WZOA$R5N$>:O3<+H/.&+' 1!#  #0@ETVV:X]5V$>ZQXPGV>=K8"K\
M6 _4W0PC1H-^67,75TY.3E(8,()",%()Z,R1@$U/[3: :4:37/*<<=0/0TD0
M=NX,$-(G(G]CH\,QE=K;AMY--)D9C3@AU)M:H:*"_$U<(Z\S...L23%\>(P6
MJX:1!%7P(VSV KHXBMRX;?*.S55@V3E *6D@'!.!3O8>+!8?86H9J'D$,T6W
M^F/=1/UY5F%BQ&(^K!7'Q!4+\:E"-H\(1[(G74*P)Q0B*J 8KQCJQH_)I4$!
M8PGR9^A/C& T@7TN'5M_U*FO#QGW77AN.F2-F6(C<"R!W"/*(C,5(7N7;'.=
ML2 EZ"SP5F(WBD%NZS*_@XA2?)UI&:@')#'_BQ&C_-^_]W7W)7.(Y%[?VC3'
MY.]&Q$T?H%?.^6"T+H6](:'KRW"07QLL\MAE#>.WRUZ;#N5N5ZO*YZ+DTU<\
M/ $M;:+9]^WEP[@='S&#CBH'&=A)3WU^T=/:*T5]C@8U*__OOSS^]-&7+&<J
M23I+,&]R9.Z4/$96%,;NN@Z,O%5=G>D_;42OZ'';Q16<R>K '\BV6SHS&.*5
M5P>CH/_UR2>/%C2$):Z^RS-,[L:@8V5&A]TH298%JJL6K>4;?710R3<=4,_*
MK)I55<];G;*+8>S<'2EL#G?<R.F;LS\X62,#R8IB >$\'A\#I;VS(?CLT;L:
M@O/%RQ/&[^DYC5BT+>@]!9DC_0 LE@MH>]7J_A<6W5* MV_R'5EFP!1E_08@
M>":S:#OU67YUT@.KC+ ,XL>//EY&Y4#3VC5(TFBE.\W[!!R7T3!?ZM<ZG%;1
MD9 +!$K[.-Q[UA5-:G=3QWF4M@\\?!(OX17,K?#,=B>NVN:E= G'[X/G=2FY
M1;X,X%?ACT4%-:+,VBRX9H@<D/B8>W,N/!'V*M@WX2'#YN45D0-,6:8I6IF;
MI45V38&1&5HOHI@J5KIO4,_J JH]N%AQ7#12F]M=L["U.57"UJQ2 D^*3EB(
M.%[\;M?-?, J)P ]*V3Z6=T:FFSC&,V-T#FYMCD)^1<2%N%B-GCT-78"US5@
M.&4^K37\Q;L%8?]VK>%G%4:&VW<67T,;YNM!"/-T&,+\O@+#IX.0WY75^EW&
M3E_CO!0I5C#&U3J/^J],[&^;PT#;4SL%5,8;;46A)9TI#/0@@0/94*96#N@3
M*;W[CHE>G1Z%T0ADH/.4E\PW>L1P"I7:>/$6\.NE7 Q3,B.QY_SAW9#8UD+$
MXLD#(_V?!7_^>(8_S_#G&?X\^^X'Y+L3#=DF7S=]$8[X)G^T0*Y:,KSFO55E
MXA*^?@:!S$9VVL@:(#+-JK@MM;DN4J4X5+FD0AZDW8)4K%'&1_,+Y8!4+.X#
M[(-/'GWY],7SEG]\_.6':LD"%V69%QPFY ;D726;K:&RMBLR6\*;#IGQ:[3_
M7]9=H0ES/<^Z#TJ7EQ9.)$-$0\8IA4(Y3_&E:\CJN$9<5 XXFP.J(SE<XJF'
M3SLOK7EI_5:AT6RB'B25&>;;&!P;9XN;+>Z.%O>LHL'N>N6K?Y%?%W2OK^JL
MV01/_.S%5\$1HTK:D;MM^3P('9-\<$J45,;PD B9VBS9!^ :9SN=[?1M&OO(
MR.#Z7'F("SW995735*PE N$]F[9F5IQC&+650&9SF\WMI+G)W85;R]P7AW"+
M6C)?XLNN,J#H+OMJ-JC9H$YW=#(5I%4_]DU1@54L/7I'V ZS3G;9=KNHN1DS
MMQK_U%YZ29MH->^BLQ7^MOQ07C5D!DG#,?/0-T: MV!$SB#E3S;['AG=;'/O
MG\T)6!!V]4'-L)XR0^_#AVGG)",X"F!(F>=K=&I *1.?0_8%F:1-D]T8S:YU
MK ,NU;41V*-=\BB)NN-TCI^R-?UZ2P]PV7LFH/2>VM*TU-YE>.NV[5E1+. K
MI>KZ\!#Q%]4AEG\G*O+397C&N+QEG9VS$U-:T<^JH#'*8J(' ^<HH$BP>HQ7
MYA$O\TS*UID^PI$''SXT3(;^6WMN1+V6 @0K1O%N)Y]^.N7R@#"K+WN@L5OC
M2!U-.E""V@$=1TY%I]\"=H$YY@4X%O(6(.*07"O!-M/7@["J_<[@C_<-U'@^
M5>N.H?_2')EMJ %')#LJ_],RS65]8P(=-YY<UEP9YJ3*&"2OBV'HD\JL6IH"
M[AM@.7C9^"T[/;#(AW-ZU\)8-YN"VX1E88;]O> V2VF0[_K-(3HY _@MGAY;
M60Z8XC!HO'9V*_*QK(;8(/DN4ND@5FZ*G7Y.[-)$ I1!\0ZI4#,4U^2\X2!E
MO:8]/ LD;VY9IZAK49A,\P30?6SPVLOQG(?&&Z&" TJ2.QT$"V<P8VFAZEEG
M<O'LQ5?\WU&NC/$[P%HR'4$'@KD*,%2#X.JG3H7_2VET2)\1DVZOS2FVT$>
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MQJ>S_:Y)WS2_(6\BT+;1U3@"LVAJC^12UQE)OW!*3^PJPG(WO1$'W_/5]UR
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M<[#'U:AZ-LG9)._L;,=A+S=Q[='>:U% =+XH$(0VM(ZBW'P"13_[Q-D W\(
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MMF)EBX<$@6].1Z/J?7")5C1VH-K&Y@&A#XHP>#Z8\CYT__+4#.:$)56=1N9
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M=%,7C9FE"MS*LB//S@PZMCC31CJO.S5($'-3A'"TZ1EJ/)$@;=N6"#WP1&9
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M_"VB]<?,4PAQ.8*V%STL5GLUS,[7%'.@M-Z-ST_V1*MH%[8'0RBBTV)DT#S
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M"1K9J/[RM]<OI4CE6;,&DU"W3CUI)A4@%3UD<3\+Q7S0>O&+#WIJLEN>+=!
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M3VF,[+(>Z7_+'BC;0QU ]_:@A*L4_[ED0E\==%:OJW#C1 %#OI9Q]R#J1J>
M03<E&M6!+\42M5G[Q9G!)>-AF(K0(UN*VZS O7#W29HNVQ\R<LIX#WU<(:):
MTJDQ)9KQG+"%;%'P!HH3B_&Z) :R"@>\ W%\,&%1?%MO>R+TE[R#Z?BY-7X$
M+ <M0H[1!T[-+8:N -G&R?V"1(,^>5J9QT6-5><I<;$L\0DM?"17J&9<T0;>
M!)'?C0]4,35)7TM#3)2['L9 OZZZME<=H\.$;[$%,JKL3F$"]-8&&BYDPIZ-
M@=\O4_W\EE(W3=LNC^Z;$^_#1 [A!"8I@._L Z"6&]YC:J P&=]XAL0L3+KC
MSJ;\CJ)'^NQS_N.*6%P3#HD(9.,#$,NHX >?%PYXAI/3YY=TLFWZ _)=Z\F+
MW3MJ7M_3L:5@8O!.WT[!>V/#0AWKOMT"!%DW=<+OT4L,\8&;8PBJ(=SL%S$&
MCF>C%S"& !>U !K"W\8WXU%Q\89QOPW)7M'*'"8!%.*8#R>=G?AWY_,T7F I
MK(1,2'JI^3%P3\9#4Q6K=K+S?=0R\KT,Y,_\+ZFKL&)H,;@2_9"V1,3$E#AR
M0B]N(%^;/U6J+JBZ;=SR,7PA2O>L6IX$?B#^P_>P#R;$\A&0/=)1]_+[_W[U
M]9-G7RXH1P^[:LFP-,(+KQ(0YY*QC!-^IUC4Y8ZQ$KG<> SYJ>HHV(0L CU@
MDM\@':K_0SO#L,#QX%PNR>Z'O-$BQMV6>TSWFUG$6+'E8XB@SKG.;S0!N5R7
MH<DT)-)%0.0,L ?U=)<]8G=;(< =0ZN5'U7 IO?N$0KR5*N@T@+,BJ!3W_:\
MQ8*2H*$+IV4D3EXI7*6M33M(R).9G[!M! IXT[3;%2<*T]OZ%XCX'E%,3II*
MT1>V:D!"]#RA7A5?^*'9Z5":ES<4I$DUA22%\6V[<./%;274*)+,A8"Z^7]!
MNLPA?TGKZLD[82PKAFQH\1] >;8$Y5DQP 0*[KNJJ>:H:M#5=2FDSUV(#T^&
MD ($5ZD$W?4 694[O/">X&:2VT4KWD'UMRM9(98PB_%8VB:NM"(7/2]W\5 $
M2^"^YR2:H.K1(189\HQJAGV["K4.!.)/&T:@@1';O;IXYM.!_N"IPG=9!9J&
M%NG$34.+MYD1!1RY]:"\L*?L&RW^'85:+3$[R%?:@)U9KY*GR9!+S=KC4#P-
M;X9(.:E*S IDLLQ>[L7)N^7/@DC(]@U9?V8P +<IT3G;^I#J[QYV:6%>@?LA
MS<Y$1E[<S@$X8@H<4@D6QKQVY"&:MI25]Z%KTIO+EHAOUWL5'7:QA2=AAJ1%
M[R=?PS_[XK)4ZF;HB$SN6MQ&6F!E9%.?D19\.!*44(Q>[4%8@OP_.;T*CS3O
M$D(7(JT\<98'@6]Y4M-LA7^Z6"2]";WR+<:2&F'3$B2"!%:@-].DT,6H=> 5
M@F%@"!<^;AKKN<G\BS:9;^$69;-6Y?INFI6+"S42=;VKP="U/=JP,&N(=51W
M@2I&P9Q=^"]NI@KJEP\;ID/9]:KO=3K6H&F6LMOP/R_>Q3\50FS7<Y6[#=3/
M+>0#+*))&ZU8A,H:8,8[A$/&#R7BDY+2Z]P?_0/5,7'U[-!JUDRR?]4TB#4E
M&"V<IS,U%?9A:"3R:,#8%TVT@5/Z;0UDR,0()]A'!5.:-_<#;VZU* YC$<YH
MD.NC[G3(\ ?C]N9Y&YW:O ]CL14:=PB5[ ?3Y5TXG2[)?XI?[0[;<,DZ08W4
MLO[>5_P?AW+'_U%J@%Y>Q9@!0VUIII3*:\IK1OLN>2.*)YEL"7N:*@'"@G\9
M](^!'<CTO/!P$2;WH-NKLK[HZLN^-R5K?@,4<E'0V&]% W%7OF/N/_X['('Q
MCUPW5;P]$^]!-ELO Y8W!E!;,#ZSBA4QI].+/)Y^FC]F_RYS5*]L9.$'DL*0
MJ +:*TM4"?2?9+KUV9=??F%:5-^]^N&%J5'EEM!-F4(^M1G>QWR.0[]%M]S0
M2#856X)&U4?O$'4432FUTM(-%JZ3P)5?M+O"CHHU[<<%()YQ>!^?%X51GU$9
M>N6J$V^3'CQ9]#=Q>S94>"23?ZF<$_*]).;VI=M ;[]Y^5W:09+45:V3(CC)
M&C=PO<D?B+P[,QQN)C-[J;1 $XU_UGWN?Q,;W>=/9XS0C!%Z-!BA^0CZ=8^@
MC^SL@;7$W]\T?8>V3$(F\;%@M;NRZYIE)?P/-#F,<7O-K@&-KFQB%.6R7>7C
M9FJ<RFPT3&ZB]([1JY;.DLNP*;=K)J3/F'./Q:A9UI7K>$25K07-4HTK\O*]
MW%*G],3WN;,YA/MH]L_'&<+=RLB;2(N S>L&1(Z$DA=(1 ;U[R@9D\%SG<67
M%CF2P2U3=%19K5LSP:IS6NRY0$B1DDFI/;W<5-M5&VKK-(_3-7L2VH B(;<D
MVJFPE_ 00"\P5QJ3I22'+U]#!SGM=9Q!W$F6T-1&"VPJ %MV+>M#E"=!68T4
M'I_Z10Y_%!.ZJE;]":8B634"'\,^[R"9O:>^RZ'E_[5O5M&WX7]P^KBIV@;$
M,XVRA!\"#?$1I8WR@RND0BON8W).]T<*MO9:XN-BI)_,GUXZDI%N;FJ'4V3E
M)1%A8L:=CBG/)&D8M=#(BU<[LA<J^?%&2)K#7Y>'TH1)X7FO*-6O%R_ZJ^@W
MN!SR#%B?S\SW#AC.\^<FETRXEH,\4*</$F^0^,=BA(3+_8Z7]<NG#G"$V-*X
MP6C!08T6?Y >.-H[54+;!%^*]U]URVW#DS2"'?9F1HQN,);XXUA,ZL;O^YBY
M+*EZ;-OC)ES&X"CDS$MOHF%[R%.\9WX'77I)_9Y:3:MYWFX^)&ZEH*S+Z,!I
M4FS<D9ONV6HI7C_O@ [\[6&1U?=@2W W(4#:\JR5:WT.>Z]R#98Q'_!VQ77?
M=:[;,-1B)W&W#&LS;G7GM"D\- ;N$JJ/G5H.D<.&LQD.+1G="5.5[/:*HIK@
M+Z)>37=HCW:TQ6>D.B,I3)LFW8(F%PAD'\QO@CGQ&BK*^<?P'S1@U6^ORD.J
MUXPKH#F*W,:T[*CS$X=ZIDW53^ZV1F.2*7>LG#A\[582E&!\[.9'[33JP.XU
MMS0:RB1Y,T)]_=&UGD9/PHLVB.%S%(Y1SV0/X]1DEU6[['<=!):9".>8N(A7
M%51\T$#$R<*/ ,!8HBF[P3$$8DJ2AM>N]KX-I +"[UH*=H<-ACYW..*-YTGL
M1$A['A^%ZS>)(DW@@K"Q#()\ MT"@&BE\X!^5[HXZ#;L :!X<$.!M<1+AOB"
M?>AB\0IQ[;Z)>1S&0.G>3@+]E(.*@\#Q<QBS('Z5WK._:06^-8;J8<@_0[+2
M':/3TRE+K3K0,ZB=J;'7J;4 KG> ?45GA\IVTE6*YGL=$X/20Y@8C2Q*H L9
M(1[. B2.M 'D0X^-OCN!A<GTY:G-4N2MEP$V;:H=-XU!,L ;Q>_T\5UT UTC
MG;&8:&Q[9.\\>TRVMJSVY@3.CS??TM=.@-3XUJ,OV:KWAL^FJ8S6XZ'M??S3
ML.WTOKR'G;*0S,%: Q*6>K.)"W*3)N";F/#8S_BSEWX>X6:,[4H9J.G$GLC\
MS::<)QMN8&G6'B8L0\U @8UD>KDQ..QCNBM[L]T'OEK_#C"TX0#D$R,4#, M
M%]7J/W_S/]]MWWWQQ=//GSW][,O?<%GU42!SH^G<!*,V]FXKU-<Q=Y4];HT7
M'*3E.AR.IW"K0190"";=:\5V!'C&1'V!=EG"FCJ-8W0/"&!?5UM/P'L_8@91
M';ZMS__P<&_K)Z9<<2MD?)(?N/B^ZT^MM10,V58]\HC%BID@Q5EMXG]LX4\!
M=>[BYZ(')91S* \&^R=)3B(80 !5_J-L5W2KND=$<:'LB-L3&%9WW.A)3#^&
MH\M? 3'<MMSMI/HAU\M@%QN:BS!%Q$0G:9\>_20V,(,Y@_LQW&!.5L $$+3)
M%38]%8SH$*E?!3X>IU<@L2"$+=S9@1\_'D7OF,XBOEO\.XY<V@@_]S00)GIP
M_L(7BQ=;.N>N-IYJS!A*Q";<BZ6;U9?JWIV</</;'B8^T+^+ZV6\II>6G'0G
M\>JW/"[-?JPX7KC?DPMU-$^)G%DWG@H"L(*N0ZYC9&G.MIR?XKK7EJOV2I62
M+F?A!(*2^NC0( K/7P::V<!0EDR6X/W#!/DS[.6RD(=IK+4=LI)@40^\A("R
M7#+70B>?C; Z=]L(3R:CP =CZ7>F:\V=FR9F=FD$#,RV=:<GM2D5B"HPF%L:
M/26 UW\/=> 46_("KSC)A$E(5D^O)<WT#:QDTA\Y*P'[>KH?#>]5'RFFVG\'
M@79B_!>@ETFEFK548A0QI*)+V$JDJP-;Y!V_LS1R/LW[:AG__YB$2YDE(QKJ
MXJL"G:W<0=\)A7HM)5F8!ZV&N'>ZIG=FR:L6;C$H=BU752,TP6EC/B"5_ AD
M+[MKF.8MT$7$*']S2TKV00<NL/)=F+C<Z91TMR=V2/$5(N*2:1(9%06],TW_
M>29D>L>?]LH:Q'I")K](DA]EX1CG"Q9?7SQ2BIW/G\WPF1D^\VC@,UE:\KO?
M?_[\LU\J+<EWCJS09?8K>?KT8PS@2-?*2KVOX@70YZ.Y Y)K@%0XN9X?[-#[
M.IXK5.%B+O=F_1^_O?S51@0_<(\.,L-G7WSQ^/)X2B?[6HGM9%*-)^$EVNCZ
M=8P_>=JL/,C$_4$B!.4L/B1TJ+ .B"@?UWU8A( F#SFVE>.+&T 91=Z)"]EH
M-47O:*53*L>Q&EC=/C#31[U]0-7<0^&;YWK&_'VG;E""*CZMP^I?4WMX $/Z
M'F$1BYRO K50D%;':*&]"DAM"RTG^L$\-IQI YF8CTP  6JGI.B#^%JZ(".%
M<C6I ,J,-),]Y+PP5@1IX7F8]45:,US_E=]K@_+]U W%OR9OQN27 [8)XPU+
M)H'X\%*U'/@&NXQ.K%M&]Z;35O$7PDJ?8R2GHL'@B;N^SY2CC-$V)"U#C>:/
M>NAQ;O[_FLW_\2Y*32?'NEH?S9R96H*-UT8$S:XSHTZ7B@L6N#=DFC/7X0.V
M?DYI(=4XU)*09YP;:G'!U"]DU(AK\>8'5IX%OOC A)'CGX@HKC[\^Q,U8F\.
ME%O'G?+O54UP@">7VV;Y[H^[^#-B<E]<?/&Y7EJN0S\^8:/.&+%:@V-XV*%&
M^\CE>=&W7 %EZ^I3Y"7K!>?WWDL6$BZ,K@=802[4I@BR3CL]RB0H9ZJHR!P7
M70CO"N[G$QM6O)>5,)6Q]R7#5 NTF@;<H?$_KIF:02H85E%A/<9W00K7W.8G
M_@:+1*=X'=<DF 5&EO%N2O?)#1]L)9$YG-I\>MK05^B1_CC.!6;SS<WWD+&T
M.),:DED/Z< 28 0V42N72=:-OFQ68AAL09F[&X<T( "JP+'$U^\/^.\QR<R:
MZV68:+3&B!@ 4Q&ZR (4>SRYA]\%5% )_=IP)3AS\ ;=T.^9="@%#;5J4?^"
MIO2_P9(PZ(E"KT[YEU/T0+HW]?6C5K:ER'-=7C>MYDO\UZ#.D5MHHK ;3RQ8
MXY*T=UF>'+&9@8]\6E1&P^8WOR?,5%]+7*VS#CYA$B*2Y#ZM-355G_EX\#U9
M&7;DO"EWXL@"#OQ)-'LJUZ_TCZ;9O*)TY#K^*."O\;B(NY=4[R 6V[RC_V T
MUK7,/'O02E\' G M [W! =7JJ%1?'[-8IEP1)*^\BG'[Z_@*R8.<P*F4.1"Q
M#4_HT9!J).(]U@&MJ'G4&KOEW][\\/9[W)<TPZ4-"C8OLHU.UB^&R 1FQ'^W
M@4@7I;\5D^'J=,+YF_^"'\3A';K_^&WU7\+&5C"[[U5+7E4(VOQ)*L!#:EM!
M[5-?AV([9)^@RF=,D8-_%%K03G7F.I.6ZP87US:;"TGXJ*XF0%AHUSCL6$?A
M8-5M3-*0AVZNA;[.Q+3[.GG?PK5YP)MV"Y(&.UN/!GDIU'.M[?.K0*QSVG24
M"!NMMF0"N@V(,H1E0_&@:2F@%A@O?N5%-444SY]2=/L8LQC;=]HKQ?A%%29&
MZOO6',.?JGM(U3^CIN-M$A*7">(NX+@$;64D 0SO8GR3Y!YT^;A0J9K@D*1C
M$07[8;UT5:\)(L48!H__=0\Z9.)FW!/5Q5<'4*QT\7RNK^B_U_ZL%U_ ^8>M
MGG$PC6*["O11Y+,1HAJ/YPH.8.74$KF;F"!1.-MYU3@2@?M+GG^T#N,6TCAP
MI9WFWRQ4.0 O90UZWD5KIPWE@M:),M]4:"P[,*5UTF@5;E *=? ^J!?5"8,>
M3;A47 :)_TTP6P'F)HFJR7LHQW=0C,/[T]7%8;5NR'<;!(YWDTX#^I2>]D(\
MZ0]NO$6F9Z",0L$3E%(X_55_2"_>  [H>W-[E,1Y,>AQX7:M8+[7@KGX44_Z
M(%G7]+NY%S8PT:,1QU=2C.5MRM[;H#*#[>2](2(E,+&!@SJ'R.D*PJU1J*WZ
M*C&_.I4N->:SM(?=V#IY)T2TQT,GE>)Y0?I=DX>)CU$UJRX1EJ1I'(OI(&[-
MV6T:3)4$CZX'IXJI4'.X<%]P;2=J)0_6 /])$Y56_ I"3NKTMF3[E#NU2-:A
M1YT4BXD$G885B&?FR8;.B='29\[&XS9@=8>8:%-03S+([KNYOQC_=E]+8+VR
MG\Y0FQ24\$G-<K%K;@F41NA"@R%@*;PB]/P)L'@Q>DX/[M>1-^&\[2CK%.;L
M_)J&% &')FV64D^(N--B8-DR*L2Y850X#@)5IX0!V2O5M,L=3CSM=N33!ER.
M![_YQ>+K0+. 0:(GB7^*'(7M?P^OFPX\D=IVC\&.]QB7'32[G"(S(5EB.%OQ
MN%OPM,QF3 K*.;&80R!P]L;/>5R9CI; B>]>0 ?2J5(X#4T%K@"8^0;[D;EV
MX#%DG\LQ%!\HYM+^B9!QQ(C,G4LK"N'=36*XLZ(@+;[>0DXX%50BBMTG>/4[
MG (*D8RQ"8?PW8"#/G>>'7V&D\2[514 VJ=4E%Z.!(E]K?_#;;-LF7W24JW]
MP7'J9>;[\B:T)J9=WK!-:"U.J.N2>;HB+O04THF)C&GLC&[2254W?-#Y$S<N
MPDXJT62"\2\ GL=_YA9=3_0S--EU*/@\$?HK-&52PZ[)=Y35JH-&7AX8_T%+
MDVR*FF+W6!5?H$7A7).*E*\0OCFL'BV\YOD,KYGA-8\&7O- Q/XI[4%2-&AY
MWW[N3!^CZ%Y(L*/)5@P^DC (U:E#5W%=<RH(QP%*U'P-8T6@K,C$HT..>1F4
M8S!]5JBY$:ILG1VQTSTU'YE7'0PKIB]R4B<F'I'[_B"D%/%D6,'+8R$*H+_I
MH+LA_&P!%L&\M'H2LN!JOUWTY!>+/U5T+0!_:R/+&+V )+6Q/I?.^-<@,Z>[
MXF1=2Z+L3[I/F0F "R_T,Y^$[M/X!JJKJI9!!":KD8E@2T$.TT *>TC11..2
M(^D_6CDU;IAK*^^=OX]4Y1DLI@T2IJ.>HLHT/R1OH6G/I?Y-'C(.J@)R1S5K
M7#>3A1"=13Q5*=&-(V47?'R)V>:IV-UMK6T0&+>LTLE<8E2VTC$'*5\%GC7T
MV;)#_KKBF(8LE1>HTW1CK-YS9X'P3+O41XO=!G=#4WZH'2/KXNZ)*U\A5+%B
MN!>%EJQ(>K'Q2P%UL/K0-C)"YL8"7:>+I['-$0K/4ZA11P>BGS-O5<FRCH&F
MVPPEI'9+80E1*M]- B(NTT^RF)+^R$K+PN3C6&*E@YG:",QEZ#PSBCBOCT(N
M9E"H%NC^$,EVBN<@#3M%%[6)YS"1CZ@C++1#(3-!X?T"^96P1' %Z^\]206J
M]R.IFDF1,?@?."]II<3[W&$XQ4K@@]RI;ORK&/5*LQKO6NM'*'GS"QT\,_G
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MADD^Q3I2$Z2[<F-BY58 OT/O[,%+6"?J%CL0T0-K92H+! ]A2WL>G("FWLL
M!N127/WQZ :EH] "A+BIJ1C6 !#9S%OJ4DF9A%F!UP,$DN3CUO-' UON;%)R
ML_*EA&?/?>9OS K(K.VYO%;>XI,46<N*U)K6L>-67F!YT$\+F?BJ$.M0M<WH
M3^!W7D:W2O!QI6\B"0SA-FP&PLO=)D9[09KT8RA)M&:N21VGWY+_1GB_KZ!#
M.WH<<+QU@],XT41(OIH_M#QK<0MBR4<Q:6EM%Y@=1&/1':3]R[B)N$3,;+4Z
M3Y%B*J\?[MFOSDF)3_)@/7_ZBXTP_Q+SLT3,@5>HX7;*9I%+2S7;U1 EMYZ"
M=O$Y3#&EQ"<G05T?/EA*J1V"-!D;5!Q 8<58DVS/AGX.@Z>C"4J!AI"O: Z!
MBTG+GE7O')2P<(_O!R;UK,F["QY+]"M/P=[Z/EWDE)7Y)=71]R>]B.F2@93@
M[O@.RAV%]JB:F"3ZX+W@X)=7H!1_T"](PGZ:DN*C^VU)TH%U]HZ&2=N@/S59
MXN&JR"E _!T?$-1\P1*F^"YZQB,)HLJ.$5_WCXOP6 $0G\T B!D ,0,@3I_!
M8T<T: &Z>;Q;_-'WF?_F@N94+5-)1SBNJ36NJI352-*-D%"*C$*/X:#<3SHI
MTJ2_/$'VLV%WV3:H/:/$ 5IH_O$'RS2R19H(2'4XI?6K72!0/#<^,!@0O\.!
MXJD/4855[F><6IR\AA;I;-E9;_EB\88[TW(,+J791E$P:B;4^"CKPR <.^95
MJ"Z]/9E-P27X(5,3NZ2"[PK#&03MS*$DJQC^-#H(X<<?\C!">-SD4:3 + @5
M[N_$E=N%J3,//;UAZIN3LQ :Q;HX=NM>VX1[2UUJ6;N*_(#*.B9J2VU%('7:
M-IUU5$6?DC@NMFB:HDV%NVRLR6Z#-RDT@"5P*9TJPI>!6E9UEX:"\DW+JO14
MGL+@'&53O8/A5J'S=/*R:Z^17YX0?N\.AM(7[W+4ND,"T )-:V6(AK0(F2*0
M">6EY*673!&9MY8L^D^@JS$(87HS;"H(@R!7X-%%JJLN1!LVX;".#L(%UG1.
M,R;&O&XTN"U<W?M,F%MFK&\#=S<1_Y:UJ-Y@D_96X$LYK=B&%9F$E%'[*)2I
M'YJ/PQ4ZO#PX5X"'$G,/5_#@";+#55=R6E(CR?Z(!Q_.I#G6O/%2<@=.NW^G
MH^A6#S+^'0VJ5V'- ";M<W&]M)C 7/NNETZN$@UF[=[/(<;B32L0P;@7X\*C
M<J^\V?P7<(/[_H0]G[4GAD>RTMF(E*?@*NCF4>:C>8O.A@/UH92HTB^IU(,'
M0*K[)+MG$ZWTO8E,>"KU.I]Y^?>#(. .C_)0>^*K0#+2=OPD;B("M]%^K0?,
M,>FUNYG5I$LPMO5B$@O@ZE@Y\1*;!ZHD;J6FRBGY!I5=BZYX-O]S?P;]$]-P
M/P)RM!7TIQ_^$&&$M""%>PP^U6VIY"@RE&\Q1)@*+3,(IP6=$-]Z^<!V<O]2
MU ^C\L_P//'S-M)Q[@[;8P9CNO3,=:880E& :V$^,)O:6[AD&K4"N,O0IQ.#
MM1-+X%!VE[(9&5Q';9M.8]*F=E1@[MHZUH7(4N:DW(RIPY&);^=Y3 **"B3W
M70C[T62*95D()12+Q_,OW!6G-V4 Z44R7PKSJ!M(P4S66Y[IRF:Z,BUL-!.9
M.UDP_+,A1,]CUA(4GN66)&P] UI#*I;EK;/RZFRH_TI#!9YQRO1$):+S)CP;
MWVQ\YXV/&[K,9#\Q8GI7(,2J9TL,)_IPM\[-^ O.5CM;[5FKG4+3UJGJ?O:$
MSJNT7!1.N-#Y[)X-\1Z&.,*^?@BI[3]#53N;X6R&;(8#RS,@T >>QR,2P\5E
MV56JECX-%EQF5EV,KG$KFC-1X&9$C:.*V[PAY@UQ=D,X%*.1N$F!2<J[6B3+
M EG#+R82@3_JG/I'9'*SQ7U\%G>6:<\82U-#KJQOT]9]=+K;'P1]96<_ M00
M?+JO#CG;6SO1F78]T,E7D#=GQEV11=X5R<?D6'8Q_F,B:S8RKGK0CS'JJ8%X
M[ ,@4%\.QB&TBS45H9Y?O8O%VX9[KV'8D :Z@97*_Q%63((_S=N BI6?J%3\
M@9O*G22O8(65,5E->F?$E&O]SAN5(K3^;KE<]IWKLUNSFB*2YET"4AA?K5Q
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MXU(5YW!#25F?9'^R%\#O1!*^Q?GW+**]!<(!G9=2>NQ#,Z/29TC.) V@U+J
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M-"2SJ#!5$7EA>ID!9M9IB+,H%^.%T&B'("(WR3@2IALE4;%W@=3.,O&Y@9"
M*#1D&IGKI 5Y4L!I^%?$5TD9?+ 6PI@C#1_L5&D&)B+C*D^-7.[-"XGFT?U&
M/' AC;?\@A-?WG&1X7PU>2B'8;A$7F(J U6H&%(V_=5F$!V3<=$_D->)&==
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MF0[B=EZ(;-QMWLFXLS<;1%##U9.:#//:P>$7)]-)RX;0#>;<T; )E#U^BW^
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M&7-H#MV8!_DA23"E&YN<S,U505+2+!54+?:R91!*AEU=BFN+&^;TPSOX+\;
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MURD>.CCO.F7+7EA1)AO.6 TTQCY*4*&R<<1<U.2&4I^"<0&D-.#]_F626N!
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MXF)FU]:N=\=[:]=^NKZS'&G#FLL/N22QFFNVBH1#.%0%]D?$."8GH9QXD&C
M9ZN,I_O;V_=9^2.'V4.NF$Z0@2> +/HIQMOK6#;P0D61%GN!<KNB>4QM[D3Y
M_3L76PP$UTIM8FB[595XQEQ1F+"O6GV#2AFUY.:J89\VZIFF>.7B+LI)Y<RA
M4&6MW<YP!C%1?EW6SRH+Q8R%TZ3^XG*TO$]A\&DJ5+LJFK=GB+XID>SB:F'+
M.I\LTT7J:E_%$6O&!TEZ_ *,]EPS.='PF"<K##1BE@"#]$=Y6M#OFD@Z/56
MPI,^%&^$OB6BZ NU59F.L73TEF:VX_TBZ^TN]\86<W2RPT07QI1GJ&,TK*&+
M3%7(@@7:8E,Q+/O_1H2NGE7,U=9^[* U46DA3%O30E89>QQG3P#"*. FX>BR
M;#?L=K=.=4*@4#'J>CX3"HCJ\*5KLEDB,5L1FH1(@R,)D\Q&VTQ\FX0_)B((
M.FY,@CK^2@CHK#.CA'73B?DBG8'Y .6Q0&<L!C.7CJ]$4TAP<1WJ8_E<)!5
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M2IYQE/L7+#6__J"BG0ZL?(0,.GT]6 W0EL^^9/^.=F/*"]0/'0]V4DQT22
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MB+? V2^G] L!2E*VB('K8+4NVKZZUM6<:EYXIQC[)5 H751/H,\SZK>(#7U
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M2N(?3H?NI?H<8KTH=_IF23'-G=J&THYE&.+;.--(,E:7">0N$N9YHZH$#+A
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MM':<1M04Q3$(^H]<7&UXM@WCC>9V-#J@Q@F!%1%V+=>MI\+&?1 GF0A@B6P
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M"Z[EL"]"N>V0CII+!3N$+V3>/XO9!;]TM8 ]@+'7BXL(IBC&R"S>U?@ --&
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M#"L+@K20Z(8\;.9#=QH#/%P"=LVJ!-5*%&F-5'[M 3DW[P2.>53@HJ,&7-2
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M;8&2##K>4P2FJA1Z9)YY]?,'_A(Y6V$'@CI\%>;_OD"V65WWYC3IM+S?=%T
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MP\J'J_%??CC_-?IT?#09#<='XQ_8ZW1HI]AK1KI_1*3[H9Q<QE[8@.)S4),
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MEA332.WGF+E6-I[L2"AN&<W8PUS<H."V3\YV%M!):]1'9^Y.9NX 0QO-=CJ
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M#$RV+I(;G"%O+_WEI^N]*YRC6^B;6^L>,V#/CIB$OS1F[Z6?^YU&V>CD.SS
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M9Q\%[4JV/YUB#8"JA 4#]M<0[ G2F2\"'B(%$2F(J\HC/O7V7YJ".)J]_U3
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MN.$LE9\WZ<5HDJ8IFJ&62'OI]-&.[^M^;_Q!977S6,ZQHOKHMA"JX8BN/1D
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MNUXR7%]8W#4"Z0BD3R^GEP;2%!F9U%^88(,JU1OV>&PO4 *L\8AFIF4@],.
MA^^7[.Y\^7A5,&Y9OCI^<5-PC6(DND9A.PB=@K^L@.H0*"%WZ_)BT*,273\)
M7HS@SK2(G#4V+828'K!<$X4P$[X+_^*ZZW>A:1?@Q'P5XNE/LY.H%7[]@3_\
M"EZ%+UJJ8WR!LCX P'-OX(?;G]8]U</7-EV$D^4I</"J@W$[!Z)QN-#' /JK
MP''71%C7:4/?F[_Z_*3J#H@T)/?Z5OS/S="2[0%W_:WU%93'S=AZQ,_@/LH
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MX*-OSWX\[W[:4(6F&(K^'%L\/U#?=9A^Z9LMXGY#%/4/ 2U(\973Q:.XP,%
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MM_:;-Z"^Y3^7YQ 2L& &WN3/IH6M9^R0N+^(GS@+XA>6?O1:!]FM3M!QNH=
M],E/?WFU8%N-(/,1OM31L07^."]L?QE 1_87X3ZUD!JK"_<1;%6(.5#_H[B-
MXX_7"@"NTA^K6U<6]FI!M7DD7M1EVG-?X#9!;:+[&MKU)SY[;<>0QM(AHSQ2
M/2 E5!NVN_WIFD\"Y%^ X.H"(C]4@TAM!#N+7H5OH?2PXG6 ZD)=BG8:620.
M?G6@%!<# +_AO.ZP(.8T'( 5R:.7@O9],^3F\1FZCWMO <>!(&FCIF9P(H'F
M>^17%^NS;6Y'9M,-_*L#EP/?!=<$K#X4>OSA>E7(0EBO:NVTF"B\C<P#?*G#
M'A/XPM?3"IS-S5)L2$%K#'_S:1]NT(M>"MZ:7/!=/N[DB:B.A!F]<]_W$3U(
M5;3&C<<Y]9TIVD/XD#50H5$AK"* 803^)KX9^PH>?F39F,O@C\C-1%1=HZ2%
M["CDSP6OCZ05S:R\+:#KSA%KW@N<55L#.K1NL;Y1D;GL!EK,=$?NJZ*QV<7=
MQOJ;8G.S+=0OIX!D/]"$:S,4\1>>RBU11WN[-?AQ.6 ):6?!1]T@CE,)=&"+
M-*$)IP+FZ(Z;!M:V;>"Q0/F8('46P#[R1:"CL'[FJ\L*U/2:E-@:?IK 7!W[
M@4^QB2&%8@&$CS0S-HGA7N&"'9",<*;F9'V;"UK!O=6678"+:RP ]*;@?U^\
M @D'BJZL@R[J=@!E]^3;R(,;FV"^1M@MX(8T152"E-N"T]ZC4;@5_CF:2.%S
M'&KK'.<\Y>OE-'^[OXE-<N@YG4%^P30VP5,X=!Y<-=Z%ZIC#( ]!S0!E$/>E
M/">Z;)]@V<;6$=+3"5)@"&/[]XO.N (FHA^9:&<7M'_W'.+W?XJJHPW6$5#I
M*13*7/)9UNN$.!-.CVZ 75#J!WU.\'(%J1\4"7?V9>['YH\?3O[8*O' 4K?"
M5[',9>>#K \"1(UD>A+/*X(JZ@JKZJS2HUA!Z>D:1U&DK@+<5.YP&BD$$^_D
M^!6;]4:\E"$2N?*FZ%(I>;NE5U^Y@W&Z&:\G1 0S^AJEN>N]/[%;8?LN-/^1
M3[)$AX;8MG8'.#(7.$2;WP+?Y->IW-?GT(Z__\$C+)W5>S1D56!0M,*2AJZH
M@#(40 *>$77:$#GZV;E_0U/J3BVIEADR2\Z,E#8@8V9)J2X42@F-I%/=%*O/
M)_'1K"IY=6ID"M58'X[D7HYT^J.BF:%3;=),5?L%5<DFZ\6J0H>?J8X3%7"7
M[['->CYV[YIW2_CR/AP9>B:?<$I2+:GUR$FQ.^BI5"JCU_L*^R*3 8Z,\V3.
M$ILUE\QH,:%3'M0G([>O<#M&"OE:S?=Z:7DVX3/9;$X>Q#-5A0^/',()5,<-
M-=/,,!U1MA/6PIOWX<C0B@9]1YJ!-%-HKN8=VA%]3YR:<3@RM*)VDQ^7C*54
M&('5HG^?K8)['L05(?SV4K*Y%.:9VEVS;?8?)IDDUZ[VXHH8'EG-9*J=H<4S
M([\^5FF*3H E656D\,@V=$A;?G5*RFHZ&9^6#7U:CU<5B@H/O0/R*.ZETHGF
MK)0HSSG?8MDL'$KO&MI-Q3K";-Y4R]V"8:R&LV09\@@3'DI.NIJ_3'0HN=X'
M8)2P6KV'!62\'3O*=+2$K-5!7<Z7U)C*JRM>E^ $=FRI66"70Y$#-:BQEVE]
MVBBD:G!+J1U[FG2H-LAV%_E16V[Z7+QBUC,=/#2TJ36>+:YHJQMOSBPY;13G
MM7$6LA2U8U<U,-$?^F:^U327 SA! 5 K&BYKQV9YM;98?NA15C/YP-_?%\;4
M/.G I^[8K;M*/"Z5W5RWJ;*,:"J=LJ^S<84FPT.E#J/W.KV!.FJW.WXB?Y]T
M>TBDR/"R4MF1DM!7N?RHW)^N5F["S)=Y/#2TK#OFCEZ)C6E'YHMBBHWE@:?U
MH4CO8!>S1B42;&VJC7C2R(S!,MXO)^!<=[!+)44[Z9KI2G*YD^@L2]+R85!<
M*/0.=M&K:7<T4X8/H_S [-X/AP_9=A\.W<$#(S[=NAO(B:6\8@KQA54?=<P[
M.'0'#]AJ<CJM#.4&&:/H7L<N99N5%%S6#B%,C=R>7EY,_&9F^5"1^$&K=-^$
MQ-JQL7*N=W^?K]#B:#8KJ*SIUC/DJ*HP.W9+M>5EO==N)IO)/#]U.[%JQ82@
MRNP@UOT*]$#&N%_(@&RG06'8&O2J<85Y22Q%U7E*Y7E:424#J@&.9!5)93E%
M)0V#[&E 8UGUX]]XP3[[?8=YN8A&5YE[V7FF36929D-8J(V,6X*+V"'U;;^L
M-#K#J=C,U&N+D;SJUNIS./3ECBO0HJ,E$C$XSU(*2ZN4HO)"3S%X$N@]4I4$
MEO[X-UZN=Z_OA-:[H$$6W(LQLJFVT]8HT0-FI@,7L8,7LZVZKM7'6FRD-J;#
M7L+RX_/:0F%V\&+<'MU-QNRJ*9MB?=!W\[R2N(=#=_#B4I;LCNOF[V0 ^@[O
M=]7%70Q.8 ?(I,AB<F (;E=61XF'N_%"6*6@C+,[V#9)%1=@/G*Z\LQ)"U)9
M34MW\D)A=\#!0-3J].JN:(_H;JPS2BX[W>(XCH:&\*A32J42O0D4(!\,V+D_
M:Z1TLX^&;O#H4#?X#]>,:*^+0;QPRW*7T6GH2QQ!\I;D=D>7/G51Z'E'G'VN
M9PU,#\3@ S3D8B+J;>H.W@IBM"_GMR_4K<!'^W*&^T)'0':6&Q,!V7GN2P1D
M9[HO5+0K7[8K[Q<9^)AU?#(B2!\@PI?"]\DH(/[-,>::)- O0W_\WQ_TC\]*
M*WM+ORFP?TT?\9W#A!T$>[M9X<[;4UN-"R-N^3INH=]1NA?)+6<'JN([/$(<
MOEO%R07CO36_N<VO5L=^B0H' \P7'5^GR^/U>SVPB*![IY>"GA?#) %.7A63
M4&<.FG^C6:\#0B_<MOAR2_3=O):C4BQBHHLT4,^(B3X'P=OUF#4-@*^MQRS]
MC<:.U^OR5JWS0TC.>:W^P[U6WPZ&'G=Q9Q_Z61^I''_+M^ !GWKOP0,'XX2(
MS;\=FU,7RN-GYT*\Q\=)WW'03=&XZP+/_7,)YMR11?-;R^%[)_CG(G<1MT;<
M^LXQ[;FPZF6[.'R@-5!-KL<*AZB"Q5P=![>L+M+:.W_6/H&5^!YR_?>U^C-,
M^'#*7**KP&G<Q]M&Y5E,KX8N***J2DI]71U':=932I%)FK(:U[AF7=68N]R#
MH!N9Q0]<, 6^$W\K[BIE UV)82@%G54HBXRJMIN]9DWV4Q4F+2TGN3RH_B!T
MH)D3=>S^[X\8\X,(RK+][P]SZ?VQ_(EN>^O/?Q"6.H$$\=U87U6G?Y!XQBT=
M_4=^DLVXEU0=!]4/;*EC'_P@7+A/\%OPR>N4ZIE9=*;34OIA9.:6L;S+BPME
MM5!XE*DN<#<\Q__[]W-*7&H4(Q+X4PG\V7EVQY9V2LFGZ8D"Z@\DJ38SBL7T
M$Z7.(GYT:1<GL6%7$=-V4]4H:SPQ>$=.H N-_(__4*1TPU/B&^)^09YN8+.4
M<;$C!V@ DJB':OW$'FLNH_I<JTOP)BX$MZ["GSJY[WOQ=@@6N=J3Q.T H7+U
M89 ;3893TO>9MK)B6K;9K2H",CF8+S0W(AF]"AD]K<=_\:;#'@)Z1[:R37;0
MHLEZ0<J[2<%[**91X0%H)7#DP0V$<[%X YNA@@JIFSJN86YM:I3;V)#0UH%S
M%0?.(S?HR&[0"?/0CFV!G-_JSPD3#VZTK&5>#D0>.E88)(/SL?5IV0Z8U.X'
M5+Q=],HC?UB/C=JF^>!5JHJ([9@;R!!1Y"2"C.,81.>W]'/"BX/;4)_#B^R\
MF%-E )01/4R6^OV%+6=$5*4)FE7T#<E<2>@%]_!!G>Y08Y$O,IDBL+L*Y(K"
M+7]KN;R'.<EFI55ZZ/$2F9SKS:EC+!KD ZKWAHYWQ!N1HZ-X2R2D4;SEZVR%
M]R24JS%C$23F\FAF][7<4+^;3PPDH>A(AJ)N!/*MD.@E1%S.7E@CG^I"3J./
M$&8Y_V2RB,TC-K_8S(L]>?R"W%UR?6J FH*B)M"H.YJ'#PU0CN0TZ!=D 2\R
MJR.S.O)]#^'[3GJF_6<C<!4D;G%+ES?")B]1[R](R,#P;J*N>DG;<CW'QZO:
M88*G22K_D.,]K]E^2):,="[?3--Q5.H<>LGB#<M^820_DN:KD.;(2?Z4DWQP
M42[+?)F;61.%C&E,\IXI+LIZH8]$&;K3T@U)<Q?N3+_'TFES&32!AP0+V#N&
M=O*19JB1(F[5Z$8)#)%+<26>\V6;,MN0EK,J@7"6P*Y@8=\K)2<JJ?&CO*CF
M5GJC68N1<3PQ"&\<%64<1#)^C6&#RS9P/B#@'84:%2NJ4QY-Y(F6SPZTDJ=B
M 0^2!&CA.I($@C?4 *2+B=O5HUNED5,5.551B.20Z0%/ H:NBI5L2WOU'#)=
M\LQBSRC0I-JHI!+#2D%A3=R9#9H6U U)1D&02%ZC(,@79@I\0%CSP&ZY#UR7
M'4TZ1G\$\G>SLH:%E7]?6*\AS!'<[(PN8D0^3A3'."-[8RL/^DW\JB;GWK#)
MSMI-WR[F>ZU,*I7@JJBW*S0V:#Z*8T0R'L4QSM%&V5? ;7YTWV!52FCFZ65-
M2]^[1E/#S9MY=,G[K:SCBXMBE*? 43WX1F(,5!<0>-=CMA'SX2_81(D20 Z,
M5Z>[VW3^%%H;-M'UKZ^S<C8"7T#R7D/K*QM-%V!<W%5UI]/JETOQHC)*FI-$
MIYLLM>;* K6G1];.C?1FT9T(+"*P^-JBRQ%2?)VY]%&DX$BM;L@J2[8]4$I!
MLA2M:1\A11#7N>+J&^LWO-5((;A2&E\'?2ZVG<+?H$*(*N=TOYZ!V*';?F\,
MSN&"_9NL]-\'XI]]ZW4<GS0?PM4W:75IYED $#O0U2C7#-8I#N:R6;VC\@S9
MK%I)B*ZXV*E$W[#T+K\TPID(9TZ/,_L4^8A YMC7>G>!3+IEB?6Z,6W.%&YA
ME)A44BI7$<@@$X[F;BAAEQ'7.^<(V-G[,9&O>T5I!"=/^WEE;9?3@"3BUN^2
M]+(GJUY]:*"0BR=RA5PC)]>)>"E%U!OE9#Y;+J3D6AUQ+R7\0\C59JYQ_TT-
M^N@T^2HS1HZCJB(V_T9L?G9)$U^JXTZX99L^C 53Q2QK@LMHQG@A\GD5PACY
M0A&W7@ZW1K[0EV]9T*0@KFEP*IY+3-45ZN* ZPVIFN;XX*ES063^?1_S+VK,
M>+:GD6M1K022&K?T>""G6V;?&_5[M1CY4$@GVF2F765J^8S%I;M5.%%\*X^Y
M$9@H5SZ2^VOS^"X^[^OOA'[*#-5A?D+9\FKH%>N.-NGV%ECH<1$C@66O(WU^
MW7 IH)&[TX;9E#"*NC9>G-MQ_A0XN7-]\<9-R@<-NQ;(9@6*YINP=M]>I--W
MR>E0GI7'JYQ9;$VJP[A"XS*+ A]U?HSD_,N2W+^1D!_<F/F0D!OW1L9R_4Q?
M!I.J-J59SBS*6,BA[2+0S-7FKZ\[3K^X"SA^LO>(&.$.;,>+><"91#[:]^D$
M=_Y$BYI.GOP6X<8Q7+T.K=V&G5T9Q5RMF6>%N]ZL_-#D42P(%W_DJ2_LY!2!
M3 0R1\E@_]8(\\6W#_= F-F<HOHF)RR;:@%TE@Y9R&4J?80PJ&H#>\T-*K<,
MM6MW.T]YM^=<\T<WA\2'O!1X3M!U51?\]@JBFVK7:'?N8F(STQ=7?H-IL945
MQ+*@GB5W0Y'2UU[VBZ3_FTK_F86;KNK:W5ZBSY!":>2-<V,R8S3M\L)U:Z,:
M%GUT!8^\$:E=74#^_@9>Y"9%ON,E)A%$5R0B-H_8_)(39O;D\0MRTH,WI( !
MH);7"=/2[ FX=MO\>YCB5W0[XN(/(38"EL/R]69)5ROC:V5AWKD?F497;W2,
MV)TI0ZLZJ&*XLZA%)*V1M)ZM7WQIKN\'1%6J=.\MGI'&<MN/YT9:T9!:!2RJ
M_'NB>@F>[WLL6[(]L+D9<T.,;:N/<RX.6X4Y,OB_D<%_CG[MQ=L>!2B8#2B7
M2%PWF?*[6OJZY51^R>4+39^<3D5GF!K,M(5"\X'=<<,R7Y@Y&DGY-Y+RLW/K
M+\%F>0".K:ONX)/272UD=97.QE4RQJG9GLV5AI-6%4DW'_ O1?]S'6D'P1O>
M3A!]M%4BWRFJ_QXUB[@&*^>5)*PW_3>!R><+W;D#Y'R;?Z!)6=&U6%RA!63R
M,#<,\]8%P @P(L"(&D:<K\%T<+1HF?$QS;=ZFDS[%*4V$J.9Z2X06N"F$;RX
M*]OAFN(]>S2-*&RG=W[+ I"GS/LZO[SO,TD5NXJ+-]>:6[H#:DNS=*\I5Q(N
M&9NT5O)#@EG=I:!A)B+#C.5O*/:+DTHCO(GPYEO?P;G6;-8=8)/Q 4U7Q((W
M6J4DJI9PZW)EM4!@@SM)W A1(XFHD424<'#"]""\F1_*RSOU[D;\?47\'95;
M/0<++6E/)J8W :@<*RIAEH1#X.2 I:$SG9\X&47X]4V]@.A4^BIS3_:4_8C-
M(S:_V.2++]5OWYF/(QOTBFS0DU_!.(XJBKCU*K@U\IC.P6.J>[8V&L"?@>,^
M-N>;^2:J[!QY29'Y&'E)$9M';!YY2:?<LHJSN7KN(FU%_/SOM\\64^;<U $^
M670'J@-<Q1>:"9$B#7U$@\%L-+)8HUBO_O4!8ZZ4_L )X^,RL,ZMJ$[9J7NH
MD'-+'?N@ IPZFNSCX2,9'#Z65,=1VOF*4&7FU*)9=W36BU&)=+%;A;3_>CKL
MD]5Q-#K,56Y2:"\F]FA"WJNYY<08M-C^C_] =B')7=UW7OP!]:P@YN@UOV[V
M/:!>DRXWC2G=F)<LR#.E]&#FNW)^+L5/RD*83F[<]P:V ^5(WTDROC@E]?NY
MX,LK<>25O;GECOOQ]UCG *O_:L;9:_6)FL:+%G^7;*J37+G"]:A>;0$%A[Z!
M#(/^?P^>"4A J(]ONAK6R;FN_PKADME,H4]QRDJF,Z3$Y/1!+>$MKH9MWE@Y
MGVO8G>&R23=IH[K0XV8KYG>AP-#<!QG&-HCD6'77?7/BQ/2%&C/Q'/ YE>U[
M+B(=NHNDXF^F@ 8F/> $7V:HF^ '1"#\#<0C-P1\S13 M\[!..K$$\57SBL:
M> G7A5Z[,?D<,[!ALB,K3%;KR2GIQL01'XM5&DM_-(L9587!=4W?OS 9R6DD
MIZ>.@U["+9V_$U*KGY@.Q3$G-F/6O-Y52+<F2G$DI%]XJ_F\8AXH+<:V+MM[
M#M;P<9>18W+VH#:3EF12-/RLDV#-&?NN_W.FKO-GB5 ML+H0IQ)F4^T.::W1
M<+-5+GZN?O.7TFTOM]'K*[/EH#M(R.!A*>57-36K-Z'W0P=.XTX_ )OE%^@8
M?I0VJVY!R_64N^2(9P?EOC>^=^Q5%=5Q?X,V(1_Z]&Y.%*O_1K'ZZ$@J8O-O
MP.;1D=27;UG06_)98$];F]=8QQTE.+S6W0JV_U"Z.YY/V<!:/+XTW<<1@7;'
M'\>+6-4J1;KCR-D.9\M@!D3K?NY;B]3B@ ;$&\'5M#2<#58)BFZ:LY$]+[F9
MTAUYG+#R7]&L!E0M8;#Q9+,]5Z:)I30P5/=(-,MF)C&0GD]8,C^KD$XL66@6
M4]!X%UGNAME94.(5ZVMWP#G@XI.;8Y%2N@H-] VCSE\,+/M&P[8@Y;50F-X:
M9\R2E(XU\^5JRV!K8KNLQ16&B^+5D81'\>J3V%H'%.^'$BW%$C%S*?OC3E?K
M*6:JW.\C\;Z:2/<;@LZ_)^A/<?"-H;X6[[>^<A:&Z:1GVFON:EK(]C(-$^AX
MV)K/$KE,)Y,R/6L4J]4UB9X!D*X<,BCXAGW:K^E2JC<HD'*2F=4SC8J4HSH+
MU-V-O^%(ZH;GF1U<]S[I@X#J.>S1/B#P_AXQJ[A;2&96#3*?ERK3-"<Y]?$A
M?8CRDU&_<Z-$L*I/5XLL-YIHO-F>Q0</M21T)"3FAA/I&TG:=1*PQSZMW8M=
M8V,NT" @Q0+-^B>+_Z/HB?I0Y)>:()NRPO,JJ]'S5'RG]'Y2A02_H>? Y4!Z
MCI_50%K_Z<=_ H_H4<W_!4_N7FB!JY=+16 H9*8\&-REC=1(*55/L- M?^\#
MJ_U;U_"PMQ3/1M.<DTEYK9',<PS8GZ-K>0C3X$-ULO:P0_N=;*TH)O*=)IT>
M,7R-]TNY255A<)<(:I>2B1 B0HB+/^LX1]?T$%;IH>%AT$ZS1;DY 4VU/U:&
M''_?RI3["!Z@F[JK9N<%GA+MR+M"MF;0!>L:$FCJ?L_5'+,'](3OP7F_[AYV
M$N94BHV'R6;&:4C)^[8[;[?P%0R1%&Y(4KS>3)K]B33OC3T+\&I2-F.]^[([
MRBWL11\1B6/X&YX47D^IB0YN3JUAKT*=?L.#FP.7JWY-_*=H\KN*RLYGJ[*B
MBDZ3;)>;KC*X*^=[*E2$N+4(=4.1;RG#2&HCJ?U^AS$'+OK\89&MEZMJE:Z[
M;+/-)^1T)A'C_/0"B2RT7=D;ACZ\_7I>_EL<O@XM2QT34]748Z9%:.K4]-1Q
MY,5'7GP4YSL+2^1)2"M01G-6,I#0+;3;U4\CGXHIX^ZBU51S#$=FD[&85ZHJ
M#.ZGP0CL#4?34>@N$OHH='>&ALRG)#[3=3N=RGTN,RI[+EESK,J"I+#$0V.&
MX:0;B7RKG?/%A>/BFN9/_#&Z,@?I;)B:>;@6]!%8G7%7GX.;*^?;I">T=N+G
MA1DO->"II@5T674L2#EW2VI3@=!"*(-KAX_=@6GW;$_R4LOAF,S7?*KDDS1C
M4=!!D[ 50TLW#!]VT7Y%,!#!P/5T7CTZ!AS<G/D[#&!6M93.UOH-N9VN\;EE
MDNDR-L8 'I5QHFY$-MRT^==UQ6GVZ,,:E?Z-VB1^!7=%;5G/JE/BP0VT;=P(
M\&('!B_'PW*ZW1NJHWK/91_L&IDK@+["DNONK+2P*RD\@IT(=LX#=J+NK&=E
M$.Z%.;7LO>K-2WVGF6'2I6&M?)]>L@N$.:A)*T7?L#O+=_8N.::UAYVWU=D6
MYP(=R>Z+T/8=WYB!\*';?F\,SAY;__O UMR)Z7 Q.'IPVVT+"^*6OA>JQI?]
M62K1(KOR*J/DF:S>K98+586ED"4G05#=>2P8 4D$)%\))*$(7(0BQ[/&/H$B
M9:68'RISK27GA[UB_JX@RN-8'*$(LLUH[H82]K+-?GLHA_X+^H4/?=<SC=4V
MT[P0_^"31^.?W#^N?O#):@!NMO-BKN9SG,)W0M$AL*G!3^L $*JFV1,XJ14J
M,V_9'GR[9Q.&::F69D)#T=U<(W%OX5:L*:^;\__\&_ZS>;@V!JJ#Y'/PSW."
M,&@::^DDR?\Y'#Z_NFZ:W>#/HYBE8^S6M/&___?_;$__R:F+:?;8=OYLP&)K
M78- .&F,&WT0ZSE '<54 [[ZCSI>J"MWO4Y!NF4V./3G$6\0(0B*O&6X_R&V
M?D8$"5%SHBYC6S1;PU1L# SOS_IKF[]AC'G\H^WB\_X_#ABK**$?/?W9<_'6
M>/;T#TW=HM(($_CK>F$L5"+<%VW6"\W /&W-OU5BX"!T^J]&.;E3L[Y[B[F!
M9!_W54!@!_GT4<C4?;CU.:EW45#%<*5H@L2K%$]#UU&4%):!_X@:22NZJ'(T
M11J\JG,_@K<>AFHAG?".K!>;]4:\E"$2N?+ZID>NE+S%) B6 #]NR$6YU*B7
MT^6*7(LW<N5271$DB9)..O.GB1'E-/$TM>/AY$_3(KR![;M0J;HW!%AJ /(H
MU'W!C1KL(D_!XV\3B!6>^^N(.'X8G;-F99[6-8IG@*(RHJ:P-* 5J<>Q"LD!
MAA4D4I)X?LT0ZD975\>&4$RWADN2GYLBKTE5=]2/*]"6>#DR+K+=EC53!)E>
MN:2:=-/,R*LJ='@DDQ4XSJ"JR>:,H[P)14WTI-V'([F7(STV1XG)^_M2<^86
MZK46-8K/DWV%4<B7(^\>$K26&MT71[-V22&!*5M* GHFX9%F2VT^+,?)U*C=
MBJ4'4JSCT?0"C@S-$SQXU4%AML@V\VU-6_6YY?W"A'9*>)[=!)M/]^]:(IGA
M5<Z:VIV'=#NN<#OFV8L;(Z^_',-G^H,\_U!V.[VJPH='(HZ*N9I6)(%44Q5Q
MXCS4<G%%"(],F9((U++-RNJR5I9&U)QOS?J*&![9DB"5XWQ%&JGC B.,.T;'
ME!<*18:'CEBO/7>H96M$U^8K28P59%:!0ZGP4$!5'[JU,;3GU&J1RG1KK9AL
MQ]'0$#NE!U5V7LW>MYK)3@]DZ:QKU\DX,D]#3Z7&/>I^F9PX9&;6B!7!@#/K
M6E^A=FR^*3U0=+Q!QD9J29C1U4*+E#@X=,?N3XMUZ2&5H2HCLUYM+^*NTQ-I
M.'3'5CW(Q?L'.Y&D9)4WJJFR6%H]%.-H:(A39FPC)3OWG#VBZ8(A.NUQF9O@
MH2%663:X@=FL%H9-OAKC'Q*Y0B6MP:$[]C5Q-]3R#ZOIM)GIV;7J,$:O?#14
M>AR*#>!'<R;P@: I,U:G+OBS^6$;<Y#V7VM^I .U0'<^MS6V?*2UH1&VYCQG
M\];UTZ@ K_8,E4JW$O.6,[^EM;>>;\-G&F-[L<&ZS>\QY S^"2RS!23"NQ;1
M&D+QBS=#U9YKCWT/',,2VB>L0'T@5>?)P/WKB (O1?L2[4NT+WO'L,DWKP]&
M&Q,)3+0OT;Z<_;Y0MU2T,5^W,1_-)7C/0#X9$<0/$.%+D>*D%/C;\S[HFJ$_
M_N\/[L=GCT/%6^:T&?;B.^&K#YX&INUUP1IO (@54!T"6#K07ZMF\W>I.E\N
M7N([O$4\8Z[K$*CWUKQ'QE[XW] 9\:/HT)\5'8HY]>64 XL.2@XYU%EZQ"2/
MGITH71F34(< S3/+I2Y/@0,-2JM/@.446"YP_QQ,#,YLJ8>[LG:.JSN!0@R"
M-R>@PRD[ 9[EYE_WZD[ VH$[?YFL?7;&_+N-1FK A0Z+-L#Y CJ8@[$]1;E3
MEV"0G2/WGGS-_WTX]7)*@?OR4C8I'QE?MJ50RCI'O6%O9ZS7DJ3%VE5N1M)3
MTB0;3@O,U,\7E-[(6=S24T]2)@>&G[S4QCZB;UR;^:8#])Q5<6P-N&[2=KT=
M::AT-Y%CLZ7%?)2?*;76@SFA[E24WL'\^ ]/W[#"KG:*5\#<D4!_48S\"@6:
M>B;0E!(7B_.9Q)'4J*ZQ^<E8G.@+NW\F IVW!JRHE]T9F>>,CM/4JCV?0@*-
MZG%*-R(?KO1P-=[PVX;(QM 2:8KZAQB;&O:4"75-V,CP/BS2G1D9#EGRZ@P]
MYN]AY<1=%W@;)"Q[ ^ T!JK5&,!]Z \2OFM:&!@G/=/"DVT[IN<!JVP8.Y R
M-\^('2_1!R.UPFK]A,SZJHCR57&Q<59X"RBO2S8BB#@P1)QEY.%[V$T'A0BO
MD*URE8G2;&;(@61)M6%5JRX4W#^6NQ'9M^K_7EX$)P,LX*AC;#>I^L2T3-=S
M<*+*5;@_)T.YTQV?'=\J.O%:SPK_OMA$6HLKA+_X,V%=>XX[X*Q3=0R/2]GY
MD<]I$T'MMO+<+*X$;0CI&YK:=>,XDOQ(\O<Q=B+)/YKE\W')-[D&R0X=TQUE
MA!H9G^;Z5HI?*'Q0".J&I,+]U*XF*A2\(BC]9(<R):[5F3DCG^[4T'#BL-"I
MEW]6R/C%-M%C)M0:"G>UK%K$8PQ/D\E5,U:K9(:NG%=-!MTIAE:0P-]0W)=T
MF8M (@*)-P)#IU[^68'$%YM/^X#$[*'<Z0GMAD^:]96BF#'+C)D()*#!Q/,W
M KVK6N\EAGZ"5Q1LUR4,QYYL+"3;.IQE]"T1[EO V?D'?4*+/WCKAU-9.#E+
MLR< ">Y;K1^\-.1YCI]+I,\EAEE@*(Z>7"CB&\;.(9J_1()_W8)__C&?XPO^
ML:R6_00_Z5,SVM'YNY&ICS.KY-PV[Q]0/:37#9B_Z/AREB&?,_)N(C*<G Q7
MG@#TRGJC2R41:U]ZXLJ>K'UY7C=.3R%,K,^)G^L3B<C\OM0U'UK#7(#,7?!N
M11QZV== OE0KG(V"7V?F.:KEK17%M1HQD2UW*C*<I3]S+2?3DYYI_\'R&\1M
M=C44HIV>T6\.<[+*<,.FJ]/I;!)7F<8W$1@RNHD0@<"W+)80!@%\?8^^4*\O
M4.8Y5,,(N ?7Y]^,84^^YFMR]ZY%VVX.2S8R%NA<'&?9H7C][EQN*$;WKJDN
M-4JO3W* 3O?QM'[\AQ>_, \LDM5+E=73.[[7EHZUGZPFEI9/DJ62-5+CU6F"
MUTJ5=@O+*O_C/PPO7F_^^@NK81TFCDS?*"7U^^:MA^AQZ6E=&_%>IZ2F0&]7
M<9=8JUL>]<I#;[0"+->LC9(%KQ9'[:"@P<+<,%^:S14!Q?<&BHO,73\^4!S)
M6GH;**1L@LM(B[PAQ_3!(,O6E&Q9P'WCT(6_<$VWOT[].H.K?=%A>I3+&B6Q
M7X2U4[(M^WDZZ]/5Y=<S6N>+&;A?>#(9$T'E86#V=539CF+7QR0\'Z6R1^)_
MA:GLUQ;P>4OZ7PI]AD[1WH(9U&2SG'?G[7).503<U1:%?;C#W\([-R_GK786
M)> 1Z![ 0?N>G!L!ML$O1(-S\OL8"!JZ[:-FQ.> D&]RSG\?BF7VC!Z=@#8?
M,JC>)-;%6UO V^_.T&+93B=CB\2*C"TZ3*',S4$JB?N"H]N"P@U'[_0<(_")
MP.<DX+-G1"H"GU,:>_N"3UQ+Q!(\/[7@0DJ-0N8NEE#(!0*?X,8B(X2KT_TZ
M\PZ(9^O:16N^5'?U]+E"T89^TS5?4Q+-*XN[LMLCP2M0F&","OQ,@0--@<D$
M&A'N0'4 8?N>B^P'.)T;HJ>ZIA8TS3!1R_&H(\9W-^*WZ11S@18SE[& 2'^R
M^#]*<5)W._?SLC+*V.5,OU=V&CR_V.DY?7:&P:_H09"FT.@</VL\OOX3=BK6
MN_7U]V).OFL'/2Q*F7-3!]A_P*C@*K[03(@4:>@C&@QFHY'%&L5Z]= Q#/H#
M7H2L.A:DHEL!3AW-,8&P*NQ-D(_>1+/:38J=EE.707DZ,B:CM)9:0F\"5WDD
M;W>T-8L292*X>P_NZ$Y.4Q[R+;F9<:LK53?N4U3_6N#N2J(IQX&[CT=-OA3N
M)D"\&W!N9B1G%G-02-W9W7D^CN".QW#WYM%X%#:Y!._K.Z[YJL,F446-*UAS
M%!.YS)A(&]M30"=4.'>U#PBHCWO (6SC683$C4(DD<]P3M=PSLSZ_G1JVMKT
MSDUC2C?F)0OR3"D]F/FNG)]+\4-'&G*E] >,[PTTQ -D*&%@*!O8$'?+3W"P
M,<I?VN)F@EO4[_E94@;S1'G9XJW2\GZA4!+.4R69&Y:A;WCRK=2U"$PB,/E^
MKOPIP.3C?OQQP:0$'S?BYMF%[#N+A'&?3/7OZ"H"$^C8B\*-*'(W-!..9KXP
MUWY[*MSE+]C$H>]ZIK':YIL7 A]\\IA9C4;LB0$'GZP&T.6IES)(D4](93Y[
M91"&,SWX;0U^6@> 4#5H'L(9KE /,<OVX%0\FS!,2[4T4QW#KZL>0'UHW5NX
M)R=;1R@<^6PI'Z6_;KK3L;I"# ;^^=@BQJ8%8H,@>'F 52!JO(B2?FQ-OW5S
M_I]_PW\VS]7&0'40H@[^><ZI#'K/&D])\G^^! *?DX!F-UKAD03I&+<U;?SO
M__T_V]-_POB89H]MY\\&R+?6M28_C3&]#V(]!ZBCF&K 5_]1QPMUY:[7*4BW
MS.8JQ)]'7< $VW++</]#;/V,"!*BYD1=QK9HME8AL3$PO#_BT^\8^O$?;-=$
M>/7' 6/<PA ]]=GS\)9X]O0/#94Z4J#PU_6"6.I6X+YHDUYP);/%E2HQ<) J
M^:]&.?FZJ+T5O&\@,$:N9A)I)H@5CQRJ[L.ESTF\BX(J5A^*Q#&ZH3(]A60!
MJ["L2"NJP,!_1(%D55J7#([Y$;SU,%0+Y2^^)>YPHL5FO1$O98A$KGP36#^Y
M4O(6DR!8 ORX(1?E4J->3M<AO?/9<B$EU^IRM9EKW"L2Y'21/>D2GF9(E-/$
M]AQQJ3+A'R*8ZY$T 9S13],BO('MN]"R<&\(L-0 9-X@X4.=0*CPW%_'F\V!
M;($U1QLB1_=ZJJ@ ((D*:]"2(@&-5X"F&T#HZ3V*Y-?LH#XFEDZ%16W(4RI9
M;\= 8I&OJ;Y510:@\'*H?=>IFGIMIH]6J;L20SV45(&+8TOQY5 RG8L9*:$B
M-/-5,BF"QJPYIO'0T 3NFD7@WR<35G,"C'(LGD@X#:.JT K]<F1E!7*V:0Z=
M45DT"^*P-O6*4AR.#,W4S(YMPVR->9EGQ^;(\ M6=XI&4J&'RI*P'%)JSR;+
M#_&1Q4\JC;Z-7A]>?[D^\+L:(\KRC!LE^,I@L*R+?333T/H'9G-T'W/4!IDD
M![6I.+]KMIIH C3S<N@PD>3J$OU@C<Q67DNEZ7FGF<9/#9&J[65YELWF&#FS
M[*;OJ<DR'J_&%29,JJHD]J9:<B*,_()]IY3&L:G20R/9T$P?C )E]:?=428V
M'B]X@RQ7ZGTX,K1\M34:.>YJE6K2H#>I&G*^ A95.%)Z.;+1BE/)QG*0;F8<
M<Y6E*L:DCM\>)O]$;R93^;I2:_*=5NI^-ITVN0)Z*!6:*>UZS=9BL1!)7Q"I
M\70RF:Q<_-305/6%TJ'E!R]-ELG"4LKEA>&BOT"$"NU4VZK<SVNY<9[T4[G^
MW$SR;;6%UA_>J3HY+\2%23]%SBBMK(F%1:%*XJ>&=XJO9-Q,LU4>)=/ZJFUT
M4U:B$5=8)?1^=O;P0$XXRR)7S5R=RK3SD_D<C0RMOS&EC>F]8O%DNS1W%*H=
MJPCC*AS)A8@Z5.VL-QZ"46;>22W,N\2(\Q=P9&BGLG'-<9)5]X$$5;N2275\
M!?7!814J-%&ULJ@4'U8];31+R@^U7$IH^24\-#33).F*8I5LCN6,4(C7FA)K
M=4OH_>&=JOB]K%9P[5@SV:&U3':HW-_Q:%'AG6+]9=:^I^79B*\[64V9#^<C
M"STUO%/&G9+PU.2X*=-CK_P@]6C+KR.BAG=J*9%Q:^3?367 L\8TQLA)8QQ7
MN/!.#9+<\*Y;2EBD6NPK32TF+ST;C0PQ=3&6,:=M94;*^8<&J/:[J7)_7H4C
M0SNE9.ZFH[M>KCM:C9:Y=$F:>WJF#T>&"#455FS,R CR:.;>K?1E)>[U.30R
MO%.9BI@D64$1Y+KEY#L3I3"4^GAH:*; G$ZG":>?'ZE4(^O1LUI3=-":J-!4
M:[*DN%INQ<E)K]@P>UVYFX'<#Y=/A59%5HT'MY.\&P&9[D_SV7K5 IA2(59)
MW:>K"S HQLC5E!TI;);1A%%<X</D'V;O[9J5LG/-<I6R=-$C.WD5C0PM2G(M
M2HEE2PJYBK<'F5RNE6'9*AP96I-4,4%'+HWY9KN6;N6JGE;.E5#C[Q#YO7DL
MT[#F=)_,6]HDP<?%=#R-GADFO^LTAP-RU6LU,^(H4?&TT;)3P$-#[Y>G?*8O
MS=V<7&8KQ119EARY@M<4(E2EFF> H[:JY*31R-ISH2Z5IGAH6$_Y@TDR,2W.
M95IGLM*P%VOQ+=2=,S350H>GJLED29!72;=DW54RB1Y7A2-#-"V(?$7,#26G
MZ2>4>RTC97)9=@%'AM;D-_D5L^JJ4UE-ESN.>B]/S1H:&9KGK%M14K.^G9.A
M_>KVR[R]2N30/,,TK7B]&)F1ZCQ93[,5?^P46'O81T/%$/,M^_FJD8[+H[I3
M+'?JZ='05=#0,$VY!34M@]3]I%E.%"1Z,KLWXPIJ_Q=Z_UUJQCB5>J,O Q4X
MC4)VV6:L.!P9(M1T;"Z:TX65DE>36FW%I9=-V4'/##-?,>VT.P([&)ED9E9:
M\15?+*(>9"%"Q?C*S"YEI\5FWJC50;=@+<@!>GN84'!7W,$=7]":JW:JTEKI
M J07>FB8^?2X(R?FJ>2RF2S4C:9@>QTOC]<4(I2XO)OFBZ!9'YF)F)>.3V>)
M*31GI#"A:%Z8CY)JJ3SB_3$H++JM12)6A2-#A%K8=HX#\;PMYSVA.NSV'GP+
M[I,4)I3<UCU65:?0F&1YZR&;J,428_3V$*&845=T58VVR+9<6\EE %+].!H9
M)M1<E72ZJ,Z[S>1D-E%8AX4:!@\-O9]1*O-,0=9;<GT^6(Y()I=HS/'0$/.U
M"XOXM)I/%D:S.=TH=AISR<VB185IFHD7VEYW(F=(T.O-XZ5EJ5FK+.!,PT1M
MT'K=$EI,=;1:4;:_NH?:'5I><&B(JDNRGI+X9C8WFMSEZBY3J'22;3PTM*R5
M-9"%&M6;RRNXF51U%HNK.IY V/)?BOVIZ<04.58>U#@]YX"5BH?NT#X/7KD.
M7YX>K:B8= >&UK#%]O'8T!1&C?FLDE],XZ/DRFKJZ9X1=_IXMF'23FB#GU-B
MIC3RF9(QN!=X+E:*8R*$%%"+9)B%M)0XLGQ74P>I5#J39(.QH7V0NU-1;&3]
MNKS*\I2T:/#%7#D8&Z)#LGSGM-QLLRR;\[M9G5138T?&M>A#9% 6I3N::K1C
M<N:.M_*4,^B9:3PTM&?SY:B8@GZ-W5QU#=GA4_JT@U9&A?=L*70K[&":7LCF
M:@+ZS;MQDU[BIX;W3+\OE3(EK3GRY45OV)G9\;B#AX;WK'M/%=MWK69:SFLU
M6>VV^?M5.1@;FD*WN()&VC#6AGRKY::Y<CIWEZCBL:$]$_I<LT$E*D,RE@/W
MH#;S\TPS($)H'UIBPM&MUD@F8_YH5O%GTC()C2:*#M,VT?<:1253T$8^51[K
M"X:LCFMX:(BVY>7$R[;\UD-SHO5!L<*(:3\8&EH8J<5K#U2Q-!I-%KPC2(!J
MT2H>&K8&C.$RGJ\R=S*?:SP\Y'LU,.5QN=4P;9<IQ:^+[95,3NPFD%<QS:G-
M%WAL: H#82DU"A1PR56F/*2F+#FG7#R%,&W=>IF+K=@,3])^6^J8]I@';?S<
ML#S<RW6V2TO5B5R.3>\ZV8:LT4@>Z%VXI&?+"YN><F0L1L?U5K6Y&#\$SPW1
M08DWXUWH@ZC-V Q4V:RG^UZYB@JIA<A@++K.Z*[&>O*DG^PEE++IM:!+1NUP
M7I5R0J44-7M'QN+"<E#1N\L$AY\:(MB#5E5+O3@8RJ;2SU /]64IML"5W$)S
MG122J5:5;:=D7C3[Z5A;N <F'AK>,QE"4[UD,H-F?LI)#J6JL>$]GFS8A&YD
ME3$SHO05F6QU'#YGZ+D)@V<;WE]'T6/)5*T+FI,!74SGR 13;.(*E>']K<_$
M:BTE"M Q6?8+O8ILYND&GN\.@SN?FX!,LZG*9BX=J\65T8/<P'5@PJ).&LEN
M6Y]D9=^S^A:9* T32.WL<#A7=9=*.FVY0/*^6W:*L<%J4<!/#2VLEU\-[(IZ
M-R#;7"OF#I9,V[_'0T,N9^Z.;[2@IADU??H!5#A:,:H,+E05WH<!FYLF.O$B
M1ZZH:GO%YWVM8>''AIU.)4M/2EXBVR(S;GPZ*O&E%&@'SPW++_ +UF#>&H[,
M5F4V:7*+RC!316/#;J<N=V,ZZ/E%&>1+;DJJCGKI 298V.]DQ_U:=Y@;#YMY
M$"?']I+EA8=@;,CQ]&4ZF[U;U-B1^B!IO5YJS,:AZT7M\#Q+QD*^HU/ISJC>
MKNN5>VG.Y4Q\^3O$C?>CSGVK5)[+\@R,<B U[-0:''YJ:,\TX#M5QII ZW=2
MR[3;3K&]:N"A(7JQ=9'IZ;UN7^99LU=3EPY7RN+2%^$] PQ7F-=35;FIYN3N
MG3R\J^3(*AX;FJTPX/HS8][LC^A.EKZ;M0JSEHZG$)8=?U(;Z,L'Y ?,Q01=
M<ZEY:180(20/U3E3SS)"!I"^O6K)^JP7*ZAXOF&\2V2Y<;-$/HQD4'ZX+_AZ
M+-N#_@JUPP6];[5GK-C+#$>Q[F %R<&,K5H?#0VM3&]I!064EI4F+WK)!^&>
M8BP+#PWKG7%CWJ?=?%>F1[E9OURA:C,/#PWM0S;I._?B6+V3Z\M8MSPF!;>?
MC*.AX7UH:H/9PINXYHB>#2=.W5V,K."Q8=H:EGKO+/EJE53G][/!7&P5%XE@
M82%Z3;T4P\KE7+V9Z2O=6$^?BS$>SR&L'QH-KY'KN;Y!QO2F*+&#><^=55'B
M?6BZQ<E27[!DRB1G6:><:<YK8W"'AX9H:R;DSJ@R*25E<]*;+*UVK4SV\-#0
MPJ;M3-LOS%:]II_IK5(:F<KE*OBB4VBNEM+)TQI37,A)P:L/'6^5P.*PRQT=
M3E;ZBG/*M2;P6VXU&6MY$Z>/QX9PO)!=Y%?Q\ATE\Q6=O%MX";6S"!86HJTE
M9QZF4W\)R P;$Y3E6']@?3AVAT=:\1?<\"Y32C?-F=<!7KD/0&N!AH;H12U=
M:)P\+-41J#.#>6PRXJDB'AJB5[65;R;]68DB)Y6"U!>E2;G?B:.A(7KE0<9F
MRC6?E&-)0>L7W14OS/#0,+V2XYC%*;%"L0GN9KG:0[VI549]/#8T!=$9I^+I
M1=YH\NTJ9Y"#;KW6QL\-TTOI6O>E?$M9D+/5/1<OECI<+8;S/T)3J%8Z+CF:
MWCTTDSHE^:O$3$Y-\=!P4&REF$8M13FDS^7S>F:XK(YS<33T_[/WIDV*.EG?
M\/LGXOX.1,]UW3$3H3V BMHS=T>@HF6Y+ZCE&P,A401!6=P^_9.9H&6UU-+=
M6J*5$S']+ZL0DI/G_,Y^\F2Q^9:3>,P^CAFAHJTWK$"#XF2)+SVA5[7:KNBU
M_&BLEZ;QN%,PU\,YFM46YIQNVQ/045JUK5@IY_IE8S70U@Q>["F]>EQ#G4R9
M@:9[XH,RW#7SB]X6%]2=\F)=USQ#$@Q3WSZ(T#T5\@FZBZ\-L<<KZ>KP<>LV
M:&Y:Y?5XEM^.-SQ4D*>T[3.3BN5 ,!=+S4%/M-+CXA@:V6R(?[K.96EQ_-#G
M=4YZT.H-OK40D_BN)R_&;6;#M52-KP2M:V\[N6J6=U+XKJ<!DJK9*0SR=(.>
M;_K\4DS;QHQ;HTM/:3O2.O2\(2X+^GRIQR?#?'_AH7Q+F'^::Z\2>3#,2_2V
M&R_GU2K7*CK^?4_E?+/HKSG=6(@@*>5;YB*;'2KXOJ>T9:O)B9OI/O&ZM&;3
MAC$RF G4IVR('RD[T#=?9F<976-RN>1(V W:N36Z](2VF:=^>ML8MZIB? BU
M\"Y=ACN(+SUYL?6R)>G\VEH)GE!.Y;2&F17M%KKTA+8UM6:E=#5KZ5ZGTJR*
M*Z>4*>.UGM*V%I=6&WG\M*#CL\=JJSCGO7(;W_94]Z_G_5FG7E[;8F?0Z4]L
MMK&>B_ZU)\NU\B/H%4PA;E0X=IY+LRJP.SR^]C1.,"_G]1Y=UNE&TS0;3$GT
MI+5/L%/\<&I.S]1LD^8JY?YF5&8->@C7$.)S5G@C-9.=AY0 'IQ*46_1#%?%
MEYZ\V:SE*<U>.S<7678A+L1$L3>0\*4G+R8QRM-3-9]%40(P+>C+_+P-_7DV
MQ.=4'\W';B6>JM&=+6"*:F&P,,<\NC3$GT_IDMFHV!!#AXD9WYCW=@;4YVR8
MS]FLF3(G/_:R8H6/KR7)2-@/P+_VA+9*RE4*[=V2%I:E5IR=23SG;?&UI[1-
M).34YBDW;(@-0> :\UJ^V$)4"/$-63E>:N8J">B^."EY]J#:H@2]!S;$-RR.
MF4UB^S3/"=M9;??4-YZLY@[?]>3%0())K9A.VA.WFRK+U/K-5EO!EY[&=7;0
M"$X,E3P-Z$Q+&YH]NI_FT:6GM$T_K0:)#F.Q-.<8O/H(.2-EK/&U)ZLURSO]
M<6TJO*@-1%V3XGE@MOW[GBQ77,WZ4HWNBD+G82@U'Q[!4.C[UYYB#6U.>HFT
M:^B-)Z PG:R@H(9&-LPWW(G-BE(MU\LTJ)>\UMJT2R4>$C?$-ZQ,GKCALO68
MT>?CIU1O/LWU:+3<$-_0V"[JLJOW"G3IP>@DJ[:DU1_PI:=^!K/VAK7R,B<N
MC9*H2!TV7GG""SCQ#?N-;:;.FU-HH=A"Q=QFEHTYP'<]W0=KLEX*VTFE)>2G
MZTUQET]XUAS?]M0WE-@GTXVGTU5ZGLW-1E9\W7B"/@D;YAOJ8)[6JSVW*7"3
M;+?,>)5XO(77<.H;FG5G9I9FE8DP+^:Z#%-1#&:%[WOJ&SYY5=NNS/-E>KNL
MU?39 VVM6VM\[=XWQ&6HA]HUOQA9M@Q#6CC@Q_Z'XPH35/(5E'NAPB?9+YAZ
M65AV5*P<5):=ENZY]OZIP=T8OSKE8SU,+/>=>;/E]:A4Z^C^%KRG:ECK?67+
M_G,<U6K_\,OPUI ([Y;!!04S^,'[2Z6Q8Z$>I,\H?WMG**+_O8\7\QQ5,_YU
MH7\J1?8E>ON2_)YDR+Y$;U^(O$1S7^CO6;(O$=P7@F/1W!>"8]'<%R(OT=P7
M(B_1W!>H]]\<2T/VA> 8V9<7.$;D)8+[DO[.9<B^1&]?B+Q$<U^@WD^3?8G>
MOB2_9PF.17!?"(Y%<U\(CD5S7PB.17-?"(Y%<U\(CD5S7PB.17-?"(Y%<U\(
MCD5S7U(DOQ_)?2$X%LU]H8G>C^2^I+ZS)"]VN7WYS:,5WBU+OAH1TK]!A(L6
M-GS2[-V/TN1DNN2G$.F];#8A$N&D\]2I$B(1<2/B1CB)<%+$B/1>H2$A$A&W
M\X1,")$^4 ]'B$0XZ3P1?4*D#Z0)"9&^GKC)EH%^B0_>ODS2YJ\)EOY]>HU?
M//.8/-]^YO'!I?_]]YAP"^&6=[F%AZM# 73)(!Q#U'FDB'1Q4;H'(GTQ<?M[
M@.:^L[>$SUW+_16:27J0Q 8_)B3)/Q42AOF>.)P!>3BH;;&A',O0E,\X)OC<
M1K$A.8Y_MB#O_Z=I Q78-E#\CQW7DO7SF4"$W7Z7W9+WS6Z^5Q;P&C[VF=C;
M5V*V%+( [HC7"&=%Q+2\-=__S#J/,,L],TM3TI2X1N**5W-;LY=UXLX=5Y1E
M;^X9D@L4PC(DTO%1;32%/P/;"0Y-CWC<(_U.V(-ZP1[W$>DX\Z;[9NOIOV?"
M#+^4YWYL_7/;]_?)*^<PSA+</?$-/[<\TR5\0S"&8$R$,"9S3WQS;HRYK+%_
M6QCC%Y+>#Z_<5ISREC$&!9GNAV\(QA"^^1/2E1W'0V=.$<XAG/-[I,M+"^VD
M H<PSOD9QP]PWP_C%("JR1K159_ .'>5SA>6GN9NPZCU9_'OL23K$QN:3<J/
M?\@R *IZS9#XFZ^>DPS)E.&C))<J !G,Q\#V"9%@8A1+L_19HQ(W1)E+!*P^
M_>V/A 2?SWE,#O8[F_HMBE#_U3;PM<RB+<FH?X'R3,UM _7_?1/A#Z..*YF*
M9"LC!WN:H_(B/AK&W7Q56([J.ZTR%"JK+/^-PB>);OPO\LZHH8X8=I1@1HC9
M1IX3GTC2 MW,!7,HU[BLJZ'B3!6_T9S#%8=B0GP%7\.L>_I]7[;SUGQAF?"C
M$WX/?/O@%LTI-WCP/.U)X("G3\UEGLVYZV^4 F1M+AG.__M6KA>_4:IESR7W
M_WW3-NX/TYLKEAM<\(TRI3FD8/"0'[[CW?!<!Q$([C!$7<@Y\ KZV_X 5Y[M
M%Z2EP @"Q]/E1")+EX5):Y1$AQ2S*3H&\?2__WY)_9\W+)A_4[W\MTG>/Z.2
M/W[EAN#K?PAR'2$73FZSYT)SHLMNGB,BI<K\<M*_T&/^#8Z56,:B>Y/*3)H)
M8-"UA@^K[4-1G5Q6B0VMS6[74Z<#<;E9BF.)9:I+FX=*+/WM9R:9BB4R*:+$
MKC^*YH9PBRBQBRJQVV*&2V3W;ILC(J'$YF/-"A20:#H+J#Y4+7#*SJ3+2GQR
MN^IF=T_B?-)P2A6KF#<'%]9EV<GC8U,</R[T_E3J:MO:-->D)U"7,= C2].Q
M+$O'N&SB@OKLTX7S)O59^J8@['SZ+'O[Z/71<)+8*8QJB;PF2+R<$CN2G'@L
M[]**6EK?!7;%$[\#74<%V_Y*#MB5.&!7&]ATJMBM,X*W3*TFH^G6<KLHF,2D
M('81R"*012#K5B K%&Z.8 L#PK[4(L"<J9<7^G9J5Z7GK4;;9&;C#9]M719S
M4M8X:3RD.DT=T(_V8Z4XD[H%;"]E(.;$LHDLP1V".P1W;AIW]E<]#S!#':IE
M,RC8">!G]J"P+=J*#\1\F4\*V8PPZ2S6EX6?<6DEM-RZ(8C><MSSUI-$FF76
M*'_&?/O)IE.Q+$=\-0) UP"@U)4RAV\!T.]1@OIGM."G#5Q),X$B2+8)J;9W
MU93X4X5=E1U+F&<&^:S./J1;J3/C#J0FO$T( (D3L*6SB8HJEHQX:D2/"F)-
MQ0"4_/:3R:1BR73R!(#^11#H<Q'H*I9 !!"(O8/LQZ4QZ'&<G71,A=7I?,5<
M;BO96K=8XR]KMK#"3%N++3U)=^*3:IU+]BOB!J-&^MO/;":63+R7,;VY!GW?
M;85/@>2AM,!Q]5,[<:J(V!,2C.(G-L"*X%;Z(=]ZY7WB*OJG9/R)U#ZG):._
M4Y&?FGGQ4[X(K]X*KY*=NI6=N@54N7PG"^'56^DY^I2=NO@Y3/>^4[> *I<]
M4.$34>7"AQ@17B6\>M>\>N;@3,&S)72?$3/"T1EFU+6>8S7,>=+D16U12+73
M8E68E\ILBEVII<?5[Y?FH*?\>+Z_*8.01\(7@GO4A+2VE) XT( M[/KK[D.6
MEA)KHS 8&HO<>CU*X>QY,@9A("0,1&"!P$+$88&H,,*KUQ_#37CU"KQZ>33Z
M)%YEHQ=P^-1$V7NV&)^IK9;9%,WH'3E9F1N9N;*VKF-&909;WGGHVC5Q.USF
MV4Z\ED\H/#2C4#KM-3/JWL9][,E'62K<1S_9AAM>/B')%BU*G#GJ&/T$^MF#
MYK=34O)EAT 0)K\M)B?[>5_[>0N@%;D^;\+DMU7L^<E9PQO8S_.WWO]VS/L*
MW:R W3[:C\W-5(@WFVN[*&0[G6GK+SKQ]\X=4(Y=.[]!W_]]T;([P%YI,G!"
MVO1[^KJ9Y)?I!QVPJBQ/Y87H/:Q''&[39V,TS<22V;#1:3<IAK>@:R+7Y''F
M$/L-8--MZQK"Y(3)W^E6.GM#TNWFFU\JSIYD>."@-_>!OD.<[ZT&IF1*Y-+,
MNK>E6;-7E)HKJ5TH8$V*&[A3Z=/!$?\B"$,0YBX0YG9J6C[6@IW@5G8QSDY4
MNI'0Q6ZRJ3#=ZN^W0OX=U)RT2-9S]+;?I3/05H\76U/EL9.?\Q!A4(]V.,(0
M@"$ <Q<-U\1.OU81PMTR^3WT](9.-+VYEM97,^XQR@0N^JVEJ@"I3OAGQW6H
M.,6[<7<*XC7)UN$5C>#/I-F)M B1';Y^DVSD*4!XG.PPV>';WN&+-^5&G@)?
M@,>_^ Y'LPF8Y.[_)G?_5E#03]SSKN_7[-V:D+S],NON\IMZM29R57>VSF?[
MM%R<C-(X;\]D8TGX_VSR=&(:D<I;Z"2*/ 6BV2UW[81#)$'I/(F*/23!WYZ@
MTG.&8L1[="I>DU:BMQW,UM5X.=TQU@B54M]^DA9< D9?"(R(&4QX_-YY_-H*
M]P8R_!]3G(V:"STE5^L*'5&>>W7@&F""S'F<VJ=C''O!&MRO+%<$6<@P@7O?
MX8L/$X@\!<@0@JL,(?AC=0@4/6])6M^FN0EG#J=YG5=U'JG#=* .O_0@ BI.
M^98/I0+X5_/2U1"D+HKT3!(^B,0T@\@3A0@'X0/"!X0/KCD](?)$^9K"0?B
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M8Y0)7/1;2U4!TIWPSX[K4'&*=^/N%,1KDJW#*QK!GTG'$^D3(CM\_4[9R%.
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MB&XJQJ;>:E(DH2$B^20T=.X3H"XE^J]Z1 DU7U[KI7I'!XE^-_Y8X<?< F,
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M/+K4:3_-N:J9'(L\6B_W[6>:B669[!V<#.*;87LRP!US7 =1&3>37-$>^](
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M_\<#_L^(*>S6/2W9[0M<)J[Q;:FWR[NM4'?H#%+[5O#"W@/.P0'!_]E+RW7
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M,5"!/"IT/J[5"[PI*#VNAQ.]F%EM$#CJ0=($6@$&TKHX^;^ FAWZ1'YY'4H
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M_D9?P%$1^A+@5%"T&U&A)S0:LF&4719S3P".B^$=:WG;0097(/4<BSA!9O-
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M>7Q<N5_VJ"GUADRM5]$[;&H2SH786C,XU\*%6H]#A_S,$QUBGV+LL:Z@GR2
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M,81,C!^60\V*S&:6$#[#;_$,?#V_;+61X!^>C>_IV;B[)7GX>*^D#5<AKEW
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M4O[@+62ES1E$O($B40F^3C4I9 9KNJH/G6>J:ANF+<(1PHNMD6)2HC?FW15
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M]8 <#QZF_]5::55&"6Z^S';C0B8TSDVBJ5!B 2YM^L<ZX:BEK>.=B5);.8-
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MPLLHEL-N@-@Y-P!&^->/_X_.^(G*:=+SSVT% .^'@UP:CP'<3!DO/M6QP-"
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MT&1J?_U+/Q^*50K"IHI(/@,&1 ?\4 A>B)P:(,RP5*P1!A5="PQU*.7A[PL
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M6"<KHR?VZ"*7FM:';3FK*Y:=QL7)7W-M?UP+_GKT^#0-=C%+IH;B:*FGG'J
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M.;S%#K&60#U49QC6G1U4V:R1B=*'@:R0](89LIQE+V[FD*-W'&(/L? .L7#
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M4Q/>HFC8;_W_L_>=O8HCVZ+?G_3^@S7WS-.,M-G' 0ST7(UDP.0,)GU!QB[
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MT!^.M1T'HA%?^37:MK^QIKEUM0/-N>.T>-T/<L:;]=[VZ>!%68\*X:(U#O-
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M.YR!Q2]NL992;#3QR+5 $[XQH>$R0+]:0EVQS?$X,ENID.X3$5,%S8H!E06
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M?[Y>M]/$>RJTN2LS"1UUT4 M- R"FUJ*1E 1K%FC>P(XZ NRIUI?"0\P'&[
MX:EE_]?TOMH=@!%^E8J(5$<%,]J*F/JA8O1C!>MEVX';@-^XT/C2@NW@YX7W
M=L/I)G3DUE@T'^P('>[H:_AFM <"PLI+"(+*?_?I<,]?Q24Q@%X+9E P<Q&
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MEG\BU)P+_RSX(@%E /K07Q^+M*9CH"MK-91=R95,NMRHC+[<+VQ_N_!5BMV
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M7D@.E,BT'Z6$<7<!5QX=B0V)!5XNY'+"+$$R\S35KS=,#JX\.M)X&@Y/(E'
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M$"0@HYR6432G\?,X4T\((25,QD>R1I/B IE.QRG[>S+JJ6P_OEE.L\T79*5
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M,EUUY;0JF9GKVDOIAJ2S$JG:=-R>E-5";YV>U"=:JIWAWB&= 9#@2WWA#TD
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MYV8[1!0_U@"P3;S2 WOW)LE8 BP_O654=<WSPMS9FFW8,F?_[VG=M*JZU9?
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MV6OWNKN=O8-EC\BNR=]^!6?DH#DCCS\C[_; &-E_S6($G78'G8,Y9T3G'G&
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MX/PX=W!33H(JJU%N\$H58H>C!@IO;MY58BO@.C "C@RRFZ0%5A';YIC;P>7
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MSD^L7)VB=M-=8#;,#V\07HT*^O$Q-XA+.I]":6+<L$UE8H!.JO.WYF:=T\$
MU=P9254=&?HILA>3XX35C<"6;J((/2VQ21-JJV;>%%EAEL51!=AB5Q83,KF[
M.?5Q#R-49E/)6?I_9O%,7U7?5\'DA97?ULY!G?4JHG*,)A/KJOGE^8 HSWX!
M;B)%B'&2.9\EUIOXL6X7]$W*Z?SUY/;Q+C+.? GUPL"PVUSU8-:;<R"X'46^
MX@:4GVBIACFRF6$5 55<4I0^6VPDH-FP,C<M0"[3EZ1*GG/7OV:W(ZK=H%($
M?XKQ:3SF" \$$@K!&KF/(.?/9>S-6Y)4N;ZCIF8==%K\T>778B+2L%3GH=#^
MVA6HO[; >+D?J)\M##*,9@?99$@@:>:H*?0S/M.KG+,V]W +@ES&DF3ETOR(
M8)/(>)4M*\EH(C&3FL:C9K+T"ZOV&/6!*<3=>5]K>L-0(B1UBIA[3-J5S.YR
M^4EU!#E"EWU6#5R4]C^8W3)[HXY/!:@QWQCB+@I&:WGFQ_Y@"Z\J[_AB1SS;
M-19VJ8F4F4-A@2F90N6'V4!A< 9@7#(I%N!AL!64G61,2> 8F$7VR#TTU0K8
MRP8CN8F=B0&I>,BRZ1TIX4%H!FDF6T!TT,LTC3';=FU 5.VUR9DMI0W69!5R
M#*%*HSF^H9?3ZPA3I$%'@<7+L+6CXGQ\2.E'A2[@4[(*@ZYN6;"V":Q5^"V
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M&3(*ICS/A5'IXW8E2I$;4BZ QRZC12M?4_^-N?/S\KIS9+":A@.+!DR5ST;
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M$=V4;U>+B&4*?QKE\;6QFX--9#>GYR>#S^>G'T^/R<4@+CZ* @?*4WSQ4\.
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M/4WY2@PH*1@;U5NTIE#JO4*@<;XY7#9S?R%R:?U45\ <YT9^]S'5KI".AC?
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M9GQ:\L-".4>%LS*KHM2744/6D<<V@=U'A$A[VYL8V#T9?.Q_/;MN$H%?DPH
MI+A:R!83SP:ZO<")'#D('%OP[-AQ*%/DO;=*D7?;2D4+[WF;P:(KJ+3L$ZPI
M@;SFI,H+*W?K4X;)F2D'2_,4,W(# 5,O:]P=\9'+$+D+@QD]BKG%T\79.B@]
M$53)=)RLJ0SM[G6ZZ)6<5PV*<QZBA\CC'$W&?=2EG]-QC!>J"7\DN/M+;O(
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MGD9K^ W;&#BX^F8WA2Z3PH4T%NVK\\7CQH);#4/(&FQ#K]/^;7J=&!7NC.K
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M"G>'(?X@?[/0U"G6M^[BQK4(\<91A_>'\N"L*+T86H7D8$5:I5XLJ#_FMX3
M*Y]-D)3#VW,]; 0)BM40$>C<-4+%1Z4TK R+$$PC@?4*%8G&H7#8A4/!@6E7
M0UEW0G"P<33BJG9BQ0P86N.?64(6 =$"F)=Z''-!U,F[UERO-18)T3(<,_KM
MM%#QA7B&-@M &Z0(!^K\J;VA7#M1,:0]5^.H*'/+!LEG[I*<D+[C6$W22Y Q
M]US*V21E4EA:I/:B>85VEIT9?D.7&Y4]+T^'0Y4[/EB0TT.?*YDWO3ZD::>2
MQ&W?:R3PXA)I6R13%SEL@J''GY$098?LIIPH^EZA$D:EYC[B)"DTC4&*M99(
MAC8S&68IUH9\%V,IK:O)+)LAX\GHG],J'K/R:>@;QJS@L6!U]-].K:S'ICY2
MY"2,79R2H1S%D/DW\T%=.N1I#48";6JPZ>V)<81;*6@L\W,3!U,E,N>*A%+.
MPT3%8:\NCPAC+ 5R/CBM=NQ46U9YC54-57W:XYH+SC0*<+F$>VWF4\;TT?:1
MUJH5\#$I/M> :+C-C9HLQZ@:S :>=FDDHF<,CJL?T;2:>L*S!H56V3(0LYCK
MR]AVHRDY"/A7SX2 ^.2$-/C,W&$!G,[X\DY=6U]'="<6:4@-_;BNP]+R/?)F
M*LT^V>3:%?+45O97]QI=U^/1J9^U>36/!LUZBEJB1\Z"%6LMX\-<H--S19[8
MGTXA287.$!7>V$?O7D*'[ESE9'[QK\3/)J0I]*2(Y"_^)?OG&5GH2(,V1B3W
M/KCN]5$15P,P5,;M\2G'&G)T0Y!$T0FI,1YR?CJA7X_-?1R0T/<H>$IK4)TW
M@8R*Y,4H0=;RI[OEAAQ$E@L.0YJ01)J*)AQ!7$K[R+1%L@)NX-JH;!YA1 1_
MJ2=E6#8&MUA4PXB;I;FTM+FZ2.,++$]<9[V^187&ACTSQ6#KWXJ33#&"V/'1
M4L].NQXY.\?L(4PY8)_#@?>]CWKL2+&@<&Q;$@W+ID/HW&@#7CB1!$^4PJU<
MU:\ICXIS_D([&#*W[M_HW(0RN[HM#'XN_26\0]:-4S-/A3/<7;O).BWTQF'&
MJ]K))[=#MR9L[IDF=)L*DS8GAFHXFJ97R[$EJ$6A)_7^)*>4+A217RK4KXR"
MC&S'![!;$^YE1)DPX7\9"CEQW0V\T&V;[_S2C9GH1PI9-@V%[4"1"8W3<"PB
MFJ;GD,H=!X\WC8(\!4"8-+B+ @P +E:,>,Z+)P)^3JJ1C_9!(]DD<J8BZ,=!
M.@$Y!9TA:607WU7[K&"A'],9RJH\2SMI7YNT;QPSNWIIKW&P,M0 +S#*\#-T
M.WW 9B=)G.-R(JF*4K*8ER0WNT-N,R&#,,Y]C"03G*Q.N';5C[6^VOW' 1F=
MT\=Q&O$D/]*HY!"0Q@1KO R]BB-;(HC3X= I'TC'-3QR?X[&9T%>;4R^OHFV
M\A2%P_F.A3IAD*3)KGN##B'9(217AY#<[Q"2'4*R0TC>(T*RK=R-$[_ Z]?3
M>&V."I-1<F23&34IA#UD-S3 7J!0VC+P])BFH9@C&?"NS(=S#5V#$W4;@>EJ
M0J4-W7_9)$66.XNKZ3!RV4V<"A#7IW5O$%)9-Y3R-'"KPQ?>AW_V2/&%)EX>
MY6Q:F);$+TB,QBJO.41Z'DK-DB4.S@O3IAI=Z,3I_.$PK6Y1,C>Z,5?C2BJS
MA2G_1M+PJPJ(J\P.<O/?70BR%A%_I.A#D,!IG \4,8D<B7KB%=40"$(G$UFF
M4:S K(/,#I,L%!2ON&!%OY@P$>F(A(DL9X3*?V+GX>D["V>(!M"C8507-2J8
M)H?FH99]Y%(3P"5,6F@!FH,N /R5KBHPUDDJ"Z!H@V6K8@%0>!=1&CM=KE'A
MY56\IM+GPZ?$61F!Z*/!,IIVQ\!.N-8<##@S7Q5&\-JZ&V01?E,QE0QKX$^S
MJLMRKDF!/RJHV[7MM2BV9WY^;E0WO[O" &8C&5EI]#%]SDD<V:N-97*E5.$O
M2 )N>UU<87_OS1\40&$8ZA>Y/O]V\*9&UK;PM$WT+"-GO;H^G(Z>HA3\5$<+
M?ZB)5,:Q&)B-9/ZTS6UH8?>QWLP=-M(=VK4<VHVCPU:RC6/RYJMI9O&64@:#
M02@0]3*I7YH/.=%@"A0-?@!-<6M.JS?V.Q;H]0GAXP!L+4?,<*E\J0L$<0HX
MT%B\&F2#0'3IL$K%?C*N6$OGD&CD64B1Y@RC8$1%ED=<B)/VCI(?!8E&S 4.
M5\S[WLD/<HDT7K'Y;;L,/1Z 8HMA54H5):*(@K$8O=9JT5>; AK&N.5BDN9"
M-*4NR%1H/$;K\Z.<0=H\K3M/%GP =V04!SIUZ0E/HEQZ6Z]X4'$Z3H5!BOZ%
M+EF'+(MGA*LI[F<?I^7;LBBS- BJS)"+:1:N[NBO+51Y-/"GVRN 42H4C.C&
M2@N<K2)3]/]\TC@C8 P1R3SP_9+,!5=;80KNCITJEF&%28=J)A&\(9-'NP6
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M_/YKCV(::4H_.-SO01EC?IGW[DG?.QT)*,X^!Z<.+[-H2ES<V8=Q A@*NK.
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MN[EFX:MM!P^#5BIS(-&&XJ]PQ9M;^CFC48THF$4*R)NF%*YBACSG2NI07E\
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M /:_1=U;J\XIUA-87%9-L+,S@.]KX:N0_/T356;GYR=L]^61NT#D*N@-IC(
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MQ0TP*<A*&- ;X83 TF8$56P0G@E4+#!X2MA"&$(7:6*L?$87)Z7+82I,VU.
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MV&V1ZPNR_65PNF-SGUV=#OZX[KM6K[^<?#H_)5N>[__6/?7]L\&9NP'5M\E
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M75PG6 *SI>#$T)'A=<1U**0NH!RZ-R6%0W^N9,@B2-9D&\ >,6"/0W3_+DQ
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M=):;8=0:?WOGA RK>-BN-^5(@#T]K/QE\JOU<],KVC1ZE<BM&, JZ.%691E
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M>Q,UA_C;<\*6QM#/@(XEC\HQW>\TNWLS(>326E:VNC=<[2NS1W\!4$L#!!0
M   ( 'NL?5:EJ;<Q<0D  -L[   7    =&UB+3(P,C(Q,C,Q>&5X,S%D,BYH
M=&WM6VMOV[@2_2N\*7:; );E1])-Y#1 'BX:W"8I4A>[^Y&6*(LWE*@E*;O>
M7W]G2,F6\FB<;KIU4!=H$I%#<H:<PSE#48?_\;QAEM L9!%Y/[KX0"(9%BG+
M# D5HP9*9]PD9"3SG&;D@BG%A2 GBD<31LA!N[O;[K0/WGC>T2%T=5JVD5E
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MX-C&;R!BN$1-A,_@C(D6C'AHPKY>I)UP[4Y?S+&S6!7?G,X!Q$(6.C,T4$1
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MMU]7RR]D(:2A'*Y2HZSX[9BGI2F(!JL>V3R-_VY9%/Q?;9"1'&9!>)V5P-A
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MT_P=Z.G_ %!+ 0(4 Q0    ( 'NL?5;IO/D>OA0  ,/?   0
M  "  0    !T;6(M,C R,C$R,S$N>'-D4$L! A0#%     @ >ZQ]5D@65*:C
M#P  +M\  !0              ( ![!0  '1M8BTR,#(R,3(S,5]C86PN>&UL
M4$L! A0#%     @ >ZQ]5FU(L87*/0  "UX$ !0              ( !P20
M '1M8BTR,#(R,3(S,5]D968N>&UL4$L! A0#%     @ >ZQ]5F;$E\)"=
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M2P$"% ,4    " ![K'U6SHP)I'H#  #L"@  %P              @ &$S@4
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M,2YH=&U02P$"% ,4    " ![K'U6D\Z:BYP%   O'   %P
M@ %SZP4 =&UB+3(P,C(Q,C,Q>&5X,S)D,BYH=&U02P$"% ,4    " ![K'U6
M=?E8ZO0,  #;.@  %@              @ %$\04 =&UB+3(P,C(Q,C,Q>&5X
=-&0S+FAT;5!+!08     #@ . +$#  !L_@4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
